PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	PENDINO, KJ; GARDNER, CR; LASKIN, JD; LASKIN, DL				PENDINO, KJ; GARDNER, CR; LASKIN, JD; LASKIN, DL			INDUCTION OF FUNCTIONALLY ACTIVE PLATELET-ACTIVATING-FACTOR RECEPTORS IN RAT ALVEOLAR MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INDUCED CALCIUM MOBILIZATION; VASCULAR ENDOTHELIAL-CELLS; INDUCED LUNG INJURY; OZONE EXPOSURE; KUPFFER CELLS; FACTOR PAF; POLYMORPHONUCLEAR LEUKOCYTES; PERITONEAL-MACROPHAGES; INFLAMMATION; NEUTROPHILS	Freshly isolated alveolar macrophages from control rats express low numbers of platelet-activating factor (PAF) receptors (4.6 x 10(3) binding sites/cell, K(d) = 1.3 nM). These receptors appeared to be functionally inert in that PAF failed to induce intracellular calcium mobilization in the cells. Following brief exposure of rats to ozone (2 ppm, 3 h), a pulmonary irritant and inflammatory agent that is rapidly converted to molecular oxygen, expression of PAF receptors was markedly up-regulated on lung phagocytes (13.1 x 10(3) binding sites/cell), with no significant effect on receptor affinity (K(d) = 2.0 nM). In these cells, PAF, but not lyso-PAF, an inactive analog, caused a rapid and transient rise in intracellular calcium demonstrating that the PAF receptors were functionally active. The calcium response to PAF, which was largely due to mobilization of calcium from intracellular stores, was found to be dose-dependent in the nanomolar concentration range and inhibitable by the PAF receptor antagonist triazolam. The results of these studies may be important in elucidating mechanisms of lung inflammation induced by this model irritant.	RUTGERS UNIV,DEPT PHARMACOL & TOXICOL,POB 789,PISCATAWAY,NJ 08855; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT ENVIRONM & COMMUNITY MED,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center				Laskin, Debra/0000-0003-1832-7311	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007148, R01ES004738] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES04738, ES05022, ES07148] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BECKER S, 1991, TOXICOL APPL PHARM, V110, P403, DOI 10.1016/0041-008X(91)90042-D; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOCK LH, 1992, J CARDIOVASC PHARM, V19, pS1, DOI 10.1097/00005344-199219002-00002; Braquet P, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17B, P822; CABELLOS C, 1992, J CLIN INVEST, V90, P612, DOI 10.1172/JCI115900; CHAO W, 1989, BIOCHEM J, V261, P77, DOI 10.1042/bj2610077; CHAO W, 1989, J BIOL CHEM, V264, P13591; CHUNG KF, 1992, CLIN SCI, V83, P127, DOI 10.1042/cs0830127; COHN LA, 1992, EXP LUNG RES, V18, P299, DOI 10.3109/01902149209031687; DRISCOLL KE, 1988, TOXICOL APPL PHARM, V93, P312, DOI 10.1016/0041-008X(88)90131-7; DRISCOLL KE, 1987, J TOXICOL ENV HEALTH, V21, P27, DOI 10.1080/15287398709531000; ELLIOTT SJ, 1992, FREE RADICAL BIO MED, V13, P635, DOI 10.1016/0891-5849(92)90038-I; ESTERLINE RL, 1989, TOXICOL APPL PHARM, V99, P229, DOI 10.1016/0041-008X(89)90005-7; FAULER J, 1989, BIOCHIM BIOPHYS ACTA, V1013, P80, DOI 10.1016/0167-4889(89)90131-6; FISHER RA, 1989, FEBS LETT, V251, P22, DOI 10.1016/0014-5793(89)81421-8; FLOCH A, 1991, J PHARMACOL EXP THER, V258, P567; FRIEDMAN M, 1992, ENVIRON HEALTH PERSP, V97, P95, DOI 10.2307/3431335; FURUKAWA M, 1992, J LIPID MEDIATOR, V5, P191; GARDNER CR, 1993, J LEUKOCYTE BIOL, V53, P190, DOI 10.1002/jlb.53.2.190; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3444; HARTUNG HP, 1983, FEBS LETT, V160, P209, DOI 10.1016/0014-5793(83)80968-5; HENSON PM, 1992, AM REV RESPIR DIS, V145, P726, DOI 10.1164/ajrccm/145.3.726; HIRAFUJI M, 1988, BIOCHEM BIOPH RES CO, V154, P910, DOI 10.1016/0006-291X(88)90226-4; HOTCHKISS JA, 1989, EXP LUNG RES, V15, P1, DOI 10.3109/01902148909069605; KOREN HS, 1991, TOXICOL PATHOL, V19, P406, DOI 10.1177/0192623391019004-109; LASKIN DL, 1990, AM J RESP CELL MOL, V2, P463, DOI 10.1165/ajrcmb/2.5.463; LASKIN DL, 1991, J LEUKOCYTE BIOL, V49, P369, DOI 10.1002/jlb.49.4.369; LIU HL, 1992, J BIOL CHEM, V267, P20811; MADDEN MC, 1991, EXP LUNG RES, V17, P47, DOI 10.3109/01902149109063281; MATSUMOTO K, 1992, CLIN EXP PHARMACOL P, V19, P509, DOI 10.1111/j.1440-1681.1992.tb00497.x; MENZEL DB, 1984, J TOXICOL ENV HEALTH, V13, P183; MORRIS DD, 1989, CIRC SHOCK, V28, P149; NGUER CM, 1992, J IMMUNOL, V149, P2742; NOJIMA S, 1991, LIPIDS, V26, P965, DOI 10.1007/BF02536485; OFLAHERTY JT, 1981, AM J PATHOL, V103, P70; OOSTING RS, 1991, TOXICOL APPL PHARM, V110, P170, DOI 10.1016/0041-008X(91)90299-T; PINO MV, 1992, TOXICOL APPL PHARM, V114, P268, DOI 10.1016/0041-008X(92)90077-6; PORRASREYES BH, 1992, SURGERY, V111, P416; PRYOR WA, 1991, FREE RADICAL BIO MED, V11, P41, DOI 10.1016/0891-5849(91)90186-7; RABIER M, 1991, J LIPID MEDIATOR, V4, P265; RABINOVICI R, 1992, J IMMUNOL, V149, P1744; RABINOVICI R, 1992, J CLIN INVEST, V89, P1669, DOI 10.1172/JCI115765; REDISKE JJ, 1992, J LEUKOCYTE BIOL, V51, P484, DOI 10.1002/jlb.51.5.484; SASAKI M, 1991, LIPIDS, V26, P1209, DOI 10.1007/BF02536533; SEINFELD JH, 1989, SCIENCE, V243, P745, DOI 10.1126/science.243.4892.745; SELAK MA, 1989, J LIPID MEDIATOR, V1, P125; SHERRY B, 1988, J CELL BIOL, V107, P1269, DOI 10.1083/jcb.107.4.1269; SPENCER DA, 1992, CLIN EXP ALLERGY, V22, P521, DOI 10.1111/j.1365-2222.1992.tb00160.x; STEWART AG, 1988, BRIT J PHARMACOL, V94, P1225, DOI 10.1111/j.1476-5381.1988.tb11642.x; SUGIURA T, 1991, LIPIDS, V26, P974, DOI 10.1007/BF02536487; TAN WC, 1992, AM REV RESPIR DIS, V146, P916, DOI 10.1164/ajrccm/146.4.916; TERASHITA Z, 1985, EUR J PHARMACOL, V109, P257, DOI 10.1016/0014-2999(85)90427-3; ZHOU WG, 1992, AM J PATHOL, V140, P971	53	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19165	19168						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8396125				2022-12-25	WOS:A1993LW81900002
J	TAIRA, M; HOCKMAN, SC; CALVO, JC; TAIRA, M; BELFRAGE, P; MANGANIELLO, VC				TAIRA, M; HOCKMAN, SC; CALVO, JC; TAIRA, M; BELFRAGE, P; MANGANIELLO, VC			MOLECULAR-CLONING OF THE RAT ADIPOCYTE HORMONE-SENSITIVE CYCLIC GMP-INHIBITED CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP PHOSPHODIESTERASE; FAT-CELLS; AMP PHOSPHODIESTERASE; INSULIN; LIPOLYSIS; TISSUE	Two distinct but related cGMP-inhibited cyclic nucleotide phosphodiesterase (cGI PDE) cDNAs were cloned from rat adipose tissue cDNA libraries. The open reading frame (3324 base pairs) of RcGIP1 encodes 1108 amino acids, including a hydrophobic membrane-association domain in the NH2-terminal portion and, in the COOH-terminal portion, a putative catalytic domain conserved among all mammalian PDEs which is preceded by a putative regulatory domain that contains three consensus cAMP-dependent protein kinase phosphorylation sites and followed by a hydrophilic COOH-terminal domain. The carboxyl-terminal portion including the conserved domain was expressed as a glutathione S-transferase fusion protein and exhibited cAMP PDE activity which was inhibited by cilostamide, a specific cGI PDE inhibitor. RcGIP1 cDNA hybridizes strongly with RNA from isolated adipocytes, and its mRNA increases dramatically during differentiation of 3T3-L1 adipocytes. The deduced sequence of the second partial cDNA clone (RcGIP2 clone 53B) is highly homologous to the corresponding region of human cardiac cGI PDE cDNA. RcGIP2 cDNA hybridized strongly with rat cardiac tissue RNA and weakly if at all with RNA from rat adipocytes or 3T3-L1 fibroblasts or adipocytes. We suggest that RcGIP1 represents the hormone-sensitive, membrane-associated rat adipocyte cGI PDE and RcGIP2, a cGI PDE from vascular elements in rat adipose tissue.	NIDR, BONE RES BRANCH, BETHESDA, MD 20892 USA; NICHHD, MOLEC GENET LAB, BETHESDA, MD 20892 USA; CHIBA UNIV, SCH MED, DEPT INTERNAL MED 2, CHIBA 280, JAPAN; CHIBA UNIV, SCH MED, DEPT BIOCHEM, CHIBA 280, JAPAN; LUND UNIV, SCH MED, DEPT PHYSIOL CHEM, S-22100 LUND, SWEDEN	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Chiba University; Chiba University; Lund University	TAIRA, M (corresponding author), NHLBI, CELLULAR METAB LAB, RM 5N-307, BLDG 10, BETHESDA, MD 20892 USA.							BEEBE SJ, 1985, J BIOL CHEM, V260, P5781; BELFRAGE P, 1986, MECHANISMS INSULIN A, P323; BODE DC, 1991, CIRC RES, V68, P1070, DOI 10.1161/01.RES.68.4.1070; BRONSTEIN I, 1989, J BIOLUM CHEMILUM, V4, P99, DOI 10.1002/bio.1170040116; Charbonneau H., 1990, CYCLIC NUCLEOTIDE PH, P267; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CONTI M, 1991, ENDOCR REV, V12, P218, DOI 10.1210/edrv-12-3-218; DEGERMAN E, 1990, P NATL ACAD SCI USA, V87, P533, DOI 10.1073/pnas.87.2.533; DEGERMAN E, 1987, J BIOL CHEM, V262, P5797; FRANCIS SH, 1982, MOL CELL BIOCHEM, V42, P109; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GETTYS TW, 1988, J BIOL CHEM, V248, P7417; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HOUSLAY MD, 1990, CYCLIC NUCLEOTIDE PH, P185; JIN SLC, 1992, J BIOL CHEM, V267, P18929; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LINDGREN S, 1991, BIOCHEM PHARMACOL, V42, P545, DOI 10.1016/0006-2952(91)90317-X; MAKINO H, 1980, J BIOL CHEM, V255, P7850; Manganiello V.C., 1990, CYCLIC NUCLEOTIDE PH, P87; MANGANIELLO VC, 1991, ADV EXP MED BIOL, V293, P239; MANGANIELLO VC, 1986, MECHANISMS INSULIN A, P147; MEACCI E, 1992, P NATL ACAD SCI USA, V89, P3721, DOI 10.1073/pnas.89.9.3721; PAWLSON LG, 1974, P NATL ACAD SCI USA, V71, P1639, DOI 10.1073/pnas.71.5.1639; SCHMITZPEIFFER C, 1992, CELL SIGNAL, V4, P37, DOI 10.1016/0898-6568(92)90006-T; SHIBATA H, 1990, BIOCHEM BIOPH RES CO, V167, P614, DOI 10.1016/0006-291X(90)92069-C; SMITH CJ, 1989, MOL PHARMACOL, V35, P381; SMITH CJ, 1991, J BIOL CHEM, V266, P13385; VAUGHAN M, 1961, J LIPID RES, V2, P293; ZINMAN B, 1974, J BIOL CHEM, V249, P2182	30	117	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18573	18579						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8395509				2022-12-25	WOS:A1993LV65900033
J	SCHRADER, M; BENDIK, I; BECKERANDRE, M; CARLBERG, C				SCHRADER, M; BENDIK, I; BECKERANDRE, M; CARLBERG, C			INTERACTION BETWEEN RETINOIC ACID AND VITAMIN-D SIGNALING PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN OSTEOCALCIN GENE; THYROID-HORMONE; X-RECEPTOR; 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR; NUCLEAR RECEPTORS; RESPONSE ELEMENTS; DNA-BINDING; RXR-ALPHA; PROTEIN; BETA	The nuclear signaling pathways for retinoids and vitamin D differ in the specificity of the respective receptors for response elements. Two pathways for the action of both retinoic acid receptors (RARs) and vitamin D receptors (VDRs) have been identified, one being retinoid X receptor (RXR)-dependent and the other being RXR-independent. Moreover, RXRs were found to function as homodimers. In several steps we converted the retinoid specific response element of the human retinoic acid receptor beta promoter into the vitamin D/retinoic acid response element of the human osteocalcin promoter. We found that VDR homodimers only bind to the motif RGGTGA. The extended osteocalcin element also contains an imperfect direct repeat based on the motif RGGTGA spaced by three nucleotides, which is bound by RXR homodimers and activated by 9-cis-retinoic acid. The responsiveness of the osteocalcin element to all-trans-retinoic acid is mediated neither by RAR homodimers nor by RAR-RXR heterodimers. However, a VDR-RAR heterodimer binds to the osteocalcin response element and mediates activation by all-trans-retinoic acid. This heterodimer also binds to pure retinoid response elements, but it does not mediate activation by vitamin D alone. In combination with all-trans-retinoic acid, however, vitamin D enhances VDR-RAR heterodimer-mediated gene expression. This finding suggests a direct interaction between nuclear signaling by retinoic acid and vitamin D increasing the combinatorial possibilities for gene regulation by the nuclear receptors involved.	HOP CANTONAL UNIV,DERMATOL CLIN,CH-1211 GENEVA 14,SWITZERLAND; LA JOLLA CANC RES FDN,CTR CANC,LA JOLLA,CA 92037; GLAXO INST MOLEC BIOL,CH-1228 PLAN LES OUATES,SWITZERLAND	University of Geneva; Sanford Burnham Prebys Medical Discovery Institute; GlaxoSmithKline			Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1993, NATURE, V361, P590, DOI 10.1038/361590a0; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; NORMAN AW, 1992, J STEROID BIOCHEM, V41, P231, DOI 10.1016/0960-0760(92)90349-N; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; OZONO K, 1990, J BIOL CHEM, V265, P21881; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; ROSS TK, 1992, P NATL ACAD SCI USA, V89, P256, DOI 10.1073/pnas.89.1.256; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHRADER M, 1993, NUCLEIC ACIDS RES, V21, P1231, DOI 10.1093/nar/21.5.1231; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SONE T, 1991, MOL ENDOCRINOL, V5, P1578, DOI 10.1210/mend-5-11-1578; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	38	160	160	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17830	17836						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8394351				2022-12-25	WOS:A1993LT74300031
J	BLOUNT, P; KRAUSE, JE				BLOUNT, P; KRAUSE, JE			FUNCTIONAL NONEQUIVALENCE OF STRUCTURALLY HOMOLOGOUS DOMAINS OF NEUROKININ-1 AND NEUROKININ-2 TYPE TACHYKININ RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTANCE-P RECEPTOR; HAMSTER OVARY CELLS; CYCLIC-AMP LEVELS; MOLECULAR CHARACTERIZATION; MAMMALIAN TACHYKININ; PHOSPHATIDYLINOSITOL HYDROLYSIS; INOSITOL PHOSPHOLIPIDS; ADENYLATE-CYCLASE; K RECEPTOR; RAT-BRAIN	The neurokinin-1 (NK-1) and neurokinin-2 (NK-2) receptors are both members of the tachykinin receptor family. Although both receptors bind peptide ligands synthesized from common precursors and activate inositol 1,4,5-triphosphate and cAMP responses, differences between these receptors have been observed in the extent and kinetics of agonist-induced responses. Here, to test if structurally homologous domains of the NK-1 and NK-2 receptors are functionally distinct, stably transfected Chinese hamster ovary (CHO) cell lines expressing receptors that had either their putative third cytoplasmic loop (C3) or carboxyl tail (CT) domains replaced with the equivalent domain of the other receptor were compared with stably transfected CHO cell lines expressing wild-type receptors. Radioligand binding demonstrated that each of these chimeric receptors had agonist binding affinities indistinguishable from wild-type receptors. However, not all chimeric receptors were equivalent in their ability to stimulate inositol phospholipid turnover and cAMP production. The data suggest that the NK-1 C3 and the NK-2 CT domains play important roles in G-protein activation that cannot be replaced by the analogous domain of the other receptor. The characterization of CHO cell lines expressing truncated forms of both receptors supported the hypothesis that the CT domain of the NK-2, but not the NK-1, receptor plays a critical role in G-protein activation. The data suggest a potential mechanism for the differences observed in response characteristics in tissues expressing NK-1 and NK-2 receptors and demonstrate that the mechanisms whereby highly homologous receptors activate G-proteins can be different.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,BOX 8108,660 S EUCLID AVE,ST LOUIS,MO 63110	Washington University (WUSTL)					NINDS NIH HHS [NS29343, NS21937, NS07129] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS029343, R55NS021937, R01NS021937] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DUFFY MJ, 1975, BIOCHIM BIOPHYS ACTA, V385, P275, DOI 10.1016/0304-4165(75)90355-4; ENGLAND BP, 1991, FEBS LETT, V279, P87, DOI 10.1016/0014-5793(91)80257-4; ERSPAMER CF, 1980, N-S ARCH PHARMACOL, V311, P61; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANLEY MR, 1980, MOL PHARMACOL, V18, P78; HELKE CJ, 1990, FASEB J, V4, P1606, DOI 10.1096/fasebj.4.6.1969374; HERSHEY AD, 1991, J BIOL CHEM, V266, P4366; HERSHEY AD, 1990, SCIENCE, V247, P958, DOI 10.1126/science.2154852; HERSHEY AD, 1991, THESIS WASHINGTON U; HUNTER JC, 1985, BIOCHEM BIOPH RES CO, V127, P616, DOI 10.1016/S0006-291X(85)80205-9; INGI T, 1991, J PHARMACOL EXP THER, V259, P968; Innis MA, 1990, PCR PROTOCOLS GUIDE; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; KRAUSE JE, 1989, BIOESSAYS, V10, P62, DOI 10.1002/bies.950100207; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LEE CM, 1982, N-S ARCH PHARMACOL, V318, P281, DOI 10.1007/BF00501166; LUBERNAROD J, 1990, EUR J PHARM-MOLEC PH, V188, P185, DOI 10.1016/0922-4106(90)90001-E; MACDONALD MR, 1989, J BIOL CHEM, V264, P15578; MACDONALD SG, 1989, J NEUROCHEM, V53, P264, DOI 10.1111/j.1471-4159.1989.tb07323.x; MAGGIO JE, 1988, ANNU REV NEUROSCI, V11, P13, DOI 10.1146/annurev.neuro.11.1.13; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P6468; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; NAKANISHI S, 1987, PHYSIOL REV, V67, P1117, DOI 10.1152/physrev.1987.67.4.1117; NAKANISHI S, 1991, ANNU REV NEUROSCI, V14, P123, DOI 10.1146/annurev.ne.14.030191.001011; NARUMI S, 1978, J NEUROCHEM, V30, P1321, DOI 10.1111/j.1471-4159.1978.tb10462.x; NAWA H, 1984, LIFE SCI, V34, P1153, DOI 10.1016/0024-3205(84)90087-0; QUIK M, 1978, BIOCHEM PHARMACOL, V27, P2209, DOI 10.1016/0006-2952(78)90079-5; QUIRION R, 1988, REGUL PEPTIDES, V22, P18, DOI 10.1016/0167-0115(88)90245-5; SACHAIS BS, 1993, J BIOL CHEM, V268, P2319; SASAI Y, 1989, BIOCHEM BIOPH RES CO, V165, P695, DOI 10.1016/S0006-291X(89)80022-1; SCATCHARD G, 1957, J AM CHEM SOC, V79, P12, DOI 10.1021/ja01558a003; SUGIYA H, 1987, BIOCHEM J, V244, P647, DOI 10.1042/bj2440647; SURPRENANT A, 1992, SCIENCE, V257, P977, DOI 10.1126/science.1354394; TACHADO SD, 1991, EXP EYE RES, V53, P729, DOI 10.1016/0014-4835(91)90108-Q; TAKEDA Y, 1992, J NEUROCHEM, V59, P740, DOI 10.1111/j.1471-4159.1992.tb09430.x; TAKEDA Y, 1991, BIOCHEM BIOPH RES CO, V179, P1232, DOI 10.1016/0006-291X(91)91704-G; TAKEDA Y, 1990, REGUL PEPTIDES, V28, P323, DOI 10.1016/0167-0115(90)90030-Z; WATSON SP, 1984, BIOCHEM PHARMACOL, V33, P3733, DOI 10.1016/0006-2952(84)90033-9; WONG SKF, 1990, J BIOL CHEM, V265, P6219; WU DQ, 1992, J BIOL CHEM, V267, P1811; YAMASHITA K, 1983, LIFE SCI, V32, P2163, DOI 10.1016/0024-3205(83)90106-6; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	50	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16388	16395						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8393861				2022-12-25	WOS:A1993LQ33600046
J	KNOWLTON, KU; MICHEL, MC; ITANI, M; SHUBEITA, HE; ISHIHARA, K; BROWN, JH; CHIEN, KR				KNOWLTON, KU; MICHEL, MC; ITANI, M; SHUBEITA, HE; ISHIHARA, K; BROWN, JH; CHIEN, KR			THE ALPHA-1A-ADRENERGIC RECEPTOR SUBTYPE MEDIATES BIOCHEMICAL, MOLECULAR, AND MORPHOLOGIC FEATURES OF CULTURED MYOCARDIAL-CELL HYPERTROPHY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATRIAL-NATRIURETIC-FACTOR; MYOSIN LIGHT CHAIN-2; PROTEIN-KINASE-C; ALPHA-ADRENERGIC STIMULATION; INOSITOL PHOSPHATE FORMATION; CARDIAC GENE-EXPRESSION; PHOSPHATIDYLINOSITOL HYDROLYSIS; ALPHA-1B-ADRENERGIC RECEPTOR; VENTRICULAR MYOCYTES; IDENTIFICATION	Alpha1-adrenergic agonists induce a hypertrophic phenotype in cultured neonatal rat ventricular myocytes. Quantifiable markers of this phenotype include stimulation of phosphoinositide hydrolysis, transcriptional induction of atrial natriuretic factor (ANF) gene expression, and an increase in myocardial cell size. The aim of the present work was to determine which al-adrenergic receptor subtype mediates the acquisition of these parameters of myocardial cell hypertrophy. Phosphoinositide hydrolysis is inhibited by low concentrations of 5-methylurapidil (log K(i) = -8.7) and (+)-niguldipine (log K(i) = -10.6). The alpha-adrenergic receptor-induced increase in transcriptional activation of an ANF luciferase reporter gene is inhibited over the same range of concentrations of 5-methylurapidil (log K(i) = -8.2) and (+)-niguldipine (log K(i) = -11.2) that inhibit phosphoinositide hydrolysis. In addition, the increase in cell size that accompanies alpha-adrenergic receptor stimulation of cultured ventricular myocytes is blocked by similar concentrations of 5-methylurapidil (log K(i) = -8.0) and (+)-niguldipine (log K(i) = -10.6). In contrast, treatment with the alpha1B selective antagonist chlorethylclonidine at a concentration of 10 muM had no effect on the adrenergically mediated induction of ANF luciferase reporter gene expression or the adrenergically induced increase in myocardial cell size. These findings demonstrate that pharmacologically identifiable alpha1-adrenergic receptors mediate not only the early effects of alpha1-adrenergic stimulation such as phosphoinositide hydrolysis, but that they activate the signaling pathways that control transcriptional induction of the ANF luciferase reporter gene and an increase in myocardial cell size. Studies using alpha1-adrenergic receptor cDNAs to delineate and alter the direct interaction of this receptor subtype with proximal signaling molecules, e.g. GTP binding proteins, should provide a powerful means of assessing their role in the induction of the molecular and morphologic parameters of myocardial cell hypertrophy.	UNIV CALIF SAN DIEGO, SCH MED, DEPT MED, 0613-C, 9500 GILMAN DR, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; UNIV ESSEN GESAMTHSCH, DEPT MED, W-4300 ESSEN 1, GERMANY	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Duisburg Essen					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045069, R01HL036139] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46435, HL-45069, HL-36139] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; ARGENTIN S, 1985, J BIOL CHEM, V260, P4568; BENFEY BG, 1990, LIFE SCI, V46, P743, DOI 10.1016/0024-3205(90)90062-V; BOER R, 1989, EUR J PHARM-MOLEC PH, V172, P131, DOI 10.1016/0922-4106(89)90004-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN JH, 1985, CIRC RES, V57, P532, DOI 10.1161/01.RES.57.4.532; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHERRINGTON JM, 1989, J VIROL, V63, P1435, DOI 10.1128/JVI.63.3.1435-1440.1989; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHIEN KR, 1993, SCIENCE, V260, P916, DOI 10.1126/science.8493528; CLARK MG, 1984, J BIOL CHEM, V259, P5204; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DELBALZO U, 1990, CIRC RES, V67, P1535, DOI 10.1161/01.RES.67.6.1535; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ENDOH M, 1991, ASIA PAC J PHARMACOL, V6, P171; GROSS G, 1988, EUR J PHARMACOL, V151, P333, DOI 10.1016/0014-2999(88)90819-9; GROSS G, 1989, EUR J PHARMACOL, V169, P325, DOI 10.1016/0014-2999(89)90032-0; HAN C, 1990, MOL PHARMACOL, V37, P903; HANFT G, 1990, BRIT J CLIN PHARMACO, V30, pS125, DOI 10.1111/j.1365-2125.1990.tb05482.x; HENDERSON SA, 1988, NUCLEIC ACIDS RES, V16, P4722, DOI 10.1093/nar/16.10.4722; IWAKI K, 1990, J BIOL CHEM, V265, P13809; JONES LG, 1988, CIRC RES, V62, P299, DOI 10.1161/01.RES.62.2.299; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; LAMORTE VJ, 1992, CIRCULATION, V86, P764; LEE HR, 1988, J BIOL CHEM, V263, P7352; LOMASNEY JW, 1991, J BIOL CHEM, V266, P6365; MICHEL MC, 1993, N-S ARCH PHARMACOL, V347, P180; MICHEL MC, 1990, N-S ARCH PHARMACOL, V341, P385; MICHEL MC, 1992, PHARMACOL TOXICOL, V70, pS1, DOI 10.1111/j.1600-0773.1992.tb01615.x; MINNEMAN KP, 1988, PHARMACOL REV, V40, P87; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; PUCEAT M, 1992, TRENDS PHARMACOL SCI, V13, P263, DOI 10.1016/0165-6147(92)90080-P; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SCHWINN DA, 1992, EUR J PHARM-MOLEC PH, V227, P433, DOI 10.1016/0922-4106(92)90162-O; SEI CA, 1991, J BIOL CHEM, V266, P15910; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; TERMAN BI, 1990, MOL PHARMACOL, V37, P526; TERZIC A, 1992, J PHYSIOL-LONDON, V447, P275, DOI 10.1113/jphysiol.1992.sp019002; THORBURN A, 1993, J BIOL CHEM, V268, P2244; WILSON KM, 1990, J BIOL CHEM, V265, P17601; WILSON KM, 1990, MOL PHARMACOL, V38, P274; WU DQ, 1992, J BIOL CHEM, V267, P25798	48	261	266	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15374	15380						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8393439				2022-12-25	WOS:A1993LN30500012
J	DIGHE, AS; FARRAR, MA; SCHREIBER, RD				DIGHE, AS; FARRAR, MA; SCHREIBER, RD			INHIBITION OF CELLULAR RESPONSIVENESS TO INTERFERON-GAMMA (IFN-GAMMA) INDUCED BY OVEREXPRESSION OF INACTIVE FORMS OF THE IFN-GAMMA RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHROMOSOME-21; EXPRESSION; PURIFICATION; CDNA; CLONING; ANTIBODIES; CELLS; IDENTIFICATION; SENSITIVITY; SYSTEM	Herein, we report that overexpression of either human or murine interferon-gamma (IFNgamma) receptors lacking their entire intracellular domains in cells bearing functionally active IFNgamma receptors ablates responsiveness to homologous ligand in a dominant negative manner. Unresponsiveness could also be induced in murine cells overexpressing murine IFNgamma receptor mutants that either lack 39 COOH-terminal amino acids or contain an alanine substitution for a functionally critical tyrosine. Overexpression of the full-length receptor did not alter cellular responsiveness to IFNgamma. The inhibitory activities of the receptor mutants were dose-dependent, generalizable to a variety of cellular responses, and specific. Cells expressing 100:1 ratios of mutant to wild-type receptor were unresponsive to IFNgamma even at doses 30,000 times greater than that required to induce a maximal response in wild-type cells. These results provide an example of a dominant negative mutation that effects the complete inactivation of a transmembrane receptor lacking a kinase domain and suggest a more general utility for dominant negative mutations in the study of cytokine receptor function.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,BOX 8118,660 S EUCLID AVE,ST LOUIS,MO 63110	Washington University (WUSTL)			Schreiber, Robert D/A-1276-2013; Dighe, Anand/AAP-9640-2020; Schreiber, Robert/Q-7550-2019; Farrar, Michael A/M-7802-2013	Schreiber, Robert D/0000-0001-6311-0432; Schreiber, Robert/0000-0003-1590-2341; Farrar, Michael/0000-0002-5569-0366; Dighe, Anand/0000-0003-4130-0758	NCI NIH HHS [CA43059] Funding Source: Medline; NIAID NIH HHS [AI24854] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA043059, R01CA043059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024854] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGUET M, 1987, J EXP MED, V165, P988, DOI 10.1084/jem.165.4.988; AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BASU MT, 1988, P NATL ACAD SCI USA, V85, P6282, DOI 10.1073/pnas.85.17.6282; CALDERON J, 1988, P NATL ACAD SCI USA, V85, P4837, DOI 10.1073/pnas.85.13.4837; CELADA A, 1985, J CLIN INVEST, V76, P2196, DOI 10.1172/JCI112228; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; COFANO F, 1990, J BIOL CHEM, V265, P4064; COX DR, 1985, ANN NY ACAD SCI, V450, P169, DOI 10.1111/j.1749-6632.1985.tb21491.x; FARRAR MA, 1991, J BIOL CHEM, V266, P19626; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FISCHER T, 1990, Cytokine, V2, P157, DOI 10.1016/1043-4666(90)90010-Q; FOUNTOULAKIS M, 1990, J BIOL CHEM, V265, P19758; FOUNTOULAKIS M, 1992, EUR J BIOCHEM, V208, P781, DOI 10.1111/j.1432-1033.1992.tb17248.x; GRAY PW, 1989, P NATL ACAD SCI USA, V86, P8497, DOI 10.1073/pnas.86.21.8497; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HEMMI S, 1989, P NATL ACAD SCI USA, V86, P9901, DOI 10.1073/pnas.86.24.9901; HERSHEY GKK, 1989, J BIOL CHEM, V264, P11981; HIBINO Y, 1991, J BIOL CHEM, V266, P6948; JUNG V, 1988, SOMAT CELL MOLEC GEN, V14, P583, DOI 10.1007/BF01535312; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KUMAR CS, 1989, J BIOL CHEM, V264, P17939; LECLAIRE RD, 1992, J LEUKOCYTE BIOL, V51, P507, DOI 10.1002/jlb.51.5.507; MUNRO S, 1989, P NATL ACAD SCI USA, V86, P9248, DOI 10.1073/pnas.86.23.9248; NOVICK D, 1987, J BIOL CHEM, V262, P8483; RAZIUDDIN A, 1984, P NATL ACAD SCI-BIOL, V81, P5504, DOI 10.1073/pnas.81.17.5504; Sambrook J, 1989, MOL CLONING LABORATO; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHREIBER RD, 1983, J IMMUNOL, V131, P826; SHEEHAN KCF, 1988, J IMMUNOL, V140, P4231; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; VILCEK J, 1985, LYMPHOKINES, V11, P1	39	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10645	10653						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8387525				2022-12-25	WOS:A1993LB80000095
J	SARTORIUS, CA; TUNG, L; TAKIMOTO, GS; HORWITZ, KB				SARTORIUS, CA; TUNG, L; TAKIMOTO, GS; HORWITZ, KB			ANTAGONIST-OCCUPIED HUMAN PROGESTERONE RECEPTORS BOUND TO DNA ARE FUNCTIONALLY SWITCHED TO TRANSCRIPTIONAL AGONISTS BY CAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST-CANCER; STEROID-HORMONE RECEPTORS; 5' FLANKING REGION; GLUCOCORTICOID RECEPTOR; CYCLIC-AMP; NEGATIVE REGULATION; ESTROGEN-RECEPTOR; GENE CONTAINS; GROWTH-FACTOR; T47D CELLS	When steroid hormone antagonists have inappropriate agonist effects, the clinical consequences are grave. Progesterone antagonists bind to two naturally occurring isoforms of human progesterone receptors (hPR), hPR(B) and the NH2-terminally truncated hPR(A), and usually inhibit agonist-stimulated transcription. It is shown here that elevation of cAMP levels in a human breast cancer cell line leads to the functional reversal of progesterone antagonist action. While hPR occupied by the antagonists RU486 and ZK112993 are transcriptionally inactive, the antagonist-occupied receptors become strong activators of transcription in the presence of 8-Br-cAMP. However, this functional switch does not occur with the progesterone antagonist ZK98299, which, unlike RU486 and ZK112993, is unable to induce hPR binding to DNA. This suggests that the 8-Br-cAMP-induced transcriptional reversal requires that the antagonist-occupied receptors be bound to DNA. Even with agonist-occupied hPR, addition of 8-Br-cAMP results in a synergistic increase in transcriptional activity. When hPR(A) alone are transiently expressed in COS-1 cells, transcription of a reporter gene is stimulated by the agonist R5020 and by 8-Br-cAMP and is synergistic when both are present; but the 8-Br-cAMP-dependent component of transcription proceeds in the absence of hPR(A), in the absence of the progesterone response element, and in the presence of a DNA-binding domain mutant of hPR(A) that cannot bind to the progesterone response element. Additionally, under the intracellular conditions in which 8-Br-cAMP activates antagonist-hPR complexes, there is no protein kinase A-mediated phosphorylation of the receptors. We discuss a model in which a gene that is independently transcribed by cAMP-responsive factors and by hPR can be selected for positive or negative regulation on the transcription complex due to additive or cooperative interactions between the two DNA-bound factors.	UNIV COLORADO,HLTH SCI CTR,DEPT MED,BOX B151,4200 E 9TH AVE,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PATHOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,MOLEC BIOL PROGRAM,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Horwitz, Kathryn/0000-0001-7402-6455	NATIONAL CANCER INSTITUTE [R01CA055595, R01CA026869, R37CA026869] Funding Source: NIH RePORTER; NCI NIH HHS [CA26869, CA55595] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ARONICA SM, 1991, ENDOCRINOLOGY, V128, P2045, DOI 10.1210/endo-128-4-2045; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BECK CA, 1992, MOL ENDOCRINOL, V6, P607, DOI 10.1210/me.6.4.607; BOWDEN RT, 1989, ENDOCRINOLOGY, V124, P2642, DOI 10.1210/endo-124-5-2642; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; ELASHRY D, 1989, MOL ENDOCRINOL, V3, P1545, DOI 10.1210/mend-3-10-1545; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAVANIS A, 1985, J CLIN ENDOCR METAB, V60, P156, DOI 10.1210/jcem-60-1-156; GRUOL DJ, 1986, J BIOL CHEM, V261, P4909; HENDERSON IC, 1989, CANCER PRINCIPLES PR, P1252; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; HORWITZ KB, 1983, ENDOCRINOLOGY, V113, P2195, DOI 10.1210/endo-113-6-2195; HORWITZ KB, 1978, CANCER RES, V38, P2434; HORWITZ KB, 1978, J BIOL CHEM, V253, P2223; HORWITZ KB, 1992, ENDOCR REV, V13, P146, DOI 10.1210/er.13.2.146; HORWITZ KB, 1982, CELL, V28, P633, DOI 10.1016/0092-8674(82)90218-5; HYMAN SE, 1988, MOL CELL BIOL, V8, P4225, DOI 10.1128/MCB.8.10.4225; JAMESON JL, 1988, J BIOL CHEM, V263, P9879; KASTNER P, 1990, J BIOL CHEM, V265, P12163; KEYDAR I, 1979, EUR J CANCER, V15, P659, DOI 10.1016/0014-2964(79)90139-7; KLEINHITPASS L, 1991, NUCLEIC ACIDS RES, V19, P1227, DOI 10.1093/nar/19.6.1227; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; LEGAULTPOISSON S, 1979, CANCER TREAT REP, V63, P1839; LOVE RR, 1990, JNCI-J NATL CANCER I, V82, P1327, DOI 10.1093/jnci/82.16.1327; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; MCGUIRE WL, 1987, BREAST CANCER RES TR, V9, P165, DOI 10.1007/BF01806377; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; NEEF G, 1984, STEROIDS, V44, P349, DOI 10.1016/S0039-128X(84)80027-6; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; PHILIBERT D, 1981, 8 INT C PHARM TOK; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; RINGOLD GM, 1975, CELL, V6, P299, DOI 10.1016/0092-8674(75)90181-6; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SHERIDAN PL, 1989, J BIOL CHEM, V264, P6520; SHERIDAN PL, 1989, J BIOL CHEM, V264, P7054; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; TAKIMOTO GS, 1991, J STEROID BIOCHEM, V39, P687, DOI 10.1016/0960-0760(91)90368-F; TAKIMOTO GS, 1992, P NATL ACAD SCI USA, V89, P300; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TURNER RT, 1987, J BONE MINER RES, V2, P449	49	175	175	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9262	9266						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8387487				2022-12-25	WOS:A1993LA68900020
J	SMRCKA, AV; STERNWEIS, PC				SMRCKA, AV; STERNWEIS, PC			REGULATION OF PURIFIED SUBTYPES OF PHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE-C BETA BY G-PROTEIN ALPHA-SUBUNIT AND BETA-GAMMA-SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE; BOVINE BRAIN; IMMUNOLOGICAL IDENTIFICATION; AFFINITY-CHROMATOGRAPHY; MULTIPLE FORMS; ACTIVATION; RECEPTOR; GTP; PHOSPHORYLATION; STIMULATION	Specific antisera were produced to peptides representing the carboxyl termini of three subtypes of phosphatidylinositol-specific phospholipase C (PIPLC) beta which have been identified by isolation of cDNAs (Kriz, R., Lin, L., Sultzman, L., Ellis, C., Heldin, C., Pawson, T., and Knopf, J. (1990) Ciba Found. Symp. 150, 112-127). Screening with the antisera indicates that PIPLC beta3 is present in a variety of cell lines and rat tissues, whereas the distribution of PIPLC beta1 and beta2 is more restricted. A combination of conventional and immunoaffinity chromatographic techniques was used to purify PIPLC beta1 and beta3 from rat brain membranes. PIPLC beta2 was purified from cytosol of HL60 cells. All three subtypes were activated by purified G protein alpha(q/11) subunits with the following relative efficacies: PIPLC beta3 greater-than-or-equal-to PIPLC beta1 >> PIPLC beta2. All three PIPLC subtypes were also activated by G protein betagamma subunits with varying efficacies. The presence of betagamma subunits depressed the ability of alpha(q/11) to activate PIPLC beta1 and beta3 at low Mg2+ concentrations (1 mM). At higher concentrations of Mg2+ (2 mM or greater), activation of PIPLC beta3, but not PIPLC beta1, by betagamma and alpha(q/11) became additive. PIPLC beta3 was activated by alpha(q/11) even in the presence of a saturating concentration of betagamma subunits. This indicates that there are separate sites for interaction of PIPLCs with G protein subunits and that this interaction differs depending on the enzyme subtype and the concentration of Mg2+.	UNIV TEXAS, SW MED CTR, SW GRAD SCH BIOMED SCI, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014489, R01GM031954] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM31954, S32-GM14489] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BLANK JL, 1992, J BIOL CHEM, V267, P23069; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KATAN M, 1988, CELL, V54, P171, DOI 10.1016/0092-8674(88)90549-1; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KRIZ R, 1990, CIBA F SYMP, V150, P112; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CH, 1992, J BIOL CHEM, V267, P16044; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; LOGOTHETIS DE, 1988, P NATL ACAD SCI USA, V85, P5814, DOI 10.1073/pnas.85.16.5814; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MUMBY S, 1988, J BIOL CHEM, V263, P2020; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PANG IH, 1990, J BIOL CHEM, V265, P18707; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; PARK D, 1992, J BIOL CHEM, V267, P16048; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1991, BIOCHEM SOC T, V19, P337, DOI 10.1042/bst0190337; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, J BIOL CHEM, V263, P14497; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WANGE RL, 1991, J BIOL CHEM, V266, P11409	39	410	410	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9667	9674						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8387502				2022-12-25	WOS:A1993LA68900077
J	SUGASAWA, K; MASUTANI, C; HANAOKA, F				SUGASAWA, K; MASUTANI, C; HANAOKA, F			CELL-FREE REPAIR OF UV-DAMAGED SIMIAN VIRUS-40 CHROMOSOMES IN HUMAN CELL-EXTRACTS .1. DEVELOPMENT OF A CELL-FREE SYSTEM DETECTING EXCISION REPAIR OF UV-IRRADIATED SV40 CHROMOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMINE DIMER EXCISION; NUCLEOSOME CORE DNA; PYRIMIDINE DIMERS; HUMAN-FIBROBLASTS; ACTIVE GENE; DHFR GENE; CHO CELLS; REPLICATION; INITIATION; CHROMATIN	Simian virus 40 minichromosomes were irradiated with ultraviolet light and used to study cell-free DNA repair reactions by soluble extracts of repair-proficient human cells. Damage-specific incorporation of labeled nucleotides was measured after linearization and electrophoresis of the viral DNA. Repair synthesis with irradiated chromosomes was dependent on the dose of ultraviolet light, but naked viral DNA irradiated at the same doses showed significantly higher template activity. The reactions absolutely required the presence of cell extract, but an extract from Chinese hamster cells was as active as those from human cells. The repair activity was apparently stimulated by the addition of unirradiated plasmid DNA, which did not affect the nucleosome density of the viral chromosomes. ATP and its regenerating system were required for the reaction, but total repair synthesis was little affected by exogenous addition of substrates for RNA synthesis and poly(ADP-ribosyl)ation. Most of the repaired viral chromosomal DNA was in the supercoiled, closed circular form, suggesting that excision repair reactions proceeded to the stage of ligation in the present cell-free system.	INST PHYS & CHEM RES, CELLULAR PHYSIOL LAB, 2-1 HIROSAWA, WAKO, SAITAMA 35101, JAPAN; INST PHYS & CHEM RES, BIODESIGN RES GRP, WAKO, SAITAMA 35101, JAPAN	RIKEN; RIKEN			Masutani, Chikahide/I-6160-2014	Masutani, Chikahide/0000-0002-8600-8227				[Anonymous], 1985, DNA REPAIR; BANERJEE S, 1990, MOL CELL BIOL, V10, P2863, DOI 10.1128/MCB.10.6.2863; BIGGERSTAFF M, 1992, J BIOL CHEM, V267, P6879; BIGGERSTAFF M, 1991, MUTAT RES, V254, P217, DOI 10.1016/0921-8777(91)90059-X; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRISTIANSEN G, 1977, J VIROL, V21, P1079, DOI 10.1128/JVI.21.3.1079-1084.1977; DECKER RS, 1987, J BIOL CHEM, V262, P10863; DRESLER SL, 1983, J BIOL CHEM, V258, P2269; ERDILE LF, 1991, COLD SH Q B, V56, P303; FRIEDBERG EC, 1991, BIOESSAYS, V13, P295, DOI 10.1002/bies.950130607; GALE JM, 1987, P NATL ACAD SCI USA, V84, P6644, DOI 10.1073/pnas.84.19.6644; GALE JM, 1990, PHOTOCHEM PHOTOBIOL, V51, P411, DOI 10.1111/j.1751-1097.1990.tb01732.x; GALE JM, 1988, J MOL BIOL, V204, P949, DOI 10.1016/0022-2836(88)90054-X; HAY RT, 1982, CELL, V28, P767, DOI 10.1016/0092-8674(82)90056-3; HOEIJMAKERS JHJ, 1990, CANCER CELL-MON REV, V2, P311; ISHIMI Y, 1991, J BIOL CHEM, V266, P16141; KANO Y, 1983, CARCINOGENESIS, V4, P1419, DOI 10.1093/carcin/4.11.1419; KAUFMANN WK, 1987, MUTAT RES, V184, P237, DOI 10.1016/0167-8817(87)90022-8; KRUDE T, 1991, MOL CELL BIOL, V11, P6257, DOI 10.1128/MCB.11.12.6257; LEBOWITZ J, 1976, J VIROL, V18, P205, DOI 10.1128/JVI.18.1.205-210.1976; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MASUTANI C, 1993, J BIOL CHEM, V268, P9105; MATHIS G, 1990, CARCINOGENESIS, V11, P1237, DOI 10.1093/carcin/11.7.1237; MORTELMANS K, 1976, P NATL ACAD SCI USA, V73, P2757, DOI 10.1073/pnas.73.8.2757; OGURA T, 1990, BIOCHEM BIOPH RES CO, V172, P377, DOI 10.1016/0006-291X(90)90683-E; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; Sambrook J, 1989, MOL CLONING LABORATO; SIBGHATULLAH, 1989, NUCLEIC ACIDS RES, V17, P4471, DOI 10.1093/nar/17.12.4471; Smerdon MJ, 1991, CURR OPIN CELL BIOL, V3, P422, DOI 10.1016/0955-0674(91)90069-B; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; SUGASAWA K, 1990, J VIROL, V64, P4820, DOI 10.1128/JVI.64.10.4820-4829.1990; SUGASAWA K, 1992, P NATL ACAD SCI USA, V89, P1055, DOI 10.1073/pnas.89.3.1055; van Holde K.E., 1988, CHROMATIN; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; WANG ZG, 1991, J BIOL CHEM, V266, P22472; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6	37	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9098	9104						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8386176				2022-12-25	WOS:A1993KX81100101
J	GOLDSTEIN, O; ASHER, C; BARBRY, P; CRAGOE, E; CLAUSS, W; GARTY, H				GOLDSTEIN, O; ASHER, C; BARBRY, P; CRAGOE, E; CLAUSS, W; GARTY, H			AN EPITHELIAL HIGH-AFFINITY AMILORIDE-BINDING SITE, DIFFERENT FROM THE NA+ CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOAD URINARY-BLADDER; SODIUM-CHANNELS; H-3 PHENAMIL; MEMBRANE-VESICLES; XENOPUS OOCYTES; TRANSPORT; ANALOGS; PROTEIN; PURIFICATION; ALDOSTERONE	Specific binding of the radioactive amiloride analogues [H-3]phenamil and [H-3]benzamil was studied in plasma membrane from chicken lower intestine. A single population of sites whose affinities and specificities towards pyrazinecarboxamides roughly resemble those of the epithelial Na+ channel, was identified. However, a matched comparison of pyrazinecarboxamide binding and Na+ transport inhibition revealed substantial differences between the high-affinity [H-3] phenamil-binding site detected, and the site whose occupancy by phenamil blocks Na+ transport. First, 5-(N-ethyl-N-isopropyl)-amiloride was found to displace bound [H-3]phenamil at concentrations that are at least 10-fold lower than those needed to block the channel. Second, the rates at which [H-3]phenamil associates and dissociates from this site are lower than the rates at which Na+ channels are inhibited and reactivated, under similar conditions. A site with high affinity to both amiloride and 5-(N-ethyl-N-isopropyl)-amiloride was detected also in membranes from other epithelia. We conclude that tight epithelia contain a major high-affinity amiloride receptor other than the Na+-conducting channel, the Na+/H+ antiport or the Na+/Ca2+ exchanger. This site could be associated with a pool of nonconducting channels, another (but structurally related) channel, or a totally unrelated protein.	WEIZMANN INST SCI, DEPT MEMBRANE RES & BIOPHYS, IL-76100 REHOVOT, ISRAEL; SOPHIA ANTIPOLIS, INST PHARMACOL MOLEC & CELLULAIRE, CNRS, UPR 411, F-06560 VALBONNE, FRANCE; UNIV GIESSEN, INST TIERPHYSIOL, W-6300 GIESSEN, GERMANY	Weizmann Institute of Science; Centre National de la Recherche Scientifique (CNRS); Justus Liebig University Giessen			Barbry, Pascal/O-5021-2016	Barbry, Pascal/0000-0001-9632-6483	NIDDK NIH HHS [DK45255] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045255] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHER C, 1988, AM J PHYSIOL, V254, pC512, DOI 10.1152/ajpcell.1988.254.4.C512; ASHER C, 1987, J BIOL CHEM, V262, P8566; ASHER C, 1992, AM J PHYSIOL, V262, pG244, DOI 10.1152/ajpgi.1992.262.2.G244; ASHER C, 1988, P NATL ACAD SCI USA, V85, P7413, DOI 10.1073/pnas.85.19.7413; ASHER C, 1992, J BIOL CHEM, V267, P16061; BARBRY P, 1986, BIOCHEM BIOPH RES CO, V135, P25, DOI 10.1016/0006-291X(86)90937-X; BARBRY P, 1990, BIOCHEMISTRY-US, V29, P1039, DOI 10.1021/bi00456a028; BARBRY P, 1987, P NATL ACAD SCI USA, V84, P4836, DOI 10.1073/pnas.84.14.4836; BARBRY P, 1989, BIOCHEMISTRY-US, V28, P3744, DOI 10.1021/bi00435a018; BARBRY P, 1990, P NATL ACAD SCI USA, V87, P7347, DOI 10.1073/pnas.87.19.7347; BENOS DJ, 1986, P NATL ACAD SCI USA, V83, P8525, DOI 10.1073/pnas.83.22.8525; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIDGES RJ, 1988, AM J PHYSIOL, V254, pC484, DOI 10.1152/ajpcell.1988.254.4.C484; BRIDGES RJ, 1989, AM J PHYSIOL, V256, pC67, DOI 10.1152/ajpcell.1989.256.1.C67; CLAUSS W, 1988, COMP BIOCHEM PHYS A, V90, P583, DOI 10.1016/0300-9629(88)90671-8; CRAGOE EJ, 1967, J MED CHEM, V10, P66, DOI 10.1021/jm00313a014; CRAGOE EJ, 1981, Patent No. 4246406; CRAGOE EJJ, 1978, Patent No. 4087526; CUTHBERT AW, 1982, PFLUG ARCH EUR J PHY, V392, P347, DOI 10.1007/BF00581630; GARTY H, 1983, J GEN PHYSIOL, V81, P785, DOI 10.1085/jgp.81.6.785; GARTY H, 1985, J BIOL CHEM, V260, P8330; GARTY H, 1983, J MEMBRANE BIOL, V74, P15, DOI 10.1007/BF01870591; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; GARTY H, 1989, METHOD ENZYMOL, V172, P155; GARVIN JL, 1986, J MEMBRANE BIOL, V90, P107, DOI 10.1007/BF01869928; GRTY H, 1983, J BIOL CHEM, V258, P13094; HINTON CF, 1989, AM J PHYSIOL, V257, pC825, DOI 10.1152/ajpcell.1989.257.4.C825; KLEYMAN TR, 1990, METHOD ENZYMOL, V191, P739; KLEYMAN TR, 1989, J BIOL CHEM, V264, P11995; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; LEWIS SA, 1982, NATURE, V297, P685, DOI 10.1038/297685a0; LI JHY, 1985, J MEMBRANE BIOL, V83, P45, DOI 10.1007/BF01868737; LINDEMANN B, 1984, ANNU REV PHYSIOL, V46, P497, DOI 10.1146/annurev.ph.46.030184.002433; LING BN, 1990, MOL CELL BIOCHEM, V99, P141, DOI 10.1007/BF00230344; LING BN, 1989, AM J PHYSIOL, V256, pF1094, DOI 10.1152/ajprenal.1989.256.6.F1094; LOO DDF, 1983, SCIENCE, V221, P1288, DOI 10.1126/science.6612343; MATALON S, 1992, AM J PHYSIOL, V262, pC1228, DOI 10.1152/ajpcell.1992.262.5.C1228; MORAN A, 1988, J BIOL CHEM, V263, P19586; PALMER LG, 1990, J GEN PHYSIOL, V96, P23, DOI 10.1085/jgp.96.1.23; PALMER LG, 1992, ANNU REV PHYSIOL, V54, P51, DOI 10.1146/annurev.ph.54.030192.000411; SARIBANSOHRABY S, 1983, AM J PHYSIOL, V245, pC167, DOI 10.1152/ajpcell.1983.245.3.C167; SMITH PR, 1991, ANNU REV PHYSIOL, V53, P509, DOI 10.1146/annurev.ph.53.030191.002453; WILLS NK, 1991, J MEMBRANE BIOL, V121, P79, DOI 10.1007/BF01870653	43	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7856	7862						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8385123				2022-12-25	WOS:A1993KW97900043
J	OHMORI, H; KUBA, M; KUMON, A				OHMORI, H; KUBA, M; KUMON, A			2 PHOSPHATASES FOR 6-PHOSPHOLYSINE AND 3-PHOSPHOHISTIDINE FROM RAT-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN HISTIDINE KINASE; NUCLEAR PROTEINS; HISTONE H-4; PHOSPHORYLATION; PURIFICATION	6-Phospholysine phosphatase (30 kDa) and 3-phosphohistidine/6-phospholysine phosphatase (150 kDa) were purified partially from rat brain cytosol. The former hydrolyzed 6-phospholysine to inorganic phosphate and lysine, and the K(m) value was 0.83 mM. The latter hydrolyzed 6-phospholysine or 3-phosphohistidine to inorganic phosphate and lysine or histidine, and the K(m) values were 0.78 and 0.38 mM for 6-phospholysine and 3-phosphohistidine, respectively. Moreover, the latter enzyme preparation dephosphorylated AMP, GMP, and p-nitrophenyl phosphate. Substrate specificities of both enzymes were distinct from those of N(omega)-phosphoarginine phosphatase (Kuba, M., Ohmori, H., and Kumon, A. (1992) Eur. J. Biochem. 208, 747-752) and phosphoamidase (EC 3.9.1.1), indicating that there are phosphatases corresponding to N-phosphorylated basic amino acids. The possibility that these enzymes work in vivo as protein phosphatases to regulate the level of N-phosphorylated proteins is discussed.			OHMORI, H (corresponding author), SAGA MED SCH,DEPT BIOCHEM,NABESHIMA 5-1-1,SAGA 849,JAPAN.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN CC, 1977, BIOCHEMISTRY-US, V16, P4852, DOI 10.1021/bi00641a016; Corbin J D, 1974, Methods Enzymol, V38, P287; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FUJIMOTO A, 1962, BIOCHIM BIOPHYS ACTA, V56, P501, DOI 10.1016/0006-3002(62)90602-9; FUJITAKI JM, 1981, BIOCHEMISTRY-US, V20, P3658, DOI 10.1021/bi00515a055; FUJITAKI JM, 1984, METHOD ENZYMOL, V107, P23; HOLZER ME, 1962, BIOCHIM BIOPHYS ACTA, V56, P491, DOI 10.1016/0006-3002(62)90601-7; HUANG JM, 1991, J BIOL CHEM, V266, P9023; HUEBNER VD, 1985, J BIOL CHEM, V260, P6106; HULTQUIST DE, 1966, BIOCHEMISTRY-US, V5, P322, DOI 10.1021/bi00865a041; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KRIVANEK J, 1991, FEBS LETT, V282, P32, DOI 10.1016/0014-5793(91)80438-9; KUBA M, 1992, EUR J BIOCHEM, V208, P747, DOI 10.1111/j.1432-1033.1992.tb17243.x; LEIS JF, 1982, P NATL ACAD SCI-BIOL, V79, P6507, DOI 10.1073/pnas.79.21.6507; MARTIN JB, 1949, ANAL CHEM, V21, P965, DOI 10.1021/ac60032a024; PARVIN R, 1969, BIOCHEMISTRY-US, V8, P1748, DOI 10.1021/bi00832a058; PESIS KH, 1988, FEBS LETT, V239, P151, DOI 10.1016/0014-5793(88)80563-5; ROSENBERG H, 1959, J CHROMATOGR, V2, P487, DOI 10.1016/S0021-9673(01)86331-7; Sheridan R. C., 2007, INORG SYN, P23; SINGER MF, 1957, J BIOL CHEM, V229, P111; SMITH DL, 1973, NATURE, V246, P103, DOI 10.1038/246103a0; SMITH LS, 1976, BIOCHEM BIOPH RES CO, V71, P459, DOI 10.1016/0006-291X(76)90809-3; SUNDARARAJAN TA, 1959, BIOCHEM J, V71, P537, DOI 10.1042/bj0710537; WALLINDER O, 1968, J BIOL CHEM, V243, P3947; WEI YF, 1989, ARCH BIOCHEM BIOPHYS, V268, P546, DOI 10.1016/0003-9861(89)90321-4; WEI YF, 1990, ANAL BIOCHEM, V190, P188, DOI 10.1016/0003-2697(90)90179-D; YOKOYAMA K, 1993, J BIOCHEM-TOKYO, V113, P236, DOI 10.1093/oxfordjournals.jbchem.a124032; ZANDER NF, 1991, BIOCHEMISTRY-US, V30, P6964, DOI 10.1021/bi00242a022; ZETTERQV.O, 1967, BIOCHIM BIOPHYS ACTA, V141, P523, DOI 10.1016/0304-4165(67)90181-X; ZETTERQV.O, 1966, BIOCHIM BIOPHYS ACTA, V113, P520, DOI 10.1016/S0926-6593(66)80010-3; ZETTERQVIST O, 1968, BIOCHIM BIOPHYS ACTA, V136, P279; ZHAO G, 1992, ANAL BIOCHEM, V202, P361	33	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7625	7627						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8385112				2022-12-25	WOS:A1993KW97900007
J	PARK, DG; JHON, DY; LEE, CW; LEE, KH; RHEE, SG				PARK, DG; JHON, DY; LEE, CW; LEE, KH; RHEE, SG			ACTIVATION OF PHOSPHOLIPASE-C ISOZYMES BY G-PROTEIN BETA-GAMMA SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SIGNAL TRANSDUCTION; ALPHA-SUBUNIT; BOVINE BRAIN; PURIFICATION; IDENTIFICATION; MEMBRANES; CYCLASE	The betagamma subunits of guanine nucleotide-binding proteins (G proteins) have been shown to activate unidentified phospholipase C (PLC) isozymes (Camps, M., Hou, C., Sidiropoulos, D., Stock, J. B., Jakobs, K. H., and Gierschik, P. (1992) Eur. J. Biochem. 206, 821-831; Blank, J. L., Brattain, K. A., and Exton, J. H. (1992) J. Biol. Chem. 267, 23069-23075). To identify these target PLC isozymes, we measured the effect of bovine brain G protein betagamma subunits on PLC-beta1, PLC-beta2, PLC-beta3, PLC-gamma1, and PLC-delta1 activity by reconstituting purified protein components with lipid vesicles containing [H-3]phosphatidylinositol 4,5-bisphosphate (PtdIns 4,5-P2). A nearly saturating concentration of betagamma produced 2.5-, 4-, 8.5-, and 2-fold increases in PLC-beta1, PLC-beta2, PLC-beta3, and PLC-delta1 activity, respectively, and no activation of PLC-gamma1, in the presence of 0.2 muM free Ca2+. The betagamma-dependent activation of the PLC-beta isozymes does not appear to be the result of increased affinity of the enzymes for Ca2+. The betagamma-dependent PLC activation could be reversed by addition of the GDP-bound form of the alpha subunit of G(o). The alpha subunits of G(q) class G proteins have been shown to activate PLC-beta isozymes in the order of PLC-beta1 greater-than-or-equal-to PLC-beta3 >> PLC-beta2, which differs from the order of PLC-beta3 > PLC-beta2 > PLC-beta1 for betagamma-dependent activation. Furthermore, the half-maximal concentration of betagamma (25 nM) required to activate PLC-beta3 is much higher than that of G(q) alpha subunits (0.6 nM) required to activate PLC-beta1. These results suggest that the extracellular signals that induce the dissociation of G(o) or G(i), the heterotrimeric G proteins abundant in brain, should enhance the hydrolysis of PtdIns 4,5-P2 in brain primarily through activation of PLC-beta3 (PLC-beta2 is not detectable in brain). However, signals that activate the less abundant G(q) class heterotrimers should result in the activation primarily of PLC-beta1 and PLC-beta3 by the corresponding alpha subunits.	NHLBI, BIOCHEM LAB, BLDG 3, RM 122, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOYER JL, 1992, J BIOL CHEM, V267, P25451; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; DEVIVO M, 1990, ADP RIBOSYLATING TOX, P267; FAIN JN, 1990, BIOCHIM BIOPHYS ACTA, V1053, P81, DOI 10.1016/0167-4889(90)90029-D; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; JHON DY, 1993, IN PRESS J BIOL CHEM; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; LOGOTHETIS DE, 1988, P NATL ACAD SCI USA, V85, P5814, DOI 10.1073/pnas.85.16.5814; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MARTIN TFJ, 1989, INOSITOL LIPIDS CELL, P81; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; NORTHUP JK, 1983, J BIOL CHEM, V258, P1361; PANG IH, 1990, J BIOL CHEM, V265, P18707; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WU DQ, 1992, J BIOL CHEM, V267, P1811	34	271	275	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4573	4576						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8383116				2022-12-25	WOS:A1993KP88400002
J	THOMAS, DC; BREWER, CB; ROTH, MG				THOMAS, DC; BREWER, CB; ROTH, MG			VESICULAR STOMATITIS-VIRUS GLYCOPROTEIN CONTAINS A DOMINANT CYTOPLASMIC BASOLATERAL SORTING SIGNAL CRITICALLY DEPENDENT UPON A TYROSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; APICAL PLASMA-MEMBRANE; POLYMERIC IMMUNOGLOBULIN RECEPTOR; POLARIZED EPITHELIAL-CELLS; AMINO-ACID CHANGE; G-PROTEIN; MDCK CELLS; VIRAL GLYCOPROTEINS; INFLUENZA HEMAGGLUTININ; INTRACELLULAR-TRANSPORT	To investigate the contribution of the cytoplasmic domain of the vesicular stomatitis virus G glycoprotein to its basolateral expression in polarized epithelial cells, chimeric proteins containing the external and transmembrane domains of an apically targeted protein, the influenza virus hemagglutinin (HA), and either the G cytoplasmic domain or an unrelated cytoplasmic sequence, were introduced into Madin-Darby canine kidney (MDCK) cells. Addition of the cytoplasmic tail of G to a truncated HA resulted in delivery of greater than 95% of the chimeric protein to the basolateral cell surface, indicating that the G cytoplasmic domain contains a dominant basolateral sorting signal. A similar chimera, containing the cytoplasmic tail of herpes simplex I glycoprotein gC, was not sorted basolaterally. Deletion of the cytoplasmic tail from G protein itself decreased the fidelity of sorting to the basolateral surface, but not the extent to which the protein reached the plasma membrane. Mutation of cytoplasmic tyrosine 501 of G caused an identical loss of basolateral targeting, suggesting that the tyrosine, or the sequence surrounding it, is required for efficient basolateral transport of G. Mutation of tyrosine 501 had no effect on internalization of G, which was much slower than that of endocytic receptors. Thus, VSV G protein contains an efficient cytoplasmic basolateral targeting signal that is not an efficient internalization signal.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Roth, Michael/0000-0002-9056-332X	NIGMS NIH HHS [GM08203, GM37547] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037547] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOMSEL M, 1991, Current Opinion in Cell Biology, V3, P647, DOI 10.1016/0955-0674(91)90036-X; BOULAN ER, 1980, CELL, V20, P45, DOI 10.1016/0092-8674(80)90233-0; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CAPLAN M, 1989, FUNCTIONAL EPITHELIA, P71; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; COMPTON T, 1989, P NATL ACAD SCI USA, V86, P4112, DOI 10.1073/pnas.86.11.4112; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; DOYLE C, 1985, J CELL BIOL, V100, P704, DOI 10.1083/jcb.100.3.704; FULLER SD, 1985, EMBO J, V4, P297, DOI 10.1002/j.1460-2075.1985.tb03629.x; GONZALEZ A, 1987, P NATL ACAD SCI USA, V84, P3738, DOI 10.1073/pnas.84.11.3738; GOTTLIEB TA, 1986, J CELL BIOL, V102, P1242, DOI 10.1083/jcb.102.4.1242; GRAEVE L, 1989, J CELL BIOL, V109, P2809, DOI 10.1083/jcb.109.6.2809; GRUENBERG J, 1987, P NATL ACAD SCI USA, V84, P5758, DOI 10.1073/pnas.84.16.5758; HOPKINS CR, 1991, CELL, V66, P827, DOI 10.1016/0092-8674(91)90427-Z; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; KONDORKOCH C, 1985, CELL, V43, P297, DOI 10.1016/0092-8674(85)90035-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LAZAROVITS J, 1990, J BIOL CHEM, V265, P4760; LAZAROVITS J, 1988, THESIS U TEXAS SW ME; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; MATLIN K, 1983, J CELL BIOL, V97, P627, DOI 10.1083/jcb.97.3.627; MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131; MCQUEEN N, 1986, P NATL ACAD SCI USA, V83, P9318, DOI 10.1073/pnas.83.24.9318; MCQUEEN NL, 1987, J BIOL CHEM, V262, P16233; MISEK DE, 1984, CELL, V39, P537, DOI 10.1016/0092-8674(84)90460-4; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; NELSON WJ, 1989, FUNCTIONAL EPITHELIA, P71; OKAMOTO CT, 1992, J BIOL CHEM, V267, P9925; PESONEN M, 1984, J CELL BIOL, V99, P796, DOI 10.1083/jcb.99.3.796; PFEIFFER S, 1985, J CELL BIOL, V101, P470, DOI 10.1083/jcb.101.2.470; PUDDINGTON L, 1987, P NATL ACAD SCI USA, V84, P2756; RINDLER MJ, 1984, J CELL BIOL, V98, P1304, DOI 10.1083/jcb.98.4.1304; RINDLER MJ, 1985, J CELL BIOL, V100, P136, DOI 10.1083/jcb.100.1.136; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROMAN LM, 1986, J CELL BIOL, V103, P2607, DOI 10.1083/jcb.103.6.2607; ROTH MG, 1986, J CELL BIOL, V102, P1271, DOI 10.1083/jcb.102.4.1271; ROTH MG, 1987, J CELL BIOL, V104, P769, DOI 10.1083/jcb.104.3.769; Sambrook J, 1989, MOL CLONING LABORATO; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; STEPHENS EB, 1986, EMBO J, V5, P237, DOI 10.1002/j.1460-2075.1986.tb04204.x; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; YOKODE M, 1992, J CELL BIOL, V117, P39, DOI 10.1083/jcb.117.1.39; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	51	141	142	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3313	3320						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8381425				2022-12-25	WOS:A1993KM16100047
J	GOLDSMITH, JO; KUO, LC				GOLDSMITH, JO; KUO, LC			PROTONATION OF ARGININE-57 OF ESCHERICHIA-COLI ORNITHINE TRANSCARBAMOYLASE REGULATES SUBSTRATE-BINDING AND TURNOVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATE KINETIC-ANALYSIS; ASPARTATE TRANSCARBAMOYLASE; SITE; SPECIFICITY; PH; CARBAMOYLTRANSFERASE; CATALYSIS	The amino acid residue Arg57 of Escherichia coli ornithine transcarbamoylase is located in the carbamoyl phosphate-binding domain of the enzyme. This residue has been implicated to be critical for efficient carbamoylation and is linked to an induced-fit protein isomerization elicited by the lead substrate carbamoyl phosphate. To elucidate its role in substrate binding and catalysis, Arg57 has been substituted by one of two amino acids, glycine and histidine, varying in size and charge. Elimination of the positive charge and steric bulk on residue 57 with an arginine-to-glycine substitution results in an enzyme which binds its substrates in a random order (Kuo, L. C., Miller, A. W., Lee, S., and Kozuma, C. (1988) Biochemistry 27, 8823-8832). Replacement of Arg57 by histidine provides a substantial portion of the steric bulk at this residue position and also brings the pK(a) of this residue into an experimentally observable window. Kinetic and pH titration experiments reveal that when His57 is deprotonated the enzyme binds its substrates randomly. However, when His57 is protonated the enzyme observes the obligatory substrate binding order as seen for the wild type. Both the Gly57 and His57 point mutants are incapable of undergoing the carbamoyl phosphate-induced protein conformational changes apparent in the wild type. These results reveal that the induced-fit isomerization of ornithine transcarbamoylase does not contribute to the order in which the substrates bind. A comparison of the reaction schemes and pH profiles of the wild-type and His57 enzymes further indicates that protonation of residue 57 facilitates formation of the binary enzyme-carbamoyl phosphate complex and augments the turnover rate of the reaction. Together with steady-state kinetic parameters derived in terms of microscopic rate constants, our results provide additional support to our earlier suggestion (Zambidis, I. and Kuo, L. C. (1990) J. Biol. Chem. 265,2620-2623) that the turnover rate of the wild-type ornithine transcarbamoylase in the forward reaction is largely dictated by the rate of the carbamoyl phosphate-induced isomerization.	MERCK SHARP & DOHME LTD, DEPT BIOL CHEM, W POINT, PA 19486 USA; STANFORD UNIV, DEPT CHEM, STANFORD, CA 94305 USA	Merck & Company; Stanford University					NIDDK NIH HHS [DK38089, DK01721] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K04DK001721, R01DK038089] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADEBODUN F, 1989, J CELL BIOCHEM, V40, P249, DOI 10.1002/jcb.240400213; ELLMAN J, 1991, METHOD ENZYMOL, V202, P301; FRIEDEN C, 1976, BIOCHEM BIOPH RES CO, V68, P914, DOI 10.1016/0006-291X(76)91232-8; Fromm H J, 1979, Methods Enzymol, V63, P467; GOLDSMITH JO, 1991, J BIOL CHEM, V266, P18626; GOLDSMITH JO, 1993, J BIOL CHEM, V268, P18481; HIMOE A, 1976, BIOCHIM BIOPHYS ACTA, V429, P720, DOI 10.1016/0005-2744(76)90320-X; HSUANYU YC, 1989, J BIOL CHEM, V264, P17259; KING EL, 1956, J PHYS CHEM-US, V60, P1375, DOI 10.1021/j150544a010; KUO LC, 1989, BIOCHEMISTRY-US, V28, P4522, DOI 10.1021/bi00436a060; KUO LC, 1985, BIOCHEMISTRY-US, V24, P4754, DOI 10.1021/bi00339a007; KUO LC, 1990, J MOL BIOL, V211, P271, DOI 10.1016/0022-2836(90)90026-I; KUO LC, 1988, BIOCHEMISTRY-US, V27, P8823, DOI 10.1021/bi00424a021; LEGRAIN C, 1976, EUR J BIOCHEM, V63, P289, DOI 10.1111/j.1432-1033.1976.tb10230.x; MARSHALL M, 1972, J BIOL CHEM, V247, P1654; MILLER AW, 1990, J BIOL CHEM, V265, P15023; SHAFER JA, 1976, BIOCHEMISTRY-US, V15, P5009; WALDROP GL, 1992, BIOCHEMISTRY-US, V31, P6585, DOI 10.1021/bi00143a031; WALDROP GL, 1992, BIOCHEMISTRY-US, V31, P6592, DOI 10.1021/bi00143a032; WARGNIES B, 1978, EUR J BIOCHEM, V89, P203, DOI 10.1111/j.1432-1033.1978.tb20914.x; ZAMBIDIS I, 1990, J BIOL CHEM, V265, P2620	21	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18485	18490						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8395503				2022-12-25	WOS:A1993LV65900019
J	BOERNER, RJ; BARRY, BA				BOERNER, RJ; BARRY, BA			ISOTOPIC LABELING AND EPR SPECTROSCOPY SHOW THAT A TYROSINE RESIDUE IS THE TERMINAL ELECTRON-DONOR, Z, IN MANGANESE-DEPLETED PHOTOSYSTEM-II PREPARATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE SIGNAL-II; SITE-DIRECTED MUTAGENESIS; NUCLEAR DOUBLE-RESONANCE; CYTOCHROME-C PEROXIDASE; OXYGEN-EVOLVING SYSTEM; PARAMAGNETIC RESONANCE; RIBONUCLEOTIDE REDUCTASE; OPTICAL CHARACTERIZATION; SPINACH-CHLOROPLASTS; D1 POLYPEPTIDE	Photosystem II contains two redox active species, D and Z, which in the oxidized and paramagnetic form give rise to similar EPR signals. Both signals are broadened by anisotropic interactions and show no well-resolved hyperfine splittings, even at room temperature. D+ is a dark stable radical of unknown function. Z, on the other hand, acts as the intermediate electron carrier between the primary chlorophyll donor and the manganese catalytic site. In manganese-depleted photosystem II preparations, where Z+ is the terminal electron donor, the Z+ EPR signal can be easily detected. Isotopic labeling of intact cells of Synechocystis 6803 and EPR spectroscopy were used to demonstrate that D+ is a tyrosine radical (Barry, B. A., and Babcock, G. T. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 7099-7103). However, since the Z+ signal is not observable in intact cyanobacterial cells, a definitive assignment of the Z redox active species has not yet been performed. Here, we describe the use of a purified photosystem II preparation to assign the Z+ EPR signal to a neutral tyrosine radical. Further, a comparison of the Z+ and D+ EPR lineshapes in deuterated samples shows that there are slight differences between the two signals. These alterations may be caused by differences in the protein environments of the D+ and Z+ radicals.	UNIV MINNESOTA,DEPT BIOCHEM,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043273] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43273] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABCOCK GT, 1975, BIOCHIM BIOPHYS ACTA, V376, P315, DOI 10.1016/0005-2728(75)90024-9; BABCOCK GT, 1973, BIOCHIM BIOPHYS ACTA, V325, P504, DOI 10.1016/0005-2728(73)90210-7; BABCOCK GT, 1975, BIOCHIM BIOPHYS ACTA, V376, P329, DOI 10.1016/0005-2728(75)90025-0; BABCOCK GT, 1983, BIOCHIM BIOPHYS ACTA, V723, P276, DOI 10.1016/0005-2728(83)90127-5; BARRY BA, 1987, P NATL ACAD SCI USA, V84, P7099, DOI 10.1073/pnas.84.20.7099; BARRY BA, 1990, J BIOL CHEM, V265, P20139; BARRY BA, 1988, CHEM SCRIPTA, V28A, P117; BARRY BA, 1993, PHOTOCHEM PHOTOBIOL, V57, P179, DOI 10.1111/j.1751-1097.1993.tb02275.x; BOERNER RJ, 1993, J BIOL CHEM, V268, P1817; BOERNER RJ, 1992, BIOCHEMISTRY-US, V31, P6660, DOI 10.1021/bi00144a005; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; DEBUS RJ, 1988, BIOCHEMISTRY-US, V27, P9071, DOI 10.1021/bi00426a001; DEBUS RJ, 1988, P NATL ACAD SCI USA, V85, P427, DOI 10.1073/pnas.85.2.427; DEKKER JP, 1984, BIOCHIM BIOPHYS ACTA, V764, P301, DOI 10.1016/0005-2728(84)90100-2; FISHEL LA, 1991, BIOCHEMISTRY-US, V30, P1986, DOI 10.1021/bi00221a036; GERKEN S, 1988, FEBS LETT, V237, P69, DOI 10.1016/0014-5793(88)80174-1; HOGANSON CW, 1988, BIOCHEMISTRY-US, V27, P5848, DOI 10.1021/bi00416a005; HOGANSON CW, 1992, BIOCHEMISTRY-US, V31, P11874, DOI 10.1021/bi00162a028; KOHL DH, 1965, NATURE, V206, P1105, DOI 10.1038/2061105a0; METZ JG, 1989, BIOCHEMISTRY-US, V28, P6960, DOI 10.1021/bi00443a028; NISHI N, 1980, BIOCHIM BIOPHYS ACTA, V590, P74, DOI 10.1016/0005-2728(80)90147-4; NOREN GH, 1991, BIOCHEMISTRY-US, V30, P3943, DOI 10.1021/bi00230a020; NOREN GH, 1992, BIOCHEMISTRY-US, V31, P3335, DOI 10.1021/bi00128a005; SMULEVICH G, 1988, BIOCHEMISTRY-US, V27, P5477, DOI 10.1021/bi00415a014; SVENSSON B, 1990, EMBO J, V9, P2051, DOI 10.1002/j.1460-2075.1990.tb07372.x; VERMAAS WFJ, 1988, P NATL ACAD SCI USA, V85, P8477, DOI 10.1073/pnas.85.22.8477; WANG JM, 1990, BIOCHEMISTRY-US, V29, P7160, DOI 10.1021/bi00483a003; WERTZ JE, 1986, ELECTRON SPIN RESONA	28	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17151	17154						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8394330				2022-12-25	WOS:A1993LQ98800043
J	AHN, J; ROSEN, OM; DONNER, DB				AHN, J; ROSEN, OM; DONNER, DB			HUMAN INSULIN-RECEPTOR MUTATED AT THREONINE 1336 FUNCTIONS NORMALLY IN CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TYROSINE KINASE; PHORBOL ESTER; DOWN-REGULATION; HEPATOMA-CELLS; PHOSPHORYLATION; BINDING; SERINE; SITE; AUTOPHOSPHORYLATION	Phosphorylation of threonine 1336 of the human insulin receptor (HIR) is stimulated by insulin or 4beta-phorbol 12-myristate 13-acetate in Chinese hamster ovary (CHO) transfectant cells expressing the wild type receptor (CHO/HIR). To examine the role of this phosphorylation in insulin signal transduction, a mutant human insulin receptor, in which threonine 1336 was replaced with asparagine, has been stably expressed in CHO cells (CHO/HIRT1336N). CHO cell lines expressing equivalent numbers of the wild type or the mutant receptor were developed, which bound I-125-insulin comparably (K(d) = 0.1 nM). After stimulation of CHO/HIR or CHO/HIRT1336N cells with insulin, the wild type and mutant receptors internalized the hormone and were down-regulated with similar rates. Hormone stimulation of the receptor tyrosine kinase activity was also unaffected by the mutation. Metabolic and mitotic effects of insulin were also unimpaired by the mutation. Thus, insulin stimulated phosphatidylinositol 3-kinase activity, glycogen synthesis, and thymidine incorporation into DNA similarly in CHO/HIR and CHO/HIRT1336N cells. These data suggest that by itself phosphorylation of threonine 1336 has no significant effect on insulin binding, regulation of insulin receptor expression, or insulin signal transduction.	CORNELL UNIV,GRAD SCH MED SCI,SLOAN KETTERING DIV,NEW YORK,NY 10021; CORNELL UNIV,MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [R01CA044747] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035158, R01DK035158] Funding Source: NIH RePORTER; NCI NIH HHS [CA44747] Funding Source: Medline; NIDDK NIH HHS [DK35158] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN JC, 1993, J BIOL CHEM, V268, P7571; CHOU CK, 1987, J BIOL CHEM, V262, P1842; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; GANGULY S, 1985, CURR TOP CELL REGUL, V27, P83; GRUNBERGER G, 1982, AM J PHYSIOL, V243, pE319, DOI 10.1152/ajpendo.1982.243.4.E319; GRUNBERGER G, 1991, CELL SIGNAL, V3, P171, DOI 10.1016/0898-6568(91)90042-S; HEIDENREICH KA, 1990, J BIOL CHEM, V265, P15076; JACOBS S, 1986, J BIOL CHEM, V261, P934; KOONTZ JW, 1985, BIOCHEM BIOPH RES CO, V131, P815, DOI 10.1016/0006-291X(85)91312-9; KOSHIO O, 1989, FEBS LETT, V254, P22, DOI 10.1016/0014-5793(89)81001-4; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEWIS RE, 1990, BIOCHEMISTRY-US, V29, P1807, DOI 10.1021/bi00459a020; LEWIS RE, 1990, J BIOL CHEM, V265, P947; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MYERS MG, 1991, J BIOL CHEM, V266, P10616; PANG DT, 1985, J BIOL CHEM, V260, P7131; PETRUZZELLI LM, 1982, P NATL ACAD SCI-BIOL, V79, P6792, DOI 10.1073/pnas.79.22.6792; PILLAY TS, 1990, BIOCHEM SOC T, V18, P494, DOI 10.1042/bst0180494; RAPUANO M, 1991, J BIOL CHEM, V266, P12902; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SATO T, 1988, ARCH BIOCHEM BIOPHYS, V260, P377, DOI 10.1016/0003-9861(88)90461-4; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; TAMURA S, 1983, J BIOL CHEM, V258, P4749; TAVARE JM, 1991, J BIOL CHEM, V266, P21804; THIES RS, 1989, J BIOL CHEM, V264, P12820; THOMOPOULOS P, 1982, EUR J BIOCHEM, V129, P389, DOI 10.1111/j.1432-1033.1982.tb07062.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WALAAS SI, 1987, FEBS LETT, V220, P311, DOI 10.1016/0014-5793(87)80837-2; WERRVE GVD, 1985, BIOCHEM J, V225, P523; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358	37	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16839	16844						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8393875				2022-12-25	WOS:A1993LQ33600106
J	INOUE, D; MATSUMOTO, T; OGATA, E; IKEDA, K				INOUE, D; MATSUMOTO, T; OGATA, E; IKEDA, K			22-OXACALCITRIOL, A NONCALCEMIC ANALOG OF CALCITRIOL, SUPPRESSES BOTH CELL-PROLIFERATION AND PARATHYROID HORMONE-RELATED PEPTIDE GENE-EXPRESSION IN HUMAN T-CELL LYMPHOTROPHIC VIRUS, TYPE I-INFECTED T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD MONONUCLEAR-CELLS; BREAST-CANCER-CELLS; VITAMIN-D; LEUKEMIA-LYMPHOMA; HUMORAL HYPERCALCEMIA; RECEPTOR SUPERFAMILY; MESSENGER-RNAS; 1,25-DIHYDROXYVITAMIN-D3; PROTEIN; 1-ALPHA,25-DIHYDROXYVITAMIN-D3	Human T cell lymphotrophic virus, type I (HTLV-I)-infected T cells overproduce parathyroid hormone-related peptide (PTHRP) and cause hypercalcemia in patients with adult T cell leukemia. The present study was undertaken to test whether 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) and its noncalcemic analogue, 22-oxa-1,25-(OH)2D3 (OCT), could suppress cell proliferation and PTHRP gene expression in an HTLV-I-infected T cell line, MT-2. OCT as well as 1,25-(OH)2D3 inhibited the proliferation of MT-2 cells in a time- and dose-dependent manner. Cell cycle analysis revealed that OCT, like the parent compound, caused a transition delay of cells through the G1 phase. OCT and 1,25-(OH)2D3 decreased the steady state levels of PTHRP mRNA, and nuclear runoff assays demonstrated that the effect of OCT occurred at a transcription level. As a result, OCT caused a reduction in PTHRP concentrations in the conditioned medium by approximately 50%. OCT inhibited not only the basal secretion but also the stimulation of PTHRP secretion by interleukin-2 or cAMP, which we had identified as two important stimulators. Northern blot analysis and the specific uptake of [H-3]1,25-(OH)2D3 revealed unexpectedly that the vitamin D receptor was abundantly expressed in MT-2 cells. These results suggest that OCT, as well as 1,25-(OH)2D3, has the potential to suppress both cell proliferation and PTHRP gene expression through binding to the vitamin D receptor overexpressed in HTLV-I-infected T cells.	UNIV TOKYO,SCH MED,DEPT INTERNAL MED 4,DIV ENDOCRINOL,3-28-6 MEJIRODAI,BUNKYO KU,TOKYO 112,JAPAN	University of Tokyo								ABE E, 1981, P NATL ACAD SCI-BIOL, V78, P4990, DOI 10.1073/pnas.78.8.4990; ABE J, 1987, FEBS LETT, V226, P58, DOI 10.1016/0014-5793(87)80550-1; ABE J, 1991, ENDOCRINOLOGY, V129, P832, DOI 10.1210/endo-129-2-832; ARYA SK, 1984, SCIENCE, V223, P1086, DOI 10.1126/science.6320374; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BHALLA AK, 1983, J CLIN ENDOCR METAB, V57, P1308, DOI 10.1210/jcem-57-6-1308; BIKLE DD, 1992, ENDOCR REV, V13, P765, DOI 10.1210/er.13.4.765; BROADUS AE, 1988, NEW ENGL J MED, V319, P556; BROWN AJ, 1989, J CLIN INVEST, V84, P728, DOI 10.1172/JCI114229; BUNN PA, 1983, NEW ENGL J MED, V309, P257, DOI 10.1056/NEJM198308043090501; CIVITELLI R, 1990, ENDOCRINOLOGY, V127, P2253, DOI 10.1210/endo-127-5-2253; DEITCH AD, 1982, J HISTOCHEM CYTOCHEM, V30, P967, DOI 10.1177/30.9.6182188; DEMAY MB, 1992, P NATL ACAD SCI USA, V89, P8097, DOI 10.1073/pnas.89.17.8097; DUSSO AS, 1991, ENDOCRINOLOGY, V128, P1687, DOI 10.1210/endo-128-4-1687; EISMAN JA, 1989, J CELL PHYSIOL, V138, P611, DOI 10.1002/jcp.1041380323; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINCH JL, 1982, J BONE MINER RES, V7, P835; FRAMPTON RJ, 1982, CANCER RES, V42, P1116; FUKUMOTO S, 1988, ARCH INTERN MED, V148, P921, DOI 10.1001/archinte.148.4.921; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; IKEDA K, 1993, J BIOL CHEM, V268, P1174; IKEDA K, 1988, J CLIN INVEST, V81, P2010, DOI 10.1172/JCI113551; IKEDA K, 1989, J BIOL CHEM, V264, P15743; IKEDA K, 1990, J BIOL CHEM, V265, P5398; IKEDA K, 1993, IN PRESS ENDOCRINOLO; KASAHARA H, 1992, BIOMED RES-TOKYO, V13, P155, DOI 10.2220/biomedres.13.155; LEMIRE JM, 1984, J CLIN INVEST, V74, P657, DOI 10.1172/JCI111465; MANGIN M, 1988, MOL ENDOCRINOL, V2, P1049, DOI 10.1210/mend-2-11-1049; MANGIN M, 1988, P NATL ACAD SCI USA, V85, P597, DOI 10.1073/pnas.85.2.597; MANGIN M, 1990, MOL ENDOCRINOL, V4, P851, DOI 10.1210/mend-4-6-851; MANGIN M, 1989, P NATL ACAD SCI USA, V86, P2408, DOI 10.1073/pnas.86.7.2408; MANOLAGAS SC, 1985, MOL CELL ENDOCRINOL, V43, P113, DOI 10.1016/0303-7207(85)90074-7; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MORRISON NA, 1991, J BONE MINER RES, V6, P893; MOTOKURA T, 1989, ANN INTERN MED, V111, P484, DOI 10.7326/0003-4819-111-6-484; OKANO T, 1989, J NUTR SCI VITAMINOL, V35, P529, DOI 10.3177/jnsv.35.529; OKAZAKI R, 1992, J BONE MINER RES, V7, P1149; OKAZAKI R, 1992, CALCIUM REGULATING H, V11, P57; OKAZAKI T, 1988, J BIOL CHEM, V263, P2203; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; PROVVEDINI DM, 1983, SCIENCE, V221, P1181, DOI 10.1126/science.6310748; REICHEL H, 1989, NEW ENGL J MED, V320, P980, DOI 10.1056/NEJM198904133201506; RIGBY WFC, 1984, J CLIN INVEST, V74, P1451, DOI 10.1172/JCI111557; RIGBY WFC, 1988, IMMUNOL TODAY, V9, P54; RIGBY WFC, 1985, J IMMUNOL, V135, P2279; SHER E, 1981, BIOCHEM J, V200, P315, DOI 10.1042/bj2000315; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SUVA LJ, 1989, GENE, V77, P95, DOI 10.1016/0378-1119(89)90363-6; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; TANAKA H, 1991, J BIOL CHEM, V266, P10888; TSOUKAS CD, 1984, SCIENCE, V224, P1438, DOI 10.1126/science.6427926; YASUDA T, 1989, J BIOL CHEM, V264, P7720; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	55	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16730	16736						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8393873				2022-12-25	WOS:A1993LQ33600092
J	GANTZ, I; MIWA, H; KONDA, Y; SHIMOTO, Y; TASHIRO, T; WATSON, SJ; DELVALLE, J; YAMADA, T				GANTZ, I; MIWA, H; KONDA, Y; SHIMOTO, Y; TASHIRO, T; WATSON, SJ; DELVALLE, J; YAMADA, T			MOLECULAR-CLONING, EXPRESSION, AND GENE LOCALIZATION OF A 4TH MELANOCORTIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOCYTE STIMULATING HORMONE; HIGHLY EFFICIENT; ALPHA-MSH; DNA; HYBRIDIZATION; PEPTIDES; PRODUCTS; SYSTEM; CELLS	The recent cloning of three melanocortin receptors suggests an unexpected diversity in this family of seven transmembrane G-protein linked receptors. Herein, we report the cloning, expression, and gene localization of a fourth human melanocortin receptor, the melanocortin-4 receptor. By Northern blot analysis and in situ hybridization, this receptor is expressed primarily in the brain, but its expression is notably absent in the adrenal cortex, melanocytes, and placenta. Agonist stimulation of COS-1 cells transiently transfected and L-cells permanently transfected with the coding region of the cloned melanocortin-4 receptor leads to increases in intracellular cyclic 3',5'-adenosine monophosphate. The profile of the responses of the melanocortin-4 receptor to different melanocortins distinguishes it from melanocortin receptors previously described. Using the technique of fluorescent in situ hybridization, the gene encoding the melanocortin-4 receptor was localized to chromosome 18 (q21.3).	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT PHYSIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT PSYCHIAT,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	GANTZ, I (corresponding author), UNIV MICHIGAN,MED CTR,DEPT SURG,ANN ARBOR,MI 48109, USA.				NIDDK NIH HHS [K08-DK01823, P30DK34933, R01DK34306] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK001823, R01DK034306, P30DK034933] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROWN NA, 1990, J BIOL CHEM, V265, P13181; CANNON JG, 1986, J IMMUNOL, V137, P2232; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHHAJLANI V, 1992, FEBS LETT, V309, P417, DOI 10.1016/0014-5793(92)80820-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK D, 1978, NATURE, V273, P163, DOI 10.1038/273163a0; DEWIED D, 1982, PHYSIOL REV, V62, P977; DEWIED D, 1991, METHODS ACHIEV EXP P, V5, P167; ELLERKMANN E, 1992, ENDOCRINOLOGY, V130, P133, DOI 10.1210/en.130.1.133; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GANTZ I, 1991, P NATL ACAD SCI USA, V88, P429, DOI 10.1073/pnas.88.2.429; GANTZ I, 1993, J BIOL CHEM, V268, P8246; GISPEN WH, 1990, TRENDS PHARMACOL SCI, V11, P221, DOI 10.1016/0165-6147(90)90244-3; GRUBER KA, 1989, AM J PHYSIOL, V257, pR681, DOI 10.1152/ajpregu.1989.257.4.R681; LEMIEUX N, 1992, CYTOGENET CELL GENET, V59, P311, DOI 10.1159/000133277; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; MURPHY MT, 1983, SCIENCE, V221, P192, DOI 10.1126/science.6602381; NAKANISHI S, 1979, NATURE, V278, P423, DOI 10.1038/278423a0; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Sambrook J, 1989, MOL CLONING LABORATO; SAMIA JA, 1990, GENOMICS, V6, P159, DOI 10.1016/0888-7543(90)90461-3; SILMAN RE, 1976, NATURE, V260, P716, DOI 10.1038/260716a0; TSONIS PA, 1988, BIOTECHNIQUES, V6, P950; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VERSTEEG DHG, 1986, LIFE SCI, V38, P835, DOI 10.1016/0024-3205(86)90600-4; WALKER JM, 1980, SCIENCE, V210, P1247, DOI 10.1126/science.6254152; WILSON JF, 1982, CLIN ENDOCRINOL, V17, P233	28	787	839	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15174	15179						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8392067				2022-12-25	WOS:A1993LL75900091
J	LEVENTHAL, PS; BERTICS, PJ				LEVENTHAL, PS; BERTICS, PJ			ACTIVATION OF PROTEIN-KINASE-C BY SELECTIVE BINDING OF ARGININE-RICH POLYPEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER NUCLEI; SIGNAL TRANSDUCTION; PHOSPHORYLATION; CALCIUM; PURIFICATION; SUBSTRATE; FAMILY; BRAIN; DOMAIN; EXPRESSION	Protein substrates for protein kinase C (PKC) have phosphorylation domains that are typically rich in the basic amino acids arginine and lysine. However, arginine-rich proteins may interact with PKC differently than lysine-rich proteins, i.e. lysine-rich histone requires phospholipid and Ca2+ to be phosphorylated whereas the arginine-rich protein, protamine, can by pass these effector requirements. We have studied the interaction of PKC with protamine, histone, poly-L-arginine, and poly-L-lysine to better understand the role of basic protein domains in PKC activation, effector dependence, and substrate specificity. Using a microtiter binding assay, PKC was found to bind tightly to protamine and poly-L-arginine, but not to histone or poly-L-lysine, in the absence of phospholipid, Ca2+, and MgATP. Furthermore, poly-L-arginine was much more potent than poly-L-lysine at inhibiting protamine phosphorylation; i. e. 1-2 nM poly-L-arginine was sufficient to cause 50% inhibition of protamine phosphorylation, whereas over 300 muM poly-L-lysine was needed to reach 50% inhibition. Autophosphorylation of PKC in the absence of activators was potently stimulated by protamine and poly-L-arginine, but not by histone or poly-L-lysine, suggesting selective stimulation of PKC by arginine-rich polypeptides. Double-reciprocal plots of protamine phosphorylation using either a mixture of isozymes (alpha/beta/gamma) or isolated PKC-beta were parabolic, and analysis of the kinetic data on velocity/[protamine] versus velocity plots indicated positive cooperativity with respect to protamine. These findings are consistent with those from autophosphorylation experiments in that PKC appears to be selectively stimulated by arginine-rich polypeptides. These results suggest that PKC can preferentially bind arginine-rich proteins in the absence of phospholipid and Ca2+. This interaction appears to be distal to the catalytic site and thus binding of arginine-rich proteins may allosterically activate PKC. Selective stimulation of PKC by arginine-rich proteins may be a mechanism by which protamine can bypass activator requirements. Furthermore, control of PKC activity by activator-independent binding of arginine-rich polypeptides suggests that altering access to certain cellular proteins may be a mechanism for PKC regulation in vivo.	UNIV WISCONSIN,DEPT BIOMOLEC CHEM,1300 UNIV AVE,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL CANCER INSTITUTE [R01CA047881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47881] Funding Source: Medline; NIGMS NIH HHS [5 T32 GM 07215] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKITA Y, 1990, J BIOL CHEM, V265, P354; AZHAR S, 1987, BIOCHEMISTRY-US, V26, P7047, DOI 10.1021/bi00396a029; BAUDIER J, 1987, J BIOL CHEM, V262, P17584; BAZZI MD, 1987, BIOCHEM BIOPH RES CO, V147, P248, DOI 10.1016/S0006-291X(87)80113-4; BAZZI MD, 1992, J BIOL CHEM, V267, P22891; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; BENNETT V, 1988, J BIOL CHEM, V263, P5860; BRADBURY EM, 1981, DNA CHROMATIN CHROMO, P1; BUCHNER K, 1992, BIOCHEM J, V286, P369, DOI 10.1042/bj2860369; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHARVIER P, 1989, MOL CELL BIOL, V9, P787; CHAUHAN VPS, 1992, LIFE SCI, V51, P537, DOI 10.1016/0024-3205(92)90031-J; CHU SHW, 1985, J CELL PHYSIOL, V124, P391, DOI 10.1002/jcp.1041240306; COUSSENS L, 1987, DNA-J MOLEC CELL BIO, V6, P389, DOI 10.1089/dna.1987.6.389; CSERMELY P, 1988, J BIOL CHEM, V263, P6487; Dixon M., 1979, ENZYMES, P55; FERRARI S, 1987, EUR J BIOCHEM, V163, P481, DOI 10.1111/j.1432-1033.1987.tb10894.x; Ferrari S., 1988, Advances in Experimental Medicine and Biology, V231, P427; FERRARI S, 1985, FEBS LETT, V184, P72, DOI 10.1016/0014-5793(85)80656-6; FERRARI S, 1987, BIOCHEM BIOPH RES CO, V144, P1324, DOI 10.1016/0006-291X(87)91455-0; GLYNN B, 1985, BIOCHEM J, V231, P489, DOI 10.1042/bj2310489; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; GREGORIO CC, 1992, P NATL ACAD SCI USA, V89, P4947, DOI 10.1073/pnas.89.11.4947; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HORNE WC, 1985, J BIOL CHEM, V260, P9073; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUANG KP, 1988, J BIOL CHEM, V263, P14839; IGARASHI M, 1991, BIOCHEM BIOPH RES CO, V178, P751, DOI 10.1016/0006-291X(91)90172-4; ISAWA Y, 1980, BIOCHEM BIOPH RES CO, V96, P180; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JAKEN S, 1987, P NATL ACAD SCI USA, V84, P4418, DOI 10.1073/pnas.84.13.4418; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KIMURA K, 1985, BIOCHEM J, V227, P271, DOI 10.1042/bj2270271; KISHIMOTO A, 1980, J BIOL CHEM, V255, P2273; KITAMURA S, 1989, J BIOL CHEM, V264, P5674; KOZARIDES T, 1988, NATURE, V336, P646; LEVENTHAL PS, 1991, BIOCHEMISTRY-US, V30, P1385, DOI 10.1021/bi00219a031; LITCHFIELD DW, 1987, J BIOL CHEM, V262, P8056; MAKOWSKE M, 1989, J BIOL CHEM, V264, P16155; MASMOUDI A, 1989, J BIOL CHEM, V264, P1172; MCFADDEN PN, 1989, J BIOL CHEM, V264, P12765; MCKEON FD, 1986, NATURE, V319, P463, DOI 10.1038/319463a0; MISRA UK, 1987, BIOCHEM BIOPH RES CO, V145, P760, DOI 10.1016/0006-291X(87)91030-8; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; MORI A, 1991, BIOCHEMISTRY-US, V30, P9341, DOI 10.1021/bi00102a029; MURTI KG, 1992, EXP CELL RES, V202, P36044; NAKADATE T, 1987, J BIOL CHEM, V262, P11507; NEWPORT JW, 1987, ANNU REV BIOCHEM, V56, P535; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1988, J BIOL CHEM, V263, P6927; ORR JW, 1992, J BIOL CHEM, V267, P15263; OSADA S, 1990, J BIOL CHEM, V265, P22434; PALUH JL, 1988, P NATL ACAD SCI USA, V85, P3728, DOI 10.1073/pnas.85.11.3728; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; PERLETTI G, 1991, BIOCHEM BIOPH RES CO, V181, P348, DOI 10.1016/S0006-291X(05)81425-1; POMMIER Y, 1990, J BIOL CHEM, V265, P9418; RANDO RR, 1992, BIOCHEMISTRY-US, V31, P2211, DOI 10.1021/bi00123a001; ROGUE P, 1990, J BIOL CHEM, V265, P4161; SAHYOUN N, 1986, P NATL ACAD SCI USA, V83, P1603, DOI 10.1073/pnas.83.6.1603; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SEKIGUCHI K, 1988, J BIOCHEM-TOKYO, V103, P759, DOI 10.1093/oxfordjournals.jbchem.a122343; SPUDICH A, 1992, CELL MOTIL CYTOSKEL, V22, P250, DOI 10.1002/cm.970220405; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; TAKAI Y, 1985, J CELL BIOCHEM, V29, P143, DOI 10.1002/jcb.240290209; TSUYAMA S, 1986, J BIOL CHEM, V261, P4110; WALTON GM, 1987, ANAL BIOCHEM, V161, P425, DOI 10.1016/0003-2697(87)90471-4; WERTH DK, 1983, J BIOL CHEM, V258, P1423; WISE BC, 1982, J BIOL CHEM, V257, P8481; WOLF M, 1986, J BIOL CHEM, V261, P3327; WOPPMANN A, 1990, NUCLEIC ACIDS RES, V18, P4427, DOI 10.1093/nar/18.15.4427; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837	80	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13906	13913						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8390981				2022-12-25	WOS:A1993LJ82500023
J	HUANG, NN; WANG, DJ; HEPPEL, LA				HUANG, NN; WANG, DJ; HEPPEL, LA			STIMULATION OF AGED HUMAN LUNG FIBROBLASTS BY EXTRACELLULAR ATP VIA SUPPRESSION OF ARACHIDONATE METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CYCLIC-AMP ACCUMULATION; SWISS 3T3 CELLS; TRANSDUCTION PATHWAYS LEAD; EPIDERMAL GROWTH-FACTOR; GTP-BINDING PROTEIN; DNA-SYNTHESIS; SIGNAL TRANSDUCTION; PROSTAGLANDIN SYNTHESIS; PROLIFERATIVE RESPONSE	The mitogenic effect of extracellular ATP on IMR-90 human fibroblasts subjected to in vitro aging was studied. ATP stimulated DNA synthesis and cell proliferation in young cells as much as epidermal growth factor (EGF) or insulin, while it stimulated aged cells to a much greater extent than seen for any other growth factor tested. When combined with EGF or insulin, ATP restored the greatly reduced mitogenic responsiveness of aged cells nearly to the level noted for young cells. Addition of prostaglandin E2 or other agents that elevate cAMP levels resulted in inhibition of DNA synthesis stimulated by EGF or insulin. Furthermore, the basal release of arachidonic acid and prostaglandin E2 and the endogenous levels of cAMP rose during aging and became much greater than in young cells. All three of these changes were suppressed by extracellular ATP. ATP-dependent suppression of cAMP accumulation was pertussis toxin-sensitive. Protein kinase C down-regulation inhibited arachidonate metabolism and enhanced DNA synthesis stimulated by ATP. These studies suggest that ATP exerts its mitogenic effect, especially on aged IMR-90 cells, at least partially by suppression of arachidonate metabolism.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853	Cornell University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK011789] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007429] Funding Source: NIH RePORTER; NIA NIH HHS [AG-07429] Funding Source: Medline; NIDDK NIH HHS [DK-11789] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; BURCH RM, 1989, J CELL PHYSIOL, V139, P29, DOI 10.1002/jcp.1041390106; COFFINO P, 1975, P NATL ACAD SCI USA, V72, P878, DOI 10.1073/pnas.72.3.878; DIAZLAVIADA I, 1991, J BIOL CHEM, V266, P1170; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; FINE A, 1987, PROSTAGLANDINS, V33, P903, DOI 10.1016/0090-6980(87)90117-1; GODSON C, 1990, J BIOL CHEM, V265, P8369; GOLDSTEIN RH, 1982, J BIOL CHEM, V257, P8630; GOLDSTEIN RH, 1984, J BIOL CHEM, V259, P9263; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HELDIN NE, 1989, J CELL PHYSIOL, V138, P17, DOI 10.1002/jcp.1041380104; HEPLER JR, 1987, BIOCHEM J, V247, P793, DOI 10.1042/bj2470793; HEPPEL LA, 1990, ANN NY ACAD SCI, V603, P432; HORI T, 1989, J CELL PHYSIOL, V141, P275, DOI 10.1002/jcp.1041410207; HORIBATA K, 1970, EXP CELL RES, V60, P61, DOI 10.1016/0014-4827(70)90489-1; HSIE AW, 1971, P NATL ACAD SCI USA, V68, P358, DOI 10.1073/pnas.68.2.358; HUANG NN, 1991, J CELL PHYSIOL, V146, P483, DOI 10.1002/jcp.1041460320; HUANG NN, 1989, P NATL ACAD SCI USA, V86, P7904, DOI 10.1073/pnas.86.20.7904; IMAGAWA W, 1988, J CELL PHYSIOL, V135, P509, DOI 10.1002/jcp.1041350320; JACKOWSKI S, 1990, J BIOL CHEM, V265, P6611; JOHNSON GS, 1971, J NATL CANCER I, V47, P1357; KARTHA S, 1985, AM J PHYSIOL, V249, pF967, DOI 10.1152/ajprenal.1985.249.6.F967; KELVIN DJ, 1989, J CELL BIOL, V108, P159, DOI 10.1083/jcb.108.1.159; LOESBERG C, 1985, EXP CELL RES, V160, P117, DOI 10.1016/0014-4827(85)90241-1; MACMANUS JP, 1969, EXP CELL RES, V58, P188, DOI 10.1016/0014-4827(69)90135-9; MAGNALDO I, 1988, BIOCHEM J, V253, P711, DOI 10.1042/bj2530711; MASUI H, 1971, P NATL ACAD SCI USA, V68, P3206, DOI 10.1073/pnas.68.12.3206; MILLAR JBA, 1988, J CELL PHYSIOL, V137, P214, DOI 10.1002/jcp.1041370203; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MURAYAMA T, 1987, J BIOL CHEM, V262, P12463; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PETERSGOLDEN M, 1990, J IMMUNOL, V144, P4320; PHILLIPS PD, 1987, J CELL PHYSIOL, V133, P135, DOI 10.1002/jcp.1041330117; PHILLIPS PD, 1984, J GERONTOL, V39, P11, DOI 10.1093/geronj/39.1.11; POLGAR P, 1980, MECH AGEING DEV, V12, P305, DOI 10.1016/0047-6374(80)90063-9; PRUSS RM, 1979, J CELL PHYSIOL, V98, P469, DOI 10.1002/jcp.1040980305; ROZENGURT E, 1982, J CELL PHYSIOL, V112, P243, DOI 10.1002/jcp.1041120213; ROZENGURT E, 1988, COLD SPRING HARB SYM, V53, P945, DOI 10.1101/SQB.1988.053.01.109; ROZENGURT E, 1983, J CELL PHYSIOL, V116, P379, DOI 10.1002/jcp.1041160316; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1983, CELL, V34, P265, DOI 10.1016/0092-8674(83)90157-5; ROZENGURT E, 1981, ADV CYCL NUCL RES<D>, V14, P429; SHIER WT, 1982, J CELL PHYSIOL, V112, P171, DOI 10.1002/jcp.1041120204; VAIRO G, 1990, J BIOL CHEM, V265, P2692; VANCOEVORDEN A, 1989, THROMB HAEMOSTASIS, V62, P573; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WANG D, 1990, BIOCHEM BIOPH RES CO, V166, P251, DOI 10.1016/0006-291X(90)91938-O; WANG DJ, 1991, J CELL PHYSIOL, V146, P473, DOI 10.1002/jcp.1041460319; WANG DJ, 1992, J CELL PHYSIOL, V153, P221, DOI 10.1002/jcp.1041530202; WILLINGHAM MC, 1972, BIOCHEM BIOPH RES CO, V48, P743, DOI 10.1016/0006-291X(72)90669-9; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1990, J BIOL CHEM, V265, P21309; ZURIER RB, 1988, EXP CELL RES, V176, P155, DOI 10.1016/0014-4827(88)90129-2	57	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10789	10795						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8388375				2022-12-25	WOS:A1993LD46600015
J	WARNOCK, DE; ROBERTS, C; LUTZ, MS; BLACKBURN, WA; YOUNG, WW; BAENZIGER, JU				WARNOCK, DE; ROBERTS, C; LUTZ, MS; BLACKBURN, WA; YOUNG, WW; BAENZIGER, JU			DETERMINATION OF PLASMA-MEMBRANE LIPID MASS AND COMPOSITION IN CULTURED CHINESE-HAMSTER OVARY CELLS USING HIGH-GRADIENT MAGNETIC AFFINITY-CHROMATOGRAPHY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHEAT-GERM-AGGLUTININ; FIBRONECTIN RECEPTOR; NUCLEOTIDE PYROPHOSPHATASE; GLUCOSYLCERAMIDE SYNTHESIS; ENDOPLASMIC-RETICULUM; TRANSFERRIN RECEPTOR; GLUCOSIDASE-II; ANIMAL-CELLS; MDCK CELLS; CHOLESTEROL	We have utilized wheat germ agglutinin conjugated to iron/dextran particles in conjunction with high gradient magnetic affinity chromatography (HIMAC) to prepare plasma membranes from cultured cells. Membrane-impermeable succinimidyl esters inactivate alkaline phosphodiesterase 1 (APDE-1) and were used to establish the proportion of APDE-1 expressed at the cell surface. The yield of inhibitable APDE-1 provides an accurate indication of plasma membrane yield, which was >90% for Chinese hamster ovary (CHO) cells. Plasma membranes prepared by HIMAC contained <5-13% of endoplasmic reticulum, Golgi, mitochondria, lysosomes, or endosomes. Pulse-chase experiments performed with the alpha5beta1 integrin receptor confirmed the high yield of plasma membrane and demonstrated the utility of this procedure for examining trafficking of proteins to and from the plasma membrane. We determined the lipid content of plasma membranes prepared by HIMAC. CHO plasma membranes contain 49% of total cellular phospholipid, 69% of sphingomyelin, and 64% of cholesterol. Phosphatidylserine was the only glycerophospholipid highly enriched (71%) in the retained fraction. The glycosphingolipids lactosylceramide and ganglioside G(M3) were enriched in the plasma membrane fraction to the same extent as sphingomyelin. The major fraction of the glycosphingolipid precursors glucosylceramide and ceramide was localized to intracellular membranes. These findings indicate that the plasma membrane of CHO cells contains approximately half of the total cellular phospholipids and an even higher percentage of sphingomyelin and cholesterol. The high efficiency and rapidity of this isolation procedure should aid the analysis of plasma membrane components significantly.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,660 S EUCLID AVE,BOX 8118,ST LOUIS,MO 63110; UNIV LOUISVILLE,HLTH SCI CTR,DEPT BIOL,LOUISVILLE,KY 40292; UNIV LOUISVILLE,HLTH SCI CTR,DEPT BIOCHEM,LOUISVILLE,KY 40292; UNIV LOUISVILLE,HLTH SCI CTR,DEPT BIOPHYS SCI,LOUISVILLE,KY 40292	Washington University (WUSTL); University of Louisville; University of Louisville; University of Louisville					NCI NIH HHS [R37-CA21923] Funding Source: Medline; NIGMS NIH HHS [GM42698] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA021923] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barrett AJ, 1977, LYSOSOMES LABORATORY, P19; BECICH MJ, 1991, EUR J CELL BIOL, V55, P71; BECICH MJ, 1991, EUR J CELL BIOL, V55, P83; BIELAWSKA A, 1992, J BIOL CHEM, V267, P18493; BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; BRILES EB, 1977, J BIOL CHEM, V252, P1107; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BURNS DM, 1982, J BIOL CHEM, V257, P9991; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; COSTE H, 1986, BIOCHIM BIOPHYS ACTA, V858, P6, DOI 10.1016/0005-2736(86)90285-3; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; ESKO JD, 1980, J BIOL CHEM, V255, P4474; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; GERLACH E, 1963, BIOCHEM Z, V337, P477; HICKMAN S, 1985, J BIOL CHEM, V260, P6098; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; KAPLAN MR, 1985, J CELL BIOL, V101, P441, DOI 10.1083/jcb.101.2.441; KOBAYASHI T, 1989, J BIOL CHEM, V264, P5966; LAEMMLI UK, 1970, NATURE, V227, P720; LANGE Y, 1983, J BIOL CHEM, V258, P5130; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LAU JTY, 1981, J BIOL CHEM, V256, P7142; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; Marshall J.C, 1980, ANAL BIOCHEM, V104, P10; MAY WS, 1985, J MEMBRANE BIOL, V88, P205, DOI 10.1007/BF01871086; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; MORRE DJ, 1989, BIOTECHNIQUES, V7, P946; PHILLIPS AH, 1962, J BIOL CHEM, V237, P2652; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; RAUB TJ, 1989, EXP CELL RES, V184, P407, DOI 10.1016/0014-4827(89)90340-6; RAZZELL WE, 1963, METHOD ENZYMOL, V6, P236, DOI 10.1016/0076-6879(63)06169-3; REBBE NF, 1991, P NATL ACAD SCI USA, V88, P5192, DOI 10.1073/pnas.88.12.5192; REITMAN ML, 1982, J BIOL CHEM, V257, P357; RENKONEN O, 1972, BIOCHIM BIOPHYS ACTA, V255, P66, DOI 10.1016/0005-2736(72)90008-9; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; SAITO T, 1971, J LIPID RES, V12, P257; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SYMINGTON FW, 1987, J BIOL CHEM, V262, P11356; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014; THOMPSON TE, 1985, ANNU REV BIOPHYS BIO, V14, P361, DOI 10.1146/annurev.biophys.14.1.361; TRINCHERA M, 1991, J BIOL CHEM, V266, P20907; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VAN MEER G, 1987, TRENDS BIOCHEM SCI, V12, P375, DOI 10.1016/0968-0004(87)90173-3; VANGENDEREN IL, 1991, J CELL BIOL, V115, P1009, DOI 10.1083/jcb.115.4.1009; YOGEESWARAN G, 1974, BIOCHEM BIOPH RES CO, V56, P1010, DOI 10.1016/S0006-291X(74)80289-5; YOUNG WW, 1993, IN PRESS ADV LIPID R	47	107	108	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10145	10153						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8387513				2022-12-25	WOS:A1993LB80000033
J	GRAZIANI, A; GRAMAGLIA, D; DALLAZONCA, P; COMOGLIO, PM				GRAZIANI, A; GRAMAGLIA, D; DALLAZONCA, P; COMOGLIO, PM			HEPATOCYTE GROWTH-FACTOR SCATTER FACTOR STIMULATES THE RAS-GUANINE NUCLEOTIDE EXCHANGER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TYROSINE KINASE-ACTIVITY; MET PROTOONCOGENE; FACTOR RECEPTOR; C-MET; GENE-EXPRESSION; P21RAS; PROTEIN; IDENTIFICATION; ACTIVATION; SERUM	Hepatocyte growth factor/scatter factor (HGF/SF) induces mitogenesis and cell dissociation upon binding to the protein-tyrosine kinase receptor encoded by the MET proto-oncogene (p190MET). The signal transduction pathways downstream from the receptor activation are largely unknown. We show that HGF/SF activates Ras protein. HGF/SF stimulation of metabolically labeled A549 cells raised the amount of Ras-bound radiolabeled guanine nucleotides by over 5-fold. Furthermore, following HGF/SF stimulation of these cells, 50% of Ras was in the GTP-bound active state. The uptake by Ras of radiolabeled GTP was also increased by 5-fold following HGF/SF stimulation in digitonin-permeabilized A549 cells. Moreover, HGF/SF treatment of A549 cells leads to stimulation of the cytosolic Ras-guanine nucleotide exchange activity, measured as accelerated release of [H-3]GDP from purified recombinant Ras protein in vitro, in a dose- and time-dependent manner. Likewise, treatment with the protein-tyrosine kinase inhibitor 3-(1',4'dihydroxytetralyl)methylene-2-oxindole of GTL-16 cells (featuring a p190MET receptor constitutively active) significantly decreased the cytosolic Ras-guanine nucleotide exchange activity. These data demonstrate that HGF/SF activates Ras protein by shifting the equilibrium toward the GTP-bound state and increases the uptake of guanine nucleotides by Ras, through mechanism(s) including the activation of a Ras-guanine nucleotide exchanger.	UNIV TURIN,DEPT BIOMED SCI & ONCOL,I-10126 TURIN,ITALY	University of Turin			Graziani, Andrea/AAB-6301-2022; GRAMAGLIA, DANIELA/A-6354-2012; graziani, andrea/B-2554-2009	Graziani, Andrea/0000-0002-6302-2317; graziani, andrea/0000-0002-6302-2317; Gramaglia, Daniela/0000-0001-6259-0059; Comoglio, Paolo/0000-0002-7056-5328				BARDELLI A, 1992, ONCOGENE, V7, P1973; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; GIBBS JB, 1990, J BIOL CHEM, V265, P24037; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MICHALOPOULOS G, 1984, CANCER RES, V44, P4414; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAGAIKE M, 1991, J BIOL CHEM, V266, P22781; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; STERN CD, 1990, DEVELOPMENT, V110, P1271; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380	40	185	195	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9165	9168						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8387483				2022-12-25	WOS:A1993LA68900003
J	LAMB, JA; ALLEN, PG; TUAN, BY; JANMEY, PA				LAMB, JA; ALLEN, PG; TUAN, BY; JANMEY, PA			MODULATION OF GELSOLIN FUNCTION - ACTIVATION AT LOW PH OVERRIDES CA2+ REQUIREMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING SITES; PIG PLASMA GELSOLIN; F-ACTIN; ELECTROPERMEABILIZED NEUTROPHILS; CALCIUM DEPENDENCE; VILLIN; CA-2+; PROTEIN; CELLS; IDENTIFICATION	The activation of gelsolin by calcium has been postulated to be involved in the receptor-mediated reorganization of the actin cytoskeleton, but cytoskeletal reorganization can also occur in cells with intracellular Ca2+ clamped at nanomolar levels. Fluorescence measurements using Fura-2 show that at pH 7.4, the Ca2+ requirement for gelsolin activation in vitro is higher than previously reported, with half-maximal activation of severing and nucleation occurring at 10 muM Ca2+. The Ca2+ requirement for gelsolin activity decreases at more acid pH and is approximately 3 muM at pH 6.5. At pH below 6.0, gelsolin no longer requires Ca2+ for activity and severs actin filaments, binds two actin monomers, and nucleates filament formation in EGTA-containing solutions. The pH-activated severing activity is inhibited by mixed lipid vesicles containing phosphatidylinositol 4,5-bisphosphate. A Ca2+-sensitive fragment consisting of the first 135 amino acids of human cytoplasmic gelsolin also demonstrates severing activity at pH <6.0 in the absence of Ca2+. In contrast, the gelsolin homologs severin and villin maintain Ca2+ regulation of severing activity at low pH. These differences suggest that activation of gelsolin at low pH cannot be explained merely by destabilization of F-actin. The difference in diffusion constants of gelsolin measured at pH 5.5 and 6.5, as determined by dynamic light scattering, suggests that the molecule undergoes a shape change similar to that reported upon binding Ca2+ at neutral pH. These results suggest a mechanism by which gelsolin may be activated in vivo under conditions where Ca2+ transients do not occur.	BRIGHAM & WOMENS HOSP,DIV EXPTL MED,221 LONGWOOD AVE,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED & BIOL CHEM,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NHLBI NIH HHS [HL07680] Funding Source: Medline; NIAMS NIH HHS [AR38910] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038910, R29AR038910] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDRE E, 1988, J BIOL CHEM, V263, P722; Berne B. J., 1976, DYNAMIC LIGHT SCATTE, P1; BRUNKHORST BA, 1992, INFECT IMMUN, V60, P2957, DOI 10.1128/IAI.60.7.2957-2968.1992; BRYAN J, 1984, J BIOL CHEM, V259, P7480; BRYAN J, 1986, J CELL BIOL, V102, P1439, DOI 10.1083/jcb.102.4.1439; BRYAN J, 1988, J CELL BIOL, V106, P1553, DOI 10.1083/jcb.106.5.1553; CHAPONNIER C, 1987, J EXP MED, V165, P97, DOI 10.1084/jem.165.1.97; COOPER JA, 1988, J CELL BIOL, V106, P1229, DOI 10.1083/jcb.106.4.1229; COPPER JA, 1987, J CELL BIOL, V104, P491; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DADABAY CY, 1991, J CELL BIOL, V112, P1151, DOI 10.1083/jcb.112.6.1151; DEARRUDA MV, 1992, J BIOL CHEM, V267, P13079; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; DOI Y, 1990, BIOCHEMISTRY-US, V29, P1392, DOI 10.1021/bi00458a008; DOWNEY GP, 1990, J CELL BIOL, V110, P1975, DOI 10.1083/jcb.110.6.1975; DOWNEY GP, 1989, BIOCHEM BIOPH RES CO, V160, P18, DOI 10.1016/0006-291X(89)91614-8; EICHINGER L, 1992, THESIS LUDWIG MAXIMI; ELSON EL, 1988, ANNU REV BIOPHYS BIO, V17, P397; GLENNEY J, 1986, J BIOL CHEM, V261, P4247; GRODEN DL, 1991, CELL CALCIUM, V12, P279, DOI 10.1016/0143-4160(91)90002-V; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARTWIG J, 1989, J CELL BIOL, V109, P467; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HESTERBERG LK, 1983, J BIOL CHEM, V258, P365; HUCKRIEDE A, 1990, CELL MOTIL CYTOSKEL, V16, P229, DOI 10.1002/cm.970160403; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; JANMEY PA, 1988, BIOCHEMISTRY-US, V27, P8218, DOI 10.1021/bi00421a035; JANMEY PA, 1985, BIOCHEMISTRY-US, V24, P3714, DOI 10.1021/bi00335a046; JANNMEY PA, 1987, J BIOL CHEM, V262, P12228; KAMBE H, 1992, J BIOCHEM-TOKYO, V111, P722, DOI 10.1093/oxfordjournals.jbchem.a123825; KAMP F, 1992, P NATL ACAD SCI USA, V89, P11367, DOI 10.1073/pnas.89.23.11367; KILHOFFER MC, 1985, BIOCHEMISTRY-US, V24, P5653, DOI 10.1021/bi00341a055; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LAHAM LE, 1992, MOL BIOL CELL, V3, pA41; LATTANZIO FA, 1991, BIOCHEM BIOPH RES CO, V177, P184, DOI 10.1016/0006-291X(91)91966-G; LEW DP, 1985, NATURE, V315, P509, DOI 10.1038/315509a0; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MANNHERZ HG, 1992, J MOL BIOL, V226, P899, DOI 10.1016/0022-2836(92)90641-V; MARKS PW, 1991, ANAL BIOCHEM, V193, P61, DOI 10.1016/0003-2697(91)90044-T; MCLAUGHLIN S, 1989, ANNU REV BIOPHYS BIO, V18, P113, DOI 10.1146/annurev.biophys.18.1.113; NACCACHE PH, 1989, J IMMUNOL, V142, P2438; NORTHROP J, 1986, J BIOL CHEM, V261, P9274; PATKOWSKI A, 1990, BIOPOLYMERS, V30, P427, DOI 10.1002/bip.360300320; POPE B, 1986, EUR J BIOCHEM, V161, P85, DOI 10.1111/j.1432-1033.1986.tb10127.x; SELVE N, 1987, EUR J BIOCHEM, V168, P111, DOI 10.1111/j.1432-1033.1987.tb13394.x; SOBER H, 1970, CRC HDB BIOCH, pJ67; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; TONETTI M, 1990, BIOCHIM BIOPHYS ACTA, V1054, P154, DOI 10.1016/0167-4889(90)90236-7; WALSH TP, 1984, BIOCHEMISTRY-US, V23, P6099, DOI 10.1021/bi00320a030; WAY M, 1988, J MOL BIOL, V203, P1127, DOI 10.1016/0022-2836(88)90132-5; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; WEEDS AG, 1986, EUR J BIOCHEM, V161, P69, DOI 10.1111/j.1432-1033.1986.tb10125.x; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; YIN HL, 1988, J CELL BIOL, V106, P805, DOI 10.1083/jcb.106.3.805; YIN HL, 1987, BIOESSAYS, V7, P176, DOI 10.1002/bies.950070409; ZIMMERLE CT, 1988, BIOCHEMISTRY-US, V27, P7766, DOI 10.1021/bi00420a027	60	106	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8999	9004						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8386174				2022-12-25	WOS:A1993KX81100089
J	BALZARINI, J; BOHMAN, C; DECLERCQ, E				BALZARINI, J; BOHMAN, C; DECLERCQ, E			DIFFERENTIAL MECHANISM OF CYTOSTATIC EFFECT OF (E)-5-(2-BROMOVINYL)-2'-DEOXYURIDINE, 9-(1,3-DIHYDROXY-2-PROPOXYMETHYL)GUANINE, AND OTHER ANTIHERPETIC DRUGS ON TUMOR-CELLS TRANSFECTED BY THE THYMIDINE KINASE GENE OF HERPES-SIMPLEX VIRUS TYPE-1 OR TYPE-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMIDYLATE SYNTHETASE; NUCLEOSIDE ANALOGS; 5-SUBSTITUTED 2'-DEOXYURIDINES; DEOXYTHYMIDINE KINASES; TARGET ENZYME; SYNTHASE; STRAINS; AGENT; 9-(2-HYDROXYETHOXYMETHYL)GUANINE; ESTABLISHMENT	After they have been transfected with the herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2) thymidine kinase (TK) gene murine mammary carcinoma (FM3A) cells become highly sensitive to the growth inhibitory properties of the antiherpetic agents (E)5-(2-bromovinyl)-2'-deoxyuridine (BVDU), 9-[(2-hydroxyethoxy)methyl]guanine (acyclovir, ACV), 9-[(1,3-dihydroxy-2-propoxy)methyl[guanine (DHPG, ganciclovir), and 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-methyluracil (FMAU). BVDU was 100-fold more potent an inhibitor of HSV TK gene-transfected tumor cell growth (50% inhibitory concentration (IC50), 0.0020-0.0047 muM) than FMAU or DHPG (IC50, 0.051-0.277 muM) and 1000-fold more potent than ACV (IC50, 0.42-4.9 muM). As a rule, the test compounds were more cytostatic to HSV-2 TK than HSV-1 TK gene-transfected FM3A cells. This may be ascribed to the higher phosphorylating capacity (V(max)/K(m)) of HSV-2 TK than HSV-1 TK and/or to the higher TK enzyme levels of the HSV-2 TK gene-transfected FM3A cells than the HSV-1 TK gene-transfected FM3A cells. Thymidylate synthase of the HSV TK gene-transfected FM3A cells appears to be the target enzyme for the cytostatic action of BVDU, but not FMAU, DHPG, or ACV. Instead, the cytostatic activity of DHPG seems to be correlated with its conversion to the triphosphate form and subsequent incorporation into the DNA of HSV TK gene-transfected FM3A cells.			BALZARINI, J (corresponding author), CATHOLIC UNIV LEUVEN,REGA INST MED RES,MINDERBROEDERSSTR 10,B-3000 LOUVAIN,BELGIUM.			De Clercq, Erik/0000-0002-2985-8890				AYUSAWA D, 1981, SOMAT CELL GENET, V7, P523, DOI 10.1007/BF01549656; AYUSAWA D, 1980, SOMAT CELL GENET, V6, P261, DOI 10.1007/BF01538800; AYUSAWA D, 1985, JPN J CANCER RES, V76, P984; BALZARINI J, 1989, METHOD FIND EXP CLIN, V11, P379; BALZARINI J, 1987, MOL PHARMACOL, V32, P410; BALZARINI J, 1984, BIOCHIM BIOPHYS ACTA, V785, P36, DOI 10.1016/0167-4838(84)90231-0; BALZARINI J, 1985, FEBS LETT, V185, P95, DOI 10.1016/0014-5793(85)80747-X; BALZARINI J, 1985, MOL PHARMACOL, V28, P581; BALZARINI J, 1982, BIOCHEM PHARMACOL, V31, P3673, DOI 10.1016/0006-2952(82)90594-9; BORRELLI E, 1988, P NATL ACAD SCI USA, V85, P7572, DOI 10.1073/pnas.85.20.7572; CHEN MS, 1978, J BIOL CHEM, V253, P1325; CHENG YC, 1981, MOL PHARMACOL, V20, P230; CHENG YC, 1983, P NATL ACAD SCI-BIOL, V80, P2767, DOI 10.1073/pnas.80.9.2767; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; De Clercq E, 1986, Verh K Acad Geneeskd Belg, V48, P261; DECLERCQ E, 1984, J ANTIMICROB CHEMOTH, V14, P85, DOI 10.1093/jac/14.suppl_A.85; DECLERCQ E, 1984, BIOCHEM PHARMACOL, V33, P2159, DOI 10.1016/0006-2952(84)90649-X; DECLERCQ E, 1980, J INFECT DIS, V141, P563, DOI 10.1093/infdis/141.5.563; DECLERCQ E, 1979, P NATL ACAD SCI USA, V76, P2947, DOI 10.1073/pnas.76.6.2947; DECLERCQ E, 1981, MOL PHARMACOL, V19, P321; ELION GB, 1977, P NATL ACAD SCI USA, V74, P5716, DOI 10.1073/pnas.74.12.5716; FIELD AK, 1983, P NATL ACAD SCI-BIOL, V80, P4139, DOI 10.1073/pnas.80.13.4139; JONES AS, 1979, TETRAHEDRON LETT, V45, P4415; LOPEZ C, 1980, ANTIMICROB AGENTS CH, V17, P803, DOI 10.1128/AAC.17.5.803; MACHIDA H, 1982, ANTIMICROB AGENTS CH, V21, P358, DOI 10.1128/AAC.21.2.358; MAR EC, 1984, J GEN VIROL, V65, P47, DOI 10.1099/0022-1317-65-1-47; MAR EC, 1985, J VIROL, V53, P776, DOI 10.1128/JVI.53.3.776-780.1985; MOOLTEN FL, 1986, CANCER RES, V46, P5276; RUTH JL, 1981, MOL PHARMACOL, V20, P415; SHIMIZU K, 1986, CELL STRUCT FUNCT, V11, P295, DOI 10.1247/csf.11.295; SMEE DF, 1985, BIOCHEM PHARMACOL, V34, P1049, DOI 10.1016/0006-2952(85)90608-2; SMEE DF, 1983, ANTIMICROB AGENTS CH, V23, P676, DOI 10.1128/AAC.23.5.676; STONE R, 1992, SCIENCE, V256, P1513, DOI 10.1126/science.1317967; ZOU FC, 1984, BIOCHEM PHARMACOL, V33, P1797, DOI 10.1016/0006-2952(84)90352-6	34	127	135	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6332	6337						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8384209				2022-12-25	WOS:A1993KT36800040
J	FORMISANO, P; SOHN, KJ; MIELE, C; DIFINIZIO, B; PETRUZZIELLO, A; RICCARDI, G; BEGUINOT, L; BEGUINOT, F				FORMISANO, P; SOHN, KJ; MIELE, C; DIFINIZIO, B; PETRUZZIELLO, A; RICCARDI, G; BEGUINOT, L; BEGUINOT, F			MUTATION IN A CONSERVED MOTIF NEXT TO THE INSULIN-RECEPTOR KEY AUTOPHOSPHORYLATION SITES DE-REGULATES KINASE-ACTIVITY AND IMPAIRS INSULIN ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; TYROSINE PROTEIN-KINASE; SKELETAL-MUSCLE CELLS; BETA-SUBUNIT; HEPATOMA-CELLS; RESIDUES 1162; PHOSPHORYLATION; REPLACEMENT; ACTIVATION; INVITRO	We have recently reported two non-insulin-dependent diabetic patients exhibiting a heterozygous point mutation (R1152-Q) next to the key tyrosine autophosphorylation sites (Y1146, Y1150, Y1151) of the insulin receptor. In the present study, we demonstrate that the Q1152 mutation alters a previously unrecognized consensus sequence in the insulin receptor family of tyrosine kinases. To define the effect of this alteration on insulin receptor function, the mutant insulin receptor (Q1152) was constructed and overexpressed in NIH-3T3 cells. In spite of normal insulin binding, ''in vivo'' and ''in vitro'' autophosphorylation as well as transphosphorylation by the wild-type receptor (WT) were deficient in Q1152 as compared with the transfected WT receptors. Insulin-stimulated kinase activity toward poly(Glu, Tyr) 4:1 and the endogenous substrates p120 and p175 were also impaired in Q1152. However, insulin-independent kinase activity of Q1152 was 2-5-fold higher than that of WT. While insulin stimulated 2-deoxyglucose uptake and glycogen synthase activity in WT-transfected cells with a sensitivity proportional to receptor number, no insulin stimulation was observed in Q1152 cells. Similar to the kinase, insulin-independent glycogen synthase activity and 2-deoxyglucose uptake were 2-fold higher in Q1152 than in either WT or parental cells. We conclude that the Q1152 mutation deregulates insulin receptor kinase and generates insulin insensitivity in cells. Alterations in this highly conserved region of the insulin receptor may contribute to non-insulin dependent diabetes mellitin pathogenesis in humans.	CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,VIA S PANSINI 5,I-80131 NAPLES,ITALY; UNIV NAPLES 2,SCH MED,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC LUIGI CALIFANO,NAPLES,ITALY; UNIV NAPLES 2,SCH MED,IST MED INTERNA,NAPLES,ITALY; OSPED SAN RAFFAELE,DIBIT,MOLEC ONCOL LAB,MILAN,ITALY; UNIV COPENHAGEN,INST MICROBIOL,COPENHAGEN K,DENMARK	Consiglio Nazionale delle Ricerche (CNR); Universita della Campania Vanvitelli; Universita della Campania Vanvitelli; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Copenhagen			Formisano, Pietro/J-4237-2018; riccardi, gabriele/A-9269-2012; PETRUZZIELLO, ARNOLFO/O-1163-2017	Formisano, Pietro/0000-0001-7020-6870; PETRUZZIELLO, ARNOLFO/0000-0003-0353-9151				ACCILI D, 1991, J BIOL CHEM, V266, P434; AVRUCH J, 1989, MOL CELLULAR BIOL DI, P65; Battey, 1986, BASIC METHODS MOL BI; BEGUINOT F, 1989, ENDOCRINOLOGY, V125, P1599, DOI 10.1210/endo-125-3-1599; BEGUINOT F, 1988, BIOCHEMISTRY-US, V27, P3222, DOI 10.1021/bi00409a015; BEGUINOT F, 1986, ENDOCRINOLOGY, V118, P446, DOI 10.1210/endo-118-1-446; CAMA A, 1992, J BIOL CHEM, V267, P8383; COCOZZA S, 1992, DIABETES, V41, P521, DOI 10.2337/diabetes.41.4.521; CUATRECASAS P, 1972, P NATL ACAD SCI USA, V69, P318, DOI 10.1073/pnas.69.2.318; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FLIER JS, 1989, MOL CELLULAR BIOL DI, V2, P175; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; GOREN HJ, 1987, BIOCHEMISTRY-US, V26, P2374, DOI 10.1021/bi00382a044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRANDORI C, 1989, NATURE, V338, P467, DOI 10.1038/338467a0; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HELIN K, 1991, ONCOGENE, V6, P825; HERRERA R, 1986, J BIOL CHEM, V261, P1980; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KASUGA M, 1982, NATURE, V298, P667, DOI 10.1038/298667a0; KLEIN HH, 1986, J BIOL CHEM, V261, P4691; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANDARINO LJ, 1986, AM J PHYSIOL, V251, pE489, DOI 10.1152/ajpendo.1986.251.4.E489; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MCCLAIN DA, 1989, MOL CELLULAR BIOL DI, V2, P53; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; NISHIDA Y, 1986, BIOCHEM BIOPH RES CO, V141, P474, DOI 10.1016/S0006-291X(86)80197-8; Potts W M, 1988, Oncogene Res, V3, P343; REESJONES RW, 1985, J BIOL CHEM, V260, P4461; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P4593; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VELU TJ, 1989, J CELL BIOCHEM, V39, P153, DOI 10.1002/jcb.240390207; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; YU KT, 1986, J BIOL CHEM, V261, P4715; ZHANG B, 1991, J BIOL CHEM, V266, P990	51	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5241	5248						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8383132				2022-12-25	WOS:A1993KP88400097
J	VOSS, T; WALLNER, E; CZERNILOFSKY, AP; FREISSMUTH, M				VOSS, T; WALLNER, E; CZERNILOFSKY, AP; FREISSMUTH, M			AMPHIPATHIC ALPHA-HELICAL STRUCTURE DOES NOT PREDICT THE ABILITY OF RECEPTOR-DERIVED SYNTHETIC PEPTIDES TO INTERACT WITH GUANINE NUCLEOTIDE-BINDING REGULATORY PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; DOPAMINE RECEPTOR; BOVINE BRAIN; MASTOPARAN; SUBUNITS; SUBTYPES; CLONING; GS; GI	In guanine nucleotide-binding regulatory protein-(G protein) coupled receptors, an amphipathic alpha-helix has been postulated to be the common structural determinant in the NH2- and COOH-terminal portions of the third intracellular loop representing the major interaction site with the G proteins. Here we assessed the ability of six peptides derived from these sites of the human dopamine D1-, D2-, and beta1-adrenergic receptors to either activate G proteins directly or to uncouple the activity of their respective receptors in a native membrane environment. In addition, the cross-reactivity was analyzed. Nonspecific effects occurring at high concentrations were differentiated from G protein-specific effects. The peptide D2N derived from the NH2-terminal part of the third intracellular loop of the dopamine D2 receptor was the only one capable of specifically reversing the action of its receptor, the dopamine-mediated inhibition of the adenylyl cyclase. Furthermore, only D2N stimulated pertussis toxin-sensitive G proteins. However, D2N as the only peptide exhibiting specific effects did not exhibit the predicted amphipathic alpha-helix observed for mastoparan (Higashijima, T., Burnier, J., and Ross, E. M. (1990) J. Biol. Chem. 265, 14176-14186) as demonstrated by circular dichroism spectroscopy. In contrast, a peptide for which a certain degree of helicality was verified spectroscopically (D1C) was neither active in GTPase and adenylyl cyclase determinations, nor did it block the receptor-mediated cyclase activation. Hence, the amphipathic alpha-helix does not represent the main structural determinant for the receptor-G protein interaction site.	UNIV VIENNA,INST PHARMACOL,A-1090 VIENNA,AUSTRIA	University of Vienna	VOSS, T (corresponding author), FA BENDER & CO,ERNST BOEHRINGER INST ARZNEIMITTELFORSCH,DEPT PROT CHEM,DR BOEHRINGER GASSE 5-11,A-1121 VIENNA,AUSTRIA.			Freissmuth, Michael/0000-0001-9398-1765				BERTIN B, 1992, J BIOL CHEM, V267, P8200; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; CHEUNG AH, 1989, MOL PHARMACOL, V34, P132; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DALTOSO R, 1989, EMBO J, V8, P4025, DOI 10.1002/j.1460-2075.1989.tb08585.x; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; FAERMAN CH, 1992, PROTEINS, V12, P111, DOI 10.1002/prot.340120204; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FREISSMUTH M, 1991, J BIOL CHEM, V266, P17778; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; HAUSLEITHNER V, 1985, BIOCHEM J, V232, P501, DOI 10.1042/bj2320501; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUROSE H, 1991, BIOCHEMISTRY-US, V30, P3335, DOI 10.1021/bi00227a024; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MCCLUE SJ, 1992, BIOCHEM J, V284, P565, DOI 10.1042/bj2840565; MUNCH G, 1991, EUR J BIOCHEM, V198, P357, DOI 10.1111/j.1432-1033.1991.tb16023.x; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; PALM D, 1989, FEBS LETT, V254, P89, DOI 10.1016/0014-5793(89)81015-4; Sambrook J, 1989, MOL CLONING LABORATO; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211	32	61	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4637	4642						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8383121				2022-12-25	WOS:A1993KP88400015
J	HAMAGUCHI, M; XIAO, H; UEHARA, Y; OHNISHI, Y; NAGAI, Y				HAMAGUCHI, M; XIAO, H; UEHARA, Y; OHNISHI, Y; NAGAI, Y			HERBIMYCIN-A INHIBITS THE ASSOCIATION OF P60(V-SRC) WITH THE CYTOSKELETAL STRUCTURE AND WITH PHOSPHATIDYLINOSITOL-3' KINASE	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; CHICKEN-EMBRYO FIBROBLASTS; GTPASE-ACTIVATING PROTEIN; INSOLUBLE CELLULAR MATRIX; PLASMA-MEMBRANE MATRIX; SRC GENE-PRODUCT; TYROSINE KINASES; TRANSFORMING PROTEIN; CELLS; PHOSPHORYLATION	To search for the biochemical prerequisites for morphological transformation by p60v-src, we examined the effect of herbimycin A, a potent inhibitor of cell transformation. on chicken embryonic fibroblasts transformed by Rous sarcoma virus. A small dose of herbimycin (0.1-0.3 mug ml-1) was enough to convert the cell morphology to a normal phenotype with a concomitant reassembly of microfilament bundles. In the cells treated with the drug, the majority of the substrates for p60v-src remained phosphorylated and p60v-src was myristylated, membrane associated and fairly active as a protein kinase. Under the same conditions, however, the association of p60v-src with the cytoskeletal structure and with phosphatidylinositol 3' kinase was strongly inhibited, suggesting that the interactions of p60v-src with the cellular structure and the enzyme were indispensable for morphological transformation.	NATL INST HLTH,DEPT ANTIBIOT,TOKYO 141,JAPAN	National Institute of Health Sciences - Japan	HAMAGUCHI, M (corresponding author), NAGOYA UNIV,SCH MED,DIS MECH & CONTROL RES INST,TURUMAI CHO 65,SHOUWA KU,NAGOYA,AICHI 466,JAPAN.							BEUG H, 1978, CELL, V45, P105; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FUKAMI Y, 1986, P NATL ACAD SCI USA, V83, P4190, DOI 10.1073/pnas.83.12.4190; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GOULD KL, 1986, J CELL BIOL, V102, P660, DOI 10.1083/jcb.102.2.660; HAMAGUCHI M, 1985, VIROLOGY, V147, P295, DOI 10.1016/0042-6822(85)90132-1; HAMAGUCHI M, 1989, ONCOGENE RES, V4, P29; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1990, MOL CELL BIOL, V10, P830, DOI 10.1128/MCB.10.2.830; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HANAFUSA H, 1969, P NATL ACAD SCI USA, V77, P1311; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P401; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KRUEGER JG, 1983, CURR TOP MICROBIOL, V107, P51; LENK R, 1977, CELL, V10, P67, DOI 10.1016/0092-8674(77)90141-6; LEVINSON AD, 1978, CELL, V15, P561, DOI 10.1016/0092-8674(78)90024-7; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PASQUALE EB, 1986, P NATL ACAD SCI USA, V83, P5507, DOI 10.1073/pnas.83.15.5507; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STOCKER AW, 1986, J VIROL, V58, P876; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; WELHAM MJ, 1988, J VIROL, V62, P1898, DOI 10.1128/JVI.62.6.1898-1906.1988	40	51	51	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					559	564						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8382356				2022-12-25	WOS:A1993KN00800005
J	BIRD, GS; BURGESS, GM; PUTNEY, JW				BIRD, GS; BURGESS, GM; PUTNEY, JW			SULFHYDRYL-REAGENTS AND CAMP-DEPENDENT KINASE INCREASE THE SENSITIVITY OF THE INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR IN HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG HEPATOCYTES; CALCIUM RELEASE; TRISPHOSPHATE; THIMEROSAL; MOBILIZATION; OSCILLATIONS; VASOPRESSIN; HORMONES; GLUCAGON; THIOL	Sulfhydryl reagents such as tert-butyl hydroperoxide (TBHP) have been shown to increase cytosolic Ca2+ concentration ([Ca2+]i) in rat hepatocytes in a way that resembles responses to Ca2+-mobilizing hormones (Saikada, I., Thomas, A. P., and Farber, J. L. (1991) J. Biol. Chem. 266, 717-722; Rooney, T. A., Renard, D. C., Sass, E. J., and Thomas, A. P. (1991) J. Biol. Chem. 266, 12272-12282) and to increase the amount of Ca2+ released by inositol 1,4,5-trisphosphate ((1,4,5)IP3) from permeable rat liver cells (Rooney et al., 1991, op. cit.; Missiaen, L., Taylor, C. W., and Berridge, M. J. (1991) Nature 352, 241-244; Renard, D. C., Seitz, M. B., and Thomas, A. P. (1992) Biochem. J. 284, 507-512). The effects of sulfhydryl reagents were studied in fura-2-injected rat and guinea pig hepatocytes and compared with the actions of cAMP (Burgess, G. M., Bird, G. St. J., Obie, J. F., and Putney, J. W., Jr. (1991) J. Biol. Chem. 261, 4772-4781). In rat liver cells, the increases in [Ca2+]i induced by TBHP and thimerosal were prevented by microinjection of the cells with the (1,4,5)IP3 receptor antagonist heparin. In guinea pig hepatocytes, TBHP was not able to increase [Ca2+]i unless the cells were pretreated with angiotensin II to raise endogenous levels of (1,4,5)IP3 or were first injected with a sub-threshold concentration of inositol 2,4,5-trisphosphate ((2,4,5)IP3). The responses to TBHP in (2,4,5)IP3-injected guinea pig cells were also blocked by heparin. In many respects, the actions of TBHP appeared to be similar to those of cAMP, which has previously been shown to increase sensitivity to (1,4,5)IP3 in intact guinea pig hepatocytes (Burgess et al., 1991, op. cit.). TBHP also mimicked the effect of cAMP-dependent kinase (PKA) in permeabilized guinea pig hepatocytes by increasing the amount of Ca2+ released by (1,4,5)IP3. The responses to TBHP and cAMP in (2,4,5)IP3-injected guinea pig hepatocytes differed, however, in that the increase in [Ca2+]i evoked by elevating intracellular cAMP was greatly reduced by Wiptide, an inhibitor of PKA, while Wiptide had no effect on the Ca2+ transients induced by TBHP. This provides evidence that the sensitizing effect of TBHP is not mediated by PKA and is more likely to be a direct effect on the inositol trisphosphate receptor. It is possible, however, that the sulfhydryl reagents and PKA act on a common regulatory site on the receptor protein.	NIEHS,CELLULAR & MOLEC PHARMACOL LAB,CALCIUM REGULAT SECT,RES TRIANGLE PK,NC 27709; SANDOZ INST MED RES,LONDON WC1E 6BN,ENGLAND	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Novartis; Sandoz			Bird, Gary/AAI-8186-2021; Putney, James W/F-7247-2019	Bird, Gary/0000-0003-1389-8748; Putney, James W/0000-0002-3379-4789				BELLOMO G, 1985, HEPATOLOGY, V5, P876, DOI 10.1002/hep.1840050529; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; BURGESS GM, 1986, MOL PHARMACOL, V30, P315; BURGESS GM, 1983, J BIOL CHEM, V258, P5336; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; CAPIOD T, 1991, J PHYSL, V427, pP22; CARROLL J, 1992, J BIOL CHEM, V267, P11196; COBBOLD PH, 1991, CELL CALCIUM, V12, P87, DOI 10.1016/0143-4160(91)90011-3; COMBETTES L, 1986, BIOCHEM J, V237, P675, DOI 10.1042/bj2370675; FURUICHI T, 1989, J NEUROSCI, V6, P954; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HATZELMANN A, 1990, BIOCHEM PHARMACOL, V39, P559, DOI 10.1016/0006-2952(90)90064-R; JENKINSON DH, 1977, BRIT J PHARMACOL, V83, P281; KRAUSFRIEDMANN N, 1986, P NATL ACAD SCI USA, V83, P8943, DOI 10.1073/pnas.83.23.8943; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MIYAZAKI S, 1992, FEBS LETT, V309, P180, DOI 10.1016/0014-5793(92)81090-9; PAROD RJ, 1980, AM J PHYSIOL, V239, pG106, DOI 10.1152/ajpgi.1980.239.2.G106; POGGIOLI J, 1986, BIOCHEM J, V235, P663, DOI 10.1042/bj2350663; RENARD DC, 1992, BIOCHEM J, V284, P507, DOI 10.1042/bj2840507; ROONEY TA, 1991, J BIOL CHEM, V266, P12272; SAKAIDA I, 1991, J BIOL CHEM, V266, P717; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; THORN P, 1992, PFLUG ARCH EUR J PHY, V422, P173, DOI 10.1007/BF00370417; WALAAS SI, 1986, J NEUROSCI, V6, P954; YANG CM, 1989, J RECEPTOR RES, V9, P159, DOI 10.3109/10799898909066051	27	106	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17917	17923						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8394353				2022-12-25	WOS:A1993LT74300044
J	STEPHENS, L; JACKSON, T; HAWKINS, PT				STEPHENS, L; JACKSON, T; HAWKINS, PT			SYNTHESIS OF PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE IN PERMEABILIZED NEUTROPHILS REGULATED BY RECEPTORS AND G-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; HUMAN PLATELETS; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; MYOINOSITOL 1,3,4,5,6-PENTAKISPHOSPHATE; INOSITOL PHOSPHOLIPIDS; AVIAN ERYTHROCYTES; KINASE	Formylated Met-Leu-Phe (fMLP), platelet-activating factor (PAF), ATP, and various nonhydrolyzable guanine nucleotides stimulated accumulation of phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4 5)P3) in intact human neutrophils. A protocol was devised to selectively inhibit the capacity of the nucleotide-sensitive receptors to elicit accumulation of PtdIns (3,4,5)P3. This enabled study of the regulation of phosphoinositide 3OH-kinase (PI3K) activities in permeabilized neutrophils free from interference due to activation of cell-surface nucleotide receptors. FMLP, PAF, and nonhydrolyzable GTP analogues stimulated an increase in the concentration, and rate of synthesis, of PtdIns(3,4,5)P3 in permeabilized neutrophils by increasing the rate of a PtdIns(4,5)P2-directed PI3K-catalyzed reaction. A number of characteristics of these responses, including their relative sensitivities to inhibition by pertussis toxin and guanosine 5'-beta(thio)diphosphate, suggested that fMLP and PAF increased this PI3K activity via the actions of heterotrimeric G-proteins. Basal and guanosine 5'-gamma(thio)triphosphate/fMLP-stimulated increases in PI3K activity were resistant to changes in free calcium concentrations, staurosporine, acute treatment with phorbol esters, and evidently to permeabilization. This, in conjunction with other work, indicates that the PAF and fMLP-induced increase in PtdIns(4,5)P2-directed PI3K activity is not being produced via activation of a currently defined G-protein regulated effector enzyme, or a protein tyrosine kinase coordinated mechanism of a type already known to regulate PI3K activities.			STEPHENS, L (corresponding author), AFRC,INST ANIM PHYSIOL & GENET RES,DEPT BIOCHEM,CAMBRIDGE CB2 4AT,ENGLAND.			Hawkins, Phillip/0000-0002-6979-0464; stephens, len/0000-0002-2771-3487				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BERKOW RL, 1990, BLOOD, V75, P2445; BILLAH MM, 1991, BIOCHEM SOC T, V19, P324, DOI 10.1042/bst0190324; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTER AN, 1992, J BIOL CHEM, V267, P14563; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; COCKCROFT S, 1991, BIOCHEM SOC T, V19, P333, DOI 10.1042/bst0190333; COWEN DS, 1990, J BIOL CHEM, V265, P16181; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; CUNNINGHAM TW, 1991, BIOCHEM BIOPH RES CO, V175, P568, DOI 10.1016/0006-291X(91)91603-A; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUJITAYAMAGUCHI Y, 1988, BIOCHEM BIOPH RES CO, V157, P955, DOI 10.1016/S0006-291X(88)80967-7; GIERSCHIK P, 1991, EUR J BIOCHEM, V197, P725, DOI 10.1111/j.1432-1033.1991.tb15964.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HUANG CK, 1990, BIOCHEM J, V269, P431, DOI 10.1042/bj2690431; HUANG SJ, 1988, BIOCHEM J, V249, P839, DOI 10.1042/bj2490839; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KING WG, 1991, BIOCHEM J, V278, P475, DOI 10.1042/bj2780475; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; NASMITH PE, 1989, BIOCHEM J, V257, P893, DOI 10.1042/bj2570893; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS LR, 1988, BIOCHEM J, V253, P721, DOI 10.1042/bj2530721; STEPHENS LR, 1990, BIOCHEM J, V265, P435, DOI 10.1042/bj2650435; STEPHENS LR, 1990, BIOCHEM J, V269, P65, DOI 10.1042/bj2690065; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STERNWEIS PC, 1992, PHILOS T ROY SOC B, V336, P35, DOI 10.1098/rstb.1992.0041; THOMAS GMH, 1991, EMBO J, V10, P2507, DOI 10.1002/j.1460-2075.1991.tb07790.x; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; VLAHOS CJ, 1992, FEBS LETT, V309, P242, DOI 10.1016/0014-5793(92)80781-B; WAHL MI, 1992, J BIOL CHEM, V267, P10447; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YAMAMOTO K, 1990, BIOCHEM BIOPH RES CO, V168, P466, DOI 10.1016/0006-291X(90)92344-Y; YATOMI Y, 1992, BIOCHEM BIOPH RES CO, V186, P1480, DOI 10.1016/S0006-291X(05)81573-6; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	46	75	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17162	17172						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8394332				2022-12-25	WOS:A1993LQ98800045
J	GEBBINK, MFBG; ZONDAG, GCM; WUBBOLTS, RW; BEIJERSBERGEN, RL; VANETTEN, I; MOOLENAAR, WH				GEBBINK, MFBG; ZONDAG, GCM; WUBBOLTS, RW; BEIJERSBERGEN, RL; VANETTEN, I; MOOLENAAR, WH			CELL-CELL ADHESION MEDIATED BY A RECEPTOR-LIKE PROTEIN-TYROSINE-PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NERVOUS-SYSTEM AXONS; GROWTH-FACTOR; INSECT CELLS; DROSOPHILA; PHOSPHORYLATION; EXPRESSION; CLONING; FAMILY; GENE	Receptor-like protein tyrosine phosphatases (receptor-PTPs) represent a novel family of transmembrane proteins that are thought to play important roles in cellular regulation. They consist of a cytoplasmic catalytic region, a single transmembrane segment and an extracellular, putative ligand-binding domain, hut the nature of their physiological ligands is unknown. We have recently cloned a new receptor-PTP (RPTPmu), the ectodomain of which includes an Ig-like and four fibronectin type III-like domains, suggesting that RPTPmu may be involved in cell-cell or cell-matrix interactions. To test this hypothesis, we expressed RPTPmu in insect Sf9 cells using recombinant baculovirus. We demonstrate that RPTPmu dramatically promotes cell-to-cell adhesion in a homophilic, Ca2+-independent manner. No adhesion is observed in Sf9 cells expressing a chimeric RPTPmu molecule containing the extracellular domain of the epidermal growth factor receptor. Furthermore, cells expressing an enzymatically inactive, point-mutated RPTPmu or a truncated form of RPTPmu, lacking the entire catalytic region, show adhesive properties indistinguishable from those of wild-type RPTPmu, indicating that the catalytic domain is not essential for RPTPmu-mediated adhesion. These results assign a physiological role for RPTPmu in signaling cell-cell recognition.			GEBBINK, MFBG (corresponding author), NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.		Wubbolts, Richard/ABH-6667-2020	Wubbolts, Richard/0000-0001-8661-7594; Beijersbergen, Roderick/0000-0003-0116-4130				BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; HARIHARAN IK, 1991, P NATL ACAD SCI USA, V88, P11266, DOI 10.1073/pnas.88.24.11266; HARLOW E, 1988, ANTIBODIES LABORATOR; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; MAURO VP, 1992, J CELL BIOL, V119, P191, DOI 10.1083/jcb.119.1.191; MOONEY RA, 1992, J BIOL CHEM, V267, P23443; PAGANO RE, 1985, J BIOL CHEM, V260, P1909; PARKER EM, 1991, J BIOL CHEM, V266, P519; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; SAITO H, 1991, CELL GROWTH DIFFER, V2, P59; SONDEREGGER P, 1992, J CELL BIOL, V119, P1387, DOI 10.1083/jcb.119.6.1387; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	25	231	236	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16101	16104						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8393854				2022-12-25	WOS:A1993LQ33600006
J	KELLY, M; LAPPALAINEN, P; TALBO, G; HALTIA, T; VANDEROOST, J; SARASTE, M				KELLY, M; LAPPALAINEN, P; TALBO, G; HALTIA, T; VANDEROOST, J; SARASTE, M			2 CYSTEINES, 2 HISTIDINES, AND ONE METHIONINE ARE LIGANDS OF A BINUCLEAR PURPLE COPPER CENTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; ELECTRON-PARAMAGNETIC RESONANCE; PSEUDOMONAS-AERUGINOSA STRAIN-P2; IONIZATION MASS-SPECTROMETRY; ABSORPTION FINE-STRUCTURE; CUA SITE; REDUCTASE CONTAINS; MULTICOPPER ENZYME; ESCHERICHIA-COLI; N2O REDUCTASE	Cytochrome c oxidase contains a copper center, Cu(A), which is involved in electron transfer from cytochrome c to the oxygen-reducing active site. This center is distinct from types 1, 2, and 3 copper sites and related only to a purple copper center in nitrous oxide reductase. At present it is not clear whether this site is mononuclear or is comprised Of two copper atoms in a mixed valence (Cu(I)-Cu(II)) configuration. Here we use a model of Cu(A), engineered into a structurally related but initially copperless protein, to study the structure of this copper center. The results from biochemical analysis, site-directed mutagenesis, and electrospray mass spectrometry support the binuclear model. Two cysteines, two histidines, and one methionine are the major ligands of two coppers. Substitution of these residues results in either a complete loss of color or dramatic changes in the absorbance spectrum. In contrast, substitution of the invariant glutamate residue, which is located between the copper-binding cysteines, leads to a minor perturbation of the optical spectrum.	EUROPEAN MOLEC BIOL LAB, MEYERHOFSTR 1, W-6900 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)			van+der+Oost, John/Y-2548-2019	Lappalainen, Pekka/0000-0001-6227-0354				Adman ET, 1991, CURR OPIN STRUC BIOL, V1, P895, DOI 10.1016/0959-440X(91)90084-7; ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; ALLEN MH, 1992, RAPID COMMUN MASS SP, V6, P308, DOI 10.1002/rcm.1290060418; ANTHOLINE WE, 1992, EUR J BIOCHEM, V209, P875, DOI 10.1111/j.1432-1033.1992.tb17360.x; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BEINERT H, 1962, J BIOL CHEM, V237, P2337; BISSON R, 1982, FEBS LETT, V150, P49, DOI 10.1016/0014-5793(82)81302-1; BOMBELKA E, 1986, BIOCHEM BIOPH RES CO, V140, P1007, DOI 10.1016/0006-291X(86)90735-7; BROMAN L, 1962, J MOL BIOL, V5, P301, DOI 10.1016/S0022-2836(62)80074-6; BROWN S, 1993, FEBS LETT, V316, P216, DOI 10.1016/0014-5793(93)81296-C; CAPALDI RA, 1982, FEBS LETT, V138, P1, DOI 10.1016/0014-5793(82)80382-7; CHAN SI, 1990, BIOCHEMISTRY-US, V29, P1, DOI 10.1021/bi00453a001; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; COYLE CL, 1985, EUR J BIOCHEM, V153, P459, DOI 10.1111/j.1432-1033.1985.tb09324.x; FARRAR JA, 1991, FEBS LETT, V294, P11, DOI 10.1016/0014-5793(91)81331-2; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; GENNIS RB, 1992, BIOCHIM BIOPHYS ACTA, V1101, P184, DOI 10.1016/0005-2728(92)90220-V; GREENWOOD C, 1988, ANN NY ACAD SCI, V550, P47, DOI 10.1111/j.1749-6632.1988.tb35321.x; GREENWOOD C, 1983, BIOCHEM J, V215, P303, DOI 10.1042/bj2150303; HALTIA T, 1992, MOL MECHANISMS BIOEN, P217; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HILL BC, 1991, J BIOL CHEM, V266, P2219; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; HUSAIN M, 1986, BIOCHEMISTRY-US, V25, P2431, DOI 10.1021/bi00357a020; HUTCHENS TW, 1992, FEBS LETT, V309, P170, DOI 10.1016/0014-5793(92)81088-4; KARLSSON BG, 1991, PROTEIN ENG, V4, P343, DOI 10.1093/protein/4.3.343; KRONECK PMH, 1990, FEBS LETT, V268, P274, DOI 10.1016/0014-5793(90)81026-K; KRONECK PMH, 1988, FEBS LETT, V242, P70, DOI 10.1016/0014-5793(88)80987-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI PM, 1987, BIOCHEMISTRY-US, V26, P2091, DOI 10.1021/bi00382a005; MALMSTROM BG, 1990, ARCH BIOCHEM BIOPHYS, V280, P233, DOI 10.1016/0003-9861(90)90325-S; MANN M, 1989, ANAL CHEM, V61, P1702, DOI 10.1021/ac00190a023; MARTIN CT, 1988, J BIOL CHEM, V263, P8420; MILLETT F, 1983, BIOCHEMISTRY-US, V22, P546, DOI 10.1021/bi00272a004; MILLETT F, 1982, BIOCHEMISTRY-US, V21, P3857, DOI 10.1021/bi00259a021; OBLAD M, 1989, BIOCHIM BIOPHYS ACTA, V975, P267, DOI 10.1016/S0005-2728(89)80257-9; PAN LP, 1991, J BIOL CHEM, V266, P1367; PUUSTINEN A, 1991, BIOCHEMISTRY-US, V30, P3936, DOI 10.1021/bi00230a019; RAMSHAW JAM, 1973, BIOCHIM BIOPHYS ACTA, V303, P269, DOI 10.1016/0005-2795(73)90357-7; RIESTER J, 1989, EUR J BIOCHEM, V178, P751, DOI 10.1111/j.1432-1033.1989.tb14506.x; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SARASTE M, 1991, BIOCHEM SOC T, V19, P608, DOI 10.1042/bst0190608; SCOTT RA, 1989, P NATL ACAD SCI USA, V86, P4082, DOI 10.1073/pnas.86.11.4082; SOOHOO CK, 1991, J BIOL CHEM, V266, P2203; SOOHOO CK, 1991, J BIOL CHEM, V266, P2210; STEFFENS GCM, 1987, EUR J BIOCHEM, V164, P295, DOI 10.1111/j.1432-1033.1987.tb11057.x; TAHA TSM, 1992, BIOCHEMISTRY-US, V31, P9090, DOI 10.1021/bi00152a053; VANDEROOST J, 1992, EMBO J, V11, P3209, DOI 10.1002/j.1460-2075.1992.tb05398.x; YOSHIKAWA S, 1988, P NATL ACAD SCI USA, V85, P1354, DOI 10.1073/pnas.85.5.1354; ZHANG CS, 1991, J BIOL CHEM, V266, P2199; ZUMFT WG, 1992, EUR J BIOCHEM, V208, P31, DOI 10.1111/j.1432-1033.1992.tb17156.x	51	150	150	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16781	16787						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8393874				2022-12-25	WOS:A1993LQ33600098
J	KOLBE, HVJ; HUBER, A; CORDIER, P; RASMUSSEN, UB; BOUCHON, B; JAQUINOD, M; VLASAK, R; DELOT, E; KREIL, G				KOLBE, HVJ; HUBER, A; CORDIER, P; RASMUSSEN, UB; BOUCHON, B; JAQUINOD, M; VLASAK, R; DELOT, E; KREIL, G			XENOXINS, A FAMILY OF PEPTIDES FROM DORSAL GLAND SECRETION OF XENOPUS-LAEVIS RELATED TO SNAKE-VENOM CYTOTOXINS AND NEUROTOXINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOMBINA-VARIEGATA-PACHYPUS; DENDROASPIS-ANGUSTICEPS; ANTIMICROBIAL ACTIVITY; MEMBRANE-FRAGMENTS; CRYSTAL-STRUCTURE; SKIN SECRETION; SEQUENCE; PROTEIN; BIOSYNTHESIS; PRECURSOR	Three new, highly similar peptides from the skin secretion of Xenopus laevis have been purified and analyzed by mass spectrometry and Edman degradation. The 66-amino-acid peptides, termed xenoxin-1, -2, and -3, contain 8 cysteines and show similarity to snake venom cytotoxins and short neurotoxins. Assignment of two out of four disulfide bonds suggests a tertiary structure similar to that of cytotoxins and short neurotoxins. A cDNA encoding pre-xenoxin-1 was isolated from a X. laevis skin cDNA library. The nucleotide sequence predicts the synthesis of a precursor with a signal peptide followed by the sequence of the mature peptide. Xenoxin-1 and -2 lack alpha-neuro-toxic activity, have apparently no antibacterial activity, are low in general toxicity as tested in mice, and have no effect on blood coagulation as measured in a Factor VIII procoagulant activity test. Potential functions of xenoxins as well as evolutionary aspects are discussed.	INST MOLEC BIOL, A-5020 SALZBURG, AUSTRIA; CNRS, URA 31, SPECTROMETRIE MASSE LAB, F-67008 STRASBOURG, FRANCE; INST PASTEUR, UNITE VENINS, F-75724 PARIS, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	KOLBE, HVJ (corresponding author), TRANSGENE SA, 11 RUE MOLSHEIM, F-67082 STRASBOURG, FRANCE.		Bouchon, Bernadette/L-5698-2015	Delot, Emmanuele/0000-0003-3541-3190				ANDREU D, 1985, EUR J BIOCHEM, V149, P531, DOI 10.1111/j.1432-1033.1985.tb08957.x; BARBERIO C, 1987, TOXICON, V25, P899, DOI 10.1016/0041-0101(87)90250-9; BARTHALMUS GT, 1988, PHARMACOL BIOCHEM BE, V30, P957, DOI 10.1016/0091-3057(88)90126-8; BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; CHAIMMATYAS A, 1991, BIOCHEM INT, V24, P415; CORFIELD PWR, 1989, J BIOL CHEM, V264, P9239; DEWEILLE JR, 1991, P NATL ACAD SCI USA, V88, P2437, DOI 10.1073/pnas.88.6.2437; DUCANCEL F, 1991, INT ENCY PHARM THERA, P385; DUFTON MJ, 1984, J MOL EVOL, V20, P128, DOI 10.1007/BF02257373; DUFTON MJ, 1991, INT ENCY PHARM THERA, P259; ENDO T, 1991, INT ENCY PHARM THERA, P165; ERSPAMER V, 1980, TRENDS PHARMACOL SCI, V1, P391, DOI 10.1016/0165-6147(80)90060-7; ERSPAMER V, 1983, NEUROENDOCRINE PERSP, V2, P37; GIBSON BW, 1986, J BIOL CHEM, V261, P5341; GIBSON BW, 1991, ACS SYM SER, V444, P222; GIOVANNINI MG, 1987, BIOCHEM J, V243, P113, DOI 10.1042/bj2430113; HARVEY AL, 1985, J TOXICOL-TOXIN REV, V4, P41, DOI 10.3109/15569548509014413; HARVEY AL, 1991, INT ENCY PHARM THERA, P131; HOFFMANN W, 1983, EMBO J, V2, P111, DOI 10.1002/j.1460-2075.1983.tb01390.x; HOFFMANN W, 1983, EMBO J, V2, P711, DOI 10.1002/j.1460-2075.1983.tb01489.x; INOUE S, 1987, FEBS LETT, V218, P17, DOI 10.1016/0014-5793(87)81009-8; KOLBE HVJ, 1985, J BIOL CHEM, V260, P5899; KRISHNAN S, 1991, EUR J BIOCHEM, V195, P637, DOI 10.1111/j.1432-1033.1991.tb15748.x; LEE CY, 1988, NATURE, V335, P303, DOI 10.1038/335303a0; MASTROMEI G, 1991, TOXICON, V29, P321, DOI 10.1016/0041-0101(91)90285-Y; MATZUK MM, 1992, BIOCHIM BIOPHYS ACTA, V1130, P105, DOI 10.1016/0167-4781(92)90472-C; MEBS D, 1991, INT ENCY PHARM THERA, P425; MOLLAY C, 1986, EUR J BIOCHEM, V160, P31, DOI 10.1111/j.1432-1033.1986.tb09935.x; MUTT V, 1986, CHEM SCRIPTA, V26B, P191; REES B, 1987, P NATL ACAD SCI USA, V84, P3132, DOI 10.1073/pnas.84.10.3132; RICHTER K, 1985, PEPTIDES, V6, P17, DOI 10.1016/0196-9781(85)90345-6; RICHTER K, 1984, EMBO J, V3, P617, DOI 10.1002/j.1460-2075.1984.tb01857.x; RICHTER K, 1986, J BIOL CHEM, V261, P3676; RIEHLBELLON N, 1989, BIOCHEMISTRY-US, V28, P2941, DOI 10.1021/bi00433a030; ROWAN EG, 1990, NUCLEIC ACIDS RES, V18, P1639, DOI 10.1093/nar/18.6.1639; SAITOH T, 1980, EUR J BIOCHEM, V105, P51, DOI 10.1111/j.1432-1033.1980.tb04473.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEITZ H, 1992, J BIOL CHEM, V267, P13928; SIMMACO M, 1991, EUR J BIOCHEM, V199, P217, DOI 10.1111/j.1432-1033.1991.tb16112.x; STRYDOM DJ, 1979, HDB EXPT PHARM, V52, P159; SURES I, 1984, P NATL ACAD SCI-BIOL, V81, P380, DOI 10.1073/pnas.81.2.380; TAMIYA N, 1983, TOXICON S, V3, P445; TU AT, 1973, ANNU REV BIOCHEM, V42, P235, DOI 10.1146/annurev.bi.42.070173.001315; VANDORSSELAER A, 1990, BIOMED ENVIRON MASS, V19, P692, DOI 10.1002/bms.1200191108; WEBER M, 1974, MOL PHARMACOL, V10, P1; WESTERHOFF HV, 1989, P NATL ACAD SCI USA, V86, P6597, DOI 10.1073/pnas.86.17.6597; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; ZASLOFF M, 1988, P NATL ACAD SCI USA, V85, P910, DOI 10.1073/pnas.85.3.910	50	36	42	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16458	16464						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8393864				2022-12-25	WOS:A1993LQ33600056
J	SHIIO, Y; YAMAMOTO, T; YAMAGUCHI, N				SHIIO, Y; YAMAMOTO, T; YAMAGUCHI, N			IDENTIFICATION OF A DNA ELEMENT THAT CAN ENHANCE P53-MEDIATED TRANSACTIVATION	ONCOGENE			English	Article							TUMOR SUPPRESSOR GENES; WILD-TYPE P53; BINDING-SITE; EXPRESSION; PROTEIN; PRODUCT	Recent studies have demonstrated that p53 binds to specific DNA sequences and the consensus sequence for the p53 binding site has been proposed. The p53 binding site has also been shown to act as positive p53-responsive element. Here we report the identification of a GC3 element that enhances p53-mediated transactivation when placed adjacent to the consensus p53 site. The GC3 element alone cannot act as a positive p53-responsive element. We also show that p53 activates transcription of the c-erbA-alpha gene through a DNA element that consists of the p53 quarter-sites and GC3 elements. Using gel mobility-shift assay, we identified a possible GC3 binding factor distinct from p53.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,TOKYO 108,JAPAN	University of Tokyo	SHIIO, Y (corresponding author), UNIV TOKYO,INST MED SCI,DEPT VIROL,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN.							AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Mackett M., 1985, DNA CLONING PRACTICA, P191; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	18	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2059	2065						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8393159				2022-12-25	WOS:A1993LP17100005
J	JESSBERGER, R; PODUST, V; HUBSCHER, U; BERG, P				JESSBERGER, R; PODUST, V; HUBSCHER, U; BERG, P			A MAMMALIAN PROTEIN COMPLEX THAT REPAIRS DOUBLE-STRAND BREAKS AND DELETIONS BY RECOMBINATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA POLYMERASE-DELTA; SIMIAN VIRUS-40 DNA; CELL NUCLEAR ANTIGEN; DROSOPHILA-MELANOGASTER EMBRYOS; SACCHAROMYCES-CEREVISIAE; HOMOLOGOUS RECOMBINATION; REPLICATION FACTOR; BINDING-PROTEIN; CALF THYMUS; PURIFICATION	We have purified a high molecular weight complex (RC-1) from calf thymus nuclei that catalyzes a recombinational repair of double-strand gaps and deletions in DNA by gene conversion as well as cross-over events leading to cointegrant products. These have been detected by polymerase chain reaction analysis using oligonucleotide primer pairs that detect joined sequences originally present on only one or the other of the recombination substrates. RC-1 has an apparent molecular mass of about 550-600 kDa and contains at least five polypeptide chains: molecular masses about 230, 210, 160, 130, and 40 kDa. RC-1 contains a DNA polymerase, identified as DNA polymerase epsilon, that copurifies with RC-1. A DNA ligase, most likely mammalian DNA ligase III, and a 5'-3' exonuclease also copurify with the RC-1. Most preparations of RC-1 contain low levels of a double-strand endonuclease, 3'-5' exonuclease and single-strand nuclease activities. However, DNA helicase, terminal deoxynucleotidyl transferase, or DNA topoisomerase I and II were not detected in RC-1. The DNA polymerase and DNA ligase in RC-1 can act in concert to repair a multiply gapped DNA to a covalently repaired duplex. The bovine single-strand-binding protein stimulates the formation of the recombination products and the repair reaction mentioned above about 4-fold.	STANFORD UNIV,MED CTR,SCH MED,BECKMAN CTR,DEPT BIOCHEM,STANFORD,CA 94305; UNIV ZURICH IRCHEL,DEPT VET BIOCHEM,CH-8057 ZURICH,SWITZERLAND	Stanford University; University of Zurich	JESSBERGER, R (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4002 BASEL,SWITZERLAND.				NATIONAL INSTITUTE ON AGING [P01AG002908] Funding Source: NIH RePORTER; NIA NIH HHS [AGO 2908-11] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; ANSORGE W, 1983, ELECTROPHORESIS 82, P235; ARAI N, 1992, J BIOL CHEM, V267, P3514; ARRAND JE, 1986, J BIOL CHEM, V261, P9079; BOLLUM JF, 1974, ENZYMES, V10, P145; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; BURGERS PMJ, 1990, EUR J BIOCHEM, V191, P617, DOI 10.1111/j.1432-1033.1990.tb19165.x; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; CHAMBON P, 1966, BIOCHEM BIOPH RES CO, V25, P638, DOI 10.1016/0006-291X(66)90502-X; CONAWAY RC, 1982, P NATL ACAD SCI-BIOL, V79, P2523, DOI 10.1073/pnas.79.8.2523; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; EISEN A, 1988, P NATL ACAD SCI USA, V85, P7481, DOI 10.1073/pnas.85.20.7481; ELLBOROUGH KM, 1990, EMBO J, V9, P2931; FISHEL RA, 1988, P NATL ACAD SCI USA, V85, P36, DOI 10.1073/pnas.85.1.36; FOCHER F, 1989, NUCLEIC ACIDS RES, V17, P1805, DOI 10.1093/nar/17.5.1805; GANEA D, 1987, MOL CELL BIOL, V7, P3124, DOI 10.1128/MCB.7.9.3124; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; HEYER WD, 1988, J BIOL CHEM, V263, P15189; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; HSIEH P, 1989, J BIOL CHEM, V264, P5089; HSIEH P, 1986, CELL, V44, P885, DOI 10.1016/0092-8674(86)90011-5; HUBSCHER U, 1977, NUCLEIC ACIDS RES, V4, P4917; HUNTER MM, 1982, J IMMUNOL, V129, P1165; JESSBERGER R, 1991, MOL CELL BIOL, V11, P445, DOI 10.1128/MCB.11.1.445; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KOLODNER R, 1987, P NATL ACAD SCI USA, V84, P5560, DOI 10.1073/pnas.84.16.5560; KRASNOW MA, 1982, J BIOL CHEM, V257, P2687; KUCHERLAPATI RS, 1985, MOL CELL BIOL, V5, P714, DOI 10.1128/MCB.5.4.714; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKO DD, 1990, J BIOL CHEM, V265, P12618; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; LOPEZ B, 1989, BIOCHEM BIOPH RES CO, V158, P454, DOI 10.1016/S0006-291X(89)80069-5; LOWENHAUPT K, 1989, J BIOL CHEM, V264, P20568; MALKAS LH, 1990, BIOCHEMISTRY-US, V29, P6362, DOI 10.1021/bi00479a004; MILLER KG, 1981, J BIOL CHEM, V256, P9334; MOORE SP, 1990, J BIOL CHEM, V265, P11108; MULLER MT, 1989, NUCLEIC ACIDS RES, V17, P9499, DOI 10.1093/nar/17.22.9499; NISHIDA C, 1988, J BIOL CHEM, V263, P501; OLIVERA BM, 1967, P NATL ACAD SCI USA, V57, P1426, DOI 10.1073/pnas.57.5.1426; ORRWEAVER TL, 1983, P NATL ACAD SCI-BIOL, V80, P4417, DOI 10.1073/pnas.80.14.4417; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; PODUST VN, 1992, CHROMOSOMA, V102, P133; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; PONTIUS BW, 1991, P NATL ACAD SCI USA, V88, P8237, DOI 10.1073/pnas.88.18.8237; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PURNELL MR, 1980, BIOCHEM J, V185, P775, DOI 10.1042/bj1850775; ROHNER KJ, 1990, J BIOL CHEM, V265, P19112; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; SIEGAL G, 1992, J BIOL CHEM, V267, P3991; SMITH GR, 1988, MICROBIOL REV, V52, P1; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUGINO A, 1988, P NATL ACAD SCI USA, V85, P3683, DOI 10.1073/pnas.85.11.3683; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SYMINGTON LS, 1983, CELL, V35, P805, DOI 10.1016/0092-8674(83)90113-7; SYMINGTON LS, 1991, EMBO J, V10, P987, DOI 10.1002/j.1460-2075.1991.tb08033.x; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; THOMMES P, 1990, J BIOL CHEM, V265, P14347; THOMMES P, 1992, J BIOL CHEM, V267, P6063; TOMKINSON AE, 1991, J BIOL CHEM, V266, P21728; TOMKINSON AE, 1991, P NATL ACAD SCI USA, V88, P400, DOI 10.1073/pnas.88.2.400; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; WEISER T, 1991, J BIOL CHEM, V266, P10420; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	66	127	134	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15070	15079						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8392064				2022-12-25	WOS:A1993LL75900078
J	TIAN, XQ; CHEN, TC; MATSUOKA, LY; WORTSMAN, J; HOLICK, MF				TIAN, XQ; CHEN, TC; MATSUOKA, LY; WORTSMAN, J; HOLICK, MF			KINETIC AND THERMODYNAMIC STUDIES OF THE CONVERSION OF PREVITAMIN-D(3) TO VITAMIN-D(3) IN HUMAN SKIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PI-FACIAL SELECTIVITY; D CALCIFEROL; PHOTOSYNTHESIS; ANALOGS; SHIFTS; NMR	The thermoisomerization of previtamin D3 to vitamin D3 is the last step in the synthesis of vitamin D3 in human skin. Kinetic and thermodynamic studies of this reaction in human skin and an organic solvent revealed that not only the equilibrium of the reaction was shifted in favor of vitamin D3 formation in human skin (equilibrium constant K at 37-degrees-C = 11.44) compared to hexane (K = 6.15), but also the rate of the reaction was increased by more than 10-fold in human skin (T1/2 at 37-degrees-C = 2.5 h) when compared to hexane (T1/2 = 30 h). This extraordinarily fast reaction rate was also confirmed in vitro in chicken skin and in vivo in human subjects. The enthalpy change for the reaction determined by the van't Hoff plot was DELTAH-degrees = -21.58 kJ mol-1 in human skin and DELTAH-degrees = -15.60 kJ mol-1 in hexane. Arrhenius plots showed that the activation energies for both the forward and the reverse reactions were lower in human skin (E(a1) = 71.05 kJ mol-1 and E(a2) = 92.63 kJ mol-1) than in hexane (E(a1) = 84.90 kJ mol-1 and E(a2) = 100.5 kJ mol-1). Activation parameters for the reaction in human skin and in hexane were also reported. Subcellular fractionation of human epidermal tissue revealed that most epidermal 7-dehydrocholesterol and previtamin D3 were in the membrane fraction, while only 20% were in the cytosol. The interaction of previtamin D3 with intracellular lipids and/or proteins in skin may be responsible for the increased vitamin D3 formation rate in the skin.	BOSTON UNIV,SCH MED,VITAMIN D SKIN & BONE RES LAB,BOSTON,MA 02118; THOMAS JEFFERSON UNIV,COLL MED,DEPT DERMATOL,PHILADELPHIA,PA 19107; SO ILLINOIS UNIV,SCH MED,DEPT MED,SPRINGFIELD,IL 62701	Boston University; Jefferson University; Southern Illinois University System; Southern Illinois University				Holick, Michael/0000-0001-6023-9062; Chen, Tai/0000-0002-5704-5694	NIAMS NIH HHS [R01-AR36963] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036963] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS JS, 1982, NEW ENGL J MED, V306, P722, DOI 10.1056/NEJM198203253061206; ALBERTY RA, 1992, PHYSICAL CHEM, P627; CASSIS EG, 1982, PHOTOCHEM PHOTOBIOL, V35, P439; CLEMENS TL, 1982, CLIN CHIM ACTA, V121, P301, DOI 10.1016/0009-8981(82)90239-X; DAUBEN WG, 1988, J ORG CHEM, V53, P5376, DOI 10.1021/jo00257a039; DAUBEN WG, 1988, J ORG CHEM, V53, P5070, DOI 10.1021/jo00256a031; ENAS JD, 1991, J AM CHEM SOC, V113, P1355, DOI 10.1021/ja00004a043; HANEWALD KH, 1961, RECL TRAV CHIM PAY B, V80, P1003; HOEGER CA, 1987, J AM CHEM SOC, V109, P4690, DOI 10.1021/ja00249a035; HOLICK MF, 1980, SCIENCE, V210, P203, DOI 10.1126/science.6251551; HOLICK MF, 1987, FASEB J, V46, P1876; MACLAUGHLIN JA, 1991, FEBS LETT, V282, P409, DOI 10.1016/0014-5793(91)80525-8; SCHLATMANN JLM, 1964, RECL TRAV CHIM PAY B, V83, P1173; SHEVES M, 1979, J AM CHEM SOC, V101, P1882, DOI 10.1021/ja00501a044; VELLUZ L, 1949, B SOC CHIM FR, V16, P501; WEBB AR, 1989, J CLIN ENDOCR METAB, V68, P882, DOI 10.1210/jcem-68-5-882; WOODWARD RB, 1965, J AM CHEM SOC, V87, P2511, DOI 10.1021/ja01089a050; YAMAMOTO JK, 1985, BIOCHEMISTRY-US, V24, P3338, DOI 10.1021/bi00334a039	18	87	93	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14888	14892						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8392061				2022-12-25	WOS:A1993LL75900055
J	EDER, JP; CHAN, VTW; NIEMIERKO, E; TEICHER, BA; SCHNIPPER, LE				EDER, JP; CHAN, VTW; NIEMIERKO, E; TEICHER, BA; SCHNIPPER, LE			CONDITIONAL EXPRESSION OF WILD-TYPE TOPOISOMERASE-II COMPLEMENTS A MUTANT ENZYME IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; DNA TOPOISOMERASES; CROSS-RESISTANCE; FUNCTIONAL EXPRESSION; LINE; GENE; RECOMBINATION; RECEPTOR; VM-26	Alterations in the amino acid composition, phosphorylation pattern, or intracellular levels of topoisomerase II have been associated with resistance to antineoplastic agents whose effects are mediated through interactions with this enzyme. To develop a model system with which to investigate the determinants of topoisomerase II sensitivity or resistance to antineoplastic agents that target this enzyme, a cDNA encoding the wild-type Drosophila melanogaster topoisomerase II was ligated into a mammalian expression vector containing a glucocorticoid-inducible mouse mammary tumor virus promoter and transfected into an epipodophyllotoxin-resistant Chinese hamster ovary cell line (VPM(r)-5). In two transfectants carrying an intact, full-length Drosophila topoisomerase II cDNA, exposure to the inducing agent, dexamethasone (10 muM), resulted in complementation of the endogenous mutant topoisomerase II and phenotypic reversion to etoposide sensitivity. In the presence of glucocorticoid, etoposide-induced cytotoxicity increased 20-fold, despite the fact that Drosophila topoisomerase II mRNA expression was only 0.1% of that of the endogenous mammalian topoisomerase II. Induced cells demonstrated a marked increase in DNA single strand breaks compared with uninduced resistant cells, thereby providing biochemical evidence supporting increased DNA strand cleavage due to activation of the Drosophila enzyme. These observations demonstrate the ability of a wild-type Drosophila topoisomerase II to complement a mutant mammalian enzyme and suggest that transfectants capable of conditional topoisomerase II expression represent a useful model for studies of the biochemical pharmacology and structure-function relationships of normal and mutant enzymes.	BETH ISRAEL HOSP, CHARLES A DANA RES LABS, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	EDER, JP (corresponding author), BETH ISRAEL HOSP, DEPT MED, DIV MED ONCOL, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.				NATIONAL CANCER INSTITUTE [K08CA001412, P01CA038493] Funding Source: NIH RePORTER; NCI NIH HHS [K08 CA01412, P01-CA-38493] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKSNIS M, 1991, J BIOL CHEM, V266, P10078; BAE YS, 1988, P NATL ACAD SCI USA, V85, P2076, DOI 10.1073/pnas.85.7.2076; BUGG BY, 1991, P NATL ACAD SCI USA, V88, P7654, DOI 10.1073/pnas.88.17.7654; CHAN VTW, 1993, J BIOL CHEM, V268, P2160; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; DEJONG S, 1991, CANCER CHEMOTH PHARM, V28, P461, DOI 10.1007/BF00685823; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FERNANDES DJ, 1990, BIOCHEMISTRY-US, V29, P4235, DOI 10.1021/bi00469a028; FRICHE E, 1991, CANCER RES, V51, P4213; GIAVER G, 1986, J BIOL CHEM, V261, P12448; GLISSON B, 1986, CANCER RES, V46, P1939; GLISSON B, 1986, CANCER RES, V46, P1934; GUPTA RS, 1983, CANCER RES, V43, P1568; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; KOHN KW, 1981, DNA REPAIR LABORATOR, P379; NITISS JL, 1993, CANCER RES, V53, P89; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; Ross W E, 1988, Important Adv Oncol, P65; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; SEDGWICK B, 1982, J MOL BIOL, V154, P169, DOI 10.1016/0022-2836(82)90424-7; SHAPIRO RA, 1989, P NATL ACAD SCI USA, V86, P9039, DOI 10.1073/pnas.86.22.9039; SULLIVAN DM, 1989, BIOCHEMISTRY-US, V28, P5680, DOI 10.1021/bi00439a051; TAN KB, 1989, J NATL CANCER I, V81, P1732, DOI 10.1093/jnci/81.22.1732; TAN KB, 1987, P NATL ACAD SCI USA, V84, P7668, DOI 10.1073/pnas.84.21.7668; TEICHER BA, 1987, CANCER RES, V47, P388; TEICHER BA, 1987, CANCER RES, V47, P5036; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6; WYCKOFF E, 1988, P NATL ACAD SCI USA, V85, P6272, DOI 10.1073/pnas.85.17.6272	32	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13844	13849						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8390979				2022-12-25	WOS:A1993LJ82500015
J	ECKERT, KA; KUNKEL, TA				ECKERT, KA; KUNKEL, TA			EFFECT OF REACTION PH ON THE FIDELITY AND PROCESSIVITY OF EXONUCLEASE-DEFICIENT KLENOW POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVITRO DNA-SYNTHESIS; ESCHERICHIA-COLI; LARGE FRAGMENT; MUTATIONAL SPECIFICITY; REVERSE-TRANSCRIPTASE; KINETIC MECHANISM; THERMUS-AQUATICUS; BASE-PAIRS; ALPHA; REPLICATION	We have examined as a function of pH the fidelity of DNA synthesis catalyzed by the 3'-->5' exonuclease-deficient form of the Klenow fragment of Escherichia coli DNA polymerase I. Increasing the pH of in vitro gap-filling reactions from pH 6.2 through 9.8 (37-degrees-C increased the frequency of base substitution and minus-one-base frameshift mutations 50- and 40-fold, respectively, as measured by reversion of a nonsense or frameshift mutation within the lacZalpha gene of bacteriophage M13mp2. To understand the mechanisms of high fidelity at low pH, we have examined the biochemical events associated with DNA synthesis at pH 6.2 that might be responsible for the observed accuracy in vitro. We show that while the steady-state frequency of T.dGTP misinsertion at the lacZalpha opal codon is 20-fold lower at pH 6.2 than at pH 7.6, pH-dependent changes in the frequencies of G.dATP and A.dCTP base misinsertions at the lacZalpha nonsense codon are insufficient to explain the fidelity changes observed in the gap-filling assay. However, the efficiency of steady-state extension synthesis from template-primers containing 3'-terminal T.G, G.A, and A.C (template-primer) mispairs was reduced up to 160-fold at pH 6.2 relative to pH 7.6. Analyses of the processivity of DNA polymerization versus pH demonstrated that at low pH the termination probability was decreased at specific template positions. Concomitantly, at sites where the termination probability was lower at pH 6.2, a decreased error rate was observed for base substitution mutations at three template positions and for minus-one-base frameshift mutations at two homopolymeric sequences relative to pH 7.6. We suggest that the observed increase in error discrimination by the exonuclease-deficient Klenow polymerase results from altered template binding properties of the enzyme at pH 6.2.	NIEHS, MOLEC GENET LAB, RES TRIANGLE PK, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788				ABBOTTS J, 1988, J BIOL CHEM, V263, P15094; ABBOTTS J, 1984, J BIOL CHEM, V259, P6712; ANTAO VP, 1990, NUCLEIC ACIDS RES, V18, P4111, DOI 10.1093/nar/18.14.4111; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BROWN T, 1990, J MOL BIOL, V212, P437, DOI 10.1016/0022-2836(90)90320-L; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; DOLINNAYA NG, 1992, P NATL ACAD SCI USA, V89, P9242, DOI 10.1073/pnas.89.19.9242; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; ECKERT KA, 1990, NUCLEIC ACIDS RES, V18, P3739, DOI 10.1093/nar/18.13.3739; FRY M, 1992, P NATL ACAD SCI USA, V89, P763, DOI 10.1073/pnas.89.2.763; GROSSE F, 1983, EMBO J, V2, P1515, DOI 10.1002/j.1460-2075.1983.tb01616.x; HOPFIELD JJ, 1980, P NATL ACAD SCI-BIOL, V77, P5248, DOI 10.1073/pnas.77.9.5248; HUNTER WN, 1986, NATURE, V320, P552, DOI 10.1038/320552a0; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1985, J BIOL CHEM, V260, P2866; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAWYER FC, 1989, J BIOL CHEM, V264, P6427; LEONARD GA, 1990, NUCLEIC ACIDS RES, V18, P5617, DOI 10.1093/nar/18.19.5617; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PAPANICOLAOU C, 1991, J MOL BIOL, V221, P805, DOI 10.1016/0022-2836(91)80177-V; Patel D.J., 1987, NUCL ACIDS MOL BIOL, V1, P70; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; SABATINO RD, 1988, BIOCHEMISTRY-US, V27, P2998, DOI 10.1021/bi00408a050; SOWERS LC, 1986, BIOCHEMISTRY-US, V25, P3983, DOI 10.1021/bi00362a002; SOWERS LC, 1987, MUTAT RES, V177, P201, DOI 10.1016/0027-5107(87)90003-0; TAN CK, 1987, NUCLEIC ACIDS RES, V15, P2269, DOI 10.1093/nar/15.5.2269; WARWICKER J, 1985, J MOL BIOL, V186, P645, DOI 10.1016/0022-2836(85)90136-6	37	54	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13462	13471						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8390464				2022-12-25	WOS:A1993LH55300064
J	HUPP, TR; KAGUNI, JM				HUPP, TR; KAGUNI, JM			DNAA5 PROTEIN IS THERMOLABILE IN INITIATION OF REPLICATION FROM THE CHROMOSOMAL ORIGIN OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTO-REGULATION; GENE; PURIFICATION; POLYMERASE; MUTANTS; OVERPRODUCTION; AMPLIFICATION; TEMPERATURE; HOLOENZYME; RESOLUTION	A mutant form of DnaA protein encoded by the dnaA5 allele has been purified and compared biochemically to its wild type counterpart. Biochemical properties of DnaA5 protein include: 1) thermolabile activity in an oriC plasmid replication system dependent on a crude enzyme fraction, 2) comparable affinity relative to DnaA protein in binding to restriction fragments containing either the Escherichia coli chromosomal origin, oriC, or the dnaA promoter, 3) formation of a nucleoprotein complex similar to DnaA protein at the DnaA boxes within the dnaA promoter as detected by protection from DNase I cleavage, 4) formation of an altered nucleoprotein complex with oriC as judged by DNase I protection experiments, 5) inactivity in unwinding of oriC, 6) inactivity in oriC plasmid replication systems dependent on purified enzymes, and 7) inhibition of DnaA protein by addition of DnaA5 protein in assays of replication and of unwinding of oriC, suggesting that mixed complexes formed between wild type and mutant proteins are inactive.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA	Michigan State University				Kaguni, Jon/0000-0002-3096-4447	NIGMS NIH HHS [GM33992, R01 GM033992] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033992] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI K, 1981, J BIOL CHEM, V256, P5247; ATLUNG T, 1985, MOL GEN GENET, V200, P442, DOI 10.1007/BF00425729; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BRAUN RE, 1985, CELL, V40, P159, DOI 10.1016/0092-8674(85)90319-8; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CARL PL, 1970, MOL GEN GENET, V109, P107, DOI 10.1007/BF00269647; CHASE JW, 1980, NUCLEIC ACIDS RES, V8, P3215, DOI 10.1093/nar/8.14.3215; COOPER S, 1968, J MOL BIOL, V31, P519, DOI 10.1016/0022-2836(68)90425-7; DEPEW RE, 1978, J BIOL CHEM, V253, P511; DIXON NE, 1984, P NATL ACAD SCI-BIOL, V81, P424, DOI 10.1073/pnas.81.2.424; DONACHIE WD, 1968, NATURE, V219, P1077, DOI 10.1038/2191077a0; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; GONZALEZ N, 1977, ARCH BIOCHEM BIOPHYS, V182, P404, DOI 10.1016/0003-9861(77)90521-5; HANSEN EB, 1984, MOL GEN GENET, V196, P387, DOI 10.1007/BF00436184; HANSEN FG, 1991, J BACTERIOL, V173, P5194, DOI 10.1128/jb.173.16.5194-5199.1991; HANSEN FG, 1992, MOL GEN GENET, V234, P14, DOI 10.1007/BF00272340; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; HUPP TR, 1993, J BIOL CHEM, V268, P13137; HUPP TR, 1993, J BIOL CHEM, V268, P13143; HWANG DS, 1990, CELL, V63, P325, DOI 10.1016/0092-8674(90)90165-B; HWANG DS, 1988, J BIOL CHEM, V263, P10633; HWANG DS, 1991, J BIOL CHEM, V266, P7537; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; KAGUNI JM, 1981, P NATL ACAD SCI USA, V76, P6250; KELLENBERGERGUJER G, 1978, MOL GEN GENET, V162, P9, DOI 10.1007/BF00333845; KOBORI JA, 1982, J BIOL CHEM, V257, P13763; KUCHERER C, 1986, MOL GEN GENET, V205, P115, DOI 10.1007/BF02428040; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; Maxam A M, 1980, Methods Enzymol, V65, P499; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MIZUUCHI K, 1984, J BIOL CHEM, V259, P9199; NAITO S, 1984, P NATL ACAD SCI-BIOL, V81, P550, DOI 10.1073/pnas.81.2.550; OGAWA T, 1985, P NATL ACAD SCI USA, V82, P3562, DOI 10.1073/pnas.82.11.3562; PIERUCCI O, 1989, J BACTERIOL, V171, P3760, DOI 10.1128/jb.171.7.3760-3766.1989; PRITCHARD R H, 1969, Symposium of the Society for General Microbiology, V19, P263; Sambrook J, 1989, MOL CLONING LABORATO; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SKARSTAD K, 1989, MOL GEN GENET, V218, P50, DOI 10.1007/BF00330564; SKARSTAD K, 1988, J BACTERIOL, V170, P852, DOI 10.1128/jb.170.2.852-858.1988; VONMEYENBURG K, 1987, ESCHERICHIA COLI SAL, P1555; WANG QP, 1987, MOL GEN GENET, V209, P518, DOI 10.1007/BF00331158; WEINER JH, 1975, J BIOL CHEM, V250, P1972; WOLD MS, 1982, P NATL ACAD SCI-BIOL, V79, P4907, DOI 10.1073/pnas.79.16.4907; YUNG BYM, 1990, J BIOL CHEM, V265, P1282; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202	48	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13128	13136						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8390455				2022-12-25	WOS:A1993LH55300020
J	SEO, YS; HURWITZ, J				SEO, YS; HURWITZ, J			ISOLATION OF HELICASE ALPHA, A DNA HELICASE FROM HELA-CELLS STIMULATED BY A FORK STRUCTURE AND SINGLE-STRANDED DNA-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE TUMOR-ANTIGEN; LARGE T-ANTIGEN; DEPENDENT ADENOSINETRIPHOSPHATASE-B; MOUSE FM3A CELLS; SV40 ORIGIN; REPLICATION PROTEIN; UNWINDING ACTIVITY; REP PROTEIN; CALF THYMUS; PURIFICATION	A DNA helicase, called DNA helicase alpha, was purified from HeLa cells to apparent homogeneity. The helicase and its single-stranded DNA-dependent ATPase activities cosedimented in glycerol gradients with two polypeptides of 110 and 90 kDa with a sedimentation coefficient of 7.4 S. The DNA helicase was markedly stimulated by DNA substrates with a 5'-tailed fork. A DNA substrate with a 3'-tailed fork structure was less stimulatory, although it was more active than substrates without a fork. The directionality of unwinding is 3' --> 5' with respect to the single-stranded DNA to which the enzyme was bound. The helicase activity also required a single-stranded DNA-binding protein (SSB) for unwinding activity. The stimulation by SSBs was nonspecific; all SSBs tested, such as human SSB, bacteriophage T4 gene 32, and Escherichia coli SSB, stimulated the DNA helicase activity to a varying extent in the presence of a fork structure. With long duplex substrates (> 500 base pairs), the presence of a fork substantially stimulated the DNA helicase activity in the presence of E. coli SSB. Human SSB stimulated the DNA helicase activity to the greatest extent (> 10-fold) with a substrate containing a fork compared with substrates without a fork. DNA helicase activity required ATP hydrolysis and could be supported by all eight nucleoside triphosphates. The K(m) values for ATP and dATP in unwinding were 28 and 48 muM, respectively. In general, ribonucleoside triphosphates were better effectors than deoxyribonucleoside triphosphates. The properties of this DNA helicase make it a candidate for a DNA replicative helicase in human cells.	MEM SLOAN KETTERING CANC CTR, SLOAN KETTERING INST, GRAD PROGRAM MOLEC BIOL, 1275 YORK AVE, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center			Seo, Yeonsoo/C-1605-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034559, R37GM034559] Funding Source: NIH RePORTER; NIGMS NIH HHS [5RO GM34559] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; CHALLBERG MD, 1986, P NATL ACAD SCI USA, V83, P9094, DOI 10.1073/pnas.83.23.9094; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DEB SP, 1987, J VIROL, V61, P3649, DOI 10.1128/JVI.61.12.3649-3654.1987; DOWNEY KM, 1990, UCLA SYM BI, V127, P141; EKI T, 1992, J BIOL CHEM, V267, P7284; GOETZ GS, 1988, J BIOL CHEM, V263, P383; GORBALENYA AE, 1988, NATURE, V333, P22, DOI 10.1038/333022a0; GRIEP MA, 1990, BIOCHEMISTRY-US, V29, P9006, DOI 10.1021/bi00490a018; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; HOTTA Y, 1978, BIOCHEMISTRY-US, V17, P1872, DOI 10.1021/bi00603a011; HUBSCHER U, 1985, NUCLEIC ACIDS RES, V13, P5471, DOI 10.1093/nar/13.15.5471; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; JONGENEEL CV, 1984, J BIOL CHEM, V259, P2925; KORNBERG A, 1978, J BIOL CHEM, V253, P3298; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE CG, 1992, J BIOL CHEM, V267, P4398; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; LEE SH, 1989, P NATL ACAD SCI USA, V86, P4877, DOI 10.1073/pnas.86.13.4877; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSUMOTO T, 1990, P NATL ACAD SCI USA, V87, P9712, DOI 10.1073/pnas.87.24.9712; MESSING J, 1983, METHOD ENZYMOL, V101, P20; POLL EHA, 1988, BIOCHEMISTRY-US, V27, P8701, DOI 10.1021/bi00424a002; SANGER F, 1978, J MOL BIOL, V125, P225, DOI 10.1016/0022-2836(78)90346-7; SEKI M, 1990, BIOCHEMISTRY-US, V29, P1003, DOI 10.1021/bi00456a024; SEKI M, 1986, BIOCHEMISTRY-US, V25, P3239, DOI 10.1021/bi00359a024; SEKI M, 1987, BIOCHEMISTRY-US, V26, P2924, DOI 10.1021/bi00384a038; SEKI M, 1988, BIOCHEMISTRY-US, V27, P1766, DOI 10.1021/bi00405a057; SEO YS, 1991, J BIOL CHEM, V266, P13161; SMITH KR, 1989, J BIOL CHEM, V264, P6119; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; SUGINO A, 1986, J BIOL CHEM, V261, P1744; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; THOMMES P, 1990, J BIOL CHEM, V265, P14347; THOMMES P, 1992, J BIOL CHEM, V267, P6063; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TUTEJA N, 1990, NUCLEIC ACIDS RES, V18, P6785, DOI 10.1093/nar/18.23.6785; TUTEJA N, 1991, NUCLEIC ACIDS RES, V19, P3613, DOI 10.1093/nar/19.13.3613; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; ZHANG SS, 1991, J BIOL CHEM, V266, P20483	55	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10282	10295						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8387516				2022-12-25	WOS:A1993LB80000050
J	DECKER, SJ				DECKER, SJ			TRANSMEMBRANE SIGNALING BY EPIDERMAL GROWTH-FACTOR RECEPTORS LACKING AUTOPHOSPHORYLATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHOSPHOLIPASE-C; TERMINAL TYROSINES; EGF RECEPTOR; KINASE; DOMAIN; PHOSPHORYLATION; CELLS; ERBB; INTERNALIZATION; ASSOCIATION	Mutant epidermal growth factor (EGF) receptors in which the five known tyrosine autophosphorylation sites (tyrosines 992, 1068, 1086, 1148, and 1173) were replaced with phenylalanine residues were expressed in NIH-3T3 cells (5F-EGFR) and transmembrane signaling parameters compared with cells expressing wild-type EGF receptor (WT-EGFR). Mutant and wild-type clones were chosen expressing similar numbers of receptors and Scatchard analysis of I-125-EGF binding showed high and low affinity binding of equal affinities for both receptor types. EGF stimulated tyrosine phosphorylation of proteins to a much lesser degree in cells expressing 5F-EGFR relative to cells expressing WT-EGFR. Tyrosine phosphorylation of the 5F-EGFR was 2-4% of WT-EGFR. Surprisingly, cells expressing WT-EGFR or 5F-EGFR showed little difference in dose response of EGF-stimulated [H-3] thymidine incorporation or EGF stimulation of mitogen-activated protein kinase activity. However, EGF did not induce anchorage-independent growth of cells expressing 5F-EGFR to the same extent as it did for cells expressing WT-EGFR. EGF treatment of 5F-EGFR cells failed to elicit an increase in phosphatidylinositol 3-kinase activity or to stimulate hydrolysis of phosphoinositides or tyrosine phosphorylation of phospholipase C-gamma1. These data suggest that a significant proportion of EGF receptor signaling can occur through receptors with altered capacity to interact with src homology 2 domain-containing proteins.	UNIV MICHIGAN,SCH MED,DEPT MICROBIOL,ANN ARBOR,MI 48104	University of Michigan System; University of Michigan	DECKER, SJ (corresponding author), PARKE DAVIS PHARMACEUT,ANN ARBOR,MI 48106, USA.				NCI NIH HHS [CA37754] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037754] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; CAMPOSGONZALES, 1992, J BIOL CHEM, V267, P14535; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; DECKER SJ, 1985, J BIOL CHEM, V260, P2003; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; DECKER SJ, 1992, J BIOL CHEM, V267, P1104; DECKER SJ, 1984, MOL CELL BIOL, V4, P1718, DOI 10.1128/MCB.4.9.1718; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; ELLIS C, 1990, SCI NATURE, V335, P377; GAMETT DC, 1986, P NATL ACAD SCI USA, V83, P6053, DOI 10.1073/pnas.83.16.6053; GLENNEY JR, 1992, BIOCHIM BIOPHYS ACTA, V1134, P113, DOI 10.1016/0167-4889(92)90034-9; HELIN K, 1991, ONCOGENE, V6, P825; HELIN K, 1991, J BIOL CHEM, V266, P8363; KOHNO M, 1985, J BIOL CHEM, V260, P1771; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; MAGNI M, 1991, BIOCHEM J, V277, P305, DOI 10.1042/bj2770305; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MEISENHELDER J, 1989, CELL, V57, P1108; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; OMICHI M, 1992, NEURON, V9, P769; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; RAINES MA, 1988, J VIROL, V62, P2444, DOI 10.1128/JVI.62.7.2444-2452.1988; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; SAWYER ST, 1985, J BIOL CHEM, V260, P8233; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SELVA E, 1993, J BIOL CHEM, V268, P2250; SORKIN A, 1991, J BIOL CHEM, V266, P8355; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WALTON GM, 1990, J BIOL CHEM, V265, P1750	35	77	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9176	9179						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8387484				2022-12-25	WOS:A1993LA68900006
J	WILLIAMS, RT; WU, LT; CARBONAROHALL, DA; TOLO, VT; HALL, FL				WILLIAMS, RT; WU, LT; CARBONAROHALL, DA; TOLO, VT; HALL, FL			IDENTIFICATION OF A NOVEL CYCLIN-LIKE PROTEIN IN HUMAN TUMOR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G1 PHASE; TYROSINE PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; G1-SPECIFIC CYCLINS; CANDIDATE ONCOGENE; KINASE; YEAST; CDC2; ACTIVATION	Cyclins are key regulatory proteins that, in concert with cyclin-dependent protein kinase subunits (cdks), function to govern critical transitions and/or restriction points during the course of cell cycle progression. Recently, a number of putative mammalian G1 cyclins have been characterized at the molecular level; however, the specific activities of the cyclin/cdk complexes and the precise biochemical pathways regulated by the G1 cyclins remain to be elucidated. In the present study we identify a novel cyclin-like protein in pediatric bone and extremity tumors that appears to be related to, but is clearly distinct from, previously identified members of the cyclin D family, as determined by its profile of antibody cross-reactivity, apparent molecular size, chromatographic behavior, physicochemical properties, and pattern of peptide mapping. This 46-kDa cyclin-like protein, tentatively designated p46cyclin X, is first expressed in synchronized MG-63 osteosarcoma cells in mid-G1, well after the induction of p36cyclin D1, yet prior to the induction of cyclins E and A. Northern analysis, utilizing an oligonucleotide probe complementary to an epitope shared by cyclins D1, D2, and X, detected a novel mRNA species, the appearance of which correlates with p46cyclin X expression. The p46cyclin X protein in Ewing's sarcomas and Wilms' tumors is electrophoretically and chromatographically distinct from both p36cyclin D1 and p34cyclin D2. Moreover, the p46cyclin X protein is 1) precipitated by p9Ckshs1-agarose beads, 2) physically associated with p33cdk2, and 3) autophosphorylated in in vitro kinase reactions. Taken together with the biochemical data, the temporal expression of the p46cyclin X/p33cdk2 kinase system is suggestive of a potential role in regulating latter G1 events (i.e. START) in the commitment to S phase.	UNIV SO CALIF, CHILDRENS HOSP LOS ANGELES,SCH MED, DIV ORTHOPAED SURG,4650 SUNSET BLVD, LOS ANGELES, CA 90054 USA; UNIV SO CALIF, SCH PHARM, DEPT MOLEC PHARMACOL & TOXICOL, LOS ANGELES, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California; University of Southern California								BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; CARBONAROHALL D, 1993, IN PRESS ONCOGENE; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CROSS F, 1989, ANNU REV CELL BIOL, V5, P341; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; ELLEDGE SJ, 1992, EMBO J, V89, P2907; FOX MH, 1987, CYTOMETRY, V8, P315, DOI 10.1002/cyto.990080312; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HALL FL, 1991, J BIOL CHEM, V266, P17430; HALL FL, 1993, IN PRESS ONCOGENE; Hall FL, 1991, CURR OPIN CELL BIOL, V3, P176, DOI 10.1016/0955-0674(91)90136-M; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; Hunt T, 1991, Semin Cell Biol, V2, P213; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MINSHULL J, 1989, J CELL SCI, P77; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY AW, 1989, J CELL SCI, P65; MURRAY AW, 1991, NATURE, V349, P367, DOI 10.1038/349367a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NORBURY CJ, 1989, BIOCHIM BIOPHYS ACTA, V989, P85, DOI 10.1016/0304-419X(89)90036-X; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PINES J, 1990, New Biologist, V2, P389; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SAMIEI M, 1991, J BIOL CHEM, V266, P14889; SANGHERA JS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P335, DOI 10.1016/0167-4889(92)90240-C; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STALLCUP MR, 1983, J BIOL CHEM, V258, P2802; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WILLIAMS RT, 1992, ONCOGENE, V7, P423; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	66	33	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8871	8880						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8386171				2022-12-25	WOS:A1993KX81100073
J	BEGUM, N; OLEFSKY, JM; DRAZNIN, B				BEGUM, N; OLEFSKY, JM; DRAZNIN, B			MECHANISM OF IMPAIRED METABOLIC SIGNALING BY A TRUNCATED HUMAN INSULIN-RECEPTOR - DECREASED ACTIVATION OF PROTEIN PHOSPHATASE-1 BY INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; CASEIN KINASE-II; COOH-TERMINAL TRUNCATION; GLYCOGEN-BINDING SUBUNIT; CATALYTIC SUBUNIT; PHOSPHOPROTEIN PHOSPHATASE; GROWTH-FACTOR; OWN RECEPTOR; PHOSPHORYLATION; PURIFICATION	Previous studies have shown that a human insulin receptor lacking the COOH-terminal 43-amino acid domain (HIRDELTACT) displays a compromised ability to stimulate glucose transport and glycogen synthase, whereas mitogenic signaling and stimulation of the insulin receptor tyrosine kinase activity remain intact (Maegawa, H., McClain, D. A., Freidenberg, G., Olefsky, J. M., Napier, M., Lipari, T., Dull, T. J., Lee, J., and Ullrich, A. (1988) J. Biol. Chem. 263, 8912-8917). In this study, we examined the effect of insulin on protein phosphatase 1 (PP-1) activity and phosphorylation in cells expressing wild-type human insulin receptor (HIRc) and HIRDELTACT cells using phosphorylase a as substrate in the presence of 3 nM okadaic acid. Basal PP-1 activity was significantly lower in HIRDELTACT than in HIRc cells (p < 0.05). Insulin stimulated PP-1 activity in HIRc cells (25-30% increase over basal activity) in a time- and dose-dependent manner. Insulin failed to stimulate PP-1 activity in HIRDELTACT cells. Western blotting with the catalytic subunit antibody and the regulatory subunit antibody revealed similar amounts of the 37-kDa band (catalytic subunit) and the 160-kDa band (presumed regulatory subunit) in HIRc and HIRDELTACT cells. We conclude that the COOH-terminal domain of the insulin receptor is an important element in mediating the effect of insulin on PP-1 and suggest that activation of PP-1 may be linked to signaling insulin's metabolic actions.	VET AFFAIRS MED CTR, DEPT MED, ENDOCRINOL SECT 111H, 1055 CLERMONT ST, DENVER, CO 80220 USA; VET AFFAIRS MED CTR, RES SERV, DENVER, CO 80220 USA; UNIV COLORADO, HLTH SCI CTR, DENVER, CO 80220 USA; UNIV CALIF SAN DIEGO, SCH MED, DEPT MED, LA JOLLA, CA 92063 USA; SAN DIEGO VET AFFAIRS MED CTR, LA JOLLA, CA 92063 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of California System; University of California San Diego					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, R37DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEMANY S, 1986, EUR J BIOCHEM, V156, P101, DOI 10.1111/j.1432-1033.1986.tb09554.x; ANDERSON CM, 1991, J BIOL CHEM, V266, P21760; BEGUM N, 1992, J CLIN INVEST, V90, P1254, DOI 10.1172/JCI115988; BRAUTIGAN DL, 1985, J BIOL CHEM, V260, P4295; CHAN CP, 1988, P NATL ACAD SCI USA, V85, P6257, DOI 10.1073/pnas.85.17.6257; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COHEN P, 1988, PROC R SOC SER B-BIO, V234, P115, DOI 10.1098/rspb.1988.0040; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN P, 1983, METHOD ENZYMOL, V99, P243; COHEN P, 1989, J BIOL CHEM, V264, P21435; COHEN P, 1985, CURR TOP CELL REGUL, V27, P23; COHEN P, 1991, METHOD ENZYMOL, V201, P389; CZECH MP, 1988, J BIOL CHEM, V263, P11017; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DENT P, 1990, FEBS LETT, V259, P281, DOI 10.1016/0014-5793(90)80027-G; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ERIKSON E, 1985, P NATL ACAD SCI USA, V82, P742, DOI 10.1073/pnas.82.3.742; ERIKSON E, 1986, J BIOL CHEM, V261, P350; FOULKES JG, 1980, EUR J BIOCHEM, V105, P195, DOI 10.1111/j.1432-1033.1980.tb04489.x; FOULKES JG, 1979, EUR J BIOCHEM, V97, P251, DOI 10.1111/j.1432-1033.1979.tb13109.x; GRUPPUSO PA, 1987, BIOCHEM BIOPH RES CO, V148, P1174, DOI 10.1016/S0006-291X(87)80256-5; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P711, DOI 10.1111/j.1432-1033.1989.tb15264.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V180, P457, DOI 10.1111/j.1432-1033.1989.tb14668.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P701, DOI 10.1111/j.1432-1033.1989.tb15263.x; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARNER J, 1990, ADV ENZYMOL RAMB, V63, P173; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; LAWRENCE JC, 1988, BIOCHEM BIOPH RES CO, V150, P197, DOI 10.1016/0006-291X(88)90505-0; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; MYERS MG, 1991, J BIOL CHEM, V266, P10616; NIMMO GA, 1978, EUR J BIOCHEM, V87, P341, DOI 10.1111/j.1432-1033.1978.tb12383.x; PETRUZZELLI L, 1984, P NATL ACAD SCI-BIOL, V81, P3327, DOI 10.1073/pnas.81.11.3327; REUSCH JEB, 1993, J BIOL CHEM, V268, P3348; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; TANG PM, 1991, J BIOL CHEM, V266, P15782; TAYLOR R, 1991, CLIN ENDOCRINOL, V34, P159, DOI 10.1111/j.1365-2265.1991.tb00287.x; THIES RS, 1989, J BIOL CHEM, V264, P12820; YU KT, 1984, J BIOL CHEM, V259, P5277; ZICK Y, 1983, J BIOL CHEM, V258, P3431	48	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7917	7922						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8385127				2022-12-25	WOS:A1993KW97900052
J	HEWLETT, EL; GRAY, MC; EHRMANN, IE; MALONEY, NJ; OTERO, AS; GRAY, L; ALLIETTA, M; SZABO, G; WEISS, AA; BARRY, EM				HEWLETT, EL; GRAY, MC; EHRMANN, IE; MALONEY, NJ; OTERO, AS; GRAY, L; ALLIETTA, M; SZABO, G; WEISS, AA; BARRY, EM			CHARACTERIZATION OF ADENYLATE-CYCLASE TOXIN FROM A MUTANT OF BORDETELLA-PERTUSSIS DEFECTIVE IN THE ACTIVATOR GENE, CYAC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI HEMOLYSIN; ERYTHROCYTE-MEMBRANES; INTRACELLULAR CAMP; SECRETION; PROTEIN; CALCIUM; BINDING; CELLS; HLYA; PROHAEMOLYSIN	Bordetella pertussis adenylate cyclase (AC) toxin has the abilities to 1) enter target cells where it catalyzes cyclic AMP production and 2) lyse sheep erythrocytes, and these abilities require post-translational modification by the product of an accessory gene cyaC (Barry, E. M., Weiss, A. A., Ehrmann, E. E., Gray, M. C., Hewlett, E. L., and Goodwin, M. St. M. (1991) J. Bacteriol. 173, 720-726). In the present study, AC toxin has been purified from an organism with a mutation in cyaC, BPDE386, and evaluated for its physical and functional properties in order to determine the basis for its lack of toxin and hemolytic activities. AC toxin from BPDE386 is indistinguishable from wild-type toxin in enzymatic activity, migration on SDS-polyacrylamide gel electrophoresis, ability to bind calcium, and calcium-dependent conformational change. Although unable to elicit cAMP accumulation, AC toxin from BPDE386 exhibits binding to the surface of Jurkat cells which is comparable to that of wild-type toxin. This target cell interaction is qualitatively different, however, in that 99% of the mutant toxin remains sensitive to trypsin, whereas approximately 20% of cell-associated wild-type toxin enters a trypsin-resistant compartment. To evaluate the ability of this mutant AC toxin to function at its intracellular site of action, the cAMP-stimulated L-type calcium current in frog atrial myocytes was used. Extracellular addition of wild-type toxin results in cAMP-dependent events that include activation of calcium channels and enhancement of calcium current. In contrast, there is no response to externally applied toxin from BPDE386. When injected into the cell interior, however, the AC toxin from BPDE386 is able to produce increases in the calcium current comparable to those observed with wild-type toxin. Although AC toxin from BPDE386 is unaffected in its enzymatic activity, calcium binding, and calcium-dependent conformational change, the mutation in cyaC does result in a toxin which is able to bind to target cells but unable to elicit cAMP accumulation. In that AC toxin from BPDE386 is able to function normally when injected artificially to an intracellular site, we conclude that the disruption of cyaC produces a defect in insertion and transmembrane delivery of the catalytic domain.	UNIV VIRGINIA,SCH MED,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,DEPT PATHOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,DEPT PHYSIOL,CHARLOTTESVILLE,VA 22908; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MICROBIOL & IMMUNOL,RICHMOND,VA 23298	University of Virginia; University of Virginia; University of Virginia; Virginia Commonwealth University	HEWLETT, EL (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,SCH MED,DEPT MED,BOX 419,CHARLOTTESVILLE,VA 22908, USA.			gray, mary/0000-0003-4441-5905				BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; BELLALOU J, 1990, INFECT IMMUN, V58, P1195, DOI 10.1128/IAI.58.5.1195-1200.1990; BHAKDI S, 1986, INFECT IMMUN, V52, P63, DOI 10.1128/IAI.52.1.63-69.1986; BOEHM DF, 1990, INFECT IMMUN, V58, P1959, DOI 10.1128/IAI.58.6.1959-1964.1990; BOEHM DF, 1990, INFECT IMMUN, V58, P1951, DOI 10.1128/IAI.58.6.1951-1958.1990; BROOKER G, 1976, SCIENCE, V194, P270, DOI 10.1126/science.184530; CLERC P, 1986, ANN INST PASTEUR MIC, V137A, P267, DOI 10.1016/S0769-2609(86)80033-3; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; EHRMANN IE, 1992, FEBS LETT, V304, P51, DOI 10.1016/0014-5793(92)80587-7; EHRMANN IE, 1991, FEBS LETT, V278, P79, DOI 10.1016/0014-5793(91)80088-K; EHRMANN IE, 1991, THESIS U VIRGINIA CH; GENTILE F, 1988, BIOCHIM BIOPHYS ACTA, V971, P63, DOI 10.1016/S0005-2728(88)80009-4; GENTILE F, 1990, J BIOL CHEM, V265, P1; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; GORDON VM, 1989, J BIOL CHEM, V264, P14972; GORDON VM, 1989, THESIS U VIRGINIA CH; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANSKI E, 1989, TRENDS BIOCHEM SCI, V14, P459, DOI 10.1016/0968-0004(89)90106-0; HANSKI E, 1985, J BIOL CHEM, V260, P5526; HARDIE KR, 1991, MOL MICROBIOL, V5, P1669, DOI 10.1111/j.1365-2958.1991.tb01914.x; HEWLETT EL, 1976, P NATL ACAD SCI USA, V73, P1926, DOI 10.1073/pnas.73.6.1926; HEWLETT EL, 1991, J BIOL CHEM, V266, P17503; HEWLETT EL, 1989, J BIOL CHEM, V264, P19379; HEWLETT EL, 1990, DHHS FDA901164 US PH; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPOINTE JY, 1987, PFLUG ARCH EUR J PHY, V410, P212, DOI 10.1007/BF00581918; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUDWIG A, 1988, NUCLEIC ACIDS RES, V12, P387; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MENESTRINA G, 1987, BIOCHIM BIOPHYS ACTA, V905, P109, DOI 10.1016/0005-2736(87)90014-9; NARGEOT J, 1983, P NATL ACAD SCI-BIOL, V80, P2395, DOI 10.1073/pnas.80.8.2395; NICAUD JM, 1985, FEBS LETT, V187, P339, DOI 10.1016/0014-5793(85)81272-2; OTERO AS, 1988, SCIENCE, V242, P443, DOI 10.1126/science.3051383; ROGEL A, 1989, EMBO J, V8, P2755, DOI 10.1002/j.1460-2075.1989.tb08417.x; ROGEL A, 1992, J BIOL CHEM, V267, P22599; ROGEL A, 1991, J BIOL CHEM, V266, P3154; ROGEL A, 1990, DHHS FDA901164 US PH, P20; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SELFE S, 1987, MOL PHARMACOL, V31, P529; Smith RM, 1974, CRITICAL STABILITY C, V1-6; STOCKBRIDGE N, 1987, COMPUT BIOL MED, V17, P299, DOI 10.1016/0010-4825(87)90019-9; THELESTAM M, 1988, TOXICON, V26, P51, DOI 10.1016/0041-0101(88)90137-7; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; WAGNER W, 1988, BIOL CHEM H-S, V369, P39, DOI 10.1515/bchm3.1988.369.1.39; WELCH RA, 1986, PROTEIN CARBOHYDRATE, P433	47	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7842	7848						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8385122				2022-12-25	WOS:A1993KW97900041
J	HAYASHI, H; NISHIOKA, Y; KAMOHARA, S; KANAI, F; ISHII, K; FUKUI, Y; SHIBASAKI, F; TAKENAWA, T; KIDO, H; KATSUNUMA, N; EBINA, Y				HAYASHI, H; NISHIOKA, Y; KAMOHARA, S; KANAI, F; ISHII, K; FUKUI, Y; SHIBASAKI, F; TAKENAWA, T; KIDO, H; KATSUNUMA, N; EBINA, Y			THE ALPHA-TYPE 85-KDA SUBUNIT OF PHOSPHATIDYLINOSITOL 3-KINASE IS PHOSPHORYLATED AT TYROSINE-368, TYROSINE-580, AND TYROSINE-607 BY THE INSULIN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-ACTIVITY; MONOCLONAL-ANTIBODY; PROTEIN-KINASE; BETA-SUBUNIT; BINDING; PURIFICATION; CLONING; CDNA; AUTOPHOSPHORYLATION; ACTIVATION	We have shown previously that insulin stimulated the tyrosine phosphorylation of the alpha-type 85-kDa subunit (p85) of phosphatidylinositol (PI) 3-kinase in vitro and in vivo. In the present work, we identified the major tyrosine phosphorylation sites of the alpha-type p85 by the insulin receptor. [P-32]Phosphopeptides obtained from lysylendopeptidase digestion of phosphorylated alpha-type p85 in intact cells after insulin treatment were analyzed using reverse-phase high performance liquid chromatography and thin layer electrophoresis. The tyrosine phosphorylation sites of alpha-type p85 in vivo were assigned to three major phosphopeptides, designated p1, p2, and p3. Highly purified insulin receptor also phosphorylated the purified p85 of PI 3-kinase from the bovine thymus at p1. The purified glutathione S-transferase (GST)-p85 (alpha-type) fusion protein and its truncated proteins from Escherichia coli were also phosphorylated by the purified insulin receptor at p1, p2, and p3 in vitro. Analysis of [P-32]phosphopeptide of the truncated GST-p85 (alpha-type) fusion proteins and radiosequence analysis revealed that the p1, p2, and p3 phosphopeptides were phosphorylated at tyrosines 607, 580, and 368, respectively. In addition, phenylalanine substitutions at tyrosine 607 and 580 reduced the p1 and p2 phosphopeptides in vivo, respectively. We conclude that the alpha-type p85 of PI 3-kinase was phosphorylated at tyrosines 368, 580, and 607 by the insulin receptor in vivo.	UNIV TOKUSHIMA,INST ENZYME RES,DEPT ENZYME GENET,3-18-15 KURAMOTO CHO,TOKUSHIMA 770,JAPAN; UNIV TOKUSHIMA,INST ENZYME RES,DEPT ENZYME CHEM,TOKUSHIMA 770,JAPAN; UNIV TOKYO,DEPT AGR CHEM,BIOCHEM LAB,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT BIOSIGNAL RES,ITABASHI KU,TOKYO 173,JAPAN	Tokushima University; Tokushima University; University of Tokyo			Fukui, Yasuhisa/E-8806-2010	Ishii, Kazuo/0000-0002-8363-8266; Hayashi, Hideki/0000-0003-4585-6542; Kamohara, Seika/0000-0002-2482-6611				CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAYASHI H, 1991, BIOCHEM J, V280, P769, DOI 10.1042/bj2800769; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; HAYASHI H, 1989, J BIOL CHEM, V264, P17222; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KITAGAWA Y, 1986, J BIOCHEM-TOKYO, V99, P1289, DOI 10.1093/oxfordjournals.jbchem.a135596; KLARLUND JK, 1988, J BIOL CHEM, V263, P1572; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORGAN DO, 1987, P NATL ACAD SCI USA, V84, P41, DOI 10.1073/pnas.84.1.41; MORGAN DO, 1986, P NATL ACAD SCI USA, V83, P328, DOI 10.1073/pnas.83.2.328; MORGAN DO, 1986, BIOCHEMISTRY-US, V25, P1364, DOI 10.1021/bi00354a026; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTHENBERG P, 1990, HDB EXPT PHARM INSUL, V92, P209; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; STADTMAUER LA, 1983, J BIOL CHEM, V258, P6682; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; ULLICH A, 1985, NATURE, V313, P756; WHITE MF, 1988, J BIOL CHEM, V263, P2969; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	37	64	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7107	7117						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8385099				2022-12-25	WOS:A1993KV14100046
J	YOSHIMURA, M; COOPER, DMF				YOSHIMURA, M; COOPER, DMF			TYPE-SPECIFIC STIMULATION OF ADENYLYLCYCLASE BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-ADRENERGIC-RECEPTOR; PHORBOL ESTER RECEPTOR; ADENYLATE-CYCLASE; RAT-BRAIN; EXPRESSION; CLONING; PHOSPHORYLATION; INHIBITION; MECHANISMS; PATHWAYS	Ca2+-stimulable (type I), Ca2+-insensitive (type II), and Ca2+-inhibitable adenylylcyclase (type VI) were transiently expressed in the human embryonic kidney 293 cell line. Phorbol 12,13-dibutyrate (PDBu) increased cAMP synthesis by the Ca2+-insensitive type II adenylylcyclase more than 9-fold within 10 min, while the treatment had no effect on the other two types of adenylylcyclases. This stimulatory effect of PDBu on type II activity was dose-dependent and synergistic with the effect of forskolin. Another phorbol ester, phorbol 12-myristate 13-acetate (PMA), had a similar stimulatory effect on type II activity, while its inactive isomer, 4alpha-phorbol 12-myristate 13-acetate (4alpha-PMA), had no effect. Staurosporine, a potent protein kinase C (PKC) inhibitor, markedly attenuated the action of PDBu on cAMP synthesis by type II adenylylcyclase. These results are particularly significant in that they indicate that a species of adenylylcyclase that is insensitive to regulation by one arm of the phosphatidylinositide pathway, i.e. Ca2+, nevertheless can be regulated by the other arm, i.e. PKC.	UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,BOX C-236,4200 E 9TH AVE,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032483] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32483] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIYAR N, 1992, CELL CALCIUM MOL PHA, V31, P180; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; CALDWELL KK, 1992, CELL CALCIUM, V13, P107, DOI 10.1016/0143-4160(92)90004-C; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; COLVIN RA, 1991, CELL CALCIUM, V12, P19, DOI 10.1016/0143-4160(91)90081-O; COOPER DMF, 1988, J CELL BIOCHEM, V36, P417, DOI 10.1002/jcb.240360410; DIXON BS, 1988, AM J PHYSIOL, V254, pC183, DOI 10.1152/ajpcell.1988.254.1.C183; EVANS T, 1984, MOL PHARMACOL, V26, P395; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FUCHS R, 1991, COMPUT APPL BIOSCI, V7, P105; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GARTE SJ, 1980, NATURE, V284, P171, DOI 10.1038/284171a0; HOUSLAY MD, 1991, EUR J BIOCHEM, V195, P9, DOI 10.1111/j.1432-1033.1991.tb15671.x; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; MONS N, 1993, IN PRESS SYNAPSE; NAKADATE T, 1988, BIOCHEM PHARMACOL, V37, P1541, DOI 10.1016/0006-2952(88)90016-0; NARAYANAN N, 1989, ENDOCRINOLOGY, V124, P484, DOI 10.1210/endo-124-1-484; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIBLEY DR, 1984, BIOCHEM BIOPH RES CO, V121, P973, DOI 10.1016/0006-291X(84)90772-1; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, J BIOL CHEM, V266, P8595; WORLEY PF, 1986, J NEUROSCI, V6, P199; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	31	180	183	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4604	4607						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8383119				2022-12-25	WOS:A1993KP88400010
J	KIJIMA, Y; SAITO, A; JETTON, TL; MAGNUSON, MA; FLEISCHER, S				KIJIMA, Y; SAITO, A; JETTON, TL; MAGNUSON, MA; FLEISCHER, S			DIFFERENT INTRACELLULAR-LOCALIZATION OF INOSITOL 1,4,5-TRISPHOSPHATE AND RYANODINE RECEPTORS IN CARDIOMYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; RELEASE CHANNELS; CALCIUM-RELEASE; PLASMA-MEMBRANE; SMOOTH-MUSCLE; CA-2+ RELEASE; PROTEIN; HEART; HYDROLYSIS	The ryanodine and inositol 1,4,5-trisphosphate (IP3) receptors have previously been found to be intracellular Ca2+ release channels characterized by their large size and 4-fold symmetry. In this study, cardiomyocytes are found to have a different intracellular localization for the two receptors. At the level of light microscopy, the IP3 receptor is immunolocalized in rat ventricular cardiomyocytes at the region of the intercalated discs. By contrast, immunoreactivity of the ryanodine receptor is observed as transverse bands throughout the length of the cardiomyocyte, coincident with the triad junction at the I-bands. At the level of electron microscopy, immunogold particles directed to the IP3 receptor specifically decorate the intercalated discs of rat ventricular and atrial cardiomyocytes, preferentially at the fascia adherens. Binding of [H-3] IP3 and [H-3]ryanodine were measured in cardiac subcellular fractions. IP3 binding is enriched in a fraction containing intercalated discs. Little or no IP3 binding was detected in longitudinal sareoplasmic reticulum (SR), junctional SR, sarcolemma, mitochondria, and submitochondrial vesicles. Ryanodine binding is the highest in junctional SR. We conclude that the IP3 receptor is present in ventricular and atrial cardiomyocytes and localized at the region of the intercalated discs. These results suggest a possible role of the IP3 receptor in Ca2+ entry through intercalated discs and/or intercellular signaling between cardiomyocytes.	VANDERBILT UNIV, MED CTR, SCH MED, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA	Vanderbilt University	KIJIMA, Y (corresponding author), VANDERBILT UNIV, DEPT MOLEC BIOL, NASHVILLE, TN 37235 USA.		Magnuson, Mark/AAY-7172-2021; Magnuson, Mark A/B-1335-2009	Magnuson, Mark/0000-0002-8824-6499; Magnuson, Mark A/0000-0002-8824-6499	NHLBI NIH HHS [P01-HL46681, HL32711] Funding Source: Medline; NIDDK NIH HHS [DK42612] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032711, P01HL046681] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042612] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BOCK HG, 1974, METHOD ENZYMOL, V31, P374; BORGATTA L, 1991, P NATL ACAD SCI USA, V88, P2486, DOI 10.1073/pnas.88.6.2486; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN JH, 1985, CIRC RES, V57, P532, DOI 10.1161/01.RES.57.4.532; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; CHAMBERLAIN BK, 1983, J BIOL CHEM, V258, P6602; ECKEL J, 1991, J MOL CELL CARDIOL, V23, P617, DOI 10.1016/0022-2828(91)90053-O; FABIATO A, 1990, RECENT ADVANCES IN CALCIUM CHANNELS AND CALCIUM ANTAGONISTS, P35; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FLEISCHER S, 1985, P NATL ACAD SCI USA, V82, P7256, DOI 10.1073/pnas.82.21.7256; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FURUICHI T, 1990, FEBS LETT, V267, P85, DOI 10.1016/0014-5793(90)80294-S; IMAGAWA T, 1989, J BIOCHEM-TOKYO, V106, P342, DOI 10.1093/oxfordjournals.jbchem.a122855; INUI M, 1987, J BIOL CHEM, V262, P15637; INUI M, 1988, J BIOL CHEM, V263, P10843; JONES LR, 1979, J BIOL CHEM, V254, P530; KAWAMOTO RM, 1986, J CELL BIOL, V103, P1405, DOI 10.1083/jcb.103.4.1405; KENSLER RW, 1980, J CELL BIOL, V86, P755, DOI 10.1083/jcb.86.3.755; KENTISH JC, 1990, AM J PHYSIOL, V258, pH610, DOI 10.1152/ajpheart.1990.258.2.H610; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEISCHER S, 1974, METHOD ENZYMOL, V31, P292; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MARKS AR, 1990, J BIOL CHEM, V265, P20719; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; PALADE P, 1983, J HISTOCHEM CYTOCHEM, V31, P971, DOI 10.1177/31.7.6189886; PALADE P, 1989, MOL PHARMACOL, V36, P664; ROTH J, 1989, METHOD CELL BIOL, V31, P513; SAITO A, 1978, J CELL BIOL, V79, P601, DOI 10.1083/jcb.79.3.601; SAITO A, 1984, J ULTRA MOL STRUCT R, V86, P277, DOI 10.1016/S0022-5320(84)90107-2; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SCHOLZ J, 1988, J PHARMACOL EXP THER, V245, P327; SEVERS NJ, 1990, INT J CARDIOL, V26, P137, DOI 10.1016/0167-5273(90)90030-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIGNE P, 1990, J BIOL CHEM, V265, P6782; VIGNE P, 1989, FEBS LETT, V249, P143, DOI 10.1016/0014-5793(89)80611-8; VITES AM, 1992, AM J PHYSIOL, V262, pH268, DOI 10.1152/ajpheart.1992.262.1.H268; WALTON PD, 1991, J CELL BIOL, V113, P1145, DOI 10.1083/jcb.113.5.1145; WIENTZEK M, 1991, J MOL CELL CARDIOL, V23, P1149, DOI 10.1016/0022-2828(91)90204-Y	43	113	113	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3499	3506						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8381433				2022-12-25	WOS:A1993KM16100074
J	MILLAR, DG; SHORE, GC				MILLAR, DG; SHORE, GC			THE SIGNAL ANCHOR SEQUENCE OF MITOCHONDRIAL MAS70P CONTAINS AN OLIGOMERIZATION DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSMEMBRANE HELICAL INTERACTIONS; OUTER-MEMBRANE PROTEIN; PRECURSOR PROTEIN; POINT MUTATION; NEU ONCOGENE; IMPORT; RECEPTOR; DIMERIZATION; AGGREGATION; ASSOCIATION	pOMD29 is a mitochondrial precursor protein that contains the NH2-terminal signal anchor sequence of Mas70p fused to dihydrofolate reductase. The signal anchor mediates insertion of pOMD29 into the outer mitochondrial membrane in the N(in)-C(cyto) orientation. Following import in vitro, pOMD29 was chemically cross-linked, via a unique cysteine residue adjacent to the signal anchor (residue 34), to form a product that was approximately twice the size of pOMD29. The cross-linked product was a dimer of pOMD29, as judged by the following. 1) It exhibited the same charge:mass ratio as pOMD29. 2) Formation of radioactive cross-linked product containing S-35-labeled pOMD29 was stimulated by co-import with unlabeled pOMD29. 3) Co-import of pOMD29 with a modified pOMD29 that contains two copies of dihydrofolate reductase resulted in formation of the predicted homo- and heterodimers. Cross-linking of pOMD29 was unaffected by concentrations of methotrexate that lock the dihydrofolate reductase moiety into its native monomeric conformation, indicating that oligomerization was mediated by the signal anchor rather than by the cytosolic domain of pOMD29. The predicted transmembrane core of the signal anchor sequence contains structural motifs similar to those found in a variety of signal-transducing cell surface receptors that dimerize through their transmembrane segments.	MCGILL UNIV,DEPT BIOCHEM,MCINTYRE MED SCI BLDG,MONTREAL H3G 1Y6,QUEBEC,CANADA	McGill University				Millar, Douglas/0000-0002-8640-7148				BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Blakley R.L., 1984, FOLATES PTERINS, V1, P191; BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; BORMANN BJ, 1992, ANNU REV BIOPH BIOM, V21, P223, DOI 10.1146/annurev.bb.21.060192.001255; COSSON P, 1992, SCIENCE, V258, P659, DOI 10.1126/science.1329208; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; HASE T, 1984, EMBO J, V3, P3157, DOI 10.1002/j.1460-2075.1984.tb02274.x; HINES V, 1993, J BIOL CHEM, V268, P449; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LI JM, 1992, SCIENCE, V256, P1815, DOI 10.1126/science.1615327; LI JM, 1992, BIOCHIM BIOPHYS ACTA, V1106, P233, DOI 10.1016/0005-2736(92)90001-3; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MCBRIDE HM, 1992, J CELL BIOL, V119, P1451, DOI 10.1083/jcb.119.6.1451; NAKAI M, 1989, J BIOCHEM-TOKYO, V105, P513, DOI 10.1093/oxfordjournals.jbchem.a122698; RUTLEDGE T, 1992, EMBO J, V11, P3245, DOI 10.1002/j.1460-2075.1992.tb05402.x; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; SHORE GC, 1992, MEMBRANE BIOGENESIS, P253; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0	22	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18403	18406						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8395500				2022-12-25	WOS:A1993LV65900002
J	PANAYOTATOS, N; RADZIEJEWSKA, E; ACHESON, A; PEARSALL, D; THADANI, A; WONG, V				PANAYOTATOS, N; RADZIEJEWSKA, E; ACHESON, A; PEARSALL, D; THADANI, A; WONG, V			EXCHANGE OF A SINGLE AMINO-ACID INTERCONVERTS THE SPECIFIC ACTIVITY AND GEL MOBILITY OF HUMAN AND RAT CILIARY NEUROTROPHIC FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; CLONING; NEURONS; PROTEIN	Human and rat ciliary neurotrophic factors (CNTF), which share 85% sequence identity, promote the survival of chicken embryo ciliary ganglia neurons in vitro, but display a 4-5-fold difference in specific activity. To explore the origin of this difference and gain insight into the structural organization of CNTF, we created chimeric proteins of these two species. Surprisingly, we found that the differences in two apparently unrelated properties, gel mobility and specific activity, resided in a single amino acid. Substituting arginine residue 63 of rat CNTF into the human sequence created a protein with the properties of rat CNTF. Conversely, substituting the human CNTF glutamine residue 63 into rat CNTF generated a protein with the properties of human CNTF. Binding experiments confirmed that the distinct specific activities of human and rat CNTF and their chimeras reside in structural differences among these ligands rather than species differences in their receptors. Alanine substitution (Q63A) had no effect on the properties of human CNTF, whereas the R63A substitution reduced both the gel mobility and the specific activity of rat CNTF. Finally, a Q95R substitution at a different position of human CNTF had no effect on its properties. These results demonstrate that Arg-63 is both specific and critical in determining the structural differences of human and rat CNTF.			PANAYOTATOS, N (corresponding author), REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591, USA.							BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CHAUDHARY T, 1992, 40TH P ASMS C MASS S, P1917; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEJONG WW, 1978, BIOCHEM BIOPH RES CO, V82, P532, DOI 10.1016/0006-291X(78)90907-5; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; KESSLER JA, 1984, DEV BIOL, V106, P91; LEUNG DW, 1992, NEURON, V8, P1045, DOI 10.1016/0896-6273(92)90126-X; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; MANTHORPE M, 1986, DEV BRAIN RES, V25, P191, DOI 10.1016/0165-3806(86)90208-7; MASIAKOWSKI P, 1991, J NEUROCHEM, V57, P1003, DOI 10.1111/j.1471-4159.1991.tb08250.x; PANAYOTATOS N, 1989, J BIOL CHEM, V264, P15066; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0	16	53	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					19000	19003						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8395524				2022-12-25	WOS:A1993LV65900093
J	ORLOWSKI, J				ORLOWSKI, J			HETEROLOGOUS EXPRESSION AND FUNCTIONAL-PROPERTIES OF AMILORIDE HIGH-AFFINITY (NHE-1) AND LOW-AFFINITY (NHE-3) ISOFORMS OF THE RAT NA/H EXCHANGER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-H+ EXCHANGER; BRUSH-BORDER MEMBRANE; GROWTH-FACTOR; PROXIMAL TUBULE; MOLECULAR-CLONING; INTRACELLULAR PH; ANTIPORT ACTIVITY; SODIUM-HYDROGEN; RABBIT ILEUM; CELL LINE	Recent molecular cloning studies have identified four distinct members (NHE-1,-2,-3,-4) of the Na/H exchanger gene family that are expressed in a tissue-specific pattern. To examine some of their functional properties, full-length cDNAs for two of these isoforms, rat NHE-1 and NHE-3, were stably transfected in Na/H exchanger-deficient Chinese hamster ovary cells (AP-1) and assayed for transport activity by measuring amiloride-inhibitable H+-activated Na-22+ influx. Pharmacological analyses revealed that the activity of NHE-1 was substantially more sensitive to inhibition by amiloride and its analogues than NHE-3. Similarly, both isoforms were differentially sensitive to inhibition by cimetidine, clonidine, and harmaline; agents also known to inhibit the activity of the Na/H exchanger. Their rank order of potency for NHE-1 was cimetidine > harmaline greater-than-or-equal-to clonidine whereas the reverse order was observed for NHE-3. The isoforms were also distinguished by their kinetic properties. While the extracellular Na+ (Na+o) dependence of both isoforms showed simple, saturating Michaelis-Menten kinetics, NHE-1 exhibited a 2-fold lower affinity for Na+o than NHE-3, with apparent K(Na) values of 10.0 +/- 1.4 and 4.7 +/- 0.6 mM, respectively. In contrast to Na+o intracellular H+ (H+i) activated both isoforms by a positive cooperative mechanism. However, NHE-1 had a 2-fold higher apparent affinity for H+i compared to NHE-3, with half-maximal activation values of pK 6.75 +/- 0.05 and 6.45 +/- 0.08, respectively. Other external cations also interacted with both exchangers. Li+o and H+o inhibited Na-22+ influx by both isoforms with similar kinetics. In contrast, K+o inhibited Na-22+ influx by NHE- 1, but had no effect on NHE-3. Thus NHE-1 and -3 exhibited diverse functional properties when expressed in the same cell type. Furthermore, the functional properties associated with NHE-3 closely mimicked those described for the apical membrane Na/H exchanger of renal proximal tubules, suggesting that these proteins are molecularly identical.			ORLOWSKI, J (corresponding author), MCGILL UNIV,DEPT PHYSIOL,MCINTYRE MED SCI BLDG,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA.			Orlowski, John/0000-0001-7371-175X				ARONSON PS, 1983, J BIOL CHEM, V258, P6767; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; ARONSON PS, 1980, AM J PHYSIOL, V238, pF210, DOI 10.1152/ajprenal.1980.238.3.F210; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BALKOVETZ DF, 1987, J PHARMACOL EXP THER, V243, P150; BIEMESDERFER D, 1992, AM J PHYSIOL, V263, pF833, DOI 10.1152/ajprenal.1992.263.5.F833; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARK JD, 1991, AM J PHYSIOL, V261, pC945, DOI 10.1152/ajpcell.1991.261.6.C945; CUTHBERT AW, 1978, BRIT J PHARMACOL, V63, P139, DOI 10.1111/j.1476-5381.1978.tb07783.x; FAFOURNOUX P, 1991, BIOCHEMISTRY-US, V30, P9510, DOI 10.1021/bi00103a018; FRANCHI A, 1986, P NATL ACAD SCI USA, V83, P9388, DOI 10.1073/pnas.83.24.9388; FRANCHI A, 1986, J BIOL CHEM, V261, P4614; FRELIN C, 1986, EUR J BIOCHEM, V154, P241, DOI 10.1111/j.1432-1033.1986.tb09388.x; FRELIN C, 1984, J BIOL CHEM, V259, P8880; FRIEDRICH T, 1986, J MEMBRANE BIOL, V94, P253, DOI 10.1007/BF01869721; GANAPATHY ME, 1986, BIOCHEM PHARMACOL, V35, P3989, DOI 10.1016/0006-2952(86)90016-X; GANAPATHY V, 1986, J PHARMACOL EXP THER, V239, P192; GEIBEL J, 1990, P NATL ACAD SCI USA, V87, P7917, DOI 10.1073/pnas.87.20.7917; GRINSTEIN S, 1984, J GEN PHYSIOL, V83, P341, DOI 10.1085/jgp.83.3.341; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HAGGERTY JG, 1988, P NATL ACAD SCI USA, V85, P6797, DOI 10.1073/pnas.85.18.6797; HELMLEKOLB C, 1990, PFLUGERS ARCH, V416, P15; HUOT SJ, 1989, J BIOL CHEM, V264, P683; IVES HE, 1983, J BIOL CHEM, V258, P9710; IVES HE, 1983, J BIOL CHEM, V258, P3513; JEAN T, 1985, J BIOL CHEM, V260, P9678; KINSELLA J, 1984, J BIOL CHEM, V259, P3224; KINSELLA JL, 1986, J MEMBRANE BIOL, V91, P183, DOI 10.1007/BF01925795; KINSELLA JL, 1980, AM J PHYSIOL, V238, pF461, DOI 10.1152/ajprenal.1980.238.6.F461; KINSELLA JL, 1981, AM J PHYSIOL, V241, pC220, DOI 10.1152/ajpcell.1981.241.5.C220; KINSELLA JL, 1981, AM J PHYSIOL, V241, pF374, DOI 10.1152/ajprenal.1981.241.4.F374; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; KNICKELBEIN R, 1983, AM J PHYSIOL, V245, pG504, DOI 10.1152/ajpgi.1983.245.4.G504; KNICKELBEIN RG, 1990, AM J PHYSIOL, V259, pG802, DOI 10.1152/ajpgi.1990.259.5.G802; KNICKELBEIN RG, 1988, J CLIN INVEST, V82, P2158, DOI 10.1172/JCI113838; KULANTHAIVEL P, 1992, BIOCHEM J, V284, P33, DOI 10.1042/bj2840033; KULANTHAIVEL P, 1990, J BIOL CHEM, V265, P1249; LALLEMAIN G, 1984, J BIOL CHEM, V259, P4313; MAHNENSMITH RL, 1985, J BIOL CHEM, V260, P2586; MAHNENSMITH RL, 1985, CIRC RES, V56, P773, DOI 10.1161/01.RES.56.6.773; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; OTSU K, 1992, J BIOL CHEM, V267, P8089; PARIS S, 1984, J BIOL CHEM, V259, P989; PARIS S, 1983, J BIOL CHEM, V258, P3503; PERIYASAMY SM, 1990, J BIOL CHEM, V265, P6035; POLLOCK AS, 1986, AM J PHYSIOL, V250, pF217, DOI 10.1152/ajprenal.1986.250.2.F217; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; PREISIG PA, 1987, J CLIN INVEST, V80, P970, DOI 10.1172/JCI113190; RAJENDRAN VM, 1990, J BIOL CHEM, V265, P8408; RALEYSUSMAN KM, 1991, J BIOL CHEM, V266, P2739; RAMASWAMY K, 1989, BIOCHIM BIOPHYS ACTA, V981, P193, DOI 10.1016/0005-2736(89)90028-X; ROSS W, 1990, J BIOL CHEM, V265, P5341; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; SACCOMANI G, 1990, AM J PHYSIOL, V258, pF1188, DOI 10.1152/ajprenal.1990.258.5.F1188; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SARDET C, 1991, J BIOL CHEM, V266, P19166; TAKAICHI K, 1992, AM J PHYSIOL, V262, pC1069, DOI 10.1152/ajpcell.1992.262.4.C1069; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TSE C M, 1991, Gastroenterology, V100, pA258; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; TSE CM, 1992, J BIOL CHEM, V267, P9340; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WANG Z, 1993, J BIOL CHEM, V268, P11925; WARNOCK DG, 1988, J BIOL CHEM, V263, P7216; WATSON AJM, 1991, AM J PHYSIOL, V261, pG229, DOI 10.1152/ajpgi.1991.261.2.G229; WU JSR, 1989, BIOCHEMISTRY-US, V28, P2980, DOI 10.1021/bi00433a036	68	262	265	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16369	16377						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8393860				2022-12-25	WOS:A1993LQ33600044
J	SMIRNOVA, IN; FALLER, LD				SMIRNOVA, IN; FALLER, LD			MECHANISM OF K+ INTERACTION WITH FLUORESCEIN 5'-ISOTHIOCYANATE-MODIFIED NA+,K+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CONFORMATIONAL-CHANGES; ACTIVE-SITE; NA,K-PUMP; SODIUM	The rate of K+ binding to fluorescein 5'-isothiocyanate-modified Na+,K+-ATPase has been measured by stopped-flow fluorometry and shown to depend sigmoidally on potassium concentration. By assuming two K+ ions must bind to cause a rate-limiting conformational change, analytical expressions for the rate and the amplitude were derived that fit the experimental data and correctly calculate the half-maximum K+ concentration in amplitude titrations from kinetically estimated rate and dissociation constants. This is the first time that sigmoidal dependence of the time constant for K+ reaction with Na+,K+-ATPase on potassium concentration has been observed. The conclusion that two K+ ions are required to cause the E1 --> E2 conformational change explains discrepancies between equilibrium and kinetic estimates of the half-maximum K+ concentration in published studies of the reaction and reconciles the mechanism of the conformational change in Na+,K+-ATPase with the transport stoichiometry of sodium pump. It is strong, additional evidence that fluorescein reports a conformational change in dephosphoenzyme that is involved in monovalent cation transport. The ratio of the K+ dissociation constants is consistent either with ordered binding to two sites with intrinsic constants differing by a factor of 4 or with binding to two independent and identical sites.	DEPT VET AFFAIRS MED CTR W LOS ANGELES,WADSWORTH DIV,LOS ANGELES,CA 90073		SMIRNOVA, IN (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,CTR ULCER RES & EDUC,LOS ANGELES,CA 90024, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036873] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36873] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBOTT AJ, 1991, BIOCHEMISTRY-US, V30, P1692, DOI 10.1021/bi00220a035; Edsall J.T., 1958, BIOPHYSICAL CHEM, V1, P477; FALLER LD, 1991, BIOCHEMISTRY-US, V30, P3503, DOI 10.1021/bi00228a022; FALLER LD, 1991, SODIUM PUMP RECENT D, P357; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; FORBUSH B, 1987, J BIOL CHEM, V262, P11116; GLYNN IM, 1985, ENZ BIOL MEMBR, V3, P79; GLYNN IM, 1984, ELECTROGENIC TRANSPO, P33; GLYNN IM, 1985, ENZ BIOL MEMBR, V3, P58; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KIRSCHNER K, 1966, P NATL ACAD SCI USA, V56, P1661, DOI 10.1073/pnas.56.6.1661; LAUGER P, 1986, EUR BIOPHYS J BIOPHY, V13, P309, DOI 10.1007/BF00254213; LIN SH, 1993, FASEB J, V7, pA1145; MATSUI H, 1982, J BIOCHEM-TOKYO, V92, P193, DOI 10.1093/oxfordjournals.jbchem.a133916; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; SMIRNOVA IN, 1993, BIOCHEMISTRY-US, V32, P5967, DOI 10.1021/bi00074a007; STEINBERG M, 1989, J BIOL CHEM, V264, P2726; XU KY, 1989, BIOCHEMISTRY-US, V28, P5764, DOI 10.1021/bi00440a010	18	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16120	16123						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8393855				2022-12-25	WOS:A1993LQ33600011
J	KLEMPERER, N; TRAKTMAN, P				KLEMPERER, N; TRAKTMAN, P			BIOCHEMICAL-ANALYSIS OF MUTANT ALLELES OF THE VACCINIA VIRUS TOPOISOMERASE-I CARRYING TARGETED SUBSTITUTIONS IN A HIGHLY CONSERVED DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE TYROSINE; DNA TOPOISOMERASE; ESCHERICHIA-COLI; DIRECTED MUTAGENESIS; GYRASE GENES; CLEAVAGE; SEQUENCE; IDENTIFICATION; MUTATIONS; CLONING	The 32-kDa topoisomerase I encoded by vaccinia virus relaxes supercoiled DNA in a manner which is mechanistically equivalent to that utilized by eucaryotic enzymes. Its amino acid sequence contains significant homology to the enzymes encoded by Saccharomyces cerevisiae, Saccharomyces pombe, human cells, and other poxviruses. The small size of the viral enzyme, and its essentiality in the viral life cycle, make it ideally suited for structural and functional analysis. In this report we present the construction and analysis of 15 mutant alleles of the topoisomerase containing amino acid substitutions in a highly conserved region. The enzymes encoded by these alleles were expressed in Escherichia coli and various parameters of their activity were examined. All of the alleles which show diminished (seven alleles) or abrogated (three alleles) DNA relaxation activity are deficient in DNA cleavage and the concomitant formation of the covalent enzyme/DNA intermediate. None are deficient in the prior step of noncovalent interaction with substrate DNA. Five of the mutant enzymes show significant temperature sensitivity in vitro. The extent of in vitro activity of the enzymes shows a good but incomplete correlation with the enzymes' abilities to lethally induce the resident lambda prophage within E. coli BL21(DE3) (via illegitimate recombination). Mutations in 1 amino acid, in particular, impair prophage induction in vivo more significantly than DNA relaxation in vitro. In sum, these studies suggest that this region of the topoisomerase (amino acids 216-225) plays a proximal role in mediating DNA cleavage and the covalent interaction between the 3'-phosphoryl of the nicked DNA and tyrosine 274 of the vaccinia topoisomerase I. The studies also provide useful reagents for the molecular genetic analysis of the role of the topoisomerase within the context of vaccinia virus infection.	CORNELL UNIV,MED CTR,COLL MED,DEPT CELL BIOL,1300 YORK AVE,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,DEPT MICROBIOL,NEW YORK,NY 10021	Cornell University; Cornell University								ANDOH T, 1987, P NATL ACAD SCI USA, V84, P5565, DOI 10.1073/pnas.84.16.5565; BAUER CE, 1985, GENE, V37, P73, DOI 10.1016/0378-1119(85)90259-8; CAMILLONI G, 1989, P NATL ACAD SCI USA, V86, P3080, DOI 10.1073/pnas.86.9.3080; CAMILLONI G, 1988, NUCLEIC ACIDS RES, V16, P7071, DOI 10.1093/nar/16.14.7071; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; ENG WK, 1989, J BIOL CHEM, V264, P13373; FOGELSONG PD, 1984, J VIROL, V49, P1; GRAHAM FL, 1970, CANCER RES, V30, P2627; ISHHOROWICZ D, 1981, NUCLEIC ACIDS RES, V9, P2989, DOI 10.1093/nar/9.13.2989; KJELDSEN E, 1988, J BIOL CHEM, V263, P3912; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; MORHAM SG, 1990, GENE DEV, V4, P515, DOI 10.1101/gad.4.4.515; MULLER MT, 1985, BIOCHIM BIOPHYS ACTA, V824, P263, DOI 10.1016/0167-4781(85)90057-0; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; PRUSS GJ, 1982, CELL, V31, P35, DOI 10.1016/0092-8674(82)90402-0; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROSEL JL, 1986, J VIROL, V60, P436, DOI 10.1128/JVI.60.2.436-449.1986; SHAFFER R, 1987, J BIOL CHEM, V262, P9309; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P3489, DOI 10.1073/pnas.86.10.3489; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1992, J BIOL CHEM, V267, P16755; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1991, P NATL ACAD SCI USA, V88, P10104, DOI 10.1073/pnas.88.22.10104; SHUMAN S, 1987, P NATL ACAD SCI USA, V84, P7478, DOI 10.1073/pnas.84.21.7478; SHUMAN S, 1989, VIROLOGY, V170, P302, DOI 10.1016/0042-6822(89)90384-X; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAMURA H, 1991, NUCLEIC ACIDS RES, V19, P69, DOI 10.1093/nar/19.1.69; UEMURA T, 1987, NUCLEIC ACIDS RES, V15, P9727, DOI 10.1093/nar/15.23.9727; UPTON C, 1990, VIROLOGY, V176, P439, DOI 10.1016/0042-6822(90)90013-H; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665	37	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15887	15899						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8393454				2022-12-25	WOS:A1993LN30500081
J	OWEN, PJ; MUSK, P; EVANS, CA; WHETTON, AD				OWEN, PJ; MUSK, P; EVANS, CA; WHETTON, AD			CELLULAR SIGNALING EVENTS ELICITED BY V-ABL ASSOCIATED WITH GROWTH-FACTOR INDEPENDENCE IN AN INTERLEUKIN-3-DEPENDENT CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CHRONIC MYELOGENOUS LEUKEMIA; GTPASE-ACTIVATING PROTEIN; COLONY-STIMULATING FACTOR; ONCOGENE PRODUCTS; NA+/H+ EXCHANGE; ABELSON VIRUS; BCR-ABL; PHOSPHATIDYLCHOLINE; PHOSPHORYLATION	A temperature-sensitive mutant of the v-abl oncoprotein has previously been shown to have markedly reduced tyrosine protein kinase activity in interleukin 3 (IL-3)-dependent cells grown at restrictive (39-degrees-C), compared to permissive (32-degrees-C) temperatures. Transfection of this mutant v-abl into the IC2.9 cell line, generated the IC.DP subclone which was dependent on IL-3 for survival at 39-degrees-C, but not at 32-degrees-C. Furthermore, IC.DP cells cultured at 32-degrees-C exhibited IL-3-independent thymidine incorporation, which was not apparent at 39-degrees-C. Switching cells from the restrictive to the permissive temperature resulted in an increase in cellular inositol-1,4,5-trisphosphate, choline phosphate and diacylglycerol levels in the IC.DP cell line. These increases were only observed after a lag period of 4 h. Within 2 h of switching IC.DP cells previously maintained at 32 to 39-degrees-C, there was a significant decrease in all three metabolites. Temperature switches had no effect upon these metabolites in the parent IC2.9 cell line. Down-regulation of protein kinase C inhibited v-abl-stimulated DNA synthesis in IC.DP cells cultured at 32-degrees-C. IC.DP cells cultured at 32-degrees-C were found to have a constitutively activated Na+/H+ antiport, although this activation was inhibited by the down-modulation of protein kinase C. These data indicate a role for phospholipid hydrolysis and protein kinase C activation in V-ABL-mediated abrogation of IL-3 dependence.	UNIV MANCHESTER, INST SCI & TECHNOL, DEPT BIOCHEM & APPL MOLEC BIOL, LEUKAEMIA RES FUND GRP, MANCHESTER M60 1QD, LANCS, ENGLAND	University of Manchester				WHETTON, ANTHONY D/0000-0002-1098-3878				BIERMAN AJ, 1987, J BIOL CHEM, V262, P9621; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CHIARUGI V, 1987, ONCOGENE, V2, P37; CHIARUGI V, 1989, BIOCHEM BIOPH RES CO, V164, P816, DOI 10.1016/0006-291X(89)91532-5; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1991, P NATL ACAD SCI USA, V88, P11335, DOI 10.1073/pnas.88.24.11335; DIAZLAVIADA I, 1990, EMBO J, V9, P3907, DOI 10.1002/j.1460-2075.1990.tb07611.x; DURKIN JP, 1990, CELL SIGNAL, V2, P569, DOI 10.1016/0898-6568(90)90079-P; DURONIO V, 1989, BIOCHEM BIOPH RES CO, V164, P804, DOI 10.1016/0006-291X(89)91530-1; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; FARRAR WL, 1985, NATURE, V315, P235, DOI 10.1038/315235a0; FRY MJ, 1985, EMBO J, V4, P3173, DOI 10.1002/j.1460-2075.1985.tb04061.x; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HAMILTON JA, 1989, J CELL PHYSIOL, V141, P618, DOI 10.1002/jcp.1041410321; KAN O, 1992, HAEMOPOIESIS PRACTIC, P123; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KIPREOS ET, 1987, P NATL ACAD SCI USA, V84, P1345, DOI 10.1073/pnas.84.5.1345; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MIYAJIMA A, 1987, GENE, V58, P273, DOI 10.1016/0378-1119(87)90382-9; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PALMER S, 1990, METHODS INOSITIDE RE, P127; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; RUGGIERO M, 1991, FEBS LETT, V291, P203, DOI 10.1016/0014-5793(91)81284-F; SHEARMAN MS, 1989, METHOD ENZYMOL, V168, P347; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SIMCHOWITZ L, 1986, MOL PHARMACOL, V30, P112; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; VALLANCE SJ, 1990, BIOCHEM J, V265, P359, DOI 10.1042/bj2650359; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; WHETTON AD, 1986, J CELL SCI, V84, P93; WHETTON AD, 1988, BIOCHEM J, V256, P585, DOI 10.1042/bj2560585; WHETTON AD, 1988, P NATL ACAD SCI USA, V85, P3284, DOI 10.1073/pnas.85.10.3284	49	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15696	15703						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8393452				2022-12-25	WOS:A1993LN30500057
J	PACIFICI, RE; KONO, Y; DAVIES, KJA				PACIFICI, RE; KONO, Y; DAVIES, KJA			HYDROPHOBICITY AS THE SIGNAL FOR SELECTIVE DEGRADATION OF HYDROXYL RADICAL-MODIFIED HEMOGLOBIN BY THE MULTICATALYTIC PROTEINASE COMPLEX, PROTEASOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; OXIDATIVELY-DENATURED PROTEINS; MOLECULAR-WEIGHT PROTEASES; MIXED-FUNCTION OXIDATION; RAT SKELETAL-MUSCLE; RED BLOOD-CELLS; GLUTAMINE-SYNTHETASE; OXYGEN RADICALS; MAMMALIAN-CELLS; ANTIGEN PRESENTATION	Red blood cells (RBC) and many other cell types exhibit increased rates of proteolysis during exposure to oxygen radicals and other activated oxygen species (oxidative stress). One of the major RBC proteins modified and proteolytically degraded during oxidative stress is hemoglobin (Hb). We now show that Hb undergoes a partial unfolding (or denaturation) during exposure to hydroxyl radicals (.OH), with an increase in hydrophobicity (hydrophobic interaction chromatography). At low .OH/Hb molar ratios, oxidatively modified Hb exhibits increased proteolytic susceptibility during incubation with RBC lysates, cell-free extracts, Fraction II, a 40-80% ((NH4)2SO4 fraction, and purified proteasome (the 670-kDa RBC multicatalytic proteinase complex that we have previously called macroxyproteinase. At higher .OH/Hb molar ratios covalent cross-linking between Hb tetramers, and decreased proteolytic susceptibility are observed. The selective degradation of .OH-modified Hb is an ATP- and ubiquitin-independent process (in fact ATP is slightly inhibitory), and antibody precipitation studies, as well as inhibitor studies, indicate that proteasome is responsible for at least 60-70% of the activity in RBC. We propose that the mechanism of oxidation-induced proteolysis involves exposure of hydrophobic amino acid R groups during the partial Hb unfolding (or partial denaturation) that occurs at relatively low .OH/Hb molar ratios. Peptide bonds flanked by hydrophobic residues are preferred substrates for the proteasome complex, which degrades .OH-modified Hb in a processive process involving apparent serine-protease, sulfhydryl-protease, and metallo-peptidase activities. Highly denatured and covalently cross-linked Hb molecules, produced at high .OH/Hb molar ratios, are poorly degraded in RBC lysates and at all stages of proteasome purification. These cross-linked Hb tetramers have molecular sizes of 120-180 kDa and are presumably too large to fit in the proteasome active site(s). Recognition of exposed hydrophobic amino acid R groups provides a simple, energy-independent, and universal explanation for the proteasome-dependent proteolysis that accompanies oxidative stress.	ALBANY MED COLL,DEPT BIOCHEM & MOLEC BIOL,NEW SCOTLAND AVE,ALBANY,NY 12208; UNIV SO CALIF,DEPT BIOCHEM,LOS ANGELES,CA 90033; UNIV SO CALIF,INST TOXICOL,LOS ANGELES,CA 90033	Albany Medical College; University of Southern California; University of Southern California				Davies, Kelvin/0000-0001-7790-3003	PHS HHS [E-03598] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; ARRIGO AP, 1988, NATURE, V331, P192, DOI 10.1038/331192a0; BAUMEISTER W, 1988, FEBS LETT, V241, P239, DOI 10.1016/0014-5793(88)81069-X; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; CERVERA J, 1988, FASEB J, V2, P2591, DOI 10.1096/fasebj.2.10.2898411; DAHLMANN B, 1983, FEBS LETT, V160, P243, DOI 10.1016/0014-5793(83)80975-2; DAHLMANN B, 1988, BIOCHEM J, V255, P750; DAHLMANN B, 1985, BIOCHEM J, V228, P171, DOI 10.1042/bj2280171; DAVIES K J A, 1986, Journal of Free Radicals in Biology and Medicine, V2, P155, DOI 10.1016/S0748-5514(86)80066-6; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1993, BIOCHEM SOC T, V21, P346, DOI 10.1042/bst0210346; DAVIES KJA, 1988, FREE RADICAL BIO MED, V5, P215, DOI 10.1016/0891-5849(88)90015-9; DAVIES KJA, 1988, FREE RADICAL BIO MED, V5, P225, DOI 10.1016/0891-5849(88)90016-0; DAVIES KJA, 1987, J BIOL CHEM, V262, P8220; DAVIES KJA, 1987, J BIOL CHEM, V262, P9908; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; DAVIES KJA, 1987, J BIOL CHEM, V262, P9914; DAVIES KJA, 1987, J BIOL CHEM, V262, P8227; DEAN RT, 1986, BIOCHEM J, V240, P489, DOI 10.1042/bj2400489; DEMARTINO GN, 1979, J BIOL CHEM, V254, P3712; Di Iorio E E, 1981, Methods Enzymol, V76, P57; FALKENBURG PE, 1988, NATURE, V331, P190, DOI 10.1038/331190a0; FAUSTMAN D, 1991, SCIENCE, V254, P1756, DOI 10.1126/science.1763324; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; GIULIVI C, 1990, J BIOL CHEM, V265, P19453; GIULIVI C, 1993, J BIOL CHEM, V268, P8752; GLYNNE R, 1991, NATURE, V353, P355; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HOUGH R, 1987, J BIOL CHEM, V262, P8303; HOUGH R, 1988, INT COMMITTEE PROTEO, P4; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; ISHIURA S, 1985, FEBS LETT, V189, P119, DOI 10.1016/0014-5793(85)80854-1; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; LEVINE RL, 1983, J BIOL CHEM, V258, P1828; LEVINE RL, 1981, P NATL ACAD SCI-BIOL, V78, P2120, DOI 10.1073/pnas.78.4.2120; LEVINE RL, 1983, J BIOL CHEM, V258, P1823; MARCILLAT O, 1988, BIOCHEM J, V254, P677, DOI 10.1042/bj2540677; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; MCGUIRE MJ, 1986, BIOCHIM BIOPHYS ACTA, V873, P279, DOI 10.1016/0167-4838(86)90055-5; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MURAKAMI K, 1990, FREE RADICAL BIO MED, V8, P217, DOI 10.1016/0891-5849(90)90066-R; MYKLES DL, 1989, ARCH BIOCHEM BIOPHYS, V274, P216, DOI 10.1016/0003-9861(89)90433-5; NAKAMURA K, 1984, P NATL ACAD SCI-BIOL, V81, P2011, DOI 10.1073/pnas.81.7.2011; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P521, DOI 10.1016/0891-5849(89)90028-2; PACIFICI RE, 1991, GERONTOLOGY, V37, P166; PACIFICI RE, 1990, METHOD ENZYMOL, V186, P485; RAY K, 1985, P NATL ACAD SCI USA, V82, P7545, DOI 10.1073/pnas.82.22.7545; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; RIVETT AJ, 1985, J BIOL CHEM, V260, P300; ROSEMAN JE, 1987, J BIOL CHEM, V262, P2101; SALO DC, 1990, J BIOL CHEM, V265, P11919; SALO DC, 1988, FREE RADICAL BIO MED, V5, P335, DOI 10.1016/0891-5849(88)90105-0; TAYLOR A, 1987, FREE RADICAL BIO MED, V3, P371, DOI 10.1016/0891-5849(87)90015-3; WAXMAN L, 1987, J BIOL CHEM, V262, P2451; WILK S, 1980, J NEUROCHEM, V35, P1172, DOI 10.1111/j.1471-4159.1980.tb07873.x; WOLFF SP, 1986, TRENDS BIOCHEM SCI, V11, P27, DOI 10.1016/0968-0004(86)90228-8; WOLFF SP, 1986, BIOCHEM J, V234, P399, DOI 10.1042/bj2340399	60	234	241	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15405	15411						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8393440				2022-12-25	WOS:A1993LN30500017
J	HSIEH, JC; JURUTKA, PW; NAKAJIMA, S; GALLIGAN, MA; HAUSSLER, CA; SHIMIZU, Y; SHIMIZU, N; WHITFIELD, GK; HAUSSLER, MR				HSIEH, JC; JURUTKA, PW; NAKAJIMA, S; GALLIGAN, MA; HAUSSLER, CA; SHIMIZU, Y; SHIMIZU, N; WHITFIELD, GK; HAUSSLER, MR			PHOSPHORYLATION OF THE HUMAN VITAMIN-D RECEPTOR BY PROTEIN-KINASE-C - BIOCHEMICAL AND FUNCTIONAL-EVALUATION OF THE SERINE-51 RECOGNITION SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; D-RESPONSIVE ELEMENT; DNA-BINDING DOMAIN; GLUCOCORTICOID RECEPTOR; OSTEOCALCIN GENE; 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR; COMPLEMENTARY-DNA; ESTROGEN-RECEPTOR; RETINOIC ACID; EXPRESSION	We have reported previously that the human vitamin D receptor (hVDR) is selectively phosphorylated by protein kinase C-beta (PKC-beta), in vitro, on a serine residue in the sequence RRS51MKRK, which is located between the two zinc fingers of hVDR and is potentially important to its transacting function (Hsieh, J.C., Jurutka, P. W., Galligan, M. A., Terpening, C. M., Haussler, C. A., Samuels, D. S., Shimizu, Y., Shimizu, N., and Haussler, M. R. (1991) Proc. Natl. Acad. Sci. U.S.A. 88,9315-9319). In the present experiments we evaluated this phosphorylation event using a series of hVDR mutants in which serine 51 or its flanking residues were modified. Alteration of serine 51 to a nonphosphorylatable residue resulted in an approximately 60% reduction in basal hVDR phosphorylation in intact cells but did not diminish 1,25-dihydroxyvitamin D3-stimulated phosphorylation. Such mutations also abolished subsequent phosphorylation of immunoprecipitated hVDR by purified PKC-beta, in vitro, as did replacement of basic residues on either side of serine 51. Mutation of serine 51 to glycine (S51G) or to aspartic acid (S51D), as well as altering the basic residues flanking serine 51, abolished the interaction of hVDR with the vitamin D-responsive element (VDRE) as monitored by gel mobility shift analysis. Thus, we conclude that unmodified serine 51 and its surrounding basic residues are crucial not only for PKC-beta substrate recognition but also for the optimal VDRE binding of native hVDR. In transactivation assays, S51G and S51D possessed only 35 and 10% of wild-type hVDR activity, respectively. Mutation of serine 51 to threonine (S51T) restored phosphorylation by PKC-beta, in vitro, to about 40% of wild-type and transactivation to 45% of that of wild-type hVDR. Alteration of serine 51 to alanine, which is the residue in the corresponding position of the glucocorticoid, progesterone, mineralocorticoid, and androgen receptors, eliminated PKC-beta phosphorylation but completely preserved the specific DNA binding activity and transactivation capacity of hVDR. Thus, phosphorylation of hVDR at serine 51 is not required for either VDRE binding or transactivation. Finally, incubation of Escherichia coli-expressed hVDR with PKC-beta elicits marked phosphorylation of the receptor and significantly inhibits its ability to complex with the VDRE. We therefore speculate that posttranslational modification of hVDR at serine 51 may constitute a negative regulatory loop which could be operative when target cells are subject to PKC activation events.	UNIV ARIZONA, ARIZONA HLTH SCI CTR, COLL MED, DEPT BIOCHEM, TUCSON, AZ 85724 USA; UNIV ARIZONA, DEPT MOLEC & CELLULAR BIOL, TUCSON, AZ 85721 USA	University of Arizona; University of Arizona Health Sciences; University of Arizona				Haussler, Mark/0000-0002-7097-1801; Haussler, Carol/0000-0001-8360-3066; Jurutka, Peter/0000-0002-4950-9161	NIAMS NIH HHS [AR-15781] Funding Source: Medline; NIDDK NIH HHS [DK-33351] Funding Source: Medline; NIGMS NIH HHS [GM-24375] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR015781, R01AR015781] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033351, R37DK033351] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024375] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BROWN TA, 1990, J BIOL CHEM, V265, P10025; CHAKRABARTTY A, 1991, NATURE, V351, P586, DOI 10.1038/351586a0; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLINEUR C, 1989, ONCOGENE, V4, P1247; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HAUSSLER M, 1991, VITAMIN D, P3; HAUSSLER MR, 1988, RECENT PROG HORM RES, V44, P263; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; HSIEH JC, 1992, J BONE MINER RES, V7, pS150; JONES BB, 1991, MOL ENDOCRINOL, V5, P1137, DOI 10.1210/mend-5-8-1137; JURUTKA PW, 1993, J BIOL CHEM, V268, P6791; KEMPPAINEN JA, 1991, 73RD M END SOC WASH, P94; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KINGSTON RE, 1990, CURRENT PROTOCOLS MO; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LUBAHN DB, 1988, SCIENCE, V240, P327, DOI 10.1126/science.3353727; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MACDONALD PN, 1991, J BIOL CHEM, V266, P18808; MARKOSE ER, 1990, P NATL ACAD SCI USA, V87, P1701, DOI 10.1073/pnas.87.5.1701; MCDONNELL DP, 1989, MOL ENDOCRINOL, V3, P635, DOI 10.1210/mend-3-4-635; MISRAHI M, 1987, BIOCHEM BIOPH RES CO, V143, P740, DOI 10.1016/0006-291X(87)91416-1; NAKAJIMA S, 1992, J BONE MINER RES, V7, pS147; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; OZONO K, 1990, J BIOL CHEM, V265, P21881; PIKE JW, 1983, J BIOL CHEM, V258, P1289; PIKE JW, 1985, BIOCHEM BIOPH RES CO, V131, P378, DOI 10.1016/0006-291X(85)91813-3; SAMUELS DS, 1992, J BIOL CHEM, V267, P11156; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SERRANO L, 1992, NATURE, V356, P453, DOI 10.1038/356453a0; SHERIDAN PL, 1989, J BIOL CHEM, V264, P6520; SMITH LI, 1989, BIOCHEMISTRY-US, V28, P4490, DOI 10.1021/bi00436a055; SONE T, 1991, J BIOL CHEM, V266, P23296; TERPENING CM, 1991, MOL ENDOCRINOL, V5, P373, DOI 10.1210/mend-5-3-373; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WEINBERGER C, 1986, COLD SPRING HARB SYM, V51, P759, DOI 10.1101/SQB.1986.051.01.089; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z	59	102	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15118	15126						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8392065				2022-12-25	WOS:A1993LL75900084
J	TAMAGNONE, L; PARTANEN, J; ARMSTRONG, E; LASOTA, J; OHGAMI, K; TAZUNOKI, T; LAFORGIA, S; HUEBNER, K; ALITALO, K				TAMAGNONE, L; PARTANEN, J; ARMSTRONG, E; LASOTA, J; OHGAMI, K; TAZUNOKI, T; LAFORGIA, S; HUEBNER, K; ALITALO, K			THE HUMAN RYK CDNA SEQUENCE PREDICTS A PROTEIN CONTAINING 2 PUTATIVE TRANSMEMBRANE SEGMENTS AND A TYROSINE KINASE CATALYTIC DOMAIN	ONCOGENE			English	Note							GENE	The human ryk tyrosine kinase cDNA was originally identified as a PCR-amplified cDNA fragment (JTK5) from K562 leukemia cells and found to represent a ubiquitously expressed gene (Partanen et al., 1990). The open reading frame of human ryk, reported here, encodes a novel type of putative tyrosine kinase of 607 amino acid residues, having two potential transmembrane domains and homology to receptor tyrosine kinases, such as met (HGF/SF-R) and IGF-1R, in its catalytic domain. The gene maps to human chromosome 3q11-25. Expression of the 3.4 kb ryk mRNA was found in all human adult tissues examined.	UNIV HELSINKI,DEPT PATHOL,MOLEC CANC BIOL LAB,POB 21,SF-00014 HELSINKI,FINLAND; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107	University of Helsinki; Jefferson University			Alitalo, Kari K/J-5013-2014; Tamagnone, Luca/J-8948-2018	Alitalo, Kari K/0000-0002-7331-0902; Tamagnone, Luca/0000-0002-2884-7946; Partanen, Juha/0000-0001-8850-4825	NATIONAL CANCER INSTITUTE [P01CA021124] Funding Source: NIH RePORTER; NCI NIH HHS [CA-21124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASLER K, 1988, CELL, V54, P299; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; Bishop JM, 1985, RNA TUMOR VIRUSES, P249; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; HUEBNER K, 1993, IN PRESS HUM GENETIC; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; MATSUSHIME H, 1990, J VIROL, V64, P2117, DOI 10.1128/JVI.64.5.2117-2125.1990; MORRIS SW, 1992, GENE CHROMOSOME CANC, V5, P385, DOI 10.1002/gcc.2870050414; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PAUL SR, 1992, INT J CELL CLONING, V10, P309, DOI 10.1002/stem.5530100509; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIEBURTH D, 1992, GENOMICS, V14, P59, DOI 10.1016/S0888-7543(05)80283-6; ULLRICH A, 1990, CELL, V61, P243; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	21	28	31	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					2009	2014						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8390040				2022-12-25	WOS:A1993LG68200034
J	HOXIE, JA; AHUJA, M; BELMONTE, E; PIZARRO, S; PARTON, R; BRASS, LF				HOXIE, JA; AHUJA, M; BELMONTE, E; PIZARRO, S; PARTON, R; BRASS, LF			INTERNALIZATION AND RECYCLING OF ACTIVATED THROMBIN RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; AGONIST-INDUCED DESENSITIZATION; PHOSPHOINOSITIDE HYDROLYSIS; MEMBRANE-GLYCOPROTEINS; COATED VESICLES; CELL-LINE; BINDING; MOBILIZATION; SPECIFICITY; EXPRESSION	Shortly after activation by either thrombin or the tethered ligand domain peptide SFLLRN, thrombin receptors undergo homologous desensitization, temporarily losing their ability to respond to both agonists. We have examined the role of receptor internalization and recycling in this process using receptor-directed antibodies as probes. The results show within 1 min of activation >85% of the approximately 200,000 thrombin receptors on megakaryoblastic human erythroleukemia (HEL) and CHRF-288 cells are sequestered into endosomes via coated pits, after which the majority are transferred to lysosomes. This process does not require proteolysis of the receptor and occurs with sufficient speed to play a major role in the regulation of thrombin receptor function. Although most of the internalized receptors are ultimately degraded, approximately 25% return to the cell surface. These recycled receptors are in a state in which they can respond to SFLLRN but not thrombin; nor do they self-activate despite the apparent continued presence of the tethered ligand. In contrast to other G protein-coupled receptors, which are internalized and then recycled in an activatable state, recovery of the thrombin response occurs only after the expression on the cell surface of adequate numbers of newly synthesized receptors.	UNIV PENN, DEPT MED,DIV HEMATOL ONCOL,SILVERSTEIN 7, 3400 SPRUCE ST, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT PATHOL, PHILADELPHIA, PA 19104 USA; EUROPEAN MOLEC BIOL LAB, W-6900 HEIDELBERG, GERMANY	University of Pennsylvania; University of Pennsylvania; European Molecular Biology Laboratory (EMBL)			Parton, Robert G/C-5673-2009	Parton, Robert G/0000-0002-7494-5248; Pizarro, Shelly/0000-0002-3193-7037	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL40387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BRASS LF, 1992, BIOCHEM J, V281, P73, DOI 10.1042/bj2810073; BRASS LF, 1991, J BIOL CHEM, V266, P958; BRASS LF, 1992, J BIOL CHEM, V267, P6044; BRASS LF, 1992, J BIOL CHEM, V267, P13795; CAROLA E, 1990, J PHARMACOL EXP THER, V253, P257; CHAO BH, 1992, BIOCHEMISTRY-US, V31, P6175, DOI 10.1021/bi00142a001; COLLER BS, 1992, BIOCHEMISTRY-US, V31, P11713, DOI 10.1021/bi00162a007; FELDMAN RD, 1986, MOL PHARMACOL, V30, P459; FUGMAN DA, 1990, BLOOD, V75, P1252; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HUANG EM, 1987, BIOCHEM J, V242, P11, DOI 10.1042/bj2420011; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HUANG RS, 1991, J BIOL CHEM, V266, P18435; HUI KY, 1992, BIOCHEM BIOPH RES CO, V184, P790, DOI 10.1016/0006-291X(92)90659-9; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; JAFFE EA, 1987, J BIOL CHEM, V262, P8557; JONES LG, 1989, MOL PHARMACOL, V36, P142; KASSIS S, 1986, J BIOL CHEM, V261, P2233; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; MANE SM, 1989, ARCH BIOCHEM BIOPHYS, V268, P360, DOI 10.1016/0003-9861(89)90597-3; PARIS S, 1988, J BIOL CHEM, V263, P11250; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; PERKINS JP, 1991, BETA ADRENERGIC RECE, P73; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; SABO T, 1992, BIOCHEM BIOPH RES CO, V188, P604, DOI 10.1016/0006-291X(92)91099-C; SEILER SM, 1992, BIOCHEM BIOPH RES CO, V182, P1296, DOI 10.1016/0006-291X(92)91873-O; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALDO GL, 1983, J BIOL CHEM, V258, P3900; YU SS, 1993, J BIOL CHEM, V268, P337	39	263	271	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13756	13763						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8390469				2022-12-25	WOS:A1993LH55300103
J	MAEKAWA, S; MAEKAWA, M; HATTORI, S; NAKAMURA, S				MAEKAWA, S; MAEKAWA, M; HATTORI, S; NAKAMURA, S			PURIFICATION AND MOLECULAR-CLONING OF A NOVEL ACIDIC CALMODULIN-BINDING PROTEIN FROM RAT-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH CONES; KINASE-C SUBSTRATE; PHOSPHORYLATION SITE; MEMBRANE SKELETON; BOVINE BRAIN; GAP-43; IDENTIFICATION; ACTIN; LOCALIZATION; NEUROMODULIN	An acidic protein was identified among the insoluble proteins of a growth cone-enriched fraction, and this protein was purified from the Triton- and high NaCl-insoluble fraction of newborn rat brain using several column chromatographies after solubilization at an alkaline condition. The purified protein showed a Ca2+-dependent calmodulin binding activity. This protein showed an anomalous behavior in SDS-polyacrylamide gel electrophoresis as that observed in case of GAP-43 (neuromodulin, F1, pp46, p57, B-50) and MARCKS (p87, p80), namely shifts of apparent molecular weights under different acrylamide concentrations. Its physicochemical characteristics, such as heat stability, acidic isoelectric point, and solubility in a 2.5% perchloric acid solution, also resemble the properties of these proteins. cDNA cloning of this protein showed that the NH2-terminal 50-amino acid sequence was almost identical to CAP-23, a previously reported chicken protein of unknown function. Since the COOH-terminal half-regions of these proteins are less similar, the entire sequences of these proteins have 65% homology (52% identity), suggesting that these proteins belong to a family. Immunoblotting of several tissue extracts using a monoclonal antibody against this protein showed its specific expression in brain.	NATL CTR NEUROSCI & PSYCHIAT, NATL INST NEUROSCI, DIV BIOCHEM & CELLULAR BIOL, KODAIRA, TOKYO 187, JAPAN	National Center for Neurology & Psychiatry - Japan	MAEKAWA, S (corresponding author), UNIV TOKYO, FAC SCI, DEPT BIOPHYS & BIOCHEM, TOKYO 113, JAPAN.							ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BASI GS, 1987, CELL, V49, P785, DOI 10.1016/0092-8674(87)90616-7; BAUDIER J, 1989, J BIOL CHEM, V264, P1824; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BRAY D, 1988, ANNU REV CELL BIOL, V4, P43, DOI 10.1146/annurev.cb.04.110188.000355; BRIDGMAN PC, 1989, J CELL BIOL, V108, P95, DOI 10.1083/jcb.108.1.95; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; COGGINS PJ, 1991, J NEUROCHEM, V56, P1095, DOI 10.1111/j.1471-4159.1991.tb11398.x; ELLIS L, 1985, J CELL BIOL, V101, P1977, DOI 10.1083/jcb.101.5.1977; ELLIS L, 1985, J NEUROSCI, V5, P1393; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; FAWCETT JW, 1989, J CELL SCI, V92, P93; GORDONWEEKS PR, 1987, NEUROSCIENCE, V21, P977, DOI 10.1016/0306-4522(87)90052-2; GOSLIN K, 1989, J CELL BIOL, V109, P1621, DOI 10.1083/jcb.109.4.1621; GOSLIN K, 1990, J CELL BIOL, V110, P1319, DOI 10.1083/jcb.110.4.1319; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; Hirs C. H. W, 1967, METHODS ENZYMOL, V11, P197; HYMAN C, 1985, J CELL BIOL, V101, P1153, DOI 10.1083/jcb.101.3.1153; IGARASHI M, 1990, EUR J BIOCHEM, V193, P551, DOI 10.1111/j.1432-1033.1990.tb19371.x; IVINS JK, 1989, DEV BIOL, V135, P147, DOI 10.1016/0012-1606(89)90165-6; JACOBSON RD, 1986, J NEUROSCI, V6, P1843; KATZ F, 1985, J NEUROSCI, V5, P1402; KLEITMAN N, 1989, CELL MOTIL CYTOSKEL, V13, P288, DOI 10.1002/cm.970130407; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LETOURNEAU PC, 1990, DEV BIOL, V138, P430, DOI 10.1016/0012-1606(90)90209-2; LETOURNEAU PC, 1991, CELL MOTIL CYTOSKEL, V20, P267, DOI 10.1002/cm.970200402; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; MAEKAWA S, 1989, CELL STRUCT FUNCT, V14, P249, DOI 10.1247/csf.14.249; MAEKAWA S, 1989, J BIOL CHEM, V264, P7458; MAEKAWA S, 1988, EXP CELL RES, V178, P127, DOI 10.1016/0014-4827(88)90384-9; MAEKAWA S, 1980, BIOCHEM BIOPH RES CO, V97, P621, DOI 10.1016/0006-291X(80)90309-5; MATTSON M, 1987, J NEUROSCI, V7, P4032; MEIRI KF, 1990, J NEUROSCI, V10, P256; MOSS DJ, 1990, J NEUROCHEM, V54, P729, DOI 10.1111/j.1471-4159.1990.tb02312.x; MUROFUSHI H, 1987, J BIOCHEM-TOKYO, V102, P1101, DOI 10.1093/oxfordjournals.jbchem.a122148; NELSON RB, 1989, J NEUROSCI, V9, P381; PATTERSON PH, 1988, NEURON, V1, P263, DOI 10.1016/0896-6273(88)90074-8; PFENNINGER KH, 1983, CELL, V35, P573, DOI 10.1016/0092-8674(83)90191-5; ROBSON SJ, 1989, CELL MOTIL CYTOSKEL, V12, P273, DOI 10.1002/cm.970120408; SBASCHNIGAGLER M, 1988, J NEUROCHEM, V51, P212, DOI 10.1111/j.1471-4159.1988.tb04858.x; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; SOBUE K, 1989, NEURON, V3, P311, DOI 10.1016/0896-6273(89)90255-9; STEISSLINGER HW, 1987, BRAIN RES, V415, P375, DOI 10.1016/0006-8993(87)90224-1; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; TSUI HCT, 1988, J CELL BIOL, V106, P2095, DOI 10.1083/jcb.106.6.2095; WIDMER F, 1990, J CELL BIOL, V111, P3035, DOI 10.1083/jcb.111.6.3035	52	94	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13703	13709						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8390468				2022-12-25	WOS:A1993LH55300096
J	ALT, M; GRASSMANN, R				ALT, M; GRASSMANN, R			RESISTANCE OF HUMAN FIBROBLASTS TO C-FOS MEDIATED TRANSFORMATION	ONCOGENE			English	Article							OSTEO-SARCOMA VIRUS; HERPESVIRUS-SAIMIRI; MAMMALIAN-CELLS; NUCLEOTIDE-SEQUENCE; DELETION MUTANTS; GENE-EXPRESSION; TRANSGENIC MICE; PROTEIN; TRANSCRIPTION; AP-1	Overexpression of the proto-oncogene c-fos induces transformation of primary avian and established rodent mesenchymal cells and tumor development in transgenic mice. As overexpression of Fos was also found in several human tumors of mesenchymal origin, we were interested whether c-fos is a transforming protein for human cells. Since fos genes transduced by infection competent vectors were most efficient in cellular transformation, expression cassettes of the human c-fos were introduced into a replication competent herpesvirus saimiri vector. Infection of human neonatal fibroblasts, cells of mesenchymal origin, resulted in episomal persistence of the recombinant viral genome and expression of c-fos in high excess. However careful examination for transformed phenotype failed to detect any changes in morphology, serum dependence, anchorage dependence, and life span, suggesting resistance of human mesechymal cells against c-fos mediated transformation.	UNIV ERLANGEN NURNBERG,INST KLIN & MOLEK VIROL,LOSCHGESTR 7,W-8520 ERLANGEN,GERMANY	University of Erlangen Nuremberg								ALT M, 1991, GENE, V102, P265, DOI 10.1016/0378-1119(91)90088-S; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; CELANDER D, 1984, NATURE, V312, P159, DOI 10.1038/312159a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; CURRAN T, 1984, CELL, V36, P259; Curran T, 1988, ONCOGENE HDB, P307; DESROSIERS RC, 1984, J VIROL, V49, P343, DOI 10.1128/JVI.49.2.343-348.1984; DESROSIERS RC, 1986, J VIROL, V57, P701, DOI 10.1128/JVI.57.2.701-705.1986; DESROSIERS RC, 1985, SCIENCE, V228, P184, DOI 10.1126/science.2983431; FAHRER C, 1989, INT J CANCER, V44, P652, DOI 10.1002/ijc.2910440416; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINKEL MP, 1966, SCIENCE, V151, P698, DOI 10.1126/science.151.3711.698; FINKEL MP, 1975, FRONTIERS RADIATION, V10, P28; FLECKENSTEIN B, 1975, J VIROL, V15, P398, DOI 10.1128/JVI.15.2.398-406.1975; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GARDELLA T, 1984, J VIROL, V50, P248, DOI 10.1128/JVI.50.1.248-254.1984; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRASSMANN R, 1989, J VIROL, V63, P1818, DOI 10.1128/JVI.63.4.1818-1821.1989; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; IBA H, 1988, ONCOGENE RES, V2, P121; LEE WMF, 1988, MOL CELL BIOL, V8, P5521, DOI 10.1128/MCB.8.12.5521; LUCIBELLO FC, 1988, ONCOGENE, V3, P43; MILLER AD, 1984, CELL, V36, P51; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SIMMER B, 1991, J GEN VIROL, V72, P1953, DOI 10.1099/0022-1317-72-8-1953; STAMMINGER T, 1990, J GEN VIROL, V71, P105, DOI 10.1099/0022-1317-71-1-105; TSAI LH, 1991, ONCOGENE, V6, P81; VANBEVEREN C, 1984, VIROLOGY, V135, P229, DOI 10.1016/0042-6822(84)90133-8; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VERMA I, 1968, TRENDS GENET, V2, P93; WARD JM, 1976, CANCER RES, V36, P3985; WISOM R, 1990, MOL CELL BIOL, V10, P5626; WU JX, 1990, ONCOGENE, V5, P989; YU SF, 1986, P NATL ACAD SCI USA, V83, P3194, DOI 10.1073/pnas.83.10.3194	42	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1421	1427						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8389028				2022-12-25	WOS:A1993LE06400004
J	MASIBAY, AS; BALAJI, PV; BOEGGEMAN, EE; QASBA, PK				MASIBAY, AS; BALAJI, PV; BOEGGEMAN, EE; QASBA, PK			MUTATIONAL ANALYSIS OF THE GOLGI RETENTION SIGNAL OF BOVINE BETA-1,4-GALACTOSYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLCHOLINE MODEL MEMBRANES; ENDOPLASMIC-RETICULUM; CELL-SURFACE; TRANSMEMBRANE PROTEINS; NEUTRON-DIFFRACTION; MESSENGER-RNA; ALPHA-SUBUNIT; GALACTOSYLTRANSFERASE; EXPRESSION; LOCALIZATION	To examine the role of the NH2-terminal region of the 402-residue-long beta-1,4-galactosyltransferase (beta-1,4-GT), a series of mutants and chimeric cDNA were constructed by polymerase chain reaction and transiently expressed in COS-7 cells, the enzyme activities were measured, and the protein was localized in the cells by subcellular fractionation or indirect immunofluorescence microscopy. We showed earlier that the deletion of the amino-terminal cytoplasmic tail and transmembrane domain from GT abolishes the stable expression of this protein in mammalian cells (Masibay, A. S., Boeggeman, E., and Qasba, P. K. (1992) Mol. Biol. Rep. 16, 99-104). Further deletion analyses of the amino-terminal region show that the first 21 amino acids of beta-1,4-GT are not essential for the stable production of the protein and are consistently localized in the Golgi apparatus. In addition, analysis of hybrid constructs showed that residues 1-25 of alpha-1,3-galactosyltransferase can functionally replace the beta-1,4-GT amino-terminal domain (residues 1-43). This fusion protein also showed Golgi localization. On the other hand, the alpha-2,6-sialyltransferase/beta-1,4-GT fusion protein (alpha-2,6-ST/beta-1,4-GT) needed additional COOH-terminal sequences flanking the transmembrane domain of the alpha-2,6-ST for stability and Golgi localization. Substitution of Arg-24, Leu-25, Leu-26, and His-33 of the beta-1,4-GT transmembrane by Ile (pLFM) or substitution of Tyr by Ile at positions 40 and 41 coupled with the insertion of 4 Ile residues at position 43 (pLB) released the mutant proteins from the Golgi and was detected on the cell surface. Our results show that (a) the transmembrane domains of beta-1,4-GT, alpha-1,3-galactosyltransferase, and alpha-2,6-ST, along with its stem region, all play a role in Golgi targeting and participate in a common mechanism that allows the protein to be processed properly and not be degraded in vivo; (b) increasing the length of the transmembrane domain overrides the Golgi retention signal and directs the enzyme to the plasma membrane; and (c) the length of the hydrophobic region of the transmembrane domain of beta-1,4-GT is an important parameter but is not sufficient by itself for Golgi retention.	NCI,DIV CANC BIOL DIAGNOSIS & CTR,MATH BIOL LAB,PK 5,ROOM 410,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Balaji, Petety/0000-0002-6018-6957				AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARBOSA MS, 1988, J VIROL, V62, P3242, DOI 10.1128/JVI.62.9.3242-3249.1988; BARCELLOSHOFF MH, 1992, EXP CELL RES, V201, P225, DOI 10.1016/0014-4827(92)90367-H; BAYNA EM, 1988, CELL, V53, P145, DOI 10.1016/0092-8674(88)90496-5; BRANDS R, 1985, J CELL BIOL, V101, P1724, DOI 10.1083/jcb.101.5.1724; BULDT G, 1979, J MOL BIOL, V134, P673, DOI 10.1016/0022-2836(79)90479-0; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; DAGOSTARO G, 1989, EUR J BIOCHEM, V183, P211, DOI 10.1111/j.1432-1033.1989.tb14915.x; ERIKSTEIN BK, 1992, EUR J IMMUNOL, V22, P1149, DOI 10.1002/eji.1830220507; GHANTA VK, 1989, ONCOGENE, V4, P1337; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; KAPSENBERG ML, 1989, EUR J IMMUNOL, V19, P1829, DOI 10.1002/eji.1830191011; Kobata A., 1984, BIOL CARBOHYDRATES, V2, P87; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNMARK A, 1976, J CELL BIOL, V71, P606, DOI 10.1083/jcb.71.2.606; LOPEZ LC, 1991, J BIOL CHEM, V266, P15984; MARCHASE RB, 1988, J CELL BIOCHEM, V36, P453, DOI 10.1002/jcb.240360413; MASIBAY AS, 1991, BIOCHIM BIOPHYS ACTA, V1090, P230, DOI 10.1016/0167-4781(91)90106-V; MASIBAY AS, 1992, MOL BIOL REP, V16, P99, DOI 10.1007/BF00419755; MASIBAY AS, 1989, P NATL ACAD SCI USA, V86, P5733, DOI 10.1073/pnas.86.15.5733; MOLENAAR CMT, 1988, EMBO J, V7, P971, DOI 10.1002/j.1460-2075.1988.tb02903.x; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; OLSON EN, 1984, J BIOL CHEM, V259, P5364; OLSON EN, 1984, J BIOL CHEM, V259, P3330; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PENNO MB, 1989, P NATL ACAD SCI USA, V86, P6057, DOI 10.1073/pnas.86.16.6057; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; QASBA PK, 1978, J BIOL CHEM, V253, P1167; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1; ROTH J, 1985, J CELL BIOL, V100, P118, DOI 10.1083/jcb.100.1.118; ROTH J, 1982, J CELL BIOL, V92, P223; ROTH S, 1971, J CELL BIOL, V51, P536, DOI 10.1083/jcb.51.2.536; ROTH S, 1972, P NATL ACAD SCI USA, V69, P485, DOI 10.1073/pnas.69.2.485; ROTHMAN JE, 1986, NATURE, V319, P96, DOI 10.1038/319096b0; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; Sadler J. E., 1984, BIOL CARBOHYDRATES, V2, P199; SHAPER NL, 1985, J CELL BIOCHEM, V38, P229; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; SIVASUBRAMANIAN N, 1987, P NATL ACAD SCI USA, V84, P1, DOI 10.1073/pnas.84.1.1; SMITH CA, 1977, J BIOL CHEM, V252, P7294; STROUS GJ, 1986, CRC CR REV BIOCH MOL, V21, P119, DOI 10.3109/10409238609113610; SUGANUMA T, 1991, J HISTOCHEM CYTOCHEM, V39, P299, DOI 10.1177/39.3.1899684; TAIARA S, 1986, J IMMUNOL, V137, P2448; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WEBB GC, 1974, J CELL BIOL, V63, P796, DOI 10.1083/jcb.63.3.796; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245; ZACCAI G, 1979, J MOL BIOL, V134, P693, DOI 10.1016/0022-2836(79)90480-7	62	123	126	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9908	9916						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8387508				2022-12-25	WOS:A1993LA68900107
J	SCHOCH, C; BLUMENTHAL, R				SCHOCH, C; BLUMENTHAL, R			ROLE OF THE FUSION PEPTIDE SEQUENCE IN INITIAL-STAGES OF INFLUENZA HEMAGGLUTININ-INDUCED CELL-FUSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED MEMBRANE-FUSION; VIRUS HEMAGGLUTININ; SURFACE-DENSITY; FLUORESCENCE; GLYCOPROTEIN; EVENTS; FIBROBLASTS; MICROSCOPY; KINETICS; BILAYERS	The fusion activity of influenza hemagglutinin (HA) and of HA proteins altered in the amino terminus of HA2 (fusion peptide) by site-directed mutagenesis (Gething, M.-J., Doms, R. W., York, D., and White, J. (1986) J. Cell Biol. 102, 11-23) was analyzed following expression in CV-1 cells using SV40-HA recombinant virus vectors. Fusion was monitored by the redistribution of lipid and cytoplasmic dyes between fluorescently labeled erythrocytes and HA-expressing CV-1 cells using spectrofluorometry and fluorescence microscopy. The kinetics of lipid redistribution after lowering the pH showed the same pattern for wild type HA and nonlethal mutants, although there were shifts in the pH threshold. The time for commitment to the fusogenic state and the temperature dependence of the processes leading to HA-mediated fusion were also the same for wild type and nonlethal mutants. However, striking differences were observed between wild type HA and the nonlethal mutants in their ability to induce pH-dependent redistribution from erythrocytes to HA-expressing cells of large molecular weight (M(r) > 10,000) fluorescently labeled dextran molecules. The data indicate that the kinetic processes which are measurable in the time range of seconds are insensitive to the structure of the fusion peptide. Surprisingly, however, the fusion peptide plays an important role in later processes related to pore widening which eventually results in delivery of the nucleocapsid into the cell.	NCI, MEMBRANE STRUCT & FUNCT SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BLUMENTHAL R, 1991, ANN NY ACAD SCI, V635, P285, DOI 10.1111/j.1749-6632.1991.tb36499.x; BOSCH ML, 1989, SCIENCE, V244, P694, DOI 10.1126/science.2541505; CHERNOMORDIK LV, 1987, BIOCHIM BIOPHYS ACTA, V906, P309, DOI 10.1016/0304-4157(87)90016-5; CLAGUE MJ, 1990, BIOCHEMISTRY-US, V29, P1303, DOI 10.1021/bi00457a028; CLAGUE MJ, 1991, J VIROL, V65, P2402, DOI 10.1128/JVI.65.5.2402-2407.1991; DANIELS RS, 1985, CELL, V40, P431, DOI 10.1016/0092-8674(85)90157-6; ELLENS H, 1990, BIOCHEMISTRY-US, V29, P9697, DOI 10.1021/bi00493a027; FREED EO, 1990, P NATL ACAD SCI USA, V87, P4650, DOI 10.1073/pnas.87.12.4650; GETHING MJ, 1981, NATURE, V293, P620, DOI 10.1038/293620a0; GETHING MJ, 1986, J CELL BIOL, V102, P11, DOI 10.1083/jcb.102.1.11; GETHING MJ, 1988, CURR TOP MEMBR TRANS, V32, P337; GODLEY L, 1992, CELL, V68, P635, DOI 10.1016/0092-8674(92)90140-8; HERRMANN A, 1991, CELL AND MODEL MEMBRANE INTERACTIONS, P89; HORTH M, 1991, EMBO J, V10, P2747, DOI 10.1002/j.1460-2075.1991.tb07823.x; HORVATH CM, 1992, J VIROL, V66, P2443, DOI 10.1128/JVI.66.4.2443-2455.1992; KAPLAN D, 1991, EXP CELL RES, V195, P137, DOI 10.1016/0014-4827(91)90509-S; KEMBLE GW, 1992, J VIROL, V66, P4940, DOI 10.1128/JVI.66.8.4940-4950.1992; KLENK HD, 1975, VIROLOGY, V68, P426, DOI 10.1016/0042-6822(75)90284-6; LOWY RJ, 1990, P NATL ACAD SCI USA, V87, P1850, DOI 10.1073/pnas.87.5.1850; LOWY RJ, 1992, J CELL BIOCH S C, V16, P131; MORRIS SJ, 1989, J BIOL CHEM, V264, P3972; POLLARD HB, 1992, BIOPHYS J, V62, P15, DOI 10.1016/S0006-3495(92)81764-2; PURI A, 1990, J VIROL, V64, P3824, DOI 10.1128/JVI.64.8.3824-3832.1990; RAFALSKI M, 1991, BIOCHEMISTRY-US, V30, P10211, DOI 10.1021/bi00106a020; RAND RP, 1989, BIOCHIM BIOPHYS ACTA, V988, P351, DOI 10.1016/0304-4157(89)90010-5; ROTT R, 1984, EMBO J, V3, P3329, DOI 10.1002/j.1460-2075.1984.tb02299.x; SARKAR DP, 1989, J CELL BIOL, V109, P113, DOI 10.1083/jcb.109.1.113; SCHOCH C, 1992, FEBS LETT, V311, P221, DOI 10.1016/0014-5793(92)81107-W; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; SPRUCE AE, 1989, NATURE, V342, P555, DOI 10.1038/342555a0; SPRUCE AE, 1991, P NATL ACAD SCI USA, V88, P3623, DOI 10.1073/pnas.88.9.3623; STEFFY KR, 1992, J VIROL, V66, P4532, DOI 10.1128/JVI.66.7.4532-4535.1992; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; WEIS WI, 1990, EMBO J, V9, P17, DOI 10.1002/j.1460-2075.1990.tb08075.x; WHARTON SA, 1988, J GEN VIROL, V69, P1847, DOI 10.1099/0022-1317-69-8-1847; WHITE J, 1983, Q REV BIOPHYS, V16, P151, DOI 10.1017/S0033583500005072; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; WHITE JM, 1987, J CELL BIOL, V56, P365; WILLIAMSON P, 1985, J CELL PHYSIOL, V123, P209, DOI 10.1002/jcp.1041230209; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	41	61	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9267	9274						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8387488				2022-12-25	WOS:A1993LA68900021
J	LANGE, AJ; LI, L; VARGAS, AM; PILKIS, SJ				LANGE, AJ; LI, L; VARGAS, AM; PILKIS, SJ			EXPRESSION OF HUMAN LIVER 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE IN ESCHERICHIA-COLI - ROLE OF N-2 PROLINE IN DEGRADATION OF THE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; RAT; 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE; FRUCTOSE-6-PHOSPHATE; ENZYME; DOMAIN; CDNA; DNA; RNA	Human liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase is 96% identical to the rat and bovine liver enzymes, and all of the critical catalytic and substrate binding residues in both the kinase and bisphosphatase domains are conserved in the three enzymes. However, in contrast to rat liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase, which is readily expressed in an Escherichia coli T-7 RNA polymerase-based expression system, the human liver bifunctional enzyme could not be expressed in this system. Western blot and slot blot analysis revealed that although both the bifunctional enzyme protein and its mRNA were rapidly induced by the addition of isopropyl-1-thio-beta-D-galactopyranoside, the protein underwent rapid degradation. Deletion of the N-2 proline residue or its mutation to arginine, the corresponding residue in the rat liver enzyme, revealed that this proline residue was responsible for its rapid degradation. The Pro-2 --> Arg mutant could be expressed with a high yield (20 mg/liter) in E. coli. The results support the hypothesis that a proline residue at N-2 facilitates bifunctional enzyme degradation in E. coli. The E. coli expressed mutant form was purified to homogeneity by phosphocellulose chromatography, and its kinetic properties were compared with those of the rat liver enzyme. The kinetic properties of the two enzymes were identical except for the presence of substrate (fructose 6-phosphate) inhibition of the human liver enzyme but not of the rat liver enzyme. The ability to express and purify large amounts of human liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase will permit structure/function and x-ray crystal structure studies of the enzyme and ultimately its targeting for drug therapy.	SUNY STONY BROOK,HLTH SCI CTR,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Vargas, Ana/GSE-1963-2022		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK038354, R01DK038354] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK3835405] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSUBLE FM, 1989, PROTOCOLS MOL BIOL; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; COLOSIA AD, 1988, J BIOL CHEM, V263, P18669; COLOSIA AD, 1987, BIOCHEM BIOPH RES CO, V142, P1092; DARVILLE MI, 1987, FEBS LETT, V224, P317, DOI 10.1016/0014-5793(87)80476-3; DARVILLE MI, 1989, P NATL ACAD SCI USA, V86, P6543, DOI 10.1073/pnas.86.17.6543; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELMAGHRABI MR, 1986, P NATL ACAD SCI USA, V83, P5005, DOI 10.1073/pnas.83.14.5005; ELMAGHRABI MR, 1987, J BIOL CHEM, V262, P11714; ELMAGHRABI MR, 1984, J BIOL CHEM, V259, P3096; ELMAGHRABI MR, 1990, FRUCTOSE 2 6 BISPHOS, P87; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; KOUNTZ PD, 1988, J BIOL CHEM, V263, P16069; LANGE AJ, 1991, ARCH BIOCHEM BIOPHYS, V290, P258, DOI 10.1016/0003-9861(91)90617-R; LANGE AJ, 1990, NUCLEIC ACIDS RES, V18, P3652, DOI 10.1093/nar/18.12.3652; LI L, 1992, J BIOL CHEM, V267, P4386; LI L, 1992, J BIOL CHEM, V267, P21588; LIN K, 1992, J BIOL CHEM, V267, P19163; LIN K, 1992, J BIOL CHEM, V267, P6556; Lin K, 1990, Protein Expr Purif, V1, P169, DOI 10.1016/1046-5928(90)90012-N; LIVELY MO, 1988, J BIOL CHEM, V263, P839; PILKIS SJ, 1982, MOL CELL ENDOCRINOL, V25, P245, DOI 10.1016/0303-7207(82)90082-X; PILKIS SJ, 1987, ENZYMES, V28, P3; RIDER MH, 1992, EUR J BIOCHEM, V207, P967, DOI 10.1111/j.1432-1033.1992.tb17131.x; SAKATA J, 1991, J BIOL CHEM, V266, P15764; SAKATA J, 1990, P NATL ACAD SCI USA, V87, P4951, DOI 10.1073/pnas.87.13.4951; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAULER A, 1989, P NATL ACAD SCI USA, V86, P7316, DOI 10.1073/pnas.86.19.7316; TAULER A, 1988, P NATL ACAD SCI USA, V85, P6642, DOI 10.1073/pnas.85.18.6642; TAULER A, 1990, J BIOL CHEM, V265, P15617; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; Varshavsky A., 1988, UBIQUITIN, P287; VENTURA F, 1992, J BIOL CHEM, V267, P17939	37	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8078	8084						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8385136				2022-12-25	WOS:A1993KW97900072
J	WEINER, JL; GUTTIEREZSTEIL, C; BLUMER, KJ				WEINER, JL; GUTTIEREZSTEIL, C; BLUMER, KJ			DISRUPTION OF RECEPTOR-G PROTEIN COUPLING IN YEAST PROMOTES THE FUNCTION OF AN SST2-DEPENDENT ADAPTATION PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FACTOR RECEPTOR; BETA-ADRENERGIC-RECEPTOR; SACCHAROMYCES-CEREVISIAE; A-FACTOR; ADAPTIVE RESPONSE; FACTOR PHEROMONES; ADENYLYL CYCLASE; SHUTTLE VECTORS; 48-KDA PROTEIN; GAMMA-SUBUNITS	In the yeast Saccharomyces cerevisiae, a G protein-linked signal transduction pathway mediates response to the oligopeptide mating pheromones alpha-factor and alpha-factor. Because cellular responses, including G1 arrest, occur transiently, cells can adapt or desensitize and resume growth. To address whether the balance between response and adaptation is influenced by the efficiency of receptor-G protein interaction, we introduced random point mutations in sequences that encode the third cytoplasmic loop of the alpha-factor receptor (STE2 gene product). Three mutations were identified that confer alpha-factor-resistant phenotypes, yet preserve normal cell-surface expression, ligand-binding affinity, and endocytosis of the receptor. However, these mutations confer partial signaling defects, as determined by cell cycle arrest and transcriptional induction assays, as well as in vitro assays of receptor-G protein interaction. Physiological tests suggested that receptors bearing third loop substitutions promote recovery from pheromone-induced growth arrest. Genetic evidence indicated that the third loop and the C-terminal domain of the receptor control independent recovery or adaptation processes. In contrast, receptor third loop substitutions caused rapid adaptation only if cells express a functional SST2 gene. Thus, disruption of pheromone receptor-G protein interaction concomitantly blunts signaling and specifically promotes the function of an SST2-dependent adaptation pathway. Possible functions for the Sst2 protein are discussed.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA	Washington University (WUSTL)			Blumer, Kendall J/C-5268-2012		NIGMS NIH HHS [GM44592] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044592] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; BLUMER KJ, 1991, ANNU REV PHYSIOL, V53, P37; BLUMER KJ, 1988, J BIOL CHEM, V263, P10836; BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; CARTWRIGHT CP, 1991, MOL CELL BIOL, V11, P2620, DOI 10.1128/MCB.11.5.2620; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061; CIEJEK E, 1979, CELL, V18, P623, DOI 10.1016/0092-8674(79)90117-X; COLE GM, 1991, CELL, V64, P703, DOI 10.1016/0092-8674(91)90500-X; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DULIC V, 1991, METHOD ENZYMOL, V194, P697; ERIOTOUBARGIOTA E, 1992, BIOCHEMISTRY-US, V31, P551, DOI 10.1021/bi00117a036; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; GREEN A, 1992, J BIOL CHEM, V267, P3223; HIRSCH JP, 1991, GENE DEV, V5, P467, DOI 10.1101/gad.5.3.467; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; KURJAN J, 1991, GENE DEV, V5, P475, DOI 10.1101/gad.5.3.475; KURJAN J, 1992, ANNU REV BIOCHEM, V61, P1097; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; MACKAY VL, 1988, P NATL ACAD SCI USA, V85, P55, DOI 10.1073/pnas.85.1.55; MARSH L, 1992, MOL CELL BIOL, V12, P3959, DOI 10.1128/MCB.12.9.3959; MCCAFFREY G, 1987, MOL CELL BIOL, V7, P2680, DOI 10.1128/MCB.7.8.2680; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; MIYAJIMA I, 1989, MOL CELL BIOL, V9, P2289, DOI 10.1128/MCB.9.6.2289; NAKAFUKU M, 1988, P NATL ACAD SCI USA, V85, P1374, DOI 10.1073/pnas.85.5.1374; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OLSON MF, 1991, ENDOCR RES, V17, P19, DOI 10.1080/07435809109027187; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; PREMONT RT, 1989, ENDOCRINOLOGY, V125, P1151, DOI 10.1210/endo-125-3-1151; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; SIKORSKI RS, 1989, GENETICS, V122, P19; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YATOMI Y, 1992, EUR J BIOCHEM, V205, P1003, DOI 10.1111/j.1432-1033.1992.tb16867.x	46	57	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8070	8077						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8385135				2022-12-25	WOS:A1993KW97900071
J	BANERJEE, A; GREGORI, L; XU, YP; CHAU, V				BANERJEE, A; GREGORI, L; XU, YP; CHAU, V			THE BACTERIALLY EXPRESSED YEAST CDC34 GENE-PRODUCT CAN UNDERGO AUTOUBIQUITINATION TO FORM A MULTIUBIQUITIN CHAIN-LINKED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYME; SHORT-LIVED PROTEIN; N-END RULE; AFFINITY PURIFICATION; CELL CYCLE; DEGRADATION; RAD6; PROTEOLYSIS; RECOGNITION; HOMOLOGS	The CDC34 gene of Saccharomyces cerevisiae encodes a 295-residue ubiquitin-conjugating enzyme (E2). The function of this ubiquitin-conjugating activity remains to be defined as its in vivo substrates are presently unknown. The bacterially expressed and purified Cdc34 protein is shown here to catalyze its own ubiquitination via an intramolecular transfer of its thiol ester-linked ubiquitin to a lysine. In this process, multiple ubiquitin groups are added to Cdc34, and these ubiquitin groups were shown to be arranged predominantly in the form of a single Lys48-specific multiubiquitin chain. Analysis of the hydroxylamine-dependent cleavage of ubiquitin-Cdc34 conjugates at the single Asn-Gly sequence in Cdc34 placed the major ubiquitin linkage site within the C-terminal 215-295 residues of Cdc34. The 4 Lys residues (Lys273, Lys277, Lys293, and Lys294) in this region of CDC34 were substituted by arginine either singly or in combination to produce a set of Cdc34 mutants. Analysis of these Cdc34 mutants for autoubiquitination revealed that the multiubiquitin chain can be formed on any one of these 4 lysines although most Cdc34 conjugates contain a single multiubiquitin chain. Since the presence of a Lys48-specific multiubiquitin chain in protein conjugates is known to target acceptor proteins for degradation in the ubiquitin-mediated proteolytic pathway, the present result raises the possibility that one function of the ubiquitin-conjugating activity in CDC34 may be used to target its own degradation.	WAYNE STATE UNIV, SCH MED, DEPT PHARMACOL, 540 E CANFIELD, DETROIT, MI 48201 USA	Wayne State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035803] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35803] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; DUNTEN RL, 1991, J BIOL CHEM, V266, P3260; ECKER DJ, 1987, J BIOL CHEM, V262, P14213; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GREGORI L, 1990, J BIOL CHEM, V265, P8354; HAAS AL, 1991, J BIOL CHEM, V266, P5104; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; KOKEN MHM, 1991, P NATL ACAD SCI USA, V88, P8865, DOI 10.1073/pnas.88.20.8865; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICKART CM, 1988, J BIOL CHEM, V263, P15076; PICKART CM, 1988, UBIQUITIN, P77; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; REISS Y, 1990, J BIOL CHEM, V265, P3685; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUNG P, 1991, EMBO J, V10, P2187, DOI 10.1002/j.1460-2075.1991.tb07754.x; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; WING SS, 1992, J BIOL CHEM, V267, P6495	31	87	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5668	5675						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8383676				2022-12-25	WOS:A1993KR82200048
J	ZHANG, HF; YANG, YH; STEINBRECHER, UP				ZHANG, HF; YANG, YH; STEINBRECHER, UP			STRUCTURAL REQUIREMENTS FOR THE BINDING OF MODIFIED PROTEINS TO THE SCAVENGER RECEPTOR OF MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HUMAN MONOCYTE-MACROPHAGES; ATHEROSCLEROTIC LESIONS; LIPID-PEROXIDATION; APOLIPOPROTEIN-B; CHOLESTEROL DEPOSITION; LYSINE RESIDUES; DEGRADATION; INVIVO; RECOGNITION	Oxidized low density lipoprotein (LDL) and certain chemically modified LDL are recognized by the scavenger receptor of macrophages. All of these modifications involve charge-neutralizing derivatization of lysine amino groups. However, it remains controversial whether recognition of modified LDL by this receptor is due to the modification per se, or to other factors such as a conformational change of apoB. In this study, LDL and other proteins including bovine serum albumin, human high density lipoprotein, and murine IgG were derivatized with oxidation products generated from arachidonic acid by thermal autoxidation. Modified proteins had increased negative charge, and showed a more than 10-fold enhancement of degradation by mouse peritoneal macrophages via the scavenger receptor pathway. Modification was prevented by blocking lysine residues of the proteins by prior reductive methylation. Amino acid analysis revealed dose-dependent modification of lysine residues with no significant effects on any other amino acid. Fab fragments of monoclonal antibodies specific for adducts of oxidation products with lysine prevented the uptake of oxidation product-modified LDL and oxidized LDL by macrophages. Chromatography of oxidation product-modified LDL over Sepharose CL-4B showed that uptake by macrophages did not require LDL aggregation. These results suggest that a relatively simple domain consisting of a cluster of suitably derivatized lysine residues is sufficient for recognition by the scavenger receptor of macrophages.	UNIV BRITISH COLUMBIA,DEPT MED,2211 WESBROOK MALL,VANCOUVER V6T 1W5,BC,CANADA	University of British Columbia								ARAI H, 1989, BIOCHEM BIOPH RES CO, V159, P1375, DOI 10.1016/0006-291X(89)92262-6; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN MS, 1980, J SUPRAMOL STR CELL, V13, P67, DOI 10.1002/jss.400130107; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; CHEN SH, 1986, J BIOL CHEM, V261, P2918; COULTER A, 1983, J IMMUNOL METHODS, V59, P199, DOI 10.1016/0022-1759(83)90031-5; DAVIS JM, 1982, J IMMUNOL METHODS, V50, P161, DOI 10.1016/0022-1759(82)90222-8; ESTERBAUER H, 1982, BIOCHEM J, V208, P129, DOI 10.1042/bj2080129; FOGELMAN AM, 1980, P NATL ACAD SCI-BIOL, V77, P2214, DOI 10.1073/pnas.77.4.2214; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; HABERLAND M, 1988, SCIENCE, V24, P215; HABERLAND ME, 1985, P NATL ACAD SCI USA, V82, P2693, DOI 10.1073/pnas.82.9.2693; HABERLAND ME, 1984, J BIOL CHEM, V259, P1305; HABERLAND ME, 1982, P NATL ACAD SCI USA, V79, P922; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOFF HF, 1989, ARTERIOSCLEROSIS, V9, P538, DOI 10.1161/01.ATV.9.4.538; Horiuchi S, 1989, J Mol Recognit, V2, P56, DOI 10.1002/jmr.300020203; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; JURGENS G, 1986, BIOCHIM BIOPHYS ACTA, V875, P103, DOI 10.1016/0005-2760(86)90016-0; KAMPS AAM, 1992, ARTERIOSCLER THROMB, V12, P1079; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; KODAMA T, 1992, CIRCULATION, V86, P549; KODAMA T, 1990, NATURE, V343, P532; LOUGHEED M, 1991, J BIOL CHEM, V266, P14519; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1979, J CLIN INVEST, V64, P743, DOI 10.1172/JCI109518; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; ROSENFELD ME, 1992, ARTERIOSCLER THROMB, V12, P985, DOI 10.1161/01.ATV.12.8.985; SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1984, J LIPID RES, V25, P1109; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; STEINBRECHER UP, 1989, J BIOL CHEM, V264, P15216; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; VIA D, 1992, FASEB J, V6, pA371; YLAHERTTUALA S, 1990, EUR HEART J, V11, P88, DOI 10.1093/eurheartj/11.suppl_E.88; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; ZHANG H, 1993, IN PRESS CLIN CHEM E	48	103	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5535	5542						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8383674				2022-12-25	WOS:A1993KR82200031
J	POLLARD, S; DUGGAN, MJ; STEPHENSON, FA				POLLARD, S; DUGGAN, MJ; STEPHENSON, FA			FURTHER EVIDENCE FOR THE EXISTENCE OF ALPHA-SUBUNIT HETEROGENEITY WITHIN DISCRETE GAMMA-AMINOBUTYRIC ACIDA-RECEPTOR SUBPOPULATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA-A RECEPTORS; BENZODIAZEPINE RECEPTORS; CEREBRAL-CORTEX; ANTIBODIES; SEQUENCE; BRAIN; CELLS; SITE	The alpha subunit complements of natural gamma-aminobutyric acid(A) (GABA(A)) receptor subpopulations were investigated by their purification from mammalian cerebral cortex and cerebellum by immunoaffinity chromatography using antibodies raised against peptide sequences unique to the alpha1, alpha2, alpha3, and alpha6 subunits. Receptors purified from cerebral cortex by anti-Cys alpha2 414-424 and anti-Cys alpha3 454-467 antibody affinity columns in series had immunoreactivity with alpha2 and alpha3 but not alpha1 subunit-specific antibodies. Receptors purified from cerebellum by a new affinity column matrix, anti-alpha6 1-16 Cys whole antibody, or the Fab fragment thereof, enriched for alpha6 subunit immunoreactivity. A further series of experiments demonstrated the partial coexistence of this alpha6 subunit immunoreactivity with that for the alpha1 but not the alpha2 and alpha3 subunits. These results provide additional evidence for the existence of GABA(A) receptor subpopulations with heterogeneous alpha subunit complements yielding increased structural diversity of natural GABA(A) receptors. Furthermore, they substantiate previous findings implicating the presence of two alpha subunits per receptor oligomer.	UNIV LONDON,DEPT PHARMACEUT CHEM,2939 BRUNSWICK SQ,LONDON WC1N 1AX,ENGLAND	University of London; University College London; University of London School of Pharmacy								BENKE D, 1991, J BIOL CHEM, V266, P4478; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; CUATRECA.P, 1968, P NATL ACAD SCI USA, V61, P636, DOI 10.1073/pnas.61.2.636; DUGGAN MJ, 1991, J BIOL CHEM, V266, P24778; DUGGAN MJ, 1992, J NEUROCHEM, V58, P72, DOI 10.1111/j.1471-4159.1992.tb09278.x; DUGGAN MJ, 1990, J BIOL CHEM, V265, P3831; DUGGAN MJ, 1989, J NEUROCHEM, V53, P132, DOI 10.1111/j.1471-4159.1989.tb07304.x; HARLOW E, 1988, ANTIBODIES LABORATOR; KATO K, 1990, J MOL BIOL, V214, P619, DOI 10.1016/0022-2836(90)90276-R; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; LUDDENS H, 1990, NATURE, V346, P648, DOI 10.1038/346648a0; MAMALAKI C, 1989, J NEUROCHEM, V52, P124, DOI 10.1111/j.1471-4159.1989.tb10906.x; MCKERNAN RM, 1991, NEURON, V7, P667, DOI 10.1016/0896-6273(91)90379-E; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SIGEL E, 1983, J BIOL CHEM, V258, P6965; STEPHENSON FA, 1990, J BIOL CHEM, V265, P21160; STEPHENSON FA, 1989, BIOCHEM J, V264, P199, DOI 10.1042/bj2640199; THOMPSON CL, 1992, NEUROSCI LETT, V144, P53, DOI 10.1016/0304-3940(92)90714-I; TURNER JD, 1992, SOC NEUR ABSTR, V120, P11; ZEZULA J, 1991, FEBS LETT, V284, P15, DOI 10.1016/0014-5793(91)80750-W	22	74	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3753	3757						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8381438				2022-12-25	WOS:A1993KM16100110
J	NAGASHIMA, M; LUNDH, E; LEONARD, JC; MORSER, J; PARKINSON, JF				NAGASHIMA, M; LUNDH, E; LEONARD, JC; MORSER, J; PARKINSON, JF			ALANINE-SCANNING MUTAGENESIS OF THE EPIDERMAL GROWTH FACTOR-LIKE DOMAINS OF HUMAN THROMBOMODULIN IDENTIFIES CRITICAL RESIDUES FOR ITS COFACTOR ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-C ACTIVATION; FACTOR-V; BINDING-SITES; THROMBIN; INACTIVATION; ANTICOAGULANT; LOCALIZATION; COAGULATION; RECEPTOR; SEQUENCE	Thrombomodulin (TM) is an endothelial cell surface-bound cofactor in thrombin-dependent formation of activated protein C, a potent anticoagulant. Cofactor activity has been localized to the carboxyl-terminal half of the six epidermal growth factor-like (EGF) domains of TM (TM(E)). To identify residues in TM(E) that are critical for activity, 77 alanine point mutants were made between Cys-333 and Cys-462 by site-directed mutagenesis (all residues except Ala, Cys, Gly, and Pro). Mutants were expressed in Escherichia coli and cofactor activity measured directly in periplasmic extracts obtained by osmotic shock. Critical residues were defined as those which when mutated had less than 25% cofactor activity of a reference TM(E). Western blots of non-reduced samples confirmed that alanine substitutions did not significantly decrease expression levels or result in the formation of multimers. In EGF4, which is essential for protein C activation by the thrombin-TM complex, critical residues were: Asp349, Glu-357, Tyr-358, and Phe-376. In EGF5-EGF6, critical residues within a proposed acidic thrombin-binding region were: Glu-408, Tyr-413, Ile-414, Leu415, Asp-416, Asp-417, Asp-423, Ile-424, Asp-425, and Glu-426. A potential Ca2+-binding site, which is comprised of residues Asp-423, Asp-425, Glu-426, Asn-439, Leu-440, and Phe-444, was also identified and overlaps the thrombin-binding region. Asp-461, in the C-loop of EGF6 previously shown to be critical for thrombin binding, was also critical. Asp-398, Asp-400, Asn-402, and Asn-429 in EGF5 were also critical. Thus, rapid alanine-scanning mutagenesis of TM(E) has identified 22 critical residues in the region comprising EGF4-6, which is essential for thrombin binding and protein C activation by the thrombin-TM complex.	BERLEX BIOSCI INC,15049 SAN PABLO AVE,POB 4099,RICHMOND,CA 94804									CLARKE JH, IN PRESS J BIOL CHEM; CUNNINGHAM BC, 1989, SCIENCE, V244, P1801; DAHLBACK B, 1990, J BIOL CHEM, V265, P18481; DITTMAN WA, 1988, J BIOL CHEM, V263, P15815; DITTMAN WA, 1990, BLOOD, V75, P329; ESMON CT, 1992, ARTERIOSCLER THROMB, V12, P135, DOI 10.1161/01.ATV.12.2.135; ESMON CT, 1982, J BIOL CHEM, V257, P7944; ESMON NL, 1983, J BIOL CHEM, V258, P2238; ESMON NL, 1982, J BIOL CHEM, V257, P859; FULCHER CA, 1984, BLOOD, V63, P486; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HAYASHI T, 1990, J BIOL CHEM, V265, P20156; JACKMAN RW, 1986, P NATL ACAD SCI USA, V83, P8834, DOI 10.1073/pnas.83.23.8834; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LEBONNIEC BF, 1991, BIOCHEMISTRY-US, V88, P7371; PARKINSON JF, 1992, BIOCHEM BIOPH RES CO, V185, P567, DOI 10.1016/0006-291X(92)91662-A; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEARNS DJ, 1989, J BIOL CHEM, V264, P3352; SUZUKI K, 1987, EMBO J, V6, P1891, DOI 10.1002/j.1460-2075.1987.tb02448.x; SUZUKI K, 1986, BIOCHIM BIOPHYS ACTA, V882, P343, DOI 10.1016/0304-4165(86)90257-6; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; SUZUKI K, 1991, J BIOL CHEM, V266, P18498; TSIANG M, 1992, J BIOL CHEM, V267, P6164; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WEN DZ, 1987, BIOCHEMISTRY-US, V26, P4350, DOI 10.1021/bi00388a025; YE J, 1991, J BIOL CHEM, V266, P23016; ZUSHI M, 1991, J BIOL CHEM, V266, P19886; ZUSHI M, 1989, J BIOL CHEM, V264, P10351	29	79	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2888	2892						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8381415				2022-12-25	WOS:A1993KK81500092
J	TARTAGLIA, LA; PENNICA, D; GOEDDEL, DV				TARTAGLIA, LA; PENNICA, D; GOEDDEL, DV			LIGAND PASSING - THE 75-KDA TUMOR-NECROSIS-FACTOR (TNF) RECEPTOR RECRUITS TNF FOR SIGNALING BY THE 55-KDA TNF RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY NGF RECEPTOR; NF-KAPPA-B; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; INTERLEUKIN-2 RECEPTOR; CELL-LINES; EXPRESSION; BINDING; ALPHA; ACTIVATION	To understand the role of the 75-kDa tumor necrosis factor (TNF) receptor in non-lymphoid cells, the cytotoxic signaling and ligand binding activities of the 55-kDa (TNF-R1) and 75-kDa (TNF-R2) TNF receptors were investigated using agonist and antagonist antibodies specific for the two receptor types. This study indicates that although TNF-R2 can significantly reduce the TNF concentration required for cell killing, the mechanism by which this is accomplished is not through the generation of an intracellular signal by TNF-R2. Instead, TNF-R2 regulates the rate of TNF association with TNF-R1, possibly by increasing the local concentration of TNF at the cell surface through rapid ligand association and dissociation. We propose that other cell-surface receptors, such as the low affinity p75 nerve growth factor receptor, may utilize an analogous ''ligand passing'' mechanism.	GENENTECH INC,DEPT MOLEC BIOL,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech								BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FRANSEN L, 1986, CELL IMMUNOL, V100, P260, DOI 10.1016/0008-8749(86)90025-0; GOEDDEL DV, 1986, COLD SPRING HARB SYM, V51, P597, DOI 10.1101/SQB.1986.051.01.072; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; HARTMAN DS, 1992, J BIOL CHEM, V267, P24516; HELLER RA, 1992, CELL, V70, P47; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; HORUK R, 1989, BIOCHEM J, V260, P657, DOI 10.1042/bj2600657; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1991, J BIOL CHEM, V266, P18324; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOWENTHAL JW, 1987, J EXP MED, V166, P1156, DOI 10.1084/jem.166.4.1156; NAUME B, 1991, J IMMUNOL, V146, P3045; OLD LJ, 1988, SCI AM, V258, P59, DOI 10.1038/scientificamerican0588-59; PENNICA D, 1993, BIOCHEMISTRY-US, V32, P3131, DOI 10.1021/bi00063a027; PENNICA D, 1992, J BIOL CHEM, V267, P21172; PENNICA D, 1992, BIOCHEMISTRY-US, V31, P1134, DOI 10.1021/bi00119a023; RICE GC, 1990, TUMOR NECROSIS FACTOR : STRUCTURE, MECHANISM OF ACTION, ROLE IN DISEASE AND THERAPY, P87; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SHALABY MR, 1990, J EXP MED, V172, P1517, DOI 10.1084/jem.172.5.1517; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STYLIANOU E, 1992, J BIOL CHEM, V267, P15836; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; VANOSTADE X, 1993, NATURE, V361, P266; WANG HM, 1987, J EXP MED, V166, P1055, DOI 10.1084/jem.166.4.1055; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WONG GHW, 1992, J IMMUNOL, V149, P3350; WONG GHW, 1992, MOL BIOL FREE RADICA, P69	41	524	534	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18542	18548						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8395508				2022-12-25	WOS:A1993LV65900028
J	THWAITES, DT; MCEWAN, GTA; BROWN, CDA; HIRST, BH; SIMMONS, NL				THWAITES, DT; MCEWAN, GTA; BROWN, CDA; HIRST, BH; SIMMONS, NL			NA+-INDEPENDENT, H+-COUPLED TRANSEPITHELIAL BETA-ALANINE ABSORPTION BY HUMAN INTESTINAL CACO-2 CELL MONOLAYERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LUMINAL-MEMBRANE-VESICLES; RABBIT PROXIMAL TUBULE; NEUTRAL AMINO-ACID; TRANSPORT-SYSTEMS; SUGAR-TRANSPORT; ALPHA-AMINOISOBUTYRATE; DEPENDENT TRANSPORT; ESCHERICHIA-COLI; PH; GRADIENT	Beta-alanine transport across intact human intestinal epithelial (Caco-2) cell layers has been investigated. In Na+-containing solutions, net absorptive flux of beta-alanine from apical-to-basal surfaces is small or absent, despite Na+-dependent intracellular beta-alanine accumulation across both apical and basal surfaces. Upon apical acidification (apical pH 6.0, basal pH 7.5), beta-alanine absorptive flux and accumulation across the apical surface are increased. In Na+-free conditions, a significant absorptive flux of beta-alanine is observed, which is markedly stimulated upon apical acidification (pH 6.0). Cellular accumulation of beta-alanine across the apical but not basal surface is observed in Na+-free conditions, and this is increased by acidic (pH 6.0) solutions. Absorptive beta-alanine flux in Na+-free conditions with acidic apical solutions displays saturation kinetics and competitive inhibition by alanine and glycine, but not valine or serine. Addition of 20 mM beta-alanine to the apical solution of epithelial monolayers loaded with the pH indicator 2',7'-bis(2-carboxyethyl-5(6)-carboxyfluorescein) causes a marked decrement in intracellular pH. Beta-alanine transport is also electrogenic, a concentration-dependent increase in an inward short circuit current being observed in voltage-clamped epithelial monolayers. We conclude that a proton-dependent, but Na+-independent, amino acid transporter is expressed at the apical membrane of human intestinal Caco-2 cells, and we provide direct evidence for amino acid-stimulated proton influx across the apical membrane in this intact epithelial cell system.			THWAITES, DT (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT PHYSIOL SCI,GASTROINTESTINAL DRUG DELIVERY RES CTR,NEWCASTLE TYNE NE2 4HH,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAHAMSE SL, 1992, PFLUG ARCH EUR J PHY, V421, P591, DOI 10.1007/BF00375056; AMARA SG, 1992, NATURE, V360, P420, DOI 10.1038/360420d0; BARKER GA, 1990, EXP PHYSIOL, V75, P3, DOI 10.1113/expphysiol.1990.sp003382; BLAIS A, 1987, J MEMBRANE BIOL, V99, P113, DOI 10.1007/BF01871231; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; CRANE RK, 1961, MEMBRANE TRANSPORT M, P439; GANAPATHY V, 1983, J BIOL CHEM, V258, P4189; GECK P, 1972, BIOCHIM BIOPHYS ACTA, V288, P486, DOI 10.1016/0005-2736(72)90272-6; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; HIDALGO IJ, 1990, BIOCHIM BIOPHYS ACTA, V1035, P97, DOI 10.1016/0304-4165(90)90179-Z; HU M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P233, DOI 10.1016/0167-4889(92)90226-2; JESSEN H, 1991, J PHYSIOL-LONDON, V436, P149, DOI 10.1113/jphysiol.1991.sp018544; LUCAS ML, 1975, PROC R SOC SER B-BIO, V192, P39, DOI 10.1098/rspb.1975.0150; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MCEWAN GTA, 1988, PROC R SOC SER B-BIO, V234, P219, DOI 10.1098/rspb.1988.0045; MUNCK LK, 1992, AM J PHYSIOL, V262, pG609, DOI 10.1152/ajpgi.1992.262.4.G609; SIMMONS NL, 1990, METHOD ENZYMOL, V191, P426; STEVENS BR, 1984, ANNU REV PHYSIOL, V46, P417; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2230; THWAITES DT, 1993, J BIOL CHEM, V268, P7640; THWAITES DT, 1993, PHARMACEUT RES, V10, P667, DOI 10.1023/A:1018995313180; VORUM H, 1988, FEBS LETT, V227, P35, DOI 10.1016/0014-5793(88)81408-X; WEST IC, 1973, BIOCHEM J, V132, P587, DOI 10.1042/bj1320587	23	82	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18438	18441						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8395502				2022-12-25	WOS:A1993LV65900011
J	CHRUNYK, BA; EVANS, J; LILLQUIST, J; YOUNG, P; WETZEL, R				CHRUNYK, BA; EVANS, J; LILLQUIST, J; YOUNG, P; WETZEL, R			INCLUSION-BODY FORMATION AND PROTEIN STABILITY IN SEQUENCE VARIANTS OF INTERLEUKIN-1-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; N-15-H-1 NMR-SPECTROSCOPY; ESCHERICHIA-COLI; PROTEOLYTIC SUSCEPTIBILITY; 3-DIMENSIONAL STRUCTURE; ABNORMAL PROTEINS; RESOLUTION; SUBSTITUTIONS	Inclusion body formation during recombinant protein expression in bacteria is of both fundamental interest and practical importance. To elucidate molecular mechanisms of this process, we are examining the in vitro folding and stability properties of a series of human interleukin-1beta (IL-1beta) sequence variants which exhibit widely differing tendencies to form inclusion bodies. Of 67 variants surveyed, nine, including wild type, were purified and their in vitro stability properties determined. One of these, a high inclusion body mutant, exhibited very low solubility in native buffer after purification and was not pursued further. For the other eight sequence variants, no strong correlations were observed between extent of inclusion body formation and either thermodynamic or thermal stability. In particular, a Lys97 --> Val mutation produces substantially more IL-1beta in inclusion bodies than the wild type (61 versus 8%) despite generating a protein more thermodynamically stable than wild type. Furthermore, the Lys97 --> Val mutant forms substantial levels of inclusion bodies at 32-degrees-C but requires incubation at temperatures greater than 48-degrees-C for thermally induced aggregation in vitro. This and other data suggest that the tendency of at least some IL-1beta variants to form inclusion bodies is most likely related to the stability or solubility of folding intermediates rather than native states. Implications of the structural locations of these mutations are also discussed.	SMITHKLINE BEECHAM PHARMACEUT, DEPT MACROMOLEC SCI, L47, KING OF PRUSSIA, PA 19406 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT MOLEC GENET, KING OF PRUSSIA, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline			Wetzel, Ronald/G-7453-2011					BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CHRUNYK BA, 1993, ACS SYM SER, V526, P46; CHRUNYK BA, 1991, J CELL BIOCH G, V15, P190; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P5671, DOI 10.1021/bi00476a004; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P7387, DOI 10.1021/bi00484a006; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; CRAIG S, 1987, BIOCHEMISTRY-US, V26, P3570, DOI 10.1021/bi00386a048; DRISCOLL PC, 1990, BIOCHEMISTRY-US, V29, P4668, DOI 10.1021/bi00471a023; FIERKE CA, 1991, BIOCHEMISTRY-US, V30, P11054, DOI 10.1021/bi00110a007; FINN BE, 1992, PROTEIN ENG PRACTICA, P167; FINZEL BC, 1989, J MOL BIOL, V209, P779, DOI 10.1016/0022-2836(89)90606-2; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; JAENICKE R, 1984, ANGEW CHEM INT EDIT, V23, P395, DOI 10.1002/anie.198403953; KING J, 1990, N HORIZ TH, P59; KING J, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P225; KRUEGER JK, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P136; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MOTT JE, 1985, P NATL ACAD SCI USA, V82, P82; MYERS CA, 1987, J BIOL CHEM, V262, P11176; Neidhardt FC., 1987, ESCHERICHIA COLI SAL, V2nd ed, P3; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; PERRY LJ, 1986, BIOCHEMISTRY-US, V25, P733, DOI 10.1021/bi00351a034; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V86, P9667, DOI 10.1073/pnas.86.24.9667; PROUTY WF, 1972, NATURE-NEW BIOL, V240, P147, DOI 10.1038/newbio240147a0; PROUTY WF, 1975, J BIOL CHEM, V250, P1112; RINAS U, 1992, BIO-TECHNOL, V10, P435, DOI 10.1038/nbt0492-435; ROE S, 1989, PROTEIN PURIFICATION, P175; SCHEIN CH, 1989, BIO-TECHNOL, V7, P1141; SIMON PL, 1993, J BIOL CHEM, V268, P9771; TRUONG HTN, 1991, BIOCHEMISTRY-US, V30, P10722; VEERAPANDIAN B, 1992, PROTEINS, V12, P10, DOI 10.1002/prot.340120103; VILLAFANE R, 1988, J MOL BIOL, V204, P607, DOI 10.1016/0022-2836(88)90359-2; WETZEL R, 1990, N HORIZ TH, P79; WETZEL R, 1991, BIO-TECHNOL, V9, P731, DOI 10.1038/nbt0891-731; WETZEL R, 1990, PROTEIN ENG, V3, P611, DOI 10.1093/protein/3.7.611; WETZEL R, 1992, PROTEIN ENG PRACTICA, P191; WETZEL R, 1992, STABILITY PROTEIN PH, P43; Wetzel R., 1983, PEPTIDES ANAL SYNTHE, P1; WILLIAMS DC, 1982, SCIENCE, V215, P687, DOI 10.1126/science.7036343; [No title captured]	42	100	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18053	18061						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8394358				2022-12-25	WOS:A1993LT74300062
J	GOVITRAPONG, P; ZHANG, XH; LOH, HH; LEE, NM				GOVITRAPONG, P; ZHANG, XH; LOH, HH; LEE, NM			TRANSFECTION OF NG108-15 CELLS WITH ANTISENSE OPIOID-BINDING CELL-ADHESION MOLECULE CDNA ALTERS OPIOID RECEPTOR-G-PROTEIN INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; PERTUSSIS TOXIN; HYBRID-CELLS; COMPLEMENTARY-DNA; OPIATE INHIBITION; CLONING; IDENTIFICATION; EXPRESSION; REDUCTION; SUBUNIT	We previously reported that transfection of antisense OBCAM (opioid-binding cell adhesion molecule) cDNA into NG108-15 neuroblastoma x glioma hybrid cells, which contain delta-opioid receptors, results in greatly reduced opioid binding (Ann, D. K., Hasegawa, J., Ko, J. L., Chen, S. T., Lee, N. M., and Loh, H. H. (1992) J. Biol. Chem. 267, 7921-7926. Here we report that these cells show altered coupling between opioid receptors and G-proteins. G-proteins were identified using cholera toxin (CTX)-induced ADP-ribosylation and antisera selective for G(i)2 and G(o)alpha subunits. In the presence of delta-opioid agonists, CTX induced the incorporation of [P-32]ADP-ribose into a 39-41-kDa protein with the same electrophoretic mobility as G(i)2 and G(o)alpha subunits. This band, which was also a pertussis toxin (PTX) substrate, exhibited decreased CTX-induced ADP-ribosylation in membranes of cells treated chronically with D-Ala2-D-Leu5-enkephalin (DADLE). In cells transfected with antisense cDNA for OBCAM, labeling of this band was also decreased, compared with either sense-transfected or untransfected cells. DADLE inhibition of adenylyl cyclase and DADLE stimulation of GTPase were also greatly impaired in antisense cells, as well as GTP and GppNHp inhibition of basal and forskolin-stimulated adenylyl cyclase. These results provide further evidence for a role of OBCAM in opioid receptor function.	UNIV MINNESOTA,SCH MED,DEPT PHARMACOL,3-249 MILLARD HALL,435 DELAWARE ST SE,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities					PHS HHS [05695, 01583, 00564] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABOOD ME, 1985, BIOCHEM BIOPH RES CO, V127, P477, DOI 10.1016/S0006-291X(85)80185-6; ANN DK, 1992, J BIOL CHEM, V267, P7921; ATTALI B, 1989, J NEUROCHEM, V53, P1636, DOI 10.1111/j.1471-4159.1989.tb08562.x; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FANTOZZI R, 1981, MOL PHARMACOL, V20, P8; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; HARRIS BA, 1985, SCIENCE, V229, P1274, DOI 10.1126/science.3839937; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KLINZ FJ, 1989, BIOCHEM BIOPH RES CO, V165, P554, DOI 10.1016/S0006-291X(89)80002-6; KOSKI G, 1981, P NATL ACAD SCI-BIOL, V78, P4185, DOI 10.1073/pnas.78.7.4185; KUROSE H, 1983, J BIOL CHEM, V258, P4870; LANE CM, 1992, P NATL ACAD SCI USA, V89, P11234, DOI 10.1073/pnas.89.23.11234; Law P Y, 1984, NIDA Res Monogr, V54, P119; LAW PY, 1982, MOL PHARMACOL, V21, P483; LAW PY, 1983, MOL PHARMACOL, V24, P413; LAW PY, 1981, J NEUROCHEM, V36, P1834, DOI 10.1111/j.1471-4159.1981.tb00438.x; MCKENZIE FR, 1990, BIOCHEM J, V267, P6134; MILLIGAN G, 1988, BIOCHEM J, V252, P369, DOI 10.1042/bj2520369; ROERIG SC, 1992, MOL PHARMACOL, V41, P822; ROY S, 1988, BIOCHEM BIOPH RES CO, V154, P688, DOI 10.1016/0006-291X(88)90194-5; ROY S, 1988, BIOCHEM BIOPH RES CO, V150, P237, DOI 10.1016/0006-291X(88)90511-6; SCHOFIELD PR, 1989, EMBO J, V8, P489, DOI 10.1002/j.1460-2075.1989.tb03402.x; SPIEGEL AM, 1990, ADP RIBOSYLATING TOX; WHITE AA, 1978, ANAL BIOCHEM, V85, P451, DOI 10.1016/0003-2697(78)90242-7	25	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18280	18285						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8394363				2022-12-25	WOS:A1993LT74300093
J	OR, E; DAVID, P; SHAINSKAYA, A; TAL, DM; KARLISH, SJD				OR, E; DAVID, P; SHAINSKAYA, A; TAL, DM; KARLISH, SJD			EFFECTS OF COMPETITIVE SODIUM-LIKE ANTAGONISTS ON NA,K-ATPASE SUGGEST THAT CATION OCCLUSION FROM THE CYTOPLASMIC SURFACE OCCURS IN 2 STEPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; POTASSIUM PUMP; CONFORMATIONAL TRANSITIONS; PHOSPHOLIPID-VESICLES; CHARGE TRANSLOCATION; OCCLUDED STATE; RUBIDIUM IONS; RB+-OCCLUSION; NA/K-ATPASE; ALPHA-CHAIN	Information on cation occlusion sites of renal NA,K-ATPase has been obtained by comparing the ability of competitive Na-like antagonists (David, P., Mayan, H., Cohen, H., Tal, D. M., and Karlish, S. J. D. (1992) J. Biol. Chem. 267, 1141-1149) with that of transported alkali metal cations to protect against covalent modification and structural perturbations of the protein. Sodium antagonists include p- or m-xylylenebisguanidium, guanidinium ions, and ethylenediamine. Experiments with proteoliposomes reconstituted with Na,K-ATPase demonstrate that p-xylylenebisguanidium has pronounced selectivity for the cytoplasmic surface. Tryptic digestion of Na,K-ATPase leading to ''19-kDa membranes,'' a specifically truncated enzyme with intact cation occlusion sites, requires the presence of alkali metal cations. Sodium antagonists do not protect 19-kDa membranes against further digestion, and occlusion is destroyed. Incubation of 19-kDa membranes at 37-degrees-C, in the absence of occluded ions, leads rapidly to loss of ability to occlude rubidium ions. Rubidium, sodium, or other alkali metal cations protect fully, whereas sodium antagonists do not protect against this thermal inactivation. Like the alkali metal cations, sodium antagonists protect Na,K-ATPase and, somewhat less effectively, 19-kDa membranes against inactivation by the carboxyl reagent N,N'-dicyclohexylcarbodiimide. Cation occlusion from the cytoplasmic surface is suggested to occur in two steps. In an initial recognition, either transported cations or sodium antagonists interact with carboxyl groups. The second step is selective for transported cations and involves occlusion of cations (either potassium or sodium ions) and a conformational change to a compact structure, which is resistant to proteolysis and thermal inactivation. Sodium antagonists are sterically hindered from becoming occluded and block Na,K-ATPase activity. Implications for the structural basis of cation specificity of the Na/K pump are discussed.	WEIZMANN INST SCI,DEPT BIOCHEM,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science					NIGMS NIH HHS [GM-32286] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032286] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUHLER R, 1991, J MEMBRANE BIOL, V121, P141, DOI 10.1007/BF01870529; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; DAVID P, 1991, J BIOL CHEM, V266, P14896; DAVID P, 1992, J BIOL CHEM, V267, P1141; ESMANN M, 1985, BIOCHEM BIOPH RES CO, V127, P857, DOI 10.1016/S0006-291X(85)80022-X; FORBUSH B, 1987, J BIOL CHEM, V262, P11104; FORBUSH B, 1988, J BIOL CHEM, V263, P7979; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GLYNN IM, 1985, J PHYSIOL-LONDON, V368, P453, DOI 10.1113/jphysiol.1985.sp015868; GLYNN IM, 1982, J PHYSIOL-LONDON, V330, P17, DOI 10.1113/jphysiol.1982.sp014326; GOLDSHLEGER R, 1990, J MEMBRANE BIOL, V113, P139, DOI 10.1007/BF01872888; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; GOLDSHLEGGER R, 1987, J PHYSIOL-LONDON, V387, P331, DOI 10.1113/jphysiol.1987.sp016576; Grell E., 1991, SODIUM PUMP RECENT D, P441; GRELL E, 1987, ION TRANSPORT MEMBRA, P41; HARA Y, 1986, J BIOL CHEM, V261, P2655; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; JORGENSEN PL, 1986, BIOCHEMISTRY-US, V25, P2889; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P53, DOI 10.1016/0005-2736(74)90293-4; JORGENSEN PL, 1982, J BIOL CHEM, V257, P7435; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; JORGENSEN PL, 1975, BIOCHIM BIOPHYS ACTA, V401, P399, DOI 10.1016/0005-2736(75)90239-4; KARLISH SJD, 1977, NATURE, V269, P715, DOI 10.1038/269715a0; KARLISH SJD, 1981, J PHYSIOL-LONDON, V312, P505, DOI 10.1113/jphysiol.1981.sp013641; KARLISH SJD, 1985, J PHYSIOL-LONDON, V359, P119, DOI 10.1113/jphysiol.1985.sp015578; KARLISH SJD, 1982, J PHYSIOL-LONDON, V328, P295, DOI 10.1113/jphysiol.1982.sp014265; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KARLISH SJD, 1988, METHOD ENZYMOL, V156, P179; KARLISH SJD, 1978, BIOCHIM BIOPHYS ACTA, V525, P252, DOI 10.1016/0005-2744(78)90219-X; KAWAMURA M, 1985, BIOCHIM BIOPHYS ACTA, V821, P115, DOI 10.1016/0005-2736(85)90161-0; KRUPKA RM, 1989, J MEMBRANE BIOL, V109, P151, DOI 10.1007/BF01870854; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUURMANSSTEKH.FM, 1989, BIOCHIM BIOPHYS ACTA, V937, P161; SHANI M, 1987, BIOCHIM BIOPHYS ACTA, V904, P13, DOI 10.1016/0005-2736(87)90081-2; SHANISEKLER M, 1988, J BIOL CHEM, V263, P19331; SKOU JC, 1980, BIOCHIM BIOPHYS ACTA, V601, P386, DOI 10.1016/0005-2736(80)90543-X; STURMER W, 1991, J MEMBRANE BIOL, V121, P163, DOI 10.1007/BF01870530; WALLMARK B, 1987, J BIOL CHEM, V262, P2077	43	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16929	16937						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8394324				2022-12-25	WOS:A1993LQ98800012
J	TRAINER, VL; MOREAU, E; GUEDIN, D; BADEN, DG; CATTERALL, WA				TRAINER, VL; MOREAU, E; GUEDIN, D; BADEN, DG; CATTERALL, WA			NEUROTOXIN BINDING AND ALLOSTERIC MODULATION AT RECEPTOR SITE-2 AND SITE-5 ON PURIFIED AND RECONSTITUTED RAT-BRAIN SODIUM-CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCORPION TOXIN BINDING; PYRETHROID INSECTICIDES; BREVETOXINS; SYNAPTOSOMES; BATRACHOTOXININ; PURIFICATION; MEMBRANES; SUBUNIT	Purified and reconstituted sodium channels have previously been shown to be functional in voltage-dependent ion conductance and in high affinity binding of tetrodotoxin and saxitoxin at neurotoxin receptor site 1 and alpha-scorpion toxins at receptor site 3, but high affinity binding of neurotoxins at receptor sites 2, 4, and 5 has not been demonstrated. The pyrethroid insecticide RU39568 enhances the specific binding of [H-3]batrachotoxinin A 20-alpha-benzoate (BTX-B) to neurotoxin receptor site 2 on purified and reconstituted sodium channels up to 500-fold, reducing the K(d) to 1.5 nm. Brevetoxins and alpha-scorpion toxins cause further allosteric enhancement of BTX-B binding. The pyrethroids deltamethrin and bifenthrin and the nonpyrethroid insecticide 2,2-bis(p-chlorophenyl)trichloroethane can partially substitute for RU39568 in enhancing BTX-B binding, but other pyrethroids are inactive. The brevetoxin PbTx-1 binds specifically to neurotoxin receptor site 5 on purified and reconstituted sodium channels with a K(d) value of approximately 30 nM. Brevetoxin binding is enhanced up to 2-fold by the combination of batrachotoxin and RU39568. The allosteric enhancement of BTX-B binding by RU39568 is voltage dependent, decreasing progressively with depolarization to 0 mV. In contrast, PbTx-1 binding is not voltage dependent and PbTx-1 reduces the voltage dependence of the effect of RU39568. The results demonstrate restoration of high affinity binding and allosteric interactions of ligands at neurotoxin receptor sites 2 and 5 on purified and reconstituted sodium channels and provide an experimental approach to covalent labeling and identification of the peptide components of those receptor sites.	ROUSSEL UCLAF,CTR RECH,F-93230 ROMAINVILLE,FRANCE; UNIV MIAMI,NIEHS,CTR MARINE & FRESHWATER BIOMED SCI,MIAMI,FL 33149	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Miami	TRAINER, VL (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SJ-30,SEATTLE,WA 98195, USA.		Trainer, Vera/AAE-9306-2022		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES005586, P30ES005705] Funding Source: NIH RePORTER; NIEHS NIH HHS [F32 ES 05586, P30 ES 05705] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BADEN DG, 1989, FASEB J, V3, P1807, DOI 10.1096/fasebj.3.7.2565840; BADEN DG, 1981, TOXICON, V19, P455, DOI 10.1016/0041-0101(81)90003-9; BARCHI RL, 1988, ANNU REV NEUROSCI, V11, P455, DOI 10.1146/annurev.ne.11.030188.002323; BLAUSTEIN MP, 1975, J PHYSIOL-LONDON, V247, P589, DOI 10.1113/jphysiol.1975.sp010949; BROWN GB, 1988, MOL PHARMACOL, V34, P54; CATTERALL WA, 1988, ISI ATLAS-PHARMACOL, V2, P190; CATTERALL WA, 1980, ANNU REV PHARMACOL, V20, P15, DOI 10.1146/annurev.pa.20.040180.000311; CATTERALL WA, 1981, J BIOL CHEM, V256, P8922; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; CATTERALL WA, 1979, J BIOL CHEM, V254, P1379; CATTERALL WA, 1977, J BIOL CHEM, V252, P8660; CORREA AM, 1990, BIOCHEMISTRY-US, V29, P6230, DOI 10.1021/bi00478a017; EDWARDS RA, 1992, MOL BRAIN RES, V14, P64, DOI 10.1016/0169-328X(92)90011-Y; FELLER DJ, 1985, J BIOL CHEM, V260, P1542; GAWLEY RE, 1992, TOXICON, V30, P780, DOI 10.1016/0041-0101(92)90014-V; HARTSHORNE RP, 1984, J BIOL CHEM, V259, P1667; LOMBET A, 1988, BRAIN RES, V459, P44, DOI 10.1016/0006-8993(88)90284-3; POLI MA, 1986, MOL PHARMACOL, V30, P129; SHARKEY RG, 1987, MOL PHARMACOL, V31, P273; SODERLUND DM, 1989, ANNU REV ENTOMOL, V34, P77, DOI 10.1146/annurev.en.34.010189.000453; TALVENHEIMO JA, 1982, J BIOL CHEM, V257, P1868; TAMKUN MM, 1984, J BIOL CHEM, V259, P1676; TEJEDOR FJ, 1988, P NATL ACAD SCI USA, V85, P8742, DOI 10.1073/pnas.85.22.8742; WANG GK, 1983, MOL PHARMACOL, V23, P519	24	57	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17114	17119						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8394327				2022-12-25	WOS:A1993LQ98800037
J	GILLESGONZALEZ, MA; GONZALEZ, G				GILLESGONZALEZ, MA; GONZALEZ, G			REGULATION OF THE KINASE-ACTIVITY OF HEME PROTEIN FIXL FROM THE 2-COMPONENT SYSTEM FIXL/FIXJ OF RHIZOBIUM-MELILOTI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL CHEMOTAXIS; ESCHERICHIA-COLI; SIGNAL TRANSDUCTION; CONSERVED ASPARTATE; RESPONSE REGULATOR; PHOSPHATE REGULON; PHOSPHORYL GROUP; NTRC; AUTOPHOSPHORYLATION; IDENTIFICATION	The Rhizobium meliloti two-component system FixL/FixJ regulates nitrogen fixation in response to oxygen during symbiosis. FixJ is a transcriptional activator of critical nif and fix promoters; its in vivo activity is enhanced by FixL in diminished oxygen (David, M., Daveran, M.-L., Batut, J., Dedieu, A., Domergue, O., Ghai, J., Hertig, C., Boistard, P., and Kahn, D. (1988) Cell 54, 671-683; Virts, E. L., Stanfield, S. W., Helinski, D. R., and Ditta, G. S. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 3062-3065). FixL* is a soluble truncated version of FixL that contains heme; it catalyzes its autophosphorylation and the phosphorylation of FixJ (Gilles-Gonzalez, M. A., Ditta, G. S., and Helinski, D. R. (1991) Nature 350, 170-172). We examine the kinetics of phosphoryl transfer in this system. First, there is a slow autophosphorylation of FixL* in ATP that is accelerated in the absence of oxygen and in the presence of Mn2+. This reaction is reversible, i.e. phospho-FixL* reacts with ADP to generate ATP. Since the reverse reaction is faster, most FixL* is not phosphorylated at equilibrium. Next, there is a rapid phosphoryl transfer directly from phospho-FixL* to FixJ that is unaffected by oxygen. Finally, phospho-FixJ is hydrolyzed; this reaction is very fast and not controlled by oxygen. We propose that in addition to the oxygen signal previously noted in vivo, energy charge and manganese concentration are also indicators of symbiosis that impact on the induction of nitrogen fixation genes.			GILLESGONZALEZ, MA (corresponding author), MRC,DIV STRUCT STUDIES,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031461] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 31461] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIBA H, 1989, J BIOL CHEM, V264, P8563; AMEMURA M, 1990, J BACTERIOL, V172, P6300, DOI 10.1128/jb.172.11.6300-6307.1990; BATUT J, 1991, J BACTERIOL, V173, P5914, DOI 10.1128/jb.173.18.5914-5917.1991; BECANA M, 1992, P NATL ACAD SCI USA, V89, P8958, DOI 10.1073/pnas.89.19.8958; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; DASILVA JJR, 1991, BIOL CHEM ELEMENTS, P370; DAVID M, 1988, CELL, V54, P671, DOI 10.1016/S0092-8674(88)80012-6; DIXON ROD, 1986, NITROGEN FIXATION PL, P45; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; HESS JF, 1987, P NATL ACAD SCI USA, V84, P7609, DOI 10.1073/pnas.84.21.7609; IGO MM, 1989, GENE DEV, V3, P598, DOI 10.1101/gad.3.5.598; JIN SG, 1990, J BACTERIOL, V172, P4945, DOI 10.1128/jb.172.9.4945-4950.1990; JIN SG, 1990, J BACTERIOL, V172, P525, DOI 10.1128/jb.172.2.525-530.1990; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUKAT GS, 1991, J BIOL CHEM, V266, P8348; MAKINO K, 1989, J MOL BIOL, V210, P551, DOI 10.1016/0022-2836(89)90131-9; MCCLEARY WR, 1990, J BACTERIOL, V172, P6661, DOI 10.1128/jb.172.12.6661-6668.1990; MONSON EK, 1992, P NATL ACAD SCI USA, V89, P4280, DOI 10.1073/pnas.89.10.4280; NINFA AJ, 1991, J BIOL CHEM, V266, P6888; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; NINFA EG, 1991, J BIOL CHEM, V266, P9764; NIXON BT, 1986, P NATL ACAD SCI USA, V83, P7850, DOI 10.1073/pnas.83.20.7850; RAMPERSAUD A, 1991, J BIOL CHEM, V266, P7633; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; VIRTS EL, 1988, P NATL ACAD SCI USA, V85, P3062, DOI 10.1073/pnas.85.9.3062; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919	32	111	112	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16293	16297						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8393856				2022-12-25	WOS:A1993LQ33600033
J	LIU, T; LIU, DJ; DEROSE, EF; MULLEN, GP				LIU, T; LIU, DJ; DEROSE, EF; MULLEN, GP			STUDIES OF THE DIMERIZATION AND DOMAIN-STRUCTURE OF GAMMA-DELTA RESOLVASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; RECOMBINATION; MUTANTS; ENZYME; NMR; RES	Gammadelta Resolvase is a site-specific recombinase (20.5 kDa) that catalyzes the resolution of a negatively supercoiled plasmid to a catenated pair of circular DNA products (Reed, R. R. (1981) Cell 25, 713-719). Cross-linking experiments and size exclusion high pressure liquid chromatography analysis of isolated fragments corresponding to specific proteolytic cleavage indicate that the intact enzyme and the large fragment exist in a monomer-dimer equilibrium (K(D)dimer = 8.0 muM, intact enzyme; K(D)dimer = 0.1 muM, large fragment) and that the small fragment, which displays DNA binding specificity, is a monomer. Dimerization is further supported by line width comparisons in one-dimensional NMR spectra and determinations of the correlation time of the protein. The one-dimensional proton NMR spectra and two-dimensional nuclear Overhauser enhancement spectroscopy spectra indicate that the overall structure of the two isolated fragments is highly similar to the structure present in the domains of the intact enzyme. The rotational correlation time of resolvase, determined from relaxation data obtained from each domain, indicates that the small domain has a limited degree of additional motion with respect to the large domain of the enzyme. The monomer-dimer equilibrium and small domain mobility may assist in the binding of resolvase to palindromic-type sites with variable spacers and in subunit exchange during catalysis.	UNIV WISCONSIN,DEPT CHEM,MILWAUKEE,WI 53201	University of Wisconsin System; University of Wisconsin Milwaukee								ABDELMEGUID SS, 1984, P NATL ACAD SCI-BIOL, V81, P2001, DOI 10.1073/pnas.81.7.2001; BLAKE PR, 1991, BIOCHEMISTRY-US, V30, P10885, DOI 10.1021/bi00109a012; GRINDLEY NDF, 1985, ANNU REV BIOCHEM, V54, P863, DOI 10.1146/annurev.biochem.54.1.863; HATFULL GF, 1989, J MOL BIOL, V208, P661, DOI 10.1016/0022-2836(89)90156-3; HATFULL GF, 1987, CELL, V49, P103, DOI 10.1016/0092-8674(87)90760-4; HATFULL GF, 1986, P NATL ACAD SCI USA, V83, P5429, DOI 10.1073/pnas.83.15.5429; HATFULL GF, 1988, TRANSPOSITION, P149; HERMANN R, 1981, BIOCHEMISTRY-US, V20, P5195, DOI 10.1021/bi00521a015; HUGHES RE, 1990, CELL, V63, P1331, DOI 10.1016/0092-8674(90)90428-H; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; MULLEN GP, 1989, J BIOL CHEM, V264, P19637; REED RR, 1981, CELL, V25, P713, DOI 10.1016/0092-8674(81)90178-1; RIMPHANITCHAYAKIT V, 1989, NUCLEIC ACIDS RES, V17, P1035, DOI 10.1093/nar/17.3.1035; SANDERSON MR, 1990, CELL, V63, P1323, DOI 10.1016/0092-8674(90)90427-G; STARK WM, 1991, EMBO J, V10, P3541, DOI 10.1002/j.1460-2075.1991.tb04918.x; STATES DJ, 1982, J MAGN RESON, V48, P268; VANDEPUTTE P, 1988, TRANSPOSITION, P183; WERBELOW LG, 1973, J AM CHEM SOC, V95, P5132, DOI 10.1021/ja00797a006; [No title captured]	19	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16309	16315						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8393857				2022-12-25	WOS:A1993LQ33600036
J	MCHOWAT, J; CORR, PB				MCHOWAT, J; CORR, PB			THROMBIN-INDUCED RELEASE OF LYSOPHOSPHATIDYLCHOLINE FROM ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PLASMINOGEN-ACTIVATOR-INHIBITOR; CANINE PURKINJE-FIBERS; PROSTACYCLIN PRODUCTION; CORONARY-THROMBOSIS; FIBRINOPEPTIDE-A; RECEPTOR; CALCIUM; ACCUMULATION; DEATH	Lysophosphatidylcholine (LPC) increases extracellularly during ischemia in vivo in both animals and man as judged by measurements from venous effluents, but more recent studies have shown little or no increase in buffer-perfused, isolated heart preparations. The appearance of LPC in blood and lymph in animals and in venous effluents in man in response to ischemia suggests a vascular site for the production of LPC. The present study was performed to assess whether thrombin could stimulate phospholipase A2 in endothelial cells and whether this would evoke an increase in and release of LPC. Endothelial cells were disassociated from canine aortas by incubating with 0.1% collagenase for 20 min. Cells were plated and allowed to grow to confluence. Measurement of LPC was performed using Bligh and Dyer extraction of lipids, high performance liquid chromatography separation, and quantification of LPC using a recently developed radiometric assay employing [H-3]acetic anhydride. Incubation of endothelial cells with thrombin (0.05 unit/ml) resulted in a 2.5-fold increase in LPC to 2.3 +/- 0.1 nmol/mg of protein at 2 min (p < 0.01) and returned to control levels within 20 min. The increase in LPC induced by thrombin exhibited a concentration-dependent response with an ED50 = 0.04 unit/ml. A concentration-dependent increase in LPC was also elicited by stimulation with the peptide portion of the thrombin receptor's tethered ligand SFLLRNPNDKYEPF with an ED50 = 8 muM. The LPC produced was rapidly and completely released into the surrounding media. Hirudin completely blocked the thrombin-induced increase in LPC. Dansylarginine N-(3-ethyl-1,5-pentanediyl)amide (0.1 muM), which rapidly inactivates thrombin's proteolytic activity in situ without impairing binding, or phenyl-prolyl-arginyl-chloromethyl ketone (PPACK, 5 nM), which inactivates thrombin due to chemical alteration of the proteolytic site, each prevented the increase in LPC in response to thrombin. Stimulation of protein kinase C with phorbol 12-myristate-13-acetate (PMA, 1 muM) enhanced the response to thrombin. In contrast, staurosporine (100 nM), H7 (15 muM), or chronic treatment with PMA for 20 h to down-regulate protein kinase C completely prevented the increase in LPC in response to thrombin. Thus, thrombin stimulation of endothelial cells in vivo during ischemia may be a primary mechanism contributing to the marked increase in LPC extracellularly during ischemia.	WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	MCHOWAT, J (corresponding author), WASHINGTON UNIV, SCH MED, DEPT MED, DIV CARDIOVASC, ST LOUIS, MO 63110 USA.			McHowat, Jane/0000-0003-3133-3388	NHLBI NIH HHS [HL-17646, HL-28995] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL017646, R01HL028995, P50HL017646] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKITA H, 1986, J CLIN INVEST, V78, P271, DOI 10.1172/JCI112561; AOMINE M, 1988, Heart and Vessels, V4, P197, DOI 10.1007/BF02058587; Barany G, 1979, PEPTIDES           A, V2, P1; BARTHA K, 1989, BIOCHEM J, V263, P149, DOI 10.1042/bj2630149; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROEKMAN MJ, 1980, J CLIN INVEST, V66, P275, DOI 10.1172/JCI109854; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CORR PB, 1984, CIRC RES, V55, P135, DOI 10.1161/01.RES.55.2.135; CORR PB, 1979, CIRC RES, V44, P822, DOI 10.1161/01.RES.44.6.822; CORR PB, 1981, CIRC RES, V49, P354, DOI 10.1161/01.RES.49.2.354; CREER MH, 1990, CARDIAC ELECTROPHYSI, P417; DATORRE SD, 1991, J MOL CELL CARDIOL, V23, P11, DOI 10.1016/0022-2828(91)90019-I; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; DELUNA AB, 1989, AM HEART J, V117, P151, DOI 10.1016/0002-8703(89)90670-4; DOBMEYER DJ, 1990, ANAL BIOCHEM, V185, P36, DOI 10.1016/0003-2697(90)90251-4; EBELING JG, 1985, P NATL ACAD SCI USA, V82, P815, DOI 10.1073/pnas.82.3.815; EISENBERG PR, 1985, CIRCULATION, V71, P912, DOI 10.1161/01.CIR.71.5.912; FALK E, 1991, AM J CARDIOL, V68, pB28, DOI 10.1016/0002-9149(91)90382-U; FENTON JW, 1989, SEMIN THROMB HEMOST, V15, P265, DOI 10.1055/s-2007-1002718; FUKUSHIMA M, 1989, INVEST OPHTH VIS SCI, V30, P1576; GELEHRTER TD, 1986, J CLIN INVEST, V77, P165, DOI 10.1172/JCI112271; GHIGO D, 1988, J BIOL CHEM, V263, P19437; GRAHAM DJ, 1990, J VASC SURG, V11, P307, DOI 10.1067/mva.1990.17098; GROSS RW, 1983, J BIOL CHEM, V258, P5221; GROSS RW, 1983, J BIOL CHEM, V258, P5165; HALLAM TJ, 1988, BIOCHEM J, V251, P243, DOI 10.1042/bj2510243; HALLDORSSON H, 1991, EUR J PHARM-MOLEC PH, V208, P193, DOI 10.1016/0922-4106(91)90095-Y; HARMON JT, 1986, J BIOL CHEM, V261, P5928; HELLER R, 1991, BIOCHIM BIOPHYS ACTA, V1093, P55, DOI 10.1016/0167-4889(91)90138-N; HIDAKA H, 1987, TRENDS PHARMACOL SCI, V8, P162, DOI 10.1016/0165-6147(87)90155-6; HUANG RS, 1991, J BIOL CHEM, V266, P18435; KAJI T, 1991, THROMB RES, V62, P509, DOI 10.1016/0049-3848(91)90024-Q; KNUPP CL, 1988, THROMB RES, V49, P23, DOI 10.1016/0049-3848(88)90356-8; LEVIN EG, 1991, J BIOL CHEM, V266, P174; LEVIN EG, 1984, J CLIN INVEST, V74, P1988, DOI 10.1172/JCI111620; LIE JT, 1975, CIRCULATION, V52, P41; MAN RYK, 1990, LIPIDS, V25, P450, DOI 10.1007/BF02538087; Markwell M A, 1981, Methods Enzymol, V72, P296; MESZAROS J, 1990, AM J PHYSIOL, V258, pH931, DOI 10.1152/ajpheart.1990.258.4.H931; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NGAIZA JR, 1991, BIOCHEM BIOPH RES CO, V179, P1656, DOI 10.1016/0006-291X(91)91765-5; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; OSHIMA S, 1990, CIRCULATION, V82, P2222, DOI 10.1161/01.CIR.82.6.2222; POLLOCK WK, 1988, BIOCHEM J, V256, P371, DOI 10.1042/bj2560371; PRESCOTT SM, 1984, P NATL ACAD SCI-BIOL, V81, P3534, DOI 10.1073/pnas.81.11.3534; SANO K, 1983, J BIOL CHEM, V258, P2010; SCHINI VB, 1989, EUR J PHARMACOL, V165, P333, DOI 10.1016/0014-2999(89)90733-4; SCHNEIDER DJ, 1992, DIABETES, V41, P890, DOI 10.2337/diabetes.41.7.890; SEDLIS SP, 1990, AM J CARDIOL, V66, P695, DOI 10.1016/0002-9149(90)91132-P; SHANKAR R, 1992, AM J PHYSIOL, V262, pC199, DOI 10.1152/ajpcell.1992.262.1.C199; SNYDER DW, 1981, AM J PHYSIOL, V241, pH700, DOI 10.1152/ajpheart.1981.241.5.H700; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WAGNER WR, 1990, J LAB CLIN MED, V116, P636; WANG FS, 1986, AM J CARDIOL, V58, P491, DOI 10.1016/0002-9149(86)90021-4; WEKSLER BB, 1978, J CLIN INVEST, V62, P923, DOI 10.1172/JCI109220; WHATLEY RE, 1989, J BIOL CHEM, V264, P6325; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775; ZAVOICO GB, 1990, J CELL PHYSIOL, V143, P596, DOI 10.1002/jcp.1041430326	59	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15605	15610						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8393449				2022-12-25	WOS:A1993LN30500044
J	HARPER, ME; BRAND, MD				HARPER, ME; BRAND, MD			THE QUANTITATIVE CONTRIBUTIONS OF MITOCHONDRIAL PROTON LEAK AND ATP TURNOVER REACTIONS TO THE CHANGED RESPIRATION RATES OF HEPATOCYTES FROM RATS OF DIFFERENT THYROID STATUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOLIC CONTROL-THEORY; TOP-DOWN APPROACH; LIVER-MITOCHONDRIA; OXIDATIVE-PHOSPHORYLATION; INNER MEMBRANE; HORMONE; STIMULATION; TRANSPORT; CELLS; CHAIN	Hepatocytes from hypothyroid rats respire more slowly than those from control animals; cells from hyperthyroid rats respire faster. We have identified the blocks of reactions whose kinetics are significantly affected by thyroid hormones and have quantified the contribution of flux through different blocks of energy-dissipating reactions to the altered oxygen consumption. In cells from hypothyroid rats compared with littermate euthyroid controls, there were significant kinetic effects on non-mitochondrial oxygen consumption reactions and on mitochondrial proton leak but not on ATP turnover. Approximately 50% of the decrease in cellular oxygen consumption of hypothyroid cells was accounted for by a decrease in mitochondrial proton leak rate and approximately 50% by decreased non-mitochondrial oxygen consumption. Metabolic control analysis showed that the distribution of control over oxidative phosphorylation and mitochondrial potential in hepatocytes from hypothyroid animals was broadly similar to its distribution in euthyroid controls. In cells from hyperthyroid rats compared with littermate euthyroid controls, there were significant kinetic effects on mitochondrial proton leak and on the reactions involved in ATP synthesis and consumption but not on non-mitochondrial oxygen consumption. Approximately 50% of the increase in cellular oxygen consumption in hyperthyroid cells was accounted for by an increased mitochondrial proton leak rate and the remainder by increased ATP turnover; there were no changes in non-mitochondrial oxygen consumption.			HARPER, ME (corresponding author), UNIV CAMBRIDGE, DEPT BIOCHEM, TENNIS COURT RD, CAMBRIDGE CB2 1QW, ENGLAND.		Brand, Martin D/A-9423-2012	Brand, Martin D/0000-0003-4418-6153; Harper, Mary-Ellen/0000-0003-3864-5886				BABIOR BM, 1973, P NATL ACAD SCI USA, V70, P98, DOI 10.1073/pnas.70.1.98; BAUR H, 1975, H-S Z PHYSIOL CHEM, V356, P827, DOI 10.1515/bchm2.1975.356.s1.827; Berry M N, 1974, Methods Enzymol, V32, P625; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BRAND MD, 1988, BIOCHEM J, V255, P535; BRAND MD, 1993, BIOCHEM J, V291, P739, DOI 10.1042/bj2910739; BRAND MD, 1987, BIOL REV, V62, P141, DOI 10.1111/j.1469-185X.1987.tb01265.x; BRAND MD, 1990, ARCH BIOCHEM BIOPHYS, V283, P278, DOI 10.1016/0003-9861(90)90643-D; BRAND MD, 1992, EUR J BIOCHEM, V206, P775, DOI 10.1111/j.1432-1033.1992.tb16984.x; BRAND MD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P128, DOI 10.1016/0005-2728(90)90232-S; BROWN GC, 1990, EUR J BIOCHEM, V188, P321, DOI 10.1111/j.1432-1033.1990.tb15406.x; BROWN GC, 1990, EUR J BIOCHEM, V192, P355, DOI 10.1111/j.1432-1033.1990.tb19234.x; CARR FE, 1984, P NATL ACAD SCI-BIOL, V81, P974, DOI 10.1073/pnas.81.3.974; CHEN RF, 1967, J BIOL CHEM, V242, P173; CLAUSEN T, 1991, PHYSIOL REV, V71, P733, DOI 10.1152/physrev.1991.71.3.733; CLOT JP, 1982, MOL CELL ENDOCRINOL, V28, P455, DOI 10.1016/0303-7207(82)90139-3; DAUNCEY MJ, 1990, P NUTR SOC, V49, P203, DOI 10.1079/PNS19900024; DAVIS RJ, 1981, BIOCHEM J, V196, P133, DOI 10.1042/bj1960133; FOLKE M, 1977, J PHYSIOL-LONDON, V269, P407, DOI 10.1113/jphysiol.1977.sp011909; FUSI F, 1992, BIOCHEM PHARMACOL, V43, P1203, DOI 10.1016/0006-2952(92)90493-3; GREGORY RB, 1991, BIOCHIM BIOPHYS ACTA, V1133, P89, DOI 10.1016/0167-4889(91)90245-S; GREGORY RB, 1992, J BIOL CHEM, V267, P8903; GROEN AK, 1982, J BIOL CHEM, V257, P2754; Guernsey DL, 1983, MOL BASIS THYROID HO, P293; HAFNER RP, 1988, EUR J BIOCHEM, V178, P511, DOI 10.1111/j.1432-1033.1988.tb14477.x; HAFNER RP, 1990, EUR J BIOCHEM, V188, P313, DOI 10.1111/j.1432-1033.1990.tb15405.x; HAFNER RP, 1990, BIOCHEM J, V265, P731, DOI 10.1042/bj2650731; HAFNER RP, 1989, FEBS LETT, V248, P175, DOI 10.1016/0014-5793(89)80455-7; HIMMSHAGEN J, 1976, ANNU REV PHYSIOL, V38, P315, DOI 10.1146/annurev.ph.38.030176.001531; HOCH FL, 1977, ARCH BIOCHEM BIOPHYS, V178, P535, DOI 10.1016/0003-9861(77)90224-7; HOEK JB, 1980, J BIOL CHEM, V255, P1458; Hoppner W, 1987, Horm Metab Res Suppl, V17, P29; HORRUM MA, 1990, MOL CELL ENDOCRINOL, V68, P137, DOI 10.1016/0303-7207(90)90186-C; HORRUM MA, 1985, MOL CELL ENDOCRINOL, V41, P163, DOI 10.1016/0303-7207(85)90019-X; IMAI Y, 1978, CYTOCHROME P450, P44; ISMAILBEIGI F, 1970, P NATL ACAD SCI USA, V67, P1071, DOI 10.1073/pnas.67.2.1071; JAKOVCIC S, 1978, J CELL BIOL, V77, P887, DOI 10.1083/jcb.77.3.887; KAMINSKY LS, 1985, EUR J BIOCHEM, V149, P479, DOI 10.1111/j.1432-1033.1985.tb08950.x; LAKINTHOMAS PL, 1987, BIOCHEM J, V246, P173, DOI 10.1042/bj2460173; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LOUD AV, 1968, J CELL BIOL, V37, P27, DOI 10.1083/jcb.37.1.27; MAK IT, 1983, ARCH BIOCHEM BIOPHYS, V226, P317, DOI 10.1016/0003-9861(83)90298-9; MIWA GT, 1978, J BIOL CHEM, V253, P1921; NOBLES CD, 1989, BIOCHIM BIOPHYS ACTA, V987, P115; NOBLES CD, 1990, J BIOL CHEM, V265, P12910; NOBLES CD, 1989, J BIOL CHEM, V976, P241; NOBLES CD, 1990, J BIOL CHEM, V265, P12903; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; OPPENHEIMER JH, 1977, J CLIN INVEST, V59, P517, DOI 10.1172/JCI108667; PORTNAY GI, 1973, BIOCHEM BIOPH RES CO, V55, P17, DOI 10.1016/S0006-291X(73)80053-1; RAM PA, 1992, J BIOL CHEM, V267, P3294; SOBOLL S, 1992, BIOCHEM J, V281, P171, DOI 10.1042/bj2810171; STERLING K, 1986, ENDOCRINOLOGY, V119, P292, DOI 10.1210/endo-119-1-292; VERHOEVEN AJ, 1985, BIOCHEM J, V226, P183, DOI 10.1042/bj2260183; Weibel E R, 1969, Int Rev Cytol, V26, P235, DOI 10.1016/S0074-7696(08)61637-X; WIGGANS GN, 1983, BEHAV RES METH INSTR, V15, P609, DOI 10.3758/BF03203736	56	162	164	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14850	14860						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8392060				2022-12-25	WOS:A1993LL75900050
J	KAWAMURA, S; HISATOMI, O; KAYADA, S; TOKUNAGA, F; KUO, CH				KAWAMURA, S; HISATOMI, O; KAYADA, S; TOKUNAGA, F; KUO, CH			RECOVERIN HAS S-MODULIN ACTIVITY IN FROG RODS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CALCIUM-BINDING PROTEIN; OUTER SEGMENTS; RETINAL RODS; GUANYLATE-CYCLASE; LIGHT ADAPTATION; PHOSPHODIESTERASE; PHOSPHORYLATION; RHODOPSIN	In vertebrate photoreceptors, light induces hydrolysis of cGMP by activating cGMP phosphodiesterase (PDE), which results in closure of the cGMP-activated cation channel. During light adaptation, the cytoplasmic Ca2+ concentration decreases, and this decrease is one of the underlying mechanisms of light adaptation. Sensitivity-modulating protein (S-modulin) is a Ca2+-binding protein involved in light adaptation in frog rods; it regulates both the light sensitivity of PDE and the lifetime of activated PDE by controlling rhodopsin phosphorylation in a Ca2+-dependent manner. Recoverin has been reported as a Ca2+-dependent regulator of guanylate cyclase in bovine rods (Dizhoor, A. M., Ray, S., Kumar, S., Niemi, G., Spencer, M., Brolley, D., Walsh, K. A., Philipov, P. P., Hurley, J. B., and Stryer, L. (1991) Science 251, 915-918). Here, we show that recoverin has similar activity as S-modulin, and the amino acid sequences of both proteins are similar. The results strongly suggest that recoverin is bovine S-modulin and regulates PDE activation.	OSAKA UNIV,FAC SCI,DEPT BIOL,TOYONAKA,OSAKA 560,JAPAN; OSAKA UNIV,SCH MED,DEPT PHARMACOL,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University	KAWAMURA, S (corresponding author), KEIO UNIV,SCH MED,DEPT PHYSIOL,SHINANO MACHI 35,SHINJUKU KU,TOKYO 160,JAPAN.							BIERNBAUM MS, 1991, VISUAL NEUROSCI, V7, P499, DOI 10.1017/S0952523800009780; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; KAUPP UB, 1992, ANNU REV PHYSIOL, V54, P153; KAWAMURA S, 1986, BIOCHIM BIOPHYS ACTA, V870, P256, DOI 10.1016/0167-4838(86)90230-X; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KAWAMURA S, 1992, BIOCHEM BIOPH RES CO, V186, P411, DOI 10.1016/S0006-291X(05)80823-X; KAWAMURA S, 1983, BIOCHIM BIOPHYS ACTA, V732, P276, DOI 10.1016/0005-2736(83)90212-2; KAWAMURA S, 1989, J GEN PHYSIOL, V94, P69; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; KUHN H, 1973, BIOCHEMISTRY-US, V12, P2495; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; Maniatis T, 1989, DECONTAMINATION DILU; MATTHEWS HR, 1988, NATURE, V334, P67, DOI 10.1038/334067a0; MCGINNIS JF, 1992, FEBS LETT, V302, P172, DOI 10.1016/0014-5793(92)80433-H; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; MILLAM AH, 1993, VISUAL NEUROSCI, V10, P1; NAKATANI K, 1988, J PHYSIOL-LONDON, V395, P695, DOI 10.1113/jphysiol.1988.sp016942; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; POLANS AS, 1991, J CELL BIOL, V112, P981, DOI 10.1083/jcb.112.5.981; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TERASAWA M, 1992, J BIOL CHEM, V267, P19596; WELLER M, 1975, P NATL ACAD SCI USA, V72, P381, DOI 10.1073/pnas.72.1.381; YAMAGATA K, 1990, NEURON, V2, P469; YAU KW, 1985, NATURE, V313, P579, DOI 10.1038/313579a0	27	146	149	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14579	14582						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8392055				2022-12-25	WOS:A1993LL75900008
J	DALY, MC; XIANG, RH; BUCHHAGEN, D; HENSEL, CH; GARCIA, DK; KILLARY, AM; MINNA, JD; NAYLOR, SL				DALY, MC; XIANG, RH; BUCHHAGEN, D; HENSEL, CH; GARCIA, DK; KILLARY, AM; MINNA, JD; NAYLOR, SL			A HOMOZYGOUS DELETION ON CHROMOSOME-3 IN A SMALL-CELL LUNG-CANCER CELL-LINE CORRELATES WITH A REGION OF TUMOR-SUPPRESSOR ACTIVITY	ONCOGENE			English	Article							SHORT ARM; DNA POLYMORPHISMS; CARCINOMA; GENE; RETINOBLASTOMA; SEQUENCE; 3P; IDENTIFICATION; HETEROZYGOSITY; PROTEIN	Small cell lung cancer (SCLC) tumors frequently display deletions on the short arm of chromosome 3 suggesting the existence of a 'tumor suppressor' gene within that region whose functional inactivation may be involved in tumorigenesis. Recently, a hybrid, HA(3)BB9F, was identified that contains a small fragment of human chromosome 3 of approximately 2 Mb on a mouse (A9) background (Killary et. al., 1992). This hybrid was utilized to define a functional tumor suppressor gene within 3p22-p21 which could suppress the tumorigenic properties of the mouse fibrosarcoma cell line. The existence of a tumor suppressor gene in the region 3p22-p21 is supported by the present report which describes the assessment of 89 SCLC and 32 non-SCLC lung cancer tumors and cell lines for the existence of a homozygous deletion(s) at 43 loci on the short arm of chromosome 3. One of the SCLC cell lines was found to harbor a homozygous deletion involving the loss of five markers on chromosome 3p. All five of the markers map to the region 3p21.3-p21.2 and four of the five markers are located within the chromosome 3 fragment exhibiting properties of tumor suppression in the HA(3)BB9F hybrid. The other tumors analysed all retained at least one copy of each of the markers assessed.	UNIV TEXAS,SW MED CTR,SIMMONS CANC INST,DALLAS,TX 75235; UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,HOUSTON,TX 77030; UNIFORMED SERV UNIV HLTH SCI,DEPT MED,MED ONCOL BRANCH,NCI NAVY MED ONCOL BRANCH,BETHESDA,MD 20814	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA	DALY, MC (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.				NATIONAL CANCER INSTITUTE [R29CA044764] Funding Source: NIH RePORTER; NCI NIH HHS [CA44764] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGERHEIM U, 1989, CANCER RES, V49, P1390; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; DALY MC, 1991, GENOMICS, V9, P113, DOI 10.1016/0888-7543(91)90227-6; DELEIJ L, 1985, CANCER RES, V45, P6024; DIDSBURY JR, 1987, FEBS LETT, V211, P160, DOI 10.1016/0014-5793(87)81428-X; DRABKINHA, 1992, GENE CHROMOSOME CANC, V5, P67; DRYJA TP, 1984, NEW ENGL J MED, V310, P550, DOI 10.1056/NEJM198403013100902; FALOR WH, 1985, CANCER GENET CYTOGEN, V16, P175, DOI 10.1016/0165-4608(85)90012-3; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5434, DOI 10.1073/pnas.85.15.5434; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GARCIA DK, 1991, CYTOGENET CELL GENET, V58, P225; GEIHL D, 1989, CYTOGENET CELL GENET, V51, P1001; GORADIA TM, 1991, GENOMICS, V10, P748, DOI 10.1016/0888-7543(91)90459-R; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; HEPPELLPARTON AC, 1992, GENE CHROMOSOME CANC, V4, P228, DOI 10.1002/gcc.2870040307; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; JOHNSON BE, 1989, J NATL CANCER I, V81, P1223, DOI 10.1093/jnci/81.16.1223; JOHNSON BE, 1988, J CLIN INVEST, V82, P502, DOI 10.1172/JCI113624; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1989, CANCER RES, V49, P651; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEWIS W H, 1988, Genomics, V3, P25, DOI 10.1016/0888-7543(88)90154-1; MULERIS M, 1987, INT J CANCER, V39, P595, DOI 10.1002/ijc.2910390509; NAYLOR S, 1991, CYTOGENET CELL GENET, V58, P170, DOI 10.1159/000133163; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUTHERLAND GR, 1988, AM J HUM GENET, V43, P331; WATERS JJ, 1988, CANCER GENET CYTOGEN, V6, P119; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; YOKOTA J, 1989, CANCER RES, V49, P3598; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; ZHANG R, 1989, CANCER RES, V49, P444	40	116	124	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1721	1729						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8390035				2022-12-25	WOS:A1993LG68200002
J	MONTERO, M; GARCIASANCHO, J; ALVAREZ, J				MONTERO, M; GARCIASANCHO, J; ALVAREZ, J			TRANSIENT INHIBITION BY CHEMOTACTIC PEPTIDE OF A STORE-OPERATED CA2+ ENTRY PATHWAY IN HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; CALCIUM ENTRY; CA-2+ CONCENTRATION; PHORBOL ESTER; ACINAR-CELLS; INFLUX; THAPSIGARGIN; ACTIVATION; POOL; 2,5-DI-(TERT-BUTYL)-1,4-BENZOHYDROQUINONE	Emptying the intracellular calcium stores of fura-2-loaded human neutrophils by treatment with the endomembrane ATPase inhibitor thapsigargin leads to a maintained increase of [Ca+]i by Ca2+ entry through a store-operated Ca2+ entry pathway. Under these conditions, [Ca2+]i was reduced transiently by N-formyl-methionyl-leucyl-phenylalanine (fMLP) and permanently by phorbol 12,13-dibutyrate (PDB). Platelet-activating factor (PAF) had no effect. The fMLP- and PDB-induced [Ca2+]i decreases were not due to stimulated Ca2+ efflux but to inhibition of store-operated Ca2+ entry pathway. PDB and fMLP, but not PAF, inhibited the entry of Ca2+, Mn2+, and Ba2+ in thapsigargin-treated cells. This inhibition was dependent on [Ca2+]i, barely detectable at [Ca2+]i of 50 nM and increasingly strong and fast to appear at 170 and 630 nM. Inhibition of entry by fMLP was complete within 5-10 s, disappeared within 2-3 min, and was partially prevented by staurosporin (100 nM). Inhibition by PDB was equally fast, but no recovery was detected within 5 min, and it was fully prevented by staurosporin. The inhibitory effect of fMLP had similar characteristics when PAF was used instead of thapsigargin to induce the entry of Ca2+ or Mn2+. We conclude that fMLP, but not PAF, is able to produce a transient inhibition of store-operated Ca2+ entry pathway, probably mediated by protein kinase C. This action could be part of a general homeostatic mechanism designed to moderate [Ca2+]i increases induced by some agonists.	UNIV VALLADOLID, FAC MED, DEPT BIOQUIM & BIOL MOLEC & FISIOL, E-47005 VALLADOLID, SPAIN	Universidad de Valladolid			Montero, Mayte/K-8212-2014; Alvarez, Javier/K-8210-2014; Garcia-Sancho, Javier/K-2975-2014	Montero, Mayte/0000-0001-7702-6653; Alvarez, Javier/0000-0003-0636-5521; Garcia-Sancho, Javier/0000-0003-4573-7930				ALONSO MT, 1990, BIOCHEM J, V272, P435, DOI 10.1042/bj2720435; ANDERSSON T, 1986, MOL PHARMACOL, V30, P437; CLEMENTI E, 1992, J BIOL CHEM, V267, P2164; DIVIRGILIO F, 1987, J BIOL CHEM, V262, P4574; GELAS P, 1992, BIOCHEM J, V287, P67, DOI 10.1042/bj2870067; GOLDSTEIN IM, 1973, J IMMUNOL, V111, P3; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; KASS GEN, 1989, J BIOL CHEM, V264, P15192; KORCHAK HM, 1984, J BIOL CHEM, V259, P4070; KWAN CY, 1990, J BIOL CHEM, V265, P678; LAGAST H, 1984, J CLIN INVEST, V73, P878, DOI 10.1172/JCI111284; LLOPIS J, 1992, BIOCHEM J, V284, P243, DOI 10.1042/bj2840243; LLOPIS J, 1991, BIOCHEM J, V277, P553, DOI 10.1042/bj2770553; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MCCARTHY SA, 1989, BIOCHEM J, V264, P357, DOI 10.1042/bj2640357; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MONTERO M, 1991, BIOCHEM J, V277, P73, DOI 10.1042/bj2770073; MONTERO M, 1992, BIOCHEM J, V288, P519, DOI 10.1042/bj2880519; NACCACHE PH, 1985, BIOCHEM BIOPH RES CO, V130, P677, DOI 10.1016/0006-291X(85)90470-X; NEYLON CB, 1991, J BIOL CHEM, V266, P4251; PERIANIN A, 1989, J BIOL CHEM, V264, P1005; POZZAN T, 1983, SCIENCE, V221, P1413, DOI 10.1126/science.6310757; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RICKARD JE, 1985, BIOCHEM J, V231, P623, DOI 10.1042/bj2310623; SAGE SO, 1992, BIOCHEM J, V285, P341, DOI 10.1042/bj2850341; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1987, BIOCHEM BIOPH RES CO, V142, P654, DOI 10.1016/0006-291X(87)91464-1	29	75	75	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13055	13061						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8390453				2022-12-25	WOS:A1993LH55300010
J	BRAND, T; MACLELLAN, WR; SCHNEIDER, MD				BRAND, T; MACLELLAN, WR; SCHNEIDER, MD			A DOMINANT-NEGATIVE RECEPTOR FOR TYPE-BETA TRANSFORMING GROWTH-FACTORS CREATED BY DELETION OF THE KINASE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MYOGENIC DIFFERENTIATION; EXPRESSION CLONING; GENE-EXPRESSION; MAMMALIAN-CELLS; PROTEIN; GALACTOSIDASE	To prove the postulated role of type beta transforming growth factors (TGFbeta) in cardiac development and other events, specific inhibitors of TGFbeta signal transduction are needed. We truncated the type II TGFbeta receptor cDNA (DELTAkTbetaRII), to delete the predicted serine/threonine kinase cytoplasmic domain. DELTAkTbetaRII was co-transfected into neonatal cardiac myocytes, together with reporter constructs for two cardiac-restricted genes that are regulated antithetically by TGFbeta. DELTAkTbetaRII impaired activation of the skeletal alpha-actin promoter by TGFbeta1, -2, and -3 and, conversely, impaired TGFbeta inhibition of alpha-myosin heavy chain transcription. Thus, a kinase-defective TbetaRII blocks signaling by all three mammalian TGFbeta isoforms, and can disrupt both positive and negative control of transcription by TGFbeta.	BAYLOR COLL MED,DEPT MED,MOLEC CARDIOL UNIT,1 BAYLOR PLAZA,RM 506C,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine			Brand, Thomas/AAR-7545-2020	Brand, Thomas/0000-0001-7090-5356	NHLBI NIH HHS [R01 HL39141, T32 HL07706, R01 HL47567] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039141, R01HL047567, T32HL007706] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BHAMBI B, 1991, AM J PATHOL, V139, P1131; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEFER AM, 1990, SCIENCE, V249, P61, DOI 10.1126/science.2164258; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZ AR, 1992, MOL CELL BIOL, V12, P1674, DOI 10.1128/MCB.12.4.1674; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MCBRIDE K, 1993, MOL CELL BIOL, V13, P600, DOI 10.1128/MCB.13.1.600; MUSLIN AJ, 1991, DEVELOPMENT, V112, P1095; NAKAMURA T, 1992, J BIOL CHEM, V267, P18924; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; PARKER TG, 1990, P NATL ACAD SCI USA, V87, P7066, DOI 10.1073/pnas.87.18.7066; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; POTTS JD, 1991, P NATL ACAD SCI USA, V88, P1516, DOI 10.1073/pnas.88.4.1516; ROBERTS AB, 1992, J CLIN INVEST, V90, P2056, DOI 10.1172/JCI116087; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SCHNEIDER M D, 1991, Progress in Growth Factor Research, V3, P1, DOI 10.1016/0955-2235(91)90010-2; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Thompson NL, 1988, GROWTH FACTORS, V1, P91, DOI 10.3109/08977198809000251; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; UENO H, 1992, J BIOL CHEM, V267, P1470; VANDENEIJNDENVANRAAIJ AJM, 1991, MECH DEVELOP, V33, P157, DOI 10.1016/0925-4773(91)90082-H; VILLARREAL FJ, 1992, AM J PHYSIOL, V262, pH1861, DOI 10.1152/ajpheart.1992.262.6.H1861; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WOOD KV, 1991, BIOLUMINESCENCE AND CHEMILUMINESCENCE, P11; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; ZENTELLA A, 1992, P NATL ACAD SCI USA, V89, P5176, DOI 10.1073/pnas.89.11.5176; ZHUANG Y, 1992, P NATL ACAD SCI USA, V89, P12132, DOI 10.1073/pnas.89.24.12132	47	111	115	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11500	11503						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8389353				2022-12-25	WOS:A1993LF28400008
J	LUTZ, MP; PINON, DI; GATES, LK; SHENOLIKAR, S; MILLER, LJ				LUTZ, MP; PINON, DI; GATES, LK; SHENOLIKAR, S; MILLER, LJ			CONTROL OF CHOLECYSTOKININ RECEPTOR DEPHOSPHORYLATION IN PANCREATIC ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASES; PHOSPHORYLATION; RHODOPSIN; ANTIGEN	Phosphorylation of cell surface receptors regulates the physiological response to many hormones and neurotransmitters. We have demonstrated that the receptor for cholecystokinin (CCK), the major secretagogue for the exocrine pancreas, is phosphorylated on serines in response to CCK (Klueppelberg, U. G., Gates, L. K., Gorelick, F. S., and Miller, L. J. (1991) J. Biol. Chem. 266, 2403-2408). Receptor phosphorylation was transient, even in the continued presence of agonist, and suggested a role for pancreatic protein phosphatases (PP) in regulating receptor phosphorylation in the intact cell. Treatment of acinar cells with okadaic acid increased the extent and duration of receptor phosphorylation induced by CCK. Receptor phosphorylated in the intact cell in response to CCK was used as substrate to analyze protein phosphatases in pancreatic acinar cell extracts. The predominant CCK receptor phosphatase activity was found in the cytosol and was potently inhibited by okadaic acid (IC50 = 0.2 nM). This phosphatase activity was unaffected by inhibitor-2, Ca2+, or Me+, suggesting that the major receptor phosphatase was PP-2A. Stimulation of cells with CCK resulted in a 3-fold increase in protein phosphatase activity toward the CCK receptor, at the same time that phosphorylase a phosphatase activity was unchanged. This increase in receptor phosphatase activity was reflected only in the cytosol, with the particulate activity unchanged. Consistent with this subcellular localization, the hormone-regulated receptor phosphatase activity was PP-2A, with chromatographic separation demonstrating activity in both PP-2A1 and PP-2A2 forms. These data suggest that CCK coordinates the activity of both protein kinases and phosphatases acting on the CCK receptor to control the extent and duration of receptor phosphorylation in the pancreatic acinar cell.	MAYO CLIN & MAYO FDN, CTR BASIC RES DIGEST DIS, GUGGENHEIM 17, ROCHESTER, MN 55905 USA; DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA	Mayo Clinic; Duke University				Lutz, Manfred/0000-0003-1989-4553	NIDDK NIH HHS [DK36466, DK32878] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032878, R37DK032878, R01DK036466] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRAUTIGAN DL, 1988, METHOD ENZYMOL, V159, P339; BRUZZONE R, 1985, BIOCHEM J, V226, P621, DOI 10.1042/bj2260621; BURNHAM DB, 1982, J BIOL CHEM, V257, P523; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; FOWLES C, 1989, BIOCHEMISTRY-US, V28, P9385, DOI 10.1021/bi00450a020; FREEDMAN SD, 1982, J CELL BIOL, V95, P903, DOI 10.1083/jcb.95.3.903; GAISANO HY, 1989, J CLIN INVEST, V83, P321, DOI 10.1172/JCI113877; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; KLUEPPELBERG UG, 1991, J BIOL CHEM, V266, P2403; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; MILLER LJ, 1992, BIOCHEM BIOPH RES CO, V183, P396, DOI 10.1016/0006-291X(92)90494-6; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; SHENOLIKAR S, 1984, METHOD ENZYMOL, V107, P102; SHENOLIKAR S, 1991, ADV 2ND MESSENGER PH, V23, P1; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SILBERMAN SR, 1984, J BIOL CHEM, V259, P2913; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; WILLIAMS JA, 1987, REGUL PEPTIDES, V18, P109, DOI 10.1016/0167-0115(87)90041-3; YANG SD, 1988, J BIOL CHEM, V263, P8856	26	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12136	12142						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8389371				2022-12-25	WOS:A1993LF28400100
J	NAKAMURA, S				NAKAMURA, S			POSSIBLE ROLE OF PHOSPHORYLATION IN THE FUNCTION OF CHICKEN MYOD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC ENHANCER; CREATINE-KINASE GENE; LOOP-HELIX PROTEINS; DNA-BINDING; EXPRESSION VECTORS; TRICHOPLUSIA-NI; CHAIN ENHANCER; MYC HOMOLOGY; REGION; FIBROBLASTS	Chicken MyoD1 (CMD1), an equivalent to the mouse MyoD1, expressed in chicken skeletal muscle (Lin, Z.Y., Dechesne, C. A., Eldridge, J., and Paterson, B. M. (1989) Genes & Dev. 3, 986-996), was produced in Spodoptera frugiperda (Sf9) cells by Baculovirus expression vector and purified to almost homogeneity. This CMD1 was directly demonstrated to be a phosphoprotein by a P-32-labeling experiment. Phosphoamino acid analysis revealed that only serine residue was phosphorylated. Phosphoamino acid of CMD1 from chick primary culture of 11-day embryonic breast muscle was also serine. Electrophoretic mobility on SDS-polyacrylamide gel electrophoresis of the phosphorylated CMD1 produced in Sf9 cells and that obtained from primary culture of muscle were indistinguishable. Gel retardation and methylation interference assays showed that purified CMD1 bound specifically to the mouse muscle creatine kinase enhancer in combination with the in vitro translated E12. CMD1 alone had almost no affinity to the target DNA. When purified CMD1 was treated with calf intestinal phosphatase, its affinity to the target DNA in combination with E12 was reduced by approximately 5-fold. The affinity recovered at least partially by possible rephosphorylation of CMD1 by kinase(s) contained in wheat germ extract. These results suggested that phosphorylation of CMD1 could be involved in the regulation of muscle differentiation.	NCI,BIOCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BOHMANN D, 1990, CANCER CELL-MON REV, V2, P337; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN T, 1990, NATURE, V346, P663, DOI 10.1038/346663a0; BRAUN T, 1991, EUR J BIOCHEM, V198, P187, DOI 10.1111/j.1432-1033.1991.tb16000.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; GRACE TDC, 1962, NATURE, V195, P788, DOI 10.1038/195788a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HINK WF, 1970, NATURE, V226, P466, DOI 10.1038/226466b0; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; Karin M, 1991, CURR OPIN CELL BIOL, V3, P467, DOI 10.1016/0955-0674(91)90075-A; KELLY DC, 1983, J GEN VIROL, V64, P1915, DOI 10.1099/0022-1317-64-9-1915; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LIN ZY, 1989, GENE DEV, V3, P986, DOI 10.1101/gad.3.7.986; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NICHOL JC, 1948, J AM CHEM SOC, V70, P80, DOI 10.1021/ja01181a025; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PATERSON B, 1972, DEV BIOL, V29, P113, DOI 10.1016/0012-1606(72)90050-4; Paterson B M, 1981, Gene Amplif Anal, V2, P417; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINBERGER J, 1986, NATURE, V322, P846, DOI 10.1038/322846a0; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	41	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11670	11677						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8389359				2022-12-25	WOS:A1993LF28400034
J	CHEN, AJ; POULTER, CD				CHEN, AJ; POULTER, CD			PURIFICATION AND CHARACTERIZATION OF FARNESYL DIPHOSPHATE GERANYLGERANYL DIPHOSPHATE SYNTHASE - A THERMOSTABLE BIFUNCTIONAL ENZYME FROM METHANOBACTERIUM-THERMOAUTOTROPHICUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYROPHOSPHATE SYNTHETASE; SACCHAROMYCES-CEREVISIAE; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; ARCHAEBACTERIA; GENE; PRENYLTRANSFERASE; BIOSYNTHESIS; HOMOGENEITY; SEQUENCE	Farnesyl diphosphate (FPP)/geranylgeranyl diphosphate (GGPP) synthase, a bifunctional enzyme that synthesizes C15 and C20 isoprenoid diphosphates from isopentenyl diphosphate and dimethylallyl diphosphate, was purified to homogeneity from the archaebacterium Methanobacterium thermoautotrophicum. The only activities detected from synthesis of FPP and GGPP copurified through (NH4)2SO4 precipitation and four chromatographic steps. The pure enzyme was a 79-kDa homodimer that catalyzed the sequential addition of isopentenyl diphosphate to dimethylallyl diphosphate, geranyl diphosphate, and FPP by a nonprocessive mechanism which allowed substantial amounts of FPP to accumulate during turnover, creating a pool for further elongation to GGPP or for synthesis of squalene. The bifunctional enzyme required Mg2+ or Mn2+ and was optimally active at 65-degrees-C. Catalysis of chain elongation in M. thermoautotrophicum differs from related reactions in eubacteria and eukaryotes, where distinct FPP synthases and GGPP synthases are found.	UNIV UTAH,DEPT CHEM,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021328, R37GM021328] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 21328] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO WR, 1992, J BIOL CHEM, V267, P7582; ANDERSON MS, 1989, J BIOL CHEM, V264, P19176; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; BARNARD GF, 1978, BIOCHEM BIOPH RES CO, V85, P1097, DOI 10.1016/0006-291X(78)90655-1; BEST AN, 1978, J BACTERIOL, V133, P240, DOI 10.1128/JB.133.1.240-250.1978; BRINKHAUS FL, 1988, ARCH BIOCHEM BIOPHYS, V266, P607, DOI 10.1016/0003-9861(88)90293-7; BULOCK JD, 1983, BIOSYNTHESIS ISOPREN, V2, P159; Creighton T. E., 1989, PROTEIN STRUCTURE PR, P155; DANIELS L, 1984, BIOCHIM BIOPHYS ACTA, V768, P113, DOI 10.1016/0304-4173(84)90002-8; DAVISSON VJ, 1986, J ORG CHEM, V51, P4768, DOI 10.1021/jo00375a005; DEROSA M, 1986, SYST APPL MICROBIOL, V7, P278; DEROSA M, 1988, PROG LIPID RES, V27, P153, DOI 10.1016/0163-7827(88)90011-2; DING VDH, 1991, BIOCHEM J, V275, P61, DOI 10.1042/bj2750061; DOGBO O, 1987, BIOCHIM BIOPHYS ACTA, V920, P140, DOI 10.1016/0005-2760(87)90253-0; DOGBO O, 1988, P NATL ACAD SCI USA, V85, P7054, DOI 10.1073/pnas.85.19.7054; EBERHARDT NL, 1975, J BIOL CHEM, V250, P863; EPSTEIN WW, 1991, P NATL ACAD SCI USA, V88, P9668, DOI 10.1073/pnas.88.21.9668; FOX GE, 1980, SCIENCE, V209, P457, DOI 10.1126/science.6771870; FUJISAKI S, 1990, J BIOCHEM-TOKYO, V108, P995, DOI 10.1093/oxfordjournals.jbchem.a123327; Garfin DE, 1990, METHOD ENZYMOL, P425; HEATHCOCK CH, 1985, SCIENCE, V229, P862, DOI 10.1126/science.3927485; HEIDE L, 1989, ARCH BIOCHEM BIOPHYS, V273, P331, DOI 10.1016/0003-9861(89)90491-8; HUGUENEY P, 1990, FEBS LETT, V273, P235, DOI 10.1016/0014-5793(90)81093-4; Kandler O., 1985, BACTERIA, P413; LAFERRIERE A, 1991, BIOCHIM BIOPHYS ACTA, V1077, P167, DOI 10.1016/0167-4838(91)90054-4; LANGWORTHY TA, 1982, ZBL BAKT MIK HYG I C, V3, P228, DOI 10.1016/S0721-9571(82)80036-7; LASKOVICS FM, 1981, BIOCHEMISTRY-US, V20, P1893, DOI 10.1021/bi00510a027; MATSUOKA S, 1991, J BIOL CHEM, V266, P3464; Poulter C. D., 1981, BIOSYNTHESIS ISOPREN, V1, P161; REED BC, 1975, BIOCHEMISTRY-US, V14, P50, DOI 10.1021/bi00672a009; SAGAMI H, 1984, BIOCHEM INT, V8, P661; SASIAK K, 1988, ARCH BIOCHEM BIOPHYS, V260, P622, DOI 10.1016/0003-9861(88)90490-0; SCHMID G, 1982, ZBL BAKT MIK HYG I C, V3, P209, DOI 10.1016/S0721-9571(82)80034-3; SCOPES RK, 1987, PROTEIN PURIFICATION, P306; SHECHTER I, 1992, J BIOL CHEM, V267, P8628; SUGA T, 1991, PHYTOCHEMISTRY, V30, P1757, DOI 10.1016/0031-9422(91)85007-M; TAKAHASHI I, 1982, J BIOCHEM-TOKYO, V92, P1527, DOI 10.1093/oxfordjournals.jbchem.a134077; TAKAHASHI I, 1981, J BIOCHEM-TOKYO, V89, P1581, DOI 10.1093/oxfordjournals.jbchem.a133352; TORNABENE TG, 1978, J MOL EVOL, V11, P259, DOI 10.1007/BF01734487; VOGELS GD, 1982, ZBL BAKT MIK HYG I C, V3, P258, DOI 10.1016/S0721-9571(82)80038-0; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; WOESE CR, 1981, SCI AM, V244, P98, DOI 10.1038/scientificamerican0681-98; YEH LS, 1977, ARCH BIOCHEM BIOPHYS, V183, P718, DOI 10.1016/0003-9861(77)90405-2; ZHANG DL, 1990, J AM CHEM SOC, V112, P1264, DOI 10.1021/ja00159a067; ZILLIG W, 1982, ZBL BAKT MIK HYG I C, V3, P218, DOI 10.1016/S0721-9571(82)80035-5	45	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11002	11007						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8388380				2022-12-25	WOS:A1993LD46600046
J	CHEVALLIERMULTON, MC; SCHWEIGHOFFER, F; BARLAT, I; BAUDOUY, N; FATH, I; DUCHESNE, M; TOCQUE, B				CHEVALLIERMULTON, MC; SCHWEIGHOFFER, F; BARLAT, I; BAUDOUY, N; FATH, I; DUCHESNE, M; TOCQUE, B			SACCHAROMYCES-CEREVISIAE CDC25(1028-1589) IS A GUANINE-NUCLEOTIDE RELEASING-FACTOR FOR MAMMALIAN RAS PROTEINS AND IS ONCOGENIC IN NIH3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE PATHWAY; POLYOMA-VIRUS ENHANCER; CDC25 GENE-PRODUCT; GDP-GTP EXCHANGE; WILD-TYPE; DOMAIN; YEAST; ACTIVATION; REQUIREMENT; SUPPRESSES	The best characterized yeast guanine nucleotide releasing factor is CDC25, which acts on RAS and thereby stimulates cAMP production in Saccharomyces cerevisiae. In order to determine if CDC25 could be a specific GDP-GTP releasing factor for the mammalian proteins Ha-ras, Ki-ras, and N-ras, its functions were studied both in vitro and in NIH3T3 cells. The 561 amino acids composing the C-terminal domain of CDC25 (CDC25 C-domain) released guanine nucleotides (both GDP and GTP) from Ha-, Ki-, and N-ras but not from Rap1A, Rab5, and Rab11. CDC25 acted on oncogenically activated Ha-ras even if the last 23 amino acids (167-189) of the Ras proteins were not present. CDC25 transformed NIH3T3 cells; its transforming capacity was enhanced by overexpression of wild-type Ha-ras. CDC25 C-domain probably exerts its effects through the activation of cellular Ras proteins. These data suggest that the CDC25 C-domain can function as an upstream activator of Ras proteins in a heterologous system and therefore could be a useful tool to study the regulation of Ras activation by growth factor receptors.	RHONE POULENC RORER,IBV,CRVA,MOLEC ONCOL LAB,13 QUAI JULES GUESDE,F-94403 VITRY,FRANCE	Sanofi-Aventis; Sanofi France								BARLAT I, 1993, ONCOGENE, V8, P215; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOYMARCOTTE E, 1989, GENE, V77, P21, DOI 10.1016/0378-1119(89)90355-7; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; CAMONIS JH, 1988, MOL CELL BIOL, V8, P2980, DOI 10.1128/MCB.8.7.2980; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; CRECHET JB, 1990, J BIOL CHEM, V265, P1563; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DAMAK F, 1991, MOL CELL BIOL, V11, P202, DOI 10.1128/MCB.11.1.202; DEFEOJONES D, 1985, SCIENCE, V228, P179, DOI 10.1126/science.3883495; DESCHENES RJ, 1987, MOL CELL BIOL, V7, P2344, DOI 10.1128/MCB.7.7.2344; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; GARREAU H, 1990, FEBS LETT, V269, P53, DOI 10.1016/0014-5793(90)81117-7; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HUGHES DA, 1990, NATURE, V344, P355, DOI 10.1038/344355a0; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; MARSHALL MS, 1987, MOL CELL BIOL, V7, P2309, DOI 10.1128/MCB.7.7.2309; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MUNDER T, 1992, MOL CELL BIOL, V12, P2091, DOI 10.1128/MCB.12.5.2091; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; REY I, 1989, MOL CELL BIOL, V9, P3904, DOI 10.1128/MCB.9.9.3904; REY I, 1991, ONCOGENE, V6, P347; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; WASYLYK B, 1988, P NATL ACAD SCI USA, V85, P7952, DOI 10.1073/pnas.85.21.7952; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0	32	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11113	11118						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8388382				2022-12-25	WOS:A1993LD46600060
J	KEEFER, JR; LIMBIRD, LE				KEEFER, JR; LIMBIRD, LE			THE ALPHA(2A)-ADRENERGIC RECEPTOR IS TARGETED DIRECTLY TO THE BASOLATERAL MEMBRANE DOMAIN OF MADIN-DARBY CANINE KIDNEY-CELLS INDEPENDENT OF COUPLING TO PERTUSSIS TOXIN-SENSITIVE GTP-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; EPITHELIAL-CELLS; ALPHA-2-ADRENERGIC RECEPTOR; MECHANISM; SURFACE; GLYCOPROTEINS; BIOGENESIS; AGONIST; COMPLEX; NA+	The alpha2-adrenergic receptor (alpha2-AR) is a member of the seven transmembrane-spanning G-protein-coupled receptor superfamily. In the kidney, the alpha2-AR is most abundant in the epithelial cells of the proximal tubule where it is important in enhancing Na+ reabsorption via the modulation of Na+/H+ exchange. Radioligand binding and physiological studies suggest that the alpha2-AR resides primarily on the basolateral surface of these proximal tubule cells in vivo. To investigate the mechanisms underlying alpha2-AR polarization in epithelial cells, we permanently expressed wild-type and an epitope-tagged version of the alpha2A-AR in Madin-Darby canine kidney (MDCK) cells. Using a steady-state surface biotinylation assay, we observe that 80-90% of the alpha2A-AR in MDCK cell clones is located on the basolateral membrane domain. Immunolocalization studies confirm the biotinylation results and demonstrate that the alpha2A-AR is actually confined primarily to the lateral domain of the basolateral surface. Metabolic labeling experiments suggest that basolateral polarization of the alpha2A-AR is achieved by direct targeting of the receptor to the basolateral domain. Targeting of the alpha2A-AR to the basolateral surface is not perturbed by pertussis toxin-treatment of MDCK cells, suggesting that coupling of the alpha2A-AR to GTP-binding proteins is not important for receptor polarization.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232	Vanderbilt University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL043671, R01HL025182, R01HL043671] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 43671, HL 25182] Funding Source: Medline; NIGMS NIH HHS [GM 07347] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; CHAN YL, 1980, J PHARMACOL EXP THER, V215, P65; CLARK JD, 1990, AM J PHYSIOL, V259, pF977, DOI 10.1152/ajprenal.1990.259.6.F977; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; GERHARDT MA, 1990, MOL PHARMACOL, V38, P214; GUYER CA, 1990, J BIOL CHEM, V265, P17318; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; LANIER SM, 1986, MOL PHARMACOL, V29, P219; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131; MATSUSHIMA Y, 1987, JPN J PHARMACOL, V45, P284, DOI 10.1254/jjp.45.284; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; NEUBIG RR, 1988, BIOCHEMISTRY-US, V27, P2374, DOI 10.1021/bi00407a019; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; POWELL SK, 1991, NATURE, V353, P76, DOI 10.1038/353076a0; RINDLER MJ, 1984, J CELL BIOL, V98, P1304, DOI 10.1083/jcb.98.4.1304; ROSS EM, 1988, COLD SPRING HARB SYM, V53, P499, DOI 10.1101/SQB.1988.053.01.057; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; SUMMERS RJ, 1984, FED PROC, V43, P2917; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	24	69	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11340	11347						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8388390				2022-12-25	WOS:A1993LD46600091
J	LAURAEUS, M; WIKSTROM, M				LAURAEUS, M; WIKSTROM, M			THE TERMINAL QUINOL OXIDASES OF BACILLUS-SUBTILIS HAVE DIFFERENT ENERGY-CONSERVATION PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; COUPLING SITE-1; CYTOCHROME-O; INHIBITION; ORGANISMS	We have analyzed the respiratory chains in the logarithmic and stationary growth phases of Bacillus subtilis cells grown in rich glucose medium. The cytochrome c branch of the respiratory chain was absent from both types of cells, which used a quinol oxidase branch for respiration. Cytochrome aa3-600 was found to be the major terminal oxidase in log phase cells. This enzyme was shown to translocate protons across the membrane in addition to the charge separation in the oxidation of quinol. Both cytochromes d and aa3-600 were expressed in the stationary phase. After inhibition of the latter by cyanide, cytochrome d was shown to catalyze charge separation during quinol oxidation, but not to pump protons across the membrane. A CO-binding membrane-bound cytochrome of approximately 17 kDa, called cytochrome b558, was presented in log phase cells. This protein did not exhibit oxidase activity and did not have the characteristics of members of the conserved terminal oxidase family.			LAURAEUS, M (corresponding author), UNIV HELSINKI,DEPT MED CHEM,HELSINKI BIOENERGET GRP,SILTAVUORENPENGER 10,SF-00170 HELSINKI 17,FINLAND.		Wikstrom, Marten KF/A-4403-2008					ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; Anthony C, 1988, BACTERIAL ENERGY TRA; BERGSMA J, 1982, EUR J BIOCHEM, V128, P151; BERGSMA J, 1981, EUR J BIOCHEM, V120, P599, DOI 10.1111/j.1432-1033.1981.tb05742.x; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURAEUS M, 1991, EUR J BIOCHEM, V197, P699, DOI 10.1111/j.1432-1033.1991.tb15961.x; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; PUUSTINEN A, 1991, P NATL ACAD SCI USA, V88, P6122, DOI 10.1073/pnas.88.14.6122; PUUSTINEN A, 1991, BIOCHEMISTRY-US, V30, P3936, DOI 10.1021/bi00230a019; SANTANA M, 1992, J BIOL CHEM, V267, P10225; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; YAGI T, 1990, ARCH BIOCHEM BIOPHYS, V281, P305, DOI 10.1016/0003-9861(90)90448-8; YAGI T, 1987, BIOCHEMISTRY-US, V26, P2822, DOI 10.1021/bi00384a025	14	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11470	11473						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8388393				2022-12-25	WOS:A1993LD46600108
J	POWERS, PA; LIU, SY; HOGAN, K; GREGG, RG				POWERS, PA; LIU, SY; HOGAN, K; GREGG, RG			MOLECULAR CHARACTERIZATION OF THE GENE ENCODING THE GAMMA-SUBUNIT OF THE HUMAN SKELETAL-MUSCLE 1,4-DIHYDROPYRIDINE-SENSITIVE CA2+ CHANNEL (CACNLG), CDNA SEQUENCE, GENE STRUCTURE, AND CHROMOSOMAL LOCATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERKALEMIC PERIODIC PARALYSIS; SENSITIVE CALCIUM CHANNELS; BETA-SUBUNIT; PARAMYOTONIA-CONGENITA; VERTEBRATE CELLS; ALPHA-SUBUNIT; BRAIN; RECEPTOR; LINKAGE; ALPHA-1-SUBUNIT	cDNA clones of the gamma subunit of the skeletal muscle 1,4-dihydropyridine-sensitive voltage-dependent Ca2+ channel were isolated from a human fetal skeletal muscle cDNA library using the rabbit gamma cDNA as a probe. The DNA sequence of the entire human cDNA was determined. Cosmids that contained the human gamma gene were isolated and used to determine the genomic organization of the coding sequences. Four exons were identified, spanning 12.5 kilobases of DNA. Reverse-transcribed polymerase chain reaction analysis detected the gamma transcript in human and mouse skeletal muscle RNAs, but not in RNA from human brain or cardiac muscle or from mouse brain, cardiac muscle, spleen, kidney, liver, or stomach. A polymorphic dinucleotide repeat within the gamma gene was identified. This repeat was used to type a subset of the Centre d'Etude du Polymorphisme Humain families. Linkage analysis indicates that the gamma gene is tightly linked (Z = 12.94, THETA = 0.001) to growth hormone at chromosome 17q23, a region that also contains the adult skeletal muscle Na+ channel.	UNIV WISCONSIN,DEPT KINDER,MADISON,WI 53705; UNIV WISCONSIN,WAISMAN CTR MENTAL RETARDAT & HUMAN DEV,MADISON,WI 53705	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	POWERS, PA (corresponding author), UNIV WISCONSIN,DEPT ANESTHESIOL,MADISON,WI 53705, USA.			Gregg, Ronald/0000-0001-5805-224X				ADAMS BA, 1990, NATURE, V346, P569, DOI 10.1038/346569a0; AHLIJANIAN MK, 1990, NEURON, V4, P819, DOI 10.1016/0896-6273(90)90135-3; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BEAM KG, 1992, NATURE, V360, P169, DOI 10.1038/360169a0; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BOSSE E, 1990, FEBS LETT, V267, P153, DOI 10.1016/0014-5793(90)80312-7; CATTERALL WA, 1991, SCIENCE, V253, P1499, DOI 10.1126/science.1654596; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FAIN PR, 1991, CYTOGENET CELL GENET, V57, P65; FONTAINE B, 1990, SCIENCE, V250, P1000, DOI 10.1126/science.2173143; HEIMANPATTERSON T, 1988, NEUROLOGY, V38, P810, DOI 10.1212/WNL.38.5.810; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KAWASAKI ES, 1989, PCR TECHNOLOGY PRINC; KIM HL, 1992, P NATL ACAD SCI USA, V89, P3251, DOI 10.1073/pnas.89.8.3251; KOCH MC, 1991, HUM GENET, V88, P71, DOI 10.1007/BF00204932; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LATHROP GM, 1985, AM J HUM GENET, V37, P482; MCCLATCHEY AI, 1992, CELL, V68, P769, DOI 10.1016/0092-8674(92)90151-2; MCCLATCHEY AI, 1992, AM J HUM GENET, V50, P896; MILLER RJ, 1992, J BIOL CHEM, V267, P1403; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NIIDOME T, 1992, FEBS LETT, V308, P7, DOI 10.1016/0014-5793(92)81038-N; OLCKERS A, 1992, GENOMICS, V14, P829, DOI 10.1016/S0888-7543(05)80206-X; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; POWERS PA, 1992, J BIOL CHEM, V267, P22967; PTACEK LJ, 1992, NEUROLOGY, V42, P431, DOI 10.1212/WNL.42.2.431; PTACEK LJ, 1991, AM J HUM GENET, V49, P851; PTACEK LJ, 1991, CELL, V67, P1021; PTACEK LJ, 1992, NEURON, V8, P891; PTACEK LJ, 1991, AM J HUM GENET, V49, P378; ROJAS CV, 1991, NATURE, V354, P387, DOI 10.1038/354387a0; SAKAMOTO J, 1991, J BIOL CHEM, V266, P18914; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0	47	44	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9275	9279						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8387489				2022-12-25	WOS:A1993LA68900022
J	TANG, TK; TAM, KB; HUANG, SC				TANG, TK; TAM, KB; HUANG, SC			HIGH-LEVEL AND ERYTHROID-SPECIFIC EXPRESSION OF HUMAN GLUCOSE-6-PHOSPHATE-DEHYDROGENASE IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT CONTROL REGION; BETA-GLOBIN GENE; LOCUS ACTIVATION REGION; SOMATIC-CELL HYBRIDS; DEFICIENCY; CHINESE; ENZYME	Human Glc-6-P dehydrogenase (Glc-6-P) cDNA spanning the entire coding region was subcloned into a pSG5 vector that contains an early SV40 promoter, intron II of the rabbit beta-globin gene, and a polyadenylation signal. This expression cassette was then placed downstream of the human beta-globin locus control region and injected into fertilized mouse eggs. Among five transgenic founders that contained intact copies of the construct, one founder expressed human Glc-6-P dehydrogenase enzyme in a high-level and erythroid-specific fashion (5 x higher than endogenous Glc-6-P dehydrogenase activity). When this male founder mated with a normal individual, all the offspring that carried the transgene showed high-level expression of Glc-6-P dehydrogenase activity in erythroid cells. The endogenous mouse Glc-6-P dehydrogenase in all high-expression mice could be competed out by forming a hybrid with human Glc-6-P dehydrogenase. Our results indicate that the locus control region can drive the human Glc-6-P dehydrogenase gene to be specifically expressed in the erythroid cells of transgenic mice. The results described here provide a basis for experiments designed to express human Glc-6-P dehydrogenase in transgenic mice and suggest a suitable approach to producing a mouse model for studying human Glc-6-P dehydrogenase deficiency.			TANG, TK (corresponding author), ACAD SINICA,INST BIOMED SCI,128 ACAD RD,SEC 2,TAIPEI 115,TAIWAN.		Tang, Tang K./S-7012-2018	Tang, Tang K./0000-0002-3660-0695				BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; BEUTLER E, 1977, BRIT J HAEMATOL, V35, P331, DOI 10.1111/j.1365-2141.1977.tb00589.x; BEUTLER E, 1990, SEMIN HEMATOL, V27, P137; BEUTLER E, 1991, NEW ENGL J MED, V324, P169; CHANG JG, 1992, BLOOD, V80, P1079; CHAO L, 1991, NUCLEIC ACIDS RES, V19, P6056, DOI 10.1093/nar/19.21.6056; CHIU DTY, 1991, BIOCHEM BIOPH RES CO, V180, P988, DOI 10.1016/S0006-291X(05)81163-5; COLLIS P, 1990, EMBO J, V9, P233, DOI 10.1002/j.1460-2075.1990.tb08100.x; DURSO M, 1983, SOMAT CELL GENET, V9, P429, DOI 10.1007/BF01543044; DURSO M, 1990, GENOMICS, V7, P531, DOI 10.1016/0888-7543(90)90196-2; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; ENVER T, 1989, P NATL ACAD SCI USA, V86, P7033, DOI 10.1073/pnas.86.18.7033; FORRESTER WC, 1989, P NATL ACAD SCI USA, V86, P5439, DOI 10.1073/pnas.86.14.5439; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HOGAN B, 1986, MANIPULATING MOUSE E, P81; HUANG NE, 1990, FORENSIC SCI, V30, P1; MILLER OJ, 1971, P NATL ACAD SCI USA, V68, P116, DOI 10.1073/pnas.68.1.116; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; TANG TK, 1992, BLOOD, V79, P2135, DOI 10.1182/blood.V79.8.2135.bloodjournal7982135; VANASSENDELFT GB, 1989, CELL, V56, P969, DOI 10.1016/0092-8674(89)90630-2; [No title captured]	22	11	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9522	9525						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8387498				2022-12-25	WOS:A1993LA68900058
J	GALLAND, F; KARAMYSHEVA, A; PEBUSQUE, MJ; BORG, JP; ROTTAPEL, R; DUBREUIL, P; ROSNET, O; BIRNBAUM, D				GALLAND, F; KARAMYSHEVA, A; PEBUSQUE, MJ; BORG, JP; ROTTAPEL, R; DUBREUIL, P; ROSNET, O; BIRNBAUM, D			THE FLT4 GENE ENCODES A TRANSMEMBRANE TYROSINE KINASE RELATED TO THE VASCULAR ENDOTHELIAL GROWTH-FACTOR RECEPTOR	ONCOGENE			English	Article							LARGE CELL LYMPHOMA; PERMEABILITY FACTOR; FMS; MITOGEN; PROTEIN; T(2-5)(P23-Q35); TRANSLOCATION; LOCALIZATION; TRANSDUCTION; DOMAINS	Three receptor tyrosine kinases, FLT1, FLK1 and FLT4, contain seven immunoglobin-like domains in their extracellular region and are strongly related by sequence similarities to each other and, to a lesser degree, to the class III receptors CSF1R/FMS, PDGFR, SLFR/KIT and FLT3/FLK2. They constitute a family of receptors putatively involved in the growth regulation of endothelial cells. We describe here the structure and pattern of expression of the human FLT4 gene. Two FLT4 transcripts of 5.8 and 4.5 kb are expressed in the human placenta and several hematopoietic celt lines. In mouse, a 5.8-kb transcript is expressed in a variety of tissues. A translational product 1298 amino acids in length is predicted to be encoded by the largest open reading frame. The FLT4 protein, when transiently expressed in Cos-7 cells and immunoprecipitated with a FLT4-specific rabbit immune serum, has an apparent molecular weight of 170 kDa.	INSERM, U119, ONCOL MOLEC LAB, 27 BD LEI ROURE, F-13009 MARSEILLE, FRANCE; CANC RES CTR, INST CARCINOGENESIS, MOSCOW 115478, RUSSIA; INSERM, U119, HEMATOL MOLEC LAB, F-13258 MARSEILLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)			Dubreuil, Patrice/V-4816-2019; Borg, Jean-Paul/AAX-8096-2020; Rosnet, Olivier/G-3536-2013; dubreuil, patrice/F-5346-2011	Dubreuil, Patrice/0000-0003-1155-1150; Borg, Jean-Paul/0000-0001-8418-3382; dubreuil, patrice/0000-0003-1155-1150; Rottapel, Robert/0000-0002-6024-5558; Birnbaum, Daniel/0000-0001-7920-9883; Rosnet, Olivier/0000-0002-3020-910X				ANDRE C, 1992, ONCOGENE, V7, P685; APRELIKOVA O, 1992, CANCER RES, V52, P746; BENZLEMOINE E, 1988, BLOOD, V72, P1045; BREIER G, 1992, DEVELOPMENT, V114, P521; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GALLAND F, 1992, GENOMICS, V13, P475, DOI 10.1016/0888-7543(92)90277-Y; GALLAND F, 1990, BIOCHIMIE, V72, P759, DOI 10.1016/0300-9084(90)90161-9; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEBEAU MM, 1989, LEUKEMIA, V3, P866; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAROC N, 1993, IN PRESS ONCOGENE; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; NOGUCHI T, 1991, Technique (Philadelphia), V3, P33; OELRICHS RB, 1993, ONCOGENE, V8, P11; PAJUSOLA K, 1992, CANCER RES, V52, P5738; RIMOKH R, 1989, BRIT J HAEMATOL, V71, P31, DOI 10.1111/j.1365-2141.1989.tb06270.x; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROSNET O, 1991, ONCOGENE, V6, P1641; ROSNET O, 1991, GENOMICS, V9, P380, DOI 10.1016/0888-7543(91)90270-O; ROSNET O, 1993, ONCOGENE, V8, P173; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; SARZANI R, 1992, BIOCHEM BIOPH RES CO, V186, P706, DOI 10.1016/0006-291X(92)90804-T; SATOH H, 1987, JPN J CANCER RES, V78, P772; SHIBUYA M, 1990, ONCOGENE, V5, P519; TERMAN BI, 1991, ONCOGENE, V6, P1677; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WARRINGTON JA, 1992, GENOMICS, V13, P803, DOI 10.1016/0888-7543(92)90156-M; WASMUTH JJ, 1991, CYTOGENET CELL GENET, V58, P261, DOI 10.1159/000133165; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	37	140	165	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1233	1240						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8386825				2022-12-25	WOS:A1993KY32800014
J	GUIZOUARN, H; BORGESE, F; PELLISSIER, B; GARCIAROMEU, F; MOTAIS, R				GUIZOUARN, H; BORGESE, F; PELLISSIER, B; GARCIAROMEU, F; MOTAIS, R			ROLE OF PROTEIN-PHOSPHORYLATION AND DEPHOSPHORYLATION IN ACTIVATION AND DESENSITIZATION OF THE CAMP-DEPENDENT NA+/H+ ANTIPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; H+ EXCHANGER; GROWTH-FACTORS; RAINBOW-TROUT; OKADAIC ACID; ERYTHROCYTES; ARRESTIN; PH; CATECHOLAMINES; INHIBITION	The Na+/H+ antiporter of trout erythrocytes is activated by agents raising intracellular cAMP, whereas other Na+/H+ exchangers are insensitive to or inhibited by cAMP. Cloning of the beta agonist-activated exchanger (betaNHE) reveals the presence of two consensus sites for phosphorylation by the cAMP-dependent protein kinase A (cAMP-PKA) on the cytoplasmic loop. Transfected to fibroblasts, betaNHE can no longer be activated by cAMP when these consensus sites are removed, indicating regulation through cAMP-PKA. Moreover, it has been shown that activation of the exchanger is rapidly followed by its desensitization. To further investigate the role of phosphorylation in these processes, we examined the effects of protein kinase and phosphatase inhibitors on the antiporter activation and desensitization in trout red cells. Na+/H+ exchange was not induced by strong acidification, indicating that betaNHE is normally in a nonfunctional state, whereas cAMP did activate the system by forcing betaNHE into a functional conformation; preincubation of cells with the kinase inhibitor H89 blocked cAMP-activation, confirming the role of cAMP-PKA in the activation process. The protein phosphatase inhibitor okadaic acid (OA) neither activated the exchange when added on unstimulated cells nor prevented deactivation of beta agonist-activated betaNHE by propranolol. Hence, the cAMP-dependent phosphorylation involved in the activating process is controlled by an OA-insensitive phosphatase. BetaNHE activated by beta agonist or cAMP shifts rapidly into a refractory state, accounting for the previously described desensitization. Desensitization was blocked and reversed by OA, indicating a control by an OA-sensitive phosphatase of the phosphorylation level of a site critical for the desensitizing process. Phosphorylation of this (site 2) and of the activating site (site 1) is mediated by cAMP-PKA, as demonstrated by the effects of both intracellular cAMP concentration and kinase inhibitor H89 on the Na+/H+ exchange activity. Based on these data, we proposed that betaNHE can exist in three different states (inactive I, activated A, and desensitized D). Conversion of I to A needs the simultaneous phosphorylation by cAMP-PKA of sites 1 and 2. These two sites might constitute the two neighboring cAMP-PKA sites located on the cytoplasmic loop as deduced from the oligonucleotide sequence. Dephosphorylation of site 2 and subsequent binding of an arrestin-like protein are assumed to account for desensitization of the antiport. This putative role of arrestin is inferred from previous results demonstrating the presence in trout red cells (immunological detection and cloning) of such a protein, which in addition has been shown to bind to bovine rhodopsin as does retinal arrestin which participates in rhodopsin desensitization.	CEA,DEPT BIOL,LAB JEAN MAETZ,BP 68,F-06230 VILLEFRANCHE MER,FRANCE	CEA				Guizouarn, Helene/0000-0002-8757-6672; BORGESE, Franck/0000-0001-7718-2111				ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BAROIN A, 1984, J PHYSIOL-LONDON, V356, P21, DOI 10.1113/jphysiol.1984.sp015450; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; BORGESE F, 1987, J PHYSIOL-LONDON, V382, P145, DOI 10.1113/jphysiol.1987.sp016360; BORGESE F, 1986, J GEN PHYSIOL, V87, P551, DOI 10.1085/jgp.87.4.551; BORGESE F, 1992, P NATL ACAD SCI USA, V89, P6765, DOI 10.1073/pnas.89.15.6765; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; GARCIAROMEU F, 1988, J GEN PHYSIOL, V91, P529, DOI 10.1085/jgp.91.4.529; GRINSTEIN S, 1985, P NATL ACAD SCI USA, V82, P1429, DOI 10.1073/pnas.82.5.1429; HAYSTEAD TAJ, 1990, EUR J BIOCHEM, V187, P199, DOI 10.1111/j.1432-1033.1990.tb15295.x; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MAHE Y, 1985, EUR J PHARMACOL, V116, P199, DOI 10.1016/0014-2999(85)90154-2; MIRSHAHI M, 1989, FEBS LETT, V258, P240, DOI 10.1016/0014-5793(89)81663-1; MOOLENAAR WH, 1986, ANNU REV PHYSIOL, V48, P363; MOTAIS R, 1989, J GEN PHYSIOL, V94, P385, DOI 10.1085/jgp.94.2.385; MOTAIS R, 1992, COMP BIOCHEM PHYS A, V102, P597, DOI 10.1016/0300-9629(92)90710-8; MOTAIS R, 1990, PROGR CELL RES; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1991, J BIOL CHEM, V266, P19166; SCHEURING U, 1990, FEBS LETT, V276, P192, DOI 10.1016/0014-5793(90)80540-Y; WAKABAYASHI S, 1992, REV PHYSIOL BIOCH P, V119, P157; WEINMAN EJ, 1988, J MEMBRANE BIOL, V101, P11, DOI 10.1007/BF01872815; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174	24	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8632	8639						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8386166				2022-12-25	WOS:A1993KX81100040
J	TSAI, AL; KULMACZ, RJ; WANG, JS; WANG, Y; VANWART, HE; PALMER, G				TSAI, AL; KULMACZ, RJ; WANG, JS; WANG, Y; VANWART, HE; PALMER, G			HEME COORDINATION OF PROSTAGLANDIN-H SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC RESONANCE; MAGNETIC CIRCULAR-DICHROISM; CYTOCHROME-C PEROXIDASE; ENDOPEROXIDE SYNTHASE; RAMAN-SPECTROSCOPY; CRYSTAL-STRUCTURE; AXIAL LIGATION; SPIN STATES; MYOGLOBIN; COMPLEXES	The heme coordination of ovine prostaglandin H synthase (PGHS) has been characterized by EPR, magnetic circular dichroism, resonance Raman, and optical spectroscopies. The EPR spectrum of ferric PGHS is consistent with an equilibrium mixture of high-spin and low-spin heme species. Both species disappear on reaction of the synthase with hydroperoxides. The high-spin to low-spin interconversion is temperature- and concentration-dependent. Correlation between the axial and rhombic ligand fields of the low-spin heme species suggests that it has bishistidine axial ligation. Magnetic circular dichroism spectra of PGHS also show a temperature-dependent spin transition. Resonance Raman spectra indicate that the enzyme exists as a mixture of six-coordinate low-spin and six-coordinate high-spin ferric heme species. No Raman bands attributable to five-coordinate high-spin heme species are detectable. The magnetic circular dichroism spectra of the fluoride, azide, cyanide, and imidazole derivatives of PGHS resemble those of the corresponding metmyoglobin derivatives and are very different from those of the catalase derivatives. EPR spectra of the imidazole derivative of these three proteins provide additional evidence that the heme coordination structure of PGHS is similar to that of metmyoglobin rather than that of catalase. The midpoint potential of the PGHS Fe(III)/Fe(II) pair is in the range observed for hemeproteins with mono- or bishistidine coordination. These data provide a convincing case that the axial heme ligands of PGHS-1 are a pair of histidine residues, with the distal histidine weakly associated and possibly exchangeable with a weak-field ligand.	FLORIDA STATE UNIV,INST MOLEC BIOPHYS,TALLAHASSEE,FL 32306; RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	State University System of Florida; Florida State University; Rice University	TSAI, AL (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DIV HEMATOL,POB 20708,HOUSTON,TX 77030, USA.				NIGMS NIH HHS [GM21337, GM30509, GM27276] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021337, R01GM021337, R01GM030509, R01GM027276] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUMBERG WE, 1968, J BIOL CHEM, V243, P1854; CHOI S, 1982, J AM CHEM SOC, V104, P4345, DOI 10.1021/ja00380a006; CHUANG WJ, 1989, J BIOL CHEM, V264, P14209; Dutton P L, 1978, Methods Enzymol, V54, P411; EGEBERG KD, 1990, BIOCHEMISTRY-US, V29, P9783, DOI 10.1021/bi00494a004; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; FITA I, 1985, J MOL BIOL, V185, P21, DOI 10.1016/0022-2836(85)90180-9; GADSBY PMA, 1990, J AM CHEM SOC, V112, P5003, DOI 10.1021/ja00169a002; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; GUNNER MR, 1991, P NATL ACAD SCI USA, V88, P9151, DOI 10.1073/pnas.88.20.9151; HARBURY HA, 1965, P NATL ACAD SCI USA, V54, P1658, DOI 10.1073/pnas.54.6.1658; HORIE S, 1978, CYTOCHROME P 450, P73; IKEDASAITO M, 1985, J BIOL CHEM, V260, P8301; IKEDASAITO M, 1975, BIOCHIM BIOPHYS ACTA, V393, P335, DOI 10.1016/0005-2795(75)90059-8; KARTHEIN R, 1987, EUR J BIOCHEM, V166, P173, DOI 10.1111/j.1432-1033.1987.tb13499.x; KAUTEN R, 1987, J BIOL CHEM, V262, P8658; KENDREW JC, 1960, NATURE, V185, P422, DOI 10.1038/185422a0; KULMACZ RJ, 1990, BIOCHEMISTRY-US, V29, P8760, DOI 10.1021/bi00489a037; KULMACZ RJ, 1987, J BIOL CHEM, V262, P10524; Kulmacz RJ, 1987, PROSTAGLANDINS RELAT, P209; Marchon J.C., 1982, ELECT TRANSF OXYG UT, P67; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MUSVETEAU I, 1992, J BIOL CHEM, V267, P16851; NAGAI M, 1989, BIOCHEMISTRY-US, V28, P2418, DOI 10.1021/bi00432a012; PEISACH J, 1977, BIOCHEMISTRY-US, V16, P2539, DOI 10.1021/bi00630a034; PEISACH J, 1971, J BIOL CHEM, V246, P3342; POULOS TL, 1980, J BIOL CHEM, V255, P575; PYRZ JW, 1985, J AM CHEM SOC, V107, P614, DOI 10.1021/ja00289a013; Que L, 1988, BIOL APPLICATIONS RA, P491; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SCHERER HJ, 1992, EUR J BIOCHEM, V205, P751, DOI 10.1111/j.1432-1033.1992.tb16839.x; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SITTER AJ, 1985, BIOCHIM BIOPHYS ACTA, V828, P229, DOI 10.1016/0167-4838(85)90301-2; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; TORII K, 1968, J BIOCHEM-TOKYO, V64, P171, DOI 10.1093/oxfordjournals.jbchem.a128877; van der Ouderaa F J, 1980, Adv Prostaglandin Thromboxane Res, V6, P139; VICKERY L, 1976, J AM CHEM SOC, V98, P351, DOI 10.1021/ja00418a006; VICKERY L, 1976, J AM CHEM SOC, V98, P343, DOI 10.1021/ja00418a005; VICKERY LE, 1978, METHOD ENZYMOL, V56, P284; WAGEN ES, 1978, NATURE, V275, P73; WITTENBERG BA, 1968, J BIOL CHEM, V243, P1863; YONETANI T, 1972, J BIOL CHEM, V247, P2447; YONETANI T, 1987, J BIOL CHEM, V262, P9547	44	50	50	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8554	8563						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8386163				2022-12-25	WOS:A1993KX81100030
J	KRANTIC, S; GUERRIER, P; DUBE, F				KRANTIC, S; GUERRIER, P; DUBE, F			MEIOSIS REINITIATION IN SURF CLAM OOCYTES IS MEDIATED VIA A 5-HYDROXYTRYPTAMINE(5)SEROTONIN MEMBRANE-RECEPTOR AND A VITELLINE ENVELOPE-ASSOCIATED HIGH-AFFINITY BINDING-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; SPISULA-SOLIDISSIMA; SEROTONIN RECEPTOR; ACTIVATION; BEHAVIOR; RAT	The neurohormone serotonin (5-hydroxytryptamine, 5HT) triggers meiosis reinitiation in prophase-arrested oocytes of Spisula solidissima. The original pharmacological profile of this response prompted us to examine whether it involved a novel type of 5HT receptor. In order to characterize these putative receptors, we performed [H-3]5HT binding assays. Given the complexity of oocyte surface architecture, [H-3]5HT-specific binding was measured in both plasma membrane and vitelline envelope fractions. Our data reveal the existence of a single class of 5HT-specific binding sites in each fraction. These binding sites appear distinct by their kinetic properties: 1) plasma membrane binding sites are of lower affinity but are more numerous than vitelline envelope sites; 2) [H-3]5HT binding is more rapid in membrane fraction. The pharmacological profiles of both binding sites were defined in competition experiments by using sixteen 5HT-related and unrelated compounds. Both membrane and vitelline envelope sites displayed novel profiles. However, only the pharmacological profile determined for the plasma membrane sites corresponds to that observed for 5HT-induced meiosis reinitiation. These new 5HT5 binding sites are therefore the physiological receptors that mediate the effects of 5HT in Spisula oocytes. The putative role of vitelline envelope sites is discussed.	UNIV QUEBEC,DEPT EXPTL IMMUNOL,RIMOUSKI G5L 3A1,QUEBEC,CANADA	University of Quebec	KRANTIC, S (corresponding author), ECOLE NORMALE SUPER LYON,BIOL MOLEC & CELLULAIRE LAB,UMR 49,46 ALLEE ITALIE,F-69364 LYON 07,FRANCE.		Krantic, Slavica/E-4802-2019; Krantic, Slavica/AAZ-5156-2021	Krantic, Slavica/0000-0002-0785-4549; Krantic, Slavica/0000-0002-0785-4549				AMLAIKY N, 1985, J BIOL CHEM, V260, P1983; APRISON MH, 1960, EXPERIENTIA, V16, P159, DOI 10.1007/BF02157734; BANDIVDEKAR AH, 1991, INVERTEBR REPROD DEV, V19, P147, DOI 10.1080/07924259.1991.9672168; BICKER G, 1989, NATURE, V337, P33, DOI 10.1038/337033a0; BOCKAERT J, 1990, MOL PHARMACOL, V37, P408; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BRADLEY PB, 1986, NEUROPHARMACOLOGY, V25, P563, DOI 10.1016/0028-3908(86)90207-8; DUDLER R, 1988, EMBO J, V7, P3963, DOI 10.1002/j.1460-2075.1988.tb03283.x; ESKIN A, 1983, SCIENCE, V220, P82, DOI 10.1126/science.6298939; FILLION G, 1976, LIFE SCI, V18, P65, DOI 10.1016/0024-3205(76)90275-7; GIBBONS MC, 1984, AQUACULTURE, V40, P189, DOI 10.1016/0044-8486(84)90356-9; HIRAI S, 1988, J EXP ZOOL, V245, P318, DOI 10.1002/jez.1402450312; KRANTIC S, 1991, DEV BIOL, V146, P491, DOI 10.1016/0012-1606(91)90250-7; KRAVITZ EA, 1988, SCIENCE, V241, P1775, DOI 10.1126/science.2902685; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCKI I, 1984, J PHARMACOL EXP THER, V228, P133; MATSUTANI T, 1987, GEN COMP ENDOCR, V67, P111, DOI 10.1016/0016-6480(87)90210-3; MAUL GG, 1980, EXP CELL RES, V129, P431, DOI 10.1016/0014-4827(80)90512-1; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; OSANAI K, 1988, Bulletin of the Marine Biological Station of Asamushi, V18, P45; PEROUTKA SJ, 1988, TRENDS NEUROSCI, V11, P496, DOI 10.1016/0166-2236(88)90011-2; Post R.L., 1967, METHODS ENZYMOLOGY, P762; QUIRION R, 1986, CAN J NEUROL SCI, V13, P503; REBHUN LI, 1964, J CELL BIOL, V22, P488, DOI 10.1083/jcb.22.2.488; Sanders-Bush Elaine, 1988, SEROTONIN RECEPTORS; SAUDOU F, 1992, EMBO J, V11, P7, DOI 10.1002/j.1460-2075.1992.tb05021.x; WITZ P, 1990, P NATL ACAD SCI USA, V87, P8940, DOI 10.1073/pnas.87.22.8940	27	52	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7983	7989						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8385130				2022-12-25	WOS:A1993KW97900061
J	LEE, NH; FRASER, CM				LEE, NH; FRASER, CM			CROSS-TALK BETWEEN M1 MUSCARINIC ACETYLCHOLINE AND BETA-2-ADRENERGIC RECEPTORS - CAMP AND THE 3RD INTRACELLULAR LOOP OF M1 MUSCARINIC RECEPTORS CONFER HETEROLOGOUS REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; PROTEIN-KINASE-C; SITE-DIRECTED MUTAGENESIS; CYCLIC-AMP; ADENYLATE-CYCLASE; PHOSPHOLIPASE-C; DOWN-REGULATION; PHOSPHORYLATION; ACTIVATION; EXPRESSION	Genes encoding the m1 muscarinic (m1 mAChR) and beta2-adrenergic receptors (beta2AR) were stably co-expressed into Chinese hamster ovary (CHO) cells to study receptor regulation and cross-talk. Persistent activation of the beta2AR/adenylate cyclase pathway by isoproterenol leads to heterologous desensitization, internalization, and down-regulation of the m1 mAChR which is comparable, but smaller in magnitude, with that seen with persistent activation of the m1 mAChR by carbachol. This heterologous effect was mimicked by dibutyryl cAMP and forskolin and antagonized by the protein kinase A (PKA) inhibitor H-8. A potential consensus sequence for phosphorylation by PKA (Lys351-Arg-Lys-Thr354) exists on the third intracellular loop of the ml mAChR, suggesting that receptor phosphorylation by PKA may be involved in heterologous regulation. The loss of ml mAChRs induced by carbachol was not reversed by H-8, indicating that homologous regulation is not dependent on PKA. Recent evidence suggests that muscarinic agonist-mediated internalization of the m1 mAChR involves the third intracellular loop (i3) (Maeda, S., Lameh, J., Mallet, W. G., Philip, M., Ramachandran, J., and Sadee, W. (1990) FEBS Lett. 269, 386-388). Three deletion mutant receptors were constructed in which the majority, or small regions, of i3 were eliminated but the membrane proximal portions of the loop were left intact. Each of the mutants was co-expressed with the beta2AR in CHO cells. A small region in i3 was identified which is crucial for carbachol- and isoproterenol-promoted internalization and down-regulation. This region contains a series of 6 serine residues within an 8-amino acid stretch. A similar domain has been identified in the carboxyl tail of the beta2AR and has been proposed to participate in receptor internalization (Hausdorff, W. P., Campbell, P. T., Ostrowski, J., Yu, S. S., Caron, M. G., and Lefkowitz, R. J. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 2979-2983).	NIAAA,MOLEC NEUROBIOL SECT,NEUROGENET LAB,ROCKVILLE,MD 20852	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)				Fraser, Claire/0000-0003-1462-2428				AKIL M, 1989, J NEUROCHEM, V53, P1479, DOI 10.1111/j.1471-4159.1989.tb08541.x; ALLEN JM, 1989, MOL PHARMACOL, V36, P248; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; BUCK MA, 1990, BIOCHEM BIOPH RES CO, V173, P666, DOI 10.1016/S0006-291X(05)80087-7; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; CAMPBELL MD, 1990, MOL PHARMACOL, V38, P282; CHUNG FZ, 1988, J BIOL CHEM, V263, P4052; CLARK RB, 1989, MOL PHARMACOL, V36, P343; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; ELFAKAHANY EE, 1990, MEMBRANE BIOCHEM, V9, P9, DOI 10.3109/09687689009026820; FELDER CC, 1989, J BIOL CHEM, V264, P20356; FRASER CM, 1989, MOL PHARMACOL, V36, P840; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUSOVSKY F, 1991, MOL PHARMACOL, V39, P124; HADCOCK JR, 1991, J BIOL CHEM, V266, P11915; HARDEN TK, 1985, J BIOL CHEM, V260, P3060; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HIKADA H, 1984, BIOCHEMISTRY-US, V23, P5036; HILL SJ, 1989, CELL SIGNAL, V1, P135, DOI 10.1016/0898-6568(89)90002-8; HO AKS, 1985, BIOCHEM BIOPH RES CO, V133, P1193, DOI 10.1016/0006-291X(85)91263-X; JOHNSON JA, 1991, MOL PHARMACOL, V39, P539; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; LAI WS, 1990, BIOCHEM J, V267, P23, DOI 10.1042/bj2670023; LAMEH J, 1992, J BIOL CHEM, V267, P13406; Lee Norman H., 1992, Society for Neuroscience Abstracts, V18, P254; LEFKOWITZ RJ, 1983, ANNU REV BIOCHEM, V52, P159, DOI 10.1146/annurev.bi.52.070183.001111; LEVEY AI, 1991, J NEUROSCI, V11, P3218; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MAEDA A, 1988, FEBS LETT, V239, P339, DOI 10.1016/0014-5793(88)80947-5; MAEDA S, 1990, FEBS LETT, V269, P386, DOI 10.1016/0014-5793(90)81199-X; MORRIS GM, 1991, J BIOL CHEM, V266, P2233; MOTOMURA S, 1990, BRIT J PHARMACOL, V101, P363, DOI 10.1111/j.1476-5381.1990.tb12715.x; NARINDRASORASAK S, 1987, J BIOL CHEM, V262, P10497; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; RICHARDSON RM, 1992, J BIOL CHEM, V267, P10127; ROSENBAUM LC, 1987, BIOCHEMISTRY-US, V26, P8183, DOI 10.1021/bi00399a024; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SAVARESE TM, 1992, J BIOL CHEM, V267, P11439; SHAPIRO RA, 1989, BIOCHEMISTRY-US, V28, P8946, DOI 10.1021/bi00448a039; SHIMADA T, 1991, BIOCHEM BIOPH RES CO, V179, P327, DOI 10.1016/0006-291X(91)91373-K; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; STADEL JM, 1983, J BIOL CHEM, V258, P3032; STRADER CD, 1985, LIFE SCI, V35, P1601; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0	51	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7949	7957						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8385129				2022-12-25	WOS:A1993KW97900057
J	LARUE, L; DOUGHERTY, N; BRADL, M; MINTZ, B				LARUE, L; DOUGHERTY, N; BRADL, M; MINTZ, B			MELANOCYTE CULTURE LINES FROM TYR-SV40E TRANSGENIC MICE - MODELS FOR THE MOLECULAR GENETIC EVOLUTION OF MALIGNANT-MELANOMA	ONCOGENE			English	Article							MURINE MELANOCYTES; TUMOR PROGRESSION; PHORBOL ESTER; GROWTH; 12-O-TETRADECANOYLPHORBOL-13-ACETATE; TRANSFORMATION; REQUIREMENT; REPLICATION; MECHANISMS; EXPRESSION	Transgenic Tyr-SV40E mice previously produced on the C57BL/6 inbred-strain background, with SV40 oncogenic sequences specifically expressed in pigment cells, are predisposed to melanoma [Bradl, M., Klein-Szanto, A., Porter, S. & Mintz, B. (1991). Proc. Natl. Acad. Sci. USA, 88, 164-1681. Separate lines of these animals differ genetically only in the number of copies and chromosomal site of integration of the transgene. Skin melanocytes from young mice with no apparent skin lesions were established in continuous culture from hemizygous donors with low, medium and high numbers of transgene copies, and from a homozygous offspring of the low-copy mouse line. The standard culture conditions enable C57BL/6 wild-type melanocytes to become stably immortalized without transformation. The transgenic cell lines all changed over time in an orderly progression. However, with greater numbers of transgene copies, the cells more rapidly displayed shorter doubling times, increased anchorage independence, reduced serum and growth factor requirements, decreased tyrosinase expression and melanin content, increased oncogene expression, and capacity to form malignant melanomas when tested by grafting. Melanocytes with the lowest number of transgene copies were of special interest. They grew more rapidly than the wild-type cells from the outset, but did not become tumorigenic until an apparently small number of still-unknown genetic changes had spontaneously occurred, or until the number of transgene copies was increased slightly by homozygosity. In contrast to the hemizygous low-copy cells, the homozygous counter-parts underwent striking and rapid transformational changes and early conversion to malignancy. Thus such low-copy transgenic melanocyte lines afford an exceptional opportunity for molecular analysis of somatic genetic evolution toward malignant melanoma.	FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111	Fox Chase Cancer Center			Larue, Lionel/I-6532-2016; Larue, Lionel/F-7355-2013	Bradl, Monika/0000-0003-2239-1586	NCI NIH HHS [CA-06927, CA-42560] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R35CA042560] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ALBINO AP, 1988, ADV PIGMENT CELL RES, P361; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BENNETT DC, 1989, ENVIRON HEALTH PERSP, V80, P49, DOI 10.2307/3430731; Berenblum I, 1941, CANCER RES, V1, P807; BRADL M, 1991, P NATL ACAD SCI USA, V88, P164, DOI 10.1073/pnas.88.1.164; BRADL M, 1991, P NATL ACAD SCI USA, V88, P6447, DOI 10.1073/pnas.88.15.6447; CHENEVIXTRENCH G, 1990, ONCOGENE, V5, P1187; DOOLEY TP, 1988, ONCOGENE, V3, P531; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; GERARD RD, 1985, MOL CELL BIOL, V5, P3231, DOI 10.1128/MCB.5.11.3231; HALABAN R, 1986, J INVEST DERMATOL, V87, P95, DOI 10.1111/1523-1747.ep12523594; HERLYN M, 1987, LAB INVEST, V56, P461; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; JAMBROSIC J, 1989, INT J CANCER, V44, P1117, DOI 10.1002/ijc.2910440630; JIMBOW K, 1975, J CELL BIOL, V66, P663, DOI 10.1083/jcb.66.3.663; KATH R, 1989, ANTICANCER RES, V9, P865; KLEINSZANTO A, 1991, P NATL ACAD SCI USA, V88, P169, DOI 10.1073/pnas.88.1.169; LARUE L, 1992, P NATL ACAD SCI USA, V89, P9534, DOI 10.1073/pnas.89.20.9534; McKusick V. A., 1986, MENDELIAN INHERITANC; MELBER K, 1989, CANCER RES, V49, P3650; Mintz B, 1981, Adv Cancer Res, V34, P211, DOI 10.1016/S0065-230X(08)60243-2; MOORE M, 1992, J VIROL, V66, P641, DOI 10.1128/JVI.66.2.641-649.1992; MULLER G, 1988, EMBO J, V7, P2723, DOI 10.1002/j.1460-2075.1988.tb03126.x; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; Romerdahl C A, 1989, Cancer Commun, V1, P209; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; TAMURA A, 1987, IN VITRO CELL DEV B, V23, P519; TERAO M, 1989, BIOCHEM BIOPH RES CO, V159, P848, DOI 10.1016/0006-291X(89)90072-7; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WILSON RE, 1989, CANCER RES, V49, P711	35	22	23	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					523	531						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8382353				2022-12-25	WOS:A1993KN00800001
J	HEINECKE, JW; LI, W; DAEHNKE, HL; GOLDSTEIN, JA				HEINECKE, JW; LI, W; DAEHNKE, HL; GOLDSTEIN, JA			DITYROSINE, A SPECIFIC MARKER OF OXIDATION, IS SYNTHESIZED BY THE MYELOPEROXIDASE-HYDROGEN PEROXIDE SYSTEM OF HUMAN NEUTROPHILS AND MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL MYRISTATE ACETATE; HYPOCHLOROUS ACID; SINGLET OXYGEN; LEUKOCYTES; SUPEROXIDE; TYROSINE; MECHANISMS; GENERATION; MEMBRANE; CATALASE	Myeloperoxidase, secreted by activated phagocytes, produces the powerful cytotoxin hypochlorous acid from H2O2 and Cl-. We show that the enzyme can also employ H2O2 to oxidize L-tyrosine to tyrosyl radical, yielding the stable cross-linked product dityrosine. Dityrosine synthesis by the myeloperoxidase-H2O2 system did not require halide and was partially inhibited by Cl-. At physiological concentrations of Cl-, L-tyrosine, and other plasma amino acids, purified myeloperoxidase utilized 26% of the H2O2 in the reaction mixture to form dityrosine. Aminotriazole, cyanide, and azide inhibited the reaction. Phorbol ester-stimulated human neutrophils and monocyte-derived macrophages similarly generated dityrosine from L-tyrosine by a pathway inhibited by catalase, aminotriazole, and azide. The requirement for H2O2 and the inhibition by heme poisons suggest that activated phagocytes synthesize dityrosine by a peroxidative mechanism. These results indicate that L-tyrosine can compete effectively with Cl- as a substrate for myeloperoxidase and raise the possibility that formation of tyrosyl radical may play a role in the phagocyte inflammatory response. Because dityrosine is protease-resistant, stable to acid hydrolysis, and intensely fluorescent, its identification in tissues may pinpoint targets where phagocytes inflict oxidative damage in vivo.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110	Washington University (WUSTL)					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029920] Funding Source: NIH RePORTER; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P60AM020579] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00954] Funding Source: Medline; NIADDK NIH HHS [AM20579] Funding Source: Medline; NICHD NIH HHS [R01 HD29920] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; AMADO R, 1984, METHOD ENZYMOL, V107, P377; Andersen S.O, 1966, ACTA PHYSIOL SC S263, V66, P1; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; BAYSE GS, 1972, BIOCHIM BIOPHYS ACTA, V284, P34; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRITIGAN BE, 1986, J BIOL CHEM, V261, P7026; BRIZA P, 1986, J BIOL CHEM, V261, P4288; BRIZA P, 1990, GENE DEV, V4, P1775, DOI 10.1101/gad.4.10.1775; CERUTTI PA, 1988, OXY RADICALS MOL BIO; DIETS T, 1984, J BIOL CHEM, V259, P13525; DOLPHIN D, 1971, P NATL ACAD SCI USA, V68, P614, DOI 10.1073/pnas.68.3.614; FOERDER CA, 1977, P NATL ACAD SCI USA, V74, P4214, DOI 10.1073/pnas.74.10.4214; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GOLDSMITH LA, 1989, METABOLIC BASIS INHE, P547; GROSS AJ, 1959, J BIOL CHEM, V234, P1611; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HARRISON JE, 1978, FEBS LETT, V92, P327, DOI 10.1016/0014-5793(78)80780-7; HEINECKE JW, 1987, J BIOL CHEM, V262, P10098; HELD AM, 1978, BIOCHEM BIOPH RES CO, V81, P878, DOI 10.1016/0006-291X(78)91433-X; HICKSTEIN DD, 1987, J BIOL CHEM, V262, P5576; HUNTER EPL, 1989, FREE RADICAL BIO MED, V6, P581, DOI 10.1016/0891-5849(89)90064-6; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; IBBOTT FA, 1974, CLIN CHEM, P565; JOSCHEK HI, 1966, J AM CHEM SOC, V88, P3273, DOI 10.1021/ja00966a019; Klebanoff S.J., 1978, NEUTROPHIL FUNCTION; KLEBANOFF SJ, 1984, METHOD ENZYMOL, V105, P399; KRINSKY NI, 1974, SCIENCE, V186, P363, DOI 10.1126/science.186.4161.363; LEHRER SS, 1967, BIOCHEMISTRY-US, V6, P757, DOI 10.1021/bi00855a017; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALMSTROM BG, 1982, ANNU REV BIOCHEM, V51, P21, DOI 10.1146/annurev.bi.51.070182.000321; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; MORITA Y, 1986, J BIOCHEM-TOKYO, V99, P761, DOI 10.1093/oxfordjournals.jbchem.a135535; Musso H., 1963, ANGEW CHEM INT EDIT, V2, P723, DOI DOI 10.1002/ANIE.196307231; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; RAKITA RM, 1990, BIOCHEMISTRY-US, V29, P1075, DOI 10.1021/bi00456a033; SEALY RC, 1985, J AM CHEM SOC, V107, P3401, DOI 10.1021/ja00298a001; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; TAUBER AI, 1977, J CLIN INVEST, V60, P374, DOI 10.1172/JCI108786; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WEISS SJ, 1983, SCIENCE, V222, P625, DOI 10.1126/science.6635660; WEISS SJ, 1977, J CLIN INVEST, V60, P370, DOI 10.1172/JCI108785; WHITE JG, 1974, AM J PATHOL, V75, P45; WRIGHT DG, 1977, AM J PATHOL, V87, P273; ZGLICZYNSKI JM, 1968, EUR J BIOCHEM, V4, P540, DOI 10.1111/j.1432-1033.1968.tb00246.x	48	421	436	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4069	4077						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8382689				2022-12-25	WOS:A1993KN53300043
J	ISOGAI, Y; IIZUKA, T; MAKINO, R; IYANAGI, T; ORII, Y				ISOGAI, Y; IIZUKA, T; MAKINO, R; IYANAGI, T; ORII, Y			SUPEROXIDE-PRODUCING CYTOCHROME-B - ENZYMATIC AND ELECTRON-PARAMAGNETIC RESONANCE PROPERTIES OF CYTOCHROME-B(558) PURIFIED FROM NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; OXIDATION-REDUCTION PROPERTIES; FERRICYTOCHROME-C; NADPH OXIDASE; PURIFICATION; MECHANISM; BINDING; CHAIN; SPECTROSCOPY	Molecular properties of superoxide (O2-)-producing cytochrome b558 purified from neutrophils were investigated focusing on the mechanism of the catalytic reaction. The purified cytochrome, which was depleted of FAD, exhibited high O2--generating activity with consumption of NADPH in the presence of microsomal NADPH-cytochrome P-450 reductase. Exogenous additions of CO, CN-, or N3- had no effect on the enzymatic activity. Potentiometric titration of the ferric-ferrous couple of the cytochrome showed that the midpoint reduction potential was -255 mV at pH 7.4. When the reaction of the reduced cytochrome with O2 was analyzed by stopped flow and rapid scanning spectrophotometry, the ferrous form was found to be converted to the ferric form at a rate constant of 9.3 x 10(6) M-1 s-1 at 10-degrees-C without showing formation of an oxygenated intermediate. EPR measurement of the ferric cytochrome at 10 K showed that the electronic spin state was in a low spin with g values of 3.2, 2.05, and 1.5. These results suggest that the heme in a six-coordinated low spin state catalyzes one electron reduction of O2 without ligation of O2 to the heme iron during the catalytic cycle.	HIMEJI INST TECHNOL,FAC SCI,HIMEJI,HYOGO 67812,JAPAN; KYOTO UNIV,FAC MED,DEPT PUBL HLTH,KYOTO 606,JAPAN	University of Hyogo; Kyoto University	ISOGAI, Y (corresponding author), RIKEN,HIROSAWA 2-1,WAKO,SAITAMA 31501,JAPAN.			Isogai, Yasuhiro/0000-0001-6905-4208				ABO A, 1991, J BIOL CHEM, V266, P23577; ABO A, 1992, J BIOL CHEM, V267, P16767; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; BUTLER J, 1982, J BIOL CHEM, V257, P747; CROSS AR, 1981, BIOCHEM J, V194, P599, DOI 10.1042/bj1940599; CROSS AR, 1985, BIOCHEM J, V226, P881, DOI 10.1042/bj2260881; CROSS AR, 1982, BIOCHEM J, V204, P479, DOI 10.1042/bj2040479; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; CURNUTTE JT, 1989, P NATL ACAD SCI USA, V86, P825, DOI 10.1073/pnas.86.3.825; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; FUJII H, 1992, BIOCHIM BIOPHYS ACTA, V1136, P239, DOI 10.1016/0167-4889(92)90112-O; HURST JK, 1991, J BIOL CHEM, V266, P1627; IIZUKA T, 1985, J BIOL CHEM, V260, P2049; IIZUKA T, 1985, BIOCHEM BIOPH RES CO, V130, P621, DOI 10.1016/0006-291X(85)90462-0; ISOGAI Y, 1991, J BIOL CHEM, V266, P13481; IYANAGI T, 1984, BIOCHEMISTRY-US, V23, P1418, DOI 10.1021/bi00302a013; IYANAGI T, 1981, BIOCHEMISTRY-US, V20, P1722, DOI 10.1021/bi00510a004; KAKINUMA K, 1987, J BIOL CHEM, V262, P12316; KOZIOL J., 1971, Methods in Enzymology, V18B, P253, DOI 10.1016/S0076-6879(71)18089-5; MAKINO R, 1980, J BIOL CHEM, V255, P1883; MAKINO R, 1986, J BIOL CHEM, V261, P1144; MIKI T, 1992, J BIOL CHEM, V267, P19673; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; OMURA T, 1970, J BIOCHEM-TOKYO, V67, P249, DOI 10.1093/oxfordjournals.jbchem.a129248; ORII Y, 1984, J BIOL CHEM, V259, P7187; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; ROOME PW, 1983, J BIOL CHEM, V258, P2593; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; SUTIN N, 1972, J BIOL CHEM, V247, P6932; TANAKA T, 1990, J BIOL CHEM, V265, P18717; TEAHAN C, 1987, NATURE, V327, P720, DOI 10.1038/327720a0; UENO I, 1991, FEBS LETT, V281, P130, DOI 10.1016/0014-5793(91)80375-D; UMEI T, 1991, J BIOL CHEM, V266, P6019; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; YEA CM, 1990, BIOCHEM J, V265, P95, DOI 10.1042/bj2650095; YONETANI T, 1971, J BIOL CHEM, V246, P7683	41	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4025	4031						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8382686				2022-12-25	WOS:A1993KN53300036
J	HALL, TR; WALLIN, R; REINHART, GD; HUTSON, SM				HALL, TR; WALLIN, R; REINHART, GD; HUTSON, SM			BRANCHED-CHAIN AMINOTRANSFERASE ISOENZYMES - PURIFICATION AND CHARACTERIZATION OF THE RAT-BRAIN ISOENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART MITOCHONDRIA; PROTEINS; TISSUES; TRANSAMINASE; MECHANISM; CULTURES; MEMBRANE; ACIDS; LIVER	This paper presents the first complete purification of the branched chain aminotransferase (EC 2.6.1.42) from rat brain cytosol (BCAT(c)). On sodium dodecyl sulfate-polyacrylamide gel electrophoresis the enzyme appeared as a single band with a molecular mass of 47 kDa; however, gel exclusion chromatography suggested that BCAT(c) is a dimer. Comparison of tryptic peptide maps of BCAT(c) and the mitochondrial form of the enzyme (BCAT(m)) indicated that they are different proteins. Experiments with protein labeling reagents, in particular sulfhydryl reagents, also suggested that there may be some distinct structural differences in BCAT(c) and BCAT(m). Nevertheless, BCAT(c) and BCAT(m) showed similar specificities for amino acid and alpha-keto acid substrates. Both enzymes transaminated branched chain amino acids, their straight chain analogs, L-alloisoleucine and glutamate. A broader range of alpha-keto acids than amino acids was accepted as substrate including alpha-ketobutyrate and the alpha-keto acid of methionine. Both enzymes exhibited ping-pong kinetics with apparent K(m) values for leucine and isoleucine of about 1 and 5 mm for valine, respectively. K(m) values for alpha-ketoglutarate ranged from about 0.6 to 3 mm depending on the amino acid substrate. Polyclonal antibodies were raised in rabbits against purified BCAT(c). BCAT(c) antiserum neutralized branched chain aminotransferase activity in rat brain cytosol but did not affect the activity in a heart mitochondrial extract. However, immunoblotting showed that BCAT(c) and BCAT(m) do share common epitopes since BCAT(m) antiserum recognized BCAT(c) on the immunoblots. The tissue distribution of BCAT(c) was examined using BCAT(c) and BCAT(m) antisera. These data showed that BCAT(c) was found in adult and fetal rat brain, cultured cells from fetal rat brain cortex, ovary, and placenta. Brain had the highest activity followed by ovary, fetal brain, and placenta. BCAT(c) was not found in fetal liver, adult rat liver, or a rat hepatoma cell line. These data provide clear evidence that BCAT(c), unlike BCAT(m), is restricted to several highly specialized tissues.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,MED CTR BLVD,WINSTON SALEM,NC 27157; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,RHEUMATOL SECT,WINSTON SALEM,NC 27157; UNIV OKLAHOMA,DEPT CHEM & BIOCHEM,NORMAN,OK 73018	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; University of Oklahoma System; University of Oklahoma - Norman					NIDDK NIH HHS [DK34738] Funding Source: Medline; NIGMS NIH HHS [GM33216] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033216] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKI K, 1969, J BIOCHEM-TOKYO, V65, P539, DOI 10.1093/oxfordjournals.jbchem.a129047; Arnone A, 1985, TRANSAMINASES, P138; BENNETT BA, 1989, BRAIN RES, V491, P109, DOI 10.1016/0006-8993(89)90092-9; BOOTH RFG, 1978, BIOCHEM J, V176, P365, DOI 10.1042/bj1760365; CLELAND WW, 1967, ADV ENZYMOL RAMB, V29, P1; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; COOPER AJL, 1987, PHYSIOL REV, V67, P440, DOI 10.1152/physrev.1987.67.2.440; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; ELDER JH, 1977, J BIOL CHEM, V252, P6510; ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GEHRING H, 1985, TRANSAMINASES, P373; GOTO M, 1977, GANN, V68, P663; HALESTRAP AP, 1978, BIOCHEM J, V172, P377, DOI 10.1042/bj1720377; HARPER AE, 1989, ANN NY ACAD SCI, V573, P413; HUTSON SM, 1990, P NATL ACAD SCI USA, V87, P1028, DOI 10.1073/pnas.87.3.1028; HUTSON SM, 1992, J BIOL CHEM, V267, P15681; HUTSON SM, 1988, J BIOL CHEM, V263, P3618; HUTSON SM, 1993, J BIOL CHEM, V268, P3084; HUTSON SM, 1988, J NUTR, V118, P1475, DOI 10.1093/jn/118.12.1475; Ichihara A, 1985, TRANSAMINASES, P430; KADOWAKI H, 1982, BIOCHEM J, V202, P777, DOI 10.1042/bj2020777; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai J.C.K., 1989, NEUROMETHODS, P43; LOWRY M, 1980, BIOCHEM J, V190, P771, DOI 10.1042/bj1900771; MAKINO M, 1984, COMP BIOCHEM PHYS B, V77, P175, DOI 10.1016/0305-0491(84)90240-2; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; NEELY JR, 1976, CIRC RES, V38, P22; OGAWA K, 1970, J BIOCHEM-TOKYO, V68, P901, DOI 10.1093/oxfordjournals.jbchem.a129429; REIDERER BM, 1987, J NEUROSCI, V7, P864; ROTH SL, 1977, CANCER RES, V37, P1147; RUDIGER HW, 1972, BIOCHEM J, V126, P445, DOI 10.1042/bj1260445; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SPACH PI, 1991, BIOCHIM BIOPHYS ACTA, V1056, P40, DOI 10.1016/S0005-2728(05)80070-2; STERNICZUK A, 1991, EUR J BIOCHEM, V196, P143, DOI 10.1111/j.1432-1033.1991.tb15797.x; TAYLOR RT, 1966, J BIOL CHEM, V241, P4396; WALLIN R, 1990, J BIOL CHEM, V265, P6019; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	39	130	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3092	3098						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8381418				2022-12-25	WOS:A1993KM16100015
J	KONTANI, K; NISHINA, H; OHOKA, Y; TAKAHASHI, K; KATADA, T				KONTANI, K; NISHINA, H; OHOKA, Y; TAKAHASHI, K; KATADA, T			NAD GLYCOHYDROLASE SPECIFICALLY INDUCED BY RETINOIC ACID IN HUMAN LEUKEMIC HL-60 CELLS - IDENTIFICATION OF THE NAD GLYCOHYDROLASE AS LEUKOCYTE CELL-SURFACE ANTIGEN CD38	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADP-RIBOSYL CYCLASE; CYCLIC METABOLITE; LINES HL-60; DIFFERENTIATION; MOLECULE; INDUCTION; PROLIFERATION; EXPRESSION; ACTIVATION; CULTURE	Human leukemic HL-60 cells are differentiated into granulocytic cells by retinoic acid, and this differentiation is preceded by the induction of an ecto-enzyme of NAD glycohydrolase (NADase). The NADase specifically induced by retinoic acid appeared to be encoded by human leukocyte cell surface antigen CD38 as follows. 1) There was an early expression of CD38 mRNA, together with the induction of the NADase activity, in the retinoic acid-treated HL-60 cells. 2) The time course of the expression of CD38 antigen on the cell surface was well correlated with that of the induction of NADase activity. 3) The NADase activity solubilized from the differentiated HL-60 cell membrane could be immunoprecipitated with an anti-CD38 monoclonal antibody. 4) Introduction of the CD38 cDNA into Escherichia coli cells resulted in the expression of an NADase, the activity of which was inhibited by dithiothreitol. The NADase activity in the differentiated cells was also inhibited by the reducing reagent. These results clearly indicated that the dithiothreitol-sensitive NADase activity induced by retinoic acid in HL-60 cells is attributed to the molecule of human leukocyte cell surface antigen CD38, which contains cysteine-rich cytoplasmic domain within its molecule.	TOKYO INST TECHNOL,DEPT LIFE SCI,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN	Tokyo Institute of Technology								ALESSIO M, 1990, J IMMUNOL, V145, P878; BAEHNER RL, 1968, NEW ENGL J MED, V278, P971, DOI 10.1056/NEJM196805022781801; BOSS MA, 1980, BLOOD, V56, P910; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COLLINS SJ, 1987, BLOOD, V70, P1233; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; FERRERO D, 1983, BLOOD, V61, P171; FUNARO A, 1990, J IMMUNOL, V145, P2390; HEMMI H, 1982, BIOCHEM BIOPH RES CO, V109, P669, DOI 10.1016/0006-291X(82)91992-1; IIRI T, 1992, J BIOL CHEM, V267, P1020; JACKSON DG, 1990, J IMMUNOL, V144, P2811; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1993, BIOCHEM BIOPH RES CO, V191, P639, DOI 10.1006/bbrc.1993.1265; LEE HC, 1989, J BIOL CHEM, V264, P1608; LINDER FT, 1989, J IMMUNOL, V143, P1815; MALAVASI F, 1992, INT J CLIN LAB RES, V22, P73, DOI 10.1007/BF02591400; MICHELLE L, 1988, J EXP MED, V168, P1247; MIYAURA C, 1981, BIOCHEM BIOPH RES CO, V102, P937, DOI 10.1016/0006-291X(81)91628-4; MULLER HM, 1983, BIOCHEM J, V212, P456; OINUMA M, 1983, ARCH BIOCHEM BIOPHYS, V224, P290; OLSSON IL, 1982, CANCER RES, V42, P3928; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TOHKIN M, 1989, FEBS LETT, V225, P187; UHHYUN K, 1988, BIOCHIM BIOPHYS ACTA, V965, P76	29	147	148	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16895	16898						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8394323				2022-12-25	WOS:A1993LQ98800007
J	WOLF, BB; VASUDEVAN, J; HENKIN, J; GONIAS, SL				WOLF, BB; VASUDEVAN, J; HENKIN, J; GONIAS, SL			NERVE GROWTH FACTOR-GAMMA ACTIVATES SOLUBLE AND RECEPTOR-BOUND SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR MASS UROKINASE; AMINO-ACID-SEQUENCE; PRO-UROKINASE; U937 MONOCYTES; HUMAN-URINE; SUBUNIT; BINDING; FORM; KALLIKREIN; MECHANISM	Nerve growth factor-gamma (NGF-gamma) is a serine proteinase which reversibly associates with the well characterized neurotrophin NGF-beta. In this study, we demonstrated that NGF-gamma cleaves recombinant single chain urokinase-type plasminogen activator (scu-PA), converting the zymogen into a two-chain form (tcu-PA). The apparent masses of the two u-PA chains were 33 and 22 kDa, as determined by SDS-polyacrylamide gel electrophoresis (PAGE). There was no evidence for secondary cleavage sites or further digestion of tcu-PA by NGF-gamma, even when conversion of scu-PA was complete. The NH2-terminal sequence of the 33-kDa band was Ile-Ile-Gly-Gly-Glu, indicating that NGF-gamma cleaved scu-PA at Lys158-Ile159, the plasmin cleavage site. Cleavage of scu-PA by NGF-gamma resulted in scu-PA activation. The k(cat) and K(m) for this reaction, as determined in a continuous assay with the tcu-PA-specific substrate L-pyroglutamyl-glycyl-arginine-p-nitroanilide hydrochloride (S-2444), were (4.1 +/- 0.6) x 10(-2) s-1 and 2.3 +/- 0.4 muM, respectively. The catalytic efficiency (k(cat)/K(m)) for scu-PA activation by NGF-gamma was 1.3 x 10(4) M-1 s-1, compared with 6.2 x 10(5) M-1 s-1 for the activation of scu-PA by plasmin. NGF-gamma-cleaved scu-PA which was bound to receptors on U937 monocytoid cells. The apparent masses of the resulting u-PA cleavage products were identical to those generated in solution as determined by SDS-PAGE. Cell-associated scu-PA was activated by NGF-gamma, as determined by the generation of activity against the tcu-PA-specific fluorogenic substrate, glutamyl-glycyl-arginine-7-amino-4-methyl coumarin. By activating scu-PA, NGF-gamma may initiate the u-PA-dependent cell-surface proteinase cascade and support NGF-beta activities which involve cellular migration and/or extracellular matrix remodeling.	UNIV VIRGINIA, HLTH SCI CTR, DEPT PATHOL, BOX 214, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT BIOCHEM, CHARLOTTESVILLE, VA 22908 USA; ABBOTT LABS, N CHICAGO, IL 60064 USA	University of Virginia; University of Virginia; Abbott Laboratories					NCI NIH HHS [CA-53462] Funding Source: Medline; NHLBI NIH HHS [HL-45786] Funding Source: Medline; NIGMS NIH HHS [GM 07267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053462] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANONICK PK, 1991, BIOCHEM J, V275, P53, DOI 10.1042/bj2750053; BERGER EA, 1977, P NATL ACAD SCI USA, V74, P3647, DOI 10.1073/pnas.74.9.3647; BOTHWELL MA, 1978, J BIOL CHEM, V253, P8458; BOYLE MDP, 1985, J IMMUNOL, V134, P564; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; DARLING TL, 1984, CELL CULTURE METHODS, V4, P79; DEMUNK GAW, 1990, FIBRINOLYSIS, V4, P1, DOI 10.1016/S0268-9499(05)80034-7; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; EDWARDS RH, 1988, J BIOL CHEM, V263, P6810; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ELLIS V, 1992, FIBRINOLYSIS, V6, P27; EVANS BA, 1985, EMBO J, V4, P133, DOI 10.1002/j.1460-2075.1985.tb02327.x; EVANS BA, 1987, J BIOL CHEM, V262, P8027; FAHNESTOCK M, 1991, CURR TOP MICROBIOL, V165, P1; GEE AP, 1983, P NATL ACAD SCI-BIOL, V80, P7215, DOI 10.1073/pnas.80.23.7215; GONIAS SL, 1988, BIOCHEM J, V255, P725; GONIAS SL, 1988, BLOOD, V72, P1658; GORETZKI L, 1992, FEBS LETT, V297, P112, DOI 10.1016/0014-5793(92)80339-I; GREENE LA, 1969, BIOCHEMISTRY-US, V8, P3735, DOI 10.1021/bi00837a037; GUNZLER WA, 1982, H-S Z PHYSIOL CHEM, V363, P1155, DOI 10.1515/bchm2.1982.363.2.1155; GUREWICH V, 1988, SEMIN THROMB HEMOST, V14, P110, DOI 10.1055/s-2007-1002763; HARRISWARRICK RM, 1980, J BIOL CHEM, V255, P1284; ICHINOSE A, 1986, J BIOL CHEM, V261, P3486; ISACKSON PJ, 1987, J CELL BIOCHEM, V33, P65, DOI 10.1002/jcb.240330107; KIMATA H, 1991, EUR J IMMUNOL, V21, P137, DOI 10.1002/eji.1830210121; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; KOIVUNEN E, 1989, J BIOL CHEM, V264, P14095; KRYSTOSEK A, 1984, J CELL BIOL, V98, P773, DOI 10.1083/jcb.98.2.773; LI AKC, 1980, P NATL ACAD SCI-BIOL, V77, P4379, DOI 10.1073/pnas.77.7.4379; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LONGSTAFF C, 1992, J BIOL CHEM, V267, P173; MARSHALL JS, 1990, J IMMUNOL, V144, P1886; MASON AJ, 1983, NATURE, V303, P300, DOI 10.1038/303300a0; MOORE JB, 1974, BIOCHEMISTRY-US, V13, P833, DOI 10.1021/bi00701a030; ORENSTEIN NS, 1978, P NATL ACAD SCI USA, V75, P5497, DOI 10.1073/pnas.75.11.5497; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; PICONE R, 1989, J CELL BIOL, V108, P693, DOI 10.1083/jcb.108.2.693; SCULLY MF, 1989, ARCH BIOCHEM BIOPHYS, V268, P438, DOI 10.1016/0003-9861(89)90311-1; SEEDS NW, 1992, ANN NY ACAD SCI, V667, P32; SMITH AP, 1968, BIOCHEMISTRY-US, V7, P3259, DOI 10.1021/bi00849a032; STEFFENS GJ, 1982, H-S Z PHYSIOL CHEM, V363, P1043, DOI 10.1515/bchm2.1982.363.2.1043; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; THOMAS KA, 1981, J BIOL CHEM, V256, P9016; THORPE LW, 1987, J NEUROSCI RES, V18, P134, DOI 10.1002/jnr.490180120; VARON S, 1967, BIOCHEMISTRY-US, V6, P2202, DOI 10.1021/bi00859a043; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WOLF BB, 1993, BIOCHEMISTRY-US, V32, P1875, DOI 10.1021/bi00058a022; WOODRUFF NR, 1986, BIOCHEMISTRY-US, V25, P7967, DOI 10.1021/bi00372a027; YOUNG M, 1988, BIOCHEMISTRY-US, V27, P6675, DOI 10.1021/bi00418a005	53	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16327	16331						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8393859				2022-12-25	WOS:A1993LQ33600039
J	ZHANG, BW; MARCUS, SL; MIYATA, KS; SUBRAMANI, S; CAPONE, JP; RACHUBINSKI, RA				ZHANG, BW; MARCUS, SL; MIYATA, KS; SUBRAMANI, S; CAPONE, JP; RACHUBINSKI, RA			CHARACTERIZATION OF PROTEIN-DNA INTERACTIONS WITHIN THE PEROXISOME PROLIFERATOR-RESPONSIVE ELEMENT OF THE RAT HYDRATASE-DEHYDROGENASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE RECEPTOR SUPERFAMILY; ACYL-COA OXIDASE; THYROID-HORMONE; BETA-OXIDATION; TRANSCRIPTION; INDUCTION; ENHANCER; ENZYMES; MEMBER; LIVER	A peroxisome proliferator-responsive element is located in the 5'-flanking region of the gene encoding rat hydratase-dehydrogenase, the second enzyme of the peroxisomal beta-oxidation pathway. DNase I foot print analysis with nuclear extracts from proliferator responsive rat H4IIEC3 cells revealed two protected regions within the 196-base pair peroxisome proliferator-responsive element. Both regions contained multiple copies of a motif related to the consensus steroid hormone receptor binding half-site TGACCT, suggesting that peroxisome proliferator-dependent activation of this gene is mediated via peroxisome proliferator-activated receptors. Region II contains three TGACCT-like motifs in a direct repeat array. An oligonucleotide corresponding to this region was sufficient to confer responsiveness to the peroxisome proliferator ciprofibrate onto a heterologous promoter, as determined by transient transfection assays. Gel retardation assays demonstrated that nuclear factors bound to the hydratase-dehydrogenase oligonucleotide. Mutation of a single G residue within the second repeat motif abolished factor binding and consequently the ability of the element to respond to ciprofibrate, directly demonstrating that factor binding is necessary for peroxisome proliferator responsiveness. These results are discussed in the context of our current understanding of the mechanism of the coordinated transcriptional induction of the genes encoding peroxisomal beta-oxidation enzymes by peroxisome proliferators.	MCMASTER UNIV,DEPT BIOCHEM,HAMILTON L8S 4L8,ONTARIO,CANADA; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	McMaster University; University of California System; University of California San Diego					NIDDK NIH HHS [DK41737] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK041737, R01DK041737] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FURUTA S, 1982, J BIOCHEM, V92, P319, DOI 10.1093/oxfordjournals.jbchem.a133937; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P463; GREEN S, 1992, BIOCHEM PHARMACOL, V43, P393, DOI 10.1016/0006-2952(92)90554-V; HAVEL RJ, 1973, ANNU REV PHARMACOL, V13, P287, DOI 10.1146/annurev.pa.13.040173.001443; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; OSUMI T, 1990, J BIOCHEM-TOKYO, V108, P614, DOI 10.1093/oxfordjournals.jbchem.a123252; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; REDDY JK, 1990, BIOCHEM SOC T, V18, P92, DOI 10.1042/bst0180092; REIK A, 1991, EMBO J, V10, P2569, DOI 10.1002/j.1460-2075.1991.tb07797.x; SHARMA RK, 1989, EUR J BIOCHEM, V184, P69, DOI 10.1111/j.1432-1033.1989.tb14991.x; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Vamecq J, 1989, Essays Biochem, V24, P115; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	28	81	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12939	12945						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8389766				2022-12-25	WOS:A1993LG65800102
J	BRYCE, DM; LIU, QR; KHOO, W; TSUI, LC; BREITMAN, ML				BRYCE, DM; LIU, QR; KHOO, W; TSUI, LC; BREITMAN, ML			PROGRESSIVE AND REGRESSIVE FATE OF LENS TUMORS CORRELATES WITH SUBTLE DIFFERENCES IN TRANSGENE EXPRESSION IN GAMMA-F-CRYSTALLIN-SV40 T-ANTIGEN TRANSGENIC MICE	ONCOGENE			English	Article							GAMMA-CRYSTALLIN GENES; MOUSE LENS; EYE LENS; REGULATORY ELEMENTS; CELL ELONGATION; RAT LENS; PROMOTER; DIFFERENTIATION; MORPHOGENESIS; ENHANCER	Regulatory elements of the mouse gammaF-crystallin gene were used to derive transgenic mice expressing SV40 large T antigen in terminally differentiating fiber cells of the ocular lens. The resulting gammaF-crystallin-T antigen mice developed either malignant or regressive lens tumors in a strain-dependent fashion. Developmental and RNA analyses revealed that in both 'tumor-progressing' and 'tumor-regressing' mouse strains expression of the transgene blocked morphological differentiation of lens fibers without appreciably affecting gamma-crystallin gene expression, a marker of terminal lens fiber cell differentiation. Strain-dependent differences in tumorigenic outcome could be correlated with both subtle differences in transgene expression and the ability of tumor cells to escape from the normal confines of the lens. The results implicate the importance of cellular environment to malignant tumor development and provide insight into those features of normal lens ontogeny that may render the lens refractory to the development of spontaneous tumors.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL 600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA; HOSP SICK CHILDREN,DEPT GENET,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto			Tsui, Lap-chee/A-1081-2010	Bryce, Dawn/0000-0002-7403-2940				BREITMAN ML, 1987, SCIENCE, V238, P1563, DOI 10.1126/science.3685993; BREITMAN ML, 1989, DEVELOPMENT, V106, P457; BREITMAN ML, 1984, P NATL ACAD SCI-BIOL, V81, P7762, DOI 10.1073/pnas.81.24.7762; CHEPELINSKY AB, 1987, MOL CELL BIOL, V7, P1807, DOI 10.1128/MCB.7.5.1807; COUNIS MF, 1989, INT J BIOCHEM, V21, P235, DOI 10.1016/0020-711X(89)90181-X; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; GORING DR, 1987, SCIENCE, V235, P456, DOI 10.1126/science.3099390; GORING DR, 1992, EXP EYE RES, V54, P785, DOI 10.1016/0014-4835(92)90034-P; GRIEP AE, 1989, GENE DEV, V3, P1075, DOI 10.1101/gad.3.7.1075; HAYASHI S, 1987, GENE DEV, V1, P818, DOI 10.1101/gad.1.8.818; LIU QR, 1991, MOL CELL BIOL, V11, P1531, DOI 10.1128/MCB.11.3.1531; LOK S, 1989, NUCLEIC ACIDS RES, V17, P3563, DOI 10.1093/nar/17.9.3563; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MATSUO I, 1991, DEVELOPMENT, V113, P539; MCAVOY JW, 1978, J EMBRYOL EXP MORPH, V44, P149; MCAVOY JW, 1978, J EMBRYOL EXP MORPH, V45, P271; MCAVOY JW, 1980, DIFFERENTIATION, V17, P137, DOI 10.1111/j.1432-0436.1980.tb01091.x; MEAKIN SO, 1989, EXP EYE RES, V48, P131, DOI 10.1016/0014-4835(89)90026-2; MURERORLANDO M, 1987, DEV BIOL, V119, P260, DOI 10.1016/0012-1606(87)90227-2; NAKAMURA T, 1989, New Biologist, V1, P193; OVERBEEK PA, 1985, P NATL ACAD SCI USA, V82, P7815, DOI 10.1073/pnas.82.23.7815; PEEK R, 1990, NUCLEIC ACIDS RES, V18, P1189, DOI 10.1093/nar/18.5.1189; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; SACHS E, 1948, AM J OPHTHALMOL, V31, P561, DOI 10.1016/0002-9394(48)90558-3; SIEZEN RJ, 1988, J MOL BIOL, V199, P475, DOI 10.1016/0022-2836(88)90619-5; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAKAHASHI Y, 1988, DEVELOPMENT, V102, P259; VANLEEN RW, 1987, DEV BIOL, V120, P457, DOI 10.1016/0012-1606(87)90249-1; YU CCK, 1990, DEVELOPMENT, V110, P131	30	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1611	1620						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8389033				2022-12-25	WOS:A1993LE06400025
J	RICHARME, G; ELYAAGOUBI, A; KOHIYAMA, M				RICHARME, G; ELYAAGOUBI, A; KOHIYAMA, M			THE MGLA COMPONENT OF THE BINDING PROTEIN-DEPENDENT GALACTOSE TRANSPORT-SYSTEM OF SALMONELLA-TYPHIMURIUM IS A GALACTOSE-STIMULATED ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MEMBRANE-VESICLES; ACTIVE-TRANSPORT; PERIPLASMIC TRANSPORT; NUCLEOTIDE-BINDING; RECONSTITUTION; INHIBITION; PERMEASE; VANADATE; MALTOSE	Binding protein-dependent transport systems mediate the accumulation of several ions, sugars, amino acids, and peptides in Gram-negative bacteria by using the energy of ATP hydrolysis and belong to a superfamily of membrane proteins which extends to eukaryotic cells and includes the multidrug resistance P-glycoprotein and the cystic fibrosis transmembrane conductance regulator. The binding protein-dependent galactose transport system of Salmonella typhimurium comprises four proteins which have been characterized previously by molecular cloning experiments (51,000-dalton MglA protein, with a stable proteolytic product of 38,000 daltons, 33,000-dalton MglB protein, 29,000-dalton MglC protein, 21,000-dalton MglE protein). By using a MglA hyperproducing strain, we have purified a galactose-stimulated ATPase which shows a single band in polyacrylamide gels under nondenaturing conditions and shows three bands at 51,000, 38,000, and 15,000 daltons on sodium dodecyl sulfate-polyacrylamide gels (our results suggest that the bands at 38,000 and 15,000 daltons represent proteolytic products of the 51,000-dalton protein). The ATPase activity coincides with the purified protein during the two last chromatographic steps of the purification procedure, and it cannot be isolated from a strain which does not contain the mglA gene. The MglA ATPase is stimulated 3-fold by galactose and hydrolyzes ATP to ADP and P(i) (K(m) ATP = 60 muM, K(a) galactose = 0.3 mM, V(max) = 140 nmol/min/mg of protein). The gamma-phosphate of ATP is transferred neither to galactose nor to the protein itself. Vanadate, N-ethylmaleimide and 5-methoxyindole-2-carboxylic acid, a specific inhibitor of binding protein-dependent transport systems, inhibit the MglA ATPase.			RICHARME, G (corresponding author), UNIV PARIS 07,INST J MONOD,TOUR 43,2 PL JUSSIEU,F-75221 PARIS 05,FRANCE.							AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AMES GF, 1989, J BIOL CHEM, V264, P3998; AMES GFL, 1981, EUR J BIOCHEM, V115, P525; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; BERGER EA, 1974, J BIOL CHEM, V249, P7747; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; BOOS W, 1974, ANNU REV BIOCHEM, V43, P123, DOI 10.1146/annurev.bi.43.070174.001011; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTTIN G, 1963, J MOL BIOL, V7, P167; CANTLEY LC, 1977, J BIOL CHEM, V252, P7421; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; DEAN DA, 1989, J BACTERIOL, V171, P503, DOI 10.1128/jb.171.1.503-510.1989; FURLONG CE, 1987, ESCHERICHIA COLI SAL, P768; GIBBONS IR, 1978, P NATL ACAD SCI USA, V75, P2220, DOI 10.1073/pnas.75.5.2220; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HAMADA H, 1987, CANCER RES, V47, P2860; HIGGINS CF, 1985, EMBO J, V4, P1033, DOI 10.1002/j.1460-2075.1985.tb03735.x; HONG JS, 1979, P NATL ACAD SCI USA, V76, P1213, DOI 10.1073/pnas.76.3.1213; HUNT AG, 1983, BIOCHEMISTRY-US, V22, P844, DOI 10.1021/bi00273a021; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KLEIN WL, 1972, J BIOL CHEM, V247, P7257; KURIKI Y, 1976, BIOCHEMISTRY-US, V15, P4951, DOI 10.1021/bi00668a001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MULLER N, 1985, J BACTERIOL, V163, P37; NIMMACK ML, 1989, P NATL ACAD SCI USA, V86, P8257; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PETRONILLI V, 1991, J BIOL CHEM, V266, P16293; PLATE CA, 1979, J BACTERIOL, V137, P221, DOI 10.1128/JB.137.1.221-225.1979; POST RL, 1965, J BIOL CHEM, V240, P1437; PROSSNITZ E, 1989, J BIOL CHEM, V264, P5006; RICHARME G, 1985, J BACTERIOL, V162, P286, DOI 10.1128/JB.162.1.286-293.1985; RICHARME G, 1992, BIOCHIM BIOPHYS ACTA, V1104, P201, DOI 10.1016/0005-2736(92)90151-B; RICHARME G, 1985, BIOCHIM BIOPHYS ACTA, V815, P37, DOI 10.1016/0005-2736(85)90471-7; RIORDAN JR, 1989, SCIENCE, V245, P1066; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SHLOMAI J, 1980, P NATL ACAD SCI-BIOL, V77, P799, DOI 10.1073/pnas.77.2.799; SIEBERS A, 1988, EUR J BIOCHEM, V178, P131, DOI 10.1111/j.1432-1033.1988.tb14438.x; SPEISER DM, 1991, J BACTERIOL, V173, P1444, DOI 10.1128/jb.173.4.1444-1451.1991; TREPTOW NA, 1985, J BACTERIOL, V163, P654, DOI 10.1128/JB.163.2.654-660.1985; WALTER C, 1992, J BIOL CHEM, V267, P8863; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	44	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9473	9477						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8387496				2022-12-25	WOS:A1993LA68900050
J	WINTER, B; BRAUN, T; ARNOLD, HH				WINTER, B; BRAUN, T; ARNOLD, HH			CAMP-DEPENDENT PROTEIN-KINASE REPRESSES MYOGENIC DIFFERENTIATION AND THE ACTIVITY OF THE MUSCLE-SPECIFIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS MYF-5 AND MYOD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY GENE; DNA-BINDING; C-MYC; EXPRESSION; ACTIVATION; ENHANCER; FAMILY; CELLS; FIBROBLASTS; MYOBLASTS	Myf-5 and MyoD are members of a family of muscle-specific basic helix-loop-helix (bHLH) proteins that are fundamental for myogenic cell differentiation and transcriptional activation of muscle-specific genes. Here we report that elevated levels of the intracellular signaling molecule cAMP and overexpression of cAMP-dependent protein kinase (PKA) inhibit myogenic differentiation. PKA represses the transcriptional activation of muscle-specific genes by the myogenic regulators Myf-5 and MyoD. The repression is directed at the basic HLH domain and is mediated through the E-box DNA consensus motif to which these proteins bind. However, phosphorylation of Myf-5 and MyoD by PKA in vitro does not affect their ability to bind to DNA. PKA specifically inhibits the activity of myogenic bHLH proteins, but not of other HLH proteins, such as the ubiquitously expressed E2A gene products E12 and E47 (E2-5). Our results demonstrate that PKA mediates the cAMP-induced inhibition of muscle cell differentiation by repressing the activity of Myf-5 and MyoD. The inhibition by PKA occurs post-translationally and presumably affects the transactivation process at a step following DNA-binding. The regulation of Myf-5 and MyoD function by a cAMP-dependent pathway may partly explain how external signals generated by serum and certain peptide growth factors can be transduced to the nucleus and inhibit dominant-acting factors that are responsible for myoblast differentiation.	TECH UNIV CAROLO WILHELMINA BRAUNSCHWEIG,DEPT CELL & MOLEC BIOL,KONSTANTIN UHDE STR 5,W-3300 BRAUNSCHWEIG,GERMANY	Braunschweig University of Technology			Braun, Thomas/B-2310-2008	Braun, Thomas/0000-0002-6165-4804				BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; BRAUN T, 1989, MOL CELL BIOL, V9, P2513, DOI 10.1128/MCB.9.6.2513; BRAUN T, 1990, NATURE, V346, P663, DOI 10.1038/346663a0; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; BRAUN T, 1991, EUR J BIOCHEM, V198, P187, DOI 10.1111/j.1432-1033.1991.tb16000.x; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRAUN T, 1991, NUCLEIC ACIDS RES, V19, P5645, DOI 10.1093/nar/19.20.5645; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHERRY JR, 1989, CELL, V56, P409, DOI 10.1016/0092-8674(89)90244-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Emerson CP, 1990, CURR OPIN CELL BIOL, V2, P1065, DOI 10.1016/0955-0674(90)90157-A; ENKEMANN SA, 1990, CELL GROWTH DIFFER, V1, P375; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HU JS, 1988, J BIOL CHEM, V263, P19670; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LI L, 1992, MOL CELL BIOL, V12, P4478, DOI 10.1128/MCB.12.10.4478; LOHSE P, 1988, NUCLEIC ACIDS RES, V16, P2787, DOI 10.1093/nar/16.7.2787; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; OTT MO, 1991, DEVELOPMENT, V111, P1097; PAYNE PA, 1987, P NATL ACAD SCI USA, V84, P8956, DOI 10.1073/pnas.84.24.8956; RAHM M, 1989, J CELL PHYSIOL, V139, P237, DOI 10.1002/jcp.1041390204; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; ROSENTHAL N, 1990, NUCLEIC ACIDS RES, V18, P6239, DOI 10.1093/nar/18.21.6239; SALMINEN A, 1991, J CELL BIOL, V115, P905, DOI 10.1083/jcb.115.4.905; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCHAFER BW, 1990, NATURE, V344, P454, DOI 10.1038/344454a0; SCHNEIDER MD, 1987, MOL CELL BIOL, V7, P1973, DOI 10.1128/MCB.7.5.1973; SCHWARZ JJ, 1992, MOL CELL BIOL, V12, P266, DOI 10.1128/MCB.12.1.266; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TAYLOR WE, 1990, P NATL ACAD SCI USA, V87, P4098, DOI 10.1073/pnas.87.11.4098; UHLER MD, 1987, J BIOL CHEM, V262, P15202; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WINTER B, 1992, EMBO J, V11, P1843, DOI 10.1002/j.1460-2075.1992.tb05236.x; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	62	92	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9869	9878						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8387507				2022-12-25	WOS:A1993LA68900102
J	URANO, T; FURUKAWA, K; SHIKU, H				URANO, T; FURUKAWA, K; SHIKU, H			EXPRESSION OF NM23 NDP KINASE PROTEINS ON THE CELL-SURFACE	ONCOGENE			English	Note							NUCLEOSIDE DIPHOSPHATE-KINASE; BINDING-PROTEINS; GENE; ASSOCIATION; DROSOPHILA; METASTASIS; CLONING	We determined whether proteins encoded by the nm23/nucleoside diphosphate (NDP) kinase gene, a potential metastasis-suppressor gene, are expressed on the cell surface. Monoclonal antibodies (mAb) specific for nm23-H1 or H2 proteins were prepared using the corresponding fusion proteins with glutathione S-transferase (GST) as immunogens. mAb H1-229 was specifically reactive with nm23-H1 protein, whereas mAb H2-439 was specific for nm23-H2 protein in immunoprecipitation and immunoblotting. mAb H1-229 was reactive with most human hematopoietic and some non-hematopoietic cell lines in flow cytometry. On the other hand, mAb H2-439 was reactive with only a limited number of cell lines. Based upon the surface expression of nm23/NDP kinase, cells were classified as nm23-H1+H2-, nm23-H1+H2+ or nm23-H1-H2-. No cell lines with nm23-H1-H2+ were found among those examined. The specificity of flow cytometry analysis was confirmed in the murine myeloma line NS-1 transfected with either the nm23-H1 or H2 genes. Both mAbs were reactive only to NS-1 transfected with the corresponding nm23 genes. Immunoprecipitation and SDS-PAGE analysis identified 20.5- and 18-kDa proteins with mAb H1-229 or H2-439, respectively, in cellular extracts of I-125-surface labeled NS-1 transfected with the corresponding genes. The presence of nm23/NDP kinase on the cell surface indicates an extracellular role for these proteins in addition to their reported intracellular functions.	NAGASAKI UNIV,SCH MED,DEPT ONCOL,1-12-4 SAKAMOTO,NAGASAKI 852,JAPAN	Nagasaki University				Urano, Takeshi/0000-0003-3383-3554				BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; Coligan JKA, 1991, CURRENT PROTOCOLS IM; GILLES AM, 1991, J BIOL CHEM, V266, P8784; HAMA H, 1991, GENE, V105, P31, DOI 10.1016/0378-1119(91)90510-I; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; KIMURA N, 1990, J BIOL CHEM, V265, P15744; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2702; OHTSUKI K, 1987, BIOCHEM BIOPH RES CO, V148, P300, DOI 10.1016/0006-291X(87)91110-7; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; URANO T, 1992, FEBS LETT, V309, P358, DOI 10.1016/0014-5793(92)80807-S; URANO T, 1992, INT J ONCOL, V1, P425; WALSER A, 1989, J VIROL, V63, P3926, DOI 10.1128/JVI.63.9.3926-3933.1989	22	74	76	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1371	1376						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8386830				2022-12-25	WOS:A1993KY32800031
J	MASUTANI, C; SUGASAWA, K; ASAHINA, H; TANAKA, K; HANAOKA, F				MASUTANI, C; SUGASAWA, K; ASAHINA, H; TANAKA, K; HANAOKA, F			CELL-FREE REPAIR OF UV-DAMAGED SIMIAN VIRUS-40 CHROMOSOMES IN HUMAN CELL-EXTRACTS .2. DEFECTIVE-DNA REPAIR SYNTHESIS BY XERODERMA-PIGMENTOSUM CELL-EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION REPAIR; PROTEIN; GENE; COMPLEMENTATION; CLONING	We have constructed a cell-free DNA repair system with UV-irradiated SV40 minichromosomes, as described in the accompanying paper (Sugasawa, K, Masutani, C., and Hanaoka, F. (1993) J. Biol. Chem 268, 9098-9104). In this study, we examined DNA repair synthesis by cell extracts from seven xeroderma pigmentosum (XP) complementation groups, A through G. DNA repair synthesis by XP cell extracts was lower than that with repair-proficient human 293 cell extract and did not increase to the level with the latter on increase in the amount of cell extract or the incubation time. The defects of XP cell extracts were complemented by addition of extracts from cells of different complementation groups, indicating that defective proteins in XP-A through G cells are directly involved in DNA repair. Addition of T4 endonuclease V, which is reported to complement defects of XP cells, stimulated DNA repair synthesis by the 293 cell extract, and also complemented the defects of all XP cell extracts. The XPAC gene product was shown to be involved in DNA repair synthesis using anti-xpac serum and xpac protein produced in Escherichia coli. Anti-xpac serum inhibited DNA repair synthesis by the 293 cell extract and xpac protein reversed the inhibition. Furthermore, xpac protein complemented the defects of extracts of two lines of XP-A cells (XP20SSV and XP12ROSV) but had no effect on the reactions of extracts from cells of other complementation groups. These findings are consistent with previous results obtained in experiments with cells, indicating that our system is useful for analyzing the mechanisms of DNA excision repair in mammalian cells.	INST PHYS & CHEM RES, CELLULAR PHYSIOL LAB, 2-1 HIROSAWA, WAKO, SAITAMA 35101, JAPAN; INST PHYS & CHEM RES, BIODESIGN RES GRP, WAKO, SAITAMA 35101, JAPAN; OSAKA UNIV, INST MOLEC & CELLULAR BIOL, SUITA, OSAKA 565, JAPAN	RIKEN; RIKEN; Osaka University			Masutani, Chikahide/I-6160-2014	Masutani, Chikahide/0000-0002-8600-8227				[Anonymous], 1985, DNA REPAIR; BIGGERSTAFF M, 1992, J BIOL CHEM, V267, P6879; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRISTIANSEN G, 1977, J VIROL, V21, P1079, DOI 10.1128/JVI.21.3.1079-1084.1977; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; FLEJTER WL, 1992, P NATL ACAD SCI USA, V89, P261, DOI 10.1073/pnas.89.1.261; FRIEDBERG EC, 1991, BIOESSAYS, V13, P295, DOI 10.1002/bies.950130607; HOEIJMAKERS JHJ, 1990, CANCER CELL-MON REV, V2, P311; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MIURA N, 1991, J BIOL CHEM, V266, P19786; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; Sambrook J, 1989, MOL CLONING LABORATO; SATOKATA I, 1990, P NATL ACAD SCI USA, V87, P9908, DOI 10.1073/pnas.87.24.9908; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIBGHATULLAH, 1989, NUCLEIC ACIDS RES, V17, P4471, DOI 10.1093/nar/17.12.4471; Smerdon MJ, 1991, CURR OPIN CELL BIOL, V3, P422, DOI 10.1016/0955-0674(91)90069-B; SUGASAWA K, 1993, J BIOL CHEM, V268, P9098; TANAKA K, 1977, P NATL ACAD SCI USA, V74, P2958, DOI 10.1073/pnas.74.7.2958; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TANAKA K, 1989, P NATL ACAD SCI USA, V86, P5512, DOI 10.1073/pnas.86.14.5512; van Holde K.E., 1988, CHROMATIN; WANG ZG, 1991, J BIOL CHEM, V266, P22472; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; WOOD RD, 1991, BIOESSAYS, V13, P447, DOI 10.1002/bies.950130904	28	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9105	9109						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8386177				2022-12-25	WOS:A1993KX81100102
J	KWON, OS; LO, SCL; KWOK, F; CHURCHICH, JE				KWON, OS; LO, SCL; KWOK, F; CHURCHICH, JE			REVERSIBLE UNFOLDING OF MYOINOSITOL MONOPHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN; PROTEIN; PURIFICATION; MYO-INOSITOL-1-PHOSPHATASE; DENATURATION; STABILITY	myo-Inositol monophosphatase isolated from pig brain is a very stable dimeric protein characterized by a rotational correlation time of 30 ns. The unfolding and dissociation of the dimeric enzyme (58 kDa) by guanidine hydrochloride have been investigated at equilibrium. The overall process was reversible as judged from the complete recovery of catalytic activity after dilution of guanidine hydrochloride-treated samples. Unfolding of myo-inositol monophosphatase was monitored by circular dichroism, fluorescence, and steady state emission anisotropy. A folded, monomeric form of the monophosphatase was not detected by the method of denaturant gel filtration. Uncoupled dissociation and unfolding of the oligomeric enzyme could not be demonstrated. The circular dichroism and emission anisotropy results are consistent with a model in which the dimeric protein unfolds in a single cooperative transition from folded dimer to two unfolded monomers.	HONGKONG POLYTECH,DEPT APPL BIOL & CHEM TECHNOL,HONG KONG,HONG KONG	Hong Kong Polytechnic University	KWON, OS (corresponding author), UNIV TENNESSEE,DEPT BIOCHEM,KNOXVILLE,TN 37996, USA.			Lo, Samuel Chun-lap/0000-0003-1134-7299				BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRISTENSEN H, 1991, EUR BIOPHYS J, V19, P221, DOI 10.1007/BF00183530; DIEHL RE, 1990, J BIOL CHEM, V265, P5946; GEE NS, 1988, BIOCHEM J, V249, P883, DOI 10.1042/bj2490883; GREENVALD A, 1974, ANAL BIOCHEM, V59, P583; HALLCHER LM, 1980, J BIOL CHEM, V255, P896; JAENICKE R, 1984, ANGEW CHEM INT EDIT, V23, P395, DOI 10.1002/anie.198403953; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LIANG H, 1991, BIOCHEMISTRY-US, V30, P2772, DOI 10.1021/bi00225a006; MAJERUS PW, 1988, J BIOL CHEM, V263, P3051; MEEK JL, 1988, BIOCHEM BIOPH RES CO, V156, P143, DOI 10.1016/S0006-291X(88)80816-7; O'Connor D. V., 1984, TIME CORRELATED SING; PACE CN, 1991, ANGEW CHEM INT EDIT, V30, P343, DOI 10.1002/anie.199103433; PAKULA AA, 1989, PROTEINS, V5, P202, DOI 10.1002/prot.340050303; PRIVALOV PL, 1986, J MOL BIOL, V190, P487, DOI 10.1016/0022-2836(86)90017-3; PTITSYN OB, 1991, FEBS LETT, V285, P176, DOI 10.1016/0014-5793(91)80799-9; TAKIMOTO K, 1985, J BIOCHEM-TOKYO, V98, P363, DOI 10.1093/oxfordjournals.jbchem.a135290; WAHL P, 1979, BIOPHYS CHEM, V10, P91, DOI 10.1016/0301-4622(79)80009-5	20	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7912	7916						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8385126				2022-12-25	WOS:A1993KW97900051
J	RODRIGUEZ, PL; CARRASCO, L				RODRIGUEZ, PL; CARRASCO, L			POLIOVIRUS PROTEIN-2C HAS ATPASE AND GTPASE ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION INITIATION FACTOR-4A; RNA HELICASE ACTIVITY; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; VIRAL-PROTEINS; REPLICATION; MUTANTS; DNA; VIRUSES; SUPERFAMILY	Poliovirus protein 2C belongs to an expanding group of proteins containing a nucleotide binding motif in their sequence. We present evidence that poliovirus 2C has nucleoside triphosphatase (NTPase) activity and binds to RNA. Poliovirus 2C was expressed in Escherichia coli cells as a fusion protein with the maltose binding protein (MBP). The fusion protein MBP-2C is efficiently cut by protease Xa within the 2C region. Thus, the fusion protein as such was used to assay for the putative activities of poliovirus 2C. Deletion mutants were constructed which lacked different portions of the 2C carboxyl terminus: mutant 2CDELTA1 lacked the last 169 amino acids, whereas mutant 2CDELTA2 had the last 74 amino acids deleted. The fusion proteins MBP-2C, MBP-2BC, and the mutant MBP-2CDELTA2 that contained the first 255 amino acids of 2C had NTPase activity. Both ATPase and GTPase activities are inhibited by antibodies directed against the MBP-2C protein. Analysis of the ability of the different proteins to bind to labeled RNA indicates that MBP-2C and MBP-2BC form a complex, whereas none of the mutants interacted with RNA, indicating that the RNA binding domain lies beyond amino acid 255. None of the fusion proteins had detectable helicase activity. We suggest that poliovirus protein 2C shows similarities to the GTPases group involved in vesicular traffic and transports the viral RNA replication complexes. These results provide the first experimental evidence that poliovirus protein 2C is an NTPase and that this protein has affinity for nucleic acids.	UNIV AUTONOMA MADRID, CTR BIOL MOLEC SEVERO OCHOA, CANTO BLANCO, E-28049 MADRID, SPAIN	Autonomous University of Madrid			Carrasco, Luis/H-3001-2017; Rodriguez, Pedro L./K-4605-2014; Carrasco, Luis/E-2435-2012	Carrasco, Luis/0000-0003-3833-8835; Rodriguez, Pedro L./0000-0002-5886-9425; 				BAILLY V, 1991, P NATL ACAD SCI USA, V88, P9712, DOI 10.1073/pnas.88.21.9712; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALTERA RF, 1989, J VIROL, V63, P4441, DOI 10.1128/JVI.63.10.4441-4444.1989; BERNSTEIN HD, 1986, J VIROL, V60, P1040, DOI 10.1128/JVI.60.3.1040-1049.1986; BIENZ K, 1990, J VIROL, V64, P1156, DOI 10.1128/JVI.64.3.1156-1163.1990; CALIGUIRI LA, 1973, SELECTIVE INHIBITORS, P257; CARRASCO L, 1989, PHARMACOL THERAPEUT, V40, P171, DOI 10.1016/0163-7258(89)90096-X; CASTRILLO JL, 1986, VIROLOGY, V152, P219, DOI 10.1016/0042-6822(86)90386-7; DAN L, 1992, NUCLEIC ACIDS RES, V20, P1967, DOI 10.1093/nar/20.8.1967; EGGERS HJ, 1985, ANTIVIR RES, P57; FAWELL E, 1990, NUCLEIC ACIDS RES, V18, P4264, DOI 10.1093/nar/18.14.4264; GEIDER K, 1981, ANNU REV BIOCHEM, V50, P233, DOI 10.1146/annurev.bi.50.070181.001313; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413; GORBALENYA AE, 1988, FEBS LETT, V235, P16, DOI 10.1016/0014-5793(88)81226-2; GORBALENYA AE, 1990, FEBS LETT, V262, P145, DOI 10.1016/0014-5793(90)80175-I; GUINEA R, 1990, EMBO J, V9, P2011, DOI 10.1002/j.1460-2075.1990.tb08329.x; GUINEA R, 1991, VIROLOGY, V185, P473, DOI 10.1016/0042-6822(91)90802-I; HARLOW E, 1988, ANTIBODIES LABORATOR; HELLEN CUT, 1989, BIOCHEMISTRY-US, V28, P9881, DOI 10.1021/bi00452a001; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; INNIS AM, 1990, PCR PROTOCOLS GUIDE; IRURZUN A, 1992, VIROLOGY, V191, P166, DOI 10.1016/0042-6822(92)90178-R; JARAMILLO M, 1991, MOL CELL BIOL, V11, P5992, DOI 10.1128/MCB.11.12.5992; JOHNSON KL, 1991, J VIROL, V65, P4341, DOI 10.1128/JVI.65.8.4341-4349.1991; Kirkegaard K, 1992, CURR OPIN GENET DEV, V2, P64, DOI 10.1016/S0959-437X(05)80324-7; KRAUSSLICH HG, 1988, BIOCHIMIE, V70, P119, DOI 10.1016/0300-9084(88)90166-6; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; KUHN RJ, 1988, P NATL ACAD SCI USA, V85, P519, DOI 10.1073/pnas.85.2.519; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIN S, 1989, GENE, V82, P357, DOI 10.1016/0378-1119(89)90063-2; LAIN S, 1990, NUCLEIC ACIDS RES, V18, P7003, DOI 10.1093/nar/18.23.7003; LAIN S, 1991, J VIROL, V65, P1, DOI 10.1016/0042-6822(91)90641-N; LAMA J, 1992, J BIOL CHEM, V267, P15932; LAMA J, 1992, GENE, V117, P185, DOI 10.1016/0378-1119(92)90728-8; LAWSON MA, 1990, CURR TOP MICROBIOL, V161, P49; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE CG, 1992, J BIOL CHEM, V267, P4398; LEE YF, 1977, P NATL ACAD SCI USA, V74, P59, DOI 10.1073/pnas.74.1.59; LI JP, 1988, J VIROL, V62, P4016, DOI 10.1128/JVI.62.11.4016-4021.1988; LI JP, 1990, J VIROL, V64, P1102, DOI 10.1128/JVI.64.3.1102-1107.1990; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; MAYNELL LA, 1992, J VIROL, V66, P1985, DOI 10.1128/JVI.66.4.1985-1994.1992; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIRZAYAN C, 1992, VIROLOGY, V189, P547, DOI 10.1016/0042-6822(92)90578-D; PAUL AV, 1987, COLD SPRING HARB SYM, V52, P343, DOI 10.1101/SQB.1987.052.01.039; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; PINCUS SE, 1986, J VIROL, V57, P638, DOI 10.1128/JVI.57.2.638-646.1986; RICHARDS OC, 1990, CURR TOP MICROBIOL, V161, P89; RODRIGUEZ PL, 1992, J VIROL, V66, P1971, DOI 10.1128/JVI.66.4.1971-1976.1992; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Sambrook J, 1989, MOL CLONING LABORATO; SARNOW P, 1990, CURR TOP MICROBIOL, V161, P155; SCHEFFNER M, 1989, CELL, V57, P955, DOI 10.1016/0092-8674(89)90334-6; SCHMID SR, 1991, MOL CELL BIOL, V11, P3463, DOI 10.1128/MCB.11.7.3463; SEMLER BL, 1982, CELL, V28, P405, DOI 10.1016/0092-8674(82)90358-0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TETERINA NL, 1992, J GEN VIROL, V73, P1977, DOI 10.1099/0022-1317-73-8-1977; TOYODA H, 1986, CELL, V45, P761, DOI 10.1016/0092-8674(86)90790-7; VANDERWERF S, 1986, P NATL ACAD SCI USA, V83, P2330; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992	63	167	173	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8105	8110						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8385138				2022-12-25	WOS:A1993KW97900075
J	SUNG, SSJ; WALTERS, JA				SUNG, SSJ; WALTERS, JA			STIMULATION OF INTERLEUKIN-1-ALPHA AND INTERLEUKIN-1-BETA PRODUCTION IN HUMAN MONOCYTES BY PROTEIN PHOSPHATASE-1 AND PHOSPHATASE-2A INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; OKADAIC ACID; C-JUN; CELL-LINES; KINASE-C; SEQUENCE; GENE; EXPRESSION; ACTIVATION; FOS	Protein phosphatases 1 and 2A are important in regulating cellular functions by controlling the phosphorylation state of their substrates. In human monocytes, the inhibitors of these phosphatases, okadaic acid and calyculin A, were found to increase the mRNA accumulation and cytokine production of interleukin-1beta and interleukin-1alpha. The increased mRNA accumulation was found to be primarily because of the increase in the transcription rate of the interleukin-1 genes. Stimulation of interleukin-1 gene transcription may be caused by the stimulation of transcription factor activities, including those of AP-1, by these protein phosphatase inhibitors. Okadaic acid increased the synthesis of the interleukin-1beta precursor and mature forms and their secretion. This increased processing and secretion correlated with the stimulation of IL-1beta convertase mRNA accumulation. The stimulation of interleukin-1alpha production by okadaic acid was more modest than that of interleukin-1beta. However, the phosphorylation of the precursor interleukin-1alpha cytokine was increased. These results show that protein phosphatase 1 and 2A inhibitors exert multiple effects on cytokine production in human monocytes and suggest that these two phosphatases play important roles in regulating interleukin-I production.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MICROBIOL & IMMUNOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,MASSEY CANC CTR,RICHMOND,VA 23298	Virginia Commonwealth University; Virginia Commonwealth University	SUNG, SSJ (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT RADIAT ONCOL,BOX 58,RICHMOND,VA 23298, USA.				NCI NIH HHS [P30-CA16059] Funding Source: Medline; NIAID NIH HHS [AI-26928] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026928] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABDULGHANI M, 1991, P NATL ACAD SCI USA, V88, P1803, DOI 10.1073/pnas.88.5.1803; BARKOUCHE O, 1992, J IMMUNOL, V148, P84; BENSI G, 1990, CELL GROWTH DIFFER, V1, P491; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BEUSCHER HU, 1990, J IMMUNOL, V144, P2179; BEUSCHER HU, 1988, J BIOL CHEM, V263, P4023; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CAO XM, 1992, J BIOL CHEM, V267, P12991; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CLARK BD, 1986, NUCLEIC ACIDS RES, V14, P7897, DOI 10.1093/nar/14.20.7897; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DINARELLO CA, 1991, BLOOD, V77, P1627; FURUTANI Y, 1986, NUCLEIC ACIDS RES, V14, P3167, DOI 10.1093/nar/14.8.3167; HAAS JG, 1990, P NATL ACAD SCI USA, V87, P9563, DOI 10.1073/pnas.87.24.9563; HENTZE MW, 1991, BIOCHIM BIOPHYS ACTA, V1090, P281, DOI 10.1016/0167-4781(91)90191-N; HOGQUIST KA, 1991, J IMMUNOL, V147, P2181; JAIN J, 1992, J EXP MED, V175, P853, DOI 10.1084/jem.175.3.853; KERN JA, 1988, J CLIN INVEST, V81, P237, DOI 10.1172/JCI113301; LAIRDOFFRINGA IA, 1992, BIOESSAYS, V14, P119, DOI 10.1002/bies.950140209; LINK E, 1992, J BIOL CHEM, V267, P239; LUND LR, 1992, FEBS LETT, V298, P177, DOI 10.1016/0014-5793(92)80050-Q; MIYASAKA T, 1990, BIOCHEM BIOPH RES CO, V168, P1237, DOI 10.1016/0006-291X(90)91161-K; NAGAMINE Y, 1991, EMBO J, V10, P117, DOI 10.1002/j.1460-2075.1991.tb07927.x; PERREGAUX D, 1992, J IMMUNOL, V149, P1294; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SAMBROOK J, 1989, MOL CLIN LABORATORY; SCHONTHAL A, 1992, NEW BIOL, V4, P16; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P959, DOI 10.1128/MCB.9.3.959; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SUNG SSJ, 1983, J CELL PHYSIOL, V116, P21, DOI 10.1002/jcp.1041160105; SUNG SSJ, 1992, J EXP MED, V176, P897, DOI 10.1084/jem.176.3.897; SUNG SSJ, 1988, J EXP MED, V167, P937, DOI 10.1084/jem.167.3.937; SUNG SSJ, 1991, J IMMUNOL, V147, P2047; SUNG SSJ, 1985, J IMMUNOL, V135, P1981; SUNG SSJ, 1989, J IMMUNOL, V142, P1274; SUTTLES J, 1990, J IMMUNOL, V144, P175; THEVENIN C, 1990, New Biologist, V2, P793; THEVENIN C, 1991, J BIOL CHEM, V266, P9363; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0	43	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5802	5809						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8383677				2022-12-25	WOS:A1993KR82200067
J	GREEN, PC; TRIPATHI, RL; KEMP, RG				GREEN, PC; TRIPATHI, RL; KEMP, RG			IDENTIFICATION OF ACTIVE-SITE RESIDUES IN PYROPHOSPHATE-DEPENDENT PHOSPHOFRUCTO-1-KINASE BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPIONIBACTERIUM-FREUDENREICHII; KINETIC MECHANISM; ESCHERICHIA-COLI; PHOSPHOFRUCTOKINASE	The primary structure of pyrophosphate-dependent phosphofructokinase (PFK) from Propionibacterium freudenreichii exhibits a low but significant level of sequence identity with Escherichia coli ATP-dependent PFK, permitting the tentative assignment of residues that may be involved in catalysis. Based on these assignments, the roles in catalysis of 2 aspartyl residues (Asp151 and Asp153) and 2 lysyl residues (Lys80 and Lys85) were examined. Mutagenesis of the Asp151 to alanine and serine reduced k(cat) by a factors of 2 x 10(4) and 4 x 10(5), respectively, while showing no change in K(m) for either substrate in the forward reaction or for metal ion in the back reaction. The k(cat) for Asp153 was decreased by a factor of 700 with no change in K(m) for pyrophosphate and an increase of about 20-fold in K(m) for fructose 6-P and close to 4-fold for magnesium ion. That these changes in the mutants were not the result of global conformational changes was indicated by their identical behavior during substrate-specific elution chromatography, ion-exchange chromatography, and limited proteolysis by trypsin and subtilisin. Mutations of Lys80 and Lys85 showed no significant changes in kinetic parameters, suggesting no involvement in mechanism or substrate binding. These and other results permit preliminary modeling of the active site of pyrophosphate-dependent PFK.	UNIV HLTH SCI CHICAGO MED SCH,DEPT BIOL CHEM,3333 GREEN BAY BLVD,N CHICAGO,IL 60064	Chicago Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019912] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19912] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERTAGNOLLI BL, 1984, BIOCHEMISTRY-US, V23, P4101, DOI 10.1021/bi00313a014; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHO YK, 1988, BIOCHEMISTRY-US, V27, P3320, DOI 10.1021/bi00409a030; CHO YK, 1989, BIOCHEMISTRY-US, V28, P4155, DOI 10.1021/bi00436a005; GREEN PC, 1992, BIOCHEMISTRY-US, V31, P4815, DOI 10.1021/bi00135a011; HALKIDES CJ, 1991, BIOCHEMISTRY-US, V30, P10313, DOI 10.1021/bi00106a032; HELLINGA HW, 1987, NATURE, V327, P437, DOI 10.1038/327437a0; LADROR US, 1991, J BIOL CHEM, V266, P16550; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OBRIEN WE, 1975, J BIOL CHEM, V250, P8690; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3	12	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5085	5088						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8383128				2022-12-25	WOS:A1993KP88400077
J	GOUTEBROZE, L; SAINTANDRE, CD; SCHERNECK, S; FEUNTEUN, J				GOUTEBROZE, L; SAINTANDRE, CD; SCHERNECK, S; FEUNTEUN, J			MUTATIONS WITHIN THE HAMSTER POLYOMAVIRUS LARGE T-ANTIGEN DOMAIN INVOLVED IN PRB-BINDING IMPAIR VIRUS PRODUCTIVE CYCLE AND IMMORTALIZATION CAPACITY	ONCOGENE			English	Article							TUMOR-ANTIGEN; RETINOBLASTOMA PROTEIN; KINASE-ACTIVITY; TRANSFORMATION; ASSOCIATION; GENE; IDENTIFICATION; PHOSPHATASE-2A; PAPOVAVIRUS; COMPLEXES	Hamster polyomavirus (HaPV) causes lymphoma and leukemia when injected into newborn Syrian hamsters and achieves full transformation of rodent fibroblasts in vitro. It offers a comprehensive model to study at a molecular level the contributions of the viral oncogenes to neoplastic transformation in vitro and in the animal. We have investigated the ability of HaPV large T antigen to form a complex with the product of the retinoblastoma gene (pRb) in vitro. In this report, we demonstrate that HaPV large T antigen can indeed complex the pRb polypeptide. In order to investigate to what extent this interaction might contribute to tumor induction by the virus, we have introduced two different point mutations within the putative pRb-binding sequence of large T antigen, and as a preliminary to in vivo experiments we have studied their effects in vitro on some biological activities relevant to tumor induction. We show that the substitution (Glu-134-->Lys) obliterates pRb binding, suggesting that Glu-134 participates in the interaction between pRb and large T antigen, whereas the substitution (Glu-135-->Lys) has no effect. The Lys-134 mutation is strongly deleterious to the immortalization capacity of the viral genome, whereas the Lys-135 mutation has no effect. Neither of the two mutations affects the capacity of the viral genome to induce foci formation in the rat established cell line F111. These results indicate that the interaction between large T and pRb is required in the immortalization process but irrelevant to transformation. Both mutants show at least partial impairment of replication and productive cycle.	INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,URA 1158,F-94805 VILLEJUIF,FRANCE; MAX DELBRUCK CENTRUM MOLEC MED TUMORIGENET,O-1115 BERLIN,GERMANY	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Helmholtz Association; Max Delbruck Center for Molecular Medicine			Goutebroze, Laurence/H-3543-2016; Feunteun, Jean/AAZ-1267-2020	Goutebroze, laurence/0000-0002-8712-000X; Feunteun, Jean/0000-0003-1212-9189				BASTIEN C, 1988, ONCOGENE, V2, P129; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1991, J VIROL, V65, P3301, DOI 10.1128/JVI.65.6.3301-3308.1991; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DELMAS V, 1985, EMBO J, V4, P1279, DOI 10.1002/j.1460-2075.1985.tb03773.x; DELMAS V, 1992, ONCOGENE, V7, P295; DIAMANDOPOULOS GT, 1972, SCIENCE, V176, P173, DOI 10.1126/science.176.4031.173; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; GOUTEBROZE L, 1992, J VIROL, V66, P2495, DOI 10.1128/JVI.66.4.2495-2504.1992; GRAFFI A, 1969, P NATL ACAD SCI USA, V64, P1172, DOI 10.1073/pnas.64.4.1172; GRAFFI A, 1968, J NATL CANCER I, V40, P867; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LEWIS AM, 1979, J NATL CANCER I, V63, P695, DOI 10.1093/jnci/63.3.695; NORKIN LC, 1982, MICROBIOL REV, V46, P384, DOI 10.1128/MMBR.46.4.384-425.1982; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; SAINTANDRE CD, 1990, VIROLOGY, V177, P532; SALZMAN NP, 1986, VIRUSES PAPOVAVIRIDA, P1; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; ZHU J, 1991, J VIROL, V65, P6782	28	5	5	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					685	693						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8382359				2022-12-25	WOS:A1993KN00800020
J	GARDNER, AM; VAILLANCOURT, RR; JOHNSON, GL				GARDNER, AM; VAILLANCOURT, RR; JOHNSON, GL			ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE EXTRACELLULAR SIGNAL-REGULATED KINASE KINASE BY G-PROTEIN AND TYROSINE KINASE ONCOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SERINE THREONINE KINASES; MAP KINASE; PERTUSSIS TOXIN; FISSION YEAST; GENE-PRODUCT; PHOSPHORYLATES; INSULIN; INVITRO; CASCADE	Mitogen-activated protein kinases (MAPKs) are rapidly phosphorylated and activated in response to a variety of extracellular stimuli in many different cell types. The kinases that activate MAPK, the MAPK/ERK Kinases (MEKs), are also activated by phosphorylation. We have studied the influence of specific oncogenes on the regulation of MEK activity in NIH3T3 and Rat1a fibroblasts. We show that a similar MEK activity phosphorylates and activates MAPK in both growth factor-stimulated (epidermal growth factor and thrombin) and oncogene (gip2, v-src, and v-raf)-transfected cells. Gip2 and v-Src activated MEK-1 in transfected Rat la cells, whereas v-Raf activated MEK-1 in transfected NIH3T3 cells. These cell-selective differences in MEK activation parallel constitutive MAPK activation in these cell lines. Stable expression of the v-ras oncogene resulted in little constitutive MEK activation in either cell line, even though both were highly transformed. The growth factor and oncoprotein regulated MEK activity co-fractionated by Mono S chromatography with the 45-kDa MEK-1 protein. We further demonstrate in NIH3T3 and Rat 1a cells that Raf-1 is activated, as measured by its ability to phosphorylate MEK-1, in response to epidermal growth factor but not thrombin. Thus, the regulatory network of protein kinases that activate MAPK converges at MEK but diverges with the kinases that phosphorylate and activate MEK.	NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI K1007,1400 JACKSON ST,DENVER,CO 80206; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Gardner, Anne/0000-0001-7095-772X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37871] Funding Source: Medline; NIGMS NIH HHS [GM 30324] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; COCHET C, 1984, J BIOL CHEM, V259, P2553; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JASPERS SR, 1991, MOL CELL BIOCHEM, V101, P167; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; NADINDAVIS SA, 1988, EMBO J, V7, P985, DOI 10.1002/j.1460-2075.1988.tb02905.x; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SETH A, 1991, J BIOL CHEM, V266, P23521; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508	42	130	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17896	17901						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8394352				2022-12-25	WOS:A1993LT74300041
J	YOKOMIZO, T; IZUMI, T; TAKAHASHI, T; KASAMA, T; KOBAYASHI, Y; SATO, F; TAKETANI, Y; SHIMIZU, T				YOKOMIZO, T; IZUMI, T; TAKAHASHI, T; KASAMA, T; KOBAYASHI, Y; SATO, F; TAKETANI, Y; SHIMIZU, T			ENZYMATIC INACTIVATION OF LEUKOTRIENE-B(4) BY A NOVEL ENZYME FOUND IN THE PORCINE KIDNEY - PURIFICATION AND PROPERTIES OF LEUKOTRIENE-B(4) 12-HYDROXYDEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; ARACHIDONIC-ACID; OMEGA-HYDROXYLASE; HUMAN-ERYTHROCYTES; HUMAN-MONOCYTES; GUINEA-PIG; HYDROLASE; METABOLITES; RAT	Leukotriene B4 (LTB4) 12-hydroxydehydrogenase was purified to apparent homogeneity from the cytosol fraction of the porcine kidney. The N-terminal amino acid sequence analysis revealed that this enzyme is a novel protein with a molecular weight of 35,000. Although the enzyme is ubiquitously distributed in various tissues and leukocytes of porcine, the kidney and liver had the highest enzyme activities. In the presence of NADP+ as a cofactor, the enzyme catalyzes the conversion of LTB4 to 12-oxo-LTB4, the structure identified by gas chromatography/mass spectrometry. 12-Oxo-LTB4 Was further converted by other enzymes to 10,11,14,15-tetrahydro-12-oxo-LTB4, which was determined by proton NMR and gas chromatography/mass spectrometry. 12-Oxo-LTB4 was 100-fold less potent than LTB4 in increasing intracellular calcium concentrations of human leukocytes. 6-trans-LTB4 and LTB4 proved to be the best substrates of the enzyme, whereas various types of monohydroxyeicosatetraenoic acids, 5(S),12(S)-dihydroxyeicosatetraenoic acid, prostaglandins, cortisol, or pregnenolone could not serve as a substrate. These results suggest that the enzyme acts specifically on the 12(R)-hydroxy group of leukotriene B4 and is involved in the metabolic inactivation of LTB4 in the porcine kidney.	UNIV TOKYO, DEPT BIOCHEM, HONGO 7-3-1, BUNKYO KU, TOKYO 113, JAPAN; UNIV TOKYO, FAC MED, DEPT OBSTET & GYNECOL, BUNKYO KU, TOKYO 113, JAPAN; TOKYO MED & DENT UNIV, BIOMED ANAL LAB, BUNKYO KU, TOKYO 113, JAPAN; TOKYO INST TECHNOL, DEPT BIOMOLEC ENGN, MIDORI KU, YOKOHAMA, KANAGAWA 227, JAPAN	University of Tokyo; University of Tokyo; Tokyo Medical & Dental University (TMDU); Tokyo Institute of Technology			Yokomizo, Takehiko/P-5673-2016	Yokomizo, Takehiko/0000-0002-5219-1553				ARDAILLOU R, 1986, AM J MED, V81, P12, DOI 10.1016/0002-9343(86)90904-6; ARMSTRONG JA, 1971, J GEN VIROL, V10, P195, DOI 10.1099/0022-1317-10-2-195; BERGHOLTE JM, 1986, ARCH BIOCHEM BIOPHYS, V245, P308, DOI 10.1016/0003-9861(86)90221-3; BORGEAT P, 1979, J BIOL CHEM, V254, P2643; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROM J, 1988, IMMUNOLOGY, V64, P509; Cattell V, 1987, Nephrol Dial Transplant, V2, P154; DALY AK, 1982, BIOCHEM J, V205, P373, DOI 10.1042/bj2050373; EVANS JF, 1985, BIOCHIM BIOPHYS ACTA, V840, P43, DOI 10.1016/0304-4165(85)90160-6; FAULER J, 1989, PROSTAG LEUKOTR ESS, V37, P193, DOI 10.1016/0952-3278(89)90085-9; FAULER J, 1989, KIDNEY INT, V36, P46, DOI 10.1038/ki.1989.159; FISCHER DB, 1992, KIDNEY INT, V41, P1155, DOI 10.1038/ki.1992.176; FU JY, 1989, BIOCHIM BIOPHYS ACTA, V1006, P121; GARRICK R, 1991, ADV EXP MED BIOL, V314, P361; GOTOH Y, 1989, EUR J BIOCHEM, V179, P315, DOI 10.1111/j.1432-1033.1989.tb14557.x; HARPER TW, 1986, J BIOL CHEM, V261, P5414; IZUMI T, 1986, BIOCHEM BIOPH RES CO, V135, P139, DOI 10.1016/0006-291X(86)90953-8; KAEVER V, 1987, BIOCHIM BIOPHYS ACTA, V922, P337, DOI 10.1016/0005-2760(87)90056-7; KAEVER V, 1988, FEBS LETT, V231, P385, DOI 10.1016/0014-5793(88)80855-X; KAEVER V, 1990, LIFE SCI, V46, P1465, DOI 10.1016/0024-3205(90)90463-2; KASIMIR S, 1991, BIOCHEM J, V279, P283, DOI 10.1042/bj2790283; KOBAYASHI Y, 1990, J ORG CHEM, V55, P5324, DOI 10.1021/jo00306a007; KORFF JM, 1982, J BIOL CHEM, V257, P2177; KUMLIN M, 1990, BIOCHEM BIOPH RES CO, V170, P23, DOI 10.1016/0006-291X(90)91235-K; KUNGCHAO DTY, 1980, BIOCHIM BIOPHYS ACTA, V614, P1, DOI 10.1016/0005-2744(80)90161-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOWITH JB, 1992, J AM SOC NEPHROL, V2, P1560; MAK OT, 1990, BIOCHIM BIOPHYS ACTA, V1035, P190; MCGEE J, 1985, J BIOL CHEM, V260, P2832; MEDINA JF, 1987, BIOCHEM BIOPH RES CO, V143, P697, DOI 10.1016/0006-291X(87)91410-0; MERAB JP, 1989, ADV PROSTAG THROMB L, V19, P221; MINAMI M, 1987, J BIOL CHEM, V262, P13873; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; OBERLE GP, 1992, KIDNEY INT, V42, P69, DOI 10.1038/ki.1992.262; OHISHI N, 1990, J BIOL CHEM, V265, P7520; ORNING L, 1990, J BIOL CHEM, V265, P14911; POWELL WS, 1984, J BIOL CHEM, V259, P3082; POWELL WS, 1989, ADV PROSTAG THROMB L, V19, P112; POWELL WS, 1990, BIOCHIM BIOPHYS ACTA, V1044, P147, DOI 10.1016/0005-2760(90)90230-U; POWELL WS, 1987, BIOCHEM BIOPH RES CO, V145, P991, DOI 10.1016/0006-291X(87)91533-6; POWELL WS, 1989, J BIOL CHEM, V264, P5364; RADMARK O, 1984, J BIOL CHEM, V259, P2339; RAHMAN MA, 1988, J CLIN INVEST, V81, P1945, DOI 10.1172/JCI113542; REYES AA, 1992, KIDNEY INT, V41, P100, DOI 10.1038/ki.1992.13; SAEED SA, 1972, BIOCHEM BIOPH RES CO, V47, P96, DOI 10.1016/S0006-291X(72)80015-9; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHONFELD W, 1991, J LEUKOCYTE BIOL, V50, P303, DOI 10.1002/jlb.50.3.303; SHAK S, 1984, J BIOL CHEM, V259, P181; SHIMIZU T, 1988, INT J BIOCHEM, V20, P661, DOI 10.1016/0020-711X(88)90160-7; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; SOBERMAN RJ, 1985, P NATL ACAD SCI USA, V82, P2292, DOI 10.1073/pnas.82.8.2292; SPURNEY RF, 1991, KIDNEY INT, V39, P95, DOI 10.1038/ki.1991.12; SUMIMOTO H, 1990, J BIOL CHEM, V265, P4348; SUMIMOTO H, 1990, J BIOCHEM, V108, P215, DOI 10.1093/oxfordjournals.jbchem.a123183; SUMIMOTO H, 1988, EUR J BIOCHEM, V172, P315, DOI 10.1111/j.1432-1033.1988.tb13889.x; THALERDAO H, 1974, FEBS LETT, V48, P204, DOI 10.1016/0014-5793(74)80468-0; TOKUMOTO H, 1982, J BIOL CHEM, V257, P13576; WAINWRIGHT S, 1990, BIOCHEMISTRY-US, V29, P1180, DOI 10.1021/bi00457a013; WAINWRIGHT SL, 1991, J BIOL CHEM, V266, P20899; YARED A, 1991, J AM SOC NEPHROL, V2, P45	60	92	95	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18128	18135						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8394361				2022-12-25	WOS:A1993LT74300072
J	MULLER, B; TSANEVA, IR; WEST, SC				MULLER, B; TSANEVA, IR; WEST, SC			BRANCH MIGRATION OF HOLLIDAY JUNCTIONS PROMOTED BY THE ESCHERICHIA-COLI RUVA AND RUVB PROTEINS .1. COMPARISON OF RUVAB-MEDIATED AND RUVB-MEDIATED REACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPAIR; RECA PROTEIN; K-12 REVEALS; GENE-PRODUCT; RECOMBINATION; RESOLUTION; PURIFICATION; MUTANTS; ENDONUCLEASE; INVITRO	The Escherichia coli RuvA and RuvB proteins mediate the branch migration of Holliday junctions in vitro. In the presence of stoichiometric amounts of RuvB (1 RuvB dimer/12 nucleotides), branch migration can occur without need for RuvA. However, RuvA is required when the RuvB concentration is reduced 4-fold or more. Under optimal conditions, we found the minimal protein requirement to be 1 RuvB dimer per 500-1100 nucleotides and 1 RuvA tetramer per 600-1200 nucleotides. To determine the roles of RuvA and RuvB in branch migration, we compared branch migration reactions mediated by RuvB only and by RuvA and RuvB. The time courses of the two reactions were similar, and both required ATP and Mg2+. However, RuvB-mediated branch migration occurred at lower ATP concentrations (greater-than-or-equal-to 200 muM) and higher Mg2+ concentrations (greater-than-or-equal-to 10 mM MgCl2) than the reaction mediated by RuvA and RuvB (greater-than-or-equal-to 1 mM ATP, greater-than-or-equal-to 5 mM MgCl2). The Mg2+ requirement for RuvB-mediated branch migration reflects the Mg2+ requirement of RuvB for DNA binding (Muller, B., Tsaneva, I. R., and West, S. C. (1993) J. Biol. Chem. 268, 17185-17189) and can be overcome by addition of RuvA. These results indicate that RuvA protein facilitates the interaction of RuvB with DNA.			MULLER, B (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.			Muller, Berndt/0000-0003-1279-5421; West, Stephen/0000-0001-8848-9418				BENSON F, 1991, MOL GEN GENET, V225, P266, DOI 10.1007/BF00269858; BENSON FE, 1988, NUCLEIC ACIDS RES, V16, P1541, DOI 10.1093/nar/16.4.1541; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; COX MM, 1981, J BIOL CHEM, V256, P4676; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; HARLOW E, 1988, ANTIBODIES LABORATOR; IWASAKI H, 1989, J BACTERIOL, V171, P5276, DOI 10.1128/jb.171.10.5276-5280.1989; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; LLOYD RG, 1984, MOL GEN GENET, V194, P303, DOI 10.1007/BF00383532; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUISIDELUCA C, 1989, GENETICS, V122, P269; MULLER B, 1993, J BIOL CHEM, V268, P17185; MULLER B, 1990, CELL, V60, P329, DOI 10.1016/0092-8674(90)90747-3; MULLER B, 1992, EMBO J, V11, P2685, DOI 10.1002/j.1460-2075.1992.tb05334.x; OTSUJI N, 1974, J BACTERIOL, V117, P337, DOI 10.1128/JB.117.2.337-344.1974; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; SAMBROOK E, 1989, MOL CLONING LABORATO; SHARPLES GJ, 1990, MOL GEN GENET, V221, P219, DOI 10.1007/BF00261724; SHARPLES GJ, 1991, J BACTERIOL, V173, P7711, DOI 10.1128/jb.173.23.7711-7715.1991; SHIBA T, 1993, MOL GEN GENET, V237, P395, DOI 10.1007/BF00279443; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; SHINAGAWA H, 1988, J BACTERIOL, V170, P4322, DOI 10.1128/jb.170.9.4322-4329.1988; SHURVINTON CE, 1982, MOL GEN GENET, V185, P352, DOI 10.1007/BF00330811; STACEY KA, 1976, MOL GEN GENET, V143, P223, DOI 10.1007/BF00266925; Stasiak A, 1988, GENETIC RECOMBINATIO, P265; TAKAHAGI M, 1991, J BACTERIOL, V173, P5747, DOI 10.1128/jb.173.18.5747-5753.1991; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; WEST SC, 1992, MOL MICROBIOL, V6, P2755, DOI 10.1111/j.1365-2958.1992.tb01454.x; WEST SC, 1982, MOL GEN GENET, V187, P209, DOI 10.1007/BF00331119; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131	35	74	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17179	17184						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8394333				2022-12-25	WOS:A1993LQ98800047
J	HELFTENBEIN, G; ALVAREZ, CV; TUOHIMAA, P; BEATO, M				HELFTENBEIN, G; ALVAREZ, CV; TUOHIMAA, P; BEATO, M			EXPRESSION OF EPITHELIAL PHENOTYPE IS ENHANCED BY V-HA-RAS IN RAT ENDOMETRIAL CELLS IMMORTALIZED BY SV40-T ANTIGEN	ONCOGENE			English	Article							GAP JUNCTION PROTEIN; HORMONAL-REGULATION; MOLECULAR-CLONING; PRIMARY CULTURES; GRANULOSA-CELLS; MESSENGER-RNA; DIFFERENTIATION; ONCOGENES; RECEPTOR; GROWTH	To study the interplay of steroid hormones and oncogenes in the control of endometrial cell proliferation and differentiation we have generated cell lines derived from rat endometrium by expressing the immortalizing oncogenes adeno EIA or SV40 large T antigen. These lines are positive for mesenchymal markers and contain very few characteristic epithelial proteins. Cell lines expressing a temperature-sensitive mutant of SV40 T antigen exhibit a temperature-dependent morphology and growth behavior, but do not manifest an epithelial phenotype at the non-permissive temperature. Cell lines additionally infected with retroviral vectors carrying the v-Ha-ras oncogene (p21ras(Arg-12)) no longer express collagen type III and recover part of their epithelial potential by expressing cytokeratins and/or cadherin E. Some of these cells also express characteristic decidual marker proteins such as desmin, whereas others express glandular epithelial markers such as uteroglobin. Uteroglobin mRNA levels in these cells are increased by glucocorticoids. The parental temperature-sensitive cells do not contain progesterone receptor but become positive for progesterone receptor at the permissive temperature after infection with the v-Ha-ras-expressing retrovirus. Our results indicate that there is a fluent transition and overlapping between mesenchymal, glandular epithelial and decidual phenotypes of endometrial cells, suggesting that these three cell types are derived from the same stem/precursor cells. The v-Ha-ras oncogene product appears to act on the differentiation pathway at an early step prior to the distinction between decidual and glandular epithelial lineage.	UNIV MARBURG,INST MOLEKULARBIOL & TUMORFORSCH,EMIL MANNKOPFF STR 2,W-3550 MARBURG,GERMANY; UNIV TAMPERE,DETP BIOMED SCI,SF-33101 TAMPERE,FINLAND	Philipps University Marburg; Tampere University			Beato, Miguel/B-5564-2015; Alvarez, Clara V/AAN-4173-2020	Beato, Miguel/0000-0002-2878-2222; Alvarez, Clara V/0000-0003-1500-4058				AMSTERDAM A, 1988, P NATL ACAD SCI USA, V85, P7582, DOI 10.1073/pnas.85.20.7582; ARCECI RJ, 1989, P NATL ACAD SCI USA, V86, P8818, DOI 10.1073/pnas.86.22.8818; AZUMA C, 1990, J MOL ENDOCRINOL, V5, P103, DOI 10.1677/jme.0.0050103; BEATO M, 1983, REGULATION GENE EXPR, P151; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BREITKREUTZ D, 1991, CANCER RES, V51, P4402; CONTI CJ, 1984, ENDOCRINOLOGY, V114, P345, DOI 10.1210/endo-114-2-345; DHAR R, 1982, SCIENCE, V217, P934, DOI 10.1126/science.6287572; EDELMAN GM, 1983, SCIENCE, V219, P450, DOI 10.1126/science.6823544; FRANKE WW, 1978, P NATL ACAD SCI USA, V75, P5034, DOI 10.1073/pnas.75.10.5034; GERSCHENSON LE, 1979, LIFE SCI, V24, P1337, DOI 10.1016/0024-3205(79)90002-X; GILULA NB, 1972, NATURE, V235, P262, DOI 10.1038/235262a0; GLASSER SR, 1988, J CELL BIOL, V107, P2409, DOI 10.1083/jcb.107.6.2409; GLASSER SR, 1986, BIOL REPROD, V35, P463, DOI 10.1095/biolreprod35.2.463; HACKENBERG R, 1992, J STEROID BIOCHEM, V43, P599, DOI 10.1016/0960-0760(92)90284-P; HAGEN G, 1990, NUCLEIC ACIDS RES, V18, P2939, DOI 10.1093/nar/18.10.2939; HANKINS WD, 1981, CELL, V26, P91, DOI 10.1016/0092-8674(81)90036-2; HELFTENBEIN G, 1991, EUR J CELL BIOL, V56, P49; HOWELLS RD, 1984, P NATL ACAD SCI-BIOL, V81, P7651, DOI 10.1073/pnas.81.23.7651; ISOM HC, 1992, CANCER RES, V52, P940; JIN DF, 1988, ENDOCRINOLOGY, V122, P1466, DOI 10.1210/endo-122-4-1466; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; LIAU G, 1985, J BIOL CHEM, V260, P531; LYNCH MP, 1986, P NATL ACAD SCI USA, V83, P4784, DOI 10.1073/pnas.83.13.4784; Maniatis T., 1982, MOL CLONING; MCCORMACK SA, 1980, ENDOCRINOLOGY, V106, P1634, DOI 10.1210/endo-106-5-1634; MISSEYANNI A, 1991, NUCLEIC ACIDS RES, V11, P2849; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; ODIN P, 1988, J HISTOCHEM CYTOCHEM, V36, P729, DOI 10.1177/36.7.3290331; PARK OK, 1991, MOL ENDOCRINOL, V5, P967, DOI 10.1210/mend-5-7-967; PARK OK, 1991, MOL ENDOCRINOL, V5, P1931; PAUL DL, 1986, J CELL BIOL, V103, P123, DOI 10.1083/jcb.103.1.123; PAYNE PA, 1987, P NATL ACAD SCI USA, V84, P8956, DOI 10.1073/pnas.84.24.8956; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; RISEK B, 1990, J CELL BIOL, V110, P269, DOI 10.1083/jcb.110.2.269; ROGENSTREIF LJ, 1989, DEV BIOL, V133, P284; ROSEN H, 1990, MOL ENDOCRINOL, V4, P146, DOI 10.1210/mend-4-1-146; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SCRATCHARD G, 1949, ANN NY ACAD SCI, V51, P660; STENBERG EA, 1989, MOL CELL BIOL, V9, P594; TABIBZADEH S, 1991, AM J REPROD IMMUNOL, V26, P5, DOI 10.1111/j.1600-0897.1991.tb00693.x; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; TUOHIMAA P, 1992, SERONO S PUBLICATION, V90, P245; VAIDYA TB, 1991, J CELL BIOL, V114, P809, DOI 10.1083/jcb.114.4.809; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WIEHLE RD, 1990, ONCOGENE, V5, P787; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG JT, 1989, J CELL BIOL, V109, P3391, DOI 10.1083/jcb.109.6.3391	53	19	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2075	2085						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8393160				2022-12-25	WOS:A1993LP17100007
J	KIM, CM; DION, SB; BENOVIC, JL				KIM, CM; DION, SB; BENOVIC, JL			MECHANISM OF BETA-ADRENERGIC-RECEPTOR KINASE ACTIVATION BY G-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-DEPENDENT PHOSPHORYLATION; GAMMA-SUBUNITS; ADENYLATE-CYCLASE; RHODOPSIN KINASE; PHOSPHOLIPASE-C; BOVINE BRAIN; TRANSLOCATION; PURIFICATION; AGONIST; MEMBRANES	The beta-adrenergic receptor kinase (beta-ARK) specifically phosphorylates the activated form of various G protein-coupled receptors such as the beta2-adrenergic receptor (beta2-AR). Recently, G protein betagamma subunits have been demonstrated to activate beta-ARK-mediated receptor phosphorylation. To further elucidate beta-ARK/G protein interactions, we have developed a direct binding assay. The direct binding of [S-35]methionine-labeled beta-ARK to either brain G(i)/G(o) or betagamma subunits was rapid and saturable with similar K(d) values of approximately 58 and approximately 32 nM, respectively. Both heterotrimeric G proteins and betagamma subunits enhanced the initial rate Of beta2-AR and rhodopsin phosphorylation approximately 10-fold. Kinetic studies demonstrate that betagamma enhances beta-ARK-mediated beta2-AR phosphorylation both by decreasing the K(m) for the beta2-AR approximately 4-fold and increasing the stoichiometry of phosphorylation from approximately 4 to approximately 11 mol/mol. An agonist- and ATP-dependent binding of beta-ARK to the reconstituted beta2-AR was also demonstrated. In addition, beta-ARK binding was enhanced in the presence of both the activated beta2-AR and betagamma subunits suggesting the formation of a transient ternary complex consisting of beta-ARK, betagamma, and beta2-AR. Overall, these studies suggest that the specific association of beta-ARK with heterotrimeric G proteins may play an important role in promoting receptor/kinase interaction and subsequent receptor phosphorylation.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107	Jefferson University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45964] Funding Source: Medline; NIGMS NIH HHS [GM44944] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CERIONE RA, 1983, NATURE, V306, P562, DOI 10.1038/306562a0; CHEN CY, 1993, J BIOL CHEM, V268, P7825; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; Cleland W W, 1979, Methods Enzymol, V63, P103; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA T, 1989, FEBS LETT, V268, P43; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; KATADA T, 1984, J BIOL CHEM, V259, P3586; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KIM CM, 1993, IN PRESS RECEPTOR; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MAYOR F, 1987, J BIOL CHEM, V262, P6468; OKABE K, 1990, J BIOL CHEM, V265, P12854; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; SHICHI H, 1978, J BIOL CHEM, V253, P7040; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032	35	91	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15412	15418						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8393441				2022-12-25	WOS:A1993LN30500018
J	FUJII, N; YAMASHITA, Y; SAITOH, Y; NAKANO, H				FUJII, N; YAMASHITA, Y; SAITOH, Y; NAKANO, H			INDUCTION OF MAMMALIAN DNA TOPOISOMERASE-I-MEDIATED DNA CLEAVAGE AND DNA WINDING BY BULGAREIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAKAGE-REUNION REACTION; GROOVE BINDING-DRUGS; P388 LEUKEMIA-CELLS; ANTITUMOR DRUGS; SUPERCOILED DNA; DISTAMYCIN; INHIBITION; NUCLEI; NETROPSIN; SEQUENCE	Bulgarein, a fungal metabolite, induced mammalian topoisomerase I-mediated DNA cleavage in vitro. The cleavage activity of bulgarein was comparable to that of camptothecin at a drug concentration range of 0.025 approximately 5 muM. The DNA cleavage induced by bulgarein was suppressed at concentrations above 12.5 muM. Treatment of a reaction mixture containing bulgarein and topoisomerase I with elevated temperature (65-degrees-C) resulted in a substantial reduction in DNA cleavage, suggesting that the topoisomerase I-mediated DNA cleavage induced by bulgarein is through the mechanism of stabilizing the reversible enzyme-DNA ''cleavable complex.'' Intensity of cleaved DNA fragments induced by bulgarein with topoisomerase I was different from that induced by camptothecin. Bulgarein inhibited catalytic activities of both topoisomerase I and topoisomerase II. The changes in absorption spectra of bulgarein in the visible region observed upon addition of increasing amounts of calf thymus DNA indicate that bulgarein interacts with DNA. DNA (un)winding assay by two-dimensional gel electrophoresis showed that bulgarein induced the winding of DNA in the opposite direction to that of an intercalator so that positively supercoiled molecules are produced. Thus, bulgarein represents a new class of drugs which stabilizes the cleavable complex of topoisomerase I and alters the structure of DNA in a manner leading to a tightening of the helical twist.			FUJII, N (corresponding author), KYOWA HAKKO KOGYO CO LTD, TOKYO RES LABS, 3-6-6 ASAHIMACHI, MACHIDA, TOKYO 194, JAPAN.							ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; BUSK H, 1987, NATURE, V327, P638, DOI 10.1038/327638a0; CAPRANICO G, 1986, CANCER RES, V46, P5499; CAPRANICO G, 1990, BIOCHEMISTRY-US, V29, P562, DOI 10.1021/bi00454a033; CAPRANICO G, 1987, CANCER RES, V47, P3752; CHEN GL, 1984, J BIOL CHEM, V259, P3560; DARPA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163, DOI 10.1016/0304-419X(89)90041-3; Edwards R. L, 1976, J CHEM SOC P1, V20, P2149; FESEN M, 1989, J BIOL CHEM, V264, P11354; GIOVANELLA BC, 1989, SCIENCE, V246, P1046, DOI 10.1126/science.2555920; HALLIGAN BD, 1985, J BIOL CHEM, V260, P2475; HIROSE S, 1988, P NATL ACAD SCI USA, V85, P718, DOI 10.1073/pnas.85.3.718; HSIANG YH, 1989, J BIOL CHEM, V264, P9713; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; KAWADA SZ, 1991, CANCER RES, V51, P2922; KOPKA ML, 1985, P NATL ACAD SCI USA, V82, P1376, DOI 10.1073/pnas.82.5.1376; LEE CS, 1991, CHEM RES TOXICOL, V4, P203, DOI 10.1021/tx00020a013; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; MANIATIS T, 1982, MOL CLONING LABORATO, P171; Maniatis T., 1982, MOL CLONING LABORATO, P86; MCHUGH MM, 1989, BIOCHEM PHARMACOL, V38, P2323, DOI 10.1016/0006-2952(89)90472-3; MCHUGH MM, 1990, BIOCHEM PHARMACOL, V39, P707, DOI 10.1016/0006-2952(90)90149-F; NELSON EM, 1984, P NATL ACAD SCI-BIOL, V81, P1361, DOI 10.1073/pnas.81.5.1361; POMMIER Y, 1987, BIOCHEM PHARMACOL, V36, P3477, DOI 10.1016/0006-2952(87)90329-7; POMMIER Y, 1985, BIOCHEMISTRY-US, V24, P6406, DOI 10.1021/bi00344a014; POMMIER Y, 1987, NUCLEIC ACIDS RES, V15, P6713, DOI 10.1093/nar/15.16.6713; ROSS WE, 1985, BIOCHEM PHARMACOL, V34, P4191, DOI 10.1016/0006-2952(85)90273-4; SNOUNOU G, 1983, J MOL BIOL, V167, P211, DOI 10.1016/S0022-2836(83)80043-6; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; TEWEY KM, 1984, J BIOL CHEM, V259, P9182; WANG JC, 1987, BIOCHIM BIOPHYS ACTA, V909, P1, DOI 10.1016/0167-4781(87)90040-6; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WOYNAROWSKI JM, 1989, MOL PHARMACOL, V35, P177; YAMASHITA Y, 1991, BIOCHEMISTRY-US, V30, P5838, DOI 10.1021/bi00238a005	34	66	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13160	13165						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8390457				2022-12-25	WOS:A1993LH55300024
J	HUPP, TR; KAGUNI, JM				HUPP, TR; KAGUNI, JM			ACTIVATION OF DNAA5 PROTEIN BY GRPE AND DNAK HEAT-SHOCK PROTEINS IN INITIATION OF DNA-REPLICATION IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIALIZED NUCLEOPROTEIN STRUCTURES; BACTERIOPHAGE-LAMBDA; CHROMOSOME-REPLICATION; SALMONELLA-TYPHIMURIUM; CELL-CYCLE; ORIGIN; GENE; GROWTH; PURIFICATION; TEMPERATURES	DnaA5 protein, inactive in replication systems dependent on purified enzymes, was activated by addition of a crude enzyme fraction. Based on this assay, two proteins in the crude enzyme fraction were identified that confer replication activity upon DnaA5 protein in a purified enzyme system. That one is DnaK protein was suggested initially from studies in which DnaK protein stimulated another mutant form of DnaA protein in replication assays dependent on a crude enzyme fraction (Hwang, D. S., and Kaguni, J. M. (1991) J. Biol. Chem. 266, 7537-7555). The identification of DnaK protein as a required protein for activation of DnaA5 protein, and its inclusion in a reconstituted enzyme system of purified replication proteins, allowed for the partial purification of the second activating protein. GrpE protein was deduced to be the second activating protein based on three criteria. First, activity in partially purified fractions correlated with a protein similar in size to GrpE protein on a sodium dodecyl sulfate-polyacrylamide gel. Second, activity in partially purified fractions correlated with a protein that reacted with anti-GrpE antibody. Third, purified GrpE protein functionally replaced the second protein in activation of DnaA5 protein.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA	Michigan State University				Kaguni, Jon/0000-0002-3096-4447	NIGMS NIH HHS [GM33992, R01 GM033992] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033992] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFANO C, 1989, J BIOL CHEM, V264, P10709; ALFANO C, 1989, J BIOL CHEM, V264, P10699; ANG D, 1989, J BACTERIOL, V171, P2748, DOI 10.1128/jb.171.5.2748-2755.1989; ATLUNG T, 1987, MOL GEN GENET, V206, P51, DOI 10.1007/BF00326535; ATLUNG T, 1981, ICN UCLA S MOL CELLU, V22, P297; BAGDASARIAN MM, 1977, J BACTERIOL, V130, P577, DOI 10.1128/JB.130.2.577-582.1977; BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BUKAU B, 1989, J BACTERIOL, V171, P6030, DOI 10.1128/jb.171.11.6030-6038.1989; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; DODSON M, 1986, P NATL ACAD SCI USA, V83, P7638, DOI 10.1073/pnas.83.20.7638; DODSON M, 1989, J BIOL CHEM, V264, P10719; DONACHIE WD, 1968, NATURE, V219, P1077, DOI 10.1038/2191077a0; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; GEORGOPOULOS CP, 1977, MOL GEN GENET, V151, P35, DOI 10.1007/BF00446910; GOMES SL, 1990, J BACTERIOL, V172, P3051, DOI 10.1128/jb.172.6.3051-3059.1990; HANSEN FG, 1991, J BACTERIOL, V173, P5194, DOI 10.1128/jb.173.16.5194-5199.1991; HARLOW E, 1988, ANTIBODIES LABORATOR, P562; HENDRICKSON WG, 1982, CELL, V30, P915, DOI 10.1016/0092-8674(82)90296-3; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; HUGHES P, 1988, CELL, V55, P343, DOI 10.1016/0092-8674(88)90057-8; HUGHES P, 1984, J MOL BIOL, V176, P155, DOI 10.1016/0022-2836(84)90386-3; HUPP TR, 1993, J BIOL CHEM, V268, P13128; HUPP TR, 1993, J BIOL CHEM, V268, P13143; HWANG DS, 1990, CELL, V63, P325, DOI 10.1016/0092-8674(90)90165-B; HWANG DS, 1988, J BIOL CHEM, V263, P10633; HWANG DS, 1991, J BIOL CHEM, V266, P7537; HWANG DS, 1990, J BIOL CHEM, V265, P19244; HWANG DS, 1988, J BIOL CHEM, V263, P10625; JARVIS TC, 1990, J BIOL CHEM, V265, P15160; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; LIBEREK K, 1988, P NATL ACAD SCI USA, V85, P6632, DOI 10.1073/pnas.85.18.6632; LIPINSKA B, 1988, NUCLEIC ACIDS RES, V16, P7545, DOI 10.1093/nar/16.15.7545; LOBNEROLESEN A, 1987, J BACTERIOL, V169, P2835, DOI 10.1128/jb.169.6.2835-2842.1987; MESSER W, 1985, EMBO J, V4, P1327, DOI 10.1002/j.1460-2075.1985.tb03780.x; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; OGAWA T, 1984, P NATL ACAD SCI USA, V82, P3562; OGDEN GB, 1988, CELL, V54, P127, DOI 10.1016/0092-8674(88)90186-9; OHKI M, 1989, NUCLEIC ACIDS RES, V17, P3479, DOI 10.1093/nar/17.9.3479; PIERUCCI O, 1989, J BACTERIOL, V171, P3760, DOI 10.1128/jb.171.7.3760-3766.1989; RUSSELL DW, 1987, CELL, V50, P1071, DOI 10.1016/0092-8674(87)90173-5; SAITO H, 1977, J MOL BIOL, V113, P1, DOI 10.1016/0022-2836(77)90038-9; SAITO H, 1978, MOL GEN GENET, V164, P1, DOI 10.1007/BF00267592; SAKAKIBARA Y, 1988, J BACTERIOL, V170, P972, DOI 10.1128/jb.170.2.972-979.1988; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SKARSTAD K, 1989, MOL GEN GENET, V218, P50, DOI 10.1007/BF00330564; SKARSTAD K, 1988, J BACTERIOL, V170, P852, DOI 10.1128/jb.170.2.852-858.1988; SMITH DW, 1985, EMBO J, V4, P1319, DOI 10.1002/j.1460-2075.1985.tb03779.x; STUITJE AR, 1983, NUCLEIC ACIDS RES, V11, P5775, DOI 10.1093/nar/11.16.5775; TANAKA M, 1985, MOL GEN GENET, V200, P21, DOI 10.1007/BF00383307; YUNG BYM, 1990, J BIOL CHEM, V265, P1282; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202; ZIMMERMAN SB, 1988, NUCLEIC ACIDS RES, V16, P6309, DOI 10.1093/nar/16.14.6309; ZYLICZ M, 1988, BIOCHIM BIOPHYS ACTA, V951, P344, DOI 10.1016/0167-4781(88)90105-4; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437	61	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13137	13142						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8390456				2022-12-25	WOS:A1993LH55300021
J	FRIEDRICH, TD; LAFFIN, J; LEHMAN, JM				FRIEDRICH, TD; LAFFIN, J; LEHMAN, JM			HYPOPHOSPHORYLATED RETINOBLASTOMA GENE-PRODUCT ACCUMULATES IN SV40-INFECTED CV-1 CELLS ACQUIRING A TETRAPLOID DNA CONTENT	ONCOGENE			English	Note							CHINESE-HAMSTER CELLS; SV40 LARGE-T; SUSCEPTIBILITY GENE; SIMIAN VIRUS-40; TRANSCRIPTION FACTOR; CYCLE PROGRESSION; TUMOR SUPPRESSOR; CARCINOMA-CELLS; RB PROTEIN; G1 PHASE	Simian virus 40 (SV40) infection of monkey kidney cells induces successive rounds of cellular DNA synthesis without intervening mitosis. To gain an understanding of the mechanisms responsible for disruption of cell cycle control during lytic infection, pRB phosphorylation and cell cycle distribution were examined following SV40 infection of CV-1 cells. The hypophosphorylated pRB present in confluent CV-1 cells was phosphorylated within 14 h following SV40 infection. Phosphorylated pRB then remained the predominant form as cells progressed from late G1 through S phase. Hypophosphorylated pRB reappeared as cells moved through G2 and acquired a tetraploid (>G2) DNA content. The reappearance of hypophosphorylated pRB in a population with decreasing numbers of cells in G1 phase and increasing numbers of cells in >G2 suggests that accumulation of hypophosphorylated pRB may be involved in T antigen-induced tetraploidy.	ALBANY MED COLL, DEPT MICROBIOL IMMUNOL & MOLEC GENET, A-68, 47 NEW SCOTLAND AVE, ALBANY, NY 12208 USA	Albany Medical College			Lehman, John M./AAU-4849-2020	Lehman, John/0000-0002-4478-4885	NCI NIH HHS [CA 41608] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041608, R55CA041608] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARTEK J, 1992, ONCOGENE, V7, P101; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; EVANS GA, 1992, BIOCHEM J, V282, P759, DOI 10.1042/bj2820759; FRIEDRICH TD, 1992, J VIROL, V66, P4576, DOI 10.1128/JVI.66.7.4576-4579.1992; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HOFFMAN BD, 1991, CYTOMETRY, V12, P26, DOI 10.1002/cyto.990120105; HORAN PK, 1974, INT J CANCER, V14, P514, DOI 10.1002/ijc.2910140411; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KHANDJIAN EW, 1992, ONCOGENE, V7, P909; KITAGAWA M, 1992, ONCOGENE, V7, P1067; Laffin J, 1990, Methods Cell Biol, V33, P271; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEHMAN JM, 1974, INT J CANCER, V14, P771, DOI 10.1002/ijc.2910140611; LEHMAN JM, 1988, CYTOMETRY, V9, P52, DOI 10.1002/cyto.990090109; LEHMAN JM, 1970, J VIROL, V6, P738, DOI 10.1128/JVI.6.6.738-749.1970; LEHMAN JM, 1992, IN VITRO CELL DEV-AN, V28A, P306; LEHMAN JM, 1974, INT J CANCER, V13, P164, DOI 10.1002/ijc.2910130203; LEHMAN JM, 1990, FLOW CYTOMETRY SORTI, P623; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUCAS JJ, 1992, J IMMUNOL, V148, P1804; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; PARSONS N, 1991, THESIS ALBANY MED CO; SHACKNEY SE, 1989, CANCER RES, V49, P3344; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TERADA N, 1991, J IMMUNOL, V147, P698; THOMAS NSB, 1991, ONCOGENE, V6, P317; TRIFILLIS P, 1990, J VIROL, V64, P1345, DOI 10.1128/JVI.64.3.1345-1347.1990; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WATSON PA, 1991, CYTOMETRY, V12, P242, DOI 10.1002/cyto.990120306; WILLIAMS RT, 1992, ONCOGENE, V7, P423; ZHANG HZ, 1992, BIOCHEM BIOPH RES CO, V189, P21, DOI 10.1016/0006-291X(92)91519-V	50	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1993	8	6					1673	1677						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8389034				2022-12-25	WOS:A1993LE06400032
J	MCDONALD, OB; MERRILL, BM; BLAND, MM; TAYLOR, LCE; SAHYOUN, N				MCDONALD, OB; MERRILL, BM; BLAND, MM; TAYLOR, LCE; SAHYOUN, N			SITE AND CONSEQUENCES OF THE AUTOPHOSPHORYLATION OF CA(2+) CALMODULIN-DEPENDENT PROTEIN-KINASE TYPE-GR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAM KINASE; MICROGRAM QUANTITIES; BINDING PROTEIN; DOMAINS; PHOSPHORYLATION; SEQUENCE; CALSPERMIN; ACTIVATION; PEPTIDES	CaM kinase-Gr is a Ca2+/calmodulin-dependent protein kinase that is enriched in brain and thymus. The enzyme was isolated from rat cerebellum, which contained alpha (M(r) 65,000) and beta (M(r) 67,000) polypeptides, and rat forebrain, which contained only the alpha polypeptide. Both enzyme preparations readily underwent autophosphorylation with dramatic up-regulation of their Ca2+/calmodulin-dependent, as well as -independent, activity. Autophosphorylation also caused a characteristic retardation in the electrophoretic gel mobility of the alpha and beta polypeptides. Treatment of autophosphorylated CaM kinase-Gr with acid phosphatase fully dephosphorylated the enzyme and reversed the changes in electrophoretic migration of both polypeptides. Phosphopeptide mapping indicated that the alpha and beta polypeptides were phosphorylated on identical or homologous sites, which probably induces similar structural and catalytic modifications in the two polypeptides. The actual site(s) of autophosphorylation was determined by the purification and amino acid sequencing of tryptic peptides from P-32-labeled CaM kinase-Gr. The major site of autophosphorylation was localized to a novel N-terminal domain, which is rich in Ser/Thr/Pro residues. The functional and structural studies on CaM kinase-Gr autophosphorylation imply that the enzyme is comprised of two regulatory domains, one on either side of a catalytic domain, followed by a C-terminal, putative association domain. The properties of such a structural model are discussed.			MCDONALD, OB (corresponding author), WELLCOME RES LABS, 3030 CORNWALLIS RD, RES TRIANGLE PK, NC 27709 USA.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; COLBRAN RJ, 1990, J BIOL CHEM, V265, P11213; ELDER JH, 1977, J BIOL CHEM, V252, P6510; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P17592; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P11309; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P4050, DOI 10.1073/pnas.88.9.4050; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LEVINE H, 1985, P NATL ACAD SCI USA, V82, P287, DOI 10.1073/pnas.82.2.287; LOU LL, 1986, P NATL ACAD SCI USA, V83, P9497, DOI 10.1073/pnas.83.24.9497; LOU LL, 1989, J NEUROSCI, V9, P2020; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MOZDZANOWSKI J, 1990, CURRENT RES PROTEIN, P87; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OHMSTEDE CA, 1991, P NATL ACAD SCI USA, V88, P5784, DOI 10.1073/pnas.88.13.5784; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OHMSTEDE CA, 1991, P NATL ACAD SCI USA, V88, P9375; ONO T, 1989, J BIOL CHEM, V264, P2081; PATTON BL, 1990, J BIOL CHEM, V265, P11204; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; SAHYOUN N, 1991, P NATL ACAD SCI USA, V88, P2643, DOI 10.1073/pnas.88.7.2643; SCHULMAN H, 1989, TRENDS BIOCHEM SCI, V14, P62, DOI 10.1016/0968-0004(89)90045-5; SCHULMAN H, 1988, ADV SEC MESS PHOSPH, V22, P39; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; WANG YH, 1988, ANAL BIOCHEM, V174, P537, DOI 10.1016/0003-2697(88)90053-X	35	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10054	10059						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8387511				2022-12-25	WOS:A1993LB80000020
J	TROTTER, PJ; STORCH, J				TROTTER, PJ; STORCH, J			FATTY-ACID ESTERIFICATION DURING DIFFERENTIATION OF THE HUMAN INTESTINAL-CELL LINE CACO-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-B SYNTHESIS; ACYL-COA SYNTHETASE; EPITHELIAL-CELLS; PLASMA-MEMBRANE; RAT-LIVER; PHOSPHATIDATE PHOSPHOHYDROLASE; OLEIC-ACID; SECRETION; CYTIDYLYLTRANSFERASE; GLYCEROPHOSPHATE	The Caco-2 human intestinal cell line was used to examine fatty acid esterification during development of the enterocytic phenotype. Acyl-CoA synthetase activity increased approximately 40%, and the incorporation of palmitic acid into triacylglycerol relative to phosphatidylcholine increased nearly 2-fold during Caco-2 differentiation. A rate-limiting enzyme activity in the glycerol 3-phosphate pathway of triacylglycerol synthesis, glycerol-3-phosphate acyltransferase, was at levels comparable with rat jejunum and remained unchanged during differentiation. In contrast, the activity of monoacylglycerol acyltransferase, which is unique to the monoacylglycerol pathway of triacylglycerol synthesis, was present at <7% of the levels in rat jejunum. Further analysis of the glycerol 3-phosphate pathway showed that the rate-limiting enzyme activities for diacylglycerol conversion to triacylglycerol, diacylglycerol acyltransferase, and phosphatidylcholine, CTP:phosphocholine cytidylyltransferase, increased 2-3-fold and decreased approximately 40%, respectively, during Caco-2 differentiation. In addition, a 2-fold increase in cellular diacylglycerol mass was observed during enterocytic conversion. These data indicate that fatty acid esterification to triacylglycerol in Caco-2 cells occurs primarily via the glycerol 3-phosphate pathway. Furthermore, the differentiation-dependent increase in fatty acid esterification to triacylglycerol relative to phosphatidylcholine appears to result from increased utilization of diacylglycerol to synthesize triacylglycerol and a concomitant decrease in diacylglycerol utilization for phosphatidylcholine synthesis.	HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM CELL & DEV BIOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School				Storch, Judith/0000-0001-5482-1777	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034854, R29DK038389, R01DK038389] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK038389, DK38389, DK34854] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brindley D N, 1974, Biomembranes, V4B, P621; BRINDLEY DN, 1982, PHOSPHOLIPIDS NEW CO, V4, P179; BRINDLEY DN, 1977, REGULATION FATTY ACI, P31; CARLSSON P, 1989, GENE, V77, P113, DOI 10.1016/0378-1119(89)90365-X; COLEMAN R, 1976, J BIOL CHEM, V251, P4537; DAAE LNW, 1970, BIOCHIM BIOPHYS ACTA, V210, P92; DASHTI N, 1990, J LIPID RES, V31, P113; FALLON HJ, 1977, BIOCHEM SOC T, V5, P37, DOI 10.1042/bst0050037; FERGUSON A, 1973, GASTROENTEROLOGY, V64, P292; FIELD FJ, 1988, J LIPID RES, V29, P1427; FIELD FJ, 1987, J LIPID RES, V28, P1057; GLICKMAN RM, 1986, P NATL ACAD SCI USA, V83, P5296, DOI 10.1073/pnas.83.14.5296; GRIGOR MR, 1982, BIOCHIM BIOPHYS ACTA, V712, P464, DOI 10.1016/0005-2760(82)90273-9; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HESLER CB, 1990, J BIOL CHEM, V265, P6600; HIDALGO IJ, 1989, GASTROENTEROLOGY, V96, P736; HUGHES TE, 1987, J BIOL CHEM, V262, P3762; HUGHES TE, 1988, J BIOL CHEM, V263, P3425; HULSMANN WC, 1976, BIOCHIM BIOPHYS ACTA, V450, P288, DOI 10.1016/0005-2760(76)90002-3; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; JOHNSTON JM, 1970, BIOCHIM BIOPHYS ACTA, V218, P124, DOI 10.1016/0005-2760(70)90099-8; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; LAMB RG, 1980, BIOCHIM BIOPHYS ACTA, V619, P385, DOI 10.1016/0005-2760(80)90086-7; LEBLOND CP, 1948, ANAT REC, V100, P357, DOI 10.1002/ar.1091000306; LEHNER R, 1992, BIOCHIM BIOPHYS ACTA, V1125, P171, DOI 10.1016/0005-2760(92)90042-T; LEVIN MS, 1992, J LIPID RES, V33, P9; Lipkin M., 1981, PHYSL GASTROINTESTIN, P145; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANSBACH CM, 1986, BIOCHIM BIOPHYS ACTA, V875, P516, DOI 10.1016/0005-2760(86)90072-X; MATTER K, 1990, J BIOL CHEM, V265, P3503; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MERRILL AH, 1982, J LIPID RES, V23, P1368; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; Neutra M, 1989, FUNCTIONAL EPITHELIA, P363; ODOHERTY PJA, 1978, ARCH BIOCHEM BIOPHYS, V190, P508, DOI 10.1016/0003-9861(78)90304-1; PAULWEBER B, 1991, J BIOL CHEM, V266, P24149; PAULWEBER B, 1991, J BIOL CHEM, V266, P24161; PINTO M, 1983, BIOL CELL, V47, P323; PREISS J, 1986, J BIOL CHEM, V261, P8597; ROUSSET M, 1986, BIOCHIMIE, V68, P1035, DOI 10.1016/S0300-9084(86)80177-8; ROUSSET M, 1985, J CELL PHYSIOL, V123, P377, DOI 10.1002/jcp.1041230313; SHIAU YF, 1979, AM J PHYSIOL, V237, pE399, DOI 10.1152/ajpendo.1979.237.5.E399; SHIAU YF, 1980, GASTROENTEROLOGY, V79, P47; SHIAU YF, 1978, AM J PHYSIOL, V234, pE236, DOI 10.1152/ajpendo.1978.234.3.E236; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TRABER MG, 1987, J LIPID RES, V28, P1350; TROTTER PJ, 1991, J LIPID RES, V32, P293; VANTHOF W, 1990, J CELL BIOL, V111, P977, DOI 10.1083/jcb.111.3.977; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; WEISER MM, 1973, J BIOL CHEM, V248, P2536; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374; YANG LY, 1991, J LIPID RES, V32, P1173	53	61	63	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10017	10023						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8387510				2022-12-25	WOS:A1993LB80000015
J	MLINAR, B; BIAGI, BA; ENYEART, JJ				MLINAR, B; BIAGI, BA; ENYEART, JJ			A NOVEL K+ CURRENT INHIBITED BY ADRENOCORTICOTROPIC HORMONE AND ANGIOTENSIN-II IN ADRENAL-CORTICAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULOSA CELLS; ALDOSTERONE SECRETION; FASCICULATA CELLS; BOVINE; CALCIUM; RAT; CHANNEL; POTASSIUM; CA-2+; ACTH	Adrenocorticotropic hormone (ACTH) and angiotensin II (AII) are peptides that regulate the production of steroid hormones by cells of the adrenal cortex. The cellular mechanisms linking these peptides to cortico-steroid hormone secretion are not understood. In patch clamp recordings from bovine adrenal zona fasciculata (AZF) cells, we have identified a novel cholera toxin-sensitive K+ current (I(AC)), which is potently inhibited by both ACTH and AII with respective EC50 values of 4.5 and 145 pM. These two peptides depolarize AZF cells with a temporal pattern and potency that parallels the inhibition Of I(AC). With the discovery Of I(AC), we have identified a common molecular target for both ACTH and AII. The convergent inhibition Of I(AC) by these two peptides suggests a mechanism whereby biochemical signals originating at the cell membrane can be transduced to depolarization-dependent Ca2+ entry and steroid hormone secretion.	OHIO STATE UNIV,COLL MED,DEPT PHARMACOL,5188 GRAVES HALL,333 W 10TH AVE,COLUMBUS,OH 43210; OHIO STATE UNIV,COLL MED,DEPT PHYSIOL,COLUMBUS,OH 43210; OHIO STATE UNIV,COLL MED,NEUROSCI PROGRAM,COLUMBUS,OH 43210	Ohio State University; Ohio State University; Ohio State University			Mlinar, Boris/A-7034-2008	Mlinar, Boris/0000-0001-9082-0827	NIDDK NIH HHS [DK-40131] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040131] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRAUNEIS U, 1991, AM J PHYSIOL, V260, pE772, DOI 10.1152/ajpendo.1991.260.5.E772; BREGESTOVSKI P, 1986, NATURE, V319, P776, DOI 10.1038/319776a0; CAPPONI AM, 1984, J BIOL CHEM, V259, P8863; COHEN CJ, 1988, P NATL ACAD SCI USA, V85, P2412, DOI 10.1073/pnas.85.7.2412; DURROUX T, 1991, ENDOCRINOLOGY, V129, P2139, DOI 10.1210/endo-129-4-2139; ENYEART JJ, 1992, SOC NEUR ABSTR, V18; GOSPODAROWICZ D, 1977, ENDOCRINOLOGY, V100, P1080; HAMILL OP, 1981, PFLUEGERS ARCH, V398, P284; KIRKWOOD A, 1991, NEURON, V6, P1009, DOI 10.1016/0896-6273(91)90240-Z; KOJIMA I, 1984, J BIOL CHEM, V259, P4448; KOJIMA I, 1986, J BIOL CHEM, V261, P9832; KOJIMA I, 1985, J BIOL CHEM, V260, P9171; KOJIMA I, 1985, J BIOL CHEM, V260, P4248; LYMANGROVER JR, 1982, ENDOCRINOLOGY, V110, P462, DOI 10.1210/endo-110-2-462; MCCLOSKEY MA, 1990, J GEN PHYSIOL, V95, P205, DOI 10.1085/jgp.95.2.205; MOYLE WR, 1973, J BIOL CHEM, V248, P2409; MULLER T, 1992, SCIENCE, V256, P1563, DOI 10.1126/science.1317969; PAYET MD, 1987, ENDOCRINOLOGY, V121, P875, DOI 10.1210/endo-121-3-875; PERCHELLET JP, 1978, SCIENCE, V199, P211; QUINN SJ, 1988, ANNU REV PHYSIOL, V50, P409, DOI 10.1146/annurev.ph.50.030188.002205; QUINN SJ, 1992, AM J PHYSIOL, V262, pC598, DOI 10.1152/ajpcell.1992.262.3.C598; QUINN SJ, 1991, ENDOCRINOLOGY, V129, P2431, DOI 10.1210/endo-129-5-2431; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; SUTHERLAND EW, 1972, SCIENCE, V177, P401, DOI 10.1126/science.177.4047.401; YANAGIBASHI K, 1990, ENDOCRINOLOGY, V127, P311, DOI 10.1210/endo-127-1-311; ZUBER MX, 1985, J BIOL CHEM, V260, P1842	26	64	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8640	8644						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8386167				2022-12-25	WOS:A1993KX81100041
J	STAHL, N; DAVIS, S; WONG, V; TAGA, T; KISHIMOTO, T; IP, NY; YANCOPOULOS, GD				STAHL, N; DAVIS, S; WONG, V; TAGA, T; KISHIMOTO, T; IP, NY; YANCOPOULOS, GD			CROSS-LINKING IDENTIFIES LEUKEMIA INHIBITORY FACTOR-BINDING PROTEIN AS A CILIARY NEUROTROPHIC FACTOR RECEPTOR COMPONENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							IL-6 SIGNAL TRANSDUCER; EXPRESSION CLONING; GP130	Ciliary neurotrophic factor (CNTF) and leukemia inhibitory factor (LIF) are cytokines that give rise to an identical set of tyrosine-phosphorylated proteins upon addition to responsive cells. One of these proteins is the interleukin-6 signal-transducing molecule gp130, which is required for signal transduction by both CNTF and LIF. Here we identify another prominent tyrosine-phosphorylated protein as LIF receptor (LIFR) beta, which was originally cloned as a LIF-binding protein. Cross-linking experiments with iodinated factors were carried out on a cell line responsive to CNTF and LIF, as well as on COS cells that were cotransfected with various combinations of gp130, LIFRbeta, and CNTF receptor (CNTFR) alpha, the previously cloned CNTF-binding protein. These experiments reveal that LIF cross-links to LIFRbeta alone, as well as to gp130 when it is coexpressed with LIFRbeta. However, cross-linking of CNTF to LIFRbeta and gp130 is only observed in the presence of CNTFRalpha. These and other data show that the two known LIF receptor components are recruited by CNTF and CNTFRalpha to form a trimeric CNTF receptor complex.	OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN	Osaka University	STAHL, N (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.		Kishimoto, Tadamitsu/C-8470-2009					BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; Davis S, 1993, Curr Opin Neurobiol, V3, P20, DOI 10.1016/0959-4388(93)90030-3; DAVIS S, 1993, IN PRESS SCIENCE; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GODARD A, 1992, J BIOL CHEM, V267, P3214; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Ip Nancy Y., 1992, Progress in Growth Factor Research, V4, P139, DOI 10.1016/0955-2235(92)90028-G; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LINNEKIN D, 1992, P NATL ACAD SCI USA, V89, P6237, DOI 10.1073/pnas.89.14.6237; MASIAKOWSKI P, 1991, J NEUROCHEM, V57, P1003, DOI 10.1111/j.1471-4159.1991.tb08250.x; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706	23	108	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7628	7631						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8385113				2022-12-25	WOS:A1993KW97900008
J	SECRIST, JP; BURNS, LA; KARNITZ, L; KORETZKY, GA; ABRAHAM, RT				SECRIST, JP; BURNS, LA; KARNITZ, L; KORETZKY, GA; ABRAHAM, RT			STIMULATORY EFFECTS OF THE PROTEIN TYROSINE PHOSPHATASE INHIBITOR, PERVANADATE, ON T-CELL ACTIVATION EVENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; PHOSPHOLIPASE C-GAMMA-1; LYMPHOCYTE-T; SIGNAL TRANSDUCTION; CROSS-LINKING; GROWTH-FACTOR; PHOSPHORYLATION; KINASE; ANTIBODY; FAMILY	Ligation of the multimeric T-cell antigen receptor complex (TCR) triggers a pleiotropic cellular activation response that includes lymphokine secretion, cell-cycle progression, and ultimately, T-cell proliferation. The earliest detectable biochemical event triggered by TCR cross-linkage is the tyrosine phosphorylation of specific intracellular proteins, which, in turn, propagate receptor-mediated signals into the cytoplasm and nucleus. In this study, we have examined the effects of pervanadate, a powerful inhibitor of protein tyrosine phosphatases (PTP), on the activation state of the human leukemic T-cell line, Jurkat. Treatment of Jurkat cells with pervanadate rapidly induced a series of proximal T-cell activation events that closely resembled those induced by TCR-dependent stimuli. Moreover, pervanadate treatment, like TCR cross-linkage, stimulated interleukin-2 production in wild-type Jurkat cells, indicating that the biochemical events initiated by this TCR-independent stimulus were sufficient to induce lymphokine gene expression. Exposure of intact cells to pervanadate also stimulated the in vitro catalytic activities of both p59fyn and p56lck, src family kinases strongly implicated in TCR-mediated signaling. The stimulatory effects of pervanadate on protein tyrosine kinase-mediated signaling events were accompanied by a marked inhibition of CD45-associated PTP activity. However, the ability of pervanadate to stimulate tyrosine phosphorylation in CD45-negative Jurkat cells suggests that PTPs other than CD45 are important intracellular targets for pervanadate. These studies demonstrate that inhibition of PTP activities in Jurkat cells leads to a T-cell activation response that is remarkably similar to that induced by TCR cross-linkage.	MAYO CLIN & MAYO FDN,DEPT IMMUNOL,RM 342B,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905; UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Mayo Clinic; Mayo Clinic; University of Iowa; University of Iowa			Koretzky, Gary/AAU-5381-2021		NATIONAL CANCER INSTITUTE [U19CA052995, R29CA056843, U01CA052995] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047286] Funding Source: NIH RePORTER; NCI NIH HHS [CA 56843, CA 52995] Funding Source: Medline; NIGMS NIH HHS [GM 47286] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; AUGUSTINE JA, 1991, J IMMUNOL, V146, P2889; BERGER AE, 1981, HUM IMMUNOL, V3, P231, DOI 10.1016/0198-8859(81)90020-3; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; CHAN A, 1992, ARTHRITIS RHEUM, V35, pS61; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HO SN, 1987, J IMMUNOL METHODS, V98, P99, DOI 10.1016/0022-1759(87)90441-8; HSI ED, 1989, J BIOL CHEM, V264, P10836; HUHN RD, 1987, P NATL ACAD SCI USA, V84, P4408, DOI 10.1073/pnas.84.13.4408; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KADOTA S, 1987, BIOCHEM BIOPH RES CO, V147, P259, DOI 10.1016/S0006-291X(87)80115-8; KANNER SB, 1992, BIOCHEM SOC T, V20, P178, DOI 10.1042/bst0200178; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KIENER PA, 1989, J IMMUNOL, V143, P23; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOLLER KJ, 1987, NATURE, V325, P542, DOI 10.1038/325542a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LUO K, 1990, ONCOGENE, V5, P921; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NOVOGRODSKY A, 1980, J EXP MED, V151, P755, DOI 10.1084/jem.151.3.755; NOVOGRODSKY A, 1974, EUR J IMMUNOL, V4, P646, DOI 10.1002/eji.1830041003; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PEYRON JF, 1991, INT IMMUNOL, V3, P1357, DOI 10.1093/intimm/3.12.1357; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; VANWAUWE JP, 1980, J IMMUNOL, V124, P2708; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; WATSON J, 1979, J EXP MED, V150, P1510, DOI 10.1084/jem.150.6.1510; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WISKOCIL R, 1985, J IMMUNOL, V134, P1599; ZICK Y, 1990, BIOCHEMISTRY-US, V29, P10240, DOI 10.1021/bi00496a013	60	291	294	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5886	5893						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8383678				2022-12-25	WOS:A1993KR82200080
J	HEINEMEYER, W; GRUHLER, A; MOHRLE, V; MAHE, Y; WOLF, DH				HEINEMEYER, W; GRUHLER, A; MOHRLE, V; MAHE, Y; WOLF, DH			PRE2, HIGHLY HOMOLOGOUS TO THE HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX-LINKED RING10 GENE, CODES FOR A YEAST PROTEASOME SUBUNIT NECESSARY FOR CHYMOTRYPTIC ACTIVITY AND DEGRADATION OF UBIQUITINATED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT PROTEINASE; CLASS-II REGION; MULTICATALYTIC PROTEINASE; SACCHAROMYCES-CEREVISIAE; MACROPAIN PROTEASOME; HUMAN MHC; PARTICLES; SEQUENCE; CLONING; CELLS	We have cloned the yeast PRE2 gene by complementation of pre2 mutants, which are defective in the chymotrypsin-like activity of the 20 S proteasome (multicatalytic-multifunctional proteinase complex). The PRE2 gene, a beta-type member of the proteasomal gene family, is essential for life and codes for a 287-amino acid proteasomal subunit with a predicted molecular mass of 31.6 kDa. Missense mutations in two pre2 mutant alleles were identified. They led to enhanced sensitivity of yeast cells against stress. At the same time, pre2 mutants accumulated ubiquitinated proteins. The Pre2 protein shows striking homology to the human Ring10 protein (60% identity excluding the 70 amino-terminal residues), which is encoded in the major histocompatibility complex class II region. It represents a component of the low molecular mass polypeptide complex, previously shown to be a special type of the 20 S proteasome. The low molecular mass polypeptide complex is assumed to be involved in antigen presentation, generating peptides from cytosolic protein antigens, which are subsequently presented to cytotoxic T-lymphocytes on the cell surface. The high homology of Pre2 to Ring10 implies the hypothesis that Ring10 is a subunit of the low molecular mass polypeptide complex central in its chymotryptic activity. One might further suggest that replacement of constitutive proteasomal components by functionally related major histocompatibility complex-linked low molecular mass polypeptides, as is Ring10, adapts mammalian proteasomes for functions in the immune response.	UNIV STUTTGART,INST BIOCHEM,PFAFFENWALDRING 55,W-7000 STUTTGART 80,GERMANY	University of Stuttgart								AKI M, 1992, FEBS LETT, V301, P65, DOI 10.1016/0014-5793(92)80211-X; [Anonymous], 1991, Methods Enzymol, V194, P1; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; DeMars R, 1992, Trends Cell Biol, V2, P81, DOI 10.1016/0962-8924(92)90077-Z; DEMARTINO GN, 1991, BIOCHIM BIOPHYS ACTA, V1079, P29, DOI 10.1016/0167-4838(91)90020-Z; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; DRISCOLL J, 1992, CELL, V68, P823, DOI 10.1016/0092-8674(92)90024-7; EMORI Y, 1991, MOL CELL BIOL, V11, P344, DOI 10.1128/MCB.11.1.344; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FRENTZEL S, 1992, FEBS LETT, V302, P121, DOI 10.1016/0014-5793(92)80420-L; FUJIWARA T, 1990, J BIOL CHEM, V265, P16604; GEORGATSOU E, 1992, FEBS LETT, V299, P29; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; HAFFTER P, 1991, NUCLEIC ACIDS RES, V19, P5075, DOI 10.1093/nar/19.18.5075; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1990, Yeast, V6, pS342; HOUGH R, 1987, J BIOL CHEM, V262, P8303; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; KLEINSCHMIDT JA, 1988, FEBS LETT, V239, P35, DOI 10.1016/0014-5793(88)80540-4; LEE DH, 1992, BIOCHEM BIOPH RES CO, V182, P452, DOI 10.1016/0006-291X(92)91753-D; LEE LW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P178, DOI 10.1016/0167-4838(90)90165-C; LEER RJ, 1984, FEBS LETT, V175, P371, DOI 10.1016/0014-5793(84)80771-1; LILLEY KS, 1990, FEBS LETT, V262, P327, DOI 10.1016/0014-5793(90)80220-D; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MORITZ M, 1991, MOL CELL BIOL, V11, P5681, DOI 10.1128/MCB.11.11.5681; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; RICHTERRUOFF B, 1992, FEBS LETT, V302, P192, DOI 10.1016/0014-5793(92)80438-M; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; Sherman F., 1986, METHODS YEAST GENETI; TANAKA K, 1992, NEW BIOL, V4, P173; TANAKA K, 1988, J BIOL CHEM, V263, P16209; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	36	242	244	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5115	5120						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8383129				2022-12-25	WOS:A1993KP88400081
J	SCHWANINGER, M; LUX, G; BLUME, R; OETJEN, E; HIDAKA, H; KNEPEL, W				SCHWANINGER, M; LUX, G; BLUME, R; OETJEN, E; HIDAKA, H; KNEPEL, W			MEMBRANE DEPOLARIZATION AND CALCIUM INFLUX INDUCE GLUCAGON GENE-TRANSCRIPTION IN PANCREATIC-ISLET CELLS THROUGH THE CYCLIC AMP-RESPONSIVE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DNA-BINDING PROTEINS; NUCLEAR FACTOR CREB; SOMATOSTATIN GENE; BETA-CELLS; INSULIN-SECRETION; PROMOTER ELEMENT; RAT SOMATOSTATIN; MAMMALIAN-CELLS; ENDOCRINE-CELLS	Glucagon-producing pancreatic islet cells generate calcium-dependent action potentials. By the control of calcium influx through voltage-gated calcium channels, calcium is a tightly regulated second messenger in these cells. It is unknown whether calcium is a signal for glucagon gene transcription. Therefore, rat glucagon reporter fusion genes were transiently transfected into pancreatic islet cell lines. High potassium-induced membrane depolarization activated glucagon gene transcription. The effects of a calcium chelator, calcium channel blockers, calmodulin antagonists, and an inhibitor of calcium/calmodulin-dependent protein kinase II (CaM kinase II) indicate that depolarization-induced glucagon gene transcription depends on calcium influx and CaM kinase II. The depolarization-responsive element was mapped to the glucagon cAMP-responsive element (CRE). The CRE-binding protein CREB was shown, by using GAL4-CREB fusion proteins, to function as a depolarization-regulated transcription factor in pancreatic islet cells. Membrane depolarization and cAMP had synergistic effects on glucagon gene transcription. These results suggest that rat glucagon gene transcription is regulated by membrane electrical activity and calcium influx in pancreatic islet cells. This signal may be transmitted via CaM kinase II and CREB to the glucagon CRE.	UNIV GOTTINGEN, DEPT BIOCHEM PHARMACOL, ROBERT KOCH STR 40, W-3400 GOTTINGEN, GERMANY; NAGOYA UNIV, SCH MED, DEPT PHARMACOL, NAGOYA, AICHI 466, JAPAN	University of Gottingen; Nagoya University				Schwaninger, Markus/0000-0002-4510-9718				ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COOK DL, 1991, TRENDS NEUROSCI, V14, P411, DOI 10.1016/0166-2236(91)90033-Q; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DAY RN, 1990, MOL ENDOCRINOL, V4, P736, DOI 10.1210/mend-4-5-736; DAY RN, 1989, J BIOL CHEM, V264, P431; DEFRANCO AL, 1991, NATURE, V352, P754, DOI 10.1038/352754a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIEM P, 1990, ENDOCRINOLOGY, V127, P1609, DOI 10.1210/endo-127-4-1609; DRUCKER DJ, 1988, ENDOCRINOLOGY, V123, P1861, DOI 10.1210/endo-123-4-1861; DRUCKER DJ, 1991, ENDOCRINOLOGY, V128, P394, DOI 10.1210/endo-128-1-394; EFRAT S, 1988, NEURON, V1, P605, DOI 10.1016/0896-6273(88)90110-9; EPSTEIN PN, 1989, CELL, V58, P1067, DOI 10.1016/0092-8674(89)90505-9; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FLINT KJ, 1991, ONCOGENE, V6, P2019; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FUKUNAGA K, 1988, J NEUROCHEM, V51, P1070, DOI 10.1111/j.1471-4159.1988.tb03070.x; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; GINTY DD, 1991, J BIOL CHEM, V266, P17454; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HABENER JF, 1991, ENDOCRINE PANCREAS, P53; HAMAGUCHI K, 1990, DIABETES, V39, P415, DOI 10.2337/diabetes.39.4.415; HIDAKA H, 1992, ANNU REV PHARMACOL, V32, P377, DOI 10.1146/annurev.pharmtox.32.1.377; HILL RS, 1987, DIABETES, V36, P4400; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HSU WH, 1991, J BIOL CHEM, V266, P837; INAGAKI N, 1992, P NATL ACAD SCI USA, V89, P1045, DOI 10.1073/pnas.89.3.1045; ISHIKAWA N, 1990, J PHARMACOL EXP THER, V254, P598; IVERSEN J, 1973, J CLIN INVEST, V52, P2102, DOI 10.1172/JCI107395; JAMESON JL, 1989, MOL ENDOCRINOL, V3, P763, DOI 10.1210/mend-3-5-763; Janis RA, 1987, ADV DRUG RES, V16, P309; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KEAHEY HH, 1989, DIABETES, V38, P188, DOI 10.2337/diabetes.38.2.188; KILBOURNE EJ, 1992, J BIOL CHEM, V267, P7563; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; KNEPEL W, 1991, MOL ENDOCRINOL, V5, P1457, DOI 10.1210/mend-5-10-1457; KNEPEL W, 1990, MOL CELL BIOL, V10, P6799, DOI 10.1128/MCB.10.12.6799; KOBIERSKI LA, 1991, P NATL ACAD SCI USA, V88, P10222, DOI 10.1073/pnas.88.22.10222; LEDOUARIN NM, 1988, CELL, V53, P169, DOI 10.1016/0092-8674(88)90375-3; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NEHER E, 1992, NATURE, V355, P298, DOI 10.1038/355298a0; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NORMAN JA, 1987, MOL PHARMACOL, V31, P535; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; OZAWA S, 1986, PHYSIOL REV, V66, P887, DOI 10.1152/physrev.1986.66.4.887; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1990, J BIOL CHEM, V265, P1465; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P817, DOI 10.1210/endo-117-3-817; POWERS AC, 1990, DIABETES, V39, P406, DOI 10.2337/diabetes.39.4.406; POWERS AC, 1989, J BIOL CHEM, V264, P10048; PRENTKI M, 1988, J BIOL CHEM, V263, P11044; RAJAN AS, 1989, DIABETES, V38, P874, DOI 10.2337/diabetes.38.7.874; RORSMAN P, 1988, J GEN PHYSIOL, V91, P223, DOI 10.1085/jgp.91.2.223; RORSMAN P, 1989, NATURE, V341, P233, DOI 10.1038/341233a0; RORSMAN P, 1988, J GEN PHYSIOL, V91, P243, DOI 10.1085/jgp.91.2.243; Sambrook J, 1989, MOL CLONING LABORATO; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SATIN LS, 1988, PFLUG ARCH EUR J PHY, V411, P401, DOI 10.1007/BF00587719; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SORYSORENSON RL, 1991, DIABETES, V40, P1365; TAKAKI R, 1986, IN VITRO CELL DEV B, V22, P120; TANAKA T, 1982, MOL PHARMACOL, V22, P4008; TEITELMAN G, 1991, RECENT PROG HORM RES, V47, P259; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; UNGER RH, 1981, NEW ENGL J MED, V304, P1518, DOI 10.1056/NEJM198106183042504; VANNGUYEN T, 1990, J NEUROSCI, V10, P2825; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; WANG JL, 1990, BIOCHEM BIOPH RES CO, V166, P813, DOI 10.1016/0006-291X(90)90882-N; WATERMAN M, 1985, SCIENCE, V229, P267, DOI 10.1126/science.2990047; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WOLLHEIM CB, 1990, BIOCHEM SOC T, V18, P111, DOI 10.1042/bst0180111; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YAN GZ, 1991, MOL ENDOCRINOL, V5, P1488, DOI 10.1210/mend-5-10-1488	85	99	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5168	5177						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8383130				2022-12-25	WOS:A1993KP88400088
J	SHOELSON, SE; LEE, JS; LYNCH, CS; BACKER, JM; PILCH, PF				SHOELSON, SE; LEE, JS; LYNCH, CS; BACKER, JM; PILCH, PF			BPA(B25) INSULINS - PHOTOACTIVATABLE ANALOGS THAT QUANTITATIVELY CROSS-LINK, RADIOLABEL, AND ACTIVATE THE INSULIN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTANT HUMAN INSULIN; BIOLOGICAL-ACTIVITY; PLASMA-MEMBRANE; BINDING-SITE; SUBUNIT STRUCTURE; PROTEIN DESIGN; SELECTIVE H-2; SIDE-CHAIN; MAIN CHAIN; ASSIGNMENT	Benzoylphenylalanine (Bpa), a photoactivatable amino acid was incorporated into the 25 position of the insulin B-chain by a combination of chemical synthesis and enzymatic semisynthesis. Bpa(B25) insulin binds specifically to the insulin receptor with an affinity almost-equal-to 40% that of native insulin. Addition of biotin or epsilon-amino-hexanoic acid-iminobiotin at the epsilon-Lys(B29) position to form Bpa(B25),B29epsilon-biotinyl (BBpa) or Bpa(B25),B29epsilon-(Aha-iminobiotin) analogues had little adverse effect on receptor binding affinity and provided a convenient handle for affinity purification, gel shift assays, and blotting of cross-linked complexes with avidin. The analogues were readily I-125-iodinated with the majority of I-125 being incorporated at the Tyr(A14) position; the monoiodo-A14 derivative was easily separated from other forms by high performance liquid chromatography. Photolysis of a complex of the insulin receptor and either Bpa(B25) insulin or [I-125]iodo-Tyr(A14),Bpa(B25) insulin yields a covalent insulin-receptor complex. The efficiency of cross-linking with these reagents was unusually high, ranging from 60 to 100%. Furthermore, cross-linking to the insulin receptor results in kinase activation in vitro, and in intact cells insulin receptor phosphorylation and internalization were both activated. Notably, even at saturating concentrations one molecule of Bpa(B25) insulin covalently cross-linked each alpha2beta2 receptor, demonstrating that holoreceptor activation occurs with one high affinity insulin binding site occupied and, if a second insulin binds with lower affinity it must be in a different orientation. Bpa insulin analogues form a new class of photoaffinity reagents which facilitate studies relating insulin-insulin receptor structure and function.	BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BOSTON UNIV,SCH MED,DEPT MED,BOSTON,MA 02118	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Boston University	SHOELSON, SE (corresponding author), JOSLIN DIABET CTR,1 JOSLIN PL,BOSTON,MA 02215, USA.		Lee, Jongsoon/AAG-1674-2020	Lee, Jongsoon/0000-0002-0891-5059; Pilch, Paul/0000-0003-1997-0499	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036424, R01DK043123, P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK43123, DK36836, R01 DK36424] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; BLUNDELL TL, 1971, NATURE, V231, P506, DOI 10.1038/231506a0; BONISCHNETZLER M, 1986, J BIOL CHEM, V261, P5281; BONISCHNETZLER M, 1987, J BIOL CHEM, V262, P8395; BREMS DN, 1991, J BIOL CHEM, V266, P1611; BRESLOW R, 1980, ACCOUNTS CHEM RES, V13, P170, DOI 10.1021/ar50150a002; CHOWDHRY V, 1979, ANNU REV BIOCHEM, V48, P293, DOI 10.1146/annurev.bi.48.070179.001453; CUTFIELD J, 1981, H-S Z PHYSIOL CHEM, V362, P755, DOI 10.1515/bchm2.1981.362.1.755; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DEMEYTS P, 1976, J BIOL CHEM, V251, P1877; DEREWENDA U, 1991, J MOL BIOL, V220, P425, DOI 10.1016/0022-2836(91)90022-X; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FABRY M, 1992, J BIOL CHEM, V267, P8950; FUDEMGOLDIN B, 1990, METHOD ENZYMOL, V184, P167; HOFMANN K, 1980, P NATL ACAD SCI-BIOL, V77, P4666, DOI 10.1073/pnas.77.8.4666; HUA QX, 1991, BIOCHEMISTRY-US, V30, P5505, DOI 10.1021/bi00236a025; HUA QX, 1992, BIOCHEMISTRY-US, V31, P11940, DOI 10.1021/bi00162a037; HUA QX, 1991, NATURE, V354, P238, DOI 10.1038/354238a0; INOUYE K, 1981, BIOPOLYMERS, V20, P1845, DOI 10.1002/bip.1981.360200909; INOUYE K, 1981, EXPERIENTIA, V37, P811, DOI 10.1007/BF01985653; INOUYE K, 1982, PEPTIDE CHEM, P277; KAUER JC, 1986, J BIOL CHEM, V261, P695; KOBAYASHI M, 1984, BIOCHEM BIOPH RES CO, V119, P49, DOI 10.1016/0006-291X(84)91616-4; KOBAYASHI M, 1982, BIOCHEM J, V206, P597, DOI 10.1042/bj2060597; LEE JS, 1993, J BIOL CHEM, V268, P4092; LIOUBIN MN, 1984, PREP BIOCHEM, V14, P303, DOI 10.1080/10826068408070637; MASSAGUE J, 1981, J BIOL CHEM, V256, P3182; MASSAGUE J, 1980, P NATL ACAD SCI-BIOL, V77, P7137, DOI 10.1073/pnas.77.12.7137; MILLER WT, 1988, P NATL ACAD SCI USA, V85, P5429, DOI 10.1073/pnas.85.15.5429; MIRMIRA RG, 1989, J BIOL CHEM, V264, P6349; NAKAGAWA SH, 1987, J BIOL CHEM, V262, P12054; NAKAGAWA SH, 1986, J BIOL CHEM, V261, P7332; NAKAGAWA SH, 1989, J BIOL CHEM, V264, P272; NG DS, 1985, BIOCHEM BIOPH RES CO, V133, P154, DOI 10.1016/0006-291X(85)91854-6; ONEIL KT, 1989, J BIOL CHEM, V264, P14571; PANG DT, 1983, J BIOL CHEM, V258, P2514; PILCH PF, 1979, J BIOL CHEM, V254, P3375; PILCH PF, 1980, J BIOL CHEM, V255, P1722; PRIGENT SA, 1990, J BIOL CHEM, V265, P9970; PULLEN RA, 1976, NATURE, V259, P369, DOI 10.1038/259369a0; SAYOUN N, 1978, P NATL ACAD SCI USA, V75, P1675; SHOELSON S, 1983, NATURE, V302, P540, DOI 10.1038/302540a0; SHOELSON S, 1983, P NATL ACAD SCI-BIOL, V80, P7390, DOI 10.1073/pnas.80.24.7390; SHOELSON SE, 1992, BIOCHEMISTRY-US, V31, P1757, DOI 10.1021/bi00121a025; SHOELSON SE, 1992, PEPTIDES CHEM BIOL, P57; SHYMKO RM, 1989, BIOCHEM BIOPH RES CO, V164, P191, DOI 10.1016/0006-291X(89)91701-4; Stewart JM, 1984, SOLID PHASE PEPTIDE; SWEET LJ, 1987, J BIOL CHEM, V262, P16730; TAGER H, 1980, P NATL ACAD SCI-BIOL, V77, P3181, DOI 10.1073/pnas.77.6.3181; TAGER H, 1979, NATURE, V281, P122, DOI 10.1038/281122a0; TAMM P, 1980, INSULIN CHEM STRUCTU; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P3448, DOI 10.1021/bi00434a045; WEDEKIND F, 1989, BIOL CHEM H-S, V370, P251, DOI 10.1515/bchm3.1989.370.1.251; WEISS MA, 1989, BIOCHEMISTRY-US, V28, P9855, DOI 10.1021/bi00451a046; WEISS MA, 1991, BIOCHEMISTRY-US, V30, P7373, DOI 10.1021/bi00244a004; WOLLMER A, 1981, H-S Z PHYSIOL CHEM, V362, P581, DOI 10.1515/bchm2.1981.362.1.581; YAJIMA H, 1988, TETRAHEDRON, V44, P805, DOI 10.1016/S0040-4020(01)86118-4; YEUNG CWT, 1980, BIOCHEMISTRY-US, V19, P2196, DOI 10.1021/bi00551a031; YIP CC, 1978, J BIOL CHEM, V253, P1743; YIP CC, 1992, J BIOL CHEM, V267, P13131; YIP CC, 1980, BIOCHEMISTRY-US, V19, P70, DOI 10.1021/bi00542a011; YIP CC, 1982, BIOCHEMISTRY-US, V21, P2940, DOI 10.1021/bi00541a021	63	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4085	4091						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8382690				2022-12-25	WOS:A1993KN53300045
J	LEE, J; STOCK, J				LEE, J; STOCK, J			PROTEIN PHOSPHATASE-2A CATALYTIC SUBUNIT IS METHYL-ESTERIFIED AT ITS CARBOXYL-TERMINUS BY A NOVEL METHYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RABBIT SKELETAL-MUSCLE; SIGNAL TRANSDUCTION; BACTERIAL CHEMOTAXIS; T-ANTIGENS; PURIFICATION; LIVER; COMPLEXES; BRAIN	In eukaryotic cells a number of different proteins with important regulatory functions are reversibly methyl-esterified at carboxyl-terminal prenylcysteine residues. These proteins include the low molecular weight GTP-binding proteins, the gamma-subunit of the heterotrimeric G-proteins, and the nuclear lamins. The methylating enzymes that catalyze this type of carboxyl methylation reaction are integral membrane proteins, and the methylated protein products tend to be membrane-associated. Analyses of protein carboxyl methylation in a wide range of vertebrate tissues revealed a major carboxyl-methylated protein that was clearly distinct from those that are modified at prenylcysteine groups (Volker, C., Miller, R. A., McCleary, W. R., Rao, A., Poenie, M., Backer, J. M., and Stock, J. B. (1991) J. Biol. Chem. 266, 21515-21522). This M(r) = 36,000 protein is localized to the cytosol. Unlike the prenylcysteine methyltransferases, the enzyme that catalyzes the methylation of the 36-kDa protein is found in the cytosol. The 36-kDa methylated protein has been purified from bovine brain. Sequence analysis of several peptides clearly shows that the protein is the catalytic subunit of protein phosphatase 2A. A soluble 40-kDa methyltransferase that catalyzes the reaction has also been purified.	PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	Princeton University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020980] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20980] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BINSTOCK J, 1984, METHOD ENZYMOL, V106, P310; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT H, 1975, J BIOL CHEM, V250, P8038; CHELSKY D, 1985, BIOCHEMISTRY-US, V24, P6651, DOI 10.1021/bi00344a053; CHELSKY D, 1989, J BIOL CHEM, V264, P7637; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; JAKES S, 1986, BIOCHIM BIOPHYS ACTA, V888, P135, DOI 10.1016/0167-4889(86)90079-0; JASPERS SR, 1991, MOL CELL BIOCHEM, V101, P167; KANAYAMA K, 1985, FEBS LETT, V184, P78, DOI 10.1016/0014-5793(85)80657-8; KHANDELWAL RL, 1985, J BIOL CHEM, V260, P4335; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; NINFA EG, 1991, J BIOL CHEM, V266, P9764; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PARIS H, 1984, J BIOL CHEM, V259, P7510; PATO MD, 1983, J BIOL CHEM, V258, P7047; PATTERSON CL, 1986, J BIOL CHEM, V261, P7791; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; STOCK J, 1991, Current Biology, V1, P154, DOI 10.1016/0960-9822(91)90218-L; STOCK JB, 1978, P NATL ACAD SCI USA, V75, P3659, DOI 10.1073/pnas.75.8.3659; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; TAN EW, 1992, BIOCHEMISTRY-US, V31, P5572, DOI 10.1021/bi00139a021; TUNG HYL, 1985, EUR J BIOCHEM, V148, P253, DOI 10.1111/j.1432-1033.1985.tb08833.x; ULUG ET, 1992, J VIROL, V66, P1458, DOI 10.1128/JVI.66.3.1458-1467.1992; VOLKER C, 1991, J BIOL CHEM, V266, P21515; WAELKENS E, 1987, J BIOL CHEM, V262, P1049; WERTH DK, 1982, J BIOL CHEM, V257, P7306; XIE HY, 1993, J BIOL CHEM, V268, P13364; YANG SD, 1986, J BIOL CHEM, V261, P5590	36	168	174	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19192	19195						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8396127				2022-12-25	WOS:A1993LW81900009
J	HUNT, J; MASSEY, V; DUNHAM, WR; SANDS, RH				HUNT, J; MASSEY, V; DUNHAM, WR; SANDS, RH			REDOX POTENTIALS OF MILK XANTHINE DEHYDROGENASE - ROOM-TEMPERATURE MEASUREMENT OF THE FAD AND 2FE/2S CENTER POTENTIALS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CENTERS; ACTIVE-SITE PROBES; REDUCTION POTENTIALS; OXIDASE; OXIDATION; FLAVIN; PURIFICATION; MOLYBDENUM; BEHAVIOR; PH	Xanthine oxidase (XO) and xanthine dehydrogenase (XDH), two forms of the same enzyme isolated from cow's milk, have differing redox potentials of their chromophores. Both XDH and XO are capable of accepting 8 electrons per active site cluster of redox acceptors. By titrating XDH with redox indicator dyes of various potentials, the potentials have been determined for the flavin as well as for the 2Fe/2S centers of the enzyme at pH 7.5, 25-degrees-C. The redox potential for the FAD/FADH. half-potential was found to be -270 +/- 5 mV and that for the FADH./FADH2 half potential, -410 +/- 5 mV. The first flavin half potential is close to the value which has been reported for XO (Porras, A. G., and Palmer, G. (1982) J. Biol. Chem. 257, 11617-11626). However, the second FAD half-potential is 180 mV lower in XDH than in XO, creating a 140-mV separation between the FAD potentials in XDH. This separation gives rise to a maximum development of the flavin semiquinone in XDH near 0.9 equivalent as confirmed by EPR quantitation of FADH. formed during reductive titrations. The potentials of both the 2Fe/2S centers in XDH were determined and found to be identical to the values which were found for the iron-sulfur centers in XO.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,DIV BIOPHYS RES,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM032785, R01GM032785] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32785] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBER MJ, 1982, BIOCHEMISTRY-US, V21, P1638, DOI 10.1021/bi00536a026; BATTELLI MG, 1973, BIOCHEM J, V131, P191, DOI 10.1042/bj1310191; Beinert H, 1978, Methods Enzymol, V54, P111; Bray R. C., 1975, ENZYMES, P300; Clark W. M., 1960, OXIDATION REDUCTION; ENGEL PC, 1967, BIOCHEM J, V105, P691, DOI 10.1042/bj1050691; FISH KM, 1990, J BIOL CHEM, V265, P19665; FOUST GP, 1969, ANAL BIOCHEM, V27, P530, DOI 10.1016/0003-2697(69)90066-9; HILLE R, 1982, J BIOL CHEM, V257, P8898; HUNT J, 1992, J BIOL CHEM, V267, P21479; JOHNSON JL, 1989, J BIOL CHEM, V264, P13440; LUDWIG ML, 1990, BIOCHEMISTRY-US, V29, P10364, DOI 10.1021/bi00497a011; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1970, J BIOL CHEM, V245, P6595; MASSEY V, 1979, J BIOL CHEM, V254, P9640; MASSEY V, 1989, J BIOL CHEM, V264, P10567; MASSEY V, 1969, J BIOL CHEM, V244, P1682; MAYHEW SG, 1969, J BIOL CHEM, V244, P794; MINNAERT K, 1965, BIOCHIM BIOPHYS ACTA, V110, P42, DOI 10.1016/S0926-6593(65)80093-5; NAKAMURA M, 1982, J BIOCHEM-TOKYO, V92, P1279, DOI 10.1093/oxfordjournals.jbchem.a134046; PALMER G, 1969, J BIOL CHEM, V244, P2614; Palmer G., 1967, METHOD ENZYMOL, V10, P594; PORRAS AG, 1982, J BIOL CHEM, V257, P1617; SAITO T, 1987, Yokohama Medical Bulletin, V38, P151; SAITO T, 1989, J BIOL CHEM, V264, P15930; SCHOPFER LM, 1988, J BIOL CHEM, V263, P13528; SPENCE JT, 1982, BIOCHEMISTRY-US, V21, P1656, DOI 10.1021/bi00536a028	27	53	53	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18685	18691						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8395516				2022-12-25	WOS:A1993LV65900051
J	KELLEY, MJ; DAVID, LL; IWASAKI, N; WRIGHT, J; SHEARER, TR				KELLEY, MJ; DAVID, LL; IWASAKI, N; WRIGHT, J; SHEARER, TR			ALPHA-CRYSTALLIN CHAPERONE ACTIVITY IS REDUCED BY CALPAIN-II IN-VITRO AND IN SELENITE CATARACT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGE-RELATED-CHANGES; RAT LENS; CULTURED LENSES; PROTEINS; ELECTROPHORESIS; PROTEOLYSIS	This study reports the first demonstration of a marked reduction in alpha-crystallin chaperone activity in an experimental model of cataract, and the study implicates activation of the cysteine protease calpain II (EC 3.4.22.17) as the in vivo protease responsible for decreased chaperone activity. Chaperone activity of normal alpha-crystallin from lenses of young rats was assayed by measuring attenuation of heat-induced aggregation and scattering of betaL-crystallin. Alpha-crystallin from the nucleus of lenses with selenite cataract showed specific selective proteolysis, and chaperone activity was diminished. Proteolysis of alpha-crystallin from selenite cataract lenses was mimicked by incubating normal alpha-crystallin with calpain II, and this also resulted in loss of chaperone activity. Two-dimensional gel electrophoresis and peptide mapping were used to identify four partially degraded alphaA- and alphaB-crystallin polypeptides following incubation of normal alpha-crystallin with calpain. Similar partially degraded alphaA and alphaB polypeptides were found in selenite cataract. Previous experiments indicated that alpha-crystallin chaperone activity decreases because of removal of the COOH terminus. Our experiments support this observation and suggest that calpain proteolysis of alpha-crystallin at the COOH terminus may result in a loss of chaperone activity in selenite cataract.	OREGON HLTH SCI UNIV,SCH DENT,DEPT ORAL MOLEC BIOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,SCH DENT,DEPT OPHTHALMOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,SCH MED,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	KELLEY, MJ (corresponding author), OREGON HLTH SCI UNIV,SCH DENT,DEPT BIOCHEM,611 SW CAMPUS DR,PORTLAND,OR 97201, USA.				NATIONAL EYE INSTITUTE [R29EY007755, R01EY007755, R01EY003600] Funding Source: NIH RePORTER; NEI NIH HHS [EY05786, EY07755, EY03600] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AZUMA M, 1992, FEBS LETT, V307, P313, DOI 10.1016/0014-5793(92)80703-J; AZUMA M, 1990, EXP EYE RES, V51, P393, DOI 10.1016/0014-4835(90)90151-J; AZUMA M, 1992, EXP EYE RES, V307, P313; COTLIER E, 1981, ALDERS PHYSL EYE, P284; DAVID LL, 1986, EXP EYE RES, V42, P227, DOI 10.1016/0014-4835(86)90057-6; DAVID LL, 1984, INVEST OPHTH VIS SCI, V25, P1275; DAVID LL, 1992, BIOCHIM BIOPHYS ACTA, V1139, P210, DOI 10.1016/0925-4439(92)90136-B; DAVID LL, 1993, IN PRESS FEBS LETT; DAVID LL, 1992, J BIOL CHEM, V268, P1937; DEJONG WW, 1975, EUR J BIOCHEM, V53, P237, DOI 10.1111/j.1432-1033.1975.tb04062.x; DEJONG WW, 1988, J BIOL CHEM, V263, P5141; EMMONS T, 1992, EXP EYE RES, V55, P551, DOI 10.1016/S0014-4835(05)80167-8; HARDING J, 1991, CATARACT BIOCH EPIDE, P30; HARDING J, 1991, CATARACT BIOCH EPIDE, P191; HORWITZ J, 1992, CURR EYE RES, V11, P817, DOI 10.3109/02713689209000754; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; JAKOB U, 1993, J BIOL CHEM, V268, P1517; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDLEY PF, 1985, OCULAR LENS STRUCTUR, P123; MERCK KB, 1993, J BIOL CHEM, V268, P1046; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PARVEEN R, 1993, J PROTEIN CHEM, V12, P93, DOI 10.1007/BF01024920; QUAXJEUKEN Y, 1985, P NATL ACAD SCI USA, V82, P5819, DOI 10.1073/pnas.82.17.5819; SHEARER TR, 1991, INVEST OPHTH VIS SCI, V32, P533; SHEARER TR, 1992, CURR EYE RES, V111, P357; TAKEMOTO L, 1991, EXP EYE RES, V53, P811, DOI 10.1016/0014-4835(91)90119-Y; TAKEMOTO L, 1993, IN PRESS BIOCH J; UCHIUMI T, 1983, EXP EYE RES, V36, P125, DOI 10.1016/0014-4835(83)90095-7; VARNUM MD, 1989, EXP EYE RES, V49, P1053, DOI 10.1016/S0014-4835(89)80026-0; YOSHIDA H, 1986, INVEST OPHTH VIS SCI, V27, P1269	30	93	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18844	18849						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8395520				2022-12-25	WOS:A1993LV65900071
J	BEGEOT, M; SHETTY, U; KILGORE, M; WATERMAN, M; SIMPSON, E				BEGEOT, M; SHETTY, U; KILGORE, M; WATERMAN, M; SIMPSON, E			REGULATION OF EXPRESSION OF THE CYP11A (P450(SCC)) GENE IN BOVINE OVARIAN LUTEAL CELLS BY FORSKOLIN AND PHORBOL ESTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION PATHWAYS; TRANSCRIPTION FACTOR SP1; GONADOTROPIN-ALPHA-GENE; AMP RESPONSE ELEMENT; RNA POLYMERASE-II; CYCLIC-AMP; SOMATOSTATIN GENE; DNA-BINDING; DEPENDENT TRANSCRIPTION	This study examines the transcriptional regulation of the bovine CYP11A (P450scc) gene by activators of protein kinase A and protein kinase C in bovine ovarian luteal cells. Cells were transfected with reporter gene constructs containing deletion mutations of the 5'- flanking region of the bovine CYP11A gene linked to the minimal beta-globin gene. A construct containing -118/-101 base pairs of CYP11A sequence retains the same degree of stimulation by forskolin and inhibition by co-treatment with phorbol 12-myristate 13-acetate as larger constructs. This sequence contains two putative binding sites for nuclear proteins, an AP1-like sequence and an overlapping GA box element. Gel shift analysis using nuclear extracts of bovine ovarian luteal cells demonstrated that both the wild-type -118/-101-base pair sequence and a consensus GC box bound Sp1 or Sp1-like proteins. Mutation of the GA box element completely suppressed stimulation by forskolin. Absence of binding using the same mutated sequence correlated with the reporter gene transcription results. Mutation of the AP1-like site had little effect on forskolin induction of phorbol 12-myristate 13-acetate inhibition. These results indicate that both stimulation by forskolin and inhibition by phorbol esters are mediated by the same GA box element, which binds Sp1 or an Sp1-like protein.	UNIV TEXAS, SW MED CTR, CECIL H & IDA GREEN CTR REPROD BIOL SCI, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT OBSTET & GYNECOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Vanderbilt University					NICHD NIH HHS [HD13234] Funding Source: Medline; NIDDK NIH HHS [DK28350] Funding Source: Medline; PHS HHS [5-T32-H07190] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028350] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHLGREN R, 1990, J BIOL CHEM, V265, P3313; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAKKE M, 1992, MOL ENDOCRINOL, V6, P1323, DOI 10.1210/me.6.8.1323; BELL JD, 1985, J BIOL CHEM, V260, P2625; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CHEN JY, 1992, BIOCHEMISTRY-US, V31, P24000; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRONIN MJ, 1986, J BIOL CHEM, V261, P13932; DARROW AL, 1990, MOL CELL BIOL, V10, P5883, DOI 10.1128/MCB.10.11.5883; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FINK JS, 1991, J BIOL CHEM, V266, P3882; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JAMESON JL, 1987, MOL CELL BIOL, V7, P3032, DOI 10.1128/MCB.7.9.3032; JOHN ME, 1986, P NATL ACAD SCI USA, V83, P4715, DOI 10.1073/pnas.83.13.4715; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KAGAWA N, 1990, J BIOL CHEM, V265, P11299; KAGAWA N, 1991, J BIOL CHEM, V266, P11199; KARIN M, 1987, MOL CELL BIOL, V7, P606, DOI 10.1128/MCB.7.2.606; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOBIERSKI LA, 1991, P NATL ACAD SCI USA, V88, P10222, DOI 10.1073/pnas.88.22.10222; LANGLOIS D, 1987, BIOCHEM BIOPH RES CO, V146, P517, DOI 10.1016/0006-291X(87)90559-6; LAUBER ME, 1991, J BIOL CHEM, V266, P11170; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; MASON JI, 1986, ENDOCR RES, V12, P447, DOI 10.3109/07435808609035450; MOMOI K, 1992, MOL ENDOCRINOL, V6, P1682, DOI 10.1210/me.6.10.1682; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MOORE CCD, 1990, MOL CELL BIOL, V10, P6013, DOI 10.1128/MCB.10.11.6013; NARINDRASORASAK S, 1987, J BIOL CHEM, V262, P10497; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RITVOS O, 1987, ENDOCRINOLOGY, V120, P1521, DOI 10.1210/endo-120-4-1521; ROSENGURT E, 1987, P NATL ACAD SCI USA, V84, P2282; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SCHAUFELE F, 1990, J BIOL CHEM, V265, P14592; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; STIRLING D, 1990, J BIOL CHEM, V265, P5; SUGDEN D, 1985, NATURE, V314, P359, DOI 10.1038/314359a0; TSUKADA T, 1987, J BIOL CHEM, V262, P8743; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0	60	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17317	17325						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8394339				2022-12-25	WOS:A1993LQ98800065
J	PARK, YS; SWEITZER, TD; DIXON, JE; KENT, C				PARK, YS; SWEITZER, TD; DIXON, JE; KENT, C			EXPRESSION, PURIFICATION, AND CHARACTERIZATION OF CTP-GLYCEROL-3-PHOSPHATE CYTIDYLYLTRANSFERASE FROM BACILLUS-SUBTILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; MOLECULAR-CLONING; ESCHERICHIA-COLI; RAT-LIVER; PHOSPHORYLCHOLINE CYTIDYLYLTRANSFERASE; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; TEICHOIC-ACID; GENE; SYNTHETASE; PROTEIN	Bacillus subtilis contains the gene for CTP:glycerol-3-phosphate cytidylyltransferase, which is involved in biosynthesis of the major teichoic acid of the B. subtilis cell wall. When this gene was expressed in Escherichia coli under the control of the T7 promoter, the glycerol-3-phosphate cytidylyltransferase accumulated to a level of about 15% of cellular protein. The expressed glycerol-3-phosphate cytidylyltransferase was purified to homogeneity by ion-exchange chromatography, gel filtration, and affinity chromatography on blue Sepharose. Approximately 47 mg of pure enzyme was obtained from a 660-ml culture. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis indicated that the subunit molecular weight of the purified enzyme was about 15,000. The molecular weight of the native enzyme was found to be 30,900 by gel filtration analysis, suggesting that the native enzyme is a homodimer. The pH optimum was very broad, from 6.5 to 9.5, and the enzyme was stable at alkaline conditions. A divalent cation, either Co2+, Mg2+, Mn2+, or Fe2+, was required for enzyme activity. K(m) values for CTP and glycerol 3-phosphate were 3.85 and 3.23 mM, respectively, and the V(max) was 185 units/mg of protein. Initial rate studies and product inhibition patterns indicated that the enzyme catalyzes the reaction by means of a rapid equilibrium random order mechanism. The availability of large amounts of glycerol-3-phosphate cytidylyltransferase will facilitate enzymological and structural studies on this model cytidylyltransferase.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,4417 MED SCI I,BOX 0606,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan			Park, Young-Seo/AAB-9366-2019	Park, Young-Seo/0000-0002-9930-4201	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR0042] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BADDILEY J, 1970, ACCOUNTS CHEM RES, V3, P98, DOI 10.1021/ar50027a003; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLELAND WW, 1963, NATURE, V198, P463, DOI 10.1038/198463a0; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; CORNELL R, 1989, J BIOL CHEM, V264, P9077; FELDMAN DA, 1987, J BIOL CHEM, V262, P9075; GOLD MH, 1974, J BIOL CHEM, V249, P2417; ICHO T, 1985, J BIOL CHEM, V260, P2078; ICHO T, 1985, J BIOL CHEM, V260, P2092; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KENNEDY EP, 1959, J BIOL CHEM, V234, P1998; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAUEL C, 1991, J GEN MICROBIOL, V137, P929, DOI 10.1099/00221287-137-4-929; PALMER T, 1985, UNDERSTANDING ENZYME, P170; POOLE HM, 1991, J GEN MICROBIOL, V137, P921, DOI 10.1099/00221287-137-4-921; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLEIGHT R, 1983, J BIOL CHEM, V258, P831; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; TIJBURG LBM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P1, DOI 10.1016/0005-2760(89)90206-3; TSUKAGOSHI Y, 1987, EUR J BIOCHEM, V169, P477, DOI 10.1111/j.1432-1033.1987.tb13635.x; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P33; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; WEINHOLD PA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P299, DOI 10.1016/0005-2760(89)90017-9; ZAPATA G, 1989, J BIOL CHEM, V264, P14769	27	67	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16648	16654						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8393871				2022-12-25	WOS:A1993LQ33600081
J	OOKAWA, K; SHISEKI, M; TAKAHASHI, R; YOSHIDA, Y; TERADA, M; YOKOTA, J				OOKAWA, K; SHISEKI, M; TAKAHASHI, R; YOSHIDA, Y; TERADA, M; YOKOTA, J			RECONSTITUTION OF THE RB GENE SUPPRESSES THE GROWTH OF SMALL-CELL LUNG-CARCINOMA CELLS CARRYING MULTIPLE GENETIC ALTERATIONS	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; HUMAN PROSTATE CARCINOMA; CANCER-CELLS; TUMOR SUPPRESSOR; OSTEO-SARCOMA; P53 GENE; C-MYC; EXPRESSION; TUMORIGENICITY; PROTEIN	Multiple genetic alterations, including inactivation of the RB gene, occur commonly in small-cell lung carcinoma (SCLC). To assess a functional role of RB inactivation in the development of SCLC, an RB expression plasmid was introduced by stable transfection into SCLC cell lines, Lu-135 and N417, in which the RB gene was inactivated. Lu-135 and N417 cells transfected with the wild-type RB gene formed G418-resistant colonies twofold less efficiently than those with a mutated RB gene or with the control vector. Intact exogenous wild-type RB genes were detected only in approximately 20% of G418-resistant clones; three of 14 in Lu-135 and three of 16 in N417, respectively. Transcripts from the transfected RB gene were also detected in two of these three clones from Lu-135 and two of three from N417 but the amount of RB mRNA and protein was less than one fifth of that in normal fibroblast celts WI-38. Furthermore, clones with exogenous wild-type RB expression showed either reduced growth rates in culture or suppressed tumorigenicity in nude mice. These findings suggest that functional correction of the RB gene is sufficient to suppress the growth of SCLC cells, even though several other genetic alterations in the cells remain uncorrected.	NATL CANC CTR,1-1 TSUKIJI 5 CHOME,CHUO KU,TOKYO 104,JAPAN; KYOTO UNIV,FAC MED,DEPT PATHOL 2,KYOTO 606,JAPAN; HIROSAKI UNIV,SCH MED,DEPT INTERNAL MED 1,HIROSAKI,AOMORI 036,JAPAN	National Cancer Center - Japan; Kyoto University; Hirosaki University								BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHEN PL, 1992, CELL GROWTH DIFFER, V3, P119; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GAZDAR AF, 1985, CANCER RES, V45, P2924; GOODRICH DW, 1992, CANCER RES, V52, P1968; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MORI N, 1989, CANCER RES, V49, P5130; MORI N, 1990, ONCOGENE, V5, P101; MUNCASTER MM, 1992, CANCER RES, V52, P654; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RABITTS P, 1990, GENE CHROMOSOME CANC, V2, P231; REISSMANN PT, 1989, ONCOGENE, V4, P839; Sambrook J, 1989, MOL CLONING LABORATO; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TERASAKI T, 1986, JPN J CLIN ONCOL, V16, P203; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; XU HJ, 1991, CANCER RES, V51, P2735; XU HJ, 1991, CANCER RES, V51, P4481; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1988, ONCOGENE, V3, P471; YOKOTA J, 1988, ONCOGENE, V2, P607	40	56	58	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2175	2181						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8393162				2022-12-25	WOS:A1993LP17100018
J	DOBROWSKY, RT; KAMIBAYASHI, C; MUMBY, MC; HANNUN, YA				DOBROWSKY, RT; KAMIBAYASHI, C; MUMBY, MC; HANNUN, YA			CERAMIDE ACTIVATES HETEROTRIMERIC PROTEIN PHOSPHATASE-2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DIFFERENTIATION; SUBUNIT; PURIFICATION	Ceramide activates a cytosolic protein phosphatase present in rat T9 glioma cells and rat brain. Ceramide-activated protein phosphatase (CAPP) was found to share several properties with protein phosphatase 2A (PP2A) leading to the hypothesis that ceramide may directly activate PP2A. PP2A was isolated as a heterotrimer (AB'C, AB(alpha)C), heterodimer (AC), or free C subunit, and the effect of ceramide on the catalytic activity was assessed. C2-ceramide, 5-20 muM, activated heterotrimeric PP2A up to 3.5-fold but had no effect on the activity of AC or C. Ceramides possessing hexanoyl, decanoyl, and myristoyl but not stearoyl acyl chains also activated heterotrimeric PP2A. Ceramide activation of heterotrimeric PP2A required the presence of a B subunit since trypsinization or heparin treatment abolished ceramide activation. Activation of heterotrimeric PP2A was specific for ceramide because related sphingolipids had no effect. Moreover, dihydro-C2-ceramide, which lacks the trans double bond in the sphingoid base, inhibited AB'C activity by >90% at 10 muM. The specificity of activation of AB'C and AB(alpgha)C by stereoisomers Of C2-ceramide was found to differ. Whereas activation of AB'C by either DL-erythro- or threo-C2-Ceramide was similar, AB(alpha)C was activated by either D- or L-erythro-C2-ceramide but not by the threo isomers. CAPP isolated from T9 cells was most effectively activated by D-erythro-C2-ceramide. CAPP was found to possess two peaks of ceramide activated phosphatase activity. The initial peak of activity was coincident with the elution of AB'C and was stimulated 1.8-fold by 20 muM C2-ceramide. A second peak of phosphatase activity was negligible in the absence of ceramide but was stimulated 5.5-fold by 20 muM C2-ceramide. These results support the hypothesis that ceramide is a specific lipid second messenger modulating heterotrimeric PP2A activity.	DUKE UNIV, MED CTR, DEPT MED, DIV HEMATOL ONCOL, BOX 3355, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	Duke University; Duke University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 31107] Funding Source: Medline; NIGMS NIH HHS [GM43825] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIELAWSKA A, 1992, FEBS LETT, V307, P211, DOI 10.1016/0014-5793(92)80769-D; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DOBROWSKY RT, 1993, ADV LIPID RES, V25, P91; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRESSLERR KA, 1992, SCIENCE, V246, P11715; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; FUJINO Y, 1962, J BIOL CHEM, V237, P2069; IMAOKA T, 1983, J BIOL CHEM, V258, P1526; KAMIBAYASHI C, 1992, J BIOL CHEM, V267, P21864; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; KIM MY, 1991, J BIOL CHEM, V266, P484; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHENOLIKAR S, 1991, ADV 2ND MESSENGER PH, V23, P1; TUNG HYL, 1985, EUR J BIOCHEM, V148, P253, DOI 10.1111/j.1432-1033.1985.tb08833.x; WAELKENS E, 1987, J BIOL CHEM, V262, P1049; YANG SD, 1986, J BIOL CHEM, V261, P5590	21	581	591	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15523	15530						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8393446				2022-12-25	WOS:A1993LN30500033
J	EIGENTHALER, M; ULLRICH, H; GEIGER, J; HORSTRUP, K; HONIGLIEDL, P; WIEBECKE, D; WALTER, U				EIGENTHALER, M; ULLRICH, H; GEIGER, J; HORSTRUP, K; HONIGLIEDL, P; WIEBECKE, D; WALTER, U			DEFECTIVE NITROVASODILATOR-STIMULATED PROTEIN-PHOSPHORYLATION AND CALCIUM REGULATION IN CGMP-DEPENDENT PROTEIN KINASE-DEFICIENT HUMAN PLATELETS OF CHRONIC MYELOCYTIC-LEUKEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; PHILADELPHIA-CHROMOSOME; TRANSFORMATION; EVOLUTION; CELLS; ABL	The presence and functional role of the cyclic nucleotide signal transduction system was investigated in platelets from patients with myeloproliferative disorders. Platelets from certain patients with chronic myelocytic leukemia showed decreased expression of cGMP-dependent protein kinase, and platelets from two such patients were studied in some detail. These platelets had very little if any cGMP-dependent protein kinase but a normal level of cAMP-dependent protein kinase. They also contained a normal level of VASP (vasodilator-stimulated phosphoprotein, a specific substrate of both cAMP- and cGMP-dependent protein kinase), as well as a functionally intact prostaglandin E1-stimulated cAMP-mediated VASP phosphorylation. In contrast, sodium nitroprusside-stimulated VASP phosphorylation was severely impaired in these cGMP-dependent protein kinase-deficient platelets, despite an exaggerated cGMP response to sodium nitroprusside. Furthermore, whereas selective activation of the cGMP-dependent protein kinase by 8-(4-chlorophenylthio)-cGMP strongly inhibited the ADP- or thrombin-evoked calcium mobilization from intracellular stores in normal platelets, this agonist-evoked calcium response was not inhibited by the cGMP analog in cGMP-dependent protein kinase-deficient platelets. The results demonstrate a defect in the nitrovasodilator-/cGMP-regulated signal transduction system in human platelets from some patients with myeloproliferative disorders, and underscore that a cGMP-dependent protein kinase regulatory system, distinct from that of cAMP-dependent protein kinase or other cGMP-dependent effectors is operative in normal human platelets.	UNIV WURZBURG, MED KLIN, KLIN FORSCH GRP, JOSEF SCHNEIDER STR 2, W-8700 WURZBURG, GERMANY; UNIV WURZBURG, TRANSFUS MED ABT, W-8700 WURZBURG, GERMANY	University of Wurzburg; University of Wurzburg			Walter, ulrich/W-2478-2017; Geiger, Joerg/I-6661-2013	Walter, ulrich/0000-0001-6784-2307; Geiger, Joerg/0000-0002-7689-531X				AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; BUTT E, 1992, BIOCHEM PHARMACOL, V43, P2591, DOI 10.1016/0006-2952(92)90148-C; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DURANTE W, 1992, BLOOD, V79, P110; EIGENTHALER M, 1992, EUR J BIOCHEM, V205, P471, DOI 10.1111/j.1432-1033.1992.tb16803.x; FOTI A, 1991, BLOOD, V77, P2441; GEIGER J, 1992, P NATL ACAD SCI USA, V89, P1031, DOI 10.1073/pnas.89.3.1031; GEIGER J, 1992, Naunyn-Schmiedeberg's Archives of Pharmacology, V345, pR18; HALBRUGGE M, 1989, EUR J BIOCHEM, V185, P41, DOI 10.1111/j.1432-1033.1989.tb15079.x; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; HALBRUGGE M, 1993, PROTEIN KINASES BLOO, P245; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; LOHMANN SM, 1991, BASIC RES CARDIOL, V86, P503, DOI 10.1007/BF02190700; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MUEHLECK SD, 1984, AM J CLIN PATHOL, V82, P1; NGUYEN BL, 1991, AM J PHYSIOL, V261, pH1043, DOI 10.1152/ajpheart.1991.261.4.H1043; ORSTAVIK S, 1992, CYTOGENET CELL GENET, V59, P270, DOI 10.1159/000133267; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; SAGE SO, 1990, BIOCHEM J, V265, P675, DOI 10.1042/bj2650675; SANDBERG M, 1991, BIOCHEM J, V279, P521, DOI 10.1042/bj2790521; SCHAFER AI, 1984, BLOOD, V64, P1; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SIESS W, 1990, BIOCHEM J, V271, P815, DOI 10.1042/bj2710815; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; ULLRICH H, 1992, European Journal of Clinical Investigation, V22, pA23; WALDMANN R, 1987, EUR J BIOCHEM, V167, P441, DOI 10.1111/j.1432-1033.1987.tb13357.x; WALTER U, 1991, ANTITHROMBOTICS PATH, P121; Walter U, 1989, REV PHYSL BIOCH PHAR, V113, P41	29	61	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13526	13531						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8390466				2022-12-25	WOS:A1993LH55300073
J	HAMA, H; WILSON, TH				HAMA, H; WILSON, TH			CATION-COUPLING IN CHIMERIC MELIBIOSE CARRIERS DERIVED FROM ESCHERICHIA-COLI AND KLEBSIELLA-PNEUMONIAE - THE AMINO-TERMINAL PORTION IS CRUCIAL FOR NA+ RECOGNITION IN MELIBIOSE TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIFICITY; SYSTEM; SUGAR; COTRANSPORT; GENE; LI+	The melibiose carrier of Escherichia coli couples sugar transport to H+, Na+, and Li+, while that of Klebsiella pneumoniae utilizes only H+ and Li+. We made five chimeric carriers derived from the two carriers to identify the region(s) involved in Na+ recognition. The chimeric carriers E2K10, E4K8, E6K6, E8K4, and E10K2 have the amino-terminal 77, 144, 197, 298, and 349 amino acid residues derived from E. coli and the rest derived from K. pneumoniae, respectively. Melibiose accumulation through the chimeric carriers E2K10, E4K8, and E6K6 was strongly stimulated by Na+ and Li+ as is the case with the E. coli carrier. On the other hand, there was very little stimulation with the carriers E8K4 and E10K2. These results suggest that, 1) the amino-terminal 77 amino acids of the E. coli carrier, which has 5 different and 4 fewer amino acids than the K. pneumoniae carrier, have a crucial role in Na+ recognition in melibiose transport and 2) the carboxyl-terminal half of the carrier also forms a part of the Na+ recognition site which may be distorted in chimeric structures. In contrast with melibiose accumulation, there was very little Na+ stimulation of TMG (methyl-1-thio-beta-D-galactopyranoside) transport and no Na+ stimulation was observed in lactose transport with any of the chimeric carriers, whereas in E. coli Na+ stimulates TMG and lactose transport. These results suggest that there is no universal Na+ recognition site for all the sugar substrates. Instead different parts of the carrier seem to participate in cation recognition for different sugar substrates.	HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK005736, R37DK005736] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK05736] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOTFIELD MC, 1988, J BIOL CHEM, V263, P12909; BOTFIELD MC, 1992, J BIOL CHEM, V267, P1818; BOTFIELD MC, 1989, J BIOL CHEM, V264, P11643; COHEN G N, 1956, Ann Inst Pasteur (Paris), V91, P693; HAMA H, 1992, J BIOL CHEM, V267, P18371; KAWAKAMI T, 1988, J BIOL CHEM, V263, P14276; LOPILATO J, 1978, J BACTERIOL, V134, P147, DOI 10.1128/JB.134.1.147-156.1978; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; POURCHER T, 1991, BIOCHEM BIOPH RES CO, V178, P1176, DOI 10.1016/0006-291X(91)91016-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIOTA S, 1985, J BACTERIOL, V162, P106, DOI 10.1128/JB.162.1.106-109.1985; TANAKA K, 1980, J BACTERIOL, V141, P1031, DOI 10.1128/JB.141.3.1031-1036.1980; TSUCHIYA T, 1985, ANN NY ACAD SCI, V456, P342, DOI 10.1111/j.1749-6632.1985.tb14884.x; TSUCHIYA T, 1978, MEMBRANE BIOCHEM, V2, P63, DOI 10.3109/09687687809063858; TSUCHIYA T, 1977, BIOCHEM BIOPH RES CO, V76, P26, DOI 10.1016/0006-291X(77)91663-1; WILSON DM, 1992, J BACTERIOL, V174, P3083, DOI 10.1128/JB.174.9.3083-3086.1992; WILSON DM, 1987, BIOCHIM BIOPHYS ACTA, V904, P191, DOI 10.1016/0005-2736(87)90368-3; WILSON TH, 1982, MEMBRANES TRANSPORT, V2, P33; YAZYU H, 1984, J BIOL CHEM, V259, P4320; YAZYU H, 1985, J BACTERIOL, V162, P933, DOI 10.1128/JB.162.3.933-937.1985	20	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10060	10065						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8387512				2022-12-25	WOS:A1993LB80000021
J	CLEMENTS, DA; WANG, JK; DIONNE, CA; GOLDFARB, M				CLEMENTS, DA; WANG, JK; DIONNE, CA; GOLDFARB, M			ACTIVATION OF FIBROBLAST GROWTH-FACTOR (FGF) RECEPTORS BY RECOMBINANT HUMAN FGF-5	ONCOGENE			English	Article							EXPRESSION; BINDING; CELLS; PURIFICATION; CLONING; GENE; MUTANT; FAMILY	We have purified biologically active recombinant human fibroblast growth factor 5 (FGF-5) from Escherichia coli. In the presence of heparin, recombinant FGF-5 is as active as native growth factor, demonstrating that glycosylation does not significantly potentiate FGF-5 activity. FGF-5 can bind and induce autophosphorylation of human FGF receptors (FGFR) 1 and 2. Competition binding studies show that the K(D) for FGF-5-FGFR-1 and FGF-5-FGFR-2 interactions are both between 0.5 and 1.5 x 10(-9) M.	COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,INTEGRATED PROGRAM CELLULAR MOLEC & BIOPHYS STUDIES,NEW YORK,NY 10032; RHONE POULENC RORER CENT RES,COLLEGEVILLE,PA 19426	Columbia University; Columbia University					NCI NIH HHS [CA48054] Funding Source: Medline; NIGMS NIH HHS [GM07367] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BATES B, 1991, MOL CELL BIOL, V11, P1840, DOI 10.1128/MCB.11.4.1840; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; HAUB O, 1991, DEVELOPMENT, V112, P397; HAUB O, 1990, P NATL ACAD SCI USA, V87, P8022, DOI 10.1073/pnas.87.20.8022; HEBERT JM, 1991, DEVELOPMENT, V112, P407; HUGHES RA, 1993, IN PRESS NEURON; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LIPTON SA, 1988, P NATL ACAD SCI USA, V85, P2388, DOI 10.1073/pnas.85.7.2388; LOBB RR, 1986, ANAL BIOCHEM, V154, P1, DOI 10.1016/0003-2697(86)90487-2; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REPRESA J, 1991, NATURE, V353, P561, DOI 10.1038/353561a0; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHAN X, 1987, ONCOGENE, V1, P369; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	35	44	50	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1311	1316						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8386828				2022-12-25	WOS:A1993KY32800024
J	RONSIN, C; MUSCATELLI, F; MATTEI, MG; BREATHNACH, R				RONSIN, C; MUSCATELLI, F; MATTEI, MG; BREATHNACH, R			A NOVEL PUTATIVE RECEPTOR PROTEIN TYROSINE KINASE OF THE MET FAMILY	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; RENAL-CELL CARCINOMA; SCATTER FACTOR; PROTOONCOGENE PRODUCT; SIGNAL TRANSDUCTION; HUMAN-CHROMOSOME; MESSENGER-RNAS; GENE-PRODUCT; DNA-SEQUENCE; REGION 3P21	By successive screenings of cDNA libraries prepared from human tumours and from human foreskin keratinocytes, we have isolated overlapping cDNAs coding for a novel protein which we call Ron, with sequence characteristics of a receptor protein tyrosine kinase. Ron is a 1400 amino acid protein structurally similar to the 1408 amino acid product of the C-MET proto-oncogene, the receptor for hepatocyte growth factor and scatter factor. The two proteins have 63% overall sequence identity in their intracellular regions. We have localised the RON gene to human chromosome region 3p21, a region frequently deleted in small cell carcinoma of the lung and in renal cell carcinoma, and which is believed to harbour unidentified tumour suppressor genes. Interestingly, normal lung tissue contains transcripts of the RON gene.	CHR NANTES,INST BIOL,INSERM,U211,9 QUAI MONCOUSU,F-44035 NANTES,FRANCE; GRP HOSP TIMONE,HOP ENFANTS,INSERM,U242,F-13385 MARSEILLE 5,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille			Muscatelli, Françoise/P-4650-2016; Breathnach, Richard/K-7599-2015	Muscatelli, Françoise/0000-0003-4001-6528; 				ANGLARD P, 1992, CANCER RES, V52, P348; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COOPER CS, 1992, ONCOGENE, V7, P3; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; GIORDANO S, 1989, ONCOGENE, V4, P1383; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HANKS SK, 1988, SCIENCE, V241, P45; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROSEN EM, 1991, CELL GROWTH DIFFER, V2, P603; Sambrook J, 1989, MOL CLONING LABORATO; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; TAYLORPAPADIMITRIOU J, 1982, CELL DIFFER DEV, V11, P169, DOI 10.1016/0045-6039(82)90008-2; TEMPEST PR, 1988, BRIT J CANCER, V58, P1; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; WITTE ON, 1989, MOL CELL BIOL, V9, P1263; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	49	325	345	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1195	1202						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8386824				2022-12-25	WOS:A1993KY32800010
J	STOREY, A; BANKS, L				STOREY, A; BANKS, L			HUMAN PAPILLOMAVIRUS TYPE-16 E6-GENE COOPERATES WITH EJ-RAS TO IMMORTALIZE PRIMARY MOUSE CELLS	ONCOGENE			English	Article							HUMAN FORESKIN KERATINOCYTES; HUMAN EPITHELIAL-CELLS; CERVICAL-CARCINOMA; ACTIVATED RAS; TUMOR-ANTIGEN; GENE-PRODUCT; E7 GENE; P53; TRANSFORMATION; EXPRESSION	Human papillomaviruses (HPVs) are small DNA tumor viruses, a subset of which is closely associated with the development of cervical cancer. The viral E6 and E7 open reading frames encode multifunctional proteins that bind respectively to the p53 protein and to the product of the retinoblastoma tumor-suppressor gene. In this study we demonstrate that the HPV-16 E6 gene cooperates with EJ-ras to immortalize primary cultures of mouse kidney epithelial cells. HPV-16-immortalized cell lines expressing E6 but not E7 contained low levels of wild-type p53 protein. In contrast, those cells immortalized by EJ-ras alone contained elevated p53 protein levels, and were shown to contain a mutation in the gene, These results suggest that activating mutations in the p53 gene can functionally substitute for HPV-16 E6 in transforming primary cells.			STOREY, A (corresponding author), INT CTR GENET ENGN & BIOTECHNOL,PADRICIANO 99,I-34012 TRIESTE,ITALY.			Storey, Alan/0000-0003-2001-9772				BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARTEK J, 1990, ONCOGENE, V5, P893; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1991, ONCOGENE, V6, P873; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KAUR P, 1989, J GEN VIROL, V70, P1261, DOI 10.1099/0022-1317-70-5-1261; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MUNGER K, 1989, J VIROL, V63, P4417; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PECORARO G, 1989, P NATL ACAD SCI USA, V86, P563, DOI 10.1073/pnas.86.2.563; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SOUSSI T, 1990, ONCOGENE, V5, P945; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989	40	73	78	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					919	924						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8384359				2022-12-25	WOS:A1993KT22000013
J	MCDONALD, TV; PREMACK, BA; GARDNER, P				MCDONALD, TV; PREMACK, BA; GARDNER, P			FLASH-PHOTOLYSIS OF CAGED INOSITOL 1,4,5-TRISPHOSPHATE ACTIVATES PLASMA-MEMBRANE CALCIUM CURRENT IN HUMAN T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; ANTIGEN RECEPTOR; LYMPHOCYTES-T; K+ CHANNELS; PATCH-CLAMP; TRISPHOSPHATE; CA-2+; PHOSPHATES; MECHANISM; ENTRY	Sustained elevation of intracellular Ca2+ by cell surface receptors is often dependent on influx of Ca2+ across the plasma membrane through routes not involving voltage-gated Ca2+ channels. We demonstrate that intracellular release of inositol 1,4,5-trisphosphate (InsP3), either from stimulation of transfected human muscarinic receptors or from photolytic release of caged InsP3, activates whole cell Ca2+ current in the Jurkat T cell line. Whole cell voltage clamp recordings indicate that the current is carried by a Ca2+-selective channel that resembles T-type voltage-gated Ca2+ channels in relative conductance of different cation species. Elevation of internal Ca2+ inactivates the channel, whereas internal perfusion with inositol 1,3,4,5-tetrakisphosphate (InsP4) does not affect it. Photolytic release of caged 1-(alpha-glycerophosphoryl)inositol 4,5-bisphosphate, an analog of InsP3 which activates InsP3 receptors but is not readily metabolized to InsP4, also activates the current. We conclude that generation of InsP3 is sufficient to activate Ca2+-selective channels in the plasma membrane of T cells. InsP3 may have its effect indirectly through depletion of Ca2+ stores, or directly with a plasma membrane-associated InSP3 receptor.	STANFORD UNIV, MED CTR,SCH MED,FALK CARDIOVASC RES CTR,DEPT MED, STANFORD, CA 94305 USA	Stanford University					NHLBI NIH HHS [K11-HL02397] Funding Source: Medline; NIDDK NIH HHS [R01-DK41324] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002397] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041324] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BIRD GS, 1992, J BIOL CHEM, V267, P17722; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CHOW SC, 1990, CELL CALCIUM, V11, P641, DOI 10.1016/0143-4160(90)90018-P; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; ELY JA, 1990, BIOCHEM J, V268, P333, DOI 10.1042/bj2680333; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GARDNER P, 1989, J BIOL CHEM, V264, P1068; GOLDSMITH MA, 1989, J BIOL CHEM, V264, P17190; GOLDSMITH MA, 1988, SCIENCE, V240, P1029, DOI 10.1126/science.3259335; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; IRVINE RF, 1986, NATURE, V320, P631, DOI 10.1038/320631a0; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; KAPLAN JH, 1990, ANNU REV PHYSIOL, V52, P897; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; KUNO M, 1986, NATURE, V323, P269, DOI 10.1038/323269a0; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; LU CY, 1989, J MEMBRANE BIOL, V109, P85, DOI 10.1007/BF01870793; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MATTESON DR, 1984, NATURE, V307, P468, DOI 10.1038/307468a0; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MINKE B, 1991, PROG RETIN RES, V11, P99, DOI 10.1016/0278-4327(91)90026-X; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; NISHIMOTO I, 1991, NEURON, V6, P547, DOI 10.1016/0896-6273(91)90057-7; OETTGEN HC, 1985, CELL, V40, P583, DOI 10.1016/0092-8674(85)90206-5; OGDEN DC, 1990, J PHYSIOL-LONDON, V422, P585, DOI 10.1113/jphysiol.1990.sp018002; PREMACK BA, 1992, IN PRESS AM J PHYSL; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; RUKNUDIN A, 1991, J CELL BIOL, V112, P125, DOI 10.1083/jcb.112.1.125; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TSIEN RW, 1987, ANNU REV BIOPHYS BIO, V16, P265; WALKER JW, 1989, BIOCHEMISTRY-US, V28, P3272, DOI 10.1021/bi00434a023; WEISS MJ, 1984, P NATL ACAD SCI-BIOL, V81, P6836, DOI 10.1073/pnas.81.21.6836	47	110	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3889	3896						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8382682				2022-12-25	WOS:A1993KN53300018
J	RESNICK, D; FREEDMAN, NJ; XU, SZ; KRIEGER, M				RESNICK, D; FREEDMAN, NJ; XU, SZ; KRIEGER, M			SECRETED EXTRACELLULAR DOMAINS OF MACROPHAGE SCAVENGER RECEPTORS FORM ELONGATED TRIMERS WHICH SPECIFICALLY BIND CROCIDOLITE ASBESTOS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HAMSTER-CELL MUTANTS; CHOLESTEROL DEPOSITION; LIGAND-BINDING; OVARY CELLS; EXPRESSION; PROTEINS; ATHEROSCLEROSIS; BIOSYNTHESIS; METABOLISM	Macrophage scavenger receptors, which have been implicated in the development of atherosclerosis and other macrophage-mediated events, are trimeric integral membrane glycoproteins whose extracellular domains have been predicted to include alpha-helical coiled-coil, collagenous and globular structures. To elucidate further the structural and functional properties of these receptors, we generated transfected Chinese hamster ovary cells which express secreted extracellular domains of the type I and type II bovine scavenger receptors and developed a solid-phase bead-binding assay to assess their ligand-binding properties. The secreted receptors exhibited the distinctive high-affinity, broad polyanionic ligand-binding specificity and the pH dependence of binding which characterize the membrane-anchored cell-surface forms of the receptors. Both the type I and type II secreted receptors were trimeric glycoproteins comprising disulfide-linked dimers and noncovalently associated monomers. Gel filtration and glycerol-gradient centrifugation established that the type II trimers were highly elongated and did not associate into higher order oligomers at the low concentrations used in these experiments. Crocilodite asbestos, which is phagocytosed by alveolar macrophages and can cause asbestosis and mesothelioma, bound efficiently to secreted type I receptors and less well to the type II receptors. This binding was specific in that it was competed by a variety of well established scavenger receptor ligands but not by negative controls. These studies have identified a new type of insoluble scavenger receptor ligand, and have raised the possibility that scavenger receptors may play a role in mediating the physiological and pathological interactions of inspired particles with alveolar macrophages.	MIT,DEPT BIOL,RM E25-236,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41484] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACTON S, 1993, J BIOL CHEM, V268, P3530; ARQUINT M, 1987, P NATL ACAD SCI USA, V84, P600, DOI 10.1073/pnas.84.2.600; ARUFFO A, 1991, J EXP MED, V174, P949, DOI 10.1084/jem.174.4.949; AXELSSON I, 1978, J CHROMATOGR, V152, P21, DOI 10.1016/S0021-9673(00)85330-3; BICKEL PE, 1992, J CLIN INVEST, V90, P1450, DOI 10.1172/JCI116012; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUAN DSR, 1991, J BIOL CHEM, V266, P413; FASMAN GD, 1976, PROTEINS, V3, P249; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GREEN SA, 1985, J BIOL CHEM, V260, P9867; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HINZ HJ, 1986, THERMODYNAMIC DATA B, P69; HOLIAN A, 1990, HOSP PRACT, V25, P53; JURGENS G, 1987, CHEM PHYS LIPIDS, V45, P315, DOI 10.1016/0009-3084(87)90070-3; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; KODAMA T, 1991, CIRCULATION, V84, P11229; KOZARSKY KF, 1986, J CELL BIOL, V102, P1567, DOI 10.1083/jcb.102.5.1567; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; KRIEGER M, 1992, TRENDS BIOCHEM SCI, V17, P141, DOI 10.1016/0968-0004(92)90322-Z; KUMAR KN, 1991, J BIOL CHEM, V266, P14947; LAX I, 1991, J BIOL CHEM, V266, P13828; LOOS M, 1983, CURR TOP MICROBIOL, V102, P1; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; MOSSMAN BT, 1989, NEW ENGL J MED, V320, P1721, DOI 10.1056/NEJM198906293202604; NAITO M, 1991, AM J PATHOL, V139, P1411; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; PENMAN M, 1991, J BIOL CHEM, V266, P23985; PETERSON GL, 1986, BIOCHEMISTRY-US, V25, P3189, DOI 10.1021/bi00359a017; PJEARSON A, 1993, J BIOL CHEM, V268, P3546; RAETZ CRH, 1988, COLD SPRING HARB SYM, V53, P973, DOI 10.1101/SQB.1988.053.01.112; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; ROM WN, 1991, AM REV RESPIR DIS, V143, P408, DOI 10.1164/ajrccm/143.2.408; Sambrook J, 1989, MOL CLONING LABORATO; Segrest JP, 1972, METHOD ENZYMOL, V28, P54, DOI DOI 10.1016/0076-6879(72)28007-7; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; STUHLMANN H, 1989, MOL CELL BIOL, V9, P100, DOI 10.1128/MCB.9.1.100; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; THIEL S, 1989, FEBS LETT, V250, P78, DOI 10.1016/0014-5793(89)80689-1; VANHOLDE KE, 1985, PHYSICAL BIOCH, P95; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221	46	79	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3538	3545						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8381434				2022-12-25	WOS:A1993KM16100080
J	YAMASHITA, H; HIROSE, M				YAMASHITA, H; HIROSE, M			OXIDATIVE REGENERATION AND SELECTIVE REDUCTION OF NATIVE DISULFIDE BONDS IN THE N-TERMINAL HALF-MOLECULE OF OVOTRANSFERRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; PARTIALLY FOLDED STATE; REVERSIBLE DENATURATION; CIRCULAR-DICHROISM; REDUCED FORM; KINETIC ROLE; INTERMEDIATE; PROTEINS; SPECTROSCOPY; RIBONUCLEASE	The denatured, disulfide-reduced form of the N-terminal half-molecule of ovotransferrin was reoxidized with either oxidized dithiothreitol or GSSG and analyzed for the localization of disulfide bonds. Chemical analyses of the reoxidized proteins revealed that the disulfide peptides corresponding to the six native protein disulfides (SS-I, SS-II, SS-III, SS-IV, SS-V, and SS-VI) are all regained in the reoxidized protein. The peptide recoveries from the reoxidized proteins were, however, about half of those from the native protein with respect to the two inner disulfides (SS-IV and SS-V) in the kringle bridges, but all the disulfide peptides corresponding to the remaining disulfides (SS-I, SS-II, SS-III, and SS-VI) were recovered at almost equivalent yields in the native and reoxidized proteins. In addition, on searching for a nonnative disulfide peptide, the two disulfides, Cys171-Cys174 and Cys174-Cys182, which can be accounted for by mispaired bridges of sulfhydryls in SS-IV and SS-V, were detected in the protein reoxidized with oxidized dithiothreitol. Upon disulfide reduction of the native protein with reduced dithiothreitol, both SS-IV and SS-V were selectively cleaved under the same buffer and temperature conditions as in the oxidative refolding. The lower stabilities of the two inner disulfide bonds in the kringle may be related to the lower recoveries of the disulfide peptides from SS-IV and SS-V and the generation of the nonnative disulfide bonds.	KYOTO UNIV, FOOD SCI RES INST, UJI, KYOTO 611, JAPAN	Kyoto University				Hirose, Masaaki/0000-0003-2672-4384				CHAU MH, 1991, FEBS LETT, V291, P296, DOI 10.1016/0014-5793(91)81305-R; Creighton T E, 1986, Methods Enzymol, V131, P83; CREIGHTON TE, 1984, METHOD ENZYMOL, V107, P305; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; GALAT A, 1981, BIOCHEMISTRY-US, V20, P594, DOI 10.1021/bi00506a023; GOTO Y, 1981, J MOL BIOL, V146, P321, DOI 10.1016/0022-2836(81)90391-0; HIGAKI JN, 1986, J BIOL CHEM, V261, P606; HIROSE M, 1991, J BIOL CHEM, V266, P1463; HIROSE M, 1989, J BIOL CHEM, V264, P16867; HIROSE M, 1988, ANAL BIOCHEM, V168, P193, DOI 10.1016/0003-2697(88)90028-0; INGHAM KC, 1992, PROTEINS, V12, P180, DOI 10.1002/prot.340120211; KOSEN PA, 1983, BIOCHEMISTRY-US, V22, P2433, DOI 10.1021/bi00279a020; LEE JY, 1992, J BIOL CHEM, V267, P14753; LIGHT A, 1991, J BIOL CHEM, V266, P7694; MOORE S, 1963, J BIOL CHEM, V238, P235; OE H, 1988, J BIOCHEM-TOKYO, V103, P1066, DOI 10.1093/oxfordjournals.jbchem.a122381; PACE CN, 1986, J MOL BIOL, V188, P477, DOI 10.1016/0022-2836(86)90169-5; SCHERAGA HA, 1987, P NATL ACAD SCI USA, V84, P5740, DOI 10.1073/pnas.84.16.5740; SEETHARAMA A, 1982, MOL CELL BIOCHEM, V44, P129; SRINIVASAN N, 1990, INT J PEPT PROT RES, V36, P147; STATES DJ, 1984, J MOL BIOL, V174, P411, DOI 10.1016/0022-2836(84)90345-0; SUEYOSHI T, 1985, J BIOCHEM-TOKYO, V97, P1811, DOI 10.1093/oxfordjournals.jbchem.a135241; TAKAHASHI N, 1992, J BIOL CHEM, V267, P11565; TAKAHASHI N, 1991, J BIOCHEM-TOKYO, V109, P846, DOI 10.1093/oxfordjournals.jbchem.a123469; WEISSMAN JS, 1992, P NATL ACAD SCI USA, V89, P9900, DOI 10.1073/pnas.89.20.9900; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WILLIAMS J, 1982, EUR J BIOCHEM, V122, P297, DOI 10.1111/j.1432-1033.1982.tb05880.x	28	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					19062	19069						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8395527				2022-12-25	WOS:A1993LV65900102
J	LEIBOVITCH, SA; GUILLIER, M; LENORMAND, JL; LEIBOVITCH, MP				LEIBOVITCH, SA; GUILLIER, M; LENORMAND, JL; LEIBOVITCH, MP			P34(CD2) PROTEIN IS COMPLEXED WITH THE C-MOS PROTEIN IN RAT SKELETAL-MUSCLE	ONCOGENE			English	Article							CELL-CYCLE; ONCOGENE PRODUCT; XENOPUS OOCYTES; KINASE-ACTIVITY; CDC2 KINASE; GERM-CELLS; MEIOSIS-II; EXPRESSION; PROTOONCOGENE; EGGS	We have used fractionation of subcellular components of the skeletal muscle followed by Western blot analyses to study the localization of the c-mos protein in adult rat muscle. We find that p43c-mos is predominantly located in the KCl supernatant fraction. We show that immunoprecipitates of p43c-mos phosphorylate in vitro two polypeptides of about 34 kDa and 80 kDa respectively. Muscle fractionation and immunodetection studies showed that the p34 protein associated with p43c-mos is the cdc2 protein. p43c-mos is coprecipitated with p34cdc2 when using either anti PSTAIR antibody, antibody directed against the conserved COOH terminal region of the p34cdc2 and by binding to beads that contain crosslinked p13suc1, a protein known to bind p34cdc2. Likewise p34cdc2 coprecipitated with p43c-mos when using anti mos antibody. However p43c-mos is not present in histone H1 kinase active p34cdc2 complex precipitated with anti p34cdc2 COOH-terminal peptide antibody. In adult muscle tissue tubulin is not complexed with p34cdc2 and p43c-mos as previously observed in c-mos and v-mos transformed cells. Gel filtration and crosslinking experiments show that a 170 kDa complex contains c-mos and p34cdc2 proteins. In addition during postnatal development of skeletal muscle we observe modifications in the migration pattern of p34cdc2 correlated with the accumulation of p43c-mos. Our findings raise the possibility of a p43c-mos-p34cdc2 complex could play a role in the differentiation process and maintenance of myotubes in Go.			LEIBOVITCH, SA (corresponding author), INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,URA126,UA 1158,39 RUE CAMILLE DESMOULINS,F-94805 VILLEJUIF,FRANCE.		Lenormand, Jean-Luc/ABF-3850-2021; Lenormand, Jean-Luc/M-6644-2014	Lenormand, Jean-Luc/0000-0002-2766-9180				BAI W, 1992, ONCOGENE, V7, P493; BAI WL, 1992, ONCOGENE, V7, P1757; DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; DOUCET JP, 1991, J BIOL CHEM, V266, P17613; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1988, ONCOGENE, V2, P533; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DUNN SMJ, 1989, J BIOL CHEM, V264, P11053; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HERZOG NK, 1989, ONCOGENE, V4, P1307; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; KREK W, 1989, EMBO J, V8, P3071, DOI 10.1002/j.1460-2075.1989.tb08458.x; KURUTA N, 1989, EMBO J, V8, P457; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEIBOVITCH SA, 1990, ONCOGENE, V5, P1149; LEIBOVITCH SA, 1991, ONCOGENE, V6, P1617; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LORCA T, 1992, EMBO J, V11, P2381, DOI 10.1002/j.1460-2075.1992.tb05302.x; LORCA T, 1991, EMBO J, V10, P2082; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PIERCE GN, 1985, J BIOL CHEM, V260, P6862; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINSET C, 1991, EMBO J, V10, P2411, DOI 10.1002/j.1460-2075.1991.tb07780.x; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TUANA BS, 1988, MOL CELL BIOCHEM, V80, P133; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604; ZHOU RP, 1992, MOL CELL BIOL, V12, P3583, DOI 10.1128/MCB.12.8.3583; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	38	12	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2361	2369						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8395677				2022-12-25	WOS:A1993LT36800006
J	THIVIERGE, M; ALAMI, N; MULLER, E; DEBRUMFERNANDES, AJ; ROLAPLESZCZYNSKI, M				THIVIERGE, M; ALAMI, N; MULLER, E; DEBRUMFERNANDES, AJ; ROLAPLESZCZYNSKI, M			TRANSCRIPTIONAL MODULATION OF PLATELET-ACTIVATING-FACTOR RECEPTOR GENE-EXPRESSION BY CYCLIC-AMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; PROTEIN-KINASE; CELLS; CAMP; PAF; MONOCYTES; CLONING; DIFFERENTIATION; PHOSPHORYLATION; MECHANISMS	We examined the effects of increasing intracellular cyclic AMP levels on the expression of human PAF receptor (hPAF-R). Peripheral blood monocytes constitutively expressed hPAF-R mRNA transcripts. A transiently elevated intracellular concentration of AMP induced with prostaglandin E2, cholera toxin, or forskolin was a sufficient signal to inhibit PAF-R expression. To determine the mechanisms of this inhibition, human monocytes were treated with dibutyryl cAMP, a cell-permeable cAMP analogue. cAMP reduced the expression of hPAF-R in a concentration- and a time-dependent manner. The effect was seen as early as 1 h and was essentially total by 4 h. Stability of hPAF-R mRNA was not markedly decreased by cAMP, as assessed by measuring the half-lives of the transcripts. Moreover, the nuclear transcription rate of the hPAF-R gene was reduced as early as 30 min after stimulation with cAMP. The inhibition of hPAF-R mRNA accumulation was associated with diminished responsiveness to PAF, as assayed by intracellular Ca2+ fluxes, decreased number of binding sites, and decreased hPAF-R protein expression on the cell surface, as assessed by flow cytometry using a polyclonal anti-hPAFR antibody. These data indicate that PAF-R expression can be regulated at the transcriptional and possibly post-transcriptional levels by elevation of intracellular cAMP.	UNIV SHERBROOKE, FAC MED, DEPT PEDIAT, DIV IMMUNOL, 3001 N 12TH AVE, SHERBROOKE J1H 5N4, QUEBEC, CANADA; UNIV SHERBROOKE, FAC MED, DEPT MED, DIV RHEUMATOL, SHERBROOKE J1H 5N4, QUEBEC, CANADA	University of Sherbrooke; University of Sherbrooke								AEPFELBACHER M, 1990, BIOCHIM BIOPHYS ACTA, V1051, P179, DOI 10.1016/0167-4889(90)90191-F; ANASTASSIOU ED, 1992, J IMMUNOL, V148, P2845; BACHELET M, 1988, EUR J PHARMACOL, V149, P73, DOI 10.1016/0014-2999(88)90044-1; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BRAQUET P, 1987, IMMUNOL TODAY, V8, P345, DOI 10.1016/0167-5699(87)90010-7; CHAO W, 1990, J BIOL CHEM, V265, P17576; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ENDRES S, 1991, IMMUNOLOGY, V72, P56; GREENBERG ME, 1990, PROTOCOLS MOL BIOL, V1; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HWANG SB, 1990, J LIPID MEDIATOR, V2, P123; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; KOLTAI M, 1991, DRUGS, V42, P9, DOI 10.2165/00003495-199142010-00002; KUNZ D, 1992, J BIOL CHEM, V267, P9101; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MULLER E, 1991, BIOCHEM BIOPH RES CO, V181, P1580, DOI 10.1016/0006-291X(91)92119-5; MULLER E, 1993, IN PRESS P NATL ACAA, V90; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; PESSIN JE, 1983, J BIOL CHEM, V258, P7386; RIABOWOL KT, 1988, NATURE, V336, P83, DOI 10.1038/336083a0; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROLAPLESZCZYNSKI M, 1992, BLOOD, V80, P1004; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SERKKOLA E, 1992, SCAND J IMMUNOL, V35, P203, DOI 10.1111/j.1365-3083.1992.tb02851.x; SUNG SSJ, 1991, J CLIN INVEST, V88, P1915, DOI 10.1172/JCI115515; VALLARI DS, 1990, J BIOL CHEM, V265, P4261; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6	30	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17457	17462						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8394344				2022-12-25	WOS:A1993LQ98800084
J	OFLAHERTY, JT; ROSSI, AG				OFLAHERTY, JT; ROSSI, AG			5-HYDROXYICOSATETRAENOATE STIMULATES NEUTROPHILS BY A STEREOSPECIFIC, G-PROTEIN-LINKED MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							12(S)-HYDROXYEICOSATETRAENOIC ACID 12(S)-HETE; PLATELET-ACTIVATING-FACTOR; HUMAN POLYMORPHONUCLEAR NEUTROPHILS; HIGH-AFFINITY BINDING; ENDOTHELIAL-CELLS; ARACHIDONIC-ACID; 12-HYDROXYEICOSATETRAENOIC ACID; MONOHYDROXYEICOSATETRAENOIC ACIDS; LIPOXYGENASE METABOLITES; KINASE-C	We examined how 5-hydroxyicosatetraenoate (5-HETE) activates human neutrophils (PMN). 5-HETE stimulates PMN to mobilize Ca2+ but has little effect on degranulation or superoxide anion production. It nonetheless stereospecifically induced these responses in cells primed with tumor necrosis factor-alpha and likewise induced PMN plasma membranes to bind S-35-labeled guanosine 5'-O-(thiotriphosphate) (GTPgammaS) and phosphohydrolyze [gamma-P-32]GTP. Pertussis toxin blocked GTPgammaS binding responses. Scatchard analyses of GTPgammaS binding data indicated that 5-HETE raised the K(a) of high affinity GTPgammaS binding sites without altering these sites' numbers or the parameters of low affinity GTPgammaS binding. Since N-formyl-Met-Leu-Phe, platelet-activating factor, and leukotriene (LT) B4 have these same bioactions, receptors for the latter agents might mediate responses to 5-HETE. However, 5-HETE desensitized degranulation responses to itself but not to the receptor agonists, the receptor agonists desensitized to themselves but not 5-HETE, and a LTB4 antagonist inhibited LTB4 but not 5-HETE in all assays. Finally, PMN and their membranes took up [H-3] 5-HETE at 4 or 37-degrees-C but, at both temperatures, also acylated the radiolabel into glycerolipids. Acylation nullified assessment of 5-HETE binding and questions reports that measure the cell binding, but not metabolism, of various HETEs. Our studies thus indicate 5-HETE acts by a down-regulatable, G protein-linked mechanism and represent the best available evidence that 5-HETE does not operate through, for example, LTB4 receptors.			OFLAHERTY, JT (corresponding author), WAKE FOREST UNIV,MED CTR,DEPT MED,INFECT DIS SECT,WINSTON SALEM,NC 27157, USA.				NHLBI NIH HHS [HL-26257, HL 27799] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL027799, R01HL026257] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTONIPILLAI I, 1990, P SOC EXP BIOL MED, V194, P224; ARENBERGER P, 1992, EUR J IMMUNOL, V22, P2469, DOI 10.1002/eji.1830220944; ARENBERGER P, 1992, EUR J CLIN INVEST, V22, P235, DOI 10.1111/j.1365-2362.1992.tb01457.x; BASS DA, 1981, BIOCHEM BIOPH RES CO, V100, P1, DOI 10.1016/S0006-291X(81)80054-X; BONSER RW, 1981, BIOCHEMISTRY-US, V20, P5297, DOI 10.1021/bi00521a032; BREZINSKI ME, 1990, P NATL ACAD SCI USA, V87, P6248, DOI 10.1073/pnas.87.16.6248; BRINKMAN HJM, 1991, EXP CELL RES, V192, P87, DOI 10.1016/0014-4827(91)90161-M; CHIPRA H, 1991, INT J CANCER, V49, P774; COSTELLO PB, 1991, INFLAMMATION, V15, P269, DOI 10.1007/BF00917312; EVANS JF, 1987, BIOCHIM BIOPHYS ACTA, V917, P406, DOI 10.1016/0005-2760(87)90119-6; FIORE S, 1992, J BIOL CHEM, V267, P16168; FKORE S, 1992, J BIOL CHEM, V267, P16168; FONLUPT P, 1991, THROMB RES, V63, P239, DOI 10.1016/0049-3848(91)90287-7; GORDON EEI, 1991, AM J PHYSIOL, V261, pC623, DOI 10.1152/ajpcell.1991.261.4.C623; GORDON JA, 1989, AM J PHYSIOL, V256, pC1, DOI 10.1152/ajpcell.1989.256.1.C1; GROB E, 1988, PROSTAGLANDINS, V36, P49; GROSS E, 1990, J INVEST DERMATOL, V94, P446, DOI 10.1111/1523-1747.ep12874543; HAAS TA, 1988, BIOCHIM BIOPHYS ACTA, V961, P153, DOI 10.1016/0005-2760(88)90108-7; HALUSHKA PV, 1989, ANN REV PHARM TOXICO, V10, P213; HANSSON A, 1986, BIOCHEM BIOPH RES CO, V134, P1215, DOI 10.1016/0006-291X(86)90380-3; HERBERTSSON H, 1992, FEBS LETT, V298, P249, DOI 10.1016/0014-5793(92)80069-S; JACKSON RH, 1992, J PHARMACOL EXP THER, V262, P80; KEMENY L, 1991, AGENTS ACTIONS, V32, P339; KOLLER M, 1991, BIOCHEM BIOPH RES CO, V175, P804, DOI 10.1016/0006-291X(91)91636-Q; LAYCHOCK SG, 1985, ENDOCRINOLOGY, V117, P1011, DOI 10.1210/endo-117-3-1011; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; LIU B, 1991, CELL REGUL, V2, P1045, DOI 10.1091/mbc.2.12.1045; MAIS DE, 1990, EICOSANOIDS, V8, P121; MARCUS AJ, 1987, J CLIN INVEST, V79, P179, DOI 10.1172/JCI112781; MEGHJI S, 1992, BONE MINER, V18, P119, DOI 10.1016/0169-6009(92)90852-5; MEXMAIN S, 1984, PROSTA LEUKOTR MED, V13, P93, DOI 10.1016/0262-1746(84)90108-2; NACCACHE PH, 1988, LIFE SCI, V43, P727; NICHOLS RC, 1990, J EXP MED, V171, P367, DOI 10.1084/jem.171.2.367; OFLAHERTY JT, 1981, AM J PATHOL, V104, P55; OFLAHERTY JT, 1988, J IMMUNOL, V140, P4323; OFLAHERTY JT, 1990, J CELL PHYSIOL, V142, P299, DOI 10.1002/jcp.1041420212; OFLAHERTY JT, 1983, BIOCHEM BIOPH RES CO, V111, P1, DOI 10.1016/S0006-291X(83)80108-9; OFLAHERTY JT, 1987, BIOCHEM BIOPH RES CO, V148, P575, DOI 10.1016/0006-291X(87)90915-6; OFLAHERTY JT, 1991, J IMMUNOL, V147, P3842; OTTO WR, 1989, J INVEST DERMATOL, V92, P683, DOI 10.1111/1523-1747.ep12696874; PALMER RMJ, 1980, PROSTAGLANDINS, V20, P411, DOI 10.1016/S0090-6980(80)80058-X; POWELL WS, 1992, J BIOL CHEM, V267, P19233; RABIER M, 1988, BIOCHEM BIOPH RES CO, V152, P1179, DOI 10.1016/S0006-291X(88)80409-1; RAZA H, 1989, BIOCHEM BIOPH RES CO, V161, P448, DOI 10.1016/0006-291X(89)92619-3; RICHARDS CF, 1989, PROSTAGLANDINS, V38, P565, DOI 10.1016/0090-6980(89)90150-0; RICHARDS CF, 1986, BIOCHIM BIOPHYS ACTA, V875, P569, DOI 10.1016/0005-2760(86)90079-2; ROSSI AG, 1988, FEBS LETT, V240, P163, DOI 10.1016/0014-5793(88)80360-0; ROSSI AG, 1989, PROSTAGLANDINS, V37, P641, DOI 10.1016/0090-6980(89)90102-0; ROSSI AG, 1991, J LIPID MEDIATOR, V4, P165; SCHAFER AI, 1986, BLOOD, V67, P373; SCHEPERS TM, 1992, J BIOL CHEM, V267, P159; SEKIYA F, 1991, BIOCHEM BIOPH RES CO, V179, P345, DOI 10.1016/0006-291X(91)91376-N; SERHAN CN, 1989, BIOCHIM BIOPHYS ACTA, V1004, P158, DOI 10.1016/0005-2760(89)90264-6; SETTY BNY, 1987, J BIOL CHEM, V262, P17613; SETTY BNY, 1986, J CLIN INVEST, V77, P202, DOI 10.1172/JCI112277; STENSON WF, 1979, J CLIN INVEST, V64, P1457, DOI 10.1172/JCI109604; STENSON WF, 1980, J IMMUNOL, V124, P2100; STENSON WF, 1979, PROSTAGLANDINS, V18, P185; STERN N, 1989, ENDOCRINOLOGY, V125, P3090, DOI 10.1210/endo-125-6-3090; SUSS R, 1990, EXP CELL RES, V191, P204, DOI 10.1016/0014-4827(90)90006-V; TANAKA Y, 1991, EICOSANOIDS, V4, P83; TURNER SR, 1975, J EXP MED, V141, P1437, DOI 10.1084/jem.141.6.1437; VANDERHOEK JY, 1982, J BIOL CHEM, V257, P2191; VANDERHOEK JY, 1982, BIOCHEM PHARMACOL, V31, P3463, DOI 10.1016/0006-2952(82)90627-X; VANDIEST MJ, 1991, J PHARMACOL EXP THER, V256, P194; WAINWRIGHT S, 1990, BIOCHEMISTRY-US, V29, P10126, DOI 10.1021/bi00495a017; WANG LX, 1990, J LIPID RES, V31, P2265; WEITBERG AB, 1990, AM J MED SCI, V299, P50, DOI 10.1097/00000441-199001000-00011; WONG PYK, 1984, J BIOL CHEM, V259, P2683; YU GH, 1990, IMMUNOPHARMACOLOGY, V20, P175, DOI 10.1016/0162-3109(90)90031-9	70	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14708	14714						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8392058				2022-12-25	WOS:A1993LL75900030
J	MATSUURA, I; KIMURA, E; TAI, K; YAZAWA, M				MATSUURA, I; KIMURA, E; TAI, K; YAZAWA, M			MUTAGENESIS OF THE 4TH CALCIUM-BINDING DOMAIN OF YEAST CALMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; RABBIT SKELETAL-MUSCLE; CARDIAC TROPONIN-C; CENTRAL HELIX; CONFORMATIONAL CHANGE; DIRECTED MUTAGENESIS; TARGET ENZYMES; BOVINE BRAIN; SEA-ANEMONE	The fourth calcium-binding domain (domain IV) of the yeast (Saccharomyces cerevisiae) calmodulin is unable to bind Ca2+ (Matsuura, I., Ishihara, K., Nakai, Y., Yazawa, M., Toda, H., and Yagi, K. (1991) J. Biochem. (Tokyo) 109, 190-;197). The functional significance of Ca2+ binding to domain IV was investigated by site-directed mutagenesis or recombinant DNA techniques. A recognition site for the restriction enzyme ClaI was introduced at the homologous position of Ile130 in the nucleotide sequence of chicken and yeast calmodulin cDNA, and chimeric proteins of the yeast and the vertebrate calmodulin were prepared. One of the resulting mutants named C4Y consisted of Ala1-Ile130 of chicken calmodulin and Asp131-Lys148 of yeast calmodulin. The mutant C4Y showed the yeast-type feature, and its enzyme activation profiles were similar to those of yeast calmodulin. A single substitution of Glu for Gln140 was carried out in the mutant C4Y. The resulting mutant (C4Y140E) bound 4 mol of Ca2+ and showed the vertebrate-type enzyme activation. Therefore, the alterations of 3 residues in the Ca2+-binding loop of the yeast-type domain IV, Ser129 --> Asp, insertion of Ile130, and Gln140 --> Glu, were enough for the recovery of Ca2+ binding and enzyme activation. Ca2+ binding to domain IV may induce the active conformation of the C-terminal half-molecular domain.	HOKKAIDO UNIV, FAC SCI, DEPT CHEM, SAPPORO, HOKKAIDO 060, JAPAN	Hokkaido University								BABU A, 1992, J BIOL CHEM, V267, P15469; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTCHER RW, 1962, J BIOL CHEM, V237, P1244; CHARBONNEAU H, 1991, BIOCHEMISTRY-US, V30, P7931, DOI 10.1021/bi00246a009; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; GEORGE SE, 1990, J BIOL CHEM, V265, P9228; GIEDROC DP, 1985, J BIOL CHEM, V260, P3406; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HEIDORN DB, 1989, BIOCHEMISTRY-US, V28, P6757, DOI 10.1021/bi00442a032; IKURA M, 1991, BIOCHEMISTRY-US, V30, P5498, DOI 10.1021/bi00236a024; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; INOUYE S, 1986, BIOCHEMISTRY-US, V25, P8425, DOI 10.1021/bi00374a015; KABAT EA, 1961, EXPT IMMUNOCHEMISTRY, P559; KAKIUCHI S, 1981, J BIOL CHEM, V256, P19; KATAOKA M, 1989, P NATL ACAD SCI USA, V86, P6944, DOI 10.1073/pnas.86.18.6944; KENDRICKJONES J, 1976, J MOL BIOL, V104, P747, DOI 10.1016/0022-2836(76)90180-7; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KRETSINGER RH, 1986, J INORG BIOCHEM, V28, P289, DOI 10.1016/0162-0134(86)80093-9; LIN TI, 1977, ANAL BIOCHEM, V77, P10, DOI 10.1016/0003-2697(77)90284-6; LUAN Y, 1987, J BIOCHEM-TOKYO, V102, P1531, DOI 10.1093/oxfordjournals.jbchem.a122201; MACKALL J, 1991, BIOCHEMISTRY-US, V30, P7242, DOI 10.1021/bi00243a028; MATSUURA I, 1991, J BIOCHEM-TOKYO, V109, P190, DOI 10.1093/oxfordjournals.jbchem.a123344; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; NAGAMOTO H, 1984, J BIOCHEM, V95, P1119, DOI 10.1093/oxfordjournals.jbchem.a134700; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; OHYA Y, 1987, EUR J BIOCHEM, V168, P13, DOI 10.1111/j.1432-1033.1987.tb13380.x; PERRIE WT, 1973, BIOCHEM J, V135, P151, DOI 10.1042/bj1350151; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; PRSECHINI A, 1988, J BIOL CHEM, V263, P12175; PUTKEY JA, 1983, J BIOL CHEM, V258, P1864; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARMA RK, 1980, J BIOL CHEM, V255, P5916; SZEBENYI DME, 1986, J BIOL CHEM, V261, P8761; TANAKA T, 1980, J BIOL CHEM, V255, P1078; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; TODA H, 1985, J BIOCHEM-TOKYO, V98, P833, DOI 10.1093/oxfordjournals.jbchem.a135342; VANBERKUM MFA, 1990, J BIOL CHEM, V265, P3750; YAZAWA M, 1990, J BIOCHEM-TOKYO, V107, P287, DOI 10.1093/oxfordjournals.jbchem.a123040; YAZAWA M, 1980, J BIOCHEM, V87, P1313, DOI 10.1093/oxfordjournals.jbchem.a132869; YAZAWA M, 1992, BIOCHEMISTRY-US, V31, P3172; YOSHINO H, 1989, J BIOL CHEM, V264, P19706	47	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13267	13273						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8390460				2022-12-25	WOS:A1993LH55300039
J	MUSCI, G; DIPATTI, MCB; FAGIOLO, U; CALABRESE, L				MUSCI, G; DIPATTI, MCB; FAGIOLO, U; CALABRESE, L			AGE-RELATED-CHANGES IN HUMAN CERULOPLASMIN - EVIDENCE FOR OXIDATIVE MODIFICATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIXED-FUNCTION OXIDATION; OXYGEN FREE-RADICALS; BLUE OXIDASES; CATALYZED OXIDATION; PROTEIN-TURNOVER; COPPER; INFLAMMATION; CENTERS; RATS; FLUORESCENCE	Human plasma or serum from donors of age comprised between 15 and 95 years was analyzed for paramagnetic and total copper content, as well as for immunoreactive ceruloplasmin content and oxidase activity. All parameters were essentially unaltered, except the paramagnetic copper content, which increased 2-fold upon aging. A dramatic change of the electron paramagnetic resonance spectrum due to ceruloplasmin occurred in individuals over 65 years old and was associated with both an increase of the type 1 copper signal intensity and the appearance of new resonances of a type 2 copper species. Ceruloplasmin was isolated from either young or old donors. Spectroscopic analyses of the isolated proteins confirmed the tendency of type 1 copper to stay reduced in the ''young'' and oxidized in the ''old'' protein. The type 2 copper signal observed in most young ceruloplasmin samples was different from the species invariably present in the old protein. The magnetic parameters of the latter species were more consistent with a partially reduced trinuclear copper site. In vitro limited proteolysis resulted in identical fragmentation patterns and kinetics in both proteins. However, changes of the net electric charge were detected in the fragments of the protein isolated from aged individuals, which exhibited a carbonyl content of 0.6 mol of carbonyl/mol of protein. The same pattern of modifications, including a higher carbonyl content (0.65 versus 0.2 mol of carbonyl/mol of protein), could be reproduced by exposure of the young protein to the metal-catalyzed oxidation system iron/ascorbate. These results suggest that during aging ceruloplasmin is subjected to oxidative modifications which are likely to be the source of conformational changes around the copper sites leading to an intramolecular electron rearrangement among the various copper sites.	UNIV ROMA LA SAPIENZA, CNR, CTR MOLEC BIOL, PIAZZALE ALDO MORO 5, I-00185 ROME, ITALY; UNIV ROMA LA SAPIENZA, DEPT BIOCHEM SCI, I-00185 ROME, ITALY; UNIV PADUA, INST INTERNAL MED, I-35100 PADUA, ITALY	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Sapienza University Rome; University of Padua			Musci, Giovanni/H-2862-2012; Bonaccorsi di Patti, Maria Carmela/F-1198-2011	Musci, Giovanni/0000-0002-5196-709X; Bonaccorsi di Patti, Maria Carmela/0000-0002-4794-7037				AMICI A, 1989, J BIOL CHEM, V264, P3341; AVIGLIANO L, 1983, FEBS LETT, V163, P274, DOI 10.1016/0014-5793(83)80834-5; BACCI M, 1983, BIOPHYS CHEM, V17, P125, DOI 10.1016/0301-4622(83)80006-4; Brumby PE, 1967, METHOD ENZYMOL, V10, P473; CALABRESE L, 1988, J BIOL CHEM, V263, P6480; CALABRESE L, 1989, J BIOL CHEM, V264, P6183; COUSINS RJ, 1985, PHYSIOL REV, V65, P238, DOI 10.1152/physrev.1985.65.2.238; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; DAVIES KJA, 1987, J BIOL CHEM, V262, P9914; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DEINUM J, 1973, BIOCHIM BIOPHYS ACTA, V310, P321, DOI 10.1016/0005-2795(73)90112-8; DISILVESTRO RA, 1988, BIOL TRACE ELEM RES, V17, P1, DOI 10.1007/BF02795442; FARBER JM, 1986, J BIOL CHEM, V261, P4574; FLEMING RE, 1991, AM J PHYSIOL, V260, pL68, DOI 10.1152/ajplung.1991.260.2.L68; FLYNN A, 1980, INFLAMMATORY DISEASE, P17; Frieden E, 1980, Ciba Found Symp, V79, P93; GARLAND D, 1988, BASIC LIFE SCI, P347; GERSHON H, 1970, NATURE, V227, P1214, DOI 10.1038/2271214a0; GOA J, 1953, SCAND J CLIN LAB INV, V5, P218, DOI 10.3109/00365515309094189; GRIFFITHS HR, 1989, FEBS LETT, V245, P95, DOI 10.1016/0014-5793(89)80199-1; GROSS AJ, 1959, J BIOL CHEM, V234, P1611; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HOLTZMAN NA, 1970, J BIOL CHEM, V245, P2350; KOSSIAKOFF AA, 1988, SCIENCE, V240, P191, DOI 10.1126/science.3353715; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz JR, 1983, PRINCIPLES FLUORESCE, P187, DOI 10.1007/978-1-4615-7658-7_7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNEC J, 1985, J CLIN INVEST, V76, P2084, DOI 10.1172/JCI112212; LYNGBYE J, 1971, CLIN CHEM, V17, P495; Malmstrom B.G., 1975, ENZYMES B, V12, P507, DOI DOI 10.1016/S1874-6047(08)60231-0; MESSERSCHMIDT A, 1990, EUR J BIOCHEM, V187, P341, DOI 10.1111/j.1432-1033.1990.tb15311.x; MUSCI G, 1992, EUR J BIOCHEM, V210, P635, DOI 10.1111/j.1432-1033.1992.tb17464.x; MUSCI G, 1990, ARCH BIOCHEM BIOPHYS, V279, P8, DOI 10.1016/0003-9861(90)90455-8; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; OLIVER CN, 1987, J AM GERIATR SOC, V35, P947, DOI 10.1111/j.1532-5415.1987.tb02297.x; ORTEL TL, 1984, P NATL ACAD SCI-BIOL, V81, P4761, DOI 10.1073/pnas.81.15.4761; PRUTZ WA, 1983, INT J RADIAT BIOL, V44, P183, DOI 10.1080/09553008314550981; Rothstein M., 1984, P209; RYDEN L, 1976, BIOCHEMISTRY-US, V15, P3411, DOI 10.1021/bi00661a003; RYDEN L, 1982, P NATL ACAD SCI-BIOL, V79, P6767, DOI 10.1073/pnas.79.22.6767; Ryden L., 1984, COPP PROTEINS COPP E, V3, P37; RYLKOV VV, 1991, EUR J BIOCHEM, V197, P185, DOI 10.1111/j.1432-1033.1991.tb15897.x; SATO M, 1990, J BIOL CHEM, V265, P2533; SCHOSINSKY KH, 1974, CLIN CHEM, V20, P1556; SEMSEI I, 1991, GERONTOLOGY, V37, P199; SHARMA HK, 1980, J BIOL CHEM, V255, P5043; SOLOMON EI, 1987, LIFE CHEM REPORTS, V5, P37; STADTMAN ER, 1986, TRENDS BIOCHEM SCI, V11, P11, DOI 10.1016/0968-0004(86)90221-5; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; STADTMAN ER, 1988, J GERONTOL, V43, pB112, DOI 10.1093/geronj/43.5.B112; STARKEREED PE, 1989, ARCH BIOCHEM BIOPHYS, V275, P559, DOI 10.1016/0003-9861(89)90402-5; WINYARD PG, 1989, BIOCHEM J, V258, P435, DOI 10.1042/bj2580435; WYNN RM, 1983, FEBS LETT, V156, P23, DOI 10.1016/0014-5793(83)80240-3	55	78	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13388	13395						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8390462				2022-12-25	WOS:A1993LH55300055
J	PHILLIPS, JD; GRAHAM, LA; TRUMPOWER, BL				PHILLIPS, JD; GRAHAM, LA; TRUMPOWER, BL			SUBUNIT-9 OF THE SACCHAROMYCES-CEREVISIAE CYTOCHROME-BC(1) COMPLEX IS REQUIRED FOR INSERTION OF EPR-DETECTABLE IRON-SULFUR CLUSTER INTO THE RIESKE IRON-SULFUR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C REDUCTASE COMPLEX; MUTATIONAL ANALYSIS; YEAST MITOCHONDRIA; BC1 COMPLEX; RESPIRATORY-CHAIN; ELECTRON-TRANSFER; RIP1; PURIFICATION; SAMPLES; IMPORT	Deletion of QCR9, the nuclear gene encoding the 7.3-kDa subunit 9 of the cytochrome bc1 complex, impairs respiration of Saccharomyces cerevisiae, coincident with loss of ubiquinol-cytochrome c oxidoreductase activity. Optical spectra of mitochondrial membranes from yeast in which the gene for subunit 9 is deleted show a diminution of cytochrome b absorption similar to the spectra of membranes from yeast in which the gene for the Rieske iron-sulfur protein is deleted, suggesting an interaction between subunit 9, iron-sulfur protein, and cytochrome b. Synthesis of cytochrome b by mitochondria from the deletion strain is unimpaired, indicating that the diminished b absorption is due to a post-assembly effect on the heme environment resulting from the absence of subunit 9. Iron-sulfur protein is present in normal amounts and processed to its mature form in the absence of subunit 9, although the protein is more labile to endogenous proteases during the isolation of membranes. EPR spectroscopy of membranes from the subunit 9 deletion strain indicates that the g = 1.90 signal characteristic of the Rieske iron-sulfur cluster is absent, even though mature sized apoprotein is present. Pre-steady state reduction of cytochrome c1 is markedly slowed, but not eliminated, in the subunit 9 deletion strain, which suggests that an EPR-silent, sluggishly reactive derivative of the iron-sulfur cluster is present. These results suggest that in the absence of subunit 9 the conformation of iron-sulfur protein is altered such that the protein is more labile, the iron-sulfur cluster is not properly inserted, and iron-sulfur protein interaction with cytochrome b is modified in a manner which distorts the heme environment. This is the first instance in which deletion of one of the supernumerary subunits of the cytochrome bc1 complex results in the loss of function of a redox center within the complex, without a concomitant loss of other subunits.	DARTMOUTH COLL,SCH MED,DEPT BIOCHEM,7200 VAIL BLDG,HANOVER,NH 03755	Dartmouth College					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020379, R37GM020379] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 20379] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKMANN JD, 1989, J BIOL CHEM, V264, P3713; BECKMANN JD, 1987, J BIOL CHEM, V262, P8901; BIANCHI A, 1990, J BIOL CHEM, V265, P1502; BOWYER JR, 1981, J BIOL CHEM, V256, P2245; BRANDT U, 1988, EUR J BIOCHEM, V173, P499, DOI 10.1111/j.1432-1033.1988.tb14026.x; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; DAUM G, 1982, J BIOL CHEM, V257, P3028; DOUGLAS MG, 1976, P NATL ACAD SCI USA, V73, P1083, DOI 10.1073/pnas.73.4.1083; GONZALEZHALPHEN D, 1988, BIOCHEMISTRY-US, V27, P7021, DOI 10.1021/bi00418a053; GRAHAM LA, 1991, J BIOL CHEM, V266, P22485; GRAHAM LA, 1992, FEBS LETT, V313, P251, DOI 10.1016/0014-5793(92)81203-X; Hanahan D., 1985, DNA CLONING; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAPA S, 1989, ARCH BIOCHEM BIOPHYS, V268, P716, DOI 10.1016/0003-9861(89)90340-8; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KRIAUCIUNAS A, 1989, BIOCHIM BIOPHYS ACTA, V976, P70, DOI 10.1016/S0005-2728(89)80190-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; LJUNGDAHL PO, 1989, J BIOL CHEM, V264, P3723; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; NEEDLEMAN RB, 1975, ANAL BIOCHEM, V64, P545, DOI 10.1016/0003-2697(75)90466-2; PHILLIPS JD, 1990, J BIOL CHEM, V265, P20813; RICH PR, 1983, BIOCHIM BIOPHYS ACTA, V722, P271, DOI 10.1016/0005-2728(83)90073-7; RIESKE JS, 1976, BIOCHIM BIOPHYS ACTA, V456, P195, DOI 10.1016/0304-4173(76)90012-4; RIESKE JS, 1967, J BIOL CHEM, V242, P4854; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; SCHMITT ME, 1990, J BIOL CHEM, V265, P17005; SCHOPPINK P, 1989, YEAST UBIQUINOL CYTO; Sherman F., 1983, METHODS YEAST GENETI; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P8697; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; TRUMPOWER BL, 1980, J BIOL CHEM, V255, P7487; YAFFE MP, 1984, P NATL ACAD SCI USA, V81, P4810; YANG XH, 1986, J BIOL CHEM, V261, P2282	36	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11727	11736						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8389362				2022-12-25	WOS:A1993LF28400042
J	CULOUSCOU, JM; CARLTON, GW; SHOYAB, M				CULOUSCOU, JM; CARLTON, GW; SHOYAB, M			BIOCHEMICAL-ANALYSIS OF THE EPITHELIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PROTEINS; PEPTIDE; BINDING; KINASE; GENE	Epithelin 1 and 2 are cysteine-rich proteins that act as growth modulators of epithelial cells. In this report, we have characterized the epithelins receptors of MDA-MB-468 human breast carcinoma cells using both binding and cross-linking techniques. Equilibrium binding studies of iodinated epithelin 1 indicated that two classes of binding sites are expressed at the surface of breast carcinoma cells. The high affinity sites had a dissociation constant of almost-equal-to 2 x 10(-10) M, with almost-equal-to 290 receptors/cell. The low affinity sites had a dissociation constant of almost-equal-to 10(-8) M, with almost-equal-to 32,000 receptors/cell. Binding of iodinated epithelin 1 was specifically inhibited by unlabeled epithelin 1, 2, or 3, but not by other growth factors tested. We also performed competition binding studies of I-125-epithelin 1 to cell surface receptors in the presence of unlabeled epithelin 1, 2, or 3. Binding results analyzed by the method of Scatchard suggested that all three epithelins interact with a same receptor. A 140-145-kDa epithelin 1-binding protein complex was identified by chemical cross-linking of I-125-epithelin 1 to breast cancer cells. Formation of such a complex was prevented by coincubation of I-125-epithelin 1 with an excess of unlabeled epithelin 1, 2, or 3.			CULOUSCOU, JM (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,3005 1ST AVE,SEATTLE,WA 98121, USA.							BATEMAN A, 1990, BIOCHEM BIOPH RES CO, V173, P1161, DOI 10.1016/S0006-291X(05)80908-8; BHANDARI V, 1992, P NATL ACAD SCI USA, V89, P1715, DOI 10.1073/pnas.89.5.1715; CASELLA SJ, 1986, J BIOL CHEM, V261, P9268; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; Culouscou JM, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046924; CULOUSCOU JM, 1991, CANCER RES, V51, P2813; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HELDIN CH, 1989, EUR J BIOCHEM, V184, P487, DOI 10.1111/j.1432-1033.1989.tb15041.x; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; OLASHAW NE, 1986, P NATL ACAD SCI USA, V83, P3834, DOI 10.1073/pnas.83.11.3834; PLOWMAN GD, 1992, J BIOL CHEM, V267, P13073; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SHOYAB M, 1990, P NATL ACAD SCI USA, V87, P7912, DOI 10.1073/pnas.87.20.7912; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	19	42	50	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10458	10462						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8387520				2022-12-25	WOS:A1993LB80000070
J	CONG, PJ; SHUMAN, S				CONG, PJ; SHUMAN, S			COVALENT CATALYSIS IN NUCLEOTIDYL TRANSFER - A KTDG MOTIF ESSENTIAL FOR ENZYME-GMP COMPLEX-FORMATION BY MESSENGER-RNA CAPPING ENZYME IS CONSERVED AT THE ACTIVE-SITES OF RNA AND DNA LIGASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACCINIA VIRUS GUANYLYLTRANSFERASE; ESCHERICHIA-COLI; (GUANINE-7-)METHYLTRANSFERASE COMPLEX; GUANYLATE INTERMEDIATE; ADENYLYLATION SITE; SEQUENCE; MECHANISM; GENE; ASSOCIATION; MUTAGENESIS	Vaccinia virus RNA capping enzyme, a heterodimer of 95- and 31-kDa subunits, catalyzes transfer of GMP from GTP to the 5'-diphosphate terminus of RNA via a covalent enzyme-guanylate intermediate. The GMP residue is attached to the 95-kDa subunit through a phosphoamide bond to the epsilon-amino group of a lysine residue. The amino acid sequence of the large subunit includes a lysine-containing motif, Tyr-X-X-X-Lys260-Thr-Asp-Gly, that is conserved in the RNA guanylyltranferases encoded by Shope fibroma virus and Saccharomyces cerevisiae. The KXDG motif is also encountered at the sites of covalent adenylylation of bacteriophage 4 RNA ligase and mammalian DNA ligase I (Thogerson, H. C., Morris, H. R., Rand, K. N., and Gait, M. J. (1985) Eur. J. Biochem. 147, 325-329; Tomkinson, A. E., Totty, N. F., Ginsburg, M., and Lindahl, T. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 400-404). We find that conservative amino acid substitutions at three out of four positions within the KTDG sequence of vaccinia capping enzyme either prevent or strongly inhibit enzyme-guanylate formation. The conserved motif is therefore an essential component of the guanylyltransferase domain. Lys260 is implicated as the active site. Comparison of the sequences of capping enzymes and polynucleotide ligases from diverse sources suggests that KX(D/N)G may be a signature element for covalent catalysis in nucleotidyl transfer.			CONG, PJ (corresponding author), SLOAN KETTERING INST CANC RES,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.							COLINAS RJ, 1990, VIROLOGY, V179, P267, DOI 10.1016/0042-6822(90)90295-3; CONG PJ, 1992, J BIOL CHEM, V267, P16424; FAUSNAUGH J, 1990, J BIOL CHEM, V265, P7669; GUMPORT RI, 1971, P NATL ACAD SCI USA, V68, P2559, DOI 10.1073/pnas.68.10.2559; GUO PX, 1990, P NATL ACAD SCI USA, V87, P4023, DOI 10.1073/pnas.87.11.4023; HAMMOND JM, 1992, NUCLEIC ACIDS RES, V20, P2667, DOI 10.1093/nar/20.11.2667; HEAPHY S, 1987, BIOCHEMISTRY-US, V26, P1688, DOI 10.1021/bi00380a030; HIGMAN MA, 1992, J BIOL CHEM, V267, P16430; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KERR SM, 1989, NUCLEIC ACIDS RES, V17, P9039, DOI 10.1093/nar/17.22.9039; KODAMA K, 1991, NUCLEIC ACIDS RES, V19, P6093, DOI 10.1093/nar/19.22.6093; LEHMAN IR, 1974, SCIENCE, V186, P790; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; MIZUMOTO K, 1987, PROG NUCLEIC ACID RE, V34, P1, DOI 10.1016/S0079-6603(08)60491-2; MOSS B, 1976, VIROLOGY, V72, P341, DOI 10.1016/0042-6822(76)90163-X; NILES EG, 1986, VIROLOGY, V153, P96, DOI 10.1016/0042-6822(86)90011-5; RAND KN, 1984, EMBO J, V3, P397, DOI 10.1002/j.1460-2075.1984.tb01819.x; ROTH MJ, 1984, J BIOL CHEM, V259, P3488; SELIGER LS, 1987, J BIOL CHEM, V262, P16298; SHIBAGAKI Y, 1992, J BIOL CHEM, V267, P9521; SHUMAN S, 1982, J BIOL CHEM, V257, P7237; SHUMAN S, 1981, P NATL ACAD SCI-BIOL, V78, P187, DOI 10.1073/pnas.78.1.187; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1990, J BIOL CHEM, V265, P11960; SHUMAN S, 1990, J BIOL CHEM, V265, P11967; SHUMAN S, 1980, J BIOL CHEM, V255, P1588; SHUMAN S, 1989, J BIOL CHEM, V264, P9690; SMITH GL, 1989, NUCLEIC ACIDS RES, V17, P9051, DOI 10.1093/nar/17.22.9051; THOGERSEN HC, 1985, EUR J BIOCHEM, V147, P325, DOI 10.1111/j.1432-1033.1985.tb08753.x; TOMKINSON AE, 1991, P NATL ACAD SCI USA, V88, P400, DOI 10.1073/pnas.88.2.400; TOYAMA R, 1983, EMBO J, V2, P2195, DOI 10.1002/j.1460-2075.1983.tb01723.x; UPTON C, 1991, VIROLOGY, V183, P773, DOI 10.1016/0042-6822(91)91009-6; VENKATESAN S, 1980, J BIOL CHEM, V255, P903; XXU G, 1990, BIOCHEMISTRY-US, V29, P6132	34	80	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7256	7260						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8385101				2022-12-25	WOS:A1993KV14100064
J	LEONE, A; SEEGER, RC; HONG, CM; HU, YY; ARBOLEDA, MJ; BRODEUR, GM; STRAM, D; SLAMON, DJ; STEEG, PS				LEONE, A; SEEGER, RC; HONG, CM; HU, YY; ARBOLEDA, MJ; BRODEUR, GM; STRAM, D; SLAMON, DJ; STEEG, PS			EVIDENCE FOR NM23 RNA OVEREXPRESSION, DNA AMPLIFICATION AND MUTATION IN AGGRESSIVE CHILDHOOD NEUROBLASTOMAS	ONCOGENE			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; DUCTAL BREAST CARCINOMAS; TUMOR-METASTASIS; N-MYC; DROSOPHILA DEVELOPMENT; PROTEIN-KINASE; GENE; EXPRESSION; ASSOCIATION; CANCER	Reduced expression of nm23 RNAs/proteins has been associated previously with high tumor metastatic potential. In contrast, we report that regional (state III) and metastatic (stage IV) childhood neuroblastomas exhibit elevated nm23 RNA levels as compared with localized tumors. Elevated neuroblastoma nm23 RNA levels were associated with significant reductions in patient survival in the overall (n = 75) and N-myc non-amplified (n = 61) portion of the cohort. Amplification of the chromosomal nm23-H1 gene was observed in 6/18 stage III and IV tumors; amplification of nm23-H2 was not demonstrated. Genomic amplification of nm23-H1 was associated with increased tumor nm23 RNA expression and reduced patient survival. Single-strand conformational polymorphism (SSCP) analysis was performed on seven neuroblastomas. Minor subpopulations of cDNAs exhibiting altered mobility were apparent in both nm23-H1 and nm23-H2 translated regions of stage III and IV tumors, suggestive.of mutations. Confirmation of the SSCP data was provided by direct sequencing of nm23-H2 in a stage IV tumor, revealing a leucine to valine mutation at position 48. The data indicate that molecular alterations to nm23 other than its reduced expression can be associated with tumor aggressiveness, and provide the first evidence for nm23 mutation in a human cancer.	NCI, PATHOL LAB, BLDG 10, ROOM 2A33, BETHESDA, MD 20892 USA; CHILDRENS HOSP LOS ANGELES, DEPT PEDIAT, DIV HEMATOL ONCOL, LOS ANGELES, CA 90027 USA; UNIV SO CALIF, SCH MED, LOS ANGELES, CA 90027 USA; CHILDRENS CANC GRP, ARCADIA, CA USA; UNIV CALIF LOS ANGELES, SCH MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90027 USA; WASHINGTON UNIV, SCH MED, DEPT PEDIAT, DIV HEMATOL ONCOL, ST LOUIS, MO 63110 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Children's Hospital Los Angeles; University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Washington University (WUSTL)			Leone, Alvaro/K-6410-2016; leone, alvaro/AAQ-7051-2020	Leone, Alvaro/0000-0003-3815-9052; 	NCI NIH HHS [CA 02649, CA49712, CA22794] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA022794, P01CA049712, U10CA002649] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMITAGE P, 1971, STATISTICAL METHODS; BARNES R, 1991, AM J PATHOL, V139, P245; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BUCKMAN VL, 1988, GENE, V70, P245; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COHN KH, 1991, LANCET, V338, P722, DOI 10.1016/0140-6736(91)91444-Y; COX DR, 1972, J R STAT SOC B, V34, P187; DEAROLF CR, 1988, DEV BIOL, V129, P159, DOI 10.1016/0012-1606(88)90170-4; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; GANSLER T, 1986, CANCER, V58, P2453, DOI 10.1002/1097-0142(19861201)58:11<2453::AID-CNCR2820581117>3.0.CO;2-I; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GOLDEN A, ONCOGENES TUMOR SUPP; HAILAT N, 1991, J CLIN INVEST, V88, P341, DOI 10.1172/JCI115299; HAMA H, 1991, GENE, V105, P31, DOI 10.1016/0378-1119(91)90510-I; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAUT M, 1991, J NATL CANCER I, V83, P712, DOI 10.1093/jnci/83.10.712; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; HIRAYAMA R, 1991, J NATL CANCER I, V83, P1259; HOSSAIN A, 1991, CLIN EXP METASTAS, V9, P500; KANEKO Y, 1987, CANCER RES, V47, P311; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LANDSCHULTZ WH, 1988, SCIENCE, V240, P1750; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1991, CANCER RES, V51, P2490; MATSUNAGA T, 1991, CANCER RES, V51, P3148; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2702; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAYAMA T, 1992, J NATL CANCER I, V84, P1349, DOI 10.1093/jnci/84.17.1349; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SASTREGARAU X, 1992, INT J CANCER, V50, P533, DOI 10.1002/ijc.2910500406; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STAHL JA, 1991, CANCER RES, V48, P6550; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STEEG PS, 1989, CANCER METASTASIS, P48; SUZUKI T, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P210; TANAKA T, 1988, CANCER RES, V48, P1030; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; YAGUE J, 1991, NUCLEIC ACIDS RES, V19, P6663, DOI 10.1093/nar/19.23.6663	43	220	223	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					855	865						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8384356				2022-12-25	WOS:A1993KT22000006
J	ONODA, K; YIN, HL				ONODA, K; YIN, HL			GCAP39 IS PHOSPHORYLATED - STIMULATION BY OKADAIC ACID AND PREFERENTIAL ASSOCIATION WITH NUCLEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASES; CELLULAR-REGULATION; CAPPING PROTEIN; CALCIUM-ION; ACTIN; GELSOLIN; CELLS; LOCALIZATION; KINETICS; FRAGMIN	gCap39 is an actin filament end-capping protein which is a member of the gelsolin family. Unlike gelsolin, gCap39 does not sever actin filaments and is a cytoplasmic as well as nuclear protein. We report here that gCap39 is phosphorylated, while gelsolin is not. gCap39 is phosphorylated on serines and threonines at multiple sites, and phospho-gCap39 is resolved by isofocusing into multiple isoforms which are more acidic than unphosphorylated gCap39. In vitro dephosphorylation eliminates the acidic isoforms. Okadaic acid, a protein phosphatase inhibitor, stimulates gCap39 phosphorylation in vivo. It preferentially increases labeling of several peptides and enhances labeling of phosphothreonines relative to phosphoserines. The phosphorylation state of gCap39 in cells is therefore regulated by a balance between kinases and okadaic acid-sensitive phosphatases, and phosphorylation sites containing threonines appear to be particularly sensitive to the phosphatases. Subcellular fractionation shows that the nuclear fraction contains 17 +/- 5% (n = 3) of total gCap39. Compared with the soluble cytoplasm, nuclear gCap39 has a 1.7 +/- 0.2 (n = 3) fold increase in the amount of P-32 label incorporation and a higher ratio of acidic/basic gCap39. We conclude that phospho-gCap39 is preferentially associated with nuclei and suggest that phosphorylation of gCap39 is functionally significant.	UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NHLBI NIH HHS [HL29113] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029113] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COOPER JA, 1988, J CELL BIOL, V106, P1229, DOI 10.1083/jcb.106.4.1229; DABIRI GA, 1992, J BIOL CHEM, V267, P16545; FURUHASHI K, 1990, J CELL BIOL, V111, P1081, DOI 10.1083/jcb.111.3.1081; FURUHASHI K, 1992, J BIOL CHEM, V267, P9326; HASEGAWA T, 1980, BIOCHEMISTRY-US, V19, P2677, DOI 10.1021/bi00553a021; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; JOHNSTON PA, 1990, J BIOL CHEM, V265, P17946; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1988, CELL, V54, P139, DOI 10.1016/0092-8674(88)90542-9; MUMBY MC, 1985, J BIOL CHEM, V260, P3763; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ONODA K, 1992, J CELL BIOL, V115, P327; PRENDERGAST GC, 1991, EMBO J, V10, P757, DOI 10.1002/j.1460-2075.1991.tb08007.x; SMITH CJ, 1980, P NATL ACAD SCI-BIOL, V77, P2641, DOI 10.1073/pnas.77.5.2641; SOUTHWICK FS, 1986, J BIOL CHEM, V261, P14191; THOMAS TP, 1988, CANCER RES, V48, P1910; WANG E, 1984, J CELL BIOL, V98, P761, DOI 10.1083/jcb.98.2.761; YIN HL, 1981, J CELL BIOL, V91, P901, DOI 10.1083/jcb.91.3.901; YIN HL, 1987, BIOESSAYS, V7, P176, DOI 10.1002/bies.950070409; YIN HL, 1980, P NATL ACAD SCI-BIOL, V77, P2188, DOI 10.1073/pnas.77.4.2188; YOUNG CL, 1990, BIOCHEMISTRY-US, V29, P2232, DOI 10.1021/bi00461a005; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; YU FX, 1991, J BIOL CHEM, V266, P19269	28	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4106	4112						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8382692				2022-12-25	WOS:A1993KN53300048
J	ITOH, T; KAIBUCHI, K; MASUDA, T; YAMAMOTO, T; MATSUURA, Y; MAEDA, A; SHIMIZU, K; TAKAI, Y				ITOH, T; KAIBUCHI, K; MASUDA, T; YAMAMOTO, T; MATSUURA, Y; MAEDA, A; SHIMIZU, K; TAKAI, Y			THE POSTTRANSLATIONAL PROCESSING OF RAS-P21 IS CRITICAL FOR ITS STIMULATION OF MITOGEN-ACTIVATED PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING PROTEINS; RAS PROTEINS; SACCHAROMYCES-CEREVISIAE; EXCHANGE-REACTION; SENSITIVE METHOD; CYCLASE PATHWAY; SMG P21S; P21RAS; PURIFICATION; CDC25	The point-mutated active form of ras p21 is known to activate mitogen-activated protein (MAP) kinase/extracellular signal-regulated kinase (ERK) in intact mammalian cells and Xenopus oocytes, although the direct target molecule of ras p21 remains to be identified. To elucidate the role of the post-translational processing of ras p21 for the MAP kinase activation, we established the cell-free system in which ras p21 activated MAP kinase. The guanosine 5'-(3-O-thio)triphosphate (GTPgammaS) bound form of post-translationally processed Ki-ras 4B p21 activated MAP kinase in the cytosol fraction of Xenopus oocytes, but the GTPgammaS bound form of post-translationally unprocessed Ki-ras 4B p21 or the GDP bound form of processed or unprocessed Ki-ras 4B p21 was far less effective. The GTPgammaS bound form of processed Ki-ras 4B p21 activated recombinant ERK2 in the presence of the cytosol fraction of Xenopus oocytes, but the unprocessed protein was far less effective. These results provide a complete biochemical assay for ras p21 to activate MAP kinase in a cell-free system and indicate that all the elements downstream of ras p21 necessary for the MAP kinase activation are cytosolic and that the post-translational processing of ras p21 is important for the MAP kinase activation.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN; NATL INST HLTH,DEPT VET SCI,TOKYO 190,JAPAN; NATL INST PHYSIOL SCI,DEPT CELL PHYSIOL,OKAZAKI,AICHI 444,JAPAN	Kobe University; National Institute of Health Sciences - Japan; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)								AHN NG, 1991, J BIOL CHEM, V266, P4220; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HORIUCHI H, 1992, MOL CELL BIOL, V12, P4515, DOI 10.1128/MCB.12.10.4515; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; YOSHIDA K, 1988, CANCER RES, V48, P5503	46	65	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3025	3028						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8381417				2022-12-25	WOS:A1993KM16100003
J	SHIEH, WR; CHEN, CS				SHIEH, WR; CHEN, CS			PURIFICATION AND CHARACTERIZATION OF NOVEL 2-ARYLPROPIONYL-COA EPIMERASES FROM RAT-LIVER CYTOSOL AND MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-INFLAMMATORY DRUGS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; METABOLIC STEREOISOMERIC INVERSION; CHIRAL INVERSION; RENAL-FAILURE; IBUPROFEN; INVITRO; PROSTAGLANDINS; RACEMIZATION; MECHANISM	Investigation on the biochemical isomerization of ibuprofen led us to the successful purification of ''2-arylpropionyl-CoA epimerase'' from rat liver cytosol and mitochondria. The purified enzymes from both subcellular fractions exhibit similar physical and catalytic properties and are distinctly different from rat liver methylmalonyl-CoA epimerase. Both are monomeric proteins with an apparent molecular mass of 42 kDa and show similar contents of most amino acids. Their UV spectra gave no indication of any bound cofactors, and their enzyme activities were not affected by exposure to EDTA or metal ions (except Cu2+). These results suggest that the cytosolic and mitochondrial epimerases may be structurally related. The purified enzymes catalyze the epimerization of various 2-arylpropionyl-CoAs with some degree of stereochemical differentiation. For 2-(4-isobutylphenyl)propionyl-CoA, the equilibrium constant was estimated to be 1.5 in favor of the R-isomer. Evidence indicated that the proton exchange may be mediated by a 2-base mechanism and that a carboxylic residue in the active site may serve as a general base for proton abstraction.	UNIV RHODE ISL, COLL PHARM, DEPT PHARMACOGNOSY & ENVIRONM HLTH SCI, KINGSTON, RI 02881 USA	University of Rhode Island					NIGMS NIH HHS [GM-39236] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039236] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS E, 1976, ADV ENZYMOL RAMB, V44, P69; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Briggs GE, 1925, BIOCHEM J, V19, P338, DOI 10.1042/bj0190338; CALDWELL J, 1988, BIOCHEM PHARMACOL, V37, P105, DOI 10.1016/0006-2952(88)90762-9; CARMICHAEL J, 1985, AM J MED, V78, P992, DOI 10.1016/0002-9343(85)90223-2; CHEN CS, 1990, BIOCHIM BIOPHYS ACTA, V1033, P1, DOI 10.1016/0304-4165(90)90185-Y; CHEN CS, 1990, J LABELLED COMPD RAD, V28, P1017, DOI 10.1002/jlcr.2580280905; CHEN CS, 1991, BIOCHIM BIOPHYS ACTA, V1078, P411, DOI 10.1016/0167-4838(91)90164-U; CLIVE DM, 1984, NEW ENGL J MED, V310, P563, DOI 10.1056/NEJM198403013100905; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; KNADLER MP, 1990, CHIRALITY, V2, P67, DOI 10.1002/chir.530020202; KNIGHTS KM, 1988, BIOCHEM PHARMACOL, V37, P3539, DOI 10.1016/0006-2952(88)90382-6; KNIHINICKI RD, 1989, BIOCHEM PHARMACOL, V38, P4389, DOI 10.1016/0006-2952(89)90647-3; KNIHINICKI RD, 1991, BIOCHEM PHARMACOL, V42, P1905, DOI 10.1016/0006-2952(91)90588-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EJD, 1984, J PHARM SCI, V73, P1542, DOI 10.1002/jps.2600731112; MARASCO WA, 1987, ARCH INTERN MED, V147, P2107, DOI 10.1001/archinte.147.12.2107; NAKAMURA Y, 1981, J PHARMACOBIO-DYNAM, V4, pS1; PREBBLE JN, 1981, MITOCHONDRIA CHLOROP, P137; PROUBEK DJ, 1991, BIOCHEM PHARMACOL, V42, pR1; STABLER SP, 1985, ARCH BIOCHEM BIOPHYS, V241, P252, DOI 10.1016/0003-9861(85)90381-9; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; WALSH CT, 1979, ENZYMATIC REACTION M; WATTIAUX R, 1978, J CELL BIOL, V78, P349, DOI 10.1083/jcb.78.2.349; WHELTON A, 1990, ANN INTERN MED, V112, P568, DOI 10.7326/0003-4819-112-8-568; ZIPSER RD, 1986, AM J MED, V81, P95, DOI 10.1016/0002-9343(86)90911-3	26	80	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3487	3493						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8381432				2022-12-25	WOS:A1993KM16100072
J	SHEN, Y; MONSMA, FJ; METCALF, MA; JOSE, PA; HAMBLIN, MW; SIBLEY, DR				SHEN, Y; MONSMA, FJ; METCALF, MA; JOSE, PA; HAMBLIN, MW; SIBLEY, DR			MOLECULAR-CLONING AND EXPRESSION OF A 5-HYDROXYTRYPTAMINE7 SEROTONIN RECEPTOR SUBTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT STOMACH FUNDUS; FUNCTIONAL EXPRESSION; 5-HT1A RECEPTOR; DISTINCT; FAMILY; BRAIN; GENE; SEQUENCE; ORGANIZATION; PATTERNS	We have utilized the polymerase chain reaction technique to selectively amplify a G protein-coupled receptor cDNA from rat kidney proximal convoluted tubule mRNA, which exhibits high homology with previously cloned serotonin receptors. Sequencing of a full-length clone isolated from a rat hippocampal cDNA library revealed an open reading frame of 1,212 base pairs encoding a 404-residue protein with seven hydrophobic regions predicted to represent transmembrane-spanning domains. Within the transmembrane regions, this receptor was found to be 44-50% identical with various members of the 5-HT1, 5-HT5, and 5-HT6 subfamilies with lower (37-40%) homology to the 5-HT2-like receptors. Northern blots revealed a approximately 3.6-kilobase transcript localized in various brain regions with the following rank order of abundance: hypothalamus > hippocampus = mesencephalon > cerebral cortex = olfactory bulb > olfactory tubercle. Expression of this clone in COS-7 cells resulted in the appearance of high affinity, saturable binding of [H-3]lysergic acid diethylamide ([H-3]LSD; K(D)= 5 nM) and [H-3]serotonin ([H-3]5-HT; K(D) = 1 nM). Among endogenous biogenic amines, only 5-HT completely inhibited radioligand binding. The inhibition of radioligand binding by other serotonergic agents revealed a pharmacological profile that does not correlate with any previously described serotonin receptor subtype. In addition, this receptor exhibits high affinity for a number of tricyclic antipsychotic and antidepressant drugs including clozapine, loxapine, and amitriptyline. In HEK-293 cells stably transfected with this receptor, serotonin elicits a potent stimulation of adenylylcyclase activity. The distinct structural and pharmacological properties of this receptor suggests that it represents a completely novel serotonin receptor subtype, which we propose to designate 5-HT7. Based on its pharmacology and its localization to limbic and cortical regions of the brain, it is likely that this receptor may play a role in several neuropsychiatric disorders that involve serotonergic systems.	NINCDS,EXPTL THERAPEUT BRANCH,MOLEC NEUROPHARMACOL SECT,BLDG 10,RM 5C-108,BETHESDA,MD 20892; VET AFFAIRS MED CTR,CTR GERIATR RES EDUC & CLIN,SEATTLE,WA; UNIV WASHINGTON,DEPT PSYCHIAT & BEHAV SCI,SEATTLE,WA 98108; GEORGETOWN UNIV,SCH MED,DEPT PEDIAT,WASHINGTON,DC 20007	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; Georgetown University			Sibley, David/AAC-3591-2019					ADHAM N, 1992, MOL PHARMACOL, V41, P1; ADHAM N, 1993, P NATL ACAD SCI USA, V90, P408, DOI 10.1073/pnas.90.2.408; ALBERT PR, 1990, J BIOL CHEM, V265, P5825; AMLAIKY N, 1992, J BIOL CHEM, V267, P19761; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CULLEN BR, 1987, GUIDE MOL CLONING TE, P684; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DEMCHYSHYN L, 1992, P NATL ACAD SCI USA, V89, P5522, DOI 10.1073/pnas.89.12.5522; FARGIN A, 1988, NATURE, V335, P358, DOI 10.1038/335358a0; FOGUET M, 1992, EMBO J, V11, P3481, DOI 10.1002/j.1460-2075.1992.tb05427.x; FOGUET M, 1992, NEUROREPORT, V3, P345, DOI 10.1097/00001756-199204000-00014; GIROS B, 1991, BIOCHEM BIOPH RES CO, V176, P1584, DOI 10.1016/0006-291X(91)90469-N; HAMBLIN MW, 1992, MOL CELL NEUROSCI, V3, P578, DOI 10.1016/1044-7431(92)90070-I; HAMBLIN MW, 1991, MOL PHARMACOL, V40, P143; HAMBLIN MW, 1992, BIOCHEM BIOPH RES CO, V184, P752, DOI 10.1016/0006-291X(92)90654-4; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; JULIUS D, 1990, P NATL ACAD SCI USA, V87, P928, DOI 10.1073/pnas.87.3.928; KURSAR JD, 1992, MOL PHARMACOL, V42, P549; LEVY FO, 1992, J BIOL CHEM, V267, P7553; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; LORIC S, 1992, FEBS LETT, V312, P203, DOI 10.1016/0014-5793(92)80936-B; LOVENBERG TW, 1993, P NATL ACAD SCI USA, V90, P2184, DOI 10.1073/pnas.90.6.2184; MAHLE CD, 1991, EUR J PHARMACOL, V205, P323, DOI 10.1016/0014-2999(91)90919-H; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; MATTHES H, 1993, MOL PHARMACOL, V43, P313; MCALLISTER G, 1992, P NATL ACAD SCI USA, V89, P5517, DOI 10.1073/pnas.89.12.5517; MONSMA FJ, 1993, MOL PHARMACOL, V43, P320; OMALLEY KL, 1992, NEW BIOL, V4, P137; OMALLEY KL, 1990, BIOCHEMISTRY-US, V29, P1367, DOI 10.1021/bi00458a003; PLASSAT JL, 1992, EMBO J, V11, P4779, DOI 10.1002/j.1460-2075.1992.tb05583.x; PRITCHETT DB, 1988, EMBO J, V7, P4135, DOI 10.1002/j.1460-2075.1988.tb03308.x; SAUDOU F, 1992, EMBO J, V11, P7, DOI 10.1002/j.1460-2075.1992.tb05021.x; STAM NJ, 1992, EUR J PHARM-MOLEC PH, V227, P153, DOI 10.1016/0922-4106(92)90123-D; SUGAMORI KS, 1993, P NATL ACAD SCI USA, V90, P11, DOI 10.1073/pnas.90.1.11; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VOIGT MM, 1991, EMBO J, V10, P4017, DOI 10.1002/j.1460-2075.1991.tb04977.x; WEINSHANK RL, 1992, P NATL ACAD SCI USA, V89, P3630, DOI 10.1073/pnas.89.8.3630; WITZ P, 1990, P NATL ACAD SCI USA, V87, P8940, DOI 10.1073/pnas.87.22.8940	38	484	531	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18200	18204						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8394362				2022-12-25	WOS:A1993LT74300082
J	CHABRY, J; GAUDRIAULT, G; VINCENT, JP; MAZELLA, J				CHABRY, J; GAUDRIAULT, G; VINCENT, JP; MAZELLA, J			IMPLICATION OF VARIOUS FORMS OF NEUROTENSIN RECEPTORS IN THE MECHANISM OF INTERNALIZATION OF NEUROTENSIN IN CEREBRAL NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; RETROGRADE AXONAL-TRANSPORT; RAT PANCREATIC ACINI; MOUSE-BRAIN; MEDIATED ENDOCYTOSIS; INTRACELLULAR CA-2+; CELL-SURFACE; BINDING; INSULIN; PURIFICATION	This report describes the kinetics and molecular aspects of neurotensin internalization in neurons. Incubation of alpha-I-125-Bolton-Hunter neurotensin-(2-13) with cortical neurons at 37-degrees-C was followed by a rapid internalization of the peptide bound to its receptors. This process was completed within 20 min and was inhibited either irreversibly by the general endocytosis inhibitor phenylarsine oxide or reversibly by incubation at low temperature (0-4-degrees-C). The discrepancy of maximal binding capacities observed in the presence (150 fmol/mg of protein) or in the absence (250 fmol/mg of protein) of internalization inhibitors could be attributed to the appearance of a new pool of neurotensin binding sites on the cell surface rather than a recycling of internalized receptors. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis in denaturing conditions revealed that three different protein subunits of 50, 60, and 100 kDa were covalently labeled at 37-degrees-C with a radioactive photoreactive analogue of neurotensin. The 50- and 60-kDa subunits remained labeled when internalization was blocked, whereas the specific labeling of the 100-kDa protein was abolished. These results suggest that neurotensin-induced internalization of the 50- and 60-kDa subunits initially present on the cell surface triggers insertion of the 100-kDa subunit into the membrane from an intracellular compartment. Subcellular fractionation experiments have shown that, in the absence of neurotensin, the 100-kDa protein is located in an intracellular vesicular fraction of neurons.	UNIV NICE SOPHIA ANTIPOLIS,CNRS,INST PHARMACOL MOLEC & CELLULAIRE,660 ROUTE LUCIOLES,F-06560 VALBONNE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			Chabry, Joelle/O-2101-2016; Mazella, Jean/A-6767-2012					BACKER JM, 1990, J BIOL CHEM, V265, P14828; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BURGEVIN MC, 1992, NEUROSCIENCE, V49, P627, DOI 10.1016/0306-4522(92)90232-Q; CASTEL MN, 1990, NEUROSCIENCE, V36, P425, DOI 10.1016/0306-4522(90)90438-A; DRAZNIN B, 1984, BIOCHEM J, V218, P307, DOI 10.1042/bj2180307; GAUDRIAULT G, 1992, PEPTIDES, V13, P1187, DOI 10.1016/0196-9781(92)90027-Z; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; JOHNSON EM, 1987, J NEUROSCI, V7, P923; KITABGI P, 1985, Reviews in Clinical and Basic Pharmacology, V5, P397; KNUTSON VP, 1983, J BIOL CHEM, V258, P2139; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOGSDON CD, 1984, BIOCHEM J, V223, P893, DOI 10.1042/bj2230893; LOW DA, 1981, P NATL ACAD SCI-BIOL, V78, P2340, DOI 10.1073/pnas.78.4.2340; MAZELLA J, 1988, J BIOL CHEM, V263, P144; MAZELLA J, 1989, J BIOL CHEM, V264, P5559; MAZELLA J, 1991, BRAIN RES, V564, P249, DOI 10.1016/0006-8993(91)91460-I; MAZELLA J, 1993, METHODS NEUROSCIENCE, V11, P334; MILLS A, 1988, J BIOL CHEM, V263, P13; MOSSNER J, 1984, J BIOL CHEM, V259, P2350; RATHINAVELU A, 1991, BIOCHEM J, V276, P493, DOI 10.1042/bj2760493; SADOUL JL, 1984, BIOCHEM BIOPH RES CO, V120, P812, DOI 10.1016/S0006-291X(84)80179-5; SATO M, 1991, DEV BRAIN RES, V58, P97, DOI 10.1016/0165-3806(91)90241-A; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; SORKIN A, 1991, J BIOL CHEM, V266, P23453; TANAKA K, 1990, NEURON, V4, P847, DOI 10.1016/0896-6273(90)90137-5; THOENEN H, 1971, P NATL ACAD SCI USA, V68, P1589; TURNER JT, 1990, J PHARMACOL EXP THER, V253, P1049; VANISBERG MA, 1991, BIOCHEM PHARMACOL, V42, P2265, DOI 10.1016/0006-2952(91)90229-X; WALLACE RA, 1972, J EXP ZOOL, V191, P303; WEISS S, 1988, J NEUROCHEM, V50, P1425, DOI 10.1111/j.1471-4159.1988.tb03026.x; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WILLIAMS JA, 1988, AM J PHYSIOL, V254, pG513, DOI 10.1152/ajpgi.1988.254.4.G513; ZHU WY, 1991, AM J PHYSIOL, V261, pG57, DOI 10.1152/ajpgi.1991.261.1.G57	34	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17138	17144						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8394329				2022-12-25	WOS:A1993LQ98800041
J	THIGPEN, AE; CALA, KM; RUSSELL, DW				THIGPEN, AE; CALA, KM; RUSSELL, DW			CHARACTERIZATION OF CHINESE-HAMSTER OVARY CELL-LINES EXPRESSING HUMAN STEROID 5-ALPHA-REDUCTASE ISOZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BENIGN PROSTATIC HYPERPLASIA; HUMAN-FIBROBLASTS; GOLGI-APPARATUS; FINASTERIDE; PROTEIN; TISSUE; INHIBITORS; DEFICIENCY; REDUCTASE; MEMBRANE	Membrane-bound isozymes of steroid 5alpha-reductase, designated 1 and 2, synthesize the potent androgen, dihydrotestosterone. Isozyme 1 has an alkaline pH optimum (7.0-8.5), whereas isozyme 2 has an acidic pH optimum (5.0). To gain insight into this enigmatic difference, Chinese hamster ovarian cell lines expressing the human 5alpha-reductase isozymes were established. The half-lives of both proteins are >30 h and are not altered by the 4-azasteroid inhibitors finasteride and 17beta-(N, N,-diethyl)carbamoyl-4-methyl-4-aza-5alpha-androstan-3-one. Nanomolar concentrations of finasteride block immunoprecipitation of isozyme 2 by antipeptide antibodies, which suggests that drug binding alters protein conformation. In contrast, finasteride (50 muM) has no effect on immunoprecipitation of isozyme 1. Both isozymes are localized to the endoplasmic reticulum by immunocytochemistry and have their carboxyl termini exposed to the cytoplasm. In cell lysates, isozyme 2 exhibits a V(max) at pH 5.0 but has a higher substrate affinity at neutral pH. In intact and permeabilized cells, isozyme 2 has an apparent substrate K(m) similar to that determined in cell lysates at neutral pH. The results suggest that isozyme 2 is more efficient at neutral pH and that the acidic pH optimum determined in lysates is a consequence of cell lysis.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,5323 HARRY HINES BLVD,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Russell, David/0000-0002-0277-403X	NICHD NIH HHS [HD-07504] Funding Source: Medline; NIGMS NIH HHS [GM-43753] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043753] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; ANDERSSON S, 1990, P NATL ACAD SCI USA, V87, P3640, DOI 10.1073/pnas.87.10.3640; ANDERSSON S, 1989, J BIOL CHEM, V264, P16249; ANDERSSON S, 1991, NATURE, V354, P159, DOI 10.1038/354159a0; ANDERSSON S, 1989, J BIOL CHEM, V264, P8229; [Anonymous], METABOLIC BASIS INHE; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAVAZOS LF, 1975, HDB PHYSL          7, V5, P353; FAWCETT DW, 1981, CELL, P195; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GORMLEY GJ, 1992, NEW ENGL J MED, V327, P1185, DOI 10.1056/NEJM199210223271701; HARRIS G, 1992, P NATL ACAD SCI USA, V89, P10787, DOI 10.1073/pnas.89.22.10787; HIRSCH KS, 1993, P NATL ACAD SCI USA, V90, P5277, DOI 10.1073/pnas.90.11.5277; HUDSON RW, 1981, J STEROID BIOCHEM, V14, P579, DOI 10.1016/0022-4731(81)90034-0; JENKINS EP, 1992, J CLIN INVEST, V89, P293, DOI 10.1172/JCI115574; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; MCCONNELL JD, 1992, J CLIN ENDOCR METAB, V74, P505, DOI 10.1210/jc.74.3.505; METCALF BW, 1989, TRENDS PHARMACOL SCI, V10, P491, DOI 10.1016/0165-6147(89)90048-5; MOORE RJ, 1976, J BIOL CHEM, V251, P5895; MOORE RJ, 1972, J BIOL CHEM, V247, P958; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; NORMINGTON K, 1992, J BIOL CHEM, V267, P19548; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; TENOVER JS, 1991, ENDOCRIN METAB CLIN, V20, P893, DOI 10.1016/S0889-8529(18)30249-4; THIGPEN AE, 1992, NEW ENGL J MED, V327, P1216, DOI 10.1056/NEJM199210223271706; THIGPEN AE, 1992, J CLIN INVEST, V90, P799, DOI 10.1172/JCI115954; THIGPEN AE, 1992, J BIOL CHEM, V267, P8577; WILSON JD, 1975, HDB PHYSL 7, V5, P491; WILSON JD, 1993, IN PRESS ENDOCRINE R	31	143	144	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17404	17412						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8394341				2022-12-25	WOS:A1993LQ98800077
J	FATHI, Z; BENYA, RV; SHAPIRA, H; JENSEN, RT; BATTEY, JF				FATHI, Z; BENYA, RV; SHAPIRA, H; JENSEN, RT; BATTEY, JF			THE 5TH TRANSMEMBRANE SEGMENT OF THE NEUROMEDIN-B RECEPTOR IS CRITICAL FOR HIGH-AFFINITY NEUROMEDIN-B BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOMBESIN RECEPTOR; LIGAND-BINDING; EXTRACELLULAR DOMAIN; CELLS; IDENTIFICATION; ACTIVATION; CLONING	The two bombesin receptor subtypes, neuromedin B (NMB-R) and gastrin releasing peptide (GRP-R) receptors, bind their respective ligands with high affinity. To identify molecular components mediating high affinity NMB binding, four mutant receptors were constructed, in which different parts of the NMB-R were replaced with the corresponding regions of the GRP-R. When stably expressed in Balb 3T3 fibroblasts, all four NMB-R/GRP-R chimeras were functional and showed NMB-induced stimulation of inositol phosphate (IP) formation. Results of I-125-[D-Tyr0]NMB displacement assays using unlabeled NMB for competition indicated that high affinity NMB binding was determined by amino acid sequences in transmembrane domain V (TM-V) of the NMB-R. To identify which amino acid(s) in TM-V of NMB-R contributed to high affinity NMB binding, four additional NMB-R mutants were constructed where non-conserved amino acids in TM-V of NMB-R were replaced by the corresponding GRP-R amino acids. Three of the mutations, TyrPheLeu220-222 --> PheTyrVal, Ile230 --> Val, and His234 --> Phe, did not affect high affinity NMB binding. The Ile216 --> Ser substitution, however, abolished high affinity NMB binding and severely impaired the ability of the mutant receptor to stimulate NMB-dependent inositol phosphate formation. These results suggest that Ile216 in TM-V of NMB-R may be critical for high affinity NMB binding.	NCI,DIV CANC TREATMENT,BIOL CHEM LAB,DEV THERAPEUT PROGRAM,BLDG 37,RM 5D02,BETHESDA,MD 20892; NIDDKD,DIGEST DIS BRANCH,BETHESDA,MD 20892; NINCDS,NEUROCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)								BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BENYA RV, 1992, MOL PHARMACOL, V42, P1058; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; CHARLIEU JP, 1991, BIOTECHNIQUES, V10, P136; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; DAVIS LG, 1986, BASIC METHODS MOL BI, P1; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FONG TM, 1992, J BIOL CHEM, V267, P25664; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KRIS RM, 1987, J BIOL CHEM, V262, P11215; MARULLO S, 1990, EMBO J, V9, P1471, DOI 10.1002/j.1460-2075.1990.tb08264.x; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; POLLOCK NJ, 1992, J BIOL CHEM, V267, P17780; SHAPIRA H, 1993, IN PRESS METHODS NEU; STRADER CD, 1989, J BIOL CHEM, V264, P13572; WADA E, 1991, NEURON, V6, P421, DOI 10.1016/0896-6273(91)90250-4; WADSWORTH HL, 1990, SCIENCE, V249, P1423, DOI 10.1126/science.2169649; WANG CD, 1991, MOL PHARMACOL, V40, P168; WESS J, 1992, J BIOL CHEM, V267, P19313; XIE YB, 1990, J BIOL CHEM, V265, P21411; YOKOTA Y, 1992, EMBO J, V11, P3585, DOI 10.1002/j.1460-2075.1992.tb05442.x	24	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14622	14626						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8392057				2022-12-25	WOS:A1993LL75900017
J	FUJIHARA, M; MUROI, M; MUROI, Y; ITO, N; SUZUKI, T				FUJIHARA, M; MUROI, M; MUROI, Y; ITO, N; SUZUKI, T			MECHANISM OF LIPOPOLYSACCHARIDE-TRIGGERED JUNB ACTIVATION IN A MOUSE MACROPHAGE-LIKE CELL-LINE (J774)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-GENE-EXPRESSION; DEPENDENT PROTEIN-KINASE; IMMEDIATE EARLY RESPONSE; MYELOID-LEUKEMIA CELLS; NF-KAPPA-B; C-JUN; FOS PROTEINS; PHOSPHORYLATION; DIFFERENTIATION; TRANSCRIPTION	The effect of lipopolysaccharide (LPS) on the activation of junB in a mouse macrophage cell line (J774) was investigated. J774 cells responded to either phorbol 12-myristate 13-acetate (PMA) or LPS by the transient increase in the expression levels of c-jun and junB mRNA, but not of junD mRNA. The prior depletion of protein kinase C from J774 cells blocked the action of PMA, but not of LPS, to activate junB. Pretreatment of cells with H-89 or H-7, but not with HA1004, W-7, ML-7, or tyrphostin 47, inhibited LPS-triggered junB activation. Treatment with forskolin also activated junB of J774 cells through an H-89- or H-7-sensitive pathway. Since cAMP-dependent protein kinase activity of J774 cells was inhibited by H-89, but not by H-7, LPS appears to activate junB through a cascade involving two steps, the one sensitive to H-89 and the other to H-7. Western blot analysis showed that LPS-triggered junB activation is accompanied by the increased expression of JunB proteins in the cell lysate as well as in the nuclear extract. JunB in nuclear fraction appears to specifically bind to 12-O-tetradecanoylphorbol-13-acetate-response element (TRE), since preincubation of nuclear extracts with anti-JunB serum reduced the amount of TRE-binding proteins and since the amount of JunB, but not of c-Jun or JunD, immunoprecipitated from TRE-cross-linked nuclear proteins increased in response to LPS. Thus, JunB may play an important role in LPS-triggered gene activation.	UNIV KANSAS, MED CTR, DEPT MICROBIOL MOLEC GENET & IMMUNOL, KANSAS CITY, KS 66160 USA	University of Kansas; University of Kansas Medical Center					NATIONAL CANCER INSTITUTE [R55CA055274, R01CA035977] Funding Source: NIH RePORTER; NCI NIH HHS [R55 CA55274, R01 CA35977, P01 CA544744] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI K, 1992, J CLIN INVEST, V89, P1657, DOI 10.1172/JCI115763; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHILES TC, 1992, J IMMUNOL, V149, P825; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORBIN JD, 1983, METHOD ENZYMOL, V99, P227; DATTA R, 1990, MOL PHARMACOL, V38, P435; DEGROOT RP, 1991, EMBO J, V10, P2523, DOI 10.1002/j.1460-2075.1991.tb07792.x; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DENHERTOG J, 1992, NUCLEIC ACIDS RES, V20, P125, DOI 10.1093/nar/20.1.125; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; KAWAKAMI Z, 1992, NUCLEIC ACIDS RES, V20, P914, DOI 10.1093/nar/20.4.914; KHALILI K, 1984, J MOL BIOL, V175, P453, DOI 10.1016/0022-2836(84)90179-7; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUROI M, 1993, IN PRESS CELL SIGNAL; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NAKAMURA T, 1991, CELL GROWTH DIFFER, V2, P267; NOVOTNEY M, 1991, BIOCHEMISTRY-US, V30, P5597, DOI 10.1021/bi00236a037; OHTSUKI M, 1992, MOL CELL BIOL, V12, P261, DOI 10.1128/MCB.12.1.261; ONODERA S, 1991, CHEM PHARM BULL, V39, P991; RALPH P, 1975, J IMMUNOL, V114, P898; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; TANNENBAUM CS, 1988, J IMMUNOL, V140, P3640; TANNENBAUM CS, 1989, J IMMUNOL, V142, P1274; TILZEY JF, 1991, BIOCHEM BIOPH RES CO, V175, P77, DOI 10.1016/S0006-291X(05)81202-1; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; VIARD I, 1992, ENDOCRINOLOGY, V130, P1193, DOI 10.1210/en.130.3.1193; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; YEH CK, 1991, BIOCHIM BIOPHYS ACTA, V1090, P173, DOI 10.1016/0167-4781(91)90098-7; YU SF, 1990, J LEUKOCYTE BIOL, V48, P412, DOI 10.1002/jlb.48.5.412	44	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14898	14905						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8392062				2022-12-25	WOS:A1993LL75900057
J	HENDRIX, P; MAYERJAEKEL, RE; CRON, P; GORIS, J; HOFSTEENGE, J; MERLEVEDE, W; HEMMINGS, BA				HENDRIX, P; MAYERJAEKEL, RE; CRON, P; GORIS, J; HOFSTEENGE, J; MERLEVEDE, W; HEMMINGS, BA			STRUCTURE AND EXPRESSION OF A 72-KDA REGULATORY SUBUNIT OF PROTEIN PHOSPHATASE-2A - EVIDENCE FOR DIFFERENT SIZE FORMS PRODUCED BY ALTERNATIVE SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; MEDIUM TUMOR-ANTIGEN; AMINO-ACID SEQUENCE; SMALL-T-ANTIGEN; CELLULAR-REGULATION; MOLECULAR-CLONING; 2 ISOZYMES; IDENTIFICATION; PURIFICATION; KINASE	The trimeric form of protein phosphatase 2A consisting of 36-, 65-, and 72-kDa subunits (previously termed polycation-stimulated protein phosphatase M) was purified from rabbit skeletal muscle. Amino acid sequence data of the 72-kDa regulatory subunit (termed PR72) were used to isolate cDNAs from human heart and fetal brain libraries and libraries derived from WI-38 and MCF-7 cells. The clones isolated from the heart cDNA library revealed an open reading frame encoding a protein with a predicted molecular mass of 62 kDa. All the peptides sequenced from the protein matched with the sequence predicted from the cDNA. However, in vitro transcription and translation from this cDNA yielded a protein with an apparent molecular mass of 72 kDa on sodium dodecyl sulfate-polyacrylamide gels. From brain we isolated cDNA clones spanning an open reading frame encoding a 130-kDa protein (termed PR130). The apparent molecular mass of the protein produced by in vitro transcription and translation was 130 kDa. This protein has exactly the same deduced C-terminal protein sequence as the PR72 subunit from amino acids 45 to 527 but has an N-terminal extension of 665 amino acids. It is likely, therefore, that these two proteins arise from the same gene by alternative splicing. In human tissues several transcripts were detected by Northern analysis generated probably by the use of different polyadenylation signals and alternative splicing. High levels of the PR72 mRNAs were detected in heart and muscle, while lower levels of PR130 transcripts were found in heart, brain, placenta, lung, muscle, and kidney.	CATHOLIC UNIV LEUVEN, FAC GENEESKUNDE, AFDELING BIOCHEM, HEREST 49, B-3000 LOUVAIN, BELGIUM; FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND	KU Leuven; Friedrich Miescher Institute for Biomedical Research								AGOSTINIS P, 1992, EUR J BIOCHEM, V205, P241, DOI 10.1111/j.1432-1033.1992.tb16774.x; ALEXANDER D, 1989, EUR J BIOCHEM, V181, P55, DOI 10.1111/j.1432-1033.1989.tb14693.x; AOKI K, 1986, FEBS LETT, V205, P313, DOI 10.1016/0014-5793(86)80919-X; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; CAYLA X, 1990, BIOCHEMISTRY-US, V29, P658, DOI 10.1021/bi00455a010; CHEN SC, 1989, J BIOL CHEM, V264, P7267; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; EMORI Y, 1986, J BIOL CHEM, V261, P9465; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GORIS J, 1988, BIOCHEM J, V256, P1029, DOI 10.1042/bj2561029; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P7330; IMAOKA T, 1983, J BIOL CHEM, V258, P1526; JAKES S, 1986, BIOCHIM BIOPHYS ACTA, V888, P135, DOI 10.1016/0167-4889(86)90079-0; JESSUS C, 1989, BIOCHEM J, V260, P45, DOI 10.1042/bj2600045; KEMP BE, 1975, P NATL ACAD SCI USA, V72, P3448, DOI 10.1073/pnas.72.9.3448; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KHEWGOODALL Y, 1988, FEBS LETT, V238, P265, DOI 10.1016/0014-5793(88)80493-9; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LOEB JE, 1989, EUR J BIOCHEM, V182, P195, DOI 10.1111/j.1432-1033.1989.tb14817.x; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MAYER RE, 1991, ADV PROTEIN PHOSPHAT, V6, P265; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; MCLEOD M, 1987, EMBO J, V6, P729, DOI 10.1002/j.1460-2075.1987.tb04814.x; MUMBY MC, 1991, CELL REGUL, V2, P589, DOI 10.1091/mbc.2.8.589; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SHENOLIKAR S, 1991, ADV 2ND MESSENGER PH, V23, P1; SNEDDON AA, 1991, ADV PROTEIN PHOSPHAT, V6, P307; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; TUNG HYL, 1985, EUR J BIOCHEM, V148, P253, DOI 10.1111/j.1432-1033.1985.tb08833.x; USUI H, 1988, J BIOL CHEM, V263, P3752; USUI H, 1991, ADV PROTEIN PHOSPHAT, V6, P287; VANZYL W, 1992, MOL CELL BIOL, V12, P4946, DOI 10.1128/MCB.12.11.4946; VANZYL WH, 1989, GENETICS, V123, P55; WAELKENS E, 1987, J BIOL CHEM, V262, P1049; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; YANG SD, 1980, J BIOL CHEM, V255, P1759; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988	51	140	144	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15267	15276						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8392071				2022-12-25	WOS:A1993LL75900104
J	ROSSI, RC; NORBY, JG				ROSSI, RC; NORBY, JG			KINETICS OF K+-STIMULATED DEPHOSPHORYLATION AND SIMULTANEOUS K+ OCCLUSION BY NA,K-ATPASE, STUDIED WITH THE K+ CONGENER TL+ - THE POSSIBILITY OF DIFFERENCES BETWEEN THE 1ST TURNOVER AND STEADY-STATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; RAPID-MIXING TECHNIQUE; CONFORMATIONAL-CHANGES; ATP HYDROLYSIS; ADENOSINE-TRIPHOSPHATASE; CHARGE TRANSLOCATION; ACTIVE-TRANSPORT; OCCLUDED STATE; RATE-CONSTANT; SODIUM-PUMP	Using the K+ congener Tl+ and rapid mixing combined with special quench techniques, we have investigated (at 20-degrees-C) what is usually assumed to be the enzymatic correlate of active transport of K+ by Na,K-ATPase: the Tl+-catalyzed dephosphorylation of the K+-sensitive phosphointermediate(s), EP, and the resulting occlusion of Tl+ in the enzyme protein. We measured [EP] and [occluded TI] as a function of time in phosphorylation, as well as dephosphorylation experiments with the following results. First, we found that with 150 mM Na+ and 600 mM Na+ - NO3- was the anion - [Tl+] = 0.1-1 mM was without influence on the phosphorylation rate. Tl+-catalyzed dephosphorylation and Tl+ occlusion appeared to be simultaneous, and the stoichiometry was always 2 Tl+ occluded/EP dephosphorylated. Second, we tried computer simulations of the transient kinetic experiments, using an Albers-Post-type reaction scheme. This produced satisfactory curve-fits only in the case of 150 mM Na+, and although we could arrange that calculated [EP]steady-state was equal to that measured, the calculated steady-state Na,Tl-ATPase hydrolysis rates were always two to four times the rates measured directly. Third, we propose, as one (possibly of several) solution to these discrepancies between model and data, an expanded kinetic model consisting of an initiation reaction sequence followed by a propagation (or steady-state) reaction cycle. In this alternative model the first turnover of the enzyme is kinetically different from subsequent reaction cycles, and this allowed us to obtain both satisfactory curve-fits and accordance between calculated and measured values of hydrolysis-rate and [EP]steady-state.	AARHUS UNIV, INST BIOPHYS, OLE WORMS ALLE 185, DK-8000 AARHUS, DENMARK; UNIV BUENOS AIRES, INST QUIM & FIS QUIM BIOL, RA-1113 BUENOS AIRES, ARGENTINA	Aarhus University; University of Buenos Aires								BEAUGE L, 1990, REGULATION POTASSIUM, P29; BEAUGE LA, 1979, NATURE, V280, P510, DOI 10.1038/280510a0; CAMPOS M, 1992, BIOCHIM BIOPHYS ACTA, V1105, P51, DOI 10.1016/0005-2736(92)90161-E; ESMANN M, 1992, BIOCHIM BIOPHYS ACTA, V1110, P20, DOI 10.1016/0005-2736(92)90289-X; ESMANN M, 1985, BIOCHIM BIOPHYS ACTA, V815, P196, DOI 10.1016/0005-2736(85)90289-5; FALLER LD, 1991, BIOCHEMISTRY-US, V30, P3503, DOI 10.1021/bi00228a022; FORBUSH B, 1987, J BIOL CHEM, V262, P11116; FORBUSH B, 1987, J GEN PHYSIOL, V90, pA17; FORBUSH B, 1987, J BIOL CHEM, V262, P11104; FORBUSH B, 1988, J BIOL CHEM, V263, P7979; FORBUSH B, 1991, SOC GEN PHY, V46, P211; FORBUSH B, 1985, SODIUM PUMP, P599; Forbush B., 1988, NA PLUS K PLUS PUM A, P229; FROEHLICH JP, 1983, CURR TOP MEMBR TRANS, V19, P513; FROEHLICH JP, 1991, SOC GEN PHY, V46, P227; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GLYNN IM, 1976, J PHYSIOL-LONDON, V256, P465, DOI 10.1113/jphysiol.1976.sp011333; GLYNN IM, 1987, J PHYSIOL-LONDON, V383, P477; GLYNN IM, 1982, J PHYSIOL-LONDON, V330, P17, DOI 10.1113/jphysiol.1982.sp014326; GLYNN IM, 1988, NA PLUS K PLUS PUM A, P435; GLYNN IM, 1985, SODIUM PUMP, P589; Gutfreund H., 1972, ENZYMES PHYSICAL PRI; Hobbs A. S., 1985, SODIUM PUMP, P355; HOBBS AS, 1980, J BIOL CHEM, V255, P3395; JENSEN J, 1989, BIOCHIM BIOPHYS ACTA, V985, P248, DOI 10.1016/0005-2736(89)90409-4; JENSEN J, 1984, J PHYSIOL-LONDON, V346, P219, DOI 10.1113/jphysiol.1984.sp015018; JENSEN J, 1983, BIOCHIM BIOPHYS ACTA, V731, P282, DOI 10.1016/0005-2736(83)90020-2; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KARLISH SJD, 1978, BIOCHIM BIOPHYS ACTA, V527, P115, DOI 10.1016/0005-2744(78)90261-9; KLODOS I, 1981, BIOCHIM BIOPHYS ACTA, V643, P463, DOI 10.1016/0005-2736(81)90089-4; KLODOS I, 1987, BIOCHIM BIOPHYS ACTA, V897, P302, DOI 10.1016/0005-2736(87)90426-3; LINDBERG O, 1956, METHODS BIOCHEMICAL, V3, P1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARDH S, 1975, BIOCHIM BIOPHYS ACTA, V391, P448, DOI 10.1016/0005-2744(75)90269-7; MARDH S, 1977, J BIOL CHEM, V252, P633; MARDH S, 1977, J BIOL CHEM, V252, P8058; MARDH S, 1974, BIOCHIM BIOPHYS ACTA, V350, P473, DOI 10.1016/0005-2744(74)90523-3; NORBY JG, 1983, J GEN PHYSIOL, V82, P725, DOI 10.1085/jgp.82.6.725; NORBY JG, 1988, METHOD ENZYMOL, V156, P191; NORBY JG, 1989, J BIOL CHEM, V264, P19548; NORBY JG, 1974, ANN NY ACAD SCI, V242, P158, DOI 10.1111/j.1749-6632.1974.tb19088.x; NORBY JG, 1988, NA PLUS K PLUS PUM A, P249; PELUFFO RD, 1992, J BIOL CHEM, V267, P6596; PLESNER IW, 1981, BIOCHIM BIOPHYS ACTA, V648, P231, DOI 10.1016/0005-2736(81)90039-0; PLESNER L, 1985, BIOCHIM BIOPHYS ACTA, V818, P222, DOI 10.1016/0005-2736(85)90563-2; POST RL, 1991, SOC GEN PHY, V46, P201; POST RL, 1972, J BIOL CHEM, V247, P6530; ROSSI RC, 1991, SODIUM PUMP RECENT D, P419; STEINBERG M, 1989, J BIOL CHEM, V264, P2726; STURMER W, 1991, J MEMBRANE BIOL, V121, P163, DOI 10.1007/BF01870530; STURMER W, 1989, J MEMBRANE BIOL, V110, P67, DOI 10.1007/BF01870994; SZEDLACSEK SE, 1991, BIOCHEM J, V279, P855, DOI 10.1042/bj2790855; TANFORD C, 1983, P NATL ACAD SCI-BIOL, V80, P3701, DOI 10.1073/pnas.80.12.3701	53	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12579	12590						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8389760				2022-12-25	WOS:A1993LG65800054
J	NAKANISHI, O; SHIBASAKI, F; HIDAKA, M; HOMMA, Y; TAKENAWA, T				NAKANISHI, O; SHIBASAKI, F; HIDAKA, M; HOMMA, Y; TAKENAWA, T			PHOSPHOLIPASE C-GAMMA-1 ASSOCIATES WITH VIRAL AND CELLULAR SRC KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-GAMMA; SIGNAL TRANSDUCTION; PROTEIN-KINASE; GROWTH-FACTOR; POLYPHOSPHOINOSITIDES; PURIFICATION; FIBROBLASTS; INHIBITOR; SEQUENCE; INVITRO	A tyrosine kinase inhibitor, genistein, caused the subcellular translocation of phosphoinositide-specific phospholipase C (PLC) activity from membrane fractions to cytosolic fractions in rat 3Y1 fibroblasts and their transformants by Rous sarcoma virus, SR-3Y1. The ratio of PLC activities associated with the membrane fractions to those of the homogenate fractions was greater in SR-3Y1 (32.6%) than in 3Y1 (20.8%) whereas membrane-associated PLC activities were strikingly reduced to the same levels in both cells by treatment with genistein. Moreover, it was found by immunoblotting analyses of membrane fractions that the amounts of PLC-gamma1 isozyme were reduced to 20.4% of initial level in SR-3Y1 and to 30.2% of that in 3Y1 cells. While the levels of PLC-delta, another detectable PLC isozyme, were not altered by genistein suggesting that tyrosine kinase plays an important role in the association of PLC-gamma1 with membranes. PLC-gamma1 molecules were detected in anti-p60src antibody immunoprecipitates of both 3Y1 and SR-3Y1 cells. The amounts of PLC-gamma1 co-immunoprecipitating with src kinases were higher in SR-3Y1 than 3Y1 cells and were reduced in both cell types by treatment with genistein. In addition, it was confirmed that PLC-gamma1 purified from rat liver was phosphorylated at a tyrosine residue and associated with viral src kinase and that src kinases associated with the recombinant SH2 region of PLC-gamma1, expressed in Escherichia coli, depending upon phosphorylation of tyrosine residues. These findings suggest that both viral and cellular src kinases associate with PLC-gamma1 and may mediate cellular signaling in normal and transformant cell growth.	TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT BIOSIGNAL RES,ITABASHI KU,TOKYO 173,JAPAN; MITSUI PHARMACEUT INC,INST BIOL SCI,MOBARA,CHIBA 297,JAPAN									AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; EMORI Y, 1989, J BIOL CHEM, V264, P21885; FUKAMI K, 1988, P NATL ACAD SCI USA, V85, P9057, DOI 10.1073/pnas.85.23.9057; FUKAMI K, 1989, J BIOL CHEM, V264, P14985; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HIDAKA M, 1991, BIOCHEM BIOPH RES CO, V180, P1490, DOI 10.1016/S0006-291X(05)81364-6; HOMMA Y, 1990, BIOCHEM J, V269, P13, DOI 10.1042/bj2690013; KAWAI S, 1980, J VIROL, V34, P772, DOI 10.1128/JVI.34.3.772-776.1980; KIM JW, 1990, J BIOL CHEM, V265, P3940; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MCBRIDE K, 1991, P NATL ACAD SCI USA, V88, P7111, DOI 10.1073/pnas.88.16.7111; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; NAKANISHI O, 1988, BIOCHEM J, V256, P453, DOI 10.1042/bj2560453; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OGAWARA H, 1986, J ANTIBIOT, V39, P606, DOI 10.7164/antibiotics.39.606; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SCHACHT J, 1978, J LIPID RES, V19, P1063; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	25	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10754	10759						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8388373				2022-12-25	WOS:A1993LD46600010
J	MOCHIZUKI, H; ITO, T; HIDAKA, H				MOCHIZUKI, H; ITO, T; HIDAKA, H			PURIFICATION AND CHARACTERIZATION OF CA2+ CALMODULIN-DEPENDENT PROTEIN KINASE-V FROM RAT CEREBRUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MR 100,000 SUBSTRATE; MOLECULAR-CLONING; BRAIN; IDENTIFICATION; SUBUNIT; CDNA; PHOSPHORYLATION; EXPRESSION; CELLS; GAMMA	A novel Ca2+/calmodulin-dependent protein kinase (CaM kinase V) from rat cerebrum was purified. This kinase phosphorylates the synthetic peptide substrate syntide-2. The purified enzyme showed a single protein band with a molecular mass of 41 kDa on SDS-polyacrylamide gel electrophoresis. The Stokes radius and the sedimentation coefficient were 31.8 angstrom and 2.83 S, respectively. An approximate molecular mass of 37 kDa was calculated for the native enzyme, and a monomeric structure of the enzyme was suggested. Expression of the enzymatic activity required the presence of both Ca2+ and calmodulin (apparent K(a) = 24 +/- 7 nm). The CaM kinase V had an apparent K(m) for ATP of 75 +/- 11 muM and for syntide-2 of 20 +/- 4 muM. CaM kinase V undergoes autophosphorylation in response to Ca2+ and calmodulin. CaM kinase V was digested with lysyl endopeptidase, and the partial amino acid sequence was determined. A computer homology search revealed no identical protein. KN-62, a selective inhibitor of Ca2+/calmodulin-dependent protein kinase II, inhibited CaM kinase V, with a K(i) of 0.8 muM. CaM kinase V phosphorylates a number of endogenous proteins.	NAGOYA UNIV, SCH MED, DEPT PHARMACOL, TSURUMAI 65, SHOWA KU, NAGOYA, AICHI 466, JAPAN	Nagoya University								BEG ZH, 1987, J BIOL CHEM, V262, P13228; BENNETT MK, 1983, J BIOL CHEM, V258, P2735; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BULLEIT RF, 1988, NEURON, V1, P63, DOI 10.1016/0896-6273(88)90210-3; CHAMBERLAIN JS, 1987, P NATL ACAD SCI USA, V84, P2886, DOI 10.1073/pnas.84.9.2886; COHEN P, 1988, MOL ASPECTS CELLULAR, V5, P145; DEREMER MF, 1992, J BIOL CHEM, V267, P13460; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ENDO T, 1981, J BIOL CHEM, V256, P2485; GOLDENRING JR, 1983, J BIOL CHEM, V258, P2632; GUERRIERO V, 1986, BIOCHEMISTRY-US, V25, P8372, DOI 10.1021/bi00374a007; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; KENNEDY MB, 1987, CALCIUM CELL FUNCTIO, V7, P62; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MIYANO O, 1992, J BIOL CHEM, V267, P1198; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAIRN AC, 1985, P NATL ACAD SCI USA, V82, P7939, DOI 10.1073/pnas.82.23.7939; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; NYGARD O, 1991, J BIOL CHEM, V266, P16425; OHMSTEDE CA, 1991, P NATL ACAD SCI USA, V88, P5784, DOI 10.1073/pnas.88.13.5784; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; Pickett-Gies CA., 1986, ENZYMES, V17, P395; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SCHULMAN H, 1988, ADV SEC MESS PHOSPH, V22, P39; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STULL JT, 1988, MOL ASPECTS CELLULAR, V5, P91; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; TOBIMATSU T, 1988, J BIOL CHEM, V263, P16082; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; YAMAUCHI T, 1983, EUR J BIOCHEM, V132, P15, DOI 10.1111/j.1432-1033.1983.tb07319.x	36	90	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9143	9147						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8386178				2022-12-25	WOS:A1993KX81100108
J	UHLINGER, DJ; TYAGI, SR; INGE, KL; LAMBETH, JD				UHLINGER, DJ; TYAGI, SR; INGE, KL; LAMBETH, JD			THE RESPIRATORY BURST OXIDASE OF HUMAN NEUTROPHILS - GUANINE-NUCLEOTIDES AND ARACHIDONATE REGULATE THE ASSEMBLY OF A MULTICOMPONENT COMPLEX IN A SEMIRECOMBINANT CELL-FREE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; ADENINE-DINUCLEOTIDE PHOSPHATE; NADPH OXIDASE; CYTOCHROME-B; SUPEROXIDE GENERATION; PLASMA-MEMBRANE; KREV-1 PROTEIN; ACTIVATION; CLONING; PHOSPHORYLATION	We recently characterized a ''semirecombinant'' cell-free NADPH-oxidase system, comprised of plasma membrane plus the recombinant cytosolic proteins p47-phox and p67-phox, wherein superoxide generation was activated by an anionic amphiphile plus guanosine 5'-O-(2-thiotriphosphate) (GTPgammaS) (Uhlinger, D. J., Inge, K. L., Kreck, M. L., Tyagi, S. R., Neckelmann, N., and Lambeth, J. D. (1992) Biochem. Biophys. Res. Commun. 186, 509-516). Based on preincubation with guanine nucleotides, we show that plasma membrane contains G protein(s) that support oxidase activation at submaximal rates. By varying p47-phox and p67-phox concentrations, kinetic parameters (EC50 and V(max)) for each were determined. For both, GTPgammaS increased the V(max) and decreased the EC50, whereas guanosine 5'-O-(2-thiodiphosphate) (GDPbetaS) produced the opposite effect, consistent with the participation of a G protein in an activation complex containing p47-phox and p67-phox. Using [S-35]methionine-labeled p47-phox and p67-phox, we investigated the association of these components with both normal plasma membranes and chronic granulomatous disease membranes lacking cytochrome b558. p47-phox translocation was stimulated by arachidonate but not GTPgammaS, was about 50% cytochrome-dependent, and occurred independently of p67-phox. Arachidonate-stimulated translocation of p67-phox required both cytochrome and p47-phox and was enhanced by GTPgammaS. The mass of p47-phox and p67-phox which assembled with cytochrome b558 indicated a ternary complex with a 1:1:1 stoichiometry.	EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University					NCI NIH HHS [CA 46508] Funding Source: Medline; NIAID NIH HHS [AI 22809] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022809] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BOURNE HR, 1992, NATURE, V358, P541, DOI 10.1038/358541a0; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BRUNGER AT, 1990, P NATL ACAD SCI USA, V87, P4849, DOI 10.1073/pnas.87.12.4849; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CROSS AR, 1982, BIOCHEM J, V204, P479, DOI 10.1042/bj2040479; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DUGGLEBY RG, 1981, ANAL BIOCHEM, V110, P9, DOI 10.1016/0003-2697(81)90104-4; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; ERICKSON RW, 1992, J CLIN INVEST, V89, P1587, DOI 10.1172/JCI115753; GABIG TG, 1987, J BIOL CHEM, V262, P1685; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; GRUNSTEIN M, 1987, CURRENT PROTOCOLS MO; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; KLEINBERG ME, 1990, J BIOL CHEM, V265, P15577; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBETH JD, 1988, J BIOL CHEM, V263, P3818; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LETO TL, 1991, J BIOL CHEM, V266, P19812; LIGETI E, 1989, BIOCHEMISTRY-US, V28, P7116, DOI 10.1021/bi00443a050; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; LOMAX KJ, 1989, SCIENCE, V246, P987, DOI 10.1126/science.2587992; LU DJ, 1990, J BIOL CHEM, V265, P13721; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MIURA Y, 1992, FEBS LETT, V297, P171, DOI 10.1016/0014-5793(92)80353-I; NAKANISHI A, 1992, J BIOL CHEM, V267, P19072; OHNO Y, 1986, BLOOD, V67, P1132; PARK JW, 1992, J BIOL CHEM, V267, P19901; PARK JW, 1992, J BIOL CHEM, V267, P17327; PARKINSON JF, 1988, J BIOENERG BIOMEMBR, V20, P653, DOI 10.1007/BF00762547; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PEMBER SO, 1983, ARCH BIOCHEM BIOPHYS, V221, P391, DOI 10.1016/0003-9861(83)90158-3; PEVERI P, 1992, P NATL ACAD SCI USA, V89, P2494, DOI 10.1073/pnas.89.6.2494; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; QUINN MT, 1992, J BIOL CHEM, V267, P7303; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; Sambrook J, 1989, MOL CLONING LABORATO; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SEIFERT R, 1987, BIOCHEM BIOPH RES CO, V146, P1296, DOI 10.1016/0006-291X(87)90790-X; SMITH RM, 1991, BLOOD, V77, P673; TYAGI SR, 1992, BIOCHEMISTRY-US, V31, P2765, DOI 10.1021/bi00125a017; UHLINGER DJ, 1991, J BIOL CHEM, V266, P20990; UHLINGER DJ, 1992, BIOCHEM BIOPH RES CO, V186, P509, DOI 10.1016/S0006-291X(05)80837-X; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195	50	71	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8624	8631						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8386165				2022-12-25	WOS:A1993KX81100039
J	PARK, J; OSEI, YD; CHURCHICH, JE				PARK, J; OSEI, YD; CHURCHICH, JE			ISOLATION AND CHARACTERIZATION OF RECOMBINANT MITOCHONDRIAL 4-AMINOBUTYRATE AMINOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI; BINDING; PROTEIN	4-Aminobutyrate aminotransferase, which catalyzes the conversion of 4-aminobutyrate to succinic semialdehyde, is a key enzyme of the 4-aminobutyrate shunt. The amino acid sequence predicted from the cDNA sequence shows that the precursor protein consists of the mature enzyme of 473 amino acid residues and an amino-terminal segment of 27 amino acids (Kwon, O. S., Park, J., and Churchich, J. E. (1992) J. Biol. Chem. 267, 7215-7216). A recombinant 4-aminobutyrate aminotransferase has been expressed in Escherichia coli using pETIId as expression vector. The protein has been purified and characterized as a dimer (2 x 55 kDa). NH2-terminal sequence analysis has revealed the presence of an extra amino-terminal segment (signal peptide) predicted from the cDNA sequence. The isolated precursor of 4-aminobutyrate aminotransferase contains pyridoxal 5-phosphate and exhibits catalytic activity (18 units/mg) comparable to that of the mature enzyme (20 units/mg). The presequence peptide of the precursor of mitochondrial 4-aminobutyrate aminotransferase does not interfere with the folding and functional properties of the mature moiety of the aminotransferase.			PARK, J (corresponding author), UNIV TENNESSEE,DEPT BIOCHEM,KNOXVILLE,TN 37996, USA.				NCRR NIH HHS [RR-07088] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALTIERI F, 1989, J BIOL CHEM, V264, P4782; BARTSCH K, 1990, J BACTERIOL, V172, P7035, DOI 10.1128/jb.172.12.7035-7042.1990; BEELER T, 1978, EUR J BIOCHEM, V85, P365, DOI 10.1111/j.1432-1033.1978.tb12248.x; BOHNI P, 1980, ORG EXPRESSION MITOC, P423; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRITTNER M, 1980, ANAL BIOCHEM, V102, P459; CHOI SY, 1986, EUR J BIOCHEM, V161, P289, DOI 10.1111/j.1432-1033.1986.tb10445.x; CHURCHICH JE, 1981, J BIOL CHEM, V256, P1101; FLETCHER A, 1980, BIOCHEM PHARMACOL, V29, P1451, DOI 10.1016/0006-2952(80)90592-4; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; KWOK F, 1979, J BIOL CHEM, V254, P1488; KWON OS, 1992, J BIOL CHEM, V267, P7215; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE AL, 1982, J BIOL CHEM, V257, P4903; LIPPERT B, 1977, EUR J BIOCHEM, V74, P441, DOI 10.1111/j.1432-1033.1977.tb11410.x	15	20	30	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7636	7639						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8385114				2022-12-25	WOS:A1993KW97900010
J	BUXEDA, RJ; NICKELS, JT; CARMAN, GM				BUXEDA, RJ; NICKELS, JT; CARMAN, GM			REGULATION OF THE 45-KDA AND 55-KDA FORMS OF PHOSPHATIDYLINOSITOL 4-KINASE FROM THE YEAST SACCHAROMYCES-CEREVISIAE BY NUCLEOTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CONTAINING SPHINGOLIPIDS; INOSITOL STARVATION; CELL-PROLIFERATION; KINETIC-ANALYSIS; MIXED MICELLES; BIOSYNTHESIS; MEMBRANE; SYNTHASE; DIPHOSPHOINOSITIDE	The synthesis of phosphatidylinositol (PI) 4-phosphate and PI 4,5-bisphosphate in the yeast Saccharomyces cerevisiae is stimulated by glucose. PI 4-kinase (ATP:phosphatidylinositol 4-phosphotransferase, EC 2.7.1.67) catalyzes the committed step in the synthesis of these phosphoinositides. Previous studies have suggested that the glucose effect on phosphoinositide synthesis is mediated by cellular levels of ATP and ADP and by the RAS/cAMP pathway. Using purified preparations of the membrane-associated 45- and 55-kDa forms of PI 4-kinase, we examined the regulation of these activities by nucleotides and cAMP-dependent protein kinase. MgADP was a potent inhibitor of both forms of the enzyme. Detailed kinetic analyses of the 45- and 55-kDa enzymes using Triton X- 100/PI-mixed micelles showed that MgADP was a competitive inhibitor (K(i) = 0.14 and 0.25 mM, respectively) with respect to MgATP and a noncompetitive inhibitor (K(i) = 1.3 and 0.9 mM, respectively) with respect to PI. The K(i) values for MgADP were about 2-fold lower than the K(m) values the enzymes have for their substrate MgATP and about 2-fold lower than the cellular concentration of ADP. The 45- and 55-kDa forms of PI 4-kinase activity were regulated differentially by CTP, an important nucleotide involved in phospholipid biosynthesis. Whereas the 55-kDa PI 4-kinase was inhibited by CTP, the 45-kDa enzyme was unaffected by CTP. CTP was a mixed type of inhibitor (K(i) = 1.5 mM) with respect to MgATP and a noncompetitive inhibitor (K(i) = 4 mM) with respect to PI. The K(i) value for CTP was 4-fold higher than the K(m) value for MgATP and 7-fold higher than the cellular concentration of CTP. The 45- and 55-kDa PI 4-kinases were neither phosphorylated nor regulated by cAMP-dependent protein kinase. These results did not support the previous conclusion that PI 4-phosphate synthesis was mediated by the RAS/cAMP pathway. Our kinetic studies supported the conclusion that the glucose effect on the synthesis of PI 4-phosphate was mediated by cellular levels of ATP and ADP through the regulation of membrane-associated PI 4-kinase activity.	RUTGERS STATE UNIV,COOK COLL,NEW JERSEY AGR EXPT STN,DEPT FOOD SCI,NEW BRUNSWICK,NJ 08903	Rutgers State University New Brunswick					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035655] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35655] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1989, J BIOL CHEM, V264, P20181; BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; BELUNIS CJ, 1988, J BIOL CHEM, V263, P18897; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BUXEDA RJ, 1991, J BIOL CHEM, V266, P13859; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; COLODZIN M, 1965, J BIOL CHEM, V240, P3771; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; FLANAGAN CA, 1992, J BIOL CHEM, V267, P24117; FRASCOTTI G, 1990, FEBS LETT, V274, P19, DOI 10.1016/0014-5793(90)81319-J; HANSON BA, 1982, J BACTERIOL, V151, P334, DOI 10.1128/JB.151.1.334-342.1982; HANSON BA, 1984, J BACTERIOL, V159, P837, DOI 10.1128/JB.159.3.837-842.1984; HENRY SA, 1977, J BACTERIOL, V130, P472, DOI 10.1128/JB.130.1.472-484.1977; HOLLAND KM, 1988, J BACTERIOL, V170, P828, DOI 10.1128/jb.170.2.828-833.1988; KAIBUCHI K, 1986, P NATL ACAD SCI USA, V83, P8172, DOI 10.1073/pnas.83.21.8172; KATO H, 1989, J BIOL CHEM, V264, P3116; KELLEY MJ, 1987, J BIOL CHEM, V262, P14563; Kennedy E. P., 1986, LIPIDS MEMBRANES PRE, P171; KINNEY AJ, 1988, P NATL ACAD SCI USA, V85, P7962, DOI 10.1073/pnas.85.21.7962; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESTER RL, 1968, J BIOL CHEM, V243, P4889; LOPEZ G, 1992, J NEUROCHEM, V59, P338; MCKENZIE MA, 1982, J FOOD BIOCHEM, V6, P77, DOI 10.1111/j.1745-4514.1982.tb00297.x; MICHELL RH, 1992, TRENDS BIOCHEM SCI, V17, P274, DOI 10.1016/0968-0004(92)90433-A; NICKELS JT, 1992, J BIOL CHEM, V267, P16297; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; OZIERKALOGEROPOULOS O, 1991, MOL GEN GENET, V231, P7, DOI 10.1007/BF00293815; PATTON JL, 1991, J BACTERIOL, V173, P3101, DOI 10.1128/JB.173.10.3101-3108.1991; PATTON JL, 1992, ARCH BIOCHEM BIOPHYS, V292, P70, DOI 10.1016/0003-9861(92)90052-X; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; QUINLAN JJ, 1992, J BIOL CHEM, V267, P18013; Segel IH., 1975, ENZYME KINETICS, P1, DOI 10.1016/0014-5793(75)80457-1; STEINER S, 1972, J BACTERIOL, V109, P81, DOI 10.1128/JB.109.1.81-88.1972; TALWALKAR RT, 1973, BIOCHIM BIOPHYS ACTA, V306, P412, DOI 10.1016/0005-2760(73)90180-X; TALWALKAR RT, 1974, BIOCHIM BIOPHYS ACTA, V360, P306, DOI 10.1016/0005-2760(74)90060-5; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; UNO I, 1988, NATURE, V333, P188, DOI 10.1038/333188a0; VANCE DE, 1980, J BIOL CHEM, V255, P1064	42	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6248	6255						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8384205				2022-12-25	WOS:A1993KT36800029
J	JURUTKA, PW; HSIEH, JC; MACDONALD, PN; TERPENING, CM; HAUSSLER, CA; HAUSSLER, MR; WHITFIELD, GK				JURUTKA, PW; HSIEH, JC; MACDONALD, PN; TERPENING, CM; HAUSSLER, CA; HAUSSLER, MR; WHITFIELD, GK			PHOSPHORYLATION OF SERINE-208 IN THE HUMAN VITAMIN-D RECEPTOR - THE PREDOMINANT AMINO-ACID PHOSPHORYLATED BY CASEIN KINASE-II, INVITRO, AND IDENTIFICATION AS A SIGNIFICANT PHOSPHORYLATION SITE IN INTACT-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; DEPENDENT RNA-POLYMERASE; PROTEIN-KINASE; 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR; THREONINE KINASES; MYC ONCOPROTEINS; T-ANTIGEN; ACTIVATION; EXPRESSION; BINDING	The human 1,25-dihydroxyvitamin D3 receptor (hVDR), like other members of the steroid/thyroid receptor superfamily, has been observed to undergo rapid phosphorylation. We report here that the hVDR is a substrate for casein kinase II (CK-II ), a regulatory enzyme of significance in the function of nuclear proteins. Intact hVDRs produced by in vitro transcription/translation or in a baculovirus overexpression system served as efficient substrates for purified bovine CK-11, and the magnitude of this phosphorylation was not affected by the addition of 1,25-dihydroxyvitamin D3. CK-II-catalyzed phosphorylation of truncated hVDRs suggested that phosphorylated residues may occur between Arg121 and Asp232, including the region of hVDR which we have previously demonstrated to contain a major site(s) of phosphorylation in intact cells (Jones, B. B., Jurutka, P. W., Haussler, C. A., Haussler, M. R., and Whitfield, G. K. (199 1) Mol. Endocrinol. 5, 1137-1146). Site-directed mutagenesis of serine/threonine residues in this region now reveals a site of phosphorylation at Ser208 contained within the sequence -S208(P)EEDSDD-, a classic CK-II consensus recognition site. Mutation of this serine to a glycine drastically reduces phosphorylation of hVDR by CK-II, in vitro. The Ser208 mutant receptor also shows a dramatic decrease in [P-32]orthophosphate incorporation when transfected into COS-7 cells. We therefore propose that phosphorylation of hVDR at Ser208 in target cells is mediated by casein kinase II or a similar enzyme, and that this quantitatively significant post-translational modification is a potential mechanism for the modulation of the activity of hVDR in controlling gene transcription.	UNIV ARIZONA, COLL MED, DEPT BIOCHEM, TUCSON, AZ 85724 USA	University of Arizona				Jurutka, Peter/0000-0002-4950-9161; Haussler, Mark/0000-0002-7097-1801; Haussler, Carol/0000-0001-8360-3066	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR015781, R37AR015781] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040372, R37DK033351, R01DK033351] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-15781] Funding Source: Medline; NIDDK NIH HHS [DK-33351, DK-40372] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BROWN TA, 1990, J BIOL CHEM, V265, P10025; BURMESTER JK, 1988, P NATL ACAD SCI USA, V85, P9499, DOI 10.1073/pnas.85.24.9499; DAHMUS ME, 1981, J BIOL CHEM, V256, P3332; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DURBAN E, 1985, EMBO J, V4, P2921, DOI 10.1002/j.1460-2075.1985.tb04024.x; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GLINEUR C, 1989, ONCOGENE, V4, P1247; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HALL FL, 1991, J BIOL CHEM, V266, P17430; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HAUSSLER MR, 1988, RECENT PROG HORM RES, V44, P263; HAUSSLER MR, 1988, VITAMIN D MOL CELLUL, P205; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; JONES BB, 1991, MOL ENDOCRINOL, V5, P1137, DOI 10.1210/mend-5-8-1137; JURUTKA PW, 1992, J BONE MINER RES, V7, pS108; KINGSTON RE, 1990, CURRENT PROTOCOLS MO; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MACDONALD PN, 1991, J BIOL CHEM, V266, P18808; MANGELSDORF DJ, 1987, BIOCHEMISTRY-US, V26, P8332, DOI 10.1021/bi00399a046; MANGELSDORF DJ, 1987, P NATL ACAD SCI USA, V84, P354, DOI 10.1073/pnas.84.2.354; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MCDONNELL DP, 1989, MOL ENDOCRINOL, V3, P635, DOI 10.1210/mend-3-4-635; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; PIKE JW, 1984, J BIOL CHEM, V259, P1167; PIKE JW, 1983, J BIOL CHEM, V258, P1289; PIKE JW, 1985, BIOCHEM BIOPH RES CO, V131, P378, DOI 10.1016/0006-291X(85)91813-3; PIKE JW, 1979, P NATL ACAD SCI USA, V76, P5485, DOI 10.1073/pnas.76.11.5485; PIKE JW, 1988, VITAMIN D MOL CELLUL, P215; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; STETLER DA, 1982, BIOCHEMISTRY-US, V21, P3721, DOI 10.1021/bi00258a030; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; TERPENING CM, 1990, BIOCHEM BIOPH RES CO, V173, P1129, DOI 10.1016/S0006-291X(05)80903-9	55	88	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6791	6799						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8384219				2022-12-25	WOS:A1993KT36800102
J	PELLERIN, S; LAFEUILLADE, B; SCHERRER, N; GAGNON, J; SHI, DL; CHAMBAZ, EM; FEIGE, JJ				PELLERIN, S; LAFEUILLADE, B; SCHERRER, N; GAGNON, J; SHI, DL; CHAMBAZ, EM; FEIGE, JJ			CORTICOTROPIN-INDUCED SECRETED PROTEIN, AN ACTH-INDUCED PROTEIN SECRETED BY ADRENOCORTICAL-CELLS, IS STRUCTURALLY RELATED TO THROMBOSPONDINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-BETA; ENDOTHELIAL-CELLS; PLATELET THROMBOSPONDIN; ADHESIVE GLYCOPROTEIN; ADRENAL-CORTEX; 1ST INTRON; BINDING; GENE; BOVINE; STEROIDOGENESIS	The treatment of primary cultures of bovine adrenocortical cells with nanomolar concentrations of ACTH induces a 10-fold increase in the synthesis of a secreted protein of apparent molecular mass 195 kDa on reducing SDS-polyacrylamide gels. This corticotropin-induced secreted protein (CISP) appears to be an oligomeric calcium-binding protein. Its secretion under serum-free culture conditions is sustained over 4 days in the continuous presence of ACTH. Induction of CISP secretion by ACTH is mimicked by cAMP analogs and adenylate cyclase activators. We report here the purification of CISP to apparent homogeneity with an overall yield of 43% using a combination of heparin-agarose and Mono-Q chromatographies. The NH2-terminal amino acid sequence and the sequence of several tryptic peptides revealed that CISP is structurally related to the members of the thrombospondin (TSP) family. Among these members, bovine CISP appeared to be more homologous to mouse TSP2 (85% identity in the 29 amino acid long NH2-terminal sequence) than to TSP1 (18% identity in the same region). We also observed that CISP binds Ca2+ and is an adhesive protein for bovine adrenocortical cells. Thus, CISP possesses both structural and functional properties of thrombospondins. Whether CISP represents the bovine form of TSP2 or a novel member of the expanding thrombospondin family will need to be elucidated by cloning and sequencing of a larger portion of the molecule.	CEN, DEPT BIOL MOLEC & STRUCT, INSERM, U244, F-38041 GRENOBLE, FRANCE; INST BIOL STRUCT, F-38027 GRENOBLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)			Gagnon, Jean/C-3136-2008; Feige, Jean-Jacques/M-8905-2017	Gagnon, Jean/0000-0002-0177-824X; Feige, Jean-Jacques/0000-0002-1354-7692				BACONBAGULEY T, 1990, J BIOL CHEM, V265, P2317; BAENZIGER NL, 1972, J BIOL CHEM, V247, P2723; BORNSTEIN P, 1990, J BIOL CHEM, V265, P16691; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BORNSTEIN P, 1991, P NATL ACAD SCI USA, V88, P8636, DOI 10.1073/pnas.88.19.8636; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Chiquet-Ehrismann R, 1991, CURR OPIN CELL BIOL, V3, P800, DOI 10.1016/0955-0674(91)90053-2; COCHET C, 1988, J BIOL CHEM, V263, P5707; DAZORD A, 1983, ANN ENDOCRINOL-PARIS, V44, P15; DIXIT VM, 1986, P NATL ACAD SCI USA, V83, P5449, DOI 10.1073/pnas.83.15.5449; DONOVIEL DB, 1988, J BIOL CHEM, V263, P18590; DUPERRAY A, 1980, J STEROID BIOCHEM, V13, P1359, DOI 10.1016/0022-4731(80)90098-9; FEIGE JJ, 1982, MOL CELL ENDOCRINOL, V28, P645, DOI 10.1016/0303-7207(82)90152-6; FEIGE JJ, 1991, ENDOCR RES, V17, P267, DOI 10.1080/07435809109027201; FRAZIER WA, 1987, J CELL BIOL, V105, P625, DOI 10.1083/jcb.105.2.625; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JAFFE EA, 1985, BLOOD, V65, P79; JAFFE EA, 1983, P NATL ACAD SCI-BIOL, V80, P998, DOI 10.1073/pnas.80.4.998; JIANG ZW, 1992, J CELL PHYSIOL, V153, P266, DOI 10.1002/jcp.1041530206; KOBAYASHI S, 1986, BIOCHEMISTRY-US, V25, P8418, DOI 10.1021/bi00374a014; KRUEGER RJ, 1983, J BIOL CHEM, V258, P159; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHERTY CD, 1989, J BIOL CHEM, V264, P11222; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LAWLER J, 1991, J BIOL CHEM, V266, P8039; LAWLER J, 1986, BLOOD, V67, P1197; LAWLER JW, 1978, J BIOL CHEM, V253, P8609; MAJACK RA, 1986, P NATL ACAD SCI USA, V83, P9050, DOI 10.1073/pnas.83.23.9050; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MCPHERSON J, 1981, J BIOL CHEM, V256, P1330; MOSHER DF, 1982, J CELL BIOL, V93, P343, DOI 10.1083/jcb.93.2.343; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; PHAN SH, 1989, BIOCHEM BIOPH RES CO, V163, P56, DOI 10.1016/0006-291X(89)92098-6; PON LA, 1986, J BIOL CHEM, V261, P6594; RAINEY WE, 1983, ENDOCRINOLOGY, V113, P48, DOI 10.1210/endo-113-1-48; RAUGI GJ, 1982, J CELL BIOL, V95, P351, DOI 10.1083/jcb.95.1.351; ROBERTS AB, 1988, RECENT PROG HORM RES, V44, P157; ROBERTS DD, 1987, J CELL BIOL, V104, P131, DOI 10.1083/jcb.104.1.131; SAEZ JM, 1981, ADV CYCL NUCL RES<D>, V14, P563; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SANTORO SA, 1987, SEMIN THROMB HEMOST, V13, P290, DOI 10.1055/s-2007-1003504; SANTORO SA, 1987, METHOD ENZYMOL, V144, P438; Schimmer B P, 1980, Adv Cyclic Nucleotide Res, V13, P181; SHI DL, 1990, J BIOL CHEM, V265, P2881; SILVERSTEIN RL, 1986, ARTERIOSCLEROSIS, V6, P245, DOI 10.1161/01.ATV.6.3.245; SIMONIAN MH, 1981, ENDOCRINOLOGY, V108, P1769, DOI 10.1210/endo-108-5-1769; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; SLAVINSKITURLEY EA, 1978, ENDOCRINOLOGY, V78, P427; TUSZYNSKI GP, 1987, SEMIN THROMB HEMOST, V13, P361, DOI 10.1055/s-2007-1003512; TUSZYNSKI GP, 1987, SCIENCE, V236, P1570, DOI 10.1126/science.2438772; VARANI J, 1988, J CLIN INVEST, V81, P1537, DOI 10.1172/JCI113486; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YAMADA KM, 1991, J BIOL CHEM, V266, P12809	60	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4304	4310						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8382699				2022-12-25	WOS:A1993KN53300072
J	CHANG, CP; LAZAR, CS; WALSH, BJ; KOMURO, M; COLLAWN, JF; KUHN, LA; TAINER, JA; TROWBRIDGE, IS; FARQUHAR, MG; ROSENFELD, MG; WILEY, HS; GILL, GN				CHANG, CP; LAZAR, CS; WALSH, BJ; KOMURO, M; COLLAWN, JF; KUHN, LA; TAINER, JA; TROWBRIDGE, IS; FARQUHAR, MG; ROSENFELD, MG; WILEY, HS; GILL, GN			LIGAND-INDUCED INTERNALIZATION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR IS MEDIATED BY MULTIPLE ENDOCYTIC CODES ANALOGOUS TO THE TYROSINE MOTIF FOUND IN CONSTITUTIVELY INTERNALIZED RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; EGF-RECEPTOR; TRANSFERRIN RECEPTOR; CYTOPLASMIC DOMAIN; KINASE-ACTIVITY; AUTOPHOSPHORYLATION SITES; INSULIN-RECEPTOR; JUXTAMEMBRANE REGION; SELF-PHOSPHORYLATION; CARBOXYL TERMINUS	Ligand-induced internalization of epidermal growth factor (EGF) receptors via a high affinity saturable pathway requires sequences located in the carboxyl terminus distal to the tyrosine kinase domain. Three regions were found to contain endocytic motifs as defined by their ability to restore internalization function to EGF receptors truncated at the distal border of the kinase domain at residue 958. Deletional analysis identified the sequence 996QQGFF as essential for function of the region encompassing residues 993-1022. QQGFF and the deduced sequence of the region encompassing residues 973-991 (973FYRAL) could effectively replace the endogenous endocytic code of the transferrin receptor (YTRF). FYRAL and YTRF were less active than QQGFF when substituted into region 993-1022 of the EGF receptor, but a synthetic sequence (NNAYF), predicted to have structural features of a tight turn, effectively replaced QQGFF for EGF receptor internalization. Whereas EGF receptor sequences functioned effectively in the transferrin receptor, function of these sequences in the EGF receptor was strictly dependent on intrinsic tyrosine kinase activity as demonstrated kinetically and by immunofluorescence using semithin cryosections. Ligand-dependent endocytosis and down-regulation of the EGF receptor thus require multiple sequence motifs that are exchangeable between ligand-dependent and -independent receptors, but that require intrinsic tyrosine kinase activity for function in the context of the EGF receptor.	UNIV CALIF SAN DIEGO, DIV CELLULAR & MOLEC MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; SALK INST BIOL STUDIES, DEPT CANC BIOL, SAN DIEGO, CA 92186 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; UNIV UTAH, SCH MED, DEPT PATHOL, SALT LAKE CITY, UT 84132 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; Salk Institute; Scripps Research Institute; Utah System of Higher Education; University of Utah	CHANG, CP (corresponding author), UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA.		Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429; Wiley, Steven/0000-0003-0232-6867	NCI NIH HHS [CA34789] Funding Source: Medline; NIDDK NIH HHS [DK39949] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039949, R37DK039949] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON RGW, 1977, CELL, V10, P351, DOI 10.1016/0092-8674(77)90022-8; BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; CARPENTIER JL, 1992, P NATL ACAD SCI USA, V89, P162, DOI 10.1073/pnas.89.1.162; CHANG CP, 1991, J BIOL CHEM, V266, P23467; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DECKER SJ, 1992, J BIOL CHEM, V267, P1104; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; FENDLY BM, 1990, CANCER RES, V50, P1550; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HALEY J, 1987, ONCOGENE RES, V1, P375; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HELIN K, 1991, J BIOL CHEM, V266, P8363; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HSUAN JJ, 1989, BIOCHEM J, V262, P659, DOI 10.1042/bj2620659; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JADOT M, 1992, J BIOL CHEM, V267, P11069; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEWIS V, 1985, J CELL BIOL, V100, P1839, DOI 10.1083/jcb.100.6.1839; LUND KA, 1990, J BIOL CHEM, V265, P15713; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; OKAMOTO CT, 1992, J BIOL CHEM, V267, P9925; OPRESKO LK, 1987, J BIOL CHEM, V262, P4116; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SORKIN A, 1992, J BIOL CHEM, V267, P8672; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THIES RS, 1990, J BIOL CHEM, V265, P10132; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WILEY HS, 1984, P NATL ACAD SCI-BIOL, V81, P7456, DOI 10.1073/pnas.81.23.7456; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	51	139	143	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19312	19320						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8396132				2022-12-25	WOS:A1993LW81900027
J	WINITZ, S; RUSSELL, M; QIAN, NX; GARDNER, A; DWYER, L; JOHNSON, GL				WINITZ, S; RUSSELL, M; QIAN, NX; GARDNER, A; DWYER, L; JOHNSON, GL			INVOLVEMENT OF RAS AND RAF IN THE G(I)-COUPLED ACETYLCHOLINE MUSCARINIC M2 RECEPTOR ACTIVATION OF MITOGEN-ACTIVATED PROTEIN (MAP) KINASE KINASE AND MAP KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING PROTEIN; SIGNALING PATHWAYS; C-MYC; GROWTH; CELLS; PHOSPHORYLATION; FIBROBLASTS; SUBUNITS; G0	Stimulation of the acetylcholine muscarinic m2 receptor (m2R) expressed in Rat 1a fibroblasts results in the activation of the cytoplasmic mitogen-activated protein kinase (MAPK). Concomitant with carbachol stimulation of the m2R was the activation of MEK (MAPK kinase) and Raf. MEK is the dual function kinase that phosphorylates and activates MAPK. Raf is a serine/threonine kinase capable of phosphorylating and activating MEK. Carbachol stimulation of the m2R also activated Ras. Pertussis toxin treatment of Rat 1a cells inhibited the m2R-mediated activation of Ras, Raf, MEK and MAPK. In contrast, epidermal growth factor receptor-mediated activation of Ras, Raf, MEK and MAPK was pertussis toxin-insensitive. m2R activation of Ras, Paf, and MAPK was insensitive to inhibition by genistein, while the epidermal growth factor receptor-induced responses were inhibited by genistein. The findings demonstrate that both Pas and Raf can be regulated by seven-membrane-spanning receptors that selectively couple to G(i) proteins.	NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,GOODMAN BLDG,RM 1007,1400 JACKSON ST,DENVER,CO 80206; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262; UNIV COLORADO,SCH MED,SCH PHARM,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Gardner, Anne/0000-0001-7095-772X	NIDDK NIH HHS [DK 37871] Funding Source: Medline; NIGMS NIH HHS [GM 30324] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030324, R37GM030324] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BARNSEL M, 1992, MOL BIOL CELL, V3, P1317; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOK SJ, 1993, IN PRESS EMBO J; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HOMBURGER V, 1987, MOL PHARMACOL, V31, P313; HUNG DT, 1992, J BIOL CHEM, V267, P20831; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; PARKER EM, 1991, J BIOL CHEM, V266, P519; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SETH A, 1991, J BIOL CHEM, V266, P23521; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WOOD KW, 1992, CELL, V68, P1040; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0	34	235	237	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19196	19199						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8396128				2022-12-25	WOS:A1993LW81900010
J	COOK, RM; BURKE, BJ; BUCHHAGEN, DL; MINNA, JD; MILLER, YE				COOK, RM; BURKE, BJ; BUCHHAGEN, DL; MINNA, JD; MILLER, YE			HUMAN AMINOACYLASE-1 - CLONING, SEQUENCE, AND EXPRESSION ANALYSIS OF A CHROMOSOME-3P21 GENE INACTIVATED IN SMALL-CELL LUNG-CANCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYLPEPTIDE HYDROLASE; KIDNEY AMINOACYLASE; DNF15S2 LOCUS; PIG-KIDNEY; 3P21; HETEROZYGOSITY; PURIFICATION; SIMILARITY; DEFICIENCY; CARCINOMA	Human aminoacylase-1 (N-acyl-L-amino-acid amidohydrolase, EC 3.5.1.14; ACY1) is a homodimeric zinc-binding enzyme that catalyzes the hydrolysis of N(alpha)-acylated amino acids. ACY1 has been assigned to chromosome 3p21.1, a region reduced to homozygosity in small cell lung cancer (SCLC), and has been reported to exhibit reduced or absent expression in SCLC cell lines and tumors. Two human cDNA libraries and one human genomic DNA library were screened with a previously isolated partial ACY1 cDNA to isolate a full-length transcript. Sequence analysis of clones from each of these libraries resulted in an ACY1 cDNA of 1438 base pairs with an open reading frame of 1224-base pairs coding for a putative protein of 408 amino acids with a predicted molecular mass of 45,882 Da. Sequence analysis revealed no homologies to previously reported cDNA or protein sequences and establishes ACY1 as the first member of a new family of zinc-binding enzymes to be so characterized. The subcellular location of ACY1 has been established as cytosolic by flow cytometry. Southern and northern analyses of ACY1 in SCLC cell lines failed to demonstrate any gross abnormalities of the ACY1 structural gene or instances of absent or aberrantly sized mRNA, respectively.	UNIV COLORADO,HLTH SCI CTR,DIV PULM SCI & CRIT CARE MED,DENVER,CO 80262; USN HOSP,NCI,NAVY MED ONCOL BRANCH,BETHESDA,MD 20889; UNIV TEXAS,SW MED CTR,SIMMONS COMPREHENS CANC CTR,DALLAS,TX 75235; UNIFORMED SERV UNIV HLTH SCI,DEPT MED,BETHESDA,MD 20814	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Uniformed Services University of the Health Sciences - USA	COOK, RM (corresponding author), VET ADM MED CTR,111A,DENVER,CO 80220, USA.				NCI NIH HHS [P50 CA58187] Funding Source: Medline; NHLBI NIH HHS [HL-07085, R01 HL45745] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058187] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007085, R01HL045745] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIES R, 1984, CLIN RES, V32, pA29; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; CARRITT B, 1992, CANCER RES, V52, P1536; CHO HY, 1987, AGR BIOL CHEM TOKYO, V51, P2793; CSAIKL F, 1986, HEREDITY, V56, P157, DOI 10.1038/hdy.1986.26; GADE W, 1981, BIOCHIM BIOPHYS ACTA, V662, P86, DOI 10.1016/0005-2744(81)90227-8; GEMMILL RM, 1991, GENOMICS, V11, P93, DOI 10.1016/0888-7543(91)90105-N; GINZINGER DG, 1992, AM J HUM GENET, V50, P826; GREENHOUGH KJ, 1991, BIOCHIM BIOPHYS ACTA, V1076, P364, DOI 10.1016/0167-4838(91)90477-H; HARBOUR JW, 1990, ANTICANCER RES, V10, P23; HEESE D, 1988, BIOL CHEM H-S, V369, P559, DOI 10.1515/bchm3.1988.369.2.559; HEESE D, 1990, EUR J BIOCHEM, V188, P175, DOI 10.1111/j.1432-1033.1990.tb15385.x; JAKOB M, 1992, BIOL CHEM H-S, V373, P1227, DOI 10.1515/bchm3.1992.373.2.1227; JONES WM, 1991, P NATL ACAD SCI USA, V88, P2194, DOI 10.1073/pnas.88.6.2194; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; KORDEL W, 1976, BIOCHIM BIOPHYS ACTA, V445, P446, DOI 10.1016/0005-2744(76)90098-X; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LOFFLER HG, 1987, BIOL CHEM H-S, V368, P481, DOI 10.1515/bchm3.1987.368.1.481; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MATALON R, 1988, AM J MED GENET, V29, P463, DOI 10.1002/ajmg.1320290234; MILLER YE, 1989, J CLIN INVEST, V83, P2120, DOI 10.1172/JCI114125; MILLER YE, 1989, J IMMUNOASSAY, V10, P129, DOI 10.1080/01971528908053232; MILLER YE, 1990, GENOMICS, V8, P19; MITTA M, 1992, J BIOCHEM-TOKYO, V112, P737, DOI 10.1093/oxfordjournals.jbchem.a123968; MOOIBROEK H, 1987, CANCER GENET CYTOGEN, V27, P361, DOI 10.1016/0165-4608(87)90020-3; NAYLOR SL, 1979, SOMAT CELL GENET, V5, P11, DOI 10.1007/BF01538782; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NAYLOR SL, 1989, GENOMICS, V4, P355, DOI 10.1016/0888-7543(89)90342-X; NAYLOR SL, 1982, AM J HUM GENET, V34, P235; SCALONI A, 1992, J BIOL CHEM, V267, P3811; SCALONI A, 1992, J LAB CLIN MED, V120, P546; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2	33	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17010	17017						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8394326				2022-12-25	WOS:A1993LQ98800022
J	CORBETT, AH; HONG, D; OSHEROFF, N				CORBETT, AH; HONG, D; OSHEROFF, N			EXPLOITING MECHANISTIC DIFFERENCES BETWEEN DRUG CLASSES TO DEFINE FUNCTIONAL-DRUG INTERACTION DOMAINS ON TOPOISOMERASE-II - EVIDENCE THAT SEVERAL DIVERSE DNA CLEAVAGE-ENHANCING AGENTS SHARE A COMMON SITE OF ACTION ON THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DROSOPHILA-MELANOGASTER; ANTINEOPLASTIC DRUGS; RESISTANT FORM; GYRB GENE; CELL-LINE; GYRASE; RELIGATION; INHIBITION; PURIFICATION	To fully understand the mechanism of action of topoisomerase II-targeted agents, the effects of these drugs on the catalytic cycle of the enzyme must be well characterized. The present study utilized a nonturnover DNA catenation assay to determine the effects of several drugs (etoposide, genistein, CP-115,953, amsacrine, and novobiocin) on the DNA strand passage event mediated by topoisomerase II. With the exception of etoposide, all of the drugs inhibited the DNA strand passage step of the topoisomerase II catalytic cycle. A series of drug competition experiments that exploited this mechanistic difference was used to determine relationships between drug interaction domains on the enzyme. While the inclusion of etoposide in nonturnover DNA catenation assays reversed the inhibition of strand passage induced by genistein, CP-115,953, and amsacrine, it had no effect on the inhibition induced by novobiocin. These results strongly suggest that etoposide can displace other DNA cleavage-enhancing agents from the enzyme.DNA complex. Therefore, it is concluded that the interaction domain of etoposide overlaps those of several DNA cleavage-enhancing drugs but, consistent with previous observations (Robinson, M. J., Corbett, A. H., and Osheroff, N. (1993) Biochemistry 32, 3638-3643), is distinct from that of novobiocin.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,621 LIGHT HALL,NASHVILLE,TN 37232	Vanderbilt University			Corbett, Anita/AAH-6106-2021	Corbett, Anita/0000-0002-0461-6895	NATIONAL CANCER INSTITUTE [T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER; NCI NIH HHS [5 T32 CA09582] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN AH, 1991, J BIOL CHEM, V266, P9203; BUGG BY, 1991, P NATL ACAD SCI USA, V88, P7654, DOI 10.1073/pnas.88.17.7654; CARON PR, 1993, MOLECULAR BIOLOGY OF DNA TOPOISOMERASES AND ITS APPLICATION CHEMOTHERAPY, P1; CHAN VTW, 1993, J BIOL CHEM, V268, P2160; CHOW KC, 1988, MOL PHARMACOL, V34, P467; CORBETT AH, 1991, J BIOL CHEM, V266, P19666; DANKS MK, 1988, BIOCHEMISTRY-US, V27, P8861, DOI 10.1021/bi00424a026; GALE KC, 1990, BIOCHEMISTRY-US, V29, P9538, DOI 10.1021/bi00493a007; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GILLIGAN PJ, 1986, Patent No. 4623650; HINDS M, 1991, CANCER RES, V51, P4729; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; LEE MS, 1992, J MOL BIOL, V223, P837, DOI 10.1016/0022-2836(92)90245-F; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; MAXWELL A, 1992, J ANTIMICROB CHEMOTH, V30, P409, DOI 10.1093/jac/30.4.409; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P157; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; ROBINSON MJ, 1993, BIOCHEMISTRY-US, V32, P3638, DOI 10.1021/bi00065a016; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROBINSON MJ, 1990, BIOCHEMISTRY-US, V29, P2511, DOI 10.1021/bi00462a012; ROBINSON MJ, 1991, J BIOL CHEM, V266, P14585; Sambrook J, 1989, MOL CLONING LABORATO; Schneider E, 1990, Adv Pharmacol, V21, P149, DOI 10.1016/S1054-3589(08)60342-7; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; SULLIVAN DM, 1989, BIOCHEMISTRY-US, V28, P5680, DOI 10.1021/bi00439a051; WILSON WR, 1981, MOL PHARMACOL, V20, P404; YAMAGISHI J, 1986, MOL GEN GENET, V204, P367, DOI 10.1007/BF00331012; YOSHIDA H, 1991, ANTIMICROB AGENTS CH, V35, P1647, DOI 10.1128/AAC.35.8.1647; ZWELLING LA, 1989, J BIOL CHEM, V264, P16411; ZWELLING LA, 1991, BIOCHEMISTRY-US, V30, P4048, DOI 10.1021/bi00230a032	34	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14394	14398						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8390992				2022-12-25	WOS:A1993LJ82500087
J	LUSTIG, KD; CONKLIN, BR; HERZMARK, P; TAUSSIG, R; BOURNE, HR				LUSTIG, KD; CONKLIN, BR; HERZMARK, P; TAUSSIG, R; BOURNE, HR			TYPE-II ADENYLYLCYCLASE INTEGRATES COINCIDENT SIGNALS FROM GS, GI, AND GQ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ADENYLATE-CYCLASE ACTIVITY; CYCLIC-AMP ACCUMULATION; GTP-BINDING PROTEIN; SWISS 3T3 CELLS; BETA-ADRENERGIC-RECEPTOR; RAT-BRAIN; REGULATORY PROTEINS; ADENOSINE RECEPTOR; MOLECULAR-CLONING	Agonists for G(i)-coupled receptors augment G(s)-stimulated cAMP synthesis in human embryonic kidney (HEK) 293 cells transiently expressing the type II isozyme of adenylylcyclase (AC-II). This augmentation, mediated by betagamma subunits released from activated G(i), can be blocked by expression of the alpha subunit (alpha(t)) of retinal transducin (G(t)), which presumably sequesters free betagamma (Federman, A. D., Conklin, B. R., Schrader, K. A., Reed, R. R., and Bourne, H. R. (1992) Nature 356, 159-161). The alpha subunit of G(q), representing a G protein family distinct from both G(s) and G(i), mimicked the inhibitory effect of alpha(t), suggesting that hormonal stimulation of endogenous G(q) might also release betagamma subunits and thereby augment AC-II activity. Agonists for either of two G(q)-coupled receptors did augment G(s)-stimulated cAMP synthesis in HEK-293 cells expressing AC-II, but this effect was not blocked by expression of alpha(t). The increased stimulation of AC-II was probably not mediated by the release of betagamma subunits from G(q) but rather by activation of protein kinase C (PKC) because of the following. (a) Phorbol esters, which activate PKC directly, elevated cAMP 2-fold in HEK-293 cells transfected with AC-II; this increase was synergistic with G(s)-mediated activation of AC-II. (b) Treatments that partially inhibit or down-regulate PKC also partially prevented stimulation of AC-II by phorbol esters or by agonists for G(q)-coupled receptors. Taken together, these results indicate that AC-II can integrate regulatory signals transmitted by at least three classes of G proteins; extracellular signals acting through G(s) are enhanced synergistically by simultaneous signals transduced by G(i) or G(q) and mediated via betagamma or PKC, respectively.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHARMACOL,CELL BIOL PROGRAM,S1212,BOX 0450,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Conklin, Bruce/E-4738-2019	Conklin, Bruce/0000-0003-1463-6061	NCI NIH HHS [CA54427] Funding Source: Medline; NHLBI NIH HHS [K11 HL02555] Funding Source: Medline; NIGMS NIH HHS [GM27800] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054427] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002555] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027800, R37GM027800] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRADE R, 1993, NEURON, V10, P83, DOI 10.1016/0896-6273(93)90244-L; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BELL JD, 1985, J BIOL CHEM, V260, P2625; CERIONE RA, 1986, J BIOL CHEM, V261, P3901; CHOI EJ, 1988, J BIOL CHEM, V263, P17167; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; FARAGO A, 1990, FEBS LETT, V268, P350, DOI 10.1016/0014-5793(90)81284-U; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GLATT CE, 1993, NATURE, V361, P536, DOI 10.1038/361536a0; GORDELADZE JO, 1989, EUR J BIOCHEM, V183, P397, DOI 10.1111/j.1432-1033.1989.tb14941.x; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; HERNANDEZSOTOMAYOR SMT, 1991, AM J PHYSIOL, V260, pC259, DOI 10.1152/ajpcell.1991.260.2.C259; KANAHO Y, 1992, J BIOL CHEM, V267, P23554; KANAHO Y, 1984, J BIOL CHEM, V259, P7378; KARBON EW, 1985, MOL PHARMACOL, V27, P53; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KELLEHER DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4316, DOI 10.1073/pnas.81.14.4316; KIKKAWA U, 1983, METHOD ENZYMOL, V99, P288; LIU CM, 1978, J BIOL CHEM, V253, P5892; MAHAN LC, 1991, MOL PHARMACOL, V40, P1; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MONS N, 1993, IN PRESS SYNAPSE; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; NABIKA T, 1985, BIOCHEM BIOPH RES CO, V131, P30, DOI 10.1016/0006-291X(85)91765-6; NAMBI P, 1985, J BIOL CHEM, V260, P2165; NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310; REBOIS RV, 1985, J BIOL CHEM, V260, P8026; RODRIGUEZPENA A, 1986, EMBO J, V5, P77, DOI 10.1002/j.1460-2075.1986.tb04180.x; ROZENGURT E, 1987, P NATL ACAD SCI USA, V84, P2282, DOI 10.1073/pnas.84.8.2282; SATTIN A, 1975, J PHARMACOL EXP THER, V192, P22; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; SUGDEN D, 1985, NATURE, V314, P359, DOI 10.1038/314359a0; SUGDEN D, 1988, J NEUROCHEM, V50, P149, DOI 10.1111/j.1471-4159.1988.tb13242.x; SUMMERS ST, 1988, ARCH BIOCHEM BIOPHYS, V262, P12, DOI 10.1016/0003-9861(88)90162-2; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; WEISS ER, 1990, J MOL ENDOCRINOL, V4, P71, DOI 10.1677/jme.0.0040071; WHEELER MB, 1989, ENDOCRINOLOGY, V125, P2414, DOI 10.1210/endo-125-5-2414; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0; ZICK Y, 1986, P NATL ACAD SCI USA, V83, P9294, DOI 10.1073/pnas.83.24.9294	52	161	162	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13900	13905						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8390980				2022-12-25	WOS:A1993LJ82500022
J	BEULLENS, M; VAN EYNDE, A; BOLLEN, M; STALMANS, W				BEULLENS, M; VAN EYNDE, A; BOLLEN, M; STALMANS, W			INACTIVATION OF NUCLEAR INHIBITORY POLYPEPTIDES OF PROTEIN PHOSPHATASE-1 (NIPP-1) BY PROTEIN KINASE-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; CATALYTIC SUBUNIT; PHOSPHORYLATION; DEPHOSPHORYLATION; PHOSPHOPROTEIN; SUBSTRATE; PEPTIDES; DARPP-32; TYPE-1; MUSCLE	We have recently purified two potent and specific inhibitory polypeptides of protein phosphatase-1 from the particulate fraction of bovine thymus nuclei (Beullens, M., Van Eynde, A., Stalmans, W., and Bollen, M. (1992) J. Biol. Chem. 267, 16538-16544). Here it is reported that these inhibitors, termed NIPP-1a (18 kDa) and NIPP-1b (16 kDa), are excellent substrates (K(m) = 0.1 muM) for phosphorylation by protein kinase A on both Ser and Thr residues. Phosphorylation was temporally closely related with an inactivation of NIPP-1. Maximal phosphorylation by protein kinase A (1.5 mol of phosphate/mol of NIPP-1) caused an 8-fold increase in the concentration of NIPP-1 required for half-complete inhibition of the catalytic subunit of protein phosphatase-1, irrespective of the concentration of the phosphatase. Phosphorylation decreased the binding of NIPP-1 to immobilized protein phosphatase-1. NIPP-1 could be efficiently and completely reactivated by incubation with the catalytic subunit of protein phosphatase-2A. The type-I catalytic subunit was much less effective, however, even when present in a molar excess to NIPP-1. Chromatography of a salt extract of the particulate nuclear fraction on Mono Q revealed three species of PP-1. One of these species, termed PP-1Nalpha, contained NIPP-1 as a subunit and could be activated 6-fold by incubation with protein kinase A under phosphorylating conditions. This activation of PP-1Nalpha is opposite to the known inhibition of cytoplasmic species of protein phosphatase-1 by protein kinase A.	CATHOLIC UNIV LEUVEN, FAK GENEESKUNDE,AFDELING BIOCHEM, CAMPUS GASTHUISBERG,HEREST 49, B-3000 LOUVAIN, BELGIUM	KU Leuven								ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; BEULLENS M, 1992, J BIOL CHEM, V267, P16538; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BOLLEN M, 1993, ADV PROTEIN PHOSPHAT, V7, P31; CHESSA G, 1983, EUR J BIOCHEM, V135, P609, DOI 10.1111/j.1432-1033.1983.tb07695.x; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HEMMINGS HC, 1990, J BIOL CHEM, V265, P20369; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4491; HUANG FL, 1977, BIOCHEM BIOPH RES CO, V78, P615, DOI 10.1016/0006-291X(77)90224-8; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KEMP BE, 1978, J BIOL CHEM, V253, P5147; KISS Z, 1985, J CELL PHYSIOL, V125, P200, DOI 10.1002/jcp.1041250205; MEEK DW, 1992, BIOCHEM J, V287, P1; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; NIMMO GA, 1978, EUR J BIOCHEM, V87, P353, DOI 10.1111/j.1432-1033.1978.tb12384.x; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OHKURA H, 1991, CELL, V64, P149, DOI 10.1016/0092-8674(91)90216-L; RAMACHANDRAN C, 1987, J BIOL CHEM, V262, P3210; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; TONKS NK, 1984, EUR J BIOCHEM, V145, P65, DOI 10.1111/j.1432-1033.1984.tb08522.x	28	70	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13172	13177						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8390458				2022-12-25	WOS:A1993LH55300026
J	KANAHO, Y; NAKAI, Y; KATOH, M; NOZAWA, Y				KANAHO, Y; NAKAI, Y; KATOH, M; NOZAWA, Y			THE PHOSPHATASE INHIBITOR 2,3-DIPHOSPHOGLYCERATE INTERFERES WITH PHOSPHOLIPASE-D ACTIVATION IN RABBIT PERITONEAL NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; METHIONYL-LEUCYL-PHENYLALANINE; LYSOSOMAL-ENZYME RELEASE; CELL-SURFACE; DEPHOSPHORYLATION; 1,4,5-TRISPHOSPHATE; PHOSPHORYLATION; ACCUMULATION; PURIFICATION; RECEPTOR	In the present study, we examined the ability of the phosphatase inhibitors p-nitrophenyl phosphate and 2,3-diphosphoglycerate (DPG) to inhibit phospholipase D (PLD) activation in the rabbit peritoneal neutrophil. Also assessed were choline, a product of PLD-catalyzed hydrolysis of phosphatidylcholine, and its metabolite phosphocholine. PLD activity was determined by measuring the accumulation, in the presence of ethanol, of [H-3]phosphatidylethanol ([H-3]PEt) in neutrophils prelabeled with 1-O-[H-3]octadecyl-2-lyso-sn-glycero-3-phosphocholine. Of the compounds tested, only DPG interfered with PLD activation by N-formyl-Met-Leu-Phe (fMLP) in a dose- and time-dependent manner. In contrast, it augmented fMLP-stimulated levels of [H-3]inositol phosphates in myo-[H-3]inositol-labeled neutrophils. DPG also prevented PLD activation by the calcium ionophore ionomycin and by phorbol 12-myristate 13-acetate. The suppression of PLD activation by DPG appeared to arise from direct interaction with the enzyme, as evidenced by a DPG competitive pattern of inhibition (K(i) = 9.0 +/- 1.5 mM) for PLD from Streptomyces chromofuscus. These results suggest that DPG may be a useful tool for investigating the role of PLD in physiological function in a wide variety of cell types. Interestingly, DPG inhibited fMLP-induced N-acetyl-beta-glucosaminidase release and O2- generation by the cytochalasin B-primed neutrophils in a dose-dependent manner, whereas it had minimal effect (at concentrations up to 5 mM) on O2- generation induced by fMLP in nonprimed cells. These results suggest that PLD plays an important role in fMLP stimulation of both N-acetyl-beta-glucosaminidase release and O2- generation in the primed neutrophils, but that a PLD-independent pathway plays the primary role in O2- generation by the nonprimed neutrophils.			KANAHO, Y (corresponding author), GIFU UNIV,SCH MED,DEPT BIOCHEM,TSUKASAMACHI 40,GIFU 500,JAPAN.							BECKER EL, 1979, AM J PATHOL, V95, P81; BENNETT JP, 1980, BIOCHIM BIOPHYS ACTA, V601, P584, DOI 10.1016/0005-2736(80)90560-X; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1987, FEBS LETT, V225, P201, DOI 10.1016/0014-5793(87)81157-2; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BONE EA, 1984, BIOCHEM J, V221, P803, DOI 10.1042/bj2210803; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CAMPAGNE MMV, 1988, BIOCHEM J, V254, P343; DELVAUX A, 1987, BIOCHEM J, V242, P193, DOI 10.1042/bj2420193; DIVIRGILIO F, 1984, NATURE, V310, P691, DOI 10.1038/310691a0; EXTON JH, 1990, J BIOL CHEM, V265, P1; GRUCHALLA RS, 1990, J IMMUNOL, V144, P2334; IMAMURA S, 1979, J BIOCHEM, V85, P79, DOI 10.1093/oxfordjournals.jbchem.a132334; KAIBUCHI K, 1981, J BIOL CHEM, V256, P7146; KAJIKAWA N, 1983, BIOCHEM BIOPH RES CO, V116, P743, DOI 10.1016/0006-291X(83)90587-9; KAKINUMA K, 1976, J BIOCHEM-TOKYO, V79, P795, DOI 10.1093/oxfordjournals.jbchem.a131132; KANAHO Y, 1992, J BIOL CHEM, V267, P23554; KANAHO Y, 1992, J IMMUNOL, V149, P622; KANAHO Y, 1991, J IMMUNOL, V146, P3536; KERMODE JC, 1988, J LEUKOCYTE BIOL, V43, P420, DOI 10.1002/jlb.43.5.420; KESSELS GCR, 1991, J BIOL CHEM, V266, P23152; KESSELS GCR, 1991, J BIOL CHEM, V266, P15870; LISCOVITCH M, 1991, BIOCHEM J, V279, P319, DOI 10.1042/bj2790319; MULLMANN TJ, 1990, J IMMUNOL, V144, P1901; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PAI JK, 1988, BIOCHEM BIOPH RES CO, V150, P355, DOI 10.1016/0006-291X(88)90528-1; PAI JK, 1988, J BIOL CHEM, V263, P12472; RUBIERA C, 1988, BIOCHEM J, V255, P131, DOI 10.1042/bj2550131; SCHWERTZ DW, 1984, J PHARMACOL EXP THER, V222, P350; SHAAFI RI, 1986, BIOCHEM BIOPH RES CO, V137, P50, DOI 10.1016/0006-291X(86)91174-5; WACKER WEC, 1956, NEW ENGL J MED, V255, P449, DOI 10.1056/NEJM195609062551001; WHITE JR, 1984, J BIOL CHEM, V259, P8605; WRIGHT CD, 1986, BIOCHEM BIOPH RES CO, V135, P749, DOI 10.1016/0006-291X(86)90992-7; YANG SF, 1967, J BIOL CHEM, V242, P477	36	38	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12492	12497						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8389759				2022-12-25	WOS:A1993LG65800041
J	NEOTE, K; DARBONNE, W; OGEZ, J; HORUK, R; SCHALL, TJ				NEOTE, K; DARBONNE, W; OGEZ, J; HORUK, R; SCHALL, TJ			IDENTIFICATION OF A PROMISCUOUS INFLAMMATORY PEPTIDE RECEPTOR ON THE SURFACE OF RED-BLOOD-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MONOCYTE CHEMOATTRACTANT PROTEIN-1; NEUTROPHIL CHEMOTACTIC FACTOR; HUMAN INTERLEUKIN-8 RECEPTOR; HOST DEFENSE CYTOKINES; LYMPHOCYTES-T; PURIFICATION; BINDING; FAMILY; NAP-1	Erythrocytes have long been appreciated as transporters and exchangers of O2 and CO2 between the lungs and the tissues. Here we examine the role of erythrocytes as potential mediators of inflammatory processes by assessing their ability to bind to a number of inflammatory peptides of the chemokine (for chemoattractant cytokine) superfamily. Radiolabeled chemokines of either the C-X-C (IL-8, MGSA/gro, NAP-2) or C-C (RANTES, MCP-1) class bind reversibly to red cell surface receptors numbering 1000-9000 sites/cell with a K(d) of approximately 5 nm. In contrast to what is seen for chemokine binding to target inflammatory cells, chemokines of either class displace heterologous chemokines, indicating that the proteins are competing, for a promiscuous receptor. Chemical cross-linking with radiolabeled chemokines reveals a 30-38-kilodalton protein on the red cell surface, and cross-linking is inhibited in the presence of heterologous unlabeled chemokines. These data show that red blood cells possess a multispecific receptor for the newly identified chemokine superfamily of inflammatory cytokines, and thus the red cell may play a novel role as a regulator of inflammatory processes.	GENENTECH INC, 460 POINT SAN BRUNO BLVD, San Francisco, CA 94080 USA	Roche Holding; Genentech								BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BROXMEYER HE, 1991, J IMMUNOL, V147, P2586; BROXMEYER HE, 1989, J EXP MED, V170, P1583, DOI 10.1084/jem.170.5.1583; DARBONNE WC, 1991, J CLIN INVEST, V88, P1362, DOI 10.1172/JCI115442; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; HEBERT CA, 1990, J IMMUNOL, V145, P3033; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HORUK R, 1993, J BIOL CHEM, V268, P541; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KUNA P, 1992, J EXP MED, V175, P489, DOI 10.1084/jem.175.2.489; KUNA P, 1992, J IMMUNOL, V149, P636; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEONARD EJ, 1991, J LEUKOCYTE BIOL, V49, P258, DOI 10.1002/jlb.49.3.258; LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MATSUSHIMA K, 1989, J EXP MED, V169, P1485, DOI 10.1084/jem.169.4.1485; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; MILLER MD, 1992, P NATL ACAD SCI USA, V89, P2950, DOI 10.1073/pnas.89.7.2950; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; SAMANTA AK, 1989, J EXP MED, V169, P1185, DOI 10.1084/jem.169.3.1185; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHALL TJ, 1993, IN PRESS J EXP MED; STECK TL, 1970, SCIENCE, V168, P255, DOI 10.1126/science.168.3928.255; SYLVESTER I, 1992, J CLIN INVEST, V90, P471, DOI 10.1172/JCI115883; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; YOSHIMURA T, 1990, J IMMUNOL, V145, P292	33	235	250	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12247	12249						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8389755				2022-12-25	WOS:A1993LG65800005
J	HALPERN, JL; LOFTUS, A				HALPERN, JL; LOFTUS, A			CHARACTERIZATION OF THE RECEPTOR-BINDING DOMAIN OF TETANUS TOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN; POLYPEPTIDE FRAGMENTS; INHIBITS EXOCYTOSIS; BOTULINUM TOXINS; BRAIN MEMBRANES; CELLS; GANGLIOSIDES; EXPRESSION; LOCALIZATION; NEUROTOXINS	The carboxyl-terminal half of the heavy chain of tetanus toxin (H(C)) contains the domain required for binding to purified gangliosides and neuronal cells. The structural requirements for the interaction of H(C) with receptor were studied by generating mutants of H(C) with deletions at either the carboxyl or amino terminus and characterizing their binding. A deletion of 10 or more amino acids from the carboxyl terminus resulted in a major loss of H(C) binding to purified gangliosides and spinal cord neuronal cells, whereas a deletion of the carboxyl-terminal 5 amino acids did not affect binding. The removal of up to 263 amino acids from the amino terminus did not inhibit binding. Each of the truncated proteins was much more sensitive to trypsin than was full-length H(C), suggesting an alteration in conformation. The receptor binding activity of H(C) was not retained in a peptide corresponding to the carboxyl-terminal 20 amino acids. These data suggest that the carboxyl-terminal region of H(C) is important for maintaining a conformation necessary for binding to receptor.			HALPERN, JL (corresponding author), US FDA,CTR BIOL EVALUAT & RES,DIV BACTERIAL PROD,BLDG 29,RM 103,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							AHNERTHILGER G, 1989, FEBS LETT, V242, P245, DOI 10.1016/0014-5793(89)80478-8; BITTNER MA, 1989, J NEUROCHEM, V53, P966, DOI 10.1111/j.1471-4159.1989.tb11800.x; EISEL U, 1986, EMBO J, V5, P2495, DOI 10.1002/j.1460-2075.1986.tb04527.x; FAIRWEATHER NF, 1986, NUCLEIC ACIDS RES, V14, P7809, DOI 10.1093/nar/14.19.7809; HABERMANN E, 1986, CURR TOP MICROBIOL, V129, P93; HALPERN JL, 1990, INFECT IMMUN, V58, P1004, DOI 10.1128/IAI.58.4.1004-1009.1990; HANNA PC, 1991, J BIOL CHEM, V266, P11037; HELTING TB, 1977, J BIOL CHEM, V252, P187; HELTING TB, 1979, J BIOL CHEM, V254, P728; HOGY B, 1992, TOXICON, V30, P63, DOI 10.1016/0041-0101(92)90502-V; HOLMGREN J, 1980, EUR J BIOCHEM, V106, P371, DOI 10.1111/j.1432-1033.1980.tb04583.x; KENIMER JG, 1983, INFECT IMMUN, V42, P942, DOI 10.1128/IAI.42.3.942-948.1983; KRIEGLSTEIN K, 1990, EUR J BIOCHEM, V188, P39; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARXEN P, 1989, TOXICON, V27, P849, DOI 10.1016/0041-0101(89)90097-4; MATSUDA M, 1974, BIOCHEM BIOPH RES CO, V57, P1257, DOI 10.1016/0006-291X(74)90831-6; MOCHIDA S, 1989, FEBS LETT, V253, P47, DOI 10.1016/0014-5793(89)80926-3; MONTECUCCO C, 1986, TRENDS BIOCHEM SCI, V11, P314, DOI 10.1016/0968-0004(86)90282-3; MORRIS NP, 1980, J BIOL CHEM, V255, P6071; PIERCE EJ, 1986, BIOCHEM J, V236, P845, DOI 10.1042/bj2360845; RANSOM BR, 1977, J NEUROPHYSIOL, V40, P1132, DOI 10.1152/jn.1977.40.5.1132; ROA M, 1985, J BIOL CHEM, V260, P6827; ROGERS TB, 1981, J BIOL CHEM, V256, P2402; ROLF JM, 1990, J BIOL CHEM, V265, P7331; SCHIAVO G, 1991, FEBS LETT, V290, P227, DOI 10.1016/0014-5793(91)81266-B; SINGH Y, 1991, J BIOL CHEM, V266, P15493; WALTON KM, 1988, J BIOL CHEM, V263, P2055; WELLER U, 1986, TOXICON, V24, P1055, DOI 10.1016/0041-0101(86)90132-7; YAVIN E, 1986, EUR J BIOCHEM, V154, P403, DOI 10.1111/j.1432-1033.1986.tb09412.x; [No title captured]	30	91	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11188	11192						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8388386				2022-12-25	WOS:A1993LD46600070
J	BOTTARO, DP; FORTNEY, E; RUBIN, JS; AARONSON, SA				BOTTARO, DP; FORTNEY, E; RUBIN, JS; AARONSON, SA			A KERATINOCYTE GROWTH-FACTOR RECEPTOR-DERIVED PEPTIDE ANTAGONIST IDENTIFIES PART OF THE LIGAND-BINDING SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EXPRESSION; CLONING	Keratinocyte growth factor (KGF) is a fibroblast growth factor (FGF) family member that acts specifically on cells of epithelial origin. Its receptor (KGFR) is a membrane-spanning tyrosine kinase, which also binds acidic FGF (aFGF) with equally high affinity, and basic FGF (bFGF) with much lower affinity. The KGFR is encoded by the bek/FGFR-2 gene, whose alternative transcript specifies a receptor with high affinity for aFGF and bFGF, but no detectable binding of KGF. The only structural difference between these two receptors is a 49-amino acid segment in the extracellular domain that is determined by single alternative exons. We report that a synthetic peptide (NH2-His199...Tyr223-COOH) corresponding to part of the predicted sequence of the KGFR alternative exon blocks KGF mitogenic activity and the interaction between KGF and its receptor. The peptide also blocks the interaction between KGF and a neutralizing monoclonal antibody raised against this growth factor. These results demonstrate that the peptide binds directly and specifically to KGF and argue that this region of the receptor constitutes part or all of the KGF binding site.			BOTTARO, DP (corresponding author), NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,RM 1E24,BETHESDA,MD 20892, USA.		Bottaro, Donald P/F-8550-2010; Bottaro, Donald P/AAF-3853-2020	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334				AARONSON SA, 1991, ANN NY ACAD SCI, V638, P62, DOI 10.1111/j.1749-6632.1991.tb49018.x; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; RON D, 1993, J BIOL CHEM, V268, P2984; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802	10	59	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9180	9183						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8387485				2022-12-25	WOS:A1993LA68900007
J	NGUYEN, TT; SCIMECA, JC; FILLOUX, C; PERALDI, P; CARPENTIER, JL; VANOBBERGHEN, E				NGUYEN, TT; SCIMECA, JC; FILLOUX, C; PERALDI, P; CARPENTIER, JL; VANOBBERGHEN, E			COREGULATION OF THE MITOGEN-ACTIVATED PROTEIN-KINASE, EXTRACELLULAR SIGNAL-REGULATED KINASE-1, AND THE 90-KDA RIBOSOMAL S6 KINASE IN PC12 CELLS - DISTINCT EFFECTS OF THE NEUROTROPHIC FACTOR, NERVE GROWTH-FACTOR, AND THE MITOGENIC FACTOR, EPIDERMAL GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASES; MAP KINASE; SWISS 3T3-CELLS; SKELETAL-MUSCLE; INSULIN; PHOSPHORYLATION; EXPRESSION; TYROSINE; INITIATION; S6-KINASE	We recently characterized the association of the 44-kDa mitogen-activated protein kinase, also known as extracellular-regulated kinase 1 (ERK1), with the 90-kDa ribosomal S6 kinase (pp90rsk), one of its putative substrates in intact PC12 cells. Using antibodies to ERK1 that precipitate a functional ERK1.pp90rsk phosphoprotein complex, we demonstrate here the regulation of both kinases by various stimuli. In mouse fibroblasts expressing human insulin receptors, insulin and vanadate swiftly stimulated ERK1 activity within 5 min. While the hormonal effect was short-lived, vanadate led to a first peak followed by a progressively increasing second phase. In PC12 cells, epidermal growth factor, which is a growth promoting factor, provokes a rapid but evanescent activation of ERK1. In contrast, nerve growth factor (NGF), which acts as a neuronal differentiation factor for PC12 cells, induced a swift monophasic response followed by a sustained second phase. This strikingly different pattern of ERK1 stimulation by NGF and epidermal growth factor was associated to a contrasting effect on ERK1 cellular translocation. Thus, NGF induced a nuclear translocation of ERK1, while epidermal growth factor was without noticeable effect on ERK1 localization. In both cell systems all effectors tested stimulated ERK1 phosphorylation on both threonine and tyrosine residues in an 1:1 ratio. During ERK1 inactivation, phosphothreonine and phosphotyrosine were dephosphorylated in a similar fashion. Concurrent with ERK1 activation was the de novo appearance of phosphothreonine and an increase in phosphoserine on pp90rsk. The pp90rsk phosphothreonine content paralleled the ERK1 activity more closely than the phosphoserine level. These results provide compelling evidence that in fibroblasts and PC12 cells ERK1 plays a direct role in the phosphorylation of pp90rsk and that pp90rsk represents a physiologically relevant substrate of extracellular-regulated kinases. Finally, we would like to suggest that the differentiating action of NGF in PC12 cells might be due, at least in part, to the conjunction of its sustained and robust stimulation of ERK1 and pp90rsk, and of its induction of ERK1 nuclear translocation.	FAC MED NICE, INSERM, U145, AVE VALOMBROSE, F-06107 NICE 2, FRANCE; CTR MED UNIV GENEVA, DEPT MORPHOL, CH-1211 GENEVA 4, SWITZERLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Geneva			Peraldi, Pascal/O-4592-2016; Scimeca, Jean-Claude/P-3830-2016	Peraldi, Pascal/0000-0003-0205-9252; Scimeca, Jean-Claude/0000-0003-3773-6110				AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1990, J BIOL CHEM, V265, P11495; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DUNCAN R, 1982, EUR J BIOCHEM, V123, P535; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HOFMANN C, 1989, ENDOCRINOLOGY, V124, P257, DOI 10.1210/endo-124-1-257; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; SCIMECA JC, 1992, J BIOL CHEM, V267, P17369; SCIMECA JC, 1991, BIOCHEMISTRY-US, V30, P9313, DOI 10.1021/bi00102a025; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SWARUP G, 1982, J BIOL CHEM, V257, P7298; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THOMAS G, 1982, CELL, V30, P235, DOI 10.1016/0092-8674(82)90029-0; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TSAO H, 1991, J BIOL CHEM, V266, P12981; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237	44	217	218	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9803	9810						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8387505				2022-12-25	WOS:A1993LA68900094
J	LAL, S; SZWERGOLD, BS; KAPPLER, F; BROWN, T				LAL, S; SZWERGOLD, BS; KAPPLER, F; BROWN, T			DETECTION OF FRUCTOSE-3-PHOSPHOKINASE ACTIVITY IN INTACT MAMMALIAN LENSES BY P-31 NMR-SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; ALDOSE REDUCTASE; FRUCTOSE 3-PHOSPHATE; SORBITOL 3-PHOSPHATE; DIABETES-MELLITUS; RABBIT LENS; GLYCOSYLATION; IDENTIFICATION; DEHYDROGENASE; METABOLISM	Recently we have identified two novel phosphorylated metabolites in the lenses of diabetic rats as sorbitol 3-phosphate (Sor-3-P) and fructose 3-phosphate (Fru-3-P). The latter compound is of particular interest since it is a potent glycating agent, which could account, at least in part, for the increased protein cross-linking and cataract formation in the lens of the diabetic rat. In order to gain insight into the mechanism of formation of these compounds, P-31 NMR spectra of rat, pig, and rabbit lenses, perfused with media supplemented with glucose, fructose, or sorbitol, were acquired. Perfusion with fructose-supplemented media resulted in the production of Fru-3-P in all three species. This compound was not produced upon perfusion with fructose-deficient media. The identification of the newly synthesized material as Fru-3-P was confirmed by spiking perchloric acid extracts of the perfused lenses with synthetic Fru-3-P. Our results provide strong evidence for the existence of a fructose-3-phosphokinase in mammalian lenses. If this enzyme is present in human lenses as well, it will reinforce the hypothesis that this enzyme and its product, Fru-3-P, may play a role in diabetic cataractogenesis and that lenticular fructose-3-phosphokinase may provide another therapeutic target in the prevention and alleviation of diabetic cataracts.			LAL, S (corresponding author), FOX CHASE CANC CTR,DEPT NUCL MAGNET RESONANCE & MED SPECT,7701 BURHOLME AVE,PHILADELPHIA,PA 19111, USA.				NATIONAL EYE INSTITUTE [R01EY008414] Funding Source: NIH RePORTER; NEI NIH HHS [EY08414] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BROWNLEE M, 1984, ANN INTERN MED, V101, P527, DOI 10.7326/0003-4819-101-4-527; CHENG H-M, 1991, Medical Science Research, V19, P91; CHENG HM, 1991, EXP EYE RES, V53, P805, DOI 10.1016/0014-4835(91)90117-W; CHENG HM, 1985, OCULAR LENS, P223; CHIOU SH, 1981, J BIOL CHEM, V256, P5176; FRANSWORTH PN, 1985, CURR EYE RES, V4, P291; GONZALEZ RG, 1988, MAGN RESON MED, V6, P435, DOI 10.1002/mrm.1910060409; GREINER JV, 1981, INVEST OPHTH VIS SCI, V21, P700; GRENIER JV, 1985, SURV OPHTHALMOL, V30, P189; JEDZINIAK JA, 1981, INVEST OPHTH VIS SCI, V20, P314; KADOR P, 1989, COMPLICATIONS DIABET, P103; KOPP SJ, 1982, SCIENCE, V215, P1622, DOI 10.1126/science.7071581; LEE JH, 1984, BIOCHEM BIOPH RES CO, V123, P888, DOI 10.1016/S0006-291X(84)80218-1; LOU MF, 1989, EXP EYE RES, V48, P11, DOI 10.1016/0014-4835(89)90014-6; MANDEL SS, 1983, BIOCHEM BIOPH RES CO, V117, P51, DOI 10.1016/0006-291X(83)91539-5; MONNIER VM, 1989, MAILLARD REACTION AG, P1; OHRLOFF C, 1973, OPHTHALMIC RES, V5, P121, DOI 10.1159/000266027; PATMORE L, 1981, MECHANISMS CATARACT, P207; PETERSEN A, 1990, J BIOL CHEM, V265, P17424; PETERSEN A, 1992, BIOCHEM J, V284, P363, DOI 10.1042/bj2840363; SZWERGOLD BS, 1989, J BIOL CHEM, V264, P9278; SZWERGOLD BS, 1990, SCIENCE, V247, P451, DOI 10.1126/science.2300805; THOMAS DM, 1988, EXP EYE RES, V46, P37, DOI 10.1016/S0014-4835(88)80091-5; VACA G, 1984, DIABETOLOGIA, V27, P482, DOI 10.1007/BF00273916; VANHEYNINGEN R, 1971, EXP EYE RES, V11, P415, DOI 10.1016/S0014-4835(71)80054-4; WIDDAS WF, 1954, J PHYSIOL-LONDON, V125, P163, DOI 10.1113/jphysiol.1954.sp005148; WILLIAMS WF, 1988, EXP EYE RES, V47, P97, DOI 10.1016/0014-4835(88)90027-9; WILLIS JA, 1986, EXP EYE RES, V43, P329, DOI 10.1016/S0014-4835(86)80070-7	28	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7763	7767						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8385119				2022-12-25	WOS:A1993KW97900030
J	GIORGETTI, S; BALLOTTI, R; KOWALSKI-CHAUVEL A; TARTARE, S; VANOBBERGHEN, E				GIORGETTI, S; BALLOTTI, R; KOWALSKI-CHAUVEL A; TARTARE, S; VANOBBERGHEN, E			THE INSULIN AND INSULIN-LIKE GROWTH FACTOR-I RECEPTOR SUBSTRATE IRS-1 ASSOCIATES WITH AND ACTIVATES PHOSPHATIDYLINOSITOL 3-KINASE INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATES TYROSINE PHOSPHORYLATION; KINASE-ACTIVITY; ENDOGENOUS SUBSTRATE; SH2 DOMAINS; PROTEIN; BINDING; EXPRESSION; SEQUENCE; ELEMENTS; SUBUNIT	Phosphatidylinositol 3-kinase (PtdIns-3-kinase) is thought to participate in the transductional cascade used by several tyrosine kinase receptors including the insulin-like growth factor (IGF)-I receptor and the insulin receptor. The major insulin receptor cellular substrate IRS-1 (pp185) has been proposed as a possible link between the insulin receptor and PtdIns-3-kinase. In this study we show that both insulin and IGF-I treatment of murine fibroblasts transfected with insulin or IGF-I receptors increase PtdIns-3-kinase activity immunoprecipitated with an antibody directed against the 85-kDa subunit of PtdIns-3-kinase. Whereas only a small amount of PtdIns-3-kinase is found associated with the insulin and IGF-I receptor, a considerable PtdIns-3-kinase activity is immunoprecipitated by an antibody raised against IRS-1. Additionally, insulin and IGF-I stimulation of murine fibroblasts expressing insulin or IGF-I receptors induce tyrosine phosphorylation of IRS-1 and its association with PtdIns-3-kinase. Since IRS-1 seems to be the connection between PtdIns-3-kinase and insulin or IGF-I receptor, we used reconstitution experiments to characterize the implication of IRS-1 in the activation of PtdIns-3-kinase. We show that immunoaffinity-purified IRS-1 can be phosphorylated by ligand-stimulated insulin and IGF-I receptors and that this phosphorylation allows the association of IRS-1 with PtdIns-3-kinase. The interaction between PtdIns-3-kinase and IRS-1 phosphorylated by the insulin or the IGF-I receptor results in the activation of PtdIns-3-kinase. In conclusion, our results demonstrate that IRS-1 is a key component in the signal transduction pathway of PtdIns-3-kinase activation induced by insulin and IGF-I.	FAC MED NICE, INSERM,U145,AVE VALOMBROSE, F-06107 NICE 2, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur			Kowalski-Chauvel, Aline/O-9212-2014; TARTARE-DECKERT, Sophie/P-6057-2015; BALLOTTI, Robert/F-8825-2013	TARTARE-DECKERT, Sophie/0000-0001-8680-5720; BALLOTTI, Robert/0000-0002-7322-4908; Giorgetti-Peraldi, Sophie/0000-0002-2751-2618				BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GAMMELTOFT S, 1986, BIOCHEM J, V235, P1; GAUTIER N, 1986, ANN ENDOCRINOL-PARIS, V47, P215; GIORGETTI S, 1992, EUR J BIOCHEM, V207, P599; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; IZUMI T, 1987, J BIOL CHEM, V262, P1282; KAHN CR, 1985, ANNU REV MED, V36, P429; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SOOS MA, 1992, J BIOL CHEM, V267, P12955; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YAMAMOTO K, 1992, ENDOCRINOLOGY, V130, P1490, DOI 10.1210/en.130.3.1490; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	38	158	158	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7358	7364						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8385105				2022-12-25	WOS:A1993KV14100077
J	BOHM, S; BAKKE, M; NILSSON, M; ZANGER, UM; SPYROU, G; LUND, J				BOHM, S; BAKKE, M; NILSSON, M; ZANGER, UM; SPYROU, G; LUND, J			COOPERATING NONCONSENSUS CAMP-RESPONSIVE ELEMENTS ARE MEDIATORS OF ADRENOCORTICOTROPIN-INDUCED VL30 TRANSCRIPTION IN STEROIDOGENIC ADRENAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER PROTEINS; BINDING-PROTEINS; GENE-EXPRESSION; CYCLIC-AMP; MOUSE RETROTRANSPOSONS; SIGNAL TRANSDUCTION; REGULATORY REGIONS; DNA; FAMILY; C/EBP	Pituitary-derived trophic hormones regulate cell-type-specific expression of VL30 retrotransposons in tissues that are engaged in steroidogenesis. We show that adrenocorticotropic hormone and forskolin induced VL30 transcription in the steroidogenic adrenal cell line Y1 and that the transcriptional activation was cell type- and protein kinase A-dependent. Three novel cAMP-responsive elements (CREs), within the VL30 long terminal repeat, were identified and shown to activate transcription synergistically when templates bearing multiple sites were compared with templates bearing a single site. This type of regulation was evident only in forskolin-treated cells, and the response elements were found to be inactive as mediators of constititutive transcription. In vitro binding analyses indicated that a consensus CRE and the nonconsensus VL30 CREs differ with respect to binding affinity and specificity to a number of nuclear factors that were identified to be related to proteins within the CREB, Jun, and C/EBP families of transcription factors. The relatively low affinity and/or a restricted binding specificity of the VL30 CREs made it possible to detect forskolin-induced binding of CREB- and Jun-related proteins to these sequences. We suggest that cAMP-induced transcription, specific for steroidogenic cells, can be mediated by a novel type of nonconsensus CREs and that the mechanism for this type of gene regulation is distinct from that mediated through a consensus CRE. We also report the identification of a novel factor, distinct from previously characterized CRE-binding proteins, that constitutively binds to the identified CREs.	KAROLINSKA INST, DEPT MED CHEM 1, S-10401 STOCKHOLM 60, SWEDEN; DEPT MED NUTR, S-14186 HUDDINGE, SWEDEN; BIOCTR, DEPT PHARMACOL, CH-4056 BASEL, SWITZERLAND	Karolinska Institutet	BOHM, S (corresponding author), KAROLINSKA INST, CTR BIOTECHNOL, NOVUM, S-14157 HUDDINGE, SWEDEN.		Zanger, Ulrich M./A-9364-2012	Zanger, Ulrich M./0000-0002-5276-2002				BAKKER O, 1991, NUCLEIC ACIDS RES, V19, P1213, DOI 10.1093/nar/19.6.1213; BOHM S, 1990, CANCER RES, V50, P1626; BOHM S, 1991, J BIOL CHEM, V266, P24834; CAREY M, 1992, J VIROL, V66, P4803, DOI 10.1128/JVI.66.8.4803-4813.1992; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROVE JR, 1989, J BIOL CHEM, V264, P19506; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; INOUE H, 1991, EUR J BIOCHEM, V195, P563, DOI 10.1111/j.1432-1033.1991.tb15738.x; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JOHN ME, 1986, P NATL ACAD SCI USA, V83, P4715, DOI 10.1073/pnas.83.13.4715; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525; KESHET E, 1982, J VIROL, V43, P50, DOI 10.1128/JVI.43.1.50-58.1982; KESHET E, 1991, ADV CANCER RES, V56, P215; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUND J, 1990, J BIOL CHEM, V265, P3304; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Ptashne M., 1986, A GENETIC SWITCH; QUINN PG, 1990, MOL CELL BIOL, V10, P3357, DOI 10.1128/MCB.10.7.3357; ROONEY RJ, 1990, MOL CELL BIOL, V10, P5138, DOI 10.1128/MCB.10.10.5138; ROTMAN G, 1986, NUCLEIC ACIDS RES, V14, P645, DOI 10.1093/nar/14.2.645; Sambrook J, 1989, MOL CLONING LABORATO; SCHIFF R, 1991, GENE DEV, V5, P521, DOI 10.1101/gad.5.4.521; Schimmer B P, 1979, Methods Enzymol, V58, P570; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Waterman M R, 1988, Prog Clin Biol Res, V274, P543; WATERMAN MR, 1990, BIOCHEM SOC T, V18, P26, DOI 10.1042/bst0180026; WEIH F, 1990, GENE DEV, V4, P1437, DOI 10.1101/gad.4.8.1437; WONG M, 1989, J BIOL CHEM, V264, P12867; YASUMURA Y, 1966, CANCER RES, V26, P529; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	50	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3952	3963						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8382684				2022-12-25	WOS:A1993KN53300026
J	CLARK, RB; FRIEDMAN, J; KUNKEL, MW; JANUARY, BG; SHENOLIKAR, S				CLARK, RB; FRIEDMAN, J; KUNKEL, MW; JANUARY, BG; SHENOLIKAR, S			OKADAIC ACID INDUCES BOTH AUGMENTATION AND INHIBITION OF BETA(2)-ADRENERGIC STIMULATION OF CAMP ACCUMULATION IN S49 LYMPHOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP LEVELS; ADENYLATE-CYCLASE; PHORBOL ESTER; PHOSPHATASE INHIBITOR; PROTEIN PHOSPHATASES; HUMAN-PLATELETS; WILD-TYPE; RECEPTOR; DESENSITIZATION; PHOSPHORYLATION	To address the role of protein phosphatases in regulating hormonal responses in mammalian cells, we investigated the effects of okadaic acid, a potent inhibitor of protein phosphatases 1 and 2A, on epinephrine and prostaglandin E1 stimulation of cAMP accumulation and adenylyl cyclase in S49 WT and kin- lymphoma cells. Depending on the dose and time of okadaic acid pretreatment of both cell lines, there were two distinguishable effects on cAMP accumulation, an augmentation and an inhibition. The augmentation occurred rapidly (t 1/2 < 1 min), was maximal with 3 muM okadaic acid, and was observed with concentrations of okadaic acid as low as 0.3 muM. Prolonged (t1/2 of 5-15 min) pretreatment of cells with okadaic acid caused an inhibition of epinephrine-stimulated cAMP accumulation, which was characterized by a 2-3-fold increase in the EC50 for the response to epinephrine. The EC50 for the okadaic acid-mediated inhibition was similar to that for the augmentation. In assays of adenylyl cyclase in membrane fractions prepared from okadaic acid-pretreated cells the inhibitory, but not the stimulatory, effects of okadaic acid pretreatment were observed. The data demonstrate that protein phosphatases play an important role in regulating adenylyl cyclase and suggest that cAMP-dependent protein kinase is not involved in either of its actions.	DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	Duke University	CLARK, RB (corresponding author), UNIV TEXAS,HLTH SCI CTR,GRAD SCH BIOMED SCI,HOUSTON,TX 77225, USA.				NIGMS NIH HHS [GM31208] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031208] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSAMRA AB, 1987, J BIOL CHEM, V262, P1129; ALEXANDER D R, 1990, New Biologist, V2, P1049; BELL JD, 1986, J BIOL CHEM, V261, P2036; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; BOARDER MR, 1988, J BIOL CHEM, V263, P15319; BROOKER G, 1979, ADV CYCLIC NUCLEOTID, V10, P2; BUTCHER RW, 1978, J CYCLIC NUCL PROT, V4, P411; CLARK RB, 1988, P NATL ACAD SCI USA, V85, P1442, DOI 10.1073/pnas.85.5.1442; CLARK RB, 1987, FASEB J, V1, P289, DOI 10.1096/fasebj.1.4.2820824; CLARK RB, 1986, ADV CYCLIC NUCL PROT, V20, P151; CLARK RB, 1991, FASEB J, V6, pA78; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1989, J BIOL CHEM, V264, P21435; CORVERA S, 1991, J BIOL CHEM, V266, P9271; DANIELISSAKANI S, 1989, J BIOL CHEM, V264, P20240; FELDER CC, 1989, J BIOL CHEM, V264, P20356; GOKA TJ, 1983, J CYCLIC NUCL PROT, V9, P49; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; JAKOBS KH, 1985, EUR J BIOCHEM, V151, P425, DOI 10.1111/j.1432-1033.1985.tb09119.x; JOHNSON JA, 1986, J CYCLIC NUCL PROT, V11, P199; JOHNSON JA, 1990, MOL PHARMACOL, V38, P289; JOHNSON JA, 1991, MOL PHARMACOL, V39, P539; JOHNSON RA, 1990, MOL PHARMACOL, V37, P296; JOHNSON RA, 1991, MOL PHARMACOL, V39, P399; KISS Z, 1985, BIOCHEM J, V227, P987; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; LEREA KM, 1992, BIOCHEMISTRY-US, V31, P6553, DOI 10.1021/bi00143a027; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SHIBATA H, 1991, J BIOL CHEM, V266, P17948; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; YANG SD, 1988, J BIOL CHEM, V263, P8856	35	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3245	3250						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8381422				2022-12-25	WOS:A1993KM16100037
J	KARLISH, SJD; GOLDSHLEGER, R; JORGENSEN, PL				KARLISH, SJD; GOLDSHLEGER, R; JORGENSEN, PL			LOCATION OF ASN(831) OF THE ALPHA-CHAIN OF NA/K-ATPASE AT THE CYTOPLASMIC SURFACE - IMPLICATION FOR TOPOLOGICAL MODELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MEMBRANE H+-ATPASE; SARCOPLASMIC-RETICULUM; PHOSPHOLIPID-VESICLES; CATALYTIC SUBUNIT; OUTER MEDULLA; CONFORMATIONAL TRANSITIONS; ADENOSINE-TRIPHOSPHATASE; TRANSMEMBRANE DOMAIN; COMPLEMENTARY-DNA	The principal objective of this work has been to determine whether Asn831 of the alpha chain of Na/K-ATPase is located at the cytoplasmic or extracellular surface. Asn831 is the N-terminal residue of a 19-kDa C-terminal tryptic fragment which, together with smaller (8-11 kDa) membrane-embedded fragments of the alpha chain and a largely intact beta chain, is produced by extensive tryptic digestion of renal Na,K-ATPase in the presence of Rb+ and absence of Ca2+ ions. In these so-called ''19-kDa membranes,'' Rb+ and Na+ occlusion capacities are normal, but ATP-dependent activities are lost. Transmembrane segments in the 19-kDa and other fragments are thought to contribute ligating residues to a cation occlusion ''cage.'' However, the arrangement of transmembrane segments of the alpha chain is uncertain, particularly in the critical C-terminal domain. Different topological models predict that the N-terminal Asn831 of the 19-kDa fragment lies at opposite surfaces, respectively. The location of Asn831 has been studied by tryptic digestion of either tight right side-out-oriented membrane vesicles isolated from renal medulla or phospholipid vesicles reconstituted with renal Na/K-ATPase, containing pumps in both right side-out and inside-out orientations. Digestion is performed in the presence of Rb+ and absence of Ca2+ ions. In native renal membrane vesicles the alpha chain is not split by trypsin. By contrast, the beta chain is partially split to a fragment of 16 kDa, beginning at the N-terminal Ala. This fragment is 4 residues longer than a 16-kDa fragment produced by digestion of purified Na/K-ATPase, a finding which shows that trypsin has full access to the extracellular surface, but not to the interior of the vesicles. In the presence of deoxycholate, which destroys the membrane permeability barrier, trypsin digests the alpha chain and the 19-kDa fragment (N-terminal Asn831) is produced. Extensive tryptic digestion of phospholipid vesicles reconstituted with the Na/K-ATPase leads to digestion of the alpha chain and appearance of intermediate fragments and then the 19-kDa fragment. About 25% of the alpha chains in the preparation are resistant to digestion. Functional studies show that the trypsin-resistant pumps are in the right side-out orientation. Observed tryptic fragments were sequenced and the following N termini were detected: Glu31, 33 kDa; Ser221, 78 kDa; Ile470, 56 kDa; Ala590, 39 kDa; and Asn831, 19 kDa. Observation of these N termini is consistent with digestion of the alpha chain of inside-out-oriented pumps at cytoplasmic sites. The results demonstrate clearly that Asn831 is located on the cytoplasmic surface of the alpha chain. Therefore, there must be two transmembrane segments between the end of the large cytoplasmic loop and Asn831, M5+M6. A model of alpha chain topology, with 10 transmembrane segments, including four in the 19-kDa fragment, appears to be a reasonable option. This is similar to the model proposed for sarcoplasmic reticulum Ca-ATPase. Nevertheless, certain eight-segment models, with only two transmembrane segments in the 19-kDa fragment, have not been excluded. Thus further experimentation is required in order to define the transmembrane folding of the C-terminal 19-kDa fragment and make a firm distinction between alternative topological models.	UNIV COPENHAGEN, AUGUST KROGH INST, BIOMEMBRANE RES CTR, DK-2100 COPENHAGEN, DENMARK	University of Copenhagen	KARLISH, SJD (corresponding author), WEIZMANN INST SCI, DEPT BIOCHEM, IL-76100 REHOVOT, ISRAEL.				PHS HHS [32286] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANTOLOVIC R, 1991, EUR J BIOCHEM, V199, P195, DOI 10.1111/j.1432-1033.1991.tb16109.x; BAYER R, 1990, BIOCHEMISTRY-US, V29, P2251, DOI 10.1021/bi00461a007; BESANCON M, 1992, ACTA PHYSIOL SCAND, V146, P77; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CHIN G, 1984, J BIOL CHEM, V259, P5255; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DZHANDZHUGAZYAN KN, 1985, BIOCHIM BIOPHYS ACTA, V817, P165, DOI 10.1016/0005-2736(85)90079-3; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; FORBUSH B, 1982, J BIOL CHEM, V257, P2678; FORBUSH B, 1984, P NATL ACAD SCI-BIOL, V81, P5310, DOI 10.1073/pnas.81.17.5310; GIOTTA GJ, 1975, J BIOL CHEM, V250, P5159; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P53, DOI 10.1016/0005-2736(74)90293-4; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; JORGENSEN PL, 1971, BIOCHIM BIOPHYS ACTA, V233, P381, DOI 10.1016/0005-2736(71)90335-X; JORGENSEN PL, 1982, J BIOL CHEM, V257, P7435; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; JORGENSEN PL, 1975, BIOCHIM BIOPHYS ACTA, V401, P399, DOI 10.1016/0005-2736(75)90239-4; KARLISH SJD, 1981, J PHYSIOL-LONDON, V312, P505, DOI 10.1113/jphysiol.1981.sp013641; KARLISH SJD, 1982, J PHYSIOL-LONDON, V328, P295, DOI 10.1113/jphysiol.1982.sp014265; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KARLISH SJD, 1982, J PHYSIOL-LONDON, V328, P333, DOI 10.1113/jphysiol.1982.sp014267; KARLISH SJD, 1988, METHOD ENZYMOL, V156, P179; KARLISH SJD, 1984, BIOCHIM BIOPHYS ACTA, V776, P288, DOI 10.1016/0005-2736(84)90218-9; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MANDALA SM, 1989, J BIOL CHEM, V264, P16276; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTHEWS I, 1990, J BIOL CHEM, V265, P18737; MATTHEWS I, 1989, BIOCHEM BIOPH RES CO, V161, P683, DOI 10.1016/0006-291X(89)92653-3; MCDONOUGH AA, 1990, FASEB J, V4, P1598, DOI 10.1096/fasebj.4.6.2156741; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; MODYANOV N, 1992, ACTA PHYSIOL SCAND, V146, P49; MONK BC, 1991, J BIOL CHEM, V266, P18097; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; OHTA T, 1986, FEBS LETT, V204, P297, DOI 10.1016/0014-5793(86)80832-8; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P269, DOI 10.1016/0014-5793(87)80676-2; OVCHINNIKOV YA, 1988, FEBS LETT, V227, P230, DOI 10.1016/0014-5793(88)80904-9; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RAO US, 1991, J BIOL CHEM, V266, P14740; REPHAELI A, 1986, J BIOL CHEM, V261, P6248; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SKRIVER E, 1983, CURR TOP MEMBR TRANS, V19, P119	50	78	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3471	3478						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8381430				2022-12-25	WOS:A1993KM16100070
J	MATSUDA, S; GOTOH, Y; NISHIDA, E				MATSUDA, S; GOTOH, Y; NISHIDA, E			PHOSPHORYLATION OF XENOPUS MITOGEN-ACTIVATED PROTEIN (MAP) KINASE KINASE BY MAP KINASE KINASE KINASE AND MAP KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SERINE THREONINE KINASES; SUBSTRATE RECOGNITION; SWISS 3T3-CELLS; IDENTIFICATION; INVITRO; FIBROBLASTS; SEQUENCE; PROGRESS; CASCADE	Xenopus 45-kDa mitogen-activated protein (MAP) kinase kinase (MAPKK) is a serine/threonine/tyrosine kinase, which activates MAP kinase (MAPK) by phosphorylating its threonine and tyrosine residues. MAPKK is active only when its threonine and/or serine residues are phosphorylated. We have identified from Xenopus eggs two protein kinases responsible for phosphorylation of MAPKK. The two kinases are separated by Sephacryl S-300 gel filtration chromatography. The higher molecular weight kinase phosphorylates MAPKK previously dephosphorylated and inactivated by phosphatase 2A treatment on mainly serine and slightly threonine residues, and reactivates the MAPKK, and is thus assumed to work as MAPKK kinase (MAPKKK) in vivo. The lower molecular weight kinase, identified as MAPK, phosphorylates the dephosphorylated MAPKK on mainly threonine and faintly serine residues, but does not reactivate the MAPKK activity. As Xenopus MAPKK contains a single phosphorylation consensus sequence (PXT388P) for MAPK in the C-terminal region, this T388 residue may be a major phosphorylation site catalyzed by MAPK. Thus, Xenopus MAPKK is phosphorylated in mature oocytes by not only an upstream kinase, MAPKKK, but also a downstream kinase, MAPK.	UNIV TOKYO, FAC SCI, DEPT BIOPHYS & BIOCHEM, TOKYO 113, JAPAN	University of Tokyo								AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HOSHI M, 1988, J BIOL CHEM, V263, P5396; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEE RM, 1992, J BIOL CHEM, V267, P1088; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NISHIDA E, 1992, INT REV CYTOL, V138, P211, DOI 10.1016/S0074-7696(08)61589-2; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHIINA N, 1992, EMBO J, V11, P3977, DOI 10.1002/j.1460-2075.1992.tb05491.x; SHIRAKABE K, 1992, J BIOL CHEM, V267, P16685; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	36	121	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3277	3281						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8381423				2022-12-25	WOS:A1993KM16100042
J	PAN, GH; LUETKE, K; JUBY, CD; BROUSSEAU, R; SADOWSKI, P				PAN, GH; LUETKE, K; JUBY, CD; BROUSSEAU, R; SADOWSKI, P			LIGATION OF SYNTHETIC ACTIVATED DNA SUBSTRATES BY SITE-SPECIFIC RECOMBINASES AND TOPOISOMERASE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLP RECOMBINASE; IDENTIFICATION; MECHANISM; CLEAVAGE; PROTEIN; BINDING; TYROSINE; INVITRO; CRE	The FLP protein of the 2-mum plasmid of Saccharomyces cerevisiae is a conservative site-specific recombinase that is involved in the amplification of the plasmid. This recombination reaction proceeds via the covalent attachment of the protein to the 3'-phosphoryl group at the site of the breaks through a phosphotyrosine linkage. We have recently developed an assay that measures FLP-mediated strand ligation independent of FLP-mediated cleavage and covalent attachment to the DNA. The substrate for ligation was produced by FLP-induced cleavage of the FLP recognition site followed by digestion with Pronase and was shown to contain (at least) a tyrosine residue at the 3'-PO4 terminus adjacent to the FLP cleavage sites. We have now synthesized artificial substrates that bear a tyrosine residue on the 3'-PO4 of an appropriate oligonucleotide and find that this substrate is ligated as efficiently as the previous ligation substrates that were isolated after FLP cleavage of the substrate. Analogous substrates for other members of the integrase family of recombinases (lambda integrase protein, P1-Cre protein) as well as for mammalian topoisomerase I are also active as ligation substrates with their cognate protein. This class of activated substrates should be useful in the study of breakage and reunion reactions involving DNA.	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA; NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,GENET ENGN SECT,MONTREAL H4P 2R2,QUEBEC,CANADA	University of Toronto; National Research Council Canada								ABREMSKI K, 1984, J BIOL CHEM, V259, P1509; ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; ARGOS P, 1986, EMBO J, V5, P443; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; Cox M. M., 1989, MOBILE DNA, P661; CRAIG NL, 1988, ANNU REV GENET, V22, P77; DEVARGAS LM, 1988, CELL, V54, P923, DOI 10.1016/0092-8674(88)90107-9; EVANS BR, 1990, J BIOL CHEM, V265, P18504; FRIESEN H, 1992, J MOL BIOL, V225, P313, DOI 10.1016/0022-2836(92)90924-9; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P3274, DOI 10.1128/MCB.5.11.3274; HOESS RH, 1984, P NATL ACAD SCI-BIOL, V81, P1026, DOI 10.1073/pnas.81.4.1026; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; PAN GH, 1992, J BIOL CHEM, V267, P12397; PAN H, 1991, J BIOL CHEM, V266, P11347; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7678; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; RICHET E, 1988, CELL, V52, P9, DOI 10.1016/0092-8674(88)90526-0; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; SVEJSTRUP JQ, 1990, J BIOL CHEM, V265, P12529; VETTER D, 1983, P NATL ACAD SCI-BIOL, V80, P7284, DOI 10.1073/pnas.80.23.7284; WEISBERG RA, 1983, LAMBDA, V2, P221	24	28	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3683	3689						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8381436				2022-12-25	WOS:A1993KM16100099
J	DEBUIRE, B; PATERLINI, P; PONTISSO, P; BASSO, G; MAY, E				DEBUIRE, B; PATERLINI, P; PONTISSO, P; BASSO, G; MAY, E			ANALYSIS OF THE P53 GENE IN EUROPEAN HEPATOCELLULAR CARCINOMAS AND HEPATOBLASTOMAS	ONCOGENE			English	Note							TUMOR-SUPPRESSOR GENE; BREAST-CANCER; CELL-LINES; MUTATIONS; POLYMORPHISM; LYMPHOMA; SARCOMAS; TP53	Human hepatocellular carcinomas (HCC) and hepatoblastomas (HB) from patients in France and Italy, respectively, which are both areas with a low incidence of HCC and a low dietary exposure to aflatoxin B1 (AFB1), were analysed for alterations of the p53 tumour suppressor gene. An abnormality in the p53 gene was detected in only one of the seven HCCs examined. Sequencing of the cDNA of this HCC revealed a G to T transversion at the first nucleotide of codon 245 that was not found in normal tissue, excluding the possibility of germinal transmission of this alteration. All tumours had the wild-type sequence at codon 249, which has been reported to be a mutational hot spot in the p53 gene in HCCs from high incidence areas, such as China and Southern Africa. Seven samples of HB, the most common hepatic tumour of children, were also tested for loss of heterozygosity (LOH) and mutations in the p53 gene. In contrast to what is observed in HCC of adulthood, for which environmental conditions are important etiological risk factors, HB probably stems uniquely from genetic disorders. PCR-direct sequencing of exons 4 to 8 and PCR-single strand conformation polymorphism (PCR-SSCP) of exons 2, 3 and 9 revealed no mutations in the coding sequences examined. LOH was observed in one of the five informative cases when codon 72 and intron 6 were subjected to polymorphism analysis.	UNIV PADUA,PEDIAT CLIN,I-35123 PADUA,ITALY; CHU NECKER,INSERM,U75,F-75073 PARIS 15,FRANCE; UNIV PADUA,MED CLIN,I-35123 PADUA,ITALY	University of Padua; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Padua	DEBUIRE, B (corresponding author), CNRS,UPR 275,F-94801 VILLEJUIF,FRANCE.		PONTISSO, PATRIZIA/K-3574-2018	PONTISSO, PATRIZIA/0000-0003-2077-9202; BASSO, GIUSEPPE/0000-0002-2634-9302				BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUETOW KH, 1992, P NATL ACAD SCI USA, V89, P9622, DOI 10.1073/pnas.89.20.9622; CHALLEN C, 1992, HEPATOLOGY, V16, P1362, DOI 10.1002/hep.1840160610; CHUMAKOV PM, 1991, NUCLEIC ACIDS RES, V19, P6969, DOI 10.1093/nar/19.24.6969-a; DEAN M, 1991, BIOTECHNIQUES, V10, P332; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DUTHU A, 1992, ONCOGENE, V7, P2161; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HARRIS AL, 1991, NATURE, V350, P377, DOI 10.1038/350377a0; HAYWARD NK, 1991, NATURE, V352, P764, DOI 10.1038/352764a0; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; KRESS S, 1992, CANCER RES, V52, P3220; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MURAKAMI Y, 1991, CANCER RES, V51, P5520; ODA T, 1992, CANCER RES, V52, P6358; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; ROMANO JW, 1989, ONCOGENE, V4, P1483; SCORSONE KA, 1992, CANCER RES, V52, P1635; SHEU JC, 1992, CANCER RES, V52, P6098; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494	27	46	46	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2303	2306						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8393166				2022-12-25	WOS:A1993LP17100034
J	MORRISON, P; TAKISHIMA, K; ROSNER, MR				MORRISON, P; TAKISHIMA, K; ROSNER, MR			ROLE OF THREONINE RESIDUES IN REGULATION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR BY PROTEIN-KINASE-C AND MITOGEN-ACTIVATED PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING-SITE; EGF-RECEPTOR; INDEPENDENT MECHANISMS; PHOSPHORYLATION SITES; SIGNAL TRANSDUCTION; TUMOR PROMOTERS; POINT MUTATION; SERINE; SUBSTITUTION; THAPSIGARGIN	Epidermal growth factor (EGF) receptor tyrosine kinase activity is down-regulated by a number of growth-modulating agents that activate protein kinase C and/or mitogen-activated protein (MAP) kinases. Although the mechanism is unclear, it has been hypothesized that phosphorylation of specific threonine residues leads to inhibition of the EGF receptor tyrosine kinase. Two sites phosphorylated on the EGF receptor in response to phorbol esters are possible mediators of this effect: threonine 654, the target of protein kinase C, and threonine 669, the target of MAP kinase and the major site of phosphorylation on the EGF receptor. In order to investigate the role of these residues in receptor regulation, we substituted glutamic acid to mimic the negative charge introduced by phosphorylation at these sites. The wild-type and mutant receptor cDNAs were then transfected into CHO cells that lack endogenous EGF receptor. The EGF binding properties of the mutant receptors were similar to those of the wild-type EGF receptors. EGF stimulated tyrosine kinase activity and DNA synthesis in cells expressing both mutant receptors, indicating that the mutant EGF receptors are biologically active. Treatment of cells with phorbol esters inhibited the high affinity EGF binding and tyrosine kinase activities of both mutant and wild-type EGF receptors. These results indicate that acidic residues at either the Thr-654 or Thr-669 site modulate but do not block EGF receptor signalling. Furthermore, this data demonstrates that the mutant EGF receptors are still a target for inhibition by phorbol esters. Thus, events other than phosphorylation of Thr-654 or Thr-669 appear to be required for receptor down-regulation by protein kinase C or MAP kinase.	UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637	University of Chicago; University of Chicago	MORRISON, P (corresponding author), UNIV CHICAGO,BEN MAY INST,CHICAGO,IL 60637, USA.				NATIONAL CANCER INSTITUTE [R01CA035541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007183] Funding Source: NIH RePORTER; NCI NIH HHS [CA35541] Funding Source: Medline; NIGMS NIH HHS [GM07183] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOWEN S, 1991, J BIOL CHEM, V266, P1162; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; COCHET C, 1984, J BIOL CHEM, V259, P2553; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; FELDER S, 1992, MOL CELL BIOL, P2302; FONG YL, 1989, J BIOL CHEM, V264, P16759; FRIEDMAN B, 1989, P NATL ACAD SCI USA, V86, P812, DOI 10.1073/pnas.86.3.812; FRIEDMAN BA, 1984, P NATL ACAD SCI-BIOL, V81, P3034, DOI 10.1073/pnas.81.10.3034; GRISWOLDPRENNER I, 1993, J BIOL CHEM, V268, P13050; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HEISERMANN GJ, 1990, J BIOL CHEM, V265, P12820; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; NARANDA T, 1991, P NATL ACAD SCI USA, V88, P10563, DOI 10.1073/pnas.88.23.10563; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; TAKISHIMA K, 1988, BIOCHEM BIOPH RES CO, V157, P740, DOI 10.1016/S0006-291X(88)80312-7; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; WITTEKIND M, 1989, BIOCHEMISTRY-US, V28, P9908, DOI 10.1021/bi00452a005	28	80	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15536	15543						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8393447				2022-12-25	WOS:A1993LN30500035
J	OSHEROFF, PL; HO, WH				OSHEROFF, PL; HO, WH			EXPRESSION OF RELAXIN MESSENGER-RNA AND RELAXIN RECEPTORS IN POSTNATAL AND ADULT-RAT BRAINS AND HEARTS - LOCALIZATION AND DEVELOPMENTAL PATTERNS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYTOCIN RELEASE; PORCINE RELAXIN; ANESTHETIZED RATS; SUBFORNICAL ORGAN; NORTHERN ANALYSIS; LACTATING RATS; NEUROHYPOPHYSIS; HYBRIDIZATION; TROPHOBLAST; INHIBITION	Relaxin is a polypeptide hormone best known for its role in parturition. However, high affinity relaxin receptors have been localized in the rat brain and heart in addition to the uterus. Several lines of evidence also suggest that relaxin may be involved in the regulation of blood pressure, heart rate, and the release of oxytocin and vasopressin. We now show by Northern analysis that a 1-kilobase relaxin transcript is detected in the rat brain as well as the ovary of pregnant rats. Using in situ hybridization, relaxin mRNA is localized in discrete regions of the male and female brains, including the anterior olfactory nucleus, tenia tecta, pyriform cortex, neocortex, and hippocampus. Developmental studies show that relaxin mRNA is present in the 1-day postnatal brain, while relaxin receptors are not detectable until 7 days after birth. The relaxin receptor binding affinity was similar in the developing brains, but there was a steady increase in relaxin binding sites during postnatal days 7 to 29, suggesting that relaxin may play a role in brain maturation. While relaxin mRNA is not detected in the heart, high levels of relaxin receptors are detected in the cardiac atrium as early as 1 day after birth. These atrial receptors remained at similar levels throughout postnatal development, suggesting an important role for relaxin in cardiovascular function.			OSHEROFF, PL (corresponding author), GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080, USA.							CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRISH JF, 1986, J BIOL CHEM, V261, P1909; DAYANITHI G, 1987, NATURE, V325, P813, DOI 10.1038/325813a0; EDDIE LW, 1989, AM J OBSTET GYNECOL, V161, P970, DOI 10.1016/0002-9378(89)90764-3; HANSELL DJ, 1991, J CLIN ENDOCR METAB, V72, P899, DOI 10.1210/jcem-72-4-899; HERKENHAM M, 1987, NEUROSCIENCE, V23, P1, DOI 10.1016/0306-4522(87)90268-5; HUDSON P, 1984, EMBO J, V3, P2333, DOI 10.1002/j.1460-2075.1984.tb02135.x; HUDSON P, 1981, NATURE, V291, P127, DOI 10.1038/291127a0; IVELL R, 1989, MOL CELL ENDOCRINOL, V66, P251, DOI 10.1016/0303-7207(89)90037-3; JONES SA, 1987, J ENDOCRINOL, V114, P241, DOI 10.1677/joe.0.1140241; KAKOURIS H, 1992, LANCET, V339, P1076, DOI 10.1016/0140-6736(92)90665-P; KEMP BE, 1984, VITAM HORM, V41, P79; KRAMER SM, 1990, IN VITRO CELL DEV B, V26, P647; KROCZEK RA, 1990, ANAL BIOCHEM, V184, P90, DOI 10.1016/0003-2697(90)90017-4; LOUMAYE E, 1980, J CLIN ENDOCR METAB, V50, P1142, DOI 10.1210/jcem-50-6-1142; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLER JW, 1957, J PHARMACOL EXP THER, V120, P426; MUMFORD AD, 1989, J ENDOCRINOL, V122, P747, DOI 10.1677/joe.0.1220747; OBYRNE KT, 1986, J ENDOCRINOL, V109, P393, DOI 10.1677/joe.0.1090393; OSHEROFF PL, 1990, J BIOL CHEM, V265, P9396; OSHEROFF PL, 1992, P NATL ACAD SCI USA, V89, P2384, DOI 10.1073/pnas.89.6.2384; OSHEROFF PL, 1991, P NATL ACAD SCI USA, V88, P6413, DOI 10.1073/pnas.88.15.6413; PARRY LJ, 1990, J NEUROENDOCRINOL, V2, P53, DOI 10.1111/j.1365-2826.1990.tb00392.x; SAKBUN V, 1990, J CLIN ENDOCR METAB, V70, P508, DOI 10.1210/jcem-70-2-508; Sherwood O.D., 1988, P585; STEINETZ BG, 1960, ENDOCRINOLOGY, V67, P102, DOI 10.1210/endo-67-1-102; STEWART DR, 1990, J CLIN ENDOCR METAB, V70, P1771, DOI 10.1210/jcem-70-6-1771; STLOUIS J, 1985, LIFE SCI, V37, P1351, DOI 10.1016/0024-3205(85)90251-6; SUMMERLEE AJS, 1984, NATURE, V309, P372, DOI 10.1038/309372a0; SUMMERLEE AJS, 1987, J ENDOCRINOL, V115, P347, DOI 10.1677/joe.0.1150347; WARD DG, 1992, BIOCHEM BIOPH RES CO, V186, P999, DOI 10.1016/0006-291X(92)90845-C; WAY SA, 1992, J ENDOCRINOL, V132, P149, DOI 10.1677/joe.0.1320149; WEISS G, 1989, BIOL REPROD, V40, P197, DOI 10.1095/biolreprod40.2.197; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671; WINSLOW JW, 1992, ENDOCRINOLOGY, V130, P2660, DOI 10.1210/en.130.5.2660	36	97	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15193	15199						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8392068				2022-12-25	WOS:A1993LL75900094
J	PREISER, P; VASISHT, V; BIRK, A; LEVINGER, L				PREISER, P; VASISHT, V; BIRK, A; LEVINGER, L			POLY(U)-BINDING PROTEIN INHIBITS DROSOPHILA PRE-5 S-RNA 3'-EXONUCLEASE DIGESTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5S RIBOSOMAL-RNA; POLYMERASE-III; XENOPUS-OOCYTES; MAMMALIAN-CELLS; BINDING-SITE; 3' TERMINI; 5-S RNA; PRECURSOR; TRANSCRIPTS; INVITRO	A approximately 50-kDa protein binds specifically to the 3' terminus of 135-nucleotide Drosophila pre-5 S RNA. Unlabeled poly(U) competes out protein binding and stimulates the activity of a 3'-exonuclease, which eventually degrades the substrate to 120 nucleotides, the size of mature 5 S RNA. In its RNA binding and UV cross-linking properties, the endogenous poly(U)-binding protein resembles human La, an autoantigen that binds the U>3 3' ends of vertebrate RNA polymerase III primary transcripts. This protein appears to inhibit a 3' exonuclease and could protect 5 S RNA for faithful processing and transport.	CUNY YORK COLL,DEPT NAT SCI BIOL DISCIPLINE,JAMAICA,NY 11451; UNIV DELAWARE,SCH LIFE & HLTH SCI,NEWARK,DE 19716	City University of New York (CUNY) System; York College NY (CUNY); University of Delaware			Preiser, Peter R/A-2201-2011		NIGMS NIH HHS [GM4603, GM08153] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROW DA, 1987, J BIOL CHEM, V262, P13959; CHAMBERS JC, 1988, J BIOL CHEM, V263, P18043; CHAN EKL, 1987, J EXP MED, V166, P1627, DOI 10.1084/jem.166.6.1627; DEWACHTER R, 1972, ANAL BIOCHEM, V49, P184, DOI 10.1016/0003-2697(72)90257-6; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GOTTLIEB EL, 1989, EMBO J, V8, P841, DOI 10.1002/j.1460-2075.1989.tb03445.x; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HAMADA H, 1979, CELL, V17, P163, DOI 10.1016/0092-8674(79)90304-0; Hardesty B., 1986, STRUCTURE FUNCTION G; HENDRICK JP, 1981, MOL CELL BIOL, V1, P1138, DOI 10.1128/MCB.1.12.1138; HUBER PW, 1986, J BIOL CHEM, V261, P3002; HUBER PW, 1986, P NATL ACAD SCI USA, V83, P1593, DOI 10.1073/pnas.83.6.1593; IYER RK, 1988, GENE ANAL TECH, V5, P125, DOI 10.1016/0735-0651(88)90012-X; JACQ B, 1977, J MOL BIOL, V117, P785, DOI 10.1016/0022-2836(77)90069-9; KEMPERSVEENSTRA AE, 1986, EMBO J, V5, P2703, DOI 10.1002/j.1460-2075.1986.tb04554.x; KLEINSCHMIDT AM, 1987, MOL CELL BIOL, V7, P3131, DOI 10.1128/MCB.7.9.3131; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINGER L, 1992, J BIOL CHEM, V267, P23683; LEVINGER L, 1992, BIOTECHNOL EDUC, V3, P68; PIPER PW, 1987, FEBS LETT, V214, P143, DOI 10.1016/0014-5793(87)80030-3; PIPER PW, 1989, FEBS LETT, V250, P311, DOI 10.1016/0014-5793(89)80745-8; PIPER PW, 1983, EMBO J, V2, P353, DOI 10.1002/j.1460-2075.1983.tb01430.x; PREISER PR, 1991, J BIOL CHEM, V266, P7509; PREISER PR, 1991, J BIOL CHEM, V266, P23602; RINKE J, 1982, CELL, V29, P149, DOI 10.1016/0092-8674(82)90099-X; ROMANIUK P, 1989, MOL BIOL RNA; RUBIN GM, 1975, CELL, V6, P207, DOI 10.1016/0092-8674(75)90011-2; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; STEITZ JA, 1988, J CELL BIOL, V106, P545, DOI 10.1083/jcb.106.3.545; TAN EM, 1982, ADV IMMUNOL, V33, P167, DOI 10.1016/S0065-2776(08)60836-6; TEKAMP PA, 1980, J BIOL CHEM, V255, P9501; TERNS MP, 1992, MOL CELL BIOL, V12, P3032, DOI 10.1128/MCB.12.7.3032; WANG J, 1991, P NATL ACAD SCI USA, V88, P7391, DOI 10.1073/pnas.88.16.7391; XING YY, 1989, GENE DEV, V3, P1008, DOI 10.1101/gad.3.7.1008; YANG H, 1992, MOL CELL BIOL, V12, P1553, DOI 10.1128/MCB.12.4.1553	35	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11553	11557						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8389357				2022-12-25	WOS:A1993LF28400018
J	AN, G; TESFAIGZI, J; CHUU, YJ; WU, R				AN, G; TESFAIGZI, J; CHUU, YJ; WU, R			ISOLATION AND CHARACTERIZATION OF THE HUMAN SPR1 GENE AND ITS REGULATION OF EXPRESSION BY PHORBOL ESTER AND CYCLIC-AMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRONCHIAL EPITHELIAL-CELLS; SEQUENCES; UV; DIFFERENTIATION; IDENTIFICATION; KERATINOCYTES; EXTRACTION; ELEMENTS; GROWTH; ASSAY	The small proline-rich protein gene (spr1) is a marker whose expression is frequently associated with squamous cell differentiation. We observed that the expression of the spr1 gene is strongly induced by phorbol 12-myristate 13-acetate (PMA). Both the time course result and the nuclear run-on transcriptional assay suggested that the regulation of spr1 expression by PMA is controlled at the transcriptional level. To understand the nature of this regulation, human genomic clones of the spr1 gene were isolated. DNA sequence analysis revealed that the human spr1 gene contains two exons and a single intron located within the 5'-untranslated region. An AP-1 binding site (TGAGTCA) is found at -142, and a putative cyclic AMP-responsive element (TGAGGTCA) at -597 base pairs upstream of the transcription start site. A chimeric construct containing the 5'-flanking region of the spr1 gene and the chloramphenicol acetyltransferase (CAT) reporter gene was used to transfect HeLa cells or monkey primary TBE cells. The CAT activity in transfected cells is stimulated 7.5-11-fold by PMA, and the stimulation is inhibited by a protein kinase C inhibitor or by pretreating cells with PMA to down-regulate the protein kinase C activity. The CAT activity is also stimulated 3.5-fold by dibutyryl cyclic AMP, a protein kinase A activator. The stimulations by PMA and cAMP are additive. These results suggest that protein kinase C and probably protein kinase A play important roles in regulating the transcription of the spr1 gene.	UNIV CALIF DAVIS, CALIF PRIMATE RES CTR, DAVIS, CA 95616 USA; UNIV CALIF DAVIS, DEPT BIOCHEM & BIOPHYS, DAVIS, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis				Tesfaigzi, Yohannes/0000-0002-3997-5839	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL035635, R01HL035635] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35635] Funding Source: Medline; NIEHS NIH HHS [ES00628] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AUERBACH O, 1961, NEW ENGL J MED, V265, P253, DOI 10.1056/NEJM196108102650601; BUSCHER M, 1988, ONCOGENE, V3, P301; CELANO P, 1989, BIOTECHNIQUES, V7, P942; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GANG A, 1992, AM J RESP CELL MOL, V7, P104, DOI 10.1165/ajrcmb/7.1.104; GIBBS S, 1990, NUCLEIC ACIDS RES, V18, P4401, DOI 10.1093/nar/18.15.4401; HARRIS CC, 1972, JNCI-J NATL CANCER I, V48, P743; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2195, DOI 10.1128/MCB.8.5.2195; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2204, DOI 10.1128/MCB.8.5.2204; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOIS R, 1989, EMBO J, V8, P1641, DOI 10.1002/j.1460-2075.1989.tb03554.x; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; Maniatis T, 1989, MOL CLONING; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NETESHEIM P, 1978, PATHOGENESIS THERAPY, P75; PFEIFER AMA, 1989, ENVIRON HEALTH PERSP, V80, P209, DOI 10.2307/3430746; ROBINSON CB, 1991, J TISSUE CULTURE MET, V13, P95; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WILLEY JC, 1984, CANCER RES, V44, P5124; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; WU R, 1985, J CELL PHYSIOL, V125, P167, DOI 10.1002/jcp.1041250202; WU R, 1986, IN VITRO MODELS RESP, P1; YOUN BS, 1991, J EXP MED, V173, P813, DOI 10.1084/jem.173.4.813	28	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10977	10982						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8388378				2022-12-25	WOS:A1993LD46600042
J	MULDER, M; LOMBARDI, P; JANSEN, H; VANBERKEL, TJC; FRANTS, RR; HAVEKES, LM				MULDER, M; LOMBARDI, P; JANSEN, H; VANBERKEL, TJC; FRANTS, RR; HAVEKES, LM			LOW-DENSITY-LIPOPROTEIN RECEPTOR INTERNALIZES LOW-DENSITY AND VERY LOW-DENSITY LIPOPROTEINS THAT ARE BOUND TO HEPARAN-SULFATE PROTEOGLYCANS VIA LIPOPROTEIN-LIPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LDL-RECEPTOR; CHYLOMICRON REMNANTS; PLASMA-LIPOPROTEINS; APOPROTEIN-E; LIVER-CELLS; RAT-LIVER; BINDING; PROTEIN; METABOLISM; MECHANISM	It has previously been shown that lipoprotein lipase (LPL) enhances the binding of low density lipoproteins (LDL) and very low density lipoproteins (VLDL) to HepG2 cells and fibroblasts, up to 80-fold. This increase in binding is LDL receptor-independent and is due to a bridging of LPL between extracellular heparan sulfate proteoglycans (HSPG) and the lipoproteins. In the present paper, we show that preincubation of the cells with LPL, followed by washing prior to the binding experiment, increased binding to the same extent as occurs when the binding is performed in the presence of LPL. This indicates that the formation of a complex of LPL with the lipoproteins is not a prerequisite of binding. Binding curves and Scatchard analyses reveal that both the number of binding sites and the affinity of the binding are increased 20-30-fold by the addition of 3.4 mug/ml LPL. The addition of LPL also resulted in an enhanced uptake and subsequent lysosomal degradation of both LDL and VLDL when compared with binding, although to a lesser extent (up to 25-fold when measured after 5 h at 37-degrees-C). Strikingly, enhanced uptake did not occur in LDL receptor-negative fibroblasts. In addition, down-regulation of the LDL receptor activity by preincubation of the cells for 48 h with either LDL or beta-VLDL resulted in a parallel decrease in the uptake of LPL-mediated HSPG-bound LDL, whereas the LPL-mediated binding itself was not diminished. These observations indicate that the uptake of LPL-mediated HSPG-bound LDL and VLDL mainly proceeds via the LDL receptor. Binding of labeled LDL to the cells at 4-degrees-C for 2 h followed by a chase period at 37-degrees-C revealed that in absolute terms, the initial rate of internalization of HSPG-bound LDL is comparable with that of LDL receptor-bound LDL (0.58 and 0.44 ng/min/mg of cell protein, respectively). We conclude that in LDL receptor-positive cells, the LPL-mediated binding of LDL and VLDL to HSPG is followed by internalization of the lipoproteins mainly through the rapid process of the classical LDL receptor recycling system, whereas only a minor portion is internalized via the much slower process of HSPG uptake.	TNO,GAUBIUS LAB,POB 430,2300 AK LEIDEN,NETHERLANDS; TNO,INST AGEING & VASC RES,2300 AK LEIDEN,NETHERLANDS; DEPT BIOCHEM & INTERNAL MED 3,ROTTERDAM,NETHERLANDS; CTR BIOPHARMACEUT SCI,LEIDEN,NETHERLANDS	Netherlands Organization Applied Science Research; Netherlands Organization Applied Science Research			Van Berkel, Theo/ABD-7677-2021					BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BIHAIN BE, 1989, J BIOL CHEM, V264, P17316; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN MS, 1983, J CLIN INVEST, V72, P743, DOI 10.1172/JCI111044; CISAR LA, 1989, J BIOL CHEM, V264, P1767; DEWATER R, 1992, BIOCHEM J, V281, P62; EISENBERG S, 1988, ARTERIOSCLEROSIS, V8, P480, DOI 10.1161/01.ATV.8.5.480; FELTS JM, 1975, BIOCHEM BIOPH RES CO, V66, P1467, DOI 10.1016/0006-291X(75)90524-0; FRIEDMAN G, BIOCHIM BIOPHYS ACTA, V711, P114; GOLDBERG IJ, 1986, J CLIN INVEST, V78, P1523, DOI 10.1172/JCI112744; HARKES L, 1989, EUR J BIOCHEM, V180, P241, DOI 10.1111/j.1432-1033.1989.tb14639.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P3623, DOI 10.1073/pnas.79.11.3623; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; LOMBARDI P, 1990, BIOCHIM BIOPHYS ACTA, V1044, P127, DOI 10.1016/0005-2760(90)90227-O; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; MULDER M, 1990, BIOCHIM BIOPHYS ACTA, V1081, P308; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; OBRIEN KD, 1992, J CLIN INVEST, V89, P1544, DOI 10.1172/JCI115747; OLIVECRONA T, 1989, CURR OPIN LIPID, V1, P112; Olivecrona T, 1990, CURR OPIN LIPIDOL, V1, P222; OWENS RT, 1991, ARTERIOSCLER THROMB, V11, P1752, DOI 10.1161/01.ATV.11.6.1752; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; SAXENA U, 1991, J BIOL CHEM, V266, P17516; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TAJIMA S, 1984, J BIOCHEM, V96, P1753, DOI 10.1093/oxfordjournals.jbchem.a135008; VANDIJK MCM, 1991, BIOCHEM J, V279, P863, DOI 10.1042/bj2790863; VIJAYAGOPAL P, 1992, ARTERIOSCLER THROMB, V12, P237, DOI 10.1161/01.ATV.12.2.237; VILARO S, 1988, AM J PHYSIOL, V254, pG711, DOI 10.1152/ajpgi.1988.254.5.G711; VILLELI E, 1991, MED SCI RES, V19, P111; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WINDLER EET, 1980, J BIOL CHEM, V255, P464; WINDLER EET, 1988, BIOCHEM J, V252, P553, DOI 10.1042/bj2520553	36	192	195	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9369	9375						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8387492				2022-12-25	WOS:A1993LA68900035
J	CARLSON, K; KRABBE, M; NYSTROM, AC; KOSTURKO, LD				CARLSON, K; KRABBE, M; NYSTROM, AC; KOSTURKO, LD			DNA DETERMINANTS OF RESTRICTION - BACTERIOPHAGE-T4 ENDONUCLEASE-II-DEPENDENT CLEAVAGE OF PLASMID DNA INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISCRETELY SIZED FRAGMENTS; ESCHERICHIA-COLI; B-DNA; BASE SEQUENCE; CURVED DNA; DEOXYRIBONUCLEIC ACID; GENETICALLY DISTINCT; MODIFICATION SYSTEM; CRYSTAL-STRUCTURE; HELIX STRUCTURE	Endonuclease II of coliphage T4 is necessary for the in vivo restriction of plasmid DNA in phage-infected cells. Double-stranded restriction cleavage at 12 sites in pBR322 commenced before 10-min postinfection with T4 at 37-degrees-C and proceeded more slowly in the presence of competing phage DNA than in its absence, utilizing the same sites in both cases; in a 200-base pair segment of the plasmid, single-stranded nicks also were frequent. The plasmid sites were cleaved with a speed that varied with the site, yielding frequencies of cleavage at different sites varying between 10 and 90%, at 50-min postinfection. All sites contained good matches to a consensus, 5'-GRCCGCNTYGC-3', most frequently cleaved around the variable central base pair, generating fragments with blunt ends or 1-2-base 5' overhangs. Using the frequency of cleavage to determine a weighted consensus, a larger sequence, 5'-CGRCCGCNTTGSYNGC-3', was identified. Thus, DNA sequence elements 3' to the cut site appear important for rapid cleavage. Several models describing the sequence-dependent structure of DNA suggest structural anomalies around the cleavage sites. The endonuclease II restriction system is most similar to type II systems, although it differs from known type II systems in several respects.	WESLEYAN UNIV,DEPT MOLEC BIOL & BIOCHEM,HALL ATWATER & SHANKLIN LABS,MIDDLETOWN,CT 06459; CONNECTICUT COLL,DEPT ZOOL,NEW LONDON,CT 06320	Wesleyan University; Connecticut College	CARLSON, K (corresponding author), UNIV UPPSALA,CTR BIOMED,DEPT MICROBIOL,S-75123 UPPSALA,SWEDEN.							AIKEN CR, 1991, J BIOL CHEM, V266, P19070; BARANY F, 1992, GENE, V112, P3, DOI 10.1016/0378-1119(92)90296-2; BERG OG, 1987, J MOL BIOL, V193, P723, DOI 10.1016/0022-2836(87)90354-8; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; CALLADINE CR, 1982, J MOL BIOL, V161, P343, DOI 10.1016/0022-2836(82)90157-7; CARLSON K, 1983, J VIROL, V48, P18, DOI 10.1128/JVI.48.1.18-30.1983; CARLSON K, 1986, GENETICS, V114, P669; CONRAD M, 1989, P NATL ACAD SCI USA, V86, P9707, DOI 10.1073/pnas.86.24.9707; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DICKERSON RE, 1983, J MOL BIOL, V166, P419, DOI 10.1016/S0022-2836(83)80093-X; Dickerson RE, 1989, EMBO J, V8, P1; DREW HR, 1988, ANNU REV CELL BIOL, V4, P1; ENDLICH B, 1985, J BIOL CHEM, V260, P5729; FRASER D, 1953, J BIOL CHEM, V205, P291; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; HAGERMAN PJ, 1990, ANNU REV BIOCHEM, V59, P755, DOI 10.1146/annurev.biochem.59.1.755; HEIDMANN S, 1989, NUCLEIC ACIDS RES, V17, P9783, DOI 10.1093/nar/17.23.9783; HEINEMANN U, 1992, EMBO J, V11, P1931, DOI 10.1002/j.1460-2075.1992.tb05246.x; HEITMAN J, 1987, J BACTERIOL, V169, P3243, DOI 10.1128/jb.169.7.3243-3250.1987; HERCULES K, 1971, J VIROL, V7, P95, DOI 10.1128/JVI.7.1.95-105.1971; JERNIGAN RL, 1986, J BIOMOL STRUCT DYN, V4, P41, DOI 10.1080/07391102.1986.10507645; KESSLER C, 1990, GENE, V92, P1, DOI 10.1016/0378-1119(90)90486-B; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1988, P NATL ACAD SCI USA, V85, P1763, DOI 10.1073/pnas.85.6.1763; KRABBE M, 1991, J BIOL CHEM, V266, P23407; KREUZER K, 1988, J BIOL CHEM, V26, P11348; KUBAREVA EA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P395, DOI 10.1016/0167-4781(91)90131-5; KUTTER EM, 1968, J MOL BIOL, V38, P395, DOI 10.1016/0022-2836(68)90394-X; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LINIAL M, 1987, P NATL ACAD SCI USA, V84, P8205, DOI 10.1073/pnas.84.23.8205; MARMUR J, 1962, J MOL BIOL, V5, P109, DOI 10.1016/S0022-2836(62)80066-7; MCCALL M, 1985, J MOL BIOL, V183, P385, DOI 10.1016/0022-2836(85)90009-9; MCCALL M, 1986, NATURE, V322, P661, DOI 10.1038/322661a0; MCCLELLAND M, 1988, NUCLEIC ACIDS RES, V16, P2283, DOI 10.1093/nar/16.5.2283; OLLER AR, 1991, BIOCHEMISTRY-US, V30, P2543, DOI 10.1021/bi00223a035; OLSON WK, 1988, COMPUT APPL BIOSCI, V4, P133; RADDING CM, 1973, ANNU REV GENET, V7, P87, DOI 10.1146/annurev.ge.07.120173.000511; RALEIGH EA, 1986, P NATL ACAD SCI USA, V83, P9070, DOI 10.1073/pnas.83.23.9070; ROBERTS RJ, 1992, NUCLEIC ACIDS RES, V20, P2167, DOI 10.1093/nar/20.suppl.2167; Sambrook J, 1989, MOL CLONING LABORATO; SCHELLMAN JA, 1980, BIOPHYS CHEM, V11, P329, DOI 10.1016/0301-4622(80)87005-0; SCHELLMAN JA, 1980, BIOPHYS CHEM, V11, P321, DOI 10.1016/0301-4622(80)87004-9; SCHELLMAN JA, 1974, BIOPOLYMERS, V13, P217, DOI 10.1002/bip.1974.360130115; SCHNEIDER TD, 1986, J MOL BIOL, V188, P415, DOI 10.1016/0022-2836(86)90165-8; SHEN CC, 1990, J MOL BIOL, V212, P67, DOI 10.1016/0022-2836(90)90305-6; SNYDER L, 1976, P NATL ACAD SCI USA, V73, P3098, DOI 10.1073/pnas.73.9.3098; SRINIVASAN AR, 1987, J BIOMOL STRUCT DYN, V5, P459, DOI 10.1080/07391102.1987.10506409; SULLIVAN KM, 1989, MOL GEN GENET, V216, P380, DOI 10.1007/BF00334379; TRIFONOV EN, 1985, CRC CR REV BIOCH MOL, V19, P89, DOI 10.3109/10409238509082540; TUNG CS, 1987, NUCLEIC ACIDS RES, V15, P4973, DOI 10.1093/nar/15.12.4973; TUNG CS, 1984, NUCLEIC ACIDS RES, V12, P3343, DOI 10.1093/nar/12.7.3343; TUNG CS, 1986, J BIOL CHEM, V261, P3700; TUNG CS, 1986, NUCLEIC ACIDS RES, V14, P381, DOI 10.1093/nar/14.1.381; ULANOVSKY LE, 1987, NATURE, V326, P720, DOI 10.1038/326720a0; VENDITTI S, 1991, J BIOL CHEM, V266, P16786; WARNER HR, 1970, J VIROL, V5, P700, DOI 10.1128/JVI.5.6.700-708.1970; WIBERG JS, 1966, P NATL ACAD SCI USA, V55, P614, DOI 10.1073/pnas.55.3.614; WILSON GG, 1991, NUCLEIC ACIDS RES, V19, P2539, DOI 10.1093/nar/19.10.2539; ZHURKIN VB, 1985, J BIOMOL STRUCT DYN, V2, P785, DOI 10.1080/07391102.1985.10506324	60	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8908	8918						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8386173				2022-12-25	WOS:A1993KX81100078
J	WANG, JL; CORBETT, JA; MARSHALL, CA; MCDANIEL, ML				WANG, JL; CORBETT, JA; MARSHALL, CA; MCDANIEL, ML			GLUCOSE-INDUCED INSULIN-SECRETION FROM PURIFIED BETA-CELLS - A ROLE FOR MODULATION OF CA2+ INFLUX BY CAMP-DEPENDENT AND PROTEIN KINASE-C-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC FREE CA-2+; PANCREATIC-ISLETS; CYCLIC-AMP; ADENYLATE-CYCLASE; ACETYLCHOLINE STIMULATION; INTRACELLULAR CA-2+; CYTOPLASMIC CA-2+; PHORBOL ESTER; MOUSE ISLETS; K+ CHANNELS	The effects of activation of cAMP- and protein kinase C-dependent signal transduction pathways were investigated on intracellular Ca2+ concentration ([Ca2+]i), cAMP content and insulin secretion from beta-cells purified by fluorescence-activated cell sorting from normal rat islets. The secretion of insulin from suspensions of purified beta-cells was dependent on glucose concentration and hormonal signals, including cAMP and activators of protein kinase C. Microfluorimetric measurement of [Ca2+]i with the fluorescent Ca2+ indicator fura-2 indicated that beta-cells differed immensely in their individual responsiveness to glucose stimulation. An increase in [Ca2+]i occurred in approximately 70% of beta-cells, whereas approximately 30% of beta-cells were nonresponsive to a glucose stimulus. Elevation of cAMP levels by theophylline or glucagon transformed nonresponsive beta-cells into cells which displayed marked increases in [Ca2+]i, and beta-cells which exhibited glucose-induced changes in [Ca2+]i showed further increases in [Ca2+]i and in the amplitude of Ca2+ oscillations. Carbachol and 12-O-tetradecanoylphorbol-13-acetate, activators of protein kinase C, did not induce any alterations in intracellular cAMP levels; nonetheless, these agents increased both the number of beta-cells which exhibited glucose-induced changes in [Ca2+]i and the amplitude of oscillations. The ability of cAMP or activators of protein kinase C to increase [Ca2+]i in single beta-cells was directly correlated with the ability of beta-cell suspensions to secrete insulin in response to a glucose stimulus. These results suggest that both cAMP- and protein kinase C-dependent pathways may regulate Ca2+ entry into beta-cells, possibly via voltage-dependent Ca2+ channels. Thus, this may represent a common mechanism whereby these different signal transduction pathways potentiate glucose-induced insulin secretion from beta-cells.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,BOX 8118,660 S EUCLID AVE,ST LOUIS,MO 63110	Washington University (WUSTL)					FIC NIH HHS [F05 TW04160] Funding Source: Medline; NIDDK NIH HHS [T32 DK0-07296, DK-06181] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK006181, T32DK007296, R56DK006181] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARKHAMMAR P, 1989, BIOCHEM J, V264, P207, DOI 10.1042/bj2640207; ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; BOYD AE, 1992, J CELL BIOCHEM, V48, P234, DOI 10.1002/jcb.240480303; COOK DL, 1984, NATURE, V311, P269, DOI 10.1038/311269a0; DERIEMER SA, 1985, NATURE, V313, P313, DOI 10.1038/313313a0; EASOM RA, 1990, J BIOL CHEM, V265, P14938; GARCIA MC, 1988, BIOCHEM J, V254, P211, DOI 10.1042/bj2540211; GRAPENGIESSER E, 1992, CELL CALCIUM, V13, P219, DOI 10.1016/0143-4160(92)90010-P; GRAPENGIESSER E, 1991, J BIOL CHEM, V266, P12207; GRAPENGIESSER E, 1989, ARCH BIOCHEM BIOPHYS, V268, P404, DOI 10.1016/0003-9861(89)90602-4; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; HENQUIN JC, 1987, BIOCHEM J, V246, P393, DOI 10.1042/bj2460393; HERMANS MP, 1989, DIABETES, V38, P198, DOI 10.2337/diabetes.38.2.198; HUGHES SJ, 1990, BIOCHEM J, V267, P227, DOI 10.1042/bj2670227; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; MISLER S, 1992, DIABETES, V41, P1221, DOI 10.2337/diabetes.41.10.1221; ONO J, 1977, ENDOCRINOL JAPON, V24, P265; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P824, DOI 10.1210/endo-117-3-824; PIPELEERS DG, 1984, METHODS DIABETES RES, P185; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; PRENTKI M, 1987, FEBS LETT, V220, P103, DOI 10.1016/0014-5793(87)80884-0; RAJAN AS, 1989, DIABETES, V38, P874, DOI 10.2337/diabetes.38.7.874; RORSMAN P, 1986, AM J PHYSIOL, V251, pC912, DOI 10.1152/ajpcell.1986.251.6.C912; SANCHEZANDRES JV, 1988, FEBS LETT, V231, P143, DOI 10.1016/0014-5793(88)80719-1; SCHUIT FC, 1985, ENDOCRINOLOGY, V117, P834, DOI 10.1210/endo-117-3-834; SHARP GWG, 1980, DIABETES, V29, P74, DOI 10.2337/diabetes.29.1.74; SHARP GWG, 1979, DIABETOLOGIA, V16, P287, DOI 10.1007/BF01223617; THAMS P, 1988, BIOCHEM J, V253, P229, DOI 10.1042/bj2530229; TSIEN RY, 1985, CELL CALCIUM, V6, P145, DOI 10.1016/0143-4160(85)90041-7; TURK J, 1987, PROG LIPID RES, V26, P125, DOI 10.1016/0163-7827(87)90010-5; VALVERDE I, 1979, SCIENCE, V206, P225, DOI 10.1126/science.225798; VANSCHRAVENDIJK CFH, 1990, DIABETOLOGIA, V33, P649, DOI 10.1007/BF00400565; VANSCHRAVENDIJK CFH, 1992, J BIOL CHEM, V267, P21344; WANG J, 1992, ENDOCRINOLOGY, V131, P146, DOI 10.1210/en.131.1.146; WANG JL, 1990, BIOCHEM BIOPH RES CO, V166, P813, DOI 10.1016/0006-291X(90)90882-N; WANG JL, 1990, BIOCHEM BIOPH RES CO, V171, P424, DOI 10.1016/0006-291X(90)91410-T; WOLF BA, 1988, AM J PHYSIOL, V254, pE121, DOI 10.1152/ajpendo.1988.254.2.E121; WOLLHEIM CB, 1988, EMBO J, V7, P2443, DOI 10.1002/j.1460-2075.1988.tb03090.x; WOLLHEIM CB, 1990, FEBS LETT, V268, P376, DOI 10.1016/0014-5793(90)81289-Z; WOLLHEIM CB, 1986, J BIOL CHEM, V261, P8314; YOSHIDA A, 1992, FEBS LETT, V309, P343, DOI 10.1016/0014-5793(92)80804-P	42	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7785	7791						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8385120				2022-12-25	WOS:A1993KW97900034
J	ALI, N; CRAXTON, A; SHEARS, SB				ALI, N; CRAXTON, A; SHEARS, SB			HEPATIC INS(1,3,4,5)P4 3-PHOSPHATASE IS COMPARTMENTALIZED INSIDE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,3,4,5-TETRAKISPHOSPHATE 3-PHOSPHATASE; RAT-LIVER; PORCINE BRAIN; L1210 CELLS; HEXAKISPHOSPHATE; 1,3,4,5,6-PENTAKISPHOSPHATE; 1,4,5-TRISPHOSPHATE; PENTAKISPHOSPHATE; METABOLISM; 1,4,5,6-TETRAKISPHOSPHATE	In pursuit of the physiological role of inositol 1,3,4,5-tetrakisphosphate 3-phosphatase, which also attacks inositol pentakisphosphate and inositol hexakisphosphate with much higher affinity (Nogimori, K., Hughes, P. J., Glennon, M. C., Hodgson, M. E., Putney, J. W., Jr., and Shears, S. B. (1991) J. Biol. Chem. 266, 16499-16506), we have studied the subcellular distribution of the enzyme in liver. Initially, we had to overcome the problem that potent endogenous inhibitor(s) compromise the detection of this enzyme in vitro (Hodgson, M. E., and Shears, S. B. (1990) Biochem. J. 267, 831-834). We partially purified these inhibitor(s) by anion-exchange chromatography and gel filtration; inhibitory activity co-eluted with standard inositol hexakisphosphate and was depleted by treatment with phytase. Thus, subcellular fractions were pretreated with phytase before assay of 3-phosphatase activity. Our experiments revealed that the hepatic 3-phosphatase was nearly exclusively restricted to the endoplasmic reticulum, and there was little or no activity in either the cytosol, plasma membranes, mitochondria, or nuclei. Detergent treatment of microsomes indicated that there was 93 +/- 2% latency to mannose-6-phosphatase, an intraorganelle enzyme activity (Vanstapel, F., Pua, K., and Blanckaert, N. (1986) Eur. J. Biochem. 156, 73-77). Similar latencies were found for the hydrolysis of inositol 1,3,4,5-tetrakisphosphate (95 +/- 1%), inositol 1,3,4,5,6-pentakisphosphate (94 +/- 1%), and inositol hexakisphosphate (93 +/- 2%). Treatment of microsomes with either sodium carbonate or phosphatidylcholine-specific phospholipase C, to release luminal contents, led to solubilization of approximately 90% of 3-phosphatase activity. Thus, hepatic 3-phosphatase has a highly restricted access to inositol polyphosphates in vivo that needs to be accounted for in the determination of the physiological role of this enzyme.			ALI, N (corresponding author), NIEHS,CELLULAR & MOLEC PHARMACOL LAB,INOSITOL LIPID SECT,RES TRIANGLE PK,NC 27709, USA.		Shears, Stephen B/C-6335-2019	Shears, Stephen B/0000-0001-7309-8916				ALI N, 1990, BIOCHEM J, V271, P185, DOI 10.1042/bj2710185; BALLA T, 1989, J BIOL CHEM, V264, P9386; BARTLES JR, 1990, METHOD ENZYMOL, V191, P825; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BLANK GE, 1971, BIOCHEM BIOPH RES CO, V44, P319, DOI 10.1016/0006-291X(71)90602-4; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNK CF, 1979, ANAL BIOCHEM, V92, P497, DOI 10.1016/0003-2697(79)90690-0; CARPENTER D, 1989, BIOCHEM SOC T, V17, P3, DOI 10.1042/bst0170003; CULLEN PJ, 1989, BIOCHEM J, V259, P931, DOI 10.1042/bj2590931; CUNHAMELO JR, 1988, J BIOL CHEM, V263, P14255; DOUGHNEY C, 1988, BIOCHEM J, V251, P927, DOI 10.1042/bj2510927; ESTRADAGARCIA T, 1991, P ROY SOC B-BIOL SCI, V244, P63, DOI 10.1098/rspb.1991.0052; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GUSE AH, 1991, J BIOL CHEM, V266, P24498; HODGSON ME, 1990, BIOCHEM J, V267, P831, DOI 10.1042/bj2670831; HOER A, 1991, BIOCHEM J, V278, P219; HOER A, 1990, BIOCHEM J, V270, P715; HOER D, 1988, BIOCHEM BIOPH RES CO, V154, P668, DOI 10.1016/0006-291X(88)90191-X; HUGHES PJ, 1990, J BIOL CHEM, V265, P9869; Irvine Robin F., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P161; JOSEPH SK, 1985, FEBS LETT, V180, P150, DOI 10.1016/0014-5793(85)81061-9; Kirk CJ., 1990, PEPTIDE HORMONE ACTI, P151; LOOMISHUSSELBEE JW, 1991, BIOCHEM J, V277, P883, DOI 10.1042/bj2770883; MATTINGLY RR, 1991, J BIOL CHEM, V266, P15144; MCCONNELL FM, 1991, BIOCHEM J, V280, P323, DOI 10.1042/bj2800323; MENNITI FS, 1990, J BIOL CHEM, V265, P11167; NOGIMORI K, 1991, J BIOL CHEM, V266, P16499; OBERDISSE E, 1990, J BIOL CHEM, V265, P726; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; Perney Teresa M., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P311; RAZZELL WE, 1963, METHOD ENZYMOL, V6, P236, DOI 10.1016/0076-6879(63)06169-3; SCHMIDT E, 1974, METHOD ENZYMAT AN, V2, P650; SCHNEIDER WC, 1950, J BIOL CHEM, V183, P123; SHEARS SB, 1989, J BIOL CHEM, V264, P19879; Shears Stephen B., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P63; SHEPHARD EH, 1969, BIOCHEM J, V113, P429, DOI 10.1042/bj1130429; STEPHENS L, 1988, BIOCHEM J, V249, P271, DOI 10.1042/bj2490271; STEPHENS LR, 1991, BIOCHEM J, V275, P485, DOI 10.1042/bj2750485; STEPHENS LR, 1988, BIOCHEM J, V249, P283, DOI 10.1042/bj2490283; ULLAH AHJ, 1987, PREP BIOCHEM, V17, P63, DOI 10.1080/00327488708062477; URADE R, 1992, J BIOL CHEM, V267, P15152; VALLEJO M, 1987, NATURE, V330, P656, DOI 10.1038/330656a0; VANSTAPEL F, 1986, EUR J BIOCHEM, V156, P73, DOI 10.1111/j.1432-1033.1986.tb09550.x; WIDNELL CC, 1964, BIOCHEM J, V92, P313, DOI 10.1042/bj0920313; WONG NS, 1992, BIOCHEM J, V286, P459, DOI 10.1042/bj2860459	50	64	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6161	6167						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8384201				2022-12-25	WOS:A1993KT36800016
J	STAUDINGER, J; PERRY, M; ELLEDGE, SJ; OLSON, EN				STAUDINGER, J; PERRY, M; ELLEDGE, SJ; OLSON, EN			INTERACTIONS AMONG VERTEBRATE HELIX-LOOP-HELIX PROTEINS IN YEAST USING THE 2-HYBRID SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DNA-BINDING DOMAIN; ESCHERICHIA-COLI; NEGATIVE REGULATOR; DROSOPHILA; GENE; MYOD; MYOGENIN; SEQUENCE; MYC; EXTRAMACROCHAETAE	The helix-loop-helix (HLH) motif is contained in a rapidly growing family of transcription factors and has been shown to mediate dimerization among heterologous HLH-containing proteins. E12 is a widely expressed HLH protein that preferentially forms heterodimers with cell type-specific HLH proteins such as MyoD, myogenin, and the achaete-scute gene products. As a first step toward screening for novel cell type-specific partners of E12, we used a modification of the two-hybrid assay for detection of protein-protein interactions in vivo to determine whether dimerization of HLH proteins with E12 can occur in yeast. Using the GAL4 DNA-binding domain fused to the E12 HLH motif and the GAL4 transcription activation domain fused to MyoD, we show that E12 and MyoD can efficiently dimerize in yeast and reconstruct a hybrid transcription factor that activates reporter genes linked to the GAL4 DNA-binding site. The GAL4 DNA-binding domain fused to E12 was used to screen a mouse T-cell cDNA library in which the cDNA was fused to the GAL4 activation domain. Several cDNA clones encoding proteins that interact with E12 were isolated, one of which corresponded to the HLH protein Id-2. Given the ability of E12 to dimerize preferentially with cell type-specific HLH proteins, this strategy should be useful for cloning novel partners for E12 from a variety of cell types.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,BOX 117,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine					NIAMS NIH HHS [AR39849, AR40339] Funding Source: Medline; NICHD NIH HHS [HD27246] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027246] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040339, R01AR039849] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALONSO MC, 1988, EMBO J, V7, P2585, DOI 10.1002/j.1460-2075.1988.tb03108.x; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHAKRABORTY T, 1992, J BIOL CHEM, V267, P17498; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CHIEN CT, 1991, NATURE, V340, P245; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; FIELDS S, 1989, P NATL ACAD SCI USA, V88, P9578; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; RIMM DL, 1989, GENE, V75, P323, DOI 10.1016/0378-1119(89)90278-3; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J, 1989, MOL CLONING LABORATO; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SCALES JB, 1990, MOL CELL BIOL, V10, P1516, DOI 10.1128/MCB.10.4.1516; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	35	55	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4608	4611						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8383120				2022-12-25	WOS:A1993KP88400011
J	BASU, A; PARK, K; ATCHISON, ML; CARTER, RS; AVADHANI, NG				BASU, A; PARK, K; ATCHISON, ML; CARTER, RS; AVADHANI, NG			IDENTIFICATION OF A TRANSCRIPTIONAL INITIATOR ELEMENT IN THE CYTOCHROME-C-OXIDASE SUBUNIT VB PROMOTER WHICH BINDS TO TRANSCRIPTION FACTORS NF-E1 (YY-1, DELTA) AND SP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; STRUCTURAL ORGANIZATION; IV GENE; DNA-BINDING; NUCLEAR FACTOR; ETS-DOMAIN; PROTEIN; SEQUENCE; EXPRESSION; ACTIVATION	We have mapped the basal promoter activity of the mouse cytochrome c oxidase (COX) subunit Vb gene to the -17 to +20 region which contains two putative ets binding sites flanking an NF-E1 site fused to an Sp1 site. A 17 nucleotide sequence flanking the major transcription start site (-8 to +9), referred to as 17Inr (initiator sequence) was able to drive CAT activity in 3T3 cells to a level comparable to the construct containing sequences -17 to +20. This suggests that the 17Inr sequence contains the initiator activity. The 17Inr contains a pyrimidine-rich sequence, commencing with a CA that corresponds to the major transcription start site. Primer extension of RNA from transfected cells demonstrated that transcription initiation with the 17Inr template occurs at a site identical to the endogenous gene. DNA-protein binding by gel mobility shift and methylation interference analyses indicated that the pyrimidine-rich sequence immediately flanking the transcription start site consists of an NF-E1 factor binding motif with an overlapping upstream Sp1 binding site. A 13-nucleotide sequence, 13Inr (-4 to +9), which retains the NF-E1 binding activity but does not bind Sp1, was able to promote chloramphenicol acetyltransferase gene expression at levels similar to the 17Inr sequence, suggesting that NF-E1 factor binding is critical for initiator function. Finally, using an in vitro transcription system from Drosophila embryos we demonstrate that NF-E1 is necessary for transcription activation of both the 17Inr and the 13Inr initiator templates. Thus NF-E1 binding appears to be important for basal promoter function of the mouse COXVb gene.	UNIV PENN,SCH VET MED,DEPT ANIM BIOL,BIOCHEM LABS,PHILADELPHIA,PA 19104	University of Pennsylvania					NATIONAL CANCER INSTITUTE [R37CA022762, R01CA022762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042415] Funding Source: NIH RePORTER; NCI NIH HHS [CA-22762] Funding Source: Medline; NIGMS NIH HHS [GM-42415] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATCHISON ML, 1989, MOL CELL BIOL, V9, P2067, DOI 10.1128/MCB.9.5.2067; ATCHISON ML, 1990, EMBO J, V9, P3109, DOI 10.1002/j.1460-2075.1990.tb07508.x; BASU A, 1991, J BIOL CHEM, V266, P15450; BHAT KS, 1989, BIOCHEMISTRY-US, V28, P763, DOI 10.1021/bi00428a052; BOYER TG, 1989, J BIOL CHEM, V264, P5177; BOYER TG, 1990, J BIOL CHEM, V265, P20524; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTER RS, 1991, ARCH BIOCHEM BIOPHYS, V288, P97, DOI 10.1016/0003-9861(91)90169-J; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; FARNHAM PJ, 1990, MOL CELL BIOL, V10, P1390, DOI 10.1128/MCB.10.4.1390; FARNHAM PJ, 1991, J BIOL CHEM, V266, P23288; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUARENTE L, 1987, ANNU REV GENET, V21, P425, DOI 10.1146/annurev.genet.21.1.425; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HARIHARAN N, 1989, GENE DEV, V3, P1789, DOI 10.1101/gad.3.11.1789; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HARIHARAN N, 1989, NUCLEIC ACIDS RES, V17, P5323, DOI 10.1093/nar/17.13.5323; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HIDGE M, 1990, MOL CELL BIOL, V10, P5510; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; LAMARCO KL, 1989, GENE DEV, V3, P1372, DOI 10.1101/gad.3.9.1372; LANDAU NR, 1987, MOL CELL BIOL, V7, P3237, DOI 10.1128/MCB.7.9.3237; LI K, 1990, J BIOL CHEM, V265, P20585; LOMAX MI, 1991, GENOMICS, V10, P1, DOI 10.1016/0888-7543(91)90476-U; MITCHELL MT, 1991, TRENDS GENET, V7, P1; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHARP PA, 1991, NATURE, V351, P16, DOI 10.1038/351016d0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUZUKI H, 1989, J BIOL CHEM, V264, P1368; SUZUKI H, 1991, J BIOL CHEM, V266, P2333; TAKESHIMA H, 1988, J MOL BIOL, V200, P1, DOI 10.1016/0022-2836(88)90328-2; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TOMURA H, 1990, J BIOL CHEM, V265, P6525; TSUZUKI T, 1987, J MOL BIOL, V198, P21, DOI 10.1016/0022-2836(87)90454-2; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; VIRBASIUS JV, 1990, NUCLEIC ACIDS RES, V18, P6581, DOI 10.1093/nar/18.22.6581; YAMADA M, 1990, J BIOL CHEM, V265, P7687	57	92	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4188	4196						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8382696				2022-12-25	WOS:A1993KN53300058
J	OTSU, K; KINSELLA, JL; HELLER, P; FROEHLICH, JP				OTSU, K; KINSELLA, JL; HELLER, P; FROEHLICH, JP			SODIUM DEPENDENCE OF THE NA+-H+ EXCHANGER IN THE PRE-STEADY STATE - IMPLICATIONS FOR THE EXCHANGE MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVILLUS MEMBRANE-VESICLES; THYMIC LYMPHOCYTES; MODIFIER SITE; AMILORIDE; ANTIPORT; TRANSPORT; INHIBITION; KINETICS; BINDING; KIDNEY	The pre-steady state time course of amiloride-sensitive Na+o uptake by the Na+-H+ exchanger in renal brush border membrane vesicles (BBMV) exhibits a burst phase at 0-degrees-C which corresponds to the initial turnover of the exchanger (Otsu, K., Kinsella, J. L., Sacktor, B. S., and Froehlich, J. P. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 4818-4822). Investigation of the Na+o dependence of the Na+-H+ exchanger between 1 and 10 mM Na+ revealed that activation of the burst phase involves at least two Na+ transport sites interacting with positive cooperativity. In this study, characterization of the Na+ transport sites contributing to the burst phase was extended to include Na+ concentrations below 1 mM. Between 0.1 and 1 mM Na+ the amplitude of the burst phase in acid-loaded BBMV (pH(i) 5.7; pH(o) 7.7) exhibited a sigmoidal dependence on [Na+]o, consistent with the presence of a second class of high affinity Na+ transport sites with cooperative binding characteristics. In contrast, steady state Na+ uptake obeyed Michaelis-Menten kinetics, similar to the behavior observed previously at higher (1-10 mm) Na+o concentrations. Treatment of the vesicles with carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone, which induced the formation of an inside-negative membrane potential, increased the burst amplitude but had no effect on the steady state uptake velocity. Experiments performed with alkaline-loaded BBMV (pH(i) 7.7; pH(o) 7.7), which permit only a single turnover of the exchanger, gave a simple hyperbolic dependence of the burst amplitude on [Na+]o (0.5-5 mM). We propose that the change in multiplicity of Na+ transport sites and membrane potential sensitivity that occurs in the transition between the pre-steady state and the steady state of Na+ uptake in acid-loaded vesicles reflects the presence of an oligomer which operates according to a ''flip-flop'' mechanism. The minimum subunit composition inferred from the biphasic [Na+]o dependence of the burst amplitude is a dimer at low (<1 mM) Na+o levels and a tetramer at high [Na+]o. Communication between the subunits producing the complex [Na+]o dependence is controlled by the intravesicular (cytoplasmic) H+ modifier site. Under alkaline conditions (pH 7.7), where this site is unoccupied, the subunits behave as independent units and cease operation after the first turnover. Occupation of the H+ modifier site activates a conformational interaction between the subunits that leads to cooperative Na+o binding, alternation of the transport sites, and repetitive cycling of the Na+-H+ exchanger.	NIA,CARDIOVASC SCI LAB,BALTIMORE,MD 21224	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)								ARONSON PS, 1981, FED PROC, V40, P2213; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; ARONSON PS, 1978, J MEMBRANE BIOL, V42, P81, DOI 10.1007/BF01870395; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BELIVEAU R, 1988, BIOCHEM BIOPH RES CO, V152, P484, DOI 10.1016/S0006-291X(88)80739-3; Booth A G, 1974, Biochem J, V142, P575; CHAPPELE.D, 1974, BIOCHEMISTRY-US, V13, P1788, DOI 10.1021/bi00706a002; DESIR GV, 1991, J BIOL CHEM, V266, P2267; GIEBEL J, 1989, AM J PHYSIOL, V257, pF790; GRINSTEIN S, 1984, J GEN PHYSIOL, V83, P341, DOI 10.1085/jgp.83.3.341; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; GRINSTEIN S, 1984, J GEN PHYSIOL, V84, P585, DOI 10.1085/jgp.84.4.585; GUTFREUND H, 1977, ENZYMES PHYSICAL PRI, P199; IVES HE, 1983, J BIOL CHEM, V258, P9710; KINSELLA JL, 1980, AM J PHYSIOL, V238, pF461, DOI 10.1152/ajprenal.1980.238.6.F461; KINSELLA JL, 1982, BIOCHIM BIOPHYS ACTA, V689, P161, DOI 10.1016/0005-2736(82)90200-0; KINSELLA JL, 1981, AM J PHYSIOL, V241, pF374, DOI 10.1152/ajprenal.1981.241.4.F374; KNICKELBEIN RG, 1990, AM J PHYSIOL, V259, pG802, DOI 10.1152/ajpgi.1990.259.5.G802; KNOTT GD, 1979, COMPUT PROG BIOMED, V10, P271, DOI 10.1016/0010-468X(79)90075-8; KURTZ I, 1989, J CLIN INVEST, V83, P616, DOI 10.1172/JCI113925; LAZDUNSKI M, 1972, CURRENT TOPICS CELLU, V6, P267; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MURER H, 1976, BIOCHEM J, V154, P597, DOI 10.1042/bj1540597; OTSU K, 1989, P NATL ACAD SCI USA, V86, P4818, DOI 10.1073/pnas.86.13.4818; OTSU K, 1986, BIOPHYS J, V49, pA553; OTSU K, 1988, BIOPHYS J, V53, pA341; OTSU K, 1992, J BIOL CHEM, V268, P8089; PARIS S, 1983, J BIOL CHEM, V258, P3503; REILLY RF, 1991, AM J PHYSIOL, V261, pF1088, DOI 10.1152/ajprenal.1991.261.6.F1088; RINDLER MJ, 1981, J BIOL CHEM, V256, P1080; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; Segel IH, 1975, ENZYME KINETICS, P346; SEIFTER JL, 1986, J CLIN INVEST, V78, P859, DOI 10.1172/JCI112671; WARNOCK DG, 1982, AM J PHYSIOL, V242, pF733, DOI 10.1152/ajprenal.1982.242.6.F733; WARNOCK DG, 1988, J BIOL CHEM, V263, P7216; WIERZBICKI W, 1990, J MEMBRANE BIOL, V117, P11, DOI 10.1007/BF01871562	36	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3184	3193						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8381420				2022-12-25	WOS:A1993KM16100028
J	MIYATA, KS; ZHANG, BW; MARCUS, SL; CAPONE, JP; RACHUBINSKI, RA				MIYATA, KS; ZHANG, BW; MARCUS, SL; CAPONE, JP; RACHUBINSKI, RA			CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR (COUP-TF) BINDS TO A PEROXISOME PROLIFERATOR-RESPONSIVE ELEMENT AND ANTAGONIZES PEROXISOME PROLIFERATOR-MEDIATED SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HORMONE RECEPTOR SUPERFAMILY; ACYL-COA OXIDASE; THYROID-HORMONE; RETINOIC ACID; BETA-OXIDATION; RAT-LIVER; GENE; MEMBER; IDENTIFICATION; DEHYDROGENASE	Peroxisome proliferators form a family of diverse xenobiotic compounds that includes hypolipidemic agents, herbicides, and plasticizers. These compounds activate transcription of a subset of nuclear genes including those encoding peroxisomal fatty acid beta-oxidation enzymes, whose elevated activities can lead to hepatocarcinogenesis. Induction of the genes encoding fatty acyl-CoA oxidase and hydratase-dehydrogenase, the first and second enzymes of the pathway, is mediated by peroxisome proliferator-activated nuclear receptors (PPARs) that bind to upstream responsive elements (PPREs) through heterodimerization with retinoid X receptors. We demonstrate that the chicken ovalbumin upstream promoter transcription factor 1 (COUP-TF1), another member of the nuclear hormone receptor superfamily, binds to the hydratase-dehydrogenase PPRE in vitro and in vivo and antagonizes PPAR-dependent signaling. These data suggest that members of the COUP-TF family play a role in modulating receptor-mediated activation of peroxisome proliferator-responsive genes.	MCMASTER UNIV,DEPT BIOCHEM,HAMILTON L8N 3Z5,ONTARIO,CANADA	McMaster University								ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; CATTLEY RC, 1989, CANCER RES, V49, P3246; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; DINGHAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FURUTA S, 1982, J BIOCHEM, V92, P319, DOI 10.1093/oxfordjournals.jbchem.a133937; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MARCUS SL, 1993, P NATL ACAD SCI USA, V90, P5723, DOI 10.1073/pnas.90.12.5723; MARSMAN DS, 1988, CANCER RES, V48, P6739; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; RAO MS, 1991, ENVIRON HEALTH PERSP, V93, P205, DOI 10.2307/3431190; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; SHARMA RK, 1989, EUR J BIOCHEM, V184, P69, DOI 10.1111/j.1432-1033.1989.tb14991.x; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Vamecq J, 1989, Essays Biochem, V24, P115; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG BW, 1993, J BIOL CHEM, V268, P12939; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	34	104	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19169	19172						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8396126				2022-12-25	WOS:A1993LW81900003
J	JANNATIPOUR, M; LIU, YX; NITISS, JL				JANNATIPOUR, M; LIU, YX; NITISS, JL			THE TOP2-5 MUTANT OF YEAST TOPOISOMERASE-II ENCODES AN ENZYME RESISTANT TO ETOPOSIDE AND AMSACRINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTITUMOR DRUGS; SACCHAROMYCES-CEREVISIAE; DNA TOPOISOMERASES; ESCHERICHIA-COLI; POINT MUTATION; CELLS; GENE; FORM; IDENTIFICATION; TRANSFORMATION	We have characterized a temperature-sensitive mutant in the yeast TOP2 gene that shows resistance to the anti-topoisomerase II agents amsacrine and etoposide. Cells carrying the top2-5 mutant have a minimum lethal concentration of amsacrine of greater than 100 mug/ml, compared to 10 mug/ml in isogenic wild-type cells, and a minimum lethal concentration of greater than 100 mug/ml etoposide, compared with 50 mug/ml for cells carrying wild-type topoisomerase II. We have cloned the top2-5 allele into a yeast vector that allows high level overexpression of the protein. As expected, the purified top2-5 activity is temperature-sensitive. The protein shows a 3-fold reduction of amsacrine-stabilized cleavage at the permissive temperature, confirming that the top2-5 protein is resistant to amsacrine in vitro. The protein also exhibits reduced cleavage in the presence of etoposide, with the largest effect at low concentrations of the drug. These results suggest that the top2-5 protein is altered in its sensitivity to anti-topoisomerase II agents. The relevant portion of the mutant allele has been sequenced, and several tightly clustered mutations have been identified. The location of the mutations identify a domain of the topoisomerase II protein that may be important in the interaction of the protein with anti-topoisomerase II anti-cancer drugs.	CHILDRENS HOSP,DIV HEMATOL ONCOL,CANC PHARMACOL SECT,BOX 126,4650 SUNSET BLVD,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT BIOCHEM,LOS ANGELES,CA 90033	Children's Hospital Los Angeles; University of Southern California; University of Southern California			Nitiss, John/E-9974-2010	Nitiss, John/0000-0002-1013-4972	NCI NIH HHS [CA 52814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052814] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beck W T, 1991, Semin Cancer Biol, V2, P235; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BUGG BY, 1991, P NATL ACAD SCI USA, V88, P7654, DOI 10.1073/pnas.88.17.7654; CHEN GL, 1984, J BIOL CHEM, V259, P3560; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; DANKS MK, 1988, BIOCHEMISTRY-US, V27, P8861, DOI 10.1021/bi00424a026; DARPA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163, DOI 10.1016/0304-419X(89)90041-3; DRLICA K, 1988, BIOCHEMISTRY-US, V27, P2253, DOI 10.1021/bi00407a001; ENG WK, 1988, MOL PHARMACOL, V34, P755; GOTO T, 1984, CELL, V36, P1073, DOI 10.1016/0092-8674(84)90057-6; HINDS M, 1991, CANCER RES, V51, P4729; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KREUZER KN, 1979, J BACTERIOL, V140, P425; LEE MS, 1992, J MOL BIOL, V223, P837, DOI 10.1016/0022-2836(92)90245-F; LIU LF, 1983, J BIOL CHEM, V258, P5365; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LIU LF, 1981, NUCLEIC ACIDS RES, V9, P3979, DOI 10.1093/nar/9.16.3979; MULLER MT, 1983, BIOCHEM BIOPH RES CO, V114, P99; NAKAMURA S, 1989, ANTIMICROB AGENTS CH, V33, P254, DOI 10.1128/AAC.33.2.254; NELSON EM, 1984, P NATL ACAD SCI-BIOL, V81, P1361, DOI 10.1073/pnas.81.5.1361; NELSON EM, 1984, P NATL ACAD SCI USA, V85, P7501; NITISS J, 1991, DNA TOPOISOMERASES C, P77; NITISS JL, 1993, CANCER RES, V53, P89; NITISS JL, 1992, CANCER RES, V52, P4467; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHILD D, 1983, CURR GENET, V7, P85, DOI 10.1007/BF00365631; TABOR S, 1989, J BIOL CHEM, V264, P6447; THOMAS W, 1991, GENETICS, V128, P703; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; UEMERA T, 1986, EMBO J, V5, P2355; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6; YAMAGISHI J, 1986, MOL GEN GENET, V204, P367, DOI 10.1007/BF00331012; ZWELLING LA, 1989, J BIOL CHEM, V264, P16411	39	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18586	18592						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8395511				2022-12-25	WOS:A1993LV65900035
J	MOLLEGAARD, NE; RASMUSSEN, PB; VALENTINHANSEN, P; NIELSEN, PE				MOLLEGAARD, NE; RASMUSSEN, PB; VALENTINHANSEN, P; NIELSEN, PE			CHARACTERIZATION OF PROMOTER RECOGNITION COMPLEXES FORMED BY CRP AND CYTR FOR REPRESSION AND BY CRP AND RNA-POLYMERASE FOR ACTIVATION OF TRANSCRIPTION ON THE ESCHERICHIA-COLI DEOP2 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP RECEPTOR PROTEIN; CYCLIC-AMP; GALACTOSE OPERON; DNA-BINDING; CAP; CONTACTS; REGIONS; LACTOSE; LAC; SALTS	The structure of the cAMP-CRP-CytR repression complex and the cAMP CRP-RNA polymerase initiation complex at the deoP2 promoter of E. coli have been probed by DNase I and uranyl footprinting. In the CRP2-CytR complex all protein DNA-phosphate contacts at CRP-1 and CRP-2 are retained, and in addition two new minor groove contacts, ascribed to phosphate-CytR interactions, are observed at -60 between the CRP sites. The contacts are compatible with a model in which the promoter DNA is wrapped around a complex of two CRPs and one CytR. In the RNA polymerase-CRP complex, the CRP-1 phosphate contacts are almost identical to those seen in the repression complex and strong RNA polymerase contacts are seen in the -10 and in the +10 regions. Most noteworthy are minor groove contacts in the -60 region ascribed to RNA polymerase contacts upstream from the CRP. Furthermore, binding of CRP to the CRP-2 target does not seem to interfere with RNA polymerase binding. Thus, a model is suggested in which the DNA is wrapped around a complex of RNA polymerase and one CRP. Finally, the results show that CytR and RNA polymerase are rivals that compete for binding with CRP at deoP2 and that CytR functions as an antiactivator.	UNIV COPENHAGEN,PANUM INST,MED BIOTECHNOL RES CTR,DEPT BIOCHEM B,BLEGDAMSVEJ 3,DK-2200 COPENHAGEN,DENMARK; UNIV ODENSE,DEPT MOLEC BIOL,DK-5230 ODENSE,DENMARK	University of Copenhagen; University of Southern Denmark				Mollegaard, Niels Erik/0000-0002-8255-3711				BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; BOTSFORD JL, 1992, MICROBIOL REV, V56, P100, DOI 10.1128/MMBR.56.1.100-122.1992; BUSBY S, 1987, GENE, V53, P145, DOI 10.1016/0378-1119(87)90002-3; BUSBY S, 1987, MICROBIOL SCI, V4, P371; BUSBY S, 1992, Current Biology, V2, P53, DOI 10.1016/0960-9822(92)90446-H; DECROMBRUGGHE B, 1984, SCIENCE, V224, P831, DOI 10.1126/science.6372090; EBRIGHT RH, 1990, NUCLEIC ACIDS RES, V18, P1457, DOI 10.1093/nar/18.6.1457; ESCHENLAUER AC, 1991, J BACTERIOL, V173, P5024, DOI 10.1128/jb.173.16.5024-5029.1991; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; GERLACH P, 1991, J BACTERIOL, V173, P5419, DOI 10.1128/jb.173.17.5419-5430.1991; GHOSAINI LR, 1988, BIOCHEMISTRY-US, V27, P5257, DOI 10.1021/bi00414a046; HOCHSCHILD A, 1986, CELL, V44, P681, DOI 10.1016/0092-8674(86)90833-0; JEPPESEN C, 1988, NUCLEIC ACIDS RES, V16, P9545, DOI 10.1093/nar/16.20.9545; JEPPESEN C, 1989, NUCLEIC ACIDS RES, V17, P497; JEPPESEN C, 1990, THESIS U COPENHAGEN; KIRKEGAARD K, 1983, P NATL ACAD SCI-BIOL, V80, P2544, DOI 10.1073/pnas.80.9.2544; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; LOBELL RB, 1991, J MOL BIOL, V218, P45, DOI 10.1016/0022-2836(91)90872-4; NIELSEN PE, 1988, FEBS LETT, V235, P122, DOI 10.1016/0014-5793(88)81245-6; NIELSEN PE, 1992, J AM CHEM SOC, V114, P4967, DOI 10.1021/ja00039a003; PEDERSEN H, 1991, J BIOL CHEM, V266, P17804; PEDERSEN H, 1992, J MOL BIOL, V227, P376; RAIBAUD O, 1989, J MOL BIOL, V205, P471, DOI 10.1016/0022-2836(89)90218-0; REZNIKOFF WS, 1992, J BACTERIOL, V174, P655, DOI 10.1128/jb.174.3.655-658.1992; RICHET E, 1991, CELL, V66, P1185, DOI 10.1016/0092-8674(91)90041-V; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHANBLATT SH, 1987, J BIOL CHEM, V262, P11422; SHANBLATT SH, 1983, P NATL ACAD SCI-BIOL, V80, P1594, DOI 10.1073/pnas.80.6.1594; SOGAARDANDERSEN L, 1991, P NATL ACAD SCI USA, V88, P4921, DOI 10.1073/pnas.88.11.4921; SOGAARDANDERSEN L, 1991, MOL MICROBIOL, V5, P969, DOI 10.1111/j.1365-2958.1991.tb00772.x; SOGAARDANDERSEN L, 1990, MOL MICROBIOL, V4, P1595, DOI 10.1111/j.1365-2958.1990.tb02071.x; SOGAARDANDERSEN L, 1990, J BACTERIOL, V172, P5706, DOI 10.1128/jb.172.10.5706-5713.1990; SPASSKY A, 1984, EMBO J, V3, P43, DOI 10.1002/j.1460-2075.1984.tb01759.x; TANIGUCHI T, 1983, NUCLEIC ACIDS RES, V11, P5165, DOI 10.1093/nar/11.15.5165; WILLIAMS R, 1991, NUCLEIC ACIDS RES, V19, P6705, DOI 10.1093/nar/19.24.6705	37	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17471	17477						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8394345				2022-12-25	WOS:A1993LQ98800086
J	SERIZAWA, H; CONAWAY, RC; CONAWAY, JW				SERIZAWA, H; CONAWAY, RC; CONAWAY, JW			MULTIFUNCTIONAL RNA POLYMERASE-II INITIATION FACTOR-DELTA FROM RAT-LIVER - RELATIONSHIP BETWEEN CARBOXYL-TERMINAL DOMAIN KINASE, ATPASE, AND DNA HELICASE ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-DELTA; PROTEIN-KINASE; FACTOR-EPSILON; FACTOR-B; SACCHAROMYCES-CEREVISIAE; NONPHOSPHORYLATED FORM; PREINITIATION COMPLEX; SUBUNIT-IIA; CTD KINASE; FACTOR-TAU	RNA polymerase II initiation factor delta was previously purified from rat liver and found to possess a closely associated DNA-dependent ATPase activity and a protein kinase activity capable of phosphorylating the carboxyl-terminal domain (CTD) of the largest subunit of RNA polymerase II (Serizawa, H., Conaway, R. C., and Conaway, J. W. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 7476-7480). In addition, delta's human homolog, BTF2(TFIIH), was recently shown to have an associated DNA helicase activity (Schaeffer, L., Roy, R., Humbert, S., Moncollin, V., Vermeulen, W., Hoeijmakers, J. H. J., Chambon, P., and Egly, J.-M. (1993) Science 259, 58-63). Here we demonstrate that initiation factor delta also possesses DNA helicase activity. In addition, we compare the properties of delta's associated CTD kinase, ATPase, and DNA helicase activities. Whereas the enzymatic properties of ATPase and DNA helicase are similar and consistent with the possibility that they could function in ATP-dependent activation of the preinitiation complex, ATPase and CTD kinase exhibit significant differences in their nucleotide specificities, responses to DNA effectors, and sensitivities to inhibitors.			SERIZAWA, H (corresponding author), OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,OKLAHOMA CITY,OK 73104, USA.			Conaway, Joan/0000-0002-2786-0663	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041628, R37GM041628] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIAS JA, 1991, J BIOL CHEM, V266, P8055; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CONAWAY JW, 1990, J BIOL CHEM, V265, P7552; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; DVIR A, 1993, J BIOL CHEM, V268, P10440; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1992, J BIOL CHEM, V267, P2786; GERARD M, 1991, J BIOL CHEM, V266, P20940; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HENRY NL, 1992, J BIOL CHEM, V267, P23388; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; KIM WY, 1986, J BIOL CHEM, V261, P14219; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MACKIE KP, 1989, J BIOL CHEM, V264, P1748; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PAYNE JM, 1993, J BIOL CHEM, V268, P80; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PETERSON MG, 1992, NATURE, V358, P620, DOI 10.1038/358620a0; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; PUGH BF, 1992, J BIOL CHEM, V267, P679; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; SUZUKI M, 1990, NATURE, V344, P562, DOI 10.1038/344562a0; TSCHOCHNER H, 1992, P NATL ACAD SCI USA, V89, P11292, DOI 10.1073/pnas.89.23.11292; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	61	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17300	17308						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8394338				2022-12-25	WOS:A1993LQ98800063
J	MULLER, E; BOLDYREFF, B; SCHEIDTMANN, KH				MULLER, E; BOLDYREFF, B; SCHEIDTMANN, KH			CHARACTERIZATION OF PROTEIN-KINASE ACTIVITIES ASSOCIATED WITH P53-LARGE-T IMMUNE-COMPLEXES FROM SV40-TRANSFORMED RAT-CELLS	ONCOGENE			English	Article							LARGE T-ANTIGEN; SV40 LARGE-T; TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING DOMAIN; WILD-TYPE; CYCLE CONTROL; P53 PROTEIN; 3T3 CELLS; MONOCLONAL-ANTIBODIES; PHOSPHORYLATION SITES	Interaction of viral oncoproteins, such as SV40 large T, with cellular growth suppressor proteins Rb and p53 is presumed to inactive or modulate their growth suppression functions, thereby leading to transformation. An additional transformation-related activity of LT leads to hyperphosphorylation of p53. To search for kinases that might be responsible for this effect, p53-LT complexes were immunopurified from different SV40-transformed rat cell lines and assayed for associated kinase activities, in vitro. Protein kinase activity was readily observed in p53-LT immunecomplexes from wild-type transformed cells but was low or undetectable in p53 from mutant-transformed or normal cells. Optimal activity required the presence of Mn++. p53 was phosphorylated at all sites found in vivo. In contrast, LT was phosphorylated only at a subset of formerly identified sites and at additional sites not seen in vivo. The p53-LT-kinase complex was assayed for the presence of casein kinases, cdk like kinases, or DNA-activated kinase, using specific effectors, antibodies, or purified enzymes as tools. DNA-activated kinase or cdc2/cdk2 were not detectable, although the purified enzymes phosphorylated p53 in vitro. Casein kinase 2 represented the major activity, which on p53 phosphorylated not only the C-terminal Ser390 but also several sites in the N-terminal region. One additional activity, not identified so far, may represent an LT-induced or activated kinase. This kinase seems to enhance overall phosphorylation of p53 and, perhaps other substrates, and may thereby contribute to transformation.	UNIV BONN,INST GENET,ABT MOLEK GENET,ROMERSTR 164,W-5300 BONN 1,GERMANY; UNIV SAARLAND,INST HUMAN GENET,W-6600 SAARBRUCKEN,GERMANY	University of Bonn; Saarland University								BALL RK, 1984, EMBO J, V3, P1488; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BAUER M, 1987, J VIROL, V61, P1821, DOI 10.1128/JVI.61.6.1821-1827.1987; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CHEN JD, 1992, ONCOGENE, V7, P1167; DEPPERT W, 1990, ONCOGENE, V5, P1701; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1988, ONCOGENE, V3, P313; ELLEDGE SJ, 1991, EMBO J, V10, P1653; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; GADBOIS DM, 1992, BIOCHEM BIOPH RES CO, V184, P80, DOI 10.1016/0006-291X(92)91160-R; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HEBEL M, 1986, Z NATURFORSCH C, V41, P94; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAY G, 1981, P NATL ACAD SCI-BIOL, V78, P2932, DOI 10.1073/pnas.78.5.2932; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25; KERN SE, 1991, ONCOGENE, V6, P131; KRAISS S, 1990, ONCOGENE, V5, P845; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1991, CANCER CELL-MON REV, V3, P341; LEESMILLER SP, 1989, J BIOL CHEM, V264, P17275; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1989, COMMON MECHANISMS TR; LUO K, 1990, ONCOGENE, V5, P921; MANFREDI JJ, 1990, J VIROL, V64, P5250, DOI 10.1128/JVI.64.11.5250-5259.1990; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MEEK DW, 1990, J VIROL, V64, P1734, DOI 10.1128/JVI.64.4.1734-1744.1990; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1990, ONCOGENE, V5, P973; MEYERSON M, 1991, COLD SPRING HARB SYM, V56, P177; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PATSCHINSKY T, 1992, J VIROL, V66, P3846, DOI 10.1128/JVI.66.6.3846-3859.1992; PERICH JW, 1992, BIOCHEMISTRY-US, V31, P5893, DOI 10.1021/bi00140a027; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SCHEIDTMANN KH, 1991, J VIROL, V65, P1479, DOI 10.1128/JVI.65.3.1479-1490.1991; SCHEIDTMANN KH, 1989, CURR TOP MICROBIOL, V144, P85; SCHNEIDER HR, 1986, EUR J BIOCHEM, V161, P733, DOI 10.1111/j.1432-1033.1986.tb10501.x; SCHNEIDER HR, 1989, BIOTEC EUROPE, V6, P82; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHOHAT O, 1987, ONCOGENE, V1, P277; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOUSSI T, 1990, ONCOGENE, V5, P949; STEINMEYER K, 1988, ONCOGENE, V3, P501; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TUZAON PT, 1991, 2ND MESSENGER PHOSPH, V23, P123; VANROY F, 1984, MOL CELL BIOL, V4, P232, DOI 10.1128/MCB.4.2.232; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WALTER G, 1980, P NATL ACAD SCI-BIOL, V77, P5197, DOI 10.1073/pnas.77.9.5197; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WEISSKER SN, 1992, ONCOGENE, V7, P1921; ZHU J, 1992, J VIROL, V66, P6872	89	25	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2193	2205						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8393163				2022-12-25	WOS:A1993LP17100020
J	MIZUTANI, A; TOKUMITSU, H; KOBAYASHI, R; HIDAKA, H				MIZUTANI, A; TOKUMITSU, H; KOBAYASHI, R; HIDAKA, H			PHOSPHORYLATION OF ANNEXIN-XI (CAP-50) IN SR-3Y1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GENE-PRODUCT; PROTEIN KINASE-C; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; PHOSPHOLIPID BINDING; SIGNAL TRANSDUCTION; SEQUENCE-ANALYSIS; LIPOCORTIN-I; MAP KINASE; INVITRO	Annexin XI (CAP-50) is a probable target protein of calcyclin. Being different from other annexins, annexin XI localizes mainly in nuclei of cultured fibroblasts. In rat embryonic fibroblasts transformed by Rous sarcoma virus oncogene, SR-3Y1 cells, phosphorylation of annexin XI was increased on both serine and threonine residues (Ser < Thr), compared with findings in control 3Y1 cells. The amount of phosphorylated annexin XI was approximately 8.5% of the total cellular annexin XI and the phosphorylated annexin XI migrated slightly slower on SDS-polyacrylamide gel electrophoresis than did the non-phosphorylated form of annexin XI. Phosphorylated annexin XI was recovered in the cytoplasmic fraction and did not bind to phosphatidylserine vesicle in the presence of high Ca2+ (over 1 mM). Annexin XI was phosphorylated by mitogen-activated protein (MAP) kinase, which was reported to be activated in v-src-transformed fibroblast (Gupta, S. K., Gallego, C. Johnson, G. L. and Heasley, L. E. (1992) J. Biol. Chem. 267, 7987-7990), on both serine and threonine residues (Ser >> Thr) in vitro. Comparative phosphopeptide mappings analyzed by reverse-phase high performance liquid chromatography suggested that the sites phosphorylated in situ in SR-3Y1 cells are distinct from the sites by MAP kinase. Annexin XI phosphorylated by MAP kinase still possessed the ability to bind to phosphatidylserine vesicle. These results suggest that annexin XI is a substrate for some Ser/Thr kinase(s) which is activated in v-src-transformed cells and that the phosphorylation may regulate the function of annexin XI in living cells.	NAGOYA UNIV,SCH MED,DEPT PHARMACOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Nagoya University			Mizutani, Akihiro/GPS-4809-2022; Tokumitsu, Hiroshi/M-3978-2015	Mizutani, Akihiro/0000-0003-4155-802X; Tokumitsu, Hiroshi/0000-0002-2193-6794				BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BRAMBILLA R, 1991, BIOCHEM J, V278, P447, DOI 10.1042/bj2780447; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; CRUMPTON MJ, 1990, NATURE, V345, P212, DOI 10.1038/345212a0; ERIKSON E, 1980, CELL, V21, P829, DOI 10.1016/0092-8674(80)90446-8; GLENNEY JR, 1985, P NATL ACAD SCI USA, V82, P7884, DOI 10.1073/pnas.82.23.7884; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOUULD KL, 1986, MOL CELL BIOL, P2738; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IWASHITA S, 1990, J BIOL CHEM, V265, P10702; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KHANNA NC, 1986, BIOCHEM BIOPH RES CO, V141, P547, DOI 10.1016/S0006-291X(86)80208-X; KOBAYASHI R, 1990, ARCH BIOCHEM BIOPHYS, V277, P203, DOI 10.1016/0003-9861(90)90570-O; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MINAMI H, 1992, FEBS LETT, V305, P217, DOI 10.1016/0014-5793(92)80671-3; MIZUTANI A, 1992, J BIOL CHEM, V267, P13498; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; POWELL MA, 1987, BIOCHEM J, V247, P321, DOI 10.1042/bj2470321; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SAWYER ST, 1985, J BIOL CHEM, V260, P8233; SCHLAEPFER DD, 1987, J BIOL CHEM, V262, P6931; SCHLAEPFER DD, 1988, BIOCHEMISTRY-US, V27, P4523; TOKUMITSU H, 1992, BIOCHEM BIOPH RES CO, V186, P1227, DOI 10.1016/S0006-291X(05)81537-2; TOKUMITSU H, 1992, J BIOL CHEM, V267, P8919; TOKUMITSU H, 1991, ARCH BIOCHEM BIOPHYS, V286, P94, DOI 10.1016/0003-9861(91)90012-8; TOWLE CA, 1992, J BIOL CHEM, V267, P5416; VARTICOVSKI L, 1988, BIOCHEMISTRY-US, V27, P3682, DOI 10.1021/bi00410a024; WEBER K, 1987, EMBO J, V6, P1599, DOI 10.1002/j.1460-2075.1987.tb02406.x	34	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15517	15522						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8393445				2022-12-25	WOS:A1993LN30500032
J	REDDY, SAG; GUO, H; TARUN, SZ; DAMUNI, Z				REDDY, SAG; GUO, H; TARUN, SZ; DAMUNI, Z			PHOSPHORYLATION AND ACTIVATION OF PROTAMINE KINASE BY 2 FORMS OF A MYELIN BASIC-PROTEIN KINASE FROM EXTRACTS OF BOVINE KIDNEY CORTEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASES; CELL-CYCLE CONTROL; SEA STAR OOCYTES; MAP KINASE; TYROSINE-PHOSPHATASE; S6 KINASE; INSULIN; PURIFICATION; MATURATION; EXPRESSION	Two myelin basic protein kinases designated MBPK-1 and MBPK-2 were purified to apparent homogeneity from extracts of bovine kidney cortex. The purified preparations exhibited an apparent M(r) almost-equal-to 40,000 by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and approximately 42,000 (MBPK-1) and 45,000 (MBPK-2) by gel permeation chromatography. Up to 0.4 and 1.8 mol of phosphoryl groups were incorporated per mol of MBPK-1 and MBPK-2, respectively, on threonines following incubation with ATP. Autophosphorylation, incubation with protein phosphatase 2A2 (PP2A2), CD45, or T-cell protein tyrosine phosphatase did not affect MBPK-1 activity. Autophosphorylation increased by about 3-fold MBPK-2 activity. This autophosphorylation and activation was reversed by PP2A2 but not by CD45 or T-cell protein tyrosine phosphatase. MBPK-1 and MBPK-2 displayed a positive reaction with an antibody to mitogen-activated protein kinase. Purified preparations of protamine kinase were activated by about 1.5-6-fold and, after inactivation with PP2A2, were reactivated by about 30% by MBPK-1 and MBPK-2. Activation and reactivation correlated with the incorporation, respectively, of 0.1-0.5 and 0.5 mol of phosphoryl groups/mol of the protamine kinase on serines. The results show that MBPK-1 and MBPK-2 are protamine kinase-activating kinases and suggest that MBPK-1 and MBPK-2 may be related to mitogen-activated protein kinase.	UNIV S CAROLINA, DEPT BIOL SCI, CLS 601, COLUMBIA, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia								ADAMS PD, 1991, FEBS LETT, V290, P77, DOI 10.1016/0014-5793(91)81230-6; AHN NG, 1990, J BIOL CHEM, V265, P11487; AMICK GD, 1992, BIOCHEM J, V287, P1019, DOI 10.1042/bj2871019; AMICK GD, 1992, BIOCHEM BIOPH RES CO, V183, P431, DOI 10.1016/0006-291X(92)90499-B; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BARRETT CB, 1992, J BIOL CHEM, V267, P4408; BLENIS J, 1991, CANCER CELL-MON REV, V3, P445; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DAMUNI Z, 1990, BIOCHEM BIOPH RES CO, V166, P449, DOI 10.1016/0006-291X(90)91966-V; DAMUNI Z, 1989, J BIOL CHEM, V264, P6412; Deibler G E, 1984, Prog Clin Biol Res, V146, P249; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENTON RM, 1986, ADV CYCLIC NUCL PROT, V20, P293; ERIKSON E, 1986, J BIOL CHEM, V261, P350; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUO H, 1993, J BIOL CHEM, V268, P11193; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEADER DP, 1980, RECENTLY DISCOVERED, P203; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; REDDY SAG, 1990, J BIOL CHEM, V265, P7748; REDDY SAG, 1992, FASEB J, V6, P225; SANGHERA JS, 1991, BIOCHIM BIOPHYS ACTA, V1095, P153, DOI 10.1016/0167-4889(91)90078-C; SANGHERA JS, 1991, J BIOL CHEM, V266, P6700; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SCIMECA JC, 1991, BIOCHEMISTRY-US, V30, P9313, DOI 10.1021/bi00102a025; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SEGER R, 1992, J BIOL CHEM, V267, P14373; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TONKS NK, 1990, J BIOL CHEM, V265, P10674; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508	51	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15298	15304						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8392073				2022-12-25	WOS:A1993LL75900108
J	GAUDETTE, DC; AUKEMA, HM; JOLLY, CA; CHAPKIN, RS; HOLUB, BJ				GAUDETTE, DC; AUKEMA, HM; JOLLY, CA; CHAPKIN, RS; HOLUB, BJ			MASS AND FATTY-ACID COMPOSITION OF THE 3-PHOSPHORYLATED PHOSPHATIDYLINOSITOL BISPHOSPHATE ISOMER IN STIMULATED HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INOSITOL PHOSPHOLIPIDS; THROMBIN; DIACYLGLYCEROL; LIPIDS	By high pressure liquid chromatography (HPLC) analysis, the occurrence of radiolabeled 3-phosphorylated phosphoinositides has been well documented in several cell systems, including agonist-stimulated platelets. The actual mass amounts and fatty acid composition of these unique lipids, however, have not been reported to date. In the present study, we report the mass and fatty acid composition of phosphatidylinositol (PI) 3,4-P2 from U46619-stimulated platelets using a thin-layer chromatographic system for the separation of PI 3,4-P2 from PI 4,5-P2. The mass of PI 3,4-P2 in the stimulated platelet was 180 +/- 9.7 pmol/1 x 10(9) platelets (mean +/- S.E., n = 4), representing 9.3% of total phosphatidylinositol bisphosphate (PIP2). Based on HPLC analysis, PI 3,4-P2 in unstimulated platelets represented <0.5% of total PIP2 (which corresponds to <7.0 pmol/l x 10(9) platelets). Fatty acid analysis of this lipid revealed a composition very similar to the conventional polyphosphoinositides (stearic and arachidonic acids accounting for 44.2 and 40.4 mol %, respectively, of the fatty acids). Since PI 3,4-P2 also did not appear to be distinct from the other polyphosphoinositides, in regard to radiolabeling properties, it was concluded that this lipid is unlikely to originate from a unique precursor pool. This conclusion validates the use of HPLC analysis of radiolabeled phosphoinositides for the estimation of PI 3,4-P2 mass in agonist-stimulated platelets. The chromatographic procedure described should prove useful for the mass and fatty acid analysis of PI 3,4-P2 from other cell systems.	UNIV GUELPH,DEPT NUTR SCI,GUELPH N1G 2W1,ONTARIO,CANADA; TEXAS A&M UNIV SYST,DEPT ANIM SCI,COLL STN,TX 77843; TEXAS A&M UNIV SYST,GRAD FAC NUTR,COLL STN,TX 77843	University of Guelph; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station				Chapkin, Robert/0000-0002-6515-3898; Aukema, Harold/0000-0002-6982-7239	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041693] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41693] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUKEMA HM, 1992, EXP MOL PATHOL, V57, P39, DOI 10.1016/0014-4800(92)90047-F; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CHOUDHURY GG, 1991, J BIOL CHEM, V266, P8068; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; EBERLE M, 1990, J BIOL CHEM, V265, P16725; GAUDETTE DC, 1990, BIOCHEM BIOPH RES CO, V170, P238, DOI 10.1016/0006-291X(90)91265-T; HOLUB BJ, 1986, ANNU REV NUTR, V6, P563, DOI 10.1146/annurev.nu.06.070186.003023; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; MAUCO G, 1984, BIOCHEM J, V224, P933, DOI 10.1042/bj2240933; MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NOLAN RD, 1990, J BIOL CHEM, V265, P2441; SKEAFF CG, 1987, BIOL EICOSANOIDS, V152, P63; SORISKY A, 1992, BIOCHEM J, V286, P581, DOI 10.1042/bj2860581; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; SULTAN C, 1990, BIOCHEM J, V269, P831, DOI 10.1042/bj2690831; THOMAS LM, 1992, PROG LIPID RES, V31, P399, DOI 10.1016/0163-7827(92)90003-2; TYSNES OB, 1985, THROMB RES, V40, P329, DOI 10.1016/0049-3848(85)90268-3; VERHOEVEN AJM, 1987, EUR J BIOCHEM, V166, P3, DOI 10.1111/j.1432-1033.1987.tb13475.x	21	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13773	13776						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8390977				2022-12-25	WOS:A1993LJ82500003
J	CHAKRABORTY, AK; ZINK, MA; BOMAN, BM; HODGSON, CP				CHAKRABORTY, AK; ZINK, MA; BOMAN, BM; HODGSON, CP			SYNTHETIC RETROTRANSPOSON VECTORS FOR GENE-THERAPY	FASEB JOURNAL			English	Note						GENE THERAPY; RETROVIRUS; VECTOR; RETROTRANSPOSON; VL30; PCR	CHROMOSOMAL POSITION; RETROVIRAL GENOMES; CELL-LINES; VIRUS; DNA; EXPRESSION; CONSTRUCTION; METHYLATION; SEQUENCE; PRIMATES	New gene therapy methods are rapidly being developed to permit the expression of tumor suppressor genes, cytotoxins, anticancer antigens, and immunoregulatory proteins in the treatment of cancer. Large-scale testing in humans has been delayed by questions concerning the safety and effectiveness of preferred retroviral vectors and helper cells. These vector systems are limited by their ability to undergo homologous recombination with endogenous retroviruses or helper-viral sequences, resulting in release of replication-competent retrovirus (RCR). In addition, transcriptional inactivation of the retroviral promoter often occurs, caused in part by methylation of CpG islands in the retroviral long terminal repeats (LTRs). We report the production of highly specific retrovectors using gene amplification together with oligonucleotide building blocks. The synthetic vectors were based on mouse VL30 retrotransposon NVL3, and lacked homology to retroviral helper gene sequences. Three of four constructs made by gene amplification yielded biologically active vectors. These constructs efficiently transmitted and stably inserted a neomycin resistance marker gene into the genome of recipient cells, expressing an abundant RNA species of the expected size in the absence of detectable replication competent retrovirus. The vectors and techniques described enable widely applicable expression modes using generic helper cells, and require only approximately 1.3 kb of cis-acting vector RNA sequences for faithful transfer and expression of genetic material.	CREIGHTON UNIV,SCH MED,CREIGHTON CANC CTR,2500 CALIF PLAZA,OMAHA,NE 68178; CREIGHTON UNIV,SCH MED,DEPT BIOMED SCI,OMAHA,NE 68178	Creighton University; Creighton University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041314] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R29GM41314-4] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS SE, 1988, MOL CELL BIOL, V8, P2989, DOI 10.1128/MCB.8.8.2989; ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; ANDERSON WF, 1992, HUM GENE THER, V3, P617, DOI 10.1089/hum.1992.3.6-617; ANDESON WF, 1992, REPORT NIH RECOMBINA, P961; ARMENTANO D, 1987, J VIROL, V61, P1647, DOI 10.1128/JVI.61.5.1647-1650.1987; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; BESTOR TH, 1990, PHILOS T ROY SOC B, V326, P179, DOI 10.1098/rstb.1990.0002; BESTWICK RK, 1988, P NATL ACAD SCI USA, V85, P5404, DOI 10.1073/pnas.85.15.5404; CARTER AT, 1983, NUCLEIC ACIDS RES, V11, P6243, DOI 10.1093/nar/11.18.6243; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK RF, 1991, BIO-TECHNOL, V9, P748, DOI 10.1038/nbt0891-748; COOK RF, 1993, J POULTRY SCI, V72, P554; CORNETTA K, 1991, HUM GENE THER, V2, P215, DOI 10.1089/hum.1991.2.3-215; CORNETTA K, 1990, HUM GENE THER, V1, P15, DOI 10.1089/hum.1990.1.1-15; DARNELL J, 1986, MOL CELL BIOL, P305; DONAHUE RE, 1992, J EXP MED, V176, P1125, DOI 10.1084/jem.176.4.1125; ECKERT AA, 1991, PCR METHODS APPLICAT, P17; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HATZOGLOU M, 1990, HUM GENE THER, V1, P385, DOI 10.1089/hum.1990.1.4-385; HODGSON CP, 1993, CURR OPIN THER PAT, V3, P223; HOEBEN RC, 1991, J VIROL, V65, P904, DOI 10.1128/JVI.65.2.904-912.1991; JAENISCH R, 1981, CELL, V24, P519, DOI 10.1016/0092-8674(81)90343-3; JAENISCH R, 1985, P NATL ACAD SCI USA, V82, P1451, DOI 10.1073/pnas.82.5.1451; JEFFREYS AJ, 1977, CELL, V12, P429, DOI 10.1016/0092-8674(77)90119-2; KOZAK M, 1978, CELL, V15, P1109, DOI 10.1016/0092-8674(78)90039-9; LINNEY E, 1984, NATURE, V308, P470, DOI 10.1038/308470a0; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MCCLINTOCK B, 1956, COLD SPRING HARB SYM, V21, P197, DOI 10.1101/SQB.1956.021.01.017; MCCLINTOCK B, 1951, COLD SPRING HARB SYM, V16, P13, DOI 10.1101/SQB.1951.016.01.004; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; MUENCHAU DD, 1990, VIROLOGY, V176, P262, DOI 10.1016/0042-6822(90)90251-L; NORTON JD, 1988, DEV BIOL, V125, P226, DOI 10.1016/0012-1606(88)90076-0; ROSENBERG SA, 1992, JAMA-J AM MED ASSOC, V268, P2416, DOI 10.1001/jama.268.17.2416; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCADDEN DT, 1990, J VIROL, V64, P424, DOI 10.1128/JVI.64.1.424-427.1990	40	18	23	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1993	7	10					971	977		10.1096/fasebj.7.10.8393821	http://dx.doi.org/10.1096/fasebj.7.10.8393821			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8393821				2022-12-25	WOS:A1993LQ33700023
J	MOLLER, LB; POLLANEN, J; RONNE, E; PEDERSEN, N; BLASI, F				MOLLER, LB; POLLANEN, J; RONNE, E; PEDERSEN, N; BLASI, F			N-LINKED GLYCOSYLATION OF THE LIGAND-BINDING DOMAIN OF THE HUMAN UROKINASE RECEPTOR CONTRIBUTES TO THE AFFINITY FOR ITS LIGAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; PLASMINOGEN-ACTIVATOR; CELL-SURFACE; MUTATIONAL ANALYSIS; MAMMALIAN-CELLS; POTENTIATION; DEGRADATION; EXPRESSION; MONOCYTES; SEQUENCE	Variations in glycosylation exist among urokinase plasminogen activator receptors (u-PARs) from different cell types. We have studied the functional role of N-linked carbohydrate within the ligand-binding domain of u-PAR. Treatment with glycosidases demonstrated that all the N-linked carbohydrates on u-PAR are complex-type oligosaccharides. Substitution of a single Asn (Asn52) to Gln by means of site-directed mutagenesis led to an active receptor mutant with a ligand-binding domain devoid of carbohydrate. The cellular distribution, the glycosyl-phosphatidylinositol anchoring, and the conformational stability after solubilization were unaffected by this single substitution. However, ligand binding analysis demonstrated a 4-5-fold decrease in affinity as compared with the wild type receptor. Two different strategies were used in order to obtain a u-PAR type completely devoid of N-linked carbohydrates. 1) Tunicamycin treatment of wild type u-PAR-expressing cells. 2) Mutation of all glycosylation sites (Hu-PAR(N5-mut)). In neither case, unglycosylated receptors with ligand binding activity were identified. However, immunofluorescence studies demonstrated that the-Hu-PAR(N5-mut) was retained inside the cells in the endoplasmic reticulum. The same result was found for Hu-PAR(N4-mut), where only the glycosylation sites outside the binding domain were mutated. These results demonstrate that some extent of glycosylation of u-PAR is necessary for cellular transport and for molecular maturation events leading to ligand binding activity. Glycosylation of the binding domain per se affects only the affinity of the receptor. The positive modulation of the Asn52 carbohydrate side chain on ligand affinity suggests that the u-PAR glycosylation variants observed in various cell types may have different functional roles.	UNIV MILAN,HOSP SAN RAFFAELE,DIPARTIMENTO GENET,I-20132 MILAN,ITALY; RIGSHOSP,FINSEN INST,DK-2100 COPENHAGEN,DENMARK; UNIV MILAN,HOSP SAN RAFFAELE,DIPARTIMENTO BIOL & BIOTECNOL,I-20132 MILAN,ITALY	University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Rigshospitalet; University of Copenhagen; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	MOLLER, LB (corresponding author), UNIV COPENHAGEN,INST MICROBIOL,OSTER FARIMAGSGADE 2A,DK-1353 COPENHAGEN K,DENMARK.			Moller, Lisbeth/0000-0002-9524-4301; Blasi, Francesco/0000-0001-9406-1784				APPELLA E, 1987, J BIOL CHEM, V262, P4437; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BEHRENDT N, 1993, IN PRESS METHODS ENZ; BLASI F, 1990, CELL DIFFER DEV, V32, P247, DOI 10.1016/0922-3371(90)90037-W; BLASI F, 1988, Fibrinolysis, V2, P73, DOI 10.1016/0268-9499(88)90370-0; BREITFELD PP, 1984, J BIOL CHEM, V259, P414; CORSARO CM, 1981, SOMAT CELL GENET, V7, P603, DOI 10.1007/BF01549662; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DANO K, 1990, UCLA S MOL CELLULAR, V132, P173; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; FREEDMAN RB, 1984, TRENDS BIOCH SCI; HOE MH, 1992, J BIOL CHEM, V267, P4916; HUNT RC, 1989, J BIOL CHEM, V264, P9643; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1991, J BIOL CHEM, V266, P17621; MOLLER LB, 1992, EUR J BIOCHEM, V208, P493, DOI 10.1111/j.1432-1033.1992.tb17213.x; MORIKAWA Y, 1991, VIROLOGY, V180, P853, DOI 10.1016/0042-6822(91)90106-L; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; NYKJAER A, 1990, BIOCHIM BIOPHYS ACTA, V1052, P399, DOI 10.1016/0167-4889(90)90149-8; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; PICONE R, 1989, J CELL BIOL, V108, P693, DOI 10.1083/jcb.108.2.693; PLOUG M, 1991, J BIOL CHEM, V266, P1926; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; QUAX PHA, 1991, CELL REGUL, V2, P793, DOI 10.1091/mbc.2.10.793; RANDS E, 1990, J BIOL CHEM, V265, P10759; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; RONNE E, 1991, FEBS LETT, V288, P233, DOI 10.1016/0014-5793(91)81042-7; ROZAKISADCOCK M, 1991, J BIOL CHEM, V266, P16472; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SLIEKER LJ, 1986, J BIOL CHEM, V261, P5233; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; WENDLAND M, 1991, J BIOL CHEM, V266, P2917	36	79	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11152	11159						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8388383				2022-12-25	WOS:A1993LD46600065
J	FIELD, MC; MEDINAACOSTA, E; CROSS, GAM				FIELD, MC; MEDINAACOSTA, E; CROSS, GAM			INHIBITION OF GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS IN LEISHMANIA-MEXICANA BY MANNOSAMINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMASTIGOTE SURFACE PROTEASE; PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; N-LINKED OLIGOSACCHARIDES; TRYPANOSOMA-BRUCEI; DONOVANI LIPOPHOSPHOGLYCAN; GLYCOPROTEIN; IDENTIFICATION; GLYCOLIPIDS; PROTEINS; GP63	In several Leishmania species, glycosylated inositol phospholipids exist as free lipids, as membrane protein anchors, and as the membrane-binding moieties of the lipophosphoglycans. Both the glycolipid-anchored cell surface metalloproteinase, gp63, and the lipophosphoglycans have been proposed to be involved in cell invasion. Moreover, the lipophosphoglycans have been implicated in the survival of Leishmania in the parasitophorous vacuole of the host macrophage. In this report we show that mannosamine effectively inhibits the biosynthesis of both free glycosylated inositol phospholipids and the lipophosphoglycans of Leishmania mexicana. [H-3]Mannosamine is incorporated into glycosylated inositol phospholipids, but not significantly into lipophosphoglycans when added as a radiochemical tracer at a subinhibitory concentration. The reversible inhibitory effect of mannosamine may be useful for studying precursor/product relationships during the biosynthesis of free glycosylated inositol phospholipids, glycolipid anchors, and the lipophosphoglycans. The implications of these data for the mode of action of mannosamine are discussed.	ROCKEFELLER UNIV, MOLEC PARASITOL LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA	Rockefeller University			Medina-Acosta, Enrique/G-3041-2010; Cross, George A M/B-7444-2011; Field, Mark/AAD-6455-2021	Medina-Acosta, Enrique/0000-0002-2529-0548; Cross, George A M/0000-0003-1374-6955; Field, Mark/0000-0002-4866-2885	NIAID NIH HHS [AI21513] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHFORD D, 1987, EUR J BIOCHEM, V166, P311, DOI 10.1111/j.1432-1033.1987.tb13516.x; BLACKWELL JM, 1985, J EXP MED, V162, P324, DOI 10.1084/jem.162.1.324; BORDIER C, 1986, P NATL ACAD SCI USA, V83, P5988, DOI 10.1073/pnas.83.16.5988; BOUVIER J, 1987, MOL BIOCHEM PARASIT, V24, P73, DOI 10.1016/0166-6851(87)90117-4; BRUN R, 1979, ACTA TROP, V36, P289; CARVER MA, 1991, J BIOL CHEM, V266, P10974; CHANG KP, 1983, INT REV CYTOL, P267; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DIECKMANNSCHUPP.A, 1992, IN PRESS EUR J BIOCH; DOERING TL, 1989, J BIOL CHEM, V264, P11168; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; Field M. C., 1992, LIPID MODIFICATION P, P155; FIELD MC, 1991, J BIOL CHEM, V266, P8392; FIELD MC, 1991, MOL BIOCHEM PARASIT, V48, P227, DOI 10.1016/0166-6851(91)90118-P; HANDMAN E, 1985, EMBO J, V4, P329, DOI 10.1002/j.1460-2075.1985.tb03633.x; ILG T, 1992, J BIOL CHEM, V267, P6834; KELLEHER M, 1992, P NATL ACAD SCI USA, V89, P6, DOI 10.1073/pnas.89.1.6; KING DL, 1988, MOL BIOCHEM PARASIT, V28, P285, DOI 10.1016/0166-6851(88)90013-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISANTI MP, 1991, EMBO J, V10, P1969, DOI 10.1002/j.1460-2075.1991.tb07726.x; LOW P, 1991, J BIOL CHEM, V266, P19250; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MCCONVILLE MJ, 1992, J BIOL CHEM, V267, P5855; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; MCCONVILLE MJ, 1991, J BIOL CHEM, V266, P15170; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCNEELY TB, 1990, J IMMUNOL, V144, P2745; MEDINAACOSTA E, 1989, MOL BIOCHEM PARASIT, V37, P263, DOI 10.1016/0166-6851(89)90158-8; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; MOSSER DM, 1992, J CELL BIOL, V116, P511, DOI 10.1083/jcb.116.2.511; OLAFSON RW, 1990, J BIOL CHEM, V265, P12240; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; PALADINI AC, 1952, BIOCHEM J, V51, P426, DOI 10.1042/bj0510426; PAN YT, 1992, J BIOL CHEM, V267, P8991; PAN YT, 1992, J BIOL CHEM, V267, P21250; PAN YT, 1985, ARCH BIOCHEM BIOPHYS, V242, P447, DOI 10.1016/0003-9861(85)90229-2; RUSSELL DG, 1988, J EXP MED, V168, P279, DOI 10.1084/jem.168.1.279; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SCHWARZ RT, 1989, BIOCHEM SOC T, V17, P746, DOI 10.1042/bst0170746; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; TALAMASROHANA P, 1990, J IMMUNOL, V144, P4817; THOMAS JR, 1992, J BIOL CHEM, V267, P6829; TURCO SJ, 1987, BIOCHEMISTRY-US, V26, P6233, DOI 10.1021/bi00393a042	45	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9570	9577						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8387500				2022-12-25	WOS:A1993LA68900065
J	CHOWDHURY, M; KUNDU, M; KHALILI, K				CHOWDHURY, M; KUNDU, M; KHALILI, K			GA GC-RICH SEQUENCE CONFERS TAT RESPONSIVENESS TO HUMAN NEUROTROPIC VIRUS PROMOTER, JCVL, IN CELLS DERIVED FROM CENTRAL-NERVOUS-SYSTEM	ONCOGENE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; HUMAN-BRAIN CELLS; TRANS-ACTIVATION; HIV-1 TAT; GENE-EXPRESSION; LOOP SEQUENCE; PROTEIN; RNA; TYPE-1	The human immunodeficiency virus type I (HIV-1) nuclear protein, Tat, is a potent transactivating factor that stimulates the rate of transcription of responsive promoters. Evidently, to exert its activity, Tat requires to be localized in close proximity of the transcription initiation site. Previous studies in our laboratory have demonstrated that Tat has the capacity to increase transcriptional activity of the late gene of a human neurotropic virus JC (JCV) in glial cells. In the present study, using deletion mutation analysis, we have identified a region upstream of the JCV late RNA start sites, termed upstream target (upTAR), that positively responds to Tat activation in glial cells. Using synthetic oligonucleotides spanning the upTAR sequence linked to a heterologous promoter, we have identified a GA/GC-rich region (GGAGGCGGAGGC) that confers TAT responsiveness preferentially on glial cell lines. Using gel mobility-shift and UV cross-linking assays, we have demonstrated that four major complexes (a-d) from glial and HeLa (non-glial) cells interact with the upTAR sequence. Whereas the molecular weights of the participant proteins in these complexes are similar in both glial and non-glial extracts, glial cells are enriched in proteins that form a major c complex. Interestingly, the participant proteins in complex c are developmentally regulated during brain development. The possible role of these proteins in increasing local concentrations of Tat in the vicinity of the JCV late RNA start sites is discussed.	THOMAS JEFFERSON UNIV,JEFFERSON INST MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107	Jefferson University			Kundu, Mondira/N-8139-2018	Kundu, Mondira/0000-0001-9946-2472	NCI NIH HHS [CA 47996] Funding Source: Medline; NIAID NIH HHS [AI 28272] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028272] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKSAMIT AJ, 1988, ANN NEUROL, V24, P471; BERGER JR, 1987, ANN INTERN MED, V107, P78, DOI 10.7326/0003-4819-107-1-78; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BERKHOUT B, 1989, J VIROL, V63, P5501, DOI 10.1128/JVI.63.12.5501-5504.1989; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CHOWDHURY M, 1992, J VIROL, V66, P7355, DOI 10.1128/JVI.66.12.7355-7361.1992; CHOWDHURY M, 1990, ONCOGENE, V5, P1737; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; KAMINE J, 1992, J VIROL, V66, P3932, DOI 10.1128/JVI.66.6.3932-3936.1992; KENNEY S, 1984, SCIENCE, V226, P1337, DOI 10.1126/science.6095453; KENNEY S, 1986, J VIROL, V58, P210; KHALILI K, 1988, EMBO J, V7, P1205, DOI 10.1002/j.1460-2075.1988.tb02932.x; KRUPP LB, 1985, ANN NEUROL, V17, P344, DOI 10.1002/ana.410170407; LEVY RM, 1985, J NEUROSURG, V62, P475, DOI 10.3171/jns.1985.62.4.0475; LIU JS, 1992, J VIROL, V66, P3883, DOI 10.1128/JVI.66.6.3883-3887.1992; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MULLER WEG, 1990, J BIOL CHEM, V265, P3803; PADGETT BL, 1973, J INFECT DIS, V127, P467, DOI 10.1093/infdis/127.4.467; ROSEN CA, 1991, GENE EXPRESSION, V1, P85; ROY S, 1990, J VIROL, V64, P1402, DOI 10.1128/JVI.64.3.1402-1406.1990; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SMALL JA, 1986, CELL, V46, P13, DOI 10.1016/0092-8674(86)90855-X; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; STONER GL, 1991, J NEUROPATH EXP NEUR, V50, P342; TADA H, 1989, J VIROL, V63, P463, DOI 10.1128/JVI.63.1.463-466.1989; TADA H, 1990, P NATL ACAD SCI USA, V87, P3479, DOI 10.1073/pnas.87.9.3479; TADA H, 1991, VIROLOGY, V52, P456; TAYLOR JP, 1992, EMBO J, V11, P3395, DOI 10.1002/j.1460-2075.1992.tb05418.x; WALKER DL, 1978, HDB CLIN NEUROLOGY, V34, P307; WALKER DL, 1985, HDB CLIN NEUROLOGY, V47, P503; WROBLEWSKA Z, 1980, ARCH VIROL, V65, P141, DOI 10.1007/BF01317325; ZURHEIN GM, 1969, PROG MED VIROL, V11, P185	40	63	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					887	892						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8384357				2022-12-25	WOS:A1993KT22000009
J	CLARKE, JH; LIGHT, DR; BLASKO, E; PARKINSON, JF; NAGASHIMA, M; MCLEAN, K; VILANDER, L; ANDREWS, WH; MORSER, J; GLASER, CB				CLARKE, JH; LIGHT, DR; BLASKO, E; PARKINSON, JF; NAGASHIMA, M; MCLEAN, K; VILANDER, L; ANDREWS, WH; MORSER, J; GLASER, CB			THE SHORT LOOP BETWEEN EPIDERMAL GROWTH FACTOR-LIKE DOMAIN-4 AND DOMAIN-5 IS CRITICAL FOR HUMAN THROMBOMODULIN FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN THROMBOMODULIN; PROTEIN-C ACTIVATION; STRUCTURAL-CHANGES; FACTOR-V; THROMBIN; BINDING; COFACTOR; CELLS; SITE; INACTIVATION	Thrombomodulin (TM) is a cofactor for activation of protein C by thrombin. We showed that 80-90% of this cofactor activity is lost by oxidation of Met388, located within the short interdomain loop between epidermal growth factor-like domains 4 and 5 (Glaser, C. B., Morser, J., Clarke, J. H., Blasko, E., McLean, K., Kuhn, I., Chang, R.-J., Lin, J.-H., Vilander, L., Andrews, W. H., and Light, D. R. (1992) J. Clin. Invest. 90, 2565-2573). For each of the 3 amino acids of the loop, site-specific mutants are described in which, 1) all possible single amino acid substitutions are made, 2) deletions are made, or 3) alanine is inserted adjacent to each residue of the loop. Most substitutions within the loop (38/57) result in a >50% decrease in cofactor activity, while changes in the length of this region result in >90% loss of activity. Only the Met388 --> Leu mutant has higher cofactor activity (2-fold) than wild-type TM. A number of soluble and full-length TM analogs with the Met388 --> Leu substitution are improved thrombin cofactors, whether produced in bacteria, insect, or mammalian cells. Detailed kinetic analysis of a soluble TM analog consisting of the six EGF-like domains secreted from insect cells shows that the enhanced activity of the Met388 --> Leu mutant results from an increased catalytic efficiency (k(cat)/K(m)). This enhancement is maximal at physiological concentrations of calcium. The loss of activity following Met388 oxidation in the wild-type protein is the result of both decreased binding to thrombin (K(d) effect) and a decreased interaction of the TM.thrombin complex with protein C (K(m) effect). We demonstrate the critical role of this interdomain loop in the biological anticoagulant properties of TM.	BERLEX BIOSCI,DEPT PROT CHEM,RICHMOND,CA 94804; BERLEX BIOSCI,DEPT CARDIOVASC RES,RICHMOND,CA 94804; BERLEX BIOSCI,DEPT MOLEC BIOL,RICHMOND,CA 94804									DITTMAN WA, 1988, J BIOL CHEM, V263, P15815; ESMON CT, 1992, ARTERIOSCLER THROMB, V12, P135, DOI 10.1161/01.ATV.12.2.135; Esmon N L, 1987, Dev Biol Stand, V67, P75; ESMON NL, 1982, J BIOL CHEM, V257, P859; Fersht AR., 1977, ENZYME STRUCTURE MEC; FULCHER CA, 1984, BLOOD, V63, P486; GLASER CB, 1992, J CLIN INVEST, V90, P2565, DOI 10.1172/JCI116151; GLASER CB, 1974, BIOCHEMISTRY-US, V13, P1044, DOI 10.1021/bi00702a033; HALKIER T, 1991, MECHANISMS BLOOD COA, P295; HAYASHI T, 1990, J BIOL CHEM, V265, P20156; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; KUROSAWA S, 1987, J BIOL CHEM, V262, P2206; MARUYAMA I, 1985, J BIOL CHEM, V260, P5432; MONTELIONE GT, 1987, P NATL ACAD SCI USA, V84, P5226, DOI 10.1073/pnas.84.15.5226; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; PARKINSON JF, 1992, BIOCHEM BIOPH RES CO, V185, P567, DOI 10.1016/0006-291X(92)91662-A; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; SUZUKI K, 1987, EMBO J, V6, P1891, DOI 10.1002/j.1460-2075.1987.tb02448.x; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; TSIANG M, 1992, J BIOL CHEM, V267, P6164; TSIANG M, 1990, BIOCHEMISTRY-US, V29, P10602, DOI 10.1021/bi00499a005; WEN DZ, 1987, BIOCHEMISTRY-US, V26, P4350, DOI 10.1021/bi00388a025; YE J, 1991, J BIOL CHEM, V266, P23016; YE J, 1992, J BIOL CHEM, V267, P11023; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3; ZUSHI M, 1991, J BIOL CHEM, V266, P19886; ZUSHI M, 1989, J BIOL CHEM, V264, P10351	28	59	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6309	6315						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8384206				2022-12-25	WOS:A1993KT36800037
J	METTERS, KM; ZAMBONI, RJ				METTERS, KM; ZAMBONI, RJ			PHOTOAFFINITY-LABELING OF THE LEUKOTRIENE-D4 RECEPTOR IN GUINEA-PIG LUNG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED BRONCHOCONSTRICTION; ANTAGONIST; BINDING; MEMBRANES; POTENT; INFLAMMATION; PHARMACOLOGY; ICI-204,219; INHIBITION; PROTEINS	The leukotriene (LT)D4 receptor has been defined as a G-protein-coupled receptor. In order to characterize this receptor, an iodinated, photoactivatable azido derivative of LTD4 (I-125-azido-LTD4) has been synthesized for use as a photoaffinity probe. The characteristics of I-125-azido-LTD4 specific binding to guinea pig lung membranes were directly comparable to those of [H-3]LTD4 specific binding to this tissue. I-125-Azido-LTD4 specific binding was saturable and of high affinity, enhanced by divalent cations and inhibited by sodium ions, but not potassium ions. I-125-Azido-LTD4 specific binding was also strongly inhibited by the nonhydrolyzable GTP analog, GTPgammaS, with ATPgammaS being 100-fold less potent, suggesting this inhibition was due to selective interaction with a G-protein. The cysteinyl leukotrienes competed for I-125-azido-LTD4 specific binding to guinea pig lung membranes with the following rank order of potency: LTD4 > LTE4 > LTC4, while the non-cysteinyl LTB4 was virtually inactive. Two structurally different LTD4 receptor antagonists, MK-571 and ICI 204,219, also competed for I-125-azido-LTD4 specific binding with nanomolar potency, whereas the leukotriene synthesis inhibitor, MK-886, was 10,000-fold less active. These data are in agreement with I-125-azido-LTD4 binding specifically to a G-protein-coupled LTD4 receptor. Photolysis of I-125-azido-LTD4 under equilibrium binding conditions resulted in the selective radiolabeling of a 45-kDa guinea pig lung membrane protein. The photolabeling of this 45-kDa protein was saturable, modulated by cations and inhibited by nucleotide analogs in an analogous way to I-125-azido-LTD4 specific binding. In addition, the photolabeling of this protein was inhibited in a concentration-dependent manner by all competing ligands, with the same rank order of potency and IC50 values as determined in the I-125-azido-LTD4 binding assay. It is proposed, therefore, that this novel 45-kDa protein is the guinea pig lung LTD4 receptor.	MERCK FROSST CTR THERAPEUT RES,DEPT MED CHEM,DORVAL H9R 4P8,PQ,CANADA	Merck & Company	METTERS, KM (corresponding author), MERCK FROSST CTR THERAPEUT RES,DEPT PHARMACOL,DORVAL H9R 4P8,PQ,CANADA.							AHARONY D, 1989, J PHARMACOL EXP THER, V248, P581; BRUNS RF, 1983, LIFE SCI, V33, P645, DOI 10.1016/0024-3205(83)90253-9; CROOKE ST, 1989, TRENDS PHARMACOL SCI, V10, P103, DOI 10.1016/0165-6147(89)90206-X; FORDHUTCHINSON AW, 1990, CRIT REV IMMUNOL, V10, P1; FREY EA, 1993, IN PRESS EUR J MOL P; GILLARD J, 1989, CAN J PHYSIOL PHARM, V67, P456, DOI 10.1139/y89-073; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JI TH, 1982, ANAL BIOCHEM, V121, P286, DOI 10.1016/0003-2697(82)90481-X; JONES TR, 1991, CAN J PHYSIOL PHARM, V69, P1847, DOI 10.1139/y91-273; JONES TR, 1989, CAN J PHYSIOL PHARM, V67, P17, DOI 10.1139/y89-004; KIPS JC, 1991, AM REV RESPIR DIS, V144, P617, DOI 10.1164/ajrccm/144.3_Pt_1.617; KRELL RD, 1990, AM REV RESPIR DIS, V141, P978, DOI 10.1164/ajrccm/141.4_Pt_1.978; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOWITZ RJ, 1983, ANNU REV BIOCHEM, V52, P159, DOI 10.1146/annurev.bi.52.070183.001111; LEWIS MA, 1991, LIPOXYGENASES THEIR, P207; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; METTERS KM, 1991, EUR J PHARMACOL, V194, P51, DOI 10.1016/0014-2999(91)90123-8; MONG S, 1984, EUR J PHARMACOL, V102, P1, DOI 10.1016/0014-2999(84)90331-5; MONG S, 1991, LIPOXYGENASES THEIR, P185; MONG S, 1985, EUR J PHARMACOL, V106, P241; OSULLIVAN BP, 1989, MOL PHARMACOL, V35, P795; PIPER PJ, 1984, PHYSIOL REV, V64, P744, DOI 10.1152/physrev.1984.64.2.744; PONG SS, 1983, P NATL ACAD SCI-BIOL, V80, P7415, DOI 10.1073/pnas.80.24.7415; RASMUSSEN JB, 1992, J ALLERGY CLIN IMMUN, V90, P193, DOI 10.1016/0091-6749(92)90071-9; ROSENTHAL HE, 1967, ANAL BIOCHEM, V20, P525, DOI 10.1016/0003-2697(67)90297-7; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHAW A, 1991, J MED CHEM, V34, P1235, DOI 10.1021/jm00108a001; SMITH LJ, 1990, AM REV RESPIR DIS, V141, P988, DOI 10.1164/ajrccm/141.4_Pt_1.988; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SNYDER DW, 1987, J PHARMACOL EXP THER, V243, P548; SNYDER DW, 1984, J PHARMACOL EXP THER, V231, P616; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; SUN FF, 1986, J BIOL CHEM, V261, P8540; TATE SS, 1978, P NATL ACAD SCI USA, V75, P4806, DOI 10.1073/pnas.75.10.4806; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V	37	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6487	6495						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8384212				2022-12-25	WOS:A1993KT36800060
J	MERTENS, S; BENKE, D; MOHLER, H				MERTENS, S; BENKE, D; MOHLER, H			GABA(A) RECEPTOR POPULATIONS WITH NOVEL SUBUNIT COMBINATIONS AND DRUG-BINDING PROFILES IDENTIFIED IN BRAIN BY ALPHA-5-SUBUNIT-SPECIFIC AND DELTA-SUBUNIT-SPECIFIC IMMUNOPURIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; A-RECEPTOR; BENZODIAZEPINE RECEPTORS; RAT-BRAIN; ALPHA-SUBUNIT; SITES; SUBTYPES; ALPHA-1-SUBUNIT; HETEROGENEITY; LOCALIZATION	The pharmacological significance and structural basis of the gamma-aminobutyrate (GABA(A)) receptor heterogeneity was investigated in situ by an immunobiochemical analysis of receptor populations characterized by the delta- and alpha5-subunit. Using an antiserum specific for the delta-subunit, a population of GABA(A) receptors (21 +/- 2% of solubilized receptors) was immunoprecipitated from rat brain extracts which contained high affinity benzodiazepine binding sites. They were distinguished from those immunoprecipitated by the alpha1- and alpha3-subunit antisera by a 4-5-fold and 5-10-fold higher affinity for diazepam and betaCCM, respectively. Using the delta-antiserum in immunoaffinity chromatography the delta-subunit was found to be associated with the alpha1-, alpha3-, beta2/3-, and gamma2-subunits, suggesting that the latter conveys benzodiazepine receptor sensitivity also to GABA(A) receptors containing the delta-subunit. The receptor population immunoprecipitated by the alpha5-subunit antiserum (10 +/- 2% of receptors solubilized from whole brain extracts) was characterized by affinities for zolpidem, betaCCM, and CL 218872 which distinguished it from all other known receptor populations. The alpha5-subunit was associated with the alpha1-, alpha3-, beta2/3- and gamma2-subunits pointing to differential subunit combinations. Indeed, when receptor populations were immunoprecipitated by the alpha5-subunit antiserum from different brain regions, zolpidem displayed striking differences in affinity pointing to the role of subunits other than alpha5 in determining receptor affinity.	UNIV ZURICH, INST PHARMACOL, GLORIASTR 32, CH-8006 ZURICH, SWITZERLAND	University of Zurich								ARAKI T, 1992, MOL BRAIN RES, V12, P293, DOI 10.1016/0169-328X(92)90132-U; BENKE D, 1991, J RECEPTOR RES, V11, P407, DOI 10.3109/10799899109066418; BENKE D, 1991, FEBS LETT, V283, P145, DOI 10.1016/0014-5793(91)80573-L; BENKE D, 1991, J BIOL CHEM, V266, P4478; BENKE D, 1991, Molecular Neuropharmacology, V1, P103; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; DUGGAN MJ, 1991, J BIOL CHEM, V266, P24778; DUGGAN MJ, 1992, J NEUROCHEM, V58, P72, DOI 10.1111/j.1471-4159.1992.tb09278.x; DUGGAN MJ, 1990, J BIOL CHEM, V265, P3831; EWERT M, 1990, J CELL BIOL, V110, P2043, DOI 10.1083/jcb.110.6.2043; FRITSCHY JM, 1992, P NATL ACAD SCI USA, V89, P6726, DOI 10.1073/pnas.89.15.6726; GUIDOTTI A, 1990, ADV BIOCHEM PSYCHOPH, V46, P73; HORSFALL AC, 1987, J IMMUNOL METHODS, V104, P43, DOI 10.1016/0022-1759(87)90485-6; KHRESTCHATISKY M, 1989, NEURON, V3, P745, DOI 10.1016/0896-6273(89)90243-2; KLEPNER CA, 1979, PHARMACOL BIOCHEM BE, V11, P457, DOI 10.1016/0091-3057(79)90125-4; KNOFLACH F, 1992, EUR J NEUROSCI, V4, P1, DOI 10.1111/j.1460-9568.1992.tb00103.x; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; MALHERBE P, 1990, FEBS LETT, V260, P261, DOI 10.1016/0014-5793(90)80118-3; MAMALAKI C, 1989, J NEUROCHEM, V52, P124, DOI 10.1111/j.1471-4159.1989.tb10906.x; MASSOTTI M, 1991, J PHARMACOL EXP THER, V256, P1154; MCKERNAN RM, 1991, NEURON, V7, P667, DOI 10.1016/0896-6273(91)90379-E; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MOHLER H, 1981, NATURE, V294, P763, DOI 10.1038/294763a0; MOHLER H, 1990, NEUROCHEM RES, V15, P199, DOI 10.1007/BF00972210; MOHLER H, 1984, EUR J PHARMACOL, V102, P191, DOI 10.1016/0014-2999(84)90358-3; MOHLER H, 1980, P NATL ACAD SCI-BIOL, V77, P1666, DOI 10.1073/pnas.77.3.1666; NIDDAM R, 1987, J NEUROCHEM, V49, P890, DOI 10.1111/j.1471-4159.1987.tb00977.x; NIELSEN M, 1980, NATURE, V286, P606, DOI 10.1038/286606a0; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; OLSEN RW, 1990, J CHEM NEUROANAT, V3, P59; POLLARD S, 1991, FEBS LETT, V295, P81, DOI 10.1016/0014-5793(91)81390-T; PRITCHETT DB, 1990, J NEUROCHEM, V54, P1802, DOI 10.1111/j.1471-4159.1990.tb01237.x; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; PUIA G, 1991, MOL PHARMACOL, V39, P691; Richards G., 1991, SEMIN NEUROSCI, V3, P191; RICHARDS JG, 1986, NEUROLOGY NEUROBIOLO, V16, P629; RUANO D, 1992, J NEUROCHEM, V58, P485, DOI 10.1111/j.1471-4159.1992.tb09747.x; SCHOCH P, 1985, NATURE, V314, P168, DOI 10.1038/314168a0; SCHOCH P, 1983, EUR J PHARMACOL, V95, P323, DOI 10.1016/0014-2999(83)90656-8; SEEBURG PH, 1990, ADV BIOCHEM PSYCHOPH, V46, P15; SHIVERS BD, 1989, NEURON, V3, P327, DOI 10.1016/0896-6273(89)90257-2; SIEGHART W, 1980, NATURE, V286, P285, DOI 10.1038/286285a0; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; WILSONSHAW D, 1991, FEBS LETT, V284, P211, DOI 10.1016/0014-5793(91)80687-X; WISDEN W, 1992, J NEUROSCI, V12, P1040; ZEZULA J, 1991, FEBS LETT, V284, P15, DOI 10.1016/0014-5793(91)80750-W	47	173	173	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5965	5973						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8383681				2022-12-25	WOS:A1993KR82200090
J	WALTER, SA; PAPADOPOULOS, PG; BAKER, GM				WALTER, SA; PAPADOPOULOS, PG; BAKER, GM			FORMATION OF HIGH-SPIN CYTOCHROME-A IN ISOLATED CYTOCHROME-C-OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRONIC STATE; HEAT-TREATMENT; SLOW FORMS; HEME; DERIVATIVES	The effect of temperature on the electronic structure of cytochromes a and a3 has been determined at two different concentrations of the solubilizing detergent, N-dodecyl beta-D-maltoside. In each case, an incubation temperature of 40-degrees-C resulted in a 20-30% increase in the 430-nm conformer of cytochrome a3 when compared with a 20-degrees-C control, but the higher detergent concentration led to additional formation of a new charge transfer band at 630 nm. Induction of this new feature was correlated with a loss of alpha-band intensity, a blue shift in the Soret absorbance, and a decrease in the Soret magnetic circular dichroism. The absorbance changes were associated with isosbestic wavelengths at 613, 581, 563, 453, and 416 nm, indicating a two-state electronic conversion. The loss of magnetic circular dichroism intensity and the lack of an isosbestic point between 630 and 655 nm were consistent with a selective effect on the electronic structure of ferricytochrome a. Comparison of these spectral changes with the model heme a studies of Carter and Palmer ( Carter, K., and Palmer, G. (1982) J. Biol. Chem. 257, 13507-13514) provides evidence for a low to high spin transition in cytochrome a in which one of the axial Fe-N bonds is either broken or sterically strained. This selective effect on cytochrome a and the associated thermal resistance of the a3-Cu(B) domain are discussed in terms of the 4-helix bundle motif that has been recently proposed for the catalytic site of cytochrome c oxidase.	NO ILLINOIS UNIV,DEPT CHEM,DE KALB,IL 60115	Northern Illinois University								BABCOCK GT, 1976, J BIOL CHEM, V251, P7907; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BAKER GM, 1987, J BIOL CHEM, V262, P595; BAKER GM, 1987, BIOCHEMISTRY-US, V26, P3038, DOI 10.1021/bi00385a014; CARTER K, 1982, J BIOL CHEM, V257, P13507; HARTZELL CR, 1974, BIOCHIM BIOPHYS ACTA, V368, P318, DOI 10.1016/0005-2728(74)90178-9; HILL BC, 1988, BIOCHEMISTRY-US, V27, P4741, DOI 10.1021/bi00413a024; LEMMIEUX LJ, 1992, J BIOL CHEM, V267, P2105; LI PM, 1988, BIOCHEMISTRY-US, V27, P7538, DOI 10.1021/bi00419a054; MINAGAWA J, 1992, J BIOL CHEM, V267, P2096; MOODY AJ, 1991, BIOCHIM BIOPHYS ACTA, V1059, P189, DOI 10.1016/S0005-2728(05)80204-X; PALMER G, 1976, P NATL ACAD SCI USA, V73, P2206, DOI 10.1073/pnas.73.7.2206; PAPADOPOULOS PG, 1991, BIOCHEMISTRY-US, V30, P840, DOI 10.1021/bi00217a038; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SARASTE M, 1991, BIOCHEM SOC T, V19, P608, DOI 10.1042/bst0190608; SCHOONOVER JR, 1988, BIOCHEMISTRY-US, V27, P5433, DOI 10.1021/bi00415a008; SHAPLEIGH JP, 1992, P NATL ACAD SCI USA, V89, P4786, DOI 10.1073/pnas.89.11.4786; SONE N, 1984, BIOCHEMISTRY-US, V23, P6550, DOI 10.1021/bi00321a042; TWEEDLE MF, 1978, J BIOL CHEM, V253, P8065; VANNESTE WH, 1966, BIOCHEMISTRY-US, V5, P838, DOI 10.1021/bi00867a005	20	1	1	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4716	4719						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8383123				2022-12-25	WOS:A1993KP88400027
J	DAVIDSON, HW; BALCH, WE				DAVIDSON, HW; BALCH, WE			DIFFERENTIAL INHIBITION OF MULTIPLE VESICULAR TRANSPORT STEPS BETWEEN THE ENDOPLASMIC-RETICULUM AND TRANS-GOLGI NETWORK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-N-ACETYLGLUCOSAMINIDASE; SEMI-INTACT CELLS; YPT1 GENE-PRODUCT; PROTEIN-TRANSPORT; STOMATITIS-VIRUS; COMPLEMENTATION GROUPS; MOLECULAR-CLONING; FUSION PROTEIN; YEAST; GLYCOSYLATION	Using the glycoprotein of the tsO45 mutant of vesicular stomatitis virus (VSV-G) as a marker, we have developed a system capable of measuring vesicular transport from the endoplasmic reticulum (ER) to the trans Golgi network (TGN) in vitro. Movement from the ER to the cis Golgi compartment was assessed by the conversion of VSV-G from a totally endoglycosidase D (endo D)-resistant form to a species containing one endo D-resistant and one endo D-sensitive oligosaccharide (G(D1)). Similarly, delivery to the medial cisternae was measured by the appearance of the completely endo D-sensitive form of VSV-G (G(D2)) or by the acquisition of complete resistance to endoglycosidase H (endo H) (G(Hr)) and delivery to the TGN by the appearance of an endo H-resistant form of VSV-G which was sensitive to digestion with neuraminidase and subsequently beta-galactosidase (G(Ht)). Movement between each sequential compartment required ATP and soluble proteins (cytosol) and was inhibited by nonhydrolyzable analogues of GTP and by an antibody toward the N-ethylmaleimide-sensitive factor NSF. In contrast, fractionation of the cytosol by ammonium sulfate precipitation indicated that distinct proteins were required for movement between successive compartments. Similarly, inclusion of a mutant form of the small molecular weight GTP-binding protein rab1A inhibited movement between the ER and cis Golgi, and between the cis and medial cisternae, but did not affect transport from the medial Golgi to the TGN. Conversely, the protein kinase inhibitor staurosporine prevented movement between the medial Golgi and the TGN but did not influence transport between the ER and early Golgi compartments. This study provides the first demonstration that vesicular transport between the ER and TGN can be reconstituted in a cytosol-dependent fashion in vitro, allowing a direct analysis of the roles of individual components in multiple transport events.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	DAVIDSON, HW (corresponding author), SCRIPPS RES INST, DEPT CELL BIOL, LA JOLLA, CA 92037 USA.				NATIONAL CANCER INSTITUTE [P01CA027489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336, R01GM033301] Funding Source: NIH RePORTER; NCI NIH HHS [CA27489] Funding Source: Medline; NIGMS NIH HHS [GM42336, GM33301] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BERGMANN JE, 1989, METHOD CELL BIOL, V32, P85; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CLARY DO, 1990, J BIOL CHEM, V265, P10109; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; ELBEIN AD, 1990, J BIOL CHEM, V265, P15599; ETCHISON JR, 1977, VIROLOGY, V78, P375, DOI 10.1016/0042-6822(77)90115-5; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FLAMAND A, 1970, J GEN VIROL, V8, P187, DOI 10.1099/0022-1317-8-3-187; GOTTLIEB C, 1975, J BIOL CHEM, V250, P3303; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HAUBRUCK H, 1989, EMBO J, V8, P1427, DOI 10.1002/j.1460-2075.1989.tb03524.x; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HUBBARD SC, 1988, J BIOL CHEM, V263, P19303; HUNT LA, 1983, ARCH BIOCHEM BIOPHYS, V226, P347, DOI 10.1016/0003-9861(83)90301-6; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LUCOCQ J, 1991, J CELL SCI, V100, P753; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MIZUOCHI T, 1984, J BIOCHEM-TOKYO, V95, P1209, DOI 10.1093/oxfordjournals.jbchem.a134711; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OHASHI M, 1991, EXP CELL RES, V197, P168, DOI 10.1016/0014-4827(91)90419-U; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1987, J BIOL CHEM, V262, P12502; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; RUOHOLA H, 1988, J CELL BIOL, V107, P1465, DOI 10.1083/jcb.107.4.1465; SCHANBAC.FL, 1970, J BIOL CHEM, V245, P5057; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SIMONS K, 1987, EMBO J, V6, P2241, DOI 10.1002/j.1460-2075.1987.tb02496.x; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; TULSIANI DRP, 1982, J BIOL CHEM, V257, P7936; TUOMIKOSKI T, 1989, NATURE, V342, P942, DOI 10.1038/342942a0; TURCO SJ, 1982, J BIOL CHEM, V257, P8674; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WOODMAN PG, 1992, J CELL BIOL, V116, P331, DOI 10.1083/jcb.116.2.331	61	96	97	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4216	4226						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8382697				2022-12-25	WOS:A1993KN53300061
J	KIRKNESS, EF; FRASER, CM				KIRKNESS, EF; FRASER, CM			A STRONG PROMOTER ELEMENT IS LOCATED BETWEEN ALTERNATIVE EXONS OF A GENE ENCODING THE HUMAN GAMMA-AMINOBUTYRIC ACID-TYPE-A RECEPTOR BETA-3 SUBUNIT (GABRB3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABAA RECEPTOR; TRANSCRIPTION INITIATION; MESSENGER-RNAS; MOLECULAR-BIOLOGY; REGION; EXPRESSION; DISTINCT; BINDING; PEPTIDE; CHROMOSOME-15	The gene that encodes the beta3 subunit of the gamma-aminobutyrate-Type A (GABA(A)) receptor is widely expressed in brain tissue and has been associated with imprinted genetic disorders. Here, the 5' regions of the human and rat genes were characterized and found to be highly conserved in both coding and non-coding sequences. A novel transcript of the human gene revealed the existence of an alternative exon 1 (exon 1a) that encodes a variant signal sequence. Relative levels of the alternative transcripts were found to vary between fetal and adult brain, and between different brain regions. Endogenous beta3 subunit transcripts were also detected in several immortalized cell lines, including human kidney 293 cells. Transcription of exon 1 is initiated from multiple sites within a pyrimidine-rich region of the gene. This region of the human gene also exhibits strong promoter activity and binds nuclear factors at a site which overlaps the transcriptional start sites. The promoter element was shown to bind Sp1 and at least one other unidentified nuclear factor.	NIAAA, NEUROGENET LAB, MOLEC NEUROBIOL SECT, ROCKVILLE, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)				Fraser, Claire/0000-0003-1462-2428				ABMAYR SM, 1991, CURRENT PROTOCOLS MO; BRENOWITZ M, 1991, CURRENT PROTOCOLS MO; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUCHSTALLER A, 1991, FEBS LETT, V287, P27, DOI 10.1016/0014-5793(91)80008-Q; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; CASALOTTI SO, 1986, J BIOL CHEM, V261, P5013; CHELLY J, 1990, NATURE, V344, P64, DOI 10.1038/344064a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DENG L, 1986, BIOCHEM BIOPH RES CO, V138, P1308, DOI 10.1016/S0006-291X(86)80425-9; DOERFLER W, 1990, FEBS LETT, V268, P329, DOI 10.1016/0014-5793(90)81280-2; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EWERT M, 1990, J CELL BIOL, V110, P2043, DOI 10.1083/jcb.110.6.2043; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; FUJITA K, 1989, ENVIRON HEALTH PERSP, V80, P127, DOI 10.2307/3430738; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2587, DOI 10.1073/pnas.86.8.2587; GAMBARANA C, 1991, NEUROSCIENCE, V45, P423, DOI 10.1016/0306-4522(91)90238-J; HALES TG, 1992, MOL PHARMACOL, V42, P197; HARIHARAN N, 1990, P NATL ACAD SCI USA, V87, P1526, DOI 10.1073/pnas.87.4.1526; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; KINGSTON RE, 1991, CURRENT PROTOCOLS MO; KIRKNESS EF, 1991, GENOMICS, V10, P985, DOI 10.1016/0888-7543(91)90189-L; KIRKNESS EF, 1989, BIOCHEM J, V259, P613, DOI 10.1042/bj2590613; KNOLL JHM, 1989, AM J MED GENET, V32, P285, DOI 10.1002/ajmg.1320320235; LAFYATIS R, 1991, NUCLEIC ACIDS RES, V19, P6419, DOI 10.1093/nar/19.23.6419; LASHAM A, 1991, J NEUROCHEM, V57, P352, DOI 10.1111/j.1471-4159.1991.tb02135.x; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; LOLAIT SJ, 1989, FEBS LETT, V246, P145, DOI 10.1016/0014-5793(89)80271-6; LUO XC, 1989, P NATL ACAD SCI USA, V86, P4042, DOI 10.1073/pnas.86.11.4042; MANGIN M, 1989, P NATL ACAD SCI USA, V86, P2408, DOI 10.1073/pnas.86.7.2408; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; MULLER M, 1992, EXPERIENTIA, V48, P118; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; POLLARD S, 1991, FEBS LETT, V295, P81, DOI 10.1016/0014-5793(91)81390-T; PRITCHETT DB, 1988, SCIENCE, V242, P1306, DOI 10.1126/science.2848320; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAITOH S, 1992, LANCET, V339, P366, DOI 10.1016/0140-6736(92)91686-3; SAITTA B, 1992, J BIOL CHEM, V267, P6188; Sambrook J, 1989, MOL CLONING LABORATO; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHIVERS BD, 1989, NEURON, V3, P327, DOI 10.1016/0896-6273(89)90257-2; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOMMER B, 1990, DNA CELL BIOL, V9, P561, DOI 10.1089/dna.1990.9.561; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WAGSTAFF J, 1991, AM J HUM GENET, V49, P330; WAGSTAFF J, 1991, GENOMICS, V11, P1071, DOI 10.1016/0888-7543(91)90034-C; WISDEN W, 1992, J NEUROSCI, V12, P1040; YMER S, 1989, EMBO J, V8, P1665, DOI 10.1002/j.1460-2075.1989.tb03557.x; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZHANG JH, 1991, J COMP NEUROL, V308, P586, DOI 10.1002/cne.903080407	57	92	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4420	4428						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8382702				2022-12-25	WOS:A1993KN53300088
J	PACAUD, P; LOIRAND, G; GREGOIRE, G; MIRONNEAU, C; MIRONNEAU, J				PACAUD, P; LOIRAND, G; GREGOIRE, G; MIRONNEAU, C; MIRONNEAU, J			NORADRENALINE-ACTIVATED HEPARIN-SENSITIVE CA2+ ENTRY AFTER DEPLETION OF INTRACELLULAR CA2+ STORE IN PORTAL-VEIN SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CALCIUM RELEASE; ACINAR-CELLS; TRISPHOSPHATE; 1,3,4,5-TETRAKISPHOSPHATE; CA-2+; THAPSIGARGIN; PHOSPHATES; METABOLISM; MECHANISM	Single portal vein smooth muscle cells were voltage-clamped using the whole cell patch-clamp technique. Intracellular free Ca2+ concentration ([Ca2+]i) was simultaneously monitored using the fluorescence from the dye indo-1. Noradrenaline (NA, 10 muM) evoked a transient increase in [Ca2+]i, due to inositol 1,4,5-trisphosphate (InsP3)-induced Ca2+ release, followed by a sustained increase in [Ca2+]i, caused by extracellular Ca2+ entry. This phase was maintained as long as NA was present and was never observed when the agonist was only briefly applied (3 s). Neither ryanodine, nor caffeine produced the Ca2+ influx whereas the complete depletion of intracellular Ca2+ pool in the absence of external Ca2+ allowed, when Ca2+ was readmitted, the activation of the Ca2+ entry which was used to replenish Ca2+ store. During NA stimulation, the Ca2+ entry was activated even if the Ca2+ pool had not been totally emptied. The Ca2+ entry pathway involved was blocked by Ni2+ and Mn2+, was not permeable to these ions, and was more sensitive to heparin than the InsP3-induced Ca2+ release. Thus, the complete depletion of Ca2+ store activates a Ca2+ influx which is modulated by NA such as in its presence, a partial depletion is enough to induce Ca2+ entry.			PACAUD, P (corresponding author), UNIV BORDEAUX 2,PHYSIOL CELLULAIRE & PHARMACOL MOLEC LAB,CNRS,URA 1489,F-33076 BORDEAUX,FRANCE.		Pacaud, Pierre/D-6392-2015; Loirand, Gervaise/K-1834-2014	Loirand, Gervaise/0000-0002-2306-3931				ALMERS W, 1985, FEBS LETT, V192, P13, DOI 10.1016/0014-5793(85)80033-8; BARON A, 1991, PFLUG ARCH EUR J PHY, V419, P553, DOI 10.1007/BF00370294; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; CHANGYA L, 1989, FEBS LETT, V251, P43, DOI 10.1016/0014-5793(89)81425-5; CULLEN PJ, 1990, BIOCHEM J, V271, P549, DOI 10.1042/bj2710549; ELY JA, 1990, BIOCHEM J, V268, P333, DOI 10.1042/bj2680333; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FERRIS CD, 1991, ANN REV PHYSL, V54, P465; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUILLEMETTE G, 1989, MOL PHARMACOL, V35, P339; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HUANG CL, 1991, J BIOL CHEM, V266, P4045; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; HWANG KS, 1987, PFLUG ARCH EUR J PHY, V408, P343, DOI 10.1007/BF00581127; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; IVORRA I, 1991, BIOCHEM J, V273, P317, DOI 10.1042/bj2730317; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; LOESSBERG PA, 1991, J BIOL CHEM, V266, P1363; LOIRAND G, 1992, J BIOL CHEM, V267, P4312; LOW AM, 1991, J PHARMACOL EXP THER, V258, P1105; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; MUALLEM S, 1988, AM J PHYSIOL, V255, pG229, DOI 10.1152/ajpgi.1988.255.2.G229; MUALLEM S, 1989, J BIOL CHEM, V264, P205; MURRAY RK, 1991, J PHYSIOL-LONDON, V435, P123, DOI 10.1113/jphysiol.1991.sp018501; PACAUD P, 1991, J PHYSIOL-LONDON, V441, P477, DOI 10.1113/jphysiol.1991.sp018763; PACAUD P, 1992, PFLUG ARCH EUR J PHY, V421, P125, DOI 10.1007/BF00374818; PACAUD P, 1991, BRIT J PHARMACOL, V104, P1000, DOI 10.1111/j.1476-5381.1991.tb12540.x; PACAUD P, 1992, J PHYSIOL-LONDON, V456, P541, DOI 10.1113/jphysiol.1992.sp019352; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1987, TRENDS PHARMACOL SCI, V8, P481, DOI 10.1016/0165-6147(87)90043-5; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; SMITH PM, 1992, BIOCHEM J, V283, P27, DOI 10.1042/bj2830027; TEPIKIN AV, 1992, J BIOL CHEM, V267, P3569; VANBREEMEN C, 1989, ANNU REV PHYSIOL, V51, P315, DOI 10.1146/annurev.physiol.51.1.315	40	75	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3866	3872						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8382680				2022-12-25	WOS:A1993KN53300015
J	RHODES, CJ; THORNE, BA; LINCOLN, B; NIELSEN, E; HUTTON, JC; THOMAS, G				RHODES, CJ; THORNE, BA; LINCOLN, B; NIELSEN, E; HUTTON, JC; THOMAS, G			PROCESSING OF PROOPIOMELANOCORTIN BY INSULIN SECRETORY GRANULE PROINSULIN PROCESSING ENDOPEPTIDASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PROOPIOMELANOCORTIN; PRO-OPIOMELANOCORTIN; MAMMALIAN-CELLS; ATT20 CELLS; PROHORMONE; CDNA; YEAST; KEX2; EXPRESSION; PROALBUMIN	A lysed preparation of isolated insulin secretory granules efficiently cleaved murine proopiomelanocortin (mPOMC) at physiologically important Lys-Arg processing sites. This processing was mostly attributed to an activity that co-eluted with the proinsulin processing type-II endopeptidase from anion exchange chromatography (Lys-Arg-directed; Davidson, H. W., Rhodes, C. J., and Hutton, J. C. (1988) Nature 333, 93-96). The principal peptide hormone products generated by the insulin secretory granule lysate were identified by specific radioimmunoassay and NH2-terminal microsequencing analysis of high performance liquid chromatography-separated products as alpha-melanocyte-stimulating hormone, corticotropin-like intermediate, gamma-lipotropin, beta-endorphin-(1-31), 18-kDa NH2-terminal fragment and, to a lesser extent, adrenocorticotrophin and beta-lipotropin. This processing had an acidic pH optimum (pH 5-5.5) and was Ca2+-dependent (K0.5 activation = 5-80 muM). With increasing Ca2+ concentrations there was an increase in the extent to which mPOMC was processed. The in vitro processing of mPOMC by the insulin secretory granule endopeptidase activity reported here is in excellent agreement with the in vivo processing of this prohormone by a combination of PC2 and PC3, candidates of prohormone endpeptidase, in gene transfer studies with cells that express the regulated secretory pathway (Thomas, L., Leduc, R., Thorne, B. A., Smeekens, S. S., Steiner, D. F., and Thomas, G. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 5297-5301).	NOVO NORDISK,NOVO ALLE 28800,DENMARK; OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Oregon Health & Science University; Addenbrooke's Hospital; University of Cambridge; Harvard University; Harvard Medical School	RHODES, CJ (corresponding author), BRIGHAM & WOMENS HOSP,JOSLIN DIABET CTR,EP JOSLIN RES LAB,1 JOSLIN PL,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037274, P30DK036836] Funding Source: NIH RePORTER; NCRR NIH HHS [BRGS07RR05673] Funding Source: Medline; NIDDK NIH HHS [P30 DK036836, DK37274, DK36836, R01 DK037274] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission)		BAILYES EM, 1992, BIOCHEM J, V285, P391, DOI 10.1042/bj2850391; BAILYES EM, 1991, ENZYME, V45, P301, DOI 10.1159/000468903; BATHURST IC, 1987, SCIENCE, V235, P348, DOI 10.1126/science.3541206; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN SO, 1988, FEBS LETT, V229, P167, DOI 10.1016/0014-5793(88)80819-6; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; DOCHERTY K, 1989, J BIOL CHEM, V264, P18335; DOUGLASS J, 1984, ANNU REV BIOCHEM, V53, P665; EDWARDS K, 1976, BIOCHEM BIOPH RES CO, V72, P310, DOI 10.1016/0006-291X(76)90995-5; EDWARDS R, 1990, PEPTIDE HORMONE SECR, P71; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; HUTTON JC, 1989, DIABETOLOGIA, V32, P271, DOI 10.1007/BF00265542; HUTTON JC, 1982, DIABETOLOGIA, V23, P365; IKEHARA Y, 1976, BIOCHEM BIOPH RES CO, V72, P319, DOI 10.1016/0006-291X(76)90996-7; LINDBERG I, 1991, PEPTIDE BIOSYTHESIS, P00141; LOH YP, 1984, ANNU REV NEUROSCI, V7, P189, DOI 10.1146/annurev.ne.07.030184.001201; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; NJUS D, 1986, BIOCHIM BIOPHYS ACTA, V853, P237, DOI 10.1016/0304-4173(87)90003-6; OLSON TS, 1988, J BIOL CHEM, V263, P7342; ORCI L, 1985, DIABETOLOGIA, V28, P528, DOI 10.1007/BF00281987; RHODES CJ, 1989, BIOCHEM J, V258, P305, DOI 10.1042/bj2580305; RHODES CJ, 1992, J BIOL CHEM, V267, P22719; RHODES CJ, 1987, J CELL BIOL, V105, P145, DOI 10.1083/jcb.105.1.145; RHODES CJ, 1989, J BIOL CHEM, V264, P14240; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMITH AI, 1988, ENDOCR REV, V9, P159, DOI 10.1210/edrv-9-1-159; STORER AC, 1976, BIOCHEM J, V159, P1; THIM L, 1986, P NATL ACAD SCI USA, V83, P6766, DOI 10.1073/pnas.83.18.6766; THOMAS G, 1988, ANNU REV PHYSIOL, V50, P323; THOMAS G, 1988, SCIENCE, V241, P226, DOI 10.1126/science.3291117; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; THORNE BA, 1989, J BIOL CHEM, V264, P3545; THORNE BA, 1990, J BIOL CHEM, V265, P8436; THORNE BA, 1991, J BIOL CHEM, V266, P13607; TOOZE J, 1987, J CELL BIOL, V105, P155, DOI 10.1083/jcb.105.1.155; UHLER M, 1983, J BIOL CHEM, V258, P257	49	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4267	4275						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8382698				2022-12-25	WOS:A1993KN53300067
J	WU, DQ; JIANG, HP; KATZ, A; SIMON, MI				WU, DQ; JIANG, HP; KATZ, A; SIMON, MI			IDENTIFICATION OF CRITICAL REGIONS ON PHOSPHOLIPASE-C-BETA-1 REQUIRED FOR ACTIVATION BY G-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNITS; DIVERSITY	In order to determine which portion of phosphoinositide-specific phospholipase C (PLC)-beta1 is required for activation by Galphaq, a series of specific deletions and truncations of PLC-beta1 cDNA were prepared. After transfection of COS-7 cells with these cDNA clones, the activity and localization of the expressed proteins were determined. Specific deletions in the C-terminal end of the protein did not lead to loss of intrinsic enzymatic activity but did result in loss of the ability to be activated by Galphaq. The region required for activation was localized to the amino acid sequence corresponding to residues 903-1142 of PLC-beta1. This region was further subdivided into two sequences; one extending from residues Thr-903 to Gln-1030 that was required for particulate fraction association as well as for activation by Galphaq and the other extending from residues Gln-1030 to Leu-1142 that was required for interaction with G alpha subunits. These results were confirmed by the observation that the C-terminal portion of PLC-beta1, when co-expressed with the muscarinic acetylcholine receptor type 1 or the alpha1C-adrenergic receptor in COS-7 cells, markedly inhibited ligand-induced release of inositol phosphates. In an in vitro system, two peptides derived from the G-protein interaction region at the C terminus were found to inhibit the guanosine 5'-3-O-(thio)triphosphate-dependent activation of PLC-beta1 by Galphaq. This further localized the sites on PLC-beta1 which are involved in interaction with G-protein alpha subunits.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA	California Institute of Technology			Katz, Arieh/F-5836-2012		NIGMS NIH HHS [GM34236] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034236, R01GM034236] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BRISTOL A, 1988, COLD SPRING HARB SYM, V53, P915, DOI 10.1101/SQB.1988.053.01.105; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; FOECKING MK, 1986, GENE, V45, P101, DOI 10.1016/0378-1119(86)90137-X; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; KATAN M, 1988, CELL, V54, P171, DOI 10.1016/0092-8674(88)90549-1; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KRIZ R, 1990, CIBA F SYMP, V150, P112; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CH, 1992, J BIOL CHEM, V267, P16044; MORRISON DF, 1987, FEBS LETT, V222, P266, DOI 10.1016/0014-5793(87)80383-6; NAKAMURA F, 1991, J BIOL CHEM, V266, P12676; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PARK D, 1992, J BIOL CHEM, V267, P16048; RHEE SG, 1991, METHOD ENZYMOL, V197, P502; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811	30	170	170	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3704	3709						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8381437				2022-12-25	WOS:A1993KM16100102
J	COTE, RH; BRUNNOCK, MA				COTE, RH; BRUNNOCK, MA			INTRACELLULAR CGMP CONCENTRATION IN ROD PHOTORECEPTORS IS REGULATED BY BINDING TO HIGH AND MODERATE AFFINITY CGMP BINDING-SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP-BINDING; OUTER SEGMENTS; RETINAL RODS; GUANOSINE 3',5'-CYCLIC-MONOPHOSPHATE; NUCLEOTIDE PHOSPHODIESTERASES; AMPHIBIAN PHOTORECEPTORS; SPATIAL-DISTRIBUTION; FROG PHOTORECEPTORS; TOAD PHOTORECEPTORS; PLASMA-MEMBRANE	cGMP is the second messenger for visual excitation in vertebrate rod photoreceptors. However, no direct correlation has been observed between the measured total cGMP concentration in the rod outer segment and the electrical response of these cells to photic stimulation. To address this discrepancy, we have quantitated the number and affinities of cGMP binding sites in the rod outer segment to determine the cytoplasmic free cGMP concentration that is involved in visual transduction. We identified two distinct classes of cGMP binding sites in amphibian rod outer segments: 1) high affinity binding sites with a K(D1) = 60 nM and a site density of 30 muM, and 2) moderate affinity binding sites with a K(D2) = 6.6 muM and a site density of 78 muM. These two classes of binding sites are calculated to bind 94% of the total cellular cGMP, thereby lowering the cytoplasmic cGMP concentration to 3.5 muM in dark-adapted rod outer segments. This value is consistent with predictions of the cytoplasmic cGMP concentration based on activation of the cGMP-gated ion channel of rod photoreceptors. The kinetics of cGMP dissociation from high affinity binding sites indicate that this class of sites would dissociate its bound cGMP too slowly to participate in visual excitation and recovery to flash illumination. This binding of cGMP to intracellular binding sites provides a non-enzymatic mechanism by which photoreceptor cells regulate the concentration and restrict the diffusion of this second messenger during visual transduction.	UNIV NEW HAMPSHIRE, DEPT BIOCHEM & MOLEC BIOL, DURHAM, NH 03824 USA	University System Of New Hampshire; University of New Hampshire			Cote, Rick/G-3363-2013	Cote, Rick/0000-0002-1573-6526	NEI NIH HHS [EY05798, R01 EY005798] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY005798] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; AMES A, 1986, J BIOL CHEM, V261, P3034; AMES A, 1988, J PHYSIOL-LONDON, V406, P163, DOI 10.1113/jphysiol.1988.sp017374; ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; Bennett J., 1985, NEUROTRANSMITTER REC, V2nd, P61; BIERNBAUM MS, 1985, J GEN PHYSIOL, V85, P83, DOI 10.1085/jgp.85.1.83; BLAZYNSKI C, 1986, J BIOL CHEM, V261, P14142; BOWNDS D, 1971, J GEN PHYSIOL, V58, P225, DOI 10.1085/jgp.58.3.225; CAMERON DA, 1990, J PHYSIOL-LONDON, V430, P419, DOI 10.1113/jphysiol.1990.sp018299; CARETTA A, 1985, EUR J BIOCHEM, V153, P49, DOI 10.1111/j.1432-1033.1985.tb09265.x; CARETTA A, 1988, EUR J BIOCHEM, V177, P139, DOI 10.1111/j.1432-1033.1988.tb14354.x; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; COHEN AI, 1988, J GEN PHYSIOL, V92, P731, DOI 10.1085/jgp.92.6.731; COOK NJ, 1987, P NATL ACAD SCI USA, V84, P585, DOI 10.1073/pnas.84.2.585; COTE RH, 1986, J BIOL CHEM, V261, P2965; COTE RH, 1989, J BIOL CHEM, V264, P15384; COTE RH, 1984, J BIOL CHEM, V259, P9635; DAWIS SM, 1988, J BIOL CHEM, V263, P8771; DEAZEREDO FAM, 1981, J BIOL CHEM, V256, P2731; FESENKO EE, 1986, PHOTOBIOCH PHOTOBIOP, V13, P345; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; GILLESPIE PG, 1989, MOL PHARMACOL, V36, P773; GOLDBERG ND, 1983, J BIOL CHEM, V258, P9213; GORDON SE, 1992, NEURON, V9, P739, DOI 10.1016/0896-6273(92)90036-D; GOVARDOVSKII VI, 1981, BIOPHYS STRUCT MECH, V7, P125, DOI 10.1007/BF00539174; HAMM HE, 1986, BIOCHEMISTRY-US, V25, P4512, DOI 10.1021/bi00364a010; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; KARPEN JW, 1992, J PHYSIOL-LONDON, V448, P257, DOI 10.1113/jphysiol.1992.sp019040; KILBRIDE P, 1979, J GEN PHYSIOL, V74, P415, DOI 10.1085/jgp.74.3.415; KINCAID RL, 1988, METHOD ENZYMOL, V159, P457; KUHN H, 1982, METHOD ENZYMOL, V81, P556; LAMB TD, 1981, J PHYSIOL-LONDON, V319, P463, DOI 10.1113/jphysiol.1981.sp013921; LAMB TD, 1992, J PHYSIOL-LONDON, V449, P719, DOI 10.1113/jphysiol.1992.sp019111; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIEBMAN PA, 1968, VISION RES, V8, P761, DOI 10.1016/0042-6989(68)90128-4; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MEYERTHOLEN EP, 1986, VISION RES, V26, P521, DOI 10.1016/0042-6989(86)90001-5; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PAULUS H, 1969, ANAL BIOCHEM, V32, P91, DOI 10.1016/0003-2697(69)90107-9; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; PUGH EN, 1986, VISION RES, V26, P1613, DOI 10.1016/0042-6989(86)90051-9; SHINOZAWA T, 1987, J BIOCHEM-TOKYO, V102, P281, DOI 10.1093/oxfordjournals.jbchem.a122052; SOPHIANOPOULOS JA, 1978, ARCH BIOCHEM BIOPHYS, V187, P132, DOI 10.1016/0003-9861(78)90015-2; THOMPSON DA, 1990, P NATL ACAD SCI USA, V87, P2201, DOI 10.1073/pnas.87.6.2201; THOMPSON WJ, 1991, PHARMACOL THERAPEUT, V51, P13, DOI 10.1016/0163-7258(91)90039-O; VOLOTOVSKII ID, 1984, MOL BIOL+, V18, P859; VOLOTOVSKY ID, 1991, EXP EYE RES, V52, P389, DOI 10.1016/0014-4835(91)90033-B; WOODRUFF ML, 1982, J GEN PHYSIOL, V80, P537, DOI 10.1085/jgp.80.4.537; WOODRUFF ML, 1979, J GEN PHYSIOL, V73, P629, DOI 10.1085/jgp.73.5.629; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; YAU KW, 1985, NATURE, V317, P252, DOI 10.1038/317252a0; YOSHIKAMI S, 1974, SCIENCE, V185, P1176, DOI 10.1126/science.185.4157.1176; YUEN PST, 1989, EXP EYE RES, V49, P75, DOI 10.1016/0014-4835(89)90077-8; ZIMMERMAN AL, 1985, P NATL ACAD SCI USA, V82, P8813, DOI 10.1073/pnas.82.24.8813	63	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17190	17198						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8394335				2022-12-25	WOS:A1993LQ98800049
J	QUINN, PG				QUINN, PG			DISTINCT ACTIVATION DOMAINS WITHIN CAMP RESPONSE ELEMENT-BINDING PROTEIN (CREB) MEDIATE BASAL AND CAMP-STIMULATED TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; RAT SOMATOSTATIN GENE; DNA-BINDING; CHLORAMPHENICOL ACETYLTRANSFERASE; KINASE INHIBITOR; MAMMALIAN-CELLS; NUCLEAR FACTORS; MESSENGER-RNA; EXPRESSION; PROMOTER	Activation of protein kinase A (PKA) by cAMP results in phosphorylation of cAMP response element-binding protein (CREB) and induction of specific gene expression. However, whether CREB participates directly in basal (PKA-independent) transcription is still an open question, and existing studies conflict over the identification of putative basal activation domains. In the present study, the activation domain of CREB, whether fused to the GAL4 DNA binding domain (CRG) or in native CREB, stimulated basal activity of the minimal tk promoter, but not the minimal SV40 early promoter. Cotransfection with PKI, a specific inhibitor of PKA, blocked PKA-induced expression of both promoters, but did not block CRG-mediated basal expression of the tk promoter. In addition, both CRG and a PKA phosphorylation site mutant provided comparable stimulation of basal tk promoter activity. Examination of a series of CREB deletion mutants mapped basal activity to interacting domains, located on either side of the previously identified PKA activation domain (amino acids 98-142). This PKA-independent activity mapped primarily to a bipartite COOH-terminal basal activation domain (amino acids 165-252). Its major component bears no obvious homology to previously identified activation domains, whereas a minor component is glutamine-rich. This COOH-terminal domain acts independently and provides the majority of basal activation but requires an NH2-terminal domain (amino acids 41-86) to provide full basal activity. A repressor domain (amino acids 142-165), deletion of which enhanced both basal and PKA-activated transcription, was also identified. This work establishes that CREB contains distinct basal and PKA-activated domains, that they operate independently for both loss of function and gain of function, and that they work on different promoters in different cell types.	PENN STATE UNIV,MILTON S HERSHEY MED CTR,PROGRAM CELL & MOLEC BIOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	QUINN, PG (corresponding author), PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT CELLULAR & MOLEC PHYSIOL,HERSHEY,PA 17033, USA.				NIDDK NIH HHS [DK 43871] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043871] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRISANI OM, 1989, P NATL ACAD SCI USA, V86, P2181, DOI 10.1073/pnas.86.7.2181; ANDRISANI OM, 1988, MOL CELL BIOL, V8, P1947, DOI 10.1128/MCB.8.5.1947; BEALE EG, 1985, J BIOL CHEM, V260, P748; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; CHENG HC, 1986, J BIOL CHEM, V261, P989; DARROW AL, 1990, METHOD ENZYMOL, V190, P110; DAY RN, 1989, J BIOL CHEM, V264, P431; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1991, P NATL ACAD SCI USA, V88, P5448, DOI 10.1073/pnas.88.12.5448; GILL G, 1990, P NATL ACAD SCI USA, V87, P2127, DOI 10.1073/pnas.87.6.2127; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GROVE JR, 1989, J BIOL CHEM, V264, P19506; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOEFFLER JP, 1990, MOL ENDOCRINOL, V4, P920, DOI 10.1210/mend-4-6-920; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KWASTWELFELD J, 1989, J BIOL CHEM, V264, P6941; KWASTWELFELD J, 1991, CANCER RES, V51, P528; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEITMAN DC, 1992, MOL CELL BIOL, V12, P1352, DOI 10.1128/MCB.12.3.1352; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; OLSEN SR, 1991, MOL ENDOCRINOL, V5, P1246, DOI 10.1210/mend-5-9-1246; PUGH BF, 1992, J BIOL CHEM, V267, P679; QUINN PG, 1990, MOL CELL BIOL, V10, P3357, DOI 10.1128/MCB.10.7.3357; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; ROMAN C, 1991, SCIENCE, V254, P94, DOI 10.1126/science.1840705; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; Sambrook J, 1989, MOL CLONING LABORATO; Shaw W V, 1975, Methods Enzymol, V43, P737; TAYLOR WE, 1990, P NATL ACAD SCI USA, V87, P4098, DOI 10.1073/pnas.87.11.4098; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YUN Y, 1990, MOL ENDOCRINOL, V4, P931, DOI 10.1210/mend-4-6-931; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	53	161	162	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16999	17009						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8394325				2022-12-25	WOS:A1993LQ98800021
J	REN, Q; KUROSE, H; LEFKOWITZ, RJ; COTECCHIA, S				REN, Q; KUROSE, H; LEFKOWITZ, RJ; COTECCHIA, S			CONSTITUTIVELY ACTIVE MUTANTS OF THE ALPHA-2-ADRENERGIC RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; KINASE; EXPRESSION; GENE; DESENSITIZATION; PHOSPHORYLATION; POLYMERASE; CLONING	We have mutated a single residue, Thr348, in the C-terminal portion of the third intracellular loop of the alpha2C10-adrenergic receptor into five different amino acids. In analogy with the effect of similar mutations in the alpha1B- and beta2-adrenergic receptors, these substitutions resulted in two major biochemical modifications: 1) increased constitutive activity of the alpha2-adrenergic receptor leading to agonist-independent inhibition of adenylyl cyclase and 2) increased affinity of the receptor for binding agonist but not antagonists. The increased constitutive activity of the mutated alpha2-adrenergic receptors could be inhibited by pertussis toxin, clearly indicating that it results from spontaneous ligand-independent receptor coupling to G(i). In contrast, the increased affinity of the mutant receptors for binding agonists was unaffected by pertussis toxin treatment, indicating that this is an inherent property of the receptors not dependent on interaction with G(i). Coexpression of the receptor mutants with the receptor-specific kinase, betaARK1, indicated that the constitutively active alpha2-adrenergic receptors are substrates for beta-adrenergic receptor kinase (betaARK)-mediated phosphorylation even in the absence of agonist. These findings strengthen the idea that constitutively active adrenergic receptors mimic the ''active'' state of a G protein-coupled receptor adopting conformations similar to those induced by agonist when it binds to wild type receptors. In addition, these results extend the notion that in the adrenergic receptor family the C-terminal portion of the third intracellular loop plays a general role in the processes involved in receptor activation.	DUKE UNIV, MED CTR,HOWARD HUGHES MED INST,DEPT MED CARDIOL, BOX 3821, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DEPT BIOCHEM, DURHAM, NC 27710 USA; FAC MED LAUSANNE, INST PHARMACOL & TOXICOL, CH-1005 LAUSANNE, SWITZERLAND	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute			Lefkowitz, Robert/AAW-2649-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENOVIC JL, 1988, J BIOL CHEM, V263, P3893; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SAMAMA P, 1993, J BIOL CHEM, V268, P4625	19	235	244	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16483	16487						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8393865				2022-12-25	WOS:A1993LQ33600059
J	WANG, ZX; HAUNERLAND, NH				WANG, ZX; HAUNERLAND, NH			STORAGE PROTEIN-UPTAKE IN HELICOVERPA-ZEA - PURIFICATION OF THE VERY HIGH-DENSITY-LIPOPROTEIN RECEPTOR FROM PERIVISCERAL FAT-BODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPHAGA-PEREGRINA; HELIOTHIS-ZEA; IDENTIFICATION; 20-HYDROXYECDYSONE; POLYACRYLAMIDE; LEPIDOPTERA; ACTIVATION; ARYLPHORIN; CECROPIA; GRANULES	In prepupae of the corn earworm, Helicoverpa zea, storage proteins are taken up by perivisceral fat body, a specialized storage tissue. In this study, the receptor protein for one of these storage proteins, a very high density lipoprotein, was identified, extracted, and purified to homogeneity. The very high density lipoprotein receptor is a glycosylated basic protein with a pI of 8.2 and an apparent molecular weight of 80,000. Binding requires the presence of Ca2+ and has a pH optimum of 7.0. Electron micrographs of immunogold labeled sections show that the receptor is located in the plasma membrane of perivisceral fat body. No receptor is detectable in peripheral fat body which does not sequester storage proteins.	SIMON FRASER UNIV, DEPT BIOL SCI, BURNABY V5A 1S6, BC, CANADA	Simon Fraser University				Haunerland, Norbert/0000-0002-0499-9400				BURMESTER T, 1992, INSECT BIOCHEM MOLEC, V22, P211, DOI 10.1016/0965-1748(92)90057-L; DEAN RL, 1985, COMPREHENSIVE INSECT, V4, P156; Ferenz H.-J., 1990, P131; FURLAN M, 1979, ANAL BIOCHEM, V96, P208, DOI 10.1016/0003-2697(79)90574-8; HAUNERLAND NH, 1990, INSECT BIOCHEM, V20, P829, DOI 10.1016/0020-1790(90)90101-Y; HAUNERLAND NH, 1986, BIOCHEM BIOPH RES CO, V134, P580, DOI 10.1016/S0006-291X(86)80459-4; JONES G, 1988, J BIOL CHEM, V263, P1089; JONES G, 1988, ARCH INSECT BIOCHEM, V7, P1, DOI 10.1002/arch.940070102; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levenbook L., 1985, P307; MUNN EA, 1969, J INSECT PHYSIOL, V15, P1935, DOI 10.1016/0022-1910(69)90023-7; PALLI SR, 1987, ARCH INSECT BIOCHEM, V5, P233, DOI 10.1002/arch.940050403; PATANA R, 1973, J ECON ENTOMOL, V66, P817, DOI 10.1093/jee/66.3.817; ROTH TF, 1964, J CELL BIOL, V20, P313, DOI 10.1083/jcb.20.2.313; SEHNAL F, 1985, COMPREHENSIVE INSECT, V3, P1; Telfer W.H., 1987, UCLA (University of California Los Angeles) Symposia on Molecular and Cellular Biology New Series, V49, P305; TELFER WH, 1991, ANNU REV ENTOMOL, V36, P205, DOI 10.1146/annurev.en.36.010191.001225; TELFER WH, 1983, INSECT BIOCHEM, V13, P601, DOI 10.1016/0020-1790(83)90034-3; TOJO S, 1978, J CELL BIOL, V78, P823, DOI 10.1083/jcb.78.3.823; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UENO K, 1982, INSECT BIOCHEM, V12, P185, DOI 10.1016/0020-1790(82)90007-5; UENO K, 1984, J BIOL CHEM, V259, P2107; UENO K, 1983, J BIOL CHEM, V258, P2210; WANG ZX, 1991, J INSECT PHYSIOL, V37, P353, DOI 10.1016/0022-1910(91)90086-F; WANG ZX, 1992, J INSECT PHYSIOL, V38, P199, DOI 10.1016/0022-1910(92)90068-O	25	22	25	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16673	16678						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8393872				2022-12-25	WOS:A1993LQ33600084
J	KHILKO, SN; CORR, M; BOYD, LF; LEES, A; INMAN, JK; MARGULIES, DH				KHILKO, SN; CORR, M; BOYD, LF; LEES, A; INMAN, JK; MARGULIES, DH			DIRECT-DETECTION OF MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I BINDING TO ANTIGENIC PEPTIDES USING SURFACE-PLASMON RESONANCE - PEPTIDE IMMOBILIZATION AND CHARACTERIZATION OF BINDING-SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSPECIFIC INTERACTION ANALYSIS; T-CELL RECEPTOR; BETA-2-MICROGLOBULIN TRANSLATED INVITRO; HLA-B27 HEAVY-CHAIN; HL-A ANTIGENS; MHC MOLECULE; VIRAL PEPTIDES; MONOCLONAL-ANTIBODY; ENVELOPE PROTEIN; SMALL SUBUNIT	We have developed model systems in which the binding of purified, genetically engineered, soluble analogues of major histocompatibility complex (MHC) class I molecules to immobilized antigenic peptides can be monitored in real time using surface plasmon resonance (SPR). Synthetic analogues of several peptides known to bind different mouse and human MHC class I molecules were prepared with cysteine residues substituted at appropriate positions. The analogue peptides were immobilized via the bifunctional reagent N-gamma-maleimidobutyryloxy-succinimide to amino groups generated on the dextran-modified gold surface of a biosensor flow cell. Using this approach, each position in the sequence of an H-2L(d)-specific viral peptide, pMCMV (YPHFMPTNL), was used for coupling, and the resulting surfaces were tested for binding of the soluble analogue of H-2L(d), H-2L(d)s. In accord with our previously described H-2L(d)/pMCMV three-dimensional structural model, only those residues of the peptide that remain exposed following binding (positions 4-8) can be replaced by cysteine and used for coupling. Stable binding of soluble MHC class I molecules, H-2L(d)s, H-2D(d)s, H-2K(b)s, and HLA-A2(s) to their respective immobilized cognate peptides was detected by SPR. Specificity of the peptide/MHC interaction was characterized both by direct binding using immobilized peptides and by competition with peptides in solution, and in general was consistent with known immunological reactivity. Some peptides bound not only their cognate MHC molecule, but others at lower apparent affinity. Measurement of real time binding of MHC class I molecules to peptides immobilized through specific side chains suggests the application of a similar approach to the study of the interaction of peptides with a wide variety of peptide-binding macromolecules.	NIAID, BIOORGAN CHEM SECT,IMMUNOL LAB,BLDG 10,RM 11N311, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA; NIAID, MOLEC BIOL SECT, BETHESDA, MD 20892 USA; UNIFORMED SERV UNIV HLTH SCI, DEPT MED, BETHESDA, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Uniformed Services University of the Health Sciences - USA				Lees, Andrew/0000-0002-8370-4876; Margulies, David/0000-0001-8530-7375				ALTSCHUH D, 1992, BIOCHEMISTRY-US, V31, P6298, DOI 10.1021/bi00142a019; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BOUILLOT M, 1989, NATURE, V339, P473, DOI 10.1038/339473a0; BOYD LF, 1992, P NATL ACAD SCI USA, V89, P2242, DOI 10.1073/pnas.89.6.2242; BRIGHAMBURKE M, 1992, ANAL BIOCHEM, V205, P125, DOI 10.1016/0003-2697(92)90588-X; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; CARRENO BM, 1990, P NATL ACAD SCI USA, V87, P3420, DOI 10.1073/pnas.87.9.3420; CHAIKEN I, 1992, ANAL BIOCHEM, V201, P197, DOI 10.1016/0003-2697(92)90329-6; CHEN BP, 1990, J EXP MED, V172, P931, DOI 10.1084/jem.172.3.931; CHOPPIN J, 1990, J EXP MED, V172, P889, DOI 10.1084/jem.172.3.889; CHRISTINCK ER, 1991, NATURE, V352, P67, DOI 10.1038/352067a0; CORR M, 1992, J EXP MED, V176, P1681, DOI 10.1084/jem.176.6.1681; CRESSWEL.P, 1974, P NATL ACAD SCI USA, V71, P2123, DOI 10.1073/pnas.71.5.2123; DEVITO LD, 1991, HUM IMMUNOL, V32, P125, DOI 10.1016/0198-8859(91)90109-M; DIBRINO M, 1993, P NATL ACAD SCI USA, V90, P1508, DOI 10.1073/pnas.90.4.1508; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; ELVIN J, 1991, EUR J IMMUNOL, V21, P2025, DOI 10.1002/eji.1830210909; Fagerstam L G, 1990, J Mol Recognit, V3, P208, DOI 10.1002/jmr.300030507; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FRELINGER JA, 1990, J EXP MED, V172, P827, DOI 10.1084/jem.172.3.827; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GODEAU F, 1992, J BIOL CHEM, V267, P24223; GREEN NM, 1971, BIOCHEM J, V125, P781, DOI 10.1042/bj1250781; GREY HM, 1973, J EXP MED, V138, P1608, DOI 10.1084/jem.138.6.1608; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JAMESON SC, 1992, EUR J IMMUNOL, V22, P2663, DOI 10.1002/eji.1830221028; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; JOST JP, 1991, NUCLEIC ACIDS RES, V19, P2788, DOI 10.1093/nar/19.10.2788; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KOSZINOWSKI UH, 1990, CURR TOP MICROBIOL, V154, P189; KOZLOWSKI S, 1992, J EXP MED, V175, P1417, DOI 10.1084/jem.175.6.1417; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LEVY F, 1991, J CELL BIOL, V115, P959, DOI 10.1083/jcb.115.4.959; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LOWE C, 1990, J MOL RECOGNIT, P117; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEND, 1992, CELL, V70, P1035; MARGULIES DH, 1990, TRANSGENIC MICE AND MUTANTS IN MHC RESEARCH, P39; MARGULIES DH, 1986, P NATL ACAD SCI USA, V83, P5252, DOI 10.1073/pnas.83.14.5252; MATSUMURA M, 1992, J BIOL CHEM, V267, P23589; MAYO CS, 1989, J IMMUNOL METHODS, V120, P105, DOI 10.1016/0022-1759(89)90295-0; ORTIZNAVARRETE V, 1991, P NATL ACAD SCI USA, V88, P3594, DOI 10.1073/pnas.88.9.3594; OSHANNESSY DJ, 1992, ANAL BIOCHEM, V205, P132, DOI 10.1016/0003-2697(92)90589-Y; OTTEN GR, 1992, J IMMUNOL, V148, P3723; PARKER KC, 1992, J BIOL CHEM, V267, P5451; PARKER KC, 1992, J IMMUNOL, V149, P3580; PARKER KC, 1992, J IMMUNOL, V149, P1896; POLLARDKNIGHT D, 1990, ANN BIOL CLIN-PARIS, V48, P642; RAETHER H, 1989, SURFACE PLASMONS SMO; REDDEHASE MJ, 1989, NATURE, V337, P651, DOI 10.1038/337651a0; RIBAUDO RK, 1992, J IMMUNOL, V149, P2935; ROGNAND, 1992, PROTEINS, V13, P70; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHNECK J, 1989, CELL, V56, P47, DOI 10.1016/0092-8674(89)90982-3; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; Schwartz R H, 1986, Adv Immunol, V38, P31, DOI 10.1016/S0065-2776(08)60006-1; SHERMAN LA, 1992, J EXP MED, V175, P1221, DOI 10.1084/jem.175.5.1221; SHIRAI M, 1992, J IMMUNOL, V148, P1657; SILVER J, 1974, NATURE, V249, P764, DOI 10.1038/249764a0; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; TAKAHASHI H, 1989, J EXP MED, V170, P2023, DOI 10.1084/jem.170.6.2023; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; VANBLEEK GM, 1990, NATURE, V348, P213; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	76	71	76	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15425	15434						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8393442				2022-12-25	WOS:A1993LN30500020
J	JULLIEN, D; TANTI, JF; HEYDRICK, SJ; GAUTIER, N; GREMEAUX, T; VANOBBERGHEN, E; LEMARCHANDBRUSTEL, Y				JULLIEN, D; TANTI, JF; HEYDRICK, SJ; GAUTIER, N; GREMEAUX, T; VANOBBERGHEN, E; LEMARCHANDBRUSTEL, Y			DIFFERENTIAL-EFFECTS OF OKADAIC ACID ON INSULIN-STIMULATED GLUCOSE AND AMINO-ACID-UPTAKE AND PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; PHOSPHATASE INHIBITOR; RAT ADIPOCYTES; OBESE MICE; TRANSPORT; PROTEIN; MUSCLE; PHOSPHORYLATION; METABOLISM; CELLS	The effect of okadaic acid, a serine/threonine phosphatase inhibitor, was analyzed in two insulin-responsive systems, the isolated mouse soleus muscle and 3T3-L1 adipocytes. While okadaic acid alone was a potent stimulator of glucose transport in both systems, it prevented transport stimulation by insulin. To gain insight into this inhibitory action, the activation of phosphatidylinositol 3-kinase (PI3-kinase), one of the earliest postreceptor steps identified so far, was studied. In 3T3-L1 adipocytes and muscle, insulin increased PI3-kinase activity in immunoprecipitates obtained with antibodies to phosphotyrosine. Okadaic acid alone had no effect but strongly inhibited this hormonal action. Okadaic acid treatment did not interfere with insulin-induced receptor autophosphorylation or with its tyrosine kinase activity toward artificial substrates. In contrast, in the presence of the phosphatase inhibitor, we did not observe tyrosine phosphorylation of the insulin receptor cellular substrate p185 (IRS-1) or immunoprecipitation of PI3-kinase by antibodies to phosphotyrosine. These results suggest that okadaic acid interferes with insulin's stimulation of glucose transport by inhibiting IRS-1 phosphorylation and its association with PI3-kinase and/or other signaling molecules. However, okadaic acid did not block the insulin stimulation of aminoisobutyric acid uptake in muscle. This would indicate that IRS-1 phosphorylation and PI3-kinase activation are not required for all the effects of insulin and that the serine/threonine phosphorylation events implicated in the translocation of glucose transporters are not controlling amino acid transport in muscle.	FAC MED NICE,INSERM,U145,AVE VALOMBROSE,F-06107 NICE 02,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur				Tanti, Jean-Francois/0000-0003-1782-1318				AKEDO H, 1962, J BIOL CHEM, V237, P118; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BORNEMANN A, 1992, DIABETES, V41, P215, DOI 10.2337/diabetes.41.2.215; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CORVERA S, 1991, J BIOL CHEM, V266, P9271; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FOLLI F, 1992, J BIOL CHEM, V267, P22171; GIORGETTI S, 1992, EUR J BIOCHEM, V207, P599; GREMEAUX T, 1987, AM J PHYSIOL, V252, pE248, DOI 10.1152/ajpendo.1987.252.2.E248; GUIDOTTI GG, 1978, BIOCHIM BIOPHYS ACTA, V515, P329, DOI 10.1016/0304-4157(78)90009-6; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; HESS SL, 1991, J CELL BIOCHEM, V45, P374, DOI 10.1002/jcb.240450411; HEYDRICK SJ, 1993, J CLIN INVEST, V91, P1358, DOI 10.1172/JCI116337; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P769, DOI 10.1210/mend-5-6-769; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KHAN CR, 1992, WILLIAMS TXB ENDOCRI, P91; KIPNIS DM, 1958, BIOCHIM BIOPHYS ACTA, V28, P226, DOI 10.1016/0006-3002(58)90466-9; KONG CT, 1993, J BIOL CHEM, V268, P1509; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; LEMARCHANDBRUSTEL Y, 1978, AM J PHYSIOL, V234, pE348, DOI 10.1152/ajpendo.1978.234.4.E348; LEMARCHANDBRUSTEL Y, 1982, AM J PHYSIOL, V243, pE74, DOI 10.1152/ajpendo.1982.243.1.E74; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; RIGGS TR, 1973, J BIOL CHEM, V248, P6540; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; SHISHEVA A, 1991, ENDOCRINOLOGY, V129, P2279; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; SUN XJ, 1992, J BIOL CHEM, V55, P1059; TANTI JF, 1991, J BIOL CHEM, V266, P2099; WARDZALA LJ, 1981, J BIOL CHEM, V256, P7090; WHITE MF, 1987, J BIOL CHEM, V262, P9769; ZORZANO A, 1986, AM J PHYSIOL, V251, pE21, DOI 10.1152/ajpendo.1986.251.1.E21	44	64	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15246	15251						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8392070				2022-12-25	WOS:A1993LL75900101
J	LEVY, LS; LOBELLERICH, PA; OVERBAUGH, J				LEVY, LS; LOBELLERICH, PA; OVERBAUGH, J			FLVI-2, A TARGET OF RETROVIRAL INSERTIONAL MUTAGENESIS IN FELINE THYMIC LYMPHOSARCOMAS, ENCODES BMI-1	ONCOGENE			English	Article							MYC TRANSGENIC MICE; LEUKEMIA-VIRUS; GENE; TRANSDUCTION; SEQUENCES; PROTEINS; ONCOGENE; LYMPHOMA; PROVIRUS; TUMORS	LC-FeLV is a myc-containing strain of feline leukemia virus which induces thymic lymphosarcoma in the domestic cat with short latency. A locus in feline DNA, termed flvi-2, is commonly interrupted in naturally occurring and experimentally induced thymic lymphosarcomas containing LC-FeLV; thus, interruption of a gene encoded by flvi-2 may cooperate with the myc oncogene in the induction of T-cell tumors by LC-FeLV. Clones homologous to flvi-2 have been isolated from a normal human thymus cDNA library. Nucleotide sequence analysis of the cDNA clones demonstrates that flvi-2 encodes bmi-1, a gene previously identified as a target for MoMuLV integration and as a myc-collaborator in retrovirally-induced B-cell lymphomas in Emu-myc transgenic mice. In feline thymic lymphomas, retroviral integrations occur downstream of the gene, and result in enhanced expression of a bmi-1 transcript of normal size. These findings demonstrate the interruption of bmi-1 in natural as well as experimentally induced tumors, implicate the activation of bmi-1 in the induction of T-cell as well as B-cell lymphoma, and support the premise that bmi-1 functions as a myc collaborator.	UNIV WASHINGTON,DEPT MICROBIOL SC-42,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	LEVY, LS (corresponding author), TULANE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,1430 TULANE AVE,NEW ORLEANS,LA 70112, USA.				NATIONAL CANCER INSTITUTE [R01CA048801, R01CA051080] Funding Source: NIH RePORTER; NCI NIH HHS [CA-48801, CA-51080] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BONHAM L, 1987, J VIROL, V61, P3072, DOI 10.1128/JVI.61.10.3072-3081.1987; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; HARDY WD, 1990, RETROVIRUS BIOL HUMA, P33; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; LEVY LS, 1988, J VIROL, V62, P4770, DOI 10.1128/JVI.62.12.4770-4773.1988; LEVY LS, 1992, J VIROL, V66, P2885, DOI 10.1128/JVI.66.5.2885-2892.1992; LEVY LS, 1984, NATURE, V308, P853, DOI 10.1038/308853a0; MATTHEWS EA, 1989, INT J CANCER, V43, P1120, DOI 10.1002/ijc.2910430627; MULLINS JI, 1984, NATURE, V308, P856, DOI 10.1038/308856a0; NEIL JC, 1984, NATURE, V308, P814, DOI 10.1038/308814a0; ONIONS D, 1987, INT J CANCER, V40, P40, DOI 10.1002/ijc.2910400108; OVERBAUGH J, 1992, VIROLOGY, V188, P558, DOI 10.1016/0042-6822(92)90510-V; PATANJALI SR, 1991, P NATL ACAD SCI USA, V88, P1943, DOI 10.1073/pnas.88.5.1943; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0	25	39	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1833	1838						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8390036				2022-12-25	WOS:A1993LG68200015
J	YAMADA, M; YOSHIDA, M; HASHINAKA, K				YAMADA, M; YOSHIDA, M; HASHINAKA, K			IDENTIFICATION OF TRANSCRIPTIONAL CIS-ELEMENTS IN INTRON-7 AND INTRON-9 OF THE MYELOPEROXIDASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA HL-60 CELLS; RNA POLYMERASE-II; RETINOIC ACID; MYELOID DIFFERENTIATION; RECEPTOR-BETA; FACTOR BINDS; EXPRESSION; CHROMATIN; SEQUENCE; PROMOTER	We studied the transcriptional cis-acting elements of the myeloperoxidase gene, which is expressed during the promyelocyte stage of granulocyte development by assay of transient expression of the chloramphenicol acetyltransferase (CAT) gene in myeloid leukemia SKM-1 cells and analysis of the DNA binding sites for HL-60 nuclear factors. Assay of CAT expression dependent on restriction fragments isolated from genomic clones indicated that the fragments located on introns 7 and 9 enhanced the expression. Methylation interference experiments showed that the guanine residues in a consensus sequence of an estrogen response element in the intron 7 fragment interacted with a nuclear factor. Gel retardation analysis indicated that this interaction of the intron 7 fragment with the nuclear factor was specifically inhibited by an oligodeoxynucleotide containing the 21-base pair (bp) estrogen response element. DNase I footprint analysis revealed that a 36-bp-specific sequence of the intron 9 fragment was protected from DNase I by nuclear extracts. This sequence contained a palindromic sequence consisting of the conserved half-motif of an estrogen response element with 5-bp spacing. The interaction of the intron 9 fragment with the nuclear extracts was specifically inhibited by an oligodeoxynucleotide of the 36-bp sequence. Furthermore, the 21- and 36-bp oligodeoxynucleotides in the constructs enhanced CAT expression in the cells. These results suggest that these elements in introns 7 and 9 are involved in expression of the myeloperoxidase gene.	OSAKA UNIV, INST PROT RES, SUITA, OSAKA 565, JAPAN	Osaka University								ATCHISON ML, 1988, ANNU REV CELL BIOL, V4, P127, DOI 10.1146/annurev.cellbio.4.1.127; BAINTON DF, 1971, J EXP MED, V134, P907, DOI 10.1084/jem.134.4.907; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHANG KS, 1991, LEUKEMIA, V5, P205; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; GLASS CK, 1991, DNA CELL BIOL, V10, P623, DOI 10.1089/dna.1991.10.623; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HASHIMOTO Y, 1989, MOL ENDOCRINOL, V3, P1046, DOI 10.1210/mend-3-7-1046; HASHINAKA K, 1992, ARCH BIOCHEM BIOPHYS, V293, P40, DOI 10.1016/0003-9861(92)90362-Z; HASHINAKA K, 1988, BIOCHEMISTRY-US, V27, P5906, DOI 10.1021/bi00416a013; HOSOKAWA Y, 1993, LEUKEMIA, V7, P441; JOHNSON K, 1989, NUCLEIC ACIDS RES, V17, P7985, DOI 10.1093/nar/17.19.7985; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; JORGENSON KF, 1991, BLOOD, V77, P159; KASUGAI I, 1988, J BIOCHEM-TOKYO, V100, P381; KAWAGUCHI R, 1992, LEUKEMIA, V6, P1296; Klebanoff SJ., 1988, INFLAMMATION BASIC P, P391; KOEFFLER HP, 1985, BLOOD, V65, P484; LAMINS LA, 1984, J VIROL, V49, P183; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LUBBERT M, 1991, BLOOD, V78, P345; MORISHITA K, 1987, J BIOL CHEM, V262, P15208; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAUSEEF WM, 1988, EUR J HAEMATOL, V40, P97; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; SAGOH T, 1988, ARCH BIOCHEM BIOPHYS, V262, P599, DOI 10.1016/0003-9861(88)90411-0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; TOBLER A, 1988, J CELL PHYSIOL, V136, P215, DOI 10.1002/jcp.1041360203; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0; YAMADA M, 1984, J BIOL CHEM, V259, P3021; YU G, 1989, J BIOL CHEM, V264, P10276	39	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13479	13485						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8390465				2022-12-25	WOS:A1993LH55300066
J	CHEN, JQ; IYENGAR, R				CHEN, JQ; IYENGAR, R			INHIBITION OF CLONED ADENYLYL CYCLASES BY MUTANT-ACTIVATED G(I)-ALPHA AND SPECIFIC SUPPRESSION OF TYPE-2 ADENYLYL CYCLASE INHIBITION BY PHORBOL ESTER TREATMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GUANINE-NUCLEOTIDE; ALPHA; IDENTIFICATION; PROTEINS; EXPRESSION; SUBSTRATE; COMPONENT; SEQUENCE; SUBUNIT; CLONING	Inhibition of the various cloned G(s)-sensitive adenylyl cyclases was studied. The effect of mutant-activated G(i2)-alpha on types 2, 3, and 6 adenylyl cyclases was analyzed after co-transfection into COS-7 cells. These adenylyl cyclases were chosen as representative members of the distinct families of mammalian adenylyl cyclases. COS-7 cells were transfected with cDNAs encoding (a) the required type of adenylyl cyclase, (b) luteinizing hormone receptor, and (c) Q205LG(i2)-alpha or Q205LG(o1)-alpha. Human chorionic gonadotropin (hCG)-stimulated cAMP accumulation was then measured. Transfection with Q205LG(i2)-alpha but not Q205LG(o1)-alpha resulted in 50-60% inhibition of hCG-stimulated cAMP accumulation of the type 2 adenylyl cyclase. hCG stimulation of types 3 and 6 adenylyl cyclases was also extensively inhibited by co-transfection with the Q205LG(i2)-alpha cDNA. Treatment with 4beta-phorbol 12-myristate 13-acetate of cells transfected with the type 2 enzyme cDNA resulted in a 2-fold increase of the hCG-stimulated cAMP accumulation and a complete suppression of the Q205LG(i2)-alpha inhibition of the type 2 adenylyl cyclase. However, similar treatment did not affect Q205LG(i2)-alpha inhibition of the type 3 and type 6 adenylyl cyclases. These data indicate that many if not all types of adenylyl cyclases may be susceptible to inhibition by G(i2)-alpha, but this inhibition can be regulated by protein kinase C in a type-specific manner.			CHEN, JQ (corresponding author), CUNY MT SINAI SCH MED,DEPT PHARMACOL,NEW YORK,NY 10029, USA.				NCI NIH HHS [CA 44998] Funding Source: Medline; NIDDK NIH HHS [DK 38761] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; CODINA J, 1983, P NATL ACAD SCI-BIOL, V80, P4276, DOI 10.1073/pnas.80.14.4276; COOPER DMF, 1982, FEBS LETT, V138, P157, DOI 10.1016/0014-5793(82)80431-6; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GLATT CE, 1993, NATURE, V361, P536, DOI 10.1038/361536a0; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; HILDEBRANDT JD, 1983, NATURE, V302, P706, DOI 10.1038/302706a0; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; IYENGAR R, 1993, IN PRESS FASEB J, V7; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; JAKOBS KH, 1979, MOL CELL ENDOCRINOL, V16, P147, DOI 10.1016/0303-7207(79)90023-6; JAKOBS KH, 1985, EUR J BIOCHEM, V151, P425, DOI 10.1111/j.1432-1033.1985.tb09119.x; JHON DY, 1993, J BIOL CHEM, V268, P6654; KATADA T, 1984, J BIOL CHEM, V259, P3578; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KROLL SD, 1992, J BIOL CHEM, V267, P23183; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LINDER ME, 1990, J BIOL CHEM, V265, P8243; LOWNDES JM, 1991, J BIOL CHEM, V266, P14193; PARMA J, 1991, BIOCHEM BIOPH RES CO, V179, P455, DOI 10.1016/0006-291X(91)91392-P; PREMONT RT, 1992, ENDOCRINOLOGY, V131, P2774, DOI 10.1210/en.131.6.2774; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9808; ROOF DJ, 1985, J BIOL CHEM, V260, P6242; SIMMOTEIT RR, 1991, FEBS LETT, V249, P189; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604	34	88	90	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12253	12256						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8389756				2022-12-25	WOS:A1993LG65800007
J	DATTA, AK; LEHRMAN, MA				DATTA, AK; LEHRMAN, MA			BOTH POTENTIAL DOLICHOL RECOGNITION SEQUENCES OF HAMSTER GLCNAC-1-PHOSPHATE TRANSFERASE ARE NECESSARY FOR NORMAL ENZYME FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED GLYCOSYLATION; PHOSPHATE N-ACETYLGLUCOSAMINE-1-PHOSPHATE TRANSFERASE; OVARY CELLS; TRYPANOSOMA-BRUCEI; OLIGOSACCHARIDES; MANNOSYLATION; SPECIFICITY; PEPTIDE; CLONING; PATHWAY	A potential dolichol recognition sequence (PDRS) with the 11-residue consensus F-I/V-X-F/Y-X-X-I-P-F-X-F/Y can be found in each of five microsomal enzymes that interact with dolichol or a dolichol derivative. However, no direct evidence demonstrating a role for the PDRSs has been reported. Hamster UDP-GlcNAc:dolichol phosphate N-acetylglucosamine-1-phosphate transferase (GPT) differs from the other enzymes by having two PDRSs. Stable CHO-K1 transfectants were created that expressed elevated amounts of normal GPT, GPT with a scramble mutation at the first PDRS (nearest the amino terminus), or GPT with a triple alanine-replacement mutation at the second PDRS. The mutant enzymes had no detectable catalytic activity in vivo, but were fully capable of conferring cellular resistance to the GPT inhibitor tunicamycin. In vitro studies with membrane preparations confirmed that the mutant enzymes were catalytically inactive and also showed that their recovery in microsomes was diminished compared with normal enzyme. These data demonstrate that each PDRS of hamster GPT is necessary for normal enzyme function. The implications of these data for possible roles of the PDRSs are discussed.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,5323 HARRY HINES BLVD,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIGMS NIH HHS [GM38545] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038545] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBRIGHT CF, 1989, P NATL ACAD SCI USA, V86, P7366, DOI 10.1073/pnas.86.19.7366; BECK PJ, 1990, SOMAT CELL MOLEC GEN, V16, P539, DOI 10.1007/BF01233094; CHAPMAN AE, 1988, ARCH BIOCHEM BIOPHYS, V260, P320, DOI 10.1016/0003-9861(88)90456-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; HELLER L, 1992, P NATL ACAD SCI USA, V89, P7013, DOI 10.1073/pnas.89.15.7013; HEMMING FW, 1985, GLYCOLIPIDS, P261; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; JANKOWSKI WJ, 1989, CHEM PHYS LIPIDS, V51, P249, DOI 10.1016/0009-3084(89)90012-1; KARLIN S, 1992, SCIENCE, V257, P39, DOI 10.1126/science.1621093; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; LEHRMAN M A, 1991, Glycobiology, V1, P553, DOI 10.1093/glycob/1.6.553; LEHRMAN MA, 1989, J BIOL CHEM, V264, P1584; LEHRMAN MA, 1988, J BIOL CHEM, V263, P19796; LIU X, 1992, MOL CELL BIOL, V12, P4112, DOI 10.1128/MCB.12.9.4112; LOW P, 1991, J BIOL CHEM, V266, P19250; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; PALAMARCZYK G, 1980, EUR J BIOCHEM, V105, P517, DOI 10.1111/j.1432-1033.1980.tb04527.x; Sambrook J, 1989, MOL CLONING LABORATO; SCOCCA JR, 1990, J BIOL CHEM, V265, P20621; STOLL J, 1988, J BIOL CHEM, V263, P10774; TURCO SJ, 1981, ANAL BIOCHEM, V118, P278, DOI 10.1016/0003-2697(81)90582-0; WALDMAN BC, 1987, J CELL PHYSIOL, V131, P302, DOI 10.1002/jcp.1041310303; ZENG Y, 1991, ANAL BIOCHEM, V193, P266, DOI 10.1016/0003-2697(91)90020-T; ZHU XY, 1990, J BIOL CHEM, V265, P14250; ZHU XY, 1992, J BIOL CHEM, V267, P8895	26	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12663	12668						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8389763				2022-12-25	WOS:A1993LG65800065
J	AZARYAN, AV; WONG, M; FRIEDMAN, TC; CAWLEY, NX; ESTIVARIZ, FE; CHEN, HC; LOH, YP				AZARYAN, AV; WONG, M; FRIEDMAN, TC; CAWLEY, NX; ESTIVARIZ, FE; CHEN, HC; LOH, YP			PURIFICATION AND CHARACTERIZATION OF A PAIRED BASIC RESIDUE-SPECIFIC YEAST ASPARTIC PROTEASE ENCODED BY THE YAP3 GENE - SIMILARITY TO THE MAMMALIAN PRO-OPIOMELANOCORTIN-CONVERTING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOBE SECRETORY VESICLES; SACCHAROMYCES-CEREVISIAE; ANTERIOR-PITUITARY; INTERMEDIATE; FURIN; KEX2; RAT; TRANSFORMATION; IDENTIFICATION; LOCALIZATION	Yeast cells express an alternate enzyme encoded by the YAP3 gene which can process pro-alpha-mating factor when this pheromone is overexpressed in KEX2-deficient mutants. The YAP3 gene product is an aspartic protease (YAP3) that cleaves at paired basic residues (Egel-Mittani, M., Flygenring, H. P., and Hansen, M. T. (1990) Yeast 6, 127-137). In this study, the YAP3 gene was overexpressed in the BJ 3501 strain of Saccharomyces cerevisiae. YAP3 was purified to apparent homogeneity using concanavalin A and pepstatin A affinity chromatography. The enzyme was characterized as an M(r) 68,000 glycoprotein with a pH optimum of 4.0-4.5. It was inhibited by pepstatin A and activated by 5 mM Ca2+. YAP3 cleaved at paired basic residues of mouse pro-opiomelanocortin (POMC) to yield adrenocorticotropin (ACTH) and beta-lipotropin (LPH); human beta-LPH to yield beta-endorphin-(1-31), beta-endorphin-(1-29), beta-endorphin-(1-28), gamma-LPH, and beta-melanocyte-stimulating hormone; and bovine N-POMC1-77 to yield gamma3-melanocyte-stimulating hormone. It also cleaved the tetrabasic residues of ACTH1-39 to yield primarily ACTH1-15 and Lys-Arg-corticotropin-like intermediate lobe peptide. The physical properties, pH optimum, and specificity of YAP3 indicate that it is a homologue of the mammalian POMC-converting enzyme (EC 3.4.23.17), a paired basic residue-specific aspartic protease from bovine pituitary intermediate lobe secretory granules (Loh, Y. P., Parish, D. C., and Tuteja, R. (1985) J. Biol. Chem. 260, 7194-7205).	NICHHD,DEV NEUROBIOL LAB,CELLULAR NEUROBIOL SECT,BLDG 49,RM 5A38,BETHESDA,MD 20892; NICHHD,ENDOCRINOL & REPROD RES BRANCH,BETHESDA,MD 20892; UNIFORMED SERV UNIV HLTH SCI,DEPT BIOCHEM,BETHESDA,MD 20814	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Uniformed Services University of the Health Sciences - USA								BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BIRCH NP, 1991, EUR J BIOCHEM, V201, P85, DOI 10.1111/j.1432-1033.1991.tb16259.x; BIRCH NP, 1989, PROTEOLYTIC ENZYMES, P211; CHANG TL, 1983, ENDOCRINOLOGY, V112, P1832, DOI 10.1210/endo-112-5-1832; CORAGGIO I, 1986, EMBO J, V5, P459, DOI 10.1002/j.1460-2075.1986.tb04234.x; EGELMITANI M, 1990, YEAST, V6, P127, DOI 10.1002/yea.320060206; EKMAN R, 1983, REGUL PEPTIDES, V6, P371, DOI 10.1016/0167-0115(83)90266-5; ESTIVARIZ FE, 1989, J BIOL CHEM, V264, P17796; ESTIVARIZ FE, 1988, J ENDOCRINOL, V116, P207, DOI 10.1677/joe.0.1160207; ESTIVARIZ FE, 1992, J BIOL CHEM, V267, P7456; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; HAKES DJ, 1991, ENDOCRINOLOGY, V129, P3053, DOI 10.1210/endo-129-6-3053; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; JONES EW, 1991, J BIOL CHEM, V266, P7963; Loh Y. P., 1993, MECHANISMS INTRACELL, P179; LOH YP, 1984, ANNU REV NEUROSCI, V7, P189, DOI 10.1146/annurev.ne.07.030184.001201; LOH YP, 1986, J BIOL CHEM, V261, P1949; LOH YP, 1985, J BIOL CHEM, V260, P7194; LOH YP, 1982, FEBS LETT, V137, P57, DOI 10.1016/0014-5793(82)80314-1; MACKAY VL, 1988, P NATL ACAD SCI USA, V85, P55, DOI 10.1073/pnas.85.1.55; MACKIN RB, 1991, ENDOCRINOLOGY, V129, P1951, DOI 10.1210/endo-129-4-1951; MAINS RE, 1990, FRONT NEUROENDOCRIN, V11, P52; PARISH DC, 1986, J BIOL CHEM, V261, P4392; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; TRICO DA, 1991, CURR PROTOCOLS MOL B, V2	31	72	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11968	11975						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8389368				2022-12-25	WOS:A1993LF28400077
J	ORLANDI, PA; CURRAN, PK; FISHMAN, PH				ORLANDI, PA; CURRAN, PK; FISHMAN, PH			BREFELDIN-A BLOCKS THE RESPONSE OF CULTURED-CELLS TO CHOLERA-TOXIN - IMPLICATIONS FOR INTRACELLULAR TRAFFICKING IN TOXIN ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; GOLGI-APPARATUS; PSEUDOMONAS TOXIN; DIPHTHERIA-TOXIN; CYCLIC-AMP; PROTEIN; INTERNALIZATION; GENERATION; ACTIVATION; MEMBRANE	Cholera toxin (CT) consists of a pentameric B subunit which binds to ganglioside G(M1) on the cell surface and an A subunit which activates adenylylcyclase. The latter process involves the reduction of A to the A1 peptide which ADP-ribosylates the stimulatory G protein, G(s) of adenylylcyclase. There is a distinct lag phase between toxin binding and activation of adenylylcyclase. Little is known about the events during this lag including where A1 is generated and how it gains access to G(s) on the cytoplasmic side of the plasma membrane. We explored the effects of several inhibitors of intracellular trafficking on the response of human SK-N-MC neurotumor and Caco-2 intestinal tumor cells to CT. Whereas chloroquine or monensin had little or no effect on CT stimulation of cyclic AMP accumulation, brefeldin A (BFA) totally inhibited the response to CT in a time- and dose-dependent and reversible manner. BFA was effective when added at the same time as CT and had an IC50 of 30 ng/ml. BFA did not alter cell surface G(M1) as cells treated with BFA for 30 min bound as much I-125-CT as control cells. Furthermore, BFA inhibited CT stimulation of G(M1)-treated rat glioma C6 cells. BFA treatment did not affect beta-adrenergic agonist stimulation of cyclic AMP. In addition, adenylyl-cyclase was activated by A1 peptide and NAD+ to the same extent in membranes from control and BFA-treated cells, or when BFA was added directly to the assay. Whereas control cells generated small amounts of A1 from bound CT with time, no A1 was detected in BFA-treated cells. BFA treatment did not prevent the internalization of CT but did inhibit its degradation. BFA is known to disrupt the organization of the Golgi complex, resulting in inhibition of protein transport from the endoplasmic reticulum and redistribution of Golgi enzymes to the endoplasmic reticulum. BFA also prevents the formation of non-clathrin-coated vesicles from Golgi membranes and thus vesicular transport between Golgi cisternae. We confirmed that BFA caused the morphological disruption of the Golgi apparatus in Caco-2 cells. The data support a role for a functional Golgi apparatus with its associated vesicular routing in CT action.	NINCDS, MOLEC & CELLULAR NEUROBIOL LAB, MEMBRANE BIOCHEM SECT, BLDG 49, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)								ALCALDE J, 1992, J CELL BIOL, V116, P69, DOI 10.1083/jcb.116.1.69; BOBAK DA, 1990, ADP RIBOSYLATING TOX, P439; BRUNING A, 1992, J BIOL CHEM, V267, P7726; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUFFY LK, 1981, J BIOL CHEM, V256, P2252; FINKELSTEIN RA, 1973, CRC CRIT R MICROBIOL, V2, P553; FISHMAN PH, 1992, FEBS LETT, V314, P371, DOI 10.1016/0014-5793(92)81508-J; FISHMAN PH, 1980, J MEMBRANE BIOL, V54, P61, DOI 10.1007/BF01875377; FISHMAN PH, 1982, J CELL BIOL, V93, P860, DOI 10.1083/jcb.93.3.860; FISHMAN PH, 1990, ADP RIBOSYLATING TOX, P127; FITZGERALD D, 1980, CELL, V21, P867, DOI 10.1016/0092-8674(80)90450-X; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HOUSLAY MD, 1981, FEBS LETT, V128, P289, DOI 10.1016/0014-5793(81)80101-9; HUDSON TH, 1991, J BIOL CHEM, V266, P18586; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; JANICOT M, 1988, BIOCHEM J, V253, P735, DOI 10.1042/bj2530735; JANICOT M, 1991, J BIOL CHEM, V266, P12858; JANICOT M, 1987, EUR J BIOCHEM, V163, P433, DOI 10.1111/j.1432-1033.1987.tb10816.x; KASSIS S, 1982, J BIOL CHEM, V257, P2148; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LEPPLA SH, 1980, J BIOL CHEM, V255, P2247; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MARNELL MH, 1982, J CELL BIOL, V93, P57, DOI 10.1083/jcb.93.1.57; MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0; MOSS J, 1980, J BIOL CHEM, V255, P1085; MOSS J, 1979, ANNU REV BIOCHEM, V48, P581, DOI 10.1146/annurev.bi.48.070179.003053; OGATA M, 1990, J BIOL CHEM, V265, P20678; OLNES S, 1985, RECEPTOR MEDIATED EN, P195; PACUSZKA T, 1992, BIOCHEMISTRY-US, V31, P4773, DOI 10.1021/bi00135a005; PACUSZKA T, 1990, J BIOL CHEM, V265, P7673; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PRYDZ K, 1992, J CELL BIOL, V119, P259, DOI 10.1083/jcb.119.2.259; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SIXMA TK, 1992, NATURE, V355, P561, DOI 10.1038/355561a0; SPIEGEL S, 1985, BIOCHEMISTRY-US, V24, P5947, DOI 10.1021/bi00342a039; SUNDAN A, 1984, J CELL PHYSIOL, V119, P15, DOI 10.1002/jcp.1041190104; TOMASI M, 1981, J BIOL CHEM, V256, P1177; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; VANDEURS B, 1986, J CELL BIOL, V102, P37, DOI 10.1083/jcb.102.1.37; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; VANHEYNINGEN S, 1983, CURR TOP MEMBR TRANS, V18, P445; WAN JS, 1992, J BIOL CHEM, V267, P13446; WISNIESKI BJ, 1981, NATURE, V289, P319, DOI 10.1038/289319a0; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838; ZAREMBA TG, 1984, MOL PHARMACOL, V26, P206; ZHOU XM, 1991, J BIOL CHEM, V266, P7462	56	118	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12010	12016						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8389369				2022-12-25	WOS:A1993LF28400083
J	XIAO, H; CROMBIE, R; DONG, ZM; ONRUST, R; ODONNELL, M				XIAO, H; CROMBIE, R; DONG, ZM; ONRUST, R; ODONNELL, M			DNA POLYMERASE-III ACCESSORY PROTEINS .3. HOLC AND HOLD ENCODING CHI AND PSI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GAMMA-SUBUNIT; HOLOENZYME; MECHANISM; SEQUENCE; TAU	Genes encoding the chi and psi accessory proteins of the DNA polymerase III holoenzyme replicase of Escherichia coli have been identified, sequenced, and used to express and purify both chi and psi in quantity. The holC gene encoding chi is located between the xerB and valS genes at 96.5 min on the chromosome; it encodes a 147-amino acid protein of 16.6 kDa. holD encoding psi lies upstream of rimI at 99.3 min and encodes a 137-amino acid protein of 15.2 kDa. The genes have been cloned into expression vectors, and both chi and psi have been purified in quantity. The accompanying report characterizes the function and physical interactions of chi and psi with other holoenzyme subunits (Xiao, H., Dong, Z., and O'Donnell, M. (1993) J. Biol. Chem. 268, 11779-11784).	CORNELL UNIV,MED CTR,COLL MED,HEARST RES FDN,DEPT MICROBIOL,1300 YORK AVE,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,HEARST RES FDN,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Cornell University; Cornell University; Howard Hughes Medical Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38839] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DONG ZM, 1993, J BIOL CHEM, V268, P11758; GIL SC, 1989, ANAL BIOCHEM, V82, P319; HARTLEIN M, 1987, NUCLEIC ACIDS RES, V15, P9081, DOI 10.1093/nar/15.21.9081; HECK JD, 1988, J BIOL CHEM, V263, P857; KODAIRA M, 1983, MOL GEN GENET, V192, P80, DOI 10.1007/BF00327650; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KORNBERG A, 1991, DNA REPLICATION, P176; MAKI S, 1988, J BIOL CHEM, V263, P6547; MAKI S, 1988, J BIOL CHEM, V263, P6555; MAKI S, 1988, J BIOL CHEM, V263, P6561; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1993, ANAL BIOCHEM, V268, P11766; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; STIRLING CJ, 1989, EMBO J, V8, P1623, DOI 10.1002/j.1460-2075.1989.tb03547.x; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WICKNER W, 1974, J BIOL CHEM, V249, P6244; XIAO H, 1993, J BIOL CHEM, V268, P11779; YOSHIKAWA A, 1987, MOL GEN GENET, V209, P481, DOI 10.1007/BF00331153	23	51	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11773	11778						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8389364				2022-12-25	WOS:A1993LF28400048
J	TOBE, K; MATUOKA, K; TAMEMOTO, H; UEKI, K; KABURAGI, Y; ASAI, S; NOGUCHI, T; MATSUDA, M; TANAKA, S; HATTORI, S; FUKUI, Y; AKANUMA, Y; YAZAKI, Y; TAKENAWA, T; KADOWAKI, T				TOBE, K; MATUOKA, K; TAMEMOTO, H; UEKI, K; KABURAGI, Y; ASAI, S; NOGUCHI, T; MATSUDA, M; TANAKA, S; HATTORI, S; FUKUI, Y; AKANUMA, Y; YAZAKI, Y; TAKENAWA, T; KADOWAKI, T			INSULIN STIMULATES ASSOCIATION OF INSULIN-RECEPTOR SUBSTRATE-1 WITH THE PROTEIN ABUNDANT SRC HOMOLOGY GROWTH-FACTOR RECEPTOR-BOUND PROTEIN-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; KINASE-ACTIVITY	Insulin activates the ras proto-oncogene product p21ras (Ras) by stimulating conversion of the inactive GDP-bound form of Ras to the active GTP-bound form. The protein ASH (for abundant Src homology) (Matuoka, K., Shibata, M., Yamakawa, A., and Takenawa, T. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 9015-9019) is composed of one Src homology (SH)2 and two SH3 domains and highly homologous to the Caenorhabditis elegans protein sem-5 that couples a tyrosine kinase to a Ras protein. We have studied an interaction of ASH with insulin-stimulated tyrosine-phosphorylated proteins in Chinese hamster ovary cells overexpressing human insulin receptors (CHO-HIR cells). In an anti-ASH (alphaASH) immunoprecipitates, we detected a 170-kDa phosphoprotein that was recognized by an anti-phosphotyrosine antibody and an anti-insulin receptor substrate 1 antibody (alphaIRS-1) from the insulin-stimulated [P-32]orthophosphate-labeled CHO-HIR cells. We failed to detect the tyrosine phosphorylation of the protein ASH. These data suggested that insulin stimulates IRS-1.ASH complex formation in intact cells. Incubation of an ASH fusion protein with the lysates of insulin-stimulated CHO-HIR cells revealed that the fusion protein of ASH was able to bind the tyrosine-phosphorylated 170-kDa protein that was recognized by alphaIRS-1. We also demonstrated that fusion protein of ASH was able to bind the fusion protein of tyrosine-phosphorylated IRS-1 fragments, suggesting that ASH is able to bind tyrosine-phosphorylated IRS-1 directly. These data suggest that IRS-1.ASH complex formation may play a role in coupling the insulin receptor kinase to a Ras signaling pathway. Furthermore, we observed an insulin-stimulated phosphatidylinositol (PI) 3-kinase activity in alphaASH immunoprecipitates, suggesting the formation of an ASH.IRS-1.PI 3-kinase complex. This complex formation was detected as early as 10 s after insulin stimulation in intact CHO-HIR cells. This is the first report that supports the notion that IRS-1 binds several signal transducing molecules containing SH2 domains, thus serves as an SH2 docking protein that transduces insulin's signal multidirectionally.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT BIOSIGNAL RES,ITABASHI KU,TOKYO 173,JAPAN; ASAHI LIFE FDN,INST DIABET CARE & RES,CHIYODA KU,TOKYO 100,JAPAN; NATL INST HLTH,DEPT PATHOL,DIV MOLEC PATHOL,SHINAGAWA KU,TOKYO 141,JAPAN; NATL INST NEUROSCI,NATL CTR NEUROL & PSYCHIAT,DIV BIOCHEM & CELLULAR BIOL,KODAIRA,TOKYO 187,JAPAN; UNIV TOKYO,FAC AGR,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo; Asahi Life Foundation; National Center for Neurology & Psychiatry - Japan; University of Tokyo			Fukui, Yasuhisa/E-8806-2010	Matsuda, Michiyuki/0000-0002-5876-9969				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BURGERING BM, 1990, EMBO J, V10, P1103; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KASUGA M, 1983, P NATL ACAD SCI-BIOL, V80, P2137, DOI 10.1073/pnas.80.8.2137; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KREBS EG, 1964, BIOCHEMISTRY-US, V3, P1022, DOI 10.1021/bi00896a003; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; STURGILL TW, 1988, NATURE, V344, P7150; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TANAKA S, 1993, IN PRESS JAP J CANCE; TOBE K, 1992, J BIOL CHEM, V267, P21089; TOBE K, 1991, J BIOL CHEM, V266, P24793; TOBE K, 1990, DIABETES, V39, P528, DOI 10.2337/diabetes.39.5.528; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958	27	97	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11167	11171						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8388384				2022-12-25	WOS:A1993LD46600067
J	RAFFANIELLO, RD; RAUFMAN, JP				RAFFANIELLO, RD; RAUFMAN, JP			GUANINE-NUCLEOTIDES ACTIVATE MULTIPLE SIGNALING PATHWAYS IN PERMEABILIZED GASTRIC CHIEF CELLS - EVIDENCE FOR GTP-GAMMA-S-INDUCED CALCIUM-INDEPENDENT PEPSINOGEN SECRETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PROMINENT CELLULAR SUBSTRATE; GUINEA-PIG STOMACH; POLYPHOSPHOINOSITIDE PHOSPHODIESTERASE; PHOSPHORYLATION; POTENTIATION	Nonhydrolyzable guanine nucleotide analogues were used to evaluate the role of guanine nucleotide binding (G) proteins in regulating pepsinogen secretion from streptolysin O-permeabilized chief cells from guinea pig stomach. In the presence of 100 nM calcium, 100 muM guanosine 5'-(beta,gamma-imido)triphosphate or guanosine 5'-3-O-(thio)triphosphate (GTPgammaS) caused a 2- to 4-fold increase in pepsinogen secretion. GTPgammaS stimulated secretion in the absence of calcium (up to 10 mM EGTA). With or without added calcium, GTP analogues caused a 2- to 3-fold increase in cAMP, whereas guanosine 5'-O-2-(thio)diphosphate and calcium alone had no effect on cAMP levels. GTP analogue-induced activation of phospholipase C was evidenced by a calcium-independent increase in cytidine diphospho-1,2-diacylglycerol levels (50% above basal). Phorbol ester- and GTPgammaS-stimulated phosphorylation of a 72-kDa acidic protein was abolished by an inhibitor of protein kinase C (CGP 41251). However, GTPgammaS-induced pepsinogen secretion was only partially inhibited by adding CGP 41251 or a protein kinase C inhibitor peptide. These results indicate that guanine nucleotides activate major signaling pathways in gastric chief cells. Nevertheless, GTPgammaS can induce pepsinogen secretion independently of changes in calcium, cAMP, or activation of protein kinase C.	SUNY HLTH SCI CTR,DEPT MED,DIV DIGEST DIS,BOX 1196,450 CLARKSON AVE,BROOKLYN,NY 11203	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center					NIDDK NIH HHS [DK 34189] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034189] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; BARROWMAN MM, 1986, NATURE, V319, P504, DOI 10.1038/319504a0; BITTNER MA, 1986, J BIOL CHEM, V261, P182; BROWN MR, 1989, AM J PHYSIOL, V257, pG99, DOI 10.1152/ajpgi.1989.257.1.G99; COCKCROFT S, 1986, BIOCHEM J, V240, P503, DOI 10.1042/bj2400503; DEMATTEIS MA, 1991, J BIOL CHEM, V266, P10452; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GODFREY PP, 1989, BIOCHEM J, V258, P621, DOI 10.1042/bj2580621; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KITTAGAWA M, 1991, BIOCHIM BIOPHYS ACTA, V1073, P129; KITTAGAWA M, 1990, AM J PHYSIOL, V259, pG157; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; NAKANO O, 1990, LIFE SCI, V47, P647, DOI 10.1016/0024-3205(90)90577-E; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; RAFFANIELLO RD, 1992, AM J PHYSIOL, V263, pG452, DOI 10.1152/ajpgi.1992.263.4.G452; RAUFMAN JP, 1984, AM J PHYSIOL, V247, pG95, DOI 10.1152/ajpgi.1984.247.1.G95; RAUFMAN JP, 1992, GASTROENTEROLOGY, V102, P699, DOI 10.1016/0016-5085(92)90124-H; RAUFMAN JP, 1987, J BIOL CHEM, V262, P5957; RAUFMAN JP, 1986, BIOCHEM BIOPH RES CO, V137, P281, DOI 10.1016/0006-291X(86)91207-6; SEIDLER U, 1991, AM J PHYSIOL, V260, pG133, DOI 10.1152/ajpgi.1991.260.1.G133; STUTCHFIELD J, 1988, BIOCHEM J, V250, P375, DOI 10.1042/bj2500375; SUTLIFF VE, 1986, AM J PHYSIOL, V251, pG96, DOI 10.1152/ajpgi.1986.251.1.G96; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; VALLAR L, 1987, J BIOL CHEM, V262, P5049; WINAND J, 1991, 2ND MESSENGERS PHOSP, V13, P173	29	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8491	8496						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8386161				2022-12-25	WOS:A1993KX81100020
J	RAYSON, BM				RAYSON, BM			CALCIUM - A MEDIATOR OF THE CELLULAR-RESPONSE TO CHRONIC NA+/K+-ATPASE INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; MESSENGER-RNAS; BETA-SUBUNIT; OUABAIN TREATMENT; TRANSPORT; CELLS; NA; INVITRO; TRANSCRIPTION; NA+,K+-ATPASE	Chronic reduction of Na+/K+-ATPase activity has been demonstrated in a number of cell systems to elicit a cellular homeostatic response. Over the course of this response, there is initially a transient stimulation of synthesis of new Na+/K+-ATPase molecules, followed by a delayed decrease in its degradation rate, eliciting an effective increase in the number of active pumps in the membrane. The resultant enhancement of pumping capacity promotes the extrusion of accumulated Na+ ions and restores the intracellular electrolyte milieu to preinsult conditions. No cellular mediators of either component of this response have previously been described. We therefore tested the possibility that changes in [Ca2+]i might contribute to the transient stimulation of synthesis observed. Indeed, an effective synthetic response to the inhibition of Na+/K+-ATPase by treatment with ouabain required elevated [Ca2+]i levels.			RAYSON, BM (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT PHYSIOL,1300 YORK AVE,NEW YORK,NY 10021, USA.							BOARDMAN L, 1974, J PHYSIOL-LONDON, V241, P771, DOI 10.1113/jphysiol.1974.sp010684; BOURDEAU JE, 1990, AM J PHYSIOL, V258, pF1497; CAYANIS R, 1992, J MEMBRANE BIOL, V125, P163; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chromczynski P, 1987, ANAL BIOCHEM, V162, P156; CURRAN T, 1987, ONCOGENE, V2, P79; GMAJ P, 1988, MINER ELECTROL METAB, V14, P22; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; LAMB JF, 1972, J PHYSIOL-LONDON, V225, P599, DOI 10.1113/jphysiol.1972.sp009959; LIU CM, 1978, J BIOL CHEM, V253, P5892; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MERCER RW, 1986, MOL CELL BIOL, V6, P3884, DOI 10.1128/MCB.6.11.3884; PAYNTON BV, 1988, DEV BIOL, V129, P304, DOI 10.1016/0012-1606(88)90377-6; PUTNEY JW, 1978, MEMBRANE PHYSL, P41; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAYSON BM, 1991, J BIOL CHEM, V266, P21335; RAYSON BM, 1989, AM J PHYSIOL, V256, pC75, DOI 10.1152/ajpcell.1989.256.1.C75; RAYSON BM, 1982, AM J PHYSIOL, V243, pF463, DOI 10.1152/ajprenal.1982.243.5.F463; RAYSON BM, 1985, J BIOL CHEM, V260, P2740; REUTER H, 1968, J PHYSIOL-LONDON, V195, P451, DOI 10.1113/jphysiol.1968.sp008467; RUBIN RP, 1982, CALCIUM CELLULAR SEC, P276; Sambrook J., 1989, MOL CLONING; SCHNEIDER JW, 1985, P NATL ACAD SCI USA, V82, P6357, DOI 10.1073/pnas.82.18.6357; TAYLOR A, 1979, AM J PHYSIOL, V236, pF505, DOI 10.1152/ajprenal.1979.236.6.F505; VAUGHAN GL, 1972, P NATL ACAD SCI USA, V69, P2627, DOI 10.1073/pnas.69.9.2627; WOLITZKY BA, 1986, J BIOL CHEM, V261, P9990; YOUNG RM, 1987, BIOCHEM BIOPH RES CO, V145, P52, DOI 10.1016/0006-291X(87)91286-1; YOUNG RM, 1987, J BIOL CHEM, V262, P4905	30	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8851	8854						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8386170				2022-12-25	WOS:A1993KX81100070
J	UDVARDY, A				UDVARDY, A			PURIFICATION AND CHARACTERIZATION OF A MULTIPROTEIN COMPONENT OF THE DROSOPHILA-26-S (1500 KDA) PROTEOLYTIC COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; MOLECULAR-WEIGHT PROTEASES; UBIQUITIN PATHWAY; SYSTEM; DEGRADATION; IDENTIFICATION; DISAPPEARANCE; NUCLEOSOMES; RESOLUTION; BREAKDOWN	A multiprotein complex, referred to as the mu particle, was purified to apparent homogeneity from Drosophila melanogaster embryos. This multiprotein complex has no protease activity, but it can be incorporated into an even larger multiprotein complex which exhibits strong and selective protease activity, i.e. it degrades only ubiquitin-conjugated proteins. Incorporation of the mu particle into the ubiquitin conjugate-degrading larger complex is absolutely ATP-dependent. On these criteria the larger complex corresponds to the 26 S (1500 kDa) proteolytic complex partially purified and characterized from reticulocytes. A procedure is described for the purification of the Drosophila 26 S (1500 kDa) proteolytic complex. It was found to be a stoichiometric complex of the mu particle and the 20 S proteosome. Although no other polypeptide was present in stoichiometric amount in the 26 S (1500 kDa) proteolytic complex besides the mu particle and the 20 S proteosome, an additional protein factor(s) is required for its assembly, the ubiquitin conjugate-degrading activity cannot be reconstituted from the purified mu particle and the 20 S proteosome. Synthesis of the mu particle is developmentally regulated; its concentration is highest in embryos. This is probably connected with massive degradation of yolk proteins during embryo-genesis. In chicken, rabbit and human cells a high molecular weight multiprotein complex can be detected, which is immunologically related to the Drosophila mu particle.			UDVARDY, A (corresponding author), HUNGARIAN ACAD SCI,CTR BIOL RES,INST BIOCHEM,POB 521,H-6701 SZEGED,HUNGARY.							BARSOUM J, 1985, J BIOL CHEM, V260, P7688; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; DRISCOLL J, 1992, P NATL ACAD SCI USA, V89, P4986, DOI 10.1073/pnas.89.11.4986; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FAGAN JM, 1987, BIOCHEM J, V243, P335, DOI 10.1042/bj2430335; FALKENBURG PE, 1988, NATURE, V331, P190, DOI 10.1038/331190a0; GANOTH D, 1988, J BIOL CHEM, V263, P12412; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; HAASS C, 1989, EXP CELL RES, V180, P243, DOI 10.1016/0014-4827(89)90228-0; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1986, PROG NUCLEIC ACID RE, V33, P19, DOI 10.1016/S0079-6603(08)60019-7; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOUGH R, 1986, J BIOL CHEM, V261, P2400; HOUGH R, 1987, J BIOL CHEM, V262, P8303; KONG SK, 1992, J BIOL CHEM, V267, P14189; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINGER L, 1982, CELL, V28, P375, DOI 10.1016/0092-8674(82)90355-5; MATSUI SI, 1979, P NATL ACAD SCI USA, V76, P6386, DOI 10.1073/pnas.76.12.6386; MUELLER RD, 1985, J BIOL CHEM, V260, P5147; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; Sambrook J, 1989, MOL CLONING LABORATO; WAXMAN L, 1987, J BIOL CHEM, V262, P2451	29	107	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9055	9062						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8386175				2022-12-25	WOS:A1993KX81100096
J	KLARLUND, JK; KHALAF, N; KOZMA, L; CZECH, MP				KLARLUND, JK; KHALAF, N; KOZMA, L; CZECH, MP			ACTIVATION OF PROTEIN-KINASES BY INSULIN AND NONHYDROLYZABLE GTP ANALOGS IN PERMEABILIZED 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BC3H-1 MURINE MYOCYTES; AUREUS ALPHA-TOXIN; S6 KINASE; RAT-LIVER; BINDING PROTEINS; GENE-EXPRESSION; CELL-CYCLE; PHOSPHORYLATION; PURIFICATION; RECEPTOR	The molecular events that lead from the interaction of insulin with its receptor to the activation of protein serine/threonine kinases are still unknown. In this study, we have examined the role of GTP-binding proteins in this signaling pathway using differentiated 3T3-L1 adipocytes permeabilized with alpha-toxin from Staphylococcus aureus. Addition of GTPgammaS (guanosine 5'-O-(3-thiotriphosphate)) or insulin to such permeabilized cells markedly increases protein kinase activities in cell lysates using the microtubule-associated protein-2 kinase substrate peptide KRELVEPLTPSGEAPNQALLR, which contains the threonine 669 phosphorylation site on the epidermal growth factor receptor. Similar stimulations of protein kinase activity by these agents are observed using the peptide KRRRLASLAA, which is selectively phosphorylated by ribosomal protein S6 kinases. The effects of insulin and GTPgammaS are not additive. Importantly, the GTP-binding protein antagonist GDPbetaS (guanosine 5'-O-(2-thiodiphosphate)) inhibits the activation of the protein kinase activities by insulin in permeabilized 3T3-L1 adipocytes. These data are consistent with the hypothesis that activation of Ras or other GTP-binding proteins is a key element of the signaling mechanism whereby insulin receptor tyrosine kinase activates the microtubule-associated protein-2 kinase cascade.	UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	KLARLUND, JK (corresponding author), UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030648] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30648] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ALLEMAIN GL, 1992, MOL CELL BIOL, V12, P2222; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALDINI G, 1991, J BIOL CHEM, V266, P4037; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BELMONTE G, 1987, EUR BIOPHYS J BIOPHY, V14, P349; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BONVINI E, 1991, BIOCHEM J, V275, P689, DOI 10.1042/bj2750689; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; CLARKE PR, 1991, J CELL SCI, V100, P409; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CZECH M, 1985, MOL BASIS INSULIN AC; CZECH MP, 1988, J BIOL CHEM, V263, P11017; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; ECKSTEIN F, 1979, J BIOL CHEM, V254, P9829; ELLIS L, 1986, COLD SPRING HARB SYM, V51, P773, DOI 10.1101/SQB.1986.051.01.090; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; ERIKSON E, 1991, METHOD ENZYMOL, V200, P252; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; KELLERER M, 1991, BIOCHEM J, V276, P103, DOI 10.1042/bj2760103; KLARLUND JK, 1991, J BIOL CHEM, V266, P4052; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KOZMA SC, 1989, EMBO J, V8, P4125, DOI 10.1002/j.1460-2075.1989.tb08597.x; KYRIAS JM, 1992, NATURE, P417; LANE HA, 1991, METHOD ENZYMOL, V200, P268; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LUTTRELL L, 1990, J BIOL CHEM, V265, P16873; LUTTRELL LM, 1988, J BIOL CHEM, V263, P6134; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PORRAS A, 1992, J BIOL CHEM, V267, P21124; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; ROTHENBERG PL, 1988, J BIOL CHEM, V263, P15546; RUTTER GA, 1992, BIOCHEM J, V281, P431, DOI 10.1042/bj2810431; SEGER R, 1992, J BIOL CHEM, V267, P14373; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TAKASHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WALSH DA, 1971, J BIOL CHEM, V246, P1977; WOLFE L, 1992, J BIOL CHEM, V267, P9749; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	69	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7646	7649						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8385115				2022-12-25	WOS:A1993KW97900013
J	KOMATSU, H; EMOTO, Y; TAWADA, K				KOMATSU, H; EMOTO, Y; TAWADA, K			HALF-STOICHIOMETRIC TRINITROPHENYLATION OF MYOSIN SUBFRAGMENT-1 IN THE PRESENCE OF PYROPHOSPHATE OR ADENOSINE-DIPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; SKELETAL-MUSCLE MYOSIN; REACTIVE LYSINE RESIDUES; ENERGY-TRANSFER; ACTIN; ENERGETICS; STATES; EQUILIBRIUM; COMPLEXES; LOCATION	A molecule of myosin subfragment 1 (S1) from skeletal muscle has one reactive lysine residue (RLR) that is rapidly and stoichiometrically modified by trinitrobenzene sulfonate (TNBS). Previous studies on the RLR modification with TNBS in the presence of inorganic pyrophosphate (PP(i)) by others suggested the nonidentical nature of the two myosin heads which is still controversial. To resolve this issue, we studied the effects of PP(i) and ADP on the trinitrophenylation reaction over a wide range of ligands more systematically, by using S1 containing the alkali 1 light chain. We herein show that MgPP(i) or MgADP reduces the maximum number of trinitrophenylated RLRs down to about 0.5 mol/mol of S1 and that this half-stoichiometric modification of RLRs is not the result of heterogeneity in the primary structure of S1. Instead, our results suggest the existence of two almost equimolar, different conformations of S1.PP(i) and S1.ADP. Furthermore, we show evidence that the two different conformations are in a slow equilibrium in the presence of TNBS. We also studied the effects of the stoichiometric and half-stoichiometric RLR modification on the EDTA- and Mg-ATPase activities of S1 and found no evidence for the functional heterogeneity of the myosin active site.	KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN; KYUSHU UNIV,GRAD SCH MED SCI,DEPT MOLEC BIOL,FUKUOKA 812,JAPAN	Kyushu University; Kyushu University								AGUIRRE R, 1989, BIOCHEMISTRY-US, V28, P799, DOI 10.1021/bi00428a058; EMOTO Y, 1988, J BIOCHEM-TOKYO, V103, P172, DOI 10.1093/oxfordjournals.jbchem.a122226; EVANS JA, 1989, BIOCHEMISTRY-US, V28, P7741, DOI 10.1021/bi00445a033; FABIAN F, 1968, BIOCHIM BIOPHYS ACTA, V162, P596, DOI 10.1016/0005-2728(68)90065-0; FOSTER F, 1969, ORGANIC CHEM SERIES, V15, P335; GREENE LE, 1980, J BIOL CHEM, V255, P543; HOZUMI T, 1981, BIOCHEMISTRY-US, V20, P2945, DOI 10.1021/bi00513a035; IKEUCHI Y, 1986, BIOCHEMISTRY-US, V25, P411, DOI 10.1021/bi00350a021; Inoue A, 1979, Adv Biophys, V13, P1; KAMATH U, 1989, J BIOL CHEM, V264, P5586; KUBO S, 1960, J BIOL CHEM, V235, P2835; LOWEY S, 1969, J MOL BIOL, V42, P1, DOI 10.1016/0022-2836(69)90483-5; MIYANISHI T, 1981, J BIOCHEM, V89, P831, DOI 10.1093/oxfordjournals.jbchem.a133266; MIYANISHI T, 1982, J BIOCHEM-TOKYO, V91, P1845, DOI 10.1093/oxfordjournals.jbchem.a133881; MIYANISHI T, 1979, J BIOCHEM, V85, P747; MORNET D, 1989, J MUSCLE RES CELL M, V10, P10, DOI 10.1007/BF01739853; MORNET D, 1980, FEBS LETT, V117, P183, DOI 10.1016/0014-5793(80)80941-0; MUHLRAD A, 1981, BIOCHEMISTRY-US, V20, P6749, DOI 10.1021/bi00527a002; OKUYAMA T, 1960, J BIOCHEM-TOKYO, V47, P454, DOI 10.1093/oxfordjournals.jbchem.a127083; PERRY SV, 1955, METHOD ENZYMOL, V2, P582, DOI 10.1016/S0076-6879(55)02258-1; PINE SH, 1987, ORGANIC CHEM, P628; SETTON A, 1988, J MUSCLE RES CELL M, V9, P132, DOI 10.1007/BF01773735; SHRIVER JW, 1981, BIOCHEMISTRY-US, V20, P2004, DOI 10.1021/bi00510a041; SHRIVER JW, 1982, BIOCHEMISTRY-US, V21, P3022, DOI 10.1021/bi00541a033; SHRIVER JW, 1981, BIOCHEMISTRY-US, V20, P6357, DOI 10.1021/bi00525a011; SHUKLA KK, 1988, J BIOL CHEM, V263, P5049; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TESI C, 1988, BIOCHEMISTRY-US, V27, P4903, DOI 10.1021/bi00413a047; TONG SW, 1983, J BIOL CHEM, V258, P3100; TONOMURA Y, 1986, ENERGY TRANSDUCING A, P5; TRAYER HR, 1988, BIOCHEMISTRY-US, V27, P5718, DOI 10.1021/bi00415a049; WAGNER PD, 1977, J MOL BIOL, V109, P455, DOI 10.1016/S0022-2836(77)80023-5; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; YASUI M, 1988, J BIOCHEM-TOKYO, V104, P550, DOI 10.1093/oxfordjournals.jbchem.a122508	35	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7799	7808						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8385121				2022-12-25	WOS:A1993KW97900036
J	MIN, JJ; HEUERTZ, RM; ZASSENHAUS, HP				MIN, JJ; HEUERTZ, RM; ZASSENHAUS, HP			ISOLATION AND CHARACTERIZATION OF AN NTP-DEPENDENT 3'-EXORIBONUCLEASE FROM MITOCHONDRIA OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; EXONUCLEASE ACTIVITY; DEGRADES; GENE; NUCLEASE; PURIFICATION; SPECIFICITY; PROTEINS; DECAY	RNA turnover in eukaryotes is thought to require 3'-exonuclease activity but so far no RNase with that specificity has been isolated from a eukaryote. We report here on the purification and characterization of a 3'-exoribonuclease isolated from the mitochondria of Saccharomyces cerevisiae. In vitro the purified enzyme displayed an absolute requirement of NTPs for activity. Each of the eight standard ribo- and deoxyribonucleotides supported activity with K(m) values ranging from 20 to 90 muM. The enzyme also displayed RNA-stimulated NTPase activity. The NTP-dependent enzyme cofractionated with three polypeptides of molecular masses 75,000, 90,000, and 110,000 daltons, although the native enzyme appears to have a molecular mass of 160,000 daltons predicted from the Stokes radius. The possible functions of this enzyme in vivo in the regulated decay of mitochondrial RNAs are discussed.	ST LOUIS UNIV,SCH MED,DEPT MICROBIOL,1402 S GRAND BLVD,ST LOUIS,MO 63104	Saint Louis University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034096] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-34096] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATWATER JA, 1990, ANNU REV GENET, V24, P519; BELASCO JG, 1988, GENE, V72, P15, DOI 10.1016/0378-1119(88)90123-0; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; DAKE E, 1988, J BIOL CHEM, V263, P7691; DYKSTRA CC, 1991, MOL CELL BIOL, V11, P2583, DOI 10.1128/MCB.11.5.2583; EICHLER DC, 1985, BIOCHEMISTRY-US, V24, P686, DOI 10.1021/bi00324a022; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GEORGIEV O, 1984, NUCLEIC ACIDS RES, V12, P8539, DOI 10.1093/nar/12.22.8539; KIM JM, 1990, GENETICS, V126, P799; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARIMER FW, 1990, GENE, V95, P85, DOI 10.1016/0378-1119(90)90417-P; LAZARUS HM, 1967, P NATL ACAD SCI USA, V57, P1386, DOI 10.1073/pnas.57.5.1386; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MUELLER DM, 1986, J BIOL CHEM, V261, P1816; MUELLER DM, 1986, J BIOL CHEM, V261, P1756; MURTHY KGK, 1991, NUCLEIC ACIDS RES, V19, P2685, DOI 10.1093/nar/19.10.2685; PELTZ SW, 1987, J BIOL CHEM, V262, P9382; ROSS J, 1986, J MOL BIOL, V188, P579, DOI 10.1016/S0022-2836(86)80008-0; ROSS J, 1987, J BIOL CHEM, V262, P9374; ROSS J, 1988, MOL BIOL MED, V5, P1; SAINI KS, 1990, MOL CELL BIOCHEM, V96, P15; STEIN M, 1974, ANAL BIOCHEM, V61, P112, DOI 10.1016/0003-2697(74)90338-8; TISHKOFF DX, 1991, MOL CELL BIOL, V11, P2593, DOI 10.1128/MCB.11.5.2593; VINCENT RD, 1988, NUCLEIC ACIDS RES, V16, P3297, DOI 10.1093/nar/16.8.3297; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; XING YY, 1989, GENE DEV, V3, P1008, DOI 10.1101/gad.3.7.1008; ZASSENHAUS HP, 1988, NUCLEIC ACIDS RES, V16, P3283, DOI 10.1093/nar/16.8.3283	27	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7350	7357						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8385104				2022-12-25	WOS:A1993KV14100076
J	LEONE, A; FLATOW, U; VANHOUTTE, K; STEEG, PS				LEONE, A; FLATOW, U; VANHOUTTE, K; STEEG, PS			TRANSFECTION OF HUMAN NM23-H1 INTO THE HUMAN MDA-MB-435 BREAST-CARCINOMA CELL-LINE - EFFECTS ON TUMOR METASTATIC POTENTIAL, COLONIZATION AND ENZYMATIC-ACTIVITY	ONCOGENE			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; YEAST SCHIZOSACCHAROMYCES-POMBE; GTP-BINDING PROTEINS; COLORECTAL-CARCINOMA; DISEASE PROGRESSION; GOOD PROGNOSIS; EXPRESSION; GENE; CANCER; DROSOPHILA	We report the phenotypic effects of transfection of human nm23-H1 cDNA into the human MDA-MB-435 breast carcinoma cell line. Upon mammary fat pad or subcutaneous injection into nude mice, both the nm23-H1 and control transfected lines produced primary tumors; however, the nm23-H1-transfected lines produced metastases in significantly fewer mice than did control transfected lines. Reductions in tumor metastatic potential in vivo were accompanied by decreased colonization in soft agar and an altered colonization response to transforming growth factor beta in vitro. Total nucleoside diphosphate kinase activity, an enzymatic activity possessed by the Nm23 family, was not directly correlated with Nm23-H1 expression levels or suppression of metastatic potential in all cases examined. The data establish that nm23-H1 has functional suppressive effects on the tumor metastatic potential of a human breast carcinoma cell line, and suggest that it may regulate signal responsiveness in the colonization response.	NIH,PATHOL LAB,BLDG 10,ROOM 2A33,BETHESDA,MD 20892; FREDERICK CANC RES & DEV FACIL,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA			leone, alvaro/AAQ-7051-2020; Leone, Alvaro/K-6410-2016	Leone, Alvaro/0000-0003-3815-9052				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARNES R, 1991, AM J PATHOL, V139, P245; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; COHN KH, 1991, LANCET, V338, P722, DOI 10.1016/0140-6736(91)91444-Y; CREANOR J, 1989, J CELL SCI, V93, P185; DEAROLF CR, 1988, DEV BIOL, V129, P169, DOI 10.1016/0012-1606(88)90171-6; DEAROLF CR, 1988, DEV BIOL, V129, P159, DOI 10.1016/0012-1606(88)90170-4; DICKINSON JR, 1983, J CELL SCI, V60, P355; FLORENES VA, 1992, CANCER RES, V52, P6088; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GOLDEN A, 1993, ONCOGENES TUMOR SUPP, P345; GORSCH SM, 1992, CANCER RES, V52, P6949; HAILAT N, 1991, J CLIN INVEST, V88, P341, DOI 10.1172/JCI115299; Hart I R, 1991, Semin Cancer Biol, V2, P87; HAUT M, 1991, J NATL CANCER I, V83, P712, DOI 10.1093/jnci/83.10.712; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; HIGASHIYAMA M, 1992, BRIT J CANCER, V66, P533, DOI 10.1038/bjc.1992.308; HIRAYAMA R, 1991, J NATL CANCER I, V83, P1249, DOI 10.1093/jnci/83.17.1249; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KANTOR JD, 1993, CANCER RES, V53, P1971; KEIM D, 1992, J CLIN INVEST, V89, P919, DOI 10.1172/JCI115672; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; KIKKAWA S, 1991, J BIOL CHEM, V266, P12795; KOBAYASHI S, 1992, JPN J CANCER RES, V83, P859, DOI 10.1111/j.1349-7006.1992.tb01991.x; LAKSO M, 1992, CELL GROWTH DIFFER, V3, P873; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1993, ONCOGENE, V8, P855; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MELKI R, 1992, BIOCHEM BIOPH RES CO, V187, P65, DOI 10.1016/S0006-291X(05)81459-7; NAKAYAMA T, 1992, J NATL CANCER I, V84, P1349, DOI 10.1093/jnci/84.17.1349; NICKERSON JA, 1984, J BIOL CHEM, V259, P1297; NICOLSON GL, 1987, CANCER RES, V47, P1473; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; PRICE JE, 1990, CANCER RES, V50, P717; RANDAZZO PA, 1991, SCIENCE, V254, P850, DOI 10.1126/science.1658935; RANDAZZO PA, 1992, J BIOL CHEM, V267, P18182; RIES AB, 1990, CANCER STATISTICS RE; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; ROYDS JA, 1993, J NATL CANCER I, V85, P727, DOI 10.1093/jnci/85.9.727; SASTREGARAU X, 1992, INT J CANCER, V50, P533, DOI 10.1002/ijc.2910500406; SCHWARZ LC, 1988, CANCER RES, V48, P6999; SIMPSON JF, 1993, LAB INVEST, V68, pA20; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1993, BREAST CANCER RES TR, V25, P175, DOI 10.1007/BF00662142; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; TENG DHF, 1991, NATURE, V353, P437, DOI 10.1038/353437a0; THEODORESCU D, 1991, J CELL PHYSIOL, V148, P380, DOI 10.1002/jcp.1041480308; THOMAS DG, 1975, COMPUT BIOMED RES, V8, P423, DOI 10.1016/0010-4809(75)90048-8; TUBIANA M, 1991, BREAST CANCER RES TR, V18, P125, DOI 10.1007/BF01990028; VANDEVIJVER MJ, 1991, BIOCHIM BIOPHYS ACTA, V1072, P33, DOI 10.1016/0304-419X(91)90005-6; WANG LM, 1993, CANCER RES, V53, P717	52	297	309	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2325	2333						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8395676				2022-12-25	WOS:A1993LT36800002
J	ROSELL, R; LI, SR; SKACEL, Z; MATE, JL; MAESTRE, J; CANELA, M; TOLOSA, E; ARMENGOL, P; BARNADAS, A; ARIZA, A				ROSELL, R; LI, SR; SKACEL, Z; MATE, JL; MAESTRE, J; CANELA, M; TOLOSA, E; ARMENGOL, P; BARNADAS, A; ARIZA, A			PROGNOSTIC IMPACT OF MUTATED K-RAS GENE IN SURGICALLY RESECTED NONSMALL CELL LUNG-CANCER PATIENTS	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; ONCOGENE ACTIVATION; ENZYMATIC AMPLIFICATION; POINT MUTATION; ADENOCARCINOMA; MARKER; DNA	Mutated K-ras oncogenes have been detected in a third of lung adenocarcinomas, located usually in codon 12, its presence correlating negatively with survival. To further define the role of K-ras point mutations in non-small cell lung cancer, we studied the presence of mutated K-ras genes in surgical specimens from 66 patients. Polymerase chain reaction was performed from sections of formalin-fixed paraffin-embedded tissue. We screened for point mutations in codons 12, 13 and 61 of the K-ras gene by dot blot hybridization analysis with mutation-specific oligonucleotide probes. Ras gene mutations were present in 13 of 66 carcinomas (20%), nine in codon 12 and four in codon 61. Three squamous cell carcinomas harbored two different point mutations in K-ras codon 12. Mutated K-ras genes were found more frequently in squamous cell carcinomas (eight of 38) than in adenocarcinoma (three of 22). Analysis of nucleotide sequence disclosed a multifarious mutation pattern of K-ras codon 12, where the most common conversion was from glycine (GGT) to valine (GTT). K-ras point mutation positive subset had poorer survival, nine of the 13 patients died during the follow-up period as compared with 22 of 53 patients with no mutation in the K-ras gene (P=0.01). The difference was also strikingly significant when stratified according to node status.	UNIV BADALONA, HOSP GERMANS & PUJOL, DEPT IMMUNOL, E-08916 BADALONA, SPAIN; UNIV BADALONA, HOSP GERMANS TRIAS & PUJA, DEPT THORAC SURG, E-08916 BADALONA, SPAIN		ROSELL, R (corresponding author), UNIV BADALONA, HOSP GERMAN TRIAS & PUJOL, DEPT MED ONCOL, E-08916 BADALONA, SPAIN.			MATE SANZ, JOSE LUIS/0000-0002-4829-3426				[Anonymous], 1982, Am J Clin Pathol, V77, P123; ANWAR K, 1992, CANCER RES, V52, P5991; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; DIXON WJ, 1983, BMDP STATISTICAL SOF, P555; ENOMOTO T, 1991, CANCER RES, V51, P5308; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; KOBAYASHI T, 1990, CANCER, V66, P289, DOI 10.1002/1097-0142(19900715)66:2<289::AID-CNCR2820660216>3.0.CO;2-6; KRAEGEL SA, 1992, CANCER RES, V52, P4724; LEVI S, 1991, CANCER RES, V51, P3497; MARIYAMA M, 1989, JPN J CANCER RES, V80, P622, DOI 10.1111/j.1349-7006.1989.tb01687.x; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; MITSUDOMI T, 1991, CANCER RES, V51, P4999; MOUNTAIN CF, 1986, CHEST, V89, pS225, DOI 10.1378/chest.89.4.225S; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; RODENHUIS S, 1992, CANCER RES, V52, pS2665; RODENHUIS S, 1988, CANCER RES, V48, P5738; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Slebos R J, 1992, Diagn Mol Pathol, V1, P136, DOI 10.1097/00019606-199206000-00007; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; SLEBOS RJC, 1991, J NATL CANCER I, V83, P1024, DOI 10.1093/jnci/83.14.1024; SLEBOS RJC, 1992, J NATL CANCER I MONO, V13, P23; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; SUGIO K, 1992, CANCER RES, V52, P2903; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TADA M, 1990, CANCER-AM CANCER SOC, V66, P930, DOI 10.1002/1097-0142(19900901)66:5<930::AID-CNCR2820660519>3.0.CO;2-W; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VRIES MV, 1986, GENE, V50, P313	31	149	151	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1993	8	9					2407	2412						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8395679				2022-12-25	WOS:A1993LT36800011
J	TANSEY, WP; SCHAUFELE, F; HESLEWOOD, M; HANDFORD, C; REUDELHUBER, TL; CATANZARO, DF				TANSEY, WP; SCHAUFELE, F; HESLEWOOD, M; HANDFORD, C; REUDELHUBER, TL; CATANZARO, DF			DISTANCE-DEPENDENT INTERACTIONS BETWEEN BASAL, CYCLIC-AMP, AND THYROID-HORMONE RESPONSE ELEMENTS IN THE RAT GROWTH-HORMONE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SV40 ENHANCER; TRANSCRIPTION FACTOR; PROLACTIN PROMOTER; GENE-EXPRESSION; GLUCOCORTICOID RECEPTOR; REGULATED EXPRESSION; ESCHERICHIA-COLI; 5'-FLANKING DNA; PIT-1; BINDING	Developmental stage- and tissue-specific expression of the rat growth hormone (rGH) gene is conferred by DNA sequences within 237 base pairs of the transcription start site. Although binding of a number of transcription factors including Pit-1, Sp1, GHF3, and thyroid hormone receptor (T3R) stimulates rGH expression, several studies have suggested that interactions between these factors are important in determining cell specificity and responsiveness to extracellular signals. We have directly tested this hypothesis by creating a set of nested insertional mutations at two positions in the rGH promoter. Sequences were inserted at either position -148, separating GHF-3 and T3R binding sites from the downstream Pit- 1 and Sp1 binding sites, or at -51, separating the above elements from the TATA box. All insertions were made in the context of the rGH gene -237/+8 5'-flanking DNA, linked to a chloramphenicol acetyltransferase reporter gene and tested for activity by transient transfection in GC pituitary tumor cells. Insertions at both -148 and -51 caused sharp distance-dependent reductions in serum-stimulated expression such that insertions of 23 base pairs at -51 or 44 base pairs at -148 were sufficient to isolate the effects of sequences upstream of the insertion point. Insertions at -148 reduced T3 responsiveness severalfold but had little or no effect on stimulation by forskolin, whereas insertions at -51 reduced both T3 and forskolin responsiveness. Our results are consistent with the hypothesis that expression and regulation of the rGH gene is dependent on short-range protein-protein interactions, which are more critically dependent on spacing than the relative orientation of the transcription factor binding sites.	UNIV SYDNEY,SCH BIOL SCI,SYDNEY,NSW 2006,AUSTRALIA; UNIV CALIF SAN FRANCISCO,METAB RES UNIT,SAN FRANCISCO,CA 94143	University of Sydney; University of California System; University of California San Francisco					NIDDK NIH HHS [DK39998] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039998] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEHRINGER RR, 1988, GENE DEV, V2, P453, DOI 10.1101/gad.2.4.453; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BRENT GA, 1991, MOL ENDOCRINOL, V5, P542, DOI 10.1210/mend-5-4-542; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BRENT GA, 1988, MOL ENDOCRINOL, V2, P792, DOI 10.1210/mend-2-9-792; CASANOVA J, 1985, J BIOL CHEM, V260, P1744; CATANZARO DF, 1987, MOL ENDOCRINOL, V1, P90, DOI 10.1210/mend-1-1-90; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLIS CM, 1989, NUCLEIC ACIDS RES, V17, P9447, DOI 10.1093/nar/17.22.9447; COPP RP, 1989, MOL ENDOCRINOL, V3, P790, DOI 10.1210/mend-3-5-790; CREW MD, 1986, J BIOL CHEM, V261, P5018; DANA S, 1989, MOL ENDOCRINOL, V3, P815, DOI 10.1210/mend-3-5-815; DYNAN WS, 1989, CELL, V58, P1, DOI 10.1016/0092-8674(89)90393-0; FLUG F, 1987, J BIOL CHEM, V262, P6373; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; HARVEY C, 1991, MOL ENDOCRINOL, V5, P836, DOI 10.1210/mend-5-6-836; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KING IN, 1993, J BIOL CHEM, V268, P495; KOENIG RJ, 1987, P NATL ACAD SCI USA, V84, P5670, DOI 10.1073/pnas.84.16.5670; LIRA SA, 1988, P NATL ACAD SCI USA, V85, P4755, DOI 10.1073/pnas.85.13.4755; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; NELSON C, 1986, NATURE, V322, P557, DOI 10.1038/322557a0; NORMAN MF, 1989, J BIOL CHEM, V264, P12063; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; ONDEK B, 1987, EMBO J, V6, P1017, DOI 10.1002/j.1460-2075.1987.tb04854.x; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHAFFNER G, 1988, J MOL BIOL, V201, P81, DOI 10.1016/0022-2836(88)90440-8; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; SCHAUFELE F, 1990, J BIOL CHEM, V265, P14592; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; TAKAHASHI K, 1986, NATURE, V319, P121, DOI 10.1038/319121a0; TANSEY WP, 1991, J BIOL CHEM, V266, P9805; VERRIJZER CP, 1991, EMBO J, V10, P3007, DOI 10.1002/j.1460-2075.1991.tb07851.x; VOZ ML, 1991, J BIOL CHEM, V266, P13397; WEST BL, 1987, MOL CELL BIOL, V7, P1193, DOI 10.1128/MCB.7.3.1193; YAN GZ, 1991, MOL ENDOCRINOL, V5, P535, DOI 10.1210/mend-5-4-535; YAN GZ, 1991, MOL ENDOCRINOL, V5, P1488, DOI 10.1210/mend-5-10-1488; YE ZS, 1988, J BIOL CHEM, V263, P7821; YE ZS, 1987, J BIOL CHEM, V262, P6313; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x	48	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14906	14911						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8392063				2022-12-25	WOS:A1993LL75900058
J	GOTTARDI, CJ; CAPLAN, MJ				GOTTARDI, CJ; CAPLAN, MJ			MOLECULAR REQUIREMENTS FOR THE CELL-SURFACE EXPRESSION OF MULTISUBUNIT ION-TRANSPORTING ATPASES - IDENTIFICATION OF PROTEIN DOMAINS THAT PARTICIPATE IN NA,K-ATPASE AND H,K-ATPASE SUBUNIT ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERRIN RECEPTOR; BETA-SUBUNIT; INTRACELLULAR-TRANSPORT; CYTOPLASMIC DOMAIN; ALPHA-SUBUNIT; H+/K+-ATPASE; ENDOCYTOSIS; PUMP	The ion-transporting H,K-ATPase and Na,K-ATPase enzymes are each composed of an alpha and a beta subunit. It is known that assembly of the alpha and beta subunits of the Na,K-ATPase is necessary for the cell-surface delivery of the active enzyme. We have examined the molecular domains involved in the assembly of the H,K-ATPase and Na,K-ATPase alpha and beta subunits by expressing individual subunits and subunit chimeras in transiently transfected COS-1 cells. Our results demonstrate that the H,K-ATPase alpha subunit requires its beta subunit for efficient cell-surface expression, as determined by indirect immunofluorescence. The H,K-ATPase beta protein appears to be able to get to the cell surface unaccompanied by any alpha subunit and appears to localize as well to a population of intracellular vesicles. We find that a transfected chimera encoding the NH2-terminal half of the H,K-ATPase alpha subunit and the COOH-terminal half of the Na,K-ATPase alpha subunit appears to assemble with the endogenous Na,K-ATPase beta subunit and to reach the plasmalemma. Transfection of the complementary alpha chimera requires coexpression with the H,K-ATPase beta subunit in order to attain surface delivery. Thus, it is the COOH-terminal half of the alpha subunit that specifies assembly with a particular beta subunit.			GOTTARDI, CJ (corresponding author), YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,333 CEDAR ST,NEW HAVEN,CT 06510, USA.		Gottardi, Cara J./AAU-4691-2021	Gottardi, Cara J./0000-0003-0912-7617; Caplan, Michael/0000-0001-5768-4405	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042136] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-42136] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; ALVAREZ E, 1990, BIOCHEM J, V267, P31, DOI 10.1042/bj2670031; BALDWIN GS, 1990, FEBS LETT, V272, P159, DOI 10.1016/0014-5793(90)80473-V; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; EAKLE KA, 1992, P NATL ACAD SCI USA, V89, P2834, DOI 10.1073/pnas.89.7.2834; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; GEERING K, 1987, J CELL BIOL, V105, P2613, DOI 10.1083/jcb.105.6.2613; GEERING K, 1988, Journal of Cell Biology, V107, p127A; GIRONES N, 1991, J BIOL CHEM, V266, P19006; GOTTARDI CJ, 1993, SCIENCE, V260, P552, DOI 10.1126/science.8386395; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; HANZEL D, 1991, EMBO J, V10, P2363, DOI 10.1002/j.1460-2075.1991.tb07775.x; JORGENSEN PL, 1982, BIOCHIM BIOPHYS ACTA, V694, P27, DOI 10.1016/0304-4157(82)90013-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEMAS MV, 1992, J BIOL CHEM, V267, P20987; LUCKIE DB, 1992, BIOPHYS J, V62, P220, DOI 10.1016/S0006-3495(92)81807-6; LUCKIE DB, 1991, FEBS LETT, V281, P231, DOI 10.1016/0014-5793(91)80400-W; MCDONOUGH AA, 1990, FASEB J, V4, P1589; NELSON W J, 1988, Journal of Cell Biology, V107, p447A; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; NOGUCHI S, 1992, BIOCHEM BIOPH RES CO, V182, P659, DOI 10.1016/0006-291X(92)91783-M; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; OKAMOTO CT, 1990, BIOCHIM BIOPHYS ACTA, V1037, P360, DOI 10.1016/0167-4838(90)90038-H; PIETRINI G, 1992, P NATL ACAD SCI USA, V89, P8414, DOI 10.1073/pnas.89.18.8414; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; SAMBROOK J, 1990, MOL CLONING LABORATO; SHULL GE, 1986, J BIOL CHEM, V261, P6788	28	111	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14342	14347						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8390991				2022-12-25	WOS:A1993LJ82500081
J	VANDELDEN, C; FOTI, M; LEW, DP; KRAUSE, KH				VANDELDEN, C; FOTI, M; LEW, DP; KRAUSE, KH			CA2+ AND MG2+ REGULATION OF INOSITOL 1,4,5-TRIPHOSPHATE BINDING IN MYELOID CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC FREE CALCIUM; HL-60 CELLS; 1,4,5-TRISPHOSPHATE RECEPTOR; TRISPHOSPHATE RECEPTOR; MICROSOMAL FRACTIONS; HUMAN-NEUTROPHILS; CA-2+ RELEASE; PROTEIN; PH; PURIFICATION	Inhibition of inositol 1,4,5-triphosphate (Ins(1,4,5)P3) binding by Ca2+ and Mg2+ remains a controversial issue: the Ca2+ effect may also be explained by Ins(1,4,5)P3 generation due to a Ca2+-sensitive phospholipase C, and the Mg2+ effect by Ins(1,4,5)P3 degradation. In this study, we have, therefore, investigated the effects of Ca2+ and Mg2+ on Ins(1,4,5)P3 binding to membranes of the myeloid cell line HL-60 and assayed in parallel phospholipase C activity and Ins(1,4,5)P3 degradation. The assays for Ins(1,4,5)P3 binding, Ins(1,4,5)P3 generation, and Ins(1,4,5)P3 degradation were performed under identical experimental conditions. Ca2+ significantly and reversibly decreased Ins(1,4,5)P3 binding at submicromolar concentrations. Ca2+ stimulated Ins(1,4,5)P3 generation only at concentrations above 1 muM. At 1 muM [Ca2+], Ins(1,4,5)P3 binding was inhibited by 46 t 6%, but no Ins(1,4,5)P3 generation was observed. [Mg2+] between 0 and 1 mm slightly stimulated, while higher concentrations inhibited, Ins(1,4,5)P3 binding. Mg2+ did not activate phospholipase C. Neither Ca2+ nor Mg2+ induced relevant Ins(1,4,5)P3 degradation under the conditions of the binding assay. The effects of Ca2+ and Mg2+ on Ins(1,4,5)P3 binding were conserved after solubilization of HL-60 membranes. However, only Mg2+, but not Ca2+, inhibited Ins(1,4,5)P3 binding to the receptor that had been partially purified by heparin affinity chromatography. The Ca2+ sensitivity of Ins(1,4,5)P3 binding to the partially purified receptor could be reconstituted by addition of the flow-through of the heparin column. No Ca2+-dependent Ins(1,4,5)P3 generation was observed in the reconstituted system. Thus, we conclude that both Ca2+ and Mg2+ can inhibit Ins(1,4,5)P3 binding independently of phospholipase C activation and Ins(1,4,5)P3 breakdown. The Ca2+ effect depends upon factors that can be separated biochemically from the Ins(1,4,5)P3 receptor. Mg2+ acts either directly on the Ins(1,4,5)P3 receptor or on a closely associated target.			VANDELDEN, C (corresponding author), UNIV HOSP GENEVA,DIV INFECT DIS,CH-1211 GENEVA,SWITZERLAND.		Krause, Karl-Heinz/E-8030-2011	Krause, Karl-Heinz/0000-0002-9033-6768; Foti, Michelangelo/0000-0001-7199-4135				DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; DEMAUREX N, 1992, J CLIN INVEST, V90, P830, DOI 10.1172/JCI115958; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; GUILLEMETTE G, 1987, J BIOL CHEM, V262, P1010; JOSEPH SK, 1989, BIOCHEM J, V258, P261, DOI 10.1042/bj2580261; KRAUSE KH, 1987, J CLIN INVEST, V80, P107, DOI 10.1172/JCI113035; KRAUSE KH, 1985, J CLIN INVEST, V76, P1348, DOI 10.1172/JCI112109; LEW PD, 1986, J BIOL CHEM, V261, P3121; MIGNERY GA, 1992, J BIOL CHEM, V267, P7450; MOUREY RJ, 1990, BIOCHEM J, V272, P383, DOI 10.1042/bj2720383; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PITTET D, 1989, J BIOL CHEM, V264, P18489; PITTET D, 1989, J BIOL CHEM, V264, P7251; RIVERA J, 1990, ENDOCRINOLOGY, V127, P155, DOI 10.1210/endo-127-1-155; ROSSIER MF, 1989, J BIOL CHEM, V264, P14078; SPAT A, 1986, BIOCHEM J, V233, P929; SPAT A, 1986, NATURE, V319, P514, DOI 10.1038/319514a0; SPAT A, 1987, BIOCHEM J, V244, P493; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TOMASZ A, 1970, NATURE, V227, P138, DOI 10.1038/227138a0; VANDELDEN C, 1992, BIOCHEM J, V281, P651, DOI 10.1042/bj2810651; VARNEY MA, 1990, BIOCHEM J, V269, P211, DOI 10.1042/bj2690211; VOLPE P, 1988, P NATL ACAD SCI USA, V85, P1091, DOI 10.1073/pnas.85.4.1091; VOLPE P, 1990, AM J PHYSIOL, V258, pC1077, DOI 10.1152/ajpcell.1990.258.6.C1077; WHITE AM, 1991, BIOCHEM J, V278, P759, DOI 10.1042/bj2780759; WORLEY PF, 1987, J BIOL CHEM, V262, P12132	26	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12443	12448						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8389758				2022-12-25	WOS:A1993LG65800035
J	DAWSON, SJ; WIMAN, B; HAMSTEN, A; GREEN, F; HUMPHRIES, S; HENNEY, AM				DAWSON, SJ; WIMAN, B; HAMSTEN, A; GREEN, F; HUMPHRIES, S; HENNEY, AM			THE 2 ALLELE SEQUENCES OF A COMMON POLYMORPHISM IN THE PROMOTER OF THE PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) GENE RESPOND DIFFERENTLY TO INTERLEUKIN-1 IN HEPG2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE-STIMULATING FACTORS; CORONARY-ARTERY DISEASE; PHASE PLASMA-PROTEINS; TUMOR-NECROSIS-FACTOR; MYOCARDIAL-INFARCTION; ENDOTHELIAL-CELLS; MESSENGER-RNA; NUCLEAR FACTOR; GROWTH-FACTOR; EXPRESSION	We have detected a common (allele frequency 0.53/0.47) single base pair insertion/deletion polymorphism 675 base pairs upstream from the start of transcription of the plasmingen activator inhibitor-1 (PAI-1) gene, using the chemical cleavage mismatch analysis. ''Band shift assays'' suggest that the allele with the single base pair insertion contains an additional protein binding site which is not present in the del allele. Competition experiments confirmed that the binding was specific to the sequence of the ins allele and suggest that proteins bound to this site may be NF-kB-like proteins. Analysis of chloramphenicol acetyltransferase (CAT) mRNA produced by constructs containing the PAI-1 promoter (-805 to +83) showed that the deletion allele produced six times more mRNA than the insertion allele in response to interleukin-1 (p < 0.001). In a sample of 107 young patients with previous myocardial infarction and 95 healthy population-based subjects, the del allele was associated with increased PAI-1 levels, 21% higher than the sample mean in the del homozygotes (p < 0.05). This study also suggested that individuals homozygous for the del allele may have an altered response to the acute phase stimulus. Taken together these results suggest that the insertion/deletion polymorphism in the PAI-1 promoter is of functional importance in regulating the expression of the PAI-1 gene.	CHARING CROSS SUNLEY MED RES CTR,LONDON,ENGLAND; KAROLINSKA HOSP,DEPT CLIN CHEM,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA HOSP,DEPT INTERNAL MED,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA INST,KING GUSTAF V RES INST,S-10401 STOCKHOLM 60,SWEDEN	University of Oxford; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet				Dawson, Sally/0000-0002-4421-2043				ALESSI MC, 1988, THROMB HAEMOSTASIS, V60, P491; ARCONE R, 1988, NUCLEIC ACIDS RES, V16, P3195, DOI 10.1093/nar/16.8.3195; AZNAR J, 1988, BRIT HEART J, V59, P535; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BAUMANN H, 1987, J IMMUNOL, V139, P4122; BAUMANN H, 1987, J BIOL CHEM, V262, P9756; BHATTACHARYYA A, 1989, J MOL BIOL, V209, P583, DOI 10.1016/0022-2836(89)90596-2; DAWSON S, 1991, ARTERIOSCLER THROMB, V11, P183, DOI 10.1161/01.ATV.11.1.183; DEBOER JP, 1991, THROMB HAEMOSTASIS, V65, P181; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; DUNNING AM, 1991, BIOCHIM BIOPHYS ACTA, V1096, P231, DOI 10.1016/0925-4439(91)90010-7; EMEIS JJ, 1986, J EXP MED, V163, P1260, DOI 10.1084/jem.163.5.1260; FEY GH, 1987, MOL BIOL MED, V4, P323; GREEN PM, 1989, EMBO J, V8, P1067, DOI 10.1002/j.1460-2075.1989.tb03474.x; HAMSTEN A, 1986, BRIT HEART J, V55, P58; HAMSTEN A, 1987, LANCET, V2, P3; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; JOHNSON O, 1984, INT J CARDIOL, V6, P380, DOI 10.1016/0167-5273(84)90199-2; KOOISTRA T, 1989, THROMB HAEMOSTASIS, V62, P723; KRUITHOF EKO, 1984, BLOOD, V64, P907; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; LUCORE CL, 1988, J BIOL CHEM, V263, P15845; LUND LR, 1987, EMBO J, V6, P1281, DOI 10.1002/j.1460-2075.1987.tb02365.x; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NONAKA M, 1990, MOL CELL BIOL, V10, P6283, DOI 10.1128/MCB.10.12.6283; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; PARAMO JA, 1985, BRIT MED J, V291, P573, DOI 10.1136/bmj.291.6495.573; PESSARA U, 1990, MOL CELL BIOL, V10, P4146, DOI 10.1128/MCB.10.8.4146; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; RICCIO A, 1988, NUCLEIC ACIDS RES, V16, P2805, DOI 10.1093/nar/16.7.2805; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SORGER PK, 1987, EMBO J, V6, P993, DOI 10.1002/j.1460-2075.1987.tb04850.x; STIKORAHM A, 1990, ARTERIOSCLEROSIS, V10, P1067, DOI 10.1161/01.ATV.10.6.1067; STRUHL K, 1989, CURRENT PROTOCOLS MO; TALMUD PJ, 1987, ATHEROSCLEROSIS, V67, P81, DOI 10.1016/0021-9150(87)90267-X; VANDENBERG EA, 1988, THROMB HAEMOSTASIS, V60, P63; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2; ZEHEB R, 1988, GENE, V73, P459, DOI 10.1016/0378-1119(88)90510-0; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818	41	538	561	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10739	10745						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8388372				2022-12-25	WOS:A1993LD46600008
J	RABON, EC; SMILLIE, K; SERU, V; RABON, R				RABON, EC; SMILLIE, K; SERU, V; RABON, R			RUBIDIUM OCCLUSION WITHIN TRYPTIC PEPTIDES OF THE H,K-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPETITIVE PHOTOAFFINITY INHIBITOR; GASTRIC MEMBRANE-VESICLES; (H+ + K+)-ATPASE; CATION-TRANSPORT; K+; H+; (H++K+)-ATPASE; (K++H+)-ATPASE; H+,K+-ATPASE; ATPASE	Rb-86+ binding to the H,K-ATPase was measured in the Mg2+-vanadate-inhibited enzyme at 4-degrees-C. The concentration dependence of Rb-86+ binding in detergent-free preparations exhibited two components, one saturable with a K0.5(Rb+) of 0.76 +/- 0.3 mM and a binding capacity of 2626 +/- 690 pmol of Rb+/mg of protein and the second nonsaturable, but linearly dependent, upon the Rb-86+ concentration. The concentration dependence of Rb-86+ binding was unaffected by digitonin treatment with a K0.5(Rb+) of 0.63 +/- 0.09 mM and a binding capacity of 2824 +/- 152 pmol of Rb+/mg of protein, but the amplitude of the nonsaturable component was eliminated. The level of Rb-86+ binding was optimized by vanadate and decreased by ADP and ATP, suggesting that cation binding is stabilized in the E2-like conformation and antagonized in the E1 conformation. The Rb+-dependent stabilization of the E2 enzyme conformation was confirmed from the fluorescent quench response of the fluorescein isothiocyanate (FITC)-labeled enzyme, where Rb-86+ bound to the FITC-labeled enzyme with a K0.5 = 0.85 +/- 0.3 mM and a saturable binding capacity of 2121 pmol of Rb-86+/mg of protein and quenched the FITC fluorescence with a K0.5(Rb+) of 3.6 +/- 0.3 mM. The K+-competitive inhibitor, 1-(2-methylphenyl)-4-methylamino-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline (MDPQ), also quenched FITC fluorescence with a K0.5(MDPQ) of 24.5 +/- 0.6 muM and competitively inhibited Rb-86+ binding with a K*0.5 = 35.8 muM (MDPQ). The MDPQ-induced quench of FITC fluorescence at Lys517 within the cytoplasmic M4/M5 nucleotide domain and displacement of Rb-86+ from a functionally defined extracytoplasmic binding domain indicate that structural determinants of the E2 conformational state exist within both cytoplasmic and extracytoplasmic domains of the H,K-ATPase and thus provide evidence of concerted conformational changes between the nucleotide and cation binding domains within the FITC-labeled H,K-ATPase. Membrane-bound fragments of the H,K-ATPase were prepared by tryptic hydrolysis in KCl medium. Tryptic digestion rapidly inactivated the phosphoenzyme site with a time course where k = 0.25 +/- 0.04 min-1 but both Rb-86+ binding and MDPQ fluorescence responses were retained. The concentration dependence of Rb-86+ binding and Rb+-dependent MDPQ fluorescence responses in the trypsin-digested membranes were described by a single class of binding sites where K0.5 = 1.2 +/- 0.3 and 0.73 +/- 0.09 mM, respectively. The stability of the Rb+ and MDPQ sites suggest their locations are near or within the membrane and are inaccessible to trypsin attack. The membrane-bound fragments of the H,K-ATPase were enriched in a peptide at molecular mass almost-equal-to 20 kDa and a second band near the dye front below the molecular mass = 14.4 kDa standard. Sequence analysis indicated that the N-terminal residue of the molecular mass almost-equal-to 20 kDa peptide began at Asn847/Leu854 within the C-terminal third of the molecule.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	RABON, EC (corresponding author), VET ADM MED CTR BRENTWOOD,CTR ULCER RES & EDUC,WADSWORTH DIV,LOS ANGELES,CA 90073, USA.				NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM034286] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM34286] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAUGE LA, 1979, NATURE, V280, P510, DOI 10.1038/280510a0; BESANCON M, 1993, IN PRESS BIOCHEMISTR; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CHANG H, 1977, BIOCHIM BIOPHYS ACTA, V464, P313, DOI 10.1016/0005-2736(77)90006-2; FALLER LD, 1989, BIOCHEMISTRY-US, V28, P6771, DOI 10.1021/bi00442a034; GANSER AL, 1973, BIOCHIM BIOPHYS ACTA, V307, P169, DOI 10.1016/0005-2736(73)90035-7; GLYNN IM, 1982, J PHYSIOL-LONDON, V330, P17, DOI 10.1113/jphysiol.1982.sp014326; GLYNN IM, 1985, SODIUM PUMP, P589; GUNTHER RD, 1987, J BIOL CHEM, V262, P13966; HELMICHDEJONG ML, 1987, BIOCHIM BIOPHYS ACTA, V905, P358, DOI 10.1016/0005-2736(87)90464-0; HELMICHDEJONG ML, 1986, BIOCHIM BIOPHYS ACTA, V858, P254, DOI 10.1016/0005-2736(86)90330-5; HELMICHDEJONG ML, 1985, BIOCHIM BIOPHYS ACTA, V821, P377, DOI 10.1016/0005-2736(85)90041-0; JACKSON RJ, 1983, BIOCHIM BIOPHYS ACTA, V731, P9, DOI 10.1016/0005-2736(83)90391-7; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; MUNSON KB, 1988, BIOCHEMISTRY-US, V27, P3932, DOI 10.1021/bi00411a007; RABON E, 1982, BIOCHIM BIOPHYS ACTA, V688, P515, DOI 10.1016/0005-2736(82)90363-7; RABON E, 1991, J BIOL CHEM, V266, P12395; RABON E, 1978, BIOCHEMISTRY-US, V17, P3345, DOI 10.1021/bi00609a027; RABON EC, 1982, J BIOL CHEM, V257, P6296; RABON EC, 1988, J BIOL CHEM, V263, P16189; SACHS G, 1992, J BIOENERG BIOMEMBR, V24, P301; SACHS G, 1976, J BIOL CHEM, V251, P7690; SCHACKMANN R, 1977, J MEMBRANE BIOL, V32, P361, DOI 10.1007/BF01905228; SHANI M, 1987, BIOCHIM BIOPHYS ACTA, V904, P13, DOI 10.1016/0005-2736(87)90081-2; SKRABANJA ATP, 1986, BIOCHIM BIOPHYS ACTA, V860, P131, DOI 10.1016/0005-2736(86)90507-9; SKRABANJA ATP, 1987, BIOCHIM BIOPHYS ACTA, V903, P434, DOI 10.1016/0005-2736(87)90050-2; SKRABANJA ATP, 1984, BIOCHIM BIOPHYS ACTA, V774, P91, DOI 10.1016/0005-2736(84)90278-5; SOUMARMON A, 1984, J BIOL CHEM, V259, P1861; STEWART B, 1981, J BIOL CHEM, V256, P2682; WALLMARK B, 1980, J BIOL CHEM, V255, P5313; WALLMARK B, 1979, J BIOL CHEM, V254, P1899	32	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8012	8018						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8385132				2022-12-25	WOS:A1993KW97900064
J	CLOSS, EI; ALBRITTON, LM; KIM, JW; CUNNINGHAM, JM				CLOSS, EI; ALBRITTON, LM; KIM, JW; CUNNINGHAM, JM			IDENTIFICATION OF A LOW AFFINITY, HIGH-CAPACITY TRANSPORTER OF CATIONIC AMINO-ACIDS IN MOUSE-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECOTROPIC RETROVIRUS RECEPTOR; CULTURED ANIMAL-CELLS; SACCHAROMYCES-CEREVISIAE; GLUCOSE TRANSPORTERS; FUNCTIONAL EXPRESSION; XENOPUS OOCYTES; PLASMA-MEMBRANE; MAMMALIAN-CELLS; SEQUENCE; GENE	The liver regulates the supply of amino acids required for protein synthesis and intermediary metabolism between feeding and fasting in mammals. The flux of amino acids between the liver and other tissues is determined, in part, by the activity of specific carrier proteins. We have identified a carrier of the cationic amino acids arginine, lysine, and ornithine in mouse liver that is closely related to a previously identified transporter with the same substrate specificity expressed in nonhepatic tissues. Uptake studies were performed in Xenopus oocytes injected with cRNA encoding these proteins. The comparison of the two transporters in these studies demonstrated that, unlike the widely-expressed transporter, arginine uptake mediated by the liver carrier is significant only at substrate concentrations that exceed systemic plasma levels and is less dependent on the intracellular concentration of cationic amino acids. These properties enable hepatocytes expressing this carrier to remove excess cationic amino acids from the blood without interfering with their uptake by nonhepatic tissues that express the related transporter.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL ONCOL,RM 925,75 FRANCIS ST,BOSTON,MA 02115; HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School			Closs, Ellen/ABD-5217-2020	Closs, Ellen/0000-0002-9505-2289	NCI NIH HHS [CA47075] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047075] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; ALTMAN P, 1967, BLOOD OTHER BODY FLU, P75; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; Cooper T., 1982, MOL BIOL YEAST SACCH, P399; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; HAEUSSINGER D, 1986, REGULATION HEPATIC M, P253; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HOFFMANN W, 1985, J BIOL CHEM, V260, P1831; JAENISCH R, 1979, VIROLOGY, V98, P289, DOI 10.1016/0042-6822(79)90552-X; KELLER K, 1989, J BIOL CHEM, V264, P18884; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRUPKA RM, 1985, J MEMBRANE BIOL, V84, P35, DOI 10.1007/BF01871646; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; SILVER J, 1989, J VIROL, V63, P1924, DOI 10.1128/JVI.63.5.1924-1928.1989; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEIN WD, 1990, CHANNELS CARRIERS PU, P127; TANAKA J, 1985, GENE, V38, P205, DOI 10.1016/0378-1119(85)90219-7; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; WEBER E, 1988, J MOL EVOL, V27, P341, DOI 10.1007/BF02101197; WHITE MF, 1982, J BIOL CHEM, V257, P4450; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WHITE MF, 1982, J BIOL CHEM, V257, P4443; WHITE MF, 1982, J BIOL CHEM, V257, P69; [No title captured]	30	182	187	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7538	7544						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8385111				2022-12-25	WOS:A1993KV14100103
J	YAMAGUCHI, A; KIMURA, T; SOMEYA, Y; SAWAI, T				YAMAGUCHI, A; KIMURA, T; SOMEYA, Y; SAWAI, T			METAL-TETRACYCLINE/H+ ANTIPORTER OF ESCHERICHIA-COLI ENCODED BY TRANSPOSON TN10 - THE STRUCTURAL RESEMBLANCE AND FUNCTIONAL DIFFERENCE IN THE ROLE OF THE DUPLICATED SEQUENCE MOTIF BETWEEN HYDROPHOBIC SEGMENT-2 AND SEGMENT-3 AND SEGMENT-8 AND SEGMENT-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE DETERMINANTS; NUCLEOTIDE-SEQUENCE; GENE; PROTEIN; EFFLUX; EVOLUTION; CLONING; VECTORS	The properties of site-directed mutants as to the putative hydrophilic loop region between hydrophobic segments 2 and 3 in the transposon Tn10-encoded metal-tetracycline/H+ antiporter (TET) were reported in our previous paper (Yamaguchi, A., Someya, Y., and Sawai, T. (1992) J. Biol. Chem. 267, 19155-19162). The loop between hydrophobic segments 8 and 9 contains a conserved sequence motif, GXXXXKXGEK, which is a derivative of the sequence motif, GXXXXRXGRR, in loop2-3. Site-directed mutagenesis studies on loop8-9 revealed that the two loops exhibit significant structural resemblance, that is, 1) when the Gly residue at the eighth position in each loop was replaced by various amino acid residues, the residual activity of the resultant mutants corresponded well to the beta-turn propensity of the substituent, 2) the Cys mutant as to the fourth position in each loop was most profoundly inactivated by N-ethylmaleimide among 10 Cys mutants as to each loop, and 3) the reactivity of a Cys residue introduced at the third position in loop8-9 with N-ethylmaleimide was lower than that in the case of the other Cys mutants, probably due to the residue being partially cryptic as to the attack of the reagent, similar to in the case of the corresponding residue in loop2-3, the latter being entirely cryptic. The Gly at the first position in loop8-9, is less important than the corresponding Gly in loop2-3, however, since the TET protein suffered a loss of activity when a bulky side chain was introduced at the first position in loop8-9 as well as in loop2-3, the structural roles of the 2 glycines are likely to be similar. These findings suggested that loop2-3 and loop8-9 may occupy similar positions in the three-dimensional structure of the TET protein. On the other hand, the two loops showed a significant functional difference; the negative charge of Asp66 and the positive charge of Arg70 in loop2-3 were essential for the transport function, but, in contrast, there was no functionally essential residue in loop8-9, indicating that loop2-3 may form an ''active'' leaflet in the TET protein, while loop8-9 may be a ''silent'' counterpart.			YAMAGUCHI, A (corresponding author), CHIBA UNIV,FAC PHARMACEUT SCI,DIV MICROBIAL CHEM,CHIBA 263,JAPAN.		Kimura-Someya, Tomomi/C-4169-2017	Kimura-Someya, Tomomi/0000-0003-2232-1801				CHOPRA I, 1986, J ANTIMICROB CHEMOTH, V18, P51, DOI 10.1093/jac/18.Supplement_C.51; CHOPRA I, 1992, J ANTIMICROB CHEMOTH, V29, P245, DOI 10.1093/jac/29.3.245; CKERT B, 1989, J BIOL CHEM, V264, P11663; CURIALE MS, 1984, J BACTERIOL, V157, P211, DOI 10.1128/JB.157.1.211-217.1984; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; HILLEN W, 1983, NUCLEIC ACIDS RES, V11, P525, DOI 10.1093/nar/11.2.525; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVITT M, 1978, BIOCHEMISTRY-US, V17, P4277, DOI 10.1021/bi00613a026; LEVY SB, 1989, J ANTIMICROB CHEMOTH, V24, P1, DOI 10.1093/jac/24.1.1; LEVY SB, 1992, ANTIMICROB AGENTS CH, V36, P695, DOI 10.1128/AAC.36.4.695; LEVY SB, 1984, ANTIMICROBIAL DRUG R, P191; MCMURRY L, 1980, P NATL ACAD SCI-BIOL, V77, P3974, DOI 10.1073/pnas.77.7.3974; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P9746, DOI 10.1021/bi00493a034; NEYFAKH AA, 1992, ANTIMICROB AGENTS CH, V36, P484, DOI 10.1128/AAC.36.2.484; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; NGUYEN TT, 1983, GENE, V25, P83, DOI 10.1016/0378-1119(83)90170-1; PHILIPSON L, 1978, CELL, V13, P189, DOI 10.1016/0092-8674(78)90149-6; RUBIN RA, 1990, J BACTERIOL, V172, P2303, DOI 10.1128/jb.172.5.2303-2312.1990; RUBIN RA, 1990, GENE, V87, P7, DOI 10.1016/0378-1119(90)90489-E; SEOL W, 1991, P NATL ACAD SCI USA, V88, P3802, DOI 10.1073/pnas.88.9.3802; STOKER NG, 1982, GENE, V18, P335, DOI 10.1016/0378-1119(82)90172-X; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WATERS SH, 1983, NUCLEIC ACIDS RES, V11, P6089, DOI 10.1093/nar/11.17.6089; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P4809; YAMAGUCHI A, 1991, J BIOL CHEM, V266, P6045; YAMAGUCHI A, 1990, FEBS LETT, V265, P17, DOI 10.1016/0014-5793(90)80872-G; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P15525; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P19155; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P7490; YAMAMOTO T, 1981, J BACTERIOL, V145, P808, DOI 10.1128/JB.145.2.808-813.1981; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOSHIDA H, 1990, J BACTERIOL, V172, P6942, DOI 10.1128/jb.172.12.6942-6949.1990	35	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6496	6504						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8384213				2022-12-25	WOS:A1993KT36800061
J	BEHRENDT, N; RONNE, E; DANO, K				BEHRENDT, N; RONNE, E; DANO, K			BINDING OF THE UROKINASE-TYPE PLASMINOGEN-ACTIVATOR TO ITS CELL-SURFACE RECEPTOR IS INHIBITED BY LOW-DOSES OF SURAMIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND UROKINASE; GROWTH-FACTOR; U937 MONOCYTES; PRO-UROKINASE; STROMAL CELLS; DEGRADATION; INVASION; SYSTEM; ADENOCARCINOMAS; POTENTIATION	The multipotent drug suramin, which is currently being studied as an anticancer agent, was found to inhibit the interaction between the urokinase-type plasminogen activator (u-PA) and its cellular receptor. 50% inhibition of binding was obtained with a suramin concentration between 30 and 60 mug/ml when using U937 cells and a ligand concentration of 0.3 nM. This concentration of the drug is well below the serum levels found in suramin-treated patients. Inhibition of binding was also demonstrated at the molecular level, using chemical cross-linking or an enzyme-linked immunosorbent assay-type technique based on the ligand interaction. The inhibition was not caused by a mere polyanion effect since polysulfates such as heparin, heparan sulfate, and pentosan polysulfate were non-inhibitory or showed only a very weak inhibition. However, polysulfonated compounds with structures resembling suramin (i.e. trypan blue and Evans blue) did prove inhibitory. The inhibition found with suramin showed a concentration dependence consistent with a mixed competitive and noncompetitive mechanism. The off-rate of prebound ligand was accelerated by the drug. It is speculated that the present effect may contribute to the anti-invasive properties of suramin by destroying the cellular potential for localized plasminogen activation and proteolytic matrix degradation.			BEHRENDT, N (corresponding author), RIGSHOSP, FINSEN LAB, STRANDBLVD 49 862, DK-2100 COPENHAGEN, DENMARK.			Behrendt, Niels/0000-0003-1833-3922				BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BEHRENDT N, 1993, METHOD ENZYMOL, V223, pCH13; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; COFFEY RJ, 1987, J CELL PHYSIOL, V132, P143, DOI 10.1002/jcp.1041320120; CORNISHB.A, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143; CUBELLIS MV, 1986, J BIOL CHEM, V261, P5819; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DIXON M, 1979, ENZYMES, P332; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1990, J BIOL CHEM, V265, P9904; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; GRONDAHLHANSEN J, 1991, AM J PATHOL, V138, P111; GUESDON JL, 1979, J HISTOCHEM CYTOCHEM, V27, P1131, DOI 10.1177/27.8.90074; HOSANG M, 1985, J CELL BIOCHEM, V29, P265, DOI 10.1002/jcb.240290310; JENTSCH KD, 1987, J GEN VIROL, V68, P2183, DOI 10.1099/0022-1317-68-8-2183; LAROCCA RV, 1990, CANCER CELL-MON REV, V2, P106; LAROCCA RV, 1990, NEUROLOGY, V40, P954; MASUCCI MT, 1991, J BIOL CHEM, V266, P8655; NAKAJIMA M, 1991, J BIOL CHEM, V266, P9661; NIELSEN LS, 1986, J IMMUNOASSAY, V7, P209, DOI 10.1080/01971528608060467; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; OSSOWSKI L, 1988, J CELL BIOL, V107, P2437, DOI 10.1083/jcb.107.6.2437; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; PEDERSEN N, 1991, FIBRINOLYSIS, V5, P155, DOI 10.1016/0268-9499(91)90017-X; PLOUG M, 1991, J BIOL CHEM, V266, P1926; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; POLLANEN J, 1991, ADV CANCER RES, V57, P273; PYKE C, 1991, AM J PATHOL, V138, P1059; QUAX PHA, 1991, CELL REGUL, V2, P793, DOI 10.1091/mbc.2.10.793; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; RONNE E, 1991, FEBS LETT, V288, P233, DOI 10.1016/0014-5793(91)81042-7; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; STEIN CA, 1989, J CLIN ONCOL, V7, P499, DOI 10.1200/JCO.1989.7.4.499; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; ZABRENETZKY VS, 1990, CANCER RES, V50, P5937	42	39	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5985	5989						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8383683				2022-12-25	WOS:A1993KR82200093
J	FATHI, Z; CORJAY, MH; SHAPIRA, H; WADA, E; BENYA, R; JENSEN, R; VIALLET, J; SAUSVILLE, EA; BATTEY, JF				FATHI, Z; CORJAY, MH; SHAPIRA, H; WADA, E; BENYA, R; JENSEN, R; VIALLET, J; SAUSVILLE, EA; BATTEY, JF			BRS-3 - A NOVEL BOMBESIN RECEPTOR SUBTYPE SELECTIVELY EXPRESSED IN TESTIS AND LUNG-CARCINOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIN-RELEASING PEPTIDE; SWISS 3T3 CELLS; BETA-2-ADRENERGIC RECEPTOR; MOLECULAR-CLONING; FUNCTIONAL-CHARACTERIZATION; PHOSPHORYLATION SITES; PROTEIN-KINASE; GROWTH-FACTOR; CDNA; DESENSITIZATION	The bombesin (BN)-like peptides mediate a diverse spectrum of biological activities and have been implicated as autocrine growth factors in the pathogenesis and progression of some human small cell lung carcinoma tumors. Previously, two mammalian BN-like peptide receptor subtypes, gastrin-releasing peptide receptor and neuromedin-B receptor, have been cloned and characterized. In this study, we have isolated and characterized human genomic and complementary DNA (cDNA) clones encoding a new BN-like peptide receptor subtype, BN receptor subtype 3 (BRS-3). Expression of BRS-3 cDNA in Xenopus oocytes encodes a functional receptor that is specifically activated by BN-like peptides. Chromosome mapping studies indicate that the BRS-3 gene is located on human chromosome X. BRS-3 mRNA expression in rat tissues is limited to secondary spermatocytes in testis. In contrast, BRS-3 mRNA is widely expressed in a panel of human cell lines from all histological types of lung carcinoma. These results suggest a role for BN-like peptides and their receptors in mammalian reproductive physiology and also indicate that BRS-3 could serve as a potential therapeutic target for human lung carcinoma.	NIDDKD, DIGEST DIS BRANCH, BETHESDA, MD 20892 USA; MONTREAL GEN HOSP, DIV ONCOL, MONTREAL H3G 1A4, QUEBEC, CANADA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); McGill University	FATHI, Z (corresponding author), NCI, DEPT CANC TREATMENT,DEV THERAPEUT PROGRAM, BIOL CHEM LAB,BLDG 37, RM 5D02, BETHESDA, MD 20892 USA.							ANASTASI A, 1971, EXPERIENTIA, V27, P166, DOI 10.1007/BF02145873; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CARNEY DN, 1987, CANCER RES, V47, P821; CLARK RB, 1989, MOL PHARMACOL, V36, P343; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; DAVIS LG, 1986, BASIC METHODS MOL BI, P1; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FINK PS, 1991, BIOTECHNIQUES, V10, P446; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAMBLIN MW, 1991, MOL PHARMACOL, V40, P143; HAMBLIN MW, 1992, BIOCHEM BIOPH RES CO, V184, P752, DOI 10.1016/0006-291X(92)90654-4; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; LEBACQVERHEYDEN AM, 1990, HDB EXPT PHARM, V95, P71; SHAPIRA H, 1991, BIOCHEM BIOPH RES CO, V176, P79, DOI 10.1016/0006-291X(91)90892-B; SHAPIRA H, 1992, IN PRESS METHODS NEU; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; SPINDEL ER, 1992, IN PRESS RECENT PROG; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; TAKEDA Y, 1991, BIOCHEM BIOPH RES CO, V179, P1232, DOI 10.1016/0006-291X(91)91704-G; TREPEL JB, 1988, BIOCHEM J, V255, P403, DOI 10.1042/bj2550403; WADA E, 1991, NEURON, V6, P421, DOI 10.1016/0896-6273(91)90250-4; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211	28	297	306	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5979	5984						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8383682				2022-12-25	WOS:A1993KR82200092
J	MENNITI, FS; MILLER, RN; PUTNEY, JW; SHEARS, SB				MENNITI, FS; MILLER, RN; PUTNEY, JW; SHEARS, SB			TURNOVER OF INOSITOL POLYPHOSPHATE PYROPHOSPHATES IN PANCREATOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOINOSITOL 1,3,4,5,6-PENTAKISPHOSPHATE; PENTAKISPHOSPHATE; HEXAKISPHOSPHATE; METABOLISM; PHOSPHATES; 1,3,4-TRISPHOSPHATE; TETRAKISPHOSPHATES; PHOSPHORYLATION; CALCIUM	There is little information concerning the intracellular function of inositol 1,3,4,5,6-pentakis- and hexakisphosphate, despite their being the most abundant inositol polyphosphates. Current opinions that they play passive roles as antioxidants (Graf, E., Mahoney, J. R., Bryant, R. G., and Eaton, J. W. (1987) J. Biol. Chem. 259, 3620-3624) or ''housekeeping'' molecules (Berridge, M. J., and Irvine, R. F. (1989) Nature 341, 197-205) arises from belief in their metabolic lethargy. However, we have discovered that celt homogenates, incubated with 5 mm fluoride and 5 mM ATP, converted both inositol hexakisphosphate (K(m) = 2 +/-0.5 muM, V(max) = 9 +/- 2 pmol/mg of protein/min) and inositol 1,3,4,5,6-pentakisphosphate (K(m) = 13 +/- 4 muM, V(max) = 11 +/- 5 pmol/mg of protein/min) to more polar products. These reactions were also observed in intact cells treated with 0.5-20 mM fluoride, and the precursor/product relationships were confirmed by comparing the effects of fluoride on cells differentially labeled with [H-3]inositol in either short-term or pulse-chase protocols. The novel products were determined to be inositol pyrophosphates because of their relatively specific hydrolysis by tobacco pyrophosphatase and alkaline phosphatase. The pyrophosphates were metabolized rapidly by cell homogenates back to their pentakisphosphate and hexakisphosphate precursors. This endogenous pyrophosphatase activity was inhibited by up to 99% by 5 mM fluoride in vitro. In intact cells incubated with 10 mM fluoride, about 20% of the inositol 1,3,4,5,6-pentakisphosphate pool, and 50% of the inositol hexakisphosphate pool were each converted to pyrophosphate derivatives within 1 h.	NIEHS,CELLULAR & MOLEC PHARMACOL LAB,INOSITOL LIPID SECT,RES TRIANGLE PK,NC 27709; NIEHS,CALCIUM REGULAT SECT,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Shears, Stephen B/C-6335-2019; Putney, James W/F-7247-2019	Shears, Stephen B/0000-0001-7309-8916; Putney, James W/0000-0002-3379-4789; Menniti, Frank/0000-0003-2612-9534				AGRANOFF BW, 1985, INOSITOL PHOSPHOINOS, pR21; BALLA T, 1989, J BIOL CHEM, V264, P9386; BARRACO RA, 1989, EUR J PHARMACOL, V173, P75, DOI 10.1016/0014-2999(89)90010-1; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIRD GSJ, 1991, BIOCHEM J, V273, P541, DOI 10.1042/bj2730541; BLACKMORE PF, 1985, J BIOL CHEM, V260, P4477; BRIGHTWELL R, 1968, ARCH BIOCHEM BIOPHYS, V124, P325, DOI 10.1016/0003-9861(68)90334-2; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; CHAPPELE.D, 1974, BIOCHEMISTRY-US, V13, P1788, DOI 10.1021/bi00706a002; EUROPEFINNER GN, 1989, J CELL SCI, V93, P585; GRAF E, 1984, J BIOL CHEM, V259, P3620; HESLOP JP, 1985, J EXP BIOL, V119, P395; ISAACKS RE, 1980, AM ZOOL, V20, P115; JI H, 1989, J BIOL CHEM, V264, P20185; Maslanski J. A., 1990, METHODS INOSITIDE RE, P109; MATTINGLY RR, 1991, J BIOL CHEM, V266, P15144; MENNITI FS, 1990, J BIOL CHEM, V265, P11167; Michell A.H., 1989, INOSITOL LIPIDS CELL; OLIVER KG, 1992, J BIOL CHEM, V267, P21528; SEARGEANT LE, 1979, CAN J BIOCHEM CELL B, V57, P1000, DOI 10.1139/o79-124; SHEARS SB, 1989, J BIOL CHEM, V264, P19879; Shears Stephen B., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P63; SHINSHI H, 1976, BIOCHEMISTRY-US, V15, P2185, DOI 10.1021/bi00655a024; STEPHENS LR, 1988, BIOCHEM J, V253, P721, DOI 10.1042/bj2530721; STEPHENS LR, 1991, BIOCHEM J, V275, P485, DOI 10.1042/bj2750485; STEWART SJ, 1987, BIOCHEM BIOPH RES CO, V145, P895, DOI 10.1016/0006-291X(87)91049-7; VALLEJO M, 1987, NATURE, V330, P656, DOI 10.1038/330656a0; WONG NS, 1988, BIOCHEM J, V252, P1	28	172	179	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3850	3856						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8382679				2022-12-25	WOS:A1993KN53300013
J	ZHOU, XM; CUNHA, MJ; EPSTEIN, J; LEVENSON, R; CANTLEY, LC; CANTLEY, LG				ZHOU, XM; CUNHA, MJ; EPSTEIN, J; LEVENSON, R; CANTLEY, LC; CANTLEY, LG			A MURINE GENOMIC DNA FRAGMENT AMPLIFIES OUABAIN-INDUCED NA,K-ATPASE ALPHA/BETA-SUBUNIT MESSENGER-RNA UP-REGULATION AND CONFERS OUABAIN RESISTANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; MOLECULAR-CLONING; EXPRESSION; CELLS; GENE; TRANSFECTION; CDNA; IDENTIFICATION; AMPLIFICATION; ALPHA-1	Transfection of primate cells with a 6.4-kilobase murine genomic DNA fragment (called ouabain resistance gene or MOR6.5) has been shown previously to confer ouabain resistance (Levenson, R., Racaniello, V., Albritton, L., and Housman, D. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 1489-1493). The mechanism by which this sequence can transfer ouabain resistance remains unclear. In order to further investigate this mechanism, we determined the full-length nucleotide sequence of MOR6.5. Other than mouse repetitive domains, this DNA does not have significant homology with any coding sequence in GenBank. Although potential open reading frames and polyadenylation signals were found, we were unable to detect an MOR6.5 transcript in CV-1 or COS-1 cells transfected with this DNA, either at early or late times following transfection. We show that in early passages of MOR6.5 transfectants which were under ouabain-selective pressure and still contained MOR6.5 DNA sequence, mRNAs for both alpha1- and beta1-subunits of the Na,K-ATPase were amplified approximately 10-fold, compared to parental CV-1 cells. These results suggest that MOR6.5 may rescue the cells from ouabain toxicity by inducing transient up-regulation of the messages for the Na,K-ATPase. This might prolong cell survival on ouabain until mutations in the alpha1-subunit occur, which permanently reduce ouabain inhibition of the pump (Cantley, L. G., Zhou, X.-M., Cunha, M., Epstein, J., and Cantley, L. C. (1992) J. Biol. Chem. 267, 17271-17278). Possible mechanisms for the up-regulation of transcription based on sequence similarities found between MOR6.5 and the 5'-flanking regions of alpha1- and beta1-subunit genes are discussed.	YALE UNIV,DEPT CELL BIOL,NEW HAVEN,CT 06510; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,BOSTON,MA 02115; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,BOSTON,MA 02215	Yale University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	ZHOU, XM (corresponding author), TUFTS UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02111, USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Levenson, Robert/0000-0002-0936-8421				Battey, 1986, BASIC METHODS MOL BI; CANESSA CM, 1992, EMBO J, V11, P1681, DOI 10.1002/j.1460-2075.1992.tb05218.x; CANTLEY LG, 1992, J BIOL CHEM, V267, P17271; CECH TR, 1983, CELL, V34, P713, DOI 10.1016/0092-8674(83)90527-5; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; COFFIN J, 1984, RNA TUMOR VIRUSES, V2, P36; EAKLE KA, 1992, P NATL ACAD SCI USA, V89, P2834, DOI 10.1073/pnas.89.7.2834; EMANUEL JR, 1988, J BIOL CHEM, V263, P7726; EMANUEL JR, 1986, MOL CELL BIOL, V6, P2476, DOI 10.1128/MCB.6.7.2476; EMANUEL JR, 1989, MOL CELL BIOL, V9, P3744, DOI 10.1128/MCB.9.9.3744; ENGLISH LH, 1985, J BIOL CHEM, V260, P1114; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; KAPLAN PL, 1987, J VIROL, V61, P1731, DOI 10.1128/JVI.61.5.1731-1734.1987; KAWAKAMI K, 1986, NUCLEIC ACIDS RES, V14, P2833, DOI 10.1093/nar/14.7.2833; KAWAMURA M, 1991, SODIUM PUMP STRUCT M, V46, P46; KENT RB, 1987, SCIENCE, V237, P901, DOI 10.1126/science.3039660; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LEVENSON R, 1984, P NATL ACAD SCI-BIOL, V81, P1489, DOI 10.1073/pnas.81.5.1489; LINGREL J B, 1990, Journal of General Physiology, V96, p1A; PRESSLEY TA, 1986, J BIOL CHEM, V261, P9779; PRICE EM, 1990, J BIOL CHEM, V265, P6638; RAYSON BM, 1991, J BIOL CHEM, V266, P21335; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER JW, 1987, BLOOD CELLS, V13, P299; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SHIMOTOHNO K, 1982, NATURE, V299, P543; SHULL MM, 1990, GENOMICS, V6, P451, DOI 10.1016/0888-7543(90)90475-A; SHYJAN AW, 1989, BIOCHEMISTRY-US, V28, P4531, DOI 10.1021/bi00437a002; SORGE J, 1982, Journal of Molecular and Applied Genetics, V1, P547; TAKEYASU K, 1987, J BIOL CHEM, V262, P10733; THOMAS RE, 1981, BURGERS MED CHEM, V3, P47; YOUNG RM, 1987, J BIOL CHEM, V262, P4905	37	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4126	4133						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8382694				2022-12-25	WOS:A1993KN53300051
J	TAANMAN, JW; CAPALDI, RA				TAANMAN, JW; CAPALDI, RA			SUBUNIT-VIA OF YEAST CYTOCHROME-C-OXIDASE IS NOT NECESSARY FOR ASSEMBLY OF THE ENZYME COMPLEX BUT MODULATES THE ENZYME-ACTIVITY - ISOLATION AND CHARACTERIZATION OF THE NUCLEAR-CODED GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; UPSTREAM ACTIVATION; MUTATIONAL ANALYSIS; DNA FRAGMENTS; CLONING; SEQUENCE; PROTEIN; BINDING; HEART	COX13, the nuclear gene for cytochrome c oxidase subunit VIa of Saccharomyces cerevisiae, has been isolated in two steps. First, the partial amino acid sequence information of the subunit was used to design two degenerate oligodeoxynucleotide primers to amplify part of the gene in a polymerase chain reaction. Next, the amplified product was used to screen a yeast genomic library in order to obtain the entire gene and its flanking sequences. COX13 is present as a single copy gene per haploid genome. Alignment of the N-terminal sequence of mature subunit VIa with the amino acid sequence deduced from the DNA sequence indicates that subunit VIa is synthesized as a precursor comprised of a leader sequence of 9 amino acid residues and a mature polypeptide of 120 amino acid residues. The mature polypeptide shares 34% identical amino acid residues with the human subunit isoform VIa-L. Sequence analysis of the 3'-flanking region of COX13 revealed that the gene is located 599 base pairs downstream of CDC55, a gene which has been mapped to the left arm of chromosome VII. Null mutants of COX13, generated by gene replacement, showed a slightly reduced growth rate on nonfermentable carbon sources. Heme spectra and analysis of immunopurified cytochrome c oxidase from a null strain demonstrated that the enzyme is fully assembled without subunit VIa. At low ionic strength, cytochrome c oxidase missing subunit VIa was more active, whereas at high ionic strength, it was less active than the enzyme complex in which subunit VIa was present. In addition, distinct effects of ATP on the activity of the null and wild type enzyme were found. The results suggest that ATP interacts specifically with subunit VIa and thereby modulates the cytochrome c oxidase activity.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA	University of Oregon			Taanman, Jan W/A-5379-2011	Taanman, Jan W/0000-0002-5476-9785	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022050] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 22050] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGELER R, 1990, J BIOL CHEM, V265, P16389; ANTHONY G, 1993, P NATL ACAD SCI USA, V90, P1652, DOI 10.1073/pnas.90.5.1652; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CALDER KM, 1991, MOL MICROBIOL, V5, P1769, DOI 10.1111/j.1365-2958.1991.tb01926.x; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CAPALDI RA, 1983, BIOCHIM BIOPHYS ACTA, V726, P135, DOI 10.1016/0304-4173(83)90003-4; CAPALDI RA, 1986, FEBS LETT, V207, P11, DOI 10.1016/0014-5793(86)80004-7; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; CHOMCZYNSKI P, 1984, BIOCHEM BIOPH RES CO, V122, P340, DOI 10.1016/0006-291X(84)90480-7; COOPER CE, 1991, BIOCHEM CELL BIOL, V69, P586, DOI 10.1139/o91-089; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWINDE JH, 1993, IN PRESS PROG NUCLEI, V45; DOWHAN W, 1985, EMBO J, V4, P179, DOI 10.1002/j.1460-2075.1985.tb02334.x; Erlich H.A., 1989, PCR TECHNOLOGY PRINC; FABRIZI GM, 1992, GENE, V119, P307, DOI 10.1016/0378-1119(92)90288-Z; FERGUSONMILLER S, 1976, J BIOL CHEM, V251, P1104; FORSBURG SL, 1989, ANNU REV CELL BIOL, V5, P153, DOI 10.1146/annurev.cb.05.110189.001101; FORSBURG SL, 1988, MOL CELL BIOL, V8, P647, DOI 10.1128/MCB.8.2.647; GATTI DL, 1989, J MOL BIOL, V205, P421, DOI 10.1016/0022-2836(89)90352-5; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HODGE MR, 1990, MOL CELL BIOL, V10, P5510, DOI 10.1128/MCB.10.10.5510; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOLLEY ME, 1984, J IMMUNOL METHODS, V67, P21, DOI 10.1016/0022-1759(84)90082-6; KADENBACH B, 1986, J BIOENERG BIOMEMBR, V18, P39, DOI 10.1007/BF00743611; KADENBACH B, 1987, CURR TOP BIOENERG, V15, P113; KADENBACH B, 1991, J BIOENERG BIOMEMBR, V23, P321, DOI 10.1007/BF00762225; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMARCHE AEP, 1992, J BIOL CHEM, V267, P22473; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LIGHTOWLERS R, 1991, J BIOL CHEM, V266, P7688; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4128, DOI 10.1021/bi00313a018; LOWRY CV, 1990, MOL CELL BIOL, V10, P5921, DOI 10.1128/MCB.10.11.5921; LUDWIG B, 1987, FEMS MICROBIOL LETT, V46, P41, DOI 10.1111/j.1574-6968.1987.tb02451.x; LUSTIG A, 1982, BIOCHEMISTRY-US, V21, P309, DOI 10.1021/bi00531a017; MARUSICH MF, 1988, J IMMUNOL METHODS, V114, P155, DOI 10.1016/0022-1759(88)90167-6; MESSING J, 1983, METHOD ENZYMOL, V101, P20; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; PATTERSON TE, 1986, J BIOL CHEM, V261, P7192; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POWER SD, 1984, J BIOL CHEM, V259, P6564; POYTON RO, 1988, ANN NY ACAD SCI, V550, P289, DOI 10.1111/j.1749-6632.1988.tb35344.x; REIMANN A, 1992, FEBS LETT, V307, P294, DOI 10.1016/0014-5793(92)80698-G; ROBERTS H, 1977, BIOCHIM BIOPHYS ACTA, V462, P215, DOI 10.1016/0005-2728(77)90204-3; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; Rothstein R., 1985, DNA CLONING, VII, P45; Sambrook J, 1989, MOL CLONING LABORATO; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SHERMAN F, 1986, LABORATORY COURSE MA; SMITH EO, 1993, IN PRESS BIOCH BIOPH; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAANMAN JW, 1992, J BIOL CHEM, V267, P22481; TAANMAN JW, 1992, BIOCHIM BIOPHYS ACTA, V1139, P155, DOI 10.1016/0925-4439(92)90095-5; TAUTZ D, 1983, ANAL BIOCHEM, V132, P14, DOI 10.1016/0003-2697(83)90419-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANGELDER BF, 1966, BIOCHIM BIOPHYS ACTA, V118, P36, DOI 10.1016/S0926-6593(66)80142-X; VANKUILENBURG ABP, 1991, EUR J BIOCHEM, V199, P615; WEISHAUPT A, 1992, BIOCHEMISTRY-US, V31, P11477, DOI 10.1021/bi00161a028; YANAMURA W, 1988, BIOCHEMISTRY-US, V27, P4909, DOI 10.1021/bi00413a048; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YONETANI T, 1965, J BIOL CHEM, V240, P4509; ZHANG YZ, 1988, BIOCHEMISTRY-US, V27, P1389, DOI 10.1021/bi00404a045; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	69	68	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18754	18761						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8395517				2022-12-25	WOS:A1993LV65900061
J	KABURAGI, Y; MOMOMURA, K; YAMAMOTOHONDA, R; TOBE, K; TAMORI, Y; SAKURA, H; AKANUMA, Y; YAZAKI, Y; KADOWAKI, T				KABURAGI, Y; MOMOMURA, K; YAMAMOTOHONDA, R; TOBE, K; TAMORI, Y; SAKURA, H; AKANUMA, Y; YAZAKI, Y; KADOWAKI, T			SITE-DIRECTED MUTAGENESIS OF THE JUXTAMEMBRANE DOMAIN OF THE HUMAN INSULIN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; INDUCED TYROSINE-PHOSPHORYLATION; KINASE-ACTIVITY; PROTEIN-KINASE; MAP KINASE; MEDIATED INTERNALIZATION; SIGNAL TRANSDUCTION; MOLECULAR MECHANISM; SWISS 3T3-CELLS	We have studied the functions of the juxtamembrane domain (941-989) of the human insulin receptor by site-directed mutagenesis. Tyrosine phosphorylation of pp185 was impaired in Chinese hamster ovary cells expressing the receptors with the alteration of Tyr960, but not of Tyr953 or Tyr972, to Phe (CHO-Y960F cells) as compared with cells expressing the normal receptors. In CHO-Y960F cells, tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1), the activation of phosphatidylinositol 3-kinase in the anti-phosphotyrosine and anti-IRS-1 immunoprecipitates, the activation of mitogen-activated protein (MAP) kinase, and biological actions were also impaired. In addition, although the deletion of residues 954-965 severely impaired insulin internalization, the deletion of NPXY (957-960), the internalization signal of the low density lipoprotein receptor, did not affect internalization. Moreover, neither the deletions around Tyr953 nor the alterations of the tyrosines (953, 960, or 972) significantly reduced internalization. These data suggest that: 1) Tyr960 is important for the recognition of pp185/IRS-1, the association of phosphatidylinositol 3-kinase with pp185/IRS-1, and the activation of MAP kinase; 2) MAP kinase may lie downstream of pp185/IRS-1 in insulin's signal transduction; and 3) the juxtamembrane domain, but not NPXY or individual tyrosines, is important for insulin internalization.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN; ASAHI LIFE FDN,INST DIABET CARE & RES,CHIYODA KU,TOKYO 100,JAPAN	University of Tokyo; Asahi Life Foundation								AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1990, J BIOL CHEM, V265, P11495; ANDO A, 1992, J BIOL CHEM, V267, P12788; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BERHANU P, 1991, MOL ENDOCRINOL, V5, P1827, DOI 10.1210/mend-5-12-1827; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CZECH MP, 1988, J BIOL CHEM, V263, P11017; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; EXTON JH, 1991, DIABETES, V40, P521, DOI 10.2337/diabetes.40.5.521; FEENER EP, 1992, DIABETES S1, V41, P167; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; KADOWAKI H, 1989, GENE, V76, P161, DOI 10.1016/0378-1119(89)90018-8; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P769, DOI 10.1210/mend-5-6-769; KASUGA M, 1990, DIABETES CARE, V13, P317, DOI 10.2337/diacare.13.3.317; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KIDA Y, 1990, J CLIN INVEST, V85, P476, DOI 10.1172/JCI114462; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PUCK TT, 1958, J EXP MED, V108, P945, DOI 10.1084/jem.108.6.945; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; RUSSEL LDS, 1987, J BIOL CHEM, V262, P11833; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; THIES RS, 1990, J BIOL CHEM, V265, P10132; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOBE K, 1992, J BIOL CHEM, V267, P21089; TOBE K, 1991, J BIOL CHEM, V266, P24793; TOBE K, 1990, DIABETES, V39, P528, DOI 10.2337/diabetes.39.5.528; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMAMOTOHONDA R, 1990, J BIOL CHEM, V265, P14777; YONEZAWA K, 1992, J BIOL CHEM, V267, P440	58	88	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16610	16622						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8393870				2022-12-25	WOS:A1993LQ33600077
J	YOSHIMURA, T; YUHKI, N; WANG, MH; SKEEL, A; LEONARD, EJ				YOSHIMURA, T; YUHKI, N; WANG, MH; SKEEL, A; LEONARD, EJ			CLONING, SEQUENCING, AND EXPRESSION OF HUMAN MACROPHAGE STIMULATING PROTEIN (MSP, MST1) CONFIRMS MSP AS A MEMBER OF THE FAMILY OF KRINGLE PROTEINS AND LOCATES THE MSP GENE ON CHROMOSOME-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; CELL CARCINOMA; SHORT ARM; LOCUS	A human hepatoma (HepG2) cell line library was screened with an oligonucleotide probe for macrophage stimulating protein (MSP) to clone an MSP cDNA. Deduced sequences of isolated clones were compared with peptide fragment sequences of MSP. MSP9 cDNA encoded most of the known sequence of MSP except for a small segment of the 5' end of the open reading frame. Consequently, a hybrid 2300-base pair cDNA that encoded the complete MSP amino acid sequence was constructed from 2 clones. Culture fluid from COS-7 cells transfected with this full-length MSP cDNA had MSP biological activity, and the expressed MSP was detected by immunoprecipitation with antibody against native MSP. The deduced amino acid sequence of MSP includes 4 kringle domains, which have been found in hepatocyte growth factor and several proteins of the blood coagulation system. Among them, MSP has the highest sequence similarity to hepatocyte growth factor (45% identity). The MSP cDNA hybridized strongly to mRNA from liver, and to a lesser extent to mRNA from kidney and pancreas, suggesting that a cell type in the liver is the source of MSP. Several cloned and sequenced MSP cDNAs had insertions or deletions, suggesting that alternatively spliced MSP mRNAs may occur. This was reflected in Northern blots probed with an MSP cDNA, which showed more than one mRNA species. Furthermore, although the gene coding for MSP is on chromosome 3, the sequence of one of the cDNAs was identical with a unique sequence in chromosome 1, indicating that there may be a family of MSP genes, located on chromosomes 3 and 1.	NCI,FREDERICK CANC RES & DEV CTR,GENET SECT,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	YOSHIMURA, T (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,IMMUNOPATHOL SECT,IMMUNOBIOL LAB,BLDG 560,RM 12-46,FREDERICK,MD 21702, USA.							ANDREADIS A, 1987, ANNU REV CELL BIOL, V3, P207, DOI 10.1146/annurev.cellbio.3.1.207; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; CARRITT B, 1986, AM J HUM GENET, V38, P428; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; LEONARD EJ, 1978, EXP CELL RES, V114, P117, DOI 10.1016/0014-4827(78)90043-5; LEONARD EJ, 1991, CURRENNT PROTOCOLS I; MAGNUSSON S, 1975, PROTEASES BIOL CONTR, P123; Maniatis T., 1982, MOL CLONING; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; PARK CH, 1986, BIOCHEMISTRY-US, V25, P3977, DOI 10.1021/bi00362a001; SANGER F, 1977, P NATL ACAD SCI USA, V74, P54; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P75; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; WELCH HM, 1989, GENOMICS, V5, P423, DOI 10.1016/0888-7543(89)90005-0; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	20	172	194	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15461	15468						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8393443				2022-12-25	WOS:A1993LN30500024
J	DANDREA, P; ZACCHETTI, D; MELDOLESI, J; GROHOVAZ, F				DANDREA, P; ZACCHETTI, D; MELDOLESI, J; GROHOVAZ, F			MECHANISM OF [CA2+]I OSCILLATIONS IN RAT CHROMAFFIN CELLS - COMPLEX CA2+-DEPENDENT REGULATION OF A RYANODINE-INSENSITIVE OSCILLATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM STORES; PAROTID ACINAR-CELLS; INOSITOL-TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; INTRACELLULAR CALCIUM; XENOPUS OOCYTES; CA-2+ STORE; POOL MODEL; RELEASE; THAPSIGARGIN	In the population of primary cultured rat chromaffin cells, over half exhibited spontaneous [Ca2+]i oscillations, whereas most others were induced to oscillate by low concentrations of bradykinin or KCl. [Ca2+]i spots were observed to pulsate in a defined cytoplasmic area (the oscillator). In silent cells those spots remained discrete, whereas in oscillating cells the [Ca2+]i increase expanded to occupy the entire cytoplasm. Alternation of these discrete and expanded events was observed in a few irregularly oscillating cells. Thapsigargin induced prompt blockade of both pulsations and oscillations and prevented recruitment of silent cells to oscillate. This indicates sarcoendoplasmic reticulum Ca2+-ATPase-type Ca2+ pump(s) to be crucial for the functioning of the oscillator. Effects of other treatments were variable, depending on the concomitant [Ca2+]i changes. Oscillations were blocked when EGTA or nitrendipine decreased Ca2+ influx and thus [Ca2+]i; they were also blocked when [Ca2+]i was markedly increased by excess KCl, bradykinin, or ryanodine. When in contrast the [Ca2+]i increases induced by the latter agents remained moderate, oscillations were stimulated. The rhythmic activity of rat chromaffin cells appears, therefore, to operate under a complex regulation that requires [Ca2+]i within an appropriate operative range and does not involve directly the ryanodine receptor but might rely on the activation of IP3 receptors.	UNIV MILAN,S RAFFAELE INST,CNR,CTR CYTOPHARMACOL,DEPT PHARMACOL,I-20132 MILAN,ITALY; UNIV MILAN,S RAFFAELE INST,BRUNO CECCARELLI CTR PERIPHERAL NEUROPATHIES,I-20132 MILAN,ITALY; UNIV MILAN,S RAFFAELE INST,DEPT BIOL & TECHNOL RES,I-20132 MILAN,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Milan; University of Milan; University of Milan			Zacchetti, Daniele/AAC-2724-2022; Grohovaz, Fabio/K-8226-2016	Zacchetti, Daniele/0000-0003-2724-7559; Grohovaz, Fabio/0000-0003-4635-259X				Berridge Michael J., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P211; BERRIDGE MJ, 1991, P ROY SOC B-BIOL SCI, V244, P57, DOI 10.1098/rspb.1991.0051; BERRIDGE MJ, 1991, CELL CALCIUM, V12, P63, DOI 10.1016/0143-4160(91)90009-4; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BRANDT BL, 1976, J PHYSIOL-LONDON, V263, P417, DOI 10.1113/jphysiol.1976.sp011638; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; BUTCHER RW, 1962, J BIOL CHEM, V237, P1244; CHEEK TR, 1990, FEBS LETT, V266, P91, DOI 10.1016/0014-5793(90)81514-O; CLEMENTI E, 1992, J BIOL CHEM, V267, P2164; CUTHBERTSON KSR, 1991, CELL CALCIUM, V12, P97, DOI 10.1016/0143-4160(91)90012-4; DELISLE S, 1992, J BIOL CHEM, V267, P7963; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; Ferris Christopher D., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P95; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FOSKETT JK, 1991, J BIOL CHEM, V266, P14535; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; FRIEL DD, 1992, NEURON, V8, P1109, DOI 10.1016/0896-6273(92)90132-W; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; GROHOVAZ F, 1991, J CELL BIOL, V133, P1331; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1988, BIOCHEM BIOPH RES CO, V152, P417, DOI 10.1016/S0006-291X(88)80730-7; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MALGAROLI A, 1991, FEBS LETT, V283, P169, DOI 10.1016/0014-5793(91)80580-V; MARTINEZSERRANO A, 1989, BIOCHEM BIOPH RES CO, V161, P965, DOI 10.1016/0006-291X(89)91337-5; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; Meldolesi Jacopo, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P187; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PARKER I, 1991, J PHYSIOL-LONDON, V433, P229, DOI 10.1113/jphysiol.1991.sp018423; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; PRENTKI M, 1988, J BIOL CHEM, V263, P11044; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; ROUSSEAU E, 1987, AM J PHYSIOL, V253, P364; SMITH JS, 1985, NATURE, V316, P446, DOI 10.1038/316446a0; SOMOGYI R, 1991, J BIOL CHEM, V266, P11068; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THAYER SA, 1988, MOL PHARMACOL, V34, P664; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; WALTON PD, 1991, J CELL BIOL, V113, P1145, DOI 10.1083/jcb.113.5.1145; ZACCHETTI D, 1991, J BIOL CHEM, V266, P20152	48	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15213	15220						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8392069				2022-12-25	WOS:A1993LL75900097
J	BLOSTEIN, R; ZHANG, RP; GOTTARDI, CJ; CAPLAN, MJ				BLOSTEIN, R; ZHANG, RP; GOTTARDI, CJ; CAPLAN, MJ			FUNCTIONAL-PROPERTIES OF AN H,K-ATPASE/NA,K-ATPASE CHIMERA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN ALTERS; NA+-K+-ATPASE; BETA-SUBUNIT; XENOPUS OOCYTES; ALPHA-SUBUNIT; NA,K-ATPASE; H+,K+-ATPASE; SUBSTITUTES; H,K-ATPASE; EXPRESSION	Cultured pig kidney epithelial cells were transfected with a chimeric P-type ATPase catalytic subunit composed of the NH2-terminal half of the rat gastric H,K-ATPase and the COOH-terminal half of the rat Na,K-ATPase (alpha1 isoform). Low concentrations of ouabain (less-than-or-equal-to 0.2 mM) were used to inhibit completely the endogenous pig Na,K-ATPase and high concentrations (5 mm) to test the sensitivity of the chimeric rodent pump. In the presence of a low concentration of ouabain, a small but significant inhibition of residual Rb+(K+) influx by 5 mm ouabain was observed in only the transfected cells. Conditions were found in which a similar component of Rb+ influx was inhibited by the gastric H,K-ATPase inhibitor SCH28080, consistent with SCH28080 binding to the extracellular H1-H2 loop of this enzyme. These experiments demonstate that this chimera behaves as a functional ion pump and indicate that the protein domains involved in cardiac glycoside binding are not confined to the amino-terminal half of the Na,K-ATPase.	YALE UNIV, SCH MED, DEPT CELL & MOLEC PHYSIOL, NEW HAVEN, CT 06510 USA; MCGILL UNIV, DEPT BIOCHEM, MONTREAL H3A 2T5, QUEBEC, CANADA	Yale University; McGill University	BLOSTEIN, R (corresponding author), MCGILL UNIV, DEPT MED, MONTREAL H3G 1A4, PQ, CANADA.		Gottardi, Cara J./AAU-4691-2021	Gottardi, Cara J./0000-0003-0912-7617; Caplan, Michael/0000-0001-5768-4405	NIGMS NIH HHS [GM42136] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042136] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; BAMBERG K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P69, DOI 10.1016/0167-4781(92)90100-E; BESANCON M, 1992, ACTA PHYSIOL SCAND, V146, P77; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; CANESSA CM, 1992, EMBO J, V11, P1681, DOI 10.1002/j.1460-2075.1992.tb05218.x; CANFIELD VA, 1990, J BIOL CHEM, V265, P19878; CROWSON MS, 1992, J BIOL CHEM, V267, P13740; EMANUEL JR, 1989, MOL CELL BIOL, V9, P3744, DOI 10.1128/MCB.9.9.3744; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; GOTTARDI CJ, 1993, IN PRESS J CELL BIOL; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LUCKIE DB, 1992, BIOPHYS J, V62, P220, DOI 10.1016/S0006-3495(92)81807-6; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; NOGUCHI S, 1988, BIOCHEM BIOPH RES CO, V155, P1237, DOI 10.1016/S0006-291X(88)81272-5; NOGUCHI S, 1990, BIOCHIM BIOPHYS ACTA, V1023, P247, DOI 10.1016/0005-2736(90)90420-S; PERRONE RD, 1988, AM J PHYSIOL, V254, pG898, DOI 10.1152/ajpgi.1988.254.6.G898; PIETRINI G, 1992, P NATL ACAD SCI USA, V89, P8414, DOI 10.1073/pnas.89.18.8414; POLVANI C, 1988, J BIOL CHEM, V263, P16757; POLVANI C, 1989, J BIOL CHEM, V264, P17854; PUDDINGTON L, 1987, P NATL ACAD SCI USA, V84, P2756; ROSSI B, 1988, METHOD ENZYMOL, V156, P323; SACHS G, 1991, Current Opinion in Cell Biology, V3, P685, DOI 10.1016/0955-0674(91)90042-W; SUZUKI Y, 1989, AM J PHYSIOL, V256, pG979, DOI 10.1152/ajpgi.1989.256.6.G979; WALLMARK B, 1980, J BIOL CHEM, V255, P5313; WALLMARK B, 1987, J BIOL CHEM, V262, P2077	26	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10654	10658						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8387526				2022-12-25	WOS:A1993LB80000096
J	BACKER, JM; MYERS, MG; SUN, XJ; CHIN, DJ; SHOELSON, SE; MIRALPEIX, M; WHITE, MF				BACKER, JM; MYERS, MG; SUN, XJ; CHIN, DJ; SHOELSON, SE; MIRALPEIX, M; WHITE, MF			ASSOCIATION OF IRS-1 WITH THE INSULIN-RECEPTOR AND THE PHOSPHATIDYLINOSITOL 3'-KINASE - FORMATION OF BINARY AND TERNARY SIGNALING COMPLEXES IN INTACT-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; PDGF RECEPTOR; BINDING SITE; BETA-SUBUNIT; PROTEIN; PHOSPHORYLATION; PURIFICATION; SUBSTRATE; 3-KINASE; TRANSDUCTION	Insulin stimulates the formation of binary and ternary signaling complexes between the phosphatidylinositol (PtdIns) 3'-kinase, IRS-1, and the insulin receptor in vivo. Binary complex formation between IRS-1 and the PtdIns 3'-kinase occurs in intact cells and requires the tyrosyl phosphorylation IRS-1, as mutant insulin receptors which weakly phosphorylate IRS-1 in vivo do not mediate formation of IRS-1/PtdIns 3'-kinase complexes in transfected CHO cells. Association with IRS-1 involves as much as 70% of total cellular PtdIns 3'-kinase activity. Insulin also stimulates the formation of ternary signaling complexes, as both IRS-1 and the PtdIns 3'-kinase are present in anti-insulin receptor immunoprecipitates from insulin-stimulated cells. Overexpression of IRS-1 in CHO cells increases the amount of PtdIns 3'-kinase activity in alphaIR immunoprecipitates, and IRS-1 markedly increases the in vitro binding of p85alpha and PtdIns 3-kinase activity to anti-receptor immunoprecipitates. The mechanism for this association is unknown, but appears to involve the binding of IRS-1/PtdIns 3'-kinase complexes to the insulin receptor. The formation of binary and ternary complexes between the insulin receptor, IRS-1 and the PtdIns 3'-kinase may play a critical role in transmission of the insulin signal.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,JOSLIN DIABET CTR,SCH MED,DEPT MED,DIV RES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038712, R29DK038712, R55DK038712, R01DK043808, P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 36836, DK-43808, DK-38712] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1991, BIOCHEMISTRY-US, V30, P6366, DOI 10.1021/bi00240a003; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHOU CK, 1987, J BIOL CHEM, V262, P1842; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; HERRERA R, 1988, J BIOL CHEM, V263, P5560; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MIRALPEIX M, 1992, BIOCHEMISTRY-US, V31, P9031, DOI 10.1021/bi00152a046; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PERLMAN R, 1989, J BIOL CHEM, V264, P8946; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1991, ENZYMES, V201, P65; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; YAMAMOTO K, 1992, J BIOL CHEM, V267, P11337; YONEZAWA K, 1992, J BIOL CHEM, V267, P440	40	161	161	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8204	8212						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8385139				2022-12-25	WOS:A1993KW97900090
J	MAROC, N; ROTTAPEL, R; ROSNET, O; MARCHETTO, S; LAVEZZI, C; MANNONI, P; BIRNBAUM, D; DUBREUIL, P				MAROC, N; ROTTAPEL, R; ROSNET, O; MARCHETTO, S; LAVEZZI, C; MANNONI, P; BIRNBAUM, D; DUBREUIL, P			BIOCHEMICAL-CHARACTERIZATION AND ANALYSIS OF THE TRANSFORMING POTENTIAL OF THE FLT3/FLK2 RECEPTOR TYROSINE KINASE	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; C-KIT RECEPTOR; GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTOR; FMS PROTO-ONCOGENE; W-MUTANT MICE; SIGNAL TRANSDUCTION; MOUSE DEVELOPMENT; PROGENITOR CELLS; BONE-MARROW	We recently cloned an additional member of the receptor type tyrosine kinase class III. This new gene, called Flt3 by our group [Rosnet, O., Mattei, M.G., Marchetto, S. & Birnbaum, D. (1991). Genomics, 9, 380-385; Rosnet, O., Marchetto, S., deLapeyriere, 0. & Birnbaum, D. (1991). Oncogene, 6, 1641-16501 and Flk2 by others [Matthews, W., Jordan, C.T., Wieg, G.W., Pardoll, D. & Lemischka, I.R. (1991). Cell, 65, 1143-11521 is strongly related to the important developmental genes Kit, Fms and Pdgfr. The murine 3.2-kb full-length cDNA, when introduced into COS-1 cells, shows the expression of two polypeptides with apparent molecular weights of 155 kDa and 132 kDa. Treatment of cells with N-linked glycosylation inhibitors results in the expression of a 110-kDa protein. We have shown that FLT3 contains an intrinsic tyrosine kinase activity. A point mutation in a highly conserved residue within the phosphoryltransferase domain inactivates the catalytic function of this receptor, whereas activation by way of a chimeric molecule between the ligand-binding domain of colony-stimulating factor type 1 (CSF-1) receptor (CSF-1R) and the kinase domain of FLT3 results, in the presence of CSF-1, in the development of the transforming activity of this receptor as shown by anchorage-independent cell growth. Finally, expression analysis of the FLT3 protein shows that, in addition to the hematopoietic system, FLT3 is strongly expressed in neural, gonadal, hepatic and placental tissues in the mouse.	INSERM, UNITE 119, MOLEC ONCOL LAB, 27 BD ROURE, F-13009 MARSEILLE, FRANCE; INSERM, UNITE 119, MOLEC HEMATOL LAB, F-13009 MARSEILLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)			Dubreuil, Patrice/V-4816-2019; Rosnet, Olivier/G-3536-2013; dubreuil, patrice/F-5346-2011	Dubreuil, Patrice/0000-0003-1155-1150; dubreuil, patrice/0000-0003-1155-1150; Maroc, Nicolas/0000-0001-7285-509X; Rottapel, Robert/0000-0002-6024-5558; Rosnet, Olivier/0000-0002-3020-910X				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BIRG F, 1903, IN PRESS BLOOD; BROXMEYER HE, 1991, CANCER CELL-MON REV, V3, P480; CAO Y, 1990, Technique (Philadelphia), V2, P109; CAROW CE, 1991, BLOOD, V78, P2216, DOI 10.1182/blood.V78.9.2216.bloodjournal7892216; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; DANIEL TO, 1987, J BIOL CHEM, V262, P9778; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LEV S, 1990, MOL CELL BIOL, V10, P6064, DOI 10.1128/MCB.10.11.6064; LINNEKIN D, 1990, BIOCHEM J, V271, P317, DOI 10.1042/bj2710317; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; METCALF D, 1991, P NATL ACAD SCI USA, V88, P6239, DOI 10.1073/pnas.88.14.6239; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MORAN MF, 1988, ONCOGENE, V3, P665; MOTRO B, 1991, DEVELOPMENT, V113, P1207; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; OHTSUKA M, 1990, MOL CELL BIOL, V10, P1664, DOI 10.1128/MCB.10.4.1664; PAPAYANNOPOULOU T, 1991, BLOOD, V78, P1403; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; QUELLE FW, 1991, J BIOL CHEM, V266, P609; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1993, IN PRESS ONCOGENE; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; ROHRSCHNEIDER LR, 1989, ONCOGENE, V4, P1015; ROSNET O, 1991, ONCOGENE, V6, P1641; ROSNET O, 1991, GENOMICS, V9, P380, DOI 10.1016/0888-7543(91)90270-O; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; ROUSSEL MF, 1990, MOL CELL BIOL, V10, P2407, DOI 10.1128/MCB.10.5.2407; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SHERR CJ, 1990, BLOOD, V75, P1; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SORRENTINO V, 1991, ONCOGENE, V6, P149; STANLEY ER, 1980, MONONUCLEAR PHAGOC 1, P415; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; TSUJI K, 1991, BLOOD, V78, P1223; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VU TH, 1989, MOL CELL BIOL, V9, P4563, DOI 10.1128/MCB.9.10.4563; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	59	91	98	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1993	8	4					909	918						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8384358				2022-12-25	WOS:A1993KT22000012
J	DATTI, A; DENNIS, JW				DATTI, A; DENNIS, JW			REGULATION OF UDP-GLCNACGAL-BETA-1-3GALNAC-R-BETA-1-6-N-ACETYLGLUCOSAMINYLTRANSFERASE(GLCNAC TO GALNAC) IN CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; WISKOTT-ALDRICH SYNDROME; LINKED SUGAR CHAINS; CYCLIC-AMP; TRANSIENT EXPRESSION; SODIUM-BUTYRATE; GLYCOSYLATION; ACTIVATION; PHOSPHORYLATION; BIOSYNTHESIS	UDP-GlcNAc:Galbeta3GalNAc-R (GcNAc to GalNAc) beta1-6-N-acetylglucosaminyltransferase (i.e. core 2 GlcNAc-T) of the O-linked oligosaccharide pathway is developmentally regulated in human T cells, and changes in its activity have been associated with malignancies and the Wiskott-Aldrich immunodeficiency syndrome. Chinese hamster ovary (CHO) cells normally express low levels of core 2 GlcNAc-T activity (8-12 pmol/mg/h) which can be accurately measured with a two-step assay employing purified bovine beta1-4Gal-T and high specific activity UDP-[H-3]Gal to radiolabel the core 2 reaction product. CHO cells treated with 2 mM sodium butyrate for 24 h exhibited a 16-fold increase in core 2 GlcNAc-T activity, whereas several other differentiating agents including dimethyl sulfoxide, retinoic acid, phorbol ester, and cholera toxin had no effect on activity. The addition of butyrate, cholera toxin, or dimethyl sulfoxide to CHO cells slowed cell proliferation and induced changes in cell morphology characteristic of cell differentiation. Induction of core 2 GlcNAc-T by butyrate was blocked by actinomycin D and cycloheximide. Butyrate treatment also elevated cytosolic cAMP levels with a time course which paralleled, but preceded, induction of core 2 GlcNAc-T activity by approximately 8 h. The protein kinase inhibitors H-7 and H-8 blocked butyrate-dependent induction of enzyme activity, whereas the inactive analogue H1004 had no effect. Core 2 GlcNAc-T showed a change in K(m) for UDP-GlcNAc, from 0.50 mM in untreated cells to 4.54 mM in butyrate + cholera toxin treated CHO cells, but no changes in K(m) for the synthetic acceptor, Galbeta1-3GalNAcalpha-paranitrophenyl. Despite the 9-fold increase in K(m) for sugar nucleotide, V(max)/K(m) was 8.8-fold greater in treated compared with untreated cells. These observations suggest that in CHO cells induction of core 2 GlcNAc-T by butyrate treatment requires de novo gene transcription/translation, activation of protein kinase(s), and is associated with changes in the kinetic properties of the enzyme.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,DEPT MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Dennis, James/E-7268-2013; Datti, Alessandro/ABA-1108-2021	Datti, Alessandro/0000-0001-6824-7382				BANERJEE DK, 1987, P NATL ACAD SCI USA, V84, P6389, DOI 10.1073/pnas.84.18.6389; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BOFFA LC, 1981, J BIOL CHEM, V256, P9612; BROCKHAUSEN I, 1991, CANCER RES, V51, P1257; BUNNELL BA, 1990, BIOCHEM BIOPH RES CO, V171, P196, DOI 10.1016/0006-291X(90)91376-4; BURNS LJ, 1988, BLOOD, V72, P1536; CUMMING D A, 1991, Glycobiology, V1, P115, DOI 10.1093/glycob/1.2.115; DANNA JA, 1980, BIOCHEMISTRY-US, V19, P2656, DOI 10.1021/bi00553a019; DATTI A, 1992, ANAL BIOCHEM, V206, P262, DOI 10.1016/0003-2697(92)90364-D; DEKORTE D, 1987, CANCER RES, V47, P1841; FLEISCHMANN RD, 1992, SOMAT CELL MOLEC GEN, V18, P103, DOI 10.1007/BF01233157; FURUKAWA K, 1990, INT IMMUNOL, V2, P105, DOI 10.1093/intimm/2.1.105; HEFFERNAN M, 1993, J BIOL CHEM, V268, P1242; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HIGGINS EA, 1991, J BIOL CHEM, V266, P6280; HSIEH P, 1983, J BIOL CHEM, V258, P2548; KAGAWA Y, 1988, J BIOL CHEM, V263, P17508; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LI AP, 1977, ARCH BIOCHEM BIOPHYS, V182, P181, DOI 10.1016/0003-9861(77)90297-1; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MILHAUD P, 1980, J CELL PHYSIOL, V104, P163, DOI 10.1002/jcp.1041040205; NIELSON SE, 1980, P NATL ACAD SCI-BIOL, V77, P985, DOI 10.1073/pnas.77.2.985; OSHIMA T, 1991, J BIOL CHEM, V266, P13621; PAREKH RB, 1987, EMBO J, V6, P1233, DOI 10.1002/j.1460-2075.1987.tb02359.x; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; PILLER F, 1991, J EXP MED, V173, P1501, DOI 10.1084/jem.173.6.1501; PILLER F, 1988, J BIOL CHEM, V263, P15146; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; SCHACHTER H, 1971, J BIOL CHEM, V246, P5321; SCHROTER H, 1981, EUR J BIOCHEM, V120, P21, DOI 10.1111/j.1432-1033.1981.tb05664.x; SHAH S, 1992, J BIOL CHEM, V267, P10652; SHARMA C, 1988, BIOCHEM BIOPH RES CO, V155, P615, DOI 10.1016/S0006-291X(88)80539-4; SHEARES BT, 1986, P NATL ACAD SCI USA, V83, P1993, DOI 10.1073/pnas.83.7.1993; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; STORRIE B, 1978, J CELL PHYSIOL, V94, P69, DOI 10.1002/jcp.1040940109; TAKEUCHI M, 1988, J BIOL CHEM, V263, P3657; WANG X, 1990, Glycobiology, V1, P25, DOI 10.1093/glycob/1.1.25; WANG XC, 1989, J BIOL CHEM, V264, P1854; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772	40	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5409	5416						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8383671				2022-12-25	WOS:A1993KR82200013
J	JACKSON, P; BOS, E; BRAITHWAITE, AW				JACKSON, P; BOS, E; BRAITHWAITE, AW			WILD-TYPE MOUSE-P53 DOWN-REGULATES TRANSCRIPTION FROM DIFFERENT VIRUS ENHANCER PROMOTERS	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; CELL NUCLEAR ANTIGEN; P53 GENE-MUTATIONS; LARGE T-ANTIGEN; TUMOR-ANTIGEN; CHLORAMPHENICOL ACETYLTRANSFERASE; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; EUKARYOTIC CELLS; DNA-REPLICATION	The protein encoded by the tumour-suppressor gene p53 can complex with SV40 virus large T antigen, the adenovirus E1B 58-kDa protein and the E6 protein of human papillomavirus type 16. The functions of these complexes are unclear, but there is some evidence to suggest that binding of p53 to these viral proteins may inactivate p53 function. Recent reports have shown that p53 is involved in regulation of transcription. We have considered the possibility that p53 may regulate transcription of viral genes important for virus replication and/or transformation. Inactivation of p53 function by formation of such complexes might then permit correct expression of these viral genes. Since p53 can bind to the SV40 virus enhancer/promoter, we have investigated the effect of p53 on transcription from this promoter and report here that mouse p53 is a potent repressor of the SV40 enhancer/promoter. Mutations within p53 severely inhibited this activity and provided some evidence to show that the N-terminus of p53 contains residues essential for this function. We also show that mouse p53 represses transcription from the promoters of viruses that do not express proteins that complex with p53: the human cytomegalovirus early promoter and the Rous sarcoma virus long terminal repeat. By studying the effect of p53 on transcription in different cell lines, we show that the effects of p53 on promoters may be cell type specific.			JACKSON, P (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV CELL BIOL,CELL TRANSFORMAT GRP,GPO BOX 334,CANBERRA,ACT 2601,AUSTRALIA.							BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; BRAITHWAITE AW, 1991, ONCOGENE, V6, P781; BRAITHWAITE AW, 1991, NEW BIOL, V3, P18; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN YM, 1991, ONCOGENE, V6, P1799; CHENG J, 1992, CANCER RES, V52, P222; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; ISAACS WB, 1991, CANCER RES, V51, P4716; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1988, ONCOGENE HDB, P403; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MERCER WF, 1990, J CELL BIOCHEM, V14, P285; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OHASHI Y, 1992, BIOCHIM BIOPHYS ACTA, V1130, P175, DOI 10.1016/0167-4781(92)90525-5; OROURKE RW, 1990, ONCOGENE, V5, P1829; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Sambrook J, 1989, MOL CLONING LABORATO; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; STURZBECHER HW, 1988, ONCOGENE, V3, P405; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TKAHASHI T, 1991, ONCOGENE, V6, P1775; TRAVALI S, 1989, J BIOL CHEM, V264, P7466; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; ZHANG XL, 1990, VIROLOGY, V180, P199	58	56	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					589	597						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8382357				2022-12-25	WOS:A1993KN00800009
J	AJCHENBAUM, F; ANDO, K; DECAPRIO, JA; GRIFFIN, JD				AJCHENBAUM, F; ANDO, K; DECAPRIO, JA; GRIFFIN, JD			INDEPENDENT REGULATION OF HUMAN D-TYPE CYCLIN GENE-EXPRESSION DURING G1-PHASE IN PRIMARY HUMAN LYMPHOCYTES-T	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; CDC2 PROTEIN-KINASE; CELL-CYCLE; MESSENGER-RNA; ACTIVATION; PRODUCT; YEAST; PROLIFERATION; PHOSPHORYLATION; PROGRESSION	Cyclins and cyclin-dependent kinases are critically involved in controlling cell cycle progression in virtually all cells. The recent identification of candidate G1 cyclins in mammalian cells has been a major advance in this field, but the exact functions of these cyclins are unknown. The expression of three D-type cyclins (D1, D2, and D3) was investigated in primary human T lymphocytes as these cells were induced to leave G0, traverse G1, and enter S phase by T cell-specific mitogens. G0 phase T cells expressed low levels of cyclin D2, but not cyclin D3. Treatment of these cells with phytohemagglutinin and 12-O-tetradecanoylphorbol-13-acetate in the presence of fetal calf serum resulted in rapid induction of cyclin D2 RNA in early G1 and slower induction of cyclin D3 in late G1. Cyclin D1 was not detected in T cells under any condition tested. Treatment of T cells with hydroxyurea to arrest cells at G1/S did not block induction of either D2 or D3. However, arrest of cells in mid G1 with deferoxamine blocked D3 expression without affecting D2. Cyclosporin A blocked the induction of both cyclin D2 and D3. Polyclonal antisera were prepared in rabbits against both cyclin D2 and cyclin D3 glutathione S-transferase fusion proteins and used to examine cyclin D2 and D3 proteins in [S-35]methionine-labeled T cells. Protein levels were found to correlate closely with RNA levels for both cyclins. No detectable histone HI kinase activity could be precipitated with either cyclin. However, several cellular proteins were observed to coprecipitate with the cyclins, including several proteins that were observed to associate only with D3. These results indicate that striking differences exist in the induction and regulation of two candidate G1 cyclins in human T cells and suggest that these cyclins could participate in multiple cell cycle check-points during G0, G1, or S phase.	HARVARD UNIV, SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL, 44 BINNEY ST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV NEOPLAST DIS MECHANISMS, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School								ADAMS RLP, 1967, J BIOL CHEM, V242, P1314; BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; JUNE CH, 1989, J IMMUNOL, V143, P153; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KUMAGAI N, 1988, J IMMUNOL, V140, P37; LEDERMAN HM, 1984, BLOOD, V64, P748; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LYN B, 1991, EMBO J, V10, P857; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1991, COLD SPRING HARB SYM, V56, P449; PINES J, 1990, New Biologist, V2, P389; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROSENTHAL ET, 1980, CELL, V20, P487, DOI 10.1016/0092-8674(80)90635-2; SHIPP MA, 1987, J IMMUNOL, V139, P2143; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; TERADA N, 1991, J IMMUNOL, V147, P698; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	41	263	271	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4113	4119						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8382693				2022-12-25	WOS:A1993KN53300049
J	BRANDES, HK; LARIMER, FW; GECK, MK; STRINGER, CD; SCHURMANN, P; HARTMAN, FC				BRANDES, HK; LARIMER, FW; GECK, MK; STRINGER, CD; SCHURMANN, P; HARTMAN, FC			DIRECT IDENTIFICATION OF THE PRIMARY NUCLEOPHILE OF THIOREDOXIN-F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI; CHLOROPLAST FRUCTOSE-1,6-BISPHOSPHATASE; SPINACH-CHLOROPLASTS; REDUCED FORM; PURIFICATION; MUTAGENESIS; ENZYME; ACTIVATION	Thioredoxin, by virtue of the proximal active-site sulfhydryls (Trp-Cys-Gly-Pro-Cys), catalyzes thiol-disulfide exchange with specific target enzymes. Considerable data (chemical modification, spectroscopic, and crystallographic) have implicated the cysteinyl residue nearest the N terminus of thioredoxin as the primary nucleophile; however, direct proof has been lacking. Proof is now provided by characterization of site-directed mutants of thioredoxin f with respect to activation of chloroplastic fructose-1,6-bisphosphatase (FBPase). The C49S mutant retains the capacity to activate FBPase, whereas the C46S mutant is totally lacking in this regard. Based on kinetics of FBPase activation, wild-type and C49S thioredoxins exhibit half-saturation values of 0.9 and 4 muM, respectively. Lack of activation by C46S is not because of failure to interact with FBPase, for it exhibits a K(i) of 5 muM in competition with wild-type thioredoxin. Therefore, in the normal thioredoxin-catalyzed reduction pathway, Cys-46 is the nucleophile required to attack the disulfide of the substrate and Cys-49 serves to cleave the mixed disulfide intermediate, thus allowing for the release of oxidized thioredoxin and the reduced target enzyme.	UNIV NEUCHATEL,BIOCHIM VEGETALE LAB,CH-2000 NEUCHATEL,SWITZERLAND	University of Neuchatel	BRANDES, HK (corresponding author), UNIV TENNESSEE,OAK RIDGE GRAD SCH BIOMED SCI,OAK RIDGE NATL LAB,DIV BIOL,PROT ENGN PROGRAM,OAK RIDGE,TN 37831, USA.							AGUILAR F, 1992, PLANT MOL BIOL, V20, P301, DOI 10.1007/BF00014497; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; DROUX M, 1987, ARCH BIOCHEM BIOPHYS, V252, P426, DOI 10.1016/0003-9861(87)90049-X; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; HOLMGREN A, 1972, J BIOL CHEM, V247, P1992; JACQUOT JP, 1978, FEBS LETT, V96, P243, DOI 10.1016/0014-5793(78)80410-4; KALLIS GB, 1980, J BIOL CHEM, V255, P261; KAMO M, 1989, EUR J BIOCHEM, V182, P315, DOI 10.1111/j.1432-1033.1989.tb14832.x; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LARIMER FW, 1990, PROTEIN ENG, V3, P227, DOI 10.1093/protein/3.3.227; LI H, 1993, BIOPHYS J, V64, pA125; LI H, 1992, FASEB J, V6, pA417; MARCUS F, 1987, BIOCHEMISTRY-US, V26, P7029, DOI 10.1021/bi00396a026; PRADEL J, 1981, EUR J BIOCHEM, V113, P507, DOI 10.1111/j.1432-1033.1981.tb05092.x; PRADO FE, 1992, PLANTA, V188, P345, DOI 10.1007/BF00192801; REUTIMANN H, 1981, J BIOL CHEM, V256, P6796; Sambrook J., 1989, MOL CLONING LABORATO, V3, pA3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIBE R, 1981, BIOCHIM BIOPHYS ACTA, V636, P58, DOI 10.1016/0005-2728(81)90075-X; SCHURMANN P, 1978, BIOCHIM BIOPHYS ACTA, V522, P130, DOI 10.1016/0005-2744(78)90329-7; SCHURMANN P, 1981, EUR J BIOCHEM, V116, P37, DOI 10.1111/j.1432-1033.1981.tb05297.x; THELANDER L, 1967, J BIOL CHEM, V242, P852; WOLOSIUK RA, 1979, J BIOL CHEM, V254, P1627; YANG YF, 1991, J BIOL CHEM, V266, P12759; ZIMMERMANN G, 1976, EUR J BIOCHEM, V70, P361, DOI 10.1111/j.1432-1033.1976.tb11025.x	27	53	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18411	18414						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8395501				2022-12-25	WOS:A1993LV65900004
J	KIM, YH; HUANG, JM; COHEN, P; MATTHEWS, HR				KIM, YH; HUANG, JM; COHEN, P; MATTHEWS, HR			PROTEIN PHOSPHATASES-1, PHOSPHATASES-2A, AND PHOSPHATASES-2C ARE PROTEIN HISTIDINE PHOSPHATASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; LABILE HISTONE PHOSPHATES; RAT-LIVER; TYROSINE PHOSPHATASES; NUCLEAR PROTEINS; PHOSPHORYLATION; KINASES; PURIFICATION; PHOSPHOHISTIDINE; IDENTIFICATION	Eukaryotic cellular proteins contain phosphohistidine. To search for protein histidine phosphatases, protein histidine kinase from Saccharomyces cerevisiae was used to phosphorylate histone H4 on histidine at position 75 in the H4 amino acid sequence. Incubation of the phosphorylated histone H4 with either protein phosphatase 1, 2A, or 2C resulted in extensive removal of phosphate from the phosphorylated histone. Thus, protein phosphatases 1, 2A, and 2C are histidine phosphatases as well as serine/threonine phosphatases. Calcium/calmodulin-regulated protein phosphatase (protein phosphatase 2B) did not remove phosphate from phosphohistidine. The histidine phosphatase reaction was tested for a magnesium requirement and effects of inhibitor-1 and okadaic acid. In all cases, the protein phosphatases behaved as they do in their serine/threonine phosphatase activity. Extracts of the yeast, S. cerevisiae, contain protein histidine phosphatase activity. Quantitative measurement of phosphatase activity shows that the activity against phosphohistidine is a major activity of protein phosphatases 1, 2A, and 2C.	UNIV CALIF DAVIS, DEPT BIOL CHEM, DAVIS, CA 95616 USA; UNIV DUNDEE, DEPT BIOCHEM, DUNDEE DD1 4HN, SCOTLAND	University of California System; University of California Davis; University of Dundee								BOYER PD, 1962, J BIOL CHEM, V237, P3306; CHAN CP, 1986, J BIOL CHEM, V261, P9890; CHEN CC, 1977, BIOCHEMISTRY-US, V16, P4852, DOI 10.1021/bi00641a016; CHEN CC, 1974, BIOCHEMISTRY-US, V13, P3785, DOI 10.1021/bi00715a026; CHERNOFF J, 1984, BIOCHEM BIOPH RES CO, V121, P141, DOI 10.1016/0006-291X(84)90698-3; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1988, METHOD ENZYMOL, V159, P427; COHEN P, 1988, METHOD ENZYMOL, V159, P390; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GORIS J, 1992, ADV PROTEIN PHOSPHAT, V5, P567; HEGDE AN, 1990, MOL CELL BIOL, V10, P2468, DOI 10.1128/MCB.10.6.2468; HEGDE AN, 1987, FEBS LETT, V217, P74, DOI 10.1016/0014-5793(87)81246-2; HUANG JM, 1991, J BIOL CHEM, V266, P9023; HUANG JM, 1992, J BIOL CHEM, V267, P15511; HUEBNER VD, 1985, J BIOL CHEM, V260, P6106; HULTQUIST DE, 1966, BIOCHEMISTRY-US, V5, P322, DOI 10.1021/bi00865a041; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; KIM Y, 1993, ANAL BIOCHEM, V211, P28, DOI 10.1006/abio.1993.1227; MCGOWAN CH, 1987, EUR J BIOCHEM, V166, P713, DOI 10.1111/j.1432-1033.1987.tb13570.x; NEWSHOLME P, 1992, BIOCHEM J, V283, P845, DOI 10.1042/bj2830845; PALLEN CJ, 1983, J BIOL CHEM, V258, P8550; PESIS KH, 1988, FEBS LETT, V239, P151, DOI 10.1016/0014-5793(88)80563-5; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; SMITH DL, 1973, NATURE, V246, P103, DOI 10.1038/246103a0; SMITH DL, 1974, BIOCHEMISTRY-US, V13, P3780, DOI 10.1021/bi00715a025; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; TAMURA S, 1989, P NATL ACAD SCI USA, V86, P1796, DOI 10.1073/pnas.86.6.1796; WEI YF, 1991, METHOD ENZYMOL, V200, P388; WEI YF, 1990, ANAL BIOCHEM, V190, P188, DOI 10.1016/0003-2697(90)90179-D	30	63	65	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18513	18518						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8395506				2022-12-25	WOS:A1993LV65900024
J	MULLAUER, L; FUJITA, H; ISHIZAKI, A; KUZUMAKI, N				MULLAUER, L; FUJITA, H; ISHIZAKI, A; KUZUMAKI, N			TUMOR-SUPPRESSIVE FUNCTION OF MUTATED GELSOLIN IN RAS-TRANSFORMED CELLS	ONCOGENE			English	Article							PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PHOSPHOLIPASE-C; HUMAN PLATELET; IDENTIFICATION; EXPRESSION; CARCINOMA; ONCOGENE; PROFILIN; SEQUENCE; PROTEINS	The flat revertant R1, isolated from human activated Ha-ras oncogene-transformed NIH3T3 fibroblasts (EJ-NIH3T3), expresses a variant form of the actin-regulatory protein gelsolin (p92-5.7). We have cloned cDNAs encoding p92-5.7 and identified as the cause of the expression of p92-5.7 a point mutation in codon 321, which results in an amino acid change from proline to histidine. In order to understand the role of p92-5.7 in reversion of ras-transformed cells, cDNAs encoding p92-5.7 or human authentic gelsolin as a control were transfected into EJ-NIH3T3 cells. All the transfectants that produced p92-5.7 and one of three transfectants that produced human authentic gelsolin either lost or reduced tumorigenicity in syngeneic mice. These results demonstrate that mutated gelsolin can suppress a ras tumor and suggest that authentic gelsolin, if expressed at increased levels, may have a similar suppressive potential. Our data propose an important role for gelsolin in celllar signal transduction pathways that involve the mammalian ras proto-oncogene.	HOKKAIDO UNIV,SCH MED,INST CANC,MOLEC GENET LAB,KITA 15 NISHI 7,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University			Müllauer, Leonhard/GSN-9884-2022	Müllauer, Leonhard/0000-0002-3399-078X				BANNO Y, 1992, J BIOL CHEM, V267, P6488; BANYARD MRC, 1990, EXP CELL RES, V187, P180, DOI 10.1016/0014-4827(90)90135-W; CHAPONNIER C, 1989, AM J PATHOL, V134, P597; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DADABAY CY, 1991, J CELL BIOL, V112, P1151, DOI 10.1083/jcb.112.6.1151; DIEFFENBACH CW, 1989, J BIOL CHEM, V264, P13281; FUJITA H, 1990, EXP CELL RES, V186, P115, DOI 10.1016/0014-4827(90)90217-X; FUKAMI K, 1988, P NATL ACAD SCI USA, V85, P9057, DOI 10.1073/pnas.85.23.9057; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KUZUMAKI N, 1989, MOL CELL BIOL, V9, P2258, DOI 10.1128/MCB.9.5.2258; KWIATKOWSKI DJ, 1988, AM J HUM GENET, V42, P565; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MACHESKY LM, 1990, CELL REGUL, V1, P937, DOI 10.1091/mbc.1.12.937; MULLAUER L, 1991, CANCER LETT, V59, P37, DOI 10.1016/0304-3835(91)90133-3; OIKAWA T, 1988, INT J CANCER, V42, P435, DOI 10.1002/ijc.2910420321; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; VANDEKERCKHOVE J, 1990, J CELL BIOL, V111, P95, DOI 10.1083/jcb.111.1.95; VOJTEK A, 1991, CELL, V66, P497, DOI 10.1016/0092-8674(81)90013-1; WANG E, 1984, J CELL BIOL, V98, P761, DOI 10.1083/jcb.98.2.761; WAY M, 1988, J MOL BIOL, V203, P1127, DOI 10.1016/0022-2836(88)90132-5; YIN HL, 1988, J CELL BIOL, V106, P805, DOI 10.1083/jcb.106.3.805; YIN HL, 1984, J BIOL CHEM, V259, P5271; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; YU FX, 1991, J BIOL CHEM, V266, P19269	32	71	72	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2531	2536						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8395682				2022-12-25	WOS:A1993LT36800025
J	KIM, JW; CUNNINGHAM, JM				KIM, JW; CUNNINGHAM, JM			N-LINKED GLYCOSYLATION OF THE RECEPTOR FOR MURINE ECOTROPIC RETROVIRUSES IS ALTERED IN VIRUS-INFECTED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; PROTEIN	Pulse-chase labeling identified incomplete maturation of the cationic amino acid transporter that serves as the receptor for ecotropic retroviruses in infected NIH 3T3 fibroblasts. The molecular basis and functional consequences of this change were studied by expressing viral and receptor proteins in Xenopus oocytes. Expression of the ecotropic, but not polytropic, envelope surface protein, gp70, interfered with N-linked glycosylation of the permissive mouse, but not the nonpermissive, human transporter. Incomplete glycosylation may be a direct consequence of gp70 binding since the glycosylated residues, Asn223 and Asn229, are present in the envelope binding domain. Receptors bearing amino acid substitutions in Asn223 and/or Asn229 that prevent glycosylation function normally in virus infection and amino acid transport. However, gp70 expression sufficient to block binding of I-125-gp70 to the receptor in the plasma membrane decreased receptor-mediated arginine uptake by 50%. Taken togther, these findings suggest that newly synthesized gp70 may bind to the receptor in the endoplasmic reticulum and prevent normal glycosylation during their transit to the plasma membrane.	BRIGHAM & WOMENS HOSP, HOWARD HUGHES MED INST,RM 925,THORN BLDG, 75 FRANCIS ST, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R29CA047075] Funding Source: NIH RePORTER; NCI NIH HHS [CA47075] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRITTON LM, 1992, GENOMICS, V12, P430, DOI 10.1016/0888-7543(92)90431-Q; ALBRITTON LM, 1993, J VIROL, V67, P2091, DOI 10.1128/JVI.67.4.2091-2096.1993; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BERGERON L, 1992, J VIROL, V66, P5777, DOI 10.1128/JVI.66.10.5777-5787.1992; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JAENISCH R, 1979, VIROLOGY, V98, P289, DOI 10.1016/0042-6822(79)90552-X; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; REIN A, 1984, VIROLOGY, V136, P144, DOI 10.1016/0042-6822(84)90255-1; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WANG H, 1992, J BIOL CHEM, V267, P23617	14	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16316	16320						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8393858				2022-12-25	WOS:A1993LQ33600037
J	ZANG, LY; MISRA, HP				ZANG, LY; MISRA, HP			GENERATION OF REACTIVE OXYGEN SPECIES DURING THE MONOAMINE OXIDASE-CATALYZED OXIDATION OF THE NEUROTOXICANT, 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-RESONANCE; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; RADICAL PRODUCTION; SUBSTANTIA NIGRA; AMINE 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; PARKINSONS-DISEASE; HYDROGEN-PEROXIDE; HYDROXYL RADICALS; RAT-BRAIN	The neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) has been shown to generate reactive oxygen species during its interaction with monoamine oxidase type B (MAO-B). The kinetic parameters, K(m) and V(max), for MAO-B-catalyzed oxidation of MPTP to the corresponding species MPDP+ were found to be 0.194 mM and 0.335 muM/min, respectively. The generation of superoxide (.O2-) and hydroxyl (.OH) radicals was detected as the 5,5-dimethyl-1-pyrroline-N-oxide (DMPO) spin adduct by spin-trapping in combination with EPR techniques. Addition of Fe2+ (10 muM) to this system caused a 5-fold enhancement in EPR signal intensity of the DMPO-OH adduct. Catalase, a scavenger of hydrogen peroxide (H2O2), inhibited the DMPO-OH spin adduct formation in a dose-dependent manner, indicating that H2O2 is produced in the MAO-B catalyzed oxidation of MPTP. Ethanol, a well known scavenger of hydroxyl radical, rapidly produced an alpha-hydroxyethyl radical signal. Superoxide dismutase inhibited the formation of DMPO-O-2- and DMPO-OH spin adducts in a dose-dependent fashion. These data suggest that superoxide radicals are produced during the oxidation of MPTP by MAO-B and that the generation of H2O2 and .OH was secondary to the production of .O2-. It appears likely that the nigrostriatal toxicity of MPTP leading to Parkinson's disease-like syndrome may in part be mediated via these reactive oxygen species.	VIRGINIA POLYTECH INST & STATE UNIV, VIRGINIA MARYLAND REG COLL VET MED, DEPT BIOMED SCI, BLACKSBURG, VA 24061 USA	Virginia Polytechnic Institute & State University								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUETTNER GR, 1986, PHOTOCHEM PHOTOBIOL, V44, P5, DOI 10.1111/j.1751-1097.1986.tb03556.x; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; CASTAGNOLI N, 1987, 10TH INT C PHARM, P875; CHACON JN, 1987, BIOCHEM BIOPH RES CO, V144, P957, DOI 10.1016/S0006-291X(87)80057-8; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHIBA K, 1984, BIOCHEM BIOPH RES CO, V120, P574, DOI 10.1016/0006-291X(84)91293-2; CHIBA K, 1985, DRUG METAB DISPOS, V13, P342; COHEN G, 1963, BIOCHEMISTRY-US, V2, P1420, DOI 10.1021/bi00906a038; ERNSTER L, 1986, CHEM SCRIPTA, V26, P525; FARHATAZIZ E, 1977, NATL STAND REF DATA, V59, P37; FINKELSTEIN E, 1982, MOL PHARMACOL, V21, P262; FINKELSTEIN E, 1980, J AM CHEM SOC, V102, P4994, DOI 10.1021/ja00535a029; FINKELSTEIN E, 1980, ARCH BIOCHEM BIOPHYS, V200, P1, DOI 10.1016/0003-9861(80)90323-9; FONG KL, 1973, J BIOL CHEM, V248, P7792; FREEMAN BA, 1982, LAB INVEST, V47, P412; FRIDOVICH I, 1977, SUPEROXIDE SUPEROXID, P551; GESSNER W, 1985, FEBS LETT, V183, P345, DOI 10.1016/0014-5793(85)80807-3; HEIKKILA RE, 1984, NATURE, V311, P467, DOI 10.1038/311467a0; HIEBERT CK, 1989, J BIOL CHEM, V264, P21516; JANZEN EG, 1984, METHOD ENZYMOL, V105, P188; JOHANNESSEN JN, 1985, LIFE SCI, V36, P219, DOI 10.1016/0024-3205(85)90062-1; KLUG D, 1972, J BIOL CHEM, V247, P4839; KLUGROTH D, 1973, J AM CHEM SOC, V95, P2786, DOI 10.1021/ja00790a007; KONTOS HA, 1985, CIRC RES, V57, P508, DOI 10.1161/01.RES.57.4.508; KRUEGER MJ, 1990, BIOCHEM J, V268, P219, DOI 10.1042/bj2680219; LAI CS, 1977, BIOCHEM BIOPH RES CO, V78, P51, DOI 10.1016/0006-291X(77)91220-7; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LANGSTON JW, 1984, NEUROSCI LETT, V48, P87, DOI 10.1016/0304-3940(84)90293-3; LEWIN R, 1984, SCIENCE, V225, P1460, DOI 10.1126/science.6433484; MCCAY PB, 1978, TOCOPHEROL OXYGEN BI, P41; MEHLHORN RJ, 1982, CAN J CHEM, V60, P1452, DOI 10.1139/v82-211; MINOTTI G, 1987, J BIOL CHEM, V262, P1098; Oreland L, 1983, Mod Probl Pharmacopsychiatry, V19, P246; OTTOBONI S, 1989, J BIOL CHEM, V264, P13684; Peters A., 1976, FINE STRUCTURE NERVO; POIRIER J, 1985, BIOCHEM BIOPH RES CO, V131, P1284, DOI 10.1016/0006-291X(85)90230-X; POIRIER J, 1985, BIOCHEM BIOPH RES CO, V128, P25, DOI 10.1016/0006-291X(85)91639-0; Riederer P, 1984, MONOAMINE OXIDASE DI, P403; ROTH JA, 1979, MONOAMINE OXIDASE ST, P153; SALACH JI, 1984, BIOCHEM BIOPH RES CO, V125, P831, DOI 10.1016/0006-291X(84)90614-4; SALACH JI, 1979, ARCH BIOCHEM BIOPHYS, V192, P128, DOI 10.1016/0003-9861(79)90078-X; SANDRI G, 1990, BIOCHIM BIOPHYS ACTA, V1035, P300, DOI 10.1016/0304-4165(90)90092-B; SILVERMAN RB, 1979, MANOAMINE OXIDASE ST, P71; SINGER TP, 1987, J NEURAL TRANSM, P1; SINGER TP, 1986, BIOCHEM J, V235, P785, DOI 10.1042/bj2350785; SINGER TP, 1985, BIOCHEM BIOPH RES CO, V127, P707, DOI 10.1016/S0006-291X(85)80219-9; SINGH A, 1982, CAN J PHYSIOL PHARM, V60, P1330, DOI 10.1139/y82-200; TIPTO KF, 1984, STRUCTURE FUNCTION M, P559; TOWELL J, 1991, ANAL BIOCHEM, V196, P111, DOI 10.1016/0003-2697(91)90126-E; TURNER MJ, 1986, J MED CHEM, V29, P2439, DOI 10.1021/jm00162a004; TYLER DD, 1975, BIOCHEM J, V147, P493, DOI 10.1042/bj1470493; WAGNER HJ, 1979, DEUT MED WOCHENSCHR, V104, P187, DOI 10.1055/s-0028-1103868; WATSON BD, 1984, J NEUROCHEM, V42, P268, DOI 10.1111/j.1471-4159.1984.tb09728.x; YOUDIM MBH, 1991, EUR NEUROL, V31, P34, DOI 10.1159/000116719; YOUNG VW, 1986, NEUROSCI LETT, V63, P56; YOUNGSTER SK, 1989, J NEUROCHEM, V53, P1837, DOI 10.1111/j.1471-4159.1989.tb09250.x; ZANG LY, 1992, J BIOL CHEM, V267, P23601; ZANG LY, 1992, PHOTOCHEM PHOTOBIOL, V56, P453, DOI 10.1111/j.1751-1097.1992.tb02188.x; ZANG LY, 1992, J BIOL CHEM, V267, P17547	60	66	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16504	16512						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8393868				2022-12-25	WOS:A1993LQ33600062
J	KLUGE, C; DIMROTH, P				KLUGE, C; DIMROTH, P			SPECIFIC PROTECTION BY NA+ OR LI+ OF THE F1F0-ATPASE OF PROPIONIGENIUM-MODESTUM FROM THE REACTION WITH DICYCLOHEXYLCARBODIIMIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SUBUNIT-C; ADENOSINE-TRIPHOSPHATASE; ESCHERICHIA-COLI; ATP SYNTHASE; ION; TRANSPORT; MEMBRANES; PUMP; F1F0; F0	Incubation of the purified F1F0-ATPase of Propionigenium modestum with dicyclohexylcarbodiimide (DCCD) led to inactivation of the enzyme in a strongly pH-dependent manner. Rapid inactivation occurred at pH 5-7, while the increase of the pH from 7 to 9 resulted in a continuous reduction of the inactivation rate. In the presence of Na+ ions, the ATPase was specifically protected from inactivation by DCCD. The protective effect of Na+ was most pronounced at pH 9.0 and less significant at pH 7.0. In addition to Na+, Li+ also protected the ATPase from inactivation by DCCD, but approximately 10 times higher concentrations were required for the same effect. Similarly, the Na+ concentration causing half-maximal stimulation of ATPase activity was about 10 times below the Li+ concentration required for the same activation. It is concluded from these results that a binding site is present for Na+ or Li+ on the enzyme with an about 10 times lower affinity for the latter alkali ion, which when occupied stimulates ATPase activity and protects it from inactivation by DCCD. Inactivation of ATPase activity by DCCD correlated well with a specific labeling of subunit c of the enzyme in the presence of the [C-14]DCCD derivative. Like ATPase inactivation, the labeling was promoted by more acidic pH values and inhibited by Na+ ions. We suggest from these data that the DCCD-reactive amino acid residue of subunit c (most likely Glu-65) must be protonated for the reaction with the carbodiimide and provides the Na+-binding site in its deprotonated state. Dissociation of the carboxylic acid (at high pH) and binding of Na+ ions to the carboxylate thus abolish the reactivity toward DCCD.			KLUGE, C (corresponding author), SWISS FED INST TECHNOL,INST MIKROBIOL,CH-8092 ZURICH,SWITZERLAND.							AZZI A, 1984, BIOCHIM BIOPHYS ACTA, V768, P209, DOI 10.1016/0304-4173(84)90017-X; BOYER PD, 1988, TRENDS BIOCHEM SCI, V13, P5, DOI 10.1016/0968-0004(88)90005-9; DIMROTH P, 1987, MICROBIOL REV, V51, P320, DOI 10.1128/MMBR.51.3.320-340.1987; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; HEISE R, 1992, EUR J BIOCHEM, V206, P553, DOI 10.1111/j.1432-1033.1992.tb16959.x; HERMOLIN J, 1989, J BIOL CHEM, V264, P3896; HILPERT W, 1984, EMBO J, V3, P1665, DOI 10.1002/j.1460-2075.1984.tb02030.x; KAIM G, 1992, EUR J BIOCHEM, V207, P463, DOI 10.1111/j.1432-1033.1992.tb17072.x; KLUGE C, 1992, BIOCHEMISTRY-US, V31, P12665, DOI 10.1021/bi00165a017; KRUMHOLZ LR, 1992, FEMS MICROBIOL LETT, V91, P37, DOI 10.1111/j.1574-6968.1992.tb05180.x; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LAUBINGER W, 1990, BIOCHEMISTRY-US, V29, P5458, DOI 10.1021/bi00475a008; LAUBINGER W, 1988, BIOCHEMISTRY-US, V27, P7531, DOI 10.1021/bi00419a053; LAUBINGER W, 1989, BIOCHEMISTRY-US, V28, P7194, DOI 10.1021/bi00444a010; LUDWIG W, 1990, EUR J BIOCHEM, V193, P395, DOI 10.1111/j.1432-1033.1990.tb19352.x; MILLER MJ, 1990, P NATL ACAD SCI USA, V87, P4900, DOI 10.1073/pnas.87.13.4900; MURPHY AJ, 1981, J BIOL CHEM, V256, P2046; NAGLE JF, 1978, P NATL ACAD SCI USA, V75, P298, DOI 10.1073/pnas.75.1.298; UCHIDA E, 1985, J BIOL CHEM, V260, P1090	19	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14557	14560						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8392053				2022-12-25	WOS:A1993LL75900002
J	LENTZ, SR; CHEN, Y; SADLER, JE				LENTZ, SR; CHEN, Y; SADLER, JE			SEQUENCES REQUIRED FOR THROMBOMODULIN COFACTOR ACTIVITY WITHIN THE 4TH EPIDERMAL GROWTH FACTOR-LIKE DOMAIN OF HUMAN THROMBOMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-C ACTIVATION; RECOMBINANT HUMAN THROMBOMODULIN; THROMBIN-CATALYZED ACTIVATION; HOMOLOGY DOMAIN; BINDING; ANTICOAGULANT; COMPLEX; HIRUDIN; LOCALIZATION; SPECIFICITY	Activation of protein C by thrombin is stimulated by the endothelial cell cofactor thrombomodulin. The structural regions of thrombomodulin necessary for cofactor activity have been localized to the fourth through sixth epidermal growth factor (EGF)-like domains. The fourth EGF-like domain is unnecessary for high affinity thrombin binding, but is required for cofactor activity. To identify essential sequences within the fourth EGF-like domain, a series of recombinant human thrombomodulins consisting of EGF-like domains four through six were expressed in human kidney cells. These mutants contain replacements of disulfide loops within the fourth EGF-like domain, thereby conserving overall disulfide bond structure. All of the mutants bound to thrombin with high affinity, and inhibited the fibrinogen-clotting activity of thrombin to a similar extent. Two regions of the fourth EGF-like domain were identified to be essential for cofactor activity: 1) the sequence consisting of amino acids Glu-357, Tyr-358, and Gln-359 shared by the overlapping first and second disulfide loops, and 2) the amino-terminal region of the third disulfide loop containing amino acids Glu-374, Gly-375, and Phe-376. These results suggest that amino acids critical for thrombomodulin cofactor activity are located near the junction between the two subdomains of the fourth EGF-like domain.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,HOWARD HUGHES MED INST,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Howard Hughes Medical Institute; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)	LENTZ, SR (corresponding author), UNIV IOWA,DEPT INTERNAL MED,DIV HEMATOL ONCOL,C303 GH,IOWA CITY,IA 52242, USA.		Sadler, Evan/D-8556-2011	Lentz, Steven/0000-0002-8885-4718; Sadler, J. Evan/0000-0001-5705-469X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007088, P50HL014147] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HLBI 07088, HLBI 14147] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOURIN MC, 1990, BIOCHEM J, V270, P419, DOI 10.1042/bj2700419; BROOKS SPJ, 1992, BIOTECHNIQUES, V13, P906; DITTMAN WA, 1990, BLOOD, V75, P329; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; ESMON CT, 1989, J BIOL CHEM, V264, P4743; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; HAYASHI T, 1990, J BIOL CHEM, V265, P20156; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; JACKMAN RW, 1987, P NATL ACAD SCI USA, V84, P6425, DOI 10.1073/pnas.84.18.6425; JAKUBOWSKI HV, 1986, J BIOL CHEM, V261, P3876; KOYAMA T, 1991, BRIT J HAEMATOL, V78, P515, DOI 10.1111/j.1365-2141.1991.tb04481.x; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; KUROSAWA S, 1987, J BIOL CHEM, V262, P2206; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; MARUYAMA I, 1985, J BIOL CHEM, V260, P5432; NAGASHIMA M, 1993, J BIOL CHEM, V268, P2888; NAWA K, 1990, BIOCHEM BIOPH RES CO, V171, P729, DOI 10.1016/0006-291X(90)91207-9; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; PARKINSON JF, 1992, BIOCHEM BIOPH RES CO, V185, P567, DOI 10.1016/0006-291X(92)91662-A; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; RICHARDSON MA, 1992, NATURE, V360, P261, DOI 10.1038/360261a0; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALEM HH, 1984, J BIOL CHEM, V259, P2246; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEARNS DJ, 1989, J BIOL CHEM, V264, P3352; STENFLO J, 1991, BLOOD, V78, P1637; SUZUKI K, 1987, EMBO J, V6, P1891, DOI 10.1002/j.1460-2075.1987.tb02448.x; TSIANG M, 1992, J BIOL CHEM, V267, P6164; TSIANG M, 1990, BIOCHEMISTRY-US, V29, P10602, DOI 10.1021/bi00499a005; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WEN DZ, 1987, BIOCHEMISTRY-US, V26, P4350, DOI 10.1021/bi00388a025; WU Q, 1979, P NATL ACAD SCI USA, V88, P6775; YE J, 1991, J BIOL CHEM, V266, P23016; YE J, 1993, J BIOL CHEM, V268, P2373; YE J, 1992, J BIOL CHEM, V267, P11023; ZUSHI M, 1991, J BIOL CHEM, V266, P19886; ZUSHI M, 1989, J BIOL CHEM, V264, P10351	41	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15312	15317						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8392074				2022-12-25	WOS:A1993LL75900110
J	COOPER, DL; LAHUE, RS; MODRICH, P				COOPER, DL; LAHUE, RS; MODRICH, P			METHYL-DIRECTED MISMATCH REPAIR IS BIDIRECTIONAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA POLYMERASE-III; BASE-PAIR MISMATCHES; ESCHERICHIA-COLI; GENE-PRODUCT; D(GATC) SEQUENCES; EXONUCLEASE-VII; GATC SEQUENCES; RECJ-GENE; PURIFICATION; HOLOENZYME	Methyl-directed mismatch repair is initiated by the mismatch-provoked, MutHLS-dependent cleavage of the unmodified strand at a hemimethylated d(GATC) sequence. This reaction is independent of the polarity of the unmodified strand and can occur either 3' or 5' to the mismatch on the unmethylated strand (Au, K. G., Welsh, K., and Modrich, P. (1992) J. Biol. Chem. 267, 12142-12148).The overall repair reaction also occurs without regard to polarity of the unmethylated strand. Both hemimethylated configurations of a linear heteroduplex containing a single d(GATC) sequence are subject to methyl-directed correction in Escherichia coli extracts and in a purified repair system. Repair of both heteroduplex orientations requires MutH, MutL, MutS, DNA helicase II, SSB, and DNA polymerase III holoenzyme, but the two substrates differ with respect to exonuclease requirements for correction. When the unmethylated d(GATC) sequence that directs repair is located 5' to the mismatch on the unmodified strand, mismatch correction requires the 5' --> 3' hydrolytic activity of exonuclease VII or RecJ exonuclease. Repair directed by an unmodified d(GATC) sequence situated 3' to the mismatch depends on the 3' --> 5' activity of exonuclease I. Specific requirements for these activities are evident with circular heteroduplexes containing a single asymmetrically placed d(GATC) sequence, with the requirement for a 5' --> 3' or 3' --> 5' hydrolytic activity being determined by the orientation of the unmethylated strand along the shorter path joining the two sites in the DNA circle. This observation suggests that the methyl-directed repair system utilizes the proximal d(GATC) sequence to direct correction. To our knowledge, these experiments represent the first instance in which exonuclease I, exonuclease VII, and RecJ have been implicated in a particular DNA metabolic pathway.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University				Modrich, Paul/0000-0001-8708-9885; Lahue, Robert/0000-0002-8870-5616	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023719, R01GM023719] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23719] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUK KG, 1992, J BIOL CHEM, V267, P12142; BRUNI R, 1988, NUCLEIC ACIDS RES, V16, P4875, DOI 10.1093/nar/16.11.4875; CHASE JW, 1974, J BIOL CHEM, V249, P4553; CHASE JW, 1986, J BIOL CHEM, V261, P4929; CHASE JW, 1977, J BACTERIOL, V129, P934, DOI 10.1128/JB.129.2.934-947.1977; CLARK AJ, 1988, RECOMBINATION GENETI, P155; EICHLER DC, 1977, J BIOL CHEM, V252, P499; FANG WH, 1993, J BIOL CHEM, V268, P11838; FEINSTEIN SI, 1986, GENETICS, V113, P13; GEFTER ML, 1972, J BIOL CHEM, V247, P3321; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; JORGENSEN SE, 1966, J BIOL CHEM, V241, P3090; Kornberg A., 1991, DNA REPLICATION; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; KUSHNER SR, 1971, P NATL ACAD SCI USA, V68, P824, DOI 10.1073/pnas.68.4.824; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LAHUE RS, 1987, P NATL ACAD SCI USA, V84, P1482, DOI 10.1073/pnas.84.6.1482; LAHUE RS, 1987, UCLA S MOL CELLULAR, V47, P125; LANGLEROUAULT F, 1987, EMBO J, V6, P1121, DOI 10.1002/j.1460-2075.1987.tb04867.x; LEHMAN IR, 1964, J BIOL CHEM, V239, P2628; LIVINGSTON DM, 1975, J BIOL CHEM, V250, P470; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; LOVETT ST, 1985, J BACTERIOL, V162, P280, DOI 10.1128/JB.162.1.280-285.1985; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; LOVETT ST, 1984, J BACTERIOL, V157, P190, DOI 10.1128/JB.157.1.190-196.1984; LU AL, 1987, J BACTERIOL, V169, P1254, DOI 10.1128/jb.169.3.1254-1259.1987; LU AL, 1983, P NATL ACAD SCI-BIOL, V80, P4639, DOI 10.1073/pnas.80.15.4639; LU AL, 1984, COLD SPRING HARB SYM, V49, P589, DOI 10.1101/SQB.1984.049.01.066; MAKI H, 1988, J BIOL CHEM, V263, P6570; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MCHENRY C, 1978, J BIOL CHEM, V253, P645; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MESELSON M, 1988, RECOMBINATION GENETI, P91; Miller J.H., 1972, EXPT MOL GENETICS; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MOLINEUX IJ, 1975, J MOL BIOL, V98, P811, DOI 10.1016/S0022-2836(75)80012-X; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; PETIT MA, 1991, GENETICS, V129, P327; PRASHER DC, 1983, J BIOL CHEM, V258, P6340; RADMAN M, 1986, ANNU REV GENET, V20, P523, DOI 10.1146/annurev.ge.20.120186.002515; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; RUNYON GT, 1993, IN PRESS BIOCHEMISTR; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SHEN P, 1986, GENETICS, V112, P441; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALES LD, 1983, J BACTERIOL, V155, P1116, DOI 10.1128/JB.155.3.1116-1122.1983; VALES LD, 1982, J BIOL CHEM, V257, P8799; WELSH KM, 1987, J BIOL CHEM, V262, P15624	52	167	172	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11823	11829						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8389365				2022-12-25	WOS:A1993LF28400056
J	SHAH, MM; AUST, SD				SHAH, MM; AUST, SD			IODIDE AS THE MEDIATOR FOR THE REDUCTIVE REACTIONS OF PEROXIDASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHITE ROT FUNGUS; PHANEROCHAETE-CHRYSOSPORIUM; OXIDATION; METHOXYBENZENES; LIGNINASE; RADICALS	Lignin peroxidase H2 (LiPH2) from the white rot fungus Phanerochaete chrysosporium catalyzed the reduction of cytochrome c, nitro blue tetrazolium, ferric iron, molecular oxygen, and triiodide in a reaction mixture containing LiPH2, H2O2, EDTA, and iodide. Activity followed first order kinetics with respect to EDTA concentration. The reductive activity observed with LiPH2 using iodide as the mediator was comparable to that obtained using a variety of other free radical mediators such as veratryl alcohol, 1,4-dimethoxybenzene, and 1,2,3- and 1,2,4-trimethoxybenzene. EDTA-derived radicals were detected by ESR spin trapping upon incubation of LiPH2 with H2O2, iodide, and EDTA. Reduction activity was also observed using other peroxidases such as lactoperoxidase, horseradish peroxidase, and myeloperoxidase. For the reduction activity of LiPH2, it is proposed that the oxidation of EDTA is mediated by the iodide radical, and the reduction of various electron acceptors is mediated by EDTA radicals. The inhibition of reduction activity at higher concentrations of iodide might be due to the combination of iodide radicals to form I2 which forms a stable triiodide complex by reacting with excess iodide.	UTAH STATE UNIV,CTR BIOTECHNOL,LOGAN,UT 84322	Utah System of Higher Education; Utah State University					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004922] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 04922] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BANERJEE RK, 1989, J BIOL CHEM, V264, P9188; BANERJEE RK, 1986, J BIOL CHEM, V261, P592; BARR DP, 1992, ARCH BIOCHEM BIOPHYS, V298, P480, DOI 10.1016/0003-9861(92)90438-3; BARR DP, 1992, J BIOL CHEM, V268, P241; BROWN JF, 1987, SCIENCE, V236, P709, DOI 10.1126/science.236.4802.709; BUMPUS JA, 1985, SCIENCE, V228, P1434, DOI 10.1126/science.3925550; Crawford R.L., 1981, LIGNIN BIODEGRADATIO; EBERSON L, 1987, ELECTRON TRANSFER RE, P46; FARHANGRAZI ZS, 1992, BIOCHEMISTRY-US, V31, P10763, DOI 10.1021/bi00159a017; FORNEY LJ, 1982, J BIOL CHEM, V257, P1455; GREENWALD RA, 1985, CRC HDB METHODS OXYG, P121; HALL PL, 1980, ENZYME MICROB TECH, V2, P170, DOI 10.1016/0141-0229(80)90043-5; HEELIS PF, 1982, CHEM SOC REV, V11, P15, DOI 10.1039/cs9821100015; KERSTEN PJ, 1985, J BIOL CHEM, V260, P2609; Neidleman S.L., 1986, BIOHALOGENATION PRIN; POPP JL, 1991, ARCH BIOCHEM BIOPHYS, V288, P145, DOI 10.1016/0003-9861(91)90176-J; RANGANATHAN V, 1987, BIOCHEMISTRY-US, V26, P5127; SEDLAK DL, 1991, ENVIRON SCI TECHNOL, V25, P1419, DOI 10.1021/es00020a009; SHAH MM, 1993, ARCH BIOCHEM BIOPHYS, V300, P253, DOI 10.1006/abbi.1993.1035; SHAH MM, 1992, J BIOL CHEM, V267, P21564; SHOEMAKER HE, 1990, RECL TRAV CHIM PAY B, V109, P255; SUGIMOTO H, 1987, J AM CHEM SOC, V109, P8081, DOI 10.1021/ja00260a021; TIEN M, 1987, CRIT REV MICROBIOL, V15, P141, DOI 10.3109/10408418709104456; TUISEL H, 1990, ARCH BIOCHEM BIOPHYS, V279, P158, DOI 10.1016/0003-9861(90)90476-F; YAMAZAKI I, 1960, ARCH BIOCHEM BIOPHYS, V86, P294, DOI 10.1016/0003-9861(60)90421-5	25	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8503	8506						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8386162				2022-12-25	WOS:A1993KX81100022
J	SCHULTZ, C; VAJANAPHANICH, M; HAROOTUNIAN, AT; SAMMAK, PJ; BARRETT, KE; TSIEN, RY				SCHULTZ, C; VAJANAPHANICH, M; HAROOTUNIAN, AT; SAMMAK, PJ; BARRETT, KE; TSIEN, RY			ACETOXYMETHYL ESTERS OF PHOSPHATES, ENHANCEMENT OF THE PERMEABILITY AND POTENCY OF CAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; INOSITOL PHOSPHATES; INTACT-CELLS; INDICATORS; ANALOGS; METABOLISM; BUTYRATE; CALCIUM; CA-2+; ACID	Acetoxymethyl esters of alkyl or aryl phosphates can be prepared by reacting their trialkylammonium or silver salts with acetoxymethyl bromide. Because acetoxymethyl esters are rapidly cleaved intracellularly, they facilitate the delivery of organophosphates into the cytoplasm without puncturing or disruption of the plasma membrane. In addition, acylation of free hydroxyls, for example with butyryl groups, is useful both for synthetic convenience and increased hydrophobicity of the permeant derivatives. The highly polar intracellular messengers cAMP and cGMP were thus converted into uncharged membrane-permeant derivatives. Extracellularly applied N6,2'-O-dibutyryl cAMP acetoxymethyl ester (Bt2cAMP/AM) is shown to simulate intracellular cAMP in three model systems, namely dissociation of cAMP-dependent protein kinase in fibroblasts, activation of Cl- secretion of monolayers of the human colon epithelial cell line T84, and dispersion of pigment granules in angel fish melanophores. Bt2cAMP/AM is effective at concentrations two or three orders of magnitude less than those required for commonly used membrane-permeant cAMP derivatives such as Bt2cAMP, 8-Br-cAMP, and 8-pCPT-cAMP lacking the acetoxymethyl ester. This methodology should be of general utility for the intracellular delivery of phosphate-containing second messengers.	UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, 0647, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego			Barrett, Kim/AAE-2794-2022; Barrett, Kim Elaine/AAE-7762-2019	Barrett, Kim Elaine/0000-0002-6704-998X; Schultz, Carsten/0000-0002-5824-2171	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027177, R37NS027177] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28305] Funding Source: Medline; NINDS NIH HHS [NS 27177] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; BARRETT KE, 1991, TXB GASTROENTEROLOGY, P265; BEEBE SJ, 1988, METHOD ENZYMOL, V159, P118; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BUNDGAARD H, 1987, BIOREVERSIBLE CARRIE, P13; CORBIN JD, 1988, METHODS ENZYMOLOGY I, V159; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, pG204, DOI 10.1152/ajpgi.1984.246.2.G204; DHARMSATHAPHORN K, 1985, J CLIN INVEST, V75, P462, DOI 10.1172/JCI111721; ENGELS J, 1977, J MED CHEM, V20, P907, DOI 10.1021/jm00217a008; FALBRIARD JL, 1967, BIOCHIM BIOPHYS ACTA, V148, P99, DOI 10.1016/0304-4165(67)90283-8; FREED JJ, 1989, BIOCHEM PHARMACOL, V38, P3193, DOI 10.1016/0006-2952(89)90613-8; GOY MF, 1991, TRENDS NEUROSCI, V14, P293, DOI 10.1016/0166-2236(91)90140-P; GRIPPO JF, 1987, J BIOL CHEM, V262, P4492; GRYNKIEWICZ G, 1987, POL J CHEM, V61, P443; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GURNEY AM, 1987, PHYSIOL REV, V67, P583, DOI 10.1152/physrev.1987.67.2.583; HARDIE DG, 1991, BIOCH MESSENGERS HOR, P147; HENION WF, 1967, BIOCHIM BIOPHYS ACTA, V148, P106, DOI 10.1016/0304-4165(67)90284-X; HUDSON RF, 1958, J CHEM SOC, P1356, DOI 10.1039/jr9580001356; IYER RP, 1989, TETRAHEDRON LETT, V30, P7141, DOI 10.1016/S0040-4039(01)93918-8; JANSEN ABA, 1965, J CHEM SOC, P2127, DOI 10.1039/jr9650002127; KOOISTRA T, 1987, BIOCHEM J, V247, P605, DOI 10.1042/bj2470605; MADARA JL, 1985, J CELL BIOL, V101, P2124, DOI 10.1083/jcb.101.6.2124; MCCRAY JA, 1989, ANNU REV BIOPHYS BIO, V18, P239, DOI 10.1146/annurev.biophys.18.1.239; MCROBERTS J A, 1989, P235; MEYER RB, 1980, BURGERS MED CHEM, P1201; NERBONNE JM, 1984, NATURE, V310, P74, DOI 10.1038/310074a0; POLOKOFF MA, 1988, J BIOL CHEM, V263, P11922; RATTO GM, 1988, J NEUROSCI, V8, P3240; REPHAELI A, 1991, INT J CANCER, V49, P66, DOI 10.1002/ijc.2910490113; Robison G.A., 1971, CYCLIC AMP, DOI [10.1146/annurev.bi.37.070168.001053, DOI 10.1146/ANNUREV.BI.37.070168.001053]; RYAN WL, 1972, SCIENCE, V177, P1002, DOI 10.1126/science.177.4053.1002; SAMMAK PJ, 1992, J CELL BIOL, V117, P57, DOI 10.1083/jcb.117.1.57; SAPERSTEIN R, 1989, BIOCHEMISTRY-US, V28, P5694, DOI 10.1021/bi00439a053; SASTRY JK, 1992, MOL PHARMACOL, V41, P441; Schliwa M., 1975, MICROTUBULES MICROTU, P215; SCHULTZ C, 1993, IN PRESS J BIOL CHEM, V268; SRIVASTVA DN, 1984, BIOORG CHEM, V12, P118, DOI 10.1016/0045-2068(84)90022-1; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; TSIEN RY, 1989, METHOD CELL BIOL, V30, P127; TSIEN RY, 1981, NATURE, V290, P527, DOI 10.1038/290527a0; WALKER JW, 1988, J AM CHEM SOC, V110, P7170, DOI 10.1021/ja00229a036; WALKER JW, 1989, BIOCHEMISTRY-US, V28, P3272, DOI 10.1021/bi00434a023; YUSTA B, 1988, J NEUROCHEM, V51, P1807, DOI 10.1111/j.1471-4159.1988.tb01162.x	45	92	99	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6316	6322						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8384207				2022-12-25	WOS:A1993KT36800038
J	WANG, YL; SWEITZER, TD; WEINHOLD, PA; KENT, C				WANG, YL; SWEITZER, TD; WEINHOLD, PA; KENT, C			NUCLEAR-LOCALIZATION OF SOLUBLE CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; PHOSPHOLIPASE-C TREATMENT; RAT-LIVER; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; CHOLINEPHOSPHATE CYTIDYLYLTRANSFERASE; INTRACELLULAR-LOCALIZATION; PHOSPHORYLATION; PROTEIN; PURIFICATION; STIMULATION	The soluble form of CTP:phosphocholine cytidylyltransferase, which has previously been assumed to be cytosolic, has been localized to the nucleus of several cell types. Indirect immunofluorescence microscopy indicated a nuclear location in HepG2, NIH-3T3, and L-cells. A comparison of the fluorescence pattern of wild-type CHO cells with a cytidylyltransferase-deficient mutant provided genetic evidence that cytidylyltransferase is nuclear in CHO cells. The enzyme is also predominantly nuclear in rat liver, as revealed by staining frozen sections of that tissue. When L-cells were fractionated by enucleation, over 95% of cytidylyltransferase activity was found in the nuclear fraction, providing biochemical evidence for a nuclear location in these cells. In light of the demonstration that the membrane-bound cytidylyltransferase in CHO cells is associated with the nuclear envelope (Watkins, J. D., and Kent, C. (1992) J. Biol. Chem. 267, 5686-5692), these results suggest that this enzyme is predominantly an intranuclear enzyme.	VET AFFAIRS MED CTR,ANN ARBOR,MI 48105	US Department of Veterans Affairs; Veterans Health Administration (VHA)	WANG, YL (corresponding author), UNIV MICHIGAN,MED CTR,DEPT BIOL CHEM,ANN ARBOR,MI 48109, USA.				NICHD NIH HHS [HD0281] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ASHIZAWA K, 1991, J BIOL CHEM, V266, P16842; BENSCH KG, 1982, J BIOL CHEM, V257, P8391; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPITANI S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P193, DOI 10.1016/0005-2760(90)90303-F; CAPRIOTTI AM, 1988, J BIOL CHEM, V263, P10029; CASOLA PG, 1980, BIOCHEM BIOPH RES CO, V96, P1209, DOI 10.1016/0006-291X(80)90080-7; CHOY PC, 1977, J BIOL CHEM, V252, P7673; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5881, DOI 10.1021/bi00238a011; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5873, DOI 10.1021/bi00238a010; ESKO JD, 1980, P NATL ACAD SCI-BIOL, V77, P5192, DOI 10.1073/pnas.77.9.5192; ESKO JD, 1981, J BIOL CHEM, V256, P7388; EXTON JH, 1990, J BIOL CHEM, V265, P1; FELDMAN DA, 1981, BIOCHIM BIOPHYS ACTA, V665, P53, DOI 10.1016/0005-2760(81)90231-9; FELDMAN DA, 1985, BIOCHIM BIOPHYS ACTA, V429, P429; FOLLETT EAC, 1974, EXP CELL RES, V84, P72, DOI 10.1016/0014-4827(74)90381-4; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GASC JM, 1990, EXP CELL RES, V186, P362, DOI 10.1016/0014-4827(90)90317-4; HAMADA S, 1983, HISTOCHEMISTRY, V79, P219, DOI 10.1007/BF00489783; HIGGINS JA, 1987, J LIPID RES, V28, P268; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; LASKO DD, 1990, J BIOL CHEM, V265, P12618; MACDONALD JIS, 1992, IN PRESS PROTEIN EXP; MORAND JN, 1989, J BIOL CHEM, V264, P13785; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; PESCE A, 1964, J BIOL CHEM, V239, P1753; SCHNEIDER WC, 1963, J BIOL CHEM, V238, P3572; SLEIGHT R, 1980, J BIOL CHEM, V255, P644; SLEIGHT R, 1983, J BIOL CHEM, V258, P824; STERN W, 1976, BIOCHIM BIOPHYS ACTA, V441, P280, DOI 10.1016/0005-2760(76)90171-5; TERCE F, 1988, J BIOL CHEM, V263, P3142; TIJBURG LBM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P1, DOI 10.1016/0005-2760(89)90206-3; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P33; VANCE JE, 1988, J BIOL CHEM, V263, P5898; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WATKINS JD, 1992, J BIOL CHEM, V267, P5686; WATKINS JD, 1990, J BIOL CHEM, V265, P2190; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; WEINHOLD PA, 1991, J BIOL CHEM, V266, P6093; WILGRAM GF, 1963, J BIOL CHEM, V238, P2615; WRIGHT PS, 1985, J BIOL CHEM, V260, P7919	42	126	126	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5899	5904						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8383679				2022-12-25	WOS:A1993KR82200082
J	LAMPHEAR, BJ; YAN, RQ; YANG, F; WATERS, D; LIEBIG, HD; KLUMP, H; KUECHLER, E; SKERN, T; RHOADS, RE				LAMPHEAR, BJ; YAN, RQ; YANG, F; WATERS, D; LIEBIG, HD; KLUMP, H; KUECHLER, E; SKERN, T; RHOADS, RE			MAPPING THE CLEAVAGE SITE IN PROTEIN-SYNTHESIS INITIATION FACTOR-EIF-4-GAMMA OF THE 2A PROTEASES FROM HUMAN COXSACKIEVIRUS AND RHINOVIRUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COMPLETE NUCLEOTIDE-SEQUENCE; MESSENGER-RNA TRANSLATION; INFECTED HELA-CELLS; FACTOR-III; POLIOVIRUS INFECTION; P220 CLEAVAGE; INVOLVEMENT; PROTEOLYSIS; INHIBITION; COMPONENT	The rate-limiting step of eukaryotic protein synthesis is the binding of mRNA to the 40 S ribosomal subunit, a step which is catalyzed by initiation factors of the eIF-4 (eukaryotic initiation factor 4) group: eIF-4A, eIF-4B, eIF-4E, and eIF-4gamma. Infection of cells with picornaviruses of the rhino- and enterovirus groups causes a shut-off in translation of cellular mRNAs but permits viral RNA translation to proceed. This change in translational specificity is thought to be mediated by proteolytic cleavage of eIF-4gamma, which is catalyzed, directly or indirectly, by the picornaviral 2A protease. In this report we have used highly purified recombinant 2A protease from either human Coxsackievirus serotype B4 or rhinovirus serotype 2 to cleave eIF-4gamma in vitro in the eIF-4 complex purified from rabbit reticulocytes. Neither the rate of cleavage nor fragment sizes were affected by addition of eIF-3. The NH2- and COOH-terminal fragments of eIF-4gamma were separated by reverse phase HPLC and identified with specific antibodies, and the NH2-terminal sequence of the COOH-terminal fragment was determined by automated Edman degradation. The cleavage site for both proteases is 479GRPALSSR down GPPRGGPG494 in rabbit eIF-4gamma, corresponding to 478GRTTLSTR down GPPRGGPG493 in human eIF-4gamma.	LOUISIANA STATE UNIV, MED CTR, DEPT BIOCHEM & MOLEC BIOL, 1501 KINGS HWY, SHREVEPORT, LA 71130 USA; UNIV VIENNA, FAK MED, INST BIOCHEM, A-1030 VIENNA, AUSTRIA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Vienna			Skern, Tim/AAC-1732-2022; Klump, Hannes/B-5397-2018	Skern, Tim/0000-0001-8865-5500; Klump, Hannes/0000-0003-3536-1212; Yan, Riqiang/0000-0001-7195-7617	NIGMS NIH HHS [GM20818] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON SD, 1969, J MOL BIOL, V42, P247, DOI 10.1016/0022-2836(69)90041-2; BONNEAU AM, 1987, J VIROL, V61, P986, DOI 10.1128/JVI.61.4.986-991.1987; DUNCAN R, 1987, J BIOL CHEM, V262, P380; EDERY I, 1983, J BIOL CHEM, V258, P1398; ETCHISON D, 1985, J VIROL, V54, P634, DOI 10.1128/JVI.54.2.634-638.1985; ETCHISON D, 1984, J VIROL, V51, P832, DOI 10.1128/JVI.51.3.832-837.1984; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; ETCHISON D, 1987, J VIROL, V61, P2702, DOI 10.1128/JVI.61.9.2702-2710.1987; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; HARLOW E, 1988, ANTIBODIES LABORATOR; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; JENKINS O, 1987, J GEN VIROL, V68, P1835, DOI 10.1099/0022-1317-68-7-1835; KRAUSSLICH HG, 1987, J VIROL, V62, P1243; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LIEBIG HD, 1993, BIOCHEMISTRY-US, V32, P7581, DOI 10.1021/bi00080a033; LLOYD RE, 1988, J VIROL, V62, P4216, DOI 10.1128/JVI.62.11.4216-4223.1988; LLOYD RE, 1986, VIROLOGY, V150, P299, DOI 10.1016/0042-6822(86)90291-6; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; PEREZ L, 1992, VIROLOGY, V189, P178, DOI 10.1016/0042-6822(92)90693-J; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RHOADS RE, 1991, TRANSLATION EUKARYOT, P109; RUECKERT RR, 1990, VIROLOGY, V2, P507; RUECKERT RR, 1990, VIROLOGY, V1, P507; SKERN T, 1991, VIROLOGY, V181, P46, DOI 10.1016/0042-6822(91)90468-Q; SKERN T, 1985, NUCLEIC ACIDS RES, V13, P2111, DOI 10.1093/nar/13.6.2111; SOMMERGRUBER W, 1992, J BIOL CHEM, V267, P22639; SONENBERG N, 1990, CURR TOP MICROBIOL, V161, P23; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; WYCKOFF EE, 1990, P NATL ACAD SCI USA, V87, P9529, DOI 10.1073/pnas.87.24.9529; WYCKOFF EE, 1992, J VIROL, V66, P2943, DOI 10.1128/JVI.66.5.2943-2951.1992; YAN RQ, 1992, J BIOL CHEM, V267, P23226	33	227	234	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19200	19203						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8396129				2022-12-25	WOS:A1993LW81900011
J	BAKKER, AHF; VANDERGREEF, W; REHBERG, EF; MAROTTI, KR; VERHEIJEN, JH				BAKKER, AHF; VANDERGREEF, W; REHBERG, EF; MAROTTI, KR; VERHEIJEN, JH			INTRODUCTION OF LYSINE AND CLOT BINDING-PROPERTIES IN THE KRINGLE ONE DOMAIN OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MOLECULAR MASS UROKINASE; PROTHROMBIN FRAGMENT-1; STRUCTURAL DOMAINS; HAGEMAN-FACTOR; HUMAN-URINE; ONE-CHAIN; FIBRIN; GENE; RESOLUTION	Despite the high overall similarity in primary structure between kringle one (K1) and kringle two (K2) of tissue-type plasminogen activator (t-PA) there exists an enormous functional difference. It is thought that, in contrast to K1, K2 mediates lysine binding and fibrin binding and is involved in stimulation of plasminogen activation by fibrin or derivatives as CNBr fragments of fibrinogen. Hypothesizing that sequence differences are responsible for differences in function, we compared the amino acid sequences of K1 and K2 with a consensus kringle sequence. Six consecutive amino acids unique to K2 of t-PA were found, i.e. from Asn248 to Trp253. To test whether these residues are involved in lysine binding, fibrin binding, and fibrin-dependent plasminogen activation, we constructed a set of t-PA mutant proteins containing only a kringle and the protease (P) domain: K2P, K1P, and k1P. In the latter molecule the original amino acid residues Ala160-Ser165 from K1 were substituted by Asn248-Trp253 from K2. As expected, K2P showed enhanced plasminogen activation in the presence of CNBr fragments of fibrinogen, bound to lysine-Sepharose and to a forming fibrin clot. K1P did not show any of these features. In contrast, k1P could be stimulated by CNBr fragments of fibrinogen and bound to lysine-Sepharose and a forming fibrin clot. These results indicate that at least a part of the functional differences between K1 and K2 of t-PA can be localized to a stretch of 6 amino acid residues from Asn248 to Trp253 present in K2.	TNO,IVVO,GAUBIUS LAB,POB 430,2300 AK LEIDEN,NETHERLANDS; UPJOHN CO,DEPT MOLEC BIOL,KALAMAZOO,MI 49001	Netherlands Organization Applied Science Research; Pfizer								BENNETT WF, 1991, J BIOL CHEM, V266, P5191; BYEON IJL, 1989, BIOCHEMISTRY-US, V28, P9350, DOI 10.1021/bi00450a016; BYEON IJL, 1991, J MOL BIOL, V222, P1035, DOI 10.1016/0022-2836(91)90592-T; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; COOL DE, 1987, J BIOL CHEM, V262, P13662; DEGEN SJF, 1987, BIOCHEMISTRY-US, V26, P6165, DOI 10.1021/bi00393a033; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; DEMUNK GAW, 1989, BIOCHEMISTRY-US, V28, P7318, DOI 10.1021/bi00444a026; DESERRANO VS, 1992, ARCH BIOCHEM BIOPHYS, V292, P206, DOI 10.1016/0003-9861(92)90069-9; DESERRANO VS, 1992, BIOCHEMISTRY-US, V31, P11698, DOI 10.1021/bi00162a005; DEVOS AM, 1992, BIOCHEMISTRY-US, V31, P270, DOI 10.1021/bi00116a037; FORSGREN M, 1987, FEBS LETT, V213, P254, DOI 10.1016/0014-5793(87)81501-6; GETHING MJ, 1988, EMBO J, V7, P2731, DOI 10.1002/j.1460-2075.1988.tb03127.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRANELLIPIPERNO A, 1978, J EXP MED, V148, P223, DOI 10.1084/jem.148.1.223; GUNZLER WA, 1982, H-S Z PHYSIOL CHEM, V363, P1155, DOI 10.1515/bchm2.1982.363.2.1155; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; ICHINOSE A, 1986, J CLIN INVEST, V78, P163, DOI 10.1172/JCI112546; JONES DH, 1990, BIOTECHNIQUES, V8, P178; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGNUSSON S, 1975, PROTEASES BIOL CONTR, P123; MCMULLEN BA, 1985, J BIOL CHEM, V260, P5328; Mulichak A M, 1990, Blood Coagul Fibrinolysis, V1, P673; MULICHAK AM, 1991, BIOCHEMISTRY-US, V30, P10576, DOI 10.1021/bi00107a029; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NESHEIM M, 1990, J BIOL CHEM, V265, P21541; NY T, 1984, P NATL ACAD SCI-BIOL, V81, P5355, DOI 10.1073/pnas.81.17.5355; PANNEKOEK H, 1990, THROMB HAEMOSTASIS, V64, P600; PARK CH, 1986, BIOCHEMISTRY-US, V25, P3977, DOI 10.1021/bi00362a001; PATTHY L, 1984, FEBS LETT, V171, P131, DOI 10.1016/0014-5793(84)80473-1; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; POHL G, 1984, BIOCHEMISTRY-US, V23, P3701, DOI 10.1021/bi00311a020; QUE BG, 1986, BIOCHEMISTRY-US, V25, P1525, DOI 10.1021/bi00355a009; RADCLIFFE R, 1978, ARCH BIOCHEM BIOPHYS, V189, P185, DOI 10.1016/0003-9861(78)90131-5; RANBY M, 1982, THROMB RES, V27, P175, DOI 10.1016/0049-3848(82)90197-9; RAUBER P, 1988, ANAL BIOCHEM, V168, P259, DOI 10.1016/0003-2697(88)90316-8; REHBERG EF, 1989, PROTEIN ENG, V2, P371, DOI 10.1093/protein/2.5.371; RICCIO A, 1985, NUCLEIC ACIDS RES, V13, P2759, DOI 10.1093/nar/13.8.2759; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; STEFFENS GJ, 1982, H-S Z PHYSIOL CHEM, V363, P1043, DOI 10.1515/bchm2.1982.363.2.1043; STERN A, 1990, GENE, V87, P305, DOI 10.1016/0378-1119(90)90318-L; STERN A, 1989, GENE, V79, P333, DOI 10.1016/0378-1119(89)90215-1; TREXLER M, 1983, P NATL ACAD SCI-BIOL, V80, P2457, DOI 10.1073/pnas.80.9.2457; TREXLER M, 1992, FIBRINOLYSIS S, V6, P88; TULINSKY A, 1988, J MOL BIOL, V202, P885, DOI 10.1016/0022-2836(88)90565-7; VANZONNEVELD AJ, 1986, P NATL ACAD SCI USA, V83, P4670; VANZONNEVELD AJ, 1986, J BIOL CHEM, V261, P14214; VERHEIJEN JH, 1985, THROMB RES, V39, P281, DOI 10.1016/0049-3848(85)90223-3; VERHEIJEN JH, 1986, EMBO J, V5, P3525, DOI 10.1002/j.1460-2075.1986.tb04678.x; VERHEIJEN JH, 1982, THROMB RES, V27, P377, DOI 10.1016/0049-3848(82)90055-X; WEENINGVERHOEFF EJD, 1990, PROTEIN ENG, V4, P191, DOI 10.1093/protein/4.2.191	52	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18496	18501						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8395505				2022-12-25	WOS:A1993LV65900021
J	GUSTAFSON, TA; CLEVINGER, EC; ONEILL, TJ; YAROWSKY, PJ; KRUEGER, BK				GUSTAFSON, TA; CLEVINGER, EC; ONEILL, TJ; YAROWSKY, PJ; KRUEGER, BK			MUTUALLY EXCLUSIVE EXON SPLICING OF TYPE-III BRAIN SODIUM CHANNEL-ALPHA SUBUNIT RNA GENERATES DEVELOPMENTALLY-REGULATED ISOFORMS IN RAT-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; SKELETAL-MUSCLE; MESSENGER-RNAS; MOLECULAR-CLONING; GATING PROPERTIES; GENE CONVERSION; XENOPUS OOCYTES; INACTIVATION; HEART; MEMBRANE	We have identified two exons of the type III rat brain sodium channel a subunit gene that undergo mutually exclusive alternative RNA splicing to produce mRNAs coding either for an isoform predominant in neonatal brain (IIIN) or a different isoform (IIIA) predominant in the adult. These exons are 92 base pairs in length and encode amino acids 203-232, which correspond to part of the S3 and most of the S4 transmembrane segments within domain I and the extracellular loop between them. Despite 21 nucleotide differences between the exons, only a single amino acid at position 209 is altered, specifying either aspartic acid (IIIA) or serine (IIIN). As evidence that these isoforms are generated via alternative splicing, we demonstrate that both exons are encoded within the type III gene. The nucleotide sequences of the neonatal and adult type III exons and the intervening intron as well as the developmental regulation of this splicing are nearly identical in the type II sodium channel gene. The conservation of the exon/intron structure and of the developmentally regulated patterns of expression of the type II and III sodium channel genes suggests that alternative mRNA splicing of this exon may play a substantial role in modulating sodium channel function during brain development by alteration of a single amino acid.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,660 W REDWOOD ST,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT PHARMACOL & EXPTL THERAPEUT,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore				Yarowsky, Paul/0000-0002-9745-8143	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016285] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44093] Funding Source: Medline; NINDS NIH HHS [NS16285] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATCHISON M, 1986, P NATL ACAD SCI USA, V83, P2300, DOI 10.1073/pnas.83.8.2300; AULD VJ, 1990, P NATL ACAD SCI USA, V87, P323, DOI 10.1073/pnas.87.1.323; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BECKH S, 1990, FEBS LETT, V262, P317, DOI 10.1016/0014-5793(90)80218-8; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CUKIERMAN S, 1988, J GEN PHYSIOL, V92, P431, DOI 10.1085/jgp.92.4.431; GAUTRON S, 1992, P NATL ACAD SCI USA, V89, P7272, DOI 10.1073/pnas.89.15.7272; GEORGE AL, 1992, P NATL ACAD SCI USA, V89, P4893, DOI 10.1073/pnas.89.11.4893; GREEN WN, 1991, ANNU REV PHYSIOL, V53, P341, DOI 10.1146/annurev.ph.53.030191.002013; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; HARADA F, 1987, P NATL ACAD SCI USA, V84, P8091, DOI 10.1073/pnas.84.22.8091; Hille B., 1992, IONIC CHANNELS EXCIT; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; KRAFTE DS, 1988, J NEUROSCI, V8, P2859; KRAFTE DS, 1990, J GEN PHYSIOL, V96, P689, DOI 10.1085/jgp.96.4.689; Maniatis T., 1982, MOL CLONING; MOORMAN JR, 1990, NEURON, V4, P243, DOI 10.1016/0896-6273(90)90099-2; MORAN O, 1992, FEBS LETT, V302, P21, DOI 10.1016/0014-5793(92)80275-L; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; ROY ML, 1992, J NEUROSCI, V12, P2104; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARAO R, 1991, NUCLEIC ACIDS RES, V19, P5673, DOI 10.1093/nar/19.20.5673; SCHALLER KL, 1992, J NEUROSCI, V12, P1370; SOMMER R, 1989, NUCLEIC ACIDS RES, V17, P6749, DOI 10.1093/nar/17.16.6749; STUHMER W, 1987, EUR BIOPHYS J BIOPHY, V14, P131, DOI 10.1007/BF00253837; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; WEISS RE, 1986, SCIENCE, V233, P361, DOI 10.1126/science.2425432; WHEELER CJ, 1990, NATURE, V347, P192, DOI 10.1038/347192a0; YANG XC, 1992, J NEUROSCI, V12, P268; YAROWSKY PJ, 1992, P NATL ACAD SCI USA, V89, P3669; YAROWSKY PJ, 1991, P NATL ACAD SCI USA, V88, P9453, DOI 10.1073/pnas.88.21.9453	35	96	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18648	18653						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8395514				2022-12-25	WOS:A1993LV65900046
J	BRADY, MJ; PALFREY, HC				BRADY, MJ; PALFREY, HC			RAPID AND SUSTAINED PHOSPHORYLATION OF A CALMODULIN-BINDING PROTEIN (CAM-BP(100)) IN NGF-TREATED PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; FACTOR-INDUCED DIFFERENTIATION; MAP KINASE-KINASE; SIGNAL TRANSDUCTION; TYROSINE PHOSPHORYLATION; PHEOCHROMOCYTOMA CELLS; TRK PROTOONCOGENE; RAS; RECEPTORS; RAF-1	Nerve growth factor (NGF) treatment of PC12 cells led to the rapid phosphorylation of a calmodulin-binding protein of 100 kDa (CaM-BP100) identified on blot overlays with I-125-labeled CaM. The effect was detected as a retardation in the mobility of the protein by an apparent 10 kDa on SDS gels. The mobility shift was complete within 5 min and was maintained for 24 h in the continued presence of NGF. The protein was present in both the soluble and crude particulate fractions, and the gel mobility shift occurred in both fractions. Epidermal growth factor elicited a similar response, but the mobility shift was reversed within 12 h. The gel retardation was due to phosphorylation of CaM-BP100, as it could be reversed if cytoplasmic extracts were held under dephosphorylating conditions at 37-degrees-C for 10 min prior to electrophoresis; dephosphorylation was inhibited by okadaic acid but not vanadate, suggesting the participation of a Ser/Thr phosphatase. Treatment with either acid or alkaline phosphatase also reversed the mobility shift. CaM-BP100 phosphorylation was stimulated by 12-O-tetradecanoylphorbol-13-acetate in intact cells, but the effect of NGF did not involve a protein kinase C-dependent process, because it occurred in PC12 cells depleted of protein kinase C. The phosphorylation event appeared to be due to an NGF-stimulated protein kinase, as mixing extracts from NGF-treated cells with extracts from control cells in the presence of ATP and Mg2+ reconstituted the mobility shift in vitro. CaM-BP100 appears to be a minor cellular phosphoprotein, as P-32 labeling of the protein could not be detected in crude cell extracts. These results suggest that receptor tyrosine kinases communicate with at least one component of the Ca2+/calmodulin-signaling pathway early in signal transduction.	UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, 947 E 58 ST, CHICAGO, IL 60637 USA	University of Chicago					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042715] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-42715] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; BAI G, 1991, J CELL PHYSIOL, V149, P414, DOI 10.1002/jcp.1041490309; BLENIS J, 1986, EMBO J, V5, P3441, DOI 10.1002/j.1460-2075.1986.tb04667.x; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADY MJ, 1990, J NEUROCHEM, V54, P1034, DOI 10.1111/j.1471-4159.1990.tb02354.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHANG F, 1992, MOL BIOL CELL, V3, P445, DOI 10.1091/mbc.3.4.445; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FLANAGAN SD, 1984, ANAL BIOCHEM, V140, P510, DOI 10.1016/0003-2697(84)90202-1; GO M, 1987, METHOD ENZYMOL, V141, P424; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GRAF E, 1980, ARCH BIOCHEM BIOPHYS, V203, P719, DOI 10.1016/0003-9861(80)90231-3; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HEASLEY LE, 1989, MOL PHARMACOL, V35, P331; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MATTHIES HJG, 1987, J NEUROSCI, V7, P1198; MCGUINNESS TL, 1985, J BIOL CHEM, V260, P1696; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NAIRN AC, 1987, J BIOL CHEM, V262, P14265; NAKIELNY S, 1992, FEBS LETT, V308, P183, DOI 10.1016/0014-5793(92)81271-M; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; PALFREY HC, 1982, P NATL ACAD SCI-BIOL, V79, P3780, DOI 10.1073/pnas.79.12.3780; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; SCHULMAN H, 1984, J CELL BIOL, V99, P11, DOI 10.1083/jcb.99.1.11; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TAPLEY P, 1992, ONCOGENE, V7, P371; THOMAS SM, 1991, MOL CELL BIOL, V11, P4739, DOI 10.1128/MCB.11.9.4739; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WATTERSON DM, 1976, J BIOL CHEM, V251, P4501; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	48	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17951	17958						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8394355				2022-12-25	WOS:A1993LT74300049
J	DENECKE, B; BARTKOWSKI, S; SENKEL, S; KLEINHITPASS, L; RYFFEL, GU				DENECKE, B; BARTKOWSKI, S; SENKEL, S; KLEINHITPASS, L; RYFFEL, GU			CHIMERIC LIVER TRANSCRIPTION FACTORS LFB1 (HNF1) CONTAINING THE ACIDIC ACTIVATION DOMAIN OF VP16 ACT AS POSITIVE DOMINANT INTERFERING MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ALBUMIN GENE; RAT HEPATOMA; DEDIFFERENTIATED VARIANTS; PROMOTER ELEMENT; TATA-BOX; BINDING; SEQUENCE; TRANSACTIVATION; COACTIVATORS	The transcription factor LFB1 (HNF1) involved in the expression of liver-specific genes is characterized by a serine/threonine-rich activation domain whose transactivation potential differs between mammals and Xenopus. Exchanging the activation domain between the Xenopus and rat LFB1, we produced chimeric transactivators whose activities are primarily determined by the origin of the activation domain. By replacing the serine/threonine-rich activation domain of LFB1 with the acidic activation domain of VP16, we generated transcription factors that act as dominant positive interfering mutants on endogenous LFB1 in differentiated hepatoma cells. As these LFB1/VP16 chimeras show no self-squelching as observed with wild-type LFB1 and increase the activity of saturating LFB1, we postulate that acidic and serine/threonine-rich activation domains use different targets of the basal transcription machinery. Stable transfection of various LFB1 derivatives, including those containing the VP16 transactivation domain, into the dedifferentiated C2 hepatoma cell resulted in cell clones stably expressing LFB1 function. However, as in none of these clones the chromosomal albumin genes are activated, we conclude that the presence of functional LFB1 may not be sufficient to reactivate liver-specific functions lost in dedifferentiated hepatoma cells.	UNIV GESAMTHHCH ESSEN,INST ZELLBIOL TUMORFORSCH,HUFELANDSTR 55,D-45122 ESSEN,GERMANY									BARTKOWSKI S, 1993, MOL CELL BIOL, V13, P421, DOI 10.1128/MCB.13.1.421; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BULLA GA, 1992, GENE DEV, V6, P316, DOI 10.1101/gad.6.2.316; CEREGHINI S, 1990, EMBO J, V9, P2257, DOI 10.1002/j.1460-2075.1990.tb07396.x; DESCHATRETTE J, 1980, CELL, V22, P501, DOI 10.1016/0092-8674(80)90360-8; DESCHATRETTE J, 1980, CELL, V19, P1043, DOI 10.1016/0092-8674(80)90095-1; DOEBBELING U, 1988, EMBO (European Molecular Biology Organization) Journal, V7, P2495; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; HERBOMEL P, 1989, MOL CELL BIOL, V9, P4750, DOI 10.1128/MCB.9.11.4750; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JOHNSON PF, 1990, CELL GROWTH DIFFER, V1, P47; KILLARY AM, 1984, BIOCHEM GENET, V22, P201, DOI 10.1007/BF00484224; KRIEG PA, 1990, NUCLEIC ACIDS RES, V18, P6463, DOI 10.1093/nar/18.21.6463; KUGLER W, 1988, NUCLEIC ACIDS RES, V16, P3165, DOI 10.1093/nar/16.8.3165; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NICOSIA A, 1990, CELL, V61, P1225, DOI 10.1016/0092-8674(90)90687-A; OTT MO, 1984, EMBO J, V3, P2505, DOI 10.1002/j.1460-2075.1984.tb02164.x; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RANEY AK, 1991, J VIROL, V65, P5774, DOI 10.1128/JVI.65.11.5774-5781.1991; RYFFEL GU, 1989, NUCLEIC ACIDS RES, V17, P939, DOI 10.1093/nar/17.3.939; SAMBROOK KJ, 1989, MOL CLONING LABORATO; SCHORPP M, 1988, J MOL BIOL, V202, P307, DOI 10.1016/0022-2836(88)90460-3; Sladek FM, 1992, CURR OPIN GENET DEV, V2, P256, DOI 10.1016/S0959-437X(05)80282-5; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TONIATTI C, 1990, EMBO J, V9, P4467, DOI 10.1002/j.1460-2075.1990.tb07897.x; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TRONCHE F, 1989, MOL CELL BIOL, V9, P4759, DOI 10.1128/MCB.9.11.4759; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704	34	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18076	18082						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8394359				2022-12-25	WOS:A1993LT74300065
J	ANEL, A; KLEINFELD, AM				ANEL, A; KLEINFELD, AM			TYROSINE PHOSPHORYLATION OF A 100-KDA PROTEIN IS CORRELATED WITH CYTOTOXIC T-LYMPHOCYTE FUNCTION - EVIDENCE FROM CIS-UNSATURATED FATTY-ACID AND PHENYLARSINEOXIDE INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PHOSPHOLIPASE-C ACTIVATION; MEDIATED CYTO-TOXICITY; CROSS-LINKING; TARGET-CELLS; KINASE; CD45; STIMULATION; LYSIS; INTERLEUKIN-2	Cis unsaturated but not saturated fatty acids (FA) have been shown to specifically inhibit certain early responses in cytotoxic T-lymphocytes (CTL) including the rise in intracellular calcium, degranulation, and lethal hit delivery. They do not, however, affect other early events such as the turnover of phosphatidylinositol, T-cell receptor recognition, and CTL-cognate target cell conjugation. Antigen stimulation of CTL results in an increase in the tyrosine phosphorylation levels of more than 10 substrates. We now find that cis unsaturated but not saturated FA specifically inhibit antigen-stimulated tyrosine phosphorylation of only a single substrate, a 100-kDa protein (pp100). The characteristics of cis FA inhibition of the tyrosine phosphorylation of pp100 are virtually identical to the cis FA inhibition of the CTL functional responses. Inhibition occurs within seconds of cis FA addition, can be reversed by extracting the unesterified FA with albumin, can be initiated after stimulation, and has the same dose and FA molecular species dependence as the inhibition of the CTL responses. In addition, low concentrations of phenylarsine oxide specifically inhibit the tyrosine phosphorylation of pp100 and the CTL responses, but have no effect on other tyrosine phosphorylation events. These striking correlations suggest that pp100 may be central to specific early signaling events including lethal hit delivery and its tyrosine phosphorylation may be regulated by a plasma membrane protein tyrosine phosphatase.	MED BIOL INST,DIV MEMBRANE BIOL,11077 N TORREY PINES RD,LA JOLLA,CA 92037				Anel, Alberto/Z-3068-2019					ALAVA MA, 1992, BIOCHEM J, V284, P189, DOI 10.1042/bj2840189; ANASTASSIOU ED, 1992, J IMMUNOL, V148, P2845; ANEL A, 1993, BIOCHEMISTRY-US, V32, P530, DOI 10.1021/bi00053a018; AUGUSTINE JA, 1990, BIOCHIM BIOPHYS ACTA, V1052, P313, DOI 10.1016/0167-4889(90)90227-5; BROWN RE, 1983, J IMMUNOL, V131, P1011; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; DINGEYOUNG J, 1987, J EXP MED, V166, P1894; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GRAY LS, 1987, J IMMUNOL, V138, P63; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANSKI E, 1979, BIOCHEMISTRY-US, V18, P846, DOI 10.1021/bi00572a017; HAVERSTICK DM, 1991, J IMMUNOL, V146, P3306; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; HOCHACHKA PW, 1986, SCIENCE, V231, P234, DOI 10.1126/science.2417316; HSI ED, 1989, J BIOL CHEM, V264, P10836; IGUCHI T, 1989, CANCER RES, V49, P821; JUNE CH, 1990, J IMMUNOL, V144, P1591; KANAKURA Y, 1991, J BIOL CHEM, V266, P490; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KLEINFELD AM, 1993, CYTOTOXIC CELLS GENE, P321; LEDBETTER JA, 1991, J IMMUNOL, V146, P1577; LEGASPI A, 1987, METABOLISM, V36, P958, DOI 10.1016/0026-0495(87)90132-6; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; Martz E, 1977, Contemp Top Immunobiol, V7, P301; MESCHER MF, 1992, J IMMUNOL, V149, P2402; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; OROURKE AM, 1992, NATURE, V358, P253, DOI 10.1038/358253a0; OSTERGAARD H, 1987, J IMMUNOL, V139, P3573; OSTERGAARD HL, 1987, NATURE, V330, P71, DOI 10.1038/330071a0; OSTERGAARD HL, 1989, J IMMUNOL, V143, P2120; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; POENIE M, 1987, EMBO J, V6, P2223, DOI 10.1002/j.1460-2075.1987.tb02494.x; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; RICHIERI GV, 1990, J IMMUNOL, V145, P1074; RICHIERI GV, 1989, J IMMUNOL, V143, P2302; RICHIERI GV, 1990, J IMMUNOL, V144, P671; RICHIERI GV, 1991, J IMMUNOL, V147, P2809; SALTZMAN EM, 1990, J BIOL CHEM, V265, P10138; SALTZMAN EM, 1988, J BIOL CHEM, V263, P6956; SAMLASKA CP, 1979, J NATL CANCER I, V62, P1427; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SITKOVSKY MV, 1993, CYTOTOXIC CELLS GENE; SPECTOR AA, 1975, J LIPID RES, V16, P165; STAERZ UD, 1985, J IMMUNOL, V134, P3994; TAKAYAMA H, 1988, J BIOL CHEM, V263, P2330; TAYLOR AS, 1985, J IMMUNOL, V134, P1130; TRENN G, 1987, NATURE, V330, P72, DOI 10.1038/330072a0; TREVES S, 1987, J EXP MED, V166, P33, DOI 10.1084/jem.166.1.33; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WEAVER CT, 1991, MOL CELL BIOL, V11, P4415, DOI 10.1128/MCB.11.9.4415; YOUNG JD, 1988, IMMUNOL TODAY, V9, P140	57	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17578	17587						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8394347				2022-12-25	WOS:A1993LQ98800100
J	CUBITT, AB; DHARMAWARDHANE, S; FIRTEL, RA				CUBITT, AB; DHARMAWARDHANE, S; FIRTEL, RA			DEVELOPMENTALLY-REGULATED CHANGES IN 1,2-DIACYLGLYCEROL IN DICTYOSTELIUM - REGULATION BY LIGHT AND G-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; INOSITOL 1,4,5-TRISPHOSPHATE; MULTICELLULAR DEVELOPMENT; GENE-EXPRESSION; PHOSPHOLIPASE-D; ALPHA-SUBUNITS; KINASE-C; DISCOIDEUM; DIACYLGLYCEROL; CELLS	We have measured 1,2-diacylglycerol (DG) mass during Dictyostelium development. DG levels are initially high in vegetative cells, decrease upon starvation, increase during aggregation, and rise dramatically during culmination, concomitant with SpiA (a spore cell-specific gene) expression. These results are consistent with DG being involved in culmination-stage morphological changes and cell-type differentiation. Mutant analysis shows that the rise in DG during aggregation requires cAMP signaling pathways but is not directly regulated through these processes but via developmental programs induced through cAMP. DG accumulation during aggregation is approximately 8-fold higher than would be expected from inositol lipid hydrolysis (1), suggesting that DG is produced from sources in addition to phosphatidylinositol 4,5-bisphosphate. Our data suggest that during aggregation, although some DG is formed through phospholipase D activity, other pathways (e.g. de novo synthesis) may be more important regulators of DG accumulation. During culmination, DG accumulation correlated with the formation of phosphatidic acid and phosphatidylethanol suggesting the activation of phospholipase D. During this time, the [H-3]palmitate labeling of a number of phospholipids decreased rapidly, suggesting a rapid metabolism of phospholipids at this time. Exposure of slugs developed in the dark to light, which initiates culmination, causes rapid DG accumulation, suggesting the activation of phospholipid hydrolysis. The temporal pattern and level of DG accumulation is altered in Galpha1 null and overexpressing strains, suggesting that Galpha1 is upstream from DG formation during culmination. These results demonstrate that specific pathways of DG formation are under developmental control and suggest a possible link between light, the activation of DG production, and induction of culmination.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,DEPT BIOL,0634,RM 225,9500 GILMAN DR,LA JOLLA,CA 92093	University of California System; University of California San Diego								AECKERLE S, 1989, BIOCHIM BIOPHYS ACTA, V1012, P196, DOI 10.1016/0167-4889(89)90096-7; AMES BN, 1960, J BIOL CHEM, V235, P769; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BOMINAAR AA, 1991, DEV GENET, V12, P19, DOI 10.1002/dvg.1020120106; BONNER JT, 1959, CELLULAR SLIME MOLDS, P134; CLARKE M, 1988, DEV GENET, V9, P315, DOI 10.1002/dvg.1020090413; CUBITT AB, 1992, BIOCHEM J, V283, P371, DOI 10.1042/bj2830371; CUBITT AB, 1992, IN PRESS COLD SPRING, V57; CUBITT AB, 1990, J BIOL CHEM, V265, P6457; DARMON M, 1975, P NATL ACAD SCI USA, V72, P3163, DOI 10.1073/pnas.72.8.3163; DAWSON RMC, 1967, BIOCHEM J, V102, P205, DOI 10.1042/bj1020205; DEVREOTES P, 1989, SCIENCE, V245, P1054, DOI 10.1126/science.2672337; ELLINGSON JS, 1974, BIOCHIM BIOPHYS ACTA, V337, P60, DOI 10.1016/0005-2760(74)90040-X; EXTON JH, 1990, J BIOL CHEM, V265, P1; FARESE RV, 1987, SCIENCE, V236, P586, DOI 10.1126/science.3107122; FIRTEL RA, 1991, TRENDS GENET, V7, P381, DOI 10.1016/0168-9525(91)90260-W; FIRTEL RA, 1989, CELL, V58, P235, DOI 10.1016/0092-8674(89)90837-4; FONTANA DR, 1991, MOL CELL BIOL, V11, P468, DOI 10.1128/MCB.11.1.468; GILROY S, 1990, NATURE, V346, P769, DOI 10.1038/346769a0; GINSBURG G, 1989, P NATL ACAD SCI USA, V86, P9332, DOI 10.1073/pnas.86.23.9332; GOMER RH, 1991, DEVELOPMENT, V112, P269; HABERSTROH L, 1990, GENE DEV, V4, P596, DOI 10.1101/gad.4.4.596; HADWIGER JA, 1991, P NATL ACAD SCI USA, V88, P8213, DOI 10.1073/pnas.88.18.8213; HASE A, 1982, ARCH BIOCHEM BIOPHYS, V219, P21, DOI 10.1016/0003-9861(82)90129-1; HII CST, 1991, J BIOL CHEM, V266, P20238; IMAI A, 1987, J BIOL CHEM, V262, P9707; JANSSENS PMW, 1987, MICROBIOL REV, V51, P396, DOI 10.1128/MMBR.51.4.396-418.1987; JANSSENS PMW, 1989, J BIOL CHEM, V264, P4329; KAY RR, 1983, NATURE, V303, P242, DOI 10.1038/303242a0; KESBEKE F, 1988, J CELL BIOL, V107, P521, DOI 10.1083/jcb.107.2.521; Kimmel AR, 1991, CURR OPIN GENET DEV, V1, P383, DOI 10.1016/S0959-437X(05)80304-1; KISHIMOTO A, 1980, J BIOL CHEM, V255, P2273; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KUMAGAI A, 1989, CELL, V57, P265, DOI 10.1016/0092-8674(89)90964-1; KUMAGAI A, 1991, J BIOL CHEM, V266, P1211; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; LUNDBERG GA, 1990, FEBS LETT, V270, P181, DOI 10.1016/0014-5793(90)81262-M; MACDONALD JIS, 1985, BIOCHIM BIOPHYS ACTA, V834, P301, DOI 10.1016/0005-2760(85)90002-5; MAHADEVAPPA VG, 1984, CAN J BIOCHEM CELL B, V62, P827, DOI 10.1139/o84-105; MALCHOW D, 1978, BIOCHIM BIOPHYS ACTA, V538, P473, DOI 10.1016/0304-4165(78)90408-7; MANN SKO, 1989, P NATL ACAD SCI USA, V86, P1924, DOI 10.1073/pnas.86.6.1924; MANN SKO, 1992, P NATL ACAD SCI USA, V89, P10701, DOI 10.1073/pnas.89.22.10701; MANN SKO, 1991, MECH DEVELOP, V35, P89, DOI 10.1016/0925-4773(91)90060-J; MILNE JL, 1991, J CELL BIOL, V112, P103, DOI 10.1083/jcb.112.1.103; MULLER WA, 1991, DEV BIOL, V147, P460, DOI 10.1016/0012-1606(91)90304-L; NEWELL PC, 1969, J BACTERIOL, V100, P763, DOI 10.1128/JB.100.2.763-768.1969; NEWELL PC, 1990, CELL BIOL, V1, P105; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OTTE AP, 1992, CELL, V68, P1021, DOI 10.1016/0092-8674(92)90074-M; PAN P, 1972, NATURE-NEW BIOL, V237, P181, DOI 10.1038/newbio237181a0; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; PUPILLO M, 1989, P NATL ACAD SCI USA, V86, P4892, DOI 10.1073/pnas.86.13.4892; RICHARDSON DL, 1991, DEV BIOL, V144, P269, DOI 10.1016/0012-1606(91)90421-X; SHACKLOCK PS, 1992, NATURE, V358, P753, DOI 10.1038/358753a0; SHARIFF A, 1992, SCIENCE, V256, P245, DOI 10.1126/science.1373523; SMITH GA, 1978, LIPIDS, V13, P92, DOI 10.1007/BF02533373; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; THEIBERT A, 1986, J BIOL CHEM, V261, P5121; VANHAASTERT PJM, 1989, ANAL BIOCHEM, V177, P115, DOI 10.1016/0003-2697(89)90024-9; VANHAASTERT PJM, 1989, BIOCHEM J, V258, P577, DOI 10.1042/bj2580577; WILLIAMS JG, 1987, CELL, V49, P185, DOI 10.1016/0092-8674(87)90559-9; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374; WU LJ, 1991, BIOCHEM BIOPH RES CO, V179, P1141, DOI 10.1016/0006-291X(91)91690-E; YANG SF, 1967, J BIOL CHEM, V242, P477	65	15	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17431	17439						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8394342				2022-12-25	WOS:A1993LQ98800081
J	PLOUG, M; KJALKE, M; RONNE, E; WEIDLE, U; HOYERHANSEN, G; DANO, K				PLOUG, M; KJALKE, M; RONNE, E; WEIDLE, U; HOYERHANSEN, G; DANO, K			LOCALIZATION OF THE DISULFIDE BONDS IN THE NH2-TERMINAL DOMAIN OF THE CELLULAR RECEPTOR FOR HUMAN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR - A DOMAIN-STRUCTURE BELONGING TO A NOVEL SUPERFAMILY OF GLYCOLIPID-ANCHORED MEMBRANE-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; DESORPTION MASS-SPECTROMETRY; PERIPHERAL-BLOOD LEUKOCYTES; AMINO-ACID-ANALYSIS; GLYCOSYL-PHOSPHATIDYLINOSITOL; LY-6 SUPERFAMILY; MESSENGER-RNAS; GENE; BINDING; CD59	The receptor for human urokinase-type plasminogen activator (uPAR) is synthesized as a 313-residue-long polypeptide containing 28 cysteine residues, the pattern of which defines three homologous repeats within the protein. These entities are believed to represent a novel protein domain structure, of which the NH2-terminal domain of uPAR can be covalently cross-linked to the epidermal growth factor-like module of urokinase after receptor-ligand interaction. The NH2-terminal domain of a recombinant, soluble uPAR derivative, labeled with [S-35]cysteine, was isolated after limited proteolysis with chymotrypsin. The four disulfide bonds present within this domain were assigned by a combination of plasma desorption mass spectrometry, amino acid composition, and sequence analyses of peptides generated by trypsin, endoproteinase Asp-N, and thermolysin. The following disulfide bond structure was determined: Cys3-Cys24, Cys6-Cys12, Cys17-Cys45, and Cys71-Cys76. Similar cysteine pairing is likely to be found within other members of this protein superfamily, i.e. the membrane inhibitor of reactive lysis, Ly-6, and the remaining two domains of uPAR. However, an additional pair of cysteines present within these domains probably forms a fifth disulfide bond.	BOEHRINGER MANNHEIM,DIV MOLEC ONCOL,W-8122 PENZBERG,GERMANY; UNIV COPENHAGEN,INST BIOCHEM GENET,DK-1353 COPENHAGEN,DENMARK	University of Copenhagen	PLOUG, M (corresponding author), RIGSHOSP,FINSEN INST,OPG 8621,STRANDBOULEVARDEN 49,DK-2100 COPENHAGEN,DENMARK.			Ploug, Michael/0000-0003-2215-4265				ALBRECHT JC, 1992, VIROLOGY, V190, P527, DOI 10.1016/0042-6822(92)91247-R; BARKHOLT V, 1989, ANAL BIOCHEM, V177, P318, DOI 10.1016/0003-2697(89)90059-6; BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BLASI F, 1988, Fibrinolysis, V2, P73, DOI 10.1016/0268-9499(88)90370-0; BOGLUM AD, 1992, AM J HUM GENET, V50, P492; BOTHWELL A, 1988, J IMMUNOL, V140, P2815; CAMPBELL ID, 1990, BIOCHEM PHARMACOL, V40, P35, DOI 10.1016/0006-2952(90)90175-K; DAVIES A, 1989, J EXP MED, V170, P637, DOI 10.1084/jem.170.3.637; ELLIS V, 1992, ANN NY ACAD SCI, V667, P13, DOI 10.1111/j.1749-6632.1992.tb51591.x; FRIEDMAN S, 1990, IMMUNOGENETICS, V31, P104, DOI 10.1007/BF00661220; HADDOCK RC, J BIOL CHEM, V266, P21466; HOJRUP P, 1989, 5TH P S ION FORM ORG, P61; KRISTENSEN P, 1991, J CELL BIOL, V115, P1763, DOI 10.1083/jcb.115.6.1763; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MAZAR AP, 1992, FIBRINOLYSIS, V6, P49, DOI 10.1016/0268-9499(92)90094-X; MCNEILL H, 1990, CELL REGUL, V1, P843, DOI 10.1091/mbc.1.11.843; MILES LA, 1987, THROMB HAEMOSTASIS, V58, P936; MOLLER LB, 1992, EUR J BIOCHEM, V208, P493, DOI 10.1111/j.1432-1033.1992.tb17213.x; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; NIELSEN PF, 1988, BIOMED ENVIRON MASS, V17, P355, DOI 10.1002/bms.1200170503; NIELSEN PF, 1989, PROTEIN ENG, V2, P449, DOI 10.1093/protein/2.6.449; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; NYKJAER A, 1990, BIOCHIM BIOPHYS ACTA, V1052, P399, DOI 10.1016/0167-4889(90)90149-8; PALFREE RGE, 1991, IMMUNOL TODAY, V12, P170, DOI 10.1016/0167-5699(91)90086-9; PATTHY L, 1987, FEBS LETT, V214, P1, DOI 10.1016/0014-5793(87)80002-9; Patthy L, 1991, CURR OPIN STRUC BIOL, V1, P351, DOI 10.1016/0959-440X(91)90033-P; PETRANKA JG, 1992, P NATL ACAD SCI USA, V89, P7876, DOI 10.1073/pnas.89.17.7876; PLOUG M, 1991, SEMIN THROMB HEMOST, V17, P183, DOI 10.1055/s-2007-1002608; PLOUG M, 1992, EUR J BIOCHEM, V208, P397, DOI 10.1111/j.1432-1033.1992.tb17200.x; PLOUG M, 1992, ELECTROPHORESIS, V13, P148, DOI 10.1002/elps.1150130130; PLOUG M, 1991, J BIOL CHEM, V266, P1926; PLOUG M, 1992, BLOOD, V79, P1447; ROBERTSON EF, 1987, ANAL BIOCHEM, V167, P290, DOI 10.1016/0003-2697(87)90166-7; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; RONNE E, 1991, FEBS LETT, V288, P233, DOI 10.1016/0014-5793(91)81042-7; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TOMITA M, 1991, Complement and Inflammation, V8, P233; TONE M, 1992, J MOL BIOL, V227, P971, DOI 10.1016/0022-2836(92)90239-G; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WEIDLE UH, 1988, GENE, V73, P439, DOI 10.1016/0378-1119(88)90508-2; Wilkinson JM, 1986, PRACTICAL PROTEIN CH; WILLIAMS AF, 1991, CELL BIOL INT REP, V15, P769, DOI 10.1016/0309-1651(91)90032-E; WILLIAMS AF, 1988, IMMUNOGENETICS, V27, P265, DOI 10.1007/BF00376121	45	133	140	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17539	17546						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8394346				2022-12-25	WOS:A1993LQ98800094
J	NEERMANARBEZ, M; SIZONENKO, SV; HALBAN, PA				NEERMANARBEZ, M; SIZONENKO, SV; HALBAN, PA			SLOW CLEAVAGE AT THE PROINSULIN B-CHAIN CONNECTING PEPTIDE JUNCTION ASSOCIATED WITH LOW-LEVELS OF ENDOPROTEASE-PC1/3 IN TRANSFORMED BETA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INSULIN; PC2; IDENTIFICATION; PITUITARY; FURIN; KEX2; ENDOPEPTIDASE; LANGERHANS; SEQUENCE; FAMILY	Conversion of rat proinsulins I and II was slower in transformed INS cells than in primary (islet) beta cells, with accumulation of des-64,65 but no detectable des-31,32-split proinsulin, indicating slow cleavage at the B-chain/connecting peptide (C-peptide) junction. Western blot analysis showed lower levels of the endoprotease PC1/3 in INS cells than in beta cells, as well as a 4-fold reduction in the ratio of PC1/3 to PC2, thus supporting the hypothesis that PC1/3 is the endoprotease responsible for cleavage at the B-chain/C-peptide junction.			NEERMANARBEZ, M (corresponding author), UNIV GENEVA,MED CTR,LABS RECH LOUIS JEANTET,1 RUE MICHEL SERVET,CH-1211 GENEVA 4,SWITZERLAND.		Sizonenko, Stephane/GXV-9222-2022	Neerman-Arbez, Marguerite/0000-0002-9351-4195; Sizonenko, Stephane/0000-0003-0093-8747	NIDDK NIH HHS [DK-35292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALARCON C, 1993, J BIOL CHEM, V268, P4276; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BAILYES EM, 1992, BIOCHEM J, V285, P391, DOI 10.1042/bj2850391; BENNETT DL, 1992, J BIOL CHEM, V267, P15299; CLARKE JL, 1969, P NATL ACAD SCI USA, V62, P10712; DAVIDSON HW, 1987, BIOCHEM J, V245, P575, DOI 10.1042/bj2450575; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; GISHIZKY ML, 1987, FEBS LETT, V223, P227, DOI 10.1016/0014-5793(87)80294-6; HALBAN PA, 1986, DIABETOLOGIA, V29, P893, DOI 10.1007/BF00870146; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMEDICO P, 1979, CELL, V18, P545, DOI 10.1016/0092-8674(79)90071-0; ORCI L, 1985, DIABETOLOGIA, V28, P528, DOI 10.1007/BF00281987; RHODES CJ, 1992, J BIOL CHEM, V267, P22719; RHODES CJ, 1987, J BIOL CHEM, V262; ROUILLER DG, 1990, EXP CELL RES, V191, P305, DOI 10.1016/0014-4827(90)90019-7; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SIZONENKO SV, 1991, BIOCHEM J, V278, P621, DOI 10.1042/bj2780621; SMEEKENS SP, 1991, CELL BIOPHYS, V19, P45, DOI 10.1007/BF02989878; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; STEINER DF, 1987, P NATL ACAD SCI USA, V84, P6184, DOI 10.1073/pnas.84.17.6184; STEINER DF, 1989, ENDOCRINOLOGY, P1263	26	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16098	16100						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8393853				2022-12-25	WOS:A1993LQ33600005
J	BOSSER, R; ALIGUE, R; GUERINI, D; AGELL, N; CARAFOLI, E; BACHS, O				BOSSER, R; ALIGUE, R; GUERINI, D; AGELL, N; CARAFOLI, E; BACHS, O			CALMODULIN CAN MODULATE PROTEIN-PHOSPHORYLATION IN RAT-LIVER CELLS NUCLEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; PROLACTIN GENE-EXPRESSION; BINDING PROTEINS; GROWTH-FACTOR; IDENTIFICATION; MATRIX; LOCALIZATION; REGENERATION; ASSOCIATION; ACTIVATION	This report describes the immunological identification of a 60-kDa calmodulin-binding protein, previously detected in the nuclei of rat liver cells (Bachs, O., Lanini, L., Serratosa, J., Coll, M. J., Bastos, R., Aligue, R., Rius, E., and Carafoli, E. (1990) J. Biol. Chem. 265, 18595-18600), as the calmodulin-dependent protein phosphatase calcineurin. Calcineurin could be extracted from the nuclei by incubation with DNase and RNase, indicating that it is associated with nuclear structures sensitive to the action of nucleases (chromatin or/and ribonucleoproteins). The presence of calcineurin in the nuclei of rat liver cells indicates that calmodulin may modulate the phosphorylation level of nuclear proteins by promoting their dephosphorylation. This report also shows that calmodulin inhibits the activity of casein kinase-2 in the nuclear fractions obtained by nuclease extraction. Phosphorylation experiments indicate that casein kinase-2 phosphorylates three major substrates of 100, 42-44, and 37 kDa as well as other minor proteins in the nuclease extracts. Calmodulin reduces the phosphorylation level of the two latter major proteins and of a minor band of 50 kDa. Thus, nuclear calmodulin in rat liver cells could regulate phosphorylation of nuclear proteins by at least two mechanisms: 1) activation of calcineurin and 2) inhibition of casein kinase-2.	UNIV BARCELONA,FAC MED,DEPT CELL BIOL,CASANOVA 143,E-08036 BARCELONA,SPAIN; SWISS FED INST TECHNOL,INST BIOCHEM,CH-8092 ZURICH,SWITZERLAND; NCI,BIOCHEM LAB,BETHESDA,MD 20892	University of Barcelona; ETH Zurich; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Agell, Neus/E-9640-2016; Carafoli, Ernesto/K-5192-2016	Agell, Neus/0000-0002-1205-6074; Carafoli, Ernesto/0000-0002-7826-0094				ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; BACHS O, 1990, J BIOL CHEM, V265, P18595; BACHS O, 1987, J BIOL CHEM, V262, P10786; BOYNTON AL, 1980, BIOCHEM BIOPH RES CO, V95, P745, DOI 10.1016/0006-291X(80)90849-9; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CHAFOULEAS JG, 1984, CALCIUM CELL FUNCTIO, V5, P101; CHAFOULEAS JG, 1982, IONS CELL PROLIFERAT, P449; CHEUNG WY, 1988, CALCIUM CALCIUM BIND, P163; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DAY RN, 1990, MOL ENDOCRINOL, V4, P736, DOI 10.1210/mend-4-5-736; FAMULSKI KS, 1984, EUR J BIOCHEM, V141, P15, DOI 10.1111/j.1432-1033.1984.tb08149.x; GUERINI D, 1984, J BIOL CHEM, V259, P5172; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARPER JF, 1980, CALCIUM CELL FUNCTIO, V1, P273; Hathaway G M, 1979, Methods Enzymol, V60, P495; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; JAKOBI R, 1989, EUR J BIOCHEM, V183, P227, DOI 10.1111/j.1432-1033.1989.tb14917.x; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KAUFMANN SH, 1984, EXP CELL RES, V155, P477, DOI 10.1016/0014-4827(84)90208-8; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEE CB, 1990, NEUROTOXICITY EXCITA, P95; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LOOMIS PA, 1990, P NATL ACAD SCI USA, V87, P8422, DOI 10.1073/pnas.87.21.8422; MEANS AR, 1982, PHYSIOL REV, V62, P1, DOI 10.1152/physrev.1982.62.1.1; MEGGIO F, 1987, FEBS LETT, V215, P241, DOI 10.1016/0014-5793(87)80154-0; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; MULNERLORILLON O, 1990, EUR J BIOCHEM, V193, P529, DOI 10.1111/j.1432-1033.1990.tb19368.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHTA Y, 1990, P NATL ACAD SCI USA, V87, P5341, DOI 10.1073/pnas.87.14.5341; PEREZ M, 1988, FEBS LETT, V238, P273, DOI 10.1016/0014-5793(88)80495-2; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PUJOL MJ, 1993, J NEUROCHEM, V60, P1422, DOI 10.1111/j.1471-4159.1993.tb03304.x; PUJOL MJ, 1989, J BIOL CHEM, V264, P18863; SAHYOUN N, 1984, J BIOL CHEM, V259, P9341; SCHNEIDER HR, 1986, EUR J BIOCHEM, V161, P733, DOI 10.1111/j.1432-1033.1986.tb10501.x; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SERRATOSA J, 1988, BIOCHEM BIOPH RES CO, V150, P1162, DOI 10.1016/0006-291X(88)90751-6; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SIKORSKA M, 1980, BIOCHEM BIOPH RES CO, V93, P1196, DOI 10.1016/0006-291X(80)90616-6; SIKORSKA M, 1983, J CELL PHYSIOL, V115, P297, DOI 10.1002/jcp.1041150313; SIMMEN RCM, 1984, J CELL BIOL, V99, P588, DOI 10.1083/jcb.99.2.588; SOMMERCORN J, 1987, J BIOL CHEM, V262, P3839; Stemmer P, 1991, Curr Opin Neurobiol, V1, P53, DOI 10.1016/0959-4388(91)90010-5; SUBRAMANYAM C, 1990, J CELL PHYSIOL, V144, P423, DOI 10.1002/jcp.1041440309; SULAKHE PV, 1971, BIOCHEM BIOPH RES CO, V42, P793, DOI 10.1016/0006-291X(71)90499-2; TASH JS, 1988, J CELL BIOL, V106, P1625, DOI 10.1083/jcb.106.5.1625; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; THOMPSON RJ, 1973, J NEUROCHEM, V21, P19, DOI 10.1111/j.1471-4159.1973.tb04222.x; THORNBURG W, 1979, BIOCHIM BIOPHYS ACTA, V571, P35, DOI 10.1016/0005-2744(79)90222-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VENDRELL M, 1991, J NEUROCHEM, V57, P622, DOI 10.1111/j.1471-4159.1991.tb03793.x; WHITE BA, 1985, J BIOL CHEM, V260, P1213	56	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15477	15483						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8393444				2022-12-25	WOS:A1993LN30500026
J	XU, J; THOMPSON, KL; SHEPHARD, LB; HUDSON, LG; GILL, GN				XU, J; THOMPSON, KL; SHEPHARD, LB; HUDSON, LG; GILL, GN			T(3) RECEPTOR SUPPRESSION OF SP1-DEPENDENT TRANSCRIPTION FROM THE EPIDERMAL GROWTH-FACTOR RECEPTOR PROMOTER VIA OVERLAPPING DNA-BINDING SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; THYROID-HORMONE RECEPTORS; RESPONSE ELEMENTS; NEGATIVE REGULATION; NUCLEAR RECEPTORS; GENE-TRANSCRIPTION; MAMMALIAN-CELLS; ACID RECEPTORS; LIGAND-BINDING; RNA-POLYMERASE	Expression of the human epidermal growth factor receptor (EGFR) gene is inhibited by ligand-activated thyroid hormone receptor (T3R). Binding sites for Sp1 and for the T3R-retinoid X receptor (RXR) complex overlap in a functional core of the EGFR promoter. Sp1 inhibited binding of the T3R complex to this 36-base pair (bp) EGFR element in vitro but did not affect binding of the T3R complex to a positive thyroid hormone response element (TRE). In Drosophila SL2 cells, which lack Sp1 and T3R, function of the EGFR promoter was strongly dependent on Sp1. Sp1-dependent promoter function was inhibited by ligand-activated T3R but not by mutant T3R defective in DNA or T3 binding. RXR increased the extent of inhibition. Sp1 enhanced activity of the 36-bp element placed 5' to a minimal TATA promoter and this enhancement was also repressed by T3R. Mutations in the 36-bp element were unable to separate Sp1 and T3R functions. However, addition of a second half-site 5' to the existing site in an inverted repeat configuration created a positive TRE. In the absence of ligand, T3R inhibited Spl stimulation from this altered element; addition of T3 reversed the inhibition. When a dimeric TRE is separated from Sp1-binding sites strong synergism was observed. The nature and location of the TRE thus strongly influence biological responses. A TRE site in the EGFR promoter that overlaps an Sp1-binding site inhibits Sp1 function but is unable to direct positive function.	UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA; NORTHWESTERN UNIV, SCH MED, DEPT PHARMACOL, CHICAGO, IL 60611 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Northwestern University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013149, R37DK013149] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK13149] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHBURNER M, 1989, DROSOPHILA LABORATOR; BARRERASALDANA H, 1985, EMBO J, V4, P3839, DOI 10.1002/j.1460-2075.1985.tb04156.x; BEATO M, 1991, FASEB J, V5, P2044, DOI 10.1096/fasebj.5.7.2010057; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARK AJL, 1985, P NATL ACAD SCI USA, V82, P8374, DOI 10.1073/pnas.82.24.8374; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CRONE DE, 1990, J BIOL CHEM, V265, P10851; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; HERMANN T, 1991, CELL REGUL, V2, P565, DOI 10.1091/mbc.2.7.565; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HUDSON LG, 1990, P NATL ACAD SCI USA, V87, P7536, DOI 10.1073/pnas.87.19.7536; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; HUDSON LG, 1989, MOL ENDOCRINOL, V3, P400, DOI 10.1210/mend-3-2-400; INOUE A, 1983, ANAL BIOCHEM, V134, P176, DOI 10.1016/0003-2697(83)90280-4; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAGEYAMA R, 1988, P NATL ACAD SCI USA, V85, P5016, DOI 10.1073/pnas.85.14.5016; KAGEYAMA R, 1988, J BIOL CHEM, V263, P6329; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KUDLOW JE, 1986, J BIOL CHEM, V261, P4134; KWIOKAWA R, 1993, IN PRESS GENES DEV; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MEIER CA, 1992, MOL ENDOCRINOL, V6, P248, DOI 10.1210/me.6.2.248; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NORTH D, 1992, PEDIATR RES, V31, P330, DOI 10.1203/00006450-199204000-00005; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RENTOUMIS A, 1990, MOL ENDOCRINOL, V4, P1522, DOI 10.1210/mend-4-10-1522; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; TAN SH, 1992, NUCLEIC ACIDS RES, V20, P251, DOI 10.1093/nar/20.2.251; TANSEY WP, 1991, J BIOL CHEM, V266, P9805; THOMPSON KL, 1992, MOL ENDOCRINOL, V6, P627, DOI 10.1210/me.6.4.627; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	62	65	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					16065	16073						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8393457				2022-12-25	WOS:A1993LN30500103
J	HU, LF; CHEN, F; ZHENG, X; ERNBERG, I; CAO, SL; CHRISTENSSON, B; KLEIN, G; WINBERG, G				HU, LF; CHEN, F; ZHENG, X; ERNBERG, I; CAO, SL; CHRISTENSSON, B; KLEIN, G; WINBERG, G			CLONABILITY AND TUMORIGENICITY OF HUMAN EPITHELIAL-CELLS EXPRESSING THE EBV ENCODED MEMBRANE-PROTEIN LMP1	ONCOGENE			English	Article							EPSTEIN-BARR-VIRUS; NASOPHARYNGEAL CARCINOMA; HUMAN KERATINOCYTES; NEOPLASTIC TRANSFORMATION; NUCLEAR ANTIGEN; BNLF-1 GENE; B-CELLS; ONCOGENE; GENOME; DEATH	Two isolates of the EBV-LMP1 gene were compared for their ability to induce phenotypic changes in a non-tumorigenic human keratinocyte line, Rhek-1, immortalized with an adenovirus 12-SV40 hybrid virus. One isolate, designated B-LMP1, was derived from B95-8, a B-cell line of marmoset origin, that carries a viral strain from a mononucleosis patient. The other, designated C-LMP1, originated from a nude mouse passaged Chinese NPC tumor, CAO. Both types of transfectants were less serum dependent than the non-transfected and the vector-transfected controls. The ability to grow on low serum increased with increasing LMP1 expression. All transfectants were more highly clonable than the non-transfected or vector-transfected controls. Clonability in soft agarose increased with increasing LMP1 expression. Nine of 24 C-LMP1 transfectants produced tumors in SCID mice. Seven of them grew invasively into the surrounding tissue. Only one of 12 B-LMP1 transfected Rhek-1 clones was tumorigenic. It did not grow invasively. All tumorigenic transfectants expressed LMP1 at high or moderate levels. All tumors were found to express LMP1. Transfectants with low LMP1 expression did not produce tumors. The untransfected Rhek-1 cells and six vector control clones failed to produce tumors.	KAROLINSKA INST,DEPT TUMOR BIOL,BOX 60400,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT PATHOL,S-14186 HUDDINGE,SWEDEN; SHANGHAI MED UNIV,TUMOR HOSP,SHANGHAI,PEOPLES R CHINA; FRED HUTCHINSON CANC RES CTR,PROGRAMME CANC BIOL,SEATTLE,WA 98104	Karolinska Institutet; Karolinska Institutet; Fudan University; Fred Hutchinson Cancer Center			Winberg, Gosta/I-5686-2013	Winberg, Gosta/0000-0002-3371-4056	NATIONAL CANCER INSTITUTE [R01CA030264] Funding Source: NIH RePORTER; NCI NIH HHS [2RQI CA30264-10] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSONANVRET M, 1977, INT J CANCER, V20, P486, DOI 10.1002/ijc.2910200403; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BAICHWAL VR, 1989, ONCOGENE, V4, P67; CHEN ML, 1992, ONCOGENE, V7, P2131; CUOMO L, 1993, IN PRESS INT J CANCE; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FIDLER IJ, 1991, ANTICANCER RES, V11, P17; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; Hausen H., 1970, NATURE, V228, P1056; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HENLE W, 1970, J NATL CANCER I, V44, P225; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P4737, DOI 10.1073/pnas.71.12.4737; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBOWITZ D, 1992, J VIROL, V66, P4612, DOI 10.1128/JVI.66.7.4612-4616.1992; MANN KP, 1987, J VIROL, V61, P2100, DOI 10.1128/JVI.61.7.2100-2108.1987; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; RHIM JS, 1989, ANTICANCER RES, V9, P1345; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; RYMO L, 1985, P NATL ACAD SCI USA, V82, P3435, DOI 10.1073/pnas.82.10.3435; SALCEDO R, 1991, J VIROL, V65, P5558, DOI 10.1128/JVI.65.10.5558-5563.1991; Sambrook J, 1989, MOL CLONING LABORATO; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WOLF H, 1973, NATURE-NEW BIOL, V244, P245, DOI 10.1038/newbio244245a0; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; ZHANG RD, 1991, CANCER RES, V51, P2029	34	178	205	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1575	1583						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8389032				2022-12-25	WOS:A1993LE06400021
J	ROE, MW; LANCASTER, ME; MERTZ, RJ; WORLEY, JF; DUKES, ID				ROE, MW; LANCASTER, ME; MERTZ, RJ; WORLEY, JF; DUKES, ID			VOLTAGE-DEPENDENT INTRACELLULAR CALCIUM RELEASE FROM MOUSE ISLETS STIMULATED BY GLUCOSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CARDIAC SARCOPLASMIC-RETICULUM; PANCREATIC B-CELLS; INOSITOL TRISPHOSPHATE; INSULIN-SECRETION; GUINEA-PIG; BETA-CELLS; CA-2+; CHANNELS; ACTIVATION; CAFFEINE	Glucose-activated beta-cell insulin secretion depends upon elevation of intracellular calcium concentration, [Ca2+]i, which is thought to arise from Ca2+ influx through voltage-dependent calcium channels. Using fura-2-loaded mouse islets, we demonstrate, in fact, that the major component of the glucose-activated [Ca2+]i rise represents voltage-dependent intracellular Ca2+ release. Furthermore, the Ca2+ release pool possesses a novel pharmacology in that it is caffeine-sensitive but ryanodine-insensitive. In the absence of external Ca2+, glucose still caused intracellular Ca2+ release, an effect blockable by tetrodotoxin. However, depolarization of the islet with KCl in low Ca2+-containing solutions induced intracellular Ca2+ release, which was resistant to tetrodotoxin. We conclude that glucose release of intracellular Ca2+ is dependent upon depolarization alone, possibly through increasing inositol 1,4,5-trisphosphate production.	GLAXO RES INST,DEPT CELL PHYSIOL & IMMUNOL,5 MOORE DR,RES TRIANGLE PK,NC 27709	GlaxoSmithKline								AMMALA C, 1991, NATURE, V353, P849, DOI 10.1038/353849a0; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; BERRIDGE MJ, 1986, J EXP BIOL, V124, P323; CALLEWAERT G, 1989, AM J PHYSIOL, V257, pC147, DOI 10.1152/ajpcell.1989.257.1.C147; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; DIARRA A, 1992, PFLUG ARCH EUR J PHY, V422, P40, DOI 10.1007/BF00381511; DUKES ID, 1993, AM J PHYSIOL, V27, pE348; GILON P, 1992, J BIOL CHEM, V267, P20713; GRAPENGIESSER E, 1988, ARCH BIOCHEM BIOPHYS, V151, P404; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GYLFE E, 1991, PFLUG ARCH EUR J PHY, V419, P639, DOI 10.1007/BF00370308; HIRIART M, 1988, J GEN PHYSIOL, V91, P617, DOI 10.1085/jgp.91.5.617; IINO E, 1992, NATURE, V360, P76; KEAHEY HH, 1989, DIABETES, V38, P188, DOI 10.2337/diabetes.38.2.188; KIMURA J, 1987, J PHYSIOL-LONDON, V384, P199, DOI 10.1113/jphysiol.1987.sp016450; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LEITER EH, 1988, FASEB J, V2, P2807, DOI 10.1096/fasebj.2.12.3044905; MALAISSE WJ, 1978, ANN NY ACAD SCI, V307, P5562; MORGAN NG, 1985, BIOCHEM J, V228, P713, DOI 10.1042/bj2280713; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PORTE D, 1991, DIABETES, V40, P166, DOI 10.2337/diabetes.40.2.166; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; RORSMAN P, 1992, EMBO J, V11, P2877, DOI 10.1002/j.1460-2075.1992.tb05356.x; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; ROUSSEAU E, 1989, AM J PHYSIOL, V256, pH328, DOI 10.1152/ajpheart.1989.256.2.H328; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; SATOH H, 1989, AM J PHYSIOL, V257, pH226, DOI 10.1152/ajpheart.1989.257.1.H226; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TOESCU EC, 1992, J BIOL CHEM, V267, P23467; VERGARA J, 1985, P NATL ACAD SCI USA, V82, P6352, DOI 10.1073/pnas.82.18.6352; WILKES LC, 1990, J ENDOCRINOL, V127, P335, DOI 10.1677/joe.0.1270335; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; ZAVECZ JH, 1989, EUR J PHARMACOL, V160, P187, DOI 10.1016/0014-2999(89)90672-9	37	108	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					9953	9956						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8387528				2022-12-25	WOS:A1993LB80000005
J	NAKAYASU, H; NISHIKAWA, M; MIZUTANI, H; KIMURA, H; KURIYAMA, K				NAKAYASU, H; NISHIKAWA, M; MIZUTANI, H; KIMURA, H; KURIYAMA, K			IMMUNOAFFINITY PURIFICATION AND CHARACTERIZATION OF GAMMA-AMINOBUTYRIC-ACID (GABA)B RECEPTOR FROM BOVINE CEREBRAL-CORTEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLET-ACTIVATING PROTEIN; GTP-BINDING PROTEINS; ADENYLATE-CYCLASE; BENZODIAZEPINE RECEPTOR; GUANINE-NUCLEOTIDES; PYRAMIDAL CELLS; GABA RECEPTOR; RAT-BRAIN; COLUMN CHROMATOGRAPHY; PERTUSSIS TOXIN	We developed a novel method for immunoaffinity purification of gamma-aminobutyric acid (GABA(B)) receptor from bovine cerebral cortex using a monoclonal antibody, which specifically recognizes an 80-kDa GABA-binding protein (Nakayasu, H., Mizutani, H., Hanai, K., Kimura, H., and Kuriyama, K. (1992) Biochem. Biophys. Res. Commun. 182, 722-726). The GABA binding activity in the solubilized synaptic membrane preparation was adsorbed on the antibody-conjugated beads and was eluted as a single protein band of 80 kDa by an acidic buffer, pH 2.5. The purified preparation mimicked the GABA(B) receptor in its binding activity for GABA, baclofen (GABA(B) receptor agonist) and 2-hydroxysaclofen (a GABA(B) receptor antagonist). The purified preparation was reconstituted with partially purified GTP-binding protein and an adenylylcyclase preparation on a phospholipid membrane. On addition of GABA or baclofen to the reconstituted membrane, the adenylylcyclase activity was inhibited, and this inhibition was antagonized by 2-hydroxysaclofen. Moreover, this inhibition by GABA was not observed in a system reconstituted system without either the 80-kDa GABA-binding protein or the GTP-binding protein. These results are strong evidence that the 80-kDa antigenic protein is the GABA(B) receptor. This is the first report of the nearly complete purification of the GABA(B) receptor.	KYOTO PREFECTURAL UNIV MED,DEPT PHARMACOL,KAWARAMACHI HIROKOJI,KAMIKYO KU,KYOTO 602,JAPAN; SHIGA UNIV MED SCI,INST MOLEC NEUROBIOL,OTSU,SHIGA 52021,JAPAN	Kyoto Prefectural University of Medicine; Shiga University of Medical Science								ANDRADE R, 1986, SCIENCE, V234, P1261, DOI 10.1126/science.2430334; ASANO T, 1985, J BIOL CHEM, V260, P2653; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BONANNO G, 1989, BRIT J PHARMACOL, V96, P341, DOI 10.1111/j.1476-5381.1989.tb11823.x; BOWERY NG, 1983, BRIT J PHARMACOL, V78, P191, DOI 10.1111/j.1476-5381.1983.tb09380.x; BOWERY NG, 1980, NATURE, V283, P92, DOI 10.1038/283092a0; BOWERY NG, 1990, GABAB RECEPTORS IN MAMMALIAN FUNCTION, P3; BOWERY NG, 1979, BRIT J PHARMACOL, V66, P108; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; CRAWFORD MLA, 1988, J NEUROCHEM, V51, P1441, DOI 10.1111/j.1471-4159.1988.tb01109.x; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; DOLPHIN AC, 1987, J PHYSIOL-LONDON, V386, P1; GAHWILER BH, 1985, P NATL ACAD SCI USA, V82, P1558, DOI 10.1073/pnas.82.5.1558; GODFREY PP, 1988, EUR J PHARMACOL, V152, P185, DOI 10.1016/0014-2999(88)90854-0; GREEN KA, 1988, BRIT J PHARMACOL, V94, P235, DOI 10.1111/j.1476-5381.1988.tb11520.x; HARRISON NL, 1988, NEUROSCI LETT, V85, P105, DOI 10.1016/0304-3940(88)90437-5; HIROUCHI M, 1987, BIOCHEM BIOPH RES CO, V146, P1471, DOI 10.1016/0006-291X(87)90815-1; HOLZ GG, 1986, NATURE, V319, P670, DOI 10.1038/319670a0; HOSFORD DA, 1992, SCIENCE, V257, P398, DOI 10.1126/science.1321503; INOUE M, 1985, BRIT J PHARMACOL, V84, P833, DOI 10.1111/j.1476-5381.1985.tb17377.x; ITO Y, 1982, BRAIN RES, V236, P351, DOI 10.1016/0006-8993(82)90720-X; KARBON EW, 1985, MOL PHARMACOL, V27, P53; KATADA T, 1986, J BIOL CHEM, V261, P5215; KURIYAMA K, 1987, NEUROCHEM INT, V10, P253, DOI 10.1016/0197-0186(87)90098-2; KURIYAMA K, 1987, J NEUROCHEM, V48, P1897, DOI 10.1111/j.1471-4159.1987.tb05753.x; KURIYAMA K, 1992, MOL NEUROPHARMACOL, V2, P155; LYNCH TJ, 1977, ARCH BIOCHEM BIOPHYS, V182, P124, DOI 10.1016/0003-9861(77)90290-9; MAY DC, 1985, J BIOL CHEM, V260, P5829; MORISHITA R, 1990, FEBS LETT, V271, P231, DOI 10.1016/0014-5793(90)80413-D; NAKAYASU H, 1991, P NATL ACAD SCI USA, V88, P10312, DOI 10.1073/pnas.88.22.10312; NAKAYASU H, 1992, BIOCHEM BIOPH RES CO, V182, P722, DOI 10.1016/0006-291X(92)91791-N; NEWBERRY NR, 1984, J PHYSIOL-LONDON, V348, P239, DOI 10.1113/jphysiol.1984.sp015107; NISHIKAWA M, 1989, NEUROCHEM INT, V14, P85, DOI 10.1016/0197-0186(89)90014-4; OHMORI Y, 1989, NEUROCHEM INT, V15, P359, DOI 10.1016/0197-0186(89)90145-9; OHMORI Y, 1990, J NEUROCHEM, V54, P80, DOI 10.1111/j.1471-4159.1990.tb13285.x; OHMORI Y, 1990, BIOCHEM BIOPH RES CO, V172, P22, DOI 10.1016/S0006-291X(05)80167-6; SATOU M, 1982, J NEUROPHYSIOL, V48, P1142, DOI 10.1152/jn.1982.48.5.1142; SOLTESZ I, 1988, BRAIN RES, V448, P351, DOI 10.1016/0006-8993(88)91275-9; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TAGUCHI J, 1987, NEUROPHARMACOLOGY, V26, P1745, DOI 10.1016/0028-3908(87)90127-4; TAGUCHI J, 1984, BRAIN RES, V323, P219, DOI 10.1016/0006-8993(84)90292-0; WALDO GL, 1987, BIOCHEM J, V246, P431, DOI 10.1042/bj2460431; ZUKIN SR, 1974, P NATL ACAD SCI USA, V71, P4802, DOI 10.1073/pnas.71.12.4802	43	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8658	8664						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8386168				2022-12-25	WOS:A1993KX81100044
J	BLITZER, RD; OMRI, G; DEVIVO, M; CARTY, DJ; PREMONT, RT; CODINA, J; BIRNBAUMER, L; COTECCHIA, S; CARON, MG; LEFKOWITZ, RJ; LANDAU, EM; IYENGAR, R				BLITZER, RD; OMRI, G; DEVIVO, M; CARTY, DJ; PREMONT, RT; CODINA, J; BIRNBAUMER, L; COTECCHIA, S; CARON, MG; LEFKOWITZ, RJ; LANDAU, EM; IYENGAR, R			COUPLING OF THE EXPRESSED ALPHA-1B-ADRENERGIC RECEPTOR TO THE PHOSPHOLIPASE-C PATHWAY IN XENOPUS OOCYTES - THE ROLE OF G(O)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; ALPHA-SUBUNIT; PERTUSSIS TOXIN; GO-PROTEIN; GLUTAMATE RECEPTOR; MOLECULAR-CLONING; MESSENGER-RNA; RAT-BRAIN; ACTIVATION; GQ	Alpha1B-adrenergic receptor mRNA was injected into Xenopus oocytes, resulting in a norepinephrine-evoked Cl- current. The response was proportional to norepinephrine concentration, blocked by prazosin, and dependent on intracellular Ca2+ derived from inositol trisphosphate-sensitive stores. Oocytes treated with 2 mug/ml pertussis toxin showed a time-dependent decrease of the norepinephrine response, taking up to 72 h to show an 80% decrease. Overnight treatment with 10 mug/ml pertussis toxin also resulted in 80% reduction. Responses to two other cloned receptors (M1-muscarinic and serotonin-1c) expressed in oocytes were also reduced 50% or more by 72 h of pertussis toxin treatment. Pertussis toxin labeling of the cloned Xenopus alpha(o)-subunit translated in vitro showed that it was a significantly poorer substrate for pertussis toxin than the two mammalian alpha(o)-subunits expressed and assayed under identical conditions. This unexpected biochemical behavior of the Xenopus alpha(o)-subunit is in agreement with the rather unusual treatment conditions required to observe the effects of pertussis toxin on the receptor-evoked Cl- current in the oocyte. Injection of mammalian heterotrimeric G(o) but not G(i3) significantly enhanced the norepinephrine-evoked Cl- current in oocytes. Injection of mixtures of anti-sense oligonucleotides to the Xenopus alpha(o)-subunit reduced the norepinephrine-evoked Cl- current by 60% within 24 h, compared with oocytes injected with the oligonucleotides encoding sense sequences. These studies indicate that the expressed alpha1B-adrenergic receptor, like the native muscarinic receptor, utilizes G(o) to couple to the phospholipase C-mediated Cl- current in Xenopus oocytes.	CUNY MT SINAI SCH MED,DEPT PHARMACOL,NEW YORK,NY 10029; VET ADM MED CTR,DEPT PSYCHIAT,BRONX,NY 10468; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; Duke University; Howard Hughes Medical Institute; Duke University; Duke University	BLITZER, RD (corresponding author), CUNY MT SINAI SCH MED,DEPT PSYCHIAT,NEW YORK,NY 10029, USA.		Lefkowitz, Robert/AAW-2649-2021	Premont, Richard/0000-0002-8053-5026	NATIONAL CANCER INSTITUTE [R01CA044998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761, R37DK019318, R01DK019318] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44998] Funding Source: Medline; NIDDK NIH HHS [DK 19318, DK 38761] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; CARTY DJ, 1990, J BIOL CHEM, V265, P6268; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; GRAF R, 1992, MOL PHARMACOL, V42, P760; GUNDERSEN CB, 1984, NATURE, V308, P421, DOI 10.1038/308421a0; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HILDEBRANDT JD, 1984, NATURE, V303, P706; HIRONO C, 1987, J PHYSIOL-LONDON, V382, P523, DOI 10.1113/jphysiol.1987.sp016382; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; HSU WH, 1990, J BIOL CHEM, V265, P11220; KANEKO S, 1992, FEBS LETT, V299, P179, DOI 10.1016/0014-5793(92)80242-9; KROLL SD, 1991, P NATL ACAD SCI USA, V88, P5182, DOI 10.1073/pnas.88.12.5182; LYNCH CJ, 1986, MOL PHARMACOL, V29, P196; MORIARTY TM, 1988, P NATL ACAD SCI USA, V85, P8865, DOI 10.1073/pnas.85.23.8865; MORIARTY TM, 1988, MOL BRAIN RES, V4, P75, DOI 10.1016/0169-328X(88)90021-6; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; MORIARTY TM, 1989, J BIOL CHEM, V264, P13524; MORIARTY TM, 1990, G PROTEINS, P479; OLATE J, 1989, FEBS LETT, V244, P188, DOI 10.1016/0014-5793(89)81190-1; OLATE J, 1988, J BIOL CHEM, V263, P10394; ORON Y, 1987, SCIENCE, V238, P1406, DOI 10.1126/science.2825350; PADRELL E, 1991, J BIOL CHEM, V266, P9771; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SAKUTA H, 1991, EUR J PHARM-MOLEC PH, V208, P31, DOI 10.1016/0922-4106(91)90048-M; Sambrook J, 1989, MOL CLONING LABORATO; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SUGIYAMA H, 1987, NATURE, V325, P531, DOI 10.1038/325531a0; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VANWEZENBEEK LACM, 1988, EUR J PHARMACOL, V151, P497, DOI 10.1016/0014-2999(88)90551-1	30	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7532	7537						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8385110				2022-12-25	WOS:A1993KV14100102
J	HAKE, LE; HECHT, NB				HAKE, LE; HECHT, NB			UTILIZATION OF AN ALTERNATIVE TRANSCRIPTION INITIATION SITE OF SOMATIC CYTOCHROME-C IN THE MOUSE PRODUCES A TESTIS-SPECIFIC CYTOCHROME-C MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; GENE-EXPRESSION; NUCLEAR FACTORS; MOLECULAR CHARACTERIZATION; NUCLEOTIDE-SEQUENCE; PROTAMINE-2 GENES; TRANSGENIC MICE; FACTORS BINDING; GAMMA-ACTIN; RAT TESTIS	The differential regulation of somatic and testis-specific cytochromes c during spermatogenesis in the mouse is accompanied by changes in mRNA length (Hake, L. E., Alcivar, A. A., and Hecht, N. B. (1990) Development 110, 249-257). In spermatogenic stem cells through early meiotic cells, we detect four somatic cytochrome c (cyt c(S)) mRNAs of 1.3, 1.1, and 0.7-0.5 kilobases (kb), whereas in postmeiotic cells we detect a larger cyt c(S) mRNA of 1.7 kb. Oligonucleotide-directed RNase H cleavage of cyt c(S) mRNA revealed that the 1.7-kb mRNA contains over 1 kb of 5'-untranslated region which is not present in the four shorter cyt c(S) mRNAs. RNase protection assays indicate that this additional sequence arises from the utilization of an alternative transcription initiation site of the functional cyt c(S) gene which is 1085 base pairs upstream of the initiation site for the four shorter cyt c(S) mRNAs. To analyze the promoter for the 1.7-kb mRNA, a genomic clone containing the cyt c(S) gene and 5 kb of 5'-flanking DNA was isolated. Sequence comparison of the putative promoter region with promoters of other postmeiotically expressed genes reveals several conserved regions. Utilization of this alternative initiation site may be involved in the down-regulation of cytochrome c(S) during spermatogenesis.	TUFTS UNIV, DEPT BIOL, MEDFORD, MA 02155 USA	Tufts University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD011878] Funding Source: NIH RePORTER; NICHD NIH HHS [HD11878] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ausubel FM, 1991, CURRENT PROTOCOLS MO; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Bellve A.R., 1979, Oxford Reviews of Reproductive Biology, V1, P159; BUNICK D, 1990, P NATL ACAD SCI USA, V87, P891, DOI 10.1073/pnas.87.3.891; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOBNER PR, 1987, NUCLEIC ACIDS RES, V15, P199, DOI 10.1093/nar/15.1.199; ERICKSON RP, 1990, TRENDS GENET, V6, P264, DOI 10.1016/0168-9525(90)90209-O; EVANS MJ, 1988, MOL CELL BIOL, V8, P35, DOI 10.1128/MCB.8.1.35; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; FISCHMAN K, 1990, MOL CELL BIOL, V10, P146, DOI 10.1128/MCB.10.1.146; FRITENSKY B, 1982, NUCLEIC ACIDS RES, V10, P6451; GARRETT JE, 1989, MOL CELL BIOL, V9, P4381, DOI 10.1128/MCB.9.10.4381; GOLDBERG E, 1977, SCIENCE, V196, P1010, DOI 10.1126/science.193188; HAKE LE, 1990, DEVELOPMENT, V110, P249; HECHT NB, 1993, CELL MOL BIOL TESTES; Hecht NB., 1986, EXPT APPROACHES MAMM, P151; HENNIG B, 1975, EUR J BIOCHEM, V55, P167, DOI 10.1111/j.1432-1033.1975.tb02149.x; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; HUET J, 1985, EMBO J, V4, P3539, DOI 10.1002/j.1460-2075.1985.tb04114.x; IVELL R, 1988, NUCLEIC ACIDS RES, V16, P7747, DOI 10.1093/nar/16.15.7747; JOHNSON PA, 1988, BIOCHIM BIOPHYS ACTA, V950, P45, DOI 10.1016/0167-4781(88)90071-1; JOHNSON PA, 1991, BIOL REPROD, V44, P127, DOI 10.1095/biolreprod44.1.127; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KILPATRICK DL, 1990, MOL CELL BIOL, V10, P3717, DOI 10.1128/MCB.10.7.3717; KIM E, 1989, MOL CELL BIOL, V9, P1875, DOI 10.1128/MCB.9.5.1875; KRAYEV AS, 1980, NUCLEIC ACIDS RES, V8, P1201, DOI 10.1093/nar/8.6.1201; KREMLING H, 1991, GENOMICS, V11, P828, DOI 10.1016/0888-7543(91)90005-Y; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KUMAR RS, 1991, J BIOL CHEM, V266, P3854; LANGFORD KG, 1991, J BIOL CHEM, V266, P15559; LIMBACH KJ, 1985, NUCLEIC ACIDS RES, V13, P617, DOI 10.1093/nar/13.2.617; MAEDA H, 1987, NUCLEIC ACIDS RES, V15, P2851, DOI 10.1093/nar/15.7.2851; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MEIJER D, 1987, EMBO J, V6, P4041, DOI 10.1002/j.1460-2075.1987.tb02749.x; MIWA K, 1987, NUCLEIC ACIDS RES, V15, P8057, DOI 10.1093/nar/15.19.8057; MIWA T, 1991, MOL CELL BIOL, V11, P3296, DOI 10.1128/MCB.11.6.3296; Ochman H., 1990, PCR PROTOCOLS GUIDE, P219; OKO R, 1991, ANAT REC, V231, P63, DOI 10.1002/ar.1092310108; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; SCHAFFNER W, 1989, TRENDS GENET, V5, P37, DOI 10.1016/0168-9525(89)90017-6; SHAPER NL, 1990, P NATL ACAD SCI USA, V87, P791, DOI 10.1073/pnas.87.2.791; SHERMAN L, 1984, NUCLEIC ACIDS RES, V12, P9349, DOI 10.1093/nar/12.24.9349; STEWART TA, 1988, MOL CELL BIOL, V8, P1748, DOI 10.1128/MCB.8.4.1748; TERUYA JH, 1990, MOL CELL BIOL, V10, P2315, DOI 10.1128/MCB.10.5.2315; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; WATANABE K, 1991, J BIOCHEM-TOKYO, V109, P828, DOI 10.1093/oxfordjournals.jbchem.a123466; WATERS SH, 1985, MOL CELL BIOL, V5, P1649, DOI 10.1128/MCB.5.7.1649; WILLISON K, 1987, TRENDS GENET, V3, P351, DOI 10.1016/0168-9525(87)90296-4; Wolgemuth D. J., 1989, The molecular biology of fertilization., P235	53	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4788	4797						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8383125				2022-12-25	WOS:A1993KP88400038
J	SEGAWA, K; MINOWA, A; SUGASAWA, K; TAKANO, T; HANAOKA, F				SEGAWA, K; MINOWA, A; SUGASAWA, K; TAKANO, T; HANAOKA, F			ABROGATION OF P53-MEDIATED TRANSACTIVATION BY SV40 LARGE T-ANTIGEN	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; TUMOR-ANTIGEN; P53 PROTEIN; DNA-REPLICATION; WILD-TYPE; TRANSFORMATION; CELLS; PROMOTERS; SEQUENCE; PRODUCT	p53 is known to bind specifically to the 44-bp human DNA sequence in an immunoprecipitation assay. We show here that the transcription of the reporter CAT gene linked with the herpesvirus thymidine kinase (tk) promoter containing the 44-base sequence is enhanced by mouse wild-type but not mutant-type p53 in F9 and p53-null Saos-2 cells. The p53-mediated transactivation was dramatically abrogated by introduction of SV40 large T antigen (SVLT) in Saos-2 cells in which p53 was clearly associated with SVLT. Furthermore, the p53-SVLT complex did not bind to the 44-base sequence at all. Thus, SVLT sequesters the transactivation function of the wild-type p53 by inhibiting the binding of p53 to the 44-base sequence. This is good evidence to show 'loss of functions' in the product of a tumor-suppressor oncogene by a dominant oncogene product at a molecular level.	INST PHYS & CHEM RES RIKEN,PHYSIOL LAB,WAKO,SAITAMA 35101,JAPAN	RIKEN	SEGAWA, K (corresponding author), KEIO UNIV,SCH MED,DEPT MICROBIOL,35 SHINANOMACHI,SHINJUKU KU,TOKYO 160,JAPAN.							AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BUCHKOVITCH K, 1989, CELL, V58, P1099; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1988, ONCOGENE, V3, P313; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOEKEN M, 1988, CELL, V55, P1171, DOI 10.1016/0092-8674(88)90261-9; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEGAWA K, 1986, VIROLOGY, V155, P334, DOI 10.1016/0042-6822(86)90197-2; SEGAWA K, 1987, MOL CELL BIOL, V7, P556, DOI 10.1128/MCB.7.1.556; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUGANO S, 1984, J VIROL, V52, P884, DOI 10.1128/JVI.52.3.884-891.1984; SUGASAWA K, 1992, P NATL ACAD SCI USA, V89, P1055, DOI 10.1073/pnas.89.3.1055; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	38	60	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					543	548						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8382354				2022-12-25	WOS:A1993KN00800003
J	STUART, RA; MACKAY, D; ADAMCZEWSKI, J; WARREN, G				STUART, RA; MACKAY, D; ADAMCZEWSKI, J; WARREN, G			INHIBITION OF INTRA-GOLGI TRANSPORT INVITRO BY MITOTIC KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; SYNTHESIZED G-PROTEIN; CELL-CYCLE CONTROL; XENOPUS OOCYTES; HELA-CELLS; SUCCESSIVE COMPARTMENTS; MEIOTIC MATURATION; SECRETORY PATHWAY; SURFACE FUNCTIONS; MITOSIS	It has previously been shown that exocytic and endocytic membrane traffic are inhibited in mitotic mammalian cells. Here we have used a cell-free intra-Golgi transport assay supplemented with heterologous cytosols to mimic this effect in vitro. Cytosols with high histone kinase activity, made either from mitotic cells or by cyclin A treatment of interphase cells, inhibited intra-Golgi transport by up to 75%. Inhibition of transport was reversed by the kinase inhibitor staurosporine or by reduction in ATP levels leading to inactivation of histone kinase. The data indicate that cell cycle control of intra-Golgi transport is due to a reversible modification of cytosol, and this assay system may be used to study the molecular mechanism of mitotic transport inhibition in mammalian cells.	IMPERIAL CANC RES FUND,CELL BIOL LAB,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND	Cancer Research UK			Mackay, Deborah JG/B-2879-2015	Mackay, Deborah JG/0000-0003-3088-4401				BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BERLIN RD, 1980, J CELL BIOL, V85, P660, DOI 10.1083/jcb.85.3.660; BERLIN RD, 1978, CELL, V15, P327, DOI 10.1016/0092-8674(78)90002-8; CERIOTTI A, 1989, J CELL BIOL, V109, P1439, DOI 10.1083/jcb.109.4.1439; CLARKE PR, 1992, EMBO J, V11, P1751, DOI 10.1002/j.1460-2075.1992.tb05227.x; CLARY DO, 1990, J BIOL CHEM, V265, P10109; COLLINS RN, 1992, J BIOL CHEM, V267, P24906; COLMAN A, 1985, J CELL BIOL, V101, P313, DOI 10.1083/jcb.101.1.313; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; DEBRABANDER MJ, 1976, CANCER RES, V36, P905; DEVAULT A, 1992, J CELL BIOL, V118, P1109, DOI 10.1083/jcb.118.5.1109; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FAWCETT DW, 1965, J HISTOCHEM CYTOCHEM, V13, P75, DOI 10.1177/13.2.75; FEATHERSTONE C, 1985, J CELL BIOL, V101, P2036, DOI 10.1083/jcb.101.6.2036; FELIX MA, 1989, EMBO J, V8, P3059, DOI 10.1002/j.1460-2075.1989.tb08457.x; HESKETH TR, 1984, J CELL BIOL, V98, P2250, DOI 10.1083/jcb.98.6.2250; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; KANKI JP, 1991, DEV BIOL, V146, P214, DOI 10.1016/0012-1606(91)90461-B; KREINER T, 1990, CELL REGUL, V1, P415, DOI 10.1091/mbc.1.5.415; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LEAF DS, 1990, DEV BIOL, V141, P1, DOI 10.1016/0012-1606(90)90097-3; LEFRANCOIS L, 1982, VIROLOGY, V121, P157, DOI 10.1016/0042-6822(82)90125-8; LORCA T, 1992, EMBO J, V11, P2381, DOI 10.1002/j.1460-2075.1992.tb05302.x; LUCOCQ J, 1991, J CELL SCI, V100, P753; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; LUCOCQ JM, 1987, J CELL BIOL, V104, P865, DOI 10.1083/jcb.104.4.865; LUCOCQ JM, 1987, EMBO J, V6, P3239, DOI 10.1002/j.1460-2075.1987.tb02641.x; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MALLER JL, 1991, CURR OPIN CELL BIOL, V3, P265; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PINES J, 1992, Current Opinion in Cell Biology, V4, P144, DOI 10.1016/0955-0674(92)90024-7; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PYPAERT M, 1991, J CELL BIOL, V114, P1159, DOI 10.1083/jcb.114.6.1159; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; THOMAS L, 1992, J BIOL CHEM, V267, P6183; TUOMIKOSKI T, 1989, NATURE, V342, P942, DOI 10.1038/342942a0; WARREN G, 1984, EMBO J, V3, P2217, DOI 10.1002/j.1460-2075.1984.tb02119.x; WARREN G, 1983, J CELL BIOL, V97, P1623, DOI 10.1083/jcb.97.5.1623; WARREN G, 1985, TRENDS BIOCHEM SCI, V10, P439, DOI 10.1016/0968-0004(85)90027-1; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WOODMAN PG, 1992, J CELL BIOL, V116, P331, DOI 10.1083/jcb.116.2.331	52	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4050	4054						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8382687				2022-12-25	WOS:A1993KN53300040
J	TROTTA, E; DAMBROSIO, E; DELGROSSO, N; RAVAGNAN, G; CIRILLI, M; PACI, M				TROTTA, E; DAMBROSIO, E; DELGROSSO, N; RAVAGNAN, G; CIRILLI, M; PACI, M			H-1-NMR STUDY OF [D(GCGATCGC)]2 AND ITS INTERACTION WITH MINOR GROOVE BINDING 4',6-DIAMIDINO-2-PHENYLINDOLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENTIAL RESONANCE ASSIGNMENTS; NUCLEIC-ACIDS; H-1-NMR SPECTRA; NANOGRAM QUANTITIES; PROTON RESONANCES; AQUEOUS-SOLUTION; DNA; SPECTROSCOPY; DAPI; RNA	Two-dimensional NMR spectroscopy has been applied to study the solution binding of 4',6-diamidino-2-phenylindole (DAPI) to synthetic DNA duplex [d(GCGATCGC)]2. The structure of the complex at a molar ratio of 1:1 drug:duplex has been investigated. NMR results indicate that DAPI binds selectively in the minor groove of the DNA region containing only two A:T base pairs. The results disagree with conclusions drawn from footprinting experiments and show that the presence of the G3NH2 group in the minor groove does not prevent the binding. A molecular model is proposed that closely resembles the crystal structure previously published for the interaction of DAPI with the dodecamer [d(CGCGAATTCGCG)]2, containing four A:T base pairs in the binding site. In this model, DAPI lies in the minor groove, nearly isohelical, with its aromatic rings adjacent to H4' protons of T5 and C6 deoxyribose and the NH indole group oriented toward the DNA axis. The binding does not perturb the B-type conformation of the duplex, and the DNA oligomer conserves its 2-fold symmetry, indicating that fast exchange dynamics exist between the two stereochemically equivalent binding sites of the palindromic sequence. The binding constant and the exchange rate between free and bound species were also measured by NMR spectroscopy.	CNR,IST MED SPERIMENTALE,VIALE MARX 15,I-00137 ROME,ITALY; CNR,IST STRUTTURISTICA CHIM,ROME,ITALY; UNIV ROMA TOR VERGATA,DIPARTIMENTO SCI & TECNOL CHIM,I-00173 ROME,ITALY	Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); University of Rome Tor Vergata			Trotta, Edoardo/AAW-4697-2020	Trotta, Edoardo/0000-0002-1417-9238				ALTONA C, 1982, RECL TRAV CHIM PAY B, V101, P413; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BOELENS R, 1985, J MAGN RESON, V62, P378, DOI 10.1016/0022-2364(85)90207-0; BOELENS R, 1990, SOFTWARE PROCESSING; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BRUNK CF, 1979, ANAL BIOCHEM, V92, P497, DOI 10.1016/0003-2697(79)90690-0; CANTOR CR, 1970, BIOPOLYMERS, V9, P1059, DOI 10.1002/bip.1970.360090909; CAPOBIANCO ML, 1991, NUCLEIC ACIDS RES, V19, P1695, DOI 10.1093/nar/19.7.1695; CAVATORTA P, 1985, BIOPHYS CHEM, V22, P11, DOI 10.1016/0301-4622(85)80021-1; CLORE GM, 1985, FEBS LETT, V179, P187, DOI 10.1016/0014-5793(85)80516-0; DANN O, 1971, LIEBIGS ANN CHEM, V749, P68; DAVIES DB, 1978, PROG NUCL MAG RES SP, V12, P135, DOI 10.1016/0079-6565(78)80006-5; GIESSNERPRETTRE C, 1987, Q REV BIOPHYS, V20, P113, DOI 10.1017/S0033583500004169; GUTOWSKY HS, 1956, J CHEM PHYS, V25, P1228, DOI 10.1063/1.1743184; HARE DR, 1983, J MOL BIOL, V171, P319, DOI 10.1016/0022-2836(83)90096-7; HOSUR RV, 1988, MAGN RESON CHEM, V26, P927, DOI 10.1002/mrc.1260261019; HOSUR RV, 1985, MAGNETIC RESONANCE B, P243; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JEPPESEN C, 1989, EUR J BIOCHEM, V182, P437, DOI 10.1111/j.1432-1033.1989.tb14850.x; KAPUSCINSKI J, 1979, NUCLEIC ACIDS RES, V6, P3535, DOI 10.1093/nar/6.11.3535; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; KUBISTA M, 1987, BIOCHEMISTRY-US, V26, P4545, DOI 10.1021/bi00388a057; LANE AN, 1991, BIOCHEMISTRY-US, V30, P1372, DOI 10.1021/bi00219a030; LARSEN TA, 1989, J BIOMOL STRUCT DYN, V7, P477, DOI 10.1080/07391102.1989.10508505; LATT SA, 1976, ANNU REV BIOPHYS BIO, V5, P1, DOI 10.1146/annurev.bb.05.060176.000245; LEE GM, 1984, ANAL BIOCHEM, V137, P221, DOI 10.1016/0003-2697(84)90374-9; LOONTIENS FG, 1991, BIOCHEMISTRY-US, V30, P182, DOI 10.1021/bi00215a027; MANZINI G, 1983, NUCLEIC ACIDS RES, V11, P8861, DOI 10.1093/nar/11.24.8861; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MUELLER L, 1987, J MAGN RESON, V72, P191, DOI 10.1016/0022-2364(87)90188-0; NAIMSKI P, 1980, ANAL BIOCHEM, V106, P471, DOI 10.1016/0003-2697(80)90550-3; PATEL DJ, 1987, Q REV BIOPHYS, V20, P35, DOI 10.1017/S0033583500004224; Perkins S. J., 1982, BIOL MAGN RESON, V4, P193; PORTUGAL J, 1987, EUR J BIOCHEM, V167, P281, DOI 10.1111/j.1432-1033.1987.tb13334.x; PORTUGAL J, 1988, BIOCHIM BIOPHYS ACTA, V949, P158, DOI 10.1016/0167-4781(88)90079-6; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; REID DG, 1983, BIOCHEMISTRY-US, V22, P2019, DOI 10.1021/bi00277a044; SCHEEK RM, 1984, BIOCHEMISTRY-US, V23, P1371, DOI 10.1021/bi00302a006; SCHEEK RM, 1983, J AM CHEM SOC, V105, P2914, DOI 10.1021/ja00347a075; SKLENAR V, 1987, J MAGN RESON, V74, P469, DOI 10.1016/0022-2364(87)90269-1; STAUFFERT I, 1990, MUTAT RES, V245, P93, DOI 10.1016/0165-7992(90)90006-6; SYKES BD, 1969, BIOCHEMISTRY-US, V8, P1110, DOI 10.1021/bi00831a043; Williamson D H, 1975, Methods Cell Biol, V12, P335; WILSON WD, 1989, J AM CHEM SOC, V111, P5008, DOI 10.1021/ja00195a080; WILSON WD, 1990, ANTI-CANCER DRUG DES, V5, P31; WILSON WD, 1990, BIOCHEMISTRY-US, V29, P8452, DOI 10.1021/bi00488a036; [No title captured]	47	47	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3944	3951						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8382683				2022-12-25	WOS:A1993KN53300025
J	WINKEL, GK; SARDET, C; POUYSSEGUR, J; IVES, HE				WINKEL, GK; SARDET, C; POUYSSEGUR, J; IVES, HE			ROLE OF CYTOPLASMIC DOMAIN OF THE NA+/H+ EXCHANGER IN HORMONAL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PROTEIN-KINASE-C; INTRACELLULAR PH REGULATION; EPIDERMAL GROWTH-FACTOR; INDEPENDENT ACTIVATION; OSMOTIC ACTIVATION; PHORBOL ESTERS; OKADAIC ACID; ANTIPORT; STIMULATION	The growth factor-activated Na+/H+ exchanger is regulated by numerous stimuli, including polypeptide hormones, phorbol esters, cell acidity, and cell shrinkage. To determine whether this regulation occurs at a common site on the cytoplasmic domain of the Na+/H+ exchanger, we microinjected polyclonal antibodies (RP1-c28) to the C-terminal 157 amino acids of the molecule and measured cell pH changes after application of a variety of stimuli known to activate the Na+/H+ exchanger. Microinjection of approximately 10 fg of RP1-c28 antibody, but not control IgG, into single cultured fibroblasts blocked subsequent activation of the exchanger by both endothelin and alpha-thrombin. In contrast, microinjected RP1-c28 did not prevent activation of Na+/H+ exchange by phorbol esters, consistent with the observation that both endothelin-1 and alpha-thrombin retained the ability to activate exchange activity in protein kinase C-depleted cells. Finally, activation of Na+/H+ exchange by both cell acidity and osmotic shrinkage was also unaffected by microinjected RP1-c28 antibody. These data indicate that activation of Na+/H+ exchange by endothelin-1 and alpha-thrombin is mechanistically distinct both from activation by protein kinase C and activation by physical factors and probably occurs at a separate site on the exchanger molecule.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DIV NEPHROL,1065 HSE BOX 0532,SAN FRANCISCO,CA 94143; UNIV NICE,CNRS,CTR BIOCHIM,F-06108 NICE 2,FRANCE	University of California System; University of California San Francisco; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur					NHLBI NIH HHS [HL41210] Funding Source: Medline; NIDDK NIH HHS [DK 07219, DK34127] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007219, R01DK034127] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; BERK BC, 1987, J BIOL CHEM, V262, P5065; BERK BC, 1987, J BIOL CHEM, V262, P5057; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; CALA PM, 1980, J GEN PHYSIOL, V76, P683, DOI 10.1085/jgp.76.6.683; CASSEL D, 1984, BIOCHEM BIOPH RES CO, V118, P675, DOI 10.1016/0006-291X(84)91356-1; CASSEL D, 1985, J CELL PHYSIOL, V122, P178, DOI 10.1002/jcp.1041220203; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; DANIEL TO, 1987, BIOCHEM BIOPH RES CO, V145, P111, DOI 10.1016/0006-291X(87)91294-0; ESCOBALES N, 1990, AM J PHYSIOL, V259, pC640, DOI 10.1152/ajpcell.1990.259.4.C640; GRINSTEIN S, 1986, BIOCHEM BIOPH RES CO, V134, P8, DOI 10.1016/0006-291X(86)90519-X; GRINSTEIN S, 1985, J GEN PHYSIOL, V85, P765, DOI 10.1085/jgp.85.5.765; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HESKETH TR, 1985, NATURE, V313, P481, DOI 10.1038/313481a0; HUANG CL, 1987, J BIOL CHEM, V262, P14134; HUANG CL, 1991, J BIOL CHEM, V266, P4045; IVES HE, 1987, P NATL ACAD SCI USA, V84, P1950, DOI 10.1073/pnas.84.7.1950; KRAMER BK, 1991, CIRC RES, V68, P269, DOI 10.1161/01.RES.68.1.269; LALLEMAIN G, 1984, J BIOL CHEM, V259, P5809; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; LOWE JHN, 1990, J BIOL CHEM, V265, P7188; MITSUHASHI T, 1988, J BIOL CHEM, V263, P8790; MITSUHASHI T, 1989, J CLIN INVEST, V84, P635, DOI 10.1172/JCI114209; MOOLENAAR WH, 1984, NATURE, V312, P371, DOI 10.1038/312371a0; MOOLENAAR WH, 1986, ANNU REV PHYSIOL, V48, P363; PARADISO AM, 1987, NATURE, V325, P447, DOI 10.1038/325447a0; PARIS S, 1984, J BIOL CHEM, V259, P989; POUYSSEGUR J, 1985, TRENDS BIOCHEM SCI, V10, P453, DOI 10.1016/0968-0004(85)90030-1; ROSOFF PM, 1986, J CELL BIOL, V103, P457, DOI 10.1083/jcb.103.2.457; ROSOFF PM, 1984, J BIOL CHEM, V259, P7056; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1991, J BIOL CHEM, V266, P19166; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; VANDYKE RW, 1988, HEPATOLOGY, V8, P960, DOI 10.1002/hep.1840080441; VARA F, 1985, BIOCHEM BIOPH RES CO, V130, P646, DOI 10.1016/0006-291X(85)90466-8; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424	37	36	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3396	3400						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8381429				2022-12-25	WOS:A1993KM16100059
J	LYONS, JG; BIRKEDALHANSEN, B; PIERSON, MC; WHITELOCK, JM; BIRKEDALHANSEN, H				LYONS, JG; BIRKEDALHANSEN, B; PIERSON, MC; WHITELOCK, JM; BIRKEDALHANSEN, H			INTERLEUKIN-1-BETA AND TRANSFORMING GROWTH-FACTOR-ALPHA EPIDERMAL GROWTH-FACTOR INDUCE EXPRESSION OF M(R) 95,000 TYPE-IV COLLAGENASE GELATINASE AND INTERSTITIAL FIBROBLAST-TYPE COLLAGENASE BY RAT MUCOSAL KERATINOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; CULTURED HUMAN KERATINOCYTES; EPITHELIAL-CELL GROWTH; NECROSIS FACTOR-ALPHA; PHORBOL ESTERS; MESSENGER-RNA; SYNOVIAL FIBROBLASTS; GENE-EXPRESSION; GLUCOCORTICOID RECEPTOR; MURINE KERATINOCYTES	Rat mucosal keratinocytes serially propagated under permanently serum-free conditions responded to interleukin (IL)-1beta/IL-alpha and to transforming growth factor (TGF)-alpha/epidermal growth factor (EGF) (as well as to 12-O-tetradecanoylphorbol-13-acetate (TPA)) by upregulation of M(r) 95,000 gelatinase (MMP-9)(M(r) 95K GL) and fibroblast-type collagenase (MMP-1) (FIB-CL), whereas control cells expressed barely detectable levels of either of these enzymes. The cells secreted 8-10 mug/10(6) cells/day (M(r) 95K GL) and 2-3 mug/10(6) cells/day (FIB-CL) of enzyme protein for at least 24 h when maximally induced. This level was attained only after a 24-h lag period, and the earliest emergence of enzyme protein in the culture medium required 10-14 h. IL-1beta was by far the most potent cytokine with maximal effect already at 10(-10) M, whereas IL-1alpha, TGF-alpha, and EGF required 20-100-fold higher concentrations. Pretreatment of the cells with TPA (10(-7) M) abolished the subsequent response to IL-1beta, TGF-alpha, and EGF and at the same time resulted in >90% reduction of cytosolic protein kinase C activity. Surprisingly, staurosporine, a potent kinase inhibitor, not only failed to block growth factor/cytokine responses but itself stimulated expression of the enzymes at a magnitude comparable to TPA. The inducing effect of TGF-alpha/EGF was down-regulated by 70-85% by 10(-7) M dexamethasone. Dexamethasone was less effective in ablating the IL-1beta response yielding 60% reduction M(r) 95K GL and little or no reduction of FIB-CL. Dexamethasone also failed to block the TPA response.	UNIV ALABAMA, SCH DENT, DEPT ORAL BIOL, SDB BOX 54, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH DENT, ORAL BIOL RES CTR, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH DENT, DEPT DIAGNOST SCI, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham			Lyons, Guy/B-1319-2012	Lyons, Guy/0000-0002-4835-4663; Whitelock, John/0000-0003-1835-802X	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE006028, P50DE008228, R01DE010631] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE10631, DE08228, DE06028] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AGGELER J, 1984, J CELL BIOL, V98, P1662, DOI 10.1083/jcb.98.5.1662; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BAUER EA, 1988, ANN NY ACAD SCI, V548, P174, DOI 10.1111/j.1749-6632.1988.tb18804.x; Bayer E A, 1980, Methods Biochem Anal, V26, P1; BIRKEDALHANSEN B, 1988, BIOCHEMISTRY-US, V27, P6751, DOI 10.1021/bi00418a016; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BIRKEDALHANSEN H, 1981, IN VITRO CELL DEV B, V17, P553, DOI 10.1007/BF02618452; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BRINCKERHOFF CE, 1986, BIOCHEMISTRY-US, V25, P6378, DOI 10.1021/bi00369a006; CARPENTER G, 1984, CELL, V37, P357, DOI 10.1016/0092-8674(84)90365-9; CASE JP, 1990, J IMMUNOL, V145, P3755; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CLARK SD, 1987, J CLIN INVEST, V80, P1280, DOI 10.1172/JCI113203; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; COLLINS MKL, 1982, J CELL PHYSIOL, V112, P42, DOI 10.1002/jcp.1041120108; CONCA W, 1989, J CLIN INVEST, V83, P1753, DOI 10.1172/JCI114077; DECLERCK YA, 1992, CANCER RES, V52, P701; DIERKSVENTLING C, 1989, INT J CANCER, V44, P865, DOI 10.1002/ijc.2910440520; DIGIOVINE FS, 1990, RHEUMATOL INT, V9, P259, DOI 10.1007/BF00541321; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FRANKLIN CC, 1989, J BIOL CHEM, V264, P6667; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; GOTTLIEB AB, 1988, J EXP MED, V167, P670, DOI 10.1084/jem.167.2.670; GREEN MR, 1983, DEV BIOL, V100, P506, DOI 10.1016/0012-1606(83)90243-9; GROSS J, 1981, P NATL ACAD SCI-BIOL, V78, P1176, DOI 10.1073/pnas.78.2.1176; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; JOHNSONMULLER B, 1978, P NATL ACAD SCI USA, V75, P4417, DOI 10.1073/pnas.75.9.4417; JOHNSONWINT B, 1985, J BIOL CHEM, V260, P2080; JOHNSONWINT B, 1984, J CELL BIOL, V98, P90, DOI 10.1083/jcb.98.1.90; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KUPPER TS, 1986, J EXP MED, V164, P2095, DOI 10.1084/jem.164.6.2095; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; LIN HY, 1987, J BIOL CHEM, V262, P6823; LIOTTA LA, 1989, J NATL CANCER I, V81, P556, DOI 10.1093/jnci/81.8.556; LYONS JG, 1989, MATRIX, V9, P7, DOI 10.1016/S0934-8832(89)80012-5; LYONS JG, 1991, BIOCHEMISTRY-US, V30, P1449, DOI 10.1021/bi00220a001; MACKAY AR, 1990, J BIOL CHEM, V265, P21929; MACNAUL KL, 1990, J BIOL CHEM, V265, P17238; MASADA MP, 1990, J PERIODONTAL RES, V25, P156, DOI 10.1111/j.1600-0765.1990.tb01038.x; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; MOSCAT J, 1988, MOL ENDOCRINOL, V2, P799, DOI 10.1210/mend-2-9-799; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NORDLUND L, 1991, J PERIODONTAL RES, V26, P333, DOI 10.1111/j.1600-0765.1991.tb02071.x; PAGANELLIPARKER K, 1988, ANN NY ACAD SCI, V548, P346; PETERSEN MJ, 1987, J BIOL CHEM, V262, P835; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; REINERS JJ, 1983, CELL, V32, P247, DOI 10.1016/0092-8674(83)90515-9; ROONEY M, 1990, RHEUMATOL INT, V10, P217, DOI 10.1007/BF02274836; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SAKO T, 1988, CANCER RES, V48, P4646; SALO T, 1991, J BIOL CHEM, V266, P11436; SAUS J, 1988, J BIOL CHEM, V263, P6742; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; STEINERT P, 1978, SCIENCE, V200, P1491, DOI 10.1126/science.566466; STEVENSON GA, 1985, BIOSCIENCE REP, V5, P1071, DOI 10.1007/BF01119628; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TISCHLER AS, 1990, J NEUROCHEM, V55, P1159, DOI 10.1111/j.1471-4159.1990.tb03120.x; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TURKSEN K, 1991, CELL REGUL, V2, P613, DOI 10.1091/mbc.2.8.613; WATANABE M, 1990, BIOCHIM BIOPHYS ACTA, V1047, P141, DOI 10.1016/0005-2760(90)90040-5; WESTACOTT CI, 1990, ANN RHEUM DIS, V49, P676, DOI 10.1136/ard.49.9.676; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YOSHIZAWA S, 1990, CANCER RES, V50, P4974; YUSPA SH, 1980, BIOCHEM BIOPH RES CO, V97, P700, DOI 10.1016/0006-291X(80)90321-6; ZHANG XK, 1991, J BIOL CHEM, V266, P8248	76	113	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					19143	19151						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8395530				2022-12-25	WOS:A1993LV65900112
J	GOODEARL, ADJ; DAVIS, JB; MISTRY, K; MINGHETTI, L; OTSU, M; WATERFIELD, MD; STROOBANT, P				GOODEARL, ADJ; DAVIS, JB; MISTRY, K; MINGHETTI, L; OTSU, M; WATERFIELD, MD; STROOBANT, P			PURIFICATION OF MULTIPLE FORMS OF GLIAL GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SCHWANN-CELLS; BOVINE PITUITARY; PERIPHERAL-NERVE; CYCLIC-AMP; PROLIFERATION; REGENERATION; MITOGEN; DIFFERENTIATION; IDENTIFICATION; RECEPTOR	Glial growth factors (GGFs) were purified from bovine pituitaries using an in vitro rat Schwann cell mitogenesis assay. In addition to an approximately 34-kDa species termed GGF-I, similar in molecular mass to a previously identified molecule (Lemke, G. E., and Brockes, J. P. (1984) J. Neuroscience 4, 75-83), two species named GGF-II and GGF-III were characterized with apparent molecular masses of approximately 59 and approximately 45 kDa, respectively. Highly purified preparations of all species share a similar dose-dependent stimulation of Schwann cell DNA synthesis at nanomolar concentrations. Forskolin synergizes with all three GGFs, shifting their dose dependence 3-8-fold into the sub-nanomolar range. The GGFs, which contain N-linked carbohydrate groups not essential for their in vitro mitogenic effects, are three distinct members of a novel family of glial cell mitogens.	UNIV COLL,MIDDLESEX HOSP BRANCH,LUDWIG INST CANC RES,91 RIDING ST,LONDON W1P 8BJ,ENGLAND; UNIV LONDON UNIV COLL,DEPT BIOCHEM & MOLEC BIOL,LONDON WC1E 6BT,ENGLAND	Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London			Minghetti, Luisa/I-9540-2014; Goodearl, Andrew/AAP-5501-2020	Minghetti, Luisa/0000-0002-7065-4689; 				AGUAYO AJ, 1976, J NEUROCYTOL, V5, P137, DOI 10.1007/BF01181653; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKES JP, 1987, METHOD ENZYMOL, V147, P217; BROCKES JP, 1984, SCIENCE, V225, P1280, DOI 10.1126/science.6474177; BROCKES JP, 1980, J BIOL CHEM, V255, P8374; BROCKES JP, 1986, CELL, V45, P301, DOI 10.1016/0092-8674(86)90394-6; BROCKES JP, 1986, ANN NEUROL, V20, P317, DOI 10.1002/ana.410200308; BROCKES JP, 1977, NATURE, V266, P364, DOI 10.1038/266364a0; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; DAVIS JB, 1990, J CELL BIOL, V110, P1353, DOI 10.1083/jcb.110.4.1353; ECCLESTON PA, 1989, J NEUROSCI RES, V24, P524, DOI 10.1002/jnr.490240410; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMKE GE, 1984, J NEUROSCI, V4, P75; Ludwin S K, 1988, Adv Neurol, V47, P215; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MASON PW, 1989, J CELL BIOL, V108, P607, DOI 10.1083/jcb.108.2.607; MORGAN L, 1991, J CELL BIOL, V112, P457, DOI 10.1083/jcb.112.3.457; NORDLUND M, 1992, GLIA, V5, P182, DOI 10.1002/glia.440050304; Peters A., 1991, FINE STRUCTURE NERVO, P212; PORTER S, 1987, P NATL ACAD SCI USA, V84, P7768, DOI 10.1073/pnas.84.21.7768; RAFF MC, 1978, CELL, V15, P813, DOI 10.1016/0092-8674(78)90266-0; RAFF MC, 1978, NATURE, V273, P672, DOI 10.1038/273672a0; RATNER N, 1988, P NATL ACAD SCI USA, V85, P6992, DOI 10.1073/pnas.85.18.6992; RATNER N, 1987, GLIAL NEURONAL COMMU; Riccardi V. M., 1992, NEUROFIBROMATOSIS PH; RIDLEY AJ, 1989, J CELL BIOL, V109, P3419, DOI 10.1083/jcb.109.6.3419; SALZER JL, 1980, J CELL BIOL, V84, P753, DOI 10.1083/jcb.84.3.753; SALZER JL, 1980, J CELL BIOL, V84, P767, DOI 10.1083/jcb.84.3.767; SALZER JL, 1980, J CELL BIOL, V84, P739, DOI 10.1083/jcb.84.3.739; SCHUBERT D, 1992, J NEUROBIOL, V23, P751; WEINMASTER G, 1990, EMBO J, V9, P915, DOI 10.1002/j.1460-2075.1990.tb08189.x; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WOOD PM, 1975, NATURE, V256, P662, DOI 10.1038/256662a0	36	97	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18095	18102						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8394360				2022-12-25	WOS:A1993LT74300068
J	SAARIALHOKERE, UK; WELGUS, HG; PARKS, WC				SAARIALHOKERE, UK; WELGUS, HG; PARKS, WC			DISTINCT MECHANISMS REGULATE INTERSTITIAL COLLAGENASE AND 92-KDA GELATINASE EXPRESSION IN HUMAN MONOCYTIC-LIKE CELLS EXPOSED TO BACTERIAL-ENDOTOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; NF-KAPPA-B; HUMAN MONONUCLEAR PHAGOCYTES; HUMAN ALVEOLAR MACROPHAGES; PHORBOL-MYRISTATE ACETATE; GENE-EXPRESSION; IV COLLAGENASE; TISSUE INHIBITOR; INSITU HYBRIDIZATION; NEUTRAL PROTEINASES	We studied the mechanisms that govern the expression of interstitial collagenase and 92-kDa gelatinase in U937 cells, a human monocyte-like cell line, exposed to bacterial lipopolysaccharide (LPS), a potent inducer of metalloproteinase expression. U937 cells were differentiated by phorbol ester (phorbol 12-myristate 13-acetate (PMA)) and, 24 h later, were exposed to LPS for an additional 24 h. Enzyme-linked immunosorbent assay and Northern hybridization showed that PMA mediated an induction of collagenase and markedly stimulated the low basal levels of 92-kDa gelatinase. Subsequent exposure to LPS substantially increased the production of both enzymes. Nuclear runoff assay demonstrated that PMA regulated collagenase and 92-kDa gelatinase transcription. LPS also stimulated collagenase transcription but did not affect transcription of 92-kDa gelatinase. Consistent with the runoff data, the decay rate of collagenase mRNA did not differ between experimental treatments, but the half-life of gelatinase mRNA increased with exposure to LPS. Furthermore, in situ hybridization showed that 92-kDa gelatinase was expressed by all cells whereas collagenase was produced by a subpopulation of cells in both PMA- and PMA/LPS-exposed cultures, and similar findings were seen with LPS-activated human alveolar macrophages. These data indicate that divergent mechanisms control metalloproteinase expression in phagocytic cells and that enzyme production differs among macrophage subpopulations.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DIV DERMATOL,216 S KINGSHIGHWAY BLVD,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL)			Parks, William C./AAH-6786-2021		NHLBI NIH HHS [HL41040, HL29594, HL48762] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048762, R29HL041040, P01HL029594] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGEL P, 1992, MATRIX METALLOPROTEI, P156; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BRINCKERHOFF CE, 1986, BIOCHEMISTRY-US, V25, P6378, DOI 10.1021/bi00369a006; CAMPBELL EJ, 1991, J IMMUNOL, V146, P1286; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHANDLER DB, 1987, J IMMUNOL, V139, P893; CHUA CC, 1990, CONNECT TISSUE RES, V25, P161, DOI 10.3109/03008209009006990; COLLIER IE, 1988, J BIOL CHEM, V263, P10711; COOPER TW, 1982, COLLAGEN REL RES, V3, P205; COROCORAN ML, 1992, J BIOL CHEM, V267, P515; CURY JD, 1988, J IMMUNOL, V141, P4306; DANIELISSAKANI S, 1988, J BIOL CHEM, V34, P20240; DEMCZUK S, 1988, J BIOL CHEM, V263, P13039; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; EVERSON MP, 1992, AM J PATHOL, V140, P503; GONZALEZ IL, 1985, P NATL ACAD SCI USA, V82, P7666, DOI 10.1073/pnas.82.22.7666; GRAY PW, 1986, J IMMUNOL, V137, P3644; HAN JH, 1991, BIOCHIM BIOPHYS ACTA, V1090, P22, DOI 10.1016/0167-4781(91)90032-H; HANCE AJ, 1985, J IMMUNOL, V134, P284; HEATH JK, 1987, INFECT IMMUN, V55, P2148, DOI 10.1128/IAI.55.9.2148-2154.1987; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; HIBBS MS, 1987, J CLIN INVEST, V80, P1644, DOI 10.1172/JCI113253; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HOHMANN HP, 1991, MOL CELL BIOL, V11, P259, DOI 10.1128/MCB.11.1.259; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; LACRAZ S, 1992, J CLIN INVEST, V90, P382, DOI 10.1172/JCI115872; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MAINARDI CL, 1984, BIOCHIM BIOPHYS ACTA, V805, P137, DOI 10.1016/0167-4889(84)90160-5; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MCCACHREN SS, 1991, ARTHRITIS RHEUM-US, V34, P1085; MINTA JO, 1985, AM J PATHOL, V119, P111; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; PARKS WC, 1988, J BIOL CHEM, V263, P4416; PIERCE RA, 1992, J BIOL CHEM, V267, P11593; POLLA BS, 1987, J CLIN INVEST, V80, P962, DOI 10.1172/JCI113189; PROSSER IW, 1989, AM J PATHOL, V135, P1073; RABBITTS PH, 1985, EMBO J, V4, P3727, DOI 10.1002/j.1460-2075.1985.tb04141.x; SAARIALHOKERE UK, 1992, J CLIN INVEST, V90, P1952, DOI 10.1172/JCI116073; SAARIALHOKERE UK, 1993, J INVEST DERMATOL, V100, P335, DOI 10.1111/1523-1747.ep12470032; Sachs A, 1990, CURR OPIN CELL BIOL, V2, P1092, DOI 10.1016/0955-0674(90)90161-7; SCHENKEIN HA, 1986, CELL IMMUNOL, V102, P307, DOI 10.1016/0008-8749(86)90424-7; SCHYNDER J, 1987, J IMMUNOL, V138, P496; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SHAPIRO DJ, 1987, BIOESSAYS, V6, P221, DOI 10.1002/bies.950060507; SHAPIRO SD, 1990, J CLIN INVEST, V86, P1204, DOI 10.1172/JCI114826; SHAPIRO SD, 1993, BIOCHEMISTRY-US, V32, P4286, DOI 10.1021/bi00067a018; SHAPIRO SD, 1993, J BIOL CHEM, V268, P8170; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STAHLEBACKDAHL M, 1992, J INVEST DERMATOL, V99, P497, DOI 10.1111/1523-1747.ep12616171; STAUBER GB, 1989, J BIOL CHEM, V264, P3573; TURNER M, 1988, BIOCHEM BIOPH RES CO, V156, P830, DOI 10.1016/S0006-291X(88)80919-7; UNEMORI EN, 1991, J CLIN INVEST, V88, P1656, DOI 10.1172/JCI115480; VINCENTI MP, 1992, J CELL PHYSIOL, V150, P204, DOI 10.1002/jcp.1041500127; WAGER RE, 1990, MOL CELL BIOL, V10, P5983, DOI 10.1128/MCB.10.11.5983; WAHL LM, 1987, CELL IMMUNOL, V105, P411, DOI 10.1016/0008-8749(87)90088-8; WELGUS HG, 1990, J BIOL CHEM, V265, P13521; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WELGUS HG, 1986, J CLIN INVEST, V77, P1675, DOI 10.1172/JCI112485; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	64	81	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17354	17361						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8394340				2022-12-25	WOS:A1993LQ98800070
J	YAMAUCHI, K; HOLT, K; PESSIN, JE				YAMAUCHI, K; HOLT, K; PESSIN, JE			PHOSPHATIDYLINOSITOL 3-KINASE FUNCTIONS UPSTREAM OF RAS AND RAF IN MEDIATING INSULIN STIMULATION OF C-FOS TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RECEPTOR TYROSINE KINASES; SIGNAL TRANSDUCTION; EGF RECEPTOR; PHOSPHOLIPASE-C; PDGF RECEPTOR; PROTEIN; PHOSPHORYLATION; SUBSTRATE; BINDING; GENE	Insulin treatment of Chinese hamster ovary (CHO) cells expressing high levels of the insulin receptor (CHO-IR) was found to markedly activate (10-20-fold) transcription of the luciferase reporter gene (Luc) driven by the serum response element (SRE) of the c-fos promoter. SRE-Luc expression was also strongly activated by co-transfection with expression plasmids encoding for either v-Ras or v-Raf. In contrast, insulin-stimulated SRE-Luc activity was inhibited by expression of a negative-dominant Ras (Ras Asn-17)- or a negative-dominant Raf (p301-1)-encoding plasmid. Furthermore, the negative-dominant Raf mutant blocked v-Ras activation whereas the negative-dominant Ras mutant had no significant effect on v-Raf activation. Together, these data demonstrate that insulin utilizes the Ras and Raf signaling pathways and that Ras functions upstream of Raf in terms of transcriptional activation of the serum response element. To assess the role of the phosphatidylinositol (PI) 3-kinase in this insulin signaling pathway, CHO-IR cells were co-transfected with the p85 regulatory subunit of the PI 3-kinase. Expression of the p85 subunit inhibited the insulin stimulation of SRE-Luc activity without affecting v-Ras or v-Raf activation. Thus, these data demonstrate that the PI 3-kinase is necessary for insulin signaling of transcriptional events and that, in a linear model of intracellular signaling, the PI 3-kinase functions upstream of both Ras and Raf.	UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa					NIDDK NIH HHS [DK01822, DK25295, DK33823] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295, K04DK001822, R37DK033823, R01DK033823] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1989, MOL CELL BIOL, V9, P4312, DOI 10.1128/MCB.9.10.4312; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FRATTALI AL, 1991, J BIOL CHEM, V266, P9829; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KELLER SR, 1991, J BIOL CHEM, V266, P12817; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; LEE RM, 1991, J BIOL CHEM, V266, P10351; LEE RM, 1992, J BIOL CHEM, V267, P1088; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; ORAHILLY S, 1992, CLIN ENDOCRINOL, V36, P121, DOI 10.1111/j.1365-2265.1992.tb00945.x; OSTEROP APRM, 1992, J BIOL CHEM, V267, P14647; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SHOELSON SE, 1993, EMBO J, V12, P796; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAYLOR R, 1991, CLIN ENDOCRINOL, V34, P159, DOI 10.1111/j.1365-2265.1991.tb00287.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y	51	141	145	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14597	14600						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8392056				2022-12-25	WOS:A1993LL75900013
J	SULLIVAN, ML; VIERSTRA, RD				SULLIVAN, ML; VIERSTRA, RD			FORMATION OF A STABLE ADDUCT BETWEEN UBIQUITIN AND THE ARABIDOPSIS UBIQUITIN-CONJUGATING ENZYME, ATUBC1+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY PURIFICATION; ACTIVATING ENZYME; PROTEIN LIGASE; RAD6 PROTEIN; MUTAGENESIS; CLONING; WHEAT	Ubiquitin conjugating enzymes (E2s) are an integral part of a multienzyme pathway that ligates ubiquitin to intracellular target proteins. This ligation has been implicated in a number of fundamental processes including protein degradation, cell cycle progression, DNA repair, and organelle biogenesis. To function, E2s form a labile thiol-ester intermediate between a specific cysteine within the E2 and the carboxyl terminus of ubiquitin; this high energy intermediate then serves as the donor for ubiquitin ligation. To aid in the characterization of E2s, we have created a stable ubiquitin-E2 intermediate using a mutant form of the 16-kDa E2 encoded by the Arabidopsis thaliana AtUBC1 gene in which the active-site cysteine at residue 88 was replaced with serine. The mutant protein synthesized in Escherichia coli formed an adduct with ubiquitin in vitro, but in this case the E2 and ubiquitin were linked via a more stable ester bond. The ester-linked ubiquitin could not be transferred subsequently to substrate proteins in an E3alpha-dependent conjugation reaction. The ester adduct was sufficiently stable to survive purification by anion exchange high performance liquid chromatography. As a result, this adduct may prove useful for the structural analysis of ubiquitin-E2 intermediates and in the study of E2s interacting with other ubiquitin pathway enzymes.	UNIV WISCONSIN, DEPT HORT, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison								CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; CIECHANOVER A, 1981, P NATL ACAD SCI-BIOL, V78, P761, DOI 10.1073/pnas.78.2.761; COOK WJ, 1992, J BIOL CHEM, V267, P15116; COOK WJ, 1992, J MOL BIOL, V223, P1183, DOI 10.1016/0022-2836(92)90270-T; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GIROD PA, 1993, J BIOL CHEM, V268, P955; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1985, PREP BIOCHEM, V15, P49; HATFIELD PM, 1990, J BIOL CHEM, V265, P15813; HATFIELD PM, 1989, BIOCHEMISTRY-US, V28, P735, DOI 10.1021/bi00428a048; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HESHKO A, 1992, ANNU REV BIOCHEM, V61, P761; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; QIN S, 1991, J BIOL CHEM, V266, P15549; REISS Y, 1990, J BIOL CHEM, V265, P3685; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SULLIVAN ML, 1991, J BIOL CHEM, V266, P23878; SUNG P, 1988, GENE DEV, V2, P1476, DOI 10.1101/gad.2.11.1476; SUNG P, 1991, J MOL BIOL, V221, P745, DOI 10.1016/0022-2836(91)80169-U; VIERSTRA RD, 1985, J BIOL CHEM, V260, P2015; VIERSTRA RD, 1993, ANNU REV PLANT PHYS, V44, P385, DOI 10.1146/annurev.pp.44.060193.002125; VIJAYKUMAR S, 1987, J BIOL CHEM, V262, P6396; WEBER K, 1969, J BIOL CHEM, V244, P4406	25	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8777	8780						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8386169				2022-12-25	WOS:A1993KX81100060
J	FUKUNAGA, K; STOPPINI, L; MIYAMOTO, E; MULLER, D				FUKUNAGA, K; STOPPINI, L; MIYAMOTO, E; MULLER, D			LONG-TERM POTENTIATION IS ASSOCIATED WITH AN INCREASED ACTIVITY OF CA2+ CALMODULIN-DEPENDENT PROTEIN KINASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HIPPOCAMPUS; CA-2+-INDEPENDENT FORM; SYNAPTIC TRANSMISSION; POSTSYNAPTIC DENSITY; AUTONOMOUS ENZYME; AUTOPHOSPHORYLATION; LOCALIZATION; BRAIN; TRANSLOCATION; GENERATION	Among the molecular mechanisms that have been proposed to contribute to long-term potentiation in hippocampus are the activation and autophosphorylation of Ca2+/calmodulin-dependent protein kinase II (CaM kinase II). Here we report that high, but not low frequency stimulation applied to two groups of CA1 afferents resulted in a long lasting increase in the Ca2+-independent and total activities of the enzyme as well as an increase in the ratio of Ca2+-independent to total activity. The effect was obtained using two different CaM kinase II substrates, it was observed in hippocampal slices and in hippocampal organotypic cultures, and it could be blocked by preincubation of slices with the N-methyl-D-aspartate receptor antagonist D-2-amino-5-phosphonopentanoate. Treatment of slices with calyculin A, a phosphatase inhibitor, modified the activity of the enzyme, but long term potentiation could still be induced and a further increase in Ca2+-independent CaM kinase II activity still observed.	CTR MED UNIV GENEVA,DEPT PHARMACOL,CH-1211 GENEVA 4,SWITZERLAND; KUMAMOTO UNIV,SCH MED,DEPT PHARMACOL,KUMAMOTO 860,JAPAN	University of Geneva; Kumamoto University								AKERS RF, 1986, SCIENCE, V231, P587, DOI 10.1126/science.3003904; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P357, DOI 10.1113/jphysiol.1973.sp010274; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DUNWIDDIE T, 1978, J PHYSIOL-LONDON, V276, P353, DOI 10.1113/jphysiol.1978.sp012239; FUKUNAGA K, 1988, J NEUROCHEM, V51, P1070, DOI 10.1111/j.1471-4159.1988.tb03070.x; FUKUNAGA K, 1990, Molecular and Cellular Neuroscience, V1, P133; FUKUNAGA K, 1989, J BIOL CHEM, V264, P21830; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; ITO I, 1991, NEUROSCI LETT, V121, P119, DOI 10.1016/0304-3940(91)90663-E; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LISMAN JE, 1985, P NATL ACAD SCI USA, V82, P3055, DOI 10.1073/pnas.82.9.3055; LISMAN JE, 1988, P NATL ACAD SCI USA, V85, P5320, DOI 10.1073/pnas.85.14.5320; LOU LL, 1986, P NATL ACAD SCI USA, V83, P9497, DOI 10.1073/pnas.83.24.9497; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MOLLOY SS, 1991, P NATL ACAD SCI USA, V88, P4756, DOI 10.1073/pnas.88.11.4756; OCORR KA, 1991, NEURON, V6, P907, DOI 10.1016/0896-6273(91)90231-N; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; OUIMET CC, 1984, P NATL ACAD SCI-BIOL, V81, P5604, DOI 10.1073/pnas.81.17.5604; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SAITOH T, 1985, J CELL BIOL, V100, P835, DOI 10.1083/jcb.100.3.835; SCHULMAN H, 1989, TRENDS BIOCHEM SCI, V14, P62, DOI 10.1016/0968-0004(89)90045-5; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M	29	347	352	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7863	7867						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8385124				2022-12-25	WOS:A1993KW97900044
J	CAMPBELL, GS; CHRISTIAN, LJ; CARTERSU, C				CAMPBELL, GS; CHRISTIAN, LJ; CARTERSU, C			EVIDENCE FOR INVOLVEMENT OF THE GROWTH-HORMONE RECEPTOR-ASSOCIATED TYROSINE KINASE IN ACTIONS OF GROWTH-HORMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERBIMYCIN-A; BETA-CHAIN; ERYTHROPOIETIN RECEPTOR; INTERLEUKIN-5 RECEPTOR; 3T3-F442A FIBROBLASTS; SIGNAL TRANSDUCTION; EXPRESSION CLONING; MOLECULAR-CLONING; PROTEIN-KINASES; IL-2 RECEPTOR	Previous observations have led to the speculation that activation of a growth hormone (GH) receptor-associated tyrosine kinase is an early, perhaps initiating, event in transmembrane signaling by GH. To test this hypothesis further, a Western blotting assay employing antibodies to phosphotyrosine was used to determine whether proteins other than the GH receptor might serve as substrates of the GH receptor-associated tyrosine kinase. The ability of inhibitors of the GH receptor-associated kinase to block actions of GH was also investigated. Over a physiologically relevant range of concentrations, GH was found to promote, in 3T3-F442A fibroblasts, rapid changes in the level of tyrosyl phosphorylation of more than 13 proteins. At the highest GH concentration employed (500 ng/ml), increased tyrosyl phosphorylation of two proteins, pp121 and pp97, was clearly visible at 1 min, the earliest time tested. Increased tyrosyl phosphorylation of a number of other proteins (pp250, pps160-180, pps140-160, pp130, pp90, pp75, pp45, pp42, pp39, and pp36) and decreased tyrosyl phosphorylation of a 140-kDa protein were apparent after 5-10 min of incubation with GH. Staurosporine, herbimycin A, and tyrphostin were identified as inhibitors of the GH receptor-associated kinase. When added to anti-GH antibody immunoprecipitates from GH-treated cells, they inhibited incorporation of P-32 from [gamma-P-32]ATP into tyrosyl residues in GH receptor complexes. When added to cells, all three inhibitors blocked all GH-dependent increases in tyrosyl phosphorylation of cellular proteins. Inhibitors of the GH receptor-associated tyrosine kinase also abolished GH-dependent activation of microtubule-associated protein (MAP) kinase. Consistent with these inhibitors inhibiting the GH receptor-associated tyrosine kinase, they had little or no effect on activation of MAP kinase by epidermal growth factor. In contrast, genistein and hydroxy-(2-naphthyl)-methylphosphonic acid, tyrosine kinase inhibitors lacking specificity for the GH receptor-associated kinase, decreased GH-dependent tyrosyl phosphorylation of only a subset of GH-responsive bands and partially blocked GH-dependent activation of MAP kinase. These data show that increased tyrosyl phosphorylation of specific cellular proteins is a very rapid response to the binding of GH by the cell and most likely involves multiple tyrosine kinases. Furthermore, inhibition of the GH receptor-associated tyrosine kinase blocks at least two actions of GH, the stimulation of tyrosyl phosphorylation of multiple proteins and MAP kinase activation. These results are consistent with the GH receptor-associated kinase playing an important, perhaps initiating, role in trans-membrane signaling by GH.			CAMPBELL, GS (corresponding author), UNIV MICHIGAN, SCH MED, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA.				NIDDK NIH HHS [DK-34171, R01 DK034171] Funding Source: Medline; NIGMS NIH HHS [GM-14099] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034171, R37DK034171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014099] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1991, J BIOL CHEM, V266, P4220; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; ASHCOM G, 1992, ENDOCRINOLOGY, V131, P1915, DOI 10.1210/en.131.4.1915; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; CHEEK DB, 1974, HDB PHYSIOLOGY END 2, V4, P159; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DAVIDSON MB, 1987, ENDOCR REV, V8, P115, DOI 10.1210/edrv-8-2-115; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GULLER S, 1991, ENDOCRINOLOGY, V129, P527, DOI 10.1210/endo-129-1-527; GULLER S, 1989, ENDOCRINOLOGY, V125, P2360, DOI 10.1210/endo-125-5-2360; GULLER S, 1992, ENDOCRINOLOGY, V130, P2609, DOI 10.1210/en.130.5.2609; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HONMA Y, 1989, CANCER RES, V49, P331; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; ISAKSSON OGP, 1987, ENDOCR REV, V8, P426, DOI 10.1210/edrv-8-4-426; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KAMPS MP, 1988, ONCOGENE RES, V3, P105; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; KUGUNAGA R, 1990, CELL, V61, P341; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LYALL RM, 1989, J BIOL CHEM, V264, P14503; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIYASAKA T, 1991, P NATL ACAD SCI USA, V88, P2653, DOI 10.1073/pnas.88.7.2653; MORIKAWA M, 1982, CELL, V29, P783, DOI 10.1016/0092-8674(82)90440-8; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; NAKANO H, 1987, J ANTIBIOT, V40, P706, DOI 10.7164/antibiotics.40.706; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NIXON T, 1984, ENDOCRINOLOGY, V114, P527, DOI 10.1210/endo-114-2-527; OHMICHI M, 1992, BIOCHEMISTRY-US, V31, P4034, DOI 10.1021/bi00131a019; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; PRESS M, 1988, DIABETES METAB REV, V4, P391, DOI 10.1002/dmr.5610040406; RILLEMA JA, 1992, ENDOCRINOLOGY, V131, P973, DOI 10.1210/en.131.2.973; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SAPERSTEIN R, 1989, BIOCHEMISTRY-US, V28, P5694, DOI 10.1021/bi00439a053; SATOH T, 1992, J BIOL CHEM, V267, P2537; SECRIST JP, 1990, J BIOL CHEM, V265, P20394; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STRED SE, 1990, ENDOCRINOLOGY, V127, P2506, DOI 10.1210/endo-127-5-2506; STRED SE, 1992, ENDOCRINOLOGY, V130, P1626, DOI 10.1210/en.130.3.1626; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG XY, 1993, J BIOL CHEM, V268, P3573; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706; ZEZULAK KM, 1986, SCIENCE, V233, P551, DOI 10.1126/science.3726546	65	98	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7427	7434						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8385106				2022-12-25	WOS:A1993KV14100086
J	ULATOWSKI, LM; LAM, M; VANDERBURG, G; STALLCUP, MR; DISTELHORST, CW				ULATOWSKI, LM; LAM, M; VANDERBURG, G; STALLCUP, MR; DISTELHORST, CW			RELATIONSHIP BETWEEN DEFECTIVE MOUSE MAMMARY-TUMOR VIRUS ENVELOPE GLYCOPROTEIN-SYNTHESIS AND GRP78 SYNTHESIS IN GLUCOCORTICOID-TREATED MOUSE LYMPHOMA-CELLS - EVIDENCE FOR TRANSLATIONAL CONTROL OF GRP78 SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN-BINDING-PROTEIN; GLUCOSE-REGULATED PROTEIN; ENDOPLASMIC-RETICULUM; MESSENGER-RNA; BIOCHEMICAL-CHARACTERIZATION; NUCLEOTIDE-SEQUENCE; HAMSTER FIBROBLASTS; MALFOLDED PROTEINS; CALCIUM IONOPHORE; 2 GENES	We have found that synthesis of the 78-kDa glucose-regulated protein, GRP78, was increased following glucocorticoid treatment of S49 and W7MG1 mouse lymphoma cell lines. These lines synthesized a 74-kDa mouse mammary tumor virus envelope glycoprotein precursor, Pr74, both constitutively and in response to glucocorticoid treatment. In these cell lines, nascent Pr74 was not processed normally, but was retained within the endoplasmic reticulum where it was bound stably by GRP78. GRP78 synthesis was not increased following glucocorticoid treatment of the W7.2 mouse lymphoma cell line, which does not synthesize Pr74, suggesting that the increase in GRP78 synthesis following glucocorticoid treatment of S49 and W7MG1 cells was secondary to the glucocorticoid-induced increase in Pr74 synthesis. Consistent with this hypothesis, the glucocorticoid-induced increase in Pr74 synthesis preceded the increase in GRP78 synthesis. Also, there was a direct correlation between the level of GRP78 synthesis and the level of Pr74 synthesis among multiple subclones of the W7-ENV/N line. This line was derived from the W7.2 line by retroviral mediated transfer of a constitutively expressed sequence encoding a defective form of Pr74 that was bound stably by GRP78 within the endoplasmic reticulum. An elevation in the steady state level of GRP78 mRNA was not detected either in glucocorticoid-treated S49 cells and W7MG1 cells or in subclones of the W7-ENV/N line that have an increased level of GRP78 synthesis. Therefore, it appears that the binding of Pr74 to GRP78 induces an increase in GRP78 synthesis that is regulated at a translational level, rather than at a transcriptional level.	CASE WESTERN RESERVE UNIV, SCH MED, BRB, DEPT MED, 10900 EUCLID AVE, CLEVELAND, OH 44106 USA; UNIV HOSP CLEVELAND, IRELAND CANC CTR, CLEVELAND, OH 44106 USA; UNIV SO CALIF, HLTH SCI CTR, DEPT PATHOL, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, HLTH SCI CTR, DEPT BIOCHEM, LOS ANGELES, CA 90033 USA	Case Western Reserve University; University Hospitals of Cleveland; University of Southern California; University of Southern California			Ulatowski, Lynn/ABI-5652-2020		NCI NIH HHS [CA42755, P30CA43703] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703, R01CA042755] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEDGOOD RM, 1992, MOL ENDOCRINOL, V6, P459, DOI 10.1210/me.6.3.459; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; BROSTROM MA, 1990, J BIOL CHEM, V265, P20539; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CHANG SC, 1987, P NATL ACAD SCI USA, V84, P680, DOI 10.1073/pnas.84.3.680; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN JC, 1979, J VIROL, V32, P483, DOI 10.1128/JVI.32.2.483-496.1979; COREY JL, 1992, MOL ENDOCRINOL, V6, P450, DOI 10.1210/me.6.3.450; DANIELSEN M, 1983, MOL CELL BIOL, V3, P1310, DOI 10.1128/MCB.3.7.1310; DORNER AJ, 1988, MOL CELL BIOL, V8, P4063, DOI 10.1128/MCB.8.10.4063; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; EARL PL, 1991, J VIROL, V65, P2047, DOI 10.1128/JVI.65.4.2047-2055.1991; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HARRIGAN MT, 1989, MOL CELL BIOL, V9, P3438, DOI 10.1128/MCB.9.8.3438; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; HORIBATA K, 1970, EXP CELL RES, V60, P61, DOI 10.1016/0014-4827(70)90489-1; HOWARD KJ, 1988, J BIOL CHEM, V263, P3474; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; KIM YK, 1987, J CELL PHYSIOL, V133, P553, DOI 10.1002/jcp.1041330317; KOCH G, 1986, J CELL SCI, V86, P217; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM M, 1992, BLOOD, V79, P3285; LEE AS, 1984, J BIOL CHEM, V259, P4616; LEE AS, 1983, J BIOL CHEM, V258, P597; LI X, 1991, MOL CELL BIOL, V11, P3446, DOI 10.1128/MCB.11.7.3446; LIN AY, 1984, P NATL ACAD SCI-BIOL, V81, P988, DOI 10.1073/pnas.81.4.988; LIU ES, 1992, J BIOL CHEM, V267, P7128; LODISH HF, 1992, J BIOL CHEM, V267, P12753; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MACER DRJ, 1988, J CELL SCI, V91, P61; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAKAKI T, 1989, MOL CELL BIOL, V9, P2233, DOI 10.1128/MCB.9.5.2233; OLDEN K, 1979, P NATL ACAD SCI USA, V76, P791, DOI 10.1073/pnas.76.2.791; POUYSSEGUR J, 1977, CELL, V11, P941, DOI 10.1016/0092-8674(77)90305-1; Reid L C, 1979, Methods Enzymol, V58, P152; RESENDEZ E, 1988, MOL CELL BIOL, V8, P4579, DOI 10.1128/MCB.8.10.4579; RESENDEZ E, 1985, MOL CELL BIOL, V5, P1212, DOI 10.1128/MCB.5.6.1212; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SARNOW P, 1989, P NATL ACAD SCI USA, V86, P5795, DOI 10.1073/pnas.86.15.5795; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SHIU RPC, 1977, P NATL ACAD SCI USA, V74, P3840, DOI 10.1073/pnas.74.9.3840; SNIDER LD, 1990, MOL ENDOCRINOL, V4, P749, DOI 10.1210/mend-4-5-749; SUGAWARA S, 1990, J IMMUNOL, V145, P1991; TING J, 1987, GENE, V55, P147, DOI 10.1016/0378-1119(87)90258-7; VAN PN, 1989, J BIOL CHEM, V264, P17494; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612	58	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7482	7488						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8385109				2022-12-25	WOS:A1993KV14100094
J	LIU, F; THOMPSON, MA; WAGNER, S; GREENBERG, ME; GREEN, MR				LIU, F; THOMPSON, MA; WAGNER, S; GREENBERG, ME; GREEN, MR			ACTIVATING TRANSCRIPTION FACTOR-I CAN MEDIATE CA2+-INDUCIBLE AND CAMP-INDUCIBLE TRANSCRIPTIONAL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; AMP RESPONSE ELEMENT; NUCLEAR FACTOR CREB; RAT SOMATOSTATIN GENE; ATF CDNA CLONES; CYCLIC-AMP; DEPENDENT PHOSPHORYLATION; TYROSINE-HYDROXYLASE; CALCIUM-CALMODULIN; C-FOS	Increased intracellular cAMP and Ca2+ levels can activate transcription of a number of eukaryotic genes through a common promoter element, the cAMP/Ca2+ response element. This element is the binding site for activating transcription factor (ATF)/CREB proteins, an extensive transcription factor family. Here we report that one member of this family, ATF-1, can mediate both Ca2+ and cAMP transcriptional responses, but that the responses to the two pathways differ in magnitude. In contrast, another family member, CREB, has been shown to mediate Ca2+ and cAMP responses to similar levels. Taken together, these results suggest a mechanism that allows cells to integrate and differentiate gene regulation by cAMP and Ca2+.	UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,373 PLANTAT ST,WORCESTER,MA 01605; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028829] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS 28829] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABEL T, 1992, GENE DEV, V6, P466, DOI 10.1101/gad.6.3.466; ANDRISANI OM, 1991, J BIOL CHEM, V266, P21444; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; FLINT KJ, 1991, ONCOGENE, V6, P2019; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODMAN RH, 1990, ANNU REV NEUROSCI, V13, P111, DOI 10.1146/annurev.neuro.13.1.111; GRIFFITH LC, 1988, J BIOL CHEM, V263, P9542; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAEKAWA T, 1991, ONCOGENE, V6, P627; MASSON N, 1992, MOL CELL BIOL, V12, P1096, DOI 10.1128/MCB.12.3.1096; MEINKOTH JL, 1991, MOL CELL BIOL, V11, P1759, DOI 10.1128/MCB.11.3.1759; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; NGUYEN TV, 1990, J NEUROSCI, V10, P2825; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SCHULMAN H, 1984, MOL CELL BIOL, V4, P1175, DOI 10.1128/MCB.4.6.1175; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SHENG M, 1990, THESIS HARVARD U BOS; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SILVER BJ, 1987, P NATL ACAD SCI USA, V83, P6682; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TSUKADA T, 1987, J BIOL CHEM, V262, P8743; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; ZHU Z, 1989, J BIOL CHEM, V264, P6550; ZU YL, 1991, J BIOL CHEM, V266, P21444	57	142	143	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6714	6720						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8384217				2022-12-25	WOS:A1993KT36800091
J	GRAMINSKI, GF; JAYAWICKREME, CK; POTENZA, MN; LERNER, MR				GRAMINSKI, GF; JAYAWICKREME, CK; POTENZA, MN; LERNER, MR			PIGMENT DISPERSION IN FROG MELANOPHORES CAN BE INDUCED BY A PHORBOL ESTER OR STIMULATION OF A RECOMBINANT RECEPTOR THAT ACTIVATES PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; PROTEIN-KINASE-C; GASTRIN-RELEASING PEPTIDE; LUNG-CARCINOMA CELLS; BOMBESIN RECEPTOR; SIGNAL TRANSDUCTION; PITUITARY-CELLS; EARLY EVENTS; POTENT; ANTAGONISTS	Pigment dispersion in frog melanophores is classically mediated by receptors that activate protein kinase A via an elevation of intracellular cyclic AMP. Here, 12-O-tetradecanoylphorbol-13-acetate (TPA), an activator of protein kinase C, is found to induce pigment dispersion. To demonstrate that an increase in cAMP is not required for the melanosome movement, a murine bombesin receptor was expressed in the melanophores. When these cells were treated with bombesin, they accumulated intracellular inositol phosphates but not cAMP and dispersed their pigment. Four agonists, one partial agonist, and two antagonists for the bombesin receptor were compared for their ability to induce or block bombesin-induced pigment dispersion. In all cases, the degree of pigment dispersion followed simple equilibrium reactions. The resulting dose-response curves allowed for the determination of the effective concentration for half-maximal pigment dispersion (EC50) or half-maximal inhibition of bombesin-stimulated pigment dispersion (IC50) for the peptides. As the pigment dispersion assay can rapidly evaluate chemicals for their effects on receptors that activate phospholipase C via a functional assay, it has potential utility for investigations of ligand-receptor interactions and for massive drug screening.	YALE UNIV, SCH MED, DEPT INTERNAL MED, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, BOYER CTR MOLEC MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA	Yale University; Yale University; Yale University; Howard Hughes Medical Institute; Yale University								ABE K, 1969, ENDOCRINOLOGY, V84, P362, DOI 10.1210/endo-84-2-362; ABE K, 1969, ENDOCRINOLOGY, V85, P674, DOI 10.1210/endo-85-4-674; ABRAO MS, 1991, PIGM CELL RES, V4, P66, DOI 10.1111/j.1600-0749.1991.tb00317.x; BALLA T, 1986, P NATL ACAD SCI USA, V83, P9323, DOI 10.1073/pnas.83.24.9323; BATTEY J, 1991, TRENDS NEUROSCI, V14, P524, DOI 10.1016/0166-2236(91)90005-F; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; COY DH, 1992, PEPTIDES, V13, P775, DOI 10.1016/0196-9781(92)90186-7; COY DH, 1991, J BIOL CHEM, V266, P16441; COY DH, 1988, J BIOL CHEM, V263, P5056; DANIOLOS A, 1990, PIGM CELL RES, V3, P38, DOI 10.1111/j.1600-0749.1990.tb00260.x; DORFLINGER LJ, 1983, ENDOCRINOLOGY, V113, P1541, DOI 10.1210/endo-113-5-1541; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; FISCHER JB, 1988, J BIOL CHEM, V263, P2808; FUJII R, 1991, J EXP ZOOL, V259, P9, DOI 10.1002/jez.1402590103; HEIKKILA R, 1987, J BIOL CHEM, V262, P16456; HERSHEY AD, 1991, ANN NY ACAD SCI, V632, P63, DOI 10.1111/j.1749-6632.1991.tb33095.x; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; ISACKE CM, 1986, EMBO J, V5, P2889, DOI 10.1002/j.1460-2075.1986.tb04584.x; JENSEN RT, 1991, TRENDS PHARMACOL SCI, V12, P13, DOI 10.1016/0165-6147(91)90483-9; LERNER MR, 1988, P NATL ACAD SCI USA, V85, P261, DOI 10.1073/pnas.85.1.261; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; LYNCH TJ, 1986, J BIOL CHEM, V261, P4212; MENNITI FS, 1990, J BIOL CHEM, V265, P11167; MORELLO L, 1991, BIOCHIM BIOPHYS ACTA, V1092, P397, DOI 10.1016/S0167-4889(97)90018-5; POTENZA MN, 1992, PIGM CELL RES, V5, P372, DOI 10.1111/j.1600-0749.1992.tb00565.x; POTENZA MN, 1992, ANAL BIOCHEM, V206, P315, DOI 10.1016/0003-2697(92)90372-E; POTENZA MN, 1991, PIGM CELL RES, V4, P186, DOI 10.1111/j.1600-0749.1991.tb00437.x; POTTER H, 1988, ANAL BIOCHEM, V174, P361, DOI 10.1016/0003-2697(88)90035-8; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; RODRIGUEZPENA A, 1986, BIOCHEM BIOPH RES CO, V140, P379, DOI 10.1016/0006-291X(86)91101-0; ROZDZIAL MM, 1986, CELL, V47, P1061, DOI 10.1016/0092-8674(86)90821-4; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1990, PHILOS T ROY SOC B, V327, P209, DOI 10.1098/rstb.1990.0055; ROZENGURT E, 1990, J CELL SCI, P43; Sambrook J, 1989, MOL CLONING LABORATO; SAMMAK PJ, 1992, J CELL BIOL, V117, P57, DOI 10.1083/jcb.117.1.57; SELDENRIJK R, 1979, CELL TISSUE RES, V198, P397, DOI 10.1007/BF00234185; SHARONI Y, 1990, CANCER RES, V50, P5257; SINNETTSMITH J, 1990, BIOCHEM J, V265, P485, DOI 10.1042/bj2650485; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; STRAUB RE, 1986, J BIOL CHEM, V261, P2712; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; SULPICE JC, 1989, ANAL BIOCHEM, V179, P90, DOI 10.1016/0003-2697(89)90206-6; TAKUWA N, 1987, J BIOL CHEM, V262, P182; VONSCHRENCK T, 1990, AM J PHYSIOL, V259, pG468, DOI 10.1152/ajpgi.1990.259.3.G468; VONSCHRENCK T, 1989, AM J PHYSIOL, V256, pG747, DOI 10.1152/ajpgi.1989.256.4.G747; WADA E, 1991, NEURON, V6, P421, DOI 10.1016/0896-6273(91)90250-4; WANG LH, 1990, BIOCHEMISTRY-US, V29, P616, DOI 10.1021/bi00455a004; WANG LH, 1990, J BIOL CHEM, V265, P15695; WESTENDORF JM, 1983, J BIOL CHEM, V258, P7527; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211	54	69	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5957	5964						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8383680				2022-12-25	WOS:A1993KR82200089
J	ICHII, S; TAKEDA, S; HORII, A; NAKATSURU, S; MIYOSHI, Y; EMI, M; FUJIWARA, Y; KOYAMA, K; FURUYAMA, J; UTSUNOMIYA, J; NAKAMURA, Y				ICHII, S; TAKEDA, S; HORII, A; NAKATSURU, S; MIYOSHI, Y; EMI, M; FUJIWARA, Y; KOYAMA, K; FURUYAMA, J; UTSUNOMIYA, J; NAKAMURA, Y			DETAILED ANALYSIS OF GENETIC ALTERATIONS IN COLORECTAL TUMORS FROM PATIENTS WITH AND WITHOUT FAMILIAL ADENOMATOUS POLYPOSIS (FAP)	ONCOGENE			English	Article							GERM-LINE MUTATIONS; APC GENE; P53 GENE; SOMATIC MUTATIONS; CANCER; IDENTIFICATION; TUMORIGENESIS; CARCINOMA; OCCUR; LOCUS	To examine early genetic events during colorectal carcinogenesis, we searched for genetic alterations in 75 adenomas from seven patients with familial polyposis coli (FAP) and in 64 sporadic colorectal tumors (63 carcinomas and one adenoma). We investigated germ-line and somatic mutations in the APC gene, somatic mutations in the K-ras and p53 genes, and loss of heterozygosity (LOH) on chromosome 8p21-22. Thirty-two FAP adenomas carried detectable somatic mutations in the APC gene. The frequency of somatic APC mutations among adenomas was the same regardless of differences in size or histopathological classification. On the other hand, K-ras mutation was very rare in small adenomas where dysplasia was mild or moderate but frequent in large adenomas with severe dysplasia. Mutation of the p53 gene was observed in only two adenomas and LOH on 8p22 was detected in none. These results imply that a second 'hit' in the APC gene, but not necessarily mutation in K-ras or p53, is an important and critical event for formation of a colorectal adenoma.	JAPANESE FDN CANC RES,INST CANC,DEPT BIOCHEM,1-37-1 KAMI IKEBUKURO,TOSHIMA KU,TOKYO 170,JAPAN; HYOGO MED UNIV,DEPT GENET,NISHINOMIYA,HYOGO 663,JAPAN; HYOGO MED UNIV,DEPT PHARMACEUT,NISHINOMIYA,HYOGO 663,JAPAN	Japanese Foundation for Cancer Research; Hyogo College of Medicine; University of Hyogo; Hyogo College of Medicine; University of Hyogo			Horii, Akira/AAW-2839-2021	Horii, Akira/0000-0002-3967-3291				AMICO DD, 1992, CANCER RES, V52, P1996; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOYNTON RF, 1992, P NATL ACAD SCI USA, V89, P3385, DOI 10.1073/pnas.89.8.3385; EMI M, 1992, CANCER RES, V52, P5368; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUJIWARA Y, 1993, CANCER RES, V53, P1172; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORII A, 1992, CANCER RES, V52, P6696; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Ichii Shigetoshi, 1992, Human Molecular Genetics, V1, P387, DOI 10.1093/hmg/1.6.387; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KANEKO K, 1991, NUCLEIC ACIDS RES, V19, P6059, DOI 10.1093/nar/19.21.6059-a; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNUDSON AG, 1985, CANCER RES, V45, P1437; LOPEZGALINDEZ C, 1988, P NATL ACAD SCI USA, V85, P3522, DOI 10.1073/pnas.85.10.3522; MIKI Y, 1992, GENE CHROMOSOME CANC, V4, P81, DOI 10.1002/gcc.2870040112; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NAGASE H, 1992, CANCER RES, V52, P4055; Nagase Hiroki, 1992, Human Mutation, V1, P467, DOI 10.1002/humu.1380010603; NAKATSURU S, 1992, HUM MOL GENET, V1, P559, DOI 10.1093/hmg/1.8.559; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; SATO T, 1990, CANCER RES, V50, P7184; TAKEDA S, 1993, IN PRESS HUM MUT, V2; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901	33	142	143	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2399	2405						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8395678				2022-12-25	WOS:A1993LT36800010
J	ALLA, SA; BUSCHKO, J; QUITTERER, U; MAIDHOF, A; HAASEMANN, M; BREIPOHL, G; KNOLLE, J; MULLERESTERL, W				ALLA, SA; BUSCHKO, J; QUITTERER, U; MAIDHOF, A; HAASEMANN, M; BREIPOHL, G; KNOLLE, J; MULLERESTERL, W			STRUCTURAL FEATURES OF THE HUMAN BRADYKININ B2 RECEPTOR PROBED BY AGONISTS, ANTAGONISTS, AND ANTIIDIOTYPIC ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN-FIBROBLASTS; BINDING-SITE; ANTIIDIOTYPIC ANTIBODIES; FUNCTIONAL EXPRESSION; KININ RECEPTORS; CLONING; PROTEINS; LIGAND; CELLS; CDNA	The human bradykinin B2 receptor belongs to the family of G-protein-coupled receptors. To characterize the receptor protein, we have solubilized the membranes of cultured human foreskin fibroblasts bearing the B2 receptor. Affinity cross-linking of the solubilized receptor with the labeled agonist, I-125-Tyr0-bradykinin, or the labeled antagonist, I-125-(4-hydroxyphenyl-propionyl)-HOE140, revealed major bands of apparent molecular mass of 69 kDa in SDS-polyacrylamide gel electrophoresis under reducing conditions, and of 59 kDa under non-reducing conditions. A 1000-fold molar excess of each of the unlabeled ligands quenched the specific labeling suggesting that the agonist and the antagonist compete for overlapping binding site(s). Covalent coupling of the receptor to bradykinin or HOE140, followed by Western blotting and immunoprinting with specific anti-ligand antibodies confirmed that the major ligand-binding form of the receptor is of 69 kDa. Anti-idiotypic antibodies which bear the internal image of bradykinin (Haasemann, M., Buschko, J., Faussner, A., Roscher, A. A., Hoebeke, J., Burch, R. M., and Muller-Esterl, W. (1991) J. Immunol. 147, 3882-3892) immunoprecipitated the I-125-labeled receptor as a major band of 68 kDa and a minor band of 47 kDa indicative of partial proteolysis. Chemical deglycosylation of the I-125-labeled receptor shifted the apparent molecular mass from 69 to 44 kDa demonstrating that the receptor is heavily glycosylated. Two-dimensional electrophoresis of the affinity-purified receptor revealed overlapping spots of 69 kDa and of pI 6.8-7.1 pointing to a microheterogeneity of the carbohydrate moiety. Elucidation of the key structural features of the B2 receptor protein will aid in understanding the structure-function relationships governing this prototypic peptide receptor.	UNIV MAINZ, INST PHYSIOL CHEM & PATHOBIOCHEM, DUESBERGWEG 6, D-55099 MAINZ 1, GERMANY; HOECHST AG, W-6230 FRANKFURT 80, GERMANY	Johannes Gutenberg University of Mainz; Sanofi-Aventis								BERTIN B, 1992, J BIOL CHEM, V267, P8200; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; BURCH RM, 1992, LIFE SCI, V50, P829, DOI 10.1016/0024-3205(92)90201-Y; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; DEVRIES JG, 1989, J NEUROCHEM, V52, P1508; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X; ESTRADA EF, 1991, BIOCHEMISTRY-US, V30, P8611, DOI 10.1021/bi00099a017; FAUSSNER A, 1991, J BIOL CHEM, V266, P9442; FIGUEROA CD, 1992, BLOOD, V79, P754; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GOODFRIEND TL, 1964, SCIENCE, V144, P1344, DOI 10.1126/science.144.3624.1344; HAASEMANN M, 1991, J IMMUNOL, V147, P3882; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; HOCK FJ, 1991, BRIT J PHARMACOL, V102, P769, DOI 10.1111/j.1476-5381.1991.tb12248.x; HOCK J, 1990, J BIOL CHEM, V265, P12005; HOSODA K, 1991, FEBS LETT, V287, P23, DOI 10.1016/0014-5793(91)80007-P; JIANG YP, 1992, J BIOL CHEM, V267, P3712; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RTW, 1989, NEUROPEPTIDES, V14, P51, DOI 10.1016/0143-4179(89)90034-6; LIEBMANN C, 1990, BIOCHEM BIOPH RES CO, V167, P910, DOI 10.1016/0006-291X(90)90610-Y; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MULLERESTERL W, 1988, METHOD ENZYMOL, V163, P240; MUNOZ CM, 1992, J BIOL CHEM, V267, P303; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NEWMAN RA, 1987, METHOD ENZYMOL, V150, P723; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PHILLIPS E, 1992, J NEUROCHEM, V58, P243, DOI 10.1111/j.1471-4159.1992.tb09302.x; PLEVIN R, 1988, TRENDS PHARMACOL SCI, V9, P387, DOI 10.1016/0165-6147(88)90059-4; REGOLI D, 1988, METHOD ENZYMOL, V163, P210; Roberts R A, 1989, Prog Growth Factor Res, V1, P237, DOI 10.1016/0955-2235(89)90013-6; ROSCHER AA, 1983, J CLIN INVEST, V72, P626, DOI 10.1172/JCI111012; ROSCHER AA, 1990, J CARDIOVASC PHARM, V15, pS39, DOI 10.1097/00005344-199015061-00008; SAKAMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P656, DOI 10.1016/0006-291X(91)90158-4; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; Schreurs J, 1990, GROWTH FACTORS, V2, P221, DOI 10.3109/08977199009071508; SILVA MRE, 1949, AM J PHYSIOL, V156, P261, DOI 10.1152/ajplegacy.1949.156.2.261; STEWART JM, 1991, BRADYKININ ANTAGONIS, P51; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOGEL R, 1988, J BIOL CHEM, V263, P12661; VOGEL R, 1990, J BIOL CHEM, V265, P12494; WHEATLEY M, 1990, RECEPTOR BIOCH PRACT, P213; WIRTH K, 1991, BRIT J PHARMACOL, V102, P774, DOI 10.1111/j.1476-5381.1991.tb12249.x	52	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17277	17285						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8394337				2022-12-25	WOS:A1993LQ98800061
J	BUECHLER, YJ; HERBERG, FW; TAYLOR, SS				BUECHLER, YJ; HERBERG, FW; TAYLOR, SS			REGULATION-DEFECTIVE MUTANTS OF TYPE-I CAMP-DEPENDENT PROTEIN-KINASE - CONSEQUENCES OF REPLACING ARGININE-94 AND ARGININE-95	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; ESCHERICHIA-COLI; BINDING; SITE; SPECIFICITY; EXPRESSION; MECHANISM; MUTATIONS; DOMAINS	The type Ialpha regulatory subunits of cAMP-dependent protein kinase contain an autoinhibitor site, Arg-94-Arg-Gly-Ala-Ile, which serves as a pseudosubstrate. To evaluate their contribution to subunit association, Arg94 and Arg95, key determinants for peptide recognition, were replaced singly and in tandem with Ala, Glu, and His. Unlike substrate peptides in which replacement of either arginine leads to an increase in K(m) of approximately 3 orders of magnitude, replacement of either arginine causes only a maximal 20-fold decrease in subunit association. Replacement of both arginine residues with alanine, however, generates a regulatory subunit that can no longer recombine with the catalytic subunit under physiological conditions when the regulatory subunit is saturated with cAMP. To evaluate more fully the specific consequences of replacing these 2 arginine residues, a rapid gel filtration chromatographic method was developed so that subunit affinity could be measured independently of assaying for catalytic activity. The R94,95A mutant shows a K(d(app)) = 677 nM, representing an increase of greater than 3 orders of magnitude compared with the native subunits in the presence of MgATP. In the absence of MgATP, the K(d(app)) for native regulatory subunit was 125 nM, whereas the K(d(app)) for the R94,R95A mutant regulatory subunit was determined to 2.87 muM. When this mutant holoenzyme is assayed at muM concentrations, no activity is observed, whereas below muM, activity is observed because of cAMP-independent subunit dissociation.	UNIV CALIF SAN DIEGO,DEPT CHEM,0654,9500 GILMAN DR,LA JOLLA,CA 92093	University of California System; University of California San Diego			Herberg, Friedrich W/B-5572-2015	Herberg, Friedrich W/0000-0001-7117-7653	NIGMS NIH HHS [GM34921] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034921] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECHTEL PJ, 1975, ADV CYCLIC NUCLEOTID, V5, P241; BEEBE SJ, 1986, ENZYMES, V17, P43; BUECHLER YJ, 1991, J BIOL CHEM, V266, P3491; BUILDER SE, 1980, J BIOL CHEM, V255, P3514; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; ENGSTROM L, 1978, CURR TOP CELL REGUL, V113, P29; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; GIBBS CS, 1991, BIOCHEMISTRY-US, V30, P5329, DOI 10.1021/bi00236a001; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GRANOT J, 1980, J BIOL CHEM, V255, P4569; HOFMANN F, 1980, J BIOL CHEM, V255, P1559; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KNIGHTON DR, 1993, IN PRESS ACTA CRYSTA; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; REED J, 1985, BIOCHEMISTRY-US, V24, P2967, DOI 10.1021/bi00333a024; SARASWAT LD, 1986, J BIOL CHEM, V261, P1091; SLICE LW, 1989, J BIOL CHEM, V264, P20940; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; WANG YH, 1991, P NATL ACAD SCI USA, V88, P2446, DOI 10.1073/pnas.88.6.2446; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; WEBER W, 1979, BIOCHEM BIOPH RES CO, V90, P1073, DOI 10.1016/0006-291X(79)91935-1; WELDON SL, 1985, J BIOL CHEM, V260, P4203; Zetterqvist O.Z., 1990, PEPTIDES PROTEIN PHO, P171	29	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16495	16503						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8393867				2022-12-25	WOS:A1993LQ33600061
J	ITO, K; INOUE, S; YAMAMOTO, K; KAWANISHI, S				ITO, K; INOUE, S; YAMAMOTO, K; KAWANISHI, S			8-HYDROXYDEOXYGUANOSINE FORMATION AT THE 5' SITE OF 5'-GG-3' SEQUENCES IN DOUBLE-STRANDED DNA BY UV-RADIATION WITH RIBOFLAVIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ULTRAVIOLET-LIGHT; SINGLET OXYGEN; AQUEOUS-SOLUTIONS; 6-4 PHOTOPRODUCT; ESCHERICHIA-COLI; PLUS LIGHT; CELLS; 8-HYDROXYGUANINE; PHOTOCARCINOGENESIS; HEMATOPORPHYRIN	DNA damage caused by UV radiation in the presence of riboflavin or hematoporphyrin was characterized by the DNA sequencing technique using P-32-labeled DNA fragments and the analysis of 8-hydroxydeoxyguanosine (8-OH-dG) formation in calf thymus DNA. Exposure of double-stranded DNA to 365 or 302 nm radiation in the presence of riboflavin induced the sequence-specific DNA cleavage which is different from that caused by 302 or 254 nm irradiation in the absence of a sensitizer. The specific cleavage sites were the guanine residues located 5' to guanine. On the other hand, when denatured single-stranded DNA was irradiated at 365 nm with riboflavin or hematoporphyrin, cleavages occurred at most guanine residues. With D2O, the sequence-specific damage of double-stranded DNA by riboflavin was not enhanced, whereas the damage to single-stranded DNA by hematoporphyrin was greatly enhanced. Photodynamic action of riboflavin caused the formation of 8-OH-dG in double-stranded DNA. The enhancing effect of D2O on 8-OH-dG formation was not observed with riboflavin. By contrast, hematoporphyrin plus 365-nm light induced the 8-OH-dG formation only in denatured single-stranded DNA and the 8-OH-dG yield was increased about 2-fold in D2O. ESR spin destruction experiments suggested that photoexcited riboflavin reacts with dGMP to produce riboflavin anion radical and guanine cation radical, but not with other mononucleotides. The estimated ratio of 8-OH-dG yield to total guanine loss indicates that the photoexcited riboflavin induces 8-OH-dG formation specifically at the guanine residue located 5' to guanine through electron transfer. The mechanism was discussed in relation to UV carcinogenesis.	KYOTO UNIV, FAC MED, DEPT PUBL HLTH, KYOTO 606, JAPAN	Kyoto University								ANANTHASWAMY HN, 1990, PHOTOCHEM PHOTOBIOL, V52, P1119, DOI 10.1111/j.1751-1097.1990.tb08452.x; CADET J, 1990, BIOORGANIC PHOTOCHEM, V1, P1; CANDEIAS LP, 1989, J AM CHEM SOC, V111, P1094, DOI 10.1021/ja00185a046; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CHENG KC, 1992, J BIOL CHEM, V267, P166; COOHILL TP, 1987, PHOTOCHEM PHOTOBIOL, V46, P1043, DOI 10.1111/j.1751-1097.1987.tb04891.x; CULLIS PM, 1987, NATURE, V330, P773, DOI 10.1038/330773a0; DEVASAGAYAM TPA, 1991, BIOCHEMISTRY-US, V30, P6283, DOI 10.1021/bi00239a029; ENNEVER JF, 1981, PEDIATR RES, V15, P956, DOI 10.1203/00006450-198106000-00015; FLOYD RA, 1990, FREE RADICAL BIO MED, V8, P327, DOI 10.1016/0891-5849(90)90097-3; FLOYD RA, 1989, ARCH BIOCHEM BIOPHYS, V273, P106, DOI 10.1016/0003-9861(89)90167-7; FLOYD RA, 1990, CARCINOGENESIS, V11, P1447, DOI 10.1093/carcin/11.9.1447; FOOTE CS, 1979, BIOCH CLIN ASPECTS O, P601; FORBES PD, 1981, J INVEST DERMATOL, V77, P139, DOI 10.1111/1523-1747.ep12479351; FRANKLIN WA, 1986, MUTAT RES, V165, P1, DOI 10.1016/0167-8817(86)90002-7; HAMILTON KK, 1992, NATURE, V356, P725, DOI 10.1038/356725a0; HUTCHINSON F, 1987, PHOTOCHEM PHOTOBIOL, V45, P897, DOI 10.1111/j.1751-1097.1987.tb07900.x; JONES CA, 1987, RADIAT RES, V110, P244, DOI 10.2307/3576902; KASAI H, 1987, CARCINOGENESIS, V8, P1959, DOI 10.1093/carcin/8.12.1959; KAWANISHI S, 1986, J BIOL CHEM, V261, P6090; KORYCKADAHL M, 1980, BIOCHIM BIOPHYS ACTA, V610, P229, DOI 10.1016/0005-2787(80)90004-0; KURATOMI K, 1977, BIOCHIM BIOPHYS ACTA, V476, P207, DOI 10.1016/0005-2787(77)90004-1; LIPPKE JA, 1981, P NATL ACAD SCI-BIOL, V78, P3388, DOI 10.1073/pnas.78.6.3388; Maxam A M, 1980, Methods Enzymol, V65, P499; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; MOAN J, 1980, ACTA CHEM SCAND B, V34, P519, DOI 10.3891/acta.chem.scand.34b-0519; PEAK JG, 1984, PHOTOCHEM PHOTOBIOL, V39, P713, DOI 10.1111/j.1751-1097.1984.tb03914.x; RESZKA K, 1984, PHOTOCHEM PHOTOBIOL, V39, P293, DOI 10.1111/j.1751-1097.1984.tb08180.x; SCHAAPER RM, 1987, J MOL BIOL, V198, P187, DOI 10.1016/0022-2836(87)90305-6; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; STRICKLAND PT, 1986, J INVEST DERMATOL, V87, P272, DOI 10.1111/1523-1747.ep12696669; SUGIYAMA H, 1990, J AM CHEM SOC, V112, P6720, DOI 10.1021/ja00174a046; SUZUKI F, 1981, CANCER RES, V41, P4916; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TYRRELL RM, 1990, J PHOTOCH PHOTOBIO B, V4, P349, DOI 10.1016/1011-1344(90)85014-N; VANTVEER LJ, 1989, MOL CELL BIOL, V9, P3314; WANG CI, 1992, BIOCHEMISTRY-US, V31, P3671, DOI 10.1021/bi00129a016; YAMAMOTO K, 1989, CHEM RES TOXICOL, V2, P234, DOI 10.1021/tx00010a004; ZIGMAN S, 1976, J INVEST DERMATOL, V67, P723, DOI 10.1111/1523-1747.ep12598612	39	329	335	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13221	13227						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8390459				2022-12-25	WOS:A1993LH55300032
J	IZUHARA, K; HARADA, N				IZUHARA, K; HARADA, N			INTERLEUKIN-4 (IL-4) INDUCES PROTEIN-TYROSINE PHOSPHORYLATION OF THE IL-4 RECEPTOR AND ASSOCIATION OF PHOSPHATIDYLINOSITOL 3-KINASE TO THE IL-4 RECEPTOR IN A MOUSE T-CELL LINE, HT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATORY FACTOR-I; RESTING B-CELLS; SIGNAL TRANSDUCTION; GROWTH-FACTOR; KINASE-ACTIVITY; RECOMBINANT INTERLEUKIN-4; MOLECULAR-CLONING; LYMPHOCYTES-B; MURINE; EXPRESSION	To study the signal transduction mechanism of interleukin-4 (IL-4), we have examined the effects of IL-4 on protein tyrosine phosphorylation in a mouse IL-2-dependent T cell line, HT2. Mouse IL-4 induces HT2 proliferation in a dose-dependent manner. Western blotting analyses using anti-phosphotyrosine antibody showed that IL-4 induces tyrosine phosphorylation of four proteins (140, 110, 100, and 92 kDa) in a dose-dependent manner. Protein tyrosine phosphorylation was detected within 1 min and reached a plateau approximately at 10 min after IL-4 stimulation. Immunoprecipitation using anti-IL-4 receptor antibody revealed that the 140-kDa tyrosine-phosphorylated protein is the IL-4 receptor (IL-4R) itself. Furthermore, we demonstrate that phosphatidylinositol 3-kinase (PI 3-kinase) activity in immunoprecipitates with anti-IL-4R antibody increases after IL-4 stimulation. These data indicate that IL-4 induces activation of tyrosine kinase and also induces association between IL-4R and PI 3-kinase.	DNAX RES INST MOLEC & CELLULAR BIOL INC, DEPT IMMUNOL, 901 CALIF AVE, PALO ALTO, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.								ASAO H, 1990, J EXP MED, V171, P637, DOI 10.1084/jem.171.3.637; AUGUSTINE JA, 1990, BIOCHIM BIOPHYS ACTA, V1052, P313, DOI 10.1016/0167-4889(90)90227-5; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; CABRILLAT H, 1987, BIOCHEM BIOPH RES CO, V149, P995, DOI 10.1016/0006-291X(87)90507-9; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHAIKIN E, 1990, J BIOL CHEM, V265, P22109; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; COUGHLIN SR, 1989, SCIENCE, V243, P1191; FINNEY M, 1990, EUR J IMMUNOL, V20, P151, DOI 10.1002/eji.1830200122; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GALIZZI JP, 1990, INT IMMUNOL, V2, P669, DOI 10.1093/intimm/2.7.669; GILLERY P, 1992, FEBS LETT, V302, P231, DOI 10.1016/0014-5793(92)80448-P; HARADA N, 1992, J BIOL CHEM, V267, P22752; HARADA N, 1990, P NATL ACAD SCI USA, V87, P857, DOI 10.1073/pnas.87.3.857; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; JUSTEMENT L, 1986, J IMMUNOL, V137, P3664; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; LOWENTHAL JW, 1988, J IMMUNOL, V140, P456; MASLINSKI W, 1992, J BIOL CHEM, V267, P15281; MCGARVIE GM, 1989, CELL SIGNAL, V1, P447, DOI 10.1016/0898-6568(89)90030-2; MCGARVIE GM, 1989, IMMUNOL LETT, V22, P221, DOI 10.1016/0165-2478(89)90195-8; MERIDA I, 1991, J IMMUNOL, V147, P2202; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MIRESLUIS AR, 1991, J BIOL CHEM, V266, P18113; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MIZUGUCHI J, 1986, J IMMUNOL, V137, P2215; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NAKAJIMA K, 1987, J IMMUNOL, V139, P774; NOELLE R, 1984, P NATL ACAD SCI-BIOL, V81, P6149, DOI 10.1073/pnas.81.19.6149; OHARA J, 1987, NATURE, V325, P537, DOI 10.1038/325537a0; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; PARK LS, 1987, P NATL ACAD SCI USA, V84, P1669, DOI 10.1073/pnas.84.6.1669; PARK LS, 1987, J EXP MED, V166, P476, DOI 10.1084/jem.166.2.476; PAUL WE, 1987, ANNU REV IMMUNOL, V5, P429, DOI 10.1146/annurev.iy.05.040187.002241; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; ROEHM NW, 1984, J EXP MED, V160, P679, DOI 10.1084/jem.160.3.679; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SHARON M, 1989, J IMMUNOL, V143, P2530; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SMITH CA, 1986, P NATL ACAD SCI USA, V83, P1857, DOI 10.1073/pnas.83.6.1857; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; TUSHINSKI RJ, 1991, EXP HEMATOL, V19, P238; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VITETTA ES, 1985, J EXP MED, V162, P1726, DOI 10.1084/jem.162.5.1726; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YOKOTA T, 1988, IMMUNOL REV, V102, P137, DOI 10.1111/j.1600-065X.1988.tb00744.x; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706	57	76	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13097	13102						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8390454				2022-12-25	WOS:A1993LH55300016
J	MIN, DS; KIM, DM; LEE, YH; SEO, JK; SUH, PG; RYU, SH				MIN, DS; KIM, DM; LEE, YH; SEO, JK; SUH, PG; RYU, SH			PURIFICATION OF A NOVEL PHOSPHOLIPASE-C ISOZYME FROM BOVINE CEREBELLUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEINS; HUMAN-PLATELETS; ALPHA-SUBUNITS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; IMMUNOLOGICAL IDENTIFICATION; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; BETA-1 ISOZYME; RECEPTOR; BRAIN	An isozyme of phosphoinositide-specific phospholipase C (PLC) was purified to near homogeneity from bovine cerebellum by a combination of several column chromatography procedures. Approximately 80 mug of pure enzyme were obtained from 4 kg of bovine cerebellum, with a final specific activity of 7.5 mumol/min/mg protein in the presence of 0.1% deoxycholate. The enzyme is specific for phosphatidylinositol and phosphatidylinositol 4,5-bisphosphate but does not hydrolyze phosphatidylcholine. The molecular weight of the enzyme determined by SDS-polyacrylamide gel electrophoresis is approximately 97,000. Polyclonal antibodies to previously characterized PLC isozymes, PLC-beta1,beta2,gamma1,gamma2, and -delta1, did not cross-react with the purified cerebellar enzyme. Moreover, polyclonal antibodies prepared against the cerebellar enzyme did not react with purified PLC-beta1, -beta2, -gamma1, -gamma2, or -delta1. However, the cerebellar enzyme was recognized by two antibodies generated against peptide sequences common to mammalian PLC isozymes. Comparison of partial amino acid sequences of the purified cerebellar enzyme with the deduced amino acid sequence of each known PLC isozyme shows that the cerebellar enzyme is a novel PLC, which could be classified as a PLC-beta-type isozyme. Thus, we have designated this enzyme PLC-beta4.	POHANG INST SCI & TECHNOL, DEPT LIFE SCI, POB 125, HYOJA DONG, POHANG 790600, SOUTH KOREA	Pohang University of Science & Technology (POSTECH)			Seo, Jeong Kon/H-4770-2016; Suh, Pann-Ghill/F-3610-2010	Ryu, Sung Ho/0000-0003-0913-3048				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BANNO Y, 1988, J BIOL CHEM, V263, P11459; BANNO Y, 1990, BIOCHEM BIOPH RES CO, V167, P396, DOI 10.1016/0006-291X(90)92035-X; BENNETT CF, 1987, J BIOL CHEM, V262, P13789; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; EMORI Y, 1989, J BIOL CHEM, V264, P21885; FUKUI T, 1988, J BIOL CHEM, V263, P17730; GRIENDLING KK, 1991, J BIOL CHEM, V266, P15498; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HOFMANN SL, 1982, J BIOL CHEM, V257, P6461; HOFMANN SL, 1982, J BIOL CHEM, V257, P4359; HOMMA Y, 1988, J BIOL CHEM, V263, P6592; KATAN M, 1988, CELL, V54, P171, DOI 10.1016/0092-8674(88)90549-1; KATAN M, 1987, EUR J BIOCHEM, V168, P413, DOI 10.1111/j.1432-1033.1987.tb13435.x; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KRIZ R, 1990, CIBA F SYMP, V150, P112; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MELDRUM E, 1991, EUR J BIOCHEM, V196, P159, DOI 10.1111/j.1432-1033.1991.tb15799.x; MORRIS AJ, 1990, J BIOL CHEM, V265, P13508; NISHIBE S, 1990, P NATL ACAD SCI USA, V87, P424, DOI 10.1073/pnas.87.1.424; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; OHTA S, 1988, FEBS LETT, V242, P31, DOI 10.1016/0014-5793(88)80979-7; PARK D, 1992, J BIOL CHEM, V267, P16048; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROY G, 1991, J BIOL CHEM, V266, P11495; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; RYU SH, 1987, J BIOL CHEM, V262, P12511; RYU SH, 1986, BIOCHEM BIOPH RES CO, V141, P137, DOI 10.1016/S0006-291X(86)80345-X; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, J BIOL CHEM, V263, P14497; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; THOMAS GMH, 1991, EMBO J, V10, P2507, DOI 10.1002/j.1460-2075.1991.tb07790.x; TOMKINS TA, 1991, J BIOL CHEM, V266, P4228; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOYOSHIMA S, 1990, J BIOL CHEM, V265, P14842; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WU DQ, 1992, J BIOL CHEM, V267, P1811	58	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12207	12212						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8389372				2022-12-25	WOS:A1993LF28400109
J	TERADA, N; FRANKLIN, RA; LUCAS, JJ; BLENIS, J; GELFAND, EW				TERADA, N; FRANKLIN, RA; LUCAS, JJ; BLENIS, J; GELFAND, EW			FAILURE OF RAPAMYCIN TO BLOCK PROLIFERATION ONCE RESTING CELLS HAVE ENTERED THE CELL-CYCLE DESPITE INACTIVATION OF P70 S6 KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUSCEPTIBILITY GENE-PRODUCT; DISTINCT MECHANISMS; CYCLOSPORINE-A; PROTEIN; ACTIVATION; EXPRESSION; PHOSPHORYLATION; HOMOLOGS; ONCOGENE; PP90RSK	Rapamycin (RAP) has recently been shown to inhibit the phosphorylation and activity of p70 S6 kinase (p70s6k). In interleukin (IL)-2-induced cell activation of the human IL-2-dependent T-cell line, Kit225, RAP inhibited p70s6k phosphorylation and activation, but not the activation of MAP kinase, p90 S6 kinase (p90rsk), early tyrosine kinases, or the transcription of the c-fos and c-myc genes. Cell cycle progression induced by IL-2 was arrested by RAP prior to p110Rb phosphorylation and the major increase in total RNA synthesis, both of which were initiated around 6 h after addition of IL-2 and 9 h before the beginning of DNA synthesis. Interestingly, RAP could not inhibit DNA synthesis if addition of the drug was delayed for 6 h after addition of IL-2, despite the fact that even at this time, RAP rapidly induced the accumulation of the dephosphorylated form of p70s6k and that p70s6k was inactivated within 1 h of RAP addition. Furthermore, when RAP was added to continuously growing Kit225 cells, cell proliferation was maintained for at least two additional cell cycles, in the absence of apparent p70s6k activity. These results indicate that 1) among the earliest detectable signals after IL-2 treatment, RAP selectively inhibits p70s6k activation, 2) RAP inactivates p70s6k regardless of the stage of the cell cycle in which the drug is added, 3) RAP blocks resting T-cells from entering the cell cycle, but does not directly arrest cell cycle progression once cells have entered the cycle, and 4) inactivation of p70s6k does not cause immediate arrest of cell cycle progression once cells have entered the cycle.	HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	TERADA, N (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DIV BASIC SCI, 1400 JACKSON ST, DENVER, CO 80206 USA.			Franklin, Richard A./0000-0003-0299-9578	NCI NIH HHS [CA-46595] Funding Source: Medline; NIAID NIH HHS [AI-26490, AI-29704] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046595, R37CA046595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029704, R01AI026490] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DARZYNKIEWICZ Z, 1976, P NATL ACAD SCI USA, V73, P2881, DOI 10.1073/pnas.73.8.2881; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HORI T, 1987, BLOOD, V70, P1069; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LIN CS, 1991, CELL IMMUNOL, V133, P269, DOI 10.1016/0008-8749(91)90103-I; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MILLER AD, 1984, CELL, V36, P51; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MORRIS RE, 1991, IMMUNOL TODAY, V12, P137; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; SAWAMI H, 1992, J CELL PHYSIOL, V151, P367, DOI 10.1002/jcp.1041510218; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TERADA N, 1991, J IMMUNOL, V147, P698; TERADA N, 1992, BIOCHEM BIOPH RES CO, V186, P1315, DOI 10.1016/S0006-291X(05)81549-9; TERADA N, 1993, J CELL PHYSIOL, V154, P7, DOI 10.1002/jcp.1041540103; THOMAS NSB, 1991, ONCOGENE, V6, P317; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TOKUNAGA K, 1987, CANCER RES, V47, P5616; XU HJ, 1989, ONCOGENE, V4, P807	31	93	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12062	12068						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8389370				2022-12-25	WOS:A1993LF28400090
J	ZHANG, BX; MUALLEM, S				ZHANG, BX; MUALLEM, S			CA2+-DEPENDENT KINASE AND PHOSPHATASE CONTROL INOSITOL 1,4,5-TRISPHOSPHATE-MEDIATED CA2+ RELEASE - MODIFICATION BY AGONIST STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECONSTITUTED LIPID VESICLES; SMOOTH-MUSCLE CELLS; CALCIUM RELEASE; PROTEIN-KINASE; ADENINE-NUCLEOTIDES; CA-2+ RELEASE; ACINAR-CELLS; TRISPHOSPHATE; INHIBITION; PHOSPHORYLATION	A permeable cell system in which Ca2+ release can be evoked by inositol 1,4,5-trisphosphate (IP3) or agonist stimulation was used to study the regulation of Ca2+ release by Ca2+ itself. At low concentrations, Ca2+ activated IP3-mediated Ca2+ release (IMCR) with half-maximal effect at about 15 nM. At high concentrations, Ca2+ inhibited IMCR giving rise to a biphasic [Ca2+] dependence of IMCR. The activation of IMCR by Ca2+ appears to be mediated by a kinase, probably the Ca2+- and calmodulin-dependent protein kinase (CaMKII). Thus, the activation required MgATP, completely blocked at 0-degrees-C, required Ca2+, and was inhibited by the CaMKII inhibitors KT5926 and KN62. The inhibition of IMCR seems to be mediated by a protein phosphatase, probably the Ca2+-dependent protein phosphatase 2B. Hence, the inhibition required Ca2+, was prevented by the general protein phosphatase inhibitor pyrophosphate and by the immunosuppressants cyclosporin A and FK506, but not by okadaic acid or VO42-, and was modified by chelating agents such as EGTA. Stimulation with agonists modified the activities of the kinase and phosphatase to make the release independent of [Ca2+]. This appears to be due to an increase in the apparent affinity for Ca2+ in stimulating IMCR and inhibition of the phosphatase. We suggest that agonist-dependent modification of the kinase/phosphatase activity ratio can be the biochemical pathway responsible for regulation of Ca2+ release and in turn [Ca2+]i oscillations.	UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK9893] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; FERRIS CD, 1992, J BIOL CHEM, V267, P7036; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; Ferris Christopher D., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P95; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; IINO M, 1991, J GEN PHYSIOL, V98, P681, DOI 10.1085/jgp.98.4.681; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JOSEPH SK, 1989, BIOCHEM J, V258, P261, DOI 10.1042/bj2580261; KEIZER J, 1992, BIOPHYS J, V61, P649, DOI 10.1016/S0006-3495(92)81870-2; KLEE CB, 1991, NEUROCHEM RES, V16, P1059, DOI 10.1007/BF00965851; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LIN J, 1991, CELL, V66, P807; Martell A. E., 1976, CRITICAL STABILITY C, V3; MATTER N, 1993, J BIOL CHEM, V268, P732; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MUALLEM S, 1988, J MEMBRANE BIOL, V106, P57, DOI 10.1007/BF01871767; NAKANISHI S, 1990, MOL PHARMACOL, V37, P482; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PAYNE R, 1990, NEURON, V4, P547, DOI 10.1016/0896-6273(90)90112-S; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; ZHANG BX, 1992, J BIOL CHEM, V267, P24387; ZHAO H, 1990, J BIOL CHEM, V265, P14822; ZHAO H, 1990, J BIOL CHEM, V265, P21419	39	99	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10997	11001						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8388379				2022-12-25	WOS:A1993LD46600045
J	ENYEDI, A; VERMA, AK; FILOTEO, AG; PENNISTON, JT				ENYEDI, A; VERMA, AK; FILOTEO, AG; PENNISTON, JT			A HIGHLY-ACTIVE 120-KDA TRUNCATED MUTANT OF THE PLASMA-MEMBRANE CA2+ PUMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; CA-2+ PUMP; CALCIUM-PUMP; FUNCTIONAL DOMAINS; MOLECULAR-CLONING; CA-2+-TRANSPORTING ATPASE; ERYTHROCYTE CA-2+-ATPASE; ENDOPLASMIC-RETICULUM; SKELETAL-MUSCLE; SMOOTH-MUSCLE	A truncated mutant (hPMCA4b(ct 120)) of the plasma membrane Ca2+ pump was expressed in COS-1 cells. The full-length pump (hPMCA4b) consisted of 1205 residues, and the mutant lacked 120 residues (including the 28-residue calmodulin-binding inhibitory domain) at the COOH terminus. To characterize this construct, Ca2+ transport was determined in a microsomal fraction. Phosphate was added to increase Ca2+ uptake, and specificity was enhanced by adding thapsigargin to inhibit the endoplasmic reticulum Ca2+ pump. The mutant showed a similar level of expression as hPMCA4b and a Ca2+ affinity and Ca2+ transport activity about equal to that of hPMCA4b when hPMCA4b was activated. Addition of the synthetic peptide C28R2, corresponding to the calmodulin binding region of the pump, inhibited the mutant and restored the non-activated state of the enzyme. In these respects, the truncated mutant acted like hPMCA4b, when hPMCA4b had been proteolyzed to cleave a bond between the calmodulin binding region and the NH2-terminal portion of the molecule. This indicates that the effects of proteolysis are due to removal of the COOH terminus and not to rearrangement of the two fragments. Since the truncated mutant was fully active and its tryptic digestion resulted in the appearance of the expected 81- and 76-kDa active fragments, we concluded that the COOH-terminal portion which is missing cannot be important in synthesis or proper folding of the enzyme.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,GUGGENHEIM 1642C,200 1ST ST SW,ROCHESTER,MN 55905	Mayo Clinic			Enyedi, Agnes/N-9742-2013	Enyedi, Agnes/0000-0002-7366-9376	NIGMS NIH HHS [GM 28835] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMO HP, 1992, BIOCHEM J, V285, P791, DOI 10.1042/bj2850791; ADAMO HP, 1992, J BIOL CHEM, V267, P14244; ADAMO HP, 1992, BIOCHEM J, V283, P355, DOI 10.1042/bj2830355; BRANDT P, 1992, J BIOL CHEM, V267, P4376; BRODIN P, 1992, EUR J BIOCHEM, V204, P939, DOI 10.1111/j.1432-1033.1992.tb16715.x; BURK SE, 1992, J BIOL CHEM, V267, P19683; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; DESMEDT H, 1983, BIOCHIM BIOPHYS ACTA, V728, P409, DOI 10.1016/0005-2736(83)90513-8; ENYEDI A, 1991, J BIOL CHEM, V266, P8952; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; ENYEDI A, 1989, BIOCHEM J, V261, P23, DOI 10.1042/bj2610023; ENYEDI A, 1987, J BIOL CHEM, V262, P6425; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; FILOTEO AG, 1992, J BIOL CHEM, V267, P11800; GREEB J, 1989, J BIOL CHEM, V264, P18569; JAMES P, 1988, J BIOL CHEM, V263, P2905; JAMES P, 1989, J BIOL CHEM, V264, P8289; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KHAN I, 1991, BIOCHEM J, V277, P345, DOI 10.1042/bj2770345; LEBERER E, 1986, BIOCHEM J, V235, P67, DOI 10.1042/bj2350067; NAKANE PK, 1974, J HISTOCHEM CYTOCHEM, V22, P1084, DOI 10.1177/22.12.1084; PAPP B, 1989, J BIOL CHEM, V264, P4577; Penniston JT, 1983, CALCIUM CELL FUNCTIO, P99; RAEYMAEKERS L, 1983, BIOCHEM J, V210, P315, DOI 10.1042/bj2100315; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VERMA AK, 1982, ARCH BIOCHEM BIOPHYS, V215, P345, DOI 10.1016/0003-9861(82)90095-9; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; ZVARITCH E, 1990, BIOCHEMISTRY-US, V29, P8070, DOI 10.1021/bi00487a012	34	72	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10621	10626						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8387523				2022-12-25	WOS:A1993LB80000092
J	ORVILLE, AM; LIPSCOMB, JD				ORVILLE, AM; LIPSCOMB, JD			SIMULTANEOUS BINDING OF NITRIC-OXIDE AND ISOTOPICALLY LABELED SUBSTRATES OR INHIBITORS BY REDUCED PROTOCATECHUATE 3,4-DIOXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOPENICILLIN-N SYNTHASE; NON-HEME IRON; ELECTRON-PARAMAGNETIC-RESONANCE; TRANSITION-STATE ANALOGS; II REACTION CENTER; ACTIVE-SITE FE-2+; GENTISATE 1,2-DIOXYGENASE; EXTRADIOL DIOXYGENASES; NITROSYL ADDUCTS; REDOX COMPONENTS	The active site Fe3+ of protocatechuate (PCA) 3,4-dioxygenase can be nonenzymatically reduced to Fe2+, to give a colorless and EPR-silent enzyme (E(r)). Nitric oxide (NO) binds to E(r) to yield a species with EPR (S = 3/2; g = 4.341, 3.693, 1.984; E/D = 0.055) and optical absorption (lambda(max) = 430 nm, epsilon almost-equal-to 1870 M-1 cm-1/iron) spectra. Addition of NO to a preformed E(r).PCA complex results in a new species (EPR: S = 3/2; g = 4.920, 2.988, 1.846; E/D = 0.175; optical: lambda(max) = 404 nm, epsilon almost-equal-to 3930 M-1 cm-1/iron). Hyperfine broadening from the substrates [O-17]PCA or [O-17]homoprotocatechuate (HPCA) is observed in the EPR spectra of E(r). substrate.NO complexes only when the O-17 (I = 5/2) is placed in the carbon-4 OH group, suggesting that only this group binds to the iron when NO is bound. Previous studies (Orville, A. M., and Lipscomb, J. D. (1989) J. Biol. Chem. 261, 8791-8801) showed that both OH groups of HPCA can bind to the Fe3+ of the oxidized enzyme. Thus, the NO may compete with the substrate carbon-3 OH group for a binding site on the Fe2+. In contrast, when either PCA or HPCA is added to a preformed E(r).NO complex, no substrate binding to the Fe2+ is detected. At 2.3 K, white light photodissociates NO from the E(r).NO and E(r).PCA.NO complexes. The E(r).NO complex is photodissociated to a greater extent than the E(r).PCA.NO complex, and different NO rebinding kinetics are observed showing that the substrate strongly influences the photodissociation/reassociation process. Photodissociation of each complex results in the formation of some Fe3+, suggesting that the nitrosyl complex has at least partial Fe3+-NO- character. In solution at 5-10-degrees-C, white light promotes conversion of preformed E(r).NO plus PCA to the E(r).PCA.NO complex, suggesting that formation of the latter complex requires dissociation of NO. It is proposed that initial NO binding blocks the single site for exogenous ligand binding on the iron, thereby inhibiting PCA association. In contrast, PCA binding before NO appears to evoke an enzyme conformational change that allows simultaneous NO binding in another ligand site. These results are consistent with the current model for the mechanism of intradiol dioxygenases in which a PCA-induced conformational change allows substrate to bind as an Fe3+ chelate and O2 reacts initially with the PCA rather than the Fe3+.	UNIV MINNESOTA,SCH MED,DEPT BIOCHEM,4-225 MILLARD HALL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities				Orville, Allen M./0000-0002-7803-1777; Lipscomb, John/0000-0002-8158-5594	NIGMS NIH HHS [GM 24689, R01 GM024689] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024689, R01GM024689] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ARCIERO DM, 1983, J BIOL CHEM, V258, P4981; ARCIERO DM, 1985, J BIOL CHEM, V260, P4035; ARCIERO DM, 1986, J BIOL CHEM, V261, P2170; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BARBARO P, 1991, J AM CHEM SOC, V113, P3181, DOI 10.1021/ja00008a062; BLACKMORE RS, 1992, J BIOL CHEM, V267, P10950; Blumberg W., 1967, MAGNETIC RESONANCE B, P119; BLUMBERG WE, 1973, ANN NY ACAD SCI, V222, P539, DOI 10.1111/j.1749-6632.1973.tb15286.x; BONNER WD, 1978, FRONTIERS BIOL ENERG, V2, P997; CHEN VJ, 1989, J BIOL CHEM, V264, P21677; CRAWFORD RL, 1975, J BACTERIOL, V121, P531, DOI 10.1128/JB.121.2.531-536.1975; DAGLEY S, 1957, BIOCHEM J, V66, P227, DOI 10.1042/bj0660227; DINER BA, 1990, BIOCHIM BIOPHYS ACTA, V1015, P141, DOI 10.1016/0005-2728(90)90225-S; FELTON RH, 1982, J AM CHEM SOC, V104, P6132, DOI 10.1021/ja00386a057; FUJISAWA H, 1968, J BIOL CHEM, V243, P2673; GIBSON QH, 1989, J BIOL CHEM, V264, P20155; HARPEL MR, 1990, J BIOL CHEM, V265, P6301; HARPEL MR, 1990, J BIOL CHEM, V265, P22187; HENDRICH MP, 1990, J AM CHEM SOC, V112, P5861, DOI 10.1021/ja00171a029; HENDRICH MP, 1989, BIOPHYS J, V56, P489, DOI 10.1016/S0006-3495(89)82696-7; JANG HG, 1991, J AM CHEM SOC, V113, P9200, DOI 10.1021/ja00024a028; LIPSCOMB JD, 1992, MET IONS BIOL SYST, V28, P243; LIPSCOMB JD, 1982, OXYGENASES OXYGEN ME, P27; MABROUK PA, 1991, J AM CHEM SOC, V113, P4053, DOI 10.1021/ja00011a001; MING LJ, 1991, BIOCHEMISTRY-US, V30, P11653, DOI 10.1021/bi00114a007; MING LJ, 1990, INORG CHEM, V29, P1111, DOI 10.1021/ic00331a001; NELSON MJ, 1987, J BIOL CHEM, V262, P12137; NELSON MJ, 1988, J AM CHEM SOC, V110, P2985, DOI 10.1021/ja00217a056; OHLENDORF DH, 1988, NATURE, V336, P403, DOI 10.1038/336403a0; ORVILLE AM, 1990, METHOD ENZYMOL, V188, P107; ORVILLE AM, 1992, BIOCHEMISTRY-US, V31, P4602, DOI 10.1021/bi00134a010; ORVILLE AM, 1989, J BIOL CHEM, V264, P8791; ORVILLE AM, 1991, J INORG BIOCHEM, V43, P558; PETROULEAS V, 1990, BIOCHIM BIOPHYS ACTA, V1015, P131, DOI 10.1016/0005-2728(90)90224-R; QUE L, 1977, BIOCHIM BIOPHYS ACTA, V485, P60; QUE L, 1976, BIOCHIM BIOPHYS ACTA, V452, P320; Que L., 1989, IRON CARRIERS IRON P, P467; RICH PR, 1978, FEBS LETT, V93, P323, DOI 10.1016/0014-5793(78)81131-4; ROE AL, 1984, J AM CHEM SOC, V106, P1676, DOI 10.1021/ja00318a021; SALERNO JC, 1985, BIOCHEM SOC T, V13, P611, DOI 10.1042/bst0130611; SALERNO JC, 1979, BIOCHIM BIOPHYS ACTA, V579, P246, DOI 10.1016/0005-2795(79)90104-1; SNETSINGER PA, 1990, J AM CHEM SOC, V112, P8155, DOI 10.1021/ja00178a046; STANIER RY, 1954, J BIOL CHEM, V210, P799; TRUE AE, 1990, BIOCHEMISTRY-US, V29, P10847, DOI 10.1021/bi00500a019; TYSON CA, 1975, J BIOL CHEM, V250, P1765; WHITTAKER JW, 1990, METHOD ENZYMOL, V188, P82; WHITTAKER JW, 1984, J BIOL CHEM, V259, P4487; WHITTAKER JW, 1984, J BIOL CHEM, V259, P4466; WHITTAKER JW, 1984, J BIOL CHEM, V259, P4476; WHITTAKER JW, 1982, ELECTRON TRANSPORT O, P279; WOLGEL SA, 1989, THESIS U MINNESOTA; ZHANG Y, 1992, J AM CHEM SOC, V114, P9189, DOI 10.1021/ja00049a062; ZIMMERMANN R, 1978, J CHEM PHYS, V69, P5463, DOI 10.1063/1.436538	54	55	55	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8596	8607						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8386164				2022-12-25	WOS:A1993KX81100036
J	MA, XJ; SAITOH, N; CURTIS, PJ				MA, XJ; SAITOH, N; CURTIS, PJ			PURIFICATION AND CHARACTERIZATION OF A NUCLEAR DNA-BINDING FACTOR COMPLEX CONTAINING TOPOISOMERASE-II AND CHROMOSOME SCAFFOLD PROTEIN-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP ANCHORAGE; GLOBIN GENES; SV40 DNA; DIFFERENTIATION; REPLICATION; YEAST; EXPRESSION; ENZYMES; SITES; CELLS	In a search for factors that influence the process of erythroid differentiation at the molecular level, we have identified UB2, a nuclear protein factor that was originally observed for its ability to bind to a very specific and highly conserved sequence motif present in human, mouse, rabbit, and chicken beta-globin genes, as well as carbonic anhydrase I, c-myb, and the immunoglobulin heavy chain enhancer region. It was also observed for its appearance in undifferentiated but not differentiated mouse erythroleukemia cells. Purification of UB2 by DEAE-cellulose chromatography and repeated passages through a DNA affinity column, revealed a complex pattern with three major components of 170, 116, and 48 kDa, respectively. The 170-kDa protein was identified as topoisomerase (topo) II by Western blot analysis, catalytic assays, and antibody interference with UB2 binding. The complex topo II in UB2, however, has a more stringent sequence requirement for DNA binding than does topo II. The 116-kDa protein has been determined to be a proteolytic product of topo II. The chromosome scaffold protein 2 (135 kDa) copurified with UB2, and anti-scaffold protein 2 serum inhibited UB2 binding to DNA.	WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104; JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205	The Wistar Institute; Johns Hopkins University					NIGMS NIH HHS [GM30985] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030985] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4145; CASTORA FJ, 1983, BIOCHIM BIOPHYS ACTA, V740, P417, DOI 10.1016/0167-4781(83)90090-8; CHAMBON P, 1966, BIOCHEM BIOPH RES CO, V25, P638, DOI 10.1016/0006-291X(66)90502-X; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; EKI T, 1991, J BIOL CHEM, V266, P3087; ENGLUND PT, 1982, ANNU REV BIOCHEM, V51, P695, DOI 10.1146/annurev.bi.51.070182.003403; FRAZER P, 1987, GENE DEV, V1, P855; FUJIMURA S, 1967, BIOCHIM BIOPHYS ACTA, V145, P247, DOI 10.1016/0005-2787(67)90043-3; GALE KC, 1992, J BIOL CHEM, V267, P12090; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; GOTO T, 1984, CELL, V36, P1073, DOI 10.1016/0092-8674(84)90057-6; HARLAND RM, 1983, NATURE, V302, P38, DOI 10.1038/302038a0; HAYAISHI O, 1977, ANNU REV BIOCHEM, V46, P95, DOI 10.1146/annurev.bi.46.070177.000523; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; INOUYE S, 1987, SYNTHESIS APPLICATIO, P181; JARMAN AP, 1988, EMBO J, V7, P3337, DOI 10.1002/j.1460-2075.1988.tb03205.x; JAZWINSKI SM, 1984, J BIOL CHEM, V259, P6852; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; KAS E, 1992, EMBO J, V11, P705, DOI 10.1002/j.1460-2075.1992.tb05103.x; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; Laemmli U. K., 1978, COLD SPRING HARB SYM, V42, P109; LEWIS CD, 1982, CELL, V29, P171, DOI 10.1016/0092-8674(82)90101-5; LIU LF, 1983, CRC CR REV BIOCH MOL, V15, P1, DOI 10.3109/10409238309102799; LUCHNIK AN, 1982, EMBO J, V39, P223; MA XJ, 1991, DIFFERENTIATION, V47, P135, DOI 10.1111/j.1432-0436.1991.tb00231.x; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MATTERN MR, 1979, BIOCHIM BIOPHYS ACTA, V563, P306, DOI 10.1016/0005-2787(79)90049-2; MATTERN MR, 1982, BIOCHIM BIOPHYS ACTA, V697, P6, DOI 10.1016/0167-4781(82)90038-0; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; NEGRI C, 1992, EXP CELL RES, V200, P452, DOI 10.1016/0014-4827(92)90195-E; NISHIO A, 1982, BIOCHEM BIOPH RES CO, V106, P1448, DOI 10.1016/0006-291X(82)91276-1; NISHIZUK.Y, 1967, J BIOL CHEM, V242, P3164; NOGUCHI H, 1983, CELL, V32, P443, DOI 10.1016/0092-8674(83)90464-6; ORD MG, 1977, BIOCHEM J, V161, P583, DOI 10.1042/bj1610583; ORR E, 1979, MOL GEN GENET, V177, P103, DOI 10.1007/BF00267259; OTAKE H, 1969, J BIOCHEM-TOKYO, V65, P145; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; SANDER M, 1985, NUCLEIC ACIDS RES, V13, P1057, DOI 10.1093/nar/13.4.1057; SHLOMAI J, 1983, NUCLEIC ACIDS RES, V11, P4019, DOI 10.1093/nar/11.12.4019; SINDEN RR, 1987, J CHEM EDUC, V64, P294, DOI 10.1021/ed064p294; SPECK WT, 1982, MUTAT RES, V104, P125, DOI 10.1016/0165-7992(82)90132-4; SUNDIN O, 1981, CELL, V25, P659, DOI 10.1016/0092-8674(81)90173-2; THOMPSON RJ, 1985, NUCLEIC ACIDS RES, V13, P873, DOI 10.1093/nar/13.3.873; UDVARDY A, 1985, CELL, V40, P933, DOI 10.1016/0092-8674(85)90353-8; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; WANG JC, 1987, BIOCHIM BIOPHYS ACTA, V909, P1, DOI 10.1016/0167-4781(87)90040-6; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665	57	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6182	6188						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8384202				2022-12-25	WOS:A1993KT36800019
J	MERIDA, I; WILLIAMSON, P; KUZIEL, WA; GREENE, WC; GAULTON, GN				MERIDA, I; WILLIAMSON, P; KUZIEL, WA; GREENE, WC; GAULTON, GN			THE SERINE-RICH CYTOPLASMIC DOMAIN OF THE INTERLEUKIN-2 RECEPTOR-BETA CHAIN IS ESSENTIAL FOR INTERLEUKIN-2-DEPENDENT TYROSINE PROTEIN-KINASE AND PHOSPHATIDYLINOSITOL-3-KINASE ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-2 RECEPTOR; SIGNAL TRANSDUCTION; REGULATES ACTIVATION; LYMPHOCYTES-T; PHOSPHORYLATION; ASSOCIATION; 3-KINASE; FAMILY; DISTINCT; BINDING	The biological activity of interleukin-2 receptors (IL-2R) is dependent on the functional coupling of IL-2Rbeta molecules to intracellular enzymes such as protein tyrosine kinase. The serine-rich, S-domain within the cytosolic portion of IL-2Rbeta plays an essential role in transduction of the IL-2 proliferative signal. Cells bearing either wild type IL-2Rbeta (Bafalpha/beta) or deletions within the S-domain (Bafalpha/beta(SD1)) were used to evaluate the importance of the S-domain in linking ligand binding to protein tyrosine kinase induction. Multiparameter, side by side comparisons showed that only those cells that expressed wild type IL-2Rbeta responded to IL-2 by increased cellular proliferation, accumulation of the c-myc proto-oncogene, and activation of protein tyrosine kinase. Activation of protein tyrosine kinase was, in turn, linked to increased tyrosine phosphorylation and activation of phosphatidylinositol-3-kinase. These findings indicate that the S-domain of the IL-2Rbeta chain is an essential component in the signal transduction cascade that links IL-2 binding to tyrosine kinase and phosphatidylinositol-3-kinase activation.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST VIROL & IMMUNOL,SAN FRANCISCO,CA 94141; UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of Pennsylvania; Duke University			Merida, Isabel/A-9713-2014	Merida, Isabel/0000-0003-2762-6241	NIGMS NIH HHS [R01 GM42626] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042626] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIMA N, 1992, J IMMUNOL, V149, P83; BICHTHUY LT, 1987, J IMMUNOL, V139, P1550; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; FUNG MR, 1991, J IMMUNOL, V147, P1253; GAULTON GN, 1986, J IMMUNOL, V136, P2470; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATAKEYAMA M, 1992, P NATL ACAD SCI USA, V89, P2022, DOI 10.1073/pnas.89.6.2022; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KUNG HF, 1989, MOL CELL BIOCHEM, V89, P29; MERIDA I, 1991, J IMMUNOL, V147, P2202; MERIDA I, 1990, J BIOL CHEM, V265, P5690; MILLS GB, 1990, J BIOL CHEM, V265, P3561; REED JC, 1987, ONCOGENE, V1, P223; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SALTZMAN EM, 1988, J BIOL CHEM, V263, P6956; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SIEGEL JP, 1987, SCIENCE, V238, P75, DOI 10.1126/science.3116668; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; WANG HM, 1987, J EXP MED, V166, P1055, DOI 10.1084/jem.166.4.1055; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118	33	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6765	6770						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8384218				2022-12-25	WOS:A1993KT36800098
J	BIALEK, G; GROSSE, F				BIALEK, G; GROSSE, F			AN ERROR-CORRECTING PROOFREADING EXONUCLEASE-POLYMERASE THAT COPURIFIES WITH DNA-POLYMERASE-ALPHA-PRIMASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; REPLICATION FACTOR-C; CALF THYMUS; SACCHAROMYCES-CEREVISIAE; 3'->5' EXONUCLEASE; DROSOPHILA-MELANOGASTER; AUXILIARY PROTEIN; DELTA; PURIFICATION; EPSILON	A DNA polymerase with a 3'- to 5'-exonuclease that copurified with polymerase-primase from calf thymus was purified and extensively characterized. Its exonuclease degraded single-stranded DNA from 3' to 5' in a strictly distributive manner. On synthetic template-primer junctions, 3'-terminal mispairs were excised with a 10- to 20-fold preference over correctly paired nucleotides. In comparison to the 3'- to 5'-exonuclease the DNA polymerase activity was rather low. The ratio of nucleotides incorporated to nucleotides excised was in the order of 1 to 3 nucleotide insertions per excision, suggesting that net forward DNA synthesis is not the primary role of this DNA polymerase. DNA synthesis was performed with a low processivity in the presence and absence of PCNA. Both the polymerase and exonuclease activities were inhibited to a comparable extent by AMP. Thus, the exonuclease-polymerase might represent a novel DNA polymerase that we tentatively designate as DNA polymerase zeta. Possible benefits of DNA polymerase zeta in the process of error correction and the apparent dichotomy of an built-in proofreading activity for the processive DNA polymerases gamma, delta, and epsilon and an obviously external proofreading function for the less processive animal cell DNA polymerases alpha and beta are discussed.	GERMAN PRIMATE CTR, DEPT VIROL & IMMUNOL, W-3400 GOTTINGEN, GERMANY	Deutsches Primatenzentrum (DPZ)								BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BIALEK G, 1989, EMBO J, V8, P1833, DOI 10.1002/j.1460-2075.1989.tb03578.x; BIALEK G, 1992, J BIOL CHEM, V267, P2915; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKE RG, 1991, J BIOL CHEM, V266, P3005; Burgers P M, 1989, Prog Nucleic Acid Res Mol Biol, V37, P235; BURGERS PMJ, 1990, EUR J BIOCHEM, V191, P617, DOI 10.1111/j.1432-1033.1990.tb19165.x; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; BYRNES JJ, 1977, BIOCHEMISTRY-US, V16, P3740, DOI 10.1021/bi00636a002; CHEN M, 1992, P NATL ACAD SCI USA, V89, P2516, DOI 10.1073/pnas.89.7.2516; CHEN YC, 1979, J BIOL CHEM, V254, P1678; COTTERILL SM, 1987, P NATL ACAD SCI USA, V84, P5635, DOI 10.1073/pnas.84.16.5635; CRUTE JJ, 1986, BIOCHEMISTRY-US, V25, P26, DOI 10.1021/bi00349a005; DENG GR, 1983, METHOD ENZYMOL, V100, P96; GOSCIN LP, 1982, BIOCHEMISTRY-US, V21, P2513, DOI 10.1021/bi00539a034; GOULIAN M, 1990, J BIOL CHEM, V265, P16402; GROSSE F, 1981, BIOCHEMISTRY-US, V20, P5470, DOI 10.1021/bi00522a019; GROSSE F, 1983, EMBO J, V2, P1515, DOI 10.1002/j.1460-2075.1983.tb01616.x; HOHN KT, 1987, BIOCHEMISTRY-US, V26, P2870, DOI 10.1021/bi00384a031; HUBSCHER U, 1992, TRENDS BIOCHEM SCI, V17, P55, DOI 10.1016/0968-0004(92)90499-Y; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1991, DNA REPLICATION; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MYWT, 1987, BIOCHEMISTRY-US, V26, P1076, DOI 10.1021/bi00378a014; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LEE MYWT, 1985, NUCLEIC ACIDS RES, V13, P8623, DOI 10.1093/nar/13.23.8623; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; LINN S, 1991, CELL, V66, P185, DOI 10.1016/0092-8674(91)90608-2; Maniatis T., 1982, MOL CLONING; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; NASHEUER HP, 1987, BIOCHEMISTRY-US, V26, P8458, DOI 10.1021/bi00399a064; NICKEL W, 1992, J BIOL CHEM, V267, P848; OTTIGER H, 1987, NUCLEIC ACIDS RES, V15, P4789, DOI 10.1093/nar/15.12.4789; OTTIGER HP, 1984, P NATL ACAD SCI-BIOL, V81, P3993, DOI 10.1073/pnas.81.13.3993; PERRINO FW, 1990, BIOCHEMISTRY-US, V29, P5226, DOI 10.1021/bi00474a002; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P3085, DOI 10.1073/pnas.86.9.3085; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; RADMAN M, 1978, NATL CANCER I MONOGR, V50, P121; RECKMANN B, 1983, NUCLEIC ACIDS RES, V11, P7251, DOI 10.1093/nar/11.20.7251; REYLAND ME, 1988, J BIOL CHEM, V263, P6518; SABATINO RD, 1990, CANCER RES, V50, P5340; SABATINO RD, 1988, BIOCHEMISTRY-US, V27, P2266, DOI 10.1021/bi00407a003; SCHOMBURG U, 1986, EUR J BIOCHEM, V160, P451, DOI 10.1111/j.1432-1033.1986.tb10061.x; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SKARNES W, 1986, J BIOL CHEM, V261, P6629; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; TAN CK, 1986, J BIOL CHEM, V261, P2310; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WRIGHT GE, 1990, PHARMACOL THERAPEUT, V47, P447, DOI 10.1016/0163-7258(90)90066-B; YODER BL, 1991, J BIOL CHEM, V266, P22689	56	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					6024	6033						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8383685				2022-12-25	WOS:A1993KR82200098
J	EYTAN, E; ARMON, T; HELLER, H; BECK, S; HERSHKO, A				EYTAN, E; ARMON, T; HELLER, H; BECK, S; HERSHKO, A			UBIQUITIN-C-TERMINAL HYDROLASE ACTIVITY ASSOCIATED WITH THE 26-S PROTEASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; DEPENDENT PROTEOLYSIS; GENE SYNTHESIS; 26S COMPLEX; ATP; RESOLUTION; SYSTEM; DEGRADATION; BREAKDOWN; IDENTIFICATION	In the ubiquitin (Ub) system for protein degradation, proteins ligated to Ub are degraded by an ATP-dependent 26 S protease complex. During or after proteolysis, free Ub is regenerated, but the mechanisms of Ub release remained unknown. It was previously observed that free Ub is released from a Ub-histone conjugate by an ATP-dependent activity present in partially purified preparations of 26 S complex, but the relationship of this activity to protein breakdown was not established. We now show that purified preparations of 26 S complex release free Ub from conjugates that are good substrates for proteolysis, such as conjugates of lysozyme with reductively methylated Ub. The activity that releases free Ub co-migrates with the 26 S protease complex in glycerol density gradient centrifugation, indicating that the responsible Ub C-terminal hydrolase is an integral part of the 26 S complex. Complex-associated hydrolase can also act on adducts in which a single Ub unit is attached to protein, such as a bacterially expressed construct in which the C terminus of Ub is fused to the alpha-NH2 group of a fragment of Ub that contains 60% of its N-terminal region. In all cases, Ub release is insensitive to Ub-aldehyde (an inhibitor of some Ub C-terminal hydrolases) and is stimulated by MgATP. ATP cannot be replaced by beta,gamma-nonhydrolyzable analogs, but it can be substituted by CTP and GTP. The nucleotide specificity of Ub release by the 26 S complex is similar to that observed previously for conjugate proteolysis and nucleotide hydrolysis. It thus seems that the activity of the Ub C-terminal hydrolase associated with the 26 S complex is tightly coupled to the proteolytic action of the complex, and it may have a role in the release of Ub from linkage to amino groups of the protein substrate at the final stages of the Ub proteolytic pathway.	TECHNION ISRAEL INST TECHNOL,B RAPPAPORT FAC MED,DEPT BIOCHEM,IL-31086 HAIFA,ISRAEL; TECHNION ISRAEL INST TECHNOL,RAPPAPORT INST RES MED SCI,IL-31086 HAIFA,ISRAEL	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology					NIDDK NIH HHS [DK25614] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025614] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGELL N, 1988, P NATL ACAD SCI USA, V85, P3693, DOI 10.1073/pnas.85.11.3693; ARMON T, 1990, J BIOL CHEM, V265, P20723; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; DEWALD DB, 1986, ANAL BIOCHEM, V154, P502, DOI 10.1016/0003-2697(86)90022-9; DRISCOLL J, 1992, P NATL ACAD SCI USA, V89, P4986, DOI 10.1073/pnas.89.11.4986; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; ECKER DJ, 1987, J BIOL CHEM, V262, P14213; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GANOTH D, 1988, J BIOL CHEM, V263, P12412; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HADARI T, 1992, J BIOL CHEM, V267, P719; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P1619, DOI 10.1073/pnas.81.6.1619; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOUGH R, 1986, J BIOL CHEM, V261, P2400; HOUGH R, 1987, J BIOL CHEM, V262, P8303; HUNTER AJ, 1985, ANAL BIOCHEM, V150, P394, DOI 10.1016/0003-2697(85)90527-5; JONNALAGADDA S, 1989, J BIOL CHEM, V264, P10637; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; MONIA BP, 1989, J BIOL CHEM, V264, P4093; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PICKART CM, 1985, J BIOL CHEM, V260, P7903; PICKART CM, 1986, J BIOL CHEM, V261, P210; REDMAN KL, 1989, NATURE, V338, P438, DOI 10.1038/338438a0; Rose I. A., 1988, UBIQUITIN, P135; ROSE IA, 1987, P NATL ACAD SCI USA, V84, P1477, DOI 10.1073/pnas.84.6.1477; ROSE IA, 1988, UBIQUITIN SYSTEM, P111; WILKINSON KD, 1986, BIOCHEMISTRY-US, V25, P6644, DOI 10.1021/bi00369a047	33	115	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4668	4674						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8383122				2022-12-25	WOS:A1993KP88400020
J	HU, ZW; SHI, XY; SAKAUE, M; HOFFMAN, BB				HU, ZW; SHI, XY; SAKAUE, M; HOFFMAN, BB			PROLONGED ACTIVATION OF PROTEIN-KINASE-C INDUCES TRANSCRIPTION AND EXPRESSION OF THE ALPHA-1B ADRENERGIC-RECEPTOR GENE IN DDT1 MF-2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; CARDIAC MYOCYTE HYPERTROPHY; PHORBOL ESTER; GROWTH-FACTOR; ALPHA-1-ADRENERGIC STIMULATION; BETA-2-ADRENERGIC RECEPTORS; INOSITOL PHOSPHATES; SIGNAL TRANSDUCTION; ANGIOTENSIN-II; RAT-HEART	Protein kinase C (PKC) regulates many cellular functions; we have examined the role of PKC in the regulation of the alpha1B adrenergic receptor gene. Exposure of DDT1 MF-2 cells to phorbol 12-myristate 13-acetate (PMA) (10 nM) increased values of alpha1B receptor mRNA with peak changes found at 4 h (3.2-fold increase). Increased values of alpha1B receptor mRNA occurred at PMA concentrations as low as 10 pM with a maximal response at 100 nm. Also, PMA induced a time-dependent increase in the number of alpha1B receptors. Stimulation of cells with phenylephrine led to an increase in IP3 production after 3, 6, and 12 h of treatment with PMA. Induction of the alpha1B receptor mRNA was suppressed by the PKC inhibitors H7 (1-(5-isoquinolinylsulsulfonyl)2-methylpiperazine) and saurosporine; the inactive phorbol ester 4alpha-phorbol didecanoate and calcium ionophores A23187 and Bay K8644 did not increase alpha1B receptor mRNA. The half-life of the alpha1B receptor mRNA was unchanged by PMA. Nuclear runoff assays demonstrated that PMA produced a marked increase in the transcription rate of alpha1B receptor gene. These results suggest that the induction of alpha1B adrenergic receptor expression is mediated by a PKC-dependent mechanism that occurs at the level of transcription.	VET ADM MED CTR, GRECC 182B, 3801 MIRANDA AVE, PALO ALTO, CA 94304 USA; STANFORD UNIV, MED CTR, SCH MED, DEPT MED, STANFORD, CA 94305 USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University					NHLBI NIH HHS [HL41315] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041315] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; BAUCH HJ, 1987, EXP PATHOL-JENA, V31, P193, DOI 10.1016/S0232-1513(87)80001-4; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRY N, 1990, P NATL ACAD SCI USA, V87, P2294, DOI 10.1073/pnas.87.6.2294; BJORGE JD, 1987, J BIOL CHEM, V262, P6615; BOUVIER M, 1987, J BIOL CHEM, V262, P3106; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLUCCI WS, 1988, BIOCHEM BIOPH RES CO, V159, P924; COWLEN MS, 1987, J PHARMACOL EXP THER, V243, P527; COWLEN MS, 1988, MOL PHARMACOL, V34, P340; DEAN NM, 1989, ANAL BIOCHEM, V183, P199, DOI 10.1016/0003-2697(89)90468-5; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EXTON JH, 1990, J BIOL CHEM, V265, P1; FARAGO A, 1990, FEBS LETT, V268, P350, DOI 10.1016/0014-5793(90)81284-U; FOLKOW B, 1982, PHYSIOL REV, V62, P347, DOI 10.1152/physrev.1982.62.2.347; GREENBERG ME, 1989, CURRENT PROTOCOLS MO; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1081, DOI 10.1016/0022-2828(88)90588-3; HEPLER JR, 1988, J BIOL CHEM, V263, P7610; HOUSLAY MD, 1991, EUR J BIOCHEM, V196, P9; IKEDA U, 1991, AM J PHYSIOL, V260, pH953, DOI 10.1152/ajpheart.1991.260.3.H953; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; KUO TH, 1991, J BIOL CHEM, V266, P2520; LAKS MM, 1973, CHEST, V64, P75, DOI 10.1378/chest.64.1.75; LEEBLUNDBERG LMF, 1987, J BIOL CHEM, V262, P3098; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MAJESKY MW, 1990, J BIOL CHEM, V265, P1082; MINNEMAN KP, 1988, PHARMACOL REV, V40, P87; MOALIC JM, 1989, J HYPERTENS, V7, P195; MORRIS GM, 1991, J BIOL CHEM, V266, P2233; OGITA K, 1990, ADV SEC MESS PHOSPH, V24, P218; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; RODGERS JR, 1985, METHOD ENZYMOL, V109, P572; ROSENBAUM JS, 1987, BIOCHEM PHARMACOL, V36, P4335, DOI 10.1016/0006-2952(87)90681-2; RUFFOLO RR, 1991, PHARMACOL REV, V43, P475; SAKAUE M, 1991, J CLIN INVEST, V88, P385, DOI 10.1172/JCI115315; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; SIMPSON PC, 1989, J MOL CELL CARDIOL, V21, P79, DOI 10.1016/0022-2828(89)90774-8; TAYLOR SH, 1990, AM HEART J, V119, P655, DOI 10.1016/S0002-8703(05)80289-3; TSUDA T, 1990, J BIOL CHEM, V265, P1165; VANKLEEF EM, 1992, CIRC RES, V70, P1122, DOI 10.1161/01.RES.70.6.1122; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; WEINSTEIN IB, 1990, ADV SEC MESS PHOSPH, V24, P307; YOSHIMASA T, 1988, MOL BIOL BRAIN ENDOC, P123	46	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3610	3615						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8381435				2022-12-25	WOS:A1993KM16100089
J	CALLEJA, M; PENA, P; UGALDE, C; FERREIRO, C; MARCO, R; GARESSE, R				CALLEJA, M; PENA, P; UGALDE, C; FERREIRO, C; MARCO, R; GARESSE, R			MITOCHONDRIAL-DNA REMAINS INTACT DURING DROSOPHILA AGING, BUT THE LEVELS OF MITOCHONDRIAL TRANSCRIPTS ARE SIGNIFICANTLY REDUCED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEGENERATIVE DISEASES; SENESCENT RAT; MELANOGASTER; ORGANIZATION; MECHANISMS; DELETIONS; DECLINE; TISSUES; ABSENCE; ADULT	It has been suggested that mutations accumulated in mitochondrial DNA during the aging process may be causally related to the decreased physiological response of the senescent organisms. We have quantified and evaluated the integrity of the mitochondrial genome during the life span of Drosophila melanogaster. Its amount remains fairly constant representing roughly 1% of the total DNA at all ages. Southern experiments have also revealed a high stability and integrity of the mitochondrial DNA (mtDNA). However, we have detected an important decrease in the steady-state levels of all mitochondrial transcripts investigated: 16 S ribosomal RNA (16SrRNA), cytochrome c oxidase, cytochrome b, and beta H+-ATP synthase subunit. These changes correlate with the shape of the life span curve, preceding the decrease in survival of the male flies used in the study, and at least in the case of 16SrRNA, is tissue-specific. Although mitochondrial DNA remains unchanged in heads, thoraces, and abdomens, 16SrRNA levels decrease more severely in heads and thoraces and much less conspicuously in abdomens. On the other hand, control non-mitochondrial transcripts investigated remain essentially unaffected. These results suggest that in Drosophila the main effect of aging on the mitochondrial genetic system is downstream from mtDNA itself. The decline in the levels of beta H+-ATPase transcript, nuclear-encoded, suggests that not only the mitochondrial machinery, but also the nuclear one involved in mitochondrial biogenesis, is affected during aging.	UAM,FAC MED,CSIC,DEPT BIOQUIM,C ARZOBISPO MORCILLO 4,E-28029 MADRID,SPAIN; UAM,FAC MED,CSIC,INST INVEST BIOMED,E-28029 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Ugalde, Cristina/P-7533-2016; Garesse, Rafael/F-3836-2012	Ugalde, Cristina/0000-0002-9742-1877; 				ASANO K, 1991, MECH AGEING DEV, V60, P275, DOI 10.1016/0047-6374(91)90040-7; BAILEY PJ, 1984, MECH AGEING DEV, V24, P233, DOI 10.1016/0047-6374(84)90074-5; BAKER GT, 1985, HDB CELL BIOL AGING, P511; BINGHAM PM, 1981, CELL, V25, P693, DOI 10.1016/0092-8674(81)90176-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN WM, 1981, ANN NY ACAD SCI, V361, P119, DOI 10.1111/j.1749-6632.1981.tb54361.x; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1976; BULTMANN H, 1973, BIOCHIM BIOPHYS ACTA, V299, P196, DOI 10.1016/0005-2787(73)90342-0; BYRNE E, 1992, MUTAT RES, V275, P125, DOI 10.1016/0921-8734(92)90017-J; CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370; DEBRUIJN MHL, 1983, NATURE, V304, P234, DOI 10.1038/304234a0; FERNANDEZSILVA P, 1991, BIOCHEM BIOPH RES CO, V176, P645, DOI 10.1016/S0006-291X(05)80233-5; Finch CE, 1990, LONGEVITY SENESCENCE; FYRBERG EA, 1983, CELL, V33, P115, DOI 10.1016/0092-8674(83)90340-9; GADALETA MN, 1990, EUR J BIOCHEM, V187, P501, DOI 10.1111/j.1432-1033.1990.tb15331.x; GADALETA MN, 1992, MUTAT RES, V275, P181, DOI 10.1016/0921-8734(92)90022-H; GARESSE R, 1988, GENETICS, V118, P649; GELLISSEN G, 1987, ANN NY ACAD SCI, V503, P391, DOI 10.1111/j.1749-6632.1987.tb40625.x; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; KRAMER JJ, 1983, METHOD ENZYMAT AN, P200; LESKO SA, 1980, BIOCHEMISTRY-US, V19, P3023, DOI 10.1021/bi00554a029; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; MASSIE HR, 1981, AGE, V4, P42, DOI 10.1007/BF02431982; MASSIE HR, 1975, GERONTOLOGY, V21, P231, DOI 10.1159/000212049; MASSIE HR, 1987, EXP GERONTOL, V22, P139, DOI 10.1016/0531-5565(87)90048-9; Medawar P., 1952, UNSOLVED PROBLEM BIO; MIQUEL J, 1984, EXP GERONTOL, V19, P31, DOI 10.1016/0531-5565(84)90029-9; MIQUEL J, 1986, MODERN AGING RES, V8, P51; MIQUEL J, 1977, FREE RADICALS BIOL, V3, P133; MULLERHOCKER J, 1992, MUTAT RES, V275, P115, DOI 10.1016/0921-8734(92)90016-I; MURGIA M, 1992, J BIOL CHEM, V267, P10939; PIKO L, 1988, MECH AGEING DEV, V43, P279, DOI 10.1016/0047-6374(88)90037-1; RITCHER C, 1988, FEBS LETT, V241, P1; Rose M.R., 1991, EVOLUTIONARY BIOL AG; Sambrook J, 1989, MOL CLONING LABORATO; TAKAHASHI A, 1970, J GERONTOL, V25, P222, DOI 10.1093/geronj/25.3.222; TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0; TURKER MS, 1987, J BIOL CHEM, V262, P2250; URIELISHOVAL S, 1982, FEBS LETT, V146, P148, DOI 10.1016/0014-5793(82)80723-0; VALLEJO CG, 1979, CELL MOL BIOL, V25, P113; VALLEJO CG, 1970, EUR J BIOCHEM, V14, P478, DOI 10.1111/j.1432-1033.1970.tb00314.x; VANN AC, 1977, EXP GERONTOL, V12, P1; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WARNER AH, 1984, DEV BIOL, V102, P264, DOI 10.1016/0012-1606(84)90191-X; YEN TC, 1989, BIOCHEM BIOPH RES CO, V165, P994, DOI 10.1016/0006-291X(89)92701-0	46	102	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18891	18897						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8395521				2022-12-25	WOS:A1993LV65900077
J	MATHEWS, LS; VALE, WW				MATHEWS, LS; VALE, WW			CHARACTERIZATION OF TYPE-II ACTIVIN RECEPTORS - BINDING, PROCESSING, AND PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; PROTEIN-KINASE; EXPRESSION CLONING; XENOPUS EMBRYOS; MESSENGER-RNA; CELLS; COMPONENT; SYSTEM	Activins bind to two classes of cell surface proteins, type I receptors of approximately 50-55 kDa and type II receptors of approximately 70-75 kDa. The two cloned type II activin receptors belong to a new subfamily of transmembrane protein serine kinases. Antibodies directed against each of these cloned receptors were generated and used in immunoprecipitation experiments to study the properties of the type II receptors in vivo. Precipitation of affinity-labeled receptors, formed by chemical cross-linking of I-125-activin A, resulted in coprecipitation of type I receptor complexes; denaturation of the lysates prior to interaction with the antibodies resulted in precipitation of only type II receptors. Treatment of both affinity-labeled and metabolically labeled receptors with peptide N-glycosidase F revealed the presence of N-linked carbohydrate chains. Metabolic labeling of cells with [P-32]orthophosphate indicated that both type II receptors were phosphoproteins containing predominantly phosphoserine, with small amounts of phosphothreonine, but no detectable phosphotyrosine. Analysis of tryptic phosphopeptide maps of wild-type and kinase-defective mutants suggested that at least some of the phosphorylated sites arose from autophosphorylation.	SALK INST BIOL STUDIES, CLAYTON FDN, PEPTIDE BIOL LABS, LA JOLLA, CA 92037 USA	Salk Institute					NICHD NIH HHS [HD-07343, HD-13527] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD013527] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CENTRELLA M, 1991, MOL CELL BIOL, V11, P250, DOI 10.1128/MCB.11.1.250; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEMMATIBRIVANLOU A, 1992, DEV DYNAM, V194, P1, DOI 10.1002/aja.1001940102; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HINO M, 1989, J BIOL CHEM, V264, P10309; INAGAKI M, 1993, IN PRESS P NATL ACAD; KONDO M, 1991, BIOCHEM BIOPH RES CO, V181, P684, DOI 10.1016/0006-291X(91)91245-8; LEGERSKI R, 1992, BIOCHEM BIOPH RES CO, V183, P672, DOI 10.1016/0006-291X(92)90535-S; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MEISENHELDER J, 1991, METHOD ENZYMOL, V197, P288; NAKAMURA T, 1992, J BIOL CHEM, V267, P18924; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAUGHAN JM, 1989, METHOD ENZYMOL, V168, P588; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	24	80	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					19013	19018						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8395525				2022-12-25	WOS:A1993LV65900095
J	GRUNE, S; ENGELKING, LR; ANWER, MS				GRUNE, S; ENGELKING, LR; ANWER, MS			ROLE OF INTRACELLULAR CALCIUM AND PROTEIN-KINASES IN THE ACTIVATION OF HEPATIC NA+/TAUROCHOLATE COTRANSPORT BY CYCLIC-AMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; GLUCOSE-TRANSPORT; POTENT INHIBITORS; HUMAN-FIBROBLASTS; NA+/H+ EXCHANGER; SKELETAL-MUSCLE; PHOSPHOLIPASE-C; ACID TRANSPORT; PHORBOL ESTER; LIVER-CELLS	Glucagon and dibutyryl cyclic AMP (Bt2cAMP) stimulate Na+/taurocholate (TC) cotransport and increase the intracellular Ca2+ concentration ([Ca2+]i) of hepatocytes. Whether the effect of cAMP is mediated via increases in [Ca2+]i, cAMP-dependent protein kinase (PKA), and/or protein kinase C (PKC) was investigated in this study. TC uptake and [Ca2+]i were determined in isolated rat hepatocytes using [C-14]TC and the fluorescent dye quin-2, respectively. Bt2cAMP, forskolin, and 8-bromo-cAMP stimulated Na+-dependent, but not Na+-independent TC uptake. Bt2cAMP increased the maximal rate of Na+/TC cotransport without affecting the apparent K(m). Increases in TC uptake and [Ca2+]i by Bt2cAMP were inhibited in hepatocytes preloaded with bis-(2-amino-5-methylphenoxy)-ethane-N,N,N',N'-tetraacetic acid (MAPTA) or preincubated with 8-diethylaminooctyl 3,4,5-trimethoxybenzoate (TMB8). Calmodulin antagonists inhibited Bt2cAMP-induced increases in TC uptake, but not [Ca2+]i. Other Ca2+-mobilizing agents (thapsigargin, vasopressin, phenylephrine, and ionomycin) increased [Ca2+]i but failed to stimulate TC uptake, indicating that an increase in [Ca2+]i alone is not a sufficient stimulus for TC uptake. However, increases in TC uptake by 1 and 10 muM Bt2cAMP were further increased by thapsigargin, indicating a permissive role for Ca2+/calmodulin. Bt2cAMP-induced increases in TC uptake and [Ca2+]i, were inhibited by known inhibitors of PKA and by an activator of PKC, but they remained unaffected by a specific inhibitor of PKC. Unlike thapsigargin, vasopressin inhibited Bt2cAMP-induced increases in TC uptake. Taken together these results indicate that stimulation of hepatic Na+/TC cotransport by cAMP 1) is mediated via PKA; 2) is potentiated, but not mediated, by Ca2+/calmodulin-dependent processes; and 3) may be down-regulated by PKC.	TUFTS UNIV,SCH VET MED,DEPT PHARMACOL,200 WESTBORO RD,N GRAFTON,MA 01536; TUFTS UNIV,SCH VET MED,DEPT MED,N GRAFTON,MA 01536	Tufts University; Tufts University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033436] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 33436] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANTHANARAYANAN M, 1991, AM J PHYSIOL, V261, pG810, DOI 10.1152/ajpgi.1991.261.5.G810; ANWER MS, 1978, H-S Z PHYSIOL CHEM, V359, P181; ANWER MS, 1988, HEPATOLOGY, V8, P887, DOI 10.1002/hep.1840080430; ANWER MS, 1976, H-S Z PHYSIOL CHEM, V357, P1477, DOI 10.1515/bchm2.1976.357.2.1477; ANWER MS, 1992, HEPATOLOGY, V16, P121; ANWER MS, 1993, IN PRESS HEPATOLOGY; BAE HR, 1990, NATURE, V348, P637, DOI 10.1038/348637a0; Belle H. V., 1981, CELL CALCIUM, V2, P483; BONEH A, 1989, BIOCHIM BIOPHYS ACTA, V1012, P308, DOI 10.1016/0167-4889(89)90113-4; BOTHAM KM, 1986, BIOCHIM BIOPHYS ACTA, V883, P26, DOI 10.1016/0304-4165(86)90130-3; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; CHERQUI G, 1989, MOL CELL ENDOCRINOL, V65, P13, DOI 10.1016/0303-7207(89)90160-3; COHEN P, 1985, EUR J BIOCHEM, V151, P439, DOI 10.1111/j.1432-1033.1985.tb09121.x; CORASANTI JG, 1989, HEPATOLOGY, V10, P8, DOI 10.1002/hep.1840100103; DIAZGUERRA MJM, 1990, BIOCHEM J, V269, P163, DOI 10.1042/bj2690163; EDMONDSON JW, 1985, AM J PHYSIOL, V249, pG427, DOI 10.1152/ajpgi.1985.249.4.G427; EMMER E, 1989, J MEMBRANE BIOL, V108, P207, DOI 10.1007/BF01871735; EXTON JH, 1988, HEPATOLOGY, V8, P152, DOI 10.1002/hep.1840080129; FLIEGEL L, 1992, BIOCHEM J, V282, P139, DOI 10.1042/bj2820139; FRELIN C, 1988, EUR J BIOCHEM, V174, P3, DOI 10.1111/j.1432-1033.1988.tb14055.x; FRIEDMAN.N, 1971, SCIENCE, V171, P400, DOI 10.1126/science.171.3969.400; FRIMMER M, 1988, BIOCHIM BIOPHYS ACTA, V947, P75, DOI 10.1016/0304-4157(88)90020-2; GUMA A, 1990, BIOCHEM J, V268, P633, DOI 10.1042/bj2680633; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HENDEY B, 1989, J BIOL CHEM, V264, P19540; HENRIKSEN EJ, 1989, J BIOL CHEM, V264, P21536; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HIDAKA H, 1983, METHOD ENZYMOL, V102, P185; KALEDA ASM, 1992, J BIOL CHEM, V267, P7021; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; LEVITAN IB, 1985, J MEMBRANE BIOL, V87, P177, DOI 10.1007/BF01871217; LITTLE PJ, 1988, J BIOL CHEM, V263, P16780; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANGANEL M, 1990, J BIOL CHEM, V265, P4284; MEIER PJ, 1988, SEMIN LIVER DIS, V8, P293, DOI 10.1055/s-2008-1040551; OWEN NE, 1982, BIOCHEM BIOPH RES CO, V109, P762, DOI 10.1016/0006-291X(82)92005-8; PITTNER RA, 1989, BIOCHEM J, V257, P455, DOI 10.1042/bj2570455; POGGIOLI J, 1986, BIOCHEM J, V235, P663, DOI 10.1042/bj2350663; RAIFORD DS, 1991, AM J PHYSIOL, V261, pG578, DOI 10.1152/ajpgi.1991.261.4.G578; REYMANN A, 1989, BIOCHIM BIOPHYS ACTA, V1011, P158, DOI 10.1016/0167-4889(89)90203-6; SIMMONS TW, 1990, BIOCHIM BIOPHYS ACTA, V1023, P462, DOI 10.1016/0005-2736(90)90140-J; SIMPSER E, 1990, GASTROENTEROLOGY, V98, P25; STADDON JM, 1986, BIOCHEM J, V238, P737, DOI 10.1042/bj2380737; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; VONDIPPE P, 1990, J BIOL CHEM, V265, P14812; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; WOODLOCK TJ, 1989, J CELL PHYSIOL, V141, P33, DOI 10.1002/jcp.1041410106	51	81	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17734	17741						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8394349				2022-12-25	WOS:A1993LT74300018
J	LANE, LK; FELDMANN, JM; FLARSHEIM, CE; RYBCZYNSKI, CL				LANE, LK; FELDMANN, JM; FLARSHEIM, CE; RYBCZYNSKI, CL			EXPRESSION OF RAT-ALPHA-1 NA,K-ATPASE CONTAINING SUBSTITUTIONS OF ESSENTIAL AMINO-ACIDS IN THE CATALYTIC CENTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMB KIDNEY (NA,K)-ATPASE; NUCLEOTIDE-BINDING DOMAIN; MOLECULAR-CLONING; FUNCTIONAL CONSEQUENCES; SARCOPLASMIC-RETICULUM; ESSENTIAL RESIDUE; ALPHA-SUBUNIT; ATP-BINDING; RAT-BRAIN; SITE	Previous chemical modification studies have suggested that Cys-369, Cys-658, Lys-482, Asp-712, and Asp-716 are essential for Na,K-ATPase function. To determine if the side chains of these amino acid residues are required for enzyme activity, rat alpha1 cDNAs containing the mutations Cys-369 --> Ser, Cys-658 --> Ala, Lys-482 --> Ala, Asp-712 --> Asn, and Asp-716 --> Asn were prepared and stably expressed in HeLa cells, which normally cannot survive in medium containing muM concentrations of ouabain. Expression of rat alpha1 wild-type and the mutants Cys-369 --> Ser, Cys-658 --> Ala, and Lys-482 --> Ala causes the appearance of HeLa cells that survive in medium containing 0.5 muM ouabain. Membranes isolated from the rat alpha1 mutant clones exhibit Na,K-ATPase activities, ratios of Na,K-ATPase:phosphoenzyme, and apparent affinities for ouabain and ATP which are comparable to those of the rat alpha1 wild-type enzyme. HeLa cells expressing mRNA and protein for Asp-712 --> Asn and Asp-716 --> Asn rat alpha1 mutants cannot survive in 0.1 muM ouabain, and membranes isolated from these clones exhibit very little or no ouabain-insensitive rat alpha1 Na,K-ATPase activity. The Asp-712 --> Asn, but not Asp-716 --> Asn, mutant rat alpha1 can be phosphorylated by ATP. We conclude that Cys-369, Cys-658, and Lys-482 are not essential for Na,K-ATPase function but that the Asp residues at 712 and 716 are both essential.			LANE, LK (corresponding author), UNIV CINCINNATI,COLL MED,DEPT PHARMACOL & CELL BIOPHYS,ML 575,CINCINNATI,OH 45267, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL22619] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVRUSH J, 1972, P NATL ACAD SCI USA, V69, P1216, DOI 10.1073/pnas.69.5.1216; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CHEN C, 1987, MOL CELL BIOL, V7, P2743; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; ESMANN M, 1988, METHOD ENZYMOL, V156, P105; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; HINZ HR, 1990, J BIOL CHEM, V265, P10260; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; KIRLEY TL, 1991, J BIOL CHEM, V266, P19953; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE LK, 1978, BIOCHEM PHARMACOL, V27, P225, DOI 10.1016/0006-2952(78)90305-2; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; OHTA T, 1986, P NATL ACAD SCI USA, V83, P2071, DOI 10.1073/pnas.83.7.2071; ORLOWSKI J, 1988, J BIOL CHEM, V263, P10436; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P111, DOI 10.1016/0014-5793(87)81253-X; PATZELTWENCZLER R, 1975, EUR J BIOCHEM, V53, P301, DOI 10.1111/j.1432-1033.1975.tb04069.x; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; WANG K, 1992, J BIOL CHEM, V267, P3577	23	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17930	17934						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8394354				2022-12-25	WOS:A1993LT74300046
J	KROEGER, PE; OSHEROFF, N; ROWE, TC				KROEGER, PE; OSHEROFF, N; ROWE, TC			ANALYSIS OF TOPOISOMERASE II-MEDIATED DNA CLEAVAGE IN THE 5'-REGION OF THE DROSOPHILA HSP70 GENE - IDENTIFICATION OF A NOVEL HALF-SITE DNA SUBSTRATE FOR TOPOISOMERASE-II CLEAVAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAKAGE-REUNION REACTION; EUKARYOTIC TOPOISOMERASE; ANTITUMOR DRUGS; STRANDED-DNA; MELANOGASTER; SEQUENCE; INTERMEDIATE; CHROMATIN; POISONS; DAMAGE	Previous in vivo studies have identified a prominent 4'-demethylepipodophyllotoxin-9-(4,6-O-thionylidine-beta-D-glucopyranoside) (VM-26)-induced double-stranded topoisomerase II cleavage site at almost-equal-to +80 relative to the start of Drosophila hsp70 transcription (Kroeger, P. E., and Rowe, T. C. (1992) Biochemistry 31, 2492-2502). Topoisomerase II binding at this site correlated with the repression of hsp70 transcription suggesting that this protein-DNA interaction was important in the regulation of hsp70 gene expression. In this paper, we investigated the interaction of purified Drosophila topoisomerase II with a 271 -base pair DNA fragment containing the +80 region of the hsp70 gene using the topoisomerase II-specific inhibitor VM-26. VM-26-induced topoisomerase II cleavage of the hsp70 DNA resulted in a major 4-base staggered double-stranded break at +84. In the absence of ATP the +84 site was the only significant VM-26-induced cleavage site. Addition of ATP to the reaction resulted in a stimulation of topoisomerase cleavage throughout the 271-base pair DNA fragment. Deletion analyses determined that almost-equal-to 15 to 25 bp of flanking sequence were required for efficient cleavage at most topoisomerase II sites within the hsp70 DNA. However, in the case of the +84 site, topoisomerase cleavage still occurred even when this site was split in half by the restriction enzyme PstI. Topoisomerase II cleavage of both ''half-site'' DNA molecules occurred at the correct positions on the 4-base single-stranded DNA overhangs generated by PstI. Cleavage was reversible indicating that topoisomerase II could reseal the single-stranded DNA break formed in each half-site substrate. Denaturation of the half-site molecules abolished topoisomerase II cleavage suggesting that cleavage required the duplex region adjacent to the single-stranded cleavage site. Identification of this unusual half-site substrate provides additional evidence that double-stranded cleavage of DNA by topoisomerase II occurs via two sequential single-stranded breaks.	UNIV FLORIDA,COLL MED,DEPT PHARMACOL & THERAPEUT,GAINESVILLE,FL 32610; VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232	State University System of Florida; University of Florida; Vanderbilt University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038859, R01GM033944] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38859, GM33944] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P6237, DOI 10.1021/bi00441a015; CAPRANICO G, 1990, NUCLEIC ACIDS RES, V18, P6611, DOI 10.1093/nar/18.22.6611; CAPRANICO G, 1990, BIOCHEMISTRY-US, V29, P562, DOI 10.1021/bi00454a033; CHEN GL, 1984, J BIOL CHEM, V259, P3560; CORCES V, 1981, P NATL ACAD SCI-BIOL, V78, P7038, DOI 10.1073/pnas.78.11.7038; DRLICA K, 1988, BIOCHEMISTRY-US, V27, P2253, DOI 10.1021/bi00407a001; GALE KC, 1990, BIOCHEMISTRY-US, V29, P9538, DOI 10.1021/bi00493a007; HSIANG YH, 1989, J BIOL CHEM, V264, P9713; Hsieh T, 1990, CURR OPIN CELL BIOL, V2, P461, DOI 10.1016/0955-0674(90)90128-2; HSIEH T-S, 1992, Current Opinion in Cell Biology, V4, P396, DOI 10.1016/0955-0674(92)90004-V; KREUZER KN, 1984, J BIOL CHEM, V259, P5347; KROEGER PE, 1992, BIOCHEMISTRY-US, V31, P2492, DOI 10.1021/bi00124a008; LEE MP, 1989, J BIOL CHEM, V264, P13510; LEVY A, 1980, NUCLEIC ACIDS RES, V8, P6059, DOI 10.1093/nar/8.24.6059; LIU LF, 1983, J BIOL CHEM, V258, P5365; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LOCK RB, 1987, ANTI-CANCER DRUG DES, V2, P151; LUND K, 1990, J BIOL CHEM, V265, P13856; MAXAM AM, 1980, P NATL ACAD SCI USA, V81, P1361; MULLER MT, 1988, BIOCHEMISTRY-US, V27, P8369, DOI 10.1021/bi00422a012; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P6402, DOI 10.1021/bi00394a015; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; POMMIER Y, 1991, NUCLEIC ACIDS RES, V19, P5973, DOI 10.1093/nar/19.21.5973; ROUGVIE A, 1989, DNA PROTEIN INTERACT, P229; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; ROWE TC, 1986, MOL CELL BIOL, V6, P985, DOI 10.1128/MCB.6.4.985; ROWE TC, 1986, CANCER RES, V46, P2021; SANDER M, 1985, NUCLEIC ACIDS RES, V13, P1057, DOI 10.1093/nar/13.4.1057; SANDER M, 1983, J BIOL CHEM, V258, P8421; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533; Sternglanz R, 1989, CURR OPIN CELL BIOL, V1, P533, DOI 10.1016/0955-0674(89)90016-1; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; TEWEY KM, 1984, J BIOL CHEM, V259, P9182; THOMSEN B, 1990, J MOL BIOL, V215, P237, DOI 10.1016/S0022-2836(05)80342-0; UDVARDY A, 1984, J MOL BIOL, V172, P385, DOI 10.1016/S0022-2836(84)80013-3; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; ZECHIEDRICH EL, 1989, BIOCHEMISTRY-US, V28, P6229, DOI 10.1021/bi00441a014	42	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16449	16457						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8393863				2022-12-25	WOS:A1993LQ33600055
J	ALI, IU; SAXENA, A; MEISSNER, S; BARRICK, J; LIDEREAU, R				ALI, IU; SAXENA, A; MEISSNER, S; BARRICK, J; LIDEREAU, R			CLOSE PROXIMITY OF C-ERBA2 AND C-ERBA-BETA GENES ON THE SHORT ARM OF CHROMOSOME-3	ONCOGENE			English	Note							THYROID-HORMONE RECEPTOR; RENAL-CELL CARCINOMA; HUMAN LUNG-CANCER; DELETION; LOCALIZATION; REGION; HETEROZYGOSITY; SEQUENCE; HOMOLOGS; PROTEIN	The common loss region on the short arm of chromosome 3 (3p) in human breast tumors harbors two members of the c-erbA receptor gene family, c-erbA2 and c-erbA-beta, both of which recognize a BamHI polymorphism in human genomic DNA. Analysis of lymphocyte DNAs from 50 normal individuals and lymphocyte and tumor DNAs from 116 breast cancer patients revealed identical genotypes (a/a, b/b or a/b) for both probes. Furthermore, deletion of the same allele (a/- or -/b) of c-erbA2 and c-erbA-beta was detected in 25% of the 66 breast tumors from patients with constitutionally heterozygous genotypes for both genes. No sequence homology was detected between the c-erbA2 and c-erbA-beta genes, suggesting a physical linkage between these two genes. Digestion of the genomic DNA with combinations of restriction enzymes and hybridization with c-erbA2, which is a genomic fragment, and c-erbA-beta, which is a cDNA clone, provide evidence that c-erbA2 and a region of the c-erbA-beta gene are physically contiguous on the short arm of chromosome 3 and are separated by no more than 1.8 kb of DNA sequences.	NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892; CTR RENE HUGUENIN,F-92211 ST CLOUD,FRANCE	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Rene Huguenin Hospital	ALI, IU (corresponding author), NINCDS,SURG NEUROL BRANCH,BETHESDA,MD 20892, USA.							ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DOBROVIC A, 1988, CANCER RES, V48, P682; DOUGLAS JB, 1991, GENOMICS, V9, P398, DOI 10.1016/0888-7543(91)90274-I; DRABKIN H, 1988, P NATL ACAD SCI USA, V85, P9258, DOI 10.1073/pnas.85.23.9258; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GOSDEN JR, 1986, CYTOGENET CELL GENET, V43, P150, DOI 10.1159/000132313; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HIBI K, 1992, ONCOGENE, V7, P445; JANSSON M, 1983, EMBO J, V2, P561, DOI 10.1002/j.1460-2075.1983.tb01463.x; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; LAUDET V, 1991, NUCLEIC ACIDS RES, V19, P1105, DOI 10.1093/nar/19.5.1105; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LEDUC F, 1989, AM J HUM GENET, V44, P282; MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; RIDER SH, 1987, ANN HUM GENET, V51, P153, DOI 10.1111/j.1469-1809.1987.tb01057.x; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SPURR NK, 1984, EMBO J, V3, P159, DOI 10.1002/j.1460-2075.1984.tb01777.x; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YOKOTA J, 1989, CANCER RES, V49, P3958; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	25	3	3	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2299	2301						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8393165				2022-12-25	WOS:A1993LP17100033
J	LEMESLEMEUNIER, D; BRIVETCHEVILLOTTE, P; DIRAGO, JP; SLONIMSKI, PP; BRUEL, C; TRON, T; FORGET, N				LEMESLEMEUNIER, D; BRIVETCHEVILLOTTE, P; DIRAGO, JP; SLONIMSKI, PP; BRUEL, C; TRON, T; FORGET, N			CYTOCHROME-B-DEFICIENT MUTANTS OF THE UBIQUINOL-CYTOCHROME-C OXIDOREDUCTASE IN SACCHAROMYCES-CEREVISIAE - CONSEQUENCE FOR THE FUNCTIONAL AND STRUCTURAL CHARACTERISTICS OF THE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME QH2-CYTOCHROME-C REDUCTASE; RHODOBACTER-SPHAEROIDES; ELECTRON-TRANSFER; MOLECULAR-BASIS; BC1 COMPLEX; Q-CYCLE; MITOCHONDRIAL-DNA; SEQUENCE-ANALYSIS; APOCYTOCHROME-B; WILD-TYPE	We characterized six novel missense mutations in mitochondrial cytochrome b (C133Y, W142R, S206L, M221K, L282F, and G340E) which impair the respiratory growth of yeast and which have differential effects on the functioning and assembly of the bc1 complex. The mutations have been mapped genetically in exons of the mitochondrial gene coding for apocytochrome b and their nucleotide sequence established. The mutants help to better define the topographical and primary sequence location of the ubiquinol oxidase (center P) and ubiquinone reductase (center N) sites on cytochrome b. Two mutants (C133Y and S206L) resulted in an active assembled complex, with selective disturbances of heme 565 and heme 562, respectively, which is consistent with the assignment of the axial ligands of these hemes; the C133Y mutation induced myxothiazol resistance, whereas the S206L did not modify the antimycin binding site, although perturbing the center N. These two amino acid replacements, along with those described elsewhere (Tron, T., and Lemesle-Meunier, D. (1990) Curr. Genet. 18, 413-419), constitute a novel class of mutants exhibiting appreciable electron transfer activity, despite their impaired ability to grow on respiratory substrates, raising the possibility that these mutants carry alleles which result in ''decoupling'' of proton translocation from electron transfer. Mutants W142R and M221K had an inactive but well assembled bc1 complex, whereas the G340E and L282F mutations impaired the assembly of the bc1 complex.	UNIV PIERRE & MARIE CURIE,CTR GENET MOLEC,CNRS,LAB PROPRE,F-91198 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay	LEMESLEMEUNIER, D (corresponding author), LCB,UNITE METAB ENERGET,BOITE POSTALE NO 3,F-13275 MARSEILLE 09,FRANCE.							ATTAASAFOADJEI E, 1991, P NATL ACAD SCI USA, V88, P492, DOI 10.1073/pnas.88.2.492; BRASSEUR R, 1988, J BIOL CHEM, V263, P12571; BRIVETCHEVILLOTTE P, 1989, FEBS LETT, V255, P5, DOI 10.1016/0014-5793(89)81050-6; CHEVILLOTTEBRIVET P, 1983, EUR J BIOCHEM, V129, P653; CHEVILLOTTEBRIVET P, 1987, BIOCHIMIE, V69, P25, DOI 10.1016/0300-9084(87)90268-9; CHEVILLOTTEBRIVET P, 1980, EUR J BIOCHEM, V111, P161; CHEVILLOTTEBRIVET P, 1987, CURR GENET, V12, P111, DOI 10.1007/BF00434665; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; CROFTS A, 1992, BIOCHIM BIOPHYS ACTA, V1101, P162, DOI 10.1016/S0005-2728(05)80009-X; CROFTS A, 1987, CYTOCHROME SYSTEMS M, P617; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2; DALDAL F, 1989, EMBO J, V8, P3951, DOI 10.1002/j.1460-2075.1989.tb08578.x; DEHAAN M, 1984, EUR J BIOCHEM, V138, P169; DEVRIES S, 1987, BIOCHIM BIOPHYS ACTA, V895, pG205; DIRAGO JP, 1990, FEBS LETT, V263, P93, DOI 10.1016/0014-5793(90)80713-S; DIRAGO JP, 1989, J BIOL CHEM, V264, P14543; DIRAGO JP, 1988, J BIOL CHEM, V263, P12564; DIRAGO JP, 1990, J BIOL CHEM, V265, P15750; DIRAGO JP, 1990, J BIOL CHEM, V265, P3332; FOURY F, 1976, J BIOL CHEM, V253, P3792; GARGOURI AF, 1989, THESIS U P M CURIE; Garland PB, 1975, ELECTRON TRANSFER CH, P351; GONZALEZHALPHEN D, 1988, BIOCHEMISTRY-US, V27, P7021, DOI 10.1021/bi00418a053; HAID A, 1979, EUR J BIOCHEM, V94, P451, DOI 10.1111/j.1432-1033.1979.tb12913.x; HATEFI Y, 1980, J BIOL CHEM, V255, P5530; HAUSKA G, 1983, BIOCHIM BIOPHYS ACTA, V726, P97, DOI 10.1016/0304-4173(83)90002-2; HAUSKA G, 1988, J BIOENERG BIOMEMBR, V20, P211, DOI 10.1007/BF00768395; HOWELL N, 1988, J MOL BIOL, V203, P607, DOI 10.1016/0022-2836(88)90195-7; HOWELL N, 1990, BIOCHEMISTRY-US, V29, P8970, DOI 10.1021/bi00490a013; HOWELL N, 1987, J BIOL CHEM, V262, P2411; JACQ C, 1980, ORG EXPRESSION MITOC, P139; KOTYLAK Z, 1977, MITOCHONDRIA 1977, P161; KOVAC L, 1967, SCIENCE, V158, P1564, DOI 10.1126/science.158.3808.1564; LAMOUROUX A, 1979, THESIS U P M CURIE; LAZOWSKA J, 1989, J MOL BIOL, V205, P275, DOI 10.1016/0022-2836(89)90341-0; LAZOWSKA J, 1980, CELL, V22, P333, DOI 10.1016/0092-8674(80)90344-X; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; MEUNIER B, 1989, EUR J BIOCHEM, V184, P651, DOI 10.1111/j.1432-1033.1989.tb15062.x; MEUNIERLEMESLE D, 1980, EUR J BIOCHEM, V111, P151; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; ROBERTSON DE, 1990, BIOCHEMISTRY-US, V29, P11249, DOI 10.1021/bi00503a014; SARASTE M, 1984, FEBS LETT, V166, P367, DOI 10.1016/0014-5793(84)80114-3; SCHOPPINK PJ, 1989, THESIS U AMSTERDAM; SCHWEYEN RJ, 1977, MITOCHONDRIA 1977 GE, P139; SEN K, 1985, ARCH BIOCHEM BIOPHYS, V242, P393, DOI 10.1016/0003-9861(85)90223-1; SLONIMSKI P P, 1978, P391; SLONIMSKI P P, 1978, P339; SLONIMSKI PP, 1976, EUR J BIOCHEM, V61, P27, DOI 10.1111/j.1432-1033.1976.tb09994.x; TRON T, 1990, CURR GENET, V18, P413, DOI 10.1007/BF00309910; TRON T, 1991, EUR J BIOCHEM, V199, P753, DOI 10.1111/j.1432-1033.1991.tb16180.x; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; WEBER S, 1988, FEBS LETT, V237, P31, DOI 10.1016/0014-5793(88)80165-0; WIDGER WR, 1984, P NATL ACAD SCI-BIOL, V81, P674, DOI 10.1073/pnas.81.3.674; YUN CH, 1991, BIOCHEMISTRY-US, V30, P6747, DOI 10.1021/bi00241a017; YUN CH, 1991, J BIOL CHEM, V266, P10967; YUN CH, 1992, J BIOL CHEM, V267, P5901	58	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15626	15632						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8393450				2022-12-25	WOS:A1993LN30500047
J	MIDDLETON, JP; KHAN, WA; COLLINSWORTH, G; HANNUN, YA; MEDFORD, RM				MIDDLETON, JP; KHAN, WA; COLLINSWORTH, G; HANNUN, YA; MEDFORD, RM			HETEROGENEITY OF PROTEIN KINASE-C-MEDIATED RAPID REGULATION OF NA/K-ATPASE IN KIDNEY EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; NA+/K+-ATPASE; NA+,K+-ATPASE ACTIVITY; PHORBOL ESTER; HELA-CELLS; PHOSPHATE-UPTAKE; PLASMA-MEMBRANE; DOWN-REGULATION; ALPHA-SUBUNIT; TUBULE CELLS	Na/K-ATPase in renal epithelium is expressed at the basolateral surface and thus is critical for vectorial solute transport. One potential mode of regulation of Na/K-ATPase involves the intracellular effector protein kinase C (PKC). In kidney cell lines, activation of PKC by the phorbol ester phorbol 12,13-dibutyrate (PDBu) (1 muM) inhibited Na/K-ATPase transport activity in OK cells (V(max) decreased 42%; p < 0.02), but not in LLC-PK1 cells. By immunoblot, both cell types expressed detectable levels of PKCalpha and PKCzeta. In response to PDBu, PKCalpha translocated from the cytosol to the membrane fractions of both cell lines. Phorbol ester treatment increased incorporation of (PO4)-P-32 in multiple substrates in both cell types, but a approximately 109-kDa substrate with neutral pI was detected only in the OK cell. Anti-LEAVE, directed against a highly conserved sequence in the H4-H5 loop of all known a isoforms of Na/K-ATPase, recognized a approximately 109-kDa membrane protein from both cell lines. Anti-LEAVE also identified a protein that comigrated with the large phosphoprotein which was only present in OK cells. Following (PO4)-P-32 loading and PDBu treatment, anti-LEAVE immunoprecipitated a approximately 109-kDa phosphoprotein in OK but not LLC-PK, cells. These data support the notion that PKC is capable of phosphorylating the a subunit and inhibiting Na/K-ATPase transport activity in intact renal cells. Furthermore, they suggest that some forms of Na/K-ATPase in the kidney are not susceptible to PKC phosphorylation and that this heterogeneity may contribute to response diversity.	DUKE UNIV, MED CTR, DEPT INTERNAL MED, DIV HEMATOL MED ONCOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; EMORY UNIV, SCH MED, DIV CARDIOL, ATLANTA, GA 30322 USA	Duke University; Duke University; Emory University	MIDDLETON, JP (corresponding author), DUKE UNIV, MED CTR, DEPT INTERNAL MED, DIV NEPHROL, DURHAM, NC 27710 USA.				NHLBI NIH HHS [HL 45933] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL045933, R01HL045933] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN JC, 1991, CIRC RES, V69, P39, DOI 10.1161/01.RES.69.1.39; APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; APERIA A, 1987, AM J PHYSIOL, V252, pF39, DOI 10.1152/ajprenal.1987.252.1.F39; BERTHON B, 1985, BRIT J PHARMACOL, V86, P151, DOI 10.1111/j.1476-5381.1985.tb09445.x; BERTORELLO AM, 1992, J CELL SCI, V101, P343; BERTORELLO AM, 1991, P NATL ACAD SCI USA, V88, P11359, DOI 10.1073/pnas.88.24.11359; CHIBALIN AV, 1992, J BIOL CHEM, V267, P22378; DONG LQ, 1991, AM J PHYSIOL, V261, pF679, DOI 10.1152/ajprenal.1991.261.4.F679; EDELMAN IS, 1985, SODIUM PUMP, P153; FRIEDLANDER G, 1989, J BIOL CHEM, V264, P3935; FUKUDA Y, 1991, PEDIATR RES, V30, P131, DOI 10.1203/00006450-199108000-00001; GICK GG, 1988, NA PLUS MINUS K PLUS, P353; GIESEN EM, 1984, BIOCHEM BIOPH RES CO, V120, P619, DOI 10.1016/0006-291X(84)91300-7; HAGGERTY JG, 1988, P NATL ACAD SCI USA, V85, P6797, DOI 10.1073/pnas.85.18.6797; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; HUNDAL HS, 1992, J BIOL CHEM, V267, P5040; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; KATZ AI, 1988, NA PLUS K PLUS PUM B, P207; KILEY S, 1990, J BIOL CHEM, V265, P15704; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LOWNDES JM, 1990, BIOCHIM BIOPHYS ACTA, V1052, P143, DOI 10.1016/0167-4889(90)90069-P; LYNCH CJ, 1986, J BIOL CHEM, V261, P4551; MEDFORD RM, 1991, J BIOL CHEM, V266, P18308; MIDDLETON JP, 1990, J CLIN INVEST, V86, P1799, DOI 10.1172/JCI114909; MIDDLETON JP, 1989, AM J PHYSIOL, V257, pF631, DOI 10.1152/ajprenal.1989.257.4.F631; MIDDLETON JP, 1990, AM J PHYSIOL, V259, pF727, DOI 10.1152/ajprenal.1990.259.4.F727; MIRCHEFF AK, 1992, AM J PHYSIOL, V262, pC470, DOI 10.1152/ajpcell.1992.262.2.C470; MODYANOV NN, 1991, FEBS LETT, V278, P91, DOI 10.1016/0014-5793(91)80091-G; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OISHI K, 1990, J BIOL CHEM, V265, P70; OLIVIER AR, 1992, J CELL PHYSIOL, V152, P240, DOI 10.1002/jcp.1041520204; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; POLLOCK AS, 1986, AM J PHYSIOL, V250, pF217, DOI 10.1152/ajprenal.1986.250.2.F217; PRESSLEY TA, 1992, AM J PHYSIOL, V262, pC743, DOI 10.1152/ajpcell.1992.262.3.C743; RESHKIN SJ, 1990, J BIOL CHEM, V265, P15261; RYVES WJ, 1991, FEBS LETT, V288, P5, DOI 10.1016/0014-5793(91)80989-G; SEGEL IH, 1987, ENZYME KINETICS; SHULL GE, 1986, NATURE, V321, P429, DOI 10.1038/321429a0; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SOLTOFF SP, 1984, J GEN PHYSIOL, V84, P601, DOI 10.1085/jgp.84.4.601; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; TRILIVAS I, 1991, J BIOL CHEM, V266, P8431; TUNG P, 1990, J BIOL CHEM, V265, P3936; VASILETS LA, 1990, J MEMBRANE BIOL, V118, P131, DOI 10.1007/BF01868470; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121	46	111	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15958	15964						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8393456				2022-12-25	WOS:A1993LN30500090
J	ALESSI, DR; SMYTHE, C; KEYSE, SM				ALESSI, DR; SMYTHE, C; KEYSE, SM			THE HUMAN CL100 GENE ENCODES A TYR/THR-PROTEIN PHOSPHATASE WHICH POTENTLY AND SPECIFICALLY INACTIVATES MAP KINASE AND SUPPRESSES ITS ACTIVATION BY ONCOGENIC RAS IN XENOPUS-OOCYTE EXTRACTS	ONCOGENE			English	Note							EPIDERMAL GROWTH-FACTOR; RABBIT SKELETAL-MUSCLE; P34CDC2; PURIFICATION; REQUIREMENT; CELLS	The expression of the human CL100 gene and its mouse homologue 3CH134 is increased up to 40-fold in fibroblasts exposed to oxidative/heat stress and growth factors. CL100 is a member of an expanding family of protein tyrosine phosphatases with amino acid sequence similarity to a Tyr/Ser-protein phosphatase encoded by the late H1 gene of vaccinia virus. Here we show that the CL100 phosphatase, expressed and purified in bacteria, rapidly and potently inactivates recombinant MAP kinase in vitro by the concomitant dephosphorylation of both its phosphothreonine and phosphotyrosine residues. Furthermore, CL100 suppresses the [val12] ras-induced activation of MAP kinase in a cell-free system from Xenopus oocytes. Both activities are abolished by mutagenesis of the highly conserved cysteine (Cys-258) within the phosphatase active site. In contrast to the vaccinia H1 phosphatase, CL100 shows no measurable catalytic activity towards a remember of other substrate proteins modified on serine, threonine or tyrosine residues. Our results demonstrate that CL100 is a dual specificity phosphatase and indicate that MAP kinase is one of its physiological targets. CL100 may be the first example of a new class of protein phosphatases responsible for modulating the activation of MAP kinase following exposure of quiescent cells to growth factors and further implicates MAP kinase activation/deactivation in the cellular response to stress.	UNIV DUNDEE, INST MED SCI,DEPT BIOCHEM,MRC, PROT PHOSPHORYLAT UNIT, DUNDEE DD1 4HN, SCOTLAND; UNIV DUNDEE, NINEWELLS HOSP & MED SCH,BIOMED RES CTR,ICRF, MOLEC PHARMACOL UNIT, DUNDEE DD1 9SY, SCOTLAND	University of Dundee; University of Dundee			Keyse, Stephen M./B-9575-2009	Keyse, Stephen M./0000-0002-5150-8221; Alessi, Dario/0000-0002-2140-9185				ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CHAMBERS TC, 1990, J BIOL CHEM, V265, P16940; CHARLES CH, 1992, ONCOGENE, V7, P187; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COHEN P, 1988, METHOD ENZYMOL, V159, P427; DEANA AD, 1990, BIOCHIM BIOPHYS ACTA, V1051, P199, DOI 10.1016/0167-4889(90)90194-I; DENT P, 1992, EUR J BIOCHEM, V210, P1037, DOI 10.1111/j.1432-1033.1992.tb17509.x; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GUAN K, 1993, TRENDS BIOCHEM SCI, V18, P6, DOI 10.1016/0968-0004(93)90079-3; GUAN K, 1992, P NATL ACAD SCI USA, V89, P12175, DOI 10.1073/pnas.89.24.12175; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HENDRIX P, 1993, J BIOL CHEM, V268, P7330; HSUAN J, 1991, METHOD ENZYMOL, V200, P378; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; MCGOWAN CH, 1987, EUR J BIOCHEM, V166, P713, DOI 10.1111/j.1432-1033.1987.tb13570.x; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NAKIELNY S, 1991, EUR J BIOCHEM, V199, P713, DOI 10.1111/j.1432-1033.1991.tb16175.x; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SATO HT, 1992, SEMIN CANCER BIOL, V3, P169; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STEWART AA, 1981, EUR J BIOCHEM, V115, P197; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; THOAMS G, 1992, CELL, V68, P3; THOM D, 1977, BIOCHEM J, V168, P187, DOI 10.1042/bj1680187; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351	45	318	330	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1993	8	7					2015	2020						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8390041				2022-12-25	WOS:A1993LG68200035
J	STACKER, SA; HOVENS, CM; VITALI, A; PRITCHARD, MA; BAKER, E; SUTHERLAND, GR; WILKS, AF				STACKER, SA; HOVENS, CM; VITALI, A; PRITCHARD, MA; BAKER, E; SUTHERLAND, GR; WILKS, AF			MOLECULAR-CLONING AND CHROMOSOMAL LOCALIZATION OF THE HUMAN HOMOLOG OF A RECEPTOR RELATED TO TYROSINE KINASES (RYK)	ONCOGENE			English	Article							DEPENDENT PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; MILLER-DIEKER SYNDROME; CATALYTIC SUBUNIT; CONSERVED FEATURES; CDNA CLONES; CELL-LINE; LOCALIZATION; SEQUENCE; GENE	A cDNA encoding the human homologue of mouse RYK (related to receptor tyrosine kinases) has been cloned from an interleukin 1 (IL-1)-stimulated human hepatoma cDNA library by cross-species hybridization using the mouse RYK cDNA as a probe. The sequence of the 3067-bp cDNA clone encoding human RYK predicts a transmembrane protein with a cytoplasmic domain that contains the consensus sequences (subdomains I-XI) of the protein tyrosine kinase (PTK) family. The highly conserved motif -D-F-G- (subdomain VII) of the catalytic domain of other receptor-type tyrosine kinases is altered to -D-N-A- in human RYK. In addition, a number of other changes were found in the ATP binding site (subdomains I and II) and the motif [-I-H-R-D-L-A-A-R-N-] found in subdomain VI. Comparison of the human and mouse RYK sequences shows a 92% conservation at the nucleotide level and 97% at the amino acid level. There was no significant homology between the extracellular domain of RYK and the other families of receptor tyrosine kinases described to date. RYK therefore appears to define a new subclass of receptor-type tyrosine kinases whose structure has remained highly conserved across species.	LUDWIG INST CANC RES, MELBOURNE TUMOUR BIOL BRANCH, PO ROYAL MELBOURNE HOSP, PARKVILLE, VIC 3050, AUSTRALIA; WOMENS & CHILDRENS HOSP, DEPT CYTOGENET & MOLEC GENET, ADELAIDE, SA 5006, AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Womens & Childrens Hospital Australia			Wilks, Andrew F/R-5542-2019; Sutherland, Grant Robert/D-2606-2012	Hovens, Christopher/0000-0002-0610-1289; Wilks, Andrew F/0000-0002-8554-2399; Stacker, Steven/0000-0003-4096-9273				ADAMS RA, 1968, CANCER RES, V28, P1121; BUECHLER JA, 1989, BIOCHEMISTRY-US, V28, P3018, DOI 10.1021/bi00433a042; CALLEN DF, 1992, GENOMICS, V13, P1178, DOI 10.1016/0888-7543(92)90035-Q; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; DEMMER LA, 1987, J BIOL CHEM, V262, P2458; DOBYNS WB, 1991, AM J HUM GENET, V48, P584; EIPERS PG, 1991, GENOMICS, V11, P621, DOI 10.1016/0888-7543(91)90069-Q; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HOVENS CH, 1962, P NATL ACAD SCI USA, V89, P11818; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOSIK KS, 1988, NEURON, V1, P127, DOI 10.1016/0896-6273(88)90196-1; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KWIATKOWSKI DJ, 1990, AM J HUM GENET, V46, P559; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMHONWAH AM, 1986, P NATL ACAD SCI USA, V83, P4864, DOI 10.1073/pnas.83.13.4864; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MORAN MF, 1988, ONCOGENE, V3, P665; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; SAMBROK J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; STARK KL, 1991, DEVELOPMENT, V113, P641; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WHITEHEAD RH, 1987, CANCER RES, V47, P2683; WILKS AF, 1988, ONCOGENE, V3, P289; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLKS AF, 1992, ADV CANCER RES, V60, P43; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZABEL BU, 1983, P NATL ACAD SCI-BIOL, V80, P6932, DOI 10.1073/pnas.80.22.6932	40	40	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1347	1356						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8386829				2022-12-25	WOS:A1993KY32800028
J	LAMY, F; WILKIN, F; BAPTIST, M; POSADA, J; ROGER, PP; DUMONT, JE				LAMY, F; WILKIN, F; BAPTIST, M; POSADA, J; ROGER, PP; DUMONT, JE			PHOSPHORYLATION OF MITOGEN-ACTIVATED PROTEIN-KINASES IS INVOLVED IN THE EPIDERMAL GROWTH-FACTOR AND PHORBOL ESTER, BUT NOT IN THE THYROTROPIN CAMP, THYROID MITOGENIC PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL-PROLIFERATION; CYCLIC-AMP; PRIMARY CULTURE; STIMULATION; INDUCTION; EXPRESSION; INSULIN; TARGET	In dog thyroid epithelial cells (thyrocytes) in primary culture, thyrotropin (TSH) acting through cAMP induces proliferation and differentiation expression, whereas epidermal growth factor (EGF) and tumor-promoting phorbol esters induce proliferation and de-differentiation. In these cells we have demonstrated mitogen-activated protein (MAP) kinase phosphorylation by P-32 labeling and two-dimensional gel electrophoresis and by immunodetection with anti-MAP kinase and anti-phosphotyrosine antibodies after one- or two-dimensional gel electrophoresis. MAP kinase localization was demonstrated by immunochemical staining. We show the following results. (i) As in other systems, EGF and phorbol esters induced p42 and p44 MAP kinases phosphorylation on tyrosine, serine, and threonine. This effect was rapid, peaking after 5 and 15 min, respectively, followed by a slow decline thereafter. It preceded a translocation of MAP kinase immunoreactivity from cytoplasm to nucleus. (ii) Carbamylcholine, a potent stimulator of the Ca2+-phosphatidylinositol cascade which is unable to induce DNA synthesis, stimulated MAP kinases phosphorylation and nuclear staining with kinetics similar to those observed after EGF action, indicating that MAP kinase phosphorylation was not sufficient for mitogenesis. (iii) The cAMP-dependent mitogenic cascade elicited by TSH and forskolin did not involve the phosphorylation and nuclear translocation of p42 and p44 MAP kinases at any time during the entire prereplicative phase. Activation of MAP kinases by phosphorylation is therefore not a necessary step in the G0-G1 transition in this mitogenic cascade.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Fred Hutchinson Cancer Center	LAMY, F (corresponding author), UNIV LIBRE BRUXELLES,INST RECH INTERDISCIPLINAIRE,CAMPUS ERASME,ROUTE LENNIK 808,B-1070 BRUSSELS,BELGIUM.			Roger, Pierre/0000-0002-5812-1783; Posada, James/0000-0003-3582-9612				ADAMS PD, 1991, FEBS LETT, V290, P77, DOI 10.1016/0014-5793(91)81230-6; ANDERSON NG, 1992, CELL SIGNAL, V4, P239, DOI 10.1016/0898-6568(92)90063-E; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHATANI Y, 1992, J BIOL CHEM, V267, P9911; CHEN RH, 1992, MOL CELL BIOL, V22, P925; CONTOR L, 1988, MOL CELL BIOL, V8, P2494, DOI 10.1128/MCB.8.6.2494; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LAMY F, 1989, J CELL PHYSIOL, V138, P568, DOI 10.1002/jcp.1041380318; LECOCQ R, 1990, ELECTROPHORESIS, V11, P200, DOI 10.1002/elps.1150110303; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RASPE E, 1992, EXP CELL RES, V198, P17, DOI 10.1016/0014-4827(92)90143-V; ROGER PP, 1986, CANCER RES, V46, P898; ROGER PP, 1987, J CELL PHYSIOL, V130, P58, DOI 10.1002/jcp.1041300110; ROGER PP, 1983, FEBS LETT, V157, P323, DOI 10.1016/0014-5793(83)80569-9; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SETH A, 1991, J BIOL CHEM, V266, P23521; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4	27	127	127	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8398	8401						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8386160				2022-12-25	WOS:A1993KX81100005
J	COONEY, AJ; LENG, XH; TSAI, SY; OMALLEY, BW; TSAI, MJ				COONEY, AJ; LENG, XH; TSAI, SY; OMALLEY, BW; TSAI, MJ			MULTIPLE MECHANISMS OF CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR-DEPENDENT REPRESSION OF TRANSACTIVATION BY THE VITAMIN-D, THYROID-HORMONE, AND RETINOIC ACID RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V-ERBA FUNCTIONS; RESPONSIVE ELEMENT; GENE-EXPRESSION; II GENE; SUPERFAMILY; BINDING; PROTEIN; DNA; IDENTIFICATION; MEMBER	The chicken ovalbumin upstream promoter transcription factor (COUP-TF) is a member of the steroid/thyroid hormone receptor superfamily about which little is known of its functional role in the cell. However, it is able to repress hormonal induction of target genes by vitamin D3 receptor (VDR), thyroid hormone receptor (TR), and retinoic acid receptor (RAR). We have shown previously that COUP-TF can bind a wide variety of A/GGGTCA repeats. This promiscuous recognition of response elements correlates with the ability of COUP-TF I to repress other receptors that bind to A/GGGTCA repeats with different spacings between the half-sites. Here we show that repression of transactivation by these receptors is a general phenomenon for the COUP-TF subfamily, as inhibition is also observed with COUP-TF II. This repression is also dose-dependent on COUP-TF. Inhibition of VDR, TR, and RAR activities also occurs through natural physiological response elements found in the osteocalcin, myosin heavy chain, and betaRAR promoters, respectively. In search of the mechanisms of repression by COUP-TF we show that it does not involve the formation of detectable functionally inactive heterodimers between COUP-TF and VDR, TR, and RAR. Instead, we show that the mechanism of repression could occur at three different levels: (a) active silencing of transcription and dual competition for; (b) occupancy of DNA binding sites; and (c), heterodimer formation with retinoid X receptor, the coregulator of VDR, TR, and RAR. The silencing activity was localized to the putative ligand binding domain of COUP-TF. We postulate that COUP-TF may play a master role in regulating transactivation by VDR, TR, and RAR.	BAYLOR COLL MED,DEPT CELL BIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030	Baylor College of Medicine					NICHD NIH HHS [HD17379, HD08188] Funding Source: Medline; NIDDK NIH HHS [DK45641] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017379, R37HD017379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK045641, R01DK045641] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAN GF, 1992, J BIOL CHEM, V267, P19513; BAGCHI MK, 1987, MOL CELL BIOL, V7, P4151, DOI 10.1128/MCB.7.12.4151; BANIAHMAD A, 1992, P NATL ACAD SCI USA, V89, P10633, DOI 10.1073/pnas.89.22.10633; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HWUNG YP, 1988, MOL CELL BIOL, V8, P2070, DOI 10.1128/MCB.8.5.2070; HWUNG YP, 1988, J BIOL CHEM, V263, P13470; ING NH, 1992, J BIOL CHEM, V267, P17617; KARIN M, 1990, New Biologist, V2, P126; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; OZONO K, 1990, J BIOL CHEM, V265, P21881; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; SAGAMI I, 1986, MOL CELL BIOL, V6, P4259, DOI 10.1128/MCB.6.12.4259; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; Wang Lee-Ho, 1991, Gene Expression, V1, P207; WANG LH, 1987, J BIOL CHEM, V262, P16080; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	56	233	234	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4152	4160						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8382695				2022-12-25	WOS:A1993KN53300054
J	ROESLER, WJ; MCFIE, PJ; PUTTICK, DM				ROESLER, WJ; MCFIE, PJ; PUTTICK, DM			EVIDENCE FOR THE INVOLVEMENT OF AT LEAST 2 DISTINCT TRANSCRIPTION FACTORS, ONE OF WHICH IS LIVER-ENRICHED, FOR THE ACTIVATION OF THE PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE PROMOTER BY CAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-PROTEIN; AMP RESPONSE ELEMENT; CYCLIC-AMP; SV40 ENHANCER; SOMATOSTATIN GENE; REGULATORY REGION; NUCLEAR-PROTEIN; ALPHA-SUBUNIT; GTP GENE; INDUCTION	A detailed analysis of the promoter sequence requirements for the cAMP induction of transcription of the gene for phosphoenolpyruvate carboxykinase (GTP) (EC 4.1.1.32) was undertaken. It was determined that the cAMP-responsive unit of this promoter consisted of two independently weak or inactive components; the typical cAMP response element (CRE) sequence located at position -85 and a region of the promoter extending from -300 to -230 which contained multiple binding sites for liver-enriched nuclear proteins. A previous study had indicated that multiple binding sites are critical for the activity of this latter region (Liu, J., Park, E. A., Gurney, A. L., Roesler, W. J., and Hanson, R. W. (1991) J. Biol. Chem. 266, 19095-19102). In the present study, we extend this observation by demonstrating that the activity of this region can be effectively substituted for by three copies of just one subsite present in that region. This would suggest that the binding of three molecules of a single liver-enriched factor is what forms this component of the cAMP response unit. The other component of the cAMP response unit, the CRE, has been shown previously to be bound by these same liver-enriched factors as well as by cAMP response element binding protein, leading to some debate as to the identity of the protein mediating the cAMP response through this element. By two different experimental approaches, we show that neither CCAAT/enhancer binding protein nor D-site binding protein is the likely mediator of the cAMP response through the CRE, while cAMP response element binding protein is a possible candidate.			ROESLER, WJ (corresponding author), UNIV SASKATCHEWAN,DEPT BIOCHEM,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA.							BOKAR JA, 1988, J BIOL CHEM, V263, P19740; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LIU JS, 1991, J BIOL CHEM, V266, P19095; LIU JS, 1990, BIOTECHNIQUES, V9, P738; MCGRANE MM, 1990, J REPROD FERTIL, P17; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NIELSEN DA, 1989, ANAL BIOCHEM, V179, P19, DOI 10.1016/0003-2697(89)90193-0; ONDEK B, 1987, EMBO J, V6, P1017, DOI 10.1002/j.1460-2075.1987.tb04854.x; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PEERS B, 1991, J BIOL CHEM, V266, P18127; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; ROESLER WJ, 1992, J BIOL CHEM, V267, P21235; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; Sambrook J, 1989, MOL CLONING LABORATO; SCHIRM S, 1987, GENE DEV, V1, P65, DOI 10.1101/gad.1.1.65; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; TRUS M, 1990, MOL CELL BIOL, V10, P2418, DOI 10.1128/MCB.10.5.2418; VANOOIJ C, 1992, MOL CELL BIOL, V12, P3023, DOI 10.1128/MCB.12.7.3023; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z	36	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3791	3796						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8381439				2022-12-25	WOS:A1993KM16100115
J	PAQUISFLUCKLINGER, V; MICHIELS, JF; VIDAL, F; ALQUIER, C; POINTIS, G; BOURDON, V; CUZIN, F; RASSOULZADEGAN, M				PAQUISFLUCKLINGER, V; MICHIELS, JF; VIDAL, F; ALQUIER, C; POINTIS, G; BOURDON, V; CUZIN, F; RASSOULZADEGAN, M			EXPRESSION IN TRANSGENIC MICE OF THE LARGE T-ANTIGEN OF POLYOMAVIRUS INDUCES SERTOLI-CELL TUMORS AND ALLOWS THE ESTABLISHMENT OF DIFFERENTIATED CELL-LINES	ONCOGENE			English	Article							C-MYC GENE; EARLY REGION; VIRUS; MOUSE; ONCOGENE; PROTEIN; INVITRO; TUMORS; TRANSFORMATION; FIBROBLASTS	The large T antigen of polyomavirus (PyLT) efficiently immortalizes rodent fibroblasts, but, unlike SV40 T antigen, it is not sufficient to achieve complete oncogenic transformation. We analysed a series of transgenic mouse families that express the PyLT protein under control of the viral enhancer-promoter region. In all of them, the transgene was expressed in the seminiferous epithelium of the testis (Sertoli and germ cells), with no pathological consequences during most of the animals' lives. However, every old male developed large bilateral tumours of the testes, generated by the proliferation of Sertoli cell derivatives. Cell lines could be readily established both from the tumours and from the still apparently normal testis before the onset of tumoral growth. They retained in vitro morphological and ultrastructural features characteristic of Sertoli cells. But, in addition to this major Sertoli component, the maintenance of a cellular contingent of germinal origin was suggested by the expression of genes that are normally transcribed during the premeiotic and early meiotic stages of spermatogenesis (LDH-X, Hox1.4 and c-kit). The two cell types remained tightly associated, even at tate passages in culture, and could not be separated by conventional cloning procedures. This association in culture of the two cell types whose interaction is critical for spermatogenesis may provide a useful toot for its molecular analysis.	FAC SCI NICE,INSERM,UNITE 273,F-06108 NICE 2,FRANCE; UNIV NICE,FAC MED,F-06100 NICE,FRANCE; FAC MED NORD,INSERM,UNITE 270,F-91007 MARSEILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			Rassoulzadegan, Minoo/O-7939-2016					ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; BAUTCH VL, 1989, MOL BIOL MED, V6, P309; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; DAWE CJ, 1987, AM J PATHOL, V127, P243; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; Finch CE, 1990, LONGEVITY SENESCENCE; FRIEDMANN T, 1979, CELL, V17, P715, DOI 10.1016/0092-8674(79)90278-2; GALIANA E, 1990, J NEUROSCI RES, V26, P269, DOI 10.1002/jnr.490260302; GALLIOT B, 1989, DEVELOPMENT, V107, P343; HADLEY MA, 1985, J CELL BIOL, V101, P1511, DOI 10.1083/jcb.101.4.1511; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HINTZ M, 1977, DEV BIOL, V57, P375, DOI 10.1016/0012-1606(77)90222-6; HOFFMAN MC, 1992, EXP CELL RES, V201, P417; HOGAN B, 1986, MANIPULATING MOUSE E; HOLLAND PWH, 1987, J CELL BIOL, V105, P473, DOI 10.1083/jcb.105.1.473; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5086; JENSEN NA, 1989, MOL BIOL MED, V6, P493; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KRIPPL B, 1988, NUCLEIC ACIDS RES, V16, P8963, DOI 10.1093/nar/16.18.8963; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Leonard Davis G., 1986, BASIC METHODS MOL BI; Maniatis T., 1982, MOL CLONING; MANOVA K, 1990, DEVELOPMENT, V110, P1057; MATHER JP, 1980, BIOL REPROD, V23, P243, DOI 10.1095/biolreprod23.1.243; MOUGNEAU E, 1988, ONCOGENE RES, V2, P177; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; PAUL D, 1988, EXP CELL RES, V175, P354, DOI 10.1016/0014-4827(88)90199-1; PESCHON JJ, 1987, P NATL ACAD SCI USA, V84, P5316, DOI 10.1073/pnas.84.15.5316; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; Russell L. D., 1990, HISTOLOGICAL HISTOPA; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; SILVER J, 1978, CELL, V15, P485, DOI 10.1016/0092-8674(78)90018-1; SOEDA E, 1979, CELL, V17, P357, DOI 10.1016/0092-8674(79)90162-4; STEINBERGER A, 1975, METHOD ENZYMOL, P283; TAHRIJOUTEI A, 1989, ENDOCRINOLOGY, V125, P605, DOI 10.1210/endo-125-2-605; TAKASE M, 1988, ENDOCRINOL JAPON, V35, P285; VANDENELSEN P, 1982, GENE, V18, P175, DOI 10.1016/0378-1119(82)90115-9; WANG R, 1991, J VIROL, V65, P5174, DOI 10.1128/JVI.65.10.5174-5183.1991; WINOCOUR E, 1963, VIROLOGY, V19, P158, DOI 10.1016/0042-6822(63)90005-9; WOLGEMUTH DJ, 1987, P NATL ACAD SCI USA, V84, P5813, DOI 10.1073/pnas.84.16.5813; ZERLIN M, 1987, ONCOGENE, V1, P19; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	44	47	49	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2087	2094						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8393161				2022-12-25	WOS:A1993LP17100008
J	SCHMIEG, FI; SIMMONS, DT				SCHMIEG, FI; SIMMONS, DT			P53 MUTANTS WITH CHANGES IN CONSERVED REGION-II - 3 CLASSES WITH DIFFERING ANTIBODY REACTIVITY, SV40-T ANTIGEN-BINDING AND ABILITY TO INHIBIT TRANSFORMATION OF RAT-CELLS	ONCOGENE			English	Article							LARGE T-ANTIGEN; WILD-TYPE P53; TUMOR SUPPRESSOR GENE; NONSPECIFIC DNA-BINDING; SIMIAN VIRUS-40; MONOCLONAL-ANTIBODY; ACTIVATING MUTATIONS; RESPONSIVE ELEMENT; PROTEINS BIND; ONCOGENE	The wild-type p53 gene is able to inhibit the ability of a number of oncogenes to induce transformation, but this inhibition is frequently lost when the p53 gene undergoes mutation. In this study, we generated mutated mouse p53 proteins containing conservative amino acid substitutions at residues 127 to 138 and at 140. The mutant proteins fell into three distinct classes. Class I proteins reacted well with PAb246 (246+), poorly with PAb240 (240-), bound to SV40 T antigen (T+), and inhibited the transformation of rat embryo fibroblasts by adenovirus E1a and activated ras. Class II proteins were 246-, 240+, T-, and failed to inhibit transformation. Class III proteins were 246+, 240-, but T-, and varied in their ability to inhibit transformation. The existence and properties of the Class III proteins suggest that the residues mutated in this class are important for binding to T antigen. They also lead us to conclude that the maintenance of an apparent wild-type structure is not sufficient for p53 to inhibit transformation and that the loss of T antigen binding does not necessarily result in loss of transformation inhibition. We propose the existence of a third activity important for the ability of p53 to inhibit transformation.			SCHMIEG, FI (corresponding author), UNIV DELAWARE,SCH LIFE & HLTH SCI,NEWARK,DE 19716, USA.				NATIONAL CANCER INSTITUTE [R55CA055234] Funding Source: NIH RePORTER; NCI NIH HHS [CA55234] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; CASEY G, 1991, ONCOGENE, V6, P1791; DEPPERT W, 1990, ONCOGENE, V5, P1701; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN HJL, 1992, J VIROL, V66, P5443, DOI 10.1128/JVI.66.9.5443-5452.1992; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; MEDCALF EA, 1992, ONCOGENE, V7, P71; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1987, ONCOGENE, V1, P453; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PROSSER J, 1990, ONCOGENE, V5, P1573; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RISSER R, 1974, VIROLOGY, V59, P477, DOI 10.1016/0042-6822(74)90457-7; RITTLING SR, 1992, ONCOGENE, V7, P935; RUGGERI B, 1991, CANCER RES, V51, P6615; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHIO Y, 1992, P NATL ACAD SCI USA, V89, P5206; SIMMONS DT, 1990, J VIROL, V64, P4858, DOI 10.1128/JVI.64.10.4858-4865.1990; SIMMONS DT, 1990, J VIROL, V64, P1973, DOI 10.1128/JVI.64.5.1973-1983.1990; SOUSSI T, 1987, ONCOGENE, V1, P71; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	52	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2043	2050						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8393158				2022-12-25	WOS:A1993LP17100003
J	KOTKOW, KJ; FURIE, B; FURIE, BC				KOTKOW, KJ; FURIE, B; FURIE, BC			THE INTERACTION OF PROTHROMBIN WITH PHOSPHOLIPID-MEMBRANES IS INDEPENDENT OF EITHER KRINGLE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; CONFORMATION-SPECIFIC ANTIBODIES; PROTEIN STRUCTURAL REQUIREMENTS; BOVINE PROTHROMBIN; BINDING-SITE; FACTOR-X; VITAMIN-K; METAL; FRAGMENT-1; REGION	Prothrombin contains two kringle domains, a structural motif common to other plasma proteins involved in hemostasis and fibrinolysis. To determine the role of the kringle domains of prothrombin, we prepared three recombinant human prothrombin forms lacking the first kringle domain (residues 63-144; PT/DELTAK1), the second kringle domain (residues 144-249; PT/ DELTAK2), or both kringle domains (63-249; PT/DELTAK1,2). The isolated prothrombin proteins were greater than 95% pure by SDS-polyacrylamide gel electrophoresis and were well carboxylated. PT/DELTAK1 displayed 50% of the specific coagulant activity of plasma prothrombin, PT/DELTAK2 had 10% of the specific coagulant activity, and PT/DELTAK1,2 was inactive. Polyclonal antibodies directed against the Ca(II)-specific conformer of prothrombin bound PT/DELTAK1 and PT/DELTAK2 with the same affinity as prothrombin, indicating that the Ca(II)-induced conformational transition does not involve sites on the prothrombin kringle domains. Gel filtration studies demonstrated that radiolabeled plasma prothrombin and all of the prothrombin kringle deletion mutants bound to phospholipid vesicles in the presence of Ca(II) but not in the presence of Mg(II) or EDTA. Relative dissociation constants of 1.10 +/- 0.75 and 0.49 +/- 0.18 muM were obtained by quasielastic light scattering for the interaction of phospholipid vesicles with plasma prothrombin and PT/DELTAK1, respectively. These data indicate that neither the first nor the second kringle domain contain unique sites for the interaction of prothrombin with phospholipid vesicles and are not required for prothrombin-phospholipid binding.	TUFTS UNIV NEW ENGLAND MED CTR, CTR HEMOSTASIS & THROMBOSIS RES, DIV HEMATOL ONCOL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL018834, R37HL018834, P01HL042443] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42443, HL18834] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BERKOWITZ P, 1992, J BIOL CHEM, V267, P4570; BLANCHARD RA, 1983, J LAB CLIN MED, V101, P242; BLOOM JW, 1978, BIOCHEMISTRY-US, V17, P4430, DOI 10.1021/bi00614a012; BOROWSKI M, 1985, J BIOL CHEM, V260, P9258; BOROWSKI M, 1986, J BIOL CHEM, V261, P4969; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; ESMON CT, 1975, J BIOL CHEM, V250, P4095; FURIE B, 1979, J BIOL CHEM, V254, P9766; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GITEL SN, 1973, P NATL ACAD SCI USA, V70, P1344, DOI 10.1073/pnas.70.5.1344; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; JORGENSEN MJ, 1987, J BIOL CHEM, V262, P6729; KAUFMAN RJ, 1982, J MOL BIOL, V159, P601, DOI 10.1016/0022-2836(82)90103-6; KAUFMAN RJ, 1986, J BIOL CHEM, V261, P9622; KOTKOW KJ, 1993, METHOD ENZYMOL, V222, P435; KUWADA M, 1983, ANAL BIOCHEM, V131, P173, DOI 10.1016/0003-2697(83)90150-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGENDRE N, 1988, BIOTECHNIQUES, V6, P154; LIM TK, 1977, BIOCHEMISTRY-US, V16, P4177, DOI 10.1021/bi00638a007; MANIATIS T, 1982, MOL CLONING LABORATO, P326; MANN KG, 1987, TRENDS BIOCHEM SCI, V12, P229, DOI 10.1016/0968-0004(87)90115-0; MCCRACKEN A A, 1984, Biotechniques, V2, P82; MIZUOCHI T, 1979, J BIOL CHEM, V254, P6419; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NELSESTUEN GL, 1974, J BIOL CHEM, V249, P6347; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P6886; PERSSON E, 1991, J BIOL CHEM, V266, P2444; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; POLLOCK JS, 1988, J BIOL CHEM, V263, P14216; PRENDERGAST FG, 1977, J BIOL CHEM, V252, P840; RATCLIFFE JV, 1993, IN PRESS J BIOL CHEM, V268; RYAN J, 1989, J BIOL CHEM, V264, P20283; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWALBE RA, 1989, J BIOL CHEM, V264, P20288; SORIANOGARCIA M, 1989, BIOCHEMISTRY-US, V28, P6805, DOI 10.1021/bi00443a004; STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730; TAI MM, 1984, J BIOL CHEM, V259, P4162; TAI MM, 1980, J BIOL CHEM, V255, P2790; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; WELSCH DJ, 1988, BIOCHEMISTRY-US, V27, P4946, DOI 10.1021/bi00413a053; WELSCH DJ, 1988, BIOCHEMISTRY-US, V27, P4939, DOI 10.1021/bi00413a052; WELSCH DJ, 1988, BIOCHEMISTRY-US, V27, P4933, DOI 10.1021/bi00413a051	44	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15633	15639						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8393451				2022-12-25	WOS:A1993LN30500048
J	MATTHIES, HJG; MILLER, RJ; PALFREY, HC				MATTHIES, HJG; MILLER, RJ; PALFREY, HC			CALMODULIN-BINDING TO AND CAMP-DEPENDENT PHOSPHORYLATION OF KINESIN LIGHT-CHAINS MODULATE KINESIN ATPASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; BOVINE BRAIN KINESIN; EXPRESS HIGH-LEVELS; SRC GENE-PRODUCT; HEAVY-CHAIN; AXONAL-TRANSPORT; KINASE-C; SUBCELLULAR-LOCALIZATION; MONOCLONAL-ANTIBODIES; ELECTRON-MICROSCOPY	Kinesin is an ubiquitous heterotetrameric microtubule-based motor which translocates membrane-bound organelles. Since organelle motility and motor protein function can be regulated by components of signaling pathways, the ability of purified bovine brain kinesin (kinesin) to be phosphorylated and to recognize calmodulin (CaM) was tested. Extensively purified ''kinesin'' was found to consist of several forms of both heavy (KHC) and light (KLC) chains. Phosphorylation of kinesin by a variety of protein kinases was examined; cAMP-dependent protein kinase (cAMP-PK) was the most active enzyme leading to the incorporation of up to 8 mol P/mol kinesin. Phosphorylation occurred predominantly on the KLCs and led to substantial acidic pl shifts. Peptide maps indicated that multiple phosphorylation sites exist on each KLC. Incubation of kinesin in vitro with protein kinase C (PKC) led to the phosphorylation of both KHCs and KLCs. In vivo phosphorylation of KHC and KLCs was demonstrated by immunoprecipitation of [P-32]-labeled kinesin from cultured rat hippocampal pyramidal neurons; kinesin phosphorylation was stimulated by 8-chlorophenylthio-cAMP or 12-O-tetradecanoylphorbol-13-acetate. Native bovine brain kinesin was shown to bind I-125-CaM by nucleotide-dependent pelleting with stable microtubules. Specific calcium-dependent binding of I-125-CaM to KLCs but not KHC was found using a ligand blotting assay. cAMP-PK phosphorylated kinesin bound I-125-CaM less well than untreated protein in both ligand blotting and microtubule-pelleting paradigms. Calcium-dependent binding of CaM to kinesin inhibited the ATPase activity of native kinesin but not of cAMP-PK phosphorylated kinesin. These results suggest that the KLCs have a regulatory function and integrate information coming from diverse signaling pathways to modulate the activity and function of kinesin.	UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA	University of Chicago			Matthies, Heinrich/B-7284-2017; Matthies, Heinrich/AAD-2375-2019	Matthies, Heinrich/0000-0003-3615-7571; Matthies, Heinrich/0000-0003-3615-7571				ADAMS RJ, 1982, NATURE, V297, P327, DOI 10.1038/297327a0; ALCAZAR A, 1988, NEUROCHEM RES, V13, P829, DOI 10.1007/BF00970750; AMOS LA, 1987, J CELL SCI, V87, P105; ANDERSON NL, 1979, ANAL BIOCHEM, V93, P312; BAUDIER J, 1987, BIOCHEMISTRY-US, V26, P2886, DOI 10.1021/bi00384a033; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BONINI NM, 1990, J CELL SCI, V95, P219; BRADY ST, 1991, NEURON, V7, P521, DOI 10.1016/0896-6273(91)90365-7; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; BREUER AC, 1992, CELL CALCIUM, V13, P249, DOI 10.1016/0143-4160(92)90013-I; BURGESS WH, 1984, J CELL BIOL, V99, P550, DOI 10.1083/jcb.99.2.550; BUSTER D, 1991, J CELL SCI, P109; COHEN P, 1988, METHOD ENZYMOL, V159, P390; COHN SA, 1987, NATURE, V328, P160, DOI 10.1038/328160a0; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; CRAIG R, 1983, NATURE, V302, P436, DOI 10.1038/302436a0; CYR JL, 1991, P NATL ACAD SCI USA, V88, P10114, DOI 10.1073/pnas.88.22.10114; DECUEVAS M, 1992, J CELL BIOL, V116, P957, DOI 10.1083/jcb.116.4.957; ELLURU RG, 1991, J CELL BIOL, V115, P389; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FLANAGAN SD, 1984, ANAL BIOCHEM, V140, P510, DOI 10.1016/0003-2697(84)90202-1; FORSCHER P, 1987, J NEUROSCI, V7, P3600; GO M, 1987, METHOD ENZYMOL, V141, P424; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GRANDORI C, 1988, J CELL BIOL, V107, P2125, DOI 10.1083/jcb.107.6.2125; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; HACKNEY DD, 1991, METHOD ENZYMOL, V196, P175; HACKNEY DD, 1991, BIOCHEM BIOPH RES CO, V174, P810, DOI 10.1016/0006-291X(91)91490-4; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HISANAGA S, 1989, CELL MOTIL CYTOSKEL, V12, P264, DOI 10.1002/cm.970120407; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; JOHNSON CS, 1990, CELL MOTIL CYTOSKEL, V16, P204, DOI 10.1002/cm.970160307; JONES PM, 1989, BIOCHEM BIOPH RES CO, V162, P998, DOI 10.1016/0006-291X(89)90772-9; KANJE M, 1981, BRAIN RES, V204, P43, DOI 10.1016/0006-8993(81)90650-8; KEMP BE, 1990, PEPTIDES PROTEIN PHO; KOSIK KS, 1990, J BIOL CHEM, V265, P3278; KUZNETSOV SA, 1989, J BIOL CHEM, V264, P589; KUZNETSOV SA, 1988, EMBO J, V7, P353, DOI 10.1002/j.1460-2075.1988.tb02820.x; KUZNETSOV SA, 1986, P NATL ACAD SCI USA, V83, P8530, DOI 10.1073/pnas.83.22.8530; LACY PE, 1975, LAB INVEST, V33, P570; LASEK RJ, 1985, NATURE, V316, P645, DOI 10.1038/316645a0; LEVITSKY DI, 1992, BIOCHEMISTRY-US, V57, P1081; LYNCH TJ, 1986, J BIOL CHEM, V261, P4212; MACRAE MB, 1990, BIOCHEM J, V271, P635, DOI 10.1042/bj2710635; MARUTA H, 1977, J BIOL CHEM, V252, P8329; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MUROFUSHI H, 1988, J BIOL CHEM, V263, P12744; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; PALFREY HC, 1987, NEUROCHEMISTRY PRACT, P161; PETRUCCI TC, 1991, J NEUROSCI, V11, P2938; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; RODIONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956, DOI 10.1073/pnas.88.11.4956; RODIONOV VI, 1990, J BIOL CHEM, V265, P5702; ROZDZIAL MM, 1986, CELL, V47, P1061, DOI 10.1016/0092-8674(86)90821-4; SAMMAK PJ, 1992, J CELL BIOL, V117, P57, DOI 10.1083/jcb.117.1.57; SANDOVAL IV, 1981, J BIOL CHEM, V256, P8795; SATOYOSHITAKE R, 1992, J BIOL CHEM, V267, P23930; SAXTON WM, 1988, P NATL ACAD SCI USA, V85, P1109, DOI 10.1073/pnas.85.4.1109; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SCHOLZ WK, 1991, J NEUROSCI, V11, P2422; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SCHROER TA, 1991, ANNU REV PHYSIOL, V53, P629, DOI 10.1146/annurev.ph.53.030191.003213; SCHULMAN H, 1984, J CELL BIOL, V99, P11, DOI 10.1083/jcb.99.1.11; SERRANO L, 1986, J BIOL CHEM, V261, P7076; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; TASH JS, 1989, CELL MOTIL CYTOSKEL, V14, P332, DOI 10.1002/cm.970140303; THEURKAUF WE, 1983, J BIOL CHEM, V258, P7883; TRYBUS KM, 1989, J CELL BIOL, V109, P2887, DOI 10.1083/jcb.109.6.2887; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALLEE RB, 1986, METHOD ENZYMOL, V134, P89; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; VANELDIK LJ, 1988, METHOD ENZYMOL, V159, P667; WAGNER MC, 1989, CELL MOTIL CYTOSKEL, V12, P195, DOI 10.1002/cm.970120403; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817; YANG JT, 1988, P NATL ACAD SCI USA, V85, P1864, DOI 10.1073/pnas.85.6.1864; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	82	100	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11176	11187						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8388385				2022-12-25	WOS:A1993LD46600069
J	REIF, K; GOUT, I; WATERFIELD, MD; CANTRELL, DA				REIF, K; GOUT, I; WATERFIELD, MD; CANTRELL, DA			DIVERGENT REGULATION OF PHOSPHATIDYLINOSITOL 3-KINASE P85-ALPHA AND P85-BETA ISOFORMS UPON T-CELL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RECEPTOR TYROSINE KINASES; ANTIGEN RECEPTOR; PHOSPHOLIPASE C-GAMMA-1; HUMAN PLATELETS; PDGF RECEPTOR; LYMPHOCYTES-T; PHOSPHORYLATION; INTERLEUKIN-2; BINDING	Phosphatidylinositol (PtdIns) 3-kinase is composed of a catalytic p110 subunit and a regulatory p85 subunit. A synthetic phosphopeptide corresponding to the kinase insert of the human PDGF beta subunit receptor and monoclonal antibodies raised against the two described p85 isoforms, p85alpha and p85beta were used to isolate PtdIns 3-kinase from human T lymphocytes. We demonstrate that T cells express both p85alpha and p85beta proteins. Both isoforms tightly associate with a p110 protein and with PtdIns 3-kinase activity in T cells. Upon triggering of the T cell antigen receptor (TCR)/CD3 complex or activation of protein kinase C (PKC) the p110 protein complexed to p85alpha becomes rapidly phosphorylated exclusively on serine residues. p85alpha does not appear to undergo a change in its basal serine phosphorylation during T cell activation. In contrast, stimulation of the TCR/CD3 complex or PKC, results in a marked and rapid increase in phosphorylation of p85beta on threonine residues. These data show that PtdIns 3-kinase can be a substrate for serine/threonine kinases in T cells. The differential phosphorylation of p85alpha and p85beta reveals the potential for divergent regulation and function of these two PtdIns 3-kinase isoforms during T cell activation.	IMPERIAL CANC RES FUND,LYMPHOCYTE ACTIVAT LAB,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND	Cancer Research UK; Ludwig Institute for Cancer Research			Reif, Karin/AAD-4692-2020	Reif, Karin/0000-0001-5490-8389				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRY N, 1989, J IMMUNOL, V143, P1407; BEVERLEY PCL, 1981, EUR J IMMUNOL, V11, P329, DOI 10.1002/eji.1830110412; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CANTRELL DA, 1988, EUR J IMMUNOL, V18, P1391, DOI 10.1002/eji.1830180914; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARTER AN, 1992, J BIOL CHEM, V267, P14563; CHAN AC, 1992, CURR OPIN IMMUNOL, V4, P246, DOI 10.1016/0952-7915(92)90072-M; COCHET C, 1991, J BIOL CHEM, V266, P637; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DAVIES AA, 1992, P NATL ACAD SCI USA, V89, P6368, DOI 10.1073/pnas.89.14.6368; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FRY MJ, 1992, BIOCHEM J, V288, P383, DOI 10.1042/bj2880383; GOUT I, 1992, BIOCHEM J, V288, P395, DOI 10.1042/bj2880395; HARLOW E, 1988, ANTIBOIDES LABORATOR; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; MERIDA I, 1991, J IMMUNOL, V147, P2202; NEL AE, 1991, J IMMUNOL, V147, P1933; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NOLAN RD, 1990, J BIOL CHEM, V265, P2441; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; RYU SH, 1990, J BIOL CHEM, V265, P17941; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Summers MD, 1987, TEXAS AGR EXP STATIO, V1555; THOMPSON PA, 1992, ONCOGENE, V7, P719; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VARTIKOVSKI L, 1969, NATURE, V342, P699; WARD SG, 1992, J BIOL CHEM, V267, P23862; WARD SG, 1992, EUR J IMMUNOL, V22, P45, DOI 10.1002/eji.1830220108; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	57	91	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10780	10788						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8388374				2022-12-25	WOS:A1993LD46600014
J	YANG, YS; RAMASWAMY, S; JAKOBY, WB				YANG, YS; RAMASWAMY, S; JAKOBY, WB			RAT-LIVER IMIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROPYRIMIDINE AMIDOHYDROLASE; PURIFICATION; ACID	Imidase, an enzyme variously identified as dihydropyrimidinase (EC 3.5.2.2), hydantoinase, dihydropyrimidine hydrase, and dihydropyrimidine amidohydrolase, has been purified to electrophoretic homogeneity from rat liver. Although a component in the chain of pyrimidine catabolism, imidase is capable of serving in a broader role that includes detoxication of xenobiotics. The enzyme catalyzes the hydrolytic cleavage of imides that range from the linear to the heterocyclic and that include hydantoins, dihydropyrimidines, and phthalimide. For some substrates, the reaction is experimentally reversible. The pH activity curves are a function of the pK(a) of the individual substrate's imino group, with cleavage favored at a pH near the respective pK(a) value. There is evidence for stereoselectivity and for stereospecificity. A mechanism is proposed for the enzyme-catalyzed reaction.	NIDDKD,BIOCHEM & METAB LAB,BLDG 10,ROOM 9N119,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BROOKS KP, 1983, ARCH BIOCHEM BIOPHYS, V226, P469, DOI 10.1016/0003-9861(83)90316-8; DUDLEY KH, 1978, DRUG METAB DISPOS, V6, P133; EADIE GS, 1949, J BIOL CHEM, V181, P449; FURBERG S, 1968, J AM CHEM SOC, V90, P469; GELLER M, 1972, BIOCHIM BIOPHYS ACTA, V287, P1, DOI 10.1016/0005-2787(72)90324-3; GRIFFITH OW, 1986, ANNU REV BIOCHEM, V55, P855, DOI 10.1146/annurev.biochem.55.1.855; Jakoby W. B, 1980, ENZYMATIC BASIS DETO; JAKOBY WB, 1990, J BIOL CHEM, V265, P20715; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MH, 1986, ARCH BIOCHEM BIOPHYS, V248, P368, DOI 10.1016/0003-9861(86)90433-9; LEE MH, 1987, ARCH BIOCHEM BIOPHYS, V259, P597, DOI 10.1016/0003-9861(87)90526-1; MAGUIRE JH, 1978, DRUG METAB DISPOS, V6, P601; MAGUIRE JH, 1978, DRUG METAB DISPOS, V6, P140; MAGUIRE JH, 1977, ANAL CHEM, V49, P292, DOI 10.1021/ac50010a028; MORIN A, 1986, Biotechnology and Applied Biochemistry, V8, P564; ROHRER DC, 1970, ACTA CRYSTALL B-STRU, VB 26, P546, DOI 10.1107/S0567740870002789; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; WALLACH DP, 1957, J BIOL CHEM, V226, P277; WIERZCHOWSKI KL, 1965, J AM CHEM SOC, V87, P4621, DOI 10.1021/ja00948a039; 1992, ENZYME NOMENCLATURE	20	43	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10870	10875						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8388376				2022-12-25	WOS:A1993LD46600026
J	FELDMAN, DA; WEINHOLD, PA				FELDMAN, DA; WEINHOLD, PA			IDENTIFICATION OF A PROTEIN COMPLEX BETWEEN CHOLINE-PHOSPHATE CYTIDYLYLTRANSFERASE AND A 112-KDA PROTEIN IN RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; CHINESE-HAMSTER OVARY; HEP G2 CELLS; PHOSPHOLIPASE-C TREATMENT; FATTY-ACIDS; PHOSPHATIDYLCHOLINE SYNTHESIS; HELA-CELLS; PHOSPHORYLCHOLINE CYTIDYLYLTRANSFERASE; IMMUNOREACTIVE CONTENT; ENDOPLASMIC-RETICULUM	Antisera raised against purified cytidylyltransferase (CT) immunoprecipitated CT activity from liver cytosol and detected the M(r) 45,000 subunit of CT on Western blots. Antisera detected a M(r) 112,000 protein on Western blots of liver cytosol. This protein was not detected in purified CT and was not detected by preimmune serum. The 112-kDa antibodies, isolated by affinity chromatography, did not immunoprecipitate CT activity. Antiserum raised against an N-terminal sequence of CT and antibodies raised against an internal sequence of CT immunoprecipitated CT activity but did not detect the 112-kDa protein. These results showed that the 112-kDa protein was not a form of CT. We concluded that the antiserum probably contained anti-idiotypic antibodies that recognized CT binding sites on the 112-kDa protein. Purified CT that was conjugated to horseradish peroxidase bound to crude 112-kDa protein immobilized on nitrocellulose. The binding was competitively reduced by purified CT and by affinity-purified antibodies to the 112-kDa protein. CT and 112-kDa protein coeluted from DEAE-Sepharose. When the putative 112-kDa protein-CT complex was chromatographed on a second DEAE-Sepharose column or on a Bio-Gel A-1.5m column, CT activity and 112-kDa protein were eluted together. Chromatography of the complex on hydroxylapatite dissociated most of the complex, producing CT free of the 112-kDa protein. We conclude that the 112-kDa protein is a CT-binding protein. The formation and/or dissociation of this complex may be important in the regulation of CT.	VET AFFAIRS MED CTR, 2215 FULLER RD, ANN ARBOR, MI 48105 USA; UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ANN ARBOR, MI 48105 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Michigan System; University of Michigan					NICHD NIH HHS [HD 02871] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD002871] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AEBERHARD EE, 1986, BIOCHIM BIOPHYS ACTA, V875, P6, DOI 10.1016/0005-2760(86)90004-4; ANDERSON KE, 1985, BIOCHIM BIOPHYS ACTA, V835, P360, DOI 10.1016/0005-2760(85)90292-9; BINION SB, 1982, J EXP MED, V156, P860, DOI 10.1084/jem.156.3.860; CHANDER A, 1988, BIOCHIM BIOPHYS ACTA, V958, P343, DOI 10.1016/0005-2760(88)90219-6; CHU AJ, 1985, BIOCHIM BIOPHYS ACTA, V834, P346, DOI 10.1016/0005-2760(85)90008-6; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P26, DOI 10.1016/0005-2760(87)90214-1; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FELDMAN DA, 1990, BIOCHIM BIOPHYS ACTA, V1045, P49, DOI 10.1016/0005-2760(90)90202-9; FELDMAN DA, 1987, J BIOL CHEM, V262, P9075; GAULTON GN, 1986, ANNU REV IMMUNOL, V4, P253, DOI 10.1146/annurev.iy.04.040186.001345; HATCH GM, 1991, BIOCHIM BIOPHYS ACTA, V1081, P25, DOI 10.1016/0005-2760(91)90245-D; JAMIL H, 1990, J BIOL CHEM, V265, P4332; JAMIL H, 1992, J BIOL CHEM, V267, P1752; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; KOHLER H, 1989, METHOD ENZYMOL, V178, P3; KOLESNICK RN, 1990, J BIOL CHEM, V265, P10900; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKINEN KK, 1982, ANAL BIOCHEM, V126, P100, DOI 10.1016/0003-2697(82)90114-2; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MOCK T, 1986, BIOCHEM CELL BIOL, V64, P413, DOI 10.1139/o86-058; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P433, DOI 10.1016/0005-2760(84)90169-3; PELECH SL, 1983, J BIOL CHEM, V258, P6782; ROONEY SA, 1990, BIOCHIM BIOPHYS ACTA, V1044, P385, DOI 10.1016/0005-2760(90)90085-C; ROONEY SA, 1986, BIOCHIM BIOPHYS ACTA, V888, P208, DOI 10.1016/0167-4889(86)90023-6; SHECHTER Y, 1984, J BIOL CHEM, V259, P6411; SLEIGHT R, 1983, J BIOL CHEM, V258, P831; SLEIGHT R, 1983, J BIOL CHEM, V258, P836; TERCE F, 1992, BIOCHEM J, V282, P333, DOI 10.1042/bj2820333; TIJBURG LBM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P1, DOI 10.1016/0005-2760(89)90206-3; UTAL AK, 1991, J BIOL CHEM, V266, P24084; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P225; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WATKINS JD, 1992, J BIOL CHEM, V267, P5686; WATKINS JD, 1990, J BIOL CHEM, V265, P2190; WEINHOLD PA, 1992, METHOD ENZYMOL, V209, P248; WEINHOLD PA, 1984, J BIOL CHEM, V259, P315; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; WEINHOLD PA, 1991, J BIOL CHEM, V266, P6093; WEINHOLD PA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P299, DOI 10.1016/0005-2760(89)90017-9	39	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3127	3135						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8381419				2022-12-25	WOS:A1993KM16100020
J	PRINZ, H; STRIESSNIG, J				PRINZ, H; STRIESSNIG, J			LIGAND-INDUCED ACCELERATED DISSOCIATION OF (+)-CIS-DILTIAZEM FROM L-TYPE CA2+ CHANNELS IS SIMPLY EXPLAINED BY COMPETITION FOR INDIVIDUAL ATTACHMENT POINTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-CHANNEL; CA-2+ CHANNELS; HIGH-AFFINITY; ACETYLCHOLINE-RECEPTOR; ALLOSTERIC REGULATION; SKELETAL-MUSCLE; BINDING-SITES; ANTAGONISTS; BRAIN; IDENTIFICATION	We have studied the kinetics of (+)-[H-3]cis-diltiazem binding to L-type Ca2+ channels. The association reaction was of the second order with a rate constant of k1 = 5.3 . 10(-5) nM-1 min-1. A dissociation rate of the first order (k-1 = 0.0022 min-1) and the monophasic equilibrium binding curve (K(D) = 42 nm) seemed to reflect the simple case of one ligand binding to one site. However, when dissociation was monitored after isotopic rather than volume dilution, the dissociation rate constant increased with the concentration of added non-radioactive (+)-cis-diltiazem. Half-logarithmic plots were linear with rate constants of 0.0058, 0.011, 0.015, and 0.020 min-1 when 3, 10, 30, and 50 muM (+)-cis-diltiazem was added, respectively. We quantitatively analyzed our experimental data in terms of three different binding models, which can account for ligand-induced accelerated dissociation: 1) the classical allosteric model of pre-existing conformational states, 2) a general reaction scheme for two sites with negative cooperativity, and 3) competition of ligands for single attachment points within one binding site. Computer fitting of the experimental data to simplified reaction schemes derived from these models revealed that all three can be used to fit our data. However, only the multipoint attachment model does not require additional structural assumptions, not even an additional binding site, and is supported by structure-activity relationship analysis of diltiazem analogues. We conclude that ligand-induced accelerated dissociation should be a widely observed phenomenon that does not prove a non-competitive binding mechanism. Instead, it can be explained with the thermodynamics of non-covalent binding, where high affinity results from the cooperative interaction of a ligand molecule with multiple attachment points.	UNIV INNSBRUCK, INST BIOCHEM PHARMAKOL, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck	PRINZ, H (corresponding author), MAX PLANCK INST MOLEK PHYSIOL, RHEINLANDDAMM 201, D-44139 DORTMUND, GERMANY.		Striessnig, Joerg/S-9334-2017	Striessnig, Joerg/0000-0002-9406-7120				BOER R, 1989, EUR J PHARM-MOLEC PH, V172, P131, DOI 10.1016/0922-4106(89)90004-7; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; CONWAY A, 1968, BIOCHEMISTRY-US, V7, P4011, DOI 10.1021/bi00851a031; DELEAN A, 1979, MOL PHARMACOL, V15, P60; DELEAN A, 1979, RECEPTORS, P143; ELBER R, 1987, SCIENCE, V235, P318, DOI 10.1126/science.3798113; ELLIS J, 1991, BIOCHEM PHARMACOL, V42, P1927, DOI 10.1016/0006-2952(91)90591-R; FEIGENBAUM P, 1988, BIOCHEM BIOPH RES CO, V154, P298, DOI 10.1016/0006-291X(88)90684-5; GLOSSMANN H, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1917; GLOSSMANN H, 1983, FEBS LETT, V160, P226, DOI 10.1016/0014-5793(83)80972-7; GLOSSMANN H, 1985, METHOD ENZYMOL, V109, P513; GLOSSMANN H, 1990, REV PHYSL BIOCH PHAR, V114, P1; GOLL A, 1984, EUR J BIOCHEM, V141, P177, DOI 10.1111/j.1432-1033.1984.tb08172.x; GRABNER M, 1991, P NATL ACAD SCI USA, V88, P727, DOI 10.1073/pnas.88.3.727; GRASSEGGER A, 1989, N-S ARCH PHARMACOL, V340, P752; HERING S, 1993, MOL PHARMACOL, V43, P820; KAISER ET, 1983, P NATL ACAD SCI USA, V80, P1137, DOI 10.1073/pnas.80.4.1137; KIMBALL SD, 1992, J MED CHEM, V35, P780, DOI 10.1021/jm00082a020; KING VF, 1989, J BIOL CHEM, V264, P5633; KING VF, 1988, J BIOL CHEM, V263, P2238; MAELICKE A, 1977, J BIOL CHEM, V252, P4811; MOEBIUS FF, 1993, MOL PHARMACOL, V43, P139; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PEDRAZZINI T, 1991, J IMMUNOL, V146, P3496; POWELLJONES CHJ, 1980, J BIOL CHEM, V255, P4001; PRINZ H, 1983, J BIOL CHEM, V258, P273; PRINZ H, 1992, BIOCHEMISTRY-US, V31, P6728, DOI 10.1021/bi00144a012; REID AA, 1990, LIFE SCI, V47, pPL77, DOI 10.1016/0024-3205(90)90531-U; REYNOLDS IJ, 1986, J PHARMACOL EXP THER, V237, P731; ROSNER AL, 1979, ARCH BIOCHEM BIOPHYS, V198, P153, DOI 10.1016/0003-9861(79)90406-5; ROTHMAN RB, 1991, MOL PHARMACOL, V39, P222; SARGENT DF, 1986, P NATL ACAD SCI USA, V83, P5774, DOI 10.1073/pnas.83.16.5774; SCHMID A, 1989, MOL PHARMACOL, V35, P766; SCHOEMAKER H, 1989, J PHARMACOL EXP THER, V248, P710; Schwyzer R, 1977, Ann N Y Acad Sci, V297, P3, DOI 10.1111/j.1749-6632.1977.tb41843.x; STAUDINGER R, 1991, J BIOL CHEM, V266, P10787; STRIESSNIG J, 1992, TRENDS RECEPTOR RES, V18, P333; STRIESSNIG J, 1991, METHODS NEUROSCI, V4, P210; VAGHY PL, 1987, J BIOL CHEM, V262, P14337; van Gunsteren W.F., 1989, COMPUTER SIMULATIONS; WALKINSHAW MD, 1980, P NATL ACAD SCI-BIOL, V77, P2400, DOI 10.1073/pnas.77.5.2400	42	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18580	18585						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8395510				2022-12-25	WOS:A1993LV65900034
J	PIPER, RC; JAMES, DE; SLOT, JW; PURI, C; LAWRENCE, JC				PIPER, RC; JAMES, DE; SLOT, JW; PURI, C; LAWRENCE, JC			GLUT4 PHOSPHORYLATION AND INHIBITION OF GLUCOSE-TRANSPORT BY DIBUTYRYL-CAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; PLASMA-MEMBRANE; INSULIN; ISOPROTERENOL; ADIPOCYTES; TRANSLOCATION; FIBROBLASTS; EXPRESSION; ADENOSINE; TERMINUS	To investigate the mechanism responsible for the inhibition of glucose transport by dibutyryl cAMP (Bt2cAMP), two different transporter isoforms (GLUT1 and GLUT4) and several GLUT1/4 chimeric transporters were expressed in Chinese hamster ovary (CHO) cells by using a Sindbis virus expression system. Bt2cAMP inhibited GLUT4-mediated 2-deoxy[H-3]glucose (2DOG) uptake by 50% but was without effect on GLUT1-mediated uptake. When the subcellular distribution of GLUT4 was assessed by quantitative immunocytochemistry, neither the overall concentration of GLUT4 nor the regional distribution of GLUT-4 within the plasma membrane was found to be altered by Bt2cAMP. Thus, inhibition of 2DOG uptake by Bt2cAMP appears to be due to a decrease in transporter activity rather than a decrease in the number of transporters exposed at the plasma membrane. By using chimeric transporters, a region of GLUT4 necessary for the inhibitory effect of Bt2cAMP was localized to the last 29 amino acids in the COOH terminus. This intracellular region contains the site (Ser488) phosphorylated in vitro by cAMP-dependent protein kinase (cAdPK). Changing Ser488 to an Ala abolished phosphorylation of GLUT4; however, the inhibitory effect of Bt2cAMP on glucose transport was not diminished by this mutation. Therefore, phosphorylation of GLUT4 was not required for the inhibition. The effects of other nucleotides on GLUT4 transport activity were assessed to investigate the role of cAdPK. Uptake of 2DOG by GLUT4 was inhibited by 8-bromo-AMP, but not by 8-bromo-cAMP, suggesting that the inhibitory effect did not involve activation of cAdPK. Results consistent with this interpretation were obtained with CHO cells (line 10248), which express a cAdPK that is resistant to activation by cAMP. No difference in the concentrations of Bt2cAMP required to inhibit GLUT4-mediated transport was observed in normal CHO cells and 10248 cells. The results presented suggest that the inhibitory effects of Bt2cAMP could be mediated by direct binding of a nucleotide to GLUT4 at a site involving the intracellular COOH terminus of the transporter.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,BOX 8103,660 S EUCLID AVE,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; UNIV UTRECHT,DEPT CELL BIOL,3584 CX UTRECHT,NETHERLANDS	Washington University (WUSTL); Washington University (WUSTL); Utrecht University				James, David/0000-0001-5946-5257; Piper, Robert/0000-0001-9995-5699	NIDDK NIH HHS [DK42503, DK28312] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312, R01DK042503] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CARRUTHERS A, 1989, BIOCHEMISTRY-US, V28, P8337, DOI 10.1021/bi00447a011; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GOODYEAR LJ, 1990, AM J PHYSIOL, V258, pE667, DOI 10.1152/ajpendo.1990.258.4.E667; Hepp D., 1970, HORM METAB RES, V2, P76; HERBERT DN, 1986, J BIOL CHEM, V261, P10093; HONNOR RC, 1992, CELL SIGNAL, V4, P87, DOI 10.1016/0898-6568(92)90010-6; HUDSON AW, 1992, J CELL BIOL, V116, P785, DOI 10.1083/jcb.116.3.785; JAMES DE, 1989, P NATL ACAD SCI USA, V86, P8368, DOI 10.1073/pnas.86.21.8368; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JOOST HG, 1987, J BIOL CHEM, V262, P11261; KAHN BB, 1991, J CLIN INVEST, V87, P561, DOI 10.1172/JCI115031; KATAGIRI H, 1992, J BIOL CHEM, V267, P22550; KELADA ASM, 1992, J BIOL CHEM, V267, P7021; KURODA M, 1987, J BIOL CHEM, V262, P245; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE JC, 1990, J BIOL CHEM, V265, P2324; LAWRENCE JC, 1992, P NATL ACAD SCI USA, V89, P3493, DOI 10.1073/pnas.89.8.3493; LEVIS R, 1990, J VIROL, V64, P1726, DOI 10.1128/JVI.64.4.1726-1733.1990; NISHIMURA H, 1991, P NATL ACAD SCI USA, V88, P11500, DOI 10.1073/pnas.88.24.11500; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; PIPER RC, 1992, J CELL BIOL, V117, P729, DOI 10.1083/jcb.117.4.729; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; PLOUG T, 1992, AM J PHYSIOL, V262, pE700, DOI 10.1152/ajpendo.1992.262.5.E700; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P771; SHANAHAN MF, 1986, BIOCHIM BIOPHYS ACTA, V887, P121, DOI 10.1016/0167-4889(86)90132-1; SHIBASAKI Y, 1992, BIOCHEM J, V281, P829, DOI 10.1042/bj2810829; SILVERMAN M, 1991, ANNU REV BIOCHEM, V60, P757, DOI 10.1146/annurev.bi.60.070191.003545; SINGH TJ, 1985, J BIOL CHEM, V260, P3927; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SLOT JW, 1991, P NATL ACAD SCI USA, V77, P2542; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; SUTHERLAND EW, 1960, PHARMACOL REV, V12, P265; XIONG C, 1989, SCIENCE, V243, P1181; YONG DA, 1985, AM J PHYSIOL, V248, pC406	36	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16557	16563						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8393869				2022-12-25	WOS:A1993LQ33600069
J	LUSKY, M; HURWITZ, J; SEO, YS				LUSKY, M; HURWITZ, J; SEO, YS			COOPERATIVE ASSEMBLY OF THE BOVINE PAPILLOMA-VIRUS E1 AND E2 PROTEINS ON THE REPLICATION ORIGIN REQUIRES AN INTACT E2 BINDING-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; T-ANTIGEN; VIRAL ORIGIN; IDENTIFICATION; ACTIVATION; AFFINITY; INVITRO; COMPLEX; TYPE-1; CELLS	Using quantitative gel retardation assays the properties of the bovine papilloma virus (BPV) origin recognition protein E1 and the effect of the viral E2 protein on the binding of E1 to BPV origin DNA were examined. As reported previously (Seo, Y. S., Mueller, F., Lusky, M., Gibbs, E., Kim, H.-Y., Phillips, B. and J. Hurwitz (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2865-2869), the E1 protein binds specifically to DNA sequences within the BPV origin (ori+) of replication. We also show that the presence Of MgCl2 and ATP could stabilize the E1.ori+ DNA complex. At low levels of E1, ori+ DNA binding was greatly stimulated by the viral E2 protein when the intact E2 binding site 12 was present on the DNA. In addition DNA-protein complexes formed in the presence of both E1 and E2 were more stable than those formed with E1 alone. In the absence of an E2 binding site the E2 protein inhibited the binding of E1 to the BPV origin. Spacing of 0 or 9 base pairs between the E1 binding site and the E2 binding site 12 abolished the stimulation of E1-DNA binding by E2, whereas spacing of 6 base pairs between the two binding sites allowed for efficient stimulation. The data presented account for a direct role of E2 in BPV DNA replication. We propose that the cooperative binding of both the E1 and E2 proteins to BPV ori+ DNA is mediated by protein-protein interactions and by protein-DNA interactions, which include the formation of specific contacts of E2 with DNA.	MEM SLOAN KETTERING CANC CTR,GRAD PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center	LUSKY, M (corresponding author), CORNELL UNIV,GRAD SCH MED SCI,HEARST MICROBIOL RES CTR,DEPT MICROBIOL,NEW YORK,NY 10021, USA.		Seo, Yeonsoo/C-1605-2011		NATIONAL CANCER INSTITUTE [R01CA051127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034559, R01GM034559] Funding Source: NIH RePORTER; NCI NIH HHS [5R0 CA51127-01] Funding Source: Medline; NIGMS NIH HHS [GM 34559] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLITZ IL, 1991, J VIROL, V65, P643; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; DEAN FB, 1992, J BIOL CHEM, V267, P14129; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; LUSKY M, 1991, P NATL ACAD SCI USA, V88, P6363, DOI 10.1073/pnas.88.14.6363; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MECSAS J, 1987, ANNU REV CELL BIOL, V3, P87, DOI 10.1146/annurev.cb.03.110187.000511; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; SANTUCCI S, 1990, J VIROL, V64, P6027, DOI 10.1128/JVI.64.12.6027-6039.1990; SEO YS, 1993, P NATL ACAD SCI USA, V90, P2865, DOI 10.1073/pnas.90.7.2865; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; SUN S, 1990, J VIROL, V64, P5093, DOI 10.1128/JVI.64.10.5093-5105.1990; USTAV M, 1991, EMBO J, V10, P4321, DOI 10.1002/j.1460-2075.1991.tb05010.x; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; WILSON VG, 1991, J VIROL, V65, P5314, DOI 10.1128/JVI.65.10.5314-5322.1991; WINOKUR PL, 1992, EMBO J, V11, P4111, DOI 10.1002/j.1460-2075.1992.tb05504.x; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0	21	67	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15795	15803						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8393453				2022-12-25	WOS:A1993LN30500070
J	RASMUSSEN, UB; GACHET, C; SCHLESINGER, Y; HANAU, D; OHLMANN, P; VANOBBERGHENSCHILLING, E; POUYSSEGUR, J; CAZENAVE, JP; PAVIRANI, A				RASMUSSEN, UB; GACHET, C; SCHLESINGER, Y; HANAU, D; OHLMANN, P; VANOBBERGHENSCHILLING, E; POUYSSEGUR, J; CAZENAVE, JP; PAVIRANI, A			A PEPTIDE LIGAND OF THE HUMAN THROMBIN RECEPTOR ANTAGONIZES ALPHA-THROMBIN AND PARTIALLY ACTIVATES PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISMS; CLONING; ENTRY	The peptide YFLLRNP antagonizes the aggregation of human platelets when induced by low concentrations of alpha-thrombin or the thrombin receptor agonist peptide (SFLLRNP), demonstrating that it interacts specifically with the thrombin receptor. Platelets exposed to YFLLRNP show immediate shape change (pseudopod formation) and potentiation of the ADP and platelet-activating factor response, but no Ca2+ mobilization, P47 (pleckstrin) phosphorylation, secretion, or aggregation. Thus, YFLLRNP induces a state of partial activation of the platelets. Furthermore, with platelets prestimulated with adrenalin (10 muM), YFLLRNP induces aggregation, but no secretion, and only in the presence of added fibrinogen. We also found that prostacyclin inhibits the YFLLRNP-induced shape change; but EDTA, aspirin, and apyrase (ADP scavenger) do not. Thus, the thrombin receptor in platelets may communicate, independently of Ca2+ mobilization and P47 phosphorylation (protein kinase C activation), with intracellular signaling mechanisms that 1) modulate the cytoskeleton structure, 2) potentiate other platelet responses, and 3) stimulate coupling between the thrombin receptor and fibrinogen binding (the glycoprotein IIb-IIIa complex). YFLLRNP may be useful for differentiating between several possible activation states of the platelet thrombin receptor.	CTR REG TRANSFUS SANGUINE,INSERM,U311,HISTOCOMPATIBIL LAB,F-67085 STRASBOURG,FRANCE; CTR BIOCHIM,CNRS,INSERM,F-06108 NICE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	RASMUSSEN, UB (corresponding author), TRANSGENE SA,DEPT MOLEC & CELLULAR BIOL,11 RUE MOLSHEIM,F-67082 STRASBOURG,FRANCE.		Gachet, Christian/H-9156-2016; Van Obberghen-Schilling, Ellen/O-1581-2016; Van Obberghen-Schilling, Ellen/Q-4372-2019; Cazenave, Jean-Pierre/AAE-2935-2019	Van Obberghen-Schilling, Ellen/0000-0003-2961-0059; Van Obberghen-Schilling, Ellen/0000-0003-2961-0059; 				BRASS LF, 1992, J BIOL CHEM, V267, P6044; CAZENAVE JP, 1983, ANN BIOL CLIN-PARIS, V41, P167; CHAO BH, 1992, BIOCHEMISTRY-US, V31, P6175, DOI 10.1021/bi00142a001; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; GACHET C, 1991, NOUV REV FR HEMATOL, V33, P347; GRABAREK J, 1992, J BIOL CHEM, V267, P10011; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HERBERT JM, 1992, FEBS LETT, V301, P155, DOI 10.1016/0014-5793(92)81237-G; HOLLENBERG MD, 1992, MOL PHARMACOL, V42, P186; HUANG RS, 1991, J BIOL CHEM, V266, P18435; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; LANZA F, 1988, EUR J BIOCHEM, V255, pH1276; LAPETINA EG, 1990, FEBS LETT, V268, P400, DOI 10.1016/0014-5793(90)81293-W; MERRITT JE, 1988, J BIOL CHEM, V263, P6161; MOLNAR J, 1961, ARCH BIOCHEM BIOPHYS, V93, P353, DOI 10.1016/0003-9861(61)90278-8; NEYLON CB, 1991, J BIOL CHEM, V266, P4251; NGAIZA JR, 1991, BIOCHEM BIOPH RES CO, V179, P165; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SEILER SM, 1992, BIOCHEM BIOPH RES CO, V182, P1296, DOI 10.1016/0006-291X(92)91873-O; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; TROYER D, 1992, J BIOL CHEM, V267, P20126; VANOBBERGHENSCH.E, 1993, IN PRESS BIOCH J; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VOURETCRAVIARI E, 1993, BIOCHEM J, V289, P209; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; ZHONG CZ, 1992, J BIOL CHEM, V267, P16975	33	78	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14322	14328						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8390990				2022-12-25	WOS:A1993LJ82500079
J	ROCA, J; BERGER, JM; WANG, JC				ROCA, J; BERGER, JM; WANG, JC			ON THE SIMULTANEOUS BINDING OF EUKARYOTIC DNA TOPOISOMERASE-II TO A PAIR OF DOUBLE-STRANDED DNA HELICES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER; SUPERCOILED DNA; DUPLEX DNA; RELAXATION; SITES; RINGS	Stabilization of crossings of pairs of DNA helices by binding of eukaryotic DNA topoisomerase II was studied by two types of experiments. In one, mixtures of yeast DNA topoisomerase II and supercoiled DNA were incubated with vaccinia virus topoisomerase, and the linking numbers of the DNA products were measured to quantitate supercoils that were constrained by the stoichiometrically bound yeast enzyme molecules; in parallel, the same yeast enzyme-supercoiled DNA mixtures were incubated with a nonhydrolyzable ATP analog AMPPNP (adenosine 5'-(beta,gamma-imido)triphosphate) instead of the vaccinia enzyme, and DNA linking number changes following the addition of AMPPNP were measured to monitor DNA transport mediated by the yeast enzyme and AMPPNP. In the second type of experiments, formation of knotted DNA rings by the addition of AMPPNP to mixtures of yeast DNA topoisomerase II and different topological forms of DNA rings was studied. These experiments indicate that binding of yeast DNA topoisomerase II to DNA crossings is significant, especially in low salt media containing Mg(II), and that this mode of binding strongly affects DNA knotting. It appears, however, that stabilization of DNA crossovers by the eukaryotic type II enzyme is not directly related to its DNA transport activity.	HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA	Harvard University				Roca, Joaquim/0000-0003-1462-954X	NIGMS NIH HHS [GM 24544] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024544, R01GM024544] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; ANNAN NK, 1992, NUCLEIC ACIDS RES, V20, P983, DOI 10.1093/nar/20.5.983; BARZILAI R, 1973, J MOL BIOL, V74, P739, DOI 10.1016/0022-2836(73)90062-4; BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; CARON PR, 1993, MOL BIOL DNA TOPOISO, P2; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; HSIEH T, 1983, J BIOL CHEM, V258, P8413; HSIEH TS, 1980, CELL, V21, P115, DOI 10.1016/0092-8674(80)90119-1; HSIEH TS, 1975, BIOCHEMISTRY-US, V14, P527, DOI 10.1021/bi00674a011; Hsieh TS, 1990, DNA TOPOLOGY ITS BIO, P243; KREUZER KN, 1983, BACTERIOPHAGE T4, P90; LEE MP, 1989, J BIOL CHEM, V264, P21779; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LIU LF, 1980, CELL, V19, P697, DOI 10.1016/S0092-8674(80)80046-8; LIU LF, 1976, J MOL BIOL, V106, P439, DOI 10.1016/0022-2836(76)90095-4; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P6402, DOI 10.1021/bi00394a015; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; OSHEROFF N, 1983, MECHANISMS DNA REPLI, P55; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; SANDER M, 1987, J MOL BIOL, V194, P219, DOI 10.1016/0022-2836(87)90370-6; WANG JC, 1982, COLD SPRING HARB SYM, V47, P85, DOI 10.1101/SQB.1983.047.01.011; WASSERMAN SA, 1991, J BIOL CHEM, V266, P20567; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x	28	82	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14250	14255						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8390987				2022-12-25	WOS:A1993LJ82500069
J	MARINI, S; GIARDINA, B; FASCIGLIONE, GF; FINAZZIAGRO, A				MARINI, S; GIARDINA, B; FASCIGLIONE, GF; FINAZZIAGRO, A			MONOCLONAL-ANTIBODY RECOGNIZES DIFFERENT QUINONE MOIETIES IN ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA AMINE OXIDASE; PYRROLOQUINOLINE QUINONE; METHYLAMINE DEHYDROGENASE; ACTIVE-SITE; PURIFICATION; 6-HYDROXYDOPA; COFACTOR; ASSAY	We produced monoclonal antibodies against the coenzyme pyrrolequinoline quinone (PQQ). These antibodies were obtained by immunizing mice with PQQ conjugated to a chemically modified polypeptide in order to induce a strong immune response. Among the various antibodies obtained, one was found to bind (besides PQQ and 6-hydroxydopamine conjugated to carrier proteins) several different quinoenzymes, namely lentil seedling and bovine serum diamine oxidases and methylamine dehydrogenase. This antibody was able to inhibit the catalytic activity of these enzymes. Moreover, the monoclonal antibody recognized different proteins of lentil seeds on Western blots. Even the variable fragment of immunoglobulin heavy chains of this monoclonal antibody expressed in Escherichia coli is able to recognize the active site of different quinoenzymes.	UNIV CATTOLICA SACRO CUORE, INST CHEM, I-00168 ROME, ITALY	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	MARINI, S (corresponding author), TOR VERGATA UNIV ROME, DEPT EXPTL MED & BIOCHEM SCI, ROME, ITALY.		Fasciglione, Giovanni Francesco/ABF-7738-2020; Marini, Stefano/B-1161-2012	Marini, Stefano/0000-0003-1299-6696				ANTHONY C, 1967, BIOCHEM J, V104, P960, DOI 10.1042/bj1040960; ANTHONY C, 1967, BIOCHEM J, V104, P953, DOI 10.1042/bj1040953; AVIGLIANO L, 1972, ITAL J BIOCHEM, V21, P248; BROWN DE, 1991, J BIOL CHEM, V266, P4049; CITRO G, 1989, FEBS LETT, V247, P201, DOI 10.1016/0014-5793(89)81334-1; DUINE JA, 1987, ADV ENZYMOL RAMB, V59, P169; FLORIS G, 1983, PHYTOCHEMISTRY, V22, P1871, DOI 10.1016/0031-9422(83)80004-1; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; HILVERT D, 1988, P NATL ACAD SCI USA, V85, P4953, DOI 10.1073/pnas.85.14.4953; IKEGAKI N, 1989, J IMMUNOL METHODS, V124, P205, DOI 10.1016/0022-1759(89)90354-2; IVERSON BL, 1989, SCIENCE, V243, P1184, DOI 10.1126/science.2922606; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KILLGORE J, 1989, SCIENCE, V245, P850, DOI 10.1126/science.2549636; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KUMAZAWA T, 1990, ARCH BIOCHEM BIOPHYS, V283, P533, DOI 10.1016/0003-9861(90)90679-S; MARINI S, 1988, HYBRIDOMA, V7, P193, DOI 10.1089/hyb.1988.7.193; MARINI S, 1989, J IMMUNOL METHODS, V120, P57, DOI 10.1016/0022-1759(89)90289-5; MARINI S, 1989, BIOL CHEM H-S, V370, P1085, DOI 10.1515/bchm3.1989.370.2.1085; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; NEOH SH, 1986, J IMMUNOL METHODS, V91, P231, DOI 10.1016/0022-1759(86)90483-7; ROBERTS VA, 1990, P NATL ACAD SCI USA, V87, P6654, DOI 10.1073/pnas.87.17.6654; ROBERTSON JG, 1989, J BIOL CHEM, V264, P19916; TURINI P, 1982, ANAL BIOCHEM, V125, P294, DOI 10.1016/0003-2697(82)90009-4; VELLIEUX FMD, 1986, EUR J BIOCHEM, V154, P383, DOI 10.1111/j.1432-1033.1986.tb09409.x; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0	26	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13352	13355						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8390461				2022-12-25	WOS:A1993LH55300050
J	YOO, JK; ZENG, HW; JI, IH; MURDOCH, WJ; JI, TH				YOO, JK; ZENG, HW; JI, IH; MURDOCH, WJ; JI, TH			COOH-TERMINAL AMINO-ACIDS OF THE ALPHA-SUBUNIT PLAY COMMON AND DIFFERENT ROLES IN HUMAN CHORIOGONADOTROPIN AND FOLLITROPIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; AFFINITY HORMONE BINDING; BETA-SUBUNIT; LUTEINIZING-HORMONE; GLYCOPROTEIN HORMONES; BIOLOGICAL-ACTIVITY; SYNTHETIC PEPTIDES; LUTROPIN RECEPTOR; REGION; SITE	Human choriogonadotropin (hCG) and follitropin (FSH) belong to the glycoprotein hormone family. These hormones are heterodimers and composed of a common alpha subunit and a distinct beta subunit which confers receptor-binding specificities. In addition to this structural similarity, they share a similar signal pathway involving G protein, adenylylcyclase and induction of cAMP synthesis. Therefore, a presumptive relationship of these common structure and function has been the subject of extensive past investigations, but a definitive clue has been elusive. As a step to address this important issue, a series of recombinant mutants of hCG and human FSH were generated in which the COOH-terminal amino acids of the alpha subunit were successively removed or substituted. Furthermore, a set of peptides were synthesized with sequences corresponding to different regions of the alpha subunit. Deletion of the alpha COOH-terminal Ser92 had no effect on receptor-binding or cAMP induction by FSH and hCG. Truncation of alphaLys91-Ser92 or alphaHis90-Lys91-Ser92 abolished the ability of both hormones to induce cAMP synthesis. It significantly reduced receptor binding of FSH but not hCG. The different functions of the alpha COOH-terminal region are further noticed with a peptide corresponding to the last 10 amino acids of alpha. It failed to bind to the FSH receptor but was capable of binding to the LH/CG receptor and stimulating cAMP synthesis. These results are the first conclusive evidence that alphaHis90-Lys91 play an essential role in cAMP induction of both hormones. In contrast to this common role, they are necessary for FSH binding to the FSH receptor but not for hCG binding to the LH/CG receptor. The hCGalpha COOH-terminal region makes direct contact with the LH/CG receptor, and this low affinity contact is necessary and sufficient to activate the receptor for signal generation. This conclusion is supported by the study using mutant hCGs in which either alphaHis90 or Lys91 was substituted.			YOO, JK (corresponding author), UNIV WYOMING, DEPT MOLEC BIOL, LARAMIE, WY 82071 USA.				NICHD NIH HHS [HD-18702] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018702] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BURLEIGH BD, 1976, J BIOL CHEM, V251, P308; CHARLESWORTH MC, 1987, J BIOL CHEM, V262, P13409; CHEN F, 1992, MOL ENDOCRINOL, V6, P914, DOI 10.1210/me.6.6.914; CHEN F, 1991, J BIOL CHEM, V266, P6904; CHENG KW, 1973, J BIOL CHEM, V248, P7930; COLOMA TAS, 1990, J BIOL CHEM, V265, P5037; COMBARNOUS Y, 1974, EUR J BIOCHEM, V42, P13, DOI 10.1111/j.1432-1033.1974.tb03308.x; EGGLESTON DL, 1990, PROSTAGLANDINS, V39, P675, DOI 10.1016/0090-6980(90)90027-S; FIDDES JC, 1979, NATURE, V281, P351, DOI 10.1038/281351a0; FIDDES JC, 1980, NATURE, V286, P684, DOI 10.1038/286684a0; GRASSO P, 1991, ENDOCRINOLOGY, V128, P2745, DOI 10.1210/endo-128-6-2745; Harlow ED, 1988, ANTIBODIES LABORATOR, P578; JAMESON JL, 1988, MOL ENDOCRINOL, V2, P806, DOI 10.1210/mend-2-9-806; JANIN J, 1990, J BIOL CHEM, V265, P16027; JI I, 1991, J BIOL CHEM, V266, P13076; JI I, 1981, P NATL ACAD SCI-BIOL, V78, P5465, DOI 10.1073/pnas.78.9.5465; JI I, 1989, J BIOL CHEM, V260, P12815; JI I, 1990, GLYCOPROTEIN HORMONE, P355; JI IH, 1991, J BIOL CHEM, V266, P14953; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; KEUTMANN HT, 1987, P NATL ACAD SCI USA, V84, P2038, DOI 10.1073/pnas.84.7.2038; KRICHEVSKY A, 1988, ENDOCRINOLOGY, V123, P584, DOI 10.1210/endo-123-1-584; LIU WK, 1976, J BIOL CHEM, V251, P316; LIU WK, 1974, J BIOL CHEM, V249, P5544; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; MERZ WE, 1979, EUR J BIOCHEM, V101, P541, DOI 10.1111/j.1432-1033.1979.tb19749.x; MISE T, 1980, J BIOL CHEM, V255, P8516; MORGAN FJ, 1975, J BIOL CHEM, V250, P5247; MOYLE WR, 1982, P NATL ACAD SCI-BIOL, V79, P2245, DOI 10.1073/pnas.79.7.2245; MOYLE WR, 1990, J BIOL CHEM, V265, P8511; PARSONS TF, 1985, METHOD ENZYMOL, V109, P736; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; Sambrook J, 1989, MOL CLONING LABORATO; SHIN J, 1985, J BIOL CHEM, V260, P4020; SHIN J, 1985, J BIOL CHEM, V260, P2822; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; XIE YB, 1990, J BIOL CHEM, V265, P21411; YOO J, 1991, J BIOL CHEM, V266, P17741; [No title captured]	39	61	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13034	13042						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8390451				2022-12-25	WOS:A1993LH55300007
J	PEEBLES, CL; BELCHER, SM; ZHANG, M; DIETRICH, RC; PERLMAN, PS				PEEBLES, CL; BELCHER, SM; ZHANG, M; DIETRICH, RC; PERLMAN, PS			MUTATION OF THE CONSERVED 1ST-NUCLEOTIDE OF A GROUP-II INTRON FROM YEAST MITOCHONDRIAL-DNA REDUCES THE RATE BUT ALLOWS ACCURATE SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; SITE SELECTION; BRANCH POINT; OLI2 REGION; U1 SNRNA; GENE; SPLICEOSOME; SEQUENCES; LARIAT	Group II introns have a phylogenetically conserved, 5'-terminal pentanucleotide, -G1U2G3C4G5-, that resembles the conserved 5' end sequence of nuclear pre-mRNA introns. No functional interaction or catalytic role for the conserved G1 position has been proposed, although a tertiary structure involving -G3C4- has been implicated in splicing in vitro. We have analyzed splicing phenotypes both in vitro and in vivo for all three point mutants affecting guanosine at position 1 (G1) of intron 5gamma from the COXI gene of yeast mitochondrial DNA. While all of these G1N substitutions slow splicing in vitro, G1C is clearly the most defective. All three mutant transcripts splice as accurately as the wild-type transcript, although the yield of lariat intron is reduced. The branched trinucleotide core includes the mutated position 1 nucleotide linked to the canonical branchpoint adenosine. The mutant lariats vary significantly in their susceptibility to the debranching activity from human cells. After wild-type, G1A was most sensitive, G1U was somewhat resistant, while G1C was highly resistant to debranching. These mutant lariats had normal ribozyme activity for promoting spliced exon reopening. The three mutant introns were transformed into otherwise normal yeast mitochondrial DNA. These mutants grow on nonfermentable carbon sources and splice aI5gamma to yield excised intron lariat and mRNA.. Nonetheless, each mutant splices with reduced efficiency, roughly parallel to their in vitro activity. In vivo, all three mutants accumulate both the pre-mRNA retaining intron 5gamma and the lariat splicing intermediate containing intron and 3' exon. Clearly, this primary sequence element, shared with nuclear pre-mRNA introns, has a very different functional significance in group II splicing.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH 43210	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University System of Ohio; Ohio State University	PEEBLES, CL (corresponding author), UNIV PITTSBURGH,DEPT BIOL SCI,PITTSBURGH,PA 15260, USA.			Belcher, Scott/0000-0002-1196-3705	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031480] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31480] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; ANZIANO PQ, 1991, P NATL ACAD SCI USA, V88, P5592, DOI 10.1073/pnas.88.13.5592; ARENAS J, 1987, J BIOL CHEM, V262, P4274; ARNBERG AC, 1980, CELL, V19, P313, DOI 10.1016/0092-8674(80)90505-X; BONITZ SG, 1980, J BIOL CHEM, V255, P1927; CHAPMAN KB, 1991, CELL, V65, P483, DOI 10.1016/0092-8674(91)90466-C; COBON GS, 1982, CURR GENET, V5, P97, DOI 10.1007/BF00365700; CONRADWEBB H, 1990, NUCLEIC ACIDS RES, V18, P1369, DOI 10.1093/nar/18.6.1369; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; FELBER BK, 1982, CELL, V29, P895, DOI 10.1016/0092-8674(82)90451-2; FOUSER LA, 1986, CELL, V45, P81, DOI 10.1016/0092-8674(86)90540-4; FOX TD, 1988, P NATL ACAD SCI USA, V85, P7288, DOI 10.1073/pnas.85.19.7288; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HALBREICH A, 1980, CELL, V19, P321, DOI 10.1016/0092-8674(80)90506-1; HARRISKERR CL, 1992, THESIS U PITTSBURGH; HARTMUTH K, 1988, MOL CELL BIOL, V8, P2011, DOI 10.1128/MCB.8.5.2011; HENSGENS LAM, 1983, J MOL BIOL, V164, P35, DOI 10.1016/0022-2836(83)90086-4; HENSGENS LAM, 1983, CELL, V32, P379, DOI 10.1016/0092-8674(83)90457-9; JACQUIER A, 1990, J MOL BIOL, V213, P437, DOI 10.1016/S0022-2836(05)80206-2; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; JACQUIER A, 1986, P NATL ACAD SCI USA, V83, P5835, DOI 10.1073/pnas.83.16.5835; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; JARRELL KA, 1988, J BIOL CHEM, V263, P3432; JOHNSTON SA, 1988, SCIENCE, V240, P1538, DOI 10.1126/science.2836954; KONARSKA MM, 1985, NATURE, V313, P552, DOI 10.1038/313552a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; NEWMAN AJ, 1985, CELL, V42, P335, DOI 10.1016/S0092-8674(85)80129-X; NOVITSKI CE, 1984, CURR GENET, V8, P135, DOI 10.1007/BF00420226; PARKER R, 1985, CELL, V41, P107, DOI 10.1016/0092-8674(85)90065-0; PEEBLES CL, 1987, COLD SPRING HARB SYM, V52, P223, DOI 10.1101/SQB.1987.052.01.027; PEEBLES CL, 1986, CELL, V44, P213, DOI 10.1016/0092-8674(86)90755-5; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SERAPHIN B, 1990, CELL, V63, P619, DOI 10.1016/0092-8674(90)90457-P; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; TREISMAN R, 1982, CELL, V29, P903, DOI 10.1016/0092-8674(82)90452-4; VANDERVEEN R, 1986, CELL, V44, P225, DOI 10.1016/0092-8674(86)90756-7; VIJAYRAGHAVAN U, 1986, EMBO J, V5, P1683, DOI 10.1002/j.1460-2075.1986.tb04412.x; WEBER S, 1987, NUCLEIC ACIDS RES, V16, P471; WIERINGA B, 1983, NATURE, V301, P38, DOI 10.1038/301038a0	45	34	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11929	11938						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8389367				2022-12-25	WOS:A1993LF28400071
J	VANHOVE, GF; VANVELDHOVEN, PP; FRANSEN, M; DENIS, S; EYSSEN, HJ; WANDERS, RJA; MANNAERTS, GP				VANHOVE, GF; VANVELDHOVEN, PP; FRANSEN, M; DENIS, S; EYSSEN, HJ; WANDERS, RJA; MANNAERTS, GP			THE COA ESTERS OF 2-METHYL-BRANCHED CHAIN FATTY-ACIDS AND OF THE BILE-ACID INTERMEDIATES DIHYDROXYCOPROSTANIC AND TRIHYDROXYCOPROSTANIC ACIDS ARE OXIDIZED BY ONE SINGLE PEROXISOMAL BRANCHED-CHAIN ACYL-COA OXIDASE IN HUMAN LIVER AND KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; BETA-OXIDATION; ZELLWEGER SYNDROME; DEFICIENCY; PROTEINS; DISORDER; ENZYMES; POLYACRYLAMIDE; GELS	Rat liver peroxisomes contain three acyl-CoA oxidases: palmitoyl-CoA oxidase, which oxidizes the CoA esters of straight chain fatty acids and prostaglandins; pristanoyl-CoA oxidase, which oxidizes the CoA esters of 2-methyl-branched fatty acids (e.g. pristanic acid); and trihydroxycoprostanoyl-CoA oxidase, which oxidizes the CoA esters of the bile acid intermediates di- and trihydroxycoprostanic acids (Van Veldhoven, P. P., Vanhove, G., Asselberghs, S., Eyssen, H. J., and Mannaerts, G. P. (1992) J. Biol. Chem. 267, 20065-20074). In the present report we demonstrate that human liver peroxisomes contain only two acyl-CoA oxidases: palmitoyl-CoA oxidase, which oxidizes the CoA esters of straight chain fatty acids and prostaglandins, and a novel branched chain acyl-CoA oxidase, which oxidizes the CoA esters of 2-methyl-branched fatty acids as well as those of the bile acid intermediates (which also possess a 2-methyl substitution in their side chains). The branched chain acyl-CoA oxidase was purified to near homogeneity by means of column chromatography. It appeared to be a 70-kDa monomeric protein that did not cross-react with antisera raised against rat palmitoyl-CoA oxidase and pristanoyl-CoA oxidase. No indication was found for the presence of a separate trihydroxycoprostanoyl-CoA oxidase in human liver. The branched chain acyl-CoA oxidase was present also in human kidney, suggesting that it is expressed in other extrahepatic tissues as well. Our results explain a number of clinical-chemical observations made in certain cases of peroxisomal beta-oxidation disorders.	CATHOLIC UNIV LEUVEN, DEPT PHARMACOL, AFDELING FARMACOL, CAMPUS GASTHUISBERG O&N, B-3000 LOUVAIN, BELGIUM; REGA INST, B-3000 LOUVAIN, BELGIUM; UNIV HOSP AMSTERDAM, DEPT CLIN BIOCHEM, 1105 AZ AMSTERDAM, NETHERLANDS	KU Leuven; KU Leuven; University of Amsterdam; Academic Medical Center Amsterdam			, Van Veldhoven Paul/U-6359-2019; Fransen, Marc/C-6262-2008; Fransen, Marc/ADL-0723-2022	, Van Veldhoven Paul/0000-0002-4478-2564; Fransen, Marc/0000-0001-9284-1197; 				BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; CASTEELS M, 1988, J BIOL CHEM, V263, P4654; CASTEELS M, 1990, J LIPID RES, V31, P1865; CHEN RF, 1967, J BIOL CHEM, V242, P173; CHRISTENSEN E, 1990, J INHERIT METAB DIS, V13, P363, DOI 10.1007/BF01799396; DECLERCQ PE, 1984, J BIOL CHEM, V259, P9064; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; FURUTA S, 1982, BIOCHEM BIOPH RES CO, V105, P639, DOI 10.1016/0006-291X(82)91482-6; GUEVARA J, 1982, ELECTROPHORESIS, V3, P197, DOI 10.1002/elps.1150030404; KASE BF, 1986, BIOCHIM BIOPHYS ACTA, V877, P37, DOI 10.1016/0005-2760(86)90115-3; KASE F, 1983, J LIPID RES, V24, P1560; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; MIURA S, 1984, J BIOL CHEM, V259, P6397; OSUMI T, 1980, J BIOCHEM, V87, P1735, DOI 10.1093/oxfordjournals.jbchem.a132918; POLLTHE BT, 1988, AM J HUM GENET, V42, P422; POULOS A, 1988, EUR J PEDIATR, V147, P143, DOI 10.1007/BF00442211; SCHEPERS L, 1988, J BIOL CHEM, V263, P2724; SCHEPERS L, 1990, J BIOL CHEM, V265, P5242; SINGH H, 1990, J LIPID RES, V31, P217; SINGH H, 1990, J INHERIT METAB DIS, V13, P387, DOI 10.1007/BF01799402; SUZUKI Y, 1988, CLIN CHIM ACTA, V172, P65, DOI 10.1016/0009-8981(88)90121-0; TAGER JM, 1985, BIOCHEM BIOPH RES CO, V126, P1269, DOI 10.1016/0006-291X(85)90322-5; TENBRINK HJ, 1992, J LIPID RES, V33, P41; VANHOVE G, 1991, J BIOL CHEM, V266, P24670; VANVELDHOVEN P, 1985, BIOCHEM J, V227, P737, DOI 10.1042/bj2270737; VANVELDHOVEN PP, 1991, BIOCHIM BIOPHYS ACTA, V1073, P203, DOI 10.1016/0304-4165(91)90203-S; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P24676; VANVELDHOVEN PP, 1992, J BIOL CHEM, V267, P20065; WANDERS RJA, 1990, J INHERIT METAB DIS, V13, P4, DOI 10.1007/BF01799330; WANDERS RJA, 1992, BIOCHIM BIOPHYS ACTA, V1124, P199, DOI 10.1016/0005-2760(92)90099-H; WANDERS RJA, 1990, BIOCHEM BIOPH RES CO, V172, P490, DOI 10.1016/0006-291X(90)90699-N	32	121	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10335	10344						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8387517				2022-12-25	WOS:A1993LB80000055
J	FEITELSON, MA; ZHU, M; DUAN, LX; LONDON, WT				FEITELSON, MA; ZHU, M; DUAN, LX; LONDON, WT			HEPATITIS-B X-ANTIGEN AND P53 ARE ASSOCIATED INVITRO AND IN LIVER-TISSUES FROM PATIENTS WITH PRIMARY HEPATOCELLULAR-CARCINOMA	ONCOGENE			English	Article							VIRUS-DNA; HEPATOMA-CELL; GENE PRODUCT; C-MYC; PROTEIN; REARRANGEMENT; INTEGRATION; TRANSACTIVATION; TRANSFORMATION; CHROMOSOME-17P	To test the hypothesis that hepatitis B x antigen (HBxAg) binds to the tumor-suppressor protein p53, immunoprecipitation was carried out with monoclonal anti-x or monoclonal anti-p53 using radiolabeled HBxAg and p53 made by in vitro translation. The results showed that anti-p53 specifically immunoprecipitates HBxAg only in the presence of p53 and that anti-x specifically immunoprecipitates p53 only in the presence of HBxAg. to determine whether HBxAg binds p53 in vivo, immunoprecipitation and Western blot analysis of liver samples from 10 hepatitis B virus (HBV)-infected patients with primary hepatocellular carcinoma (PHC) were carried out. A protein band at 53 000 daltons that specifically immunoprecipitated with a monoclonal anti-x was identified as p53 by Western blotting with a monoclonal anti-p53. Anti-p53 specifically immunoprecipitated bands of 28 000, 17 000 and 13 000 daltons, which were identified as HBxAg polypeptides by Western blotting with anti-HBx. These findings suggest that HBxAg binds to p53 and that this association is important to the development of PHC.	MIL MED UNIV 4, XIAN, SHAANXI, PEOPLES R CHINA; FOX CHASE CANC CTR, PHILADELPHIA, PA 19111 USA; THOMAS JEFFERSON UNIV, DIV INFECT DIS, PHILADELPHIA, PA 19107 USA	Air Force Military Medical University; Fox Chase Cancer Center; Jefferson University	FEITELSON, MA (corresponding author), THOMAS JEFFERSON UNIV, DEPT PATHOL & CELL BIOL, ROOM 219, JALUMNI HALL, PHILADELPHIA, PA 19107 USA.				NCI NIH HHS [CA-40737, CA-06927] Funding Source: Medline; NCRR NIH HHS [RR-05895] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005895] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AOKI N, 1989, MOL BIOL MED, V6, P395; AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; Beasley R.P., 1984, VIRAL HEPATITIS LIVE, P209; BEUTOW KH, 1989, P NATL ACAD SCI USA, V86, P8852; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; DEJEAN A, 1984, P NATL ACAD SCI-BIOL, V81, P5350, DOI 10.1073/pnas.81.17.5350; DEJEAN A, 1990, MOL BIOL MED, V7, P213; FEITELSON MA, 1990, VIROLOGY, V177, P357, DOI 10.1016/0042-6822(90)90491-9; FEITELSON MA, 1990, VIROLOGY, V177, P367, DOI 10.1016/0042-6822(90)90492-A; FUJIMORI M, 1991, CANCER RES, V51, P89; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GU JR, 1988, CARCINOGENESIS, V9, P697, DOI 10.1093/carcin/9.5.697; HATADA I, 1988, ONCOGENE, V3, P537; HINO O, 1991, P NATL ACAD SCI USA, V88, P9248, DOI 10.1073/pnas.88.20.9248; HINO O, 1989, CANCER GENET CYTOGEN, V37, P273, DOI 10.1016/0165-4608(89)90059-9; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOSONO S, 1991, ONCOGENE, V6, P237; HOWLEY PM, 1991, ADV AP BIOT, V13, P139; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HU KQ, 1990, P NATL ACAD SCI USA, V87, P7140, DOI 10.1073/pnas.87.18.7140; ISHIKAWA F, 1986, P NATL ACAD SCI USA, V83, P3209, DOI 10.1073/pnas.83.10.3209; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KOCH S, 1984, EMBO J, V3, P2185, DOI 10.1002/j.1460-2075.1984.tb02111.x; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LONDON WT, 1981, HUM PATHOL, V12, P1085, DOI 10.1016/S0046-8177(81)80329-2; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATSUBARA K, 1990, MOL BIOL MED, V7, P243; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MORIARTY AM, 1985, SCIENCE, V227, P429, DOI 10.1126/science.2981434; MOROY T, 1986, NATURE, V324, P276, DOI 10.1038/324276a0; MOROY T, 1989, ONCOGENE, V4, P59; MURAKAMI Y, 1991, CANCER RES, V51, P3356; OKUDA K, 1992, HEPATOLOGY, V15, P948, DOI 10.1002/hep.1840150532; OU J, 1985, P NATL ACAD SCI USA, V82, P83, DOI 10.1073/pnas.82.1.83; PASQUINELLI C, 1988, J VIROL, V62, P629, DOI 10.1128/JVI.62.2.629-632.1988; RITTER SE, 1991, VIROLOGY, V182, P841, DOI 10.1016/0042-6822(91)90626-M; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEFFNER M, 1990, CELL, V63, P1129; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHAFRITZ DA, 1981, NEW ENGL J MED, V305, P1067, DOI 10.1056/NEJM198110293051807; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SIMON D, 1990, CANCER GENET CYTOGEN, V45, P255, DOI 10.1016/0165-4608(90)90091-N; SLAGLE BL, 1991, CANCER RES, V51, P49; Szmuness W, 1978, Prog Med Virol, V24, P40; TAKADA S, 1990, J VIROL, V64, P822, DOI 10.1128/JVI.64.2.822-828.1990; TAKADA S, 1989, ONCOGENE, V4, P189; TOKINO T, 1987, J VIROL, V61, P3848, DOI 10.1128/JVI.61.12.3848-3854.1987; TROWBRIDGE R, 1988, VIRAL HEPATITIS LIVE, P764; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; WALKER GJ, 1991, CANCER RES, V51, P4367; WANG J, 1992, ONCOGENE, V7, P1653; WANG WL, 1991, CANCER RES, V51, P4971; WANG WL, 1991, HEPATOLOGY, V14, P29, DOI 10.1002/hep.1840140106; WILL H, 1985, P NATL ACAD SCI USA, V82, P891, DOI 10.1073/pnas.82.3.891; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; ZHOU YZ, 1988, J VIROL, V62, P4224, DOI 10.1128/JVI.62.11.4224-4231.1988	60	320	337	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1109	1117						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8386823				2022-12-25	WOS:A1993KY32800001
J	BRANDT, U; YU, L; YU, CA; TRUMPOWER, BL				BRANDT, U; YU, L; YU, CA; TRUMPOWER, BL			THE MITOCHONDRIAL TARGETING PRESEQUENCE OF THE RIESKE IRON-SULFUR PROTEIN IS PROCESSED IN A SINGLE STEP AFTER INSERTION INTO THE CYTOCHROME-BC1 COMPLEX IN MAMMALS AND RETAINED AS A SUBUNIT IN THE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BEEF-HEART UBIQUINOL; AMINO-ACID SEQUENCE; C-REDUCTASE; BC1 COMPLEX; PRECURSOR; CLEAVAGE; CLONING	The amino acid sequence of subunit 9 of the bovine heart cytochrome bc1 complex is identical to the 78-amino acid presequence that is removed post-translationally from the Rieske iron-sulfur protein as it is imported and targeted to the mitochondrial cytochrome bc1 complex. Iron-sulfur protein precursor, generated by in vitro transcription and translation, is processed to mature size in a single step when incubated with rat liver mitochondria, and generates a peptide that comigrates on SDS-polyacrylamide gel electrophoresis with subunit 9. These results suggest that the Rieske protein is processed in a single proteolytic step after it is inserted into the cytochrome bc1 complex in mammals, and that the processed presequence remains as a subunit of the complex. This is apparently the first instance in which a cleaved targeting presequence has been shown to be retained in the cell, possibly exhibiting a second function in addition to its function in protein trafficking.	DARTMOUTH COLL,SCH MED,DEPT BIOCHEM,7200 VAIL BLDG,HANOVER,NH 03755; OKLAHOMA STATE UNIV,DEPT BIOCHEM,STILLWATER,OK 74078	Dartmouth College; Oklahoma State University System; Oklahoma State University - Stillwater			Brandt, Ulrich/C-4406-2008	Brandt, Ulrich/0000-0003-1869-6811	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020379, R01GM020379] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 20379] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORCHART U, 1985, FEBS LETT, V191, P125, DOI 10.1016/0014-5793(85)81007-3; CONBOY JG, 1981, P NATL ACAD SCI-BIOL, V78, P3073, DOI 10.1073/pnas.78.5.3073; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GEIER BM, 1992, EUR J BIOCHEM, V208, P375, DOI 10.1111/j.1432-1033.1992.tb17197.x; GLICK BS, 1992, TRENDS BIOCHEM SCI, V17, P453, DOI 10.1016/0968-0004(92)90487-T; GRAHAM LA, 1993, IN PRESS J BIOENERG; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; ISAYA G, 1991, J CELL BIOL, V113, P65, DOI 10.1083/jcb.113.1.65; JAPA S, 1989, ARCH BIOCHEM BIOPHYS, V268, P716, DOI 10.1016/0003-9861(89)90340-8; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; NISHIKIMI M, 1990, BIOCHEM INT, V20, P155; NISHIKIMI M, 1989, BIOCHEM BIOPH RES CO, V159, P19, DOI 10.1016/0006-291X(89)92398-X; SCHAGGER H, 1987, FEBS LETT, V219, P161, DOI 10.1016/0014-5793(87)81210-3; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; USUI S, 1990, BIOCHEM BIOPH RES CO, V167, P575, DOI 10.1016/0006-291X(90)92063-6; ZHOU C, 1990, BIOTECHNIQUES, V8, P172; 1992, COMMENTS, V17, P31	21	100	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8387	8390						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8386158				2022-12-25	WOS:A1993KX81100002
J	JIANG, H; GIEDROC, D; KODADEK, T				JIANG, H; GIEDROC, D; KODADEK, T			THE ROLE OF PROTEIN-PROTEIN INTERACTIONS IN THE ASSEMBLY OF THE PRESYNAPTIC FILAMENT FOR T4 HOMOLOGOUS RECOMBINATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; BACTERIOPHAGE-T4 UVSX-PROTEIN; RECA PROTEIN; ESCHERICHIA-COLI; GENETIC-RECOMBINATION; BINDING-PROTEIN; GENE-32 PROTEIN; COMPLEXES; PURIFICATION; PHAGE-T4	The presynaptic filament is an obligatory intermediate in general genetic recombination. It is composed of a strand transferase protein polymerized along single-stranded DNA. In bacteriophage T4-infected cells, the presynaptic filament is composed of at least three proteins. In addition to the strand transferase (the uvsX protein), the uvsY (an accessory factor), and gene 32 (a helix-destabilizing factor), proteins also bind to the single-stranded DNA. In this report, we probe the assembly of the T4 presynaptic filament and the organization of the proteins in the complex. We find that interactions between the uvsY protein and the C terminus of the gene 32 protein are required to load UvsY onto gene 32 protein-covered DNA. Efficient binding of the uvsY protein to DNA is shown to be necessary for subsequent loading of the uvsX protein.	UNIV TEXAS,DEPT CHEM & BIOCHEM,AUSTIN,TX 78712; TEXAS A&M UNIV SYST,DEPT BIOCHEM & BIOPHYS,COLL STN,TX 77843	University of Texas System; University of Texas Austin; Texas A&M University System; Texas A&M University College Station			Giedroc, David/A-8608-2018	Giedroc, David/0000-0002-2342-1620	NIGMS NIH HHS [GM-39393] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039393] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; BITTNER M, 1979, J BIOL CHEM, V254, P9565; BUJALOWSKI W, 1988, J BIOL CHEM, V263, P4629; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; CONKLING MA, 1984, GENETICS, V107, P505; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; CURTIS MJ, 1976, J MOL BIOL, V102, P793, DOI 10.1016/0022-2836(76)90292-8; EGNER C, 1987, J BACTERIOL, V169, P3422, DOI 10.1128/jb.169.8.3422-3428.1987; FLORY J, 1984, P NATL ACAD SCI-BIOL, V81, P7026, DOI 10.1073/pnas.81.22.7026; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FORMOSA T, 1984, COLD SPRING HARB SYM, V49, P363, DOI 10.1101/SQB.1984.049.01.043; FORMOSA T, 1986, J BIOL CHEM, V261, P6107; GIEDROC DP, 1992, BIOCHEMISTRY-US, V31, P765, DOI 10.1021/bi00118a018; GRIFFITH J, 1985, J BIOL CHEM, V260, P4484; HARRIS LD, 1989, J MOL BIOL, V206, P19, DOI 10.1016/0022-2836(89)90520-2; HARRIS LD, 1988, BIOCHEMISTRY-US, V27, P6954, DOI 10.1021/bi00418a042; HARRIS LD, 1987, J BIOL CHEM, V262, P9285; HASHIMOTO K, 1991, J BIOL CHEM, V266, P4893; HINTON DM, 1986, J BIOL CHEM, V261, P5663; KODADEK T, 1989, J BIOL CHEM, V264, P16451; KODADEK T, 1990, BIOCHEM BIOPH RES CO, V172, P804, DOI 10.1016/0006-291X(90)90746-A; KODADEK T, 1990, J BIOL CHEM, V265, P20966; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KRASSA KB, 1991, P NATL ACAD SCI USA, V88, P4010, DOI 10.1073/pnas.88.9.4010; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; MESSELSON M, 1975, P NATL ACAD SCI USA, V72, P358; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MINAGAWA T, 1988, MOL GEN GENET, V211, P350, DOI 10.1007/BF00330615; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; RADDING CM, 1982, ANNU REV GENET, V16, P405, DOI 10.1146/annurev.ge.16.120182.002201; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STASIAK A, 1986, BIOPHYS J, V49, P5, DOI 10.1016/S0006-3495(86)83569-X; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TAYLOR A, 1980, CELL, V22, P447, DOI 10.1016/0092-8674(80)90355-4; TSANG SS, 1985, BIOCHEMISTRY-US, V24, P3226, DOI 10.1021/bi00334a023; TSANG SS, 1985, J MOL BIOL, V185, P295, DOI 10.1016/0022-2836(85)90405-X; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; WILLIAMS KR, 1983, BACTERIOPHAGE T4, P82; WILLIAMS RC, 1986, J MOL BIOL, V187, P109, DOI 10.1016/0022-2836(86)90410-9; YONESAKI T, 1989, J BIOL CHEM, V264, P7814; YONESAKI T, 1985, EMBO J, V4, P3321, DOI 10.1002/j.1460-2075.1985.tb04083.x	43	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7904	7911						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8385125				2022-12-25	WOS:A1993KW97900050
J	TAGLICHT, D; PADAN, E; SCHULDINER, S				TAGLICHT, D; PADAN, E; SCHULDINER, S			PROTON-SODIUM STOICHIOMETRY OF NHAA, AN ELECTROGENIC ANTIPORTER FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; NA+-H+ ANTIPORT; MEMBRANE-VESICLES; PH HOMEOSTASIS; TRANSPORT; ANT; PROTEOLIPOSOMES; PURIFICATION; BACTERIA; GRADIENT	The H+:Na+ exchange stoichiometry of NhaA, a sodium-proton antiporter coded by the nhaA gene of Escherichia coli, has been determined using purified NhaA protein reconstituted into sodium-loaded proteoliposomes. One approach involved measuring, in parallel experiments, the Na+ efflux and H+ influx from such proteoliposomes and calculating the stoichiometry from the ratio of these fluxes. A second approach was based on measuring the membrane potential generated by NhaA at various sodium gradients and assuming complete coupling and thermodynamic equilibrium between the membrane potential and the ion gradients. The results from both methods agree with a stoichiometry of 2 H+ exchanged for each Na+. This value is independent of pH between pH 7.2 and 8.1. These results support the suggestion that a change in the catalytic rate of NhaA rather than its stoichiometry is crucial for its role in regulation of intracellular pH in alkaline environments.	HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,DIV MICROBIAL & MOLEC ECOL,IL-91904 JERUSALEM,ISRAEL	Hebrew University of Jerusalem			Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237				ADMON A, 1985, J MEMBRANE BIOL, V86, P45, DOI 10.1007/BF01871609; BAKKER EP, 1990, FEMS MICROBIOL LETT, V75, P319, DOI 10.1111/j.1574-6968.1990.tb04105.x; BASSILANA M, 1984, BIOCHEMISTRY-US, V23, P1015, DOI 10.1021/bi00300a033; BASSILANA M, 1984, BIOCHEMISTRY-US, V23, P5288, DOI 10.1021/bi00317a029; BECK JC, 1979, ARCH BIOCHEM BIOPHYS, V194, P208, DOI 10.1016/0003-9861(79)90611-8; BOOTH IR, 1985, MICROBIOL REV, V49, P395; BORON WF, 1983, J MEMBRANE BIOL, V72, P1, DOI 10.1007/BF01870311; CASTLE AM, 1986, J BIOL CHEM, V261, P3288; CASTLE AM, 1986, J BIOL CHEM, V261, P7797; GARLID KD, 1991, J BIOL CHEM, V266, P6518; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; HAUSSINGER D, 1988, PH HOMEOSTASIS MECHA; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P1207, DOI 10.1021/bi00600a011; KARPEL R, 1988, J BIOL CHEM, V263, P10408; MACNAB RM, 1987, BIOPHYS J, V52, P637, DOI 10.1016/S0006-3495(87)83255-1; MINTA A, 1989, J BIOL CHEM, V264, P19449; PADAN E, 1989, J BIOL CHEM, V264, P20297; PADAN E, 1981, BIOCHIM BIOPHYS ACTA, V650, P1151; PAN JW, 1990, J BIOL CHEM, V265, P9247; PINNER E, 1992, J BIOL CHEM, V267, P11064; PINNER E, 1993, IN PRESS J BIOL CHEM; POUYSSEGUR J, 1988, NAPLUS HPLUS EXCHANG, P337; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SCHULDINER S, 1978, BIOCHEMISTRY-US, V17, P706, DOI 10.1021/bi00597a023; SHAHAK Y, 1982, FEBS LETT, V150, P27, DOI 10.1016/0014-5793(82)81298-2; SLONCZEWSKI JL, 1981, P NATL ACAD SCI-BIOL, V78, P6271, DOI 10.1073/pnas.78.10.6271; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; WEST IC, 1974, BIOCHEM J, V144, P87, DOI 10.1042/bj1440087	28	135	135	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5382	5387						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8383669				2022-12-25	WOS:A1993KR82200010
J	WANG, YL; MACDONALD, JIS; KENT, C				WANG, YL; MACDONALD, JIS; KENT, C			REGULATION OF CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE IN HELA-CELLS - EFFECT OF OLEATE ON PHOSPHORYLATION AND INTRACELLULAR-LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE-HAMSTER OVARY; CHOLINE-PHOSPHATE CYTIDYLYLTRANSFERASE; PHOSPHOLIPASE-C TREATMENT; HEP G2 CELLS; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; FATTY-ACIDS; ENDOPLASMIC-RETICULUM; MAMMALIAN-CELLS; RAT-LIVER; II CELLS	The mechanism by which oleate induced the translocation of CTP:phosphocholine cytidylyltransferase from the soluble to particulate fraction was studied in HeLa cells. Addition of 0.5 mM oleate caused a 10-fold stimulation of [methyl-H-3]choline incorporation into phosphatidylcholine. The stimulation of phosphatidylcholine synthesis was correlated with a decrease in phosphocholine and an increase in CDP-choline, indicating that cytidylyltransferase is regulatory under these conditions. The stimulation of cytidylyltransferase activity upon oleate treatment was concomitant with the translocation of this enzyme from the soluble to particulate fraction. Immunoblot analysis revealed the soluble form as multiple slowly migrating bands, and the particulate form as a faster migrating, single band. The slowly migrating form could be converted to the fast migrating form by phosphatase treatment, suggesting that the mobility difference was due to phosphorylation. In vivo P-32 labeling showed that the soluble cytidylyltransferase was highly phosphorylated and the particulate form was much less phosphorylated. The kinetics of the translocation showed that the conversion of the majority of cytidylyltransferase from the soluble to the particulate form occurred within about 15 min following addition of oleate and that the translocation showed a good correlation with dephosphorylation. In contrast, the relocation of cytidylyltransferase from the particulate to the soluble fraction after the removal of oleate occurred within 1 min, and extensive phosphorylation was not required for cytidylyltransferase to leave the membrane. The relocated, soluble cytidylyltransferase was phosphorylated at a much slower rate than that at which the enzyme left the membrane. Immunolocalization showed that the cytidylyltransferase translocated to the nuclear envelope instead of the endoplasmic reticulum. These results indicate that activation of cytidylyltransferase by dephosphorylation and translocation to the nuclear envelope may be a general mechanism occurring in many cell types. Moreover, in HeLa cells, multiple mechanism exist for regulating cytidylyltransferase activity.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NICHD NIH HHS [HD 10580] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD010580] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BLANK ML, 1988, J BIOL CHEM, V263, P5656; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURKHARDT R, 1988, BIOCHEM J, V254, P495, DOI 10.1042/bj2540495; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COHEN PTW, 1988, GENE, V69, P131, DOI 10.1016/0378-1119(88)90385-X; COHEN PTW, 1989, BIOCHEM J, V260, P931, DOI 10.1042/bj2600931; COOK HW, 1989, J BIOL CHEM, V264, P2746; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P26, DOI 10.1016/0005-2760(87)90214-1; DAWSON DB, 1987, BIOCHIM BIOPHYS ACTA, V923, P389; EXTON JH, 1990, J BIOL CHEM, V265, P1; HATCH GM, 1991, BIOCHIM BIOPHYS ACTA, V1081, P25, DOI 10.1016/0005-2760(91)90245-D; HIGGINS JA, 1987, J LIPID RES, V28, P268; JAMIL H, 1990, J BIOL CHEM, V265, P4332; JAMIL H, 1992, J BIOL CHEM, V267, P1752; JOHNSON GD, 1981, J IMMUNOL METHODS, V43, P349, DOI 10.1016/0022-1759(81)90183-6; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORAND JN, 1989, J BIOL CHEM, V264, P13785; Nigg EA, 1989, CURR OPIN CELL BIOL, V1, P435, DOI 10.1016/0955-0674(89)90002-1; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P433, DOI 10.1016/0005-2760(84)90169-3; PELECH SL, 1983, J BIOL CHEM, V258, P6782; PESCE A, 1964, J BIOL CHEM, V239, P1753; SLACK BE, 1991, J BIOL CHEM, V266, P24503; SLEIGHT R, 1980, J BIOL CHEM, V255, P644; SLEIGHT R, 1983, J BIOL CHEM, V258, P831; SLEIGHT R, 1983, J BIOL CHEM, V258, P836; SLEIGHT R, 1983, J BIOL CHEM, V258, P824; TERCE F, 1992, BIOCHEM J, V282, P333, DOI 10.1042/bj2820333; TERCE F, 1988, J BIOL CHEM, V263, P3142; TERCE F, 1991, BIOCHIM BIOPHYS ACTA, V1084, P69, DOI 10.1016/0005-2760(91)90057-O; UTAL AK, 1991, J BIOL CHEM, V266, P24084; VANCE JE, 1988, J BIOL CHEM, V263, P5898; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WATKINS JD, 1992, J BIOL CHEM, V267, P5686; WATKINS JD, 1990, J BIOL CHEM, V265, P2190; WEINHOLD PA, 1984, J BIOL CHEM, V259, P315; WEINHOLD PA, 1991, J BIOL CHEM, V266, P6093; WEINHOLD PA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P299, DOI 10.1016/0005-2760(89)90017-9; WRIGHT PS, 1985, J BIOL CHEM, V260, P7919; YAO ZM, 1990, J BIOL CHEM, V265, P4326; YAVIN E, 1976, J BIOL CHEM, V251, P1392	42	100	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5512	5518						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8383672				2022-12-25	WOS:A1993KR82200027
J	LEE, HS; GHOSEDASTIDAR, J; WINAWER, S; FRIEDMAN, E				LEE, HS; GHOSEDASTIDAR, J; WINAWER, S; FRIEDMAN, E			SIGNAL TRANSDUCTION THROUGH EXTRACELLULAR SIGNAL-REGULATED KINASE-LIKE PP57 BLOCKED IN DIFFERENTIATED CELLS HAVING LOW PROTEIN KINASE-C-BETA ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; PHORBOL ESTER; MITOGEN; DIACYLGLYCEROL; ACTIVATION; INSULIN; ERKS; AUTOPHOSPHORYLATION; EXPRESSION; ISOZYMES	pp57 is a cytoplasmic kinase which is related antigenically and functionally to the extracellular signal regulated kinase or the mitogen-activated kinase family of signal transduction proteins. Two undifferentiated colon carcinoma cell lines responded to the diacylglycerol diolein by growth and a rapid 3-4-fold increase in tyrosine phosphorylation of pp57, and smaller increases in threonine and serine phosphorylation. By enhancing tyrosine phosphorylation of pp57, diolein increased pp57 kinase activity on myelin basic protein. Two enterocytic differentiated colon carcinoma cell lines, when treated with diolein, exhibited neither increased pp57 tyrosine phosphorylation nor increased growth. Both enterocytic lines exhibited 30% of the total PKC activity, 10-20% of the abundance of PKCbeta as detected by Western blotting with anti-peptide antisera, and 10-20% of the PKCbeta activity, by immune complex kinase reactions, that was expressed in the undifferentiated cell lines. The abundance of three other PKC isozymes, alpha, epsilon, and zeta appeared unchanged in the undifferentiated and enterocytic lines, reflecting their common parental cell line origin. The association between loss of PKCbeta activity and blocked signaling through pp57 in each of two cell lines suggests that PKCbeta is part of a signal transduction system activating pp57.	MEM SLOAN KETTERING CANC CTR,GI TUMOR BIOL LAB,1275 YORK AVE,BOX 244,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NCI NIH HHS [CA50645] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BELL RM, 1991, J BIOL CHEM, V266, P4661; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOPER JA, 1981, MOL CELL BIOL, V1, P741; FRIEDMAN E, 1989, CANCER RES, V49, P544; GANONG BR, 1984, BIOCHEMISTRY-US, V23, P4977, DOI 10.1021/bi00316a023; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HAFEZ MM, 1992, CELL GROWTH DIFFER, V3, P753; HOMAN EC, 1991, J BIOL CHEM, V266, P5676; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KOLESNICK RN, 1990, J BIOL CHEM, V265, P10900; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LEE H, 1993, IN PRESS J BIOL CHEM; LESUFFLEUR T, 1991, J CELL BIOL, V115, P1409, DOI 10.1083/jcb.115.5.1409; LIN TH, 1992, J BIOL CHEM, V267, P1335; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MARIAN B, 1989, CANCER RES, V49, P4231; MELLONI E, 1989, J BIOL CHEM, V264, P18414; MOROTOMI M, 1990, CANCER RES, V50, P3595; OTTE AP, 1992, CELL, V68, P1021, DOI 10.1016/0092-8674(92)90074-M; PFEFFER LM, 1990, P NATL ACAD SCI USA, V87, P6537, DOI 10.1073/pnas.87.17.6537; POWELL CT, 1992, P NATL ACAD SCI USA, V89, P147, DOI 10.1073/pnas.89.1.147; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; TOBE K, 1991, J BIOL CHEM, V266, P24793; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; YAN ZF, 1992, ONCOGENE, V7, P801	36	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5255	5263						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8383133				2022-12-25	WOS:A1993KP88400099
J	ROSENWALD, AG; PAGANO, RE				ROSENWALD, AG; PAGANO, RE			INHIBITION OF GLYCOPROTEIN TRAFFIC THROUGH THE SECRETORY PATHWAY BY CERAMIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NECROSIS-FACTOR-ALPHA; GOLGI-APPARATUS; CELL-DIFFERENTIATION; CULTURED FIBROBLASTS; SPHINGOMYELIN TURNOVER; PLASMA-MEMBRANE; RAT-LIVER; METABOLISM; ANALOG; SPHINGOLIPIDS	Incubation of vesicular stomatitis virus-infected cells with short-chain, cell-permeable ceramide (Cer) analogs decreased the rate of viral glycoprotein transport through the Golgi complex and reduced the number of infectious virions released from cells in a concentration-dependent manner. These effects appeared to be caused directly by Cer, rather than by one of its metabolites. Cer treatment also disrupted the Golgi apparatus within 1 h, although cells treated for up to 24 h with Cer remained viable. Our results suggest that endogenous Cer may modulate secretory protein traffic and that exogenously added Cer analogs may be useful as antiviral agents.	CARNEGIE INST WASHINGTON,DEPT EMBRYOL,115 W UNIV PKWY,BALTIMORE,MD 21210	Carnegie Institution for Science					NIGMS NIH HHS [R37 GM22942] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022942] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COSTE H, 1985, BIOCHIM BIOPHYS ACTA, V814, P1, DOI 10.1016/0005-2736(85)90412-2; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; KALEN A, 1992, BIOCHIM BIOPHYS ACTA, V1125, P90, DOI 10.1016/0005-2760(92)90160-W; KIM MY, 1991, J BIOL CHEM, V266, P484; Kolesnick Richard, 1992, Trends in Cell Biology, V2, P232, DOI 10.1016/0962-8924(92)90310-J; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KOVAL M, 1991, BIOCHIM BIOPHYS ACTA, V1082, P113, DOI 10.1016/0005-2760(91)90184-J; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; LARSEN D, 1982, THESIS J HOPKINS U B; LIPSKY NG, 1983, P NATL ACAD SCI-BIOL, V80, P2608, DOI 10.1073/pnas.80.9.2608; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; LUCOCQ J, 1991, J CELL SCI, V100, P753; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PAGANO RE, 1990, BIOCHEM SOC T, V18, P361, DOI 10.1042/bst0180361; PAGANO RE, 1988, BIOCHEMISTRY-US, V27, P4439, DOI 10.1021/bi00412a034; ROSENWALD AG, 1992, BIOCHEMISTRY-US, V31, P3581, DOI 10.1021/bi00129a005; ROSENWALD AG, 1993, IN PRESS ADV LIPID R; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0	30	90	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4577	4579						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8383117				2022-12-25	WOS:A1993KP88400003
J	WANG, Y; WEINER, H				WANG, Y; WEINER, H			THE PRESEQUENCE OF RAT-LIVER ALDEHYDE DEHYDROGENASE REQUIRES THE PRESENCE OF AN ALPHA-HELIX AT ITS N-TERMINAL REGION WHICH IS STABILIZED BY THE HELIX AT ITS C-TERMINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPORTED MITOCHONDRIAL PROTEIN; OUTER-MEMBRANE PROTEIN; 12 AMINO-ACIDS; LEADER PEPTIDE; SIGNAL PEPTIDE; ORNITHINE TRANSCARBAMYLASE; TARGETING SEQUENCES; PRE-SEQUENCE; YEAST; PRECURSOR	Previous nuclear magnetic resonance data showed that the conformation of the signal peptide of rat liver mitochondrial aldehyde dehydrogenase in a micelle environment contained a N-helix and a C-helix which were separated by a flexible hinge region (Karslake, C., Piotto, M. E., Pak, Y. K., Weiner, H. and Gorenstein, D. (1990) Biochemistry 29, 9872-9878). Deletion of either helix from the presequence caused complete loss of the precursor import. Switching the positions of the two helices had little effect on import but decreased processing efficiency. Import was not affected by replacing the C-helix with the N-terminal helix of the presequence of cytochrome c oxidase subunit IV, however, it was decreased by replacing the C-helix with the C-terminal random coil of the oxidase's presequence. Circular dichroism studies on the synthesized signal peptides indicated that a helix in the C-segment of aldehyde dehydrogenase signal peptide was needed to stabilize the N-helix. It is concluded that a stable helix in the N-terminal region is necessary for a functional mitochondrial presequence. This helix could be obtained from its own sequence, or from the interaction with other portions of the presequence.	PURDUE UNIV,DEPT BIOCHEM,1153 BIOCHEM BLDG,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008512, R03AA008532] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA00028, AA08532, AA08512] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BEDWELL DM, 1989, MOL CELL BIOL, V9, P1014, DOI 10.1128/MCB.9.3.1014; BIBUS CR, 1988, J BIOL CHEM, V263, P13097; BRUCH MD, 1990, J BIOL CHEM, V265, P3851; CHANG CT, 1978, ANAL BIOCHEM, V91, P12; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; ENDO T, 1989, J BIOCHEM, V106, P396, DOI 10.1093/oxfordjournals.jbchem.a122864; EPAND RM, 1986, J BIOL CHEM, V261, P17; FARRES J, 1989, EUR J BIOCHEM, V180, P67, DOI 10.1111/j.1432-1033.1989.tb14616.x; GLICK B, 1991, ANNU REV GENET, V25, P21; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HALDI M, 1989, J BIOL CHEM, V264, P17107; HORWICH AL, 1986, CELL, V44, P451, DOI 10.1016/0092-8674(86)90466-6; HORWICH AL, 1985, EMBO J, V4, P1129, DOI 10.1002/j.1460-2075.1985.tb03750.x; HOYT DW, 1991, J BIOL CHEM, V266, P21693; HURT EC, 1985, EMBO J, V4, P3509, DOI 10.1002/j.1460-2075.1985.tb04110.x; HURT EC, 1987, J BIOL CHEM, V262, P1420; HURT EC, 1985, EMBO J, V4, P2061, DOI 10.1002/j.1460-2075.1985.tb03892.x; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KARSLAKE C, 1990, BIOCHEMISTRY-US, V29, P9872, DOI 10.1021/bi00494a017; KLEIBER J, 1990, P NATL ACAD SCI USA, V87, P7978, DOI 10.1073/pnas.87.20.7978; KRAUS JP, 1988, P NATL ACAD SCI USA, V85, P8905, DOI 10.1073/pnas.85.23.8905; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMIRE BD, 1989, J BIOL CHEM, V264, P20206; NELSON J W, 1986, Proteins Structure Function and Genetics, V1, P211, DOI 10.1002/prot.340010303; NISHI T, 1989, J BIOL CHEM, V264, P6044; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PABO CO, 1982, NATURE, V298, P443, DOI 10.1038/298443a0; PAK YK, 1990, J BIOL CHEM, V265, P14298; PILGRIM D, 1986, MOL CELL BIOL, V7, P294; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER H, 1990, J BIOL CHEM, V265, P9881; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; TAMM LK, 1990, FEBS LETT, V272, P29, DOI 10.1016/0014-5793(90)80441-K; VASSAROTTI A, 1987, J BIOL CHEM, V262, P411; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WANG TTY, 1989, ARCH BIOCHEM BIOPHYS, V272, P440, DOI 10.1016/0003-9861(89)90238-5	42	41	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4759	4765						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8383124				2022-12-25	WOS:A1993KP88400034
J	BOYER, CS; MOORE, GA; MOLDEUS, P				BOYER, CS; MOORE, GA; MOLDEUS, P			SUBMITOCHONDRIAL LOCALIZATION OF THE NAD+ GLYCOHYDROLASE - IMPLICATIONS FOR THE ROLE OF PYRIDINE-NUCLEOTIDE HYDROLYSIS IN MITOCHONDRIAL CALCIUM FLUXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; ADP-RIBOSYLATION; CA-2+ RELEASE; MEMBRANE; INNER; METABOLISM; INHIBITION; PROOXIDANTS; TRANSFERASE; STATE	The submitochondrial location of the NAD+ glycohydrolase (NADase) and its role in mitochondrial ADP-ribosyl transfer reactions were investigated in isolated rat liver mitochondria. The NADase catalyzes the hydrolysis of NAD+ to ADP-ribose and nicotinamide. Hydrolysis of intramitochondrial NAD+ has been suggested to be the first step in a nonenzymatic mono(ADP-ribosylation) by free ADP-ribose of an inner membrane-associated acceptor peptide and that this protein is involved in regulating calcium efflux from mitochondria during exposure to oxidants. The results of the present study indicate that mitochondrial NADase activity lies outside the matrix space, however. This was determined by assessing the rates of hydrolysis of externally added NAD+ by intact mitochondria and comparing these rates with those obtained when the mitochondria were permeabilized with detergent. No significant difference was observed in the rate of NAD+ hydrolysis when detergent was added indicating that NAD+ hydrolysis by mitochondria does not necessitate its access to the matrix space. The submitochondrial location of the NADase was investigated further by digitonin titration of isolated mitochondria. Digitonin titration of the mitochondria released NADase activity with the outer membrane marker, monoamine oxidase. The digitonin titration data also suggest that the outer membrane is the exclusive location of the NADase. The incorporation of radioactive label derived from [H-3]NAD+ into submitochondrial particles proceeds at comparable rates in the absence or presence of NADase activity, indicating that the production of free ADP-ribose is not necessary for intramitochondrial ADP-ribosyl transfer reactions. Thus the conclusions of this study suggest that due to the submitochondrial location of the NADase, it does not participate in intramitochondrial pyridine nucleotide hydrolysis or nonenzymatic mono(ADP-ribosylation) during oxidative stress in mitochondria.	NATL CHEM INSPECTORAT,DEPT SCI RES & DOCUMENTAT,S-17127 SOLNA,SWEDEN		BOYER, CS (corresponding author), KAROLINSKA INST,DEPT TOXICOL,POB 60400,S-10401 STOCKHOLM 60,SWEDEN.							BARRIO JR, 1972, P NATL ACAD SCI USA, V69, P2039, DOI 10.1073/pnas.69.8.2039; BELLOMO G, 1982, J BIOL CHEM, V257, P1558; BOQUIST L, 1984, BIOCH INT, V9, P597; BOYER CS, 1991, DRUG METAB DISPOS, V19, P81; BRDICZKA D, 1974, H-S Z PHYSIOL CHEM, V355, P731, DOI 10.1515/bchm2.1974.355.1.731; BURGESS GM, 1983, J BIOL CHEM, V258, P5336; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CAYAMA E, 1973, J BIOL CHEM, V248, P6479; CROMPTON M, 1988, BIOCHEM J, V255, P357; FAGIAN MM, 1990, J BIOL CHEM, V265, P19955; FREI B, 1988, BIOCHEMISTRY-US, V27, P529, DOI 10.1021/bi00402a004; FREI B, 1986, FEBS LETT, V198, P99, DOI 10.1016/0014-5793(86)81192-9; FREI B, 1985, EUR J BIOCHEM, V149, P633, DOI 10.1111/j.1432-1033.1985.tb08971.x; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GRAF M, 1985, BIOCHEM BIOPH RES CO, V129, P18, DOI 10.1016/0006-291X(85)91396-8; HILZ H, 1984, P NATL ACAD SCI-BIOL, V81, P3929, DOI 10.1073/pnas.81.13.3929; HOFFSTETTER W, 1981, EUR J BIOCHEM, V117, P361; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; JONES DP, 1981, J CHROMATOGR, V225, P446, DOI 10.1016/S0378-4347(00)80293-5; Kun E, 1979, Methods Enzymol, V55, P115; KUN E, 1975, P NATL ACAD SCI USA, V72, P1436, DOI 10.1073/pnas.72.4.1436; LEHNINGER AL, 1978, P NATL ACAD SCI USA, V75, P1690, DOI 10.1073/pnas.75.4.1690; LOTSCHER HR, 1980, J BIOL CHEM, V255, P9325; LOTSCHER HR, 1979, P NATL ACAD SCI USA, V76, P4340, DOI 10.1073/pnas.76.9.4340; MASMOUDI A, 1987, BIOCHEMISTRY-US, V26, P1965, DOI 10.1021/bi00381a027; MCCREANOR GM, 1983, BIOCHIM BIOPHYS ACTA, V759, P222, DOI 10.1016/0304-4165(83)90316-1; MOSER B, 1983, ARCH BIOCHEM BIOPHYS, V224, P358, DOI 10.1016/0003-9861(83)90220-5; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; PASCOE GA, 1989, FREE RADICAL BIO MED, V6, P209, DOI 10.1016/0891-5849(89)90118-4; Pedersen P L, 1978, Methods Cell Biol, V20, P411, DOI 10.1016/S0091-679X(08)62030-0; PHILLIPS AH, 1962, J BIOL CHEM, V237, P2652; RICHTER C, 1990, BIOCHEM J, V269, P735, DOI 10.1042/bj2690735; RICHTER C, 1987, BIOCHEM BIOPH RES CO, V143, P609, DOI 10.1016/0006-291X(87)91397-0; RICHTER C, 1990, BIOCHEM PHARMACOL, V40, P779, DOI 10.1016/0006-2952(90)90315-C; RICHTER C, 1990, FREE RADICAL RES COM, V8, P329, DOI 10.3109/10715769009053366; RICHTER C, 1988, FREE RADICAL BIO MED, V4, P365, DOI 10.1016/0891-5849(88)90088-3; RICHTER C, 1983, P NATL ACAD SCI-BIOL, V80, P3188, DOI 10.1073/pnas.80.11.3188; RICHTER C, 1987, ADP RIBOSYLATION PRO, P209; ROTTENBERG H, 1990, BIOCHIM BIOPHYS ACTA, V1016, P77, DOI 10.1016/0005-2728(90)90009-S; RYLE CM, 1984, BIOCHEM J, V222, P553, DOI 10.1042/bj2220553; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; WEIS M, 1992, J BIOL CHEM, V267, P804; ZAMMIT VA, 1985, BIOCHEM J, V230, P389, DOI 10.1042/bj2300389	44	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4016	4020						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8382685				2022-12-25	WOS:A1993KN53300034
J	HWONG, CL; CHEN, CY; SHANG, HF; HWANG, JL				HWONG, CL; CHEN, CY; SHANG, HF; HWANG, JL			INCREASED SYNTHESIS AND DEGRADATION OF DNA TOPOISOMERASE-I DURING THE INITIAL PHASE OF HUMAN T-LYMPHOCYTE PROLIFERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; TRANSCRIPTION; INVITRO; RNA; CAMPTOTHECIN; TEMPLATE; PROTEINS; CLEAVAGE; ENZYMES; NUCLEAR	The regulation of DNA topoisomerase I was studied in human T lymphocytes following phytohemagglutinin (PHA) stimulation. As T lymphocytes began to enter the S phase 24 h after stimulation, there was a rapid increase in DNA topoisomerase I mRNA. The level of DNA topoisomerase I mRNA increased continuously over the next 18 h and peaked (>50-fold increase) 42 h after stimulation with PHA. A concomitant increase in DNA topoisomerase I protein was also observed. However, the maximal increase in DNA topoisomerase I protein was only 6-fold. To explain the quantitative difference between the mRNA and protein levels, we investigated the change in the rates of DNA topoisomerase I protein synthesis versus degradation in human T lymphocytes following PHA stimulation. The increase in the mRNA parallels the increase in protein synthesis. However, the half-life of the enzyme protein was reduced to 9 h in proliferating T lymphocytes compared to a half-life of 36 h in resting lymphocytes. These results indicate that, in addition to the growth-regulated increase in the expression of DNA topoisomerase I, there was also a concomitant increase in the degradation of DNA topoisomerase I protein.	ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN; NATL YANG MING MED COLL, INST BIOCHEM, TAIPEI 11221, TAIWAN; NATL YANG MING MED COLL, INST MICROBIOL & IMMUNOL, TAIPEI 11221, TAIWAN	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University								BAE YS, 1988, P NATL ACAD SCI USA, V85, P2076, DOI 10.1073/pnas.85.7.2076; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HSIANG YH, 1988, CANCER RES, V48, P1722; HSIANG YH, 1988, CANCER RES, V48, P3230; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; HWONG CL, 1990, CANCER RES, V50, pS5649; HWONG CL, 1989, J BIOL CHEM, V264, P14923; JUAN CC, 1988, P NATL ACAD SCI USA, V85, P8910, DOI 10.1073/pnas.85.23.8910; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU LF, 1983, CRC CR REV BIOCH MOL, V15, P1, DOI 10.3109/10409238309102799; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; MILLER KG, 1981, J BIOL CHEM, V256, P9334; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; POCCIA DL, 1978, DEV BIOL, V64, P273, DOI 10.1016/0012-1606(78)90078-7; ROSENBERG BH, 1976, NUCLEIC ACIDS RES, V3, P3305, DOI 10.1093/nar/3.12.3305; TAUDOU G, 1984, FEBS LETT, V176, P431, DOI 10.1016/0014-5793(84)81212-0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TRICOLI JV, 1985, EXP CELL RES, V158, P1, DOI 10.1016/0014-4827(85)90426-4; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; WILKINSON M, 1988, NUCLEIC ACIDS RES, V16, P10934, DOI 10.1093/nar/16.22.10934; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950; ZHANG H, 1988, P NATL ACAD SCI USA, V85, P1060, DOI 10.1073/pnas.85.4.1060	34	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18982	18986						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8395523				2022-12-25	WOS:A1993LV65900090
J	LEBONNIEC, BF; GUINTO, ER; MACGILLIVRAY, RTA; STONE, SR; ESMON, CT				LEBONNIEC, BF; GUINTO, ER; MACGILLIVRAY, RTA; STONE, SR; ESMON, CT			THE ROLE OF THROMBINS TYR-PRO-PRO-TRP MOTIF IN THE INTERACTION WITH FIBRINOGEN, THROMBOMODULIN, PROTEIN-C, ANTITHROMBIN-III, AND THE KUNITZ INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; COMPLEMENTARY DEOXYRIBONUCLEIC-ACID; BLOOD-COAGULATION; HIRUDIN COMPLEX; CRYSTAL-STRUCTURE; FACTOR-XIII; ARG CHLOROMETHYLKETONE; SEQUENCE-ANALYSIS; HEPARIN COFACTOR; RESIDUES 7-16	When amino acids Pro60B, Pro60C, and Trp60D are deleted from thrombin, the resulting mutant (des-PPW) exhibits (compared to the wild-type enzyme): a similar second order rate constant of inhibition (k(on)) for diisopropyl fluorophosphate, and a comparable inhibition constant (K(i)) for benzamidine, suggesting that the charge stabilizing system and the primary binding pocket are little altered, if at all, by the mutation. As predicted from the x-ray structure, des-PPW is remarkably sensitive to the bovine pancreatic trypsin inhibitor, with a K(i) over 3 x 10(3) times tighter relative to thrombin, but des-PPW is also markedly less susceptible to inactivation by antithrombin III, with a k(on) that is over 100-fold lower. The catalytic constant (k(cat)) for most p-nitroanilide substrates tested is preserved or even increased, but the Michaelis constant (K(m)) increases. In contrast, the K(m) for the fibrinogen A alpha-chain is essentially unchanged, whereas k(cat) decreases almost-equal-to 50-fold. Unlike thrombin, the rate of fibrinopeptide B release becomes, following a lag phase, comparable to that of fibrinopeptide A. Inasmuch as des-PPW cleaves an additional peptide bond in the bovine fibrin alpha-chain, it remains a highly specific serine protease, which releases a single peptide from denatured casein (versus two with thrombin). Protein C activation by des-PPW is almost-equal-to 30 times slower than by thrombin in the absence, as well as in the presence, of calcium and thrombomodulin. Although this study confirms that the B-insertion restricts access to the active site cleft, it also suggests that other motifs and/or discrete amino acids are mainly responsible for the narrow specificity of thrombin.	OKLAHOMA MED RES FDN, CARDIOVASC BIOL RES PROGRAM, OKLAHOMA CITY, OK 73104 USA; UNIV BRITISH COLUMBIA, DEPT BIOCHEM, VANCOUVER V6T 1W5, BC, CANADA; UNIV OKLAHOMA HLTH SCI CTR, HLTH SCI CTR, DEPT PATHOL, OKLAHOMA CITY, OK 73103 USA; HOWARD HUGHES MED INST, OKLAHOMA CITY, OK 73103 USA; UNIV OKLAHOMA HLTH SCI CTR, HLTH SCI CTR, DEPT BIOCHEM, OKLAHOMA CITY, OK 73103 USA	Oklahoma Medical Research Foundation; University of British Columbia; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute; University of Oklahoma System; University of Oklahoma Health Sciences Center	LEBONNIEC, BF (corresponding author), UNIV CAMBRIDGE, CTR MRC, DEPT HAEMATOL, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.		Le Bonniec, Bernard/ABA-1366-2020; Le Bonniec, Bernard/S-5756-2016	Le Bonniec, Bernard/0000-0002-8432-7363; Le Bonniec, Bernard/0000-0002-8432-7363	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029807, R37HL030340] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37-HL30340, R01-HL29807] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASCENZI P, 1988, BIOCHIM BIOPHYS ACTA, V956, P156, DOI 10.1016/0167-4838(88)90262-2; BANFIELD DK, 1992, P NATL ACAD SCI USA, V89, P2779, DOI 10.1073/pnas.89.7.2779; BANNER DW, 1991, J BIOL CHEM, V266, P20085; BERLINER LJ, 1977, BIOCHEMISTRY-US, V16, P4622, DOI 10.1021/bi00640a015; BERLINER LJ, 1986, ANN NY ACAD SCI, V485, P80, DOI 10.1111/j.1749-6632.1986.tb34570.x; BETZ A, 1991, BIOCHEMISTRY-US, V30, P9848, DOI 10.1021/bi00105a006; BETZ A, 1991, BIOCHEM J, V275, P801, DOI 10.1042/bj2750801; BJORK I, 1992, J BIOL CHEM, V267, P1976; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BODE W, 1992, PROTEIN SCI, V1, P426; BRAUN PJ, 1988, BIOCHEMISTRY-US, V27, P6517, DOI 10.1021/bi00417a048; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3244, DOI 10.1021/bi00282a032; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3250, DOI 10.1021/bi00282a033; CHUNG DW, 1982, PROTEINS BIOL MED, P309; COOL DE, 1985, J BIOL CHEM, V260, P3666; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; EHRLICH HJ, 1990, EMBO J, V9, P2367, DOI 10.1002/j.1460-2075.1990.tb07411.x; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GARDELL SJ, 1989, J BIOL CHEM, V264, P17947; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; HIGGINS DL, 1983, J BIOL CHEM, V258, P9276; HOFSTEENGE J, 1987, EUR J BIOCHEM, V168, P49, DOI 10.1111/j.1432-1033.1987.tb13385.x; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P2144, DOI 10.1021/bi00406a049; HORNYAK TJ, 1992, BIOCHEMISTRY-US, V31, P423, DOI 10.1021/bi00117a017; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KARSHIKOV A, 1992, PROTEIN SCI, V1, P727, DOI 10.1002/pro.5560010605; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P5824, DOI 10.1021/bi00645a029; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P6970; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P19341; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P4855, DOI 10.1021/bi00365a020; LORAND L, 1986, ANN NY ACAD SCI, V485, P144, DOI 10.1111/j.1749-6632.1986.tb34577.x; LORAND L, 1981, METHOD ENZYMOL, V80, P333; MAGNUSSON S, 1975, PROTEASES BIOL CONTR, P123; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MARTIN PD, 1992, J BIOL CHEM, V267, P7911; MOSESSON MW, 1983, ANN NY ACAD SCI, V408, P97, DOI 10.1111/j.1749-6632.1983.tb23237.x; MUTA T, 1990, J BIOL CHEM, V265, P22426; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; NI F, 1989, BIOCHEMISTRY-US, V28, P3094, DOI 10.1021/bi00433a053; NI F, 1989, BIOCHEMISTRY-US, V28, P3082, DOI 10.1021/bi00433a052; OKADA M, 1983, ANN NY ACAD SCI, V408, P233, DOI 10.1111/j.1749-6632.1983.tb23248.x; Reimerdes E H, 1976, Methods Enzymol, V45, P26, DOI 10.1016/S0076-6879(76)45005-X; RICHARDSON MA, 1992, NATURE, V360, P261, DOI 10.1038/360261a0; RIXON MW, 1983, BIOCHEMISTRY-US, V22, P3237, DOI 10.1021/bi00282a031; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; STONE SR, 1991, BIOCHEMISTRY-US, V30, P3950, DOI 10.1021/bi00230a021; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; STONE SR, 1987, BIOCHEMISTRY-US, V26, P4617, DOI 10.1021/bi00389a004; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; TIMPL R, 1977, BIOCHIM BIOPHYS ACTA, V490, P420, DOI 10.1016/0005-2795(77)90017-4; TSIANG M, 1990, BIOCHEMISTRY-US, V29, P10602, DOI 10.1021/bi00499a005; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALZ DA, 1986, ANN NY ACAD SCI, V485, P323, DOI 10.1111/j.1749-6632.1986.tb34594.x; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; YE J, 1992, J BIOL CHEM, V267, P11023	67	74	77	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					19055	19061						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8395526				2022-12-25	WOS:A1993LV65900101
J	WU, L; KOUDELKA, GB				WU, L; KOUDELKA, GB			SEQUENCE-DEPENDENT DIFFERENCES IN DNA-STRUCTURE INFLUENCE THE AFFINITY OF P22 OPERATOR FOR P22 REPRESSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONCONTACTED BASES; 434 REPRESSOR; RESOLUTION; PROTEINS; TRACT	Although the central bases of the P22 operator are not contacted by P22 repressor, the affinity of repressor for operator varies with the sequence of these bases. The KMnO4 and .OH radical susceptibilities of the central bases of the operator vary with their sequence, whether or not the operator is complexed with protein or free in solution. These data show that the minor groove of a lower affinity operator which bears central C-G bases (9C) is more open than that of the higher affinity 9T operator, which bears central T-A bases. This difference in minor groove width is seen both in the absence and presence of repressor. Results of ring closure studies show that, in the absence of repressor, an operator bearing central C.G base pairs operator is overtwisted relative to an operator which contains central T.A base pairs. The binding of P22 repressor unwinds the two operators to similar extents, thereby preserving the relative differences in twists of these DNAs. Although repressor alters the twist of the operator DNA, our results show that differences in DNA torsional flexibility have no role in determining the affinity of operator for protein. Instead, the results indicate that central sequences affect operator affinity for protein by limiting the degree to which the operator can be deformed in the protein-DNA complex. The stability of the complex is apparently modulated, in a central sequence-dependent manner, by alterations in the number and/or geometry of protein-DNA contacts.	SUNY Buffalo, DEPT BIOL SCI, COOKE HALL, N CAMPUS, BUFFALO, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			Koudelka, Gerald B./AAI-3738-2020	Koudelka, Gerald B./0000-0001-6280-0837	NIGMS NIH HHS [GM42138] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM042138, R01GM042138] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ANDERSON JE, 1987, NATURE, V326, P888; BARKLEY MD, 1979, J CHEM PHYS, V70, P2991, DOI 10.1063/1.437838; DEANDA J, 1983, J BIOL CHEM, V258, P536; DICKERSON RE, 1992, METHOD ENZYMOL, V211, P67; FRIED MG, 1983, NUCLEIC ACIDS RES, V11, P141, DOI 10.1093/nar/11.1.141; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; HOCHSCHILD A, 1983, CELL, V32, P319, DOI 10.1016/0092-8674(83)90451-8; HOROWITZ DS, 1984, J MOL BIOL, V173, P75, DOI 10.1016/0022-2836(84)90404-2; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; KOUDELKA GB, 1991, NUCLEIC ACIDS RES, V19, P4115, DOI 10.1093/nar/19.15.4115; KOUDELKA GB, 1992, NATURE, V355, P89, DOI 10.1038/355089a0; KOUDELKA GB, 1988, P NATL ACAD SCI USA, V85, P4633, DOI 10.1073/pnas.85.13.4633; MCCARTHY JG, 1991, NUCLEIC ACIDS RES, V19, P3421, DOI 10.1093/nar/19.12.3421; MCCARTHY JG, 1989, NUCLEIC ACIDS RES, V17, P7541, DOI 10.1093/nar/17.18.7541; MESSING J, 1983, METHOD ENZYMOL, V101, P20; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; POTEETE AR, 1980, J MOL BIOL, V137, P81, DOI 10.1016/0022-2836(80)90158-8; POTEETE AR, 1982, J MOL BIOL, V157, P21, DOI 10.1016/0022-2836(82)90511-3; PRICE MA, 1992, METHOD ENZYMOL, V212, P194; Ptashne M., 1986, A GENETIC SWITCH; RUBIN CM, 1980, NUCLEIC ACIDS RES, V8, P4613, DOI 10.1093/nar/8.20.4613; SAUER RT, 1982, NATURE, V298, P447, DOI 10.1038/298447a0; SHORE D, 1983, J MOL BIOL, V170, P983, DOI 10.1016/S0022-2836(83)80199-5; WHARTON RP, 1985, NATURE, V316, P601, DOI 10.1038/316601a0; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; WU L, 1992, J BIOL CHEM, V267, P9134	28	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18975	18981						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8395522				2022-12-25	WOS:A1993LV65900089
J	KITAGAWA, M; OKABE, T; OGINO, H; MATSUMOTO, H; SUZUKITAKAHASHI, I; KOKUBO, T; HIGASHI, H; SAITOH, S; TAYA, Y; YASUDA, H; OHBA, Y; NISHIMURA, S; TANAKA, N; OKUYAMA, A				KITAGAWA, M; OKABE, T; OGINO, H; MATSUMOTO, H; SUZUKITAKAHASHI, I; KOKUBO, T; HIGASHI, H; SAITOH, S; TAYA, Y; YASUDA, H; OHBA, Y; NISHIMURA, S; TANAKA, N; OKUYAMA, A			BUTYROLACTONE-I, A SELECTIVE INHIBITOR OF CDK2 AND CDC2 KINASE	ONCOGENE			English	Article							TRANSCRIPTION FACTOR E2F; RETINOBLASTOMA-SUSCEPTIBILITY GENE; MATURATION-PROMOTING FACTOR; CELL-CYCLE CONTROL; PROTEIN-KINASE; POTENT INHIBITOR; RB PROTEIN; SACCHAROMYCES-CEREVISIAE; S-PHASE; PHOSPHORYLATION	We screened cdc2 kinase inhibitors from cultured mediums of micro organisms using purified mouse cyclin B-cdc2 kinase and a specific substrate peptide for cdc2 kinase. A selective inhibitor of cdc2 kinase was isolated from the cultured medium of Aspergillus species F-25799, and identified as butyrolactone I. Butyrolactone I inhibited cdc2 and cdk2 kinases but it had little effect on mitogen-activated protein kinase, protein kinase C, cyclic-AMP dependent kinase, casein kinase II, casein kinase I or epidermal growth factor-receptor tyrosine kinase. Its inhibitory effect was found to be due to competition with ATP. Butyrolactone I selectively inhibited the H1 histone phosphorylation in nuclear extracts. It also inhibited the phosphorylation of the product of retinoblastoma susceptibility gene in nuclear extracts and intact cells. Thus butyrolactone I should be very useful for elucidating the function of cdc2 and cdk2 kinases in cell cycle regulation.	MERCK RES LABS, BANYU TSUKUBA RES INST COLLABORAT, OKUBO 3, TSUKUBA 30033, JAPAN; NATL CANC CTR, RES INST, DIV BIOL, CHUO KU, TOKYO 104, JAPAN; KANAZAWA UNIV, FAC PHARMACEUT SCI, DIV BIOL, KANAZAWA, ISHIKAWA 920, JAPAN	National Cancer Center - Japan; Kanazawa University			Higashi, Hideaki/F-6872-2012					ABE K, 1991, EXP CELL RES, V192, P122, DOI 10.1016/0014-4827(91)90166-R; AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; AKIYAMA T, 1990, ONCOGENE, V5, P179; Beavo J A, 1974, Methods Enzymol, V38, P299; BRAUN S, 1984, J BIOL CHEM, V259, P2051; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KIRIYAMA N, 1977, CHEM PHARM BULL, V25, P2593; KITAGAWA M, 1992, ONCOGENE, V7, P1067; KITAGAWA M, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P431; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MINEO C, 1986, EXP CELL RES, V167, P53, DOI 10.1016/0014-4827(86)90203-X; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NAKAJO S, 1986, BIOCHEM INT, V13, P701; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PARKER PJ, 1985, EUR J BIOCHEM, V148, P579, DOI 10.1111/j.1432-1033.1985.tb08879.x; PINES J, 1990, New Biologist, V2, P389; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAY LB, 1988, J BIOL CHEM, V263, P12721; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SETO M, 1992, ONCOGENE, V7, P1401; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SZEPETOWSKI P, 1992, ONCOGENE, V7, P751; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TAYA Y, 1990, GENETIC BASIS FOR CARCINOGENESIS, P171; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; YASUDA H, 1981, BIOCHEMISTRY-US, V20, P4414, DOI 10.1021/bi00518a028; YASUDA H, 1991, CELL STRUCT FUNCT, V16, P105, DOI 10.1247/csf.16.105; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	73	247	256	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1993	8	9					2425	2432						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8395680				2022-12-25	WOS:A1993LT36800013
J	BURNS, JM; PARSONS, M; ROSMAN, DE; REED, SG				BURNS, JM; PARSONS, M; ROSMAN, DE; REED, SG			MOLECULAR-CLONING AND CHARACTERIZATION OF A 42-KDA PROTEIN PHOSPHATASE OF LEISHMANIA-CHAGASI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR ACID-PHOSPHATASE; ESCHERICHIA-COLI; PHOSPHOPROTEIN PHOSPHATASE; TRYPANOSOMA-BRUCEI; GENE REPLACEMENT; EXPRESSION; DONOVANI; IDENTIFICATION; RNA; IA	Using rabbit serum raised against a potent T cell-stimulating antigen fraction of Leishmania chagasi promastigotes, we have cloned and expressed the Leishmania type 2C serine/threonine protein phosphatase, LcPP2C. LcPP2C was shown to be present as a 42-kDa protein in both the infective promastigote and tissue amastigote stages of L. chagasi and Leishmania amazonensis. DNA hybridization studies established the close conservation of LcPP2C among eight of eight geographically diverse species of Leishmania which cause a spectrum of human diseases. To support the relationship between LcPP2C and mammalian type 2C protein phosphatases observed through predicted amino acid sequence comparisons, we expressed enzymatically active rLcPP2C in Escherichia coli. We demonstrated that purified rLcPP2C readily dephosphorylated [P-32]casein, an activity dependent on Mg2+ and insensitive to okadaic acid. In agreement with studies of rat liver PP2C, activity was maintained when Mg+2 was replaced with Mn+2 but not with Ca2+. As these parameters are characteristic of the eukaryotic type 2C serine/threonine protein phosphatases, LcPP2C can be classified as a member of this protein family. We further showed that of the four major classes of eukaryotic serine/threonine protein phosphatases, PP2C- and PP1-like activities, are readily detectable in Leishmania.	SEATTLE BIOMED RES INST, 4 NICKERSON ST, SEATTLE, WA 98109 USA; CORNELL UNIV, MED CTR, COLL MED, NEW YORK, NY 10021 USA	Center for Infectious Disease Research; Cornell University					NIAID NIH HHS [AI25038] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025038] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BURNS JM, 1991, J IMMUNOL, V146, P742; BURNS JM, 1993, P NATL ACAD SCI USA, V90, P775, DOI 10.1073/pnas.90.2.775; BURNS JM, 1992, P NATL ACAD SCI USA, V89, P1239, DOI 10.1073/pnas.89.4.1239; Chang K. P., 1985, Leishmaniasis. (Human Parasitic Diseases Vol.1.), P1; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN P, 1991, METHOD ENZYMOL, V201, P389; COHEN PTW, 1989, BIOCHEM J, V260, P931, DOI 10.1042/bj2600931; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; DAS S, 1986, MOL BIOCHEM PARASIT, V20, P143, DOI 10.1016/0166-6851(86)90026-5; DEVLIN PE, 1988, GENE, V65, P13, DOI 10.1016/0378-1119(88)90412-X; ERONDU NE, 1991, MOL BIOCHEM PARASIT, V49, P303, DOI 10.1016/0166-6851(91)90074-G; EVERS R, 1990, NUCLEIC ACIDS RES, V18, P5089, DOI 10.1093/nar/18.17.5089; FEAGIN JE, 1990, J BIOL CHEM, V265, P19373; GOTTLIEB M, 1982, MOL CELL BIOL, V2, P76, DOI 10.1128/MCB.2.1.76; GOTTLIEB M, 1981, EXP PARASITOL, V52, P117, DOI 10.1016/0014-4894(81)90067-9; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIRAGA A, 1981, EUR J BIOCHEM, V119, P503, DOI 10.1111/j.1432-1033.1981.tb05636.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lainson R., 1987, LEISHMANIASES BIOL M, P1; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; LOVELACE JK, 1986, MOL BIOCHEM PARASIT, V20, P243, DOI 10.1016/0166-6851(86)90105-2; MAURICE J, 1991, TDR NEWS, V37, P1; MCGOWAN CH, 1988, METHOD ENZYMOL, V159, P416; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PATO MD, 1983, J BIOL CHEM, V258, P7055; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REED SG, 1990, J CLIN INVEST, V85, P690, DOI 10.1172/JCI114493; REMALEY AT, 1985, J BIOL CHEM, V260, P880; REMALEY AT, 1984, J BIOL CHEM, V259, P1173; Russo D M, 1993, Prog Clin Parasitol, V3, P119; Sacks D. L., 1993, Immunology and molecular biology of parasitic infections., P237; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKEIKY YAW, 1992, J EXP MED, V176, P201, DOI 10.1084/jem.176.1.201; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAMURA S, 1989, BIOCHEM BIOPH RES CO, V163, P131, DOI 10.1016/0006-291X(89)92109-8; TAMURA S, 1989, P NATL ACAD SCI USA, V86, P1796, DOI 10.1073/pnas.86.6.1796; TOMICH CSC, 1989, NUCLEIC ACIDS RES, V17, P3179, DOI 10.1093/nar/17.8.3179; WALTER RD, 1982, MOL BIOCHEM PARASIT, V6, P287, DOI 10.1016/0166-6851(82)90061-5; 1991, TROPICAL DISEASES PR, P79	43	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17155	17161						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8394331				2022-12-25	WOS:A1993LQ98800044
J	FINNERTY, H; KELLEHER, K; MORRIS, GE; BEAN, K; MERBERG, DM; KRIZ, R; MORRIS, JC; SOOKDEO, H; TURNER, KJ; WOOD, CR				FINNERTY, H; KELLEHER, K; MORRIS, GE; BEAN, K; MERBERG, DM; KRIZ, R; MORRIS, JC; SOOKDEO, H; TURNER, KJ; WOOD, CR			MOLECULAR-CLONING OF MURINE FLT AND FLT4	ONCOGENE			English	Note							RECEPTOR TYROSINE KINASE; CHROMOSOMAL LOCALIZATION; SEQUENCE-ANALYSIS; GROWTH-FACTOR; FAMILY; GENE; IDENTIFICATION	A wide range of growth and differentiation processes are regulated by the signalling of receptor tyrosine kinases (RTKs). We have developed a nested polymerase chain reaction (PCR) procedure with degenerate primers, and used it to identify RTKs expressed in murine fetal thymus. A novel RTK, called FLT4, and the murine homologue of FLT were found, and their PCR fragment sequences were used to isolate larger cDNA clones spanning the complete coding regions of these receptors. FLT4 was found to contain an extracellular region similar to the corresponding sequences of FLT and Flk-1, containing seven immunoglobulin domains.			FINNERTY, H (corresponding author), GENET INST INC, 87 CAMBRIDGE PK DR, CAMBRIDGE, MA 02140 USA.							APRELIKOVA O, 1992, CANCER RES, V52, P746; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; GALLAND F, 1992, GENOMICS, V13, P475, DOI 10.1016/0888-7543(92)90277-Y; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HUNTER T, 1991, METHOD ENZYMOL, P3; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAUL SR, 1992, INT J CELL CLONING, V10, P309, DOI 10.1002/stem.5530100509; PONCZ M, 1982, P NATL ACAD SCI-BIOL, V79, P4298, DOI 10.1073/pnas.79.14.4298; RAZ V, 1991, ONCOGENE, V6, P753; ROSNET O, 1991, GENOMICS, V9, P380, DOI 10.1016/0888-7543(91)90270-O; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBUYA M, 1990, ONCOGENE, V5, P519; TERMAN BI, 1991, ONCOGENE, V6, P1677; VONHEIJNE G, 1987, SEQUENCE ANAL MOL BI, P113; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YOSHIDA MC, 1987, CYTOGENET CELL GENET, V46, P724	22	86	100	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2293	2298						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8393164				2022-12-25	WOS:A1993LP17100032
J	MUKUND, S; ADAMS, MWW				MUKUND, S; ADAMS, MWW			CHARACTERIZATION OF A NOVEL TUNGSTEN-CONTAINING FORMALDEHYDE FERREDOXIN OXIDOREDUCTASE FROM THE HYPERTHERMOPHILIC ARCHAEON, THERMOCOCCUS-LITORALIS - A ROLE FOR TUNGSTEN IN PEPTIDE CATABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARCHAEBACTERIUM PYROCOCCUS-FURIOSUS; IRON-SULFUR PROTEIN; CARBOXYLIC-ACID REDUCTASE; FORMATE DEHYDROGENASE; SP-NOV; FORMYLMETHANOFURAN DEHYDROGENASE; CLOSTRIDIUM-THERMOACETICUM; PURIFICATION; BACTERIA; DINUCLEOTIDE	Thermococcus litoralis is a strictly anaerobic archaeon (archaebacterium) that grows at temperatures up to 98-degrees-C by fermenting peptides. Its growth is stimulated by tungsten, and a tungsten-containing iron-sulfur protein that has formaldehyde ferredoxin oxidoreductase (FOR) activity has been purified. FOR is a homotetramer with a subunit M(r) of 70,000. It contains approximately four irons, four acid-labile sulfides, and one tungsten atom per subunit. The tungsten appears to be present as a pterin cofactor, and the Fe/S seems to comprise an unusual [4Fe-4S] cluster that in the reduced state exists in a pH-independent S = 3/2 form and a pH-dependent S = 1/2 form. FOR catalyzed the oxidation of C1-C3 aldehydes with a temperature optimum greater-than-or-equal-to 90-degrees-C and used T. litoralis ferredoxin as an electron acceptor. It did not oxidize aldehyde phosphates, utilize CoASH, or reduce NAD(P). The N-terminal sequence of FOR shows homology with the tungsto-iron-sulfur aldehyde ferredoxin oxidoreductase previously purified from the saccharolytic, hyperthermophilic archaeon Pyrococcus furiosus, in which it is proposed to function in a novel pyroglycolytic pathway (Mukund, S., and Adams, M. W. W. (1991) J. Biol. Chem. 266, 14208-14216). We show here that P. furiosus, which will also grow on peptides, albeit poorly, contains a second aldehyde-oxidizing enzyme analogous to FOR. Similarly, T. litoralis, which utilizes saccharides if limited for peptides, contains low concentrations of an enzyme analogous to AOR. It is proposed that formaldehyde (apparent K(m), 62 mM) is not the true substrate for FOR; rather, the enzyme has an as yet unknown role in peptide fermentation in hyperthermophilic archaea.	UNIV GEORGIA, DEPT BIOCHEM, LIFE SCI BLDG, ATHENS, GA 30602 USA; UNIV GEORGIA, CTR METALLOENZYME STUDIES, ATHENS, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia				Adams, Michael/0000-0002-9796-5014				ADAMS MWW, 1992, ACS SYM SER, V498, P1; ADAMS MWW, 1992, ADV INORG CHEM, V38, P341, DOI 10.1016/S0898-8838(08)60068-9; ADAMS MWW, 1990, FEMS MICROBIOL LETT, V75, P219, DOI 10.1016/0378-1097(90)90533-V; ANDREESE.JR, 1973, J BACTERIOL, V116, P867, DOI 10.1128/JB.116.2.867-873.1973; AONO S, 1989, J BACTERIOL, V171, P3433, DOI 10.1128/jb.171.6.3433-3439.1989; BARKER HA, 1981, ANNU REV BIOCHEM, V50, P23, DOI 10.1146/annurev.bi.50.070181.000323; BLAKE PR, 1991, BIOCHEMISTRY-US, V30, P10885, DOI 10.1021/bi00109a012; BLAMEY JM, 1993, BIOCHIM BIOPHYS ACTA, V1161, P19, DOI 10.1016/0167-4838(93)90190-3; BLUMENTALS II, 1990, APPL ENVIRON MICROB, V56, P1992, DOI 10.1128/AEM.56.7.1992-1998.1990; BORNER G, 1991, FEBS LETT, V290, P31, DOI 10.1016/0014-5793(91)81218-W; BRYANT FO, 1989, J BIOL CHEM, V264, P5070; CHEN JS, 1977, ANAL BIOCHEM, V79, P157, DOI 10.1016/0003-2697(77)90390-6; CONOVER RC, 1990, J BIOL CHEM, V265, P8533; CONSALVI V, 1991, EUR J BIOCHEM, V202, P1189, DOI 10.1111/j.1432-1033.1991.tb16489.x; COSTANTINO HR, 1990, J BACTERIOL, V172, P3654, DOI 10.1128/jb.172.7.3654-3660.1990; CRAMER SP, 1989, J INORG BIOCHEM, V23, P119; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EGGEN R, 1990, FEMS MICROBIOL LETT, V71, P17; FERRY JG, 1990, FEMS MICROBIOL LETT, V87, P377, DOI 10.1111/j.1574-6968.1990.tb04940.x; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; GEORGE GN, 1992, J AM CHEM SOC, V114, P3521, DOI 10.1021/ja00035a055; HALES BJ, 1987, J BIOL CHEM, V262, P16205; JONES JB, 1981, J BIOL CHEM, V256, P656; JUSZCZAK A, 1991, J BIOL CHEM, V266, P13834; KARRASCH M, 1990, FEBS LETT, V274, P48, DOI 10.1016/0014-5793(90)81326-J; LJUNGDAHL LG, 1986, ANNU REV MICROBIOL, V40, P415, DOI 10.1146/annurev.mi.40.100186.002215; LOVENBERG W, 1963, J BIOL CHEM, V238, P3899; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MUKUND S, 1991, J BIOL CHEM, V266, P14208; MUKUND S, 1990, J BIOL CHEM, V265, P11508; NEUNER A, 1990, ARCH MICROBIOL, V153, P205, DOI 10.1007/BF00247822; PARK JB, 1991, J BIOL CHEM, V266, P19351; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; ROBB FT, 1992, BIOCHIM BIOPHYS ACTA, V1120, P267, DOI 10.1016/0167-4838(92)90247-B; SCHAFER T, 1992, ARCH MICROBIOL, V158, P188, DOI 10.1007/BF00290815; SCHMITZ RA, 1992, EUR J BIOCHEM, V207, P559, DOI 10.1111/j.1432-1033.1992.tb17082.x; SPIRO TG, 1985, MOLYBDENUM ENZYMES, P1; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1111/j.1574-6968.1990.tb04089.x; STETTER KO, 1986, THERMOPHILES GENERAL, P39; STROBL G, 1992, BIOL CHEM H-S, V373, P123, DOI 10.1515/bchm3.1992.373.1.123; WEBER K, 1972, METHOD ENZYMOL, V26, P2; WHITE H, 1989, EUR J BIOCHEM, V184, P89, DOI 10.1111/j.1432-1033.1989.tb14993.x; WHITE H, 1991, BIOL CHEM H-S, V372, P999, DOI 10.1515/bchm3.1991.372.2.999; WINTER J, 1984, SYST APPL MICROBIOL, V5, P457, DOI 10.1016/S0723-2020(84)80003-X; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; YAMAMOTO I, 1983, J BIOL CHEM, V258, P1826; ZELLNER G, 1987, FEMS MICROBIOL LETT, V40, P81	49	97	99	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13592	13600						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8390467				2022-12-25	WOS:A1993LH55300082
J	LEBRUN, C; BARON, V; KALIMAN, P; GAUTIER, N; DOLAISKITABGI, J; TAYLOR, S; ACCILI, D; VANOBBERGHEN, E				LEBRUN, C; BARON, V; KALIMAN, P; GAUTIER, N; DOLAISKITABGI, J; TAYLOR, S; ACCILI, D; VANOBBERGHEN, E			ANTIBODIES TO THE EXTRACELLULAR RECEPTOR DOMAIN RESTORE THE HORMONE-INSENSITIVE KINASE AND CONFORMATION OF THE MUTANT INSULIN-RECEPTOR VALINE-382	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; TYROSINE KINASE; PHOSPHORYLATION; BINDING; MUTATION; IMPAIRS; DEFECT	A mutation substituting a valine for phenylalanine at residue 382 in the insulin receptor alpha-subunit has been found in two sisters with a genetic form of extreme insulin resistance. This receptor mutation impairs the ability of the hormone to activate autophosphorylation of solubilized receptors and phosphorylation of substrates (Accili, D., Mosthaf, L., Ullrich, A., and Taylor, S. I. (1991) J. Biol. Chem. 266, 434-439). We have previously demonstrated that in native receptors insulin induces a conformational change in the receptor beta-subunit, which is thought to be necessary for receptor activation (Baron, V., Gautier, N., Komoriya, A., Hainaut, P., Scimeca, J. C., Mervic, M., Lavielle, S., Dolais-Kitabgi, J., and Van Obberghen, E. (1990) Biochemistry 29, 4634-4641). Hence, it was thought that a defect in this conformational change might explain the functional defect of the mutant receptor. This appears to be the case, as we demonstrate here that the mutant receptor is locked in its inactive configuration. However, we found two monoclonal antibodies, directed to the extracellular domain, which are capable of restoring the mutant receptor kinase activity. The activation of the mutant receptor was accompanied by restoration of conformational changes in the beta-subunit C terminus. From these data, we draw the two following conclusions. (i) A causal link exists between receptor kinase activation and the occurrence of conformational changes. (ii) Ligands other than insulin, such as antibodies, which perturb the extracellular domain, can function as alternative ways to restore the mutant receptor kinase.	FAC MED NICE,INSERM,U145,AVE VALOMBROSE,F-06107 NICE 2,FRANCE; NIDDKD,DIABET BRANCH,BETHESDA,MD 20892	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				lebrun-frenay, christine/0000-0002-3713-2416				ACCILI D, 1992, J BIOL CHEM, V267, P586; ACCILI D, 1991, J BIOL CHEM, V266, P434; ACCILI D, 1989, EMBO J, V8, P2509, DOI 10.1002/j.1460-2075.1989.tb08388.x; BARON V, 1992, J BIOL CHEM, V267, P23290; BARON V, 1990, BIOCHEMISTRY-US, V29, P4634, DOI 10.1021/bi00471a019; DEBANT A, 1987, AM J PHYSIOL, V252, pE273, DOI 10.1152/ajpendo.1987.252.2.E273; EBINA Y, 1985, P NATL ACAD SCI USA, V82, P8014, DOI 10.1073/pnas.82.23.8014; FABRY M, 1992, J BIOL CHEM, V267, P8950; FUJITAYAMAGUCHI Y, 1983, J BIOL CHEM, V258, P5045; GRIGORESCU F, 1984, J BIOL CHEM, V259, P5003; GRUNBERGER G, 1984, SCIENCE, V223, P932, DOI 10.1126/science.6141638; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KASUGA M, 1982, NATURE, V298, P667, DOI 10.1038/298667a0; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMARCHANDBRUSTEL Y, 1985, NATURE, V315, P676, DOI 10.1038/315676a0; QUON MJ, 1992, BIOCHEMISTRY-US, V31, P9947, DOI 10.1021/bi00156a013; TAYLOR SI, 1992, ENDOCR REV, V13, P566, DOI 10.1210/er.13.3.566; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANOBBERGHEN E, 1982, FEBS LETT, V143, P179, DOI 10.1016/0014-5793(82)80094-X; VANOBBERGHEN E, 1981, P NATL ACAD SCI-BIOL, V78, P1052; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858	22	25	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11272	11277						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8388389				2022-12-25	WOS:A1993LD46600081
J	GRANOT, Y; ERIKSON, E; FRIDMAN, H; VANPUTTEN, V; WILLIAMS, B; SCHRIER, RW; MALLER, JL				GRANOT, Y; ERIKSON, E; FRIDMAN, H; VANPUTTEN, V; WILLIAMS, B; SCHRIER, RW; MALLER, JL			DIRECT EVIDENCE FOR TYROSINE AND THREONINE PHOSPHORYLATION AND ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE BY VASOPRESSIN IN CULTURED RAT VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR MESANGIAL CELLS; MYELIN BASIC-PROTEIN; SWISS 3T3 CELLS; ANGIOTENSIN-II; PHORBOL ESTERS; MAP KINASE; S6 KINASE; ARGININE VASOPRESSIN; SIGNALING PATHWAYS; RAPIDLY STIMULATE	Mitogen-activated protein (MAP) kinases are members of a 40-45-kDa family of serine/threonine protein kinases that phosphorylate several substrates including microtubule-associated protein-2, S6 kinase, and myelin basic protein. Activity of MAP kinases is regulated by growth factors that stimulate the phosphorylation of threonine 188 and tyrosine 190 in the kinase. In this paper direct evidence is presented for tyrosine and threonine phosphorylation of MAP kinase in concert with elevated activity in response to vasopressin in primary cultures of vascular smooth muscle cells. Activation of MAP kinase is correlated with activation of S6 kinase activity related to S6 kinase II. Data support the concept that the activation of MAP kinase by vasopressin is mediated by pertussis toxin-independent biochemical pathways.	UNIV COLORADO, SCH MED,HOWARD HUGHES MED INST,C-236, 4200 E 9TH AVE, DENVER, CO 80262 USA; UNIV COLORADO, SCH MED, DEPT MED, DENVER, CO 80262 USA; UNIV COLORADO, SCH MED, DEPT PHARMACOL, DENVER, CO 80262 USA; BEN GURION UNIV NEGEV, DEPT LIFE SCI, IL-84120 BEER SHEVA, ISRAEL	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Ben Gurion University				Williams, Bryan/0000-0002-8094-1841	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028353] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28353] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1990, J BIOL CHEM, V265, P11495; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANDERSON NG, 1991, J BIOL CHEM, V266, P10131; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BARRETT CB, 1992, J BIOL CHEM, V267, P4408; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARAMELO C, 1989, AM J PHYSIOL, V256, pF875, DOI 10.1152/ajprenal.1989.256.5.F875; CARAMELO C, 1990, KIDNEY INT, V38, P47, DOI 10.1038/ki.1990.165; CIRILLO DM, 1986, MOL CELL BIOL, V6, P4641, DOI 10.1128/MCB.6.12.4641; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; ERIKSON E, 1987, MOL CELL BIOL, V7, P3147, DOI 10.1128/MCB.7.9.3147; ERIKSON E, 1991, METHOD ENZYMOL, V200, P252; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FISHMAN JB, 1987, J BIOL CHEM, V262, P14049; FISHMAN JB, 1985, J BIOL CHEM, V260, P2641; FORCE T, 1991, J BIOL CHEM, V266, P6650; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GRANOT Y, 1990, BIOCHEM BIOPH RES CO, V168, P566, DOI 10.1016/0006-291X(90)92358-7; GRANOT Y, 1990, J AM SOC NEPHROL, V1, P470; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KOHNO M, 1986, BIOCHEM J, V238, P451, DOI 10.1042/bj2380451; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; POUYSSEGUR J, 1990, G PROTEINS, P555; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAKEDA K, 1988, AM J PHYSIOL, V254, pF254, DOI 10.1152/ajprenal.1988.254.2.F254; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; TSUDA T, 1991, FEBS LETT, V285, P44, DOI 10.1016/0014-5793(91)80721-E; UHING RJ, 1986, J BIOL CHEM, V261, P2140; VANPUTTEN V, 1991, J AM SOC NEPHROL, V2, P446; WHITEHOUSE S, 1983, METHOD ENZYMOL, V99, P80; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0	49	95	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9564	9569						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8387499				2022-12-25	WOS:A1993LA68900064
J	KOVARIK, A; PEAT, N; WILSON, D; GENDLER, SJ; TAYLORPAPADIMITRIOU, J				KOVARIK, A; PEAT, N; WILSON, D; GENDLER, SJ; TAYLORPAPADIMITRIOU, J			ANALYSIS OF THE TISSUE-SPECIFIC PROMOTER OF THE MUC1 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHIC EPITHELIAL MUCIN; MOLECULAR-CLONING; CORE PROTEIN; EXPRESSION; CELLS; TRANSCRIPTION; ACTIVATION; SP1; EPISIALIN; HORMONE	The 5'-sequences flanking the human MUC1 gene have been analyzed for their ability to direct expression of a reporter gene (the chloramphenicol acetyltransferase gene (CAT)) in cell lines that normally express or do not express the MUC1 gene. A construct containing 2.9 kilobase pairs of MUC1 5'-flanking sequence sequence showed expression of CAT in breast and pancreatic cell lines but not in the non-epithelial cell lines HT-1080, SK23, and HTB96. Deletion analysis showed that maximum expression was obtained in ZR-75 (breast cancer line) and HPAF (pancreatic cancer line) with only 743 base pairs of 5'-flanking sequence. Sequences within 1.6 kilobase pairs of the transcriptional start site showed enhancing activity in a vector carrying an enhancerless SV40 promoter. Analysis of proximal 5'-sequences in a promoterless CAT vector carrying the SV40 enhancer showed that sequences between -60 and -150 were crucial for tissue-specific expression. An Spl site at -99/-90 and an E box (E-MUC1) at -84/-64 in this region were shown by mutational analysis to play a role in the regulation of transcription. Gel shift analysis with oligonucleotides and nuclear extracts of ZR-75 showed protein binding to both of these sites. Sp1 binding activity was similar in ZR-75 and HT1080 cells, whereas binding of factors to the E-MUC1 oligonucleotide revealed quantitative and qualitative differences between epithelial and non-epithelial cells.	IMPERIAL CANC RES FUND, POB 123, 44 LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND	Cancer Research UK			Kovarik, Ales/H-1952-2014	Kovarik, Ales/0000-0003-2896-0698				ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; BURCHELL J, 1983, J IMMUNOL, V131, P508; BURCHELL J, 1987, CANCER RES, V47, P5476; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FREBOURG T, 1988, GENE, V65, P315, DOI 10.1016/0378-1119(88)90468-4; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GIRLING A, 1989, INT J CANCER, V43, P1072, DOI 10.1002/ijc.2910430620; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HOPPESEYLER F, 1991, NUCLEIC ACIDS RES, V19, P5080, DOI 10.1093/nar/19.18.5080; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KYPRIANOU N, 1992, ONCOGENE, V7, P57; LAN MS, 1990, J BIOL CHEM, V265, P15294; LANCASTER CA, 1990, BIOCHEM BIOPH RES CO, V173, P1019, DOI 10.1016/S0006-291X(05)80888-5; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; Maxam A M, 1980, Methods Enzymol, V65, P499; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; PARRY G, 1992, J CELL SCI, V101, P191; PEAT N, 1992, CANCER RES, V52, P1954; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; SEGAL R, 1991, J BIOL CHEM, V266, P20406; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SPICER AP, 1991, J BIOL CHEM, V266, P15099; TAYLOR-PAPADIMITRIOU J-T, 1988, Cancer Reviews, V11-12, P11; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VOS HL, 1991, BIOCHEM BIOPH RES CO, V181, P121, DOI 10.1016/S0006-291X(05)81390-7; VOS HL, 1992, J BIOL CHEM, V267, P12192; VYAS P, 1992, CELL, V69, P781, DOI 10.1016/0092-8674(92)90290-S; WATSON CJ, 1991, NUCLEIC ACIDS RES, V19, P6603, DOI 10.1093/nar/19.23.6603; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x; ZOTTER S, 1988, Cancer Reviews, V11-12, P55	37	116	127	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9917	9926						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8387509				2022-12-25	WOS:A1993LA68900108
J	NEGISHI, M; SUGIMOTO, Y; IRIE, A; NARUMIYA, S; ICHIKAWA, A				NEGISHI, M; SUGIMOTO, Y; IRIE, A; NARUMIYA, S; ICHIKAWA, A			2 ISOFORMS OF PROSTAGLANDIN-E RECEPTOR EP3 SUBTYPE - DIFFERENT COOH-TERMINAL DOMAINS DETERMINE SENSITIVITY TO AGONIST-INDUCED DESENSITIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; ADENYLATE-CYCLASE; BETA-2-ADRENERGIC RECEPTOR; DOWN-REGULATION; CELLS; RAT; INHIBITION; SITES	We recently identified two isoforms of mouse prostaglandin (PG) E receptor EP3 subtype, EP3alpha and EP3beta, which are produced by alternative splicing and different only in the carboxyl-terminal domain (Sugimoto, Y., Negishi, M., Hayashi, Y., Namba, T., Honda, A., Watabe, A., Hirata, M., Narumiya, S., and Ichikawa, A. (1993) J. Biol. Chem. 268, 2712-2718). We examined here agonist-induced desensitization of the two isoforms using Chinese hamster ovary cells stably expressing these isoforms. Exposure of the EP3alpha isoform to PGE2 for 30 min did not change maximal response but increased PGE2 concentration needed to inhibit forskolin-induced cAMP accumulation in the cells. Further exposure of this isoform to PGE2 suppressed the maximal response as well as sensitivity to PGE2 in a time-dependent manner; after 24-h exposure, it elicited only 50% of the maximal response of the control cells. Consistent with these results, short term exposure sequestered the EP3alpha isoform away from the cell surface and long term incubation decreased the total receptor number in the cells. In contrast, exposure of the EP3beta isoform to PGE2 did not affect its dose-response curve for PGE2, and no sequestration or decrease in the receptor number was observed in this isoform. Thus, alternative splicing produced the two isoforms with different carboxyl-terminal domains, which are different in sensitivity to agonist-induced desensitization.	KYOTO UNIV,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 606,JAPAN	Kyoto University; Kyoto University			Sugimoto, Yukihiko/AAV-6470-2021	Sugimoto, Yukihiko/0000-0001-6973-932X				ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CHEN MCY, 1988, GASTROENTEROLOGY, V94, P1121, DOI 10.1016/0016-5085(88)90002-9; COLEMAN R A, 1987, British Journal of Pharmacology, V91, p407P; COLEMAN RA, 1989, COMPREHENSIVE MED CH, V3, P643; DALTOSO R, 1989, EMBO J, V8, P4025, DOI 10.1002/j.1460-2075.1989.tb08585.x; GARCIAPEREZ A, 1984, J CLIN INVEST, V74, P63, DOI 10.1172/JCI111419; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HEDQVIST P, 1972, NEUROPHARMACOLOGY, V11, P177, DOI 10.1016/0028-3908(72)90090-1; HERTEL C, 1985, J BIOL CHEM, V260, P2547; KASSIS S, 1985, J BIOL CHEM, V260, P8911; KRALL JF, 1984, J ENDOCRINOL, V102, P329, DOI 10.1677/joe.0.1020329; LIMAS C, 1987, ARCH BIOCHEM BIOPHYS, V259, P89, DOI 10.1016/0003-9861(87)90473-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MONCADA S, 1985, PHARMACOL BASIS THER, P660; MONSMA FJ, 1989, NATURE, V342, P926, DOI 10.1038/342926a0; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; NAKAO A, 1989, AM J PHYSIOL, V256, pC652, DOI 10.1152/ajpcell.1989.256.3.C652; RICHELSEN B, 1984, J LIPID RES, V26, P127; ROBERTSON RP, 1983, ENDOCRINOLOGY, V113, P1732, DOI 10.1210/endo-113-5-1732; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SHAMMA MS, 1988, PROSTAGLANDINS, V36, P329, DOI 10.1016/0090-6980(88)90074-3; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; TOMOI M, 1990, PROSTAGLANDINS, V39, P113, DOI 10.1016/0090-6980(90)90068-7; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089	29	142	143	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9517	9521						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8387497				2022-12-25	WOS:A1993LA68900057
J	GUNTHER, R; SRINIVASAN, M; HAUGEJORDEN, S; GREEN, M; EHBRECHT, IM; KUNTZEL, H				GUNTHER, R; SRINIVASAN, M; HAUGEJORDEN, S; GREEN, M; EHBRECHT, IM; KUNTZEL, H			FUNCTIONAL REPLACEMENT OF THE SACCHAROMYCES-CEREVISIAE TRG1-PDI1 PROTEIN BY MEMBERS OF THE MAMMALIAN PROTEIN DISULFIDE ISOMERASE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-BINDING-PROTEIN; ENDOPLASMIC-RETICULUM; PROLYL 4-HYDROXYLASE; MOLECULAR-CLONING; PHOSPHOLIPASE-C; BETA-SUBUNIT; YEAST GENE; GLYCOSYLATION; SEQUENCES; COMPONENT	The TRG1/PDI1 gene of Saccharomyces cerevisiae is essential for growth and encodes a lumenal endoplasmic reticulum (ER) glycoprotein that is structurally related to thioredoxin and is involved in the secretory pathway. We have tested whether the yeast Trg1/Pdi1 protein can be replaced in vivo by three members of the mammalian thioredoxin-related protein family, protein disulfide isomerase (PDI), ERp72, and ERp61. Multicopy plasmids containing galactose-inducible rodent PDI and ERp72 genes support germination and growth of haploid trg1 null mutants in galactose-containing media, whereas the ERp61 gene is inactive. Strains expressing PDI or ERp72 instead of Trg1 are thermosensitive. An overproduced mutant Trg1 protein lacking the HDEL retention signal supports growth, whereas a truncated version of the protein containing only one thioredoxin-like domain is inactive. The mammalian proteins were localized to both the soluble and microsomal membrane fraction of yeast cells. Our observations indicate that the two unglycosylated mammalian proteins PDI and ERp72 are capable of replacing at least some of the critical functions of Trg1, in spite of the fact that the three proteins diverge considerably in sequences surrounding the thioredoxin-related domains.	MAX PLANCK INST EXPTL MED, HERMANN REIN STR 3, W-3400 GOTTINGEN, GERMANY; ST LOUIS UNIV, SCH MED, DEPT MICROBIOL, ST LOUIS, MO 63104 USA	Max Planck Society; Saint Louis University								ANDRES DA, 1990, J BIOL CHEM, V265, P5952; BENNETT CF, 1988, NATURE, V334, P268, DOI 10.1038/334268a0; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BULLEID NJ, 1990, EMBO J, V9, P3527, DOI 10.1002/j.1460-2075.1990.tb07561.x; CHAUDHURI MM, 1992, BIOCHEM J, V281, P645, DOI 10.1042/bj2810645; CHENG SY, 1987, J BIOL CHEM, V262, P11221; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; FARQUHAR R, 1991, GENE, V108, P81, DOI 10.1016/0378-1119(91)90490-3; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; GUNTHER R, 1991, J BIOL CHEM, V266, P24557; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; HOLMGREN A, 1968, EUR J BIOCHEM, V6, P475, DOI 10.1111/j.1432-1033.1968.tb00470.x; HUANG SH, 1991, J BIOL CHEM, V266, P5353; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; LEWIS MJ, 1986, ARCH BIOCHEM BIOPHYS, V245, P389, DOI 10.1016/0003-9861(86)90230-4; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MINK M, 1990, MOL GEN GENET, V223, P107, DOI 10.1007/BF00315802; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1991, P NATL ACAD SCI USA, V88, P1986, DOI 10.1073/pnas.88.5.1986; NOIVA R, 1991, J BIOL CHEM, V266, P19645; PARKKONEN T, 1988, BIOCHEM J, V256, P1005, DOI 10.1042/bj2561005; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; SCHAIFF WT, 1992, J EXP MED, V176, P657, DOI 10.1084/jem.176.3.657; SEGAL MS, 1992, J CELL BIOL, V118, P227, DOI 10.1083/jcb.118.2.227; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SRIVASTAVA SP, 1991, J BIOL CHEM, V266, P20337; TACHIKAWA H, 1991, J BIOCHEM, V110, P306, DOI 10.1093/oxfordjournals.jbchem.a123576; TASANEN K, 1988, J BIOL CHEM, V263, P16218; URADE R, 1992, J BIOL CHEM, V267, P15152; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800	34	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7728	7732						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8385117				2022-12-25	WOS:A1993KW97900024
J	MOLLOY, CJ; TAYLOR, DS; WEBER, H				MOLLOY, CJ; TAYLOR, DS; WEBER, H			ANGIOTENSIN-II STIMULATION OF RAPID PROTEIN TYROSINE PHOSPHORYLATION AND PROTEIN-KINASE ACTIVATION IN RAT AORTIC SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SIGNAL TRANSDUCTION; HYPERTROPHY; INDUCTION; PROLIFERATION; HYPERPLASIA; VASOPRESSIN; INHIBITION; CLONING; INJURY	In cultured rat aortic smooth muscle cells, angiotensin II (AII) treatment led to increased tyrosine phosphorylation of cellular proteins with apparent molecular masses of 42, 44, 75, and 120 kDa, respectively, as assessed by antiphosphotyrosine immunoblotting. Increased protein tyrosine phosphorylation was observed within 1 min of AII addition and was maximal by 30 min. The overall pattern of AII-stimulated protein tyrosine phosphorylation was distinct from that observed following treatment of rat aortic smooth muscle cells with platelet-derived growth factor-BB. Specific antibodies were used to identify the AII-stimulated 42- and 44-kDa tyrosine-phosphorylated proteins as the ''mitogen-activated protein kinases,'' p42mapk and p44mapk, respectively. Raf-1, a 70-74-kDa serine/threonine protein kinase, was not tyrosine-phosphorylated in response to AII but was found to be hyperphosphorylated as evidenced by retarded protein mobility in SDS gel analysis. Taken together, these data indicate that AII binding to vascular smooth muscle cells leads to rapid activation of a complex cascade of protein kinases, including protein kinase C, Raf-1, MAP kinases, and an undefined intracellular protein tyrosine kinase(s) that may be coordinately involved in signal transduction leading to cell proliferation.			MOLLOY, CJ (corresponding author), BRISTOL MYERS SQUIBB, PRI, DEPT CARDIOVASC BIOCHEM, POB 4000, PRINCETON, NJ 08543 USA.		Molloy, Christopher/A-6821-2013	Molloy, Christopher/0000-0003-2964-6166				BLENIS J, 1991, CANCER CELL-MON REV, V3, P445; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CAMPBELLBOSWELL M, 1981, EXP MOL PATHOL, V35, P265, DOI 10.1016/0014-4800(81)90066-6; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; Chiu A T, 1991, Receptor, V1, P133; CLOWES AW, 1989, J CARDIOVASC PHARM, V14, pS12, DOI 10.1097/00005344-198906146-00005; COHEN RB, 1993, PEPTIDES, V14, P345, DOI 10.1016/0196-9781(93)90051-H; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DIMARCO E, 1989, ONCOGENE, V4, P831; FORCE T, 1991, J BIOL CHEM, V266, P6650; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GIBBONS GH, 1992, J CLIN INVEST, V90, P456, DOI 10.1172/JCI115881; GIBBONS GH, 1990, CARDIOVASC DRUG THER, V4, P237, DOI 10.1007/BF01857638; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KAUFFMAN RF, 1991, LIFE SCI, V49, pPL223, DOI 10.1016/0024-3205(91)90298-P; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; LIU MW, 1989, CIRCULATION, V79, P1374, DOI 10.1161/01.CIR.79.6.1374; LYALL F, 1988, J HYPERTENS, V6, pS438, DOI 10.1097/00004872-198812040-00138; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MOLLOY CJ, 1992, MOL CELL BIOL, V12, P3903, DOI 10.1128/MCB.12.9.3903; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; OLASHAW NE, 1988, ADV SEC MESS PHOSPH, V22, P139; OSTERRIEDER W, 1991, JHYPERTENSION S2, V18, P60; OWENS GK, 1991, ADV EXP MED BIOL, V308, P71; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; OWENS GK, 1982, CIRC RES, V51, P280, DOI 10.1161/01.RES.51.3.280; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; PAUL M, 1992, TRENDS CARDIOVAS MED, V2, P94, DOI 10.1016/1050-1738(92)90013-I; PEACH MJ, 1990, J CARDIOVASC PHARM, V16, pS25, DOI 10.1097/00005344-199016004-00007; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; POWELL JS, 1990, J CARDIOVASC PHARM, V16, pS42, DOI 10.1097/00005344-199016004-00010; RAPP UR, 1991, ONCOGENE, V6, P495; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SANDBERG K, 1992, J BIOL CHEM, V267, P9455; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SCHELLING P, 1991, J HYPERTENS, V9, P3; SCOTTBURDEN T, 1990, J CARDIOVASC PHARM, V16, pS36, DOI 10.1097/00005344-199016004-00009; SECRIST JP, 1990, J BIOL CHEM, V265, P20394; STOUFFER GA, 1992, CIRC RES, V70, P820, DOI 10.1161/01.RES.70.4.820; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; ULLRICH A, 1986, COLD SPRING HARB SYM, V51, P713, DOI 10.1101/SQB.1986.051.01.084; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WONG PC, 1990, J PHARMACOL EXP THER, V255, P584	57	262	270	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7338	7345						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8385103				2022-12-25	WOS:A1993KV14100074
J	DING, JB; BADWEY, JA				DING, JB; BADWEY, JA			NEUTROPHILS STIMULATED WITH A CHEMOTACTIC PEPTIDE OR A PHORBOL ESTER EXHIBIT DIFFERENT ALTERATIONS IN THE ACTIVITIES OF A BATTERY OF PROTEIN-KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; OKADAIC ACID; SYNERGISTIC STIMULATION; SUPEROXIDE RELEASE; RABBIT NEUTROPHILS; POLYACRYLAMIDE-GEL; RESPIRATORY BURST; SENSITIVE METHOD; PHOSPHORYLATION	Protein kinases in neutrophils that undergo changes in activity during cell stimulation have been investigated by two recently described procedures. These methods are based on the ability of renatured kinases to undergo autophosphorylation or to phosphorylate protein substrates fixed in gels. Using these techniques, we report that neutrophils contain a battery of protein kinases with molecular masses of 65-61 kDa (termed ''group A kinases'') that are rapidly activated upon stimulation of the cells with the chemotactic peptide N-fMet-Leu-Phe (fMLP). Activity was maximal within 30 s with this stimulus and returned to the basal level seen in unstimulated cells within 3 min. In contrast, stimulation of neutrophils with 4beta-phorbol 12-myristate 13-acetate resulted in a diminution of these kinase activities. Treatment of neutrophils with antagonists of type 1 and 2A protein phosphatases (calyculin A, okadaic acid) inhibited the activation of the group A kinases by fMLP, whereas norokadanone, an analog of okadaic acid that is a poor inhibitor of protein phosphatases, had no effect. Exposure of neutrophils to calyculin A alone resulted in the activation of several additional protein kinases with molecular masses different from the group A kinases. These data indicate that the signal transduction pathways of neutrophils are likely to be far more complicated than previously appreciated and involve a number of uncharacterized protein kinases.	BOSTON BIOMED RES INST,DEPT CELL & MOLEC BIOL,20 STANIFORD ST,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Boston Biomedical Research Institute; Harvard University; Harvard Medical School					NIAID NIH HHS [AI28342, AI23323] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028342, R01AI023323] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Badwey J A, 1986, Methods Enzymol, V132, P365; BADWEY JA, 1989, BIOCHEM BIOPH RES CO, V158, P1029, DOI 10.1016/0006-291X(89)92825-8; BADWEY JA, 1988, J BIOL CHEM, V263, P2779; BADWEY JA, 1989, J BIOL CHEM, V264, P20676; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; CHATILA TA, 1989, J CELL BIOL, V109, P3435, DOI 10.1083/jcb.109.6.3435; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COUTURIER A, 1984, BIOCHEM BIOPH RES CO, V121, P448, DOI 10.1016/0006-291X(84)90203-1; COX CC, 1986, J IMMUNOL, V136, P4611; DING JB, 1992, J BIOL CHEM, V267, P6442; DOWNEY GP, 1992, J CELL BIOL, V116, P695, DOI 10.1083/jcb.116.3.695; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GEAHLEN RL, 1986, ANAL BIOCHEM, V153, P151, DOI 10.1016/0003-2697(86)90074-6; GOMEZCAMBRONERO J, 1992, P NATL ACAD SCI USA, V89, P7551, DOI 10.1073/pnas.89.16.7551; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HEYWORTH PG, 1989, J BIOL CHEM, V264, P14935; HEYWORTH PG, 1990, J BIOENERG BIOMEMBR, V22, P1, DOI 10.1007/BF00762842; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HUANG CK, 1988, J BIOL CHEM, V263, P13144; ISHIHARA H, 1989, J PHARMACOL EXP THER, V250, P388; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KAIBUCHI K, 1983, J BIOL CHEM, V258, P6701; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; LACKS SA, 1980, J BIOL CHEM, V255, P7467; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; MELLONI E, 1986, J BIOL CHEM, V261, P4101; NISHIWAKI S, 1990, CARCINOGENESIS, V11, P1837, DOI 10.1093/carcin/11.10.1837; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; SIESS W, 1988, BIOCHEM J, V255, P309; SMOLEN JE, 1980, J CLIN INVEST, V65, P1077, DOI 10.1172/JCI109760; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TUSZYNSKI GP, 1987, PLATELET RESPONSES M, V2, P187; TYAGI SR, 1991, J BIOL CHEM, V266, P3498; WHITE JR, 1984, J BIOL CHEM, V259, P8605; WHITE JR, 1983, J BIOL CHEM, V258, P4041	45	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5234	5240						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8383131				2022-12-25	WOS:A1993KP88400096
J	TANG, CL; HENRY, HL				TANG, CL; HENRY, HL			OVEREXPRESSION IN ESCHERICHIA-COLI AND AFFINITY PURIFICATION OF CHICK KIDNEY FERREDOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; AMINO-ACID SEQUENCE; RECOMBINANT PROTEINS; MITOCHONDRIAL FERREDOXIN; LIVER-MITOCHONDRIA; BOVINE ADRENODOXIN; CHROMATOGRAPHY; CYTOCHROME-P-450; PHOSPHORYLATION; HYDROXYLATION	Vertebrate ferredoxins are 12-14-kDa iron-sulfur proteins, some of which transfer electrons to mitochondrial cytochrome P450s. The function of many of these cytochrome P450s is to catalyze stereospecific hydroxylation of endogenous steroids. As part of our interest in the kidney mitochondrial 1alpha-hydroxylation of 25-hydroxyvitamin D3, we have constructed an expression plasmid coding for a fusion protein containing the chick kidney ferredoxin. We subcloned chick kidney ferredoxin cDNA, obtained from our vitamin D-deficient chick kidney library by polymerase chain reaction (Brandt, M. E., Gabrik, A. H., and Vickery, L. E. (1991) Gene (Amst.) 97, 113-117) into Qiagen's pQE9, which contains an N-terminal 6xHis tag (peptide sequence for 6 adjacent histidines present in the recombinant proteins). The coding sequence was preceded by a factor Xa cleavage site. The resulting plasmid, pQTcFdx, was overexpressed in Escherichia coli, and the soluble fusion protein was purified from the cell lysate in one step by Ni(II)-nitrilotriacetic acid-agarose chromatography. We obtained 7-10 mg of greater than 99% homogeneous fusion protein from a 1-liter culture and 4-6 mg of mature ferredoxin cleaved by factor Xa. The fusion protein possessed an absorption spectrum and an electron paramagnetic resonance spectrum quantitatively indistinguishable from those published for ferredoxin purified from adrenal glands and placenta or expressed in E. coli with another vector. The fusion protein was active in supporting the 1alpha-hydroxylation of 25-hydroxyvitamin D3 in a reconstitution assay of a solubilized, partially purified preparation of cytochrome P450 from vitamin D-deficient chick kidney. We conclude that the procedure described here is an efficient way to produce and purify vertebrate ferredoxin; the [2Fe-2S] cofactor is assembled in vivo and effectively incorporated into the fusion protein in E. coli; slight alterations at the N terminus do not alter incorporation of the [2Fe-2S] cofactor or the biological activity of ferredoxin, and post-translational modifications, such as phosphorylation, are not an absolute requirement for ferredoxin electron transporting activity. The recombinant ferredoxin can be used for physical studies and other structure-function studies.	UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92521	University of California System; University of California Riverside								ATSUTA Y, 1978, J BIOL CHEM, V253, P4653; Beinert H., 1965, NONHEME IRON PROTEIN, P23; BLANCHARD RK, 1991, VITAMIN D, P269; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRNADT ME, 1991, GENE AMST, V97, P113; BUSH GL, 1991, J BIOL CHEM, V266, P13811; COGHLAN VM, 1989, P NATL ACAD SCI USA, V86, P835, DOI 10.1073/pnas.86.3.835; COGHLAN VM, 1988, ARCH BIOCHEM BIOPHYS, V264, P376, DOI 10.1016/0003-9861(88)90302-5; COGHLAN VM, 1992, J BIOL CHEM, V267, P8932; CUNNINGHAM NS, 1986, BIOCHIM BIOPHYS ACTA, V881, P480, DOI 10.1016/0304-4165(86)90042-5; DRISCOLL WJ, 1986, J BIOL CHEM, V261, P4122; FRASER DR, 1970, NATURE, V228, P764, DOI 10.1038/228764a0; GERMINO J, 1984, P NATL ACAD SCI-BIOL, V81, P4692, DOI 10.1073/pnas.81.15.4692; HARRIS TJR, 1983, GENET ENG, V4, P130; HEMDAN ES, 1989, P NATL ACAD SCI USA, V86, P1811, DOI 10.1073/pnas.86.6.1811; HENRY HL, 1984, ANNU REV NUTR, V4, P493, DOI 10.1146/annurev.nu.04.070184.002425; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; INGLEDEW WJ, 1984, MICROBIOL REV, V48, P222, DOI 10.1128/MMBR.48.3.222-271.1984; KAGIMOTO K, 1988, BIOCHEM BIOPH RES CO, V155, P379, DOI 10.1016/S0006-291X(88)81096-9; KIMURA T, 1968, J BIOCHEM-TOKYO, V63, P716, DOI 10.1093/oxfordjournals.jbchem.a128836; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MONNIER N, 1987, EUR J BIOCHEM, V169, P147, DOI 10.1111/j.1432-1033.1987.tb13592.x; NEMANI R, 1989, J BIOL CHEM, V264, P15361; OFTEBRO H, 1979, J BIOL CHEM, V254, P4331; OFTEBRO H, 1981, J LIPID RES, V22, P1254; OMDAHL JL, 1992, ARCH BIOCHEM BIOPHYS, V293, P213, DOI 10.1016/0003-9861(92)90387-C; PALMER G, 1967, BIOCHEMISTRY-US, V6, P1658, DOI 10.1021/bi00858a012; PEDERSEN JI, 1977, BIOCHEM BIOPH RES CO, V76, P666, DOI 10.1016/0006-291X(77)91552-2; PEDERSEN JI, 1976, J BIOL CHEM, V251, P3933; PONCHON G, 1969, J CLIN INVEST, V48, P1273, DOI 10.1172/JCI106093; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; SAMBROOK J, 1989, MOL CLONING LAB MANU, pF6; Sambrook J, 1989, MOL CLONING LABORATO; SASSENFELD HM, 1984, BIO-TECHNOL, V2, P76, DOI 10.1038/nbt0184-76; SHUBHRA M, 1988, ARCH BIOCHEM BIOPHYS, V264, P383; SIEGEL N, 1986, J BIOL CHEM, V261, P6998; SIMPSON ER, 1978, ARCH BIOCHEM BIOPHYS, V190, P800, DOI 10.1016/0003-9861(78)90340-5; SMITH MC, 1988, J BIOL CHEM, V263, P7211; SUHARA K, 1972, BIOCHIM BIOPHYS ACTA, V263, P272, DOI 10.1016/0005-2795(72)90079-7; TANAKA M, 1973, J BIOL CHEM, V248, P1141; ULLMANN A, 1984, GENE, V29, P27, DOI 10.1016/0378-1119(84)90162-8; VOSTERS AF, 1992, PROTEIN EXPRES PURIF, V3, P18, DOI 10.1016/1046-5928(92)90051-W; WATARI H, 1966, BIOCHEM BIOPH RES CO, V24, P106, DOI 10.1016/0006-291X(66)90417-7; QIAEXPRESSIONIST, P32	44	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5069	5076						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8383127				2022-12-25	WOS:A1993KP88400075
J	KELLY, KL; RUDERMAN, NB				KELLY, KL; RUDERMAN, NB			INSULIN-STIMULATED PHOSPHATIDYLINOSITOL 3-KINASE - ASSOCIATION WITH A 185-KDA TYROSINE-PHOSPHORYLATED PROTEIN (IRS-1) AND LOCALIZATION IN A LOW-DENSITY MEMBRANE VESICLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTORS; ISOLATED FAT-CELLS; GLUCOSE-TRANSPORTER; RAT ADIPOCYTES; BOVINE BRAIN; PHOSPHOINOSITIDE METABOLISM; SACCHAROMYCES-CEREVISIAE; SIGNAL TRANSDUCTION; 3T3-L1 ADIPOCYTES; PLASMA-MEMBRANE	Insulin stimulates the appearance of anti-tyrosine(P)-immunoprecipitable phosphatidylinositol 3-kinase (PI 3-kinase) activity in adipocytes, predominantly in an intracellular membrane fraction (Kelly, K. L., Ruderman, N. B., and Chen, K. S. (1992) J. Biol. Chem. 267, 3423-3428). Neither the mechanism underlying this activation nor the precise subcellular compartment in which it occurs is known. To address these questions, studies were performed using isolated rat adipocytes and subcellular fractions of these cells. In intact cells, insulin stimulated the rapid appearance of phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate in P-32-labeled adipocytes without changing the labeling of phosphatidylinositol 3-phosphate, phosphatidylinositol 4-phosphate, or phosphatidylinositol 4,5-bisphosphate. This effect was accompanied by the tyrosyl phosphorylation of a 185-kDa protein, tentatively identified as IRS-1, with which PI 3-kinase became associated. The majority of the p85, the regulatory subunit of PI 3-kinase, in untreated adipocytes was present in the cytosol; however, neither the activity of PI 3-kinase nor the total amount of p85 in this fraction was modified in response to insulin. In contrast, insulin increased the association of p85 with IRS-1, the tyrosyl phosphorylation of the IRS-1 associated with p85, and the total activity of PI 3-kinase in the plasma membranes and low density membranes. After insulin treatment, similar amounts of p85 were bound to IRS-1 in the low density and plasma membrane fractions; however, tyrosyl-phosphorylated IRS-1 and PI 3-kinase activity were an order of magnitude greater in the low density membranes. The complex of tyrosyl-phosphorylated IRS-1.p85 that formed in response to insulin was localized to a very low density vesicle subpopulation that could be distinguished from vesicles containing the GLUT-4 glucose transporter and the insulin receptor. These data suggest that the activation of PI 3-kinase by insulin in the adipocyte involves the formation of a complex between IRS-1 and PI 3-kinase in a very low density membrane fraction that is not enriched in GLUT-4 or insulin receptors. They also suggest that PI 3-kinase activation correlates more closely with the extent of tyrosyl phosphorylation of the IRS-1 complexed to PI 3-kinase than it does to the amount of p85 bound to IRS-1.	BOSTON UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02118	Boston University	KELLY, KL (corresponding author), BOSTON UNIV,SCH MED,EVANS DEPT MED,DIABET & METAB UNIT,E-211,88 E NEWTON ST,BOSTON,MA 02118, USA.			Ruderman, Neil/0000-0002-6589-6587	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007224] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042621] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32HL07224] Funding Source: Medline; NIDDK NIH HHS [DK42621] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGER KR, 1989, J BIOL CHEM, V264, P20181; AUGERT G, 1988, J BIOL CHEM, V263, P3600; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COHEN B, 1990, P NATL ACAD SCI USA, V265, P40458; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DELVECCHIO RL, 1989, BIOCHIM BIOPHYS ACTA, V986, P41, DOI 10.1016/0005-2736(89)90270-8; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; GIBBS EM, 1986, J BIOL CHEM, V261, P6597; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HAYASHI H, 1991, BIOCHEM J, V280, P769, DOI 10.1042/bj2800769; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; JAMES DE, 1988, BIOCHEM J, V256, P725, DOI 10.1042/bj2560725; JAMES DE, 1987, J BIOL CHEM, V262, P11817; JERGIL B, 1983, J BIOL CHEM, V258, P7968; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KASUGA M, 1982, NATURE, V298, P667, DOI 10.1038/298667a0; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KELLER SR, 1991, J BIOL CHEM, V266, P12817; KELLY KL, 1987, J BIOL CHEM, V262, P15285; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KELLY KL, 1989, J BIOL CHEM, V264, P1274; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPS DL, 1989, J BIOL CHEM, V264, P19911; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MCKEEL DW, 1970, J CELL BIOL, V44, P417, DOI 10.1083/jcb.44.2.417; MOONEY RA, 1989, ENDOCRINOLOGY, V124, P422, DOI 10.1210/endo-124-1-422; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PENNINGTON SR, 1985, J BIOL CHEM, V260, P1039; PETRUZZELLI LM, 1982, P NATL ACAD SCI-BIOL, V79, P6792, DOI 10.1073/pnas.79.22.6792; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUSA M, 1992, J BIOL CHEM, V267, P22951; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YOAKIM M, 1992, J VIROL, V66, P5485, DOI 10.1128/JVI.66.9.5485-5491.1992	57	210	211	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4391	4398						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8382701				2022-12-25	WOS:A1993KN53300084
J	BEGUM, N; LEITNER, W; REUSCH, JEB; SUSSMAN, KE; DRAZNIN, B				BEGUM, N; LEITNER, W; REUSCH, JEB; SUSSMAN, KE; DRAZNIN, B			GLUT-4 PHOSPHORYLATION AND ITS INTRINSIC ACTIVITY - MECHANISM OF CA2+-INDUCED INHIBITION OF INSULIN-STIMULATED GLUCOSE-TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; CYTOSOLIC FREE CALCIUM; GLYCOGEN-BINDING SUBUNIT; DEPENDENT PROTEIN-KINASE; RAT ADIPOCYTES; CATALYTIC SUBUNIT; PLASMA-MEMBRANE; PHOSPHATASE-1G; RESISTANCE; ATP	In this study, we examined the influence of high levels of cytosolic calcium on phosphorylation status and function of GLUT-4 in isolated rat adipocytes. Intracellular calcium was elevated by exposing adipocytes to either extracellular ATP (1.6 mM) or thapsigargin (100 nM). Both agents increased cytosolic calcium 2-3-fold. While basal glucose uptake was unaffected, both ATP and thapsigargin reduced insulin-stimulated glucose transport by 40-70% (p < 0.05). Neither ATP nor thapsigargin affected GLUT-4 content or its translocation from the low density microsomes to the plasma membrane (PM). In contrast, GLUT-4 immunoprecipitated from the PM of adipocytes exposed to either ATP or thapsigargin was phosphorylated to a greater extent than the GLUT-4 isolated from control cells. ATP and thapsigargin also abolished insulin-stimulated dephosphorylation of GLUT-4. At the same time, GLUT-4 intrinsic activity was significantly reduced in adipocytes with high levels of cytosolic calcium (p < 0.05). Preincubation of adipocytes with cAMP antagonist, RpcAMP (10(-4) M), and calcium channel blocker, nitrendipine (30 muM), improved the ability of insulin to dephosphorylate GLUT-4 and restored insulin-stimulated GLUT-4 intrinsic activity. We conclude that elevated levels of cytosolic calcium interfere with insulin's ability to dephosphorylate GLUT-4, thus reducing its intrinsic activity.	VET ADM MED CTR,DEPT MED,ENDOCRINOL SECT 111H,1055 CLERMONT ST,DENVER,CO 80220; VET AFFAIRS MED CTR,RES SERV,DENVER,CO 80220; UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80262	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Reusch, Jane/0000-0001-8620-1003				ALEMANY S, 1986, EUR J BIOCHEM, V156, P101, DOI 10.1111/j.1432-1033.1986.tb09554.x; BEGUM N, 1992, J CLIN INVEST, V90, P1254, DOI 10.1172/JCI115988; BEGUM N, 1991, CELL CALCIUM, V12, P423, DOI 10.1016/0143-4160(91)90068-P; BEGUM N, 1992, J BIOL CHEM, V267, P5959; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COEVERA S, 1991, J BIOL CHEM, V266, P9271; COHEN P, 1988, PROC R SOC SER B-BIO, V234, P115, DOI 10.1098/rspb.1988.0040; COHEN P, 1989, J BIOL CHEM, V264, P21435; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4158; DENT P, 1990, FEBS LETT, V259, P281, DOI 10.1016/0014-5793(90)80027-G; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DRAZNIN B, 1989, ENDOCRINOLOGY, V125, P2341, DOI 10.1210/endo-125-5-2341; DRAZNIN B, 1988, J CLIN INVEST, V82, P1848, DOI 10.1172/JCI113801; DRAZNIN B, 1987, J BIOL CHEM, V262, P14385; GINTY DD, 1991, J BIOL CHEM, V266, P17454; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P711, DOI 10.1111/j.1432-1033.1989.tb15264.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V180, P457, DOI 10.1111/j.1432-1033.1989.tb14668.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P701, DOI 10.1111/j.1432-1033.1989.tb15263.x; JAMES DE, 1989, P NATL ACAD SCI USA, V86, P8368, DOI 10.1073/pnas.86.21.8368; LAWRENCE JC, 1990, J BIOL CHEM, V265, P2324; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; LIN SH, 1985, J BIOL CHEM, V260, P7850; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; NAGELKERKE JF, 1989, BIOCHEM J, V263, P347, DOI 10.1042/bj2630347; REUSCH JEB, 1991, ENDOCRINOLOGY, V129, P3269, DOI 10.1210/endo-129-6-3269; REUSCH JEB, 1993, J BIOL CHEM, V268, P3348; RODBELL M, 1964, J BIOL CHEM, V239, P375; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SMITH PK, 1985, ANAL BIOCHEM, V150, P2324; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; VOLKER TT, 1985, ANAL BIOCHEM, V144, P347, DOI 10.1016/0003-2697(85)90127-7; Weber T. M., 1988, INSULIN RECEPTORS B, P171	35	104	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3352	3356						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8381427				2022-12-25	WOS:A1993KM16100053
J	CZARNECKA, H; YOKOYAMA, S				CZARNECKA, H; YOKOYAMA, S			REGULATION OF LECITHIN-CHOLESTEROL ACYLTRANSFERASE REACTION BY ACYL ACCEPTORS AND DEMONSTRATION OF ITS IDLING REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; SYNTHETIC PEPTIDE ANALOGS; LOW-DENSITY LIPOPROTEINS; HUMAN-PLASMA; LYSOLECITHIN ACYLTRANSFERASE; DISCOIDAL COMPLEXES; SURFACE-PROPERTIES; ACTIVATION; PHOSPHATIDYLCHOLINE; PHOSPHOLIPASE-A2	The mechanism for regulation of cholesterol esterification by lecithin-cholesterol acyltransferase (LCAT) was studied using the highly isolated enzyme from pig plasma. In the reaction with phosphatidylcholine small unilamellar vesicles, cholesterol, water, diacylglycerol, and lysophosphatidylcholine were all potent acceptors of an acyl group cleaved from the sn-2 position of egg phosphatidylcholine, generating cholesteryl ester, free fatty acid, triglyceride, and phosphatidylcholine, respectively. All of these reactions required activation by human apolipoprotein A-I, suggesting that this activation leads to the deacylation of phosphatidylcholine. Those acceptors competed against each other in this vesicle reaction system, and cholesterol was the most potent acyl acceptor. Lysophosphatidylcholine that was endogenously generated by deacylation of phosphatidylcholine in the first step of the LCAT reaction was also a good acyl acceptor, showing that the reaction is always partly ''idling.'' Bovine serum albumin partially inhibited this idling reaction in a concentration-dependent manner up to 80% at 0.60 mM. The above results were essentially reproducible with high density lipoprotein, except that cholesterol is less potent than lysophosphatidylcholine in accepting the acyl group under the condition used. Unlike the apolipoprotein A-I-activated reaction, cholesterol was esterified only slightly by the LCAT reaction on low density lipoprotein and, consequently, did not compete against lysophosphatidylcholine for generation of phosphatidylcholine. Thus, apoB may activate LCAT in a very different manner from apoA-I. The rate of esterification of lysophosphatidylcholine on low density lipoprotein was one-tenth of that on the vesicles and on high density lipoprotein. Thus, LCAT is active on low density lipoprotein but mostly idling as deacylating and reacylating glycerophospholipids.	UNIV ALBERTA,DEPT MED,LIPID & LIPOPROTEIN RES GRP,EDMONTON T6G 2S2,BC,CANADA	University of Alberta								AGGERBECK LP, 1976, J BIOL CHEM, V251, P3823; AKANUMA Y, 1968, J LIPID RES, V9, P3620; ALBERS JJ, 1978, SCAND J CLIN LAB INV, V38, P48, DOI 10.3109/00365517809104899; ANANTHARAMAIAH GM, 1990, ARTERIOSCLEROSIS, V10, P95, DOI 10.1161/01.ATV.10.1.95; ANDO S, 1990, BIOCHIM BIOPHYS ACTA, V1043, P289, DOI 10.1016/0005-2760(90)90029-W; ARON L, 1978, J BIOL CHEM, V253, P7220; CHUNG BH, 1985, J BIOL CHEM, V260, P256; CHUNG J, 1979, J BIOL CHEM, V254, P7456; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; FITCH WM, 1977, GENETICS, V86, P623; FUKUSHIMA D, 1979, J AM CHEM SOC, V101, P3703, DOI 10.1021/ja00507a068; FUKUSHIMA D, 1980, J BIOL CHEM, V255, P651; GLOMSET JA, 1968, J LIPID RES, V9, P155; GLOMSET JA, 1983, METABOLIC BASIS INHE, P643; HACHIMORI Y, 1971, BIOCHEMISTRY-US, V10, P4084, DOI 10.1021/bi00798a012; JONAS A, 1984, J BIOL CHEM, V259, P6369; KITABATAKE K, 1979, BIOCHIM BIOPHYS ACTA, V573, P145, DOI 10.1016/0005-2760(79)90181-4; KNIPPING G, 1987, BIOCHEMISTRY-US, V26, P7945, DOI 10.1021/bi00398a060; KUPFERBERG JP, 1981, J BIOL CHEM, V256, P6274; LETIZIA JY, 1991, BIOCHEMISTRY-US, V30, P866, DOI 10.1021/bi00217a041; LIU M, 1992, J BIOL CHEM, V267, P5139; LUNDKATZ S, 1984, BIOCHEMISTRY-US, V23, P1130, DOI 10.1021/bi00301a015; LUNDKATZ S, 1985, BIOCHEMISTRY-US, V26, P1562; MCLACHLAN AD, 1977, NATURE, V267, P465, DOI 10.1038/267465a0; NISHIKAWA O, 1988, J BIOCHEM, V103, P188, DOI 10.1093/oxfordjournals.jbchem.a122229; OKABE H, 1988, J BIOCHEM, V104, P141, DOI 10.1093/oxfordjournals.jbchem.a122411; PATTNAIK NM, 1976, J BIOL CHEM, V251, P1984; PIRAN U, 1976, J BIOCHEM-TOKYO, V80, P887, DOI 10.1093/oxfordjournals.jbchem.a131352; PIRAN U, 1979, LIPIDS, V14, P478, DOI 10.1007/BF02533465; PONSIN G, 1986, J BIOL CHEM, V261, P9202; POWNALL HJ, 1980, P NATL ACAD SCI-BIOL, V77, P3154, DOI 10.1073/pnas.77.6.3154; RYAN RO, 1992, BIOCHEMISTRY-US, V31, P4509, DOI 10.1021/bi00133a018; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SIGLER GF, 1976, P NATL ACAD SCI USA, V73, P1422, DOI 10.1073/pnas.73.5.1422; SOUTAR AK, 1975, BIOCHEMISTRY-US, V14, P3057, DOI 10.1021/bi00685a003; STEINMETZ A, 1985, J BIOL CHEM, V260, P2258; SUBBAIAH PV, 1980, J BIOL CHEM, V255, P9275; TAJIMA S, 1983, J BIOL CHEM, V258, P73; THOMAS PD, 1988, BIOCHEM J, V251, P55, DOI 10.1042/bj2510055; YOKOYAMA S, 1980, J BIOL CHEM, V255, P7333; YOKOYAMA S, 1982, J BIOCHEM, V91, P1267, DOI 10.1093/oxfordjournals.jbchem.a133811; YOKOYAMA S, 1978, BIOCHIM BIOPHYS ACTA, V530, P258; YOKOYAMA S, 1985, J BIOL CHEM, V260, P6375; YOKOYAMA S, 1977, J BIOCHEM-TOKYO, V81, P1227; ZORICH N, 1985, J BIOL CHEM, V260, P8831	45	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19334	19340						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8396134				2022-12-25	WOS:A1993LW81900030
J	SOLA, MM; SALTO, R; OLIVER, FJ; GUTIERREZ, M; VARGAS, AM				SOLA, MM; SALTO, R; OLIVER, FJ; GUTIERREZ, M; VARGAS, AM			EFFECTS OF AMP AND FRUCTOSE 2,6-BISPHOSPHATE ON FLUXES BETWEEN GLUCOSE-6-PHOSPHATE AND TRIOSE-PHOSPHATE IN RENAL CORTICAL EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-KIDNEY CORTEX; CARBOHYDRATE-METABOLISM; CONTROL COEFFICIENTS; GLUCONEOGENESIS; GLYCOLYSIS; LIVER; PHOSPHOFRUCTOKINASE; ENZYMES; PATHWAY; CYCLE	Gluconeogenic flux exceeds glycolytic flux at the hexose-phosphate steps when measured in extracts of kidney cortex from well-fed rats. Addition of AMP and/or fructose 2,6-bisphosphate to the assay medium partially eradicates the difference. Using principles developed by Kacser, H., and Burns, J. A. ((1973) in Rate Control of Biological Processes (Davies, D. D., ed) pp. 65-104, Cambridge University Press, London) and Heinrich R., and Rapoport T. A. ((1974) Eur. J. Biochem. 42, 97-105), flux control coefficients of enzymes participating in the pathway segments from glucose 6-phosphate to triose-phosphates and from glycerol 3-phosphate to glucose 6-phosphate were determined by additions of the respective enzyme to the system. Results show that the flux control coefficients are highly modulated by the presence of allosteric effectors, as might be expected according to the regulatory properties of phosphofructokinase and fructose-1, 6-bisphosphatase purified from this origin. Measured reductions of fructose 2,6-bisphosphate and AMP levels during acidosis, starvation, or after phenylephrine treatment suggest that these changes contribute to enhanced gluconeogenesis under these conditions.	UNIV GRANADA, FAC CIENCIAS, DEPT BIOQUIM & BIOL MOLEC, AVE FUENTENUEVA S-N, E-18071 GRANADA, SPAIN	University of Granada			Salto, Rafael/A-6486-2011; Oliver, Javier/S-1725-2018	Salto, Rafael/0000-0002-7044-3611; Oliver, Javier/0000-0001-8468-1998				BARTLETT S, 1984, BIOCHEM J, V219, P73, DOI 10.1042/bj2190073; BERGMEYER HU, 1974, METHOD ENZYMAT AN, P1101; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLAUS TH, 1984, CURR TOP CELL REGUL, V23, P57; CRABTREE B, 1987, BIOCHEM J, V247, P113, DOI 10.1042/bj2470113; FELL DA, 1992, BIOCHEM J, V286, P313, DOI 10.1042/bj2860313; FLINT HJ, 1981, BIOCHEM J, V200, P231, DOI 10.1042/bj2000231; GARCIASALGUERO L, 1989, MOL CELL BIOCHEM, V85, P91; GARCIASALGUERO L, 1989, COMP BIOCHEM PHYS B, V92, P67, DOI 10.1016/0305-0491(89)90314-3; GIL J, 1986, BIOCHEM BIOPH RES CO, V136, P498, DOI 10.1016/0006-291X(86)90468-7; GROEN AK, 1986, BIOCHEM J, V237, P379, DOI 10.1042/bj2370379; GROEN AK, 1982, J BIOL CHEM, V257, P2754; GUDER WG, 1984, KIDNEY INT, V26, P101, DOI 10.1038/ki.1984.143; HEINRICH R, 1974, EUR J BIOCHEM, V42, P97, DOI 10.1111/j.1432-1033.1974.tb03319.x; HERS HG, 1983, ANNU REV BIOCHEM, V52, P617, DOI 10.1146/annurev.bi.52.070183.003153; Hohmann B, 1975, Curr Probl Clin Biochem, V4, P47; JANSSENS P, 1980, BIOCHEM J, V190, P27, DOI 10.1042/bj1900027; Jaworek D, 1974, METHODS ENZYMATIC AN, P2127, DOI 10.1016/B978-0-12-091304-6.50066-5; KACSER H, 1981, GENETICS, V97, P639; KACSER H, 1973, RATE CONTROL BIOL PR, P65; MALEQUE A, 1980, FEBS LETT, V116, P154, DOI 10.1016/0014-5793(80)80631-4; MELENDEZHEVIA E, 1990, NATO ADV SCI I A-LIF, V190, P231; MIDDLETON RJ, 1983, GENETICS, V105, P633; MUNOZCLARES R, 1979, FEBS LETT, V99, P340, DOI 10.1016/0014-5793(79)80987-4; NEWSHOLME EA, 1966, BIOCHEM J, V99, pC24; NOLTMANN EA, 1966, METHOD ENZYMOL, V9, P557; OLIVER J, 1990, LIFE SCI, V47, P401, DOI 10.1016/0024-3205(90)90297-5; PILKIS SJ, 1986, ANN NY ACAD SCI, V478, P1, DOI 10.1111/j.1749-6632.1986.tb15517.x; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; QUANT PA, 1993, TRENDS BIOCHEM SCI, V18, P26; REGEN DM, 1984, J THEOR BIOL, V111, P635, DOI 10.1016/S0022-5193(84)80259-3; RONGSTAD R, 1979, BIOCHIM BIOPHYS ACTA, V586, P242; ROSS BD, 1986, KIDNEY INT, V29, P54, DOI 10.1038/ki.1986.8; Ross BD, 1982, METABOLIC COMPARTMEN, P363; SALTER M, 1986, BIOCHEM J, V234, P635, DOI 10.1042/bj2340635; SALTO R, 1991, KIDNEY INT, V39, P1162, DOI 10.1038/ki.1991.147; SCHOOLWERTH AC, 1988, MINER ELECTROL METAB, V14, P347; SOLA MD, 1991, COMP BIOCHEM PHYS B, V98, P495; TORRES NV, 1988, FEBS LETT, V233, P83, DOI 10.1016/0014-5793(88)81360-7; TORRES NV, 1986, BIOCHEM J, V234, P169, DOI 10.1042/bj2340169; VANDEWALLE A, 1981, AM J PHYSIOL, V240, pF492, DOI 10.1152/ajprenal.1981.240.6.F492; VANSCHAFTINGEN E, 1980, BIOCHEM J, V192, P263, DOI 10.1042/bj1920263; VANSCHAFTINGEN E, 1980, BIOCHEM J, V192, P887, DOI 10.1042/bj1920887; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; VARGAS AM, 1990, J BIOL CHEM, V265, P15368; [No title captured]	46	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19352	19357						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8396135				2022-12-25	WOS:A1993LW81900033
J	BATES, MD; OLSEN, CL; BECKER, BN; ALBERS, FJ; MIDDLETON, JP; MULHERON, JG; JIN, SLC; CONTI, M; RAYMOND, JR				BATES, MD; OLSEN, CL; BECKER, BN; ALBERS, FJ; MIDDLETON, JP; MULHERON, JG; JIN, SLC; CONTI, M; RAYMOND, JR			ELEVATION OF CAMP IS REQUIRED FOR DOWN-REGULATION, BUT NOT AGONIST-INDUCED DESENSITIZATION, OF ENDOGENOUS DOPAMINE-D(1) RECEPTORS IN OPOSSUM KIDNEY-CELLS - STUDIES IN CELLS THAT STABLY EXPRESS A RAT CAMP-PHOSPHODIESTERASE (RPDE3) CDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-A; CYCLIC-AMP; MESSENGER-RNA; MEDIATED ENDOCYTOSIS; ADENYLYL CYCLASE; ACCUMULATION; GONADOTROPIN; CLONING; SIGNAL; ASSAY	D1 dopamine receptors stimulate cAMP accumulation in opossum kidney (OK) cells, but this response is attenuated by pretreatment with dopamine. Dopamine pretreatment also causes a reduction in D1 dopamine receptor number. We transfected OK cells with a rat cAMP phosphodiesterase cDNA (rPDE3) in order to determine the contribution of elevations of cAMP to those two phenomena. Wild-type (WT) OK cells were compared to three clones (C, H, and N) which demonstrated stable expression of the rPDE3 phenotype and genotype. rPDE3 RNA expression was confirmed in clones C, H, and N (but not in WT-OK cells) by reverse transcriptase-polymerase chain reaction. A functional rPDE3 phenotype was demonstrated in that dopamine-responsive cAMP accumulation was absent in clones C, H, and N in intact cells, but could be restored by preincubation with cAMP phosphodiesterase inhibitors, or by using washed membranes from those clones. All three clones had increased cAMP phosphodiesterase activity when compared to WT-OK cells (almost-equal-to 100% increase), and blunted or absent dopamine (1 muM)-induced protein kinase A activation. After pretreatment with dopamine (1 muM) for 1 h, clones C, H, and N desensitized equally well as WT-OK cells (almost-equal-to 40-50% reduction in maximal increase in cAMP). In contrast, down-regulation of D1 dopamine receptors was blunted for clone C (20% receptor loss) and absent for clones H and N, when compared to a 45% loss of receptors for WT-OK cells. These findings suggest that in OK cells pretreated with 1 muM dopamine (i) cAMP accumulation is not necessary for dopamine-induced desensitization, but (ii) is necessary for down-regulation of D1 dopamine receptors, and (iii) that the down-regulation and desensitization processes may be differentially regulated.	DUKE UNIV, MED CTR, DEPT MED, DIV NEPHROL, BOX 3459, DURHAM, NC 27710 USA; CHILDRENS HOSP MED CTR, DEPT PEDIAT, BOSTON, MA 02115 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; STANFORD UNIV, MED CTR, DEPT OBSTET & GYNECOL, DIV REPROD BIOL, STANFORD, CA 94305 USA; DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA; DEPT VET AFFAIRS MED CTR, MED SERV, NEPHROL SECT, DURHAM, NC 27705 USA; GLAXO INC, DEPT MOLEC BIOL, RES TRIANGLE PK, NC 27709 USA	Duke University; Harvard University; Boston Children's Hospital; Duke University; Stanford University; Duke University; Howard Hughes Medical Institute; GlaxoSmithKline					NINDS NIH HHS [NS30927] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030927] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; ANDERSEN PH, 1990, TRENDS PHARMACOL SCI, V11, P231, DOI 10.1016/0165-6147(90)90249-8; ASCOLI M, 1984, J CELL BIOL, V99, P1242, DOI 10.1083/jcb.99.4.1242; BADGER TM, 1992, MOL CELL NEUROSCI, V3, P91, DOI 10.1016/1044-7431(92)90013-R; BALMFORTH AJ, 1990, J NEUROCHEM, V55, P2111, DOI 10.1111/j.1471-4159.1990.tb05803.x; BARTON AC, 1990, MOL PHARMACOL, V38, P531; BATES MD, 1991, AM J PHYSIOL, V260, pF937, DOI 10.1152/ajprenal.1991.260.6.F937; BEEBE SJ, 1986, ENZYMES, V17, P43; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CHNEIWEISS H, 1990, EUR J PHARM-MOLEC PH, V189, P287, DOI 10.1016/0922-4106(90)90121-D; COLLINS S, 1992, TRENDS BIOCHEM SCI, V17, P37, DOI 10.1016/0968-0004(92)90425-9; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; FARGIN A, 1989, J BIOL CHEM, V264, P14848; GROVE JR, 1987, SCIENCE, V238, P530; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HILZ H, 1975, EUR J BIOCHEM, V56, P106; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; JIN SLC, 1992, J BIOL CHEM, V267, P18929; KEMP BE, 1978, J BIOL CHEM, V253, P5147; KINOSHITA S, 1990, AM J PHYSIOL, V258, pF1068, DOI 10.1152/ajprenal.1990.258.4.F1068; KOYAMA H, 1978, IN VITRO CELL DEV B, V14, P239; MEMO M, 1982, P NATL ACAD SCI-BIOL, V79, P4456, DOI 10.1073/pnas.79.14.4456; MIDDLETON JP, 1989, AM J PHYSIOL, V257, pF631, DOI 10.1152/ajprenal.1989.257.4.F631; MOYLAN RD, 1982, J BIOL CHEM, V257, P4947; OLSON MF, 1992, MOL ENDOCRINOL, V6, P1095, DOI 10.1210/me.6.7.1095; RAYMOND JR, 1990, HYPERTENSION, V15, P119, DOI 10.1161/01.HYP.15.2.119; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGAL JH, 1990, J CLIN INVEST, V86, P1442, DOI 10.1172/JCI114860; SEGALOFF DL, 1990, MOL ENDOCRINOL, V4, P1856, DOI 10.1210/mend-4-12-1856; STEFFEY ME, 1991, EUR J PHARM-MOLEC PH, V207, P311, DOI 10.1016/0922-4106(91)90005-3; SWINNEN JV, 1991, J BIOL CHEM, V266, P14383; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P5325, DOI 10.1073/pnas.86.14.5325; WANG H, 1991, J BIOL CHEM, V266, P780; ZHOU XM, 1991, J BIOL CHEM, V266, P7462	37	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14757	14763						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8392059				2022-12-25	WOS:A1993LL75900036
J	BRIGGS, MR; YOKOYAMA, C; WANG, XD; BROWN, MS; GOLDSTEIN, JL				BRIGGS, MR; YOKOYAMA, C; WANG, XD; BROWN, MS; GOLDSTEIN, JL			NUCLEAR-PROTEIN THAT BINDS STEROL REGULATORY ELEMENT OF LOW-DENSITY-LIPOPROTEIN RECEPTOR PROMOTER .1. IDENTIFICATION OF THE PROTEIN AND DELINEATION OF ITS TARGET NUCLEOTIDE-SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION; GENE; ACTIVATION; CELLS; SP1	The current paper reports the identification of a protein in rat liver nuclei that binds to the sterol regulatory element (SRE-1) in the promoter of the gene for the low density lipoprotein receptor. The 10-base pair SRE-1 is embedded within a 16-base pair sequence designated Repeat 2 located immediately upstream of a related sequence designated Repeat 3. To confirm that DNA recognition by the SRE-1 binding protein (SREBP) correlates with sterol-regulated transcription, we synthesized an artificial promoter that contains two copies of wild-type or mutant Repeat 2 + 3 sequences immediately upstream of a TATA box from adenovirus. The synthetic promoters were inserted upstream of a reporter gene and tested for transcriptional activity in the absence and presence of sterols after transient transfection into monkey CV-1 cells. The reporter gene with two copies of the wild-type Repeat 2 + 3 sequence was transcribed actively in sterol-deprived cells and was repressed by more than 80% when sterols were present. Binding of SREBP to the SRE-1 sequence, assessed by gel mobility shift assays, correlated precisely on a nucleotide-by-nucleotide basis with the transcriptional activity of each of 16 synthetic promoters with point mutations in Repeat 2. The SREBP bound to the nine mutant promoters that were positive for sterol-regulated transcription, and it did not bind to any of the nine point mutants that abolished transcription. We conclude that SREBP is a DNA binding protein that mediates sterol-regulated transcription of the low density lipoprotein receptor gene.			BRIGGS, MR (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, F32HL007833] Funding Source: NIH RePORTER; NHLBI NIH HHS [5F32HL07833, HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BISHOP RW, 1992, J LIPID RES, V33, P549; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; FREEDMAN LP, 1989, SCIENCE, V245, P298, DOI 10.1126/science.2473529; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; LEE F, 1984, NUCLEIC ACIDS RES, V12, P4191, DOI 10.1093/nar/12.10.4191; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; Sambrook J, 1989, MOL CLONING LABORATO; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SMITH JR, 1990, J BIOL CHEM, V265, P2306; SMITH JR, 1988, J BIOL CHEM, V263, P18480; STARK HC, 1992, P NATL ACAD SCI USA, V89, P2180, DOI 10.1073/pnas.89.6.2180; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; WANG XD, 1993, J BIOL CHEM, V268, P14497	21	363	384	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14490	14496						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8390995				2022-12-25	WOS:A1993LJ82500100
J	REISSMANN, PT; KOGA, H; TAKAHASHI, R; FIGLIN, RA; HOLMES, EC; PIANTADOSI, S; CORDONCARDO, C; SLAMON, DJ				REISSMANN, PT; KOGA, H; TAKAHASHI, R; FIGLIN, RA; HOLMES, EC; PIANTADOSI, S; CORDONCARDO, C; SLAMON, DJ			INACTIVATION OF THE RETINOBLASTOMA SUSCEPTIBILITY GENE IN NON-SMALL-CELL LUNG-CANCER	ONCOGENE			English	Article							RAS ONCOGENE ACTIVATION; GROWTH-FACTOR RECEPTORS; OSTEO-SARCOMA; RB GENE; ALTERED EXPRESSION; DNA-SEQUENCE; HUMAN-BREAST; SHORT ARM; EGF-R; CARCINOMA	Mutations that prevent the normal expression of the retinoblastoma susceptibility gene (RB) have been linked to the pathogenesis of several human malignancies. Mutational inactivation of this tumor-suppressor gene appears to initiate the development of retinoblastoma, and may also contribute to the pathogenesis of osteosarcomas, soft-tissue sarcomas, small-cell lung cancer and other malignancies. In cooperation with the Lung Cancer Study Group, we studied the structure and expression of the RB gene in a cohort of 219 primary non-small-cell lung cancers (NSCLCs). RB gene structure was studied at the DNA level by Southern blot and chromosome 13 restriction fragment length polymorphism analyses. Expression of the RB gene was evaluated by Northern analysis of the transcript and immunohistochemical analysis of the protein (p105RB). Immunohistochemistry of the RB protein proved to be the most sensitive method for the detection of Rb gene inactivation. Absent or abnormal RB protein staining was detected in 53/163 (32%) evaluable cases studied, while Northern analysis showed 22/219 cases to have an altered or absent RB transcript. Southern analysis revealed only two cases of structural alteration of the gene, but loss of heterozygosity from chromosome 13 was common in tumors that failed to express the protein. Analysis of the clinical outcomes of the patients whose tumors were studied did not show any correlation of RB inactivation with time to relapse or death. The data from this study indicate that the RB gene is inactivated in a significant number of NSCLCs. The role that these mutations may play in the development of NSCLC remains to be defined.	UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90024 USA; BAYLOR UNIV, CTR BIOTECHNOL, THE WOODLANDS, TX 77381 USA; JOHNS HOPKINS UNIV, JOHNS HOPKINS ONCOL CTR, BALTIMORE, MD 21205 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT SURG, LOS ANGELES, CA 90024 USA; MEM SLOAN KETTERING CANC CTR, DEPT PATHOL, NEW YORK, NY 10021 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Baylor College of Medicine; Baylor University; Johns Hopkins University; Johns Hopkins Medicine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [CA 55827] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351; ABRAMSON DH, 1976, T AM ACAD OPHTHALMOL, V81, pP454; BALABAN G, 1982, CANCER GENET CYTOGEN, V6, P213, DOI 10.1016/0165-4608(82)90058-9; BENEDICT WF, 1983, CANCER GENET CYTOGEN, V10, P311, DOI 10.1016/0165-4608(83)90090-0; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CANCE WG, 1990, NEW ENGL J MED, V323, P1457, DOI 10.1056/NEJM199011223232105; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CERNY T, 1986, BRIT J CANCER, V54, P265, DOI 10.1038/bjc.1986.172; CHAUM E, 1984, CYTOGENET CELL GENET, V38, P82, DOI 10.1159/000132037; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHENG J, 1990, BLOOD, V75, P730; CHIBA I, 1990, ONCOGENE, V5, P1603; COX DR, 1972, J R STAT SOC B, V34, P187; DAZZI H, 1989, BRIT J CANCER, V59, P746, DOI 10.1038/bjc.1989.156; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HENDLER FJ, 1984, J CLIN INVEST, V74, P647, DOI 10.1172/JCI111463; HENSEL CH, 1990, CANCER RES, V50, P3067; HOVIG E, 1987, CANCER GENET CYTOGEN, V24, P327, DOI 10.1016/0165-4608(87)90115-4; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KAGIMOTO M, 1985, INT J CANCER, V35, P809, DOI 10.1002/ijc.2910350618; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KITCHIN FD, 1974, J MED GENET, V11, P244, DOI 10.1136/jmg.11.3.244; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOGA H, UNPUB; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MANIATIS T, 1982, MOL CLONING LABORATO, P282; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; MIYAKI M, 1985, JPN J CANCER RES, V76, P260; MORI N, 1990, ONCOGENE, V5, P1713; MURAKAMI Y, 1991, ONCOGENE, V6, P37; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; REISSMANN PT, 1989, ONCOGENE, V4, P839; RODENHUIS S, 1988, CANCER RES, V48, P5738; RYGAARD K, 1990, CANCER RES, V50, P5312; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASANO H, 1990, CANCER, V66, P2150, DOI 10.1002/1097-0142(19901115)66:10<2150::AID-CNCR2820661018>3.0.CO;2-7; SHERWIN SA, 1981, CANCER RES, V41, P3538; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; VARLEY JM, 1989, ONCOGENE, V4, P725; VEALE D, 1987, BRIT J CANCER, V55, P513, DOI 10.1038/bjc.1987.104; VOGEL F, 1979, HUM GENET, V52, P1; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; XU HJ, 1991, CANCER RES, V51, P2735; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1988, ONCOGENE, V3, P471; YOKOTA J, 1988, ONCOGENE, V2, P607	67	153	157	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1993	8	7					1913	1919						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8390038				2022-12-25	WOS:A1993LG68200024
J	TZENG, YJ; GUHL, E; GRAESSMANN, M; GRAESSMANN, A				TZENG, YJ; GUHL, E; GRAESSMANN, M; GRAESSMANN, A			BREAST-CANCER FORMATION IN TRANSGENIC ANIMALS INDUCED BY THE WHEY ACIDIC PROTEIN SV40 T-ANTIGEN (WAP-SV-T) HYBRID GENE	ONCOGENE			English	Article							HA-RAS; MICE; EXPRESSION; ONCOGENES; CELLS; TRANSCRIPTION; INFORMATION; MECHANISMS; CARCINOMA; RECEPTORS	After injection of the whey acidic protein (WAP)-SV-T hybrid gene into fertilized mouse eggs, eight independent transgenic mouse lines were obtained. Females from three lines developed mammary carcinomas with high frequency, coinciding mostly with lactation. In contrast to the endogenous WAP gene, expression of the hybrid gene continued after lactation. The tumor cells had a very invasive growth characteristic. Tumor regression in vivo was not observed. However, after transfer into tissue culture 25% of the cells ceased to express the hybrid gene and acquired the growth characteristic of normal cells. It was possible to retransform these cells by injection of wild-type SV40 DNA, but not after transfer of the hybrid WAP-SV-T gene. Inactivation of the endogenous WAP and of the WAP-SV-T transgene did not correlate with DNA methylation.	FREE UNIV BERLIN,INST MOLEK BIOL & BIOCHEM,ARNIMALLEE 22,W-1000 BERLIN 33,GERMANY	Free University of Berlin								ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; BERGER MS, 1988, CANCER RES, V48, P1238; BURDON T, 1991, J BIOL CHEM, V266, P6909; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; CAMPBELL SM, 1984, NUCLEIC ACIDS RES, V12, P8685, DOI 10.1093/nar/12.22.8685; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GRAESSMANN A, 1973, DEV BIOL, V35, P180, DOI 10.1016/0012-1606(73)90016-X; GRAESSMANN A, 1993, DNA METHYLATION MOL, P404; GRAESSMANN M, 1976, P NATL ACAD SCI USA, V73, P366, DOI 10.1073/pnas.73.2.366; GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482; GRAESSMANN M, 1984, J MOL BIOL, V180, P111, DOI 10.1016/0022-2836(84)90433-9; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HENDERSON BE, 1988, CANCER RES, V48, P246; HOGAN B, 1986, MANPULATING MOUSE EM; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MESSING A, 1985, NATURE, V316, P461, DOI 10.1038/316461a0; PARKIN DM, 1984, B WORLD HEALTH ORGAN, V62, P163, DOI 10.1139/b84-027; PITTIUS CW, 1988, MOL ENDOCRINOL, V2, P1027, DOI 10.1210/mend-2-11-1027; Sambrook J, 1989, MOL CLONING LABORATO; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; SCHWABE JWR, 1991, TRENDS BIOCHEM SCI, V16, P291, DOI 10.1016/0968-0004(91)90121-B; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TOOZE J, 1981, MOL BIOL TUMOR VIR 2; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049	30	67	70	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1965	1971						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8390039				2022-12-25	WOS:A1993LG68200029
J	KNUDSON, CM; STANG, KK; JORGENSEN, AO; CAMPBELL, KP				KNUDSON, CM; STANG, KK; JORGENSEN, AO; CAMPBELL, KP			BIOCHEMICAL-CHARACTERIZATION AND ULTRASTRUCTURAL-LOCALIZATION OF A MAJOR JUNCTIONAL SARCOPLASMIC-RETICULUM GLYCOPROTEIN (TRIADIN)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; CA-2+ RELEASE CHANNEL; PURIFIED RYANODINE RECEPTOR; DIHYDROPYRIDINE RECEPTOR; MOLECULAR-CLONING; 1,4-DIHYDROPYRIDINE RECEPTOR; STRUCTURAL CHARACTERIZATION; 53,000-DALTON GLYCOPROTEIN; TERMINAL CISTERNAE; TRANSVERSE TUBULES	Monoclonal antibodies were used to identify a 94-kDa protein that was greatly enriched in triads and junctional face membranes (9.3 +/- 0.2%) but not detected in the transverse tubular and nonjunctional sarcoplasmic reticulum membranes. The 94-kDa protein is a hydrophobic glycoprotein based on endoglycosidase H sensitivity, concanavalin A binding, and labeling with a hydrophobic probe. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis in the absence and presence of reducing agents suggests that this protein is present as a population of multimeric structures containing a variable number of the 94-kDa subunits. Immunofluorescent staining of serial transverse sections of skeletal muscle shows staining of all fiber types with preferential staining of type II fast fibers. Specific immunofluorescence staining in longitudinal sections of skeletal muscle is confined to the interface between the A- and I-bands where the triad structures are localized. Immunocolloidal gold labeling revealed the 94-kDa glycoprotein to be localized over a region of the junctional sarcoplasmic reticulum where the ryanodine receptor/Ca2+ release channel is localized. The distribution and high abundance of the 94-kDa glycoprotein in the junctional membrane suggest that it performs a structural or functional role in the storage or release of calcium from the junctional sarcoplasmic reticulum in skeletal muscle.	UNIV IOWA, COLL MED, HHMI, DEPT PHYSIOL & BIOPHYS, 400A EMRB, IOWA CITY, IA 52242 USA; UNIV TORONTO, DEPT ANAT & CELL BIOL, TORONTO M5S 1A8, ONTARIO, CANADA	Howard Hughes Medical Institute; University of Iowa; University of Toronto				Knudson, Charles Michael/0000-0003-3964-5466; Campbell, Kevin/0000-0003-2066-5889	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039265] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL14388, HL39265] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BRANDT NR, 1990, J MEMBRANE BIOL, V113, P237, DOI 10.1007/BF01870075; BRUNNER J, 1981, BIOCHEMISTRY-US, V20, P7174, DOI 10.1021/bi00528a019; CAMPBELL KP, 1981, J BIOL CHEM, V256, P4626; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1197; CAMPBELL KP, 1984, J BIOL CHEM, V259, P5384; CAMPBELL KP, 1980, BIOCHIM BIOPHYS ACTA, V602, P97, DOI 10.1016/0005-2736(80)90293-X; CASWELL AH, 1991, BIOCHEMISTRY-US, V30, P7507, DOI 10.1021/bi00244a020; CHADWICK CC, 1988, J BIOL CHEM, V263, P10872; CHIOVETTI R, 1985, SCI BIOL SPECIMEN PR; COSTELLO B, 1986, J CELL BIOL, V103, P741, DOI 10.1083/jcb.103.3.741; Eisenberg B. R., 2010, COMPREHENSIVE PHYSL, P73; FILL M, 1989, ANN NY ACAD SCI, V560, P155, DOI 10.1111/j.1749-6632.1989.tb24092.x; FLUCHER BE, 1990, NEURON, V5, P339, DOI 10.1016/0896-6273(90)90170-K; FOSSET M, 1983, J BIOL CHEM, V258, P6086; FRANZINI.C, 1970, J CELL BIOL, V47, P488, DOI 10.1083/jcb.47.2.488; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1988, METHOD ENZYMOL, V157, P490; JAY SD, 1991, J BIOL CHEM, V266, P3287; JORGENSEN AO, 1987, J HISTOCHEM CYTOCHEM, V35, P723, DOI 10.1177/35.7.2953782; JORGENSEN AO, 1988, CIRC RES, V63, P1060, DOI 10.1161/01.RES.63.6.1060; JORGENSEN AO, 1988, CELL MOTIL CYTOSKEL, V9, P164, DOI 10.1002/cm.970090208; JORGENSEN AO, 1989, J CELL BIOL, V109, P135, DOI 10.1083/jcb.109.1.135; JORGENSEN AO, 1990, J CELL BIOL, V110, P1173, DOI 10.1083/jcb.110.4.1173; JORGENSEN AO, 1983, J CELL BIOL, V97, P1573, DOI 10.1083/jcb.97.5.1573; KAWAMOTO RM, 1986, J CELL BIOL, V103, P1405, DOI 10.1083/jcb.103.4.1405; KIM KC, 1990, BIOCHEMISTRY-US, V29, P9281, DOI 10.1021/bi00491a025; KNUDSON CM, 1989, J BIOL CHEM, V264, P10795; KNUDSON CM, 1990, J BIOL CHEM, V265, P2421; KNUDSON CM, 1993, J BIOL CHEM, V268, P12646; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LEBERER E, 1989, J BIOL CHEM, V264, P3484; LEBERER E, 1989, P NATL ACAD SCI USA, V86, P6047, DOI 10.1073/pnas.86.16.6047; LEBERER E, 1990, J BIOL CHEM, V265, P10118; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MacLennan D., 1983, CALCIUM CELL FUNCT, V4, P151; MACLENNAN DH, 1971, P NATL ACAD SCI USA, V68, P1231, DOI 10.1073/pnas.68.6.1231; MICHALAK M, 1980, J BIOL CHEM, V255, P1317; MITCHELL RD, 1983, J BIOL CHEM, V258, P9867; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; ROSEMBLATT M, 1981, J BIOL CHEM, V256, P8140; SHARP AH, 1987, J BIOL CHEM, V262, P12309; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YUAN SH, 1991, J CELL BIOL, V112, P289, DOI 10.1083/jcb.112.2.289; ZAIDI NF, 1989, J BIOL CHEM, V264, P21737; ZAIDI NF, 1989, J BIOL CHEM, V264, P21725; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	54	95	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12637	12645						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8389762				2022-12-25	WOS:A1993LG65800062
J	SLAPAK, CA; KHARBANDA, S; SALEEM, A; KUFE, DW				SLAPAK, CA; KHARBANDA, S; SALEEM, A; KUFE, DW			DEFECTIVE TRANSLOCATION OF PROTEIN-KINASE-C IN MULTIDRUG-RESISTANT HL-60 CELLS CONFERS A REVERSIBLE LOSS OF PHORBOL ESTER-INDUCED MONOCYTIC DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMYELOCYTIC LEUKEMIA-CELLS; TRANSCRIPTION FACTOR AP-1; COLONY-STIMULATING FACTOR; TUMOR NECROSIS FACTOR; FOS GENE-EXPRESSION; MOLECULAR-CLONING; P-GLYCOPROTEIN; HL60 CELLS; TERMINAL DIFFERENTIATION; ERYTHROLEUKEMIA-CELLS	Previous studies have demonstrated that human HL-60 myeloid leukemia cells differentiate in response to phorbol esters. This event is associated with induction of the c-jun early response gene and appearance of a monocytic phenotype. The present studies have examined the effects of vincristine-selected, multidrug resistance on 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced HL-60 cell differentiation. The results demonstrate that multidrug-resistant HL-60 cells, designated HL-60/vinc, fail to respond to TPA with an increase in c-jun transcripts or other phenotypic characteristics of monocytic differentiation. By contrast, treatment of HL-60/vinc cells with okadaic acid, an inhibitor of serine/threonine protein phosphatases, induces c-jun transcription, growth arrest, and expression of the c-fms gene. Studies were also performed with an HL-60/vinc revertant (HL-60/vinc/R) line that has regained partial sensitivity to vincristine. The finding that HL-60/vinc/R cells respond to TPA with induction of a monocytic phenotype, but not c-jun expression, suggests that c-jun induction is not obligatory for monocytic differentiation. Other studies further demonstrate that the jun-B and fra-1 genes are induced by TPA in both HL-60/vinc and HL-60/vinc/R cells, whereas c-fos expression is attenuated in the HL-60/vinc line. Since TPA activates protein kinase C (PKC), we examined translocation of PKC from the cytosol to the membrane fraction. Although HL-60 and HL-60/vinc/R cells demonstrated translocation of PKC activity, this subcellular redistribution was undetectable in HL-60/vinc cells. Activity of the mitogen-activated protein kinase family with associated phosphorylation of c-Jun Y-peptide was markedly diminished in TPA-treated HL-60/vinc cells, but not in response to okadaic acid. Taken together, these findings suggest that vincristine resistance confers insensitivity to TPA-induced differentiation and can include defects in PKC-mediated signaling events and induction of jun/fos early response gene expression.			SLAPAK, CA (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,CLIN PHARMACOL LAB,BOSTON,MA 02115, USA.				NCI NIH HHS [CA-01613, CA42802] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042802] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADUNYAH SE, 1992, J CELL PHYSIOL, V151, P415, DOI 10.1002/jcp.1041510223; AIHARA H, 1991, P NATL ACAD SCI USA, V88, P11062, DOI 10.1073/pnas.88.24.11062; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AQUINO A, 1988, CANCER RES, V48, P3324; BECK WT, 1986, CANCER RES, V46, P4571; BHALLA K, 1985, CANCER RES, V45, P3657; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER R, 1991, ONCOGENE, V6, P229; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; DATTA R, 1991, CELL GROWTH DIFFER, V2, P43; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; FINE RL, 1988, P NATL ACAD SCI USA, V85, P582, DOI 10.1073/pnas.85.2.582; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HAYASHI M, 1986, LEUKEMIA RES, V10, P1051, DOI 10.1016/0145-2126(86)90258-4; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOMMA Y, 1986, P NATL ACAD SCI USA, V83, P7316, DOI 10.1073/pnas.83.19.7316; HORIGUCHI J, 1989, MOL CELL BIOL, V9, P252, DOI 10.1128/MCB.9.1.252; HUBERMAN E, 1979, P NATL ACAD SCI USA, V76, P1293, DOI 10.1073/pnas.76.3.1293; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; JORDAN MA, 1991, CANCER RES, V51, P2212; KAWASAKI ES, 1985, SCIENCE, V230, P291, DOI 10.1126/science.2996129; KHARBANDA S, 1992, CELL GROWTH DIFFER, V3, P391; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEUNG MF, 1992, CANCER RES, V52, P949; LOTEM J, 1979, P NATL ACAD SCI USA, V76, P5158, DOI 10.1073/pnas.76.10.5158; MA LD, 1991, J BIOL CHEM, V266, P5593; MAXWELL SA, 1991, CELL GROWTH DIFFER, V2, P115; MCGRATH T, 1988, CANCER RES, V48, P3959; MELLONI E, 1988, P NATL ACAD SCI USA, V85, P3835, DOI 10.1073/pnas.85.11.3835; MELLONI E, 1990, P NATL ACAD SCI USA, V87, P4417, DOI 10.1073/pnas.87.12.4417; MICHAELI J, 1990, MOL CELL BIOL, V10, P3535, DOI 10.1128/MCB.10.7.3535; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NAKAMURA T, 1991, CELL GROWTH DIFFER, V2, P267; NISHIKAWA M, 1990, CANCER RES, V50, P621; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHERMAN ML, 1990, J BIOL CHEM, V265, P3320; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SOLOMON DH, 1991, CELL GROWTH DIFFER, V2, P187; STAATS J, 1990, J BIOL CHEM, V265, P4084; STONE RM, 1988, BLOOD, V72, P208; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; TONETTI DA, 1992, CELL GROWTH DIFFER, V3, P739; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; WANG AM, 1985, SCIENCE, V228, P149, DOI 10.1126/science.3856324; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WILLIAM F, 1990, J BIOL CHEM, V265, P18166; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	70	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12267	12273						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8389757				2022-12-25	WOS:A1993LG65800010
J	CHEN, TM; CHEN, CA; HSIEH, CY; CHANG, DY; CHEN, YH; DEFENDI, V				CHEN, TM; CHEN, CA; HSIEH, CY; CHANG, DY; CHEN, YH; DEFENDI, V			THE STATE OF P53 IN PRIMARY HUMAN CERVICAL CARCINOMAS AND ITS EFFECTS IN HUMAN PAPILLOMAVIRUS-IMMORTALIZED HUMAN CERVICAL CELLS	ONCOGENE			English	Article							WILD-TYPE P53; CELLULAR TUMOR-ANTIGEN; ACTIVATING MUTATIONS; GEL-ELECTROPHORESIS; EPITHELIAL-CELLS; MUTANT P53; PROTEIN; DNA; LINES; TRANSFORMATION	Wild-type (wt) p53 acts as a tumor suppressor, while certain mutant type (mt) p53 may exhibit 'oncogenic' function. We have recently demonstrated that human papillomavirus type 18 (HPV-18) E6 can partially overcome the growth-suppressive effects of wt p53, but it remains unclear what role p53 plays in cervical carcinogenesis. In this report, we have examined nine HPV-immortalized human cervical epithelial cell lines and 13 HPV-positive and two HPV-negative primary cervical cancers for p53 mutations by polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP). None of them contained p53 mutations in exons 5-9 where most p53 mutations in human tumors have been found. The entire p53-coding region of the two HPV-negative cervical cancers was sequenced and no mutations were noted. In order to examine the effects of wt p53 and mt p53 on HPV-immortalized human cells, we transfected HPV-immortalized cell lines with wt p53 and a mt p53 (mtp43Val-135). The results indicate that HPV-immortalized cells cannot tolerate large amounts of exogenous wt p53, while mt p53Val-135 can enhance transformation of these cells. The results support the notion that inactivation of wt p53 by E6 may be important for HPV-associated transformation and also suggests that mt p53 can act as an oncogene in HPV-immoralized human cells.	NYU MED CTR,DEPT PATHOL,550 1ST AVE,NEW YORK,NY 10016; NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016; NATL TAIWAN UNIV,COLL MED,DEPT OBSTET & GYNECOL,TAIPEI,TAIWAN; NATL TAIWAN UNIV,COLL MED,DEPT PHARM,TAIPEI,TAIWAN	New York University; New York University; National Taiwan University; National Taiwan University				CHEN, CHI-AN/0000-0001-6670-7939; defendi, vittorio/0000-0002-0707-6900				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1990, ONCOGENE, V5, P893; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN TM, 1992, ONCOGENE, V7, P1541; CROOK T, 1991, ONCOGENE, V6, P873; DEAN SW, 1989, EXP CELL RES, V183, P473, DOI 10.1016/0014-4827(89)90406-0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUJITA M, 1992, CANCER RES, V52, P5323; Gai X X, 1988, Oncogene Res, V3, P377; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOSONO S, 1991, ONCOGENE, V6, P237; HOWLEY PM, 1991, CANCER RES, V51, pS5019; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; INOUE H, 1992, VIROLOGY, V187, P343, DOI 10.1016/0042-6822(92)90325-J; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; LEE YY, 1992, P AM ASSOC CANC RES, V33, P339; LEHMAN TA, 1991, CANCER RES, V51, P4090; Manos M. M., 1990, PCR PROTOCOLS GUIDE, P356; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; OKAMOTO A, 1991, CANCER RES, V51, P5632; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PECORARO G, 1989, P NATL ACAD SCI USA, V86, P563, DOI 10.1073/pnas.86.2.563; PECORARO G, 1991, AM J PATHOL, V138, P1; POHL J, 1988, MOL CELL BIOL, V8, P2078, DOI 10.1128/MCB.8.5.2078; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; RIOU G, 1990, LANCET, V335, P1171; ROVINSKI B, 1988, ONCOGENE, V2, P445; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; WRIGHT PA, 1991, ONCOGENE, V6, P1693; YAGINUMA Y, 1991, CANCER RES, V51, P6506; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	56	40	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1511	1518						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8389030				2022-12-25	WOS:A1993LE06400014
J	OGRIS, E; MUDRAK, I; WINTERSBERGER, E				OGRIS, E; MUDRAK, I; WINTERSBERGER, E			DISTINCT AMOUNTS OF POLYOMAVIRUS LARGE T-ANTIGEN ARE REQUIRED FOR DIFFERENT FUNCTIONS OF THE PROTEIN	ONCOGENE			English	Article							SIMIAN VIRUS-40; BINDING-SITES; TUMOR-ANTIGEN; DNA HELICASE; REPLICATION; FIBROBLASTS; INFECTION; PHOSPHORYLATION; IMMORTALIZATION; TRANSFORMATION	Many cellular and some virally coded proteins regulating key events in higher cells have been found to be multifunctional. One example of such a protein is the polyomavirus large T antigen, which is involved not only in viral DNA replication and gene expression but also in the induction of the S phase in host cells, in the immortalization of various cell types and in the transactivation of some cellular genes. We recently constructed cell lines in which T antigen was synthesized under the control of a hormone-inducible promoter. This allowed us to induce different concentrations of the protein in the cell and to investigate the levels of large T antigen required for replication, S-phase induction and transactivation of a growth-regulated promoter. We found that significantly higher concentrations of large T antigen are required for the replication function of the protein than for either S phase induction or transactivation. These observations for the first time provide clear evidence for a potential regulation of different functions of a pleiotropic protein by the amount of that protein produced in the cell.	UNIV VIENNA,INST MOLEK BIOL,DR BOHR GASSE 9,A-1030 VIENNA,AUSTRIA	University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)				Ogris, Egon/0000-0001-5950-9264				BERGER H, 1986, J VIROL, V60, P768, DOI 10.1128/JVI.60.2.768-770.1986; BOCKUS BJ, 1987, J VIROL, V61, P1147, DOI 10.1128/JVI.61.4.1147-1154.1987; CHENG SH, 1990, MOL CELL BIOL, V10, P5569, DOI 10.1128/MCB.10.10.5569; COWIE A, 1984, J VIROL, V52, P750, DOI 10.1128/JVI.52.3.750-760.1984; COWIE A, 1986, MOL CELL BIOL, V6, P4344, DOI 10.1128/MCB.6.12.4344; DILWORTH SM, 1982, P NATL ACAD SCI-BIOL, V79, P1059, DOI 10.1073/pnas.79.4.1059; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; FRIEDMAN M, 1986, CONTEMP POLICY ISSUE, V4, P1, DOI 10.1111/j.1465-7287.1986.tb00827.x; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JAT PS, 1986, J VIROL, V59, P746, DOI 10.1128/JVI.59.3.746-750.1986; KINGSTON RE, 1986, MOL CELL BIOL, V10, P3343; LORIMER HE, 1991, J VIROL, V65, P687, DOI 10.1128/JVI.65.2.687-699.1991; MARTENS I, 1989, J VIROL, V63, P2126, DOI 10.1128/JVI.63.5.2126-2133.1989; OGRIS E, 1992, J VIROL, V66, P53, DOI 10.1128/JVI.66.1.53-61.1992; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PARSONS RE, 1991, J VIROL, V65, P2798, DOI 10.1128/JVI.65.6.2798-2806.1991; POMERANTZ BJ, 1984, J VIROL, V49, P925, DOI 10.1128/JVI.49.3.925-937.1984; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; ROTHENEDER H, 1991, NUCLEIC ACIDS RES, V19, P6805, DOI 10.1093/nar/19.24.6805; Sambrook J, 1989, MOL CLONING LABORATO; SEKI M, 1990, BIOCHEMISTRY-US, V29, P1003, DOI 10.1021/bi00456a024; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRAUSS M, 1990, ONCOGENE, V5, P1223; TEMPLETON D, 1986, J VIROL, V57, P367, DOI 10.1128/JVI.57.1.367-370.1986; TOOZE J, 1980, DNA TUMOURS VIRUSES; TURLER H, 1985, J VIROL, V53, P579; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WANG EH, 1991, J BIOL CHEM, V266, P12668; WEICHSELBRAUN I, 1989, J VIROL, V63, P961, DOI 10.1128/JVI.63.2.961-964.1989; WEINBERG RA, 1990, TRENDS BIOCHEM SCI, V15, P199, DOI 10.1016/0968-0004(90)90162-5; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; ZHU JY, 1989, J VIROL, V63, P4777, DOI 10.1128/JVI.63.11.4777-4786.1989	34	10	10	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1277	1283						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8386826				2022-12-25	WOS:A1993KY32800020
J	XU, A; HAWKINS, C; NARAYANAN, N				XU, A; HAWKINS, C; NARAYANAN, N			PHOSPHORYLATION AND ACTIVATION OF THE CA2+-PUMPING ATPASE OF CARDIAC SARCOPLASMIC-RETICULUM BY CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MODULATING CALCIUM-UPTAKE; DEPENDENT PHOSPHORYLATION; PLASMA-MEMBRANE; PHOSPHOLAMBAN PHOSPHORYLATION; RYANODINE RECEPTOR; HEART-MUSCLE; CA-2+ PUMP; TRANSPORT; IDENTIFICATION; SITE	It is well known that phosphorylation of the membrane protein phospholamban by cAMP-dependent or Ca2+/calmodulin-dependent protein kinase results in the activation of the Ca2+-pumping ATPase of cardiac sarcoplasmic reticulum (SR); such enzyme activation is thought to be due to the disruption of an inhibitory interaction of non-phosphorylated phospholamban with the ATPase. We describe here a novel mechanism for the regulation of the ATPase through direct phosphorylation of this enzyme by a Ca2+/calmodulin-dependent protein kinase (CaM kinase) associated with the SR membrane. It is shown that incubation of cardiac SR in the presence of Ca2+ and calmodulin results in the phosphorylation of the ATPase in addition to the previously recognized substrates of CaM kinase, viz. phospholamban and Ca2+ channel. The phosphorylated amino acid in the ATPase has been identified as serine. Phosphorylation of the membrane-bound ATPase is stimulated by exogenous CaM kinase. Furthermore, ATPase purified from cardiac SR is phosphorylated by exogenous CaM kinase and the phosphorylated enzyme displays 2-fold increase in catalytic activity without any appreciable change in its Ca2+ sensitivity. Thus, direct phosphorylation of the Ca2+-pumping ATPase by CaM kinase can stimulate its enzymatic activity and, therefore, Ca2+ transport function.	UNIV WESTERN ONTARIO, DEPT PHYSIOL, MED SCI BLDG, LONDON N6A 5C1, ONTARIO, CANADA	Western University (University of Western Ontario)								BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BUSS JE, 1983, METHOD ENZYMOL, V99, P7; CHIESI M, 1987, EUR J BIOCHEM, V162, P371, DOI 10.1111/j.1432-1033.1987.tb10611.x; CHIESI M, 1987, EUR J BIOCHEM, V162, P365, DOI 10.1111/j.1432-1033.1987.tb10610.x; COLL RJ, 1984, J BIOL CHEM, V259, P4249; CORVERA S, 1988, J BIOL CHEM, V263, P3116; DONAT ME, 1991, MOL CELL BIOCHEM, V106, P41; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FUKUDA T, 1990, J BIOCHEM-TOKYO, V108, P629, DOI 10.1093/oxfordjournals.jbchem.a123254; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; JETT MF, 1987, ARCH BIOCHEM BIOPHYS, V255, P354, DOI 10.1016/0003-9861(87)90403-6; JIANG MT, 1993, CIRC RES, V72, P102, DOI 10.1161/01.RES.72.1.102; JIANG MT, 1990, MECH AGEING DEV, V54, P87, DOI 10.1016/0047-6374(90)90018-B; KHAN I, 1993, CELL CALCIUM, V14, P111, DOI 10.1016/0143-4160(93)90081-G; KIRCHBERGER MA, 1986, BIOCHEMISTRY-US, V25, P5484, DOI 10.1021/bi00367a021; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPEUCH CJ, 1979, BIOCHEMISTRY-US, V18, P5150, DOI 10.1021/bi00590a019; NARAYANAN N, 1982, BIOCHEM BIOPH RES CO, V108, P1158, DOI 10.1016/0006-291X(82)92122-2; NARAYANAN N, 1989, CAN J PHYSIOL PHARM, V67, P999, DOI 10.1139/y89-157; NARAYANAN N, 1983, BIOCHIM BIOPHYS ACTA, V735, P53, DOI 10.1016/0005-2736(83)90260-2; NARAYANAN N, 1991, BIOCHIM BIOPHYS ACTA, V1070, P83, DOI 10.1016/0005-2736(91)90149-3; NEYSES L, 1985, J BIOL CHEM, V260, P283; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; SASAKI T, 1992, J BIOL CHEM, V267, P1674; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; SULAKHE PV, 1978, BIOCHEM J, V175, P171, DOI 10.1042/bj1750171; SUZUKI T, 1986, J BIOL CHEM, V261, P7018; TADA M, 1975, J BIOL CHEM, V250, P2640; TADA M, 1978, PHYSIOL REV, V58, P1; TADA M, 1982, ANNU REV PHYSIOL, V44, P401, DOI 10.1146/annurev.ph.44.030182.002153; TAKASAGO T, 1991, J BIOCHEM-TOKYO, V109, P163, DOI 10.1093/oxfordjournals.jbchem.a123339; WANG KKW, 1991, J BIOL CHEM, V266, P9078; WITCHER DR, 1992, J BIOL CHEM, V267, P4963; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; WUYTACK F, 1992, J BIOENERG BIOMEMBR, V24, P285	37	144	144	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8394	8397						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8386159				2022-12-25	WOS:A1993KX81100004
J	KENNELLY, PJ; OXENRIDER, KA; LENG, J; CANTWELL, JS; ZHAO, NY				KENNELLY, PJ; OXENRIDER, KA; LENG, J; CANTWELL, JS; ZHAO, NY			IDENTIFICATION OF A SERINE THREONINE-SPECIFIC PROTEIN PHOSPHATASE FROM THE ARCHAEBACTERIUM SULFOLOBUS-SOLFATARICUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASES; ACIDOCALDARIUS; PHOSPHORYLATION; BACTERIA; PHOSPHOTYROSINE; QUANTITATION; PURIFICATION; PROKARYOTES; CALMODULIN; KINASES	We have observed that soluble extracts from the extreme acidothermophilic archaebacterium sulfolobus solfataricus contained protein phosphatase activity that was greatly stimulated by the divalent metal ions Mn'', Me+, Ni2+, or Co2+. This activity apparently arose from a single enzyme since (a) stimulation by these divalent metal ions was not additive and (b) protein phosphatase activity eluted as a single peak from both a DE52 ion-exchange column and a Sephadex G-100 gel filtration column. Its apparent molecular mass was almost-equal-to 28,000 daltons. The enzyme dephosphorylated a variety of phosphoserine-containing substrates including casein, histone H2a, phosphorylase kinase, or glycogen phosphorylase. The enzyme would not dephosphorylate either histone H1 or a number of phosphotyrosine-containing compounds. It removed only half the phosphate bound to histone H2b, which is phosphorylated at two sites by the cAMP-dependent protein kinase. Protein phosphatase activity was inhibited by EDTA, Cu2+, Zn2+, NaF, inorganic phosphate, or pyrophosphate; but was unaffected by other potential activators and inhibitors such as microcystin, okadaic acid, vanadate, polyamines, or sulfhydryl modifying reagents. This enzyme represents the first protein phosphatase to be identified in any member of the third and oldest phylogenetic kingdom in nature, the archaebacteria.			KENNELLY, PJ (corresponding author), VIRGINIA POLYTECH INST & STATE UNIV, DEPT BIOCHEM & NUTR, BLACKSBURG, VA 24061 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045368] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45368] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUER J, 1989, CAN J MICROBIOL, V35, P200, DOI 10.1139/m89-031; BALLOU LM, 1986, ENZYMES, V17, P311; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCK TD, 1972, ARCH MIKROBIOL, V84, P54, DOI 10.1007/BF00408082; CHARBONNEAU H, 1983, METHOD ENZYMOL, V102, P17; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, J BIOL CHEM, V264, P21435; COHEN P, 1991, METHOD ENZYMOL, V201, P389; COHEN PTW, 1989, BIOCHEM J, V260, P931, DOI 10.1042/bj2600931; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COZZONE AJ, 1988, ANNU REV MICROBIOL, V42, P97, DOI 10.1146/annurev.mi.42.100188.000525; DEROSA M, 1975, J GEN MICROBIOL, V86, P156, DOI 10.1099/00221287-86-1-156; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HASHIMOTO E, 1976, J BIOL CHEM, V251, P6287; HUNTER T, 1991, METHODS ENZYMOL, V201; HUNTER T, 1991, METHODS ENZYMOL, V200; KAINE BP, 1983, P NATL ACAD SCI-BIOL, V80, P3309, DOI 10.1073/pnas.80.11.3309; KING MM, 1986, J BIOL CHEM, V261, P4081; KUCHINO Y, 1982, NATURE, V298, P684, DOI 10.1038/298684a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKE JA, 1988, NATURE, V331, P184, DOI 10.1038/331184a0; MARTIN JB, 1949, ANAL CHEM, V21, P965, DOI 10.1021/ac60032a024; MCGOWAN CH, 1988, METHOD ENZYMOL, V159, P416; MEISLER MH, 1969, J BIOL CHEM, V244, P4961; Miles E W, 1977, Methods Enzymol, V47, P431; PUHLER G, 1989, P NATL ACAD SCI USA, V86, P4569, DOI 10.1073/pnas.86.12.4569; REITER WD, 1988, NUCLEIC ACIDS RES, V16, P1, DOI 10.1093/nar/16.1.1; SCHRODER J, 1991, EUR J BIOCHEM, V195, P321, DOI 10.1111/j.1432-1033.1991.tb15709.x; SKORKO R, 1989, BIOCHIMIE, V71, P1089, DOI 10.1016/0300-9084(89)90115-6; SKORKO R, 1984, EUR J BIOCHEM, V145, P617, DOI 10.1111/j.1432-1033.1984.tb08601.x; SPUDICH EN, 1981, J CELL BIOL, V91, P895, DOI 10.1083/jcb.91.3.895; SPUDICH JL, 1980, J BIOL CHEM, V255, P5501; STEWART AA, 1981, EUR J BIOCHEM, V115, P197; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; SWARUP G, 1989, J BIOL CHEM, V264, P7801; THOMM M, 1988, NUCLEIC ACIDS RES, V16, P151, DOI 10.1093/nar/16.1.151; WESTHEIMER FH, 1987, SCIENCE, V235, P1173, DOI 10.1126/science.2434996; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1985, BACTERIA TREATISE ST, V8; ZILLIG W, 1980, ARCH MICROBIOL, V125, P259, DOI 10.1007/BF00446886	43	38	39	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6505	6510						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8384214				2022-12-25	WOS:A1993KT36800062
J	LUSSKA, A; SHEN, E; WHITLOCK, JP				LUSSKA, A; SHEN, E; WHITLOCK, JP			PROTEIN-DNA INTERACTIONS AT A DIOXIN-RESPONSIVE ENHANCER - ANALYSIS OF 6 BONA-FIDE DNA-BINDING SITES FOR THE LIGANDED AH RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-P1-450 GENE-EXPRESSION; ARYL-HYDROCARBON HYDROXYLASE; TRANSCRIPTION FACTOR; NEGATIVE REGULATION; MESSENGER-RNA; SEQUENCE; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; RECOGNITION; REPRESSION; ELEMENT	The DNA upstream of the dioxin-inducible CYP1A1 gene contains six distinct sites to which the liganded Ah receptor binds in intact mouse hepatoma cells. Here, we have analyzed these six bona fide receptor-binding sites in order to study the relationships between DNA sequence, receptor binding, and dioxin responsiveness. Gel retardation studies reveal that the sites vary by about 7-fold in their relative affinities for the liganded receptor. Within this range, there is no obvious association between the strength of receptor binding and the degree of dioxin responsiveness, as measured in transfection experiments. In fact, one site binds the receptor well but fails to respond to dioxin. This observation implies that the receptor-DNA binding event per se is not sufficient to confer dioxin responsiveness upon a linked gene. Comparison of the DNA sequences of the six receptor-binding sites permits the derivation of a ''functional consensus'' recognition sequence, which is more extended in length than the ''core'' binding sequence previously described. In corroboration of these results, protein-DNA cross-linking studies indicate that the liganded receptor contacts base pairs beyond the core sequence. Our observations also indicate that the liganded receptor can tolerate limited sequence heterogeneity at its DNA-binding site and still elicit a response to dioxin. This finding might reflect corresponding heterogeneity in the amino acid sequence of the liganded receptor's DNA-binding domain.			LUSSKA, A (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT PHARMACOL,STANFORD,CA 94305, USA.				NIEHS NIH HHS [ES 03719] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003719] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; Bailar J C 3rd, 1991, N Engl J Med, V324, P260, DOI 10.1056/NEJM199101243240409; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CROW KD, 1981, CLIN EXP DERMATOL, V6, P243, DOI 10.1111/j.1365-2230.1981.tb02300.x; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DROUIN J, 1989, MOL CELL BIOL, V9, P5305, DOI 10.1128/MCB.9.12.5305; DURRIN LK, 1989, MOL CELL BIOL, V9, P5733, DOI 10.1128/MCB.9.12.5733; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; ELFERINK CJ, 1990, J BIOL CHEM, V265, P5718; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FINGERHUT MA, 1991, NEW ENGL J MED, V324, P212, DOI 10.1056/NEJM199101243240402; FISHER JM, 1990, J BIOL CHEM, V265, P9676; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; GASIEWICZ TA, 1991, BIOCHEMISTRY-US, V30, P2909, DOI 10.1021/bi00225a026; HANKINSON O, 1983, SOMAT CELL GENET, V9, P497, DOI 10.1007/BF01543050; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; JONES PBC, 1985, SCIENCE, V227, P1499, DOI 10.1126/science.3856321; JONES PBC, 1986, P NATL ACAD SCI USA, V83, P2802, DOI 10.1073/pnas.83.9.2802; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; MILLER AG, 1983, J BIOL CHEM, V258, P3523; MORGAN JE, 1992, P NATL ACAD SCI USA, V89, P11622, DOI 10.1073/pnas.89.23.11622; NEBERT DW, 1989, CRIT REV TOXICOL, V20, P153, DOI 10.3109/10408448909017908; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1976, J BIOL CHEM, V251, P4936; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SHEN ES, 1992, J BIOL CHEM, V267, P6815; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; TINDALL JP, 1985, J AM ACAD DERMATOL, V13, P539, DOI 10.1016/S0190-9622(85)70196-X; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; WU L, 1992, P NATL ACAD SCI USA, V89, P4811, DOI 10.1073/pnas.89.11.4811; YAO EF, 1992, BIOCHEMISTRY-US, V31, P5060, DOI 10.1021/bi00136a019; YEOWELL HN, 1987, MOL PHARMACOL, V32, P340; YEOWELL HN, 1989, ARCH BIOCHEM BIOPHYS, V271, P508, DOI 10.1016/0003-9861(89)90302-0	43	151	153	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6575	6580						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8384216				2022-12-25	WOS:A1993KT36800072
J	CANTIELLO, HF; PRAT, AG; BONVENTRE, JV; CUNNINGHAM, CC; HARTWIG, JH; AUSIELLO, DA				CANTIELLO, HF; PRAT, AG; BONVENTRE, JV; CUNNINGHAM, CC; HARTWIG, JH; AUSIELLO, DA			ACTIN-BINDING PROTEIN CONTRIBUTES TO CELL-VOLUME REGULATORY ION CHANNEL ACTIVATION IN MELANOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							POTASSIUM CONDUCTANCE; APICAL MEMBRANE; BARIUM; CYTOSKELETON; INHIBITION; EPITHELIUM; TUBULES	The cell volume regulatory response to a hypotonic stimulus is frequently initiated by activation of K+ and Cl- channels. We have characterized the hypotonic cell volume regulatory response of human melanoma cells devoid of actin-binding protein (ABP) and their genetically rescued counterpart transfected with the cDNA for ABP. ABP-deficient cells were unable to volume-regulate or activate K+ channels when exposed to a hypotonic stimulus. Genetic rescue with ABP resulted in recovery of both the cell volume regulatory response and the osmotically linked K+ channel activation. These data are consistent with a functional interaction between the actin cytoskeleton and osmotically sensitive ion transport.	MASSACHUSETTS GEN HOSP,RENAL UNIT,BOSTON,MA 02114; BRIGHAM & WOMENS HOSP,DIV EXPTL MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02129	Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School								CANTIELLO HF, 1990, J BIOL CHEM, V265, P21624; CANTIELLO HF, 1991, AM J PHYSIOL, V261, pC882, DOI 10.1152/ajpcell.1991.261.5.C882; CHRISTENSEN O, 1987, NATURE, V330, P66, DOI 10.1038/330066a0; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; FALKE LC, 1989, J GEN PHYSIOL, V94, pA34; FOSKETT JK, 1985, AM J PHYSIOL, V248, pC27, DOI 10.1152/ajpcell.1985.248.1.C27; FOX JEB, 1985, J BIOL CHEM, V260, P1970; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; KAWAHARA K, 1985, J MEMBRANE BIOL, V88, P283, DOI 10.1007/BF01871092; LEWIS SA, 1990, NEWS PHYSIOL SCI, V5, P112; LINSHAW MA, 1991, AM J PHYSIOL, V261, pF60, DOI 10.1152/ajprenal.1991.261.1.F60; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MELMED RN, 1981, J CELL BIOL, V90, P761, DOI 10.1083/jcb.90.3.761; NAGEL W, 1979, BIOCHIM BIOPHYS ACTA, V552, P346, DOI 10.1016/0005-2736(79)90289-X; OHTA Y, 1991, CELL, V67, P1; OKADA Y, 1989, NEWS PHYSIOL SCI, V4, P238; ONIEL RG, 1988, J MEMBRANE BIOL, V91, P469; PLANELLES G, 1981, N-S ARCH PHARMACOL, V318, P135; REUSS L, 1988, RENAL PHYSIOL BIOCH, V11, P187; SACKIN H, 1989, P NATL ACAD SCI USA, V86, P1731, DOI 10.1073/pnas.86.5.1731; SCHULTZ SG, 1989, NEWS PHYSIOL SCI, V4, P169; UBL J, 1988, J MEMBRANE BIOL, V104, P223, DOI 10.1007/BF01872324; VANDRIESSCHE W, 1980, J MEMBRANE BIOL, V56, P31, DOI 10.1007/BF01869349; WELLING PA, 1985, AM J PHYSIOL, V249, pF20, DOI 10.1152/ajprenal.1985.249.1.F20; WELSH MJ, 1983, AM J PHYSIOL, V244, pF639, DOI 10.1152/ajprenal.1983.244.6.F639; ZIYADEH FN, 1992, AM J PHYSIOL, V262, pF468, DOI 10.1152/ajprenal.1992.262.3.F468	27	132	136	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4596	4599						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8383118				2022-12-25	WOS:A1993KP88400008
J	GREGORY, JD; SERPERSU, EH				GREGORY, JD; SERPERSU, EH			ARRANGEMENT OF SUBSTRATES AT THE ACTIVE-SITE OF YEAST PHOSPHOGLYCERATE KINASE - EFFECT OF SULFATE ION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMIUM(III) ADENOSINE 5'-TRIPHOSPHATE; 3-PHOSPHOGLYCERATE KINASE; MAGNETIC-RESONANCE; BINDING-SITE; STAPHYLOCOCCAL NUCLEASE; DIRECTED MUTAGENESIS; ENZYME; RELAXATION; 5'-DIPHOSPHATE; COMPLEXES	Beta-gamma-bidentate CrATP, a stable exchange-inert metal-nucleotide analog, was used as a probe of the conformation of the substrates at the active site of yeast phosphoglycerate kinase (PGK). The paramagnetic effects of Cr3+ on the longitudinal relaxation rates (1/T1p) of the H-1, P-31, and C-13 nuclei of 3-phospho-D-glycerate (3PGA) were examined to determine the distances between enzyme-bound CrATP and the nuclei of 3PGA in the ternary PGK.CrATP.3PGA complex. Kinetic studies indicated that K(i(CrATP)) was dependent on the concentration of 3PGA that was abolished in the presence of activator sulfate ion. Similarly, NMR studies showed that the environment of CrATP bound at the active site was altered by the presence of sulfate ion. The determined metal-to-nucleus distances show the close proximity of the substrates at the active site of PGK, which is consistent with a hinge-bending mechanism of the enzyme for bringing the two substrates together. Additionally, the presence of an activating concentration of sulfate was observed to cause significant changes in both the relative Cr3+-to-3PGA distances and the overall conformation of 3PGA when compared to the findings in the absence of sulfate. This is consistent with the active site being in a ''less closed'' configuration when sulfate is present. Under both conditions, models can be constructed that allow for direct transfer of a phosphoryl group between the bound substrates.	UNIV TENNESSEE,DEPT BIOCHEM,M407 WALTERS SCI BLDG,KNOXVILLE,TN 37996	University of Tennessee System; University of Tennessee Knoxville					NCRR NIH HHS [RR02231] Funding Source: Medline; NIGMS NIH HHS [R29 GM422661] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002231] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BANKS RD, 1979, NATURE, V279, P773, DOI 10.1038/279773a0; BEISENHERZ G, 1955, METHOD ENZYMOL, V1, P391, DOI 10.1016/0076-6879(55)01063-X; BLAKE CCF, 1981, PHILOS T ROY SOC B, V293, P93, DOI 10.1098/rstb.1981.0063; Bucher T, 1942, NATURWISSENSCHAFTEN, V30, P756, DOI 10.1007/BF01488658; CARR HY, 1954, PHYS REV, V94, P630, DOI 10.1103/PhysRev.94.630; DUNAWAYMARIANO D, 1980, BIOCHEMISTRY-US, V19, P1496, DOI 10.1021/bi00548a037; DUNAWAYMARIANO D, 1980, BIOCHEMISTRY-US, V19, P1506, DOI 10.1021/bi00548a038; FAIRBROTHER WJ, 1989, EUR J BIOCHEM, V183, P57, DOI 10.1111/j.1432-1033.1989.tb14896.x; FREEMAN R, 1971, J CHEM PHYS, V54, P3367, DOI 10.1063/1.1675352; FRY DC, 1985, BIOCHEMISTRY-US, V24, P4680, DOI 10.1021/bi00338a030; GREGORY JD, 1991, FASEB J, V5, pA1149; GUPTA RK, 1976, J BIOL CHEM, V251, P2421; HARLOS K, 1992, PROTEINS, V12, P133, DOI 10.1002/prot.340120207; JAFFE EK, 1982, J BIOL CHEM, V257, P7650; JOAO HC, 1992, EUR J BIOCHEM, V205, P93, DOI 10.1111/j.1432-1033.1992.tb16755.x; KHAMIS MM, 1981, BIOCHIM BIOPHYS ACTA, V657, P190, DOI 10.1016/0005-2744(81)90142-X; KULBE KD, 1982, METHOD ENZYMOL, V90, P115; MANDL I, 1957, METHOD ENZYMOL, V3, P208, DOI 10.1016/S0076-6879(57)03374-1; MAS MT, 1987, BIOCHEMISTRY-US, V26, P5369, DOI 10.1021/bi00391a023; Mildvan A S, 1972, Methods Enzymol, V26, P654; MINARD P, 1990, PROTEIN ENG, V3, P515, DOI 10.1093/protein/3.6.515; MOORE JM, 1985, BIOCHEMISTRY-US, V24, P5328, DOI 10.1021/bi00341a009; PICKOVER CA, 1979, J BIOL CHEM, V254, P1323; RAO BDN, 1978, J BIOL CHEM, V253, P8056; RAY BD, 1988, BIOCHEMISTRY-US, V27, P5579, DOI 10.1021/bi00415a028; RAY BD, 1988, BIOCHEMISTRY-US, V27, P5574, DOI 10.1021/bi00415a027; REED GH, 1970, J BIOL CHEM, V245, P6547; ROUSTAN C, 1980, BIOCHEMISTRY-US, V19, P5168, DOI 10.1021/bi00564a003; SCHIERBECK B, 1979, BIOCHIM BIOPHYS ACTA, V568, P195, DOI 10.1016/0005-2744(79)90286-9; SCOPES RK, 1971, BIOCHEM J, V122, P89, DOI 10.1042/bj1220089; SCOPES RK, 1978, EUR J BIOCHEM, V85, P503, DOI 10.1111/j.1432-1033.1978.tb12266.x; SCOPES RK, 1978, EUR J BIOCHEM, V91, P119, DOI 10.1111/j.1432-1033.1978.tb20944.x; SERPERSU EH, 1987, BIOCHEMISTRY-US, V26, P1289, DOI 10.1021/bi00379a014; SERPERSU EH, 1988, BIOCHEMISTRY-US, V27, P8034, DOI 10.1021/bi00421a010; SERPERSU EH, 1992, J INORG BIOCHEM, V48, P203, DOI 10.1016/0162-0134(92)84031-H; SHERMAN MA, 1991, PROTEIN ENG, V4, P935, DOI 10.1093/protein/4.8.935; TANSWELL P, 1976, EUR J BIOCHEM, V63, P249, DOI 10.1111/j.1432-1033.1976.tb10227.x; WATSON HC, 1982, EMBO J, V1, P1635, DOI 10.1002/j.1460-2075.1982.tb01366.x; WEBB MR, 1980, J BIOL CHEM, V255, P1775; WIKSELL E, 1987, J BIOL CHEM, V262, P14472; WOLKERS WF, 1991, J BIOL CHEM, V266, P20761; WROBEL JA, 1978, EUR J BIOCHEM, V85, P345, DOI 10.1111/j.1432-1033.1978.tb12245.x; [No title captured]	43	18	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3880	3888						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8382681				2022-12-25	WOS:A1993KN53300017
J	SASAKI, Y; ZHANG, XF; NISHIYAMA, M; AVRUCH, J; WANDS, JR				SASAKI, Y; ZHANG, XF; NISHIYAMA, M; AVRUCH, J; WANDS, JR			EXPRESSION AND PHOSPHORYLATION OF INSULIN-RECEPTOR SUBSTRATE-1 DURING RAT-LIVER REGENERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EPIDERMAL GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; KINASE; AUTOPHOSPHORYLATION; ACTIVATION; ONCOGENES; PROTEINS; BLOOD	Insulin has been shown to be important for normal liver regeneration to occur. The mechanisms whereby insulin may exert its effects on hepatocyte growth, however, are still unknown. The rat and human insulin receptor substrate 1 (IRS-1) is a specific target molecule for the insulin receptor beta subunit kinase and will bind to signal transducing molecules containing Src homology 2 domains through its multiple tyrosyl phosphorylation (TP) sites. This investigation examined how IRS-1 may be involved in insulin action during hepatocyte growth induced by two-thirds partial hepatectomy. The TP of IRS-1 was strikingly enhanced prior to the major wave of hepatocyte DNA synthesis at 24 h; IRS-1 protein and mRNA expression increased in parallel to a lesser extent after partial hepatectomy. TP of insulin receptor beta subunit, which enhances its kinase activity toward IRS-1, was increased in association with TP of IRS-1. Finally, phosphatidylinositol 3-kinase, one of signal transducing molecules containing Src homology 2 domains, was associated with IRS-1 following TP in vivo. These observations suggest that IRS-1 protein may play an important role in transmitting the insulin signal to intracellular regulators involved in hepatocyte growth.	MASSACHUSETTS GEN HOSP,CTR CANC,MOLEC HEPATOL LAB,149 13TH ST,7TH FLOOR,BOSTON,MA 02129; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DIABET UNIT,BOSTON,MA 02129	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital					NCI NIH HHS [CA-35711] Funding Source: Medline; NIAAA NIH HHS [AA-08169, AA-02666] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035711, R37CA035711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA002666, R01AA008169, R37AA002666] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AVRUCH J, 1982, J BIOL CHEM, V257, P5162; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BERGERON JJM, 1985, ANNU REV PHYSIOL, V47, P383; BUCHER NLR, 1973, CANCER RES, V33, P3189; BUCHER NLR, 1978, CIBA F S, V55, P95; Bucher NRL, 1971, REGENERATION LIVER K, P17; BURGESS JW, 1992, J BIOL CHEM, V267, P10077; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DOHERTY JJ, 1990, J CELL BIOL, V110, P35, DOI 10.1083/jcb.110.1.35; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; FAURE R, 1992, J BIOL CHEM, V267, P11215; FISHER EH, 1991, SCIENCE, V253, P401; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GRISHAM JW, 1962, CANCER RES, V22, P842; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; Higgins GM, 1931, ARCH PATHOL, V12, P186; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KWOK YC, 1986, ARCH BIOCHEM BIOPHYS, V244, P102, DOI 10.1016/0003-9861(86)90098-6; Leffert H. L., 1978, CIBA F S, V55, P61; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MEYEROVITCH J, 1991, J CLIN INVEST, V87, P1286, DOI 10.1172/JCI115131; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Sambrook J, 1989, MOL CLONING LABORATO; STARZL TE, 1973, SURG GYNECOL OBSTET, V137, P179; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WANDS JR, 1979, GASTROENTEROLOGY, V77, P526; WHITE MF, 1988, J BIOL CHEM, V263, P2969; YOUNGER LR, 1966, CANCER RES, V26, P1408	33	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3805	3808						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8382678				2022-12-25	WOS:A1993KN53300003
J	ERICKSON, JW; CERIONE, RA				ERICKSON, JW; CERIONE, RA			REGULATION OF THE CGMP PHOSPHODIESTERASE IN BOVINE ROD OUTER SEGMENTS - USE OF RESONANCE ENERGY-TRANSFER TO DISTINGUISH BETWEEN ASSOCIATIVE AND DISSOCIATIVE ACTIVATION MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; NUCLEOTIDE-BINDING-PROTEIN; INHIBITORY GAMMA-SUBUNIT; ALPHA-SUBUNIT; RETINAL RODS; TRANSDUCIN; ANTIBODIES; PARAMETERS	Resonance energy transfer was used to monitor the interactions of the gamma subunit of the cyclic GMP phosphodiesterase (gamma(PDE)) With the alpha and beta subunits, which together comprise the catalytic core of the enzyme (alphabeta(PDE)). An iodoacetamidofluorescein (IAF)-labeled alphabeta(PDE) (IAF-PDE(t)) served as the acceptor species in these experiments while a coumarin maleimide-modified gamma(PDE) (CPM-gamma(PDE)) served as the fluorescent donor. Trypsin treatment of an IAF-labeled, intact phosphodiesterase (PDE) complex resulted in the selective proteolysis of the gamma(PDE); and full activation of enzyme activity. The binding of IAF-PDE(t) to the CPM-gamma(PDE) was monitored directly by measuring the quenching (25-35%) of the CPM fluorescence emission or by measuring the changes in the rate cGMP hydrolysis by IAF-PDE(t) using the pH electrode method. Both methods yielded titration curves which were well fitted using a single affinity constant (K(d) approximately 1-2 nM). Under conditions where added CPM-gamma(PDE) resulted in complete inhibition of the IAF-PDE(t) activity and, conversely, a maximal quenching of the CPM-gamma(PDE) fluorescence by added IAF-PDE(t), the subsequent addition of guanosine 5'-O-(thiotriphosphate) bound form of the alpha subunit of transducin (alpha(T)GTPgammaS) restored approximately 50% of the enzyme activity while restoring <30% of the CPM-gamma(PDE) fluorescence emission. Based on these results, we suggest that a portion of the observed PDE activation by alpha(T)GTPgammaS occurs via an associated complex of alpha(T)GTPgammaS and the enzyme.			ERICKSON, JW (corresponding author), CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853, USA.				NATIONAL EYE INSTITUTE [R01EY006429, F32EY006204] Funding Source: NIH RePORTER; NEI NIH HHS [EY06429, EY06204] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BENNETT N, 1989, BIOCHEMISTRY-US, V28, P7418, DOI 10.1021/bi00444a040; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; ERICKSON JW, 1991, BIOCHEMISTRY-US, V30, P7112, DOI 10.1021/bi00243a011; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; GIERSCHIK P, 1984, FEBS LETT, V172, P321, DOI 10.1016/0014-5793(84)81149-7; GRISWOLDPRENNER I, 1989, BIOCHEMISTRY-US, V28, P6145, DOI 10.1021/bi00441a003; HINGORANI VN, 1987, BIOCHEMISTRY-US, V26, P1633, DOI 10.1021/bi00380a022; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; KROLL S, 1989, J BIOL CHEM, V264, P4490; OPPERT B, 1991, J BIOL CHEM, V266, P16607; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; PHILLIPS WJ, 1989, J BIOL CHEM, V264, P16679; PINES M, 1985, P NATL ACAD SCI USA, V82, P4095, DOI 10.1073/pnas.82.12.4095; SITARAMAYYA A, 1986, BIOCHEMISTRY-US, V25, P651, DOI 10.1021/bi00351a021; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; WHALEN MM, 1990, BIOCHEM J, V265, P655, DOI 10.1042/bj2650655; YEE R, 1978, J BIOL CHEM, V253, P8902	21	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3328	3333						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8381426				2022-12-25	WOS:A1993KM16100049
J	BRENNER, MC; ZHANG, H; SCOTT, RA				BRENNER, MC; ZHANG, H; SCOTT, RA			NATURE OF THE LOW ACTIVITY OF S-METHYL-COENZYME-M REDUCTASE AS DETERMINED BY ACTIVE-SITE TITRATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOAUTOTROPHICUM STRAIN MARBURG; METHYLCOENZYME-M METHYLREDUCTASE; METHANOBACTERIUM-THERMOAUTOTROPHICUM; METHANE FORMATION; COMPONENT-C; DELTA-H; SYSTEM; ANALOGS; NICKEL	Purified S-methyl-coenzyme M reductase (methyl-reductase) exhibits a very low fraction of its in vivo activity, suggesting either enzyme inactivation during cell lysis and chromatographic purification or the lack of an activating component in assay mixtures. Evidence that all methylreductase molecules in the purified protein can catalyze slow substrate turnover is found in a study of turnover-dependent in vitro incorporation of radiolabeled HS-CoM at the enzyme active site (Hartzell, P. L., Donnelly, M. I., and Wolfe, R. S. (1987) J. Biol. Chem. 262, 5581-5586). We have conducted active site titrations of purified methylreductase and of a highly active partially purified preparation (Rospert, S., Bocher, R., Albracht, S. P. J., and Thauer, R. K. (1991) FEBS Lett. 291, 371-375) using the reversible competitive inhibitor bromopropanesulfonate (K(i) = 0.05 muM). Curve fitting the data based on an equilibrium binding model shows that 0.1-1.4% of purified methylreductase has functional inhibitor binding sites while up to 25% of a highly active preparation binds the inhibitor. An EPR titration of highly active methylreductase with this inhibitor is consistent with this result, showing that the MCR-red1 and -red2 EPR signals (Albracht, S. P. J., Ankel-Fuchs, D., Bocher, R., Ellermann, J., Moll, J., van der Zwann, J. W., and Thauer, R. K. (1988) Biochim. Biophys. Acta 955, 86-102) are titrated in parallel with this active fraction. Attempts to observe turnover-dependent uptake of radiolabel from [thio-S-35]2-methylthioethane-sulfonate by methylreductase were unsuccessful. These results suggest that the low activity of purified methylreductase is due primarily to low percentages of catalytically competent enzyme.	UNIV GEORGIA,DEPT CHEM,ATHENS,GA 30602; UNIV GEORGIA,CTR METALLOENZYME STUDIES,ATHENS,GA 30602; UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia				Scott, Robert/0000-0003-2236-1336				AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ALBRACHT SPJ, 1988, BIOCHIM BIOPHYS ACTA, V955, P86, DOI 10.1016/0167-4838(88)90182-3; ANKELFUCHS D, 1986, EUR J BIOCHEM, V156, P171, DOI 10.1111/j.1432-1033.1986.tb09563.x; BONACKER LG, 1992, EUR J BIOCHEM, V206, P87, DOI 10.1111/j.1432-1033.1992.tb16904.x; BRENNER MC, 1992, BIOCHIM BIOPHYS ACTA, V1120, P160, DOI 10.1016/0167-4838(92)90264-E; ELLERMANN J, 1989, EUR J BIOCHEM, V184, P63, DOI 10.1111/j.1432-1033.1989.tb14990.x; ELLERMANN J, 1988, EUR J BIOCHEM, V172, P669, DOI 10.1111/j.1432-1033.1988.tb13941.x; FRIEDMANN HC, 1990, FEMS MICROBIOL LETT, V87, P339; GUNSALUS RP, 1978, BIOCHEMISTRY-US, V17, P2374, DOI 10.1021/bi00605a019; HARTZELL PL, 1987, J BIOL CHEM, V262, P5581; HUSTER R, 1985, EUR J BIOCHEM, V148, P107, DOI 10.1111/j.1432-1033.1985.tb08813.x; NAGLE DP, 1983, P NATL ACAD SCI-BIOL, V80, P2151, DOI 10.1073/pnas.80.8.2151; NOLL KM, 1987, J BIOL CHEM, V262, P513; Romesser J A, 1980, Methods Enzymol, V67, P545; ROSPERT S, 1992, EUR J BIOCHEM, V210, P101, DOI 10.1111/j.1432-1033.1992.tb17396.x; ROSPERT S, 1990, EUR J BIOCHEM, V194, P871, DOI 10.1111/j.1432-1033.1990.tb19481.x; ROSPERT S, 1991, FEBS LETT, V291, P371, DOI 10.1016/0014-5793(91)81323-Z; WACKETT LP, 1987, BIOCHEMISTRY-US, V26, P6012, DOI 10.1021/bi00393a010; Wackett LP, 1988, BIOINORGANIC CHEM NI, P249	19	9	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18491	18495						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8395504				2022-12-25	WOS:A1993LV65900020
J	YILLA, M; TAN, A; ITO, K; MIWA, K; PLOEGH, HL				YILLA, M; TAN, A; ITO, K; MIWA, K; PLOEGH, HL			INVOLVEMENT OF THE VACUOLAR H+-ATPASES IN THE SECRETORY PATHWAY OF HEPG2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; PROTEIN-TRANSPORT; HUMAN-FIBROBLASTS; CONCANAMYCIN-B; ACIDIFICATION; COMPARTMENTS; MONENSIN; COMPLEX; GLYCOSYLATION	The macrolide antibiotic concanamycin B is a highly selective inhibitor (IC50 = 5 nm) of the H+-ATPases of the vacuolar system. We have examined the effects of concanamycin B on the constitutive secretory pathway of the human hepatoma cell line, HepG2. In cells exposed to 10 nm concanamycin B, transport from the endoplasmic reticulum to the Golgi occurs at normal rates, as determined by pulse-chase analysis of endoglycosidase H-sensitive product in conjunction with subcellular fractionation experiments. However, intra-Golgi trafficking or Golgi to plasma membrane delivery is significantly impaired. A delay in the onset of secretion of the major secretory proteins, albumin, alpha1-antitrypsin and transferrin is observed. Processing of N-linked glycans by sialyltransferases is inhibited, resulting in secreted glycoproteins which are modified less extensively. In view of the acidic pH of the trans-Golgi and the trans-Golgi network, these studies suggest that acidification by vacuolar ATPases is critical to achieving timely secretion and correct N-linked glycan modifications of proteins which follow the constitutive secretory pathway.	MIT,CTR CANC RES,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)								ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURKE B, 1984, EMBO J, V3, P551, DOI 10.1002/j.1460-2075.1984.tb01845.x; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FRIES E, 1984, EMBO J, V3, P147, DOI 10.1002/j.1460-2075.1984.tb01775.x; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; KINASHI H, 1984, J ANTIBIOT, V37, P1333, DOI 10.7164/antibiotics.37.1333; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KLIONSKY DJ, 1992, J BIOL CHEM, V267, P3416; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAURIE SM, 1991, J CELL PHYSIOL, V147, P215, DOI 10.1002/jcp.1041470205; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; MATTSSON JP, 1991, BIOCHIM BIOPHYS ACTA, V1065, P261, DOI 10.1016/0005-2736(91)90238-4; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MIRIYAMA Y, 1989, J BIOL CHEM, V264, P18445; MOREMEN KW, 1986, J BIOL CHEM, V261, P945; NEEFJES JJ, 1986, HUM IMMUNOL, V16, P169, DOI 10.1016/0198-8859(86)90046-7; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; NELSON N, 1992, Current Opinion in Cell Biology, V4, P654, DOI 10.1016/0955-0674(92)90086-R; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; ORCI L, 1984, CELL, V39, P39, DOI 10.1016/0092-8674(84)90189-2; ORCI L, 1991, CELL, V64, P1183; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; STROUS GJ, 1985, J CELL BIOL, V101, P531, DOI 10.1083/jcb.101.2.531; TAN A, 1992, J CELL BIOL, V116, P1357, DOI 10.1083/jcb.116.6.1357; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; THORENS B, 1986, NATURE, V321, P618, DOI 10.1038/321618a0; UCHIDA N, 1980, J BIOL CHEM, V255, P8638; WOO JT, 1992, EUR J BIOCHEM, V207, P383, DOI 10.1111/j.1432-1033.1992.tb17061.x; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737	41	77	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					19092	19100						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8395529				2022-12-25	WOS:A1993LV65900106
J	TOMINAGA, N; MINAMI, Y; SAKAKIBARA, R; UYEDA, K				TOMINAGA, N; MINAMI, Y; SAKAKIBARA, R; UYEDA, K			SIGNIFICANCE OF THE AMINO-TERMINUS OF RAT TESTIS FRUCTOSE-6-PHOSPHATE,2-KINASE-FRUCTOSE-2,6-BISPHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; FRUCTOSE-6-PHOSPHATE 2-KINASE; FRUCTOSE 2,6-BISPHOSPHATASE; PHOSPHORYLATION SITES; KINETIC-PROPERTIES; MOLECULAR-CLONING; ACID-SEQUENCE; EXPRESSION; ACTIVATION	In order to assess the functional properties of the extreme amino-terminal peptide of rat testis fructose-6-phosphate, 2-kinase:fructose-2, 6-bisphosphatase, 24 and 30 amino acids from the NH2 terminus were deleted using oligonucleotide-directed mutagenesis. The expressed wild-type (WT) and the mutant (Del 24 and Del 30) enzymes were purified to homogeneity. These enzymes were homodimers of subunit M(r) values 54,000, 51,300, and 50,600. Deletion of 1-24 and 1-30 residues resulted in over 70% loss of Fru-6-P, 2-kinase activity and 2-fold increase in Fru-2,6-bisphosphatase. K(m)Fru-6-P increased 7.5-fold, but there was no significant change in K(m)Fru-2,6P2 of the phosphatase. These mutant enzymes were more susceptible to protein concentration-dependent dissociation and thermal inactivation. In 2 M urea the kinase and the phosphatase activities of WT increased 17 and 56%, respectively, but no activation of any of the mutant enzymes was observed. At higher urea concentrations, all the enzymes were inactivated. Unfolding in urea, followed with intrinsic tryptophan fluorescence, showed that the unfolding proceeded in at least two stages. Fluorescence intensity at 338 nm of all these enzymes decreased below 2 M urea in which the enzyme activities remained the same (Del 24) or activated (WT). The second stage of unfolding was seen as the maximum shifted to 342 nm in 2-4 M urea, presumably involving dissociation. Complete unfolding above 4 M urea resulted in further shift in fluorescence maximum to 350 nm.	VET AFFAIRS MED CTR,RES SERV,4500 S LANCASTER RD,DALLAS,TX 75216; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75216	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ALGAIER J, 1988, BIOCHEM BIOPH RES CO, V153, P328, DOI 10.1016/S0006-291X(88)81226-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CREIGHTON TE, 1979, J MOL BIOL, V129, P235, DOI 10.1016/0022-2836(79)90279-1; CREPIN KM, 1989, BIOCHEM J, V264, P151, DOI 10.1042/bj2640151; DARVILLE MI, 1987, EUR J BIOCHEM, V159, P359; ELMAGHRABI MR, 1982, P NATL ACAD SCI-BIOL, V79, P315, DOI 10.1073/pnas.79.2.315; FURUYA E, 1982, P NATL ACAD SCI-BIOL, V79, P325, DOI 10.1073/pnas.79.2.325; FURUYA E, 1981, J BIOL CHEM, V256, P7109; KITAJIMA S, 1984, J BIOL CHEM, V259, P6896; KITAMURA K, 1989, J BIOL CHEM, V264, P9799; KITAMURA K, 1987, J BIOL CHEM, V262, P679; KITAMURA K, 1988, J BIOL CHEM, V263, P16796; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIVELY MO, 1988, J BIOL CHEM, V263, P839; SAKAKIBARA R, 1984, J BIOL CHEM, V259, P41; SAKATA J, 1991, J BIOL CHEM, V266, P15764; SAKATA J, 1990, P NATL ACAD SCI USA, V87, P4951, DOI 10.1073/pnas.87.13.4951; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TANDON S, 1990, J BIOL CHEM, V265, P5967; UYEDA K, 1970, J BIOL CHEM, V245, P2268; UYEDA K, 1981, J BIOL CHEM, V256, P8394; Uyeda K, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P193; UYEDA K, 1978, J BIOL CHEM, V253, P8319; UYEDA K, 1991, CRC REV, V2, P445; VANSCHAFTINGEN E, 1981, BIOCHEM BIOPH RES CO, V103, P362, DOI 10.1016/0006-291X(81)91701-0	25	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15951	15957						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8393455				2022-12-25	WOS:A1993LN30500089
J	CREPIN, KM; VERTOMMEN, D; DOM, G; HUE, L; RIDER, MH				CREPIN, KM; VERTOMMEN, D; DOM, G; HUE, L; RIDER, MH			RAT MUSCLE 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE - STUDY OF THE KINASE DOMAIN BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PHOSPHOFRUCTOKINASE; AMINO-ACID-SEQUENCE; LIVER 6-PHOSPHOFRUCTO-2-KINASE; ACTIVE-SITE; HEPATIC FRUCTOSE-2,6-BISPHOSPHATASE; FRUCTOSE 2,6-BISPHOSPHATASE; BOVINE HEART; ENZYME; DNA; 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE	Sequence alignment and modeling of the 2-kinase domain of the liver bifunctional enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase, on 6-phosphofructo-1-kinase from Bacillus stearothermophilus and Escherichia coli (Bazan, J. F., Fletterick, R. J., and Pilkis, S. J. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 9642-9646) suggested that Cys-160 of the 2-kinase would correspond to Asp-127 of the 1-kinase, which acts as a general base catalyst. We have studied the validity of this alignment by site-directed mutagenesis of residues in the 2-kinase domain of skeletal muscle 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. Cys-160 was mutated to Asp or Ser. Two adjacent residues, Glu-157 and Asp-162, either of which could act as a general base catalyst, were mutated to Ala. Asp-162 corresponds to Asp-129 in the bacterial 1-kinase, which is also essential for catalysis and might bind Mg2+. None of these mutations significantly decreased the V(max) of the 2-kinase, suggesting that the mutated amino acids are not essential for catalysis and therefore do not play the same role as Asp-127 and Asp-129 in the bacterial 1-kinase. Mutation of Glu-157 and Asp-162 to alanine had no effect on the kinetic parameters of the bifunctional enzyme, indicating that these two negatively charged residues are not involved in catalysis and substrate binding.	INT INST CELLULAR & MOLEC PATHOL,HORMONE & METAB RES UNIT,B-1200 BRUSSELS,BELGIUM; UNIV CATHOLIQUE LOUVAIN,SCH MED,B-1200 BRUSSELS,BELGIUM	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel				Vertommen, Didier/0000-0001-7648-8282				BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; BERGER SA, 1992, BIOCHEMISTRY-US, V31, P9237, DOI 10.1021/bi00153a017; BERGER SA, 1990, NATURE, V343, P575, DOI 10.1038/343575a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTANO JG, 1979, J BIOL CHEM, V254, P5576; CIFUENTES ME, 1991, J BIOL CHEM, V266, P1557; CREPIN KM, 1992, J BIOL CHEM, V267, P21698; CREPIN KM, 1988, FEBS LETT, V227, P136, DOI 10.1016/0014-5793(88)80884-6; CREPIN KM, 1989, EUR J BIOCHEM, V183, P433, DOI 10.1111/j.1432-1033.1989.tb14946.x; DARVILLE MI, 1987, FEBS LETT, V224, P317, DOI 10.1016/0014-5793(87)80476-3; ELMAGHRABI MR, 1986, P NATL ACAD SCI USA, V83, P5005, DOI 10.1073/pnas.83.14.5005; ELMAGHRABI MR, 1984, J BIOL CHEM, V259, P3104; ELMAGHRABI MR, 1987, J BIOL CHEM, V262, P11714; HELLINGA HW, 1987, NATURE, V327, P437, DOI 10.1038/327437a0; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; JAENICKE R, 1989, PROTEIN STRUCTURE, P198; KITAJIMA S, 1984, J BIOL CHEM, V259, P6896; KRETSCHMER M, 1984, BIOCHEM BIOPH RES CO, V124, P793, DOI 10.1016/0006-291X(84)91027-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAINE R, 1992, EUR J BIOCHEM, V207, P1109, DOI 10.1111/j.1432-1033.1992.tb17148.x; LI L, 1992, J BIOL CHEM, V267, P4386; LIVELY MO, 1988, J BIOL CHEM, V263, P839; Maniatis T., 1982, MOL CLONING; MARCHAND MJ, 1992, BIOCHEM J, V285, P413, DOI 10.1042/bj2850413; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; PILKIS SJ, 1984, J BIOL CHEM, V259, P949; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; PILKIS SJ, 1987, J BIOL CHEM, V262, P12672; RIDER MH, 1985, BIOCHEM J, V231, P193, DOI 10.1042/bj2310193; RIDER MH, 1992, EUR J BIOCHEM, V207, P967, DOI 10.1111/j.1432-1033.1992.tb17131.x; SAKATA J, 1991, J BIOL CHEM, V266, P15764; SAKATA J, 1990, P NATL ACAD SCI USA, V87, P4951, DOI 10.1073/pnas.87.13.4951; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; STEWART HB, 1985, J BIOL CHEM, V260, P2935; STUDIER FW, 1990, METHOD ENZYMOL, V185, P69; TAULER A, 1990, J BIOL CHEM, V265, P15617; VANSCHAFTINGEN E, 1986, EUR J BIOCHEM, V159, P359; VENTURA F, 1992, J BIOL CHEM, V267, P17939	39	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15277	15284						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8392072				2022-12-25	WOS:A1993LL75900105
J	TURCHI, JJ; BAMBARA, RA				TURCHI, JJ; BAMBARA, RA			COMPLETION OF MAMMALIAN LAGGING-STRAND DNA-REPLICATION USING PURIFIED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; POLYMERASE-DELTA; EUKARYOTIC DNA; SIMIAN VIRUS-40; CALF THYMUS; SACCHAROMYCES-CEREVISIAE; LIGASE-I; T-ANTIGEN; INVITRO; INITIATION	We have modeled the reactions involved in the completion of lagging strand DNA replication using a synthetic DNA substrate and purified enzymes from calf thymus. We have demonstrated that each polymerase, alpha, delta, and epsilon, is capable of extending an upstream 3' terminus to generate a nick in the DNA substrate that is subsequently ligated by DNA ligase 1. Synthesis by each polymerase and subsequent ligation occurred efficiently after the addition of the 50-kDa 5'- to 3'-exonuclease. Analyses are presented which show that a substantial proportion of the ligated products is the result of polymerase epsilon, exonuclease, and DNA ligase I, all acting on the same DNA template. That is, polymerase fills in the gap, then both the polymerase and exonuclease act, one adding and the other removing nucleotides, followed by ligation. Results presented suggest that polymerase alpha, delta, or epsilon may functionally interact with DNA ligase I and the 5'- to 3'-exonuclease to perform the enzymatic reactions required for the completion of lagging strand DNA synthesis.	UNIV ROCHESTER,MED CTR,SCH MED & DENT,DEPT BIOCHEM,BOX 607,601 ELMWOOD AVE,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester			Turchi, John J/B-5807-2015	Turchi, John J/0000-0001-5375-2992	NATIONAL CANCER INSTITUTE [T32CA009363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA09363] Funding Source: Medline; NIGMS NIH HHS [GM24441] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BARNES DE, 1990, P NATL ACAD SCI USA, V87, P6679, DOI 10.1073/pnas.87.17.6679; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; CHAN JYH, 1988, J BIOL CHEM, V263, P18231; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; ELDER RH, 1990, BIOCHEMISTRY-US, V29, P6009, DOI 10.1021/bi00477a019; FOCHER F, 1989, NUCLEIC ACIDS RES, V17, P1805, DOI 10.1093/nar/17.5.1805; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HAND R, 1978, CELL, V15, P317, DOI 10.1016/0092-8674(78)90001-6; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KESTI T, 1991, J BIOL CHEM, V266, P6336; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MEZZINA M, 1989, NUCLEIC ACIDS RES, V17, P3091, DOI 10.1093/nar/17.8.3091; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MYERS TW, 1990, STRUCTURAL ORG ASPEC; NASHEUER HP, 1987, BIOCHEMISTRY-US, V26, P8458, DOI 10.1021/bi00399a064; NETHANEL T, 1990, J VIROL, V64, P5912, DOI 10.1128/JVI.64.12.5912-5918.1990; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; ROBERTS JD, 1991, P NATL ACAD SCI USA, V88, P3465, DOI 10.1073/pnas.88.8.3465; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; SIEGAL G, 1992, J BIOL CHEM, V267, P3991; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; TAN CK, 1986, J BIOL CHEM, V261, P2310; TOMKINSON AE, 1990, PROG CLIN BIOL RES, V340, P283; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; TURCHI JJ, 1992, BIOCHEMISTRY-US, V31, P9008, DOI 10.1021/bi00152a043; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643	35	77	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15136	15141						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8392066				2022-12-25	WOS:A1993LL75900086
J	LAHAM, LE; LAMB, JA; ALLEN, PG; JANMEY, PA				LAHAM, LE; LAMB, JA; ALLEN, PG; JANMEY, PA			SELECTIVE BINDING OF GELSOLIN TO ACTIN MONOMERS CONTAINING ADP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND ADENOSINE 5'-TRIPHOSPHATE; F-ACTIN; NUCLEOTIDE EXCHANGE; PLASMA GELSOLIN; ATP HYDROLYSIS; MUSCLE ACTIN; COMPLEX; POLYMERIZATION; FILAMENTS; PROFILIN	The rate of reaction and the stoichiometry of binding between gelsolin and actin monomers depends on adenine nucleotides. In the presence of Ca2+ but not Mg2+, gelsolin retains the ability to sever actin filaments when incubated for more than 20 min with an excess of G-actin in the presence of ATP but loses severing activity within seconds when mixed with G-actin in ADP. Immunoprecipitation of gelsolin removes more actin from ADP than from ATP solutions. Monomeric ATP-actin in 2 mM MgCl2 and 150 mM KCl slowly destroys the filament-severing activity of gelsolin with kinetics that are first order in actin concentration and with an apparent bimolecular rate constant of 0.021 +/-0.007 muM-1 s-1. Coincident with the slow complex formation in MgCl2, the actin bound to the calcium-sensitive actin binding domain of gelsolin hydrolyzes its ATP to ADP. These results suggest a further level of gelsolin regulation and a functional similarity between actin and GTP-binding proteins.	HARVARD UNIV, SCH MED, PROGRAM CELL & DEV BIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	LAHAM, LE (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, DIV EXPTL MED, 221 LONGWOOD AVE, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR038910, R01AR038910] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07680] Funding Source: Medline; NIAMS NIH HHS [AR38910] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKTORIES K, 1989, J CELL BIOL, V109, P1385, DOI 10.1083/jcb.109.4.1385; ALLENDE JE, 1988, FASEB J, V2, P2356, DOI 10.1096/fasebj.2.8.2452111; BARDEN JA, 1987, BIOCHEMISTRY-US, V26, P6023, DOI 10.1021/bi00393a012; BRYAN J, 1985, J CELL BIOL, V101, P1236, DOI 10.1083/jcb.101.4.1236; BRYAN J, 1988, J CELL BIOL, V106, P1553, DOI 10.1083/jcb.106.5.1553; CARLIER MF, 1989, INT REV CYTOL, V115, P139; CHAPONNIER C, 1987, J EXP MED, V165, P97, DOI 10.1084/jem.165.1.97; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; COUE M, 1986, J BIOL CHEM, V261, P1588; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DANIEL JL, 1986, EUR J BIOCHEM, V156, P677, DOI 10.1111/j.1432-1033.1986.tb09631.x; DOI Y, 1992, BIOCHEMISTRY-US, V31, P10061, DOI 10.1021/bi00156a028; DREWES G, 1991, J BIOL CHEM, V266, P5508; GOLDSCHMIDTCLERMONT PJ, 1992, MOL BIOL CELL, V3, P1015, DOI 10.1091/mbc.3.9.1015; HARRIS HE, 1985, FEBS LETT, V190, P81, DOI 10.1016/0014-5793(85)80432-4; HEGYI G, 1986, BIOCHEMISTRY-US, V25, P5793, DOI 10.1021/bi00367a067; HOZUMI T, 1990, BIOCHEM INT, V20, P45; JANMEY PA, 1990, NATURE, V347, P95, DOI 10.1038/347095a0; JANMEY PA, 1986, J MUSCLE RES CELL M, V7, P446, DOI 10.1007/BF01753587; JANMEY PA, 1986, BIOCHEM BIOPH RES CO, V136, P72, DOI 10.1016/0006-291X(86)90878-8; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KAMBE H, 1992, J BIOCHEM-TOKYO, V111, P722, DOI 10.1093/oxfordjournals.jbchem.a123825; KORN ED, 1987, SCIENCE, V238, P638, DOI 10.1126/science.3672117; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; LAL AA, 1985, J BIOL CHEM, V260, P132; LAMB JA, 1993, J BIOL CHEM, V268, P8999; LIU DF, 1990, BIOCHEM J, V266, P453, DOI 10.1042/bj2660453; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; ORLOVA A, 1992, J MOL BIOL, V227, P1043, DOI 10.1016/0022-2836(92)90520-T; POLLARD TD, 1992, J BIOL CHEM, V267, P20339; RANDERATH E, 1964, J CHROMATOGR, V16, P126, DOI 10.1016/S0021-9673(01)82446-8; SCHUTT CE, 1992, P NATL ACAD SCI USA, V89, P319, DOI 10.1073/pnas.89.1.319; SELVE N, 1987, EUR J BIOCHEM, V168, P111, DOI 10.1111/j.1432-1033.1987.tb13394.x; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; TELLAM RL, 1986, BIOCHEMISTRY-US, V25, P5799, DOI 10.1021/bi00367a068; YIN HL, 1987, BIOESSAYS, V7, P176, DOI 10.1002/bies.950070409	40	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14202	14207						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8390984				2022-12-25	WOS:A1993LJ82500062
J	BU, GJ; MAKSYMOVITCH, EA; SCHWARTZ, AL				BU, GJ; MAKSYMOVITCH, EA; SCHWARTZ, AL			RECEPTOR-MEDIATED ENDOCYTOSIS OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR BY LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN ON HUMAN HEPATOMA HEPG2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LDL-RECEPTOR; INHIBITOR TYPE-1; LINE HEP-G2; ALPHA-2-MACROGLOBULIN RECEPTOR; MYOCARDIAL-INFARCTION; EXTRACELLULAR-MATRIX; HUMAN HEPATOCYTES; BINDING-PROTEIN; SEC RECEPTOR; RAT-LIVER	Hepatic parenchymal cells play an essential role in the clearance of circulating tissue-type plasminogen activator (t-PA) in vivo as a major pathway in the regulation of plasma fibrinolytic activity. Previous studies have identified plasminogen activator inhibitor type 1 (PAI-1)-dependent t-PA-binding sites in the human hepatoma cell line HepG2. In this study, we demonstrate that receptor-mediated binding and endocytosis of the t-PA.PAI-1 complex are largely mediated by a recently identified low density lipoprotein receptor-related protein (LRP). A 39-kDa LRP receptor-associated protein that modulates ligand binding to LRP was found to bind specifically to HepG2 cells and to inhibit approximately 70-80% of specific I-125-t-PA.PAI-1 binding. This inhibition by the 39-kDa protein was not due to inhibition of complex formation between I-125-t-PA and PAI-1; instead, the 39-kDa protein inhibited I-125-t-PA.PAI-1 binding to LRP. Polyclonal anti-LRP antibody raised against purified human LRP also inhibited 70-80% of specific I-125-t-PA.PAI-1 binding. A similar extent of inhibition by the 39-kDa protein was also observed for I-125-t-PA.PAI-1 endocytosis and degradation. Chemical cross-linking experiments demonstrated the direct interaction between I-125-t-PA.PAI-1 and LRP on HepG2 cells as anti-LRP antibody, in addition to anti-t-PA and anti-PAI-1 antibodies, was able to immunoprecipitate the I-125-t-PA.PAI-1 complex following binding of I-125-t-PA-PAI-1 to HepG2 cells and cross-linking. This interaction of the t-PA.PAI-1 complex with LRP on HepG2 cells was also observed when the unlabeled t-PA.PAI-1 complex was cross-linked to [S-35]methionine-labeled HepG2 cells. In addition, the direct binding of the 39-kDa protein to LRP on HepG2 cells was demonstrated by similar cross-linking experiments. Thus, these data clearly show that LRP is the major cell-surface receptor responsible for t-PA.PAI-1 complex binding and endocytosis on human hepatoma HepG2 cells and extend the multifunctional nature of LRP as an endocytosis receptor for several structurally and functionally distinct ligands.	WASHINGTON UNIV, SCH MED, EDWARD MALLINCKRODT DEPT PEDIAT, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, EDWARD MALLINCKRODT DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL017646, P50HL017646] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL17646] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKHIT C, 1988, Fibrinolysis, V2, P31, DOI 10.1016/0268-9499(88)90062-8; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; BU GJ, 1992, J BIOL CHEM, V267, P15595; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BUGELSKI PJ, 1989, THROMB RES, V53, P287, DOI 10.1016/0049-3848(89)90104-7; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLEN D, 1989, DRUGS, V38, P346, DOI 10.2165/00003495-198938030-00003; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; EMEIS JJ, 1985, THROMB HAEMOSTASIS, V54, P661; FUCHS HE, 1985, BLOOD, V65, P539; GARABEDIAN HD, 1986, AM J CARDIOL, V58, P673, DOI 10.1016/0002-9149(86)90336-X; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; JOSLIN G, 1991, J BIOL CHEM, V266, P11282; KRAUSE J, 1990, BIOCHEM J, V267, P647, DOI 10.1042/bj2670647; KUIPER J, 1988, J BIOL CHEM, V263, P18220; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIJNEN HR, 1991, THROMB HAEMOSTASIS, V66, P88; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; MEYTS PD, 1976, J BIOL CHEM, V251, P1877; MORTON PA, 1990, J BIOL CHEM, V265, P14093; MORTON PA, 1989, J BIOL CHEM, V264, P7228; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; OWENSBY DA, 1988, J BIOL CHEM, V263, P10587; OWENSBY DA, 1989, J BIOL CHEM, V264, P18180; OWENSBY DA, 1991, J BIOL CHEM, V266, P4334; PERLMUTTER DH, 1990, J BIOL CHEM, V265, P16713; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PLOUG M, 1991, J BIOL CHEM, V266, P1926; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RIJKEN DC, 1990, THROMB RES, P63; RIJKEN DC, 1986, BIOCHEM J, V238, P643, DOI 10.1042/bj2380643; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHWARTZ AL, 1981, J BIOL CHEM, V256, P8878; SIMOONS ML, 1989, ANNU REV MED, V40, P181; SPRENGERS ED, 1985, J LAB CLIN MED, V105, P751; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; UNDERHILL DM, 1992, BLOOD, V80, P2746; VANDEWERF F, 1984, NEW ENGL J MED, V310, P609; VERSTRAETE M, 1986, THROMB HAEMOSTASIS, V56, P1; WING LR, 1991, FEBS LETT, V278, P95, DOI 10.1016/0014-5793(91)80092-H; WING LR, 1991, J LAB CLIN MED, V117, P109; WING LR, 1992, FIBRINOLYSIS, V6, P2; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; 1985, NEW ENGL J MED, V310, P609	52	89	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					13002	13009						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8389767				2022-12-25	WOS:A1993LG65800112
J	SHAY, JW; WRIGHT, WE; BRASISKYTE, D; VANDERHAEGEN, BA				SHAY, JW; WRIGHT, WE; BRASISKYTE, D; VANDERHAEGEN, BA			E6 OF HUMAN PAPILLOMAVIRUS TYPE-16 CAN OVERCOME THE M1 STAGE OF IMMORTALIZATION IN HUMAN MAMMARY EPITHELIAL-CELLS BUT NOT IN HUMAN FIBROBLASTS	ONCOGENE			English	Article							HUMAN BREAST-CANCER; RETINOBLASTOMA SUSCEPTIBILITY GENE; HUMAN-DIPLOID FIBROBLASTS; LARGE TUMOR-ANTIGEN; LARGE T-ANTIGEN; P53 MUTATIONS; SV40-TRANSFORMED CELLS; CELLULAR SENESCENCE; TRANSFORMED-CELLS; GROWTH	Immortalization is the consequence of the inactivation or bypass of two mortality stage mechanisms, M1 and M2, which are controlled by several genes including Rb and p53 in human fibroblasts. Abrogation of the M1 controls can be obtained through the activity of DNA tumor virus genes such as E6 and E7 of human papillomavirus 16 (HPV16). Fibroblasts expressing both E6 (which binds p53) and E7 (which binds Rb) bypass MI and continue replicating (exhibit an extended lifespan) until an independent mechanism, M2, is activated. The inactivation of the M2 mechanism finally results in celt immortalization. The present study establishes a difference in the tissue-specific mechanisms for the control of the M1 stage of cellular senescence. The expression of HPV16 E6 was sufficient to bypass the MI stage of cellular senescence and confer an extended lifespan in human mammary epithelial cells but not in fibroblasts. This implies that the M1 mechanism in human mammary epithelial cells does not involve the constitutive activation of Rb function as it does in fibroblasts. In addition, the results confirmed that the expression of HPV16 E6 (or both E6 and E7) did not directly immortalize the human mammary epithelial cells, since the inactivation of a second event, M2, was required to achieve immortalization. These observations are considered in the context of the telomere shortening model of cellular senescence.			SHAY, JW (corresponding author), UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.		Shay, Jerry W/F-7878-2011		NCI NIH HHS [CA50195] Funding Source: Medline; NIA NIH HHS [AG07992] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007992] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLSOP RC, 1992, IN PRESS P NATL ACAD; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BARTEK J, 1990, ONCOGENE, V5, P893; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BRONSTEIN I, 1990, BIOTECHNIQUES, V8, P310; COLES C, 1992, CANCER RES, V52, P5291; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DAVIDOFF AM, 1991, CANCER RES, V51, P2605; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DUNBAR BS, 1987, 2 DIMENSIONAL ELECTR, P335; GILLESPIE PG, 1991, P NATL ACAD SCI USA, V88, P2563, DOI 10.1073/pnas.88.6.2563; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; GRIEDER CW, 1990, BIOESSAYS, V12, P363; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P538; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HAYFLICK L, 1980, AGING ITS CHEM, P227; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; KIPLING D, 1992, HUM MOL GENET, V1, P3, DOI 10.1093/hmg/1.1.3-a; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LINDER S, 1990, EXP CELL RES, V191, P1, DOI 10.1016/0014-4827(90)90027-8; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTIN GM, 1977, AM J PATHOL, V89, P484; MAZARS R, 1992, CANCER RES, V52, P3918; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MUNGER K, 1989, J VIROL, V63, P4417; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OSBORNE RJ, 1991, CANCER RES, V51, P6194; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; PIRISI L, 1992, J VIROL, V44, P268; Pollock Raphael E., 1992, Cancer Bulletin (Houston), V44, P268; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SCHEFFNER M, 1990, CELL, V63, P11291; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAY JW, 1992, EXP GERONTOL, V27, P477, DOI 10.1016/0531-5565(92)90003-I; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1992, MUTAT RES, V277, P163, DOI 10.1016/0165-1110(92)90003-R; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; SIDRANSKY D, 1992, CANCER RES, V52, P2984; STAMPFER M, 1980, IN VITRO CELL DEV B, V16, P415; STAMPS AC, 1992, EUR J CANCER, V28A, P1495, DOI 10.1016/0959-8049(92)90552-D; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STEIN GH, 1985, J CELL PHYSIOL, V125, P36, DOI 10.1002/jcp.1041250106; VANDERHAEGEN BA, 1993, IN PRESS IN VIGRO CE; VARLEY JM, 1991, ONCOGENE, V6, P413; WATANABE S, 1989, J VIROL, V63, P965, DOI 10.1128/JVI.63.2.965-969.1989; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088	79	230	239	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1407	1413						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8389027				2022-12-25	WOS:A1993LE06400002
J	GUO, H; REDDY, SAG; DAMUNI, Z				GUO, H; REDDY, SAG; DAMUNI, Z			PURIFICATION AND CHARACTERIZATION OF AN AUTOPHOSPHORYLATION-ACTIVATED PROTEIN SERINE THREONINE KINASE THAT PHOSPHORYLATES AND INACTIVATES PROTEIN PHOSPHATASE-2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; CATALYTIC SUBUNIT; PROTAMINE KINASE; TYROSINE-PHOSPHATASE; SEQUENCE; S6; CYTOSOL; BRAIN; LIVER; CELLS	Protein phosphatase 2A2 is inactivated by phosphorylation following incubation with purified preparations of an autophosphorylation-activated protein kinase (Hong Guo and Zahi Damuni (1992) Proc. Natl. Acad. Sci. U. S. A. 90, 2500-2504). This protein kinase was purified about 250,000-fold from extracts of bovine kidney to apparent homogeneity. The purified preparations exhibited a single polypeptide of apparent M(r) almost-equal-to 36,000. Up to 1 mol of phosphoryl groups was incorporated per mol of the purified kinase following incubation with ATP. This autophosphorylation reaction (t1/2 almost-equal-to 0.5-1 min) was accompanied by a approximately 10-fold activation of the kinase. Autophosphorylation and activation were reversed by protein phosphatase 2A2 or the catalytic subunit of protein phosphatase 1. Phosphoamino acid analysis indicated that the kinase underwent autophosphorylation on threonines. The rate of autophosphorylation was independent of the concentration of the enzyme and a slope of 0.97 (gamma = 0.998) was obtained by van't Hoff's plot indicating that autophosphorylation was intramolecular. Relative to myelin basic protein, the enzyme exhibited about 8, 62, 130, 33, 5, and <0.1% activity with histones H1, H2A, H2B, H3, and H4 and with glycogen synthase a, respectively. Heparin inhibited the activity of the enzyme half-maximally at about 20 mug/ml. The results indicate that this autophosphorylation-activated kinase is a new protein kinase.	UNIV S CAROLINA, DEPT BIOL SCI, CLS 601, COLUMBIA, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia								AMICK GD, 1992, BIOCHEM J, V287, P1019, DOI 10.1042/bj2871019; AMICK GD, 1992, BIOCHEM BIOPH RES CO, V183, P431, DOI 10.1016/0006-291X(92)90499-B; AMICK GD, 1992, ARCH BIOCHEM BIOPHYS, V297, P80, DOI 10.1016/0003-9861(92)90643-B; ARINO J, 1988, P NATL ACAD SCI USA, V85, P4252, DOI 10.1073/pnas.85.12.4252; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAYLA X, 1990, BIOCHEMISTRY-US, V29, P658, DOI 10.1021/bi00455a010; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1982, NATURE, V296, P613, DOI 10.1038/296613a0; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; CZECH MP, 1988, J BIOL CHEM, V263, P11017; DAMUNI Z, 1990, BIOCHEM BIOPH RES CO, V166, P449, DOI 10.1016/0006-291X(90)91966-V; DAMUNI Z, 1989, J BIOL CHEM, V264, P6412; Deibler G E, 1984, Prog Clin Biol Res, V146, P249; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ERIKSON E, 1986, J BIOL CHEM, V261, P350; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; Krebs EG, 1986, ENZYMES, V17, P3, DOI 10.1016/S1874-6047(08)60426-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; NESTLER EJ, 1983, NATURE, V305, P583, DOI 10.1038/305583a0; REDDY SAG, 1990, J BIOL CHEM, V265, P7748; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; SILVA OBD, 1987, FEBS LETT, V221, P415, DOI 10.1016/0014-5793(87)80966-3; SILVA OBDC, 1987, FEBS LETT, V226, P176; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TODHUNTER JA, 1977, BIOCHIM BIOPHYS ACTA, V485, P87, DOI 10.1016/0005-2744(77)90195-4; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TUNG HYL, 1985, EUR J BIOCHEM, V148, P253, DOI 10.1111/j.1432-1033.1985.tb08833.x; USUI H, 1988, J BIOL CHEM, V263, P3752; USUI H, 1991, ADV PROTEIN PHOSPHAT, V6, P287; VANTHOFF JH, 1884, ETUDES DYNAMIQUE CHI, P87; YANG SD, 1987, J BIOL CHEM, V262, P7034; YANG SD, 1987, J BIOL CHEM, V262, P9421	43	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11193	11198						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8388387				2022-12-25	WOS:A1993LD46600071
J	HEGUY, A; BALDARI, CT; CENSINI, S; GHIARA, P; TELFORD, JL				HEGUY, A; BALDARI, CT; CENSINI, S; GHIARA, P; TELFORD, JL			A CHIMERIC TYPE-II/TYPE-I INTERLEUKIN-1 RECEPTOR CAN MEDIATE INTERLEUKIN-1 INDUCTION OF GENE-EXPRESSION IN T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; GROWTH-FACTOR RECEPTOR; IL-1 RECEPTOR; B-CELLS; SIGNAL TRANSDUCTION; MAMMALIAN-CELLS; BETA-CHAIN; ANTAGONIST; BINDING; INTERNALIZATION	The type I interleukin-1 receptor (IL-1R) is capable of transducing a signal resulting in promoter activation in T cells. This signal transduction is dependent on the cytoplasmic domain, which consists of 213 amino acids. In contrast to the type I receptor, the type II IL-1R has a small cytoplasmic tail, and it is not clear whether this receptor is a signal-transducing or a regulatory molecule. Here we report that the type II IL-1R does not mediate gene activation in Jurkat cells. However, a hybrid receptor composed of the extracellular and transmembrane regions of the human type II interleukin-1 fused to the cytoplasmic domain of the human type I IL-IR was capable of transducing a signal across the membrane resulting in a pattern of gene activation identical to that mediated by the type I IL-1R. Our results indicated that the extracellular domain of the type II IL-1R was capable of functionally interacting with interleukin-1 and transmitting the resulting signal to a heterologous cytoplasmic domain.	IRIS,VIA FIORENTINA 1,I-53100 SIENA,ITALY; UNIV SIENA,DEPT EVOLUT BIOL,I-53100 SIENA,ITALY	Novartis; University of Siena			Telford, John Laird/ABG-8144-2020	Baldari, Cosima/0000-0002-4414-6744				BALDARI CT, 1992, FEBS LETT, V304, P261, DOI 10.1016/0014-5793(92)80633-R; BALDARI CT, 1991, J BIOL CHEM, V266, P19103; BALDARI CT, 1992, J BIOL CHEM, V267, P4289; BERNARD O, 1987, P NATL ACAD SCI USA, V84, P2125, DOI 10.1073/pnas.84.8.2125; BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; CASAGLI MC, 1989, PREP BIOCHEM, V19, P23, DOI 10.1080/10826068908544894; CURTIS BM, 1989, P NATL ACAD SCI USA, V86, P3045, DOI 10.1073/pnas.86.9.3045; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; DRIPPS DJ, 1991, J BIOL CHEM, V266, P20311; EISENBERG SP, 1991, P NATL ACAD SCI USA, V88, P5232, DOI 10.1073/pnas.88.12.5232; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GEHRKE L, 1990, J BIOL CHEM, V265, P5922; GILLIS S, 1980, J EXP MED, V152, P1709, DOI 10.1084/jem.152.6.1709; GIRI JG, 1984, J IMMUNOL, V132, P223; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANOWITZ EV, 1991, J BIOL CHEM, V266, P14147; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HEGUY A, 1991, CELL GROWTH DIFFER, V2, P311; HEGUY A, 1992, J BIOL CHEM, V267, P2605; HORUK R, 1989, BIOCHEM J, V260, P657, DOI 10.1042/bj2600657; JU G, 1991, P NATL ACAD SCI USA, V88, P2658, DOI 10.1073/pnas.88.7.2658; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LEV S, 1990, MOL CELL BIOL, V10, P6064, DOI 10.1128/MCB.10.11.6064; MACCHIA G, 1990, MOL CELL BIOL, V10, P2731, DOI 10.1128/MCB.10.6.2731; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; SCAPIGLIATI G, 1989, FEBS LETT, V243, P394, DOI 10.1016/0014-5793(89)80169-3; SCAPIGLIATI G, 1991, J IMMUNOL METHODS, V138, P31, DOI 10.1016/0022-1759(91)90061-J; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YAN H, 1991, SCIENCE, V252, P561, DOI 10.1126/science.1850551	42	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10490	10494						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8387521				2022-12-25	WOS:A1993LB80000074
J	COHEN-ARMON, M; SOKOLOVSKY, M				COHEN-ARMON, M; SOKOLOVSKY, M			EVIDENCE FOR INVOLVEMENT OF THE VOLTAGE-DEPENDENT NA+ CHANNEL GATING IN DEPOLARIZATION-INDUCED ACTIVATION OF G-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; SENSITIVE SODIUM-CHANNELS; MUSCARINIC ACETYLCHOLINE-RECEPTORS; BETA-ADRENERGIC RECEPTORS; HIGH-AFFINITY BINDING; RAT-BRAIN; PERTUSSIS-TOXIN; ION CHANNELS; GTP-BINDING; PHOSPHOLIPID-VESICLES	Evidence for activation of pertussis-toxin-sensitive G-proteins by membrane depolarization in rat brain-stem synaptoneurosomes was recently reported (Coben-Armon, M., and Sokolovsky, M. (1991) J. Biol. Chem. 266, 2595-2605; (1991) Neurosci. Lett. 126, 87-90) and is further supported in this study by the observation that the depolarization-induced effect is inhibited when G-proteins are stabilized in the non-activated state with guanosine 5'-O-(2-thiodiphosphate) (GDPbetaS), which was introduced into synaptoneurosomes during the process of permeabilization and resealing. In the present study, agents that either keep the voltage-dependent Na+ channel in persistently activated state (while Na+ currents are blocked) or prevent it from activation were used in an attempt to determine whether the voltage-dependent Na+ channels are involved in the depolarization-induced activation of pertussis-toxin-sensitive G-proteins. The main probe employed was the cardiotonic and antiarrhythmic agent DPI, which is a racemic mixture of two enantiomers, one of which (the R enantiomer) reportedly prevents depolarization-induced activation of the Na+ channel while the other (the S enantiomer) inhibits Na+ channel inactivation. The results suggest that while inactivation of the voltage-dependent Na+ channel does not interfere with the putative depolarization-induced activation of G-proteins, membrane depolarization affects G-proteins and the coupled muscarinic receptors only if the voltage-dependent Na+ channels are capable of being activated. Thus, inhibition of the depolarization-induced activation of Na+ channels was accompanied by inhibition of the depolarization-induced activation of pertussis-toxin-sensitive G-proteins and by modifications of both the coupling of G-proteins to muscarinic receptors and the ADP-ribosylation of G(o)-proteins. These effects could be counteracted by persistent activation of the voltage-dependent Na+ channels (while Na+ current was blocked). Our observations may suggest that the voltage-dependent Na+ channel gating is involved in the depolarization-induced activation of pertussis toxin-sensitive G-proteins and may provide evidence for a possible mechanism of membrane depolarization signal transduction in excitable cells.	TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, DEPT BIOCHEM, NEUROBIOCHEM LAB, IL-69978 TEL AVIV, ISRAEL	Tel Aviv University	COHEN-ARMON, M (corresponding author), TEL AVIV UNIV, SACKLER SCH MED, DEPT PHYSIOL & PHARMACOL, IL-69978 TEL AVIV, ISRAEL.							AVIGAN J, 1992, BIOCHEMISTRY-US, V31, P7736, DOI 10.1021/bi00148a039; AVISSAR S, 1988, NATURE, V331, P440, DOI 10.1038/331440a0; BARCHI RL, 1988, ANNU REV NEUROSCI, V11, P455, DOI 10.1146/annurev.ne.11.030188.002323; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; BUTTERWORTH JF, 1990, ANESTHESIOLOGY, V72, P711, DOI 10.1097/00000542-199004000-00022; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P4155, DOI 10.1073/pnas.75.9.4155; CATTERALL WA, 1980, ANNU REV PHARMACOL, V20, P15, DOI 10.1146/annurev.pa.20.040180.000311; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; CATTERALL WA, 1975, J BIOL CHEM, V250, P4053; CATTERALL WA, 1981, MOL PHARMACOL, V20, P356; CERIONE RA, 1986, J BIOL CHEM, V261, P3901; CHENG K, 1980, J MEMBRANE BIOL, V56, P191, DOI 10.1007/BF01869476; COHEN-ARMON M, 1985, BIOCHEM BIOPH RES CO, V127, P326, DOI 10.1016/S0006-291X(85)80162-5; COHEN-ARMON M, 1986, J BIOL CHEM, V261, P2498; COHEN-ARMON M, 1991, NEUROSCI LETT, V126, P87, DOI 10.1016/0304-3940(91)90378-7; COHEN-ARMON M, 1985, P NATL ACAD SCI USA, V82, P3524, DOI 10.1073/pnas.82.10.3524; COHEN-ARMON M, 1988, BIOCHEMISTRY-US, V27, P368, DOI 10.1021/bi00401a055; COHEN-ARMON M, 1991, J BIOL CHEM, V266, P2595; COULTER S, 1992, P NATL ACAD SCI USA, V89, P5842, DOI 10.1073/pnas.89.13.5842; DALY JW, 1982, J TOXICOL-TOXIN REV, V1, P33, DOI 10.3109/15569548209016467; DRAPEAU P, 1983, J NEUROSCI, V3, P703; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; GIERSCHIK P, 1986, P NATL ACAD SCI USA, V83, P2258, DOI 10.1073/pnas.83.7.2258; GURWITZ D, 1985, MOL PHARMACOL, V28, P297; GUSOVSKY F, 1988, CELL MOL NEUROBIOL, V8, P157, DOI 10.1007/BF00711242; GUSOVSKY F, 1987, MOL PHARMACOL, V32, P479; HAGA K, 1989, MOL PHARMACOL, V35, P286; HAGA K, 1986, J BIOL CHEM, V261, P133; HEPPEL LA, 1985, J MEMBRANE BIOL, V86, P189, DOI 10.1007/BF01870597; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HOLLINGSWORTH EB, 1985, J NEUROSCI, V5, P2240; JENKINSON DH, 1960, J PHYSIOL-LONDON, V152, P309, DOI 10.1113/jphysiol.1960.sp006489; KHODOROV BI, 1985, PROG BIOPHYS MOL BIO, V45, P57, DOI 10.1016/0079-6107(85)90005-7; KLOOG Y, 1979, MOL PHARMACOL, V15, P545; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNING DR, 1984, J BIOL CHEM, V259, P749; MCKINNEY M, 1984, ANNU REV PHARMACOL, V24, P121; MCNEAL ET, 1985, J MED CHEM, V28, P381, DOI 10.1021/jm00381a019; MILLIGAN G, 1988, BIOCHEM J, V255, P1; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; PAUWELS PJ, 1986, EUR J PHARMACOL, V132, P289, DOI 10.1016/0014-2999(86)90618-7; POSTMA SW, 1984, MOL PHARMACOL, V25, P219; ROMEY G, 1987, P NATL ACAD SCI USA, V84, P896, DOI 10.1073/pnas.84.3.896; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SOKOLOVSKY M, 1989, ADV DRUG RES, V18, P431; SPIEGEL AM, 1990, ADP RIBOSYLATION TOX, P207; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TAMURA M, 1982, BIOCHEMISTRY-US, V21, P5516, DOI 10.1021/bi00265a021; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UI M, 1990, ADP RIBOSYLATING TOX, P45; VOEIKOV VL, 1980, BIOCHIM BIOPHYS ACTA, V629, P266, DOI 10.1016/0304-4165(80)90100-2; WAGGONER A, 1976, J MEMBRANE BIOL, V27, P317, DOI 10.1007/BF01869143; WANG G, 1990, MOL PHARMACOL, V37, P17; WINSLOW JW, 1987, J BIOL CHEM, V262, P4501; YAMAMOTO H, 1992, NEUROSCI LETT, V139, P194, DOI 10.1016/0304-3940(92)90550-Q	60	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9824	9838						15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8387506				2022-12-25	WOS:A1993LA68900097
J	DUPREZ, E; GJERTSEN, BT; BERNARD, O; LANOTTE, M; DOSKELAND, SO				DUPREZ, E; GJERTSEN, BT; BERNARD, O; LANOTTE, M; DOSKELAND, SO			ANTIAPOPTOTIC EFFECT OF HETEROZYGOUSLY EXPRESSED MUTANT RI (ALA336-]ASP) SUBUNIT OF CAMP KINASE-I IN A RAT LEUKEMIA-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CYCLIC-NUCLEOTIDE BINDING; AMINO-ACID-SEQUENCE; REGULATORY SUBUNIT; PREDICTED STRUCTURES; CHOLERA-TOXIN; SITES; APOPTOSIS; DEATH; AMP	cAMP induced rapid apoptosis (>90% cell death in 6 h) of non-growth-arrested rat leukemia IPC-81 cells. A cell clone selected for cAMP resistance had a normally functioning apoptotic machinery whose triggering required about 30-fold higher cellular cAMP than in the parent cells. The cAMP subresponsiveness was due to a heterozygous point mutation (Ala336 --> Asp) in the RI subunit of cAMP-dependent protein kinase I. In fact, apoptosis correlated with intracellular cAMP binding to the subresponsive RI. The mutated alanine is invariantly present in cyclic nucleotide kinases, but of unknown function. The mutation decreased the cAMP affinity to site B by increasing the cAMP dissociation rate 500x. The ability of site B to discriminate adenine-modified cAMP analogues was affected, suggesting that Ala336 faced the adenine moiety of cAMP. That the heterozygously expressed RI(336)was a dominant suppressor of apoptosis was explained by a higher expression of R than C subunits in the mutant cells, by preferential expression of the mutant form of RI, and by the ability of mutant RI to exert dominant negative control of activation of wild type cAMP kinase at moderate cAMP levels. Apoptosis was induced at a similar cAMP level in cells treated with cholera toxin or other cAMP elevating agents, indicating that cAMP kinase was essential for toxin action.	UNIV BERGEN, SCH MED, DEPT ANAT & CELL BIOL, N-5009 BERGEN, NORWAY	University of Bergen	DUPREZ, E (corresponding author), HOP ST LOUIS, CTR HAYEM, INST HEMATOL, INSERM, U301, F-75010 PARIS, FRANCE.		duprez, estelle a/R-2357-2016; Gjertsen, Bjorn T/O-1542-2015; Gjertsen, Bjørn T/AAP-3281-2020; Bernard, Olivier A./E-5721-2016	Gjertsen, Bjorn T/0000-0001-9358-9704; Gjertsen, Bjørn T/0000-0001-9358-9704; Doskeland, Stein Ove/0000-0002-4009-4756				ALLES A, 1991, FASEB J, V5, P2127, DOI 10.1096/fasebj.5.8.2022310; BEEBE SJ, 1986, ENZYMES, V17, P43; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSCH W, 1992, TRENDS PHARMACOL SCI, V13, P245, DOI 10.1016/0165-6147(92)90077-J; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEWIT RJW, 1984, EUR J BIOCHEM, V142, P255; DOSKELAND SO, 1988, METHOD ENZYMOL, V159, P147; DOSKELAND SO, 1983, BIOCHEMISTRY-US, V22, P1094; DOSKELAND SO, 1984, J BIOL CHEM, V259, P2291; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EKANGER R, 1989, J BIOL CHEM, V264, P4374; FRANCIS ML, 1992, J IMMUNOL, V148, P1999; FRIEDRICH U, 1977, P NATL ACAD SCI USA, V74, P679, DOI 10.1073/pnas.74.2.679; HERMOUET S, 1990, FEBS LETT, V267, P221, DOI 10.1016/0014-5793(90)80929-D; HOFMANN F, 1977, J BIOL CHEM, V252, P1441; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; KUNO T, 1987, BIOCHEM BIOPH RES CO, V146, P878, DOI 10.1016/0006-291X(87)90612-7; LANOTTE M, 1986, LEUKEMIA RES, V10, P1319, DOI 10.1016/0145-2126(86)90340-1; LANOTTE M, 1991, J CELL PHYSIOL, V146, P73, DOI 10.1002/jcp.1041460110; LOCKSHIN RA, 1990, J GERONTOL, V45, pB135, DOI 10.1093/geronj/45.5.B135; MCKAY DB, 1982, J BIOL CHEM, V257, P9518; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OGREID D, 1989, EUR J BIOCHEM, V181, P19; OGREID D, 1982, FEBS LETT, V150, P161, DOI 10.1016/0014-5793(82)81326-4; QURESHI SA, 1991, MOL CELL BIOL, V11, P102, DOI 10.1128/MCB.11.1.102; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; SHABB JB, 1991, J BIOL CHEM, V266, P24320; SHUNTOH H, 1991, J CELL PHYSIOL, V146, P86, DOI 10.1002/jcp.1041460112; SUDGEN PH, 1976, BIOCHEM J, V159, P409; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; TORTORA G, 1991, P NATL ACAD SCI USA, V88, P2011, DOI 10.1073/pnas.88.5.2011; VINTERMYR OK, 1993, IN PRESS EXP CELL RE; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Wyllie A H, 1980, Int Rev Cytol, V68, P251	42	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8332	8340						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8385140				2022-12-25	WOS:A1993KW97900107
J	JONES, GH				JONES, GH			COMBINED PURIFICATION OF ACTINOMYCIN SYNTHETASE-I AND 3-HYDROXYANTHRANILIC ACID 4-METHYLTRANSFERASE FROM STREPTOMYCES-ANTIBIOTICUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHENOXAZINONE SYNTHASE GENE; 4-METHYL-3-HYDROXYANTHRANILIC ACID; MOLECULAR-CLONING; EXPRESSION; LIVIDANS; ENZYME	Actinomycin synthetase I, which activates the precursor of the chromophore of actinomycin, has been purified nearly 1000-fold from extracts of Streptomyces antibioticus. The enzyme has an M(r) of 45,000 and appears to function as a single polypeptide chain. The formation of the enzyme is repressed when S. antibioticus mycelium is grown on glucose as a carbon source. Several benzoic acid derivatives, including intermediates in the putative pathway for actinomycin biosynthesis, were capable of supporting ATP-pyrophosphate exchange catalyzed by actinomycin synthetase I. Interestingly, three synthetic phenoxazinones also functioned as substrates in the exchange reaction. It proved possible to purify a second enzyme involved in actinomycin biosynthesis, 3-hydroxyanthranilic acid 4-methyltransferase, from the same extracts prepared for the purification of actinomycin synthetase I and by similar procedures. Streptomyces lividans, previously shown to contain a silent gene for the enzyme phenoxazinone synthase, apparently does not contain a silent pathway for the complete synthesis of actinomycin since neither actinomycin synthetase I nor the methyltransferase could be detected in strains containing a cloned sequence that activates phenoxazinone synthase expression.			JONES, GH (corresponding author), EMORY UNIV,DEPT BIOL,ATLANTA,GA 30322, USA.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOY HA, 1981, ARCH BIOCHEM BIOPHYS, V211, P55, DOI 10.1016/0003-9861(81)90429-X; FAWAZ F, 1988, J BIOL CHEM, V263, P4602; JONES GH, 1987, J BACTERIOL, V169, P5575, DOI 10.1128/jb.169.12.5575-5578.1987; JONES GH, 1984, J BIOL CHEM, V259, P4158; JONES GH, 1984, J BIOL CHEM, V259, P4151; JONES GH, 1979, BIOCHEMISTRY-US, V18, P4542, DOI 10.1021/bi00588a014; KATZ E, 1962, J BIOL CHEM, V237, P882; KELLER U, 1987, J BIOL CHEM, V262, P5852; KELLER U, 1984, BIOCHEMISTRY-US, V23, P1479, DOI 10.1021/bi00302a022; KELLER U, 1992, J BIOL CHEM, V267, P11745; KELLY KS, 1991, J BACTERIOL, V173, P2297, DOI 10.1128/JB.173.7.2297-2300.1991; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADU AC, 1989, GENE, V84, P287, DOI 10.1016/0378-1119(89)90502-7; MARSHALL R, 1968, ARCH BIOCHEM BIOPHYS, V123, P317, DOI 10.1016/0003-9861(68)90141-0; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; TROOST T, 1979, J GEN MICROBIOL, V111, P121, DOI 10.1099/00221287-111-1-121; WAKSMAN SA, 1968, ACTINOMYCIN NATURE F	18	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6831	6834						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8385097				2022-12-25	WOS:A1993KV14100003
J	WILSON, DW; LEWIS, MJ; PELHAM, HRB				WILSON, DW; LEWIS, MJ; PELHAM, HRB			PH-DEPENDENT BINDING OF KDEL TO ITS RECEPTOR INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUMINAL ER PROTEINS; ACIDIC INTRACELLULAR COMPARTMENTS; ENDOPLASMIC-RETICULUM; SECRETORY PROTEINS; GOLGI-APPARATUS; RETENTION; YEAST; CELLS; SPECIFICITY; MEMBRANES	The erd2 protein is the receptor responsible for recycling proteins bearing the carboxyl-terminal sequence KDEL (single-letter amino acid code) to the endoplasmic reticulum, following their loss from that organelle by the process of forward transport. To study the interaction of erd2p with the sequence KDEL we have reconstituted binding of erd2p to its ligand in vitro. Binding in vitro exhibits the same sequence specificity as retention of lumenal proteins in vivo and is strikingly sensitive to pH. Our results raise the possibility that erd2p-mediated sorting of lumenal endoplasmic reticulum proteins is facilitated by the pH differences between compartments of the secretory pathway.	MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology								ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; ANDRES DA, 1991, J BIOL CHEM, V266, P14277; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GLICKMAN J, 1983, J CELL BIOL, V97, P1303, DOI 10.1083/jcb.97.4.1303; HARDWICK KG, 1992, EMBO J, V11, P4187, DOI 10.1002/j.1460-2075.1992.tb05512.x; HARLOW E, 1988, ANTIBODIES LABORATOR; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; ORCI L, 1987, NATURE, V326, P77, DOI 10.1038/326077a0; PELHAM HRB, 1988, EMBO J, V7, P1757, DOI 10.1002/j.1460-2075.1988.tb03005.x; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; ROBBI M, 1991, J BIOL CHEM, V266, P20498; ROTHMAN JE, 1981, SCIENCE, V213, P1212, DOI 10.1126/science.7268428; SCHWARTZ AL, 1985, EMBO J, V4, P899, DOI 10.1002/j.1460-2075.1985.tb03716.x; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SEMENZA JC, 1992, J MOL BIOL, V224, P1, DOI 10.1016/0022-2836(92)90571-Z; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SWEET DJ, 1992, EMBO J, V11, P423, DOI 10.1002/j.1460-2075.1992.tb05071.x; TABAS I, 1979, J BIOL CHEM, V254, P1655; TAKEMOTO H, 1992, ARCH BIOCHEM BIOPHYS, V296, P129, DOI 10.1016/0003-9861(92)90554-A; YOSHIMORI T, 1990, J BIOL CHEM, V265, P15984; ZAGOURAS P, 1989, J CELL BIOL, V109, P2633, DOI 10.1083/jcb.109.6.2633	30	175	176	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7465	7468						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8385108				2022-12-25	WOS:A1993KV14100091
J	HARA, E; OKAMOTO, S; NAKADA, S; TAYA, Y; SEKIYA, S; ODA, K				HARA, E; OKAMOTO, S; NAKADA, S; TAYA, Y; SEKIYA, S; ODA, K			PROTEIN-PHOSPHORYLATION REQUIRED FOR THE FORMATION OF E2F COMPLEXES REGULATES N-MYC TRANSCRIPTION DURING DIFFERENTIATION OF HUMAN EMBRYONAL CARCINOMA-CELLS	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; DNA-BINDING PROTEINS; CYCLIN-A; TRANSIENT DECREASE; STEM-CELLS; RB GENE; EXPRESSION; REGION; TRANSACTIVATION; ADENOVIRUS-E1A	The human embryonal carcinoma (EC) cell line NEC14 can be induced to differentiate morphologically by the addition of 10(-2) M N,N'-hexamethylene-bis-acetamide (HMBA). The N-myc gene is expressed at a high level in the undifferentiated cells, but the level decreased steeply after 12-24 h HMBA treatment, returning to its original level after 48 h. The alteration in the N-myc level was well correlated with the formation of complexes with the E2F motif in the N-myc promoter region, and no complex was formed with cell extracts prepared from cells treated with HMBA for 12-24 h. The absence of E2F complexes during this period was caused by an inhibitor generated by a phosphatase reaction. Treatment of the 12-h extract with a cyclic AMP-dependent protein kinase resulted in the formation of E2F complexes, and treatment of the undifferentiated (0 h) and 48-h extracts with a calf intestinal phosphatase abolished complex formation completely. An inhibitor generated by the 0-h extract after treatment with a phosphatase inhibited E2F complex formation by the untreated 0-h extract in the presence of phosphatase inhibitors, okadaic acid and sodium vanadate. One of the two E2F complexes in the undifferentiated cells contained cyclin A, but the complex with similar mobility, formed after the transient decrease in the N-myc level, did not.	SCI UNIV TOKYO,DEPT BIOL SCI & TECHNOL,NODA,CHIBA 278,JAPAN; SCI UNIV TOKYO,DEPT APPL BIOL SCI,NODA,CHIBA 278,JAPAN; CHIBA UNIV,SCH MED,DEPT OBSTET & GYNECOL,CHIBA 280,JAPAN; NATL CANC CTR,RES INST,DIV BIOL,CHUO KU,TOKYO 104,JAPAN	Tokyo University of Science; Tokyo University of Science; Chiba University; National Cancer Center - Japan								ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FRIEND M, 1981, NUCLEIC ACIDS RES, V9, P6509; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GORMAN CM, 1985, CELL, V42, P519, DOI 10.1016/0092-8674(85)90109-6; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARA E, 1991, NUCLEIC ACIDS RES, V19, P7097, DOI 10.1093/nar/19.25.7097; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HASEGAWA T, 1990, DIFFERENTIATION, V42, P191, DOI 10.1111/j.1432-0436.1990.tb00761.x; HASEGAWA T, 1991, DIFFERENTIATION, V47, P107, DOI 10.1111/j.1432-0436.1991.tb00228.x; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JACOBOVITS A, 1985, NATURE, V318, P188; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KATO K, 1990, MOL CELL BIOL, V10, P486, DOI 10.1128/MCB.10.2.486; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MATSUNO K, 1989, J BIOL CHEM, V264, P18707; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PINES J, 1990, New Biologist, V2, P389; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; REICHEL R, 1987, CELL, V48, P501, DOI 10.1016/0092-8674(87)90200-5; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Sambrook J, 1989, MOL CLONING LABORATO; SEJERSEN T, 1986, J CELL PHYSIOL, V127, P274, DOI 10.1002/jcp.1041270213; SEKIYA S, 1990, GYNECOL ONCOL, V36, P69, DOI 10.1016/0090-8258(90)90111-W; SEKIYA S, 1985, DIFFERENTIATION, V29, P259, DOI 10.1111/j.1432-0436.1985.tb00325.x; SEKIYA S, 1988, INT J GYNECOL PATHOL, V7, P373, DOI 10.1097/00004347-198812000-00008; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Silver L.M., 1983, TERATOCARCINOMA STEM; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TAKEHANA K, 1991, GENE, V103, P219, DOI 10.1016/0378-1119(91)90276-H; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VELCICH A, 1985, NATURE, V318, P595; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	59	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1023	1032						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8384353				2022-12-25	WOS:A1993KT22000026
J	MCCONKEY, DJ; ORRENIUS, S; OKRET, S; JONDAL, M				MCCONKEY, DJ; ORRENIUS, S; OKRET, S; JONDAL, M			CYCLIC-AMP POTENTIATES GLUCOCORTICOID-INDUCED ENDOGENOUS ENDONUCLEASE ACTIVATION IN THYMOCYTES	FASEB JOURNAL			English	Note						APOPTOSIS; PROGRAMMED CELL DEATH; CALCIUM; GLUCOCORTICOID RECEPTOR	DNA FRAGMENTATION; CELL-DEATH; DEPENDENT PHOSPHORYLATION; IMMATURE THYMOCYTES; RECEPTOR; APOPTOSIS; PROTEIN; MODULATION; CLEAVAGE; NUCLEI	The present study was undertaken to determine whether specific interactions between cAMP and glucocorticoids regulate apoptosis in thymocytes. Incubation of murine thymocytes with agents that elevate the cAMP level resulted in enhancement of glucocorticoid-induced Ca2+ increases, DNA fragmentation, and cell death compared to levels observed in thymocytes treated with steroid alone. cAMP did not affect DNA fragmentation in thymocytes treated with Ca2+ ionophore, a compound that induces endonuclease activation via an independent mechanism. Treatment with cAMP also increased glucocorticoid potency by lowering the concentration of steroid required for induction of apoptosis. The mechanism of cAMP action appeared to involve the glucocorticoid receptor, since the glucocorticoid antagonist RU-486 abrogated the cAMP response in animals treated with the adenosine analog NECA in vivo. Analysis of cellular glucocorticoid binding and receptor protein levels revealed modest cAMP-stimulated increases that appeared insufficient to account for the effects of cAMP on endogenous endonuclease activation, suggesting the possible involvement of a posttranslational mechanism in the response. These results demonstrate that cAMP and glucocorticoids synergize to promote apoptosis in thymocytes via a mechanism that appears to involve modification of glucocorticoid receptor activity.	KAROLINSKA INST,DEPT TOXICOL,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA INST,DEPT MED NUTR,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA INST,DEPT IMMUNOL,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet								BASILE DV, 1975, P NATL ACAD SCI USA, V70, P3055; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; COHEN JJ, 1984, J IMMUNOL, V132, P38; DICKEN ES, 1992, MOL CELL BIOL, V12, P589; DONG Y, 1989, J BIOL CHEM, V264, P13679; DOWD DR, 1992, MOL CELL BIOL, V12, P3600, DOI 10.1128/MCB.12.8.3600; GRANDICS P, 1984, BIOCHEM BIOPH RES CO, V120, P59, DOI 10.1016/0006-291X(84)91413-X; GRUOL DJ, 1989, MOL ENDOCRINOL, V3, P2119, DOI 10.1210/mend-3-12-2119; GRUOL DJ, 1986, J BIOL CHEM, V261, P4909; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOECK W, 1989, J BIOL CHEM, V264, P14396; HOECK W, 1990, J BIOL CHEM, V265, P5403; HOMODELARCHE F, 1985, J IMMUNOL, V135, P506; HOUSLEY PR, 1983, J BIOL CHEM, V258, P4630; KIZAKI H, 1990, J BIOL CHEM, V265, P5280; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCONKEY DJ, 1990, J IMMUNOL, V145, P1227; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; MCCONKEY DJ, 1990, J BIOL CHEM, V265, P3009; MENDEL DB, 1987, J BIOL CHEM, V262, P5644; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; OKRET S, 1984, P NATL ACAD SCI-BIOL, V81, P1609, DOI 10.1073/pnas.81.6.1609; ORTI E, 1989, J BIOL CHEM, V264, P9728; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; PRATT RM, 1975, P NATL ACAD SCI USA, V72, P874, DOI 10.1073/pnas.72.3.874; SHI YF, 1990, J IMMUNOL, V144, P3326; SINGH VB, 1985, J BIOL CHEM, V260, P3684; SOMERS JP, 1992, MOL ENDOCRINOL, V6, P26, DOI 10.1210/me.6.1.26; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	32	57	59	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR 1	1993	7	6					580	585		10.1096/fasebj.7.6.8386120	http://dx.doi.org/10.1096/fasebj.7.6.8386120			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KY009	8386120				2022-12-25	WOS:A1993KY00900012
J	NIKOLAKAKI, E; COFFER, PJ; HEMELSOET, R; WOODGETT, JR; DEFIZE, LHK				NIKOLAKAKI, E; COFFER, PJ; HEMELSOET, R; WOODGETT, JR; DEFIZE, LHK			GLYCOGEN-SYNTHASE KINASE-3 PHOSPHORYLATES JUN FAMILY MEMBERS INVITRO AND NEGATIVELY REGULATES THEIR TRANSACTIVATING POTENTIAL IN INTACT-CELLS	ONCOGENE			English	Article							DNA-BINDING ACTIVITY; PROTEIN-KINASE; C-JUN; FOS PROTEINS; METALLOTHIONEIN GENE; TRANSCRIPTION; ACTIVATION; PRODUCT; EXPRESSION; AP-1	Expression of immediate-early genes involving the 12-O-tetradecanoyl phorbol 13-acetate (TPA)-responsive element (TRE) is modulated by post-translational modification of pre-existing activator protein 1 (AP-1) constituents. One of the components of AP-1, c-Jun, has been shown to be phosphorylated by glycogen synthase kinase 3 (GSK-3) in vitro in a region proximal to the DNA-binding domain, resulting in decreased DNA binding. Here, we have used transient transfection to show that AP-1 activity is inhibitable by coexpression of GSK-3 in intact cells. Furthermore, we show that the c-Jun-related proteins JunD and JunB are subject to similar regulation by GSK-3 in intact cells. Comparison of tryptic phosphopeptide maps of the three Jun proteins incubated with GSK-3 in vitro with maps of the same proteins immunoprecipitated from P-32-labelled cells indicates similar sites of phosphorylation. Together, these data support the hypothesis that GSK-3 is an important regulator of AP-1 activity in vivo.	HUBRECHT LAB DEV BIOL,UPPSALALAAN 8,3584 CT UTRECHT,NETHERLANDS; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Ludwig Institute for Cancer Research			Coffer, Paul/AAF-7970-2020; Woodgett, Jim/F-1087-2010; Coffer, Paul J/A-5769-2009	Woodgett, Jim/0000-0003-3731-5797; 				ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BENBROOK DM, 1990, ONCOGENE, V5, P295; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DWARKI VJ, 1990, EMBO J, V9003, P2253; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODE N, 1992, J BIOL CHEM, V267, P16878; HUGHES K, 1992, EUR J BIOCHEM, V203, P305, DOI 10.1111/j.1432-1033.1992.tb19860.x; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MULLER R, 1987, ONCOGENE RES, V2, P19; PULVERER B, 1992, IN PRESS ONCOGENE; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAYLOR WE, 1990, P NATL ACAD SCI USA, V87, P4098, DOI 10.1073/pnas.87.11.4098; Woodgett J R, 1990, Semin Cancer Biol, V1, P389; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3	40	190	194	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					833	840						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8384354				2022-12-25	WOS:A1993KT22000003
J	KLECZKOWSKI, LA; VILLAND, P; PREISS, J; OLSEN, OA				KLECZKOWSKI, LA; VILLAND, P; PREISS, J; OLSEN, OA			KINETIC MECHANISM AND REGULATION OF ADP-GLUCOSE PYROPHOSPHORYLASE FROM BARLEY (HORDEUM-VULGARE) LEAVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADPGLUCOSE PYROPHOSPHORYLASE; MOLECULAR CHARACTERIZATION; SUBUNIT STRUCTURE; MAIZE ENDOSPERM; LEAF; ORTHOPHOSPHATE; PURIFICATION; PROTEINS	Barley (Hordeum vulgare, cv. Bomi) leaf ADP-glucose pyrophosphorylase (AGP) was purified to near-homogeneity, using ammonium sulfate fractionation and heat treatment as well as ion exchange, hydrophobic, and dye-ligand chromatography. The enzyme was found to be composed of two subunit types of 51 and 54 kDa, which were recognized by the respective rabbit antibodies against the small and/or large subunit of spinach leaf AGP. Substrate kinetics and product inhibition studies, carried out in the direction of ADP-glucose synthesis, suggested a sequential Iso Ordered Bi Bi kinetic mechanism for the enzyme. In addition, inhibition patterns with CrATP, a dead-end inhibitor of ATP-utilizing enzymes, were consistent with ATP (synthesis reaction) and ADP-glucose (pyrophosphorolysis reaction) binding first to different free forms of the enzyme. The AGP was potently activated by 3-phosphoglycerate (PGA) (K(alpha) of 5 muM) and inhibited by orthophosphate (P(i)), with the ratio of the two effectors playing a major role in modulating AGP activity. At low [PGA]/[P(i)] ratios, P(i) could reverse the activating effect of PGA. However, at the [PGA]/[P(i)] ratios of 1.4, or higher, some activating effect of P(i) in the presence of PGA was observed. PGA decreased the K(m) values for all substrates of AGP (in both the synthesis and pyrophosphorolysis directions). Properties of the barley leaf AGP are compared to those of AGP from barley seed endosperm, which is insensitive to PGA/P(i) regulation.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University	KLECZKOWSKI, LA (corresponding author), NLVF,PLANT MOLEC BIOL LAB,N-1432 AS,NORWAY.			Kleczkowski, Leszek A./0000-0001-8685-9665				ANDERSON JM, 1991, GENE, V97, P199, DOI 10.1016/0378-1119(91)90052-D; BALL S, 1991, PLANTA, V185, P17, DOI 10.1007/BF00194509; BLOOMFIELD V, 1962, J AM CHEM SOC, V84, P4375, DOI 10.1021/ja00882a002; CHARNG YY, 1992, PLANT MOL BIOL, V20, P37, DOI 10.1007/BF00029147; DEPAMPHILIS ML, 1973, BIOCHEMISTRY-US, V12, P3714, DOI 10.1021/bi00743a022; FUCHS RL, 1979, BIOCHIM BIOPHYS ACTA, V566, P40, DOI 10.1016/0005-2744(79)90246-8; GHOSH HP, 1966, J BIOL CHEM, V241, P4491; HAUGEN TH, 1979, J BIOL CHEM, V254, P127; HELDT HW, 1977, PLANT PHYSIOL, V59, P1146, DOI 10.1104/pp.59.6.1146; IGLESIAS AA, 1991, PLANT PHYSIOL, V97, P1187, DOI 10.1104/pp.97.3.1187; KLECZKOWSKI LA, IN PRESS PLANT PHYSL, V101; KLECZKOWSKI LA, 1991, Z NATURFORSCH, V460, P605; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; KRISHNAN HB, 1986, PLANT PHYSIOL, V81, P642, DOI 10.1104/pp.81.2.642; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORELL M, 1988, J BIOL CHEM, V263, P633; MORELL MK, 1987, PLANT PHYSIOL, V85, P182, DOI 10.1104/pp.85.1.182; NAKAMURA Y, 1992, PHYSIOL PLANTARUM, V84, P336, DOI 10.1034/j.1399-3054.1992.840303.x; OKITA TW, 1990, PLANT PHYSIOL, V93, P785, DOI 10.1104/pp.93.2.785; OLIVE MR, 1989, PLANT MOL BIOL, V12, P525, DOI 10.1007/BF00036967; PAULE MR, 1971, J BIOL CHEM, V246, P4602; PLAXTON WC, 1987, PLANT PHYSIOL, V83, P105, DOI 10.1104/pp.83.1.105; PREISS J, 1990, PLANT PHYSIOL, V92, P881, DOI 10.1104/pp.92.4.881; Preiss J, 1991, OXFORD SURVEYS PLANT, V7, P59; SANWAL GG, 1968, PLANT PHYSIOL, V43, P417, DOI 10.1104/pp.43.3.417; Segel I.H., 1975, ENZYME KINETICS; SHAW JR, 1992, PLANT PHYSIOL, V98, P1214, DOI 10.1104/pp.98.3.1214; SINGH BK, 1984, PLANT PHYSIOL, V74, P711, DOI 10.1104/pp.74.3.711; SMITHWHITE BJ, 1992, J MOL EVOL, V34, P449, DOI 10.1007/BF00162999; SOWOKINOS JR, 1982, PLANT PHYSIOL, V69, P1459, DOI 10.1104/pp.69.6.1459; SOWOKINOS JR, 1981, PLANT PHYSIOL, V68, P924, DOI 10.1104/pp.68.4.924; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI CY, 1970, PLANT PHYSIOL, V46, P299, DOI 10.1104/pp.46.2.299; TSUBOI KK, 1969, J BIOL CHEM, V244, P1008; VILLAND P, 1992, PLANT MOL BIOL, V19, P381, DOI 10.1007/BF00023385; VILLAND P, 1992, PLANT PHYSIOL, V100, P1617, DOI 10.1104/pp.100.3.1617; ZEWE V, 1965, BIOCHEMISTRY-US, V4, P782, DOI 10.1021/bi00880a024	37	64	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6228	6233						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8384204				2022-12-25	WOS:A1993KT36800026
J	BENIT, L; CHARON, M; COCAULT, L; WENDLING, F; GISSELBRECHT, S				BENIT, L; CHARON, M; COCAULT, L; WENDLING, F; GISSELBRECHT, S			THE WS-MOTIF COMMON TO V-MPL AND MEMBERS OF THE CYTOKINE RECEPTOR SUPERFAMILY IS DISPENSABLE FOR MYELOPROLIFERATIVE LEUKEMIA-VIRUS PATHOGENICITY	ONCOGENE			English	Note							MURINE SARCOMA-VIRUS; MOLECULAR-CLONING; PROGENITOR CELLS; ONCOGENICITY; EXPRESSION; RETROVIRUS; SEQUENCES; INVITRO	Several motifs are conserved in the extracellular domain of the cloned chains of the recently described cytokine receptor superfamily. One of them, usually close to the transmembrane region, is the 'WS motif'. Its function remains unknown, but it has been recently shown that the integrity of this motif is essential for interleukin 2 receptor beta-chain and erythropoietin receptor activity [Miyazaki, T., Maruyama, M., Yamada, G., Hatakeyama, M. & Taniguchi, T. (1991). EMBO J., 10, 3191-3197; Watowich, S.S., Yoshimura, A., Longmore, G.D., Hilton, D.J., Hoshimura, Y. & Lodish, H.R. (1992). Proc. Natl. Acad. Sci. USA, 89, 2140-21441. This WS motif is present in the v-mpl oncogene, which has been transduced in the myeloproliferative leukemia virus (MPLV). v-mpl encodes a truncated transmembrane protein that belongs to this growth factor receptor family. We demonstrate that determinants of MPLV pathogenesis are encoded by the env-mpl fusion gene and that the complete deletion of the WS motif does not abolish MPLV oncogenic properties.	HOP COCHIN,ICGM,INSERM,U363,27 RUE FAUBOURG ST JACQUES,F-75674 PARIS 14,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier				PETIT, Laurence/0000-0002-2475-9367				BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CHIBA T, 1992, BIOCHEM BIOPH RES CO, V184, P485, DOI 10.1016/0006-291X(92)91220-K; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HANAFUSA H, 1977, J EXP MED, V146, P1735, DOI 10.1084/jem.146.6.1735; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; OLIFF AI, 1980, J VIROL, V33, P475, DOI 10.1128/JVI.33.1.475-486.1980; PENCIOLELLI JF, 1987, J VIROL, V61, P579, DOI 10.1128/JVI.61.2.579-583.1987; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; SOUYRI M, 1989, J VIROL, V63, P3944, DOI 10.1128/JVI.63.9.3944-3953.1989; VELU TJ, 1989, J VIROL, V63, P1384, DOI 10.1128/JVI.63.3.1384-1392.1989; VIGON I, 1992, IN PRESS P NATL ACAD; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WENDLING F, 1989, LEUKEMIA, V3, P475; WENDLING F, 1986, VIROLOGY, V149, P242, DOI 10.1016/0042-6822(86)90125-X; WENDLING F, 1989, BLOOD, V73, P1161	25	9	13	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					787	790						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8382360				2022-12-25	WOS:A1993KN00800032
J	TEDESCO, D; FISCHERFANTUZZI, L; VESCO, C				TEDESCO, D; FISCHERFANTUZZI, L; VESCO, C			LIMITS OF TRANSFORMING COMPETENCE OF SV40 NUCLEAR AND CYTOPLASMIC LARGE T-MUTANTS WITH ALTERED RB-BINDING SEQUENCES	ONCOGENE			English	Article							LARGE TUMOR-ANTIGEN; RETINOBLASTOMA SUSCEPTIBILITY GENE; SIMIAN VIRUS-40; DNA-REPLICATION; EMBRYO FIBROBLASTS; TRANSGENIC MICE; ORIGIN-BINDING; HUMAN-CELLS; PROTEIN; PHOSPHORYLATION	Multiple amino acid substitutions were introduced into the SV40 large T region that harbors the retinoblastoma protein (Rb) binding site and the nuclear transport signal, changing either one or both of these determinants. Mutant activities were examined in a set of assays allowing different levels of transforming potential to be, distinguished; phenotypic changes in established and pre-crisis rat embryo fibroblasts (REFs) were detected under isogenic cell conditions, and comparisons made with other established rodent cells. The limit of the transforming ability of mutants with important substitutions in the Rb binding site fell between two transformation levels of the same established rat cells. Such cells could be induced to form dense foci but not agar colonies (their parental pre-crises REFs, as expected, were untransformed either way). Nonetheless, agar colony induction was possible in other cell lines, such as mouse NIH3T3 and (for one of the mutants) rat F2408. All these mutants efficiently immortalized pre-crisis REFs. The transforming ability of cytoplasmic mutants appeared to depend on the integrity of the Rb-binding sequence to approximately the same extent as that of the wild-type large T, although evidence of in vivo Rb-cytoplasmic large T complexes was not found. The presence or absence of small t was critical when the transforming task of mutants was near the limit of their abilities.	CNR,INST BIOL CELLULARE,VIALE MARX 43,I-00137 ROME,ITALY	Consiglio Nazionale delle Ricerche (CNR)								ASSELIN C, 1985, J VIROL, V56, P958, DOI 10.1128/JVI.56.3.958-968.1985; BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; CHEN S, 1987, J VIROL, V61, P3521, DOI 10.1128/JVI.61.11.3521-3527.1987; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEPPERT W, 1990, J VIROL, V64, P838, DOI 10.1128/JVI.64.2.838-846.1990; DOBBELSTEIN M, 1992, ONCOGENE, V7, P837; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FANTUZZI LF, 1988, MOL CELL BIOL, V8, P5495; FANTUZZI LF, 1987, ONCOGENE RES, V1, P229; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; FRIEDMAN M, 1986, CONTEMP POLICY ISSUE, V4, P1, DOI 10.1111/j.1465-7287.1986.tb00827.x; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GRAND RJA, 1989, ONCOGENE, V4, P1291; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; LANFORD RE, 1985, MOL CELL BIOL, V5, P1043, DOI 10.1128/MCB.5.5.1043; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MANFREDI JJ, 1990, J VIROL, V64, P5250, DOI 10.1128/JVI.64.11.5250-5259.1990; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MONTANO X, 1990, P NATL ACAD SCI USA, V87, P7448, DOI 10.1073/pnas.87.19.7448; PANNUTI A, 1987, J VIROL, V61, P1296, DOI 10.1128/JVI.61.4.1296-1299.1987; PEDEN KWC, 1990, J VIROL, V64, P2912, DOI 10.1128/JVI.64.6.2912-2921.1990; PINKERT CA, 1987, VIROLOGY, V160, P169, DOI 10.1016/0042-6822(87)90057-2; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; RUTILA JE, 1989, ONCOGENE RES, V4, P303; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHEIDTMANN KH, 1991, J VIROL, V65, P1479, DOI 10.1128/JVI.65.3.1479-1490.1991; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; SLEIGH MJ, 1978, CELL, V14, P79, DOI 10.1016/0092-8674(78)90303-3; SOMPAYRAC L, 1988, VIROLOGY, V163, P391, DOI 10.1016/0042-6822(88)90279-6; SOMPAYRAC L, 1985, MOL CELL BIOL, V5, P1191, DOI 10.1128/MCB.5.5.1191; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; THIMMAPPAYA B, 1979, J VIROL, V30, P668, DOI 10.1128/JVI.30.3.668-673.1979; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; VANDYKE TA, 1987, J VIROL, V61, P2029, DOI 10.1128/JVI.61.6.2029-2032.1987; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WILDEMAN AG, 1989, P NATL ACAD SCI USA, V86, P2123, DOI 10.1073/pnas.86.7.2123; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116; ZHU JY, 1991, J VIROL, V65, P2778, DOI 10.1128/JVI.65.6.2778-2790.1991; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	54	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					549	557						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8382355				2022-12-25	WOS:A1993KN00800004
J	AMBROSIO, G; ZWEIER, JL; DUILIO, C; KUPPUSAMY, P; SANTORO, G; ELIA, PP; TRITTO, I; CIRILLO, P; CONDORELLI, M; CHIARIELLO, M; FLAHERTY, JT				AMBROSIO, G; ZWEIER, JL; DUILIO, C; KUPPUSAMY, P; SANTORO, G; ELIA, PP; TRITTO, I; CIRILLO, P; CONDORELLI, M; CHIARIELLO, M; FLAHERTY, JT			EVIDENCE THAT MITOCHONDRIAL RESPIRATION IS A SOURCE OF POTENTIALLY TOXIC OXYGEN-FREE RADICALS IN INTACT RABBIT HEARTS SUBJECTED TO ISCHEMIA AND REFLOW	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE GENERATION; SPIN RESONANCE SPECTROSCOPY; RECOMBINANT SUPEROXIDE-DISMUTASE; MYOCARDIAL REPERFUSION INJURY; THIOBARBITURIC ACID REACTION; NADH-UBIQUINONE REDUCTASE; CYTOCHROME-C REDUCTASE; PERFUSED RAT-HEART; LIPID-PEROXIDATION; POSTISCHEMIC REPERFUSION	Previous in vitro studies have shown that isolated mitochondria can generate oxygen radicals. However, whether a similar phenomenon can also occur in intact organs is unknown. In the present study, we tested the hypothesis that resumption of mitochondrial respiration upon reperfusion might be a mechanism of oxygen radical formation in postischemic hearts, and that treatment with inhibitors of mitochondrial respiration might prevent this phenomenon. Three groups of Langendorff-perfused rabbit hearts were subjected to 30 min of global ischemia at 37-degrees-C, followed by reflow. Throughout ischemia and early reperfusion the hearts received, respectively: (a) 5 mM KCl (controls), (b) 5 mm sodium amobarbital (Amytal(TM), which blocks mitochondrial respiration at Site I, at the level of NADH dehydrogenase), and (c) 5 mM potassium cyanide (to block mitochondrial respiration distally, at the level of cytochrome c oxidase). The hearts were then processed to directly evaluate oxygen radical generation by electron paramagnetic resonance spectroscopy, or to measure oxygen radical-induced membrane lipid peroxidation by malonyl dialdehyde (M-DA) content of subcellular fractions. Severity of ischemia, as assessed by P-31-nuclear magnetic resonance measurements of cardiac ATP, phosphocreatine, and pH, was similar in all groups. Oxygen-centered free radical concentration averaged 3.84 +/- 0.54 muM in reperfused control hearts, and it was significantly reduced by Amytal treatment (1.98 +/- 0.26; p < 0.05), but not by KCN (2.58 +/- 0.96 muM; p = not significant (NS)), consistent with oxygen radicals being formed in the mitochondrial respiratory chain at Site I. Membrane lipid peroxidation of reperfused hearts was also reduced by treatment with Amytal, but not with KCN. MDA content of the mitochondrial fraction averaged 0.75 +/- 0.06 nM/mg protein in controls, 0.72 +/- 0.06 in KCN-treated hearts, and 0.54 +/- 0.05 in Amytal-treated hearts (p < 0.05 versus both groups). Similarly, MDA content of lysosomal membrane fraction was 0.64 +/- 0.09 nm/mg protein in controls, 0.79 +/- 0.15 in KCN-treated hearts, and 0.43 +/-0.06 in Amytal-treated hearts (p < 0.05 versus both groups). Since the effects of Amytal are known to be reversible, in a second series of experiments we investigated whether transient mitochondrial inhibition during the initial 10 min of reperfusion was also associated with beneficial effects on subsequent recovery of cardiac function after wash-out of the drug. At the end of the experiment, recovery of left ventricular end-diastolic and of developed pressure was significantly greater in those hearts that had been treated with Amytal during ischemia and early reflow, as compared to untreated hearts. In conclusion, our data demonstrate that in intact hearts electron flow through the respiratory chain may be an important source of oxygen radicals, which may form at the sites of interactions between Fe-S clusters and ubiquinone, and that resumption of mitochondrial respiration upon reoxygenation might contribute to reperfusion injury.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CARDIOL,BALTIMORE,MD 21205	Johns Hopkins University	AMBROSIO, G (corresponding author), UNIV NAPLES,SCH MED 2,DEPT MED,DIV CARDIOL,VIA S PANSINI 5,I-80131 NAPLES,ITALY.		Tritto, Isabella/Y-8881-2019; Duilio, Carlo/AAW-3929-2021; Ambrosio, Giuseppe/C-6596-2013; CIRILLO, Plinio/K-9263-2016	Ambrosio, Giuseppe/0000-0002-9677-980X; CIRILLO, Plinio/0000-0001-7818-4952; TRITTO, Isabella/0000-0003-0026-7154	NHLBI NIH HHS [HL-38324] Funding Source: Medline; NIOSH CDC HHS [P5OHL 17655] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038324, R29HL038324] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIOSH CDC HHS; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMBROSIO G, 1991, J MOL CELL CARDIOL, V23, P1359, DOI 10.1016/0022-2828(91)90183-M; AMBROSIO G, 1987, CIRCULATION, V75, P282, DOI 10.1161/01.CIR.75.1.282; AMBROSIO G, 1992, AM J PHYSIOL, V262, pH23, DOI 10.1152/ajpheart.1992.262.1.H23; AMBROSIO G, 1991, J CLIN INVEST, V87, P2056, DOI 10.1172/JCI115236; ARDUINI A, 1988, BIOCHIM BIOPHYS ACTA, V970, P113, DOI 10.1016/0167-4889(88)90169-3; BAKER JE, 1988, P NATL ACAD SCI USA, V85, P2786, DOI 10.1073/pnas.85.8.2786; BAKER JE, 1989, FEBS LETT, V244, P311, DOI 10.1016/0014-5793(89)80552-6; BECKER LC, 1987, PROG CARDIOVASC DIS, V30, P23, DOI 10.1016/0033-0620(87)90009-0; BIRD RP, 1984, METHOD ENZYMOL, V105, P299; BOLLI R, 1988, J CLIN INVEST, V82, P476, DOI 10.1172/JCI113621; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; CHAMBERS DE, 1985, J MOL CELL CARDIOL, V17, P145, DOI 10.1016/S0022-2828(85)80017-1; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; COPELAND ES, 1975, J MAGN RESON, V20, P124, DOI 10.1016/0022-2364(75)90158-4; DEJONG JW, 1990, CIRC RES, V67, P770, DOI 10.1161/01.RES.67.3.770; EYER P, 1986, ANAL BIOCHEM, V153, P57, DOI 10.1016/0003-2697(86)90061-8; FANTINI GA, 1992, AM J PHYSIOL, V263, pH981, DOI 10.1152/ajpheart.1992.263.3.H981; FANTONE JC, 1982, AM J PATHOL, V107, P394; FERRARI R, 1985, J MOL CELL CARDIOL, V17, P937, DOI 10.1016/S0022-2828(85)80074-2; FLAHERTY JT, 1982, CIRCULATION, V65, P561, DOI 10.1161/01.CIR.65.3.561; FREEMAN BA, 1982, LAB INVEST, V47, P412; GARLICK PB, 1987, CIRC RES, V61, P757, DOI 10.1161/01.RES.61.5.757; GAYESKI TEJ, 1991, AM J PHYSIOL, V260, pH522, DOI 10.1152/ajpheart.1991.260.2.H522; GRILL HP, 1992, J AM COLL CARDIOL, V20, P1604, DOI 10.1016/0735-1097(92)90457-X; GRUM CM, 1986, BIOCHEM BIOPH RES CO, V141, P1104, DOI 10.1016/S0006-291X(86)80157-7; GUPTA M, 1989, CIRC RES, V64, P398, DOI 10.1161/01.RES.64.2.398; HEARSE DJ, 1977, J MOL CELL CARDIOL, V9, P605, DOI 10.1016/S0022-2828(77)80357-X; HESS ML, 1984, J MOL CELL CARDIOL, V16, P969, DOI 10.1016/S0022-2828(84)80011-5; HOCESTEIN P, 1981, FED PROC, V40, P183; HOERTER JA, 1988, AM J PHYSIOL, V255, pC192, DOI 10.1152/ajpcell.1988.255.2.C192; JACOBUS WE, 1978, J MOL CELL CARDIOL, V10, P39, DOI 10.1016/0022-2828(78)90121-9; JOSEPHSON RA, 1991, J BIOL CHEM, V266, P2354; JULICHER RHM, 1984, LIFE SCI, V35, P1281, DOI 10.1016/0024-3205(84)90099-7; KNOWLES PF, 1969, BIOCHEM J, V111, P53, DOI 10.1042/bj1110053; KOLLER PT, 1989, CIRC RES, V65, P838, DOI 10.1161/01.RES.65.3.838; KUPRIYANOV VV, 1991, BIOCHIM BIOPHYS ACTA, V1058, P386, DOI 10.1016/S0005-2728(05)80135-5; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; LIEDTKE AJ, 1984, BASIC RES CARDIOL, V79, P513, DOI 10.1007/BF01910480; LOSCHEN G, 1974, FEBS LETT, V42, P68, DOI 10.1016/0014-5793(74)80281-4; LOSCHEN G, 1971, FEBS LETT, V18, P261, DOI 10.1016/0014-5793(71)80459-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; NAKAZAWA H, 1988, AM J PHYSIOL, V255, pH213, DOI 10.1152/ajpheart.1988.255.1.H213; NETTAR D, 1985, J MAGN RESON, V64, P61, DOI 10.1016/0022-2364(85)90030-7; NIELSEN H, 1981, LIPIDS, V16, P215, DOI 10.1007/BF02535019; NISHIKI K, 1979, AM J PHYSIOL, V237, pC221, DOI 10.1152/ajpcell.1979.237.5.C221; NOHL H, 1978, EUR J BIOCHEM, V90, P385, DOI 10.1111/j.1432-1033.1978.tb12615.x; NOHL H, 1987, FEBS LETT, V214, P269, DOI 10.1016/0014-5793(87)80068-6; NOHL H, 1978, EUR J BIOCHEM, V82, P563, DOI 10.1111/j.1432-1033.1978.tb12051.x; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; OTANI H, 1984, CIRC RES, V55, P168, DOI 10.1161/01.RES.55.2.168; PALLER MS, 1984, J CLIN INVEST, V74, P1156, DOI 10.1172/JCI111524; RENLUND DG, 1985, CIRC RES, V57, P876, DOI 10.1161/01.RES.57.6.876; ROMASCHIN AD, 1987, J MOL CELL CARDIOL, V19, P289, DOI 10.1016/S0022-2828(87)80596-5; ROMASCHIN AD, 1990, AM J PHYSIOL, V259, pH116, DOI 10.1152/ajpheart.1990.259.1.H116; SHLAFER M, 1990, BASIC RES CARDIOL, V85, P318, DOI 10.1007/BF01907125; SHLAFER M, 1987, J MOL CELL CARDIOL, V19, P1195, DOI 10.1016/S0022-2828(87)80530-8; Slater E., 1967, METHODS ENZYMOLOGY, P48; SLATER TF, 1984, METHOD ENZYMOL, V105, P283; TAKESHIGE K, 1979, BIOCHEM J, V180, P129, DOI 10.1042/bj1800129; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TURRENS JF, 1982, ARCH BIOCHEM BIOPHYS, V217, P411, DOI 10.1016/0003-9861(82)90519-7; TURRENS JF, 1991, FREE RADICAL RES COM, V12-3, P681, DOI 10.3109/10715769109145847; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; TURRENS JF, 1983, OXY RADICALS THEIR S, V2, P365; TURRENS JF, 1990, CLIN ISCHEMIC SYNDRO, P203; VANDEPLASSCHE G, 1991, CARDIOSCIENCE, V2, P47; VANDEPLASSCHE G, 1989, J MOL CELL CARDIOL, V21, P383, DOI 10.1016/0022-2828(89)90649-4; WEGLICKI WB, 1980, J BIOL CHEM, V255, P3605; WELMAN E, 1976, J MOL CELL CARDIOL, V8, P443, DOI 10.1016/0022-2828(76)90019-5; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404; ZWEIER JL, 1988, J BIOL CHEM, V263, P1353; ZWEIER JL, 1987, J CLIN INVEST, V80, P1728, DOI 10.1172/JCI113264; ZWEIER JL, 1989, J BIOL CHEM, V264, P18890	78	475	487	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18532	18541						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8395507				2022-12-25	WOS:A1993LV65900027
J	TEBAR, F; RAMIREZ, I; SOLEY, M				TEBAR, F; RAMIREZ, I; SOLEY, M			EPIDERMAL GROWTH-FACTOR MODULATES THE LIPOLYTIC ACTION OF CATECHOLAMINES IN RAT ADIPOCYTES - INVOLVEMENT OF A GI-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL 12-MYRISTATE 13-ACETATE; BINDING REGULATORY PROTEIN; CARDIAC ADENYLATE-CYCLASE; ISLET-ACTIVATING PROTEIN; PERTUSSIS-TOXIN; ADIPOSE-TISSUE; SIGNAL TRANSDUCTION; ADP-RIBOSYLATION; FACTOR RECEPTOR; HEPATOCYTES	In isolated adipocytes, epidermal growth factor (EGF) did not affect basal (nonstimulated) lipolysis, but interfered with the lipolytic action of isoproterenol (ISO) or glucagon. Similarly, EGF did not affect basal levels of cyclic AMP but interfered with the signal generated by ISO. However, EGF did not affect lipolysis stimulated by forskolin or cyclic AMP analogues. These results suggest that EGF interfered with the signal transduction between lipolytic hormone receptors and adenylate cyclase. To determine whether EGF was activating a G(i) protein, adenosine deaminase (ADA) was added to degrade endogenously released adenosine. While the nonmetabolizable adenosine analogue N6-(phenylisopropyl)adenosine (PIA) inhibited ADA-stimulated lipolysis, EGF affected neither ADA-stimulated lipolysis nor the dose-response curve for PIA. However, EGF did not affect ISO-stimulated lipolysis in pertussis toxin-treated cells. Similarly, in the presence of ADA, the effects of ISO on lipolysis and on cyclic AMP levels were not affected by EGF. The addition of PIA restored the effect of EGF on both lipolysis and cyclic AMP. Since EGF decreased the IC50 for the inhibitory effect of PIA on (ISO + ADA)-stimulated lipolysis, we suggest that EGF modulates the interaction between G(s) and G(i) in the control of adenylate cyclase.	UNIV BARCELONA,FAC BIOL,DEPT BIOQUIM & FISIOL,UNITAT BIOQUIM & BIOL MOLEC B,DIAGONAL 645,E-08071 BARCELONA,SPAIN	University of Barcelona			Tebar, Francesc/H-1498-2015	Tebar, Francesc/0000-0002-9522-9726				Belfrage P., 1984, P365; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOSCH F, 1986, BIOCHEM J, V239, P523, DOI 10.1042/bj2390523; BUDNIK LT, 1991, J BIOL CHEM, V266, P13908; BURGAYA F, 1989, BIOCHEM J, V259, P159, DOI 10.1042/bj2590159; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHURCH JG, 1988, J BIOL CHEM, V263, P4242; CROUCH MF, 1990, BIOCHEM BIOPH RES CO, V167, P1369, DOI 10.1016/0006-291X(90)90674-C; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; FAIN JN, 1983, J LIPID RES, V24, P945; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOREN HJ, 1985, CAN J PHYSIOL PHARM, V63, P1017, DOI 10.1139/y85-167; HART MJ, 1990, J BIOL CHEM, V265, P5990; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; HAYSTEAD TAJ, 1986, BIOCHEM J, V234, P279, DOI 10.1042/bj2340279; HILDEBRANDT JD, 1990, J BIOL CHEM, V265, P9825; HOLLENBERG MD, 1975, J BIOL CHEM, V250, P3845; HONNOR RC, 1985, J BIOL CHEM, V260, P5130; HUGHES BP, 1987, BIOCHEM J, V248, P911, DOI 10.1042/bj2480911; JOHNSON RM, 1986, P NATL ACAD SCI USA, V83, P2032, DOI 10.1073/pnas.83.7.2032; JOHNSON RM, 1987, J BIOL CHEM, V262, P17285; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KATADA T, 1982, P NATL ACAD SCI-BIOL, V79, P3129, DOI 10.1073/pnas.79.10.3129; KRUPINSKI J, 1988, J BIOL CHEM, V263, P12333; LIANG M, 1991, J BIOL CHEM, V266, P13342; LONDOS C, 1978, P NATL ACAD SCI USA, V75, P5362, DOI 10.1073/pnas.75.11.5362; NAIR BG, 1990, J BIOL CHEM, V265, P21317; NAIR BG, 1989, BIOCHEM J, V264, P563, DOI 10.1042/bj2640563; NAKAGAWA Y, 1991, BIOCHEM PHARMACOL, V42, P2333, DOI 10.1016/0006-2952(91)90238-Z; RICHELSEN B, 1991, DAN MED BULL, V38, P228; RODBELL M, 1964, J BIOL CHEM, V239, P375; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SERRERO G, 1987, BIOCHEM BIOPH RES CO, V146, P194, DOI 10.1016/0006-291X(87)90710-8; SERRERO G, 1991, P NATL ACAD SCI USA, V88, P3912, DOI 10.1073/pnas.88.9.3912; SHECHTER Y, 1982, ENDOCRINOLOGY, V110, P1579, DOI 10.1210/endo-110-5-1579; SMITH CJ, 1991, J BIOL CHEM, V266, P13385; SOLEY M, 1987, ARCH BIOCHEM BIOPHYS, V255, P136, DOI 10.1016/0003-9861(87)90303-1; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATANABE Y, 1988, FEBS LETT, V236, P372, DOI 10.1016/0014-5793(88)80058-9; WIELAND OH, 1983, METHOD ENZYMAT AN, P504; YANG LJ, 1991, J BIOL CHEM, V266, P22451; YANG LJ, 1993, J BIOL CHEM, V268, P3739	43	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17199	17204						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8394336				2022-12-25	WOS:A1993LQ98800050
J	HSU, KC; CHAO, MV				HSU, KC; CHAO, MV			DIFFERENTIAL EXPRESSION AND LIGAND-BINDING PROPERTIES OF TUMOR-NECROSIS-FACTOR RECEPTOR CHIMERIC MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; FACTOR TNF RECEPTOR; FACTOR-ALPHA; MOLECULAR-CLONING; SOLUBLE FORM; ACTIVATION; CELLS; PROTEINS; GENE; ANTIGEN	The receptors for tumor necrosis factor (TNF) are represented by two transmembrane.proteins, p55TNFR and p75TNFR, which are members of a family of cell surface molecules, including the Fas antigen, CD30, CD40, OX40, a Shope fibroma virus protein, and the low affinity p75 nerve growth factor receptor. A common structural feature is a sequence of 40 amino acids that is found in adjacent repeated domains, with 6 cysteine residues in a conserved register. To assess the functional significance of this cysteine-rich domain (CRD), we have constructed chimeric receptors between each TNF receptor and the low affinity nerve growth factor receptor. The chimeric receptor cDNAs were expressed efficiently in COS-1 and 3T3 fibro-blasts, as assessed by affinity cross-linking, cell surface biotinylation and immunoprecipitation, and equilibrium binding. Receptors with two CRD of either TNF receptor were incapable of binding TNF, whereas receptors with all four CRD retained the ability to bind TNF with wild type affinity. These results, in conjunction with previous deletion mutation studies, suggest that TNF binding to each receptor requires all four cysteine-rich repeats. Furthermore, analysis of chimeric receptors containing domains of p55TNFR suggests that cytoplasmic sequences directly influence the levels of receptor expression.	CORNELL UNIV,MED CTR,COLL MED,DEPT CELL BIOL & ANAT,DIV HEMATOL ONCOL,1300 YORK AVE,NEW YORK,NY 10021	Cornell University				Chao, Moses/0000-0002-6969-3744				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARAKAWA T, 1987, J BIOL CHEM, V262, P7484; BALDWIN AN, 1992, J BIOL CHEM, V267, P8352; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CAMERINI D, 1991, J IMMUNOL, V147, P3165; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; ECK MJ, 1989, J BIOL CHEM, V264, P17595; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GOEDDEL DV, 1986, COLD SPRING HARB SYM, V51, P597, DOI 10.1101/SQB.1986.051.01.072; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HELLER RA, 1992, CELL, V70, P47; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MALLETT S, 1991, IMMUNOL TODAY, V12, P220, DOI 10.1016/0167-5699(91)90033-P; MARSTERS SA, 1992, J BIOL CHEM, V267, P5747; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; PALOMBELLA VJ, 1989, J BIOL CHEM, V264, P18128; PENNICA D, 1992, BIOCHEMISTRY-US, V31, P1134, DOI 10.1021/bi00119a023; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH RA, 1989, J BIOL CHEM, V264, P14646; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; STAUBER GB, 1988, J BIOL CHEM, V263, P19098; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; VANDENABEELE P, 1992, J EXP MED, V176, P1015, DOI 10.1084/jem.176.4.1015; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P159, DOI 10.1073/pnas.88.1.159; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WOLF FW, 1992, J BIOL CHEM, V267, P1317; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; YAN H, 1991, J BIOL CHEM, V266, P12099	46	26	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16430	16436						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8393862				2022-12-25	WOS:A1993LQ33600052
J	TANIGUCHI, K; MARDH, S				TANIGUCHI, K; MARDH, S			REVERSIBLE CHANGES IN THE FLUORESCENCE ENERGY-TRANSFER ACCOMPANYING FORMATION OF REACTION INTERMEDIATES IN PROBE-LABELED (NA+,K+)-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT ADENOSINE-TRIPHOSPHATASE; ADP-SENSITIVE PHOSPHOENZYME; AMINO-ACID-SEQUENCE; CONFORMATIONAL CHANGE; INORGANIC-PHOSPHATE; SODIUM-TRANSPORT; OCCLUSION SITES; ACTIVE-SITE; NA+; NA+,K+-ATPASE	A preparation of pig kidney Na+,K+-ATPase showed changes in fluorescence energy transfer between probes bound to the alpha-subunit. Excitation (305 nm) of an N-(p-(2-benzimidazolyl)phenyl)maleimide (BIPM) probe, which was covalently bound to Cys-964, and excitation (470 nm) of a fluorescein 5'-isothiocyanate (FITC) probe at Lys-501 gave different FITC fluorescence intensity changes at 520 nm in BIPM-FITC doubly labeled enzyme accompanying formation of reaction intermediates. Addition of acetyl phosphate to a Na+-bound enzyme (NaE1) to accumulate acetate-sensitive phosphoenzyme (E1P) induced a faster and greater FITC fluorescence decrease when excited at 470 nm than at 305 nm. An oligomycin-sensitive transition of E1P to K+-sensitive phosphoenzyme (E2P) was also accompanied by a larger FITC fluorescence decrease when excited at 470 nm. The addition of K+ to [P-32]E2P to form a K+-bound enzyme (KE2) induced a rapid dephosphorylation (140/s) with both a slow rate of FITC fluorescence increase and a larger fluorescence increase when excited at 470 nm. The addition of Na+ to KE2 induced both a slow increase of FITC fluorescence and a larger fluorescence increase when excited at 470 nm. The data suggest that fluorescence energy transfer from the BIPM to the FITC probe accompanies the processes of migration of Na+ and K+ in the pump molecules. The dynamic fluorescence changes after phosphorylation and dephosphorylation seem to reflect changes in the binding state or the process of migration of these ions.	UNIV UPPSALA,CTR BIOMED,DEPT MED & PHYSIOL CHEM,S-75123 UPPSALA,SWEDEN	Uppsala University	TANIGUCHI, K (corresponding author), HOKKAIDO UNIV,FAC SCI,DEPT CHEM,SAPPORO,HOKKAIDO 060,JAPAN.							ALBERS RW, 1976, ENZYMES BIOLOGICAL M, V3, P283; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; DAVID P, 1991, J BIOL CHEM, V266, P14896; ESMANN M, 1985, BIOCHEM BIOPH RES CO, V127, P857, DOI 10.1016/S0006-291X(85)80022-X; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; FORBUSH B, 1988, J BIOL CHEM, V263, P7961; FORTES PAG, 1984, J BIOL CHEM, V259, P1176; FROEHLICH JP, 1991, SODIUM PUMP STRUCTUR, P226; FUKUSHIMA Y, 1978, J BIOL CHEM, V253, P6853; FUKUSHIMA Y, 1980, J BIOL CHEM, V255, P7813; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GLYNN IM, 1984, J PHYSIOL-LONDON, V351, P531, DOI 10.1113/jphysiol.1984.sp015261; HAYASHI Y, 1977, BIOCHIM BIOPHYS ACTA, V482, P185, DOI 10.1016/0005-2744(77)90365-5; HOBBS AS, 1983, J BIOL CHEM, V258, P8163; JORGENSEN PL, 1991, SODIUM PUMP STRUCTUR, P189; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KARLISH SJD, 1978, BIOCHIM BIOPHYS ACTA, V527, P115, DOI 10.1016/0005-2744(78)90261-9; KIRLEY TL, 1984, BIOCHEM BIOPH RES CO, V125, P767, DOI 10.1016/0006-291X(84)90605-3; MARDH S, 1975, BIOCHIM BIOPHYS ACTA, V391, P464; MARDH S, 1977, J BIOL CHEM, V252, P633; MATSUI H, 1982, J BIOCHEM-TOKYO, V92, P193, DOI 10.1093/oxfordjournals.jbchem.a133916; NAGAI M, 1986, J BIOL CHEM, V261, P3197; NAKAO T, 1965, BIOCHEM BIOPH RES CO, V19, P755, DOI 10.1016/0006-291X(65)90323-2; NORBY JG, 1983, J GEN PHYSIOL, V82, P725, DOI 10.1085/jgp.82.6.725; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; POST RL, 1975, J BIOL CHEM, V250, P691; POST RL, 1969, J GEN PHYSIOL, V54, pS306, DOI 10.1085/jgp.54.1.306; Post RL, 1967, METHOD ENZYMOL, V10, P773; REPHAELI A, 1986, J BIOL CHEM, V261, P6248; REPKE KRH, 1992, BIOL REV, V67, P31; SAKURAYA M, 1987, JPN J PHARMACOL, V44, P311, DOI 10.1254/jjp.44.311; SCHULL GE, 1985, NATURE, V316, P691; STADTMAN ER, 1957, METHOD ENZYMOL, V3, P228, DOI 10.1016/S0076-6879(57)03379-0; STEINBERG M, 1989, J BIOL CHEM, V264, P2726; SUZUKI K, 1987, J BIOL CHEM, V262, P11752; TANIGUCHI K, 1975, J BIOL CHEM, V250, P3010; TANIGUCHI K, 1983, J BIOL CHEM, V258, P6927; TANIGUCHI K, 1991, J BIOCHEM-TOKYO, V109, P299; TANIGUCHI K, 1986, J BIOL CHEM, V261, P3272; TANIGUCHI K, 1984, J BIOL CHEM, V259, P5228; TANIGUCHI K, 1986, J BIOCHEM-TOKYO, V100, P1231, DOI 10.1093/oxfordjournals.jbchem.a121828; TANIGUCHI K, 1982, J BIOL CHEM, V257, P659; TANIGUCHI K, 1988, J BIOL CHEM, V263, P12943; Taniguchi K, 1988, Prog Clin Biol Res, V268A, P369; TANIGUCHI K, 1980, J BIOCHEM-TOKYO, V88, P609, DOI 10.1093/oxfordjournals.jbchem.a133010; XU KY, 1989, BIOCHEMISTRY-US, V28, P5764, DOI 10.1021/bi00440a010; YODA S, 1986, J BIOL CHEM, V261, P1147	48	24	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15588	15594						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8393448				2022-12-25	WOS:A1993LN30500042
J	SIMONIN, F; HOFFERER, L; PANZETER, PL; MULLER, S; DEMURCIA, G; ALTHAUS, FR				SIMONIN, F; HOFFERER, L; PANZETER, PL; MULLER, S; DEMURCIA, G; ALTHAUS, FR			THE CARBOXYL-TERMINAL DOMAIN OF HUMAN POLY(ADP-RIBOSE) POLYMERASE - OVERPRODUCTION IN ESCHERICHIA-COLI, LARGE-SCALE PURIFICATION, AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE DIPHOSPHORIBOSYL TRANSFERASE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); DNA-BINDING DOMAIN; ADP-RIBOSYLTRANSFERASE; AUTOMODIFICATION DOMAIN; ENZYMATIC-ACTIVITY; CDNA SEQUENCE; SYNTHETASE; PROTEINS; EXPRESSION	The cDNA encoding the carboxyl-terminal 40-kDa domain of human poly(ADP-ribose) polymerase was inserted into an expression vector. The recombinant protein was overproduced in Escherichia coli, and purified to homogeneity. The 40-kDa domain had the same affinity (K(m)) for NAD+ as the full-length enzyme, expressed abortive NAD+ glycohydrolase activity, catalyzed the initiation, elongation, and branching of ADP-ribose polymers, but exhibited no DNA dependence. Its specific activity was approximately 500-fold lower than that of the whole enzyme activated by DNA strand breaks. Surprisingly, the carboxyl-terminal 40-kDa domain exhibited the processive mode of polymer attachment typical of full-length poly(ADP-ribose) polymerase and was able to modify histones H1 and H2B. Finally, the polymer sizes formed by the 40-kDa domain were influenced by histone H1.	UNIV ZURICH, TIERSPITAL, INST PHARMACOL & TOXICOL, WINTERTHURERSTR 260, CH-8057 ZURICH, SWITZERLAND; CNRS, INST BIOL MOLEC & CELLULAIRE, F-67094 STRASBOURG, FRANCE; UPR CANCEROGENESE & MUTAGENESE STRUCT 9003, F-67094 STRASBOURG, FRANCE; UPR STRUCT MACROMOLEC BIOL & MECHANISMS RECONNAISS, F-67094 STRASBOURG, FRANCE	University of Zurich; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Muller, Sylviane/J-5319-2014					Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; ALTHAUS FR, 1992, J CELL SCI, V102, P663; ALVAREZGONZALEZ R, 1987, BIOCHEMISTRY-US, V26, P3218, DOI 10.1021/bi00385a042; ATANASSOV C, 1991, CLIN EXP IMMUNOL, V86, P124; BAUER PI, 1990, BIOCHEM J, V270, P17, DOI 10.1042/bj2700017; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUKI KG, 1991, BIOCHEM BIOPH RES CO, V180, P496, DOI 10.1016/S0006-291X(05)81092-7; BUKI KG, 1988, BIOCHEMISTRY-US, V27, P5990, DOI 10.1021/bi00416a024; BURTSCHER HJ, 1986, ANAL BIOCHEM, V152, P285, DOI 10.1016/0003-2697(86)90410-0; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; CHERNEY BW, 1991, BIOCHEMISTRY-US, V30, P10420, DOI 10.1021/bi00107a009; COURTNEY M, 1984, P NATL ACAD SCI-BIOL, V81, P669, DOI 10.1073/pnas.81.3.669; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; GINER H, 1992, GENE, V114, P279, DOI 10.1016/0378-1119(92)90588-G; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; GRADWOHL G, 1987, BIOCHEM BIOPH RES CO, V148, P913, DOI 10.1016/S0006-291X(87)80219-X; IKEJIMA M, 1989, BIOCHEM BIOPH RES CO, V163, P739, DOI 10.1016/0006-291X(89)92285-7; IKEJIMA M, 1990, J BIOL CHEM, V265, P21907; KAMESHITA I, 1984, J BIOL CHEM, V259, P4770; KAWAICHI M, 1981, J BIOL CHEM, V256, P9483; KEITH G, 1990, ANAL BIOCHEM, V191, P309, DOI 10.1016/0003-2697(90)90224-W; KIRSTEN E, 1991, EXP CELL RES, V194, P1, DOI 10.1016/0014-4827(91)90122-B; KUROSAKI T, 1987, J BIOL CHEM, V262, P15990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; LOEB LA, 1969, J BIOL CHEM, V244, P1672; Maniatis T., 1982, MOL CLONING; MAZEN A, 1989, NUCLEIC ACIDS RES, V17, P4689, DOI 10.1093/nar/17.12.4689; MENISSIERDEMURCIA J, 1989, J MOL BIOL, V210, P229, DOI 10.1016/0022-2836(89)90302-1; MIWA M, 1982, ADP RIBOSYLATION REA, P43; NAEGELI H, 1989, J BIOL CHEM, V264, P14382; NAEGELI H, 1991, J BIOL CHEM, V266, P10596; NIEDERGANG C, 1979, EUR J BIOCHEM, V102, P43, DOI 10.1111/j.1432-1033.1979.tb06261.x; NISHIKIMI M, 1982, J BIOL CHEM, V257, P6102; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; PANZETER PL, 1992, BIOCHEMISTRY-US, V31, P1379, DOI 10.1021/bi00120a014; PANZETER PL, 1990, NUCLEIC ACIDS RES, V18, P2194, DOI 10.1093/nar/18.8.2194; REALINI CA, 1992, J BIOL CHEM, V267, P18858; SASTRY SS, 1988, J BIOL CHEM, V263, P1505; SASTRY SS, 1990, BIOCHEM BIOPH RES CO, V167, P842, DOI 10.1016/0006-291X(90)92102-6; SCHREIBER V, 1992, EMBO J, V11, P3263, DOI 10.1002/j.1460-2075.1992.tb05404.x; SHIZUTA Y, 1985, P52; SIMONIN F, 1990, J BIOL CHEM, V265, P19249; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCHIDA K, 1987, BIOCHEM BIOPH RES CO, V148, P617, DOI 10.1016/0006-291X(87)90921-1; UEDA K, 1987, PYRIDINE NUCLEOTIDES, P549; USHIRO H, 1987, J BIOL CHEM, V262, P2352; ZAHRADKA P, 1984, EUR J BIOCHEM, V142, P503, DOI 10.1111/j.1432-1033.1984.tb08314.x	48	61	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13454	13461						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8390463				2022-12-25	WOS:A1993LH55300063
J	CONSTANTINESCU, A; HAN, D; PACKER, L				CONSTANTINESCU, A; HAN, D; PACKER, L			VITAMIN-E RECYCLING IN HUMAN ERYTHROCYTE-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADICAL CHAIN OXIDATION; ALPHA-TOCOPHEROL; LIPID-PEROXIDATION; ELECTRON-TRANSPORT; MODEL MEMBRANES; INHIBITION; HEMOLYSIS; PROTECTION; REDUCTASE; PLASMA	Vitamin E, the major lipid chain-breaking antioxidant in erythrocyte membranes, is present in low concentration, suggesting that mechanisms should exist to protect against its loss. Enzymatic pathways for the recycling of vitamin E from its tocopheroxyl radical have been observed previously in inner membranes of mitochondria and microsomes. These pathways use electron transport enzymes and their substrates to regenerate vitamin E. Erythrocyte membranes also contain significant NADH-cytochrome c reductase activity, as well as cytochrome b5, the function of which is not yet known. Using an enzymatic oxidation system composed of lipoxygenase and arachidonic acid, free radicals were produced in human erythrocyte membranes, and their reaction with chromanols was followed by ESR and high performance liquid chromatography (HPLC). Since the endogenous vitamin E content of the membranes is very low, we used a vitamin E homologue lacking the hydrocarbon chain (2,2,5,7,8-pentamethyl-6-hydroxychromane) as a probe molecule for ESR measurements. However, parallel HPLC determinations of lipid hydroperoxides and of endogenous vitamin E confirmed the results obtained by ESR. It was found that protection against the loss of vitamin E can be provided either by NADH-cytochrome b5-dependent enzymatic recycling or by a nonenzymatic pathway involving ascorbate and dihydrolipoic acid.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,251 LSA,BERKELEY,CA 94720	University of California System; University of California Berkeley					NATIONAL CANCER INSTITUTE [R01CA047597] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47597] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEUTLER E, 1986, BLOOD CELLS, V12, P57; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUDER G, 1980, BIOCHIM BIOPHYS ACTA, V600, P739, DOI 10.1016/0005-2736(80)90477-0; BURTON GW, 1985, LIPIDS, V20, P29, DOI 10.1007/BF02534359; CHAN AC, 1991, J BIOL CHEM, V266, P17290; Chiu D, 1982, FREE RADICAL BIO MED, V5, P115; CHOURY D, 1981, J CLIN INVEST, V67, P149, DOI 10.1172/JCI110007; CRANE FL, 1985, BIOCHIM BIOPHYS ACTA, V811, P233, DOI 10.1016/0304-4173(85)90013-8; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; DORMANDY TL, 1965, J PHYSIOL-LONDON, V180, P684, DOI 10.1113/jphysiol.1965.sp007724; DOUGLAS RH, 1978, P NATL ACAD SCI USA, V75, P3118, DOI 10.1073/pnas.75.7.3118; GORDONSMITH EC, 1980, CLIN HAEMATOL, V9, P557; HALLIWELL B, 1989, FREE RADICAL BIO MED, P324; HORTON AA, 1987, CRC CR REV TOXICOL, V18, P27, DOI 10.3109/10408448709089856; KAGAN VE, 1990, ARCH BIOCHEM BIOPHYS, V282, P221, DOI 10.1016/0003-9861(90)90108-B; KAGAN VE, 1992, BIOCHEM BIOPH RES CO, V186, P74, DOI 10.1016/S0006-291X(05)80777-6; KAGAN VE, 1992, J LIPID RES, V33, P385; KAGAN VE, 1993, IN PRESS BIOCH PHARM, V41; KOZLOVA NM, 1986, BIOKHIMIYA, V56, P342; LANG JK, 1986, ANAL BIOCHEM, V157, P106, DOI 10.1016/0003-2697(86)90203-4; LOW H, 1978, BIOCHIM BIOPHYS ACTA, V515, P141, DOI 10.1016/0304-4157(78)90002-3; MAGUIRE JJ, 1989, J BIOL CHEM, V264, P21462; MEHLHORN RJ, 1990, METHOD ENZYMOL, V186, P670; NIKI E, 1987, CHEM PHYS LIPIDS, V44, P227, DOI 10.1016/0009-3084(87)90052-1; NIKI E, 1988, J BIOL CHEM, V263, P19809; NIKI E, 1987, ANN NY ACAD SCI, V498, P186, DOI 10.1111/j.1749-6632.1987.tb23761.x; PACKER JE, 1979, NATURE, V278, P737, DOI 10.1038/278737a0; PACKER L, 1989, BIOCHEM BIOPH RES CO, V159, P229, DOI 10.1016/0006-291X(89)92427-3; ROSE RC, 1990, BIOCHEM BIOPH RES CO, V169, P430, DOI 10.1016/0006-291X(90)90349-R; SEVERCAN F, 1990, CHEM PHYS LIPIDS, V53, P17, DOI 10.1016/0009-3084(90)90129-F; SRIVASTAVA S, 1983, BIOCHIM BIOPHYS ACTA, V734, P353, DOI 10.1016/0005-2736(83)90135-9; Steck T L, 1974, Methods Enzymol, V31, P172; STERN A, 1985, OXIDATIVE STRESS; SUN IL, 1990, BIOCHEM BIOPH RES CO, V172, P979, DOI 10.1016/0006-291X(90)91542-Z; TOMODA A, 1979, J BIOL CHEM, V254, P119; VANDENBERG JJM, 1990, CHEM PHYS LIPIDS, V53, P309, DOI 10.1016/0009-3084(90)90028-P; YAMAMOTO Y, 1987, ANAL BIOCHEM, V160, P7, DOI 10.1016/0003-2697(87)90606-3; YAMAMOTO Y, 1985, BIOCHIM BIOPHYS ACTA, V819, P29, DOI 10.1016/0005-2736(85)90192-0; YAMAMOTO Y, 1986, J NUTR SCI VITAMINOL, V32, P475, DOI 10.3177/jnsv.32.475	39	160	163	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10906	10913						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8388377				2022-12-25	WOS:A1993LD46600032
J	MURAKAMI, Y; HURWITZ, J				MURAKAMI, Y; HURWITZ, J			DNA POLYMERASE-ALPHA STIMULATES THE ATP-DEPENDENT BINDING OF SIMIAN-VIRUS TUMOR T-ANTIGEN TO THE SV40 ORIGIN OF REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE ORIGIN; INVITRO REPLICATION; STRUCTURAL-CHANGES; REGION-I; INITIATION; P53; PROTEIN; DELTA; SEQUENCES; TEMPLATE	The ATP-dependent binding of simian virus 40 (SV40) large tumor antigen (T antigen) to the SV40 origin of replication is an essential step in the initiation of SV40 DNA synthesis. Previous studies indicated that the ATP-dependent complex consists of a double hexamer of T antigen at the origin. The binding reaction and the subsequent unwinding of the duplex DNA from the origin were examined using a gel mobility shift assay. T antigen bound to the core origin cooperatively in the presence of ATP. In the presence of human single-stranded DNA-binding protein (HSSB), T antigen, complexed to the core origin, started the unwinding of duplex DNA. At low concentrations of T antigen and in the presence of ATP, DNA polymerase alpha (pol alpha) stimulated the binding of T antigen to the core origin, while HSSB did not. This stimulation resulted in an increase in the subsequent unwinding reaction in the presence of HSSB. Primase alone did not affect the binding reaction and was not required for the stimulation by pol alpha. The stimulation required the hydrolysis of ATP and the AT tract domain of the core origin. Kinetic studies showed that while pol alpha stimulated the binding of T antigen to the core origin, it did not stabilize the complex. Pol alpha also stimulated the formation of the ATP-dependent T antigen-site I complex, a region that also contains an AT-rich sequence. These observations imply a regulatory role for pol alpha in the initiation of SV40 DNA replication.			MURAKAMI, Y (corresponding author), MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.							BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BELL SP, 1992, NATURE, V357, P169; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOROWIEC JA, 1988, P NATL ACAD SCI USA, V85, P64, DOI 10.1073/pnas.85.1.64; BOROWIEC JA, 1991, J VIROL, V65, P1228, DOI 10.1128/JVI.65.3.1228-1235.1991; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8267, DOI 10.1073/pnas.84.23.8267; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8981, DOI 10.1073/pnas.84.24.8981; DEAN FB, 1991, J BIOL CHEM, V266, P5062; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DEB S, 1986, MOL CELL BIOL, V6, P4578, DOI 10.1128/MCB.6.12.4578; DEB S, 1986, MOL CELL BIOL, V6, P1663, DOI 10.1128/MCB.6.5.1663; DEB SP, 1987, J VIROL, V61, P3649, DOI 10.1128/JVI.61.12.3649-3654.1987; DELUCIA AL, 1986, J VIROL, V57, P138, DOI 10.1128/JVI.57.1.138-144.1986; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORNREITER M, 1992, EMBO J, V11, P769; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EKI T, 1992, J BIOL CHEM, V267, P7284; GANNON J V, 1990, New Biologist, V2, P84; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GOETZ GS, 1988, J BIOL CHEM, V263, P383; GUO ZS, 1989, MOL CELL BIOL, V9, P3593, DOI 10.1128/MCB.9.9.3593; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1992, J BIOL CHEM, V267, P10910; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LEVENS D, 1985, MOL CELL BIOL, V5, P2307, DOI 10.1128/MCB.5.9.2307; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11008; MURAKAMI Y, 1992, P NATL ACAD SCI USA, V89, P952, DOI 10.1073/pnas.89.3.952; PARSONS R, 1990, J VIROL, V64, P509, DOI 10.1128/JVI.64.2.509-518.1990; PARSONS RE, 1991, J VIROL, V65, P2798, DOI 10.1128/JVI.65.6.2798-2806.1991; ROBERTS JM, 1989, P NATL ACAD SCI USA, V86, P3939, DOI 10.1073/pnas.86.11.3939; RYDER K, 1985, CELL, V42, P539, DOI 10.1016/0092-8674(85)90111-4; RYDER K, 1986, CELL, V44, P719, DOI 10.1016/0092-8674(86)90838-X; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P3839, DOI 10.1128/MCB.9.9.3839; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643	50	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11018	11027						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8388381				2022-12-25	WOS:A1993LD46600048
J	HOFMANN, F; JAMES, P; VORHERR, T; CARAFOLI, E				HOFMANN, F; JAMES, P; VORHERR, T; CARAFOLI, E			THE C-TERMINAL DOMAIN OF THE PLASMA-MEMBRANE CA2+ PUMP CONTAINS 3 HIGH-AFFINITY CA2+ BINDING-SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; ION MOTIVE ATPASES; MOLECULAR-CLONING; CA-2+ PUMP; CA-2+-TRANSPORTING ATPASE; HUMAN-ERYTHROCYTES; ESCHERICHIA-COLI; CALCIUM-PUMP; CALMODULIN; PROTEINS	The C-terminal portion of the plasma membrane Ca2+-ATPase contains different regulatory domains. A recombinant C-terminal fragment of the human plasma membrane Ca2+-ATPase 1b isoform (E1079-P1180) was used to study the role of two acidic amino acid stretches located on either side of the calmodulin binding domain, corresponding to synthetic peptides A18 (Vorherr, T., James, P., Krebs, J., Enyedi, A., McCormick, D. J., Penniston, J. T., and Carafoli, E. (1990) Biochemistry 29, 355-365) and B28 (James, P., Pruschy, M., Vorherr, T., Penniston, J. T., and Carafoli, E. (1989) Biochemistry 28, 4253-4258), respectively. The molecular mass of the recombinant C-terminal fragment, as determined by electrospray ionization mass spectrometry, was higher by 39 mass units than the calculated value (12,055 Da). This difference was the result of an EGTA-insensitive Ca2+ ion, which was located by chymotryptic proteolysis in a fragment corresponding to the last 37 amino acids of the expressed protein. Fluorescence experiments on the dansylated recombinant C-terminal fragment titrated with increasing amounts of free Ca2+ revealed two additional Ca2+ binding sites with affinities corresponding to K(D) values of about 30 and 300 nM, respectively. Stains All spectra of different synthetic peptides, corresponding to subdomains of the expressed protein, indicated that the site with the K(D) of 30 nM was probably located in the acidic sequence on the N-terminal side of the calmodulin binding domain (peptide A18); the site with the 300 nm K(D) was apparently located on the C-terminal side of the calmodulin binding domain (peptide B28) or, alternatively, formed by the cooperation of distant residues of the domain.	SWISS FED INST TECHNOL,INST BIOCHEM,UNIV STR 16,CH-8092 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich			Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BRODIN P, 1992, EUR J BIOCHEM, V204, P939, DOI 10.1111/j.1432-1033.1992.tb16715.x; CADAY CG, 1985, J BIOL CHEM, V260, P5985; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CHEN RF, 1968, ANAL BIOCHEM, V25, P412, DOI 10.1016/0003-2697(68)90116-4; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; GOFF SA, 1984, P NATL ACAD SCI-BIOL, V81, P6647, DOI 10.1073/pnas.81.21.6647; GREEB J, 1989, J BIOL CHEM, V264, P18569; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; JAMES P, 1988, J BIOL CHEM, V263, P2905; JAMES P, 1989, J BIOL CHEM, V264, P8289; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; KESSLER F, 1992, BIOCHEMISTRY-US, V31, P11785, DOI 10.1021/bi00162a016; KLEINSCHMIDT J, 1986, EMBO J, V5, P3547, DOI 10.1002/j.1460-2075.1986.tb04681.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LETSINGER RL, 1975, J AM CHEM SOC, V97, P3278, DOI 10.1021/ja00844a090; MANIATIS T, 1982, MOL CLONING LABORATO, V1, P121; MARTELL AE, 1974, CRITICAL STABILITY C, V1, P269; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MESSING J, 1983, METHOD ENZYMOL, V101, P20; NIGGLI V, 1979, J BIOL CHEM, V254, P9955; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; SANDER F, 1977, P NATL ACAD SCI USA, V74, P5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586; Strynadka NCJ, 1991, CURR OPIN STRUC BIOL, V1, P905, DOI 10.1016/0959-440X(91)90085-8; TAKANO E, 1988, BIOCHEMISTRY-US, V27, P1964, DOI 10.1021/bi00406a024; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VORHERR T, 1991, J BIOL CHEM, V266, P22; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; WANG KKW, 1991, J BIOL CHEM, V266, P9078; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693	39	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10252	10259						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8387515				2022-12-25	WOS:A1993LB80000046
J	CHRISTIANSEN, K; SVEJSTRUP, ABD; ANDERSEN, AH; WESTERGAARD, O				CHRISTIANSEN, K; SVEJSTRUP, ABD; ANDERSEN, AH; WESTERGAARD, O			EUKARYOTIC TOPOISOMERASE I-MEDIATED CLEAVAGE REQUIRES BIPARTITE DNA INTERACTION - CLEAVAGE OF DNA SUBSTRATES CONTAINING STRAND INTERRUPTIONS IMPLICATES A ROLE FOR TOPOISOMERASE-I IN ILLEGITIMATE RECOMBINATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; TYPE-1 TOPOISOMERASE; BINDING SEQUENCE; ESCHERICHIA-COLI; RAT-LIVER; SV40 DNA; SITES; BREAKAGE; CAMPTOTHECIN; CHROMATIN	Topoisomerase I-mediated cleavage has previously been demonstrated to require interaction of the enzyme with a DNA duplex region encompassing the cleavage site (Svejstrup, J. Q., Christiansen, K., Andersen, A. H., Lund, R., and Westergaard, O (1990) J. Biol. Chem. 265, 12529-12535). The required region, designated region A, includes positions -5 through -1 on the noncleaved strand and positions -7 through +2 on the scissile strand, relative to the cleavage site. Utilizing defined DNA substrates in topoisomerase I cleavage assays we show that efficient cleavage within region A requires additional interaction of the enzyme with duplex DNA on the side holding the 5'-OH end generated by cleavage. By analyzing the interaction of topoisomerase I with DNA substrates varying by single nucleotides on either strand outside region A, an additional duplex region, designated region B, was delimited to positions 6-11. The ability of topoisomerase I to interact separately with regions A and B was assayed on sets of DNA substrates containing a nested series of single-stranded branch sites. The obtained results demonstrate that the normal reversible cleavage/religation equilibrium established by topoisomerase I on continuous duplex DNA is replaced by irreversible cleavage on DNA substrates containing branch sites between the cleavage site and region B as these DNA substrates allow cleavage but prevent religation due to release of the incised strands. The intramolecular bipartite interaction mode of topoisomerase I during the cleavage reaction is thus indicated by both the absence of enzyme-mediated duplex stabilization and the wide tolerance for protruding strands between the cleavage site and region B. Since the irreversibly cleaved topoisomerase I-DNA complexes are kinetically competent to ligate added DNA fragments carrying free 5'-OH ends, the results suggest a role of topoisomerase I in illegitimate recombination.	AARHUS UNIV,DEPT MOLEC BIOL,CF MOLLERS ALLE,BLDG 130,DK-8000 AARHUS,DENMARK	Aarhus University			Andersen, Anni/O-1162-2017	Andersen, Anni/0000-0001-7194-3258				ANDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P6237, DOI 10.1021/bi00441a015; BEEN MD, 1981, P NATL ACAD SCI-BIOL, V78, P2883, DOI 10.1073/pnas.78.5.2883; BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; BEEN MD, 1984, J MOL BIOL, V180, P515, DOI 10.1016/0022-2836(84)90025-1; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; BULLOCK P, 1985, SCIENCE, V230, P954, DOI 10.1126/science.2997924; BUSK H, 1987, NATURE, V327, P638, DOI 10.1038/327638a0; CAMILLONI G, 1989, P NATL ACAD SCI USA, V86, P3080, DOI 10.1073/pnas.86.9.3080; CHAMPOUX JJ, 1977, P NATL ACAD SCI USA, V74, P3800, DOI 10.1073/pnas.74.9.3800; CHAMPOUX JJ, 1988, GENETIC RECOMBINATIO, P655; CHRISTIANSEN K, 1987, J MOL BIOL, V193, P517, DOI 10.1016/0022-2836(87)90264-6; EDWARDS KA, 1982, NUCLEIC ACIDS RES, V10, P2565, DOI 10.1093/nar/10.8.2565; HALLIGAN BD, 1982, J BIOL CHEM, V257, P3995; KJELDSEN E, 1988, J MOL BIOL, V202, P333, DOI 10.1016/0022-2836(88)90462-7; KROGH S, 1991, NUCLEIC ACIDS RES, V19, P1235, DOI 10.1093/nar/19.6.1235; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; NESS PJ, 1988, J MOL BIOL, V200, P127, DOI 10.1016/0022-2836(88)90338-5; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; PORTER SE, 1989, MOL CELL BIOL, V9, P541, DOI 10.1128/MCB.9.2.541; PRELL B, 1980, EUR J BIOCHEM, V6108, P389; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P3489, DOI 10.1073/pnas.86.10.3489; SHUMAN S, 1991, P NATL ACAD SCI USA, V88, P10104, DOI 10.1073/pnas.88.22.10104; STEVNSNER T, 1989, J BIOL CHEM, V264, P10110; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; SVEJSTRUP JQ, 1990, J BIOL CHEM, V265, P12529; THOMSEN B, 1987, EMBO J, V6, P1817, DOI 10.1002/j.1460-2075.1987.tb02436.x; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; WALSH CT, 1984, ANNU REV BIOCHEM, V53, P493, DOI 10.1146/annurev.bi.53.070184.002425; WANG HP, 1991, J VIROL, V65, P2381, DOI 10.1128/JVI.65.5.2381-2392.1991; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x	34	81	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9690	9701						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8387503				2022-12-25	WOS:A1993LA68900080
J	LEONIS, MA; SILBERT, DF				LEONIS, MA; SILBERT, DF			CHARACTERIZATION OF A 2ND HAMSTER LUNG FIBROBLAST MUTANT WITH DEFECTS IN PHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; THROMBIN-INDUCED MITOGENESIS; PHOSPHOINOSITIDE BREAKDOWN; INOSITOL TRISPHOSPHATE; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCTION; BETA-1 ISOZYME; GQ CLASS; RECEPTOR; DESENSITIZATION	We report here further characterization of the Chinese hamster lung fibroblast mutant D1-9b displaying elevated agonist-induced phosphatidylinositol (Pt) turnover responses relative to CCL39, the parental cell line (Rath, H. M., Doyle, G. A. R., and Silbert, D. F. (1989) J. Biol. Chem. 264, 13387-13390). These differences in PI turnover responses are further enhanced by long term (24 h) pretreatment of cells with the phorbol ester 4beta-phorbol 12beta-myristate 13alpha-acetate (PMA). Short term pretreatment (15 min) with PMA attenuates the agonist-induced PI turnover response of both wild type and mutant D1-9b cell lines to that of unstimulated controls, suggesting that PMA-induced desensitization responses in D1-9b are intact. Both cytosolic and membrane/particulate fractions prepared from mutant D1-9b have decreased phospholipase C (PLC) activities relative to wild type when assayed with either of four different PI/phosphatidylinositol 4,5-bisphosphate-mixed micelle/vesicle substrate combinations. Thermolability studies, Mono Q anion-exchange chromatography, and Western blot studies identified the source of cytosolic PLC deficiency in D1-9b as being due to the absence of PLCdelta1, one of at least two PLC isozymes previously shown to be in wild type CCL39 cytosol (Rath, H. M., Fee, J. A., Rhee, S. G., and Silbert, D. F. (1990) J. Biol. Chem. 265, 3080-3087). We also report here the presence of two peaks of PLC activities (i.e. peaks mA and mB) following Mono Q chromatography of wild type CCL39 membrane/particulate extracts; membrane/particulate extracts prepared from mutant D1-9b are missing the first of these two peaks of activities (peak mA). Immunoblot analysis confirms the presence of PLCbeta1, but not PLCgamma1 or PLCdelta1, in peak mB. Comparisons are made between D1-9b and the previously characterized mutant D1-6b, which displays diminished agonist-induced PI turnover responses yet in vitro biochemical deficiencies similar to those of mutant D1-9b. Somatic cell hybridization experiments suggest that the defects found in mutant D1-9b are codominant relative to wild type phenotype and that mutant D1-9b belongs to the same genetic complementation group as mutant D1-6b. Possible explanations to explain these different agonist-induced responses in light of the two mutants similar in vitro biochemical deficiencies are addressed.	WASHINGTON UNIV, SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS, 660 S EUCLID AVE,BOX 8231, ST LOUIS, MO 63110 USA	Washington University (WUSTL)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038540, T32GM007200] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32 GM-07200, GM-38540] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BLACKMORE PF, 1985, J BIOL CHEM, V260, P4477; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORNER C, 1992, J BIOL CHEM, V267, P12892; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HEPLER JR, 1988, J BIOL CHEM, V263, P7610; HUANG EM, 1987, BIOCHEM J, V242, P11, DOI 10.1042/bj2420011; JAFFE EA, 1987, J BIOL CHEM, V262, P8557; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; Kennett R H, 1979, Methods Enzymol, V58, P345; KRIZ R, 1990, CIBA F SYMP, V150, P112; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLEMAIN G, 1986, J CELL PHYSIOL, V129, P167, DOI 10.1002/jcp.1041290207; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LEACH KL, 1988, J BIOL CHEM, V263, P13223; MAGNALDO I, 1988, BIOCHEM J, V253, P711, DOI 10.1042/bj2530711; MAJERUS PW, 1988, J BIOL CHEM, V263, P3051; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PARIS S, 1987, J BIOL CHEM, V262, P1977; PARIS S, 1988, J BIOL CHEM, V263, P11250; Patterson D, 1987, Methods Enzymol, V151, P121, DOI 10.1016/S0076-6879(87)51013-8; RATH HM, 1989, J BIOL CHEM, V264, P13387; RATH HM, 1990, J BIOL CHEM, V265, P3080; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROSS TS, 1991, J BIOL CHEM, V266, P9086; SUH PG, 1988, J BIOL CHEM, V263, P14497; TAYLOR GD, 1992, BIOCHEM BIOPH RES CO, V188, P1176, DOI 10.1016/0006-291X(92)91355-T; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; ZOELLER RA, 1989, J BIOL CHEM, V264, P21872	38	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9416	9424						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8387494				2022-12-25	WOS:A1993LA68900043
J	STEVENS, VL				STEVENS, VL			REGULATION OF GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS BY GTP - STIMULATION OF N-ACETYLGLUCOSAMINE-PHOSPHATIDYLINOSITOL DEACETYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEINS; GLYCOSYL-PHOSPHATIDYLINOSITOL; TRYPANOSOMA-BRUCEI; MEMBRANE ANCHOR; GLYCOLIPID PRECURSORS; RESISTANT GLYCOLIPIDS; ESCHERICHIA-COLI; LYMPHOMA-CELLS; MUTANTS; IDENTIFICATION	Glycosylphosphatidylinositol (GPI) is biosynthesized by the sequential addition of carbohydrates to phosphatidylinositol (PI). In the first two reactions, GlcNAc is transferred from UDP-GlcNAc to PI and then deacetylated to form GlcNAc-PI and GlcN-PI, respectively. In this paper, stimulation of GlcNAc-PI deacetylation by GTP, is reported. Addition of this nucleotide triphosphate to incubations in which GPI precursors were synthesized from UDP-[6-H-3]GlcNAc by microsomes prepared from the lymphoma cell line EL4 resulted in a shift in the relative amount of each intermediate formed such that [6-H-3]GlcN-PI was the predominant product. GTP also increased the total synthesis of the first GPI intermediate, GlcNAc-PI, by inhibiting reactions that metabolize UDP-[6-H-3]GlcNAc into non-GPI-related products. However, unlike the stimulation of GlcNAc-PI deacetylation, ATP was equally effective in increasing the formation of GlcNAc-PI. An additional product, tentatively identified as [6-H-3]GlcN-PI(acylinositol), was also detected when GTP was present in the incubation. The synthesis of this GPI precursor, which is proposed to be the third intermediate in GPI biosynthesis in mammals, was increased by GTP because the level of GlcN-PI, the substrate for acylation, was elevated. To isolate the effects of GTP on the GlcNAc-PI deacetylation, this reaction was studied directly by using [6-H-3]GlcNAc-PI as the substrate. The stimulation was found to be specific for the guanosine-containing nucleotide triphosphate and optimal with approximately 1 mM GTP. Both the reaction rate at early time points and the total amount of deacetylated product formed in 60 min were increased by GTP. The effect on the second reaction of the pathway does not appear to be coupled to the first reaction because GlcNAc-PI deacetylation was increased by GTP in microsomes from cells defective in the GlcNAc-PI synthesis. Finally, 0.5 mM GTPgammaS (guanosine 5'-O-(thiotriphosphate)) completely inhibited the stimulation of GlcNAc-PI deacetylation caused by 1 mM GTP, indicating that hydrolysis of the nucleotide triphosphate was required for this effect. Although the mechanism and role of the GTP stimulation of GlcNAc-PI deacetylation is not clear, this regulation could influence the biosynthesis of mature GPI precursors and the subsequent expression of GPI-anchored proteins.	EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University								AMTHAUER R, 1992, P NATL ACAD SCI USA, V89, P6124, DOI 10.1073/pnas.89.13.6124; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; CHAPMAN A, 1980, J BIOL CHEM, V255, P4441; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; DOERING TL, 1989, J BIOL CHEM, V264, P11168; Ferguson MAJ, 1991, CURR OPIN STRUC BIOL, V1, P522, DOI 10.1016/S0959-440X(05)80072-7; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HIROSE S, 1992, P NATL ACAD SCI USA, V89, P6025, DOI 10.1073/pnas.89.13.6025; HYMAN R, 1988, TRENDS GENET, V4, P5, DOI 10.1016/0168-9525(88)90120-5; HYMAN R, 1973, J NATL CANCER I, V50, P415, DOI 10.1093/jnci/50.2.415; KAMITANI T, 1992, J BIOL CHEM, V267, P24611; KLEINEKE J, 1979, FEBS LETT, V107, P198, DOI 10.1016/0014-5793(79)80494-9; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MENON AK, 1992, J BIOL CHEM, V267, P15277; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; RADIKA K, 1988, J BIOL CHEM, V263, P14859; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; STEVENS VL, 1990, J BIOL CHEM, V265, P15653; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; URAKAZE M, 1992, J BIOL CHEM, V267, P6459	29	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9718	9724						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8387504				2022-12-25	WOS:A1993LA68900083
J	DUMONT, DJ; GRADWOHL, GJ; FONG, GH; AUERBACH, R; BREITMAN, ML				DUMONT, DJ; GRADWOHL, GJ; FONG, GH; AUERBACH, R; BREITMAN, ML			THE ENDOTHELIAL-SPECIFIC RECEPTOR TYROSINE KINASE, TEK, IS A MEMBER OF A NEW SUBFAMILY OF RECEPTORS	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTORS; IMMUNOGLOBULIN SUPERFAMILY; BINDING-SITE; CELL-LINE; HETEROGENEITY; SEQUENCE; DOMAINS; GAP; DNA	We have cloned a 4.2-kb murine cDNA encoding the Tek receptor tyrosine kinase (RTK), which is expressed in endothelial cells and their progenitors. The 1122-residue protein contains an extracellular domain comprising three fibronectin type III repeats fused to two immunoglobulin-like loops that are in turn separated by three epidermal growth factor-like repeats. The association of these different structural motifs and their characteristic arrangement in the Tek extracellular domain has been reported for only one other RTK, Tie, an endothelial-specific RTK of human origin. We show here that Tek and Tie are encoded by distinct genes and that, together, these receptors define a new subfamily of RTKs. In addition, we demonstrate that the tek cDNA, when introduced into COS cells, encodes a product of 140 kDa and that this protein and/or tek transcripts are detectable in highly vascularized embryonic tissues and in some, but not all, cell lines of endothelial origin.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV WISCONSIN,CTR DEV BIOL,MADISON,WI 53706	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Wisconsin System; University of Wisconsin Madison			Gradwohl, Gérard/AFM-9024-2022; Gradwohl, Gérard/H-8543-2014	Gradwohl, Gérard/0000-0002-6730-2615; Gradwohl, Gérard/0000-0002-6730-2615				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUBOIS NA, 1991, EXP CELL RES, V196, P302, DOI 10.1016/0014-4827(91)90265-V; DUMONT JD, 1992, ONCOGENE, V7, P1471; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GERRITSEN ME, 1987, BIOCHEM PHARMACOL, V36, P2701, DOI 10.1016/0006-2952(87)90252-8; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; GUMKOWSKI F, 1987, BLOOD VESSELS, V24, P11; HARLOW E, 1988, ANTIBODIES LABORATOR; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; NODEN DM, 1989, AM REV RESPIR DIS, V140, P1097, DOI 10.1164/ajrccm/140.4.1097; NODEN DM, 1988, DEVELOPMENT, V103, P121; OBESO J, 1990, LAB INVEST, V63, P259; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PENDL J, 1992, IN PRESS DEV BIOL; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Sambrook J, 1989, MOL CLONING LABORATO; SCWARZBAUER JE, 1987, EMBO J, V6, P2573; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TERMAN BI, 1991, ONCOGENE, V6, P1677; WAGNER RC, 1980, ADV MICROCIRCULAT, V9, P45; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YAMAGUCHI TP, 1993, IN PRESS DEVELOPMENT	32	158	180	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1293	1301						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8386827				2022-12-25	WOS:A1993KY32800022
J	OBRIEN, WJ; WALLICK, ET; LINGREL, JB				OBRIEN, WJ; WALLICK, ET; LINGREL, JB			AMINO-ACID-RESIDUES OF THE NA,K-ATPASE INVOLVED IN OUABAIN SENSITIVITY DO NOT BIND THE SUGAR MOIETY OF CARDIAC-GLYCOSIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; TRANSPORT ADENOSINE-TRIPHOSPHATASE; ALPHA-SUBUNIT; (NA+; DIGITALIS; KIDNEY; ENZYME; CELLS; DNA; IDENTIFICATION	The identification of amino acid substitutions in the alpha subunit of the Na,K-ATPase that alter cardiac glycoside sensitivity provides a unique opportunity to examine the role these residues play in binding to the structural domains of these drugs. Substitution of a residue(s) involved in binding to the sugar moiety of cardiac glycosides would be expected to yield similar affinities for ouabain and its aglycone, ouabagenin. Sheep Na,K-ATPase alpha1 subunit amino acid substitutions previously shown to influence ouabain sensitivity were tested for activity in the presence of ouabain and ouabagenin. These substitutions included both transmembrane and extracellular regions: C104F, D121E, N122D, Q111K,N122K, and Q111R,A112S. Na,K-ATPase activity versus drug concentration curves yielded I50 values over a 1000-fold range for wild type HeLa and HeLa transfectants. Interestingly, the I50 ratio for ouabagenin to ouabain in all mutants tested indicated a 19-24-fold lower affinity of the Na,K-ATPase for ouabagenin. This constant ratio among all mutations tested implies that the first transmembrane region and the first extracellular loop (H1-H2) do not participate in the binding of the sugar moiety of cardiac glycosides.	UNIV CINCINNATI, COLL MED, DEPT MOLEC GENET BIOCHEM & MICROBIOL, 231 BETHESDA AVE, CINCINNATI, OH 45267 USA; UNIV CINCINNATI, COLL MED, DEPT PHARMACOL, CINCINNATI, OH 45267 USA	University of Cincinnati; University of Cincinnati					NHLBI NIH HHS [HL 41496] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS RJ, 1982, NATURE, V296, P167, DOI 10.1038/296167a0; ADAMS RJ, 1983, J CARDIOVASC PHARM, V5, P468, DOI 10.1097/00005344-198305000-00020; AKERA T, 1977, PHARMACOL REV, V29, P187; AKERA T, 1981, HDB EXPT PHARM, V56, P287; ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; BAKER ME, 1986, BIOCHEM BIOPH RES CO, V139, P281, DOI 10.1016/S0006-291X(86)80110-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown A., 1982, ATP ATPASE DETERMINA, P223; CANESSA CM, 1992, EMBO J, V11, P1681, DOI 10.1002/j.1460-2075.1992.tb05218.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FORBUSH B, 1983, CURR TOP MEMBR TRANS, V19, P167; FORBUSH B, 1978, BIOCHEMISTRY-US, V17, P3667, DOI 10.1021/bi00610a037; HANSEN O, 1984, PHARMACOL REV, V36, P143; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; LANE LK, 1973, J BIOL CHEM, V248, P7197; LINGREL JB, 1991, SOC GEN PHY, V46, P1; LYTTON J, 1985, J BIOL CHEM, V260, P1177; MCPARLAND RA, 1991, SODIUM PUMP RECENT D, P297; ORCHINNIKOV YA, 1987, FEBS LETT, V217, P269; PERIYASAMY SM, 1983, COMP BIOCHEM PHYS B, V76, P449, DOI 10.1016/0305-0491(83)90274-2; PRICE EM, 1989, J BIOL CHEM, V264, P21902; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; PRICE EM, 1990, J BIOL CHEM, V265, P6638; REPKE K, 1965, BIOCHEM PHARMACOL, V14, P1785, DOI 10.1016/0006-2952(65)90269-8; REPKE KRH, 1963, 1ST P INT PHARM M ST, V3, P46; ROSSI B, 1980, J BIOL CHEM, V255, P9936; RUOHO A, 1974, P NATL ACAD SCI USA, V71, P2352, DOI 10.1073/pnas.71.6.2352; SATOH K, 1989, BIOCHIM BIOPHYS ACTA, V994, P104, DOI 10.1016/0167-4838(89)90149-0; SCHATZMANN HJ, 1953, HELV PHYSIOL PHARM A, V11, P346; SCHULTHEIS PJ, 1993, BIOCHEMISTRY-US, V32, P544, DOI 10.1021/bi00053a020; SCHWARTZ A, 1969, J PHARMACOL EXP THER, V168, P31; SCHWARTZ A, 1975, PHARMACOL REV, V27, P3; SCHWARTZ A, 1980, CIRC RES, V46, P1154; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SHULL MM, 1989, J BIOL CHEM, V264, P17532; SMITH T W, 1988, New England Journal of Medicine, V318, P358; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P62; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; THOMAS R, 1974, J PHARM SCI, V63, P1649, DOI 10.1002/jps.2600631102; Thomas R., 1990, ADV DRUG RES, P311; THOMAS RC, 1972, PHYSIOL REV, V52, P563, DOI 10.1152/physrev.1972.52.3.563; TOBIN T, 1972, BIOCHEM PHARMACOL, V21, P1553, DOI 10.1016/0006-2952(72)90305-X; WALLICK ET, 1974, J PHARMACOL EXP THER, V189, P434; WALLICK ET, 1980, ARCH BIOCHEM BIOPHYS, V202, P442, DOI 10.1016/0003-9861(80)90448-8; YODA A, 1975, MOL PHARMACOL, V11, P653; YODA A, 1974, ANN NY ACAD SCI, V242, P598, DOI 10.1111/j.1749-6632.1974.tb19120.x	48	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7707	7712						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8385116				2022-12-25	WOS:A1993KW97900021
J	UEKI, K; KINCAID, RL				UEKI, K; KINCAID, RL			INTERCHANGEABLE ASSOCIATIONS OF CALCINEURIN REGULATORY SUBUNIT ISOFORMS WITH MAMMALIAN AND FUNGAL CATALYTIC SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN PHOSPHATASE; CALMODULIN-BINDING-PROTEIN; CALCIUM-BINDING; IDENTIFICATION; CLONING; CDNA; EXPRESSION; ISOZYMES; SEQUENCE; BRAIN	Two mammalian genes for the Ca2+-binding regulatory subunit of the calmodulin-dependent protein phosphatase (calcineurin) were identified recently, suggesting unique associations with tissue-specific catalytic subunits. The murine brain (beta1) and testis (beta2) isoforms of the regulatory subunit were expressed with poly-histidine carboxyl termini and purified by Ni2+-chelate chromatography, each exhibiting high affinity Ca2+ binding on nitrocellulose overlays. Using chromatographic methods to assess complex formation, the beta1 and beta2 isoforms appeared indistinguishable in their binding to bacterially expressed forms of the murine brain (alpha1) or testis (alpha3) catalytic subunits; this suggests that multiple heterodimeric forms may be present in some tissues. Furthermore, both beta1 and beta2 formed complexes with the recombinant catalytic subunit from Neurospora crassa. For this catalytically active fungal enzyme, stoichiometric amounts of mammalian regulatory subunit increased calmodulin-dependent activity without affecting that stimulated by Mn2+ alone. Maximal hydrolysis of p-nitrophenyl phosphate by the N. crassa catalytic subunit was stimulated 80-120% with the beta1 isoform and 30-50% by beta2. Significantly, the incubation time at 4-degrees-C required for optimal activation (6-8 h) was much greater than that for association (1 h), indicating that the catalytic subunit undergoes a slow transition to an activated conformation after binding the regulatory subunit. The production of functional heterodimers of mammalian and fungal proteins implies highly conserved interaction domains on the catalytic and regulatory subunits of this phosphatase.			UEKI, K (corresponding author), NIAAA,MOLEC & CELLULAR NEUROBIOL LAB,IMMUNOL SECT,ROCKVILLE,MD 20852, USA.							AITKEN A, 1982, FEBS LETT, V150, P314, DOI 10.1016/0014-5793(82)80759-X; AITKEN A, 1984, EUR J BIOCHEM, V139, P663, DOI 10.1111/j.1432-1033.1984.tb08055.x; BILLINGSLEY ML, 1985, P NATL ACAD SCI USA, V82, P7585, DOI 10.1073/pnas.82.22.7585; COHEN P, 1989, J BIOL CHEM, V264, P21435; GIRI PR, 1992, DNA CELL BIOL, V11, P415, DOI 10.1089/dna.1992.11.415; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; GUERINI D, 1989, DNA-J MOLEC CELL BIO, V8, P675, DOI 10.1089/dna.1.1989.8.675; HIGUCHI S, 1991, J BIOL CHEM, V266, P18104; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; ITO A, 1989, BIOCHEM BIOPH RES CO, V163, P1492, DOI 10.1016/0006-291X(89)91148-0; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KINCAID RL, 1984, J BIOL CHEM, V259, P5158; KINCAID RL, 1989, P NATL ACAD SCI USA, V86, P9183; KINCAID RL, 1991, ADV PROT PHOSPHATASE, V6, P73; KINCAID RL, 1988, METHOD ENZYMOL, V163, P627; KING MM, 1984, J BIOL CHEM, V259, P8847; Klee C B, 1980, Ann N Y Acad Sci, V356, P43, DOI 10.1111/j.1749-6632.1980.tb29598.x; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KUNO T, 1989, BIOCHEM BIOPH RES CO, V165, P1352, DOI 10.1016/0006-291X(89)92752-6; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MCPARTLIN AE, 1991, BIOCHIM BIOPHYS ACTA, V1088, P308, DOI 10.1016/0167-4781(91)90069-X; MERAT DL, 1985, J BIOL CHEM, V260, P1053; MUKAI H, 1991, BIOCHEM BIOPH RES CO, V179, P1325, DOI 10.1016/0006-291X(91)91718-R; MURAMATSU T, 1992, BIOCHEM BIOPH RES CO, V188, P265, DOI 10.1016/0006-291X(92)92379-C; MURAMATSU T, 1992, P NATL ACAD SCI USA, V89, P529, DOI 10.1073/pnas.89.2.529; NISHIO H, 1992, BIOCHEM BIOPH RES CO, V182, P34, DOI 10.1016/S0006-291X(05)80108-1; STARK MJR, 1987, GENE, V51, P255, DOI 10.1016/0378-1119(87)90314-3; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SUGIMOTO M, 1991, BIOCHEM BIOPH RES CO, V180, P1476, DOI 10.1016/S0006-291X(05)81362-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEKI K, 1992, BIOCHEM BIOPH RES CO, V187, P537, DOI 10.1016/S0006-291X(05)81527-X; YOKOYAMA N, 1990, J BIOL CHEM, V265, P8170	33	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6554	6559						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8384215				2022-12-25	WOS:A1993KT36800069
J	BOIE, Y; ADAM, M; RUSHMORE, TH; KENNEDY, BP				BOIE, Y; ADAM, M; RUSHMORE, TH; KENNEDY, BP			ENANTIOSELECTIVE ACTIVATION OF THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA OXIDASE; RESPONSIVE ELEMENT; ENZYME-ACTIVITIES; RAT-LIVER; INDUCTION; ACID; GENE; MECHANISMS; DNA; HEPATOCARCINOGENESIS	A cell-based transactivation assay was established using the mouse full-length peroxisome proliferator-activated receptor (PPAR) cDNA sequence and the positive peroxisome proliferator-responsive regulatory element (-578 to -553) of the rat acyl-CoA oxidase gene promoter. Activation of the reporter plasmid was dependent on co-transfection of the full-length PPAR cDNA, and the response was greatly stimulated, up to 100-fold, by peroxisome proliferators such as Wy-14,643 ([4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid), nafenopin (2-methyl-2[p-(1,2,3,4-tetra-hydro-1-naphtyl)phenoxy]-propionic acid), and clofibric acid (2-([p]-chlorophenoxy)-2-methylpropionic acid). Activation of the reporter plasmid promoter by the full-length PPAR cDNA also occurred at peroxisomal proliferator concentrations 40 times lower than that required for similar stimulation by a glucocorticoid-PPAR chimeric receptor. By using the stereoisomers of MK-571 ((+/)-3-(((3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)((3-(dimethylamino)-3-oxopropyl)-thio)methyl)-thio)propanoic acid), a potent leukotriene D4 receptor antagonist, we could show enantioselective activation of PPAR. The use of this compound in mice results in peroxisome proliferation; however, nearly all of the peroxisome proliferating activity can be attributed to the S enantiomer. Our results show a similar enantiomeric discrimination in PPAR activation of the reporter plasmid promoter, where again most of the activity can be attributed to the S enantiomer. The equivalent activities of these stereoisomers both in vivo and in the PPAR transactivation assay strongly implicate PPAR as a major component of the peroxisome proliferating mechanism in rodents.	MERCK FROSST CANADA INC,MERCK FROSST CTR THERAPEUT RES,DEPT MOLEC BIOL,POB 1005,POINTE CLAIRE H9R 4P8,PQ,CANADA	Merck & Company								CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHINJE E, 1991, BIOCHEM PHARMACOL, V41, P769, DOI 10.1016/0006-2952(91)90079-K; COHEN AJ, 1981, FOOD COSMET TOXICOL, V19, P585, DOI 10.1016/0015-6264(81)90509-5; CONWAY JG, 1989, DRUG METAB REV, V21, P65, DOI 10.3109/03602538909029956; ESBENSHADE TA, 1990, BIOCHEM PHARMACOL, V40, P1263, DOI 10.1016/0006-2952(90)90392-X; GAUTHIER JY, 1990, J MED CHEM, V33, P2841, DOI 10.1021/jm00172a025; GREEN S, 1992, BIOCHEM PHARMACOL, V43, P393, DOI 10.1016/0006-2952(92)90554-V; GROSSMAN SJ, 1992, TOXICOL APPL PHARM, V116, P217, DOI 10.1016/0041-008X(92)90301-8; HAWKINS JM, 1987, DRUG METAB REV, V18, P441, DOI 10.3109/03602538708994130; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KENNEDY BP, 1991, J BIOL CHEM, V266, P8511; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAKE BG, 1987, TOXICOL IND HEALTH, V3, P165, DOI 10.1177/074823378700300212; LEHMANN PA, 1986, TRENDS PHARMACOL SCI, V7, P281, DOI 10.1016/0165-6147(86)90353-6; LEIGHTON F, 1975, J CELL BIOL, V67, P281, DOI 10.1083/jcb.67.2.281; LOCK EA, 1989, ANNU REV PHARMACOL, V29, P145; LUNDGREN B, 1987, EUR J BIOCHEM, V163, P423, DOI 10.1111/j.1432-1033.1987.tb10815.x; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; MOODY DE, 1976, J CELL BIOL, V71, P768, DOI 10.1083/jcb.71.3.768; NEMALI MR, 1989, TOXICOL APPL PHARM, V97, P72, DOI 10.1016/0041-008X(89)90056-2; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; RAO MS, 1989, DRUG METAB REV, V21, P103, DOI 10.3109/03602538909029957; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; REDDY JK, 1986, TRENDS PHARMACOL SCI, V7, P438, DOI 10.1016/0165-6147(86)90416-5; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x	32	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5530	5534						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8383673				2022-12-25	WOS:A1993KR82200030
J	THULASI, R; HARBOUR, DV; THOMPSON, EB				THULASI, R; HARBOUR, DV; THOMPSON, EB			SUPPRESSION OF C-MYC IS A CRITICAL STEP IN GLUCOCORTICOID-INDUCED HUMAN LEUKEMIC-CELL LYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE ERYTHROLEUKEMIA-CELLS; DNA-BINDING; NEOPLASTIC-CELLS; GENE-EXPRESSION; RECEPTOR; TRANSCRIPTION; LINE; DIFFERENTIATION; ONCOGENE; APOPTOSIS	Glucocorticoids evoke cytolysis in clonal human leukemic CEM-C7 cells. Suppression of c-myc mRNA by dexamethasone closely correlates with cell lysis only in CEM clones with both glucocorticoid receptor and intact lysis functions. We tested the theory that c-myc repression is essential for glucocorticoid-induced lymphocytolysis by preventing down-regulation of c-myc gene in the presence of dexamethasone and by reducing c-myc mRNA levels with antisense oligonucleotides. We find that sustained expression of c-myc provides resistance to dexamethasone-induced lysis, and antisense c-myc oligomers induce cell lysis. The lethal effects of dexamethasone in these leukemic cells appear to involve reduction of c-myc below the levels required to maintain cellular growth and integrity.	UNIV TEXAS, MED BRANCH, DEPT HUMAN BIOL CHEM & GENET, GALVESTON, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston					NCI NIH HHS [CA 41407] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041407] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ASKEW DS, 1991, ONCOGENE, V6, P1915; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOURGEOIS S, 1978, CANCER RES, V38, P4279; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CHILTON DG, 1990, IN VITRO CELL DEV B, V26, P561; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COMPTON MM, 1987, J STEROID BIOCHEM, V27, P201, DOI 10.1016/0022-4731(87)90311-6; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; DROUIN J, 1989, J STEROID BIOCHEM, V34, P63, DOI 10.1016/0022-4731(89)90066-6; EASTMANREKS SB, 1986, CANCER RES, V46, P2457; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EVANS RM, 1989, RECENT PROG HORM RES, V45, P1; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; GASSON JC, 1983, J CELL BIOL, V96, P409, DOI 10.1083/jcb.96.2.409; GRACE LC, 1983, CELL, V31, P443; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HARBOUR DV, 1990, J STEROID BIOCHEM, V35, P1, DOI 10.1016/0022-4731(90)90137-H; HARMON JM, 1979, J CELL PHYSIOL, V98, P267, DOI 10.1002/jcp.1040980203; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANDERS J P, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P19; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MANIATIS T, 1982, MOL CLONING LABORATO, P88; MIESFELD R, 1989, CRITICAL REV BIOCH M, P101; NAKAI Y, 1991, J STEROID BIOCHEM, V40, P301, DOI 10.1016/0960-0760(91)90195-B; NAZARETH LV, 1991, J BIOL CHEM, V266, P12976; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NICHOLSON ML, 1981, CANCER RES, V41, P3530; NORMAN MR, 1977, CANCER RES, V37, P3785; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; STEVENS J, 1983, BIOCHEM ACTION HORM, V10, P383; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; THOMPSON EB, 1986, STEROID HORMONE RESI, P111; TOURAY M, 1991, ONCOGENE, V6, P1227; Yamamoto K R, 1976, Recent Prog Horm Res, V32, P3; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YUH YS, 1989, J BIOL CHEM, V264, P10904; YUH YS, 1987, SOMAT CELL MOLEC GEN, V13, P33, DOI 10.1007/BF02422297; YUH YS, 1987, THESIS U TEXAS MED B	49	120	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18306	18312						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8394364				2022-12-25	WOS:A1993LT74300097
J	ENYEDI, A; PENNISTON, JT				ENYEDI, A; PENNISTON, JT			AUTOINHIBITORY DOMAINS OF VARIOUS CA2+ TRANSPORTERS CROSS-REACT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; CARDIAC SARCOPLASMIC-RETICULUM; MEMBRANE CA-2+ PUMP; PLASMA-MEMBRANE; PROTEIN-KINASE; MOLECULAR CHARACTERIZATION; FUNCTIONAL DOMAINS; CALCIUM-TRANSPORT; PHOSPHOLAMBAN; ATPASE	Synthetic peptides having the sequence of the calmodulin-binding autoinhibitory domain of the Na+/Ca2+ exchanger (XIP) and of the plasma membrane Ca2+ pump (C28R2) inhibited the sarcoplasmic reticulum (SERCA) and plasma membrane (PMCA) Ca2+ pumps. XIP was nearly as effective in inhibiting both systems as C28R2, which had previously been considered to be the most powerful peptide inhibitor of PMCA. In contrast, calmodulin-binding peptides from non-Ca2+ transport proteins (calmodulin-dependent protein kinase II and myosin light chain kinase) showed only weak inhibition. The relative specificity and effectiveness of the peptides from the Ca2+ transport proteins, as well as the characteristics of their actions were similar in both SERCA and PMCA, suggesting a high degree of functional relatedness between these autoinhibitory regions. Secondary structure predictions show that the calmodulin-binding autoinhibitory domains of the Na+/Ca2+ exchanger and PMCA are predicted to form a beta structure which might be necessary for the observed cross-inhibition. The results also indicate that other domains of the Ca2+ transporters have common structural elements which interact with the autoinhibitory domains.	MAYO CLIN & MAYO FDN, DEPT BIOCHEM & MOLEC BIOL, ROCHESTER, MN 55905 USA; NATL INST HAEMATOL & BLOOD TRANSFUS, DEPT CELL METAB, H-1113 BUDAPEST, HUNGARY	Mayo Clinic			Enyedi, Agnes/N-9742-2013	Enyedi, Agnes/0000-0002-7366-9376	NIGMS NIH HHS [GM 28835] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CHIESI M, 1989, FEBS LETT, V244, P241, DOI 10.1016/0014-5793(89)81201-3; CHIESI M, 1991, BIOCHEMISTRY-US, V30, P7978, DOI 10.1021/bi00246a015; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; ENYEDI A, 1991, J BIOL CHEM, V266, P8952; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; FALCHETTO R, 1992, PROTEIN SCI, V1, P1613, DOI 10.1002/pro.5560011209; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; FILOTEO AG, 1992, J BIOL CHEM, V267, P11800; FOSTER CJ, 1990, ARCH BIOCHEM BIOPHYS, V280, P397, DOI 10.1016/0003-9861(90)90348-3; FUJII J, 1989, J BIOL CHEM, V264, P12950; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; JAMES P, 1988, J BIOL CHEM, V263, P2905; JAMES P, 1989, J BIOL CHEM, V264, P8289; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; KIM HW, 1990, J BIOL CHEM, V265, P1702; KOMURO I, 1992, P NATL ACAD SCI USA, V89, P4769, DOI 10.1073/pnas.89.10.4769; LEPEUCH CJ, 1979, BIOCHEMISTRY-US, V18, P5150, DOI 10.1021/bi00590a019; LI ZP, 1991, J BIOL CHEM, V266, P1014; MACLENNAN DH, 1992, BIOCHEM SOC T, V20, P559, DOI 10.1042/bst0200559; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; PAPP B, 1989, J BIOL CHEM, V264, P4577; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PHILIPSON KD, 1990, CALCIUM HEART, P85; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SARKADI B, 1980, BIOCHIM BIOPHYS ACTA, V598, P326, DOI 10.1016/0005-2736(80)90010-3; SARKADI B, 1977, BIOCHIM BIOPHYS ACTA, V464, P93, DOI 10.1016/0005-2736(77)90373-X; SASAKI T, 1992, J BIOL CHEM, V267, P1674; SMITH MK, 1990, J BIOL CHEM, V265, P1837; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586; TADA M, 1979, J BIOL CHEM, V254, P319; TADA M, 1982, ANNU REV PHYSIOL, V44, P401, DOI 10.1146/annurev.ph.44.030182.002153; TADA M, 1988, METHOD ENZYMOL, V157, P107; TOYOFUKU T, 1993, J BIOL CHEM, V268, P2809; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VORHERR T, 1992, BIOCHEMISTRY-US, V31, P371, DOI 10.1021/bi00117a009; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; XU ZC, 1989, J BIOL CHEM, V264, P16644; ZVARITCH E, 1990, BIOCHEMISTRY-US, V29, P8070, DOI 10.1021/bi00487a012	39	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17120	17125						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8394328				2022-12-25	WOS:A1993LQ98800038
J	AGGELER, R; CAPALDI, RA				AGGELER, R; CAPALDI, RA			ATP HYDROLYSIS-LINKED STRUCTURAL-CHANGES IN THE N-TERMINAL PART OF THE GAMMA-SUBUNIT OF ESCHERICHIA-COLI F1-ATPASE EXAMINED BY CROSS-LINKING STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADENOSINE-TRIPHOSPHATASE ACTIVITY; NUCLEOTIDE BINDING-SITES; EPSILON-SUBUNIT; BETA-SUBUNIT; MOLECULAR SWITCH; CATALYTIC SITES; H+-ATPASE; F1 ATPASE; INHIBITION; FORMS	A mutant of Escherichia coli F1-ATPase (ECF1) in which the serine residue in position 8 of the gamma subunit has been replaced by a cysteine residue (gammaS8C) has been used to study nucleotide-dependent cross-linking of the gamma subunit to a beta subunit. When examined in the presence of ADP + Mg2+, either supplied directly or as produced during catalytic turnover of ATP + Mg2+, the main cross-linked product generated using the heterobifunctional, photoactivatable, cross-linker tetrafluorophenylazide maleimide-6 had a M(r(app)) of 108,000. When ATP hydrolysis was inhibited, either by cold or by reaction with sodium azide, or when ATP hydrolysis was prevented by the use of adenyl-5'-yl beta,gamma-imidodiphosphate, the main cross-linked products were species with M(r(app)) of 102,000 and 84,000. The nucleotide-dependent switching from one cross-linking pattern to another could only be observed when the epsilon subunit was bound to ECF1; it was not seen in ECF1*, an enzyme preparation missing delta and epsilon subunits, but was observed in preparations selectively depleted of the delta subunit. We conclude that the changes detected in these cross-linking experiments are occurring during the hydrolysis of ATP when the beta-gamma phosphate bond is cleaved and that they are related to the coupling of ATP hydrolysis to proton translocation.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA	University of Oregon					NHLBI NIH HHS [HL 24236] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGELER R, 1990, BIOCHEMISTRY-US, V29, P10387, DOI 10.1021/bi00497a013; AGGELER R, 1992, J BIOL CHEM, V267, P21355; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; CAPALDI RA, 1992, J BIOENERG BIOMEMBR, V24, P435, DOI 10.1007/BF00762359; CROSS RL, 1982, J BIOL CHEM, V257, P2874; CROSS RL, 1988, J BIOENERG BIOMEMBR, V20, P395, DOI 10.1007/BF00762200; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DOWNER NW, 1976, BIOCHEMISTRY-US, V15, P2930, DOI 10.1021/bi00658a036; DUNCAN TM, 1992, J BIOENERG BIOMEMBR, V24, P453, DOI 10.1007/BF00762362; DUNN SD, 1982, J BIOL CHEM, V257, P7354; DUNN SD, 1986, ANAL BIOCHEM, V159, P35, DOI 10.1016/0003-2697(86)90304-0; FUTAI M, 1992, J BIOENERG BIOMEMBR, V24, P463, DOI 10.1007/BF00762363; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; HANADA H, 1989, FEBS LETT, V257, P465, DOI 10.1016/0014-5793(89)81597-2; HARRIS DA, 1989, BIOCHIM BIOPHYS ACTA, V974, P156, DOI 10.1016/S0005-2728(89)80368-8; IDA K, 1991, J BIOL CHEM, V266, P5424; IWAMOTO A, 1993, J BIOL CHEM, V268, P3156; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4134, DOI 10.1021/bi00313a019; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NOUMI T, 1987, FEBS LETT, V213, P381, DOI 10.1016/0014-5793(87)81526-0; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SENIOR AE, 1979, BIOCHEM J, V180, P103, DOI 10.1042/bj1800103; TOZER RG, 1987, J BIOL CHEM, V262, P10706; TUTTASDORSCHUG R, 1989, BIOCHEMISTRY-US, V28, P5107, DOI 10.1021/bi00438a030; WISE JG, 1981, J BIOL CHEM, V256, P383; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P	29	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14576	14579						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8392054				2022-12-25	WOS:A1993LL75900007
J	GRISWOLDPRENNER, I; CARLIN, CR; ROSNER, MR				GRISWOLDPRENNER, I; CARLIN, CR; ROSNER, MR			MITOGEN-ACTIVATED PROTEIN-KINASE REGULATES THE EPIDERMAL GROWTH-FACTOR RECEPTOR THROUGH ACTIVATION OF A TYROSINE PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3T3-L1 CELLS; PHOSPHORYLATION; THREONINE; SUBSTRATE; INVIVO	Epidermal growth factor (EGF) receptor tyrosine kinase activity is inhibited by growth factor-stimulated kinases involved in cellular signaling. Mitogen-activated protein (MAP) kinase is activated in response to a wide variety of growth modulating agents including EGF. To determine whether MAP kinase can inactivate the EGF receptor tyrosine kinase, we investigated the effect of pp42 MAP kinase on the EGF receptor. The results indicate that direct phosphorylation of the EGF receptor by MAP kinase does not alter receptor tyrosine kinase activity. However, MAP kinase can decrease EGF receptor tyrosine phosphorylation through a vanadate-sensitive pathway involving activation of a tyrosine phosphatase.	UNIV CHICAGO, BEN MAY INST, MC6027, 5841 S MARYLAND AVE, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA	University of Chicago; University of Chicago; Case Western Reserve University					NATIONAL CANCER INSTITUTE [R01CA035541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007197] Funding Source: NIH RePORTER; NCI NIH HHS [CA35541] Funding Source: Medline; NIGMS NIH HHS [GM07197] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P1974, DOI 10.1073/pnas.82.7.1974; FAURE R, 1992, J BIOL CHEM, V267, P11215; FRIEDMAN B, 1989, P NATL ACAD SCI USA, V86, P812, DOI 10.1073/pnas.86.3.812; GRATECOS D, 1974, BIOCHEM BIOPH RES CO, V58, P960, DOI 10.1016/S0006-291X(74)80237-8; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORRISON P, 1992, J CELL BIOCH B S, V16, P199; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; PELLECH SL, 1992, SCIENCE, V257, P1355; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROSNER MR, 1991, GROWTH REGULATION CA, P199; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; TAKISHIMA K, 1988, BIOCHEM BIOPH RES CO, V157, P740, DOI 10.1016/S0006-291X(88)80312-7; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207	26	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13050	13054						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8390452				2022-12-25	WOS:A1993LH55300009
J	SCOTT, CF; WHITAKER, EJ; HAMMOND, BF; COLMAN, RW				SCOTT, CF; WHITAKER, EJ; HAMMOND, BF; COLMAN, RW			PURIFICATION AND CHARACTERIZATION OF A POTENT 70-KDA THIOL LYSYLPROTEINASE (LYS-GINGIVAIN) FROM PORPHYROMONAS-GINGIVALIS THAT CLEAVES KININOGENS AND FIBRINOGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; BLACK-PIGMENTED BACTEROIDES; PLASMA KALLIKREIN; PROTEINASE-INHIBITORS; DEGRADATION; NEUTROPHILS; COMPLEMENT; ELASTASE; ANTICOAGULANT; INACTIVATION	We isolated an enzyme from a major periodontal pathogen, Porphyromonas gingivalis (also called Bacteroides gingivalis), that is capable of initially increasing the coagulant activity of high molecular weight kininogen (HK), releasing bradykinin from HK and low molecular weight kininogen (LK), and destroying the light chain (coagulant portion) of HK. This enzyme, a membrane-bound thiol proteinase that preferentially cleaves the P1-Lys position of tripeptide substrates, is also able to rapidly render fibrinogen nonclottable. We will refer to this enzyme as lys-gingivain because of its origin from P. gingivalis, its classification as a thiol proteinase, and its action as a lysyl-amidase. The activity of lys-gingivain is enhanced by beta-mercaptoethanol, and the enzyme has a molecular mass of 68-70 kDa, a pH optimum of 7.4, and is not inactivated by plasma protease inhibitors. The second-order rate constant for the destruction of the coagulant activity of the HK light chain (surface-binding domain) at 23-degrees-C is 2.3 x 10(7) M-1 s-1, and, for cleavages that render fibrinogen unclottable, is 2.05 x 10(6) M-1 s-1. These data suggest that lys-gingivain is a very potent proteinase that would be fully functional in anaerobic periodontal crevices and might participate in the pathogenesis of periodontitis. Lys-gingivain appears to be the most potent kininogenase and fibrase to be described to date.	TEMPLE UNIV,SOL SHERRY THROMBOSIS RES CTR,SCH MED,PHILADELPHIA,PA 19122; TEMPLE UNIV,SCH DENT,PHILADELPHIA,PA 19140; MED COLL PENN,PHILADELPHIA,PA 19129	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania; Drexel University				Whitaker, Eugene/0000-0002-8626-5282	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL045486] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45486] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETT AJ, 1991, ICOP NEWSLETTER  AUG, P6; CARLSSON J, 1984, INFECT IMMUN, V43, P644, DOI 10.1128/IAI.43.2.644-648.1984; CHEN ZX, 1992, J BIOL CHEM, V267, P18896; DELACADENA RA, 1992, PROTEIN SCI, V1, P151; EBERSOLE JL, 1980, J DENT RES, V59, P329; FERRY JD, 1952, P NATL ACAD SCI USA, V38, P566, DOI 10.1073/pnas.38.7.566; FORSCHER BK, 1944, J DENT RES, V33, P444; FUJIMURA S, 1987, INFECT IMMUN, V55, P716, DOI 10.1128/IAI.55.3.716-720.1987; FUJIMURA S, 1992, ORAL MICROBIOL IMMUN, V7, P212, DOI 10.1111/j.1399-302X.1992.tb00027.x; GHEBREHIWET B, 1981, J EXP MED, V153, P665, DOI 10.1084/jem.153.3.665; HERMANS J, 1982, SEMIN THROMB HEMOST, V8, P11, DOI 10.1055/s-2007-1005039; HIGASHIYAMA S, 1986, BIOCHEMISTRY-US, V25, P1669, DOI 10.1021/bi00355a034; KAPLAN AP, 1972, J EXP MED, V135, P81, DOI 10.1084/jem.135.1.81; KLENIEWSKI J, 1988, J EXP MED, V167, P1895, DOI 10.1084/jem.167.6.1895; KLENIEWSKI J, 1987, J LAB CLIN MED, V109, P469; KLENIEWSKI J, 1988, J LAB CLIN MED, V111, P93; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANTZ MS, 1986, INFECT IMMUN, V54, P654, DOI 10.1128/IAI.54.3.654-658.1986; LONGSTAFF C, 1992, THROMB HAEMOSTASIS, V67, P533; MAIER M, 1983, J IMMUNOL, V130, P2352; MALINCONICO SM, 1984, J LAB CLIN MED, V104, P842; MARDER VJ, 1969, J BIOL CHEM, V244, P2111; NILSSON T, 1985, INFECT IMMUN, V50, P467, DOI 10.1128/IAI.50.2.467-471.1985; NUSSENZWEIG V, 1961, ANN I PASTEUR PARIS, V100, P377; PANDYA BV, 1984, BIOCHEMISTRY-US, V23, P460, DOI 10.1021/bi00298a010; PIRKLE H, 1991, THROMB HAEMOSTASIS, V66, P264; RATNOFF OD, 1951, J LAB CLIN MED, V37, P316; SCHAPIRA M, 1982, J CLIN INVEST, V69, P1199, DOI 10.1172/JCI110557; SCHIFFMAN S, 1975, J CLIN INVEST, V56, P1082, DOI 10.1172/JCI108182; SCHWARTZ LB, 1985, J IMMUNOL, V135, P2762; SCOTT CF, 1986, ARCH BIOCHEM BIOPHYS, V249, P480, DOI 10.1016/0003-9861(86)90025-1; SCOTT CF, 1985, J BIOL CHEM, V260, P856; SCOTT CF, 1992, J LAB CLIN MED, V119, P77; SCOTT CF, 1984, J CLIN INVEST, V73, P954, DOI 10.1172/JCI111319; SILVA MRE, 1949, AM J PHYSIOL, V156, P261, DOI 10.1152/ajplegacy.1949.156.2.261; SLOTS J, 1977, SCAND J DENT RES, V85, P114; SPIEGEL CA, 1979, J PERIONDONTAL RES, V4, P376; SUEYOSHI T, 1985, FEBS LETT, V182, P193, DOI 10.1016/0014-5793(85)81182-0; SUNDQVIST G, 1985, J MED MICROBIOL, V19, P85, DOI 10.1099/00222615-19-1-85; SUNDQVIST GK, 1984, SCAND J DENT RES, V92, P14; TANNER ACR, 1979, J CLIN PERIODONTOL, V6, P278, DOI 10.1111/j.1600-051X.1979.tb01931.x; TODA K, 1984, J PERIODONTAL RES, V19, P372, DOI 10.1111/j.1600-0765.1984.tb01010.x; WACHTFOGEL YT, 1983, J CLIN INVEST, V72, P1672, DOI 10.1172/JCI111126; WEITZ JI, 1987, J EXP MED, V166, P1836, DOI 10.1084/jem.166.6.1836; WILLIAMS BL, 1979, J CLIN PERIODONTOL, V6, P210, DOI 10.1111/j.1600-051X.1979.tb01923.x; WINGROVE JA, 1992, J BIOL CHEM, V267, P18902; YOSHIMURA F, 1984, ARCH ORAL BIOL, V29, P559, DOI 10.1016/0003-9969(84)90078-5; ZAMBON JJ, 1981, INFECT IMMUN, V32, P198, DOI 10.1128/IAI.32.1.198-203.1981	48	120	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7935	7942						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8385128				2022-12-25	WOS:A1993KW97900055
J	JAISWAL, RK; MURPHY, MB; LANDRETH, GE				JAISWAL, RK; MURPHY, MB; LANDRETH, GE			IDENTIFICATION AND CHARACTERIZATION OF A NERVE GROWTH FACTOR-STIMULATED MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVATOR IN PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; TYROSINE PHOSPHORYLATION; TRK PROTOONCOGENE; MAP KINASES; THREONINE; INSULIN; K-252A; PC12-CELLS; OUTGROWTH; INCREASE	Nerve growth factor treatment of PC12 cells results in the rapid activation of MAP kinases. These enzymes are activated through interaction with a protein ''activator.'' The mitogen-activated protein (MAP) kinase activator has been partially purified by ion exchange and gel filtration chromatography. The activator has an apparent molecular mass of 50-60 kDa. The MAP kinase activator is rapidly generated in response to nerve growth factor (NGF) and can be detected within 30 s of exposure, reaching maximal levels within 2 min and then declining to near basal levels by 15-20 min. The activation of MAP kinase is dependent upon the time of incubation with the activator and on activator concentration. The MAP kinase activator is itself a protein kinase that phosphorylates MAP kinases and mediates their activation. The NGF-stimulated MAP kinase activator phosphorylates MAP kinase on serine, threonine, and tyrosine residues, establishing this enzyme as dual specific kinase. The MAP kinase activator is itself a phosphoprotein whose phosphorylation on tyrosine residues is stimulated upon NGF treatment of the cells. The enzyme activity of MAP kinase activator is abolished by treatment with both the tyrosine-specific phosphatase PTP-1 and the serine/threonine-specific phosphatase PP2A. The activator is produced in response to NGF, epidermal growth factor, and fibroblast growth factor. The protein kinase inhibitor K252a selectively inhibits the ability of NGF to generate MAP kinase activator activity. These data suggest that the upstream events governing MAP kinase activation involve the regulated phosphorylation of dual specificity MAP kinase activator as an immediate consequence of receptor activation.	CASE WESTERN RESERVE UNIV,SCH MED,CTR ALZHEIMER,ALZHEIMER RES LAB,E504,2119 ABINGTON,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT NEUROL & NEUROSCI,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034908] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34908] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1992, J NEUROCHEM, V59, P147, DOI 10.1111/j.1471-4159.1992.tb08885.x; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ALETTA J, 1987, METHODS ENZYUMOL, V147, P207; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BERG MM, 1992, J BIOL CHEM, V267, P13; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; GAUN K, 1990, P NATL ACAD SCI USA, V87, P1501; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREENE LA, 1976, P NATL ACAD SCI USA, V83, P2714; HALEGOUA S, 1991, NERVE GROWTH FACTOR, P119; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; JOHNSON KW, 1991, J BIOL CHEM, V266, P3402; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KOIZUMI S, 1988, J NEUROSCI, V8, P715; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LALLEMAIN G, 1992, MOL CELL BIOL, V12, P2222, DOI 10.1128/MCB.12.5.2222; LANDRETH GE, 1987, NEUROCHEM RES, V12, P943, DOI 10.1007/BF00966317; LANDRETH GE, 1990, J NEUROCHEM, V55, P514, DOI 10.1111/j.1471-4159.1990.tb04165.x; LAZAROVICI P, 1989, J NEUROSCI RES, V23, P1, DOI 10.1002/jnr.490230102; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MIYASAKA T, 1990, BIOCHEM BIOPH RES CO, V168, P1237, DOI 10.1016/0006-291X(90)91161-K; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROSSAMANDO A, 1992, P NATL ACAD SCI USA, V9, P5221; RYDEL RE, 1987, J NEUROSCI, V7, P3639; SANO M, 1990, J NEUROCHEM, V55, P427, DOI 10.1111/j.1471-4159.1990.tb04154.x; SCHANENKING C, 1991, NEURON, V6, P915, DOI 10.1016/0896-6273(91)90232-O; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SEGER R, 1992, J BIOL CHEM, V267, P14373; SMITH AP, 1968, BIOCHEMISTRY-US, V7, P3259, DOI 10.1021/bi00849a032; SMITH DS, 1989, J NEUROCHEM, V53, P800, DOI 10.1111/j.1471-4159.1989.tb11776.x; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SWARUP G, 1981, J BIOL CHEM, V256, P8197; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WUU J, 1991, P NATL ACAD SCI USA, V88, P9508	55	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7055	7063						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8385098				2022-12-25	WOS:A1993KV14100038
J	JOSEPH, SK; SAMANTA, S				JOSEPH, SK; SAMANTA, S			DETERGENT SOLUBILITY OF THE INOSITOL TRISPHOSPHATE RECEPTOR IN RAT-BRAIN MEMBRANES - EVIDENCE FOR ASSOCIATION OF THE RECEPTOR WITH ANKYRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROCYTE ANKYRIN; 1,4,5-TRISPHOSPHATE INSP3 RECEPTOR; RECONSTITUTED LIPID VESICLES; CEREBELLAR PURKINJE-CELLS; CALCIUM RELEASE; SUBCELLULAR-DISTRIBUTION; EPITHELIAL-CELLS; PLASMA-MEMBRANE; P-400 PROTEIN; LIGHT CHAIN	Rat cerebellar membranes sedimenting at 10,000 x g contain significantly greater amounts of [H-3]D-myo inositol 1,4,5-trisphosphate- (IP3) binding sites that are resistant to extraction by Triton X-100 than membranes sedimenting at 100,000 x g. Scatchard analysis of the Triton X-100-resistant binding site revealed the presence of a single binding site with an 8-fold higher affinity for IP3 than present in 10,000 x g membranes. The Triton X-100-resistant binding site displayed high specificity for Ins(1,4,5)P3 and was sensitive to inhibition by both heparin and calcium. A polyclonal antibody to the C terminus of the IP3 receptor (IP3R) and biotinylated concanavalin A recognized the same 235 kDa band in Western blots of membrane and Triton X-100-insoluble fractions. The ligand binding activity of the IP3R could be measured in immunoprecipitates obtained from detergent-soluble extracts treated with IP3R antibody. An antibody to chick erythrocyte ankyrin also immunoprecipitated [H-3]IP3-binding sites and immunoreactive IP3R protein. These effects of ankyrin antibody were prevented by preadsorption to erythrocyte ghosts and were not reproduced by spectrin antibodies. Cross-reactivity of the ankyrin antibody with the IP3R was excluded by the demonstration of selective loss of immunoreactive ankyrin protein when IP3R antibody immunoprecipitates were boiled in SDS buffers or when membranes were alkali-treated. These results suggest that a population of IP3R in brain may be attached to an isoform of ankyrin. This may mediate interactions of the IP3R with the cytoskeleton and account for observations regarding the detergent insolubility of the protein.			JOSEPH, SK (corresponding author), THOMAS JEFFERSON UNIV,SCH MED,DEPT PATHOL & CELL BIOL,RM 230A JAH,1020 LOCUST ST,PHILADELPHIA,PA 19107, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007186] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA-07186] Funding Source: Medline; NIDDK NIH HHS [R01-DK-34804] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1991, J CLIN INVEST, V87, P1483, DOI 10.1172/JCI115157; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOND JM, 1991, CELL SIGNAL, V3, P607, DOI 10.1016/0898-6568(91)90037-U; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; DAVIES AA, 1984, BIOCHEM J, V219, P301, DOI 10.1042/bj2190301; DAVIS JQ, 1986, J BIOL CHEM, V261, P6198; DAVIS JQ, 1992, J CELL BIOL, V115, P43; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; DEBLASI A, 1989, TRENDS PHARMACOL SCI, V10, P227, DOI 10.1016/0165-6147(89)90266-6; EDELMAN AM, 1985, J NEUROSCI, V5, P2609; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FLUCHER BE, 1990, NEURON, V5, P339, DOI 10.1016/0896-6273(90)90170-K; FRAPPIER T, 1991, BIOCHEM J, V275, P521, DOI 10.1042/bj2750521; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GILLESPIE CS, 1989, BIOCHEM J, V260, P689, DOI 10.1042/bj2600689; GUILLEMETTE G, 1990, MOL PHARMACOL, V38, P841; HARLOW E, 1988, ANTIBODIES LABORATOR; HILL TD, 1987, BIOCHEM BIOPH RES CO, V149, P897, DOI 10.1016/0006-291X(87)90492-X; JOSEPH SK, 1989, BIOCHEM J, V258, P261, DOI 10.1042/bj2580261; JOSEPH SK, 1992, IN PRESS ANN REPORTS; KRAUSE KH, 1991, FEBS LETT, V285, P225, DOI 10.1016/0014-5793(91)80806-E; KUNIMOTO M, 1989, J BIOCH, V190, P195; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAEDA N, 1988, J NEUROCHEM, V51, P1724, DOI 10.1111/j.1471-4159.1988.tb01151.x; MIGNERY GA, 1992, J BIOL CHEM, V267, P7450; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MIKOSHIBA K, 1979, DEV NEUROSCI-BASEL, V2, P254, DOI 10.1159/000112489; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; MOLDAY LL, 1990, J BIOL CHEM, V265, P18690; MOUREY RJ, 1990, BIOCHEM J, V272, P383, DOI 10.1042/bj2720383; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; OTSU H, 1990, CELL STRUCT FUNCT, V15, P163, DOI 10.1247/csf.15.163; OTTO E, 1991, J CELL BIOL, V114, P241, DOI 10.1083/jcb.114.2.241; Putney J W Jr, 1991, Adv Pharmacol, V22, P251, DOI 10.1016/S1054-3589(08)60037-X; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TASAKA K, 1991, AGENTS ACTIONS, V33, P44, DOI 10.1007/BF01993123; THEIBERT AB, 1987, BIOCHEM BIOPH RES CO, V148, P1283, DOI 10.1016/S0006-291X(87)80272-3; TYALOR CW, 1991, PHARMACOL THERAPEUT, V51, P97; WORLEY PF, 1987, J BIOL CHEM, V262, P12132	58	124	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6477	6486						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8384211				2022-12-25	WOS:A1993KT36800059
J	MCLAUGHLIN, MM; CIESLINSKI, LB; BURMAN, M; TORPHY, TJ; LIVI, GP				MCLAUGHLIN, MM; CIESLINSKI, LB; BURMAN, M; TORPHY, TJ; LIVI, GP			A LOW-K(M), ROLIPRAM-SENSITIVE, CAMP-SPECIFIC PHOSPHODIESTERASE FROM HUMAN BRAIN - CLONING AND EXPRESSION OF CDNA, BIOCHEMICAL-CHARACTERIZATION OF RECOMBINANT PROTEIN, AND TISSUE DISTRIBUTION OF MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP PHOSPHODIESTERASE; DROSOPHILA DUNCE+ GENE; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE PHOSPHODIESTERASES; SELECTIVE INHIBITORS; MOLECULAR-CLONING; ALPHA-SUBUNIT; RAT HOMOLOGS; IDENTIFICATION; YEAST	We have isolated cDNA clones from human frontal cortex cDNA libraries that encode a unique subtype of the low-K(m), cAMP-specific phosphodiesterases (PDEs IV). The 564-amino acid sequence of the protein (human brain PDE IV (hPDE IV(B)) shows significant homology to a PDE IV subtype expressed in human monocytes (hPDE IV(A)), particularly within the approximately 300-amino acid PDE IV catalytic domain. The degree of protein sequence identity is much greater between hPDE IV(B) and a homolog derived from rat brain (92% over 562 amino acids) than between hPDE IV(B) and hPDE IV(A) (76% over 538 amino acids), suggesting a greater subtype-specific versus species-specific conservation of protein sequence. Analysis of the distribution of hPDE IV(B) mRNA expression revealed a restricted pattern, with an approximately 4-kilobase mRNA detected in brain, heart, lung, and skeletal muscle and not in placenta, liver, kidney, or pancreas. An additional approximately 5-kilobase hPDE IV(B)-related mRNA species was detected in brain tissue. Recombinant hPDE IV(B) displayed all of the expected kinetic characteristics for a PDE IV, including sensitivity to the isozyme-selective inhibitor rolipram (K(i) = 0.085 muM). Scatchard analysis of (R)-[H-3]rolipram binding data suggested the presence of two noninteracting high affinity rolipram-binding sites (K(d) = 0.4 and 6 nM) or a negatively cooperative interaction among multiple binding sites.	SMITHKLINE BEECHAM PHARMACEUT,DEPT GENE EXPRESS SCI,POB 1539,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT PHARMACOL,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline								BAEHR W, 1991, FEBS LETT, V278, P107, DOI 10.1016/0014-5793(91)80095-K; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; CHARBONNEAU H, 1986, P NATL ACAD SCI USA, V83, P9308, DOI 10.1073/pnas.83.24.9308; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; CHARBONNEAU H, 1990, CYCLIC NUCLEOTIDE PH, V2, P267; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; Cleland W W, 1979, Methods Enzymol, V63, P103; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; CONTI M, 1991, ENDOCR REV, V12, P218, DOI 10.1210/edrv-12-3-218; DAVIS RL, 1989, P NATL ACAD SCI USA, V86, P3604, DOI 10.1073/pnas.86.10.3604; HENKELTIGGES J, 1990, MOL PHARMACOL, V37, P7; HICKS JB, 1976, GENETICS, V83, P245; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIVI GP, 1990, MOL CELL BIOL, V10, P2678, DOI 10.1128/MCB.10.6.2678; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCHALE MM, 1991, MOL PHARMACOL, V39, P109; MEACCI E, 1992, P NATL ACAD SCI USA, V89, P3721, DOI 10.1073/pnas.89.9.3721; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NICHOLSON CD, 1991, TRENDS PHARMACOL SCI, V12, P19, DOI 10.1016/0165-6147(91)90484-A; NIKAWA JI, 1987, MOL CELL BIOL, V7, P3629, DOI 10.1128/MCB.7.10.3629; PARI G, 1991, MOL CELL BIOL, V11, P4796, DOI 10.1128/MCB.11.9.4796; PITTLER SJ, 1990, GENOMICS, V6, P272, DOI 10.1016/0888-7543(90)90567-E; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASS P, 1986, P NATL ACAD SCI USA, V83, P9303, DOI 10.1073/pnas.83.24.9303; SCHNEIDER HH, 1986, EUR J PHARMACOL, V127, P105, DOI 10.1016/0014-2999(86)90210-4; SCHULTZ JE, 1986, N-S ARCH PHARMACOL, V333, P23, DOI 10.1007/BF00569655; SONNENBURG WK, 1991, J BIOL CHEM, V266, P17655; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P5325, DOI 10.1073/pnas.86.14.5325; TORPHY TJ, 1990, MOL PHARMACOL, V37, P206; TORPHY TJ, 1991, THORAX, V46, P512, DOI 10.1136/thx.46.7.512; TORPHY TJ, 1992, J BIOL CHEM, V267, P1798; TORPHY TJ, 1993, IN PRESS DRUG NEWS P, V5; WACHTEL H, 1983, NEUROPHARMACOLOGY, V22, P267, DOI 10.1016/0028-3908(83)90239-3; WILSON RB, 1988, MOL CELL BIOL, V8, P505, DOI 10.1128/MCB.8.1.505	38	125	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6470	6476						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8384210				2022-12-25	WOS:A1993KT36800058
J	PALCZEWSKI, K; BUCZYLKO, J; LEBIODA, L; CRABB, JW; POLANS, AS				PALCZEWSKI, K; BUCZYLKO, J; LEBIODA, L; CRABB, JW; POLANS, AS			IDENTIFICATION OF THE N-TERMINAL REGION IN RHODOPSIN KINASE INVOLVED IN ITS INTERACTION WITH RHODOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; RETINALDEHYDE-BINDING PROTEIN; ADRENERGIC-RECEPTOR KINASE; ROD OUTER SEGMENTS; PHOSPHODIESTERASE ACTIVATION; CATALYTIC SUBUNIT; PHOTOEXCITED RHODOPSIN; CGMP PHOSPHODIESTERASE; CRYSTAL-STRUCTURE; DISK MEMBRANES	Upon illumination rhodopsin kinase (RK) phosphorylates the visual pigment, rhodopsin, in a reaction that is thought to terminate in part the biochemical events that follow photon absorption. In this paper, RK was studied to assign functional regions to the primary structure of the enzyme. Peptides derived from the sequence of RK were used to prepare site-specific antipeptide antibodies against: 1) the N-terminal region located between residues 17 and 34, which contains an autophosphorylation site; 2) the Lys/Arg-rich region corresponding to residues 216-237 near the catalytic domain; 3) the region located between residues 483 and 497, which encompasses the major autophosphorylation sites; and 4) the C-terminal region located between residues 539 and 556, close to the isoprenylation site of RK. Antibodies also were raised against purified RK. Application of the antibodies directed against the N-terminal domain blocks RK activity toward Rho*, but has no affect on the phosphorylation of a synthetic peptide substrate. Additionally, a significant portion of the inhibitory effect seen with an antibody directed against whole RK could be reversed by the peptide derived from the N-terminal region. We conclude that the N-terminal region of RK contains a sequence involved in the recognition of photolyzed Rho. Furthermore, the inhibition of RK activity eliminates the effect of ATP during the inactivation of cGMP phosphodiesterase, implying that RK is a necessary component of a cascade of reactions involved in the quenching of phototransduction. Light microscopic immunocytochemistry using these antibodies revealed that RK was localized to the rod and cone outer segments of human and bovine retinas.	UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA; GOOD SAMARITAN HOSP, RS DOW NEUROL SCI INST, PORTLAND, OR 97209 USA; UNIV S CAROLINA, DEPT CHEM, COLUMBIA, SC 29208 USA; W ALTON JONES CELL SCI CTR, PROT CHEM FACIL, LAKE PLACID, NY 12946 USA	University of Washington; University of Washington Seattle; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	PALCZEWSKI, K (corresponding author), UNIV WASHINGTON, DEPT OPHTHALMOL, SEATTLE, WA 98195 USA.				NATIONAL CANCER INSTITUTE [P01CA037589] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY008061, R29EY008061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038639] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37589] Funding Source: Medline; NEI NIH HHS [EY08061] Funding Source: Medline; NIDDK NIH HHS [DK38639] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANT JS, 1992, J BIOL CHEM, V267, P687; ANANT JS, 1992, BIOCHEM BIOPH RES CO, V183, P468, DOI 10.1016/0006-291X(92)90505-F; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCZYLKO J, 1991, P NATL ACAD SCI USA, V88, P2568, DOI 10.1073/pnas.88.6.2568; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; CHARLTON LA, 1992, J BIOL CHEM, V267, P8840; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; CRABB JW, 1988, J BIOL CHEM, V263, P18678; CRABB JW, 1991, J BIOL CHEM, V266, P16674; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FOWLES C, 1988, FEBS LETT, V238, P56, DOI 10.1016/0014-5793(88)80224-2; FUKADA Y, 1990, BIOCHEMISTRY-US, V29, P10102, DOI 10.1021/bi00495a013; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; HAGA K, 1992, J BIOL CHEM, V267, P2222; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; HURLEY JB, 1992, J BIOENERG BIOMEMBR, V24, P219, DOI 10.1007/BF00762680; INGLESE J, 1992, J BIOL CHEM, V267, P1422; KAPLAN MW, 1993, IN PRESS METHODS NEU; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389; KUHN H, 1984, PROG RETIN RES, V3, P1123; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LEBIODA L, 1990, FEBS LETT, V266, P102, DOI 10.1016/0014-5793(90)81517-R; LIEBMAN PA, 1980, NATURE, V287, P734, DOI 10.1038/287734a0; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MILLER JL, 1986, BIOCHEMISTRY-US, V25, P4983, DOI 10.1021/bi00366a002; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P8764, DOI 10.1021/bi00448a013; PALCZEWSKI K, 1988, J BIOL CHEM, V263, P14067; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1992, NEURON, V8, P117, DOI 10.1016/0896-6273(92)90113-R; PALCZEWSKI K, 1988, BIOCHEMISTRY-US, V27, P2306, DOI 10.1021/bi00407a010; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PALCZEWSKI K, 1992, J BIOL CHEM, V267, P18991; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; POLANS AS, 1991, J CELL BIOL, V112, P981, DOI 10.1083/jcb.112.5.981; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SITARAMAYYA A, 1983, J BIOL CHEM, V258, P1205; SOVITZKY A, 1964, ANAL CHEM, V36, P1627; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; WALTER AE, 1986, INVEST OPHTH VIS SCI, V27, P1609; WEST KA, 1992, CURRENT RES PROTEIN, P37; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; ZUCKERMAN R, 1986, FEBS LETT, V207, P35, DOI 10.1016/0014-5793(86)80008-4	54	128	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					6004	6013						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8383684				2022-12-25	WOS:A1993KR82200096
J	ZIEGLER, SF; BIRD, TA; SCHNERINGER, JA; SCHOOLEY, KA; BAUM, PR				ZIEGLER, SF; BIRD, TA; SCHNERINGER, JA; SCHOOLEY, KA; BAUM, PR			MOLECULAR-CLONING AND CHARACTERIZATION OF A NOVEL RECEPTOR PROTEIN TYROSINE KINASE FROM HUMAN PLACENTA	ONCOGENE			English	Article							EGF-LIKE REPEATS; LEUKEMIA-CELLS; GENE-PRODUCT; DOMAINS; ENCODES; FAMILY; NOTCH; IMMUNOGLOBULIN; FIBRONECTIN; HOMOLOGY	Using a polymerase chain reaction-based approach we have isolated and characterized a cDNA (HPK-6) from human placental RNA encoding a novel receptor protein tvrosine kinase. This receptor tyrosine kinase has a unique extracellular domain, with an immunoglobulin-like domain at the amino terminus followed by three EGF-like cysteine repeats and three fibronectin type III repeats, giving the HPK-6 gene extracellular domain a novel combination of structural motifs. A comparison of the HPK-6 sequence with other receptor tyrosine kinases shows that the HPK-6 gene is the human homolog of the murine tek gene and very closely related to the recently described receptor tyrosine kinase tie. The HPK-6 gene is expressed predominantly in placenta and lung, with a lower level in umbilical vein endothelial cells, brain and kidney. The HPK-6 cDNA, when transfected into COS-7 cells, encodes a 140-kDa protein with in vitro kinase activity.			ZIEGLER, SF (corresponding author), IMMUNEX CORP,51 UNIV ST,SEATTLE,WA 98101, USA.							APRELIKOVA O, 1992, CANCER RES, V52, P746; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; CHAN J, 1991, ONCOGENE, V6, P1057; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIS C G, 1990, New Biologist, V2, P410; DUMONT DJ, 1992, ONCOGENE, V7, P1471; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; KITAGAWA T, 1976, J BIOCHEM-TOKYO, V79, P233, DOI 10.1093/oxfordjournals.jbchem.a131053; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; RESCIGNO J, 1991, ONCOGENE, V6, P1909; SASAKI M, 1988, J BIOL CHEM, V263, P1653; SCHROEDER HW, 1987, SCIENCE, V238, P791, DOI 10.1126/science.3118465; SIEGELMAN MH, 1990, CELL, V61, P611, DOI 10.1016/0092-8674(90)90473-R; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TERMAN BI, 1991, ONCOGENE, V6, P1677; ULLRICH A, 1990, CELL, V61, P243; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	35	95	108	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					663	670						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8382358				2022-12-25	WOS:A1993KN00800017
J	LOIS, AF; WEINSTEIN, M; DITTA, GS; HELINSKI, DR				LOIS, AF; WEINSTEIN, M; DITTA, GS; HELINSKI, DR			AUTOPHOSPHORYLATION AND PHOSPHATASE-ACTIVITIES OF THE OXYGEN-SENSING PROTEIN FIXL OF RHIZOBIUM-MELILOTI ARE COORDINATELY REGULATED BY OXYGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TRANSCRIPTIONAL ACTIVATOR; AGROBACTERIUM-TUMEFACIENS; BACTERIAL CHEMOTAXIS; VIRG PROTEIN; GENES; PHOSPHORYLATION; EXPRESSION; SENSOR; KINASE	The FixL and FixJ proteins of Rhizobium meliloti control the expression of other nif and fix genes in response to oxygen levels. FixL is a hemoprotein kinase that senses oxygen availability and responds to the absence of oxygen by activation of its autophosphorylating activity followed by transfer of the phosphate to FixJ. FixJ in turn activates the nifA and fixK promoters. In vitro studies reported here with a soluble truncated version of FixL (FixL*) indicate that, while low oxygen tension specifically increases the autophosphorylating activity of FixL*, the ability of phospho-FixL* to act as a phosphate donor to FixJ is not affected by the presence or absence of oxygen. FixL* is also shown to possess a phosphatase activity that is repressed under anaerobic conditions only when the protein is in the phosphorylated form. A fixL mutant that induces a higher level of nifA promoter activity in the presence of fixJ in vivo displayed both an increased autophosphorylating activity and a decreased phosphatase activity in vitro. These data provide evidence for a role for both autophosphorylation and phosphatase activities of FixL in the mechanism by which oxygen tension within the alfalfa nodule induces expression of bacterial nitrogen fixation genes during symbiosis.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					PHS HHS [5 RO1 6M 44400/02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; APPLEBY CA, 1984, ANNU REV PLANT PHYS, V35, P443, DOI 10.1146/annurev.pp.35.060184.002303; BALDWIN TO, 1984, BIOCHEMISTRY-US, V23, P3663, DOI 10.1021/bi00311a014; BATUT J, 1989, EMBO J, V8, P1279, DOI 10.1002/j.1460-2075.1989.tb03502.x; CARTER P, 1985, NUCLEIC ACIDS RES, V13, P4431, DOI 10.1093/nar/13.12.4431; CORBIN D, 1982, J BACTERIOL, V149, P221, DOI 10.1128/JB.149.1.221-228.1982; DAVID M, 1988, CELL, V54, P671, DOI 10.1016/S0092-8674(88)80012-6; DEPHILIP P, 1990, J BACTERIOL, V172, P4255, DOI 10.1128/jb.172.8.4255-4262.1990; DITTA G, 1987, J BACTERIOL, V169, P3217, DOI 10.1128/jb.169.7.3217-3223.1987; EARL CD, 1987, J BACTERIOL, V169, P1127, DOI 10.1128/jb.169.3.1127-1136.1987; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; GUARENTE L, 1980, CELL, V20, P543, DOI 10.1016/0092-8674(80)90640-6; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; IGO MM, 1989, GENE DEV, V3, P598, DOI 10.1101/gad.3.5.598; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; JIN SG, 1990, J BACTERIOL, V172, P4945, DOI 10.1128/jb.172.9.4945-4950.1990; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOIS AF, 1992, IN PRESS J BACTERIOL; MCMALLY DF, 1991, P NATL ACAD SCI USA, V88, P6269; MONSON EK, 1992, P NATL ACAD SCI USA, V89, P4280, DOI 10.1073/pnas.89.10.4280; Ninfa A J, 1991, Genet Eng (N Y), V13, P39; NINFA AJ, 1987, CELL, V50, P1039, DOI 10.1016/0092-8674(87)90170-X; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; NINFA EG, 1991, J BIOL CHEM, V266, P9764; ROITSCH T, 1990, J BACTERIOL, V172, P6054, DOI 10.1128/jb.172.10.6054-6060.1990; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; VANDEWIEL C, 1990, EMBO J, V9, P1; Vincent JM, 1970, INT BIOL PROGRAM HDB, V15; VIRTS EL, 1988, P NATL ACAD SCI USA, V85, P3062, DOI 10.1073/pnas.85.9.3062; WEINSTEIN M, 1992, MOL MICROBIOL, V6, P2041, DOI 10.1111/j.1365-2958.1992.tb01377.x; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919; [No title captured]	34	107	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4370	4375						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8382700				2022-12-25	WOS:A1993KN53300081
J	YIM, MB; CHOCK, PB; STADTMAN, ER				YIM, MB; CHOCK, PB; STADTMAN, ER			ENZYME FUNCTION OF COPPER, ZINC SUPEROXIDE-DISMUTASE AS A FREE-RADICAL GENERATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-RESONANCE; HYDROGEN-PEROXIDE; HYDROXYL RADICALS; GLUTATHIONE-PEROXIDASE; PULSE-RADIOLYSIS; CATION RADICALS; INACTIVATION; KINETICS; PARAQUAT; TRAPS	The peroxidative activity-of Cu,Zn-containing superoxide dismutase (Cu,Zn-SOD) was studied by using a chromogen, 2,2'-azinobis-(3-ethylbenzthiazoline-6-sulfonate) (ABTS) which reacts with .OH radicals to form ABTS+., and the spin traps, N-tert-butyl-alpha-phenylnitrone (PBN) and 5,5-dimethyl-1-pyrroline N-oxide (DMPO). The formation of ABTS+. in this study required both active Cu,Zn-SOD and H2O2 and followed first order kinetics with respect to SOD and H2O2. However, it showed a binding isotherm with ABTS that yielded a dissociation constant of ABTS-enzyme as K(d) = 7.1 +/- 0.5 muM. The K(d) values for DMPO and PBN were obtained as 0.63 and 11 mM, respectively, by competition reactions. A radical scavenger, formate anion, inhibits the formation of ABTS+., whereas ethanol does not. The results together indicate that DMPO and anionic scavengers have easy access inside the positively charged active channel of Cu,Zn-SOD and are thus in a position to intercept the newly formed .OH radicals. PBN and ethanol, however, stay outside of the channel and are not able to compete with ABTS for .OH radicals. We trapped free radicals, which were produced in the presence of free radical scavengers, with PBN. The formation curve of PBN-hydroxyethyl radical adduct observed in the presence of ethanol indicated that the enzyme became inactivated in a relatively short period. In contrast, in the presence of anionic scavenger formate, formyl radicals were produced catalytically, and the enzyme activity was protected by the formate against H2O2 inactivation. Thus Cu,Zn-SOD behaves as an enzyme that catalyzes the formation of free radicals using anionic scavengers and H2O2 as substrates.			YIM, MB (corresponding author), NHLBI, BIOCHEM LAB, BLDG 3, RM 202, BETHESDA, MD 20892 USA.							[Anonymous], 1971, METHODS ENZYMOLOGY; BLECH DM, 1983, ARCH BIOCHEM BIOPHYS, V224, P579, DOI 10.1016/0003-9861(83)90245-X; BORDERS CL, 1985, ARCH BIOCHEM BIOPHYS, V241, P472, DOI 10.1016/0003-9861(85)90572-7; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; BRAY RC, 1974, BIOCHEM J, V139, P43, DOI 10.1042/bj1390043; BRITIGAN BE, 1990, J BIOL CHEM, V265, P17533; BUXTON GV, 1988, J PHYS CHEM REF DATA, V17, P513, DOI 10.1063/1.555805; CHILDS RE, 1975, BIOCHEM J, V145, P93, DOI 10.1042/bj1450093; CUDD A, 1982, J BIOL CHEM, V257, P1443; DAQUINO M, 1989, BIOCHEM BIOPH RES CO, V161, P1199, DOI 10.1016/0006-291X(89)91369-7; DEFREITAS DM, 1984, BIOCHEMISTRY-US, V23, P2079, DOI 10.1021/bi00304a031; EMMONS WD, 1957, J AM CHEM SOC, V79, P5739, DOI 10.1021/ja01578a043; FEE JA, 1986, J BIOL CHEM, V261, P3000; FINKELSTEIN E, 1980, J AM CHEM SOC, V102, P4994, DOI 10.1021/ja00535a029; FINKELSTEIN E, 1980, ARCH BIOCHEM BIOPHYS, V200, P1, DOI 10.1016/0003-9861(80)90323-9; GALLATI H, 1979, J CLIN CHEM CLIN BIO, V17, P1; GETZOFF ED, 1983, NATURE, V306, P287, DOI 10.1038/306287a0; GREENSTOCK CL, 1982, CAN J CHEM, V60, P1560, DOI 10.1139/v82-503; HARBOUR JR, 1974, CAN J CHEM, V52, P3549, DOI 10.1139/v74-527; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; HUNIG S, 1964, LIEBIGS ANN CHEM, V676, P32; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; JANZEN EG, 1978, CAN J CHEM, V56, P2237, DOI 10.1139/v78-368; JANZEN EG, 1971, ACCOUNTS CHEM RES, V4, P31, DOI 10.1021/ar50037a005; KELNER MJ, 1990, J BIOL CHEM, V265, P10872; KLUG D, 1972, J BIOL CHEM, V247, P4839; KOPPENOL WH, 1981, OXYGEN OXYRADICALS C, P617; KOTAKE Y, 1991, J AM CHEM SOC, V113, P9503, DOI 10.1021/ja00025a013; KRALL J, 1988, J BIOL CHEM, V263, P1910; KRALL J, 1991, ARCH BIOCHEM BIOPHYS, V286, P311, DOI 10.1016/0003-9861(91)90045-K; LOPEZ J, 1984, B CHEM SOC JPN, V57, P673, DOI 10.1246/bcsj.57.673; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MOREHOUSE KM, 1988, J BIOL CHEM, V263, P1204; MOTTLEY C, 1986, BIOCHEM BIOPH RES CO, V141, P622, DOI 10.1016/S0006-291X(86)80218-2; NETA P, 1980, J PHYS CHEM-US, V84, P532, DOI 10.1021/j100442a017; NETA P, 1988, CHEM KINETICS SMALL, P187; OKADA K, 1983, J HETEROCYCLIC CHEM, V20, P723, DOI 10.1002/jhet.5570200343; RIGO A, 1977, BIOCHEM BIOPH RES CO, V79, P776, DOI 10.1016/0006-291X(77)91179-2; RUSH JD, 1988, J AM CHEM SOC, V110, P4957, DOI 10.1021/ja00223a013; SAPRIN AN, 1977, ARCH BIOCHEM BIOPHYS, V180, P480, DOI 10.1016/0003-9861(77)90063-7; SINET PM, 1981, ARCH BIOCHEM BIOPHYS, V212, P411, DOI 10.1016/0003-9861(81)90382-9; SRIDHAR R, 1984, OXYGEN RADICALS CHEM, P101; SYMONYAN MA, 1972, FEBS LETT, V28, P22, DOI 10.1016/0014-5793(72)80667-7; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; THOMAS JK, 1965, T FARADAY SOC, V61, P702, DOI 10.1039/tf9656100702; TROUSSON P, 1985, J PHYS CHEM-US, V89, P1954, DOI 10.1021/j100256a028; TURRENS JF, 1991, FREE RADICAL RES COM, V12-3, P681, DOI 10.3109/10715769109145847; VANCAMP HL, 1982, BIOCHIM BIOPHYS ACTA, V704, P75, DOI 10.1016/0167-4838(82)90134-0; WITTENKELLER L, 1991, J AM CHEM SOC, V113, P7872, DOI 10.1021/ja00021a008; WOLFENDEN BS, 1982, J CHEM SOC PERK T 2, P805, DOI 10.1039/p29820000805; YIM MB, 1990, P NATL ACAD SCI USA, V87, P5006, DOI 10.1073/pnas.87.13.5006; YIM MB, 1990, P NATL ACAD SCI USA, V87, P394, DOI 10.1073/pnas.87.1.394; ZIPPLIES MF, 1986, J AM CHEM SOC, V108, P4433, DOI 10.1021/ja00275a033	54	225	231	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4099	4105						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8382691				2022-12-25	WOS:A1993KN53300047
J	MULLER, B; TSANEVA, IR; WEST, SC				MULLER, B; TSANEVA, IR; WEST, SC			BRANCH MIGRATION OF HOLLIDAY JUNCTIONS PROMOTED BY THE ESCHERICHIA-COLI RUVA AND RUVB PROTEINS .2. INTERACTION OF RUVB WITH DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECA PROTEIN; REPAIR	Using recombination intermediates made by RecA protein, we have shown that the Escherichia coli RuvB protein can mediate the branch migration of Holliday junctions in vitro. The reaction is dependent on the presence of greater-than-or-equal-to 10 mm Mg2+ and stoichiometric amounts of RuvB. The presence of E. coli RuvA protein reduces the requirement for Mg2+ and also the stoichiometric requirement for RuvB (Muller, B., Tsaneva, I. R., and West, S. C. (1993) J. Biol. Chem. 268, 17179-17184). To determine the roles of the two proteins during branch migration, we have investigated the interaction of RuvB with DNA in the absence or presence of RuvA, by (i) gel retardation of protein-DNA complexes, (ii) stimulation of the RuvB ATPase, and (iii) protection of DNA from DNase I. The interaction of RuvB with duplex DNA was Mg2+-dependent and correlated with the Mg2+ requirement of the RuvB-mediated branch migration reaction. RuvB also interacted with ssDNA, but the affinity was significantly lower than for duplex DNA. In contrast to RuvB, the interaction of RuvA with duplex DNA occurred in the absence of Mg2+ and was inhibited by Mg2+ in a concentration-dependent manner. At 5 mM Mg2+ RuvA protein facilitated the interaction of RuvB with DNA, leading to the formation of a complex containing RuvA, RuvB, and duplex DNA.			MULLER, B (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.			Muller, Berndt/0000-0003-1279-5421; West, Stephen/0000-0001-8848-9418				IWASAKI H, 1989, J BACTERIOL, V171, P5276, DOI 10.1128/jb.171.10.5276-5280.1989; MULLER B, 1993, J BIOL CHEM, V268, P17179; MULLER B, 1992, EMBO J, V11, P2685, DOI 10.1002/j.1460-2075.1992.tb05334.x; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; SAMBROOK E, 1989, MOL CLONING LABORATO; SHIBA T, 1993, MOL GEN GENET, V237, P395, DOI 10.1007/BF00279443; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; WEST SC, 1982, MOL GEN GENET, V187, P209, DOI 10.1007/BF00331119; WEST SC, 1983, CELL, V32, P817, DOI 10.1016/0092-8674(83)90068-5	11	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17185	17189						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8394334				2022-12-25	WOS:A1993LQ98800048
J	NOSAKA, K; KANEKO, Y; NISHIMURA, H; IWASHIMA, A				NOSAKA, K; KANEKO, Y; NISHIMURA, H; IWASHIMA, A			ISOLATION AND CHARACTERIZATION OF A THIAMIN PYROPHOSPHOKINASE GENE, THI80, FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPRESSIBLE ACID-PHOSPHATASE; BINDING PROTEINS; YEAST; DNA; TRANSFORMATION; SEQUENCE; RNA; TRANSCRIPTION; METABOLISM; VECTORS	The thi80 mutant of Saccharomyces cerevisiae (Nishimura, H., Kawasaki, Y., Nosaka, K., Kaneko, Y., and Iwashima, A. (1991) J. Bacteriol. 173, 2716-2719) shows markedly reduced activity of thiamin pyrophosphokinase (TPK; EC 2.7.6.2). We have isolated a DNA fragment carrying the THI80 gene from a yeast genomic library by its ability to complement constitutive synthesis of the thiamin-repressible acid phosphatase, encoded by the PHO3 gene, of thi80 mutant cells. On the other hand, the thi80 locus was found to be located 3.3 centimorgans proximal to the smp3 locus on the right arm of chromosome XV by genetic mapping analysis, and one more fragment bearing the THI80 gene trailing SMP3 gene was obtained by the plasmid eviction method. The nucleotide sequence of the overlapped region between the two isolated DNAs contained an open reading frame of 957 base pairs, encoding a 319-amino acid polypeptide with a calculated molecular weight of 36,616. When the intact THI80 open reading frame was expressed as a fusion protein carrying three vector-encoded amino acids at its N terminus in Escherichia coli lacking TPK, marked TPK activity was detected in the procaryotic cells, proving that the THI80 gene of S. cerevisiae encodes a structural gene of TPK. A gene disruption experiment demonstrated that the THI80 gene was essential for growth, and therefore, revealed that TPK is the only enzyme capable of synthesizing thiamin pyrophosphate in yeast. Studies of Northern blot analysis and the enzyme assay demonstrated that the THI80 gene expression is regulated mainly at the mRNA level by the intracellular thiamin pyrophosphate and requires the positive regulatory factors encoded by THI2 and THI3 genes. However, unlike thiamin-repressible acid phosphatase and the enzymes involved in thiamin synthesis of S. cerevisiae, TPK was found to be expressed constitutively at a low level and incompletely repressed by exogenous thiamin.	INST FERMENTAT, YODOGAWA KU, OSAKA 532, JAPAN		NOSAKA, K (corresponding author), KYOTO PREFECTURAL UNIV MED, DEPT BIOCHEM, KAMIGYO KU, KYOTO 602, JAPAN.							AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; EGI Y, 1992, BIOCHIM BIOPHYS ACTA, V1160, P171, DOI 10.1016/0167-4838(92)90004-W; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; HAMADA M, 1969, Seikagaku, V41, P837; HANSCHE PE, 1978, GENETICS, V88, P673; HOFFMAN CS, 1987, GENE, V57, P268; IRIE K, 1991, MOL GEN GENET, V225, P257, DOI 10.1007/BF00269857; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; IWASHIMA A, 1979, BIOCHIM BIOPHYS ACTA, V557, P460, DOI 10.1016/0005-2736(79)90343-2; KAJIRO Y, 1959, J BIOCHEM-TOKYO, V46, P1523; KAWASAKI Y, 1990, J BACTERIOL, V172, P6145, DOI 10.1128/jb.172.10.6145-6147.1990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGFORD CJ, 1983, CELL, V33, P519, DOI 10.1016/0092-8674(83)90433-6; LEDER IG, 1975, METABOLIC PATHWAYS, V7, P57; LEMIRE JM, 1985, MOL CELL BIOL, V5, P2131, DOI 10.1128/MCB.5.8.2131; MORTIMER RK, 1989, YEAST, V5, P321, DOI 10.1002/yea.320050503; NISHIMURA H, 1992, J BACTERIOL, V174, P4701, DOI 10.1128/JB.174.14.4701-4706.1992; NISHIMURA H, 1991, J BACTERIOL, V173, P2716, DOI 10.1128/jb.173.8.2716-2719.1991; NISHINO H, 1971, BIOCHEM BIOPH RES CO, V45, P363, DOI 10.1016/0006-291X(71)90827-8; NOSAKA K, 1990, BIOCHIM BIOPHYS ACTA, V1037, P147, DOI 10.1016/0167-4838(90)90160-H; NOSAKA K, 1992, FEBS LETT, V305, P244, DOI 10.1016/0014-5793(92)80678-A; NOSAKA K, 1989, FEMS MICROBIOL LETT, V60, P55, DOI 10.1016/0378-1097(89)90077-3; PERKINS DD, 1949, GENETICS, V34, P607; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J, 1989, MOL CLONING LABORATO; SANEMORI H, 1980, J BIOCHEM, V88, P223; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER R, 1986, NUCLEIC ACIDS RES, V14, P1303, DOI 10.1093/nar/14.3.1303; SCHWEINGRUBER ME, 1986, J BIOL CHEM, V261, P5877; SIKORSKI RS, 1989, GENETICS, V122, P19; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOHE A, 1975, MOL GEN GENET, V141, P81, DOI 10.1007/BF00332380; TOKUDA Y, 1964, VITAMINS KYOTO, V29, P40; WAKABAYASHI H, 1978, J NUTR SCI VITAMINOL, V52, P223; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WICKERHAM LJ, 1951, TECH B US DEP AGRIC, V1029, P1; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2; [No title captured]	44	70	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17440	17447						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8394343				2022-12-25	WOS:A1993LQ98800082
J	HILLY, M; PIETRIROUXEL, F; COQUIL, JF; GUY, M; MAUGER, JP				HILLY, M; PIETRIROUXEL, F; COQUIL, JF; GUY, M; MAUGER, JP			THIOL REAGENTS INCREASE THE AFFINITY OF THE INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECONSTITUTED LIPID VESICLES; CALCIUM RELEASE; TRISPHOSPHATE RECEPTOR; SARCOPLASMIC-RETICULUM; RYANODINE RECEPTOR; RAT HEPATOCYTES; CA2+ RELEASE; CA-2+; OSCILLATIONS; INHIBITION	Thiol reagents have been shown to increase cytosolic Ca2+ in several cell types. In non-muscle cells, these agents induce Ca2+ spikes by increasing the sensitivity of the intracellular Ca2+ stores to D-myo-inositol-1,4,5-trisphosphate (InsP3). We have investigated the effects of thimerosal and oxidized glutathione on the binding properties of the InsP3 receptor in permeabilized hepatocytes and liver and cerebellar membranes. Thimerosal, at the maximal concentration of 100 muM, decreased the K(D) for the InsP3 binding to permeabilized hepatocytes and cerebellar membranes from 16 to 3 nM and from 25 to 8 nM, respectively, without affecting the maximal binding capacities. On liver membranes, both thimerosal and high Ca2+ concentrations increased the affinity for InsP3 binding. The Ca2+ and the thimerosal effects were differentiated by kinetic experiments. In low Ca2+ media, two kinetic components were identified and thimerosal decreased the rate of dissociation from both these components without affecting the rate of association. In the high Ca2+ medium, a single kinetic component was found with a very slow rate of dissociation. These data suggest that the InsP3 receptor exists in different states. The high-affinity inactive state induced by high Ca2+ concentrations displays slow rates of association and dissociation. The binding properties of the receptor in its active state can be regulated by thiol reagents which increase the affinity by decreasing the dissociation rate constants. At a resting concentration of 100-200 nM, Ca2+ has two effects: it increases the affinity of the active state of the receptor as thiol reagents do and transforms part of the receptors into the inactive high-affinity state.			HILLY, M (corresponding author), UNIV PARIS 11, INSERM, U274, BAT 443, F-91405 ORSAY, FRANCE.			Pietri-Rouxel, France/0000-0002-6258-7594				ABRAMSON JJ, 1989, J BIOENERG BIOMEMBR, V21, P283, DOI 10.1007/BF00812073; ADUNYAH SE, 1986, J BIOL CHEM, V261, P3071; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOOBIS AR, 1989, TRENDS PHARMACOL SCI, V10, P275, DOI 10.1016/0165-6147(89)90027-8; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; CARROLL J, 1992, J BIOL CHEM, V267, P11196; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; COMBETTES L, 1993, CELL CALCIUM, V14, P279, DOI 10.1016/0143-4160(93)90049-C; DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GUILLEMETTE G, 1988, MOL ENDOCRINOL, V2, P1249, DOI 10.1210/mend-2-12-1249; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JONES DP, 1983, J BIOL CHEM, V258, P6390; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MARSHALL ICB, 1993, J BIOL CHEM, V268, P13214; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MIYAZAKI S, 1992, FEBS LETT, V309, P180, DOI 10.1016/0014-5793(92)81090-9; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; OGDEN DC, 1990, J PHYSIOL-LONDON, V422, P585, DOI 10.1113/jphysiol.1990.sp018002; PIETRI F, 1990, J BIOL CHEM, V265, P17478; PIETRIROUXEL F, 1992, J BIOL CHEM, V267, P20017; PRPIC V, 1984, J BIOL CHEM, V259, P1382; PRUIJN FB, 1991, BIOCHEM PHARMACOL, V42, P1977, DOI 10.1016/0006-2952(91)90598-Y; RASHED HM, 1987, J BIOL CHEM, V262, P15953; RENARD DC, 1992, BIOCHEM J, V284, P507, DOI 10.1042/bj2840507; ROONEY TA, 1991, J BIOL CHEM, V266, P12272; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; SAYERS LG, 1993, BIOCHEM J, V289, P883, DOI 10.1042/bj2890883; STAUDERMAN KA, 1988, BIOCHEM J, V255, P677; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; SWILLENS S, 1992, TRENDS PHARMACOL SCI, V13, P430, DOI 10.1016/0165-6147(92)90139-W; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; VARNEY MA, 1990, BIOCHEM J, V269, P211, DOI 10.1042/bj2690211	43	87	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16488	16494						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8393866				2022-12-25	WOS:A1993LQ33600060
J	NORMAN, AW; OKAMURA, WH; FARACHCARSON, MC; ALLEWAERT, K; BRANISTEANU, D; NEMERE, I; MURALIDHARAN, KR; BOUILLON, R				NORMAN, AW; OKAMURA, WH; FARACHCARSON, MC; ALLEWAERT, K; BRANISTEANU, D; NEMERE, I; MURALIDHARAN, KR; BOUILLON, R			STRUCTURE-FUNCTION STUDIES OF 1,25-DIHYDROXYVITAMIN-D3 AND THE VITAMIN-D ENDOCRINE SYSTEM - 1,25-DIHYDROXY-PENTADEUTERIO-PREVITAMIN-D3 (AS A 6-S-CIS ANALOG) STIMULATES NONGENOMIC BUT NOT GENOMIC BIOLOGICAL RESPONSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEO-SARCOMA CELLS; D-BINDING PROTEIN; CALCIUM-TRANSPORT; PERFUSED DUODENA; NORMAL CHICKS; D METABOLITES; 1-ALPHA,25-DIHYDROXYVITAMIN-D3; RECEPTOR; CA-2+; ENHANCEMENT	The hormone 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) generates biological responses via both genomic and nongenomic mechanisms. This article addresses activity differences between the 6-s-trans (extended) and the 6-s-cis (steroid-like) conformation of 1,25-(OH)2D3 to initiate these responses. Because of facile interconversion of the 6-s-trans and 6-s-cis conformers of 1,25-(OH)2D3, kinetically competent amounts of both conformers exist to interact with any potential receptors for 1,25-(OH)2D3. We have chemically synthesized 1,25-(OH)2-9,14,19,19,19-pentadeuterio-pre-D3 (1,25-(OH)2-d5-pre-D3), an analog of the 6-s-cis conformation of 1,25-(OH)2D3. We found that 1,25-(OH)2-d5-pre-D3 and 1,25-(OH)2D3 were equivalently active in two nongenomic systems (transcaltachia as measured in the perfused chick intestine and Ca-45(2+ uptake through voltage-gated Ca2+ channels in ROS 17/2.8 cells). 1,25-(OH)2-d5-pre-D3 was significantly less active both in binding in vitro to the plasma vitamin D-binding protein (7%) and to the chick (10%) and pig (4%) intestinal nuclear 1,25-(OH)2D3 receptors generating genomic biological responses in vivo (induction of plasma levels of osteocalcin, < 5%) or in cultured cells (inhibition of HL-60 cell differentiation, < 5%; inhibition of MG-63 proliferation, < 2%; and induction of osteocalcin, < 2%). These results suggest that the genomic and nongenomic responses are mediated by separate receptors. Further, the 6-s-cis form (steroid-like conformation) of the natural hormone, 1,25-(OH)2D3, may be selectively responsible for its nongenomic function(s).	UNIV CALIF RIVERSIDE,DIV BIOMED SCI,RIVERSIDE,CA 92521; UNIV CALIF RIVERSIDE,DEPT CHEM,RIVERSIDE,CA 92521; UNIV TEXAS,DENT BRANCH,DEPT BIOL CHEM,HOUSTON,TX 77225; CATHOLIC UNIV LEUVEN,GASTHUISBERG,EXPTL GENEESKUNDE & ENDOCRINOL LAB,B-3000 LOUVAIN,BELGIUM	University of California System; University of California Riverside; University of California System; University of California Riverside; University of Texas System; KU Leuven	NORMAN, AW (corresponding author), UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92521, USA.		Branisteanu, Dumitru D/C-2907-2011; Nemere, Ilka/A-7077-2008	Farach-Carson, Mary/0000-0002-4526-3088	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009012, R37DK009012, R01DK016595] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-10,318-01] Funding Source: Medline; NIDDK NIH HHS [DK-09012-28, DK-16,595] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARAN DT, 1989, FEBS LETT, V259, P205, DOI 10.1016/0014-5793(89)81529-7; BOUILLON R, 1980, J STEROID BIOCHEM, V13, P1029, DOI 10.1016/0022-4731(80)90133-8; BOUILLON R, 1992, J BIOL CHEM, V267, P3044; BOURDEAU A, 1990, ENDOCRINOLOGY, V127, P2738, DOI 10.1210/endo-127-6-2738; CAFFREY JM, 1989, J BIOL CHEM, V264, P20265; CIVITELLI R, 1990, ENDOCRINOLOGY, V127, P2253, DOI 10.1210/endo-127-5-2253; CURTIN ML, 1991, J AM CHEM SOC, V113, P6958, DOI 10.1021/ja00018a038; DEBOLAND AR, 1990, BIOCHEM BIOPH RES CO, V166, P217, DOI 10.1016/0006-291X(90)91933-J; FARACHCARSON MC, 1991, ENDOCRINOLOGY, V129, P1876, DOI 10.1210/endo-129-4-1876; HAUSSLER MR, 1969, P NATL ACAD SCI USA, V62, P155, DOI 10.1073/pnas.62.1.155; KOEFFLER HP, 1990, MOL CELL ENDOCRINOL, V70, P1, DOI 10.1016/0303-7207(90)90053-B; LIEBERHERR M, 1989, J BIOL CHEM, V264, P20403; LOWE K E, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P65; MAJESKA RJ, 1982, J BIOL CHEM, V257, P3362; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; NEMERE I, 1984, ENDOCRINOLOGY, V115, P1476, DOI 10.1210/endo-115-4-1476; NEMERE I, 1992, MOL BIOL CELL, V3, P297; NORMAN AW, 1992, J CELL BIOCHEM, V49, P1, DOI 10.1002/jcb.240490102; OKAMURA WH, 1974, P NATL ACAD SCI USA, V71, P4194, DOI 10.1073/pnas.71.10.4194; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; REICHEL H, 1989, NEW ENGL J MED, V320, P980, DOI 10.1056/NEJM198904133201506; SIEBERT PD, 1979, BIOCHEM BIOPH RES CO, V91, P827, DOI 10.1016/0006-291X(79)91954-5; TSUTSUMI M, 1985, AM J PHYSIOL, V249, pF117, DOI 10.1152/ajprenal.1985.249.1.F117; VANBAELEN H, 1986, BINDING PROTEINS STE, P69; VANHAM G, 1988, J STEROID BIOCHEM, V29, P381, DOI 10.1016/0022-4731(88)90246-4; Wecksler W R, 1980, Methods Enzymol, V67, P494; WING RM, 1974, SCIENCE, V196, P939; YOSHIMOTO Y, 1986, ENDOCRINOLOGY, V118, P2300, DOI 10.1210/endo-118-6-2300; YOSHIMOTO Y, 1986, J STEROID BIOCHEM, V25, P905, DOI 10.1016/0022-4731(86)90322-5; ZHOU JY, 1989, BLOOD, V74, P82; ZHOU LX, 1992, J BONE MINER RES, V7, P457	31	91	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13811	13819						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8390978				2022-12-25	WOS:A1993LJ82500010
J	ELLISDAVIES, GCR; KAPLAN, JH				ELLISDAVIES, GCR; KAPLAN, JH			MODIFICATION OF LYSINE 501 IN NA,K-ATPASE REVEALS COUPLING BETWEEN CATION OCCUPANCY AND CHANGES IN THE ATP BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; RENAL NA,K-ATPASE; ALPHA-SUBUNIT; FLUORESCEIN ISOTHIOCYANATE; ADENOSINE-TRIPHOSPHATASE; SARCOPLASMIC-RETICULUM; LABELED PEPTIDE; CATALYTIC SITE; CDNA SEQUENCE; ACTIVE-SITE	Treatment of the canine renal Na,K-ATPase with N-(2-nitro-4-isothiocyanophenyl)-imidazole (NIPI) results in irreversible loss of enzymatic activity. The reactivity of the protein toward the probe is about 10-fold greater in the E1 . Na or sodium-bound form than when it is in the E2 . K or potassium-bound form. Fully inactivated enzyme does not bind ATP but binds sodium and potassium and undergoes the major enzyme conformational transitions (Ellis-Davies, G. C. R., and Kaplan, J. H. (1990) J. Biol. Chem. 265, 20570-20576). Labeling of the sodium pump protein with [H-3] NIPI in either the E1 . Na or E2 . K conformations results in the covalent incorporation of one molecule of probe per alpha-subunit of ATPase. Trypsin treatment of purified alpha-subunit, and separation of the digest using reverse-phase high performance liquid chromatography, yields five major radioactive fragments in each case. Amino acid sequencing indicates that only one residue, lysine 501, is labeled by NIPI. This suggests that the integrity of the domain containing Lys501 is essential for both high and low affinity binding of ATP by the Na,K-ATPase. Furthermore, the spatial organization of the protein close to lysine 501 is changed in the E1 . Na and E2 . K form of the enzyme. This change is reflected in the greater reactivity of lysine 501 in the E1 . Na conformation and indicates that the binding of either sodium or potassium ions to their sites on the sodium pump has differential effects on the nucleotide binding domain containing lysine 501.	UNIV PENN, DEPT PHYSIOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania				Kaplan, Jack/0000-0002-7048-6574	NIGMS NIH HHS [GM39500] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039500] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGUELLO JM, 1990, BIOCHEMISTRY-US, V29, P5775, DOI 10.1021/bi00476a019; BAXTERLOWE LA, 1989, FEBS LETT, V257, P181, DOI 10.1016/0014-5793(89)81816-2; BROTHERUS JR, 1981, BIOCHEM BIOPH RES CO, V100, P146, DOI 10.1016/S0006-291X(81)80075-7; CANTLEY LC, 1978, BIOCHEMISTRY-US, V17, P418, DOI 10.1021/bi00596a006; DEPONT JJHHM, 1977, BIOCHIM BIOPHYS ACTA, V482, P213, DOI 10.1016/0005-2744(77)90367-9; ELLISDAVIES GCR, 1990, J BIOL CHEM, V265, P20570; ELLISDAVIES GCR, 1992, BIOPHYS J, V61, P134; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GREEN NM, 1989, BIOCHEM SOC T, V17, P972, DOI 10.1042/bst0170972; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; KAPLAN JH, 1985, ANNU REV PHYSIOL, V47, P535, DOI 10.1146/annurev.ph.47.030185.002535; KAPLAN JH, 1989, RED BLOOD CELL MEMBR, P455; KAPLAN JH, 1990, SODIUM PUMP STRUCTUR, P117; KAWAKAMI K, 1986, J BIOCHEM-TOKYO, V100, P389, DOI 10.1093/oxfordjournals.jbchem.a121726; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; KIRLEY TL, 1984, BIOCHEM BIOPH RES CO, V125, P767, DOI 10.1016/0006-291X(84)90605-3; LACAPERE JJ, 1991, BIOPHYS J, V59, P561; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBOVITZ RM, 1989, EMBO J, V8, P193, DOI 10.1002/j.1460-2075.1989.tb03364.x; LIANG SM, 1976, BIOCHIM BIOPHYS ACTA, V452, P552, DOI 10.1016/0005-2744(76)90207-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; MERCER RW, 1986, MOL CELL BIOL, V6, P3884, DOI 10.1128/MCB.6.11.3884; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; OHTA T, 1986, P NATL ACAD SCI USA, V83, P2071, DOI 10.1073/pnas.83.7.2071; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P111, DOI 10.1016/0014-5793(87)81253-X; PEDEMONTE CH, 1992, FEBS LETT, V314, P97, DOI 10.1016/0014-5793(92)81470-7; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; PEDEMONTE CH, 1988, BIOCHEMISTRY-US, V27, P7966, DOI 10.1021/bi00420a056; SCHOOT BM, 1978, BIOCHIM BIOPHYS ACTA, V522, P602, DOI 10.1016/0005-2744(78)90091-8; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; VERREY F, 1989, AM J PHYSIOL, V256, pF1034, DOI 10.1152/ajprenal.1989.256.6.F1034; XU KY, 1989, BIOCHEMISTRY-US, V28, P5764, DOI 10.1021/bi00440a010	39	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11622	11627						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8389358				2022-12-25	WOS:A1993LF28400029
J	DELEEUW, B; SUIJKERBUIJK, RF; BALEMANS, M; SINKE, RJ; DEJONG, B; MOLENAAR, WM; MELONI, AM; SANDBERG, AA; GERAGHTY, M; HOFKER, M; ROPERS, HH; VANKESSEL, AG				DELEEUW, B; SUIJKERBUIJK, RF; BALEMANS, M; SINKE, RJ; DEJONG, B; MOLENAAR, WM; MELONI, AM; SANDBERG, AA; GERAGHTY, M; HOFKER, M; ROPERS, HH; VANKESSEL, AG			SUBLOCALIZATION OF THE SYNOVIAL SARCOMA-ASSOCIATED T(X-18) CHROMOSOMAL BREAKPOINT IN XP11.2 USING COSMID CLONING AND FLUORESCENCE INSITU HYBRIDIZATION	ONCOGENE			English	Article							EPITHELIAL DIFFERENTIATION; TUMORS; TRANSLOCATION; ABERRATIONS; SEQUENCES; FEATURES	In a previous study we localized the synovial sarcoma-associated t(X;18)(p11;q11) breakpoint within the ornithine aminotransferase-like 1 (OATL1) cluster on the X chromosome. This localization was delineated from both somatic cell hybrid and fluorescence in situ hybridization (FISH) analysis of patient material, using OAT-specific cDNA and YAC probes. Simultaneously, Knight et al. (1992, MoL Hum. Genet, in press) mapped this same breakpoint in their patient material adjacent to the more proximal OATL2 region on the X chromosome. Here we report the analysis of two additional tumors and demonstrate that again in these cases the chromosomal break occurs within the OATL1 cluster. In order to further specify the breakpoint, we subcloned the OATL1 YAC (no. 2) into cosmids. At least one of these cosmids (0.38) hybridizes to sequences that bracket the translocation breakpoint, as demonstrated by both Southern blot and FISH analysis. These observations confirm and substantiate our previous findings. In addition, cosmid 0.38 should be a valuable instrument for the ultimate isolation and identification of the gene(s) involved in the development of synovial sarcoma.	UNIV GRONINGEN,DEPT HUMAN GENET,9700 AB GRONINGEN,NETHERLANDS; UNIV GRONINGEN,DEPT PATHOL,9700 AB GRONINGEN,NETHERLANDS; GENET CTR,SCOTTSDALE,AZ; CANC CTR,SCOTTSDALE,AZ; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; LEIDEN UNIV,DEPT HUMAN GENET,2300 RA LEIDEN,NETHERLANDS	University of Groningen; University of Groningen; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Leiden University; Leiden University - Excl LUMC	DELEEUW, B (corresponding author), CATHOLIC UNIV NIJMEGEN,DEPT HUMAN GENET,POB 9101,6500 HB NIJMEGEN,NETHERLANDS.		Sinke, Richard J/A-1462-2009; van Kessel, Ad Geurts/A-2810-2010					ARNOLDUS EPJ, 1989, HUM GENET, V83, P231, DOI 10.1007/BF00285162; BATES PF, 1983, GENE, V26, P137, DOI 10.1016/0378-1119(83)90183-X; BERGER W, 1992, NAT GENET, V1, P199, DOI 10.1038/ng0692-199; DRIESEN MS, 1991, GENOMICS, V11, P1079, DOI 10.1016/0888-7543(91)90035-D; ENZINGER FM, 1988, SOFT TISSUE TUMORS, P658; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FISHER C, 1986, HUM PATHOL, V17, P996, DOI 10.1016/S0046-8177(86)80083-1; FLETCHER JA, 1991, NEW ENGL J MED, V324, P436, DOI 10.1056/NEJM199102143240702; GILGENKRANTZ S, 1990, ONCOGENE, V5, P1063; KNIGHT JC, 1992, IN PRESS MOL HUM GEN; LANDEGENT JE, 1987, HUM GENET, V77, P366, DOI 10.1007/BF00291428; LEEUW BD, 1993, GENE CHROMOSOME CANC, V6, P182; LIMON J, 1991, GENE CHROMOSOME CANC, V3, P338, DOI 10.1002/gcc.2870030504; MIETTINEN M, 1983, VIRCHOWS ARCH B, V44, P187, DOI 10.1007/BF02890169; MITCHELL GA, 1988, J BIOL CHEM, V263, P1488; MITELMAN F, 1990, CATALOG CHROMOSOME A; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA; SUIJKERBUIJK RF, 1992, CANCER GENET CYTOGEN, V63, P8, DOI 10.1016/0165-4608(92)90056-E; SUIJKERBUIJK RF, 1991, AM J HUM GENET, V48, P269; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; WIEACKER P, 1984, AM J HUM GENET, V36, P265	22	37	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1457	1463						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8389029				2022-12-25	WOS:A1993LE06400008
J	YAMAZAKI, A; YAMAZAKI, M; TSUBOI, S; KISHIGAMI, A; UMBARGER, KO; HUTSON, LD; MADLAND, WT; HAYASHI, F				YAMAZAKI, A; YAMAZAKI, M; TSUBOI, S; KISHIGAMI, A; UMBARGER, KO; HUTSON, LD; MADLAND, WT; HAYASHI, F			REGULATION OF G-PROTEIN FUNCTION BY AN EFFECTOR IN GTP-DEPENDENT SIGNAL TRANSDUCTION - AN INHIBITORY SUBUNIT OF CGMP PHOSPHODIESTERASE INHIBITS GTP HYDROLYSIS BY TRANSDUCIN IN VERTEBRATE ROD PHOTORECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; OUTER SEGMENTS; MOLECULAR MECHANISM; VISUAL EXCITATION; MEMBRANES; SITES	The regulation of cGMP phosphodiesterase in vertebrate rod photoreceptors is a typical G protein-dependent signal transduction mechanism. The interaction of Pgamma, an inhibitory subunit of cGMP phosphodiesterase, with transducin alpha subunit (Talpha) is essential for the activation of cGMP phosphodiesterase. It has been shown that, in a homogenized preparation of frog (Rana catesbiana) rods, Pgamma interacts with GTP.Talpha and remains tightly bound to GDP.Talpha after GTP hydrolysis on Talpha. Association of this complex with betagamma subunits of transducin (Tbetagamma) triggers the release of Pgamma from the complex and the subsequent inactivation of cGMP phosphodiesterase. In a system reconstituted with purified components, both GTP- and GDP-bound forms of Talpha were found to interact with Pgamma. Under these conditions, Pgamma inhibited GTP hydrolysis by transducin in a noncompetitive manner with a K(i) of 92 nm. Binding of an hydrolysis-resistant GTP analog to Talpha was also inhibited by Pgamma. These inhibitions of transducin function were resulted from the inhibition of both hydrolysis of GTP bound to Talpha and interaction of GDP.Talpha with membrane-bound Tbetagamma. However, after GDP.Talpha reassociated with membrane-bound Tbetagamma, the inhibitory effect of Pgamma on the binding of an hydrolysis-resistant GTP analog to Talpha was greatly diminished, suggesting that the GTP/GDP exchange on Talpha was not inhibited by Pgamma. These data indicate that the Talpha function is altered during complexing with Pgamma. G protein functions may be modified by interacting with an effector in the G protein-dependent signal transduction.	WAYNE STATE UNIV, SCH MED, DEPT OPHTHALMOL, DETROIT, MI 48201 USA; WAYNE STATE UNIV, SCH MED, DEPT PHARMACOL, DETROIT, MI 48201 USA; LOS ALAMOS NATL LAB, DIV LIFE SCI, LOS ALAMOS, NM 87545 USA	Wayne State University; Wayne State University; United States Department of Energy (DOE); Los Alamos National Laboratory	YAMAZAKI, A (corresponding author), WAYNE STATE UNIV, SCH MED, KRESGE EYE INST, 4717 ST ANTOINE ST, DETROIT, MI 48201 USA.		kishigami, Akio/B-5906-2018	kishigami, Akio/0000-0001-8333-5794	NEI NIH HHS [EY07546, EY09631] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007546, R01EY009631] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGLESON JK, 1992, INVEST OPHTH VIS SCI, V33, P1103; ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1992, INVEST OPHTH VIS SCI, V33, P1103; BIRNBAUMER L, 1987, KIDNEY INT, V32, pS14; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; CASSEL D, 1976, BIOCHIM BIOPHYS ACTA, V452, P538, DOI 10.1016/0005-2744(76)90206-0; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; HO YK, 1989, CURR TOP CELL REGUL, V30, P171; HURLEY JB, 1987, ANNU REV PHYSIOL, V49, P793; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; MILLER WH, 1990, INVEST OPHTH VIS SCI, V31, P1664; MORRISON DF, 1989, J BIOL CHEM, V264, P11671; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; STEIN PJ, 1985, J BIOL CHEM, V260, P9081; STRYER L, 1991, J BIOL CHEM, V266, P10711; TING TD, 1991, BIOCHEMISTRY-US, V30, P8996, DOI 10.1021/bi00101a013; UMBARGER KO, 1992, J BIOL CHEM, V267, P19494; WANG N, 1990, J BIOL CHEM, V265, P1239; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619; YAMAZAKI A, 1992, ADV SEC MESS PHOSPH, V25, P135; YAMAZAKI A, 1992, INVEST OPHTH VIS SCI, V33, P1103	33	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8899	8907						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8386172				2022-12-25	WOS:A1993KX81100077
J	BOURGUIGNON, LYW; JIN, HT; IIDA, N; BRANDT, NR; ZHANG, SH				BOURGUIGNON, LYW; JIN, HT; IIDA, N; BRANDT, NR; ZHANG, SH			THE INVOLVEMENT OF ANKYRIN IN THE REGULATION OF INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR-MEDIATED INTERNAL CA2+ RELEASE FROM CA2+ STORAGE-VESICLES IN MOUSE T-LYMPHOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; TRANSMEMBRANE GLYCOPROTEIN; TRISPHOSPHATE RECEPTOR; PLASMA-MEMBRANE; ERYTHROCYTE ANKYRIN; RYANODINE RECEPTOR; EPITHELIAL-CELLS; CALCIUM RELEASE; PHOSPHORYLATION; BINDING	Mouse T-lymphoma cells contain a unique type of internal vesicle which bands at the relatively light density of 1.07 g/cc. These vesicles do not contain any detectable Golgi, endoplasmic reticulum, plasma membrane, or lysosomal marker protein activities. Binding of [H-3]inositol 1,4,5-trisphosphate (IP3) to these internal vesicles reveals the presence of a single, high affinity class of IP3 receptor with a dissociation constant (K(d)) of 1.6 +/- 0.3 nM. Using a panel of monoclonal and polyclonal antibodies against IP3 receptor, we have established that the IP3 receptor (approximately 260 kDa) displays immunological cross-reactivity with the rat brain IP3 receptor. Polymerase chain reaction analysis of first-strand cDNAs from both mouse T-lymphoma cells and rat brain tissues reveals that the IP3 receptor transcript in mouse T-lymphoma cells belongs to the short form (non-neuronal form) and not the long form (neuronal form) detected in rat brain tissue. Scatchard plot analysis shows that high affinity binding occurs between ankyrin and the IP3 receptor with a K(d) of 0.2 nM. Most importantly, the binding of ankyrin to the light density vesicles significantly inhibits IP3 binding and IP3-induced internal Ca2+ release. These findings suggest that the cytoskeleton plays a pivotal role in the regulation of IP3 receptor-mediated internal Ca2+ release during lymphocyte activation.	UNIV MIAMI,SCH MED,DEPT MOLEC PHARMACOL,MIAMI,FL 33101	University of Miami	BOURGUIGNON, LYW (corresponding author), UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,1600 NW 10TH AVE,MIAMI,FL 33101, USA.				NIGMS NIH HHS [GM 36353] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036353] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT V, 1980, J BIOL CHEM, V255, P2540; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BERRIDGE MJ, 1987, ANN REV BIOCH, V5, P6159; BOURGUIGNON GJ, 1981, BIOCHIM BIOPHYS ACTA, V646, P109, DOI 10.1016/0005-2736(81)90277-7; BOURGUIGNON LYW, 1990, J IMMUNOL, V144, P2242; BOURGUIGNON LYW, 1986, J CELL BIOL, V102, P2115, DOI 10.1083/jcb.102.6.2115; BOURGUIGNON LYW, 1991, J BIOL CHEM, V266, P11761; BOURGUIGNON LYW, 1984, INT REV CYTOL, V87, P195, DOI 10.1016/S0074-7696(08)62443-2; BOURGUIGNON LYW, 1986, J CELL PHYSIOL, V127, P146, DOI 10.1002/jcp.1041270118; BOURGUIGNON LYW, 1992, MOL CELL BIOL, V12, P4464, DOI 10.1128/MCB.12.10.4464; BOURGUIGNON LYW, 1992, ENCY IMMUNOLOGY, P1044; CHADWICK CC, 1992, J BIOL CHEM, V267, P3473; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; COLEMAN TR, 1989, CELL MOTIL CYTOSKEL, V12, P225, DOI 10.1002/cm.970120405; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; DAVIS JQ, 1991, J CELL BIOL, V116, P43; DRENCKHAHN D, 1985, SCIENCE, V230, P1287, DOI 10.1126/science.2933809; ENTMAN ML, 1986, J BIOL CHEM; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; Fleischer S., 1967, METHOD ENZYMOL, V10, P406; FLUCHER BE, 1989, NEURON, V3, P163, DOI 10.1016/0896-6273(89)90029-9; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; GUILLEMETTE G, 1987, J BIOL CHEM, V262, P1010; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; KALOMIRIS EL, 1988, J CELL BIOL, V106, P319, DOI 10.1083/jcb.106.2.319; KELLIE S, 1986, EXP CELL RES, V165, P216, DOI 10.1016/0014-4827(86)90546-X; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KOOB R, 1987, European Journal of Cell Biology, V45, P230; KORDELI E, 1991, J CELL BIOL, V114, P1243, DOI 10.1083/jcb.114.6.1243; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB GD, 1990, J PHYSIOL-LONDON, V423, P519, DOI 10.1113/jphysiol.1990.sp018037; LEW DP, 1989, EUR J CLIN INVEST, V19, P338, DOI 10.1111/j.1365-2362.1989.tb00240.x; LOKESHWAR VB, 1991, J BIOL CHEM, V266, P17983; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MONNERON A, 1978, J CELL BIOL, V27, P211; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PESSAH IN, 1985, BIOCHEM BIOPH RES CO, V128, P449, DOI 10.1016/0006-291X(85)91699-7; ROSSIER MF, 1989, J BIOL CHEM, V264, P14078; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; SCHUSTER VL, 1986, AM J PHYSIOL, V251, pC347, DOI 10.1152/ajpcell.1986.251.3.C347; SHARP AH, 1992, J BIOL CHEM, V267, P7444; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; SUCHARD SJ, 1988, J CELL PHYSIOL, V134, P67, DOI 10.1002/jcp.1041340108; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; THEIBERT AB, 1992, J BIOL CHEM, V267, P9071; VOLPE P, 1988, P NATL ACAD SCI USA, V85, P1091, DOI 10.1073/pnas.85.4.1091; WALTON PD, 1991, J CELL BIOL, V113, P1145, DOI 10.1083/jcb.113.5.1145; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISS A, 1989, FUNDAMENTAL IMMUNOLO, P359	60	146	146	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7290	7297						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8385102				2022-12-25	WOS:A1993KV14100069
J	COLBRAN, RJ				COLBRAN, RJ			INACTIVATION OF CA2+/CALMODULIN-DEPENDENT PROTEIN KINASE-II BY BASAL AUTOPHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; CA-2+ CALMODULIN; MOLECULAR-CLONING; ALPHA-SUBUNIT; CA-2+-INDEPENDENT ACTIVITY; AUTONOMOUS ENZYME; BRAIN; ACTIVATION; MECHANISM; SITE	Incubation of either purified rat forebrain Ca2+/calmodulin-independent protein kinase II (CaMKII) or the purified recombinant, baculovirus-expressed mouse a subunit of CaMKII (Brickey, D. A., Colbran, R. J., Fong, Y.-L., and Soderling, T. R. (1990) Biochem. Biophys. Res. Commun. 173, 578-584) with EGTA, magnesium acetate, and [gamma-P-32]ATP resulted in the incorporation of up to 1.0 mol of (PO4)-P-32/mol of subunit within 60 min at 30-degrees-C; both serine and threonine residues became autophosphorylated. The V(max) for this basal autophosphorylation was 0.051 +/- 0.005 mol of (PO4)-P-32/mol of subunit/min, and the K(m)(ATP) was 145 +/- 8 muM. V(max) and K-(ATP) values for Ca2+/calmodulin-dependent autophosphorylation were determined to be 1.3 +/- 0.4 mol/mol/min and 19 +/- 2 muM, respectively. Basal autophosphorylation resulted in inactivation of Ca2+/calmodulin-dependent kinase activity toward exogenous peptide substrate; there was no measurable increase in Ca2+-independent CaMKII activity. Inactivation was not observed following preincubation with non-hydrolyzable ATP analogs in place of ATP. CaMKII that had been inactivated by basal autophosphorylation could be fully re-activated by incubation with the purified catalytic subunit of protein phosphatase 2A. Following basal autophosphorylation, the calmodulin-binding ability of CaMKII was also reduced, presumably accounting for the observed inactivation. Both the inactivation and the decrease in calmodulin-binding that resulted from basal autophosphorylation were abrogated by mutation of threonine 306 to alanine, but not by mutation of threonine 305 to alanine. Furthermore, mutation of threonine 306, but not threonine 305, to alanine reduced the extent of basal autophosphorylation at threonine residues. Thus, basal autophosphorylation at threonine 306 blocks calmodulin binding, resulting in inactivation of CaMKII.			COLBRAN, RJ (corresponding author), VANDERBILT UNIV, MED CTR,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS, RM 762, MED RES BLDG, NASHVILLE, TN 37232 USA.		Colbran, Roger/AAU-7708-2021	Colbran, Roger/0000-0001-7401-8244	NCRR NIH HHS [RR0524] Funding Source: Medline; NIGMS NIH HHS [GM 47973] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047973] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; BULLEIT RF, 1988, NEURON, V1, P63, DOI 10.1016/0896-6273(88)90210-3; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; COLBRAN RJ, 1992, NEUROCHEM INT, V21, P469, DOI 10.1016/0197-0186(92)90080-B; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; COLBRAN RJ, 1990, J BIOL CHEM, V265, P11213; FONG YL, 1989, J BIOL CHEM, V264, P16759; FUKUNAGA K, 1990, Molecular and Cellular Neuroscience, V1, P133; FUKUNAGA K, 1989, J BIOL CHEM, V264, P21830; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HANLEY RM, 1988, BIOCHEM BIOPH RES CO, V152, P122, DOI 10.1016/S0006-291X(88)80688-0; HANLEY RM, 1989, NUCLEIC ACIDS RES, V17, P3992, DOI 10.1093/nar/17.10.3992; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1992, J BIOL CHEM, V267, P17216; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JEFFERSON AB, 1991, J BIOL CHEM, V266, P1484; KELLY PT, 1988, P NATL ACAD SCI USA, V85, P4991, DOI 10.1073/pnas.85.14.4991; KING MM, 1988, J BIOL CHEM, V263, P4754; KING MM, 1988, ARCH BIOCHEM BIOPHYS, V267, P467, DOI 10.1016/0003-9861(88)90052-5; KURET J, 1985, J BIOL CHEM, V260, P6427; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; LOU LL, 1986, P NATL ACAD SCI USA, V83, P9497, DOI 10.1073/pnas.83.24.9497; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MORROY SS, 1991, P NATL ACAD SCI USA, V88, P4756; OCORR KA, 1991, NEURON, V6, P907, DOI 10.1016/0896-6273(91)90231-N; PATTON BL, 1990, J BIOL CHEM, V265, P11204; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PONGOR S, 1987, METHOD ENZYMOL, V154, P450; SAITOH T, 1985, J CELL BIOL, V100, P835, DOI 10.1083/jcb.100.3.835; SCHULMAN H, 1988, ADV SEC MESS PHOSPH, V22, P39; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; SHIELDS SM, 1984, J NEUROCHEM, V43, P1599, DOI 10.1111/j.1471-4159.1984.tb06084.x; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SMITH MK, 1992, J BIOL CHEM, V267, P1761; SUMMERS MD, 1988, TEX AGR EXP STN B, V1555; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; TOBIMATSU T, 1988, J BIOL CHEM, V263, P16082	50	119	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7163	7170						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8385100				2022-12-25	WOS:A1993KV14100054
J	MATHER, MW; SPRINGER, P; HENSEL, S; BUSE, G; FEE, JA				MATHER, MW; SPRINGER, P; HENSEL, S; BUSE, G; FEE, JA			CYTOCHROME-OXIDASE GENES FROM THERMUS-THERMOPHILUS - NUCLEOTIDE-SEQUENCE OF THE FUSED GENE AND ANALYSIS OF THE DEDUCED PRIMARY STRUCTURES FOR SUBUNIT-I AND SUBUNIT-III OF CYTOCHROME-CAA3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; AMINO-ACID-SEQUENCES; C-OXIDASE; EXTREME THERMOPHILE; ESCHERICHIA-COLI; MOLECULAR-CLONING; PROTON PUMP; RESPIRATORY PROTEINS; MEMBRANE-PROTEINS; MITOCHONDRIAL-DNA	Cytochrome caa3, a cytochrome c oxidase from Thermus thermophilus, has been purified and extensively characterized as a two-subunit enzyme containing the metal centers characteristic of cytochrome c oxidases (cytochromes a and a3; copper centers Cu(A) and Cu(B)) and an additional cytochrome c (Fee, J. A., Kuila, D., Mather, M. W., and Yoshida, T. (1986) Biochim. Biophys. Acta 853, 153-185). We have now cloned and sequenced the genes encoding the subunits of this enzyme. The smaller subunit consists of a typical oxidase subunit II sequence fused to a cytochrome c domain (Mather, M. W., Springer, P., and Fee, J. A. (1991) J. Biol. Chem. 266, 5025-5035). The larger subunit, the A-protein, is encoded by a fusion gene lying immediately downstream of the subunit IIc gene. The 5' portion of this gene encodes an oxidase subunit I homolog, whereas the 3' portion is homologous to oxidase subunits III. The A-protein from the purified enzyme appears too small from SDS-polyacrylamide gel electrophoresis and quantitative amino acid analyses to be a complete subunit I/III fusion, but it is currently not known if proteolytic processing occurs. Analyses of the sequences of oxidase subunits are presented which clearly identify T. thermophilus cytochrome caa3 as a bona fide member of the greater family of heme- and copper-requiring oxidases. As one consequence, it is confirmed that the set of invariant histidine residues (potential ligands of the metal centers) in cytochrome c oxidase subunits I and II is reduced to 8. Possible topological and helix packing models are developed based on considerations of homology, hydropathy, and variability.	LOS ALAMOS NATL LAB, BIOCHEM SECT, LOS ALAMOS, NM 87545 USA; LOS ALAMOS NATL LAB, STABLE ISOTOPE RESOURCE SPECT & BIOCHEM GRP, LOS ALAMOS, NM 87545 USA; RHEIN WESTFAL TH AACHEN, INST BIOCHEM, W-5100 AACHEN, GERMANY	United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory; RWTH Aachen University				Mather, Michael/0000-0002-1062-0137	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035342] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35342] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABCOCK GT, 1983, BIOCHEMISTRY-US, V22, P2314, DOI 10.1021/bi00279a002; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BISSON R, 1985, J INORG BIOCHEM, V23, P177, DOI 10.1016/0162-0134(85)85023-6; BONITZ SG, 1980, J BIOL CHEM, V255, P1927; BOWEN D, 1988, BIOCHEM J, V254, P509, DOI 10.1042/bj2540509; BURGER G, 1982, EMBO J, V1, P1385, DOI 10.1002/j.1460-2075.1982.tb01327.x; BUSE G, 1989, EUR J BIOCHEM, V181, P261, DOI 10.1111/j.1432-1033.1989.tb14720.x; CAPALDI RA, 1983, BIOCHIM BIOPHYS ACTA, V726, P135, DOI 10.1016/0304-4173(83)90003-4; CAPALDI RA, 1990, ARCH BIOCHEM BIOPHYS, V280, P252, DOI 10.1016/0003-9861(90)90327-U; CASEY RP, 1980, J BIOL CHEM, V255, P3994; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; CHAN SI, 1990, BIOCHEMISTRY-US, V29, P1, DOI 10.1021/bi00453a001; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; CHEPURI V, 1990, J BIOL CHEM, V265, P12978; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CLINE J, 1983, J BIOL CHEM, V258, P5124; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; COVELLO PS, 1990, NUCLEIC ACIDS RES, V18, P5189, DOI 10.1093/nar/18.17.5189; DEKKER K, 1991, J BACTERIOL, V173, P3078, DOI 10.1128/JB.173.10.3078-3083.1991; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Doolittle R. F., 1986, URFS ORFS PRIMER ANA; DOOLITTLE RF, 1981, SCIENCE, V214, P149, DOI 10.1126/science.7280687; ESPOSTI MD, 1989, ITAL J BIOCHEM, V38, P1; ESPOSTI MD, 1990, EUR J BIOCHEM, V190, P207; FAWCETT TW, 1990, BIOTECHNIQUES, V9, P46; FEE JA, 1988, ANN NY ACAD SCI, V550, P33, DOI 10.1111/j.1749-6632.1988.tb35319.x; FEE JA, 1980, P NATL ACAD SCI-BIOL, V77, P147, DOI 10.1073/pnas.77.1.147; FEE JA, 1986, BIOCHIM BIOPHYS ACTA, V853, P153, DOI 10.1016/0304-4173(86)90009-1; FEE JA, 1993, IN PRESS J BIOENERG; GOODMAN G, 1985, BIOCHEMISTRY-US, V24, P2310, DOI 10.1021/bi00330a028; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; GRIBSKOV M, 1988, COMPUT APPL BIOSCI, V4, P61; GUALBERTO JM, 1989, NATURE, V341, P660, DOI 10.1038/341660a0; GUALBERTO JM, 1990, NUCLEIC ACIDS RES, V18, P3771, DOI 10.1093/nar/18.13.3771; HALTIA T, 1991, EMBO J, V10, P2015, DOI 10.1002/j.1460-2075.1991.tb07731.x; HARDY CM, 1991, CURR GENET, V20, P99, DOI 10.1007/BF00312772; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOLM L, 1987, EMBO J, V6, P2819, DOI 10.1002/j.1460-2075.1987.tb02578.x; HONNAMI K, 1984, BIOCHEMISTRY-US, V23, P454, DOI 10.1021/bi00298a009; ISHIZUKA M, 1990, J BIOCHEM-TOKYO, V108, P866, DOI 10.1093/oxfordjournals.jbchem.a123294; ITAYA M, 1991, NUCLEIC ACIDS RES, V19, P4443, DOI 10.1093/nar/19.16.4443; KAGAWA Y, 1984, J BIOL CHEM, V259, P2956; KOYAMA Y, 1990, J BACTERIOL, V172, P3490, DOI 10.1128/jb.172.6.3490-3495.1990; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANG BF, 1984, EMBO J, V3, P2129, DOI 10.1002/j.1460-2075.1984.tb02102.x; LAUER G, 1991, J BACTERIOL, V173, P5047, DOI 10.1128/jb.173.16.5047-5053.1991; LEMIEUX LJ, 1992, J BIOL CHEM, V267, P2105; LUBBEN M, 1992, EMBO J, V11, P805, DOI 10.1002/j.1460-2075.1992.tb05117.x; LUDWIG B, 1987, FEMS MICROBIOL LETT, V46, P41, DOI 10.1111/j.1574-6968.1987.tb02451.x; LUNDEEN M, 1986, INORG CHEM, V25, P4852, DOI 10.1021/ic00247a016; MAHENDRAN R, 1991, NATURE, V349, P434, DOI 10.1038/349434a0; MALATESTA F, 1982, BIOCHEM BIOPH RES CO, V109, P1180, DOI 10.1016/0006-291X(82)91901-5; MALMSTROM BG, 1990, CHEM REV, V90, P1247, DOI 10.1021/cr00105a008; MARTIN CT, 1985, J BIOL CHEM, V260, P2857; MATHER MW, 1991, J BIOL CHEM, V266, P5025; MATHER MW, 1988, BIOTECHNIQUES, V6, P444; MATHER MW, 1990, 41ST P MOSB C, P94; MINAGAWA J, 1992, J BIOL CHEM, V267, P2096; NUREKI O, 1991, J BIOL CHEM, V266, P3268; OSHIMA T, 1974, INT J SYST BACTERIOL, V24, P102, DOI 10.1099/00207713-24-1-102; PALMER G, 1987, PURE APPL CHEM, V59, P749, DOI 10.1351/pac198759060749; PEISACH J, 1978, FRONTIERS BIOL ENERG, V2, P873; PEL HJ, 1992, CURR GENET, V21, P139, DOI 10.1007/BF00318473; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; PUETTNER I, 1985, J BIOL CHEM, V260, P3719; RAITIO M, 1987, EMBO J, V6, P2825, DOI 10.1002/j.1460-2075.1987.tb02579.x; REES DC, 1989, ANNU REV BIOCHEM, V58, P607; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1991, EUR J BIOCHEM, V195, P517, DOI 10.1111/j.1432-1033.1991.tb15732.x; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SATO S, 1988, BIOCHIM BIOPHYS ACTA, V950, P303, DOI 10.1016/0167-4781(88)90126-1; SEIDLER L, 1987, NUCLEIC ACIDS RES, V15, P9263, DOI 10.1093/nar/15.22.9263; SHAPLEIGH JP, 1992, P NATL ACAD SCI USA, V89, P4786, DOI 10.1073/pnas.89.11.4786; SHAW JM, 1988, CELL, V53, P401, DOI 10.1016/0092-8674(88)90160-2; STEFFENS GJ, 1979, H-S Z PHYSIOL CHEM, V360, P613; STEVENS TH, 1981, J BIOL CHEM, V256, P1069; SURERUS KK, 1992, P NATL ACAD SCI USA, V89, P3195, DOI 10.1073/pnas.89.8.3195; THONYMEYER L, 1989, CELL, V57, P683, DOI 10.1016/0092-8674(89)90137-2; VAHRENHOLZ C, 1985, MOL GEN GENET, V201, P213, DOI 10.1007/BF00425662; VANDERSPEK H, 1990, EMBO J, V9, P257, DOI 10.1002/j.1460-2075.1990.tb08103.x; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WIKSTROM M, 1985, ENZYMES BIOL MEMBR, P111; XU J, 1991, BIOCHEM BIOPH RES CO, V176, P1313, DOI 10.1016/0006-291X(91)90429-B; YAKHNIN AV, 1990, NUCLEIC ACIDS RES, V18, P3659, DOI 10.1093/nar/18.12.3659; YASUNOBU KT, 1980, J SCI IND RES INDIA, V39, P796; YEATES TO, 1987, P NATL ACAD SCI USA, V84, P6438, DOI 10.1073/pnas.84.18.6438; YOSHIDA T, 1984, J BIOL CHEM, V259, P112	88	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5395	5408						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8383670				2022-12-25	WOS:A1993KR82200012
J	LAXMINARAYAN, KM; MATZARIS, M; SPEED, CJ; MITCHELL, CA				LAXMINARAYAN, KM; MATZARIS, M; SPEED, CJ; MITCHELL, CA			PURIFICATION AND CHARACTERIZATION OF A 43-KDA MEMBRANE-ASSOCIATED INOSITOL POLYPHOSPHATE 5-PHOSPHATASE FROM HUMAN PLACENTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; HUMAN-PLATELETS; RAT-LIVER; 1,4,5-TRISPHOSPHATE PHOSPHATASE; BRAIN; POLYPHOSPHATE-5-PHOSPHATASE; TETRAKISPHOSPHATE; IDENTIFICATION; METABOLISM	We have identified, isolated, and characterized a membrane-associated inositol polyphosphate 5-phosphatase (5-phosphatase) from the particulate fraction of human placenta. The enzyme was purified 3700-fold from a detergent extract of human placental membranes to apparent homogeneity, by chromatography on DEAE-Sepharose, S-Sepharose, hydroxylapatite, and Biosil SEC 250 HPLC gel filtration. The purified 5-phosphatase has a molecular mass of 43 kDa as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and gel filtration chromatography. The enzyme hydrolyzes inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) to inositol 1,4 bisphosphate (Ins(1,4)P2) with an apparent K(m) of 5 muM. The 43-kDa 5-phosphatase also hydrolyzes inositol 1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P4) with an apparent K(m) of 1.2 muM. The enzyme requires Mg2+ ions for activity and is inhibited by Ca2+ concentrations greater than 100 muM. Polyclonal antibodies developed against the membrane-associated enzyme immunoprecipitate the purified membrane-associated placental 5-phosphatase and the platelet Type I cytosolic enzyme, but not the 75-kDa platelet Type II 5-phosphatase. These results demonstrate that the purified membrane 5-phosphatase bears physical and immunological similarity with the Type I cytosolic platelet enzyme.			LAXMINARAYAN, KM (corresponding author), BOX HILL HOSPITAL,MONASH MED SCH,DEPT MED,MELBOURNE,AUSTRALIA.			Mitchell, Christina A/0000-0001-9372-3192				ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CONNOLLY TM, 1985, J BIOL CHEM, V260, P7868; CONNOLLY TM, 1986, CELL, V46, P951, DOI 10.1016/0092-8674(86)90077-2; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; ERNEUX C, 1989, EUR J BIOCHEM, V181, P317, DOI 10.1111/j.1432-1033.1989.tb14726.x; ERNEUX C, 1986, BIOCHEM BIOPH RES CO, V134, P351, DOI 10.1016/0006-291X(86)90570-X; HANSEN CA, 1987, J BIOL CHEM, V262, P17319; HOLLANDE F, 1992, BIOCHEM J, V277, P293; JOSEPH SK, 1985, FEBS LETT, V180, P150, DOI 10.1016/0014-5793(85)81061-9; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KING WG, 1989, J BIOL CHEM, V264, P6070; KUKITA M, 1986, BIOCHIM BIOPHYS ACTA, V885, P121, DOI 10.1016/0167-4889(86)90046-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERRIL CR, 1981, SCIENCE, V211, P3501; MITCHELL CA, 1989, J BIOL CHEM, V264, P8873; OGAWA Y, 1968, J BIOCHEM-TOKYO, V64, P255, DOI 10.1093/oxfordjournals.jbchem.a128887; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RANA RS, 1986, J BIOL CHEM, V261, P5237; ROSS TS, 1991, J BIOL CHEM, V266, P20283; SEYFRED MA, 1984, J BIOL CHEM, V259, P3204; SHARP AH, 1992, J BIOL CHEM, V267, P7444; SHEARS SB, 1989, BIOCHEM J, V260, P313, DOI 10.1042/bj2600313; SHEARS SB, 1987, BIOCHEM J, V246, P139, DOI 10.1042/bj2460139; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; STOREY DJ, 1984, NATURE, V312, P374, DOI 10.1038/312374a0; TAKIMOTO K, 1989, J BIOCHEM-TOKYO, V106, P684, DOI 10.1093/oxfordjournals.jbchem.a122917; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEDIA LMM, 1986, J BIOL CHEM, V261, P10493; VERJANS B, 1992, EUR J BIOCHEM, V204, P1083, DOI 10.1111/j.1432-1033.1992.tb16732.x; VERJANS B, 1990, CELL SIGNAL, V2, P595, DOI 10.1016/0898-6568(90)90082-L	33	53	53	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4968	4974						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8383126				2022-12-25	WOS:A1993KP88400062
J	GRADIN, K; WILHELMSSON, A; POELLINGER, L; BERGHARD, A				GRADIN, K; WILHELMSSON, A; POELLINGER, L; BERGHARD, A			NONRESPONSIVENESS OF NORMAL HUMAN FIBROBLASTS TO DIOXIN CORRELATES WITH THE PRESENCE OF A CONSTITUTIVE XENOBIOTIC RESPONSE ELEMENT-BINDING FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYP1A1 MESSENGER-RNA; AMINO-ACID-SEQUENCE; HEAT-SHOCK PROTEIN; REGULATORY ELEMENTS; AH RECEPTOR; INDUCIBLE EXPRESSION; HYPERSENSITIVE SITES; P-450C GENE; DNA; MOUSE	Polychlorinated aromatic hydrocarbons such as 2,3,7,8-tetrachlorodibenzofuran (TCDF) have been shown to induce transcription of the cytochrome P-450IA1 gene by activating an intracellular receptor protein (the Ah- or dioxin receptor) to bind to specific DNA sequences, termed xenobiotic response elements (XREs). However, the expression and inducibility of the cytochrome P-450IA1 activity exhibit tissue-specific differences. With regard to the TCDF induction response, we have examined three human cell types of endodermal (the hepatoma cell line HepG2), ectodermal (normal keratinocytes), and mesodermal origin (normal fibroblasts). DNase I hypersensitivity analysis of the 5' flank and first intron of the P-450IA1 gene showed that in the nonresponsive fibroblasts the chromatin structure lacked open regions while in the two responsive cell types (keratinocytes and HepG2) several constitutive hypersensitive sites as well as TCDF-induced alterations in the chromatin structure could be detected. This observation might correlate with the fact that the XRE, in either the context of the P-450IA1 gene sequences or in front of a heterologous promoter, was inefficient in directing a TCDF induction response in fibroblasts. In in vitro DNA binding studies, the dioxin receptor was activated to a DNA-binding nuclear form in all three cell types. However, in fibroblast nuclear extracts two novel constitutive protein-XRE complexes were detected. The fibroblast factor(s) were immunochemically distinct from the receptor but exhibited indistinguishable DNA binding specificity. These data are compatible with a model where the P-450IA1 is noninducible in fibroblasts due to the presence of a putative repressor(s) which may compete effectively with the receptor for binding to the response element as indicated by in vitro DNA-binding off-rate experiments.	NOVUM,KAROLINSKA INST,CTR BIOTECHNOL,BLICKAGANGEN 6,S-14157 HUDDINGE,SWEDEN; NOVUM,KAROLINSKA INST,DEPT MED NUTR,S-14157 HUDDINGE,SWEDEN	Karolinska Institutet; Karolinska Institutet								ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BERGHARD A, 1992, CARCINOGENESIS, V13, P651, DOI 10.1093/carcin/13.4.651; BERGHARD A, 1990, J BIOL CHEM, V265, P21086; BRADFIELD CA, 1991, MOL PHARMACOL, V39, P13; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEY A, 1989, P NATL ACAD SCI USA, V86, P7446, DOI 10.1073/pnas.86.19.7446; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FUJIIKURIYAMA Y, 1992, FASEB J, V6, P706, DOI 10.1096/fasebj.6.2.1537460; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GIACHELLI CM, 1991, J BIOL CHEM, V266, P3981; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAPGOOD J, 1991, MOL CELL BIOL, V11, P4314, DOI 10.1128/MCB.11.9.4314; HINES RN, 1988, CARCINOGENESIS, V9, P1599, DOI 10.1093/carcin/9.9.1599; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; IOANNIDES C, 1990, DRUG METAB REV, V22, P1, DOI 10.3109/03602539008991444; ISRAEL DI, 1985, J BIOL CHEM, V260, P5648; JAISWAL AK, 1985, SCIENCE, V228, P80, DOI 10.1126/science.3838385; JONES KW, 1990, MOL CELL BIOL, V10, P5098, DOI 10.1128/MCB.10.10.5098; JONES SN, 1991, NUCLEIC ACIDS RES, V19, P6547, DOI 10.1093/nar/19.23.6547; MIRKOVITCH J, 1991, GENE DEV, V5, P83, DOI 10.1101/gad.5.1.83; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PAULSON KE, 1990, MOL CELL BIOL, V10, P1841, DOI 10.1128/MCB.10.5.1841; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; POELLINGER L, 1992, TRENDS PHARMACOL SCI, V13, P241, DOI 10.1016/0165-6147(92)90076-I; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1991, MOL PHARMACOL, V39, P20; REINERS JJ, 1992, BIOCHEM BIOPH RES CO, V183, P193, DOI 10.1016/0006-291X(92)91627-3; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; SAATCIOGLU F, 1990, MOL CELL BIOL, V10, P6408, DOI 10.1128/MCB.10.12.6408; Sambrook J, 1989, MOL CLONING LABORATO; SHU HP, 1987, REGUL TOXICOL PHARM, V7, P57, DOI 10.1016/0273-2300(87)90048-1; STRUHL K, 1990, CURRENT PROTOCOLS MO; SUSKIND RR, 1985, SCAND J WORK ENV HEA, V165, P165; TEIFELD RM, 1989, DNA-J MOLEC CELL BIO, V8, P329, DOI 10.1089/dna.1.1989.8.329; WANG X, 1991, ARCH BIOCHEM BIOPHYS, V287, P186, DOI 10.1016/0003-9861(91)90405-8; WATSON AJ, 1992, MOL CELL BIOL, V12, P2115, DOI 10.1128/MCB.12.5.2115; WATSON AJ, 1992, J BIOL CHEM, V266, P6874; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x; WU L, 1992, P NATL ACAD SCI USA, V89, P4811, DOI 10.1073/pnas.89.11.4811; YANAGIDA A, 1990, MOL CELL BIOL, V10, P1470, DOI 10.1128/MCB.10.4.1470	46	74	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4061	4068						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8382688				2022-12-25	WOS:A1993KN53300042
J	PIPPIG, S; ANDEXINGER, S; DANIEL, K; PUZICHA, M; CARON, MG; LEFKOWITZ, RJ; LOHSE, MJ				PIPPIG, S; ANDEXINGER, S; DANIEL, K; PUZICHA, M; CARON, MG; LEFKOWITZ, RJ; LOHSE, MJ			OVEREXPRESSION OF BETA-ARRESTIN AND BETA-ADRENERGIC-RECEPTOR KINASE AUGMENT DESENSITIZATION OF BETA(2)-ADRENERGIC RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; BETA-2-ADRENERGIC RECEPTOR; CYCLIC-AMP; PHOSPHORYLATION SITES; OPERATIONAL MODEL; LYMPHOMA-CELLS; WILD-TYPE; EXPRESSION; ACTIVATION; RHODOPSIN	Receptor-specific or homologous desensitization of beta2-adrenergic receptors is thought to be effected via phosphorylation of the receptor by the beta-adrenergic receptor kinase (betaARK), followed by binding of beta-arrestin. We have generated stably transfected Chinese hamster ovary cell lines overexpressing either of the two regulatory proteins and also expressing low or high levels of beta2-adrenergic receptors (almost-equal-to 80 and almost-equal-to 600 fmol/mg of membrane protein). In these cells, we studied the process of desensitization induced by the beta-adrenergic receptor agonist isoproterenol. In cells expressing high levels of beta2-adrenergic receptors, desensitization to high concentrations of isoproterenol (previously shown to be mediated by both betaARK and protein kinase A) amounted to almost-equal-to 50% in control cells, almost-equal-to 80% in betaARK-overexpressing cells, and almost-equal-to 90% in beta-arrestin-overexpressing cells. In cells expressing low levels of beta2-adrenergic receptors, these values were almost-equal-to 50, almost-equal-to 60, and almost-equal-to 60%, respectively. Desensitization to low concentrations of isoproterenol (previously shown to be essentially protein kinase A-mediated and not receptor-specific, i.e. heterologous) was not affected by overexpression of either betaARK or beta-arrestin. These data suggest that in cells expressing high levels of beta2-adrenergic receptors, beta-arrestin and betaARK become limiting for homologous receptor desensitization. They provide further support for the involvement of these two proteins in the regulation of beta2-adrenergic receptor function.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute	PIPPIG, S (corresponding author), UNIV MUNICH,MAX PLANCK INST BIOCHEM,MOLEC BIOL LAB,W-8033 MARTINSRIED,GERMANY.		Lohse, Martin J/A-7160-2012; Lefkowitz, Robert/AAW-2649-2021	Lohse, Martin J/0000-0002-0599-3510; 				BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BENOVIC JL, 1986, NATURE, V322, P869; BLACK JW, 1985, BRIT J PHARMACOL, V84, P561, DOI 10.1111/j.1476-5381.1985.tb12941.x; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEUNG AH, 1989, MOL PHARMACOL, V34, P132; CLARK RB, 1988, P NATL ACAD SCI USA, V85, P1442, DOI 10.1073/pnas.85.5.1442; CLARK RB, 1987, FASEB J, V1, P289, DOI 10.1096/fasebj.1.4.2820824; COLLINS S, 1991, ANNU REV PHYSIOL, V53, P497, DOI 10.1146/annurev.physiol.53.1.497; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; HADCOCK JR, 1991, TRENDS NEUROSCI, V14, P242, DOI 10.1016/0166-2236(91)90124-D; HARLOW E, 1988, ANTIBODIES LABORATOR; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; JAKOBS KH, 1976, J CYCLIC NUCL PROT, V2, P381; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITZKI A, 1988, SCIENCE, V241, P800, DOI 10.1126/science.2841758; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LOHSE MJ, 1986, MOL PHARMACOL, V30, P403; LOHSE MJ, 1992, N-S ARCH PHARMACOL, V345, P444; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, J BIOL CHEM, V265, P3210; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LOHSE MJ, 1992, SIGNAL TRANSMISSION, P160; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6875; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; UNGERER M, 1993, IN PRESS CIRCULATION; WALSETH TF, 1979, BIOCHIM BIOPHYS ACTA, V562, P11, DOI 10.1016/0005-2787(79)90122-9; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; ZHOU XM, 1991, J BIOL CHEM, V266, P7462	43	194	195	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3201	3208						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8381421				2022-12-25	WOS:A1993KM16100030
J	CHAHINE, KG; BARACCHINI, E; GOLDMAN, D				CHAHINE, KG; BARACCHINI, E; GOLDMAN, D			COUPLING MUSCLE ELECTRICAL-ACTIVITY TO GENE-EXPRESSION VIA A CAMP-DEPENDENT 2ND MESSENGER SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR ALPHA-SUBUNIT; RAT SKELETAL-MUSCLE; PROTEIN KINASE-C; ACETYLCHOLINE-RECEPTOR; CYCLIC-AMP; BETA-SUBUNIT; NEUROMUSCULAR SYNAPSES; ADENYLATE-CYCLASE; CHICKEN MYOTUBES; GAMMA-SUBUNIT	Embryonic-type nicotinic acetylcholine receptor (nAChR) gene expression is regulated by muscle activity. The mechanism by which this activity is transduced to the genome is not known. We have addressed this issue by using a rat primary muscle cell culture system that mimics the in vivo effects of muscle activity on nAChR expression. We report here that the suppression of nAChR gene expression by muscle activity can be reversed by increasing intracellular cAMP levels. This effect is specific to the embryonic-type receptor genes. Electrically insensitive genes such as those encoding the adult-type nAChR epsilon-subunit and creatine kinase are not up-regulated by cAMP. In addition, muscle inactivity caused either by tetrodotoxin or denervation increases cAMP levels and protein kinase A activity, consistent with their proposed role in mediating nAChR gene expression. Finally, we report that this same mechanism appears to regulate other genes, such as those encoding the tetrodotoxin-insensitive sodium channel, MyoD, and myogenin which, like the nAChR, are regulated by muscle electrical activity. Based on these results it is proposed that muscle electrical activity is coupled to gene expression via a cAMP-dependent second messenger system.	UNIV MICHIGAN, MENTAL HLTH RES INST, 205 ZINA PITCHER PL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; SCRIPPS CLIN & RES FDN, LA JOLLA, CA 92037 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Scripps Research Institute								BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BETZ H, 1979, NATURE, V278, P749, DOI 10.1038/278749a0; BLOSSER JC, 1980, J BIOL CHEM, V255, P1235; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER HR, 1990, NATURE, V344, P544, DOI 10.1038/344544a0; CARLSEN RC, 1975, J PHYSIOL-LONDON, V247, P343, DOI 10.1113/jphysiol.1975.sp010935; CHAHINE KG, 1992, DEVELOPMENT, V115, P213; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; CLELAND PJF, 1989, J BIOL CHEM, V264, P17704; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DUCLERT A, 1990, P NATL ACAD SCI USA, V87, P1391, DOI 10.1073/pnas.87.4.1391; EFTIMIE R, 1991, P NATL ACAD SCI USA, V88, P1349, DOI 10.1073/pnas.88.4.1349; FONTAINE B, 1987, J CELL BIOL, V105, P1337, DOI 10.1083/jcb.105.3.1337; GOLDMAN D, 1988, NEURON, V1, P329, DOI 10.1016/0896-6273(88)90081-5; GOLDMAN D, 1991, NEURON, V7, P649, DOI 10.1016/0896-6273(91)90377-C; GOLDMAN D, 1989, NEURON, V3, P219, DOI 10.1016/0896-6273(89)90035-4; GOLDMAN D, 1989, NUCLEIC ACIDS RES, V17, P3049, DOI 10.1093/nar/17.8.3049; GOLDMAN D, 1985, J NEUROSCI, V5, P2553; GREEN WN, 1991, P NATL ACAD SCI USA, V88, P854, DOI 10.1073/pnas.88.3.854; HOPKINS D, 1981, BIOCHIM BIOPHYS ACTA, V678, P388, DOI 10.1016/0304-4165(81)90119-7; HUANG CF, 1992, NEURON, V9, P671, DOI 10.1016/0896-6273(92)90030-H; JAYNES JB, 1986, MOL CELL BIOL, V6, P2855, DOI 10.1128/MCB.6.8.2855; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; KLARSFELD A, 1985, P NATL ACAD SCI USA, V82, P4558, DOI 10.1073/pnas.82.13.4558; KLARSFELD A, 1989, NEURON, V2, P1229, DOI 10.1016/0896-6273(89)90307-3; KLARSFELD A, 1987, MOL CELL BIOL, V7, P951, DOI 10.1128/MCB.7.2.951; LAUFER R, 1991, EUR J BIOCHEM, V202, P813, DOI 10.1111/j.1432-1033.1991.tb16437.x; MCMANAMAN JL, 1982, BIOCHIM BIOPHYS ACTA, V720, P28, DOI 10.1016/0167-4889(82)90035-0; MERLIE JP, 1984, J CELL BIOL, V99, P332, DOI 10.1083/jcb.99.1.332; MERLIE JP, 1989, NEURON, V2, P1295, DOI 10.1016/0896-6273(89)90067-6; MORIYAMA Y, 1976, EXP CELL RES, V101, P159, DOI 10.1016/0014-4827(76)90425-0; NGUYEN TV, 1990, J NEUROSCI, V10, P2825; NOVAK E, 1972, ARCH BIOCHEM BIOPHYS, V150, P511, DOI 10.1016/0003-9861(72)90069-0; OFFORD J, 1989, NEURON, V2, P147; PIASCIK MT, 1980, J BIOL CHEM, V255, P4176; RUBIN LL, 1985, P NATL ACAD SCI USA, V82, P7121, DOI 10.1073/pnas.82.20.7121; RYMOND M, 1982, EUR J BIOCHEM, V125, P395, DOI 10.1111/j.1432-1033.1982.tb06696.x; SAYERS ST, 1988, NEUROCHEM RES, V13, P1125, DOI 10.1007/BF00971629; SCHUETZE SM, 1987, ANNU REV NEUROSCI, V10, P403, DOI 10.1146/annurev.ne.10.030187.002155; SHERMAN SJ, 1985, J NEUROSCI, V5, P1570; SMITH MK, 1990, J BIOL CHEM, V265, P1837; SMITH PB, 1980, BIOCHIM BIOPHYS ACTA, V628, P19; TSAY HJ, 1990, FEBS LETT, V274, P69, DOI 10.1016/0014-5793(90)81331-H; WITZEMANN V, 1991, J CELL BIOL, V114, P125, DOI 10.1083/jcb.114.1.125; WITZEMANN V, 1990, EUR J BIOCHEM, V194, P437, DOI 10.1111/j.1432-1033.1990.tb15637.x; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; ZALIN RJ, 1974, CELL, V2, P103, DOI 10.1016/0092-8674(74)90098-1; ZALIN RJ, 1975, EXP CELL RES, V93, P55, DOI 10.1016/0014-4827(75)90422-X	50	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2893	2898						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8381416				2022-12-25	WOS:A1993KK81500093
